PUBCHEM_RESULT_TAG,PUBCHEM_SID,PUBCHEM_CID,PUBCHEM_EXT_DATASOURCE_SMILES,PUBCHEM_ACTIVITY_OUTCOME,PUBCHEM_ACTIVITY_SCORE,PUBCHEM_ACTIVITY_URL,PUBCHEM_ASSAYDATA_COMMENT,Species,Strain/Sex,Route,Dose,Tumor Site: Type of Lesion,Results,Reference
RESULT_TYPE,,,,,,,,STRING,STRING,STRING,STRING,STRING,STRING,STRING
1,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,DOG,BEAGLE,ORAL,8.3-10.9 MG/KG/D (AVE DAILY INTAKE) FOR 68.5-91 MO (TOTAL DOSE: 90-198 G),LIVER: CARCINOMA; URINARY BLADDER: PAPILLOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
2,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,HAMSTER,SYRIAN,ORAL,"5 MG FOR 22 WK THEN 15 MG FOR 4 WK, THEN 10 MG 2/WK AFTER 42 WK",URINARY BLADDER: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 356]"
3,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,HAMSTER,"SYRIAN/ MALE, FEMALE","INTRAPERITONEAL, ORAL","5 MG/100 G 3/WK FOR 3 WK, THEN 0.06% IN DIET",URINARY BLADDER; LIVER: CHOLANGIOCARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 356]"
4,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,HAMSTER,SYRIAN/FEMALE,ORAL,0.025% IN DIET FOR LIFE,LIVER: INTRAHEPATIC BILE DUCT CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 361]"
5,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,MOUSE,"CBA/ MALE, FEMALE",ORAL,3 MG/MOUSE 2/WK,MAMMARY GLAND; URINARY BLADDER; LIVER,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y-47 439][WEISBURGER,EK AND WEISBURGER,JH; CHEMISTRY, CARCINOGENICITY, AND METABOLISM OF 2-FLUORENAMINE AND RELATED COMPOUNDS; ADV. CANCER RES. 5:356-357, 1958, ]"
6,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,MOUSE,"STRAIN-IF/ MALE, FEMALE",ORAL,3 MG/MOUSE 2/WK,URINARY BLADDER; LIVER; MAMMARY GLAND,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y-47 439][WEISBURGER,EK AND WEISBURGER,JH; CHEMISTRY, CARCINOGENICITY, AND METABOLISM OF 2-FLUORENAMINE AND RELATED COMPOUNDS; ADV. CANCER RES. 5:356-357, 1958, ]"
7,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,MOUSE,"R-III/ MALE, FEMALE",ORAL,3 MG/MOUSE 2/WK,URINARY BLADDER; LIVER,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y-47 439][WEISBURGER,EK AND WEISBURGER,JH; CHEMISTRY, CARCINOGENICITY, AND METABOLISM OF 2-FLUORENAMINE AND RELATED COMPOUNDS; ADV. CANCER RES. 5:356-357, 1958, ]"
8,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,MOUSE,"STRAIN-A/ MALE, FEMALE",ORAL,3 MG/MOUSE 2/WK,URINARY BLADDER,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y-47 439][WEISBURGER,EK AND WEISBURGER,JH; CHEMISTRY, CARCINOGENICITY, AND METABOLISM OF 2-FLUORENAMINE AND RELATED COMPOUNDS; ADV. CANCER RES. 5:356-357, 1958, ]"
9,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RABBIT,NZW/FEMALE,ORAL,100 MG IN 1 ML CORN OIL 2/WK FOR LIFE,URINARY BLADDER: TRANSITIONAL CELL TUMOR; KIDNEY: TRANSITIONAL CELL TUMOR,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 361]"
10,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RABBIT,"NZW/ MALE, FEMALE",ORAL,100 MG 2/WK (TOTAL DOSE 21-52 G AS POWDER),"URINARY BLADDER: PAPILLOMA, ADENOCARCINOMA; URETER: PAPILLOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
11,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,ALBINO/FEMALE,ORAL,0.125% IN DIET,URINARY BLADDER: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y-47 439]"
12,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,ALBINO/MALE,ORAL,0.018; 0.036% IN DIET FOR 90 DAYS,LIVER: HEPATOMA; EAR (DUCT); INTESTINES (SMALL),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
13,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,"ALBINO/ MALE, FEMALE",ORAL,0.036% IN DIET FOR 8 MO,LIVER: HEPATOMA; MAMMARY GLAND; EAR (DUCT),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
14,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,"BUFFALO/ MALE, FEMALE",ORAL,0.05% IN DIET FOR 23 WK (580 MG/RAT),LIVER: HEPATOMA; EAR (DUCT): CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
15,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,STRAIN-CD/FEMALE,ORAL,80; 250 PPM IN DIET FOR 78 WK (LOW DOSE) OR 50 WK (HIGH DOSE),"LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA",POSITIVE,"[WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
16,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,STRAIN-CD/MALE,ORAL,80; 250 PPM IN DIET FOR 78 WK (LOW DOSE) OR 50 WK (HIGH DOSE),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
17,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,FEMALE,ORAL,0.03% IN DIET,EYE,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
18,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,FEMALE,ORAL,1.62 MMOL/KG DIET FOR 8 MO,MAMMARY GLAND; EAR (DUCT); INTESTINES (SMALL),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
19,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,F344/MALE,ORAL,"0.06% IN DIET FOR 3 WK, THEN CONTROL DIET FOR 1 WK, REPEATED 3X","TESTES: MESOTHELIOMA; LIVER: HEPATOCELLULAR CARCINOMA, CHOLANGIOCARCINOMA",POSITIVE,"[CABRAL,JRP AND NEAL,GE; TESTICULAR MESOTHELIOMAS IN RATS EXPOSED TO N-2-FLUORENYLACETAMIDE (FAA); TUMORI 69:195-199, 1983]"
20,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,HOLTZMAN/FEMALE,ORAL,1.62 MMOL/KG IN DIET,MAMMARY GLAND; EAR (DUCT); INTESTINES (SMALL),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
21,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,HOLTZMAN/MALE,ORAL,1.62 MMOL/KG IN DIET,LIVER; EAR (DUCT); INTESTINES (SMALL),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
22,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,"LONG-EVANS/ MALE, FEMALE",ORAL,IN DIET,EAR (AUDITORY CANAL): SQUAMOUS CELL CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
23,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,MALE,ORAL,1.62 MMOL/KG IN DIET FOR 8 MO,LIVER: HEPATOMA; INTESTINES (SMALL); EAR (DUCT),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
24,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,PIEBALD/FEMALE,ORAL,0.03% IN DIET,MAMMARY GLAND: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
25,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,"PIEBALD/ MALE, FEMALE",ORAL,4 MG DAILY IN DIET FOR 25 WK,LIVER: HEPATOMA; EAR (DUCT): CARCINOMA; INTESTINES: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
26,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,"SHERMAN/ MALE, FEMALE",ORAL,0.03% IN DIET FOR LIFE,LIVER: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
27,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,300 MG/KG IN SEMI-PURIFIED OR STOCK DIET,EAR (DUCT): CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
28,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,1 MG/0.1 ML 3/WK FOR 4 WK (TOTAL DOSE 0.17 MMOL/RAT),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 356]"
29,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,WISTAR/MALE,DERMAL,IN ACETONE,LIVER: HEPATOMA; INTESTINES: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
30,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,"WISTAR/ MALE, FEMALE",ORAL,0.07% IN DIET,LIVER: HEPATOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
31,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,"WISTAR/ MALE, FEMALE",ORAL,0.03% IN DIET FOR LIFE,LIVER: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
32,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,"SHEFFIELD/ MALE, FEMALE",ORAL,4 MG DAILY IN DIET FOR 25 WK,LIVER: HEPATOMA; EAR (DUCT): CARCINOMA; INTESTINES: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
33,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,AES/FEMALE,ORAL,300 MG/KG IN SEMI-PURIFIED OR STOCK DIET,EAR (DUCT): CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
34,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,RAT,PIEBALD/MALE,DERMAL,IN ACETONE,LIVER: HEPATOMA; INTESTINES: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 497]"
35,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,MOUSE,BALB/C/FEMALE,ORAL,0; 75; 100; 150 PPM IN DIET UP TO 33 MO (STUDY DURATION: 33 MO),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[SHINOHARA,Y AND FRITH,CH; CORRELATION BETWEEN SPONTANEOUS AND EXPERIMENTALLY INDUCED TUMORS IN FEMALE BALB/C MICE IN A LARGE 2-ACETYLAMINOFLUORENE STUDY; J. ENVIRON. PATHOL. TOXICOL. ONCOL. 6(5-6):85-96, 1986]"
36,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Inactive,,,,FISH,"GUPPY/ MALE,  FEMALE",IMMERSION,"0; 1 MG/L IN WELL WATER FOR 1 6 HR EXPOSURE OR FOR 1,2,3 OR 4 12 HR EXPOSURES, MULTIPLE EXPOSURES GIVEN AT WEEKLY INTERVALS (STUDY DURATION: 52 WK)",,NEGATIVE,"[JAMES,MO, HAWKINS,WE AND WALKER,WW; PHASE 1 AND PHASE 2 BIOTRANSFORMATION AND CARCINOGENICITY OF 2-ACETYLAMINOFLUORENE IN MEDAKA AND GUPPY; AQUAT. TOXICOL. 28(1-2):79-95, 1994]"
37,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Inactive,,,,FISH,"MEDAKA/ MALE, FEMALE",IMMERSION,"0; 1 MG/L IN WELL WATER FOR 1 6 HR EXPOSURE OR FOR 1,2,3 OR 4 12 HR EXPOSURES, MULTIPLE EXPOSURES GIVEN AT WEEKLY INTERVALS (STUDY DURATION: 52 WK)",,NEGATIVE,"[JAMES,MO, HAWKINS,WE AND WALKER,WW; PHASE 1 AND PHASE 2 BIOTRANSFORMATION AND CARCINOGENICITY OF 2-ACETYLAMINOFLUORENE IN MEDAKA AND GUPPY; AQUAT. TOXICOL. 28(1-2):79-95, 1994]"
38,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Inactive,,,,FISH,"MEDAKA/ MALE, FEMALE",IMMERSION,"0; 1 MG/L IN WELL WATER FOR 7 D CONTINUOUS EXPOSURE, SOLUTIONS RENEWED EVERY 24 HR (STUDY DURATION: 52 WK)",,NEGATIVE,"[JAMES,MO, HAWKINS,WE AND WALKER,WW; PHASE 1 AND PHASE 2 BIOTRANSFORMATION AND CARCINOGENICITY OF 2-ACETYLAMINOFLUORENE IN MEDAKA AND GUPPY; AQUAT. TOXICOL. 28(1-2):79-95, 1994]"
39,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,FISH,"GUPPY/ MALE, FEMALE",IMMERSION,"0; 1 MG/L IN WELL WATER FOR 7 D CONTINUOUS EXPOSURE, SOLUTIONS RENEWED EVERY 24 HR (STUDY DURATION: 52 WK)",LIVER: TUMOR,POSITIVE,"[JAMES,MO, HAWKINS,WE AND WALKER,WW; PHASE 1 AND PHASE 2 BIOTRANSFORMATION AND CARCINOGENICITY OF 2-ACETYLAMINOFLUORENE IN MEDAKA AND GUPPY; AQUAT. TOXICOL. 28(1-2):79-95, 1994]"
40,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Active,,,,MOUSE,EU-PIM-1/MALE,GAVAGE,0; 25; 100 MG/KG 1/D FOR 38 WK (STUDY DURATION: 38 WK),LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[STORER,RD, CARTWRIGHT,ME, COOK,WO, SOPER,KA AND NICOLS,WW; SHORT-TERM CARCINOGENESIS BIOASSAY OF GENOTOXIC PROCARCINOGENS IN PM TRANSGENIC MICE; CARCINOGENESIS 16(2):285-293, 1995]"
41,363897951,5897,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,Inactive,,,,MOUSE,EU-PIM-1/FEMALE,GAVAGE,0; 25; 100 MG/KG 1/D FOR 38 WK (STUDY DURATION: 38 WK),,NEGATIVE,"[STORER,RD, CARTWRIGHT,ME, COOK,WO, SOPER,KA AND NICOLS,WW; SHORT-TERM CARCINOGENESIS BIOASSAY OF GENOTOXIC PROCARCINOGENS IN PM TRANSGENIC MICE; CARCINOGENESIS 16(2):285-293, 1995]"
42,363897952,178,CC(=O)N,Active,,,,RAT,WISTAR/MALE,ORAL,1.25; 2.5; 5% IN DIET FOR ONE YR,"LIVER: TRABECULAR CARCINOMA, ADENOCARCINOMA, HEPATOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 197 Y74]"
43,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Active,,,,MOUSE,"STRAIN-IF/MALE,FEMALE",ORAL,0.5; 1.0% IN DIET FOR 18 MO,"LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA",POSITIVE,"[FLAKS,A AND FLAKS,B; INDUCTION OF LIVER CELL TUMOURS IN IF MICE BY PARACETAMOL; CARCINOGENESIS 4:363-368, 1983]"
44,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 600; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-394 Y93]"
45,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 600; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-394 Y93]"
46,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 600; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-394 Y93]"
47,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.45; 0.9% IN DIET FOR 104 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[HIRAGA,K AND FUJII,T; CARCINOGENICITY TESTING OF ACETAMINOPHEN IN F344 RATS; JPN. J. CANCER RES. (GANN) 76(2):79-85, 1985]"
48,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.65; 1.3% IN DIET FOR 104 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[HIRAGA,K AND FUJII,T; CARCINOGENICITY TESTING OF ACETAMINOPHEN IN F344 RATS; JPN. J. CANCER RES. (GANN) 76(2):79-85, 1985]"
49,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Active,,,,MOUSE,STRAIN-IF/MALE,ORAL,0; 0.5; 1% IN DIET FOR 18 MO (STUDY DURATION: 18 MO),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[FLAKS,A AND FLAKS,B; INDUCTION OF LIVER CELL TUMOURS IN IF MICE BY PARACETAMOL; CARCINOGENESIS 4:363-368, 1983]"
50,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Active,,,,MOUSE,STRAIN-IF/FEMALE,ORAL,0; 0.5; 1% IN DIET FOR 18 MO (STUDY DURATION: 18 MO),LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,POSITIVE,"[FLAKS,A AND FLAKS,B; INDUCTION OF LIVER CELL TUMOURS IN IF MICE BY PARACETAMOL; CARCINOGENESIS 4:363-368, 1983]"
51,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET BEGINNING AT 6 WK OF AGE AND CONTINUING FOR 70 WK (STUDY DURATION: 72 WK),,NEGATIVE,"[HAGIWARA,A AND WARD,JM; THE CHRONIC HEPATOTOXIC, TUMOR-PROMOTING, AND CARCINOGENIC EFFECTS OF ACETAMINOPHEN IN MALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 7:376-386, 1986]"
52,363897953,1983,CC(=O)NC1=CC=C(C=C1)O,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 600; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 106 WK),MULTIPLE ORGANS: MONONUCLEAR CELL LEUKEMIA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-394 Y93]"
53,363897954,1989,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 6359; 12718 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-50 Y78]"
54,363897954,1989,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 6359; 12718 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-50 Y78]"
55,363897954,1989,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 10000; 20000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-50 Y78]"
56,363897954,1989,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,Inactive,,,,RAT,F344/MALE,ORAL,0; 10000; 20000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-50 Y78]"
57,363897955,67180,CC(=NO)C,Active,,,,RAT,WISTAR/MALE,ORAL,1.0 G/L IN DRINKING WATER 5/WK FOR 18 MO,LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[MIRVISH,SS, SALMASI,S AND RUNGE,RG; CARCINOGENICITY TEST OF ACETOXIME IN MRC-WISTAR RATS; J. NATL. CANCER INST. 69:961-962, 1982]"
58,363897956,345512,CC1(C=CC2=C3C(=C(C=C2O1)OC)C(=O)C4=CC=CC=C4N3C)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 3.75; 7.5; 15 MG/KG FOR 52 WK (STUDY DURATION: 80-82 WK),MAMMARY GLAND: FIBROADENOMA; PERITONEAL CAVITY: SARCOMA OR FIBROSARCOMA OR MESOTHELIOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-49 Y78]"
59,363897956,345512,CC1(C=CC2=C3C(=C(C=C2O1)OC)C(=O)C4=CC=CC=C4N3C)C,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 3.75; 7.5; 15 MG/KG FOR 51-52 WK (STUDY DURATION: 51-82 WK),MUSCULOSKELETAL SYSTEM: OSTEOSARCOMA; PERITONEAL CAVITY: SARCOMA OR FIBROSARCOMA OR MESOTHELIOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-49 Y78]"
60,363897957,6579,C=CC(=O)N,Active,,,,MOUSE,"STRAIN-A/MALE, FEMALE",ORAL,6.25; 12.5; 25 MG/KG IN WATER 3/WK FOR 8 WK,LUNG: ADENOMA,POSITIVE,"[BULL,RJ, ROBINSON,M, LAURIE,RD, STONER,GD, GREISIGER,E, MEIER,JR AND STOBER,J; CARCINOGENIC EFFECTS OF ACRYLAMIDE IN SENCAR AND A/J MICE; CANCER RES. 44:107-111, 1984]"
61,363897957,6579,C=CC(=O)N,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,1-60 MG/KG IN WATER 3/WK FOR 8 WK,LUNG: ADENOMA,POSITIVE,"[BULL,RJ, ROBINSON,M, LAURIE,RD, STONER,GD, GREISIGER,E, MEIER,JR AND STOBER,J; CARCINOGENIC EFFECTS OF ACRYLAMIDE IN SENCAR AND A/J MICE; CANCER RES. 44:107-111, 1984]"
62,363897957,6579,C=CC(=O)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.01; 0.1; 0.5; 2.0 MG/KG/D IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),TESTES: MALIGNANT MESOTHELIOMA,POSITIVE,"[JOHNSON,KA, GORZINSKI,SJ, BODNER,KM, CAMPBELL,RA, WOLF,CH, FRIEDMAN,MA AND MAST,RW; CHRONIC TOXICITY AND ONCOGENICITY STUDY ON ACRYLAMIDE INCORPORATED IN THE DRINKING WATER OF FISCHER 344 RATS; TOXICOL. APPL. PHARMACOL. 85:154-168,1986]"
63,363897957,6579,C=CC(=O)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.01; 0.1; 0.5; 2.0 MG/KG/D IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),THYROID GLAND: ADENOCARCINOMA OR ADENOMA; ORAL CAVITY: SQUAMOUS CELL PAPILLOMA; UTERUS: ADENOCARCINOMA; MAMMARY GLAND: BENIGN TUMOR,POSITIVE,"[JOHNSON,KA, GORZINSKI,SJ, BODNER,KM, CAMPBELL,RA, WOLF,CH, FRIEDMAN,MA AND MAST,RW; CHRONIC TOXICITY AND ONCOGENICITY STUDY ON ACRYLAMIDE INCORPORATED IN THE DRINKING WATER OF FISCHER 344 RATS; TOXICOL. APPL. PHARMACOL. 85:154-168,1986]"
64,363897957,6579,C=CC(=O)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.1; 0.5; 2 MG/KG/D IN DRINKING WATER FOR 108 WK (STUDY DURATION: 108 WK),TESTES: MESOTHELIOMA; THYROID: FOLLICULAR CELL ADENOMA,POSITIVE,"[FRIEDMAN,MA, DULAK,LH AND STEDHAM,MA; A LIFETIME ONCOGENICITY STUDY IN RATS WITH ACRYLAMIDE; FUNDAM. APPL. TOXICOL. 27(1):95-105, 1995]"
65,363897957,6579,C=CC(=O)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 1; 3 MG/KG/D IN DRINKING WATER FOR 108 WK (STUDY DURATION: 108 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[FRIEDMAN,MA, DULAK,LH AND STEDHAM,MA; A LIFETIME ONCOGENICITY STUDY IN RATS WITH ACRYLAMIDE; FUNDAM. APPL. TOXICOL. 27(1):95-105, 1995]"
66,363897957,6579,C=CC(=O)N,Inactive,,,,Mouse,"CD1, Female (25/Group)",Oral,"3-4 mg/kg daily for 2, 6, or 8 mo (2 groups per dose, one group per dose treated with thyroxine)",Thyroid,Negative. Length of experiment may have been insufficient to express tumors.,"[JIN,L, CHICO-GALDO,V, MASSART,C, GERVY,C, DE MAERTALAERE,V, FRIEDMAN,M, VAN SANDE,J; ACRYLAMIDE DOES NOT INDUCE TUMORIGENESIS OR MAJOR DEFECTS IN MICE IN VIVO. JOURNAL OF ENDOCRINOLOGY. 198(2): 301-307, 2008]"
67,363897958,7855,C=CC#N,Active,,,,HUMAN,,INHALATION,,LUNG; COLON,POSITIVE,"[NIOSH CURRENT INTELLIGENCE BULLETIN 18, ACRYLONITRILE; U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH, CINCINNATI, OHIO, JULY 1, 1977, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 73 Y79]"
68,363897958,7855,C=CC#N,Active,,,,RAT,,ORAL,,FORESTOMACH; STOMACH; NERVOUS SYSTEM (CENTRAL); EAR (ZYMBAL GLAND),POSITIVE,"[NIOSH CURRENT INTELLIGENCE BULLETIN 18, ACRYLONITRILE; U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH, CINCINNATI, OHIO, JULY 1, 1977, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 73 Y79]"
69,363897958,7855,C=CC#N,Active,,,,RAT,,INHALATION,,MAMMARY GLAND; NERVOUS SYSTEM (CENTRAL); EAR (ZYMBAL GLAND),POSITIVE,"[NIOSH CURRENT INTELLIGENCE BULLETIN 18, ACRYLONITRILE; U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH, CINCINNATI, OHIO, JULY 1, 1977, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 73 Y79]"
70,363897958,7855,C=CC#N,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 20; 100; 500 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: 2 YR),ZYMBAL'S GLAND: TUMOR,POSITIVE,"[GALLAGHER,GT, MAULL,EA, KOVACS,K AND SZABO,S; NEOPLASMS IN RATS INGESTING ACRYLONITRILE FOR TWO YEARS; J. AM. COLL. TOXICOL. 7(5):603-615, 1988]"
71,363897958,7855,C=CC#N,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 60 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 97 WK ADMINISTRATION STARTED WITH EMBRYOS ON DAY 12 OF GESTATION (STUDY DURATION: 104 WK),ZYMBAL GLAND: CARCINOMA; LIVER: HEPATOMA; BRAIN: GLIOMA,POSITIVE,"[MALTONI,C, CILIBERTI,A, COTTI,G AND PERINO,G; LONG-TERM BIOASSAYS ON ACRYLONITRILE ADMINISTERED BY INHALATION AND BY INGESTION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):179-202, 1988]"
72,363897958,7855,C=CC#N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 60 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 97 WK ADMINISTRATION STARTED WITH EMBRYOS ON DAY 12 OF GESTATION (STUDY DURATION: 104 WK),MAMMARY GLAND: TUMORS; LIVER: ANGIOSARCOMA; BRAIN: GLIOMA,POSITIVE,"[MALTONI,C, CILIBERTI,A, COTTI,G AND PERINO,G; LONG-TERM BIOASSAYS ON ACRYLONITRILE ADMINISTERED BY INHALATION AND BY INGESTION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):179-202, 1988]"
73,363897958,7855,C=CC#N,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 5 MG/KG IN OLIVE OIL 1/D 3 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, CILIBERTI,A, COTTI,G AND PERINO,G; LONG-TERM BIOASSAYS ON ACRYLONITRILE ADMINISTERED BY INHALATION AND BY INGESTION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):179-202, 1988]"
74,363897958,7855,C=CC#N,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 5 MG/KG IN OLIVE OIL 1/D 3 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, CILIBERTI,A, COTTI,G AND PERINO,G; LONG-TERM BIOASSAYS ON ACRYLONITRILE ADMINISTERED BY INHALATION AND BY INGESTION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):179-202, 1988]"
75,363897958,7855,C=CC#N,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 60 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 8 WK ADMINISTRATION STARTED WITH EMBRYOS ON 12TH DAY OF GESTATION (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, CILIBERTI,A, COTTI,G AND PERINO,G; LONG-TERM BIOASSAYS ON ACRYLONITRILE ADMINISTERED BY INHALATION AND BY INGESTION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):179-202, 1988]"
76,363897958,7855,C=CC#N,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 60 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 8 WK ADMINISTRATION STARTED WITH EMBRYOS ON 12TH DAY OF GESTATION (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, CILIBERTI,A, COTTI,G AND PERINO,G; LONG-TERM BIOASSAYS ON ACRYLONITRILE ADMINISTERED BY INHALATION AND BY INGESTION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):179-202, 1988]"
77,363897958,7855,C=CC#N,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 5 MG/KG BW IN OLIVE OIL 3/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
78,363897958,7855,C=CC#N,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 5 MG/KG BW IN OLIVE OIL 3/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
79,363897958,7855,C=CC#N,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 2.5; 10; 20 MG/KG/D  5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA, EPITHELIAL HYPERPLASIA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA; OVARY BENIGN OR MALIGNANT GRANULOSA CELL TUMORS; LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA OR CARCINOMA",POSITIVE,"[CATTERALL,F COPELAND,E CLIFFORD,MN AND IOANNIDES,S; EFFECTS OF BLACK TEA THEAFULVINS ON AFLATOXIN B1 MUTAGENESIS IN THE AMES TEST; MUTAGENESIS 18(2):145-150, 2003]"
80,363897958,7855,C=CC#N,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 2.5; 10; 20 MG/KG/D  5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA, EPITHELIAL HYPERPLASIA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[CATTERALL,F COPELAND,E CLIFFORD,MN AND IOANNIDES,S; EFFECTS OF BLACK TEA THEAFULVINS ON AFLATOXIN B1 MUTAGENESIS IN THE AMES TEST; MUTAGENESIS 18(2):145-150, 2003]"
81,363897958,7855,C=CC#N,Active,,,,RAT,F344/MALE,ORAL,0; 1; 3; 10; 30; 100 PPM IN DRINKING WATER FOR LIFETIME (STUDY DURATION: 26 MO),"BRAIN: ASTROCYTOMA; SPINAL CORD: ASTROCYTOMA; ZYMBAL'S GLAND: SQUAMOUS CELL PAPILLOMA, ADENOMA/CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA/CARCINOMA",POSITIVE,"[JOHANNSEN,FR AND LEVINSKAS,GJ; CHRONIC TOXICITY AND ONCOGENIC DOSE-RESPONSE EFFECTS OF LIFETIME ORAL ACRYLONITRILE EXPOSURE TO FISCHER 344 RATS; TOXICOL. LETT. 132(3):221-247, 2002]"
82,363897958,7855,C=CC#N,Active,,,,RAT,F344/FEMALE,ORAL,0; 1; 3; 10; 30; 100 PPM IN DRINKING WATER FOR LIFETIME (STUDY DURATION: 26 MO),"BRAIN: ASTROCYTOMA; ZYMBAL'S GLAND: SQUAMOUS CELL PAPILLOMA, ADENOMA/CARCINOMA; MAMMARY GLAND: FIBROADENOMA;  FORESTOMACH: SQUAMOUS CELL PAPILLOMA/CARCINOMA",POSITIVE,"[JOHANNSEN,FR AND LEVINSKAS,GJ; CHRONIC TOXICITY AND ONCOGENIC DOSE-RESPONSE EFFECTS OF LIFETIME ORAL ACRYLONITRILE EXPOSURE TO FISCHER 344 RATS; TOXICOL. LETT. 132(3):221-247, 2002]"
83,363897958,7855,C=CC#N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 0.1; 10 MG/KG/D 7D/WK FOR 20 MO (STUDY DURATION: 20 MO),"BRAIN: ASTROCYTOMA; ZYMBAL'S GLAND/EAR CANAL: CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA/PAPILLOMA, SQUAMOUS CELL CARCINOMA; MAMMARY GLAND: CARCINOMA",POSITIVE,"[JOHANNSEN,FR AND LEVINSKAS,GJ; COMPARATIVE CHRONIC TOXICITY AND CARCINOGENICITY OF ACRYLONITRILE BY DRINKING WATER AND ORAL INTUBATION TO SPARTAN SPRAGUE-DAWLEY RATS; TOXICOL. LETT. 132(3):197-219, 2002]"
84,363897958,7855,C=CC#N,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 0.1; 10 MG/KG/D 7D/WK FOR 20 MO (STUDY DURATION: 20 MO),"BRAIN: ASTROCYTOMA; ZYMBAL'S GLAND/EAR CANAL: CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA/PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[JOHANNSEN,FR AND LEVINSKAS,GJ; COMPARATIVE CHRONIC TOXICITY AND CARCINOGENICITY OF ACRYLONITRILE BY DRINKING WATER AND ORAL INTUBATION TO SPARTAN SPRAGUE-DAWLEY RATS; TOXICOL. LETT. 132(3):197-219, 2002]"
85,363897958,7855,C=CC#N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 1; 100 PPM IN DRINKING WATER FOR 22 MO (STUDY DURATION: 20 MO),BRAIN: ASTROCYTOMA; ZYMBAL'S GLAND/EAR CANAL: ADENOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA/PAPILLOMA OR SQUAMOUS CELL CARCINOMA; MAMMARY GLAND: CARCINOMA,POSITIVE,"[JOHANNSEN,FR AND LEVINSKAS,GJ; COMPARATIVE CHRONIC TOXICITY AND CARCINOGENICITY OF ACRYLONITRILE BY DRINKING WATER AND ORAL INTUBATION TO SPARTAN SPRAGUE-DAWLEY RATS; TOXICOL. LETT. 132(3):197-219, 2002]"
86,363897958,7855,C=CC#N,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 1; 100 PPM IN DRINKING WATER FOR 22 MO (STUDY DURATION: 20 MO),BRAIN: ASTROCYTOMA; ZYMBAL'S GLAND/EAR CANAL: ADENOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA/PAPILLOMA OR SQUAMOUS CELL CARCINOMA,POSITIVE,"[JOHANNSEN,FR AND LEVINSKAS,GJ; COMPARATIVE CHRONIC TOXICITY AND CARCINOGENICITY OF ACRYLONITRILE BY DRINKING WATER AND ORAL INTUBATION TO SPARTAN SPRAGUE-DAWLEY RATS; TOXICOL. LETT. 132(3):197-219, 2002]"
87,363897958,7855,C=CC#N,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 2.5; 10; 20 MG/KG 5D/WK FOR 104-105 WK (STUDY DURATION: 104-105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[GHANAYEM,BI BRISTOL,DW BUCHER,JR HAILEY,JR HASEMAN,JK  HERBERT,RA MARONPOT,RR NYSKA,A PEDDADA,SD ORZECH,DP RAO,GN  ROYCROFT,JH SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL  REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF  ACRYLONITRILE (CAS NO. 107-31-1) IN B6C3F1 MICE (GAVAGE  STUDIES); NATL. TOXICOL. PROGRAM TECH REP. SER. 506: 1-197,  2001]"
88,363897958,7855,C=CC#N,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 2.5; 10; 20 MG/KG 5D/WK FOR 104-105 WK (STUDY DURATION: 104-105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[GHANAYEM,BI BRISTOL,DW BUCHER,JR HAILEY,JR HASEMAN,JK  HERBERT,RA MARONPOT,RR NYSKA,A PEDDADA,SD ORZECH,DP RAO,GN  ROYCROFT,JH SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL  REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF  ACRYLONITRILE (CAS NO. 107-31-1) IN B6C3F1 MICE (GAVAGE  STUDIES); NATL. TOXICOL. PROGRAM TECH REP. SER. 506: 1-197,  2001]"
89,363897958,7855,C=CC#N,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 2.5; 10; 20 MG/KG 5D/WK FOR 104-105 WK (STUDY DURATION: 104-105 WK),OVARY: MALIGNANT GRANULOSA CELL TUMOR; LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA OR CARCINOMA,EQUIVOCAL,"[GHANAYEM,BI BRISTOL,DW BUCHER,JR HAILEY,JR HASEMAN,JK  HERBERT,RA MARONPOT,RR NYSKA,A PEDDADA,SD ORZECH,DP RAO,GN  ROYCROFT,JH SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL  REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF  ACRYLONITRILE (CAS NO. 107-31-1) IN B6C3F1 MICE (GAVAGE  STUDIES); NATL. TOXICOL. PROGRAM TECH REP. SER. 506: 1-197,  2001]"
90,363897958,7855,C=CC#N,Active,,,,Rat,"Sprague Dawley/Male (80/group, Controls; 48/group, Experimental)",Oral,0; 35; 100; 300 ppm (0; 3.4; 8.5; 21.3 mg/kg in drinking water for 2 yr),"Nervous system (brain and spinal cord): Combined focal or multifocal glial cell proliferation and/or astrocytoma (1/80, 12/47, 22/48, 30/48) ; Tongue:  Papilloma or carcinoma of squamous epithelium (1/80, 2/47, 4/48, 5/48); Stomach: Squamous cell papilloma and carcinoma of forestomach (0/80, 2/47, 23/48, 39/48); Zymbal gland: (3/80, 4/47, 3/48, 16/48)",Positive,"[QUAST,JF; TWO-YEAR TOXICITY AND ONCOGENICTY STUDY WITH  ACRYLONITRILE INCORPORATED IN THE DRINKING WATER OF  RATS;TOXICOL. LETT. 132(3):153-196, 2002]"
91,363897958,7855,C=CC#N,Active,,,,Rat,"Sprague Dawley/Female (80/group, Controls; 48/group, Experimental)",Oral,0; 35; 100; 300 ppm (0; 4.4; 10.8; 25.0 mg/kg) in drinking water for 2 yr,"Nervous system (brain and spinal cord): Combined focal or multifocal glial cell proliferation and/or astrocytoma (1/80, 20/48, 25/48, 31/48); Tongue: Papilloma or carcinoma of squamous epithelium (0/80, 1/48, 2/48, 12/48); Stomach: Squamous cell papilloma and/or carcinoma of forestomach (1/80, 1/48, 12/48, 30/48); Zymbal gland: Carcinoma and/or adenoma (1/80, 5/48, 9/48, 18/48); Mammary gland: Benign and/or malignant (58/80, 42/48, 42/48, 35/48) ; Small intestine: Mucous cystadenocarcinoma (0/80, 1/48, 4/48, 4/48)",Positive,"[QUAST,JF; TWO-YEAR TOXICITY AND ONCOGENICTY STUDY WITH  ACRYLONITRILE INCORPORATED IN THE DRINKING WATER OF  RATS;TOXICOL. LETT. 132(3):153-196, 2002]"
92,363897959,457193,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C,Active,,,,RAT,,INTRAPERITONEAL,,PERITONEAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 29 Y76]"
93,363897960,5280707,C1=COC(=C1)/C(=C/C2=CC=C(O2)[N+](=O)[O-])/C(=O)N,Active,,,,HAMSTER,SYRIAN/MALE,ORAL,0.25% IN DIET,"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA; BILE DUCT: ADENOMA",POSITIVE,"[SANO,T, KAWACHI,T, MATSUKURA,N, SASAJIMA,K AND SUGIMURA,T; CARCINOGENICITY OF A FOOD ADDITIVE, AF-2, IN HAMSTERS AND MICE; Z. KREBSFORSCH. 89:61-68, 1977]"
94,363897960,5280707,C1=COC(=C1)/C(=C/C2=CC=C(O2)[N+](=O)[O-])/C(=O)N,Active,,,,MOUSE,"CD-1/MALE,FEMALE",ORAL,0.4% IN DIET FOR 18 MO,"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[TAKAYAMA,S AND KUWABARA,N; CARCINOGENIC ACTIVITY OF 2-(2-FURYL)-3-(5-NITRO-2-FURYL)ACRYLAMIDE, A FOOD ADDITIVE, IN MICE AND RATS; CANCER LETT. 3:115-120, 1977]"
95,363897960,5280707,C1=COC(=C1)/C(=C/C2=CC=C(O2)[N+](=O)[O-])/C(=O)N,Active,,,,MOUSE,DDY/MALE,ORAL,0.25% IN DIET FOR 308 DAYS,FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[SANO,T, KAWACHI,T, MATSUKURA,N, SASAJIMA,K AND SUGIMURA,T; CARCINOGENICITY OF A FOOD ADDITIVE, AF-2, IN HAMSTERS AND MICE; Z. KREBSFORSCH. 89:61-68, 1977]"
96,363897960,5280707,C1=COC(=C1)/C(=C/C2=CC=C(O2)[N+](=O)[O-])/C(=O)N,Active,,,,MOUSE,"ICR/MALE,FEMALE",ORAL,0.08; 0.4% IN DIET FOR 440 DAYS,"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[YOKORO,K, KAJIHARA,H, KODAMA,Y, NAGAO,K, HAMADA,K AND KINOMURA,A; CHRONIC TOXICITY OF 2-(2-FURYL)-3-(5-NITRO-2-FURYL)ACRYLAMIDE (AF-2) IN MICE, WITH SPECIAL REFERENCE TO CARCINOGENICITY IN THE FORESTOMACH; GANN 68:825-828, 1977]"
97,363897960,5280707,C1=COC(=C1)/C(=C/C2=CC=C(O2)[N+](=O)[O-])/C(=O)N,Active,,,,RAT,WISTAR/FEMALE,ORAL,0.08; 0.4% IN DIET FOR 18 MO,MAMMARY GLAND: ADENOCARCINOMA; FORESTOMACH: PAPILLOMA,POSITIVE,"[TAKAYAMA,S AND KUWABARA,N; CARCINOGENIC ACTIVITY OF 2-(2-FURYL)-3-(5-NITRO-2-FURYL)ACRYLAMIDE, A FOOD ADDITIVE, IN MICE AND RATS; CANCER LETT. 3:115-120, 1977]"
98,363897960,5280707,C1=COC(=C1)/C(=C/C2=CC=C(O2)[N+](=O)[O-])/C(=O)N,Active,,,,RAT,WISTAR/MALE,ORAL,0.4% IN DIET FOR 18 MO,FORESTOMACH: PAPILLOMA,POSITIVE,"[TAKAYAMA,S AND KUWABARA,N; CARCINOGENIC ACTIVITY OF 2-(2-FURYL)-3-(5-NITRO-2-FURYL)ACRYLAMIDE, A FOOD ADDITIVE, IN MICE AND RATS; CANCER LETT. 3:115-120, 1977]"
99,363897961,104744,COC1=C2C3=C([C@H](CC3)O)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,RAT,F344/MALE,ORAL,50; 200 PPB IN DIET 2/WK FOR 12 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NIXON,JE, HENDRICKS,JD, PAWLOWSKI,NE, LOVELAND,PM AND SINNHUBER,RO; CARCINOGENICITY OF AFLATOXICOL IN FISCHER 344 RATS; J. NATL. CANCER INST. 66:1159-1163, 1981]"
100,363897961,104744,COC1=C2C3=C([C@H](CC3)O)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,TROUT,MT. SHASTA RAINBOW,ORAL,29 PPB IN DIET FOR 12 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[SCHOENHARD,GL, HENDRICKS,JD, NIXON,JE, LEE,DJ, WALES,JH, SINNHUBER,RO AND PAWLOWSKI,NE; AFLATOXICOL-INDUCED HEPATOCELLULAR CARCINOMA IN RAINBOW TROUT (SALMO GAIRDNERI) AND THE SYNERGISTIC EFFECTS OF CYCLOPROPENOID FATTY ACIDS; CANCER RES. 41:1011-1014, 1981]"
101,363897961,104744,COC1=C2C3=C([C@H](CC3)O)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",IMMERSION,0; 0.01; 0.025; 0.05; 0.1; 0.25; 0.5 PPM SOLUTION IN WATER FOR 1 HR EXPOSURE OF EMBRYOS (STUDY DURATION: 13 MO),LIVER: TUMORS,POSITIVE,"[BAILEY,GS, LOVELAND,PM, PEREIRA,C, PIERCE,D, HENDRICKS,JD AND GROOPMAN,JD; QUANTITATIVE CARCINOGENESIS AND DOSIMETRY IN RAINBOW TROUT FOR AFLATOXIN B1 AND AFLATOXICOL, TWO AFLATOXINS THAT FORM THE SAME DNA ADDUCT; MUTAT. RES. 313(1):25-38, 1994]"
102,363897961,104744,COC1=C2C3=C([C@H](CC3)O)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",ORAL,0; 4; 8; 16; 32; 64 PPB IN DIET FOR 2 WK FOLLOWED BY CONTROL DIET FOR THE DURATION OF STUDY (STUDY DURATION: 9 MO),LIVER: TUMOR,POSITIVE,"[BAILEY,GS, LOVELAND,PM, PEREIRA,C, PIERCE,D, HENDRICKS,JD AND GROOPMAN,JD; QUANTITATIVE CARCINOGENESIS AND DOSIMETRY IN RAINBOW TROUT FOR AFLATOXIN B1 AND AFLATOXICOL, TWO AFLATOXINS THAT FORM THE SAME DNA ADDUCT; MUTAT. RES. 313(1):25-38, 1994]"
103,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,HUMAN,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 145 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 51 Y76]"
104,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MOUSE,,INTRAPERITONEAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 51 Y76]"
105,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 145 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 51 Y76]"
106,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,RAT,F344/MALE,ORAL,50 PPB IN DIET 2/WK FOR 12 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NIXON,JE, HENDRICKS,JD, PAWLOWSKI,NE, LOVELAND,PM AND SINNHUBER,RO; CARCINOGENICITY OF AFLATOXICOL IN FISCHER 344 RATS; J. NATL. CANCER INST. 66:1159-1163, 1981]"
107,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,RAT,,"INTRAPERITONEAL, ORAL",,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 145 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 51 Y76]"
108,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,TROUT,MT. SHASTA RAINBOW,ORAL,4 PPB IN DIET FOR 12 MO,LIVER: HEPATOMA,POSITIVE,"[SINNHUBER,RO, LEE,DJ, WALES,JH, LANDERS,MK AND KEYL,AC; HEPATIC CARCINOGENESIS OF AFLATOXIN M1 IN RAINBOW TROUT (SALMO GAIRDNERI) AND ITS ENHANCEMENT BY CYCLOPROPENE FATTY ACIDS; J. NATL. CANCER INST. 53:1285-1288, 1974]"
109,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,TROUT,MT. SHASTA RAINBOW,ORAL,20 PPB IN DIET FOR 12 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[SCHOENHARD,GL, HENDRICKS,JD, NIXON,JE, LEE,DJ, WALES,JH, SINNHUBER,RO AND PAWLOWSKI,NE; AFLATOXICOL-INDUCED HEPATOCELLULAR CARCINOMA IN RAINBOW TROUT (SALMO GAIRDNERI) AND THE SYNERGISTIC EFFECTS OF CYCLOPROPENOID FATTY ACIDS; CANCER RES. 41:1011-1014, 1981]"
110,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,FISH,RAINBOW,DIET,"0, 6 PPB FOR UP TO 1 YR",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[HENDRICKS,JD, PUTNAM,TP AND SINNHUBER,RO; EFFECT OF DIETARY DIELDRIN ON AFLATOXIN B1 CARCINOGENESIS IN RAINBOW TROUT (SALMO GARDINERI); J. ENVIRON. PATHOL. TOXICOL. 2:719-728, 1979]"
111,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,RAT,SPRAGUE-DAWLEY,DIET,"0, 25 UG/D FOR 15 DOSES",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NEWBERNE,PM; BIOLOGIC EFFECTS OF PLANT TOXINS AND AFLATOXINS IN RATS; J. NATL. CANCER INST. 56(3):551-555, 1976]"
112,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MONKEY,"RHESUS/MALE,FEMALE",INTRAPERITONEAL,"99-134 MG TOTAL DOSE, 1/WK FOR AT LEAST 2 YR","LIVER: CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; GALL BLADDER (BILE DUCT): ADENOCARCINOMA; PANCREAS: HEMANGIOENDOTHELIAL SARCOMA; BRAIN (OLFACTORY BULB): NEUROEPITHELIOMA; BONE: TIBIAL OSTEOSARCOMA",POSITIVE,"[ADAMSON,RH AND SIEBER,SM; THE USE OF NONHUMAN PRIMATES FOR CHEMICAL CARCINOGENESIS STUDIES; ECOTOXICOL. ENVIRON. QUAL. 2:275-296, 1979]"
113,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MONKEY,"CYNOMOLGUS/MALE,FEMALE",INTRAPERITONEAL,"99-134 MG TOTAL DOSE, 1/WK FOR AT LEAST 2 YR","LIVER: CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; GALL BLADDER (BILE DUCT): ADENOCARCINOMA; PANCREAS: HEMANGIOENDOTHELIAL SARCOMA; BRAIN (OLFACTORY BULB): NEUROEPITHELIOMA; BONE: TIBIAL OSTEOSARCOMA",POSITIVE,"[ADAMSON,RH AND SIEBER,SM; THE USE OF NONHUMAN PRIMATES FOR CHEMICAL CARCINOGENESIS STUDIES; ECOTOXICOL. ENVIRON. QUAL. 2:275-296, 1979]"
114,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MONKEY,"AFRICAN GREEN/MALE,FEMALE",INTRAPERITONEAL,"99-134 MG TOTAL DOSE, 1/WK FOR AT LEAST 2 YR","LIVER: CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; GALL BLADDER (BILE DUCT): ADENOCARCINOMA; PANCREAS: HEMANGIOENDOTHELIAL SARCOMA; BRAIN (OLFACTORY BULB): NEUROEPITHELIOMA; BONE: TIBIAL OSTEOSARCOMA",POSITIVE,"[ADAMSON,RH AND SIEBER,SM; THE USE OF NONHUMAN PRIMATES FOR CHEMICAL CARCINOGENESIS STUDIES; ECOTOXICOL. ENVIRON. QUAL. 2:275-296, 1979]"
115,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MONKEY,"RHESUS/MALE,FEMALE",ORAL,"99-134 MG TOTAL DOSE, 1/WK FOR AT LEAST 2 YR","LIVER: CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; GALL BLADDER (BILE DUCT): ADENOCARCINOMA; PANCREAS: HEMANGIOENDOTHELIAL SARCOMA; BRAIN (OLFACTORY BULB): NEUROEPITHELIOMA; BONE: TIBIAL OSTEOSARCOMA",POSITIVE,"[ADAMSON,RH AND SIEBER,SM; THE USE OF NONHUMAN PRIMATES FOR CHEMICAL CARCINOGENESIS STUDIES; ECOTOXICOL. ENVIRON. QUAL. 2:275-296, 1979]"
116,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MONKEY,"CYNOMOLGUS/MALE,FEMALE",ORAL,"99-134 MG TOTAL DOSE, 1/WK FOR AT LEAST 2 YR","LIVER: CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; GALL BLADDER (BILE DUCT): ADENOCARCINOMA; PANCREAS: HEMANGIOENDOTHELIAL SARCOMA; BRAIN (OLFACTORY BULB): NEUROEPITHELIOMA; BONE: TIBIAL OSTEOSARCOMA",POSITIVE,"[ADAMSON,RH AND SIEBER,SM; THE USE OF NONHUMAN PRIMATES FOR CHEMICAL CARCINOGENESIS STUDIES; ECOTOXICOL. ENVIRON. QUAL. 2:275-296, 1979]"
117,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MONKEY,"AFRICAN GREEN/MALE,FEMALE",ORAL,"99-134 MG TOTAL DOSE, 1/WK FOR AT LEAST 2 YR","LIVER: CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; GALL BLADDER (BILE DUCT): ADENOCARCINOMA; PANCREAS: HEMANGIOENDOTHELIAL SARCOMA; BRAIN (OLFACTORY BULB): NEUROEPITHELIOMA; BONE: TIBIAL OSTEOSARCOMA",POSITIVE,"[ADAMSON,RH AND SIEBER,SM; THE USE OF NONHUMAN PRIMATES FOR CHEMICAL CARCINOGENESIS STUDIES; ECOTOXICOL. ENVIRON. QUAL. 2:275-296, 1979]"
118,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,FISH,MT. SHASTA RAINBOW TROUT,IMMERSION,0; 0.5 PPM AQUEOUS SOLUTION FOR 15 MIN EXPOSURE OF EMBRYOS 4-5 D BEFORE HATCHING (STUDY DURATION: 12 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[BAILEY,GS, WILLIAMS,DE, WILCOX,JS, LOVELAND,PM, COULOMBE,RA AND HENDRICKS,JD; AFLATOXIN B1 CARCINOGENESIS AND ITS RELATION TO DNA ADDUCT FORMATION AND ADDUCT PERSISTENCE IN SENSITIVE AND RESISTANT SALMONID FISH; CARCINOGENESIS 9(11): 1919-1926, 1988]"
119,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,FISH,MT. SHASTA RAINBOW TROUT,ORAL,0; 20 PPB IN DIET FOR 4 WK (STUDY DURATION: 12 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[BAILEY,GS, WILLIAMS,DE, WILCOX,JS, LOVELAND,PM, COULOMBE,RA AND HENDRICKS,JD; AFLATOXIN B1 CARCINOGENESIS AND ITS RELATION TO DNA ADDUCT FORMATION AND ADDUCT PERSISTENCE IN SENSITIVE AND RESISTANT SALMONID FISH; CARCINOGENESIS 9(11): 1919-1926, 1988]"
120,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Inactive,,,,FISH,COHO SALMON,IMMERSION,0; 0.5 PPM AQUEOUS SOLUTION FOR 30 MIN EXPOSURE OF EMBRYOS 4-5 D BEFORE HATCHING (STUDY DURATION: 12 MO),,NEGATIVE,"[BAILEY,GS, WILLIAMS,DE, WILCOX,JS, LOVELAND,PM, COULOMBE,RA AND HENDRICKS,JD; AFLATOXIN B1 CARCINOGENESIS AND ITS RELATION TO DNA ADDUCT FORMATION AND ADDUCT PERSISTENCE IN SENSITIVE AND RESISTANT SALMONID FISH; CARCINOGENESIS 9(11): 1919-1926, 1988]"
121,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Inactive,,,,FISH,COHO SALMON,DIET,0; 40 PPB IN DIET FOR 4 WK (STUDY DURATION: 12 MO),,NEGATIVE,"[BAILEY,GS, WILLIAMS,DE, WILCOX,JS, LOVELAND,PM, COULOMBE,RA AND HENDRICKS,JD; AFLATOXIN B1 CARCINOGENESIS AND ITS RELATION TO DNA ADDUCT FORMATION AND ADDUCT PERSISTENCE IN SENSITIVE AND RESISTANT SALMONID FISH; CARCINOGENESIS 9(11): 1919-1926, 1988]"
122,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Inactive,,,,FISH,COHO SALMON,DIET,0; 5000 PPB FOR 3 WK (STUDY DURATION: 12 MO),,NEGATIVE,"[BAILEY,GS, WILLIAMS,DE, WILCOX,JS, LOVELAND,PM, COULOMBE,RA AND HENDRICKS,JD; AFLATOXIN B1 CARCINOGENESIS AND ITS RELATION TO DNA ADDUCT FORMATION AND ADDUCT PERSISTENCE IN SENSITIVE AND RESISTANT SALMONID FISH; CARCINOGENESIS 9(11): 1919-1926, 1988]"
123,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,FISH,RAINBOW TROUT,ORAL,0; 1.5; 7.5 UG/DIET FOR 5.5 MO (STUDY DURATION: 5.5 MO),LIVER: HEPATOMA,POSITIVE,"[LAFONT,P, SIRIWARDANA,MG AND LAFONT,J; GENOTOXICITY OF HYDROXY-AFLATOXINS M1 AND M4; MICROBIOL., ALIMENTS, NUTR. 7(1):1-8,1989]"
124,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,RAT,F344/MALE,ORAL,0; 50 PPB IN AGAR BASED SEMISYNTHETIC DIET FOR STUDY DURATION (STUDY DURATION: 17 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[HSIEH,DPH, CULLEN,JM AND RUEBNER,BH; COMPARATIVE HEPATOCARCINOGENICITY OF AFLATOXINS B1 AND M1 IN THE RAT; FOOD CHEM. TOXICOL. 22(12):1027-1028, 1984]"
125,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",IMMERSION,0; 0.01; 0.025; 0.05; 0.1; 0.25; 0.5 PPM SOLUTION IN WATER FOR 1 HR EXPOSURE OF EMBRYOS (STUDY DURATION: 13 MO),LIVER: TUMOR,POSITIVE,"[BAILEY,GS, LOVELAND,PM, PEREIRA,C, PIERCE,D, HENDRICKS,JD AND GROOPMAN,JD; QUANTITATIVE CARCINOGENESIS AND DOSIMETRY IN RAINBOW TROUT FOR AFLATOXIN B1 AND AFLATOXICOL, TWO AFLATOXINS THAT FORM THE SAME DNA ADDUCT; MUTAT. RES. 313(1):25-38, 1994]"
126,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",ORAL,0; 4; 8; 16; 32; 64 PPB IN DIET FOR 2 WK FOLLOWED BY CONTROL DIET FOR THE DURATION OF STUDY (STUDY DURATION: 9 MO),LIVER: TUMOR,POSITIVE,"[BAILEY,GS, LOVELAND,PM, PEREIRA,C, PIERCE,D, HENDRICKS,JD AND GROOPMAN,JD; QUANTITATIVE CARCINOGENESIS AND DOSIMETRY IN RAINBOW TROUT FOR AFLATOXIN B1 AND AFLATOXICOL, TWO AFLATOXINS THAT FORM THE SAME DNA ADDUCT; MUTAT. RES. 313(1):25-38, 1994]"
127,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MOUSE,DDK/MALE,TRANSPLACENTAL,0; 20; 40; 80; 120 MG/KG ADMINISTERED INTRAPERITONEALLY TO MOTHERS ON DAY 14 OF GESTATION AND OFFSPRING OBSERVED FOR 12 MO AFTER BIRTH (STUDY DURATION: 12 MO),LIVER: TUMOR,POSITIVE,"[HOMMA,S, OKA,M, GOTO,N, TOMIZAWA,M, MIURA,K AND IMAMURA,K; EFFECTS OF PHENOBARBITAL ON THE TRANSPLACENTAL TUMORIGENESIS BY AFLATOXIN B1 IN MICE OF DDK STRAIN; DEV. FOOD SCI. 7(TOXIGENIC FUNGI):272-281, 1984]"
128,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Inactive,,,,MOUSE,DDK/FEMALE,TRANSPLACENTAL,0; 20; 40; 80; 120 MG/KG ADMINISTERED INTRAPERITONEALLY TO MOTHERS ON DAY 14 OF GESTATION AND OFFSPRING OBSERVED FOR 12 MO AFTER BIRTH (STUDY DURATION: 12 MO),,NEGATIVE,"[HOMMA,S, OKA,M, GOTO,N, TOMIZAWA,M, MIURA,K AND IMAMURA,K; EFFECTS OF PHENOBARBITAL ON THE TRANSPLACENTAL TUMORIGENESIS BY AFLATOXIN B1 IN MICE OF DDK STRAIN; DEV. FOOD SCI. 7(TOXIGENIC FUNGI):272-281, 1984]"
129,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,MOUSE,DDK/MALE,TRANSPLACENTAL,0; 40 MG/KG ADMINISTERED INTRAPERITONEALLY TO MOTHERS ON DAY 14 OF GESTATION AND OFFSPRING OBSERVED FOR 6 MO AFTER BIRTH (STUDY DURATION: 6 MO),LIVER: TUMOR,POSITIVE,"[HOMMA,S, OKA,M, GOTO,N, TOMIZAWA,M, MIURA,K AND IMAMURA,K; EFFECTS OF PHENOBARBITAL ON THE TRANSPLACENTAL TUMORIGENESIS BY AFLATOXIN B1 IN MICE OF DDK STRAIN; DEV. FOOD SCI. 7(TOXIGENIC FUNGI):272-281, 1984]"
130,363897962,186907,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Inactive,,,,MOUSE,DDK/FEMALE,TRANSPLACENTAL,0; 40 MG/KG ADMINISTERED INTRAPERITONEALLY TO MOTHERS ON DAY 14 OF GESTATION AND OFFSPRING OBSERVED FOR 6 MO AFTER BIRTH (STUDY DURATION: 6 MO),,NEGATIVE,"[HOMMA,S, OKA,M, GOTO,N, TOMIZAWA,M, MIURA,K AND IMAMURA,K; EFFECTS OF PHENOBARBITAL ON THE TRANSPLACENTAL TUMORIGENESIS BY AFLATOXIN B1 IN MICE OF DDK STRAIN; DEV. FOOD SCI. 7(TOXIGENIC FUNGI):272-281, 1984]"
131,363897963,2724360,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5CCO[C@@H]5OC4=C1,Active,,,,HUMAN,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 145 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 51 Y76]"
132,363897963,2724360,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5CCO[C@@H]5OC4=C1,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 145 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 51 Y76]"
133,363897964,2724361,COC1=C2C3=C(C(=O)OCC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,HUMAN,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 145 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 51 Y76]"
134,363897964,2724361,COC1=C2C3=C(C(=O)OCC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,Active,,,,RAT,,ORAL,,KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 145 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 51 Y76]"
135,363897965,15558498,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4C(=C1)O[C@@H]5[C@]4(C=CO5)O,Active,,,,TROUT,MT. SHASTA RAINBOW,ORAL,4; 16; 32; 64 PPB IN DIET FOR 12 MO,LIVER: HEPATOMA,POSITIVE,"[SINNHUBER,RO, LEE,DJ, WALES,JH, LANDERS,MK AND KEYL,AC; HEPATIC CARCINOGENESIS OF AFLATOXIN M1 IN RAINBOW TROUT (SALMO GAIRDNERI) AND ITS ENHANCEMENT BY CYCLOPROPENE FATTY ACIDS; J. NATL. CANCER INST. 53:1285-1288, 1974]"
136,363897965,15558498,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4C(=C1)O[C@@H]5[C@]4(C=CO5)O,Active,,,,FISH,RAINBOW TROUT,ORAL,0; 1.5; 7.5; UG/KG DIET FOR 5.5 MO (STUDY DURATION: 5.5 MO),LIVER: HEPATOMA,POSITIVE,"[LAFONT,P, SIRIWARDANA,MG AND LAFONT,J; GENOTOXICITY OF HYDROXY-AFLATOXINS M1 AND M4; MICROBIOL., ALIMENTS, NUTR. 7(1):1-8,1989]"
137,363897965,15558498,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4C(=C1)O[C@@H]5[C@]4(C=CO5)O,Active,,,,RAT,F344/MALE,ORAL,0; 0.5; 5; 50 PPB IN AGAR BASED SEMISYNTHETIC DIET FOR STUDY DURATION (STUDY DURATION: 21 MO),"LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA",POSITIVE,"[HSIEH,DPH, CULLEN,JM AND RUEBNER,BH; COMPARATIVE HEPATOCARCINOGENICITY OF AFLATOXINS B1 AND M1 IN THE RAT; FOOD CHEM. TOXICOL. 22(12):1027-1028, 1984]"
138,363897966,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-230 Y82]"
139,363897966,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-230 Y82]"
140,363897966,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-230 Y82]"
141,363897966,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-230 Y82]"
142,363897967,2086,CC(C)(C=NOC(=O)NC)SC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2; 6 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-136 Y79]"
143,363897967,2086,CC(C)(C=NOC(=O)NC)SC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2; 6 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-136 Y79]"
144,363897967,2086,CC(C)(C=NOC(=O)NC)SC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2; 6 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-136 Y79]"
145,363897967,2086,CC(C)(C=NOC(=O)NC)SC,Inactive,,,,RAT,F344/MALE,ORAL,0; 2; 6 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-136 Y79]"
146,363897968,12310947,C1[C@@H]2C=C[C@H]1[C@H]3[C@@H]2[C@]4(C(=C([C@@]3(C4(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3; 6 PPM IN DIET FOR 80 WK (STUDY DURATION: 112-113 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-21 Y78]"
147,363897968,12310947,C1[C@@H]2C=C[C@H]1[C@H]3[C@@H]2[C@]4(C(=C([C@@]3(C4(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 4; 8 PPM IN DIET FOR 74 WK (STUDY DURATION: 111-112 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-21 Y78]"
148,363897968,12310947,C1[C@@H]2C=C[C@H]1[C@H]3[C@@H]2[C@]4(C(=C([C@@]3(C4(Cl)Cl)Cl)Cl)Cl)Cl,Unspecified,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 30; 60 PPM IN DIET FOR 80 WK (STUDY DURATION: 112-113 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA; ADRENAL GLAND: CORTICAL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-21 Y78]"
149,363897968,12310947,C1[C@@H]2C=C[C@H]1[C@H]3[C@@H]2[C@]4(C(=C([C@@]3(C4(Cl)Cl)Cl)Cl)Cl)Cl,Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 30; 60 PPM IN DIET FOR 74 WK (STUDY DURATION: 111-112 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-21 Y78]"
150,363897969,7850,C=CCCl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,0; 55; 73 MG/KG N CORN OIL 5 D/WK FOR 78 (STUDY DURATION: 108-111 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-73 Y78]"
151,363897969,7850,C=CCCl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,0; 57; 77 MG/KG IN CORN OIL 5 D/WK FOR 78 (STUDY DURATION: 108-111 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-73 Y78]"
152,363897969,7850,C=CCCl,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 172; 199 MG/KG IN CORN OIL 5 D/WK FOR 78 (STUDY DURATION: 92 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-73 Y78]"
153,363897969,7850,C=CCCl,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 129; 258 MG/KG IN CORN OIL 5 D/WK FOR 78 (STUDY DURATION: 92 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA OR PAPILLOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-73 Y78]"
154,363897970,5971,C=CCN=C=S,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 12; 25 MG/KG IN CORN OIL FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-234 Y82]"
155,363897970,5971,C=CCN=C=S,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 12; 25 MG/KG IN CORN OIL FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-234 Y82]"
156,363897970,5971,C=CCN=C=S,Active,,,,RAT,F344/MALE,GAVAGE,0; 12; 25 MG/KG IN CORN OIL FOR 103 WK (STUDY DURATION: 103 WK),URINARY BLADDER: TRANSITIONAL CELL PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-234 Y82]"
157,363897970,5971,C=CCN=C=S,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 12; 25 MG/KG IN CORN OIL FOR 103 WK (STUDY DURATION: 103 WK),INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-234 Y82]"
158,363897971,17816,CC(C)CC(=O)OCC=C,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 31; 62 MG/KG IN CORN OIL FOR 103 WK,LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-253 Y83]"
159,363897971,17816,CC(C)CC(=O)OCC=C,Active,,,,RAT,F344/MALE,GAVAGE,0; 31; 62 MG/KG IN CORN OIL FOR 103 WK,HEMATOPOIETIC SYSTEM (LEUKEMIA): MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-253 Y83]"
160,363897972,11937,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)N,Active,,,,HAMSTER,SYRIAN,DERMAL,"4 DROPS OF 1% SOLN IN ACETONE 2/WK FOR 10 WK, 8 DROPS FOR 40 WK, 4 DROPS FOR 5 WK","INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, EPIDERMAL TUMOR",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 2 464]"
161,363897972,11937,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)N,Active,,,,MOUSE,"MALE,FEMALE",DERMAL,"1% SATURATED SOLN IN ACETONE 2/WK (0.025 ML FOR 30 D OR 0.1 ML FOR 140 D), THEN 0.05 ML THEREAFTER",INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL EPITHELIOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 2 464]"
162,363897972,11937,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)N,Active,,,,RAT,ALBINO/MALE,DERMAL,1% IN ACETONE 2/WK FOR 34-36 WK,"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA, BASAL CELL EPITHELIOMA, FIBROSARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 572]"
163,363897972,11937,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)N,Active,,,,RAT,"F344/MALE,FEMALE",DERMAL,0.18 ML OF 1% SOLN IN ACETONE 2/WK FOR 180 OR 250-300 D,"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA, BASAL CELL EPITHELIOMA, FIBROSARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 572]"
164,363897972,11937,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0.05; 1.0; 2.5 MG IN 1 ML SESAME OIL 1/3 D FOR 10 D (TOTAL DOSE 0.5-25 MG),MAMMARY GLAND,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 352]"
165,363897972,11937,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)N,Active,,,,RAT,"HOLTZMAN/MALE,FEMALE",DERMAL,0.18 ML OF 1% SOLN IN ACETONE 2/WK FOR 180 OR 250-300 D,"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA, BASAL CELL EPITHELIOMA, FIBROSARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 572]"
166,363897972,11937,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)N,Active,,,,RAT,"LONG-EVANS/MALE,FEMALE",DERMAL,0.18 ML OF 1% SOLN IN ACETONE 2/WK FOR 180 OR 250-300 D,"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA, BASAL CELL EPITHELIOMA, FIBROSARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 572]"
167,363897973,8341,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C=C(C=C3)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.5; 1.0% OF DIET,LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-144 Y78]"
168,363897973,8341,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C=C(C=C3)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1.0% OF DIET,"LIVER: HEPATOCELLULAR CARCINOMA, ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-144 Y78]"
169,363897973,8341,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C=C(C=C3)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.35; 0.69% OF DIET,"LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-144 Y78]"
170,363897974,6051,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 53 Y75]"
171,363897974,6051,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,Active,,,,RAT,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 53 Y75]"
172,363897974,6051,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.3 UMOL/G IN TRIOCTANOIN ONCE ON DAY 1 FOLLOWED BY 0.4 UMOL/G ONCE ON DAY 8, 15 AND 22 (STUDY DURATION: UP TO 10 MO)",LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
173,363897974,6051,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 0.3 UMOL/G IN TRIOCTANOIN ONCE ON DAY 1 FOLLOWED BY 0.4 UMOL/G ONCE ON DAY 8, 15 AND 22 (STUDY DURATION: UP TO 10 MO)",,NEGATIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
174,363897974,6051,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.017; 0.05; 0.15; 0.45 UMOL/G ONCE IN TRIOCTANOIN (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
175,363897974,6051,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,Active,,,,MOUSE,C3H/MALE,INTRAPERITONEAL,0; 0.45 UMOL/G ONCE IN TRIOCTANOIN (STUDY DURATION: 11 MO),LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
176,363897974,6051,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,Active,,,,MOUSE,C57BL/MALE,INTRAPERITONEAL,0; 0.45 UMOL ONCE IN TRIOCTANOIN (STUDY DURATION: 11 MO),LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
177,363897974,6051,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,Inactive,,,,RAT,F344/MALE,INTRAPERITONEAL,"0; 0.3 UMOL/G IN TRIOCTANOIN ONCE ON DAY 1 FOLLOWED BY 0.4 UMOL/G ONCE ON D 8, 15 AND 22 (STUDY DURATION: 24 MO)",,NEGATIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
178,363897975,7340,CC1=CC=CC=C1N=NC2=CC(=C(C=C2)N)C,Active,,,,DOG,,ORAL,,LIVER; GALL BLADDER; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 61 Y75]"
179,363897975,7340,CC1=CC=CC=C1N=NC2=CC(=C(C=C2)N)C,Active,,,,HAMSTER,,ORAL,,LIVER; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 61 Y75]"
180,363897975,7340,CC1=CC=CC=C1N=NC2=CC(=C(C=C2)N)C,Active,,,,MOUSE,,"INTRAPERITONEAL, ORAL, SUBCUTANEOUS, DERMAL",,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 61 Y75]"
181,363897975,7340,CC1=CC=CC=C1N=NC2=CC(=C(C=C2)N)C,Active,,,,MOUSE,,"ORAL, SUBCUTANEOUS",,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 61 Y75]"
182,363897975,7340,CC1=CC=CC=C1N=NC2=CC(=C(C=C2)N)C,Active,,,,RAT,,"ORAL, SUBCUTANEOUS",,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 61 Y75]"
183,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,DOG,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 74 Y72]"
184,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,HUMAN,,"ORAL, INHALATION, DERMAL",,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 74 Y72]"
185,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,MOUSE,,ORAL,,URINARY BLADDER; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 74 Y72]"
186,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,MOUSE,,SUBCUTANEOUS,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 74 Y72]"
187,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,RABBIT,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 74 Y72]"
188,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,RAT,,SUBCUTANEOUS,,MAMMARY GLAND; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 74 Y72]"
189,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
190,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
191,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
192,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
193,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,MOUSE,BALB/CSTCRLFC3HF/NCTR/MALE,ORAL,0; 7; 14; 28; 55; 110; 220 PPM IN DRINKING WATER FOR 96 WK (STUDY DURATION: 96 WK),BLOOD VESSELS: ANGIOSARCOMA; BLADDER: CARCINOMA,POSITIVE,"[SCHIEFERSTEIN,GJ, LITTLEFIELD,NA, GAYLOR,DW, SHELDON,WG AND BURGER,GT; CARCINOGENESIS OF 4-AMINOBIPHENYL IN BALB/CSTCRLFC3HF/NCTR MICE; EUR. J. CANCER CLIN. ONCOL. 21(7):865-873, 1985]"
194,363897976,7102,C1=CC=C(C=C1)C2=CC=C(C=C2)N,Active,,,,MOUSE,BALB/CSTCRLFC3HF/NCTR/FEMALE,ORAL,0; 7; 19; 38; 75; 150; 300 PPM IN DRINKING WATER FOR 96 WK (STUDY DURATION: 96 WK),BLOOD VESSELS: ANGIOSARCOMA; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[SCHIEFERSTEIN,GJ, LITTLEFIELD,NA, GAYLOR,DW, SHELDON,WG AND BURGER,GT; CARCINOGENESIS OF 4-AMINOBIPHENYL IN BALB/CSTCRLFC3HF/NCTR MICE; EUR. J. CANCER CLIN. ONCOL. 21(7):865-873, 1985]"
195,363897977,5284347,C1=CC=C(C=C1)C2=CC=CC=C2N.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),"BLOOD VESSELS: HEMANGIOMA, HEMANGIOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-233 Y82]"
196,363897977,5284347,C1=CC=C(C=C1)C2=CC=CC=C2N.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-233 Y82]"
197,363897977,5284347,C1=CC=C(C=C1)C2=CC=CC=C2N.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-233 Y82]"
198,363897977,5284347,C1=CC=C(C=C1)C2=CC=CC=C2N.Cl,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),SPLEEN: HEMANGIOSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-233 Y82]"
199,363897978,49970,C1=CC2=NC3=C(N2C=C1)N=C(C=C3)N,Active,,,,RAT,F344/MALE,ORAL,0; 500 PPM IN DIET (AV DAILY DOSE: 7.5 MG) FOR 24 MO (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR CARCINOMA OR ANAPLASTIC HEPATOMA; SMALL INTESTINE: ADENOMA OR ADENOCARCINOMA OR MUCINOUS CARCINOMA; LARGE INTESTINE: ADENOMA OR ADENOCARCINOMA OR MUCINOUS CARCINOMA,POSITIVE,"[TAKAYAMA,S, MASUDA,M, MOGAMI,M, OHGAKI,H, SATO,S AND SUGIMURA,T; INDUCTION OF CANCERS IN THE INTESTINE, LIVER AND VARIOUS OTHER ORGANS OF RATS BY FEEDING MUTAGENS FROM GLUTAMIC ACID PYROLYSATE; GANN 75:207-213, 1984]"
200,363897978,49970,C1=CC2=NC3=C(N2C=C1)N=C(C=C3)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 500 PPM IN DIET (AV DAILY DOSE: 4.9 MG) FOR 24 MO (STUDY DURATION: 104 WK),SMALL INTESTINE: ADENOMA OR ADENOCARCINOMA OR MUCINOUS CARCINOMA; LARGE INTESTINE: ADENOMA OR ADENOCARCINOMA OR MUCINOUS CARCINOMA; ZYMBAL GLAND: SQUAMOUS CELL CARCINOMA; CLITORAL GLAND: TUMOR,POSITIVE,"[TAKAYAMA,S, MASUDA,M, MOGAMI,M, OHGAKI,H, SATO,S AND SUGIMURA,T; INDUCTION OF CANCERS IN THE INTESTINE, LIVER AND VARIOUS OTHER ORGANS OF RATS BY FEEDING MUTAGENS FROM GLUTAMIC ACID PYROLYSATE; GANN 75:207-213, 1984]"
201,363897978,49970,C1=CC2=NC3=C(N2C=C1)N=C(C=C3)N,Active,,,,MOUSE,CDF1/MALE,ORAL,0; 0.05% IN DIET FOR UP TO 685 D (STUDY DURATION: 685 D),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; BLOOD VESSELS: HEMANGIOENDOTHELIOMA OR HEMANGIOENDOTHELIAL SARCOMA,POSITIVE,"[OHGAKI,H, MATSUKURA,N, MORINO,K, KAWACHI,T, SUGIMURA,T AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM GLUTAMIC ACID AND SOYBEAN GLOBULIN PYROLYZATES; CARCINOGENESIS 5(6):815-819, 1984]"
202,363897978,49970,C1=CC2=NC3=C(N2C=C1)N=C(C=C3)N,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 0.05% IN DIET FOR UP TO 685 D (STUDY DURATION: 685 D),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; BLOOD VESSELS: HEMANGIOENDOTHELIOMA OR HEMANGIOENDOTHELIAL SARCOMA,POSITIVE,"[OHGAKI,H, MATSUKURA,N, MORINO,K, KAWACHI,T, SUGIMURA,T AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM GLUTAMIC ACID AND SOYBEAN GLOBULIN PYROLYZATES; CARCINOGENESIS 5(6):815-819, 1984]"
203,363897979,28207,CCOC1=C(C=C(C=C1)NC(=O)C)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.4; 0.8% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-112 Y78]"
204,363897979,28207,CCOC1=C(C=C(C=C1)NC(=O)C)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.4; 0.8% OF DIET,"THYROID GLAND: FOLLICULAR CELL ADENOMA, CARCINOMA, ADENOCARCINOMA, ADENOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-112 Y78]"
205,363897979,28207,CCOC1=C(C=C(C=C1)NC(=O)C)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.4; 1.5% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-112 Y78]"
206,363897979,28207,CCOC1=C(C=C(C=C1)NC(=O)C)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.4; 1.5% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-112 Y78]"
207,363897981,1539,C1C2=CC=CC=C2C3=C1C=C(C=C3)N,Active,,,,MOUSE,"MALE,FEMALE",DERMAL,"4% SOLN IN ACETONE, 90 APPLICATIONS (TOTAL DOSE: 270 MG)",LIVER: HEPATOMA; INTESTINES,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 2 462]"
208,363897981,1539,C1C2=CC=CC=C2C3=C1C=C(C=C3)N,Active,,,,RAT,HOLTZMAN/FEMALE,ORAL,1.62 MMOL/KG IN DIET,MAMMARY GLAND; EAR (DUCT),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 506]"
209,363897981,1539,C1C2=CC=CC=C2C3=C1C=C(C=C3)N,Active,,,,RAT,HOLTZMAN/MALE,ORAL,1.62 MMOL/KG IN DIET,LIVER; EAR (DUCT); INTESTINES (SMALL),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 506]"
210,363897981,1539,C1C2=CC=CC=C2C3=C1C=C(C=C3)N,Active,,,,RAT,WISTAR/MALE,DERMAL,4% SOLN IN ACETONE 3/WK FOR 30 WK (TOTAL DOSE: 270 MG),LIVER: HEPATOCELLULAR CARCINOMA; EAR (ZYMBAL GLAND): CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 580]"
211,363897981,1539,C1C2=CC=CC=C2C3=C1C=C(C=C3)N,Inactive,,,,RAT,F344/MALE,INJECTION,0; 1 UMOL IN 0.5 ML OF SOLUTION CONTAINING 0.4 ML PHOSPHATE BUFFERED SALINE/ GENTAMYCIN (PH 7) AND 0.1 ML DMSO INJECTED INTO HETEROTOPICALLY TRANSPLANTED BLADDERS 1/WK FOR 20 WK (STUDY DURATION: 50 WK),,NEGATIVE,"[WANG,CY, IMAIDA,K, ZUKOWSKI,K AND LEE,MS; LACK OF CARCINOGENICITY OF 2-AMINOFLUORENE, ITS GLUCURONIDE AND THE GLUCURONIDE OF N-HYDROXY-2- ACETYLAMINOFLUORENE IN HETEROTOPIC BLADDER OF THE RAT; CANCER LETT. 56(2):153-157, 1991]"
212,363897982,6702,CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.06% OF DIET (2 DOSAGE REGIMENS--A & B RECEIVING SAME CONC), TWA","LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-111 Y78]"
213,363897982,6702,CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.06% OF DIET (2 DOSAGE REGIMENS--A & B RECEIVING SAME CONC), TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-111 Y78]"
214,363897982,6702,CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.10; 0.20% OF DIET,"LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-111 Y78]"
215,363897982,6702,CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.10; 0.20% OF DIET,"LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE; KIDNEY: TUBULAR CELL ADENOMA, TUBULAR CELL ADENOCARCINOMA, ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-111 Y78]"
216,363897983,49971,CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,Active,,,,RAT,F344/MALE,ORAL,0; 500 PPM IN DIET (AV DAILY DOSE: 7.4 MG) FOR 24 MO (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR CARCINOMA OR ANAPLASTIC HEPATOMA; SMALL INTESTINE: ADENOMA OR ADENOCARCINOMA OR MUCINOUS CARCINOMA; LARGE INTESTINE: ADENOMA OR ADENOCARCINOMA OR MUCINOUS CARCINOMA; ZYMBAL GLAND: SQUAMOUS CELL CARCINOMA,POSITIVE,"[TAKAYAMA,S, MASUDA,M, MOGAMI,M, OHGAKI,H, SATO,S AND SUGIMURA,T; INDUCTION OF CANCERS IN THE INTESTINE, LIVER AND VARIOUS OTHER ORGANS OF RATS BY FEEDING MUTAGENS FROM GLUTAMIC ACID PYROLYSATE; GANN 75:207-213, 1984]"
217,363897983,49971,CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 500 PPM IN DIET (AV DAILY DOSE: 4.3 MG) FOR 24 MO (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR CARCINOMA OR ANAPLASTIC HEPATOMA; SMALL INTESTINE: ADENOMA OR ADENOCARCINOMA OR MUCINOUS CARCINOMA; LARGE INTESTINE: ADENOMA OR ADENOCARCINOMA OR MUCINOUS CARCINOMA; ZYMBAL GLAND: SQUAMOUS CELL CARCINOMA,POSITIVE,"[TAKAYAMA,S, MASUDA,M, MOGAMI,M, OHGAKI,H, SATO,S AND SUGIMURA,T; INDUCTION OF CANCERS IN THE INTESTINE, LIVER AND VARIOUS OTHER ORGANS OF RATS BY FEEDING MUTAGENS FROM GLUTAMIC ACID PYROLYSATE; GANN 75:207-213, 1984]"
218,363897983,49971,CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,Active,,,,MOUSE,CDF1/MALE,ORAL,0; 0.05% IN DIET FOR 12 MO (STUDY DURATION: 12 MO),BROWN ADIPOSE TISSUE: HEMANGIOENDOTHELIAL SARCOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: PULMONARY ADENOMA OR CARCINOMA,POSITIVE,"[SAKAMOTO,M, TAKAYAMA,S AND HOSODA,Y; HEMANGIOENDOTHELIAL SARCOMA IN BROWN ADIPOSE TISSUE OF MOUSE INDUCED BY CARCINOGENIC HETEROCYCLIC AMINE, GLU-P-1; TOXICOL. PATHOL. 17(4, PT.2):754-758, 1989]"
219,363897983,49971,CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
220,363897983,49971,CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
221,363897983,49971,CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
222,363897983,49971,CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
223,363897983,49971,CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,Active,,,,MOUSE,CDF1/MALE,ORAL,0; 0.05% IN DIET FOR UP TO 685 D (STUDY DURATION: 685 D),BLOOD VESSELS: HEMANGIOENDOTHELIOMA OR HEMANGIOENDOTHELIAL SARCOMA,POSITIVE,"[OHGAKI,H, MATSUKURA,N, MORINO,K, KAWACHI,T, SUGIMURA,T AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM GLUTAMIC ACID AND SOYBEAN GLOBULIN PYROLYZATES; CARCINOGENESIS 5(6):815-819, 1984]"
224,363897983,49971,CC1=CC=CN2C1=NC3=C2N=C(C=C3)N,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 0.05% IN DIET FOR UP TO 685 D (STUDY DURATION: 685 D),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; BLOOD VESSELS: HEMANGIOENDOTHELIOMA OR HEMANGIOENDOTHELIAL SARCOMA,POSITIVE,"[OHGAKI,H, MATSUKURA,N, MORINO,K, KAWACHI,T, SUGIMURA,T AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM GLUTAMIC ACID AND SOYBEAN GLOBULIN PYROLYZATES; CARCINOGENESIS 5(6):815-819, 1984]"
225,363897984,62244,CC1=CC2=C(NC3=CC=CC=C32)N=C1N,Active,,,,MOUSE,CDF1/MALE,ORAL,0; 0.05% IN DIET FOR UP TO 685 D (STUDY DURATION: 685 D),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; BLOOD VESSELS: HEMANGIOENDOTHELIOMA OR HEMANGIOENDOTHELIAL SARCOMA,POSITIVE,"[OHGAKI,H, MATSUKURA,N, MORINO,K, KAWACHI,T, SUGIMURA,T AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM GLUTAMIC ACID AND SOYBEAN GLOBULIN PYROLYZATES; CARCINOGENESIS 5(6):815-819, 1984]"
226,363897984,62244,CC1=CC2=C(NC3=CC=CC=C32)N=C1N,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 0.08% IN DIET FOR UP TO 685 D (STUDY DURATION: 685 D),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; BLOOD VESSELS: HEMANGIOENDOTHELIOMA OR HEMANGIOENDOTHELIAL SARCOMA,POSITIVE,"[OHGAKI,H, MATSUKURA,N, MORINO,K, KAWACHI,T, SUGIMURA,T AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM GLUTAMIC ACID AND SOYBEAN GLOBULIN PYROLYZATES; CARCINOGENESIS 5(6):815-819, 1984]"
227,363897984,62244,CC1=CC2=C(NC3=CC=CC=C32)N=C1N,Active,,,,RAT,F344/MALE,ORAL,0; 0.01; 0.02% IN DIET FOR 100 WK (STUDY DURATION: 100 WK),LIVER: HEPATOCELLULAR CARCINOMA; PANCREAS: ACINAR CELL ADENOMA; SKIN (SUBCUTIS): FIBROMA,POSITIVE,"[TAMANO,S, HASEGAWA,R, HAGIWARA,A, NAGAO,M, SUGIMURA,T AND ITO,N; CARCINOGENICITY OF A MUTAGENIC COMPOUND FROM FOOD, 2-AMINO-3-METHYL-9H-PYRIDO [2,3-B]INDOLE (MEAALPHAC), IN MALE F344 RATS; CARCINOGENESIS 15(9):2009-2015, 1994]"
228,363897985,61205,C1=C(OC(=C1)[N+](=O)[O-])C2=NN=C(S2)N,Active,,,,RAT,,ORAL,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 143 Y74]"
229,363897986,3417419,C1=CC(=C(C=C1N)[N+](=O)[O-])O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 2500 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-94 Y78]"
230,363897986,3417419,C1=CC(=C(C=C1N)[N+](=O)[O-])O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1250; 2500 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-94 Y78]"
231,363897986,3417419,C1=CC(=C(C=C1N)[N+](=O)[O-])O,Active,,,,RAT,F344/MALE,ORAL,0; 1250; 2500 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-94 Y78]"
232,363897986,3417419,C1=CC(=C(C=C1N)[N+](=O)[O-])O,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 1250; 2500 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),BLADDER: CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-94 Y78]"
233,363897987,8486,C1=C(SC(=N1)N)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 50; 100 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-53 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V31 71 Y83]"
234,363897987,8486,C1=C(SC(=N1)N)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 50; 100 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-53 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V31 71 Y83]"
235,363897987,8486,C1=C(SC(=N1)N)[N+](=O)[O-],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 300; 600 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-53 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V31 71 Y83]"
236,363897988,62805,C1=CC=C2C(=C1)C3=C(N2)N=C(C=C3)N,Active,,,,MOUSE,CDF1/MALE,ORAL,0; 0.08% IN DIET FOR UP TO 685 D (STUDY DURATION: 685 D),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; BLOOD VESSELS: HEMANGIOENDOTHELIOMA OR HEMANGIOENDOTHELIAL SARCOMA,POSITIVE,"[OHGAKI,H, MATSUKURA,N, MORINO,K, KAWACHI,T, SUGIMURA,T AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM GLUTAMIC ACID AND SOYBEAN GLOBULIN PYROLYZATES; CARCINOGENESIS 5(6):815-819, 1984]"
237,363897988,62805,C1=CC=C2C(=C1)C3=C(N2)N=C(C=C3)N,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 0.08% IN DIET FOR UP TO 685 D (STUDY DURATION: 685 D),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; BLOOD VESSELS: HEMANGIOENDOTHELIAL SARCOMA,POSITIVE,"[OHGAKI,H, MATSUKURA,N, MORINO,K, KAWACHI,T, SUGIMURA,T AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM GLUTAMIC ACID AND SOYBEAN GLOBULIN PYROLYZATES; CARCINOGENESIS 5(6):815-819, 1984]"
238,363897988,62805,C1=CC=C2C(=C1)C3=C(N2)N=C(C=C3)N,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 75 MG/KG IN 5 ML CORN OIL 1/D ON DAYS 43-47 AND 50-54 OF AGE ADMINISTERED TO RATS PLACED ON HIGH-FAT (23.5% CORN OIL) DIETS 2 D POST DOSING (STUDY DURATION: 50 WK),,NEGATIVE,"[SNYDERWINE,EG, SADRIEH,N, KING,RS AND SCHUT,HAJ; FORMATION OF DNA ADDUCTS OF THE FOOD-DERIVED MUTAGEN 2-AMINO-9H-PYRIDO[2,3-B]INDOLE (A(ALPHA)C) AND BIOASSAY OF MAMMARY GLAND CARCINOGENICITY IN SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 36(12):1033-1041, 1998]"
239,363897989,17083,C(CCCCCN)CCCCC(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 7500; 15000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-216 Y82]"
240,363897989,17083,C(CCCCCN)CCCCC(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 7500; 15000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-216 Y82]"
241,363897989,17083,C(CCCCCN)CCCCC(=O)O,Active,,,,RAT,F344/MALE,ORAL,0; 7500; 15000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),LIVER: NEOPLASTIC NODULE; URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-216 Y82]"
242,363897989,17083,C(CCCCCN)CCCCC(=O)O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 7500; 15000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-216 Y82]"
243,363897990,1639,C1=NNC(=N1)N,Active,,,,MOUSE,,ORAL,,LIVER; THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 31 Y74]"
244,363897990,1639,C1=NNC(=N1)N,Active,,,,RAT,,ORAL,,LIVER; THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 31 Y74]"
245,363897990,1639,C1=NNC(=N1)N,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE; LIVER; THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 31 Y74]"
246,363897990,1639,C1=NNC(=N1)N,Active,,,,RAT,WISTAR/MALE,ORAL,0; 1; 10; 100 PPM IN DIET (TOTAL DOSE: 0; 0.06; 0.6; 5.8 G/KG) FOR 1137-1143 D (STUDY DURATION: LIFETIME),THYROID GLAND: MALIGNANT TUMOR,POSITIVE,"[STEINHOFF,D, WEBER,H, MOHR,U AND BOEHME,K; EVALUATION OF AMITROLE (AMINOTRIAZOLE) FOR POTENTIAL CARCINOGENICITY IN ORALLY DOSED RATS, MICE, AND GOLDEN HAMSTERS; TOXICOL. APPL. PHARMACOL. 69:161-169, 1983]"
247,363897990,1639,C1=NNC(=N1)N,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 1; 10; 100 PPM IN DIET (TOTAL DOSE: 0; 0.08; 0.8; 7.9 G/KG) FOR 1140-1143 D (STUDY DURATION: LIFETIME),THYROID GLAND: MALIGNANT TUMOR,POSITIVE,"[STEINHOFF,D, WEBER,H, MOHR,U AND BOEHME,K; EVALUATION OF AMITROLE (AMINOTRIAZOLE) FOR POTENTIAL CARCINOGENICITY IN ORALLY DOSED RATS, MICE, AND GOLDEN HAMSTERS; TOXICOL. APPL. PHARMACOL. 69:161-169, 1983]"
248,363897990,1639,C1=NNC(=N1)N,Inactive,,,,MOUSE,NMRI/MALE,ORAL,0; 1; 10; 100 PPM IN DIET (TOTAL DOSE: 0; 0.13; 1.3; 13.1 G/KG) FOR 1022-1028 D (STUDY DURATION: LIFETIME),,NEGATIVE,"[STEINHOFF,D, WEBER,H, MOHR,U AND BOEHME,K; EVALUATION OF AMITROLE (AMINOTRIAZOLE) FOR POTENTIAL CARCINOGENICITY IN ORALLY DOSED RATS, MICE, AND GOLDEN HAMSTERS; TOXICOL. APPL. PHARMACOL. 69:161-169, 1983]"
249,363897990,1639,C1=NNC(=N1)N,Inactive,,,,MOUSE,NMRI/FEMALE,ORAL,0; 1; 10; 100 PPM IN DIET (TOTAL DOSE: 0; 0.17; 1.7; 18.2 G/KG) FOR 970-1027 D (STUDY DURATION: LIFETIME),,NEGATIVE,"[STEINHOFF,D, WEBER,H, MOHR,U AND BOEHME,K; EVALUATION OF AMITROLE (AMINOTRIAZOLE) FOR POTENTIAL CARCINOGENICITY IN ORALLY DOSED RATS, MICE, AND GOLDEN HAMSTERS; TOXICOL. APPL. PHARMACOL. 69:161-169, 1983]"
250,363897990,1639,C1=NNC(=N1)N,Inactive,,,,HAMSTER,SYRIAN/MALE,ORAL,0; 1; 10; 100 PPM IN DIET (TOTAL DOSE: 0; 0.08; 0.8; 7.2 G/KG) FOR 885-979 D (STUDY DURATION: LIFETIME),,NEGATIVE,"[STEINHOFF,D, WEBER,H, MOHR,U AND BOEHME,K; EVALUATION OF AMITROLE (AMINOTRIAZOLE) FOR POTENTIAL CARCINOGENICITY IN ORALLY DOSED RATS, MICE, AND GOLDEN HAMSTERS; TOXICOL. APPL. PHARMACOL. 69:161-169, 1983]"
251,363897990,1639,C1=NNC(=N1)N,Inactive,,,,HAMSTER,SYRIAN/FEMALE,ORAL,0; 1; 10; 100 PPM IN DIET (TOTAL DOSE: 0; 0.07; 0.6; 6.6 G/KG) FOR 822-856 D (STUDY DURATION: LIFETIME),,NEGATIVE,"[STEINHOFF,D, WEBER,H, MOHR,U AND BOEHME,K; EVALUATION OF AMITROLE (AMINOTRIAZOLE) FOR POTENTIAL CARCINOGENICITY IN ORALLY DOSED RATS, MICE, AND GOLDEN HAMSTERS; TOXICOL. APPL. PHARMACOL. 69:161-169, 1983]"
252,363897992,38052,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)N,Active,,,,RAT,F344/FEMALE,ORAL,0.166% IN DIET FOR 52 WK,"FORESTOMACH: PAPILLOMA, CARCINOMA; URINARY BLADDER: PAPILLOMA, CARCINOMA",POSITIVE,"[WANG,CY, KAMIRYO,Y AND CROFT,WA; CARCINOGENICITY OF 2-AMINO-4-(5-NITRO- 2-FURYL)THIAZOLE IN RATS BY ORAL AND SUBCUTANEOUS ADMINISTRATION; CARCINOGENESIS 3:275-277, 1982]"
253,363897992,38052,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)N,Active,,,,RAT,"F344/MALE,FEMALE",SUBCUTANEOUS,"10 MG/KG IN DMSO:WATER 1/WK FOR 8 WK, THEN 1.4 MG/RAT 1/WK FOR 46 WK",INJECTION SITE: SARCOMA,POSITIVE,"[WANG,CY, KAMIRYO,Y AND CROFT,WA; CARCINOGENICITY OF 2-AMINO-4-(5-NITRO- 2-FURYL)THIAZOLE IN RATS BY ORAL AND SUBCUTANEOUS ADMINISTRATION; CARCINOGENESIS 3:275-277, 1982]"
254,363897993,7541,C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-104 Y78]"
255,363897993,7541,C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-104 Y78]"
256,363897993,7541,C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Cl)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-104 Y78]"
257,363897993,7541,C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Cl)Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-104 Y78]"
258,363897993,7541,C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Cl)Cl)Cl,Inactive,,,,Mouse,CD-1/Male,Oral,0; 50; 250; 1250 ppm in feed for 2 yrs,,Negative; Purity 93.5%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ANILAZINE (MARCH 17, 1999)]"
259,363897993,7541,C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Cl)Cl)Cl,Inactive,,,,Mouse,CD-1/Female,Oral,0; 50; 250; 1250 ppm in feed for 2 yrs,,Negative; Purity 93.5%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ANILAZINE (MARCH 17, 1999)]"
260,363897993,7541,C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Cl)Cl)Cl,Inactive,,,,Rat,Sprague Dawley/Male,Oral,0; 50; 330; 2000 ppm in feed for 104 wks,,Negative; Purity 93.5%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ANILAZINE (MARCH 17, 1999)]"
261,363897993,7541,C1=CC=C(C(=C1)NC2=NC(=NC(=N2)Cl)Cl)Cl,Inactive,,,,Rat,Sprague Dawley/Female,Oral,0; 50; 330; 2000 ppm in feed for 104 wks,,Negative; Purity 93.5%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ANILAZINE (MARCH 17, 1999)]"
262,363897994,6115,C1=CC=C(C=C1)N,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.15 UMOL/G ONCE IN SODIUM ACETATE BUFFER (STUDY DURATION: 10 MO),,NEGATIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
263,363897995,8870,C1=CC=C(C=C1)N.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.6; 1.2% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-130 Y78]"
264,363897995,8870,C1=CC=C(C=C1)N.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.6; 1.2% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-130 Y78]"
265,363897995,8870,C1=CC=C(C=C1)N.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.3; 0.6% OF DIET,"SPLEEN OR BODY CAVITIES (BOTH PLEURAL AND PERITONEAL): FIBROSARCOMA OR SARCOMA, NOS",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-130 Y78]"
266,363897995,8870,C1=CC=C(C=C1)N.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 0.3; 0.6% OF DIET,"SPLEEN AND BODY CAVITIES (BOTH PLEURAL AND PERITONEAL): FIBROSARCOMA OR SARCOMA, NOS, HEMANGIOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-130 Y78]"
267,363897995,8870,C1=CC=C(C=C1)N.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 108 WK),SPLEEN OR PERITONEUM: SARCOMA,POSITIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
268,363897995,8870,C1=CC=C(C=C1)N.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 108 WK),SPLEEN OR PERITONEUM: SARCOMA,POSITIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
269,363897996,8638,COC1=CC=CC=C1N.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),"URINARY BLADDER: TRANSITIONAL CELL CARCINOMA, TRANSITIONAL CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-89 Y78]"
270,363897996,8638,COC1=CC=CC=C1N.Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104-105 WK),"URINARY BLADDER: TRANSITIONAL CELL CARCINOMA, TRANSITIONAL CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-89 Y78]"
271,363897996,8638,COC1=CC=CC=C1N.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 83-103 WK (STUDY DURATION: 83-107 WK),"URINARY BLADDER: TRANSITIONAL CELL CARCINOMA, TRANSITIONAL CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-89 Y78]"
272,363897996,8638,COC1=CC=CC=C1N.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 88-103 WK (STUDY DURATION: 88-106 WK),"KIDNEY OR KIDNEY (PELVIS): TRANSITIONAL CELL CARCINOMA; URINARY BLADDER: TRANSITIONAL CELL CARCINOMA, TRANSITIONAL CELL PAPILLOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR FOLLICULAR CELL CARCINOMA OR CYSTADENOMA (NOS) OR PAPILLARY CYSTADENOMA OR PAPILLARY CYSTADENOCARCINOMA (NOS)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-89 Y78]"
273,363897997,2734956,COC1=CC=C(C=C1)N.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.5; 1.0% OF DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-116 Y78]"
274,363897997,2734956,COC1=CC=C(C=C1)N.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1.0% OF DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-116 Y78]"
275,363897997,2734956,COC1=CC=C(C=C1)N.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.3; 0.6% OF DIET FOR 103 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-116 Y78]"
276,363897997,2734956,COC1=CC=C(C=C1)N.Cl,Unspecified,,,,RAT,F344/MALE,ORAL,0; 0.3; 0.6% OF DIET FOR 103 WK (STUDY DURATION: 104-105 WK),PREPUTIAL GLAND: ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-116 Y78]"
277,363897998,9118,C1=CC2=C3C(=C1)C=C4C=CC5=C6C4=C3C(=CC6=CC=C5)C=C2,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[CAVALIERI,E, MAILANDER,P AND PELFRENE,A; CARCINOGENIC ACTIVITY OF ANTHANTHRENE ON MOUSE SKIN; Z. KREBSFORSCH. 89(2):113-118, 1977]"
278,363897998,9118,C1=CC2=C3C(=C1)C=C4C=CC5=C6C4=C3C(=CC6=CC=C5)C=C2,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.16; 0.83 MG IN BEESWAX/TRIOCTANOIN (STUDY DURATION: LIFETIME),LUNG: EPIDERMOID CARCINOMA,POSITIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G, DETTBARN,G AND MISFELD,J; EXPERIMENTAL STUDIES IN RAT LUNGS ON THE CARCINOGENICITY AND DOSE- RESPONSE RELATIONSHIPS OF EIGHT FREQUENTLY OCCURRING ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS; J. NATL. CANCER INST. 71(3):539-544, 1983]"
279,363897999,227,C1=CC=C(C(=C1)C(=O)O)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-36 Y78]"
280,363897999,227,C1=CC=C(C(=C1)C(=O)O)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-36 Y78]"
281,363897999,227,C1=CC=C(C(=C1)C(=O)O)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 15000; 30000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-36 Y78]"
282,363897999,227,C1=CC=C(C(=C1)C(=O)O)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 15000; 30000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-36 Y78]"
283,363898000,24666,CCOC1=CC=C(C=C1)NC(=O)C.CC(=O)OC1=CC=CC=C1C(=O)O.CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.7; 1.4% OF DIET FOR 78 WK (STUDY DURATION: 94 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-67 Y78]"
284,363898000,24666,CCOC1=CC=C(C=C1)NC(=O)C.CC(=O)OC1=CC=CC=C1C(=O)O.CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.7; 1.4% OF DIET FOR 78 WK (STUDY DURATION: 94 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-67 Y78]"
285,363898000,24666,CCOC1=CC=C(C=C1)NC(=O)C.CC(=O)OC1=CC=CC=C1C(=O)O.CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.7; 1.4% OF DIET FOR 78 WK (STUDY DURATION: 113 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-67 Y78]"
286,363898000,24666,CCOC1=CC=C(C=C1)NC(=O)C.CC(=O)OC1=CC=CC=C1C(=O)O.CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 0.7; 1.4% OF DIET FOR 78 WK (STUDY DURATION: 113 WK),"BLADDER: TRANSITIONAL CELL CARCINOMA; KIDNEY: TUBULAR CELL ADENOCARCINOMA, TRANSITIONAL CELL PAPILLOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-67 Y78]"
287,363898001,8809,CC(COC1=CC=C(C=C1)C(C)(C)C)OS(=O)OCCCl,Active,,,,DOG,"MONGREL/MALE,FEMALE",ORAL,0; 500; 828-1420 PPM IN DIET FOR 3.5 YR,BILE DUCT: ADENOCARCINOMA; GALL BLADDER: ADENOCARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 39 Y74]"
288,363898001,8809,CC(COC1=CC=C(C=C1)C(C)(C)C)OS(=O)OCCCl,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE/ORAL,464 MG/KG FROM D 7-28 OF LIFE THEN 1112 PPM IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 39 Y74]"
289,363898001,8809,CC(COC1=CC=C(C=C1)C(C)(C)C)OS(=O)OCCCl,Active,,,,RAT,"WISTAR/MALE,FEMALE",ORAL,500; 1580; 5000 PPM IN DIET FOR 2 YR,"LIVER: HEPATOMA, CHOLANGIOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 39 Y74]"
290,363898002,56841539,COC1=CC=CC2=C3C(=C(C=C21)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O.COC1=CC=CC2=C3C(=C(C=C21)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O.C1OC2=C(O1)C3=C(C(=C2)C(=O)O)C(=CC4=CC=CC=C43)[N+](=O)[O-],Active,,,,RAT,WISTAR/FEMALE,GAVAGE,"0.1; 1.0; 10 MG/KG/D, 7 D/WK FOR 3 MO (LOW DOSE ALSO GIVEN FOR 6 OR 12 MO)","FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[MENGS,U, LANG,W AND POCH,JA; THE CARCINOGENIC ACTION OF ARISTOLOCHIC ACID IN RATS; ARCH. TOXICOL. 51:107-119, 1982]"
291,363898002,56841539,COC1=CC=CC2=C3C(=C(C=C21)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O.COC1=CC=CC2=C3C(=C(C=C21)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O.C1OC2=C(O1)C3=C(C(=C2)C(=O)O)C(=CC4=CC=CC=C43)[N+](=O)[O-],Active,,,,RAT,WISTAR/MALE,GAVAGE,"0.1; 1.0; 10 MG/KG/D, 7 D/WK FOR 3 MO (LOW DOSE ALSO GIVEN FOR 6 OR 12 MO)","FORESTOMACH: PAPILLOMA, CARCINOMA; URINARY BLADDER: PAPILLOMA, CARCINOMA; KIDNEY: CARCINOMA",POSITIVE,"[MENGS,U, LANG,W AND POCH,JA; THE CARCINOGENIC ACTION OF ARISTOLOCHIC ACID IN RATS; ARCH. TOXICOL. 51:107-119, 1982][MENGS,U; ON THE HISTOPATHOGENESIS OF RAT FORESTOMACH CARCINOMA CAUSED BY ARISTOLOCHIC; ACID  ARCH. TOXICOL. 52:209-220, 1983]"
292,363898004,4909,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 600; 1300; 2500 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-476 Y00]"
293,363898004,4909,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 300; 600; 1300 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, OR HEPATOBLASTOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-476 Y00]"
294,363898004,4909,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 300; 600; 1300 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, OR HEPATOBLASTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-476 Y00]"
295,363898004,4909,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,Unspecified,,,,RAT,F344/MALE,ORAL,0; 600; 1300; 2500 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL ADENOMA OR CARCINOMA; KIDNEY: RENAL TUBULE ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-476 Y00]"
296,363898005,5359596,[As],Active,,,,HUMAN,,"INHALATION, ORAL",,LUNG; INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 48 Y73]"
297,363898006,,,Active,,,,HUMAN,,"ORAL, INHALATION",,LUNG; LARYNX; BODY CAVITIES: MESOTHELIOMA; GASTROINTESTINAL TRACT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 62 Y77]"
298,363898007,54670067,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-247 Y83][DOUGLAS,JF AND HUFF,J; NO EVIDENCE OF CARCINOGENICITY FOR L-ASCORBIC ACID (VITAMIN C) IN RODENTS; J. TOXICOL. ENVIRON. HEALTH 14:605-609, 1984, ]"
299,363898007,54670067,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-247 Y83][DOUGLAS,JF AND HUFF,J; NO EVIDENCE OF CARCINOGENICITY FOR L-ASCORBIC ACID (VITAMIN C) IN RODENTS; J. TOXICOL. ENVIRON. HEALTH 14:605-609, 1984, ]"
300,363898007,54670067,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-247 Y83][DOUGLAS,JF AND HUFF,J; NO EVIDENCE OF CARCINOGENICITY FOR L-ASCORBIC ACID (VITAMIN C) IN RODENTS; J. TOXICOL. ENVIRON. HEALTH 14:605-609, 1984, ]"
301,363898007,54670067,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-247 Y83][DOUGLAS,JF AND HUFF,J; NO EVIDENCE OF CARCINOGENICITY FOR L-ASCORBIC ACID (VITAMIN C) IN RODENTS; J. TOXICOL. ENVIRON. HEALTH 14:605-609, 1984, ]"
302,363898007,54670067,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,Inactive,,,,Rat,F344/Male (9-15/group),Oral,0; 1%; 1% with 0.2% sodium nitrite in diet for 32 wk; study duration 32 wk in surgically altered rats to produce chronic acid reflux esophagitis,Esophagus examined,Negative (Significant increase in hyperplasia observed in combined chemical group. Low survival rate complicates interpretation of study),"[YUICHI,K OKAMURA,T ISHII,Y UMEMURA,T TASAKI,M KANKI,K MITSUMORI,K HIROSE,M AND NIHIKAWA,A; ENHANCEMENT OF ESOPHAGEAL CARCINOGENESIS IN ACID REFLUX MODEL RATS TREATED WITH ASCORBIC ACID AND SODIUM NITRITE IN COMBINATION WITH OR WITHOUT INITIATION; CANCER SCIENCE 99(1):7-13, 2008]"
303,363898008,10298,CN(C)C1=CC=C(C=C1)C(=N)C2=CC=C(C=C2)N(C)C,Active,,,,HUMAN,,"ORAL, INHALATION, DERMAL",,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 69 Y72]"
304,363898008,10298,CN(C)C1=CC=C(C=C1)C(=N)C2=CC=C(C=C2)N(C)C,Active,,,,MOUSE,,ORAL,,LIVER; LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 69 Y72]"
305,363898008,10298,CN(C)C1=CC=C(C=C1)C(=N)C2=CC=C(C=C2)N(C)C,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 69 Y72]"
306,363898008,10298,CN(C)C1=CC=C(C=C1)C(=N)C2=CC=C(C=C2)N(C)C,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 69 Y72]"
307,363898009,,,Active,,,,MOUSE,,INTRAPERITONEAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 39 Y77]"
308,363898010,9444,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,33; 62; 90 MG/KG IN STEROID SUSPENDING VEHICLE (TOTAL DOSES),LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 37 Y81][STONER,GD, SHIMKIN,MB, KNIAZEFF,AJ, WEISBURGER,JH, WEISBURGER,EK AND GORI,G; TEST FOR CARCINOGENICITY OF FOOD ADDITIVES AND CHEMOTHERAPEUTIC AGENTS BY THE PULMONARY TUMOR RESPONSE IN STRAIN A MICE; CANCER RES. 33:3069-3085, 1973, ]"
309,363898010,9444,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Active,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,0; 2.2; 4.4 MG/KG 3/WK FOR 52 WKS,HEMATOPOIETIC SYSTEM: GRANULOCYTIC LEUKEMIA OR GRANULOCYTIC SARCOMA; MULTIPLE SITES: LYMPHOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-42 Y78]"
310,363898010,9444,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Inactive,,,,HAMSTER,"SYRIAN/MALE, FEMALE",INTRAPERITONEAL,"0; 5 MG/KG 2/WK UNTIL SACRIFICE AT 7, 15, 21, 27, 52, 61 AND 70 WK (STUDY DURATION: 70 WK)",,NEGATIVE,"[HAMMOND,WG, YELLIN,A, GABRIEL,A, PALADUGU,RR, AZUMI,N, HILL,LR AND BENFIELD,JR; EFFECTS OF 5-AZACYTIDINE IN SYRIAN GOLDEN HAMSTERS: TOXICITY, TUMORIGENICITY, AND DIFFERENTIAL MODULATION OF BRONCHIAL CARCINOGENESIS; EXP. MOL. PATHOL. 53(1):34-51, 1990]"
311,363898010,9444,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Active,,,,RAT,F344/MALE,INTRAPERITONEAL,0; 2.5; 10 MG/KG 2/WK FOR 9 MO (STUDY DURATION: 18 MO),TESTIS: INTERSTITIAL CELL TUMOR; SKIN: TUMOR,POSITIVE,"[CARR,BI, REILLY,JG, SMITH,SS, WINBERG,C AND RIGGS,A; THE TUMORIGENICITY OF 5-AZACYTIDINE IN THE MALE FISCHER RAT; CARCINOGENESIS 5(12):1583-1590, 1984]"
312,363898010,9444,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Active,,,,RAT,F344/MALE,INTRAPERITONEAL,0; 0.025; 0.25; 2.5 MG/KG IN 0.9% SALINE 3/WK FOR 1 YR (STUDY DURATION: 1 YR),TESTIS: TUMOR,POSITIVE,"[CARR,BI, RAHBAR,S, ASMERON,Y, RIGGS,A AND WINBERG,CD; CARCINOGENICITY AND HAEMOGLOBIN SYNTHESIS INDUCTION BY CYTIDINE ANALOGUES; BR. J. CANCER 57:395-402, 1988]"
313,363898011,460129,C([C@@H](C(=O)O)N)OC(=O)C=[N+]=[N-],Active,,,,RAT,"WISTAR/MALE,FEMALE",INTRAPERITONEAL,5 MG/KG 1-2 TIMES PER WK FOR 6 MO,"KIDNEY: PAPILLARY EPITHELIAL TUMOR, CLEAR CELL TUMOR, TUBULAR ADENOMA; PANCREAS: ADENOCARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 73 Y76]"
314,363898012,2265,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Active,,,,MOUSE,"SWISS/MALE,FEMALE",INTRAPERITONEAL,40 MG/KG IN NAOH-SALINE 1/D ON D 1-4 AFTER BIRTH,HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 47 Y81]"
315,363898012,2265,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Active,,,,RAT,"F344/MALE,FEMALE",ORAL,150 MG/KG IN DIET FOR 52 WK,EAR: SQUAMOUS CELL CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 47 Y81]"
316,363898012,2265,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,1.5; 2.2 G/RAT IN DIET (ESTIMATED TOTAL),THYMUS GLAND: LYMPHOMA; EAR (DUCT): SQUAMOUS CELL CARCINOMA,POSITIVE,"[COHEN,SM, ERTURK,E, SKIBBA,JL AND BRYAN,GT;AZATHIOPRINE INDUCTION OF LYMPHOMAS AND SQUAMOUS CELL CARCINOMAS IN RATS; CANCER RES. 43:2768-2772, 1983]"
317,363898012,2265,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5; 20 PPM IN DIET FOR 100 WK (STUDY DURATION: 100 WK),HEMATOPOIETIC SYSTEM: LYMPHOMA; UTERUS: HEMANGIODOTHELIOMA,POSITIVE,"[ITO,A, MORI,M AND NAITO,M; INDUCTION OF UTERINE HEMANGIOENDOTHELIOMA AND LYMPHOMA IN (C57BL/6N X C3H/2N)F1 MICE BY ORAL ADMINISTRATION OF AZATHIOPRINE; JPN. J. CANCER RES. 80(5):419-423, 1989]"
318,363898012,2265,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5; 20 PPM IN DIET FOR 100 WK (STUDY DURATION: 100 WK),,NEGATIVE,"[ITO,A, MORI,M AND NAITO,M; INDUCTION OF UTERINE HEMANGIOENDOTHELIOMA AND LYMPHOMA IN (C57BL/6N X C3H/2N)F1 MICE BY ORAL ADMINISTRATION OF AZATHIOPRINE; JPN. J. CANCER RES. 80(5):419-423, 1989]"
319,363898013,2268,COP(=S)(OC)SCN1C(=O)C2=CC=CC=C2N=N1,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 62.5; 125 PPM IN DIET FOR 80 WK (STUDY DURATION: 92-93 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-69 Y78]"
320,363898013,2268,COP(=S)(OC)SCN1C(=O)C2=CC=CC=C2N=N1,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 31.3; 62.5 PPM IN DIET FOR 80 WK (STUDY DURATION: 92-93 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-69 Y78]"
321,363898013,2268,COP(=S)(OC)SCN1C(=O)C2=CC=CC=C2N=N1,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 62.5; 125 PPM IN DIET FOR 80 WK (STUDY DURATION: 114-115 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-69 Y78]"
322,363898013,2268,COP(=S)(OC)SCN1C(=O)C2=CC=CC=C2N=N1,Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 78; 156 PPM IN DIET FOR 80 WK (STUDY DURATION: 114-115 WK),THYROID GLAND: TUMOR; PANCREAS: ISLET CELL ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-69 Y78]"
323,363898013,2268,COP(=S)(OC)SCN1C(=O)C2=CC=CC=C2N=N1,Inactive,,,,Rat,Wistar/Male,Oral,0; 15; 45 ppm (vehicle= 1% DAB8 peanut oil) in feed for 24 mo.,,Negative; Purity = 87.2%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR AZINPHOS-METHYL (SEPTEMBER 1, 1987)]"
324,363898013,2268,COP(=S)(OC)SCN1C(=O)C2=CC=CC=C2N=N1,Inactive,,,,Rat,Wistar/Female,Oral,0; 15; 45 ppm (vehicle= 1% DAB8 peanut oil) in feed for 24 mo.,,Negative; Purity = 87.2%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR AZINPHOS-METHYL (SEPTEMBER 1, 1987)]"
325,363898014,61215,COCCOC1=C(C(=O)C(=C(C1=O)N2CC2)OCCOC)N3CC3,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 51 Y75]"
326,363898015,2272,C1=CC=C(C=C1)N=NC2=CC=CC=C2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 208; 545 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-154 Y79]"
327,363898015,2272,C1=CC=C(C=C1)N=NC2=CC=CC=C2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 200; 400 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-154 Y79]"
328,363898015,2272,C1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,RAT,F344/FEMALE,ORAL,0; 200; 400 PPM IN DIET,"SPLEEN: FIBROSARCOMA, OSTEOSARCOMA; PERITONEAL CAVITY: SARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-154 Y79]"
329,363898015,2272,C1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,RAT,F344/MALE,ORAL,0; 200; 400 PPM IN DIET,SPLEEN: FIBROSARCOMA; PERITONEAL CAVITY: SARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-154 Y79]"
330,363898015,2272,C1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,RAT,F344/MALE,ORAL,0; 200; 400 PPM IN DIET FOR 106 WK (STUDY DURATION: 106 WK),SPLEEN OR PERITONEUM: SARCOMA,POSITIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
331,363898015,2272,C1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,RAT,F344/FEMALE,ORAL,0; 200; 400 PPM IN DIET FOR 106 WK (STUDY DURATION: 106 WK),SPLEEN OR PERITONEUM: SARCOMA,POSITIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
332,363898016,519246,CCN=[N+](CC)[O-],Active,,,,RAT,,ORAL,,LIVER: HEMANGIOENDOTHELIOMA,POSITIVE,"[DRUCKREY,H; SPECIFIC CARCINOGENIC AND TERATOGENIC EFFECT OF 'INDIRECT' ALKYLATING METHYL AND ETHYL COMPOUNDS, AND THEIR DEPENDENCY ON STAGES OF ONTOGENIC DEVELOPMENTS; XENOBIOTICA 3(5):271-303, 1973]"
333,363898016,519246,CCN=[N+](CC)[O-],Active,,,,RAT,,SUBCUTANEOUS,,MAMMARY GLAND; BRAIN (OLFACTORY BULB): NEUROBLASTOMA; BRAIN: GLIOMA HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[DRUCKREY,H; SPECIFIC CARCINOGENIC AND TERATOGENIC EFFECT OF 'INDIRECT' ALKYLATING METHYL AND ETHYL COMPOUNDS, AND THEIR DEPENDENCY ON STAGES OF ONTOGENIC DEVELOPMENTS; XENOBIOTICA 3(5):271-303, 1973]"
334,363898016,519246,CCN=[N+](CC)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 14; 55 MG/ML IN A NEUTRAL DEIONIZED DRINKING WATER SOLUTION 5 D/WK FOR 30 WK (TOTAL DOSE 42; 132 MG) (STUDY DURATION: LIFESPAN),"LIVER: CARCINOMA, HEMANGIOSARCOMA; ESOPHAGUS: TUMOR; NASAL CAVITY: SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; ORGAN-SPECIFIC CARCINOGENESIS IN RATS BY METHYL AND ETHYLAZOXYALKANES; CANCER RES. 45(1):76-79, 1985]"
335,363898017,33184,CN=[N+](C)[O-],Active,,,,RAT,STRAIN-BD,SUBCUTANEOUS,>6 MG/KG ONCE,COLON: ADENOCARCINOMA; NERVOUS SYSTEM: NEUROBLASTOMA; KIDNEY: NEPHROBLASTOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 478]"
336,363898017,33184,CN=[N+](C)[O-],Active,,,,RAT,STRAIN-BD,SUBCUTANEOUS,>6 MG/KG ONCE,COLON: ADENOCARCINOMA; KIDNEY: NEPHROBLASTOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 478]"
337,363898017,33184,CN=[N+](C)[O-],Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,8 MG/KG 1/WK FOR 10 WK,"COLON: ADENOMA, CARCINOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 416]"
338,363898017,33184,CN=[N+](C)[O-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,8 MG/KG 1/WK FOR 24 WK,INTESTINES (LARGE AND SMALL): ADENOCARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 416]"
339,363898017,33184,CN=[N+](C)[O-],Active,,,,MOUSE,ICR/MALE,SUBCUTANEOUS,0; 0.3 MG/MOUSE IN SALINE 1/WK FOR 20 WK (STUDY DURATION: 36 WK),"COLON: ADENOMA OR ADENOCARCINOMA, ADENOMA OR ADENOCARCINOMA OR CARCINOMA; RECTUM: CARCINOMA; BLOOD VESSELS: ANGIOMA OR ANGIOSARCOMA",POSITIVE,"[MORIYA,M, HARADA,T AND SHIRASU,Y; INHIBITION OF CARCINOGENICITIES OF 1,2-DIMETHYLHYDRAZINE AND AZOXYMETHANE BY PYRAZOLE; CANCER LETT. 17:147-152, 1982]"
340,363898017,33184,CN=[N+](C)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 1.0; 4.0 MG/WK IN DRINKING WATER FOR 30 WK (STUDY DURATION: LIFETIME),"LIVER: CARCINOMA, SARCOMA; KIDNEY: INTERSTITIAL CELL SARCOMA OR NEUROSARCOMA OR RENAL CARCINOMA; COLON: ADENOMA OR CARCINOMA",POSITIVE,"[LIJINSKI,W, REUBER,MD AND SAAVEDRA,JE; THE EFFECT OF DEUTERIUM SUBSTITUTION ON CARCINOGENESIS BY AZOXYMETHANE; CANCER LETT. 24:273-280, 1984]"
341,363898017,33184,CN=[N+](C)[O-],Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,"0; 7.4 MG/KG IN 0.9% SALINE 1/WK FOR 10 WK ADMINISTERED TO RATS MAINTAINED ON NORMAL-PROTEIN (25% CASEIN), LOW-PROTEIN (10% CASEIN) OR VERY-LOW-PROTEIN (5% CASEIN) DIET (STUDY DURATION: 30 WK)",COLON: TUMOR,POSITIVE,"[TATSUTA,M, IISHI,H, BABA,M AND TANIGUCHI,H;ENHANCED INDUCTION OF COLON CARCINOGENESIS BY AZOXYMETHANE IN WISTAR RATS FED A LOW-PROTEIN DIET; INT. J. CANCER 50(1):108-111, 1992]"
342,363898017,33184,CN=[N+](C)[O-],Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 2 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 22 WK (TOTAL DOSE 1.2 MMOL) (STUDY DURATION: LIFESPAN),COLON: TUMOR; ZYMBAL GLAND: TUMOR,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
343,363898017,33184,CN=[N+](C)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 10; 40 MG/ML IN A NEUTRAL DEIONIZED DRINKING WATER SOLUTION 5 D/WK FOR 30 WK (TOTAL DOSE 30; 120 MG) (STUDY DURATION: LIFESPAN),"LIVER: CARCINOMA, HEMANGIOSARCOMA; KIDNEY: TUMOR; COLON: ADENOCARCINOMA, ADENOMA",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; ORGAN-SPECIFIC CARCINOGENESIS IN RATS BY METHYL AND ETHYLAZOXYALKANES; CANCER RES. 45(1):76-79, 1985]"
344,363898017,33184,CN=[N+](C)[O-],Unspecified,,,,MOUSE,"AKR/J/MALE,FEMALE",INTRAPERITONEAL INJECTION,"10 MG/KG BW WEEKLY FOR 2, 4, 8 WKS (STUDY DURATION: 6 MO)",COLON: ADENOMAS,ONLY 5% OF ANIMALS AT 4 WK TREATMENT DEVELOPED TUMORS,"[BISSAHOYO,A, PEARSALL,RS, HANLON,K, AMANN,V, HICKS,D, GODFREY,VL AND THREADGILL,DW; AZOXYMETHANE IS A GENETIC BACKFROUND-DEPENDENT COLORECTAL TUMOR INITIATOR AND PROMOTER IN MICE: EFFECTS OF DOSE, ROUTE, AND DIET; TOXICOL. SCI. 88(2):340-345, 2005]"
345,363898017,33184,CN=[N+](C)[O-],Unspecified,,,,MOUSE,"AKR/J/MALE,FEMALE",SUBCUTANEOUS,10 MG/KG BW WEEKLY FOR 4 WK (STUDY DURATION: 6 MO),COLON: ADENOMA,ONLY ABOUT 5% DEVELOPED TUMORS,"[BISSAHOYO,A, PEARSALL,RS, HANLON,K, AMANN,V, HICKS,D, GODFREY,VL AND THREADGILL,DW; AZOXYMETHANE IS A GENETIC BACKFROUND-DEPENDENT COLORECTAL TUMOR INITIATOR AND PROMOTER IN MICE: EFFECTS OF DOSE, ROUTE, AND DIET; TOXICOL. SCI. 88(2):340-345, 2005]"
346,363898017,33184,CN=[N+](C)[O-],Active,,,,MOUSE,"SWR/J/MALE,FEMALE",INTRAPERITONEAL INJECTION,"10 MG/KG BW FOR 2, 4, OR 8 WKS, ONCE A WK (STUDY DURATION: 6 MO)",COLON: ADENOMA,POSITIVE- TUMOR INCIDENCE 30-100%,"[BISSAHOYO,A, PEARSALL,RS, HANLON,K, AMANN,V, HICKS,D, GODFREY,VL AND THREADGILL,DW; AZOXYMETHANE IS A GENETIC BACKFROUND-DEPENDENT COLORECTAL TUMOR INITIATOR AND PROMOTER IN MICE: EFFECTS OF DOSE, ROUTE, AND DIET; TOXICOL. SCI. 88(2):340-345, 2005]"
347,363898017,33184,CN=[N+](C)[O-],Active,,,,MOUSE,"SWR/J/MALE,FEMALE",SUBCUTANEOUS INJECTION,10 MG/KG BW ONCE A WK FOR 4 WK,COLON: ADENOMA,POSITIVE; RESPONSE ABOUT 30%,"[BISSAHOYO,A, PEARSALL,RS, HANLON,K, AMANN,V, HICKS,D, GODFREY,VL AND THREADGILL,DW; AZOXYMETHANE IS A GENETIC BACKFROUND-DEPENDENT COLORECTAL TUMOR INITIATOR AND PROMOTER IN MICE: EFFECTS OF DOSE, ROUTE, AND DIET; TOXICOL. SCI. 88(2):340-345, 2005]"
348,363898017,33184,CN=[N+](C)[O-],Active,,,,MOUSE,"A/J/MALE,FEMALE",SUBCUTANEOUS INJECTION,10 MG/KG BW ONCE A WK FOR 4 WK,COLON: ADENOMA,POSITIVE; ALMOST 80% INCIDENCE,"[BISSAHOYO,A, PEARSALL,RS, HANLON,K, AMANN,V, HICKS,D, GODFREY,VL AND THREADGILL,DW; AZOXYMETHANE IS A GENETIC BACKFROUND-DEPENDENT COLORECTAL TUMOR INITIATOR AND PROMOTER IN MICE: EFFECTS OF DOSE, ROUTE, AND DIET; TOXICOL. SCI. 88(2):340-345, 2005]"
349,363898017,33184,CN=[N+](C)[O-],Active,,,,MOUSE,"A/J/MALE,FEMALE",INTRAPERITONEAL INJECTION,"10 MG/KG ONCE WEEKLY FOR  2, 4, 8 WKS",COLON: ADENOMA,POSITIVE; RESPONSE OF APPROXIMATELY 25% WITH 2 DOSES TO ALMOST 100%  AT 4 OR 8 DOSES,"[BISSAHOYO,A, PEARSALL,RS, HANLON,K, AMANN,V, HICKS,D, GODFREY,VL AND THREADGILL,DW; AZOXYMETHANE IS A GENETIC BACKFROUND-DEPENDENT COLORECTAL TUMOR INITIATOR AND PROMOTER IN MICE: EFFECTS OF DOSE, ROUTE, AND DIET; TOXICOL. SCI. 88(2):340-345, 2005]"
350,363898017,33184,CN=[N+](C)[O-],Active,,,,MOUSE,"A/J/MALE,FEMALE",INTRAPERITONEAL INJECTION,"5, 10 MG/KG BW ONCE A WEEK FOR 4 WKS",COLON: TUMORS (ADENOMA); % OF TUMOR BEARING MICE WAS 10X HIGHER IN 10 MG/KG GROUP,POSITIVE; ALL ANIMALS GIVEN 20 MG/KG DIED,"[BISSAHOYO,A, PEARSALL,RS, HANLON,K, AMANN,V, HICKS,D, GODFREY,VL AND THREADGILL,DW; AZOXYMETHANE IS A GENETIC BACKFROUND-DEPENDENT COLORECTAL TUMOR INITIATOR AND PROMOTER IN MICE: EFFECTS OF DOSE, ROUTE, AND DIET; TOXICOL. SCI. 88(2):340-345, 2005]"
351,363898018,5284406,CC(=O)[O-].CC(=O)[O-].[OH-].[OH-].[OH-].[OH-].[Pb+2].[Pb+2].[Pb+2],Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,30; 75; 150 MG/KG 3/WK FOR 5 WK,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 325 Y80]"
352,363898018,5284406,CC(=O)[O-].CC(=O)[O-].[OH-].[OH-].[OH-].[OH-].[Pb+2].[Pb+2].[Pb+2],Active,,,,MOUSE,SWISS/MALE,ORAL,0.1% IN DIET FOR TWO YR,"KIDNEY: ADENOMA, CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 325 Y80]"
353,363898018,5284406,CC(=O)[O-].CC(=O)[O-].[OH-].[OH-].[OH-].[OH-].[Pb+2].[Pb+2].[Pb+2],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,1% IN DIET,"KIDNEY: ADENOMA, CARCINOMA; BRAIN: GLIOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 325 Y80]"
354,363898018,5284406,CC(=O)[O-].CC(=O)[O-].[OH-].[OH-].[OH-].[OH-].[Pb+2].[Pb+2].[Pb+2],Active,,,,RAT,"WISTAR/MALE,FEMALE",ORAL,0.1; 1.0% IN DIET FOR UP TO 29 MO,KIDNEY: CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 325 Y80]"
355,363898019,5954,C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C=C32,Active,,,,MOUSE,,ORAL,,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 45 Y73]"
356,363898019,5954,C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C=C32,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 45 Y73]"
357,363898019,5954,C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C=C32,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 45 Y73]"
358,363898019,5954,C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C=C32,Active,,,,MOUSE,,IMPLANT,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 45 Y73]"
359,363898019,5954,C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C=C32,Active,,,,MOUSE,"SWISS/MALE,FEMALE",INTRAPERITONEAL,"0; 2800 NMOL TOTAL DOSE; D 1, 8, AND 15 OF LIFE","LUNG: ADENOMA, MALIGNANT LYMPHOMA",POSITIVE,"[WISLOCKI,PG, KAPITULNIK,J, LEVIN,W, LEHR,R, SCHAEFER-RIDDER,M, KARLE,JM, JERINA,DM AND CONNEY,AH; EXCEPTIONAL CARCINOGENIC ACTIVITY OF BENZ(A)ANTHRACENE 3,4-DIHYDRODIOL IN THE NEWBORN MOUSE AND THE BAY REGION THEORY; CANCER RES. 38(3):693-696, 1978]"
360,363898019,5954,C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C=C32,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1600 NMOL IN 35 UL DMSO TOTAL DOSE AT 1 D (1/7 TOTAL DOSE), 8 D (2/7 TOTAL DOSE), AND 15 D (4/7 TOTAL DOSE) OF AGE (STUDY DURATION: 12 MONTHS)","LIVER: ADENOMA, CARCINOMA",POSITIVE,"[VON TUNGELN,LS XIA,Q AND FU,PP; BENZ[A]ANTHRACENE IS A POTENT LIVER TUMORIGEN IN THE NEONATAL B6C3F1 MOUSE; POLYCYCLIC AROMAT. COMPD. 16(1-4):245-254, 1999]"
361,363898020,241,C1=CC=CC=C1,Active,,,,Mouse,C57BL/6 (wild type)/Male,Inhalation,"0; 33; 100; 300 ppm 6 hr/d, 5 d/wk for 26 wks; then no exposure for lifetime","Blood: Hematopoietic neoplasms (10, 21,16, 56%). Lymphoid tissue: Thymic lymphoma (0, 0,11, 28%)",Positive (Highest dose),"[KAWASAKI,Y, HIRABAYASHI,Y, KANEKO,T, KANNO,J, KODAMA,Y, MATSUSHIMA,Y, OGAWA,Y, SAITOH,M, SEKITA,K, UCHIDA,O, UMEMURA,T, YOON,B, INOUE,T; BENZENE-INDUCED HEMATOPOIETIC NEOPLASMS INCLUDING MYELOID LEUKEMIA IN TRP53-DEFICIENT C57BL/6 AND C3H/HE MICE. TOXICOL. SCI. 110(2): 293-306, 2009]"
362,363898020,241,C1=CC=CC=C1,Active,,,,Mouse,C57BL/6 (heterozygous Trp53-deficient)/Male,Inhalation,"0; 33; 100; 300 ppm 6 hr/d, 5 d/wk for 26 wks; then no exposure for lifetime","Blood: hematopoietic neoplasms (38, 41, 36, 89%). Lymphoid tissue: thymic lymphoma (0, 4,16, 73%)",Positive (Highest dose),"[KAWASAKI,Y, HIRABAYASHI,Y, KANEKO,T, KANNO,J, KODAMA,Y, MATSUSHIMA,Y, OGAWA,Y, SAITOH,M, SEKITA,K, UCHIDA,O, UMEMURA,T, YOON,B, INOUE,T; BENZENE-INDUCED HEMATOPOIETIC NEOPLASMS INCLUDING MYELOID LEUKEMIA IN TRP53-DEFICIENT C57BL/6 AND C3H/HE MICE. TOXICOL. SCI. 110(2): 293-306, 2009]"
363,363898020,241,C1=CC=CC=C1,Inactive,,,,Mouse,C57BL/6 (homozygous Trp53-deficient)/Male,Inhalation,"0; 33; 100; 300 ppm 6 hr/d, 5 d/wk for 26 wks; then no exposure for lifetime",,Negative,"[KAWASAKI,Y, HIRABAYASHI,Y, KANEKO,T, KANNO,J, KODAMA,Y, MATSUSHIMA,Y, OGAWA,Y, SAITOH,M, SEKITA,K, UCHIDA,O, UMEMURA,T, YOON,B, INOUE,T; BENZENE-INDUCED HEMATOPOIETIC NEOPLASMS INCLUDING MYELOID LEUKEMIA IN TRP53-DEFICIENT C57BL/6 AND C3H/HE MICE. TOXICOL. SCI. 110(2): 293-306, 2009]"
364,363898020,241,C1=CC=CC=C1,Inactive,,,,Mouse,C57BL/6 (homozygous Trp53-deficient)/Male,Inhalation,"0; 33; 100; 300 ppm 6 hr/d, 5 d/wk for 26 wks; then no exposure for lifetime",,Negative,"[KAWASAKI,Y, HIRABAYASHI,Y, KANEKO,T, KANNO,J, KODAMA,Y, MATSUSHIMA,Y, OGAWA,Y, SAITOH,M, SEKITA,K, UCHIDA,O, UMEMURA,T, YOON,B, INOUE,T; BENZENE-INDUCED HEMATOPOIETIC NEOPLASMS INCLUDING MYELOID LEUKEMIA IN TRP53-DEFICIENT C57BL/6 AND C3H/HE MICE. TOXICOL. SCI. 110(2): 293-306, 2009]"
365,363898020,241,C1=CC=CC=C1,Inactive,,,,Mouse,C57BL/6 (wild type)/Male,Inhalation,"0; 100; 300 ppm 6 hr/d, 5 d/wk for 26 wks; then no exposure for lifetime","Blood: hematopoietic neoplasms (8, 25,30%). Lymphoid tissue: thymic lymphoma (0,17, 0%)",Negative,"[KAWASAKI,Y, HIRABAYASHI,Y, KANEKO,T, KANNO,J, KODAMA,Y, MATSUSHIMA,Y, OGAWA,Y, SAITOH,M, SEKITA,K, UCHIDA,O, UMEMURA,T, YOON,B, INOUE,T; BENZENE-INDUCED HEMATOPOIETIC NEOPLASMS INCLUDING MYELOID LEUKEMIA IN TRP53-DEFICIENT C57BL/6 AND C3H/HE MICE. TOXICOL. SCI. 110(2): 293-306, 2009]"
366,363898020,241,C1=CC=CC=C1,Active,,,,Mouse,C57BL/6 (heterozygous Trp53-deficient)/Male,Inhalation,"0; 100; 300 ppm 6 hr/d, 5 d/wk for 26 wks; then no exposure for lifetime","Blood: hematopoietic neoplasms (325, 83,100%). Lymphoid tissue: thymic lymphoma (4, 50, 25%)",Positive (Highest dose),"[KAWASAKI,Y, HIRABAYASHI,Y, KANEKO,T, KANNO,J, KODAMA,Y, MATSUSHIMA,Y, OGAWA,Y, SAITOH,M, SEKITA,K, UCHIDA,O, UMEMURA,T, YOON,B, INOUE,T; BENZENE-INDUCED HEMATOPOIETIC NEOPLASMS INCLUDING MYELOID LEUKEMIA IN TRP53-DEFICIENT C57BL/6 AND C3H/HE MICE. TOXICOL. SCI. 110(2): 293-306, 2009]"
367,363898020,241,C1=CC=CC=C1,Active,,,,HUMAN,,"INHALATION, DERMAL",,HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[TOMATIS,L, AGTHE,C, BARTSCH,H, HUFF,J, MONTESANO,R, SARACCI,R, WALKER,E AND WILBOURN,J; EVALUATION OF THE CARCINOGENICITY OF CHEMICALS: A REVIEW OF THE MONOGRAPH PROGRAM OF THE INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (1971-1977); CANCER RES. 38:877-885, 1978][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS: CHEMICALS, INDUSTRIAL PROCESSES AND INDUSTRIES ASSOCIATED WITH CANCER IN HUMANS, IARC MONOGRAPHS VOLUMES 1 TO 29, SUPPLEMENT 4, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, 1982]"
368,363898020,241,C1=CC=CC=C1,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",GAVAGE,"0; 500 MG/KG BW, 1/WK",ORAL CAVITY: SQUAMOUS CELL CARCINOMA; ZYMBAL GLAND: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B AND SCARNATO,C; SQUAMOUS CELL CARCINOMAS OF THE ORAL CAVITY IN SPRAGUE-DAWLEY RATS FOLLOWING EXPOSURE TO BENZENE BY INGESTION. FIRST EXPERIMENTAL DEMONSTRATION; MED. LAV. 73(4):441-445, 1982]"
369,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,C57BL/MALE,INHALATION,"0; 300 PPM 6 HR/D, 5 D/WK FOR LIFE",HEMATOPOIETIC SYSTEM: LYMPHOCYTIC LYMPHOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V29 93 Y82][SNYDER,CA, GOLDSTEIN,BD, SELLAKUMAR,A, BROMBERG,I, LASKIN,S AND ALBERT,RE; THE INHALATION TOXICOLOGY OF BENZENE: INCIDENCE OF HEMATOPOIETIC NEOPLASMS AND HEMATOTOXICITY IN AKR/J AND C57BL/6J MICE; TOXICOL. APPL. PHARMACOL. 54:323-331, 1980, ]"
370,363898020,241,C1=CC=CC=C1,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,"0; 50; 250 MG/KG BW, 1/D, 4-5 D/WK FOR 52 WK",ZYMBAL GLAND: CARCINOMA; MAMMARY GLAND: CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V29 93 Y82][MALTONI,C AND SCARNATO,C; FIRST EXPERIMENTAL DEMONSTRATION OF THE CARCINOGENIC EFFECTS OF BENZENE. LONG-TERM BIOASSAYS ON SPRAGUE-DAWLEY RATS BY ORAL ADMINISTRATION; MED. LAV. 70:352-357, 1979, ]"
371,363898020,241,C1=CC=CC=C1,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,"0; 50; 250 MG/KG BW, 1/D, 4-5 D/WK FOR 52 WK",HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V29 93 Y82][MALTONI,C AND SCARNATO,C; FIRST EXPERIMENTAL DEMONSTRATION OF THE CARCINOGENIC EFFECTS OF BENZENE. LONG-TERM BIOASSAYS ON SPRAGUE-DAWLEY RATS BY ORAL ADMINISTRATION; MED. LAV. 70:352-357, 1979, ]"
372,363898020,241,C1=CC=CC=C1,Active,,,,RAT,F344/MALE,GAVAGE,0; 50; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; ORAL CAVITY: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; EAR (ZYMBAL GLAND): CARCINOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-289 Y86]"
373,363898020,241,C1=CC=CC=C1,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 25; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"ORAL CAVITY: SQUAMOUS CELL PAPILLOMA OR CARCINOMA; EAR (ZYMBAL GLAND): CARCINOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-289 Y86]"
374,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 25; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA; HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA, LEUKEMIA OR LYMPHOMA; PREPUTIAL GLAND: SQUAMOUS CELL CARCINOMA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA; EAR (ZYMBAL GLAND): SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-289 Y86]"
375,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 25; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA; MAMMARY GLAND: CARCINOMA, CARCINOSARCOMA; OVARIES: GRANULOSA CELL TUMOR, GRANULOSA CELL TUMOR OR CARCINOMA, BENIGN MIXED TUMOR; EAR (ZYMBAL GLAND): SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-289 Y86]"
376,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,CBA/CA BNL/MALE,INHALATION,0; 100; 300 PPM 6 HR/D 5 D/WK FOR 16 WK (STUDY DURATION: >1100 D),HEMATOPOIETIC SYSTEM: MYELOGENOUS NEOPLASM,POSITIVE,"[CRONKITE,EP, DREW,RT, INOUE,T, HIRABAYASHI,Y AND BULLIS,JE; HEMATOTOXICITY AND CARCINOGENICITY OF INHALED BENZENE; ENVIRON. HEALTH PERSPECT. 82:97-108, 1989]"
377,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,CBA/CA BNL/FEMALE,INHALATION,0; 300 PPM 6 HR/D 5 D/WK FOR 16 WK (STUDY DURATION: >1100 D),HEMATOPOIETIC SYSTEM: MYELOGENOUS NEOPLASM,POSITIVE,"[CRONKITE,EP, DREW,RT, INOUE,T, HIRABAYASHI,Y AND BULLIS,JE; HEMATOTOXICITY AND CARCINOGENICITY OF INHALED BENZENE; ENVIRON. HEALTH PERSPECT. 82:97-108, 1989]"
378,363898020,241,C1=CC=CC=C1,Inactive,,,,MOUSE,C57BL/MALE,INHALATION,"0; 1200 PPM 6HR/D, 5D/WK FOR 10 WK (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[SNYDER,CA, SELLAKUMAR,AR, JAMES,DJ AND ALBERT,RE; THE CARCINOGENICITY OF DISCONTINUOUS INHALED BENZENE EXPOSURES IN CD-1 AND C57BL/6 MICE; ARCH. TOXICOL. 62(5):331-335, 1988]"
379,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,CD-1/MALE,INHALATION,"0; 1200 PPM 6HR/D, 5D/WK FOR 10 WK (STUDY DURATION: LIFESPAN)",LUNG: ADENOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA OR LYMPHOMA; ZYMBAL GLAND: CARCINOMA,POSITIVE,"[SNYDER,CA, SELLAKUMAR,AR, JAMES,DJ AND ALBERT,RE; THE CARCINOGENICITY OF DISCONTINUOUS INHALED BENZENE EXPOSURES IN CD-1 AND C57BL/6 MICE; ARCH. TOXICOL. 62(5):331-335, 1988]"
380,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,CD-1/MALE,INHALATION,"0; 300 PPM 6HR/D, 5D/WK FOR 1 WK FOLLOWED BY 2 WK NO TREATMENT, CYCLE REPEATED FOR LIFESPAN (STUDY DURATION: LIFESPAN)",LUNG: ADENOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA OR LYMPHOMA; ZYMBAL GLAND: CARCINOMA,POSITIVE,"[SNYDER,CA, SELLAKUMAR,AR, JAMES,DJ AND ALBERT,RE; THE CARCINOGENICITY OF DISCONTINUOUS INHALED BENZENE EXPOSURES IN CD-1 AND C57BL/6 MICE; ARCH. TOXICOL. 62(5):331-335, 1988]"
381,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,C57BL/MALE,INHALATION,"0; 300 PPM 6HR/D, 5D/WK FOR 1 WK FOLLOWED BY 2 WK NO TREATMENT, CYCLE REPEATED FOR LIFESPAN (STUDY DURATION: LIFESPAN)",LUNG: ADENOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA OR LYMPHOMA; ZYMBAL GLAND: CARCINOMA,POSITIVE,"[SNYDER,CA, SELLAKUMAR,AR, JAMES,DJ AND ALBERT,RE; THE CARCINOGENICITY OF DISCONTINUOUS INHALED BENZENE EXPOSURES IN CD-1 AND C57BL/6 MICE; ARCH. TOXICOL. 62(5):331-335, 1988]"
382,363898020,241,C1=CC=CC=C1,Active,,,,RAT,WISTAR/MALE,GAVAGE,0; 500 MG/KG IN OLIVE OIL 1/D FOR 4 TO 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),ZYMBAL GLAND: CARCINOMA; ORAL CAVITY: CARCINOMA; NASAL CAVITY: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B, PERINO,G AND DI MAIO,V;FURTHER EVIDENCE OF BENZENE CARCINOGENICITY. RESULTS ON WISTAR RATS AND SWISS MICE TREATED BY INGESTION; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):412-426, 1988]"
383,363898020,241,C1=CC=CC=C1,Active,,,,RAT,WISTAR/FEMALE,GAVAGE,0; 500 MG/KG IN OLIVE OIL 1/D FOR 4 TO 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),ZYMBAL GLAND: CARCINOMA; ORAL CAVITY: CARCINOMA; NASAL CAVITY: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B, PERINO,G AND DI MAIO,V;FURTHER EVIDENCE OF BENZENE CARCINOGENICITY. RESULTS ON WISTAR RATS AND SWISS MICE TREATED BY INGESTION; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):412-426, 1988]"
384,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,SWISS/MALE,GAVAGE,0; 500 MG/KG IN OLIVE OIL 1/D FOR 4 TO 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; ZYMBAL GLAND: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B, PERINO,G AND DI MAIO,V;FURTHER EVIDENCE OF BENZENE CARCINOGENICITY. RESULTS ON WISTAR RATS AND SWISS MICE TREATED BY INGESTION; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):412-426, 1988]"
385,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 500 MG/KG IN OLIVE OIL 1/D FOR 4 TO 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),MAMMARY GLAND: CARCINOMA; LUNG: TUMORS; ZYMBAL GLAND: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B, PERINO,G AND DI MAIO,V;FURTHER EVIDENCE OF BENZENE CARCINOGENICITY. RESULTS ON WISTAR RATS AND SWISS MICE TREATED BY INGESTION; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):412-426, 1988]"
386,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,,INHALATION,0; 300 PPM 6 HR/D 5 D/WK FOR 16 WK (STUDY DURATION: LIFETIME),HEMATOPOIETIC SYSTEM: LYMPHOMA,POSITIVE,"[CRONKITE,EP, DREW,RT AND BULLIS,JE; BENZENE TOXICITY AND HOW TO APPROACH THE PROBLEM OF CHEMICAL LEUKEMOGENESIS; IMMUNOL. HEMATOL. RES. MONOGR. 3(ENVIRON. POLLUT. MAN):156-160, 1984]"
387,363898020,241,C1=CC=CC=C1,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 36.1; 137.3 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
388,363898020,241,C1=CC=CC=C1,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 36.1; 137.3 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
389,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,C57BL/FEMALE,INHALATION,0; 300 PPM 6 HR/D 5 D/WK FOR 16 WK (STUDY DURATION: 750 D),"HEMATOPOIETIC SYSTEM: LYMPHOCYTIC LEUKEMIA, LEUKEMIA; THYMUS GLAND: LEUKEMIA; ZYMBAL GLAND: TUMOR; OVARY: TUMOR",POSITIVE,"[CRONKITE,EP, DREW,RT, INOUE,T AND BULLIS,JE; BENZENE HEMATOTOXICITY AND LEUKEMOGENESIS; AM. J. IND. MED. 7(5-6):447-456, 1985]"
390,363898020,241,C1=CC=CC=C1,Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAGASTRIC,0; 500 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
391,363898020,241,C1=CC=CC=C1,Inactive,,,,RAT,STRAIN-CD/MALE,INTRAGASTRIC,0; 500 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
392,363898020,241,C1=CC=CC=C1,Active,,,,RAT,STRAIN-CD/MALE,INTRAGASTRIC,0; 500 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 104 WK (STUDY DURATION: LIFESPAN),ZYMBAL GLAND: CARCINOMA; ORAL CAVITY: CARCINOMA; NASAL CAVITY: CARCINOMA; SKIN: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
393,363898020,241,C1=CC=CC=C1,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAGASTRIC,0; 500 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 104 WK (STUDY DURATION: LIFESPAN),ZYMBAL GLAND: CARCINOMA; LIVER: ANGIOSARCOMA; ORAL CAVITY: CARCINOMA; HEMOLYMPHORETICULAR: TUMOR,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
394,363898020,241,C1=CC=CC=C1,Active,,,,RAT,STRAIN-CD/FEMALE,INHALATION,0; 200 PPM 4 HR/D FOR 7 WK THEN 7 HR/D FOR 12 WK THEN 300 PPM 7 HR/D 5 D/WK FOR 85 WK TO RATS ALSO EXPOSED IN UTERO (STUDY DURATION: LIFESPAN),ZYMBAL GLAND: CARCINOMA; ORAL CAVITY: CARCINOMA; NASAL CAVITY: CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA; LIVER: HEPATOMA,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
395,363898020,241,C1=CC=CC=C1,Active,,,,RAT,STRAIN-CD/MALE,INHALATION,0; 200 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D FOR 12 WK THEN 300 PPM 7 HR/D 5 D/WK FOR 85 WK TO RATS ALSO EXPOSED IN UTERO (STUDY DURATION: LIFESPAN),ZYMBAL GLAND: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
396,363898020,241,C1=CC=CC=C1,Active,,,,RAT,STRAIN-CD/FEMALE,INHALATION,0; 200 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D FOR 12 WK THEN 300 PPM 7 HR/D 5 D/WK FOR 85 WK (STUDY DURATION: LIFESPAN),MAMMARY GLAND: ADENOCARCINOMA; ORAL CAVITY: CARCINOMA; ZYMBAL GLAND: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
397,363898020,241,C1=CC=CC=C1,Active,,,,RAT,WISTAR/MALE,INTRAGASTRIC,0; 500 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 104 WK (STUDY DURATION: LIFESPAN),ZYMBAL GLAND: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
398,363898020,241,C1=CC=CC=C1,Active,,,,RAT,STRAIN-CD/MALE,INTRAGASTRIC,0; 50; 250 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFESPAN),HEMOLYMPHORETICULAR SYSTEM: TUMOR,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
399,363898020,241,C1=CC=CC=C1,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAGASTRIC,0; 50; 250 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFESPAN),ZYMBAL GLAND: CARCINOMA,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
400,363898020,241,C1=CC=CC=C1,Active,,,,RAT,WISTAR/FEMALE,INTRAGASTRIC,0; 500 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 104 WK (STUDY DURATION: LIFESPAN),ZYMBAL GLAND: CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA; HEMOLYMPHORETICULAR SYSTEM: TUMOR,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
401,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,SWISS/FEMALE,INTRAGASTRIC,0; 500 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 78 WK (STUDY DURATION: LIFESPAN),LUNG: ADENOMA; MAMMARY GLAND: MALIGNANT TUMOR,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
402,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,SWISS/MALE,INTRAGASTRIC,0; 500 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 78 WK (STUDY DURATION: LIFESPAN),ZYMBAL GLAND: CARCINOMA; LUNG: ADENOMA,POSITIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
403,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,CBA/MALE,INHALATION,0; 300 PPM 6 HR/D 5 D/WK FOR 16 WK (STUDY DURATION: 22 MO),LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA; PREPUTIAL GLAND: SQUAMOUS CELL CARCINOMA; LUNG: ADENOMA,POSITIVE,"[FARRIS,GM, EVERITT,JI, IRONS,RD AND POPP,JA; CARCINOGENICITY OF INHALED BENZENE IN CBA MICE; FUNDAM. APPL. TOXICOL. 20(4):503-507, 1993]"
404,363898020,241,C1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 50; 250 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
405,363898020,241,C1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 50; 250 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
406,363898020,241,C1=CC=CC=C1,Active,,,,MOUSE,C57BL/FEMALE,INHALATION,0; 300 PPM 6 HR/D 5 D/WK FOR 16 WK (STUDY DURATION: 64 WK),LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[CRONKITE,EP, BULLIS,J, INOUE,T AND DREW,RT;BENZENE INHALATION PRODUCES LEUKEMIA IN MICE; TOXICOL. APPL. PHARMACOL. 75(2):358-361, 1984]"
407,363898020,241,C1=CC=CC=C1,Inactive,,,,MOUSE,EU-PIM-1/MALE,GAVAGE,0; 50; 100 MG/KG 1/D FOR 40 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[STORER,RD, CARTWRIGHT,ME, COOK,WO, SOPER,KA AND NICOLS,WW; SHORT-TERM CARCINOGENESIS BIOASSAY OF GENOTOXIC PROCARCINOGENS IN PM TRANSGENIC MICE; CARCINOGENESIS 16(2):285-293, 1995]"
408,363898020,241,C1=CC=CC=C1,Inactive,,,,MOUSE,EU-PIM-1/FEMALE,GAVAGE,0; 50; 100 MG/KG 1/D FOR 40 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[STORER,RD, CARTWRIGHT,ME, COOK,WO, SOPER,KA AND NICOLS,WW; SHORT-TERM CARCINOGENESIS BIOASSAY OF GENOTOXIC PROCARCINOGENS IN PM TRANSGENIC MICE; CARCINOGENESIS 16(2):285-293, 1995]"
409,363898021,7111,C1=CC(=CC=C1C2=CC=C(C=C2)N)N,Active,,,,DOG,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 80 Y72]"
410,363898021,7111,C1=CC(=CC=C1C2=CC=C(C=C2)N)N,Active,,,,HAMSTER,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 80 Y72]"
411,363898021,7111,C1=CC(=CC=C1C2=CC=C(C=C2)N)N,Active,,,,HUMAN,,"ORAL, INHALATION, DERMAL",,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 80 Y72]"
412,363898021,7111,C1=CC(=CC=C1C2=CC=C(C=C2)N)N,Active,,,,MOUSE,,SUBCUTANEOUS,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 80 Y72]"
413,363898021,7111,C1=CC(=CC=C1C2=CC=C(C=C2)N)N,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 80 Y72]"
414,363898021,7111,C1=CC(=CC=C1C2=CC=C(C=C2)N)N,Active,,,,RAT,,SUBCUTANEOUS,,LIVER; EAR (ZYMBAL GLAND); INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 80 Y72]"
415,363898022,9153,C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 69 Y73]"
416,363898022,9153,C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1,Active,,,,MOUSE,CD-1,DERMAL,"0, 10, 30, 100 UG TOTAL FOR 10 DOSES GIVEN EVERY OTHER D, THEN AFTER 10 D 2.5 UG 3/WK FOR 20 WK",INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[LAVOIE,EJ, AMIN,S, HECHT,SS, FURUYA,K AND HOFFMANN,D; TUMOR INITIATING ACTIVITY OF DIHYDRODIOLS OF BENZO(B)FLUORANTHENE, BENZO(J)FLUORANTHENE AND BENZO(K)FLUORANTHENE; CARCINOGENESIS 3(1):49-52, 1982]"
417,363898022,9153,C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1,Active,,,,MOUSE,NMRI/FEMALE,DERMAL,"0, 3.4, 5.6, 9.2 PG 2/WK",INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[HABS,M, SCHMAEHL,D AND MISFELD,J; LOCAL CARCINOGENICITY OF SOME ENVIRONMENTALLY RELEVANT POLYCYCLIC AROMATIC HYDROCARBONS AFTER LIFELONG TOPICAL APPLICATION TO MOUSE SKIN; ARCH. GESCHWULSTFORSCH. 50(3):266-274, 1980]"
418,363898022,9153,C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1,Active,,,,MOUSE,"XVII-NC/Z/MALE,FEMALE",SUBCUTANEOUS,"0.6 MG, 3 INJ OVER 2 MO",INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 69 Y73][LACASSAGNE,A, BUU-HOI,NP, ZAJDELA,F, LAVIT-LAMY,D AND CHALVET,O; ACTIVITE CANCEROGENE D'HYDROCARBURES AROMATIQUES POLYCYCLIQUES A NOYAU FLUORANTHENE; ACTA UNIO. INT. CANCRUM 19:490, 1963, ]"
419,363898022,9153,C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.1; 0.3; 1.0 MG IN BEESWAX/TRIOCTANOIN (STUDY DURATION: LIFETIME),"LUNG: EPIDERMOID CARCINOMA, PLEOMORPHIC SARCOMA",POSITIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G, DETTBARN,G AND MISFELD,J; EXPERIMENTAL STUDIES IN RAT LUNGS ON THE CARCINOGENICITY AND DOSE- RESPONSE RELATIONSHIPS OF EIGHT FREQUENTLY OCCURRING ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS; J. NATL. CANCER INST. 71(3):539-544, 1983]"
420,363898022,9153,C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 10; 50; 100; 200 MG/KG BW ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[ROSS,JA, NELSON,GB, WILSON,KH, RABINOWITZ,JR, GALATI,A, STONER,GD, NESNOW,S AND MASS,MJ; ADENOMAS INDUCED BY POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MOUSE LUNG CORRELATE WITH TIME-INTEGRATED DNA ADDUCT LEVELS; CANCER RES. 55(5): 1039-1044, 1995]"
421,363898022,9153,C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 10; 50; 100; 200 MG/KG ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[MASS,MJ, ABU-SHAKRA,A, ROOP,BC, NELSON,G, GALATI,AJ, STONER,GD, NESNOW,S AND ROSS,JA;BENZO[B]FLUORANTHENE: TUMORIGENICITY IN STRAIN A/J MOUSE LUNGS, DNA ADDUCTS AND MUTATIONS IN THE KI-RAS ONCOGENE; CARCINOGENESIS 17(8):1701-1704, 1996]"
422,363898022,9153,C1=CC=C2C3=C4C(=CC=C3)C5=CC=CC=C5C4=CC2=C1,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0-200 MG/KG IN TRICAPRYLIN ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[NESNOW,S, ROSS,JA, STONER,GD AND MASS,MJ; TUMORIGENESIS OF CARCINOGENIC ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MICE: LINKAGE TO DNA ADDUCTS AND MUTATIONS IN ONCOGENES; POLYCYCLIC AROMAT. COMPD. 10(1-4):259-266, 1996]"
423,363898023,9152,C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC5=C4C3=CC=C5,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 82 Y73]"
424,363898023,9152,C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC5=C4C3=CC=C5,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.2; 1.0; 5.0 MG IN BEESWAX/TRIOCTANOIN (STUDY DURATION: LIFETIME),LUNG: EPIDERMOID CARCINOMA,POSITIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G, DETTBARN,G AND MISFELD,J; EXPERIMENTAL STUDIES IN RAT LUNGS ON THE CARCINOGENICITY AND DOSE- RESPONSE RELATIONSHIPS OF EIGHT FREQUENTLY OCCURRING ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS; J. NATL. CANCER INST. 71(3):539-544, 1983]"
425,363898023,9152,C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC5=C4C3=CC=C5,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.11; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
426,363898023,9152,C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC5=C4C3=CC=C5,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.11; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
427,363898024,9158,C1=CC=C2C=C3C4=CC=CC5=C4C(=CC=C5)C3=CC2=C1,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[WYNDER,EL AND HOFFMANN,D; THE CARCINOGENICITY OF BENZOFLUORANTHENES; CANCER 12:1194-1199, 1959]"
428,363898024,9158,C1=CC=C2C=C3C4=CC=CC5=C4C(=CC=C5)C3=CC2=C1,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.16; 0.83; 4.15 MG IN BEESWAX/TRIOCTANOIN (STUDY DURATION: LIFETIME),LUNG: EPIDERMOID CARCINOMA,POSITIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G, DETTBARN,G AND MISFELD,J; EXPERIMENTAL STUDIES IN RAT LUNGS ON THE CARCINOGENICITY AND DOSE- RESPONSE RELATIONSHIPS OF EIGHT FREQUENTLY OCCURRING ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS; J. NATL. CANCER INST. 71(3):539-544, 1983]"
429,363898025,8400,C1=CC=C(C=C1)C(C(=O)C2=CC=CC=C2)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-204 Y80]"
430,363898025,8400,C1=CC=C(C=C1)C(C(=O)C2=CC=CC=C2)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-204 Y80]"
431,363898025,8400,C1=CC=C(C=C1)C(C(=O)C2=CC=CC=C2)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 250; 500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-204 Y80]"
432,363898025,8400,C1=CC=C(C=C1)C(C(=O)C2=CC=CC=C2)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 125; 250 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-204 Y80]"
433,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,HAMSTER,,GAVAGE,,"FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73]"
434,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,HAMSTER,,INTRATRACHEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73]"
435,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,HAMSTER,,SUBCUTANEOUS,,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73]"
436,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,,PERITONEAL CAVITY: FIBROSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73]"
437,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73]"
438,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RABBIT,,DERMAL,,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73]"
439,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAVENOUS,,MAMMARY GLAND: CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73]"
440,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73]"
441,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,"CFW/MALE, FEMALE",ORAL,30-250 PPM IN DIET FOR 70-197 D,STOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][NEAL,J AND RIGDON,RH; GASTRIC TUMORS IN MICE FED BENZO(A)PYRENE: A QUANTITATIVE STUDY; TEX. REP. BIOL. MED. 25:553, 1967, ]"
442,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,"CFW/MALE, FEMALE",ORAL,250 PPM IN DIET FOR 1-30 D; OBSERVED UNTIL 103-107 D,FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][NEAL,J AND RIGDON,RH; GASTRIC TUMORS IN MICE FED BENZO(A)PYRENE: A QUANTITATIVE STUDY; TEX. REP. BIOL. MED. 25:553, 1967, ]"
443,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,2-5 MG 2/WK FOR 1-11 MO,"STOMACH: CARCINOMA, PAPILLOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][DONTENWILL,W AND MOHR,U; EXPERIMENTELLE UNTERSUCHUNGEN ZUM PROBLEM DER CARCINOMENTSTEHUNG IM RESPIRATIONSTRAKT. I. DIE UNTERSCHIEDLICKE WIRKUNG DES BENZPYRENS AUF DIE EPITHELIEN DER HAUT, DER MUNDHOHLE UND DER TRACHEA DES GOLDHAMSTERS; Z. KREBSFORSCH. 65:56, 1962, ]"
444,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RABBIT,,DERMAL,"0.001-0.5%, 5/WK",INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][WYNDER,EL, FRITZ,L AND FURTHE,N; EFFECT OF CONCENTRATION OF BENZOPYRENE IN SKIN CARCINOGENESIS; J. NATL. CANCER INST. 19:361, 1957, ]"
445,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,"0.01-0.5%, 3/WK","INTEGUMENTARY SYSTEM (SKIN): CARCINOMA, PAPILLOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][WYNDER,EL AND HOFFMANN,D; A STUDY OF TOBACCO CARCINOGENESIS. VII. THE ROLE OF HIGHER POLYCYCLIC HYDROCARBONS; CANCER 12:1079, 1959, ]"
446,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,C3H,DERMAL,"0.00002-0.02%, 3/WK FOR UP TO 80 WK",INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][BINGHAM,E AND FALK,HL; ENVIRONMENTAL CARCINOGENS. THE MODIFYING EFFECT OF COCARCINOGENS ON THE THRESHOLD RESPONSE; ARCH. ENVIRON. HEALTH 19:779, 1969, ]"
447,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,"0.1-9 UG, 3/WK FOR < 700 D",INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][ROE,FJC, PETO,R, KEARNS,F AND BISHOP,D; THE MECHANISM OF CARCINOGENESIS BY THE NEUTRAL FRACTION OF CIGARETTE SMOKE CONDENSATE; BR. J. CANCER 24:788, 1970, ]"
448,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,C3H/MALE,DERMAL,"0.15-470 UG, 3/WK FOR LIFE",INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][POEL,WE; SKIN AS A TEST SITE FOR THE BIOASSAY OF CARCINOGENS AND CARCINOGEN PRECURSORS; NATL. CANCER INST. MONOGR. 10:611, 1963, ]"
449,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,CAF1,DERMAL,"0.0005, 0.001, 0.5%, 3/WK",INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][WYNDER,EL, FRITZ,L AND FURTHE,N; EFFECT OF CONCENTRATION OF BENZOPYRENE IN SKIN CARCINOGENESIS; J. NATL. CANCER INST. 19:361, 1957, ]"
450,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,C57BL,DERMAL,"0.0001-0.5%, 3/WK",INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][WYNDER,EL, FRITZ,L AND FURTHE,N; EFFECT OF CONCENTRATION OF BENZOPYRENE IN SKIN CARCINOGENESIS; J. NATL. CANCER INST. 19:361, 1957, ]"
451,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,HAMSTER,,ORAL,500 PPM IN DIET 4 D/WK FOR UP TO 14 MO,ESOPHAGUS; FORESTOMACH; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][CHU,EW AND MALMGREN,RA; AN INHIBITORY EFFECT OF VITAMIN A ON THE INDUCTION OF TUMORS OF FORESTOMACH AND CERVIX IN THE SYRIAN HAMSTER BY CARCINOGENIC POLYCYCLIC HYDROCARBONS; CANCER RES. 25:884, 1965, ]"
452,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,,INTRATRACHEAL,"0.0005-2.5 MG, 1/MO FOR 10 MO; OBSERVED 2 YR",LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][YANISHEVA,NYA; THE SUBSTANTIATION OF THE MAXIMUM PERMISSIBLE CONCENTRATION OF BENZ(A)PYRENE IN THE ATMOSPHERE OF SETTLEMENTS; GIG. I SANIT. 37:87, 1971, ]"
453,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,HAMSTER,"MALE,FEMALE",INTRATRACHEAL,"0.25-2 MG, 1/WK FOR 30 WK",RESPIRATORY TRACT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][SAFFIOTTI,U, MONTESANO,R, SELLAKUMAR,AR AND KAUFMAN,DG; RESPIRATORY TRACT CARCINOGENESIS INDUCED IN HAMSTERS BY DIFFERENT DOSE LEVELS OF BENZO(A)PYRENE AND FERRIC OXIDE; J. NATL. CANCER INST. 49:1199, 1972, ]"
454,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MONKEY,,INTRATRACHEAL,"3-15 MG, 1/WK",LUNG: SQUAMOUS CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][CROCKER,TT, CHASE,JE, WELLS,SA AND NUNES,LL; PRELIMINARY REPORT ON EXPERIMENTAL SQUAMOUS CARCINOMA OF THE LUNG IN HAMSTERS AND IN A PRIMATE (GALAGO CRASSICAUDATUS); IN: NETTESHEIM,P., HANNA,M.G. AND DEATHERAGE,J.W., (EDS.), MORPHOLOGY EXPERIMENTAL RESPIRATORY CARCINOGENESIS, US ATOMIC ENERGY COMMISSION SYMPOSIUM SERIES NO. 21, P. 317, 1970, ]"
455,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,C3H/MALE,SUBCUTANEOUS,"0.00195-8.0 MG, SINGLE DOSE",INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][BRYAN,WR AND SHIMKIN,MB; QUANTITATIVE ANALYSIS OF DOSE-RESPONSE DATA OBTAINED WITH THREE CARCINOGENIC HYDROCARBONS IN STRAIN C3H MALE MICE; J. NATL. CANCER INST. 3:503, 1943, ]"
456,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,C57BL,SUBCUTANEOUS,"0.00004, 0.0004, 0.004, 0.04 MG, SINGLE DOSE",INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][HIEGER,I; CARCINOGENESIS BY CHOLESTEROL; BR. J. CANCER 13:439, 1959, ]"
457,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,CFW,SUBCUTANEOUS,"0.001-2 MG, SINGLE DOSE",INJECTION SITE: FIBROSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][RIGDON,RH AND NEAL,J; TUMORS IN MICE INDUCED BY AIR PARTICULATE MATTER FROM A PETROCHEMICAL INDUSTRIAL AREA; TEX. REP. BIOL. MED. 29:109, 1971, ]"
458,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,,SUBCUTANEOUS,"0.05, 0.1, 0.5, 1.0 MG, SINGLE DOSE",INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][OBERLING,C, GUERIN,M AND GUERIN,P; PARTICULARITES EVOLUTIVES DES TUMEURS PRODUITES AVEC DE FORTES DOSES DE BENZOPYRENE; BULL. ASSOC. FR. ETUDE CANCER 28:198, 1939, ]"
459,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,HAMSTER,,SUBCUTANEOUS,"2.5 MG, 3 MO",INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][HALBERSTAEDTER,L; A BENZPYRENE TUMOUR STRAIN IN HAMSTERS WITH TENDENCY TO METASTASIS FORMATION; NATURE (LOND.) 144:377, 1939, ]"
460,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",SUBCUTANEOUS,"0.0005-80 MG, 10 DOSES",INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][RIVIERE,MR, CHOUROULINKOV,I AND GUERIN,M; PRODUCTION DE TUMEURS AU MOYEN DE SUBSTANCES CHIMIQUES CANCERIGENES CHEZ LE HAMSTER; BULL. ASSOC. FR. ETUDE CANCER 50:275, 1963, ]"
461,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MONKEY,"TUPAIA GLIS/MALE,FEMALE",SUBCUTANEOUS,"10 MG, SINGLE DOSE",INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][NOYES,WF; CARCINOGEN-INDUCED SARCOMA IN THE PRIMITIVE PRIMATE, TUPAIA GLIS; PROC. SOC. EXP. BIOL. (N.Y.) 127:594, 1968, ]"
462,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,"STRAIN-A/MALE, FEMALE",INTRAPERITONEAL,"2 MG, 1/WK",PERITONEAL CAVITY: FIBROSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][PAYNE,S; THE PATHOLOGICAL EFFECTS OF THE INTRAPERITONEAL INJECTION OF 3,4-BENZPYRENE INTO RATS AND MICE; BR. J. CANCER 12:65, 1958, ]"
463,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAVENOUS,"39 MG/KG, SINGLE DOSE",MAMMARY GLAND: CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 91 Y73][PATAKI,J AND HUGGINS,C; MOLECULAR SITE OF SUBSTITUENTS OF BENZ(A)ANTHRACENE RELATED TO CARCINOGENICITY; CANCER RES. 29:506, 1969, ]"
464,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 2.2; 6.6; 20 NMOL IN 50 UL ACETONE 2/WK FOR 48 WK (STUDY DURATION: 61 WK),SKIN: PAPILLOMA; SKIN: SQUAMOUS CELL CARCINOMA,POSITIVE,"[CAVALIERI,E, MUNHALL,A, ROGAN,E, SALMASI,S AND PATIL,K; SYNCARCINOGENIC EFFECT OF THE ENVIRONMENTAL POLLUTANTS CYCLOPENTENO[CD]PYRENE AND BENZO[A]PYRENE IN MOUSE SKIN; CARCINOGENESIS 4(4):393-397, 1983]"
465,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 22.2; 66.6; 200 NMOL IN 50 UL ACETONE 2/WK FOR 48 WK (STUDY DURATION: 61 WK),SKIN: SQUAMOUS CELL CARCINOMA,POSITIVE,"[CAVALIERI,E, MUNHALL,A, ROGAN,E, SALMASI,S AND PATIL,K; SYNCARCINOGENIC EFFECT OF THE ENVIRONMENTAL POLLUTANTS CYCLOPENTENO[CD]PYRENE AND BENZO[A]PYRENE IN MOUSE SKIN; CARCINOGENESIS 4(4):393-397, 1983]"
466,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.1; 0.3; 1.0 MG IN BEESWAX/TRIOCTANOIN (STUDY DURATION: LIFETIME),"LUNG: EPIDERMOID CARCINOMA, PLEOMORPHIC SARCOMA",POSITIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G, DETTBARN,G AND MISFELD,J; EXPERIMENTAL STUDIES IN RAT LUNGS ON THE CARCINOGENICITY AND DOSE- RESPONSE RELATIONSHIPS OF EIGHT FREQUENTLY OCCURRING ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS; J. NATL. CANCER INST. 71(3):539-544, 1983]"
467,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,SENCAR/MALE,DERMAL,0; 12.6; 25.2; 50.5; 101; 202 UG/WK FOR 50-52 WK (STUDY DURATION: 1 YR),SKIN: CARCINOMA,POSITIVE,"[NESNOW,S, TRIPLETT,LL AND SLAGA,TJ; MOUSE SKIN TUMOR INITIATION-PROMOTION AND COMPLETE CARCINOGENESIS BIOASSAYS: MECHANISMS AND BIOLOGICAL ACTIVITIES OF EMISSION SAMPLES; ENVIRON. HEALTH PERSPECT. 47:255-268, 1983]"
468,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,SENCAR/FEMALE,DERMAL,0; 12.6; 25.2; 50.2; 101; 202 UG/WK FOR 50-52 WK (STUDY DURATION: 1 YR),SKIN: CARCINOMA,POSITIVE,"[NESNOW,S, TRIPLETT,LL AND SLAGA,TJ; MOUSE SKIN TUMOR INITIATION-PROMOTION AND COMPLETE CARCINOGENESIS BIOASSAYS: MECHANISMS AND BIOLOGICAL ACTIVITIES OF EMISSION SAMPLES; ENVIRON. HEALTH PERSPECT. 47:255-268, 1983]"
469,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 59.5 UG TOTAL DOSE (8.5 UG/5 UL, 17 UG/10 UL, 34 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
470,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 59.5 UG TOTAL DOSE (8.5 UG/5 UL, 17 UG/10 UL, 34 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
471,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,FISH,"MT. SHASTA RAINBOW TROUT/MALE, FEMALE",TRANSCHORIONIC INJECTION,0; 0.09; 0.9; 9 UG IN DMSO ADMINISTERED IN OVO APPROXIMATELY 2 DAYS PRIOR TO HATCHING (STUDY DURATION: 1 YR),,NEGATIVE,"[BLACK,JJ, MACCUBBIN,AE AND JOHNSTON,CJ; CARCINOGENICITY OF BENZO[A]PYRENE IN RAINBOW TROUT RESULTING FROM EMBRYO MICROINJECTION; AQUAT. TOXICOL. 13(4): 297-308, 1988]"
472,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,FISH,"MT. SHASTA RAINBOW TROUT/MALE, FEMALE",TRANSCHORIONIC INJECTION,0; 4.5; 9; 18 UG IN DMSO ADMINISTERED IN OVO APPROXIMATELY 2 DAYS PRIOR TO HATCHING,LIVER: TUMOR,POSITIVE,"[BLACK,JJ, MACCUBBIN,AE AND JOHNSTON,CJ; CARCINOGENICITY OF BENZO[A]PYRENE IN RAINBOW TROUT RESULTING FROM EMBRYO MICROINJECTION; AQUAT. TOXICOL. 13(4): 297-308, 1988]"
473,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,INTRAPULMONARY IMPLANT,0; 0.03; 0.1; 0.3 MG IN BEESWAX AND TRIOCTANOIN IMPLANTED IN LUNG (STUDY DURATION: 141 WK),LUNG: CARCINOMA,POSITIVE,"[WENZEL-HARTUNG,R, BRUNE,H, GRIMMER,G, GERMANN,P, TIMM,J AND WOSNIOK,W; EVALUATION OF THE CARCINOGENIC POTENCY OF 4 ENVIRONMENTAL POLYCYCLIC AROMATIC COMPOUNDS FOLLOWING INTRAPULMONARY APPLICATION IN RATS; EXP. PATHOL. 40(4):221-227, 1990]"
474,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,F344/MALE,LUNG IMPLANT,0; 50; 100; 200 UG IN BEESWAX/TRICAPRYLIN INTO LEFT LUNG ONCE (STUDY DURATION: 100 WK),LUNG: SQUAMOUS CELL CARCINOMA,POSITIVE,"[HORIKAWA,K, SERA,N, OTOFUJI,T, MURAKAMI,K, TOKIWA,H, IWAGAWA,M, IZUMI,K AND OTSUKA,H; PULMONARY CARCINOGENICITY OF 3,9- AND 3,7-DINITROFLUORANTHENE, 3-NITROFLUORANTHENE AND BENZO[A]PYRENE IN F344 RATS; CARCINOGENESIS 12(6):1003-1007, 1991]"
475,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,FISH,"SHEEPSHEAD MINNOW/MALE, FEMALE",IMMERSION,0; 2; 30; 200 PPB APPROXIMATE CONCENTRATIONS ADMINISTERED 1/WK FOR 6 OR 24 HR FOR 1 OR 2 WK (STUDY DURATION: 39 WK),,NEGATIVE,"[HAWKINS,WE, WALKER,WW, LYTLE,TF, LYTLE,JS AND OVERSTREET,RM; STUDIES ON THE CARCINOGENIC EFFECTS OF BENZO[A]PYRENE AND 7,12-DIMETHYLBENZ[A]ANTHRACENE ON THE SHEEPSHEAD MINNOW (CYPRINODON VARIEGATUS); ASTM SPEC. TECH. PUBL. 1124(AQUAT. TOXICOL. RISK ASSESS.: 14TH VOL.):97-104, 1991]"
476,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.005; 0.015 UMOL/G ONCE AT 12 DAYS OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; THE STRONG HEPATOCARCINOGENICITY OF THE ELECTROPHILIC AND MUTAGENIC METABOLITE 6-SULFOOXYMETHYLBENZO[A]PYRENE AND ITS FORMATION OF BENZYLIC DNA ADDUCTS IN THE LIVERS OF INFANT MALE B6C3F1 MICE; BIOCHEM. BIOPHYS. RES. COMMUN. 172(1):85-91, 1990]"
477,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INJECTION,0; 0.25; 1 UMOL PER MAMMARY GLAND (STUDY DURATION: 24 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[CAVALIERI,EL, HIGGINBOTHAM,S, RAMAKRISHNA,NVS, DEVANESAN,PD, TODOROVIC,R, ROGAN,EG AND SALMASI,S; COMPARATIVE DOSE-RESPONSE TUMORIGENICITY STUDIES OF DIBENZO[A,L]PYRENE VERSUS 7,12-DIMETHYLBENZ[A]ANTHRACENE, BENZO[A]PYRENE AND TWO DIBENZO[A]PYRENE DIHYDRODIOLS IN MOUSE SKIN AND RAT MAMMARY GLAND; CARCINOGENESIS 12(10):1939-1944, 1991]"
478,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,FISH,"RAINBOW TROUT/MALE, FEMALE",ORAL,0; 1000 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),LIVER: CARCINOMA,POSITIVE,"[HENDRICKS,JD, MEYERS,TR, SHELTON,DW, CASTEEL,JL AND BAILEY,GS; HEPATOCARCINOGENICITY OF BENZO[A]PYRENE TO RAINBOW TROUT BY DIETARY EXPOSURE AND INTRAPERITONEAL INJECTION; JNCI, J. NATL. CANCER INST. 74(4):839-851, 1985]"
479,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,FISH,"RAINBOW TROUT/MALE, FEMALE",INTRAPERITONEAL,0; 1 MG IN 0.4 ML PROPYLENE GLYCOL 1/MO FOR 12 MO BEGINNING AT 10 MO OF AGE (STUDY DURATION: 18 MO),LIVER: CARCINOMA,POSITIVE,"[HENDRICKS,JD, MEYERS,TR, SHELTON,DW, CASTEEL,JL AND BAILEY,GS; HEPATOCARCINOGENICITY OF BENZO[A]PYRENE TO RAINBOW TROUT BY DIETARY EXPOSURE AND INTRAPERITONEAL INJECTION; JNCI, J. NATL. CANCER INST. 74(4):839-851, 1985]"
480,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,HAMSTER,SYRIAN/FEMALE,INTRATRACHEAL,0; 1 MG IN 0.1 ML PHOSPHATE BUFFER 15/WK FOR 4 MO (STUDY DURATION: 443 D),TRACHEA: PAPILLOMA OR CARCINOMA,POSITIVE,"[YAMAMOTO,A, HISANAGA,A AND ISHINISHI,N; COMPARATIVE STUDY ON THE CARCINOGENICITY OF N-NITROSODIETHYLAMINE AND BENZO[A]PYRENE TO THE LUNG OF SYRIAN GOLDEN HAMSTERS INDUCED BY INTERMITTENT INSTILLATIONS TO THE TRACHEA; CANCER LETT. 25(3):271-276, 1985]"
481,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 1; 4; 8 NMOL IN 100 UL ACETONE 2/WK FOR 40 WK (STUDY DURATION: 48 WK),,NEGATIVE,"[HIGGINBOTHAM,S, RAMAKRISHNA,NVS, JOHANSSON,SL, ROGAN,EG AND CAVALIERI,EL; TUMOR-INITIATING ACTIVITY AND CARCINOGENICITY OF DIBENZO[A,L]PYRENE VERSUS 7,12-DIMETHYLBENZ[A]ANTHRACENE AND BENZO[A]PYRENE AT LOW DOSE IN MOUSE SKIN; CARCINOGENESIS 14(5):875-878, 1993]"
482,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 5; 10; 50; 100; 200 MG/KG BW ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[ROSS,JA, NELSON,GB, WILSON,KH, RABINOWITZ,JR, GALATI,A, STONER,GD, NESNOW,S AND MASS,MJ; ADENOMAS INDUCED BY POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MOUSE LUNG CORRELATE WITH TIME-INTEGRATED DNA ADDUCT LEVELS; CANCER RES. 55(5): 1039-1044, 1995]"
483,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/FEMALE,ORAL,0; 16; 98 PPM IN DIET FOR 260 D (STUDY DURATION: 260 D),LUNG: TUMOR; FORESTOMACH: TUMOR,POSITIVE,"[WEYAND,EH, CHEN,YC, WU,Y, KOGANTI,A, DUNSFORD,HA AND RODRIGUEZ,LV; DIFFERENCES IN THE TUMORIGENIC ACTIVITY OF A PURE HYDROCARBON AND A COMPLEX MIXTURE FOLLOWING INGESTION: BENZO[A]PYRENE VS MANUFACTURED GAS PLANT RESIDUE; CHEM. RES. TOXICOL. 8(7):949-954, 1995]"
484,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/MALE,SUBCUTANEOUS,0; 0.5; 1 MG IN 1% AQUEOUS GELATIN INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
485,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,MOUSE,C57BL/MALE,SUBCUTANEOUS,0; 0.5; 1 MG IN 1% AQUEOUS GELATIN INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),,NEGATIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
486,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,MOUSE,C57BR/CDJ/MALE,SUBCUTANEOUS,0; 0.5; 1 MG IN 1% AQUEOUS GELATIN INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),,NEGATIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
487,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,NIGP(S)/FEMALE,SUBCUTANEOUS,0; 40; 62.5; 125; 250; 500; 1000 UG INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
488,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,NIGP(S)/MALE,SUBCUTANEOUS,0; 40; 62.5; 125; 250; 500; 1000 UG INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
489,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/FEMALE,SUBCUTANEOUS,0; 40; 62.5; 125; 250; 500; 1000 UG INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
490,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/MALE,SUBCUTANEOUS,0; 40; 62.5; 125; 250; 500; 1000 UG INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
491,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,NIGP(S)/FEMALE,SUBCUTANEOUS,0; 0.5; 1 MG IN 1% AQUEOUS GELATIN INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
492,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,NIGP(S)/MALE,SUBCUTANEOUS,0; 0.5; 1 MG IN 1% AQUEOUS GELATIN INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
493,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,MOUSE,C57BR/CDJ/FEMALE,SUBCUTANEOUS,0; 0.5; 1 MG IN 1% AQUEOUS GELATIN INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),,NEGATIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
494,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,MOUSE,C57BL/FEMALE,SUBCUTANEOUS,0; 0.5; 1 MG IN 1% AQUEOUS GELATIN INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),,NEGATIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
495,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/FEMALE,SUBCUTANEOUS,0; 0.5; 1 MG IN 1% AQUEOUS GELATIN INJECTED IN THE SCAPULAR REGION OF NEWBORN MICE ONCE (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[YUN,TK, KIM,SH AND LEE,YS; TRIAL OF A NEW MEDIUM-TERM MODEL USING BENZO(A)PYRENE INDUCED LUNG TUMOR IN NEWBORN MICE; ANTICANCER RES. 15(3): 839-845, 1995]"
496,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,F344/MALE,PULMONARY IMPLANT,0; 50; 100; 200 UG IN 50 UL BEESWAX/TRICAPRYLIN IMPLANTED FOR UP TO 100 WK (STUDY DURATION: 100 WK),LUNG: TUMOR,POSITIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, OTOFUJI,T, TOKIWA,H, IZUMI,K AND OTSUKA,H; CARCINOGENICITY OF DINITROBENZO[A]PYRENES AND DINITROFLUORANTHENES IN F344 RATS; IN: DAI,Q, ARMOUR,MA AND ZHENG,Q (EDS.), RECENT ADV. CHEM. MOL. BIOL. CANCER RES., INT. SYMP., SCIENCE PRESS, BEIJING, CHINA, 1991, PP. 319-325]"
497,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,F344/MALE,SUBCUTANEOUS IMPLANT,0; 8; 40; 200; 1000 UG IN 50 UL BEESWAX/TRICAPRYLIN IMPLANTED FOR UP TO 45 WK (STUDY DURATION: 45 WK),IMPLANT SITE: TUMOR,POSITIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, OTOFUJI,T, TOKIWA,H, IZUMI,K AND OTSUKA,H; CARCINOGENICITY OF DINITROBENZO[A]PYRENES AND DINITROFLUORANTHENES IN F344 RATS; IN: DAI,Q, ARMOUR,MA AND ZHENG,Q (EDS.), RECENT ADV. CHEM. MOL. BIOL. CANCER RES., INT. SYMP., SCIENCE PRESS, BEIJING, CHINA, 1991, PP. 319-325]"
498,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,RAT,STRAIN-CD/FEMALE,GAVAGE,0; 50 UMOL IN 0.5 ML TRIOCTANOIN 1/WK FOR 8 WK (STUDY DURATION: 49 WK),"MAMMARY GLAND: FIBROADENOMA, DESMOPLASTIC ADENOMA, ADENOCARCINOMA",POSITIVE,"[EL-BAYOUMY,K, CHAE,YH, UPADHYAYA,P, RIVENSON,A, KURTZKE,C, REDDY,B AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF BENZO[A]PYRENE, 1-NITROPYRENE AND 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE ADMINISTERED BY GAVAGE TO FEMALE CD RATS; CARCINOGENESIS 16(2):431-434, 1995]"
499,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/FEMALE,GAVAGE,0; 1; 2; 3 UMOL IN 0.1 ML COTTONSEED OIL 1/WK FOR 8 WK (STUDY DURATION: 26 WK),LUNG: ADENOMA; FORESTOMACH: TUMOR,POSITIVE,"[HECHT,SS, ISAACS,S AND THRUSHIN,N; LUNG TUMOR INDUCTION IN A/J MICE BY THE TOBACCO SMOKE CARCINOGENS 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE AND BENZO[A]PYRENE: A POTENTIALLY USEFUL MODEL FOR EVALUATION OF CHEMOPREVENTIVE AGENTS; CARCINOGENESIS 15(12):2721-2725, 1994]"
500,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 1; 2; 3 UMOL IN 0.1 ML COTTONSEED OIL 1/WK FOR 8 WK (STUDY DURATION: 26 WK),LUNG: ADENOMA; FORESTOMACH: TUMOR,POSITIVE,"[HECHT,SS, ISAACS,S AND THRUSHIN,N; LUNG TUMOR INDUCTION IN A/J MICE BY THE TOBACCO SMOKE CARCINOGENS 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE AND BENZO[A]PYRENE: A POTENTIALLY USEFUL MODEL FOR EVALUATION OF CHEMOPREVENTIVE AGENTS; CARCINOGENESIS 15(12):2721-2725, 1994]"
501,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRATRACHEAL,0; 0.5; 1 MG ON CHARCOAL POWDER INSTILLED 8 TIMES (STUDY DURATION: 13 WK),LUNG: SQUAMOUS CELL CARCINOMA OR ADENOCARCINOMA,POSITIVE,"[KIM,SH AND LEE,CS; INDUCTION OF BENIGN AND MALIGNANT PULMONARY TUMORS IN MICE WITH BENZO[A]PYRENE; ANTICANCER RES. 16(1):465-470, 1996]"
502,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,C57BL/FEMALE,INTRATRACHEAL,0; 1 MG ON CHARCOAL POWDER INSTILLED 8 TIMES (STUDY DURATION: 13 WK),LUNG: SQUAMOUS CELL CARCINOMA OR ADENOCARCINOMA,POSITIVE,"[KIM,SH AND LEE,CS; INDUCTION OF BENIGN AND MALIGNANT PULMONARY TUMORS IN MICE WITH BENZO[A]PYRENE; ANTICANCER RES. 16(1):465-470, 1996]"
503,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,MOUSE,DBA/2/FEMALE,INTRATRACHEAL,0; 1 MG ON CHARCOAL POWDER INSTILLED 8 TIMES (STUDY DURATION: 13 WK),,NEGATIVE,"[KIM,SH AND LEE,CS; INDUCTION OF BENIGN AND MALIGNANT PULMONARY TUMORS IN MICE WITH BENZO[A]PYRENE; ANTICANCER RES. 16(1):465-470, 1996]"
504,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,MOUSE,N:GP(S)/FEMALE,INTRATRACHEAL,0; 1 MG ON CHARCOAL POWDER INSTILLED 8 TIMES (STUDY DURATION: 13 WK),,NEGATIVE,"[KIM,SH AND LEE,CS; INDUCTION OF BENIGN AND MALIGNANT PULMONARY TUMORS IN MICE WITH BENZO[A]PYRENE; ANTICANCER RES. 16(1):465-470, 1996]"
505,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/MALE,SUBCUTANEOUS,0; 40; 62.5; 125; 250; 500; 1000 UG FOR 9 WK (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[KIM,SH AND LEE,CS; INDUCTION OF BENIGN AND MALIGNANT PULMONARY TUMORS IN MICE WITH BENZO[A]PYRENE; ANTICANCER RES. 16(1):465-470, 1996]"
506,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/FEMALE,SUBCUTANEOUS,0; 40; 62.5; 125; 250; 500; 1000 UG FOR 9 WK (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[KIM,SH AND LEE,CS; INDUCTION OF BENIGN AND MALIGNANT PULMONARY TUMORS IN MICE WITH BENZO[A]PYRENE; ANTICANCER RES. 16(1):465-470, 1996]"
507,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,N:GP(S)/MALE,SUBCUTANEOUS,0; 40; 62.5; 125; 250; 500; 1000 UG FOR 9 WK (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[KIM,SH AND LEE,CS; INDUCTION OF BENIGN AND MALIGNANT PULMONARY TUMORS IN MICE WITH BENZO[A]PYRENE; ANTICANCER RES. 16(1):465-470, 1996]"
508,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,N:GP(S)/FEMALE,SUBCUTANEOUS,0; 40; 62.5; 125; 250; 500; 1000 UG FOR 9 WK (STUDY DURATION: 9 WK),LUNG: ADENOMA,POSITIVE,"[KIM,SH AND LEE,CS; INDUCTION OF BENIGN AND MALIGNANT PULMONARY TUMORS IN MICE WITH BENZO[A]PYRENE; ANTICANCER RES. 16(1):465-470, 1996]"
509,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 125; 250; 375 UG ADMINISTERED TO 15-DAY OLD MICE ONCE (STUDY DURATION: 52 WK),LIVER: TUMOR,POSITIVE,"[RODRIGUEZ,LV, DUNSFORD,HA, STEINBERG,M, CHALOUPKA,KK, ZHU,L, SAFE,S, WOMACK,JE AND GOLDSTEIN,LS; CARCINOGENICITY OF BENZO[A]PYRENE AND MANUFACTURED GAS PLANT RESIDUES IN INFANT MICE; CARCINOGENESIS 18(1):127-135, 1997]"
510,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,EU-PIM-1/MALE,GAVAGE,0; 4.3; 13; 39 MG/KG BW IN 0.1 ML SOY OIL 3/WK FOR 13 WK (STUDY DURATION: 291 D),LYMPHATIC SYSTEM: LYMPHOMA; FORESTOMACH: TUMOR,POSITIVE,"[KROESE,ED, DORTANT,PM, VAN STEEG,H, VAN OOSTROM,CTM, VAN OORDT,CW, VAN KRANEN,HJ, DE VRIES,A, WESTER,PW AND VAN KREIJL,CF; USE OF EU-PIM-1 TRANSGENIC MICE FOR SHORT-TERM IN VIVO CARCINOGENICITY TESTING: LYMPHOMA INDUCTION BY BENZO[A]PYRENE BUT NOT BY TPA; CARCINOGENESIS 18(5):975-980, 1997]"
511,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,WILDTYPE/MALE,GAVAGE,0; 13; 39 MG/KG BW IN 0.1 ML SOY OIL 3/WK FOR 13 WK (STUDY DURATION: 291 D),LYMPHATIC SYSTEM: LYMPHOMA; FORESTOMACH: TUMOR,POSITIVE,"[KROESE,ED, DORTANT,PM, VAN STEEG,H, VAN OOSTROM,CTM, VAN OORDT,CW, VAN KRANEN,HJ, DE VRIES,A, WESTER,PW AND VAN KREIJL,CF; USE OF EU-PIM-1 TRANSGENIC MICE FOR SHORT-TERM IN VIVO CARCINOGENICITY TESTING: LYMPHOMA INDUCTION BY BENZO[A]PYRENE BUT NOT BY TPA; CARCINOGENESIS 18(5):975-980, 1997]"
512,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0-200 MG/KG IN TRICAPRYLIN ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[NESNOW,S, ROSS,JA, STONER,GD AND MASS,MJ; TUMORIGENESIS OF CARCINOGENIC ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MICE: LINKAGE TO DNA ADDUCTS AND MUTATIONS IN ONCOGENES; POLYCYCLIC AROMAT. COMPD. 10(1-4):259-266, 1996]"
513,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5; 25; 100 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),FORESTOMACH: PAPILLOMA OR CARCINOMA; ESOPHAGUS: PAPILLOMA OR CARCINOMA; TONGUE: PAPILLOMA OR CARCINOMA,POSITIVE,"[CULP,SJ, GAYLOR,DW, SHELDON,WG, GOLDSTEIN,LS AND BELAND,FA; A COMPARISON OF THE TUMORS INDUCED BY COAL TAR AND BENZO[A]PYRENE IN A 2-YEAR BIOASSAY; CARCINOGENESIS 19(1):117-124, 1998]"
514,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Active,,,,MOUSE,A/J/MALE,INTRAPERITONEAL,0; 10; 100 MG/KG BW IN TRICAPRYLIN ONCE AT 4-5 WK OF AGE (STUDY DURATION: 7-8 MO),LUNG: TUMOR,POSITIVE,"[GRAY,DL WARSHAWSKY,D XUE,W NINES,R WANG,Y YAO,R AND STONER,GD; THE EFFECTS OF A BINARY MIXTURE OF BENZO(A)PYRENE AND 7H-DIBENZO(C,G)CARBAZOLE ON LUNG TUMORS AND K-RAS ONCOGENE MUTATIONS IN STRAIN A/J MICE; EXP. LUNG RES. 27(3):245-253, 2001]"
515,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,Mouse,129 x MF1 wild type (14-16 males and females),Intraperitoneal,"200 mg/kg, once, study duration 5 mo","Lung: adenoma (incidence 29% vs 25% in controls, multiplicity 0.4 vs 0.3 in controls)",Negative,"[RITCHIE,KJ HENDERSON,CJ WANG,XJ VASSIEVA,O CARRIE,D FARMER,PB GASKILL,M PARK,K AND WOLF,RC; GLUTATHIONE TRANSFERASE PI PLAYS A CRITICAL ROLE IN THE DEVELOPMENT OF LUNG CARCINOGENESIS FOLLOWING EXPOSURE TO TOBACCO-RELATED CARCINOGENS AND URETHANE; CANCER RESEARCH 67(19):9248-9257, 2007]"
516,363898026,2336,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,Inactive,,,,Mouse,129 x MF1 Gstp-null (14-15 males and females),Intraperitoneal,"200 mg/kg, once, study duration 5 mo","Lung: adenoma (incidence 71% vs 27% in controls, multiplicity 3.0 vs 0.3 in controls)",Negative,"[RITCHIE,KJ HENDERSON,CJ WANG,XJ VASSIEVA,O CARRIE,D FARMER,PB GASKILL,M PARK,K AND WOLF,RC; GLUTATHIONE TRANSFERASE PI PLAYS A CRITICAL ROLE IN THE DEVELOPMENT OF LUNG CARCINOGENESIS FOLLOWING EXPOSURE TO TOBACCO-RELATED CARCINOGENS AND URETHANE; CANCER RESEARCH 67(19):9248-9257, 2007]"
517,363898027,104853,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=C[C@@H]([C@H]5O)O)C=C2,Active,,,,MOUSE,C57BL/FEMALE,DERMAL,0.15; 0.30 UMOL IN ACETONE/NH4OH (1000:1) EVERY 2 WK FOR 60 WK,INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA,POSITIVE,"[LEVIN,W, WOOD,AW, YAGI,H, JERINA,DM AND CONNEY,AH; (+/-)-TRANS-7,8-DIHYDROXY-7,8-DIHYDRO-BENZO(A)PYRENE: A POTENT SKIN CARCINOGEN WHEN APPLIED TOPICALLY TO MICE; PROC. NATL. ACAD. SCI. USA 73:3867-3871, 1976]"
518,363898027,104853,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=C[C@@H]([C@H]5O)O)C=C2,Active,,,,MOUSE,"SWISS/MALE,FEMALE",INTRAPERITONEAL,"200 NMOL ON FIRST D OF LIFE, 400 NMOL ON D 8, 800 NMOL ON D 15",LUNG: ADENOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA,POSITIVE,"[KAPITULNIK,J, LEVIN,W, CONNEY,AH, YAGI,H AND JERINA,DM; BENZO(A)PYRENE-7,8-DIHYDRODIOL IS MORE CARCINOGENIC THAN BENZO(A)PYRENE IN NEWBORN MICE; NATURE 266:378-380, 1977]"
519,363898027,104853,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=C[C@@H]([C@H]5O)O)C=C2,Active,,,,FISH,"RAINBOW TROUT/MALE,FEMALE",INJECTION,0; 0.01; 1 UG INJECTED INTO NEWLY HATCHED SAC-FRY ONCE (STUDY DURATION: 9 MO),LIVER: TUMOR,POSITIVE,"[KELLY,JD, DUTCHUK,M, HENDRICKS,JD AND WILLIAMS,DE; HEPATOCARCINOGENIC POTENCY OF MIXED AND PURE ENANTIOMERS OF TRANS-7,8-DIHYDROBENZO[A]PYRENE-7,8-DIOL IN TROUT; CANCER LETT. 68(2-3):225-229, 1993]"
520,363898028,7220,C1=CC2=NNN=C2C=C1,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 11700; 23500 PPM IN DIET FOR 104 WK (STUDY DURATION: 106-109 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-88 Y78]"
521,363898028,7220,C1=CC2=NNN=C2C=C1,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 11700; 23500 PPM IN DIET FOR 104 WK (STUDY DURATION: 106-109 WK),LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-88 Y78]"
522,363898028,7220,C1=CC2=NNN=C2C=C1,Unspecified,,,,RAT,F344/MALE,ORAL,0; 6700; 12100 PPM IN DIET FOR 78 WK (STUDY DURATION: 105-106 WK),BRAIN: TUMOR,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-88 Y78]"
523,363898028,7220,C1=CC2=NNN=C2C=C1,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 6700; 12100 PPM IN DIET FOR 78 WK (STUDY DURATION: 105-106 WK),BRAIN: TUMOR,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-88 Y78]"
524,363898029,7503,C1=CC=C(C=C1)CCl,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 217 Y76]"
525,363898029,7503,C1=CC=C(C=C1)CCl,Inactive,,,,RAT,F344/MALE,ORAL (GAVAGE),0; 15; 30 MG/KG BW 3 X A WK FOR 2 YRS (TEST MATERIAL SOLVENT: CORN OIL),,NEGATIVE,"[LIJINSKY,W; CHRONIC BIOASSAY OF BENZYL CHLORIDE IN F344 RATS  (C57BL/6J X BALB/C)F1 MICE;  J. NATL. CANCER INST. 76(6):1231-1236, 1986]"
526,363898029,7503,C1=CC=C(C=C1)CCl,Active,,,,RAT,F344/FEMALE,ORAL (GAVAGE),0; 15; 30 MG/KG BW 3 X A WK FOR 2 YRS (TEST MATERIAL SOLVENT: CORN OIL),THYROID: C-CELL NEOPLASMS,POSITIVE,"[LIJINSKY,W; CHRONIC BIOASSAY OF BENZYL CHLORIDE IN F344 RATS  (C57BL/6J X BALB/C)F1 MICE;  J. NATL. CANCER INST. 76(6):1231-1236, 1986]"
527,363898029,7503,C1=CC=C(C=C1)CCl,Active,,,,MOUSE,B6C3F1/MALE,ORAL (GAVAGE),0; 50; 100 MG/KG BW 3 X A WK FOR 2 YRS (TEST MATERIAL SOLVENT: CORN OIL),FORESTOMACH: CARCINOMA AND PAPILLOMA; LIVER: CARCINOMA OR ADENOMA (LOWER DOSE ONLY); CIRCULATORY SYSTEM: HEMANGIOMA OR HEMANGIOSARCOMA (HIGH DOSE),POSITIVE,"[LIJINSKY,W; CHRONIC BIOASSAY OF BENZYL CHLORIDE IN F344 RATS  (C57BL/6J X BALB/C)F1 MICE;  J. NATL. CANCER INST. 76(6):1231-1236, 1986]"
528,363898029,7503,C1=CC=C(C=C1)CCl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL (GAVAGE),0; 50; 100 MG/KG BW 3 X A WK FOR 2 YRS (TEST MATERIAL SOLVENT: CORN OIL),"FORESTOMACH: CARCINOMA AND PAPILLOMA; LUNG: ALVEOLAR-BRONCHIOLAR ADENOMA OR CARCINOMA (HIGH DOSE ONLY, P=0.053)",POSITIVE,"[LIJINSKY,W; CHRONIC BIOASSAY OF BENZYL CHLORIDE IN F344 RATS  (C57BL/6J X BALB/C)F1 MICE;  J. NATL. CANCER INST. 76(6):1231-1236, 1986]"
529,363898030,23691992,CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](C)C)C=C3)C4=CC=C(C=C4)N(CC)CC5=CC(=CC=C5)S(=O)(=O)[O-].[Na+],Active,,,,RAT,,ORAL,,MAMMARY GLAND; INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V16 153 Y78]"
530,363898030,23691992,CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](C)C)C=C3)C4=CC=C(C=C4)N(CC)CC5=CC(=CC=C5)S(=O)(=O)[O-].[Na+],Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V16 153 Y78]"
531,363898030,23691992,CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](C)C)C=C3)C4=CC=C(C=C4)N(CC)CC5=CC(=CC=C5)S(=O)(=O)[O-].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
532,363898030,23691992,CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](C)C)C=C3)C4=CC=C(C=C4)N(CC)CC5=CC(=CC=C5)S(=O)(=O)[O-].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
533,363898031,5460467,[Be],Active,,,,RAT,WISTAR/FEMALE,INTRATRACHEAL,0.5; 2.5 MG/RAT IN SALINE SUSPENDED ONCE,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80]"
534,363898031,5460467,[Be],Active,,,,RAT,WISTAR/FEMALE,INTRATRACHEAL,"0, 0.5, 2.5 MG, SINGLE DOSE IN SALINE SUSPENSION",LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80][GROTH,DH, KOMMINENI,C AND MACKAY,GR; CARCINOGENICITY OF BERYLLIUM HYDROXIDE AND ALLOYS; ENVIRON. RES. 21:63-84, 1980, ]"
535,363898032,61577,[Be+2].C(=O)([O-])[O-],Active,,,,RABBIT,,INTRAMEDULLARY,O; O.5 ML OF A 2% SOLN 1/WK FOR 30 WK,BONE: OSTEOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80][MATSUURA,K; EXPERIMENTAL STUDIES ON THE PRODUCTION OF OSTEOSARCOMA BY BERYLLIUM COMPOUNDS, AND THE EFFECTS OF IRRADIATION (JPN.); JPN. J. ORTHOP. ASSOC. 48:403-418, 1974, ]"
536,363898033,14775,[Be]=O,Active,,,,RABBIT,,"INTRAVENOUS, INTRAMEDULLARY",,BONE: OSTEOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 17 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80]"
537,363898034,26077,[Be+2].[O-]S(=O)(=O)[O-],Active,,,,MONKEY,RHESUS,INHALATION,,LUNG: ANAPLASTIC CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 17 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80]"
538,363898034,26077,[Be+2].[O-]S(=O)(=O)[O-],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
539,363898034,26077,[Be+2].[O-]S(=O)(=O)[O-],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
540,363898035,62672,[Be+2].O.O.O.O.[O-]S(=O)(=O)[O-],Active,,,,RAT,SHERMAN,INHALATION,"35.7 UG/M3 8 HR/D, 5.5 D/WK FOR 6 MO",LUNG: CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80]"
541,363898035,62672,[Be+2].O.O.O.O.[O-]S(=O)(=O)[O-],Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",INHALATION,0; 34.25 UG/M3 BERYLLIUM FOR UP TO 56 WK,LUNG: ALVEOLAR ADENOCARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80][REEVES,AL AND VORWALD,AJ; BERYLLIUM CARCINOGENESIS. II. PULMONARY DEPOSITION AND CLEARANCE OF INHALED BERYLLIUM SULFATE IN THE RAT; CANCER RES. 27:446-451, 1967, ]"
542,363898035,62672,[Be+2].O.O.O.O.[O-]S(=O)(=O)[O-],Active,,,,RAT,WISTAR,INHALATION,"35.7 UG/M3 8 HR/D, 5.5 D/WK FOR 6 MO",LUNG: CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80]"
543,363898035,62672,[Be+2].O.O.O.O.[O-]S(=O)(=O)[O-],Active,,,,MOUSE,A/J/MALE,INTRAPERITONEAL,0; 0.48; 1.20; 2.40 MG IN DISTILLED WATER (TOTAL DOSE) GIVEN AS 0; 0.02; 0.05; 0.1 MG DOSES 3/WK FOR 8 WK (STUDY DURATION: 32 WK),LUNG: ADENOMA,POSITIVE,"[ASHBY,J, ISHIDATE,M, STONER,GD, MORGAN,MA, RATPAN,F AND CALLANDER,RD; STUDIES ON THE GENOTOXICITY OF BERYLLIUM SULFATE IN VITRO AND IN VIVO; MUTAT. RES. 240(3): 217-25, 1990]"
544,363898035,62672,[Be+2].O.O.O.O.[O-]S(=O)(=O)[O-],Active,,,,MONKEY,RHESUS,INHALATION,,LUNG: ANAPLASTIC CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 17  Y72]"
545,363898036,14767,[Be+2].[Be+2].[Be+2].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[Al+3].[Al+3],Active,,,,RAT,ALBINO/MALE,INHALATION,"15 MG/M3 6 HR/DAY, 5 DAY/WK FOR 17 MO",LUNG: ADENOCARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 17 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80]"
546,363898037,62432,C1CN1P(=S)(N2CC2)N3CCOCC3,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 55 Y75]"
547,363898038,8115,C(CCl)OCCCl,Active,,,,MOUSE,B6AKF1/MALE,GAVAGE/ORAL,100 MG/KG FROM DAY 7-28 OF LIFE THEN 300 MG/KG IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 117 Y75]"
548,363898038,8115,C(CCl)OCCCl,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE/ORAL,100 MG/KG FROM DAY 7-28 OF LIFE THEN 300 MG/KG IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 117 Y75]"
549,363898038,8115,C(CCl)OCCCl,Inactive,,,,RAT,"STRAIN-CD/MALE,FEMALE",GAVAGE,25; 50 MG/KG IN STEROID SUSPENDING VEHICLE 2/WK FOR 78 WK,,NEGATIVE,"[WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
550,363898038,8115,C(CCl)OCCCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 13.1; 4.36 UMOL IN DMSO 1/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NORPOTH,K, HEGER,M, MULLER,G, MOHTASHAMIPUR,E, KEMENA,A AND WITTING,C; INVESTIGATIONS ON METABOLISM, GENOTOXIC EFFECTS AND CARCINOGENICITY OF 2,2'-DICHLORODIETHYLETHER; J. CANCER RES. CLIN. ONCOL. 112(2):125-130, 1986]"
551,363898039,10307,C1=CC=C2C=C(C=CC2=C1)N(CCCl)CCCl,Active,,,,HUMAN,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 119 Y74]"
552,363898039,10307,C1=CC=C2C=C(C=CC2=C1)N(CCCl)CCCl,Active,,,,MOUSE,STRAIN-A,INTRAPERITONEAL,75; 300; 1200; 4800 MG/KG IN 12 DOSES OVER 4 WK,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 119 Y74]"
553,363898039,10307,C1=CC=C2C=C(C=CC2=C1)N(CCCl)CCCl,Active,,,,RAT,,SUBCUTANEOUS,40 MG IN REPEATED DOSES,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 119 Y74]"
554,363898040,10967,C(OCCl)Cl,Active,,,,HUMAN,,INHALATION,,LUNG: OAT CELL CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 231 Y74]"
555,363898040,10967,C(OCCl)Cl,Active,,,,MOUSE,STRAIN-A,INHALATION,"0.005 MG/L 6 HR/D, 5 D/WK FOR A TOTAL OF 82 D OVER 27 WK",LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 231 Y74]"
556,363898040,10967,C(OCCl)Cl,Active,,,,MOUSE,"ICR/MALE,FEMALE",SUBCUTANEOUS,12.5 UL/KG IN PEANUT OIL ONCE,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 231 Y74]"
557,363898040,10967,C(OCCl)Cl,Active,,,,MOUSE,ICR/FEMALE,DERMAL,2 MG IN 0.1 ML BENZENE 3/WK FOR 325 D,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 231 Y74]"
558,363898040,10967,C(OCCl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY,INHALATION,0.5 MG/M3 FOR 101 EXPOSURES,LUNG: SQUAMOUS CELL CARCINOMA; NASAL CAVITY: ESTHESIONEUROEPITHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 231 Y74]"
559,363898040,10967,C(OCCl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,3 MG IN 0.1 ML NUJOL 1/WK FOR 100 D THEN 1 MG 1/WK OR 3/MO FOR 200 D,INJECTION SITE: FIBROSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 231 Y74]"
560,363898040,10967,C(OCCl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,"0; 1; 10; 100 PPB 6 HR/D, 5 D/WK FOR 6 MO (STUDY DURATION: 19-28 MO)",NASAL CAVITY: ESTHESIONEUROEPITHELIOMA,POSITIVE,"[LEONG,BKJ, KOCIBA,RJ AND JERSEY,GC; A LIFETIME STUDY OF RATS AND MICE EXPOSED TO VAPORS OF BIS(CHLOROMETHYL)ETHER; TOXICOL. APPL. PHARMACOL. 58:269-281, 1981]"
561,363898040,10967,C(OCCl)Cl,Active,,,,MOUSE,ICR/MALE,INHALATION,"0; 10; 100 PPB 6 HR/D, 5 D/WK FOR 6 MO (STUDY DURATION: 24 MO)",LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[LEONG,BKJ, KOCIBA,RJ AND JERSEY,GC; A LIFETIME STUDY OF RATS AND MICE EXPOSED TO VAPORS OF BIS(CHLOROMETHYL)ETHER; TOXICOL. APPL. PHARMACOL. 58:269-281, 1981]"
562,363898041,7944,CC(CCl)OC(C)CCl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-191 Y79]"
563,363898041,7944,CC(CCl)OC(C)CCl,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-191 Y79]"
564,363898041,7944,CC(CCl)OC(C)CCl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5/WK FOR 103 WK,"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-239 Y82]"
565,363898041,7944,CC(CCl)OC(C)CCl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5/WK FOR 103 WK,"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-239 Y82]"
566,363898044,23662398,C(CO)N(CCO)C(=S)[S-].[K+],Active,,,,MOUSE,B6AKF1/MALE,GAVAGE/ORAL,464 MG/KG FROM D 7-28 OF LIFE THEN 1112 MG/KG IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 183 Y76]"
567,363898044,23662398,C(CO)N(CCO)C(=S)[S-].[K+],Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE/ORAL,464 MG/KG FROM D 7-28 OF LIFE THEN 1112 MG/KG IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 183 Y76]"
568,363898044,23662398,C(CO)N(CCO)C(=S)[S-].[K+],Inactive,,,,RAT,"STRAIN-CD/MALE,FEMALE",ORAL,500; 1000 PPM IN DIET FOR 78 WK,,NEGATIVE,"[WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
569,363898045,6623,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,Inactive,,,,Mouse,CD-1/Female (24/group),Subcutaneous,"0; 10; 100; 1000 ug/kg in corn oil, once a day from days 1-5 of life; study duration 18 mo)",Uterus; leiomyoma (0/18; 1/23; 2/20; 1/16 [multiple lesions]),Negative (Nonneoplastic and preneoplastic lesions observed in ovary/oviduct and uterus),"[NEWBOLD,RR JEFFERSON,WN AND PADILLA-BANKS,E; LONG-TERM ADVERSE EFFECTS OF NEONATAL EXPOSURE TO BISPHENOL A ON THE MURINE FEMALE REPRODUCTIVE TRACT; REPRODUCTIVE TECHNOLOGY 24(2):253-258, 2007]"
570,363898045,6623,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-215 Y82]"
571,363898045,6623,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),HEMATOPOIETIC SYSTEM: LYMPHOMA OR LEUKEMIA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-215 Y82]"
572,363898045,6623,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),HEMATOPOIETIC SYSTEM: LEUKEMIA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-215 Y82]"
573,363898045,6623,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,Unspecified,,,,RAT,F344/MALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),HEMATOPOIETIC SYSTEM: LEUKEMIA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-215 Y82]"
574,363898045,6623,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,Active,,,,Rat,Wistar-Furth/Female (?/group with maximum of 8 pups per dam),Osmotic pump to dams,0; 2.5; 25; 250; 1000 ug/kg bw/day from embryonic day 9 to postnatal day 1; study duration 50 or 95 postnatal days,Mammary gland; ductal hyperplasia,Positive (Significant increase at all dose levels at PND 50; significant at 2.5 ug at PND 95,"[MURRAY,T MAFFINI,M UCCI,A SONNENSCHEIN,C AND SOTO,A;  INDUCTION OF MAMMARY GLAND DUCTAL HYPERPLASIAS AND CARCINOMA  IN SITU FOLLOWING FETAL BISPHENOL A EXPOSURE; REPRODUCTIVE  TOXICOLOGY 23(3):383-390, 2007]"
575,363898046,8507,CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(=[N+](CC)CC)C=C2)C3=C(C=C(C=C3)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+],Active,,,,RAT,,"SUBCUTANEOUS, INTRAMUSCULAR",,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V16 163 Y78]"
576,363898047,19700,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5S(=O)(=O)[O-].[Na+].[Na+],Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V16 171 Y78]"
577,363898047,19700,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,STRAIN-CD/MALE,ORAL,0; 0.1; 1; 2% IN DIET FOR 116 WK (PARENTS FED 0; 0.1; 1; 2% RESPECTIVELY IN DIET) (STUDY DURATION: LIFETIME),,NEGATIVE,"[BORZELLECA,JF, DEPUKAT,K AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDIES OF FD AND C BLUE NO. 1 (BRILLIANT BLUE FCF) IN RATS AND MICE; FOOD CHEM. TOXICOL. 28(4):221-34, 1990]"
578,363898047,19700,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 0.1; 1; 2% IN DIET FOR 111 WK (PARENTS FED 0; 0.1; 1; 2% RESPECTIVELY IN DIET) (STUDY DURATION: LIFETIME),,NEGATIVE,"[BORZELLECA,JF, DEPUKAT,K AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDIES OF FD AND C BLUE NO. 1 (BRILLIANT BLUE FCF) IN RATS AND MICE; FOOD CHEM. TOXICOL. 28(4):221-34, 1990]"
579,363898047,19700,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 0.5; 1.5; 5% IN DIET FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[BORZELLECA,JF, DEPUKAT,K AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDIES OF FD AND C BLUE NO. 1 (BRILLIANT BLUE FCF) IN RATS AND MICE; FOOD CHEM. TOXICOL. 28(4):221-34, 1990]"
580,363898047,19700,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.5; 1.5; 5% IN DIET FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[BORZELLECA,JF, DEPUKAT,K AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDIES OF FD AND C BLUE NO. 1 (BRILLIANT BLUE FCF) IN RATS AND MICE; FOOD CHEM. TOXICOL. 28(4):221-34, 1990]"
581,363898047,19700,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 128.8 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
582,363898047,19700,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 128.8 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
583,363898048,5558,C(Br)(Br)Br,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-350 Y89]"
584,363898048,5558,C(Br)(Br)Br,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-350 Y89]"
585,363898048,5558,C(Br)(Br)Br,Active,,,,RAT,F344/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),LARGE INTESTINE: ADENOMATOUS POLYP OR ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-350 Y89]"
586,363898048,5558,C(Br)(Br)Br,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),LARGE INTESTINE: ADENOMATOUS POLYP; LARGE INTESTINE: ADENOMATOUS POLYP OR ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-350 Y89]"
587,363898048,5558,C(Br)(Br)Br,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[THEISS,JC, STONER,GD, SHIMKIN,MB AND WEISBURGER,EK; TEST FOR CARCINOGENICITY OF ORGANIC CONTAMINANTS OF UNITED STATES DRINKING WATERS BY PULMONARY TUMOR RESPONSE IN STRAIN A MICE; CANCER RES. 37:2717-2720, 1977]"
588,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,625; 1250 PPM 6 HR/D 5/WK FOR 61 WK,"LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA; MYOCARDIUM: HEMANGIOSARCOMA; FORESTOMACH: PAPILLOMA, SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; MAMMARY GLAND: ACINAR CELL CARCINOMA, ADENOSQUAMOUS CARCINOMA; OVARIES: GRANULOSA CELL TUMOR, CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-288 Y84]"
589,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,625; 1250 PPM 6 HR/D 5/WK FOR 60 WK,"LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA; MYOCARDIUM: HEMANGIOSARCOMA; FORESTOMACH: PAPILLOMA, SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-288 Y84]"
590,363898049,7845,C=CC=C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 1000; 8000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),UTERUS: SARCOMA; MAMMARY GLAND: ADENOMA; ZYMBAL GLAND: CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA,POSITIVE,"[OWEN,PE AND GLAISTER,JR; INHALATION TOXICITY AND CARCINOGENICITY OF 1,3-BUTADIENE IN SPRAGUE-DAWLEY RATS; ENVIRON. HEALTH PERSPECT. 86:19-25, 1990]"
591,363898049,7845,C=CC=C,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 1000; 8000 PPM 6 HR/D 5 D/WK FOR 111 WK (STUDY DURATION: 111 WK),PANCREAS: ACINAR CELL ADENOMA; TESTES: LEYDIG CELL TUMOR,POSITIVE,"[OWEN,PE AND GLAISTER,JR; INHALATION TOXICITY AND CARCINOGENICITY OF 1,3-BUTADIENE IN SPRAGUE-DAWLEY RATS; ENVIRON. HEALTH PERSPECT. 86:19-25, 1990]"
592,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 6.25; 20; 62.5; 200 PPM 6 HR/D 5 D/WK FOR 65 WK (STUDY DURATION: 104 WK),HEART: HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIOLAR TUMOR; MAMMARY GLAND: ADENOCARCINOMA; OVARY: GRANULOSA CELL TUMOR,POSITIVE,"[MELNICK,RL, HUFF,JE, ROYCROFT,JH, CHOU,BJ AND MILLER,RA; INHALATION TOXICOLOGY AND CARCINOGENICITY OF 1,3-BUTADIENE IN B6C3F1 MICE FOLLOWING 65 WEEKS OF EXPOSURE; ENVIRON. HEALTH PERSPECT. 86:27-36, 1990]"
593,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 6.25; 20; 62.5; 200 PPM, 6 HR/D 5 D/WK FOR 65 WK (STUDY DURATION: 104 WK)",HEART: HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIOLAR TUMOR; HARDERIAN GLAND: ADENOMA,POSITIVE,"[MELNICK,RL, HUFF,JE, ROYCROFT,JH, CHOU,BJ AND MILLER,RA; INHALATION TOXICOLOGY AND CARCINOGENICITY OF 1,3-BUTADIENE IN B6C3F1 MICE FOLLOWING 65 WEEKS OF EXPOSURE; ENVIRON. HEALTH PERSPECT. 86:27-36, 1990]"
594,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 6.25; 20; 62.5; 200; 625 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),"HEMATOPOIETIC SYSTEM: LYMPHOCYTIC LYMPHOMA, LYMPHOMA; BLOOD VESSELS: HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIOLAR TUMOR; FORESTOMACH: SQUAMOUS CELL TUMOR",POSITIVE,"[MELNICK,RL, HUFF,J, CHOE,BJ AND MILLER,RA; CARCINOGENICITY OF 1,3-BUTADIENE IN C57BL/6 X C3H F1 MICE AT LOW EXPOSURE CONCENTRATIONS; CANCER RES. 50(20):6592-6599, 1990]"
595,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 6.25; 20; 62.5; 200; 625 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),PREPUTIAL GLAND: ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR TUMOR; HARDERIAN GLAND: TUMOR,POSITIVE,"[MELNICK,RL, HUFF,J, CHOE,BJ AND MILLER,RA; CARCINOGENICITY OF 1,3-BUTADIENE IN C57BL/6 X C3H F1 MICE AT LOW EXPOSURE CONCENTRATIONS; CANCER RES. 50(20):6592-6599, 1990]"
596,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 6.25; 20; 62.5; 200; 625 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),"HEMATOPOIETIC SYSTEM: LYMPHOCYTIC LYMPHOMA, LYMPHOMA; BLOOD VESSELS: HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIOLAR TUMOR; FORESTOMACH: SQUAMOUS CELL TUMOR",POSITIVE,"[MELNICK,RL, HUFF,J, CHOE,BJ AND MILLER,RA; CARCINOGENICITY OF 1,3-BUTADIENE IN C57BL/6 X C3H F1 MICE AT LOW EXPOSURE CONCENTRATIONS; CANCER RES. 50(20):6592-6599, 1990]"
597,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 6.25; 20; 62.5; 200; 625 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),HARDERIAN GLAND: ADENOMA OR ADENOCARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA; OVARIES: GRANULOSA CELL TUMOR,POSITIVE,"[MELNICK,RL, HUFF,J, CHOE,BJ AND MILLER,RA; CARCINOGENICITY OF 1,3-BUTADIENE IN C57BL/6 X C3H F1 MICE AT LOW EXPOSURE CONCENTRATIONS; CANCER RES. 50(20):6592-6599, 1990]"
598,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 6.25; 20; 62.5; 200; 625 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),"HEART: HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA OR CARCINOMA; PREPUTIAL GLAND: CARCINOMA; KIDNEY: RENAL TUBULE ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-434 Y93]"
599,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 200 PPM 6 HR/D 5 D/WK FOR 40 WK; 625 PPM FOR 13 WK; 312 PPM FOR 52 WK OR 625 PPM FOR 26 WK FOLLOWED BY CONTROL CHAMBER FOR DURATION OF STUDY (STUDY DURATION: 2 YR),"HEART: HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA; HARDERIAN GLAND: ADENOMA OR CARCINOMA; PREPUTIAL GLAND: CARCINOMA; KIDNEY: RENAL TUBULE ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-434 Y93]"
600,363898049,7845,C=CC=C,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 6.25; 20; 62.5; 200; 625 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),"HEART: HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA OR CARCINOMA; OVARY: BENIGN OR MALIGNANT GRANULOSA CELL TUMOR, ADENOMA OR BENIGN MIXED TUMOR; MAMMARY GLAND: ADENOCANTHOMA, CARCINOMA OR MALIGNANT MIXED TUMOR",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-434 Y93]"
601,363898049,7845,C=CC=C,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 1000; 5000; 10000 PPM FOR 2 HR ONCE (STUDY DURATION: 2 YR),,NEGATIVE,"[BUCHER,JR, MELNICK,RL AND HILDEBRANDT,PK; LACK OF CARCINOGENICITY IN MICE EXPOSED ONCE TO HIGH CONCENTRATIONS OF 1,3-BUTADIENE; J. NATL. CANCER INST. 85(22):1866-1867, 1993]"
602,363898049,7845,C=CC=C,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 1000; 5000; 10000 PPM FOR 2 HR ONCE (STUDY DURATION: 2 YR),,NEGATIVE,"[BUCHER,JR, MELNICK,RL AND HILDEBRANDT,PK; LACK OF CARCINOGENICITY IN MICE EXPOSED ONCE TO HIGH CONCENTRATIONS OF 1,3-BUTADIENE; J. NATL. CANCER INST. 85(22):1866-1867, 1993]"
603,363898050,42094,CCCCN(C(CCC)OC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,38 UMOL/KG IN OLIVE OIL 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA,POSITIVE,"[TAKAHASHI,M, KUROKAWA,Y, MAEKAWA,A, KOKUBO,T, FURUKAWA,F, MOCHIZUKI,M, ANJO,T AND OKADA,M; COMPARATIVE CARCINOGENICITIES OF MODEL COMPOUNDS OF METABOLICALLY ACTIVATED N,N-DIBUTYLNITROSAMINE IN RATS; GANN 73:687-694, 1982]"
604,363898050,42094,CCCCN(C(CCC)OC(=O)C)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,38 UMOL/KG IN OLIVE OIL 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; LUNG: ADENOMA,POSITIVE,"[TAKAHASHI,M, KUROKAWA,Y, MAEKAWA,A, KOKUBO,T, FURUKAWA,F, MOCHIZUKI,M, ANJO,T AND OKADA,M; COMPARATIVE CARCINOGENICITIES OF MODEL COMPOUNDS OF METABOLICALLY ACTIVATED N,N-DIBUTYLNITROSAMINE IN RATS; GANN 73:687-694, 1982]"
605,363898051,42095,CCCCN(COC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,6.6 MG/KG 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA,POSITIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, MOCHIZUKI,M, ANJO,T, OKADA,M AND ODASHIMA,S; CARCINOGENICITY OF N-ALKYL-N-(ACETOXYMETHYL)- NITROSAMINES AFTER SUBCUTANEOUS INJECTIONS IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 104:13-21, 1982]"
606,363898051,42095,CCCCN(COC(=O)C)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,6.6 MG/KG 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; LUNG: ADENOMA OR ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA,POSITIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, MOCHIZUKI,M, ANJO,T, OKADA,M AND ODASHIMA,S; CARCINOGENICITY OF N-ALKYL-N-(ACETOXYMETHYL)- NITROSAMINES AFTER SUBCUTANEOUS INJECTIONS IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 104:13-21, 1982]"
607,363898052,,,Active,,,,HAMSTER,SYRIAN/MALE,ORAL,1; 2% IN DIET FOR 24 WK,FORESTOMACH: PAPILLOMA,POSITIVE,"[ITO,N, FUKUSHIMA,S, IMAIDA,K, SAKATA,T AND MASUI,T; INDUCTION OF PAPILLOMA IN THE FORESTOMACH OF HAMSTERS BY BUTYLATED HYDROXYANISOLE; GANN 74:459-461, 1983]"
608,363898052,,,Active,,,,RAT,"F344/MALE,FEMALE",ORAL,O.5; 2% IN DIET,"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[ITO,N, HAGIWARA,A, SHIBATA,M, OGISO,T AND FUKUSHIMA,S; INDUCTION OF SQUAMOUS CELL CARCINOMA IN THE FORESTOMACH OF F344 RATS TREATED WITH BUTYLATED HYDROXYANISOLE; GANN 73:332-334, 1982][ITO,N, FUKUSHIMA,S, HAGIWARA,A, SHIBATA,M AND OGISO,T; CARCINOGENICITY OF BUTYLATED HYDROXYANISOLE IN F344 RATS; J. NATL. CANCER INST. 70:343-352, 1983]"
609,363898052,,,Active,,,,RAT,F344/MALE,ORAL,0; 1.0; 2.0% IN DIET FOR 104 WK (STUDY DURATION: 24 MO),"FORESTOMACH: HYPERPLASIA, PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[ITO,N, HIROSE,M, FUKUSHIMA,S, TSUDA,H, TATEMATSU,M AND ASAMOTO,M; MODIFYING EFFECTS OF ANTIOXIDANTS ON CHEMICAL CARCINOGENESIS; TOXICOL. PATHOL. 14(3):315-323, 1986]"
610,363898052,,,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1.0% IN DIET FOR 104 WK (STUDY DURATION: 24 MO),FORESTOMACH: HYPERPLASIA,POSITIVE,"[ITO,N, HIROSE,M, FUKUSHIMA,S, TSUDA,H, TATEMATSU,M AND ASAMOTO,M; MODIFYING EFFECTS OF ANTIOXIDANTS ON CHEMICAL CARCINOGENESIS; TOXICOL. PATHOL. 14(3):315-323, 1986]"
611,363898052,,,Active,,,,HAMSTER,SYRIAN/MALE,ORAL,0; 1.0; 2.0% IN DIET FOR 104 WK (STUDY DURATION: 24 MO),"FORESTOMACH: HYPERPLASIA, PAPILLOMA",POSITIVE,"[ITO,N, HIROSE,M, FUKUSHIMA,S, TSUDA,H, TATEMATSU,M AND ASAMOTO,M; MODIFYING EFFECTS OF ANTIOXIDANTS ON CHEMICAL CARCINOGENESIS; TOXICOL. PATHOL. 14(3):315-323, 1986]"
612,363898052,,,Active,,,,RAT,F344/MALE,ORAL,0; 0.125; 0.25; 0.5; 1.0; 2% IN DIET FOR 104 WK (STUDY DURATION: 2 YR),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA, HYPERPLASIA",POSITIVE,"[ITO,N, FUKUSHIMA,S, TAMANO,S, HIROSE,M AND HAGIWARA,A; DOSE RESPONSE TO BUTYLATED HYDROXYANISOLE INDUCTION OF FORESTOMACH CARCINOGENESIS IN F344 RATS; J. NATL. CANCER INST. 77(6):1261-1265, 1986]"
613,363898052,,,Inactive,,,,SHREW,SUNCUS/MALE,ORAL,0; 0.5; 1% IN DIET FOR 80 WK (STUDY DURATION: 85 WK),,NEGATIVE,"[AMO,H, KUBOTA,H, LU,J AND MATSUYAMA,M; ADENOMATOUS HYPERPLASIA AND ADENOMAS IN THE LUNG INDUCED BY CHRONIC FEEDING OF BUTYLATED HYDROXYANISOLE TO JAPANESE HOUSE MUSK SHREW (SUNCUS MURINUS); CARCINOGENESIS (LONDON) 11(1):151-4, 1990]"
614,363898052,,,Inactive,,,,SHREW,SUNCUS/FEMALE,ORAL,0; 0.5; 1% IN DIET FOR 80 WK (STUDY DURATION: 85 WK),,NEGATIVE,"[AMO,H, KUBOTA,H, LU,J AND MATSUYAMA,M; ADENOMATOUS HYPERPLASIA AND ADENOMAS IN THE LUNG INDUCED BY CHRONIC FEEDING OF BUTYLATED HYDROXYANISOLE TO JAPANESE HOUSE MUSK SHREW (SUNCUS MURINUS); CARCINOGENESIS (LONDON) 11(1):151-4, 1990]"
615,363898052,,,Active,,,,FISH,RIVULUS OCELLATUS MARMORATUS,ORAL,0; 0.01; 0.05; 0.2; 0.8% IN DIET FOR 12 D (STUDY DURATION: 6 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[PARK,EH, CHANG,HH AND CHA,YN; INDUCTION OF HEPATIC TUMORS WITH BUTYLATED HYDROXYANISOLE IN THE SELF-FERTILIZING HERMAPHRODITIC FISH RIVULUS OCELLATUS MARMORATUS; JPN. J. CANCER RES. 81(8):738-741, 1990]"
616,363898052,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 24 WK (STUDY DURATION: 24 WK),,NEGATIVE,"[HIROSE,M, UWAGAWA,S, OZAKI,K, TAKABA,K AND ITO,N; EFFECTS OF BUTYLATED HYDROXYANISOLE PRETREATMENT ON LOW DOSE N-METHYL-N'-NITRO-N-NITROSOGUANIDINE- OR N,N-DIBUTYLNITROSAMINE-INDUCED RAT FORESTOMACH OR ESOPHAGEAL CARCINOGENESIS; CARCINOGENESIS 12(10):1773-1776, 1991]"
617,363898052,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 24 WK (STUDY DURATION: 48 WK),,NEGATIVE,"[HIROSE,M, UWAGAWA,S, OZAKI,K, TAKABA,K AND ITO,N; EFFECTS OF BUTYLATED HYDROXYANISOLE PRETREATMENT ON LOW DOSE N-METHYL-N'-NITRO-N-NITROSOGUANIDINE- OR N,N-DIBUTYLNITROSAMINE-INDUCED RAT FORESTOMACH OR ESOPHAGEAL CARCINOGENESIS; CARCINOGENESIS 12(10):1773-1776, 1991]"
618,363898052,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 24 WK (STUDY DURATION: 72 WK),,NEGATIVE,"[HIROSE,M, UWAGAWA,S, OZAKI,K, TAKABA,K AND ITO,N; EFFECTS OF BUTYLATED HYDROXYANISOLE PRETREATMENT ON LOW DOSE N-METHYL-N'-NITRO-N-NITROSOGUANIDINE- OR N,N-DIBUTYLNITROSAMINE-INDUCED RAT FORESTOMACH OR ESOPHAGEAL CARCINOGENESIS; CARCINOGENESIS 12(10):1773-1776, 1991]"
619,363898052,,,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369(CHEM. INDUCED CELL PROLIFERATION):43-52, 1991]"
620,363898052,,,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369(CHEM. INDUCED CELL PROLIFERATION):43-52, 1991]"
621,363898052,,,Inactive,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",ORAL,0; 0.6% IN DIET FOR 8 MO (STUDY DURATION: 8.5 MO),,NEGATIVE,"[HENDRICKS,JD, ARBOGAST,DN, PEREIRA,CB AND BAILEY,GS; LONG-TERM, HIGH-DOSE DIETARY EXPOSURE OF RAINBOW TROUT TO BUTYLATED HYDROXYANISOLE IS NON-CARCINOGENIC; CANCER LETT. 78(1-3):189-193, 1994]"
622,363898052,,,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369:43-52, 1991]"
623,363898052,,,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369:43-52, 1991]"
624,363898052,,,Inactive,,,,RAT,F344/MALE,ORAL,"0, 0.4% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK)",,NEGATIVE,"[HIROSE,M, TAKESADA,Y, TANAKA,H, TAMANO,S, KATO,T AND SHIRAI,T; CARCINOGENICITY OF ANTIOXIDANTS BHA, CAFFEIC ACID, SESAMOL, 4-METHOXYPHENOL AND CATECHOL AT LOW DOSES, EITHER ALONE OR IN COMBINATION, AND MODULATION OF THEIR EFFECTS IN A RAT MEDIUM-TERM MULTI-ORGAN CARCINOGENESIS MODEL; CARCINOGENESIS 19(1):207-212, 1998]"
625,363898052,,,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),"FORESTOMACH: SQUAMOUS CELL CARCINOMA, PAPILLOMA",POSITIVE,"[TAMANO,S, HIROSE,M, TANAKA,H, HAGIWARA,H AND SHIRAI,T; VARIATION IN SUSCEPTIBILITY TO THE INDUCTION OF FORESTOMACH TUMOURS BY BUTYLATED HYDROXYANISOLE AMONG RATS OF DIFFERENT STRAINS; FOOD CHEM. TOXICOL. 36(4):299-304, 1998]"
626,363898052,,,Active,,,,RAT,SHR/MALE,ORAL,0; 2% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),"FORESTOMACH: SQUAMOUS CELL CARCINOMA, PAPILLOMA",POSITIVE,"[TAMANO,S, HIROSE,M, TANAKA,H, HAGIWARA,H AND SHIRAI,T; VARIATION IN SUSCEPTIBILITY TO THE INDUCTION OF FORESTOMACH TUMOURS BY BUTYLATED HYDROXYANISOLE AMONG RATS OF DIFFERENT STRAINS; FOOD CHEM. TOXICOL. 36(4):299-304, 1998]"
627,363898052,,,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 2% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),"FORESTOMACH: SQUAMOUS CELL CARCINOMA, PAPILLOMA",POSITIVE,"[TAMANO,S, HIROSE,M, TANAKA,H, HAGIWARA,H AND SHIRAI,T; VARIATION IN SUSCEPTIBILITY TO THE INDUCTION OF FORESTOMACH TUMOURS BY BUTYLATED HYDROXYANISOLE AMONG RATS OF DIFFERENT STRAINS; FOOD CHEM. TOXICOL. 36(4):299-304, 1998]"
628,363898052,,,Active,,,,RAT,LEWIS/MALE,ORAL,0; 2% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),FORESTOMACH: PAPILLOMA,POSITIVE,"[TAMANO,S, HIROSE,M, TANAKA,H, HAGIWARA,H AND SHIRAI,T; VARIATION IN SUSCEPTIBILITY TO THE INDUCTION OF FORESTOMACH TUMOURS BY BUTYLATED HYDROXYANISOLE AMONG RATS OF DIFFERENT STRAINS; FOOD CHEM. TOXICOL. 36(4):299-304, 1998]"
629,363898052,,,Active,,,,RAT,F344/MALE,ORAL,2% IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: PAPILLOMA; SQUAMOUS CELL CARCINOMA,POSITIVE,"[KANEKO,M MORIMURA,K NISHIKAWA,T WANIBUCHI,H TAKADA,N OSUGI,H KINOSHITA,H AND FUKUSHIMA,S; DIFFERENT GENETIC ALTERATIONS IN RAT FORESTOMACH TUMORS INDUCED BY GENOTOXIC AND ON-GENOTOXIC CARCINOGENS; CARCINOGENESIS 23(10):1729-1735, 2002]"
630,363898053,31404,CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-150 Y79]"
631,363898053,31404,CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-150 Y79]"
632,363898053,31404,CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,Inactive,,,,MOUSE,"B6C3F1/MALE,FEMALE",ORAL,200; 1000; 5000 PPM IN DIET FOR 96 WK,,NEGATIVE,"[SHIRAI,T, HAGIWARA,A, KURATA,Y, SHIBATA,M, FUKUSHIMA,S AND ITO,N; LACK OF CARCINOGENICITY OF BUTYLATED HYDROXYTOLUENE ON LONG-TERM ADMINISTRATION TO B6C3F1 MICE; FOOD CHEM. TOXICOL. 20:861-865, 1982]"
633,363898053,31404,CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-150 Y79]"
634,363898053,31404,CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-150 Y79]"
635,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105-106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-213 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
636,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104-106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-213 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
637,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Active,,,,RAT,F344/MALE,ORAL,0; 3000; 6000; 12000 PPM IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),"PANCREAS: ACINAR CELL ADENOMA, ACINAR CELL ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-458 Y97]"
638,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Active,,,,RAT,F344/MALE,ORAL,"0; 12000 PPM IN DIET FOR 105 WK, CONTROL AND DOSED GROUPS FED AD LIBITUM (STUDY DURATION 2 YR)",PANCREAS(ACINUS): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
639,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Active,,,,RAT,F344/MALE,ORAL,"0; 12000 PPM IN DIET FOR 105 WK, CONTROL GROUP WAS WEIGHT-MATCHED TO DOSED GROUP (STUDY DURATION: 2 YR)",PANCREAS(ACINUS): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
640,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Inactive,,,,RAT,F344/MALE,ORAL,"0; 12000 PPM IN DIET FOR 105 WK, CONTROL GROUP DIET RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUPS (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
641,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Inactive,,,,RAT,F344/MALE,ORAL,"0; 12000 PPM IN DIET FOR 128 WK, CONTROL GROUP DIET RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUP (STUDY DURATION: LIFETIME)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
642,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 24000 PPM IN DIET FOR 106 WK, CONTROL AND DOSED GROUP FED AD LIBITUM (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
643,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 24000 PPM IN DIET FOR 106 WK, CONTROL GROUP WAS WEIGHT-MATCHED TO DOSED GROUP (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
644,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 24000 PPM IN DIET FOR 105 WK, CONTROL GROUP DIET RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUP (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
645,363898054,2347,CCCCOC(=O)C1=CC=CC=C1C(=O)OCC2=CC=CC=C2,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 6000; 12000 ; 24000 PPM IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),PANCREAS: ACINAR CELL ADENOMA; URINARY BLADDER: TRANSITIONAL EPITHELIAL PAPILLOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-458 Y97]"
646,363898055,35370,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Inactive,,,,RAT,STRAIN-CD/MALE,GAVAGE,"0; 80; 220; 600 MG/KG/D, HIGH DOSE LOWERED TO 450 MG/KG THEN 300 MG/KG ON DAYS 91 AND 278, RESPECTIVELY (STUDY DURATION: 24 MO)",,NEGATIVE,"[AYERS,KM, CLIVE,D, TUCKER,WE, HAJIAN,G AND DE MIRANDA,P; NONCLINCAL TOXICOLOGY STUDIES WITH ZIDOVUDINE: GENETIC TOXICITY TESTS AND CARCINOGENICITY BIOASSAYS IN MICE AND RATS; FUNDAM. APPL. TOXICOL. 32(2):148-158, 1996]"
647,363898055,35370,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Inactive,,,,MOUSE,CD-1/MALE,GAVAGE,0; 30; 60; 120 MG/KG/D ON DAY 91 OF STUDY DOSES LOWERED TO 20; 30; 40 MG/KG/D (STUDY DURATION: 19 MO),,NEGATIVE,"[AYERS,KM, CLIVE,D, TUCKER,WE, HAJIAN,G AND DE MIRANDA,P; NONCLINCAL TOXICOLOGY STUDIES WITH ZIDOVUDINE: GENETIC TOXICITY TESTS AND CARCINOGENICITY BIOASSAYS IN MICE AND RATS; FUNDAM. APPL. TOXICOL. 32(2):148-158, 1996]"
648,363898055,35370,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Active,,,,MOUSE,CD-1/FEMALE,GAVAGE,0; 30; 60; 120 MG/KG/D ON DAY 91 OF STUDY DOSES LOWERED TO 20; 30; 40 MG/KG (STUDY DURATION: 22 MO),VAGINA: SQUAMOUS CELL CARCINOMA,POSITIVE,"[AYERS,KM, CLIVE,D, TUCKER,WE, HAJIAN,G AND DE MIRANDA,P; NONCLINCAL TOXICOLOGY STUDIES WITH ZIDOVUDINE: GENETIC TOXICITY TESTS AND CARCINOGENICITY BIOASSAYS IN MICE AND RATS; FUNDAM. APPL. TOXICOL. 32(2):148-158, 1996]"
649,363898055,35370,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Active,,,,MOUSE,CD-1/FEMALE,INTRAVAGINAL,0; 5; 20 MG/ML IN 0.9% SALINE ADMINISTERED AT 0.2 ML 2/D (STUDY DURATION: 24 MO),VAGINA: SQUAMOUS CELL CARCINOMA,POSITIVE,"[AYERS,KM, CLIVE,D, TUCKER,WE, HAJIAN,G AND DE MIRANDA,P; NONCLINCAL TOXICOLOGY STUDIES WITH ZIDOVUDINE: GENETIC TOXICITY TESTS AND CARCINOGENICITY BIOASSAYS IN MICE AND RATS; FUNDAM. APPL. TOXICOL. 32(2):148-158, 1996]"
650,363898055,35370,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 30; 60; 120 MG/KG BW IN 0.5% METHYLCELLULOSE ADMINISTERED IN TWO EQUAL DOSES DAILY 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"VAGINA: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-469 Y99]"
651,363898055,35370,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 30; 60; 120 MG/KG BW IN 0.5% METHYLCELLULOSE ADMINISTERED IN TWO EQUAL DOSES DAILY 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"KIDNEY: RENAL TUBULE ADENOMA, RENAL TUBULE CARCINOMA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-469 Y99]"
652,363898055,35370,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Active,,,,Mouse,Swiss (CD-1)/Male F1 Generation,In utero,0; 50; 100; 200; 300 mg/kg by gavage to F0 generation females 7 d/wk for 29-39 d (delivery day): females mated with unexposed males on study days 9-13.,"Lung; Alveolar/Bronchiolar Carcinoma (5/50, 11/50, 6/50, 11/37, 8/32); Alveolar/Bronchiolar adenoma or carcinoma (14/50, 20/50, 13/50, 18/37, 18/32)",Positive; Decreased litter size and fertility rates at two highest doses,[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
653,363898055,35370,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Inactive,,,,Mouse,Swiss (CD-1)/Female F1 Generation,In utero,0; 50; 100; 200; 300 mg/kg by gavage to F0 generation females 7 d/wk for 29-39 d (delivery day): females mated with unexposed males on study days 9-13.,,Negative; Decreased litter size and fertility rates at two highest doses,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-522 Y06]"
654,363898056,6554,CCC(C)Br,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[POIRIER,LA, STONER,DK AND SHIMKIN,MB; BIOASSAY OF ALKYL HALIDES AND NUCLEOTIDE BASE ANALOGS BY PULMONARY TUMOR RESPONSE IN STRAIN A MICE; CANCER RES. 35:1411-1415, 1975]"
655,363898057,10485,CC(C)(C)Br,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[POIRIER,LA, STONER,DK AND SHIMKIN,MB; BIOASSAY OF ALKYL HALIDES AND NUCLEOTIDE BASE ANALOGS BY PULMONARY TUMOR RESPONSE IN STRAIN A MICE; CANCER RES. 35:1411-1415, 1975]"
656,363898058,149520,CCCCN(C(CCC)OO)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,38 UMOL/KG IN OLIVE OIL 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA,POSITIVE,"[TAKAHASHI,M, KUROKAWA,Y, MAEKAWA,A, KOKUBO,T, FURUKAWA,F, MOCHIZUKI,M, ANJO,T AND OKADA,M; COMPARATIVE CARCINOGENICITIES OF MODEL COMPOUNDS OF METABOLICALLY ACTIVATED N,N-DIBUTYLNITROSAMINE IN RATS; GANN 73:687-694, 1982]"
657,363898059,51804,CCCCN(C1CCC(=O)O1)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,38 UMOL/KG IN OLIVE OIL 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; LUNG: ADENOMA,POSITIVE,"[TAKAHASHI,M, KUROKAWA,Y, MAEKAWA,A, KOKUBO,T, FURUKAWA,F, MOCHIZUKI,M, ANJO,T AND OKADA,M; COMPARATIVE CARCINOGENICITIES OF MODEL COMPOUNDS OF METABOLICALLY ACTIVATED N,N-DIBUTYLNITROSAMINE IN RATS; GANN 73:687-694, 1982]"
658,363898060,13362,CCCCN(C(=O)N)N=O,Active,,,,MOUSE (NEWBORN),"CD-1/MALE,FEMALE",SUBCUTANEOUS,333 MG/KG IN 1% GEL SOLN WITHIN 24 HR OF BIRTH,"LUNG: ADENOMA, ADENOCARCINOMA; LIVER: ADENOMA",POSITIVE,"[FUJII,K AND NOMOTO,K-I; TUMOR INDUCTION BY A SINGLE SUBCUTANEOUS INJECTION OF 1-BUTYL-1-NITROSOUREA OR 1-BUTYLUREA IN NEWBORN MICE; CANCER LETT. 18:321-328, 1983]"
659,363898060,13362,CCCCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 15 MG/ML (TOTAL DOSE 0; 1.7 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 40 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
660,363898060,13362,CCCCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 15 MG/ML (TOTAL DOSE 0; 1.7 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 40 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: TUMOR; MAMMARY GLAND: TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
661,363898060,13362,CCCCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 15 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 40 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LUNG: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
662,363898060,13362,CCCCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 15 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 40 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LUNG: TUMOR; MAMMARY GLAND: TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
663,363898061,18303,CC1CC(=O)O1,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 225 Y76]"
664,363898061,18303,CC1CC(=O)O1,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 225 Y76]"
665,363898061,18303,CC1CC(=O)O1,Active,,,,RAT,,GAVAGE,,FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 225 Y76]"
666,363898061,18303,CC1CC(=O)O1,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 225 Y76]"
667,363898062,23973,[Cd],Active,,,,HUMAN,,"INHALATION, ORAL, DERMAL",,PROSTATE GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76]"
668,363898062,23973,[Cd],Active,,,,RAT,LONG-EVANS/FEMALE,INTRAMUSCULAR,14; 28 MG,"INJECTION SITE: RHABDOMYOSARCOMA, FIBROSARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76]"
669,363898062,23973,[Cd],Active,,,,RAT,"F344/MALE,FEMALE",INTRAMUSCULAR,5 MG GIVEN IN 2 INJECTIONS AT MONTHLY INTERVALS (STUDY DURATION: 12 MO),INJECTION SITE: FIBROSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76][FURST,A AND CASSETTA,D; FAILURE OF ZINC TO NEGATE CADMIUM CARCINOGENESIS; PROC. AM. ASSOC. CANCER RES. 13:62, 1972, ]"
670,363898064,24947,Cl[Cd]Cl,Active,,,,MOUSE,CD-1/MALE,SUBCUTANEOUS,5.5 MG/KG ONCE,TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76]"
671,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,5.5 MG/KG ONCE,INJECTION SITE: SARCOMA; TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76]"
672,363898064,24947,Cl[Cd]Cl,Active,,,,MOUSE,CD-1/MALE,SUBCUTANEOUS,"0, 0.03 MMOL/KG BW (5.5 MG/KG BW), SINGLE DOSE",TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76][GUNN,SA, GOULD,TC AND ANDERSON,WAD; CADMIUM-INDUCED INTERSTITIAL-CELL TUMOURS IN RATS AND MICE AND THEIR PREVENTION BY ZINC; J. NATL. CANCER INST. 31:745-753, 1963, ]"
673,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,"0, 0.03 MMOL/KG BW (5.5 MG/KG BW), SINGLE DOSE",TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76][GUNN,SA, GOULD,TC AND ANDERSON,WAD; CADMIUM-INDUCED INTERSTITIAL-CELL TUMOURS IN RATS AND MICE AND THEIR PREVENTION BY ZINC; J. NATL. CANCER INST. 31:745-753, 1963, ]"
674,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR,SUBCUTANEOUS,"0, 0.03 MMOL/KG BW (5.5 MG/KG BW), SINGLE DOSE",INJECTION SITE: SARCOMA; TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76][GUNN,SA, GOULD,TC AND ANDERSON,WAD; EFFECT OF ZINC ON CANCEROGENESIS BY CADMIUM; PROC. SOC. EXP. BIOL. (N.Y.) 115:653-657, 1964, ]"
675,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR,SUBCUTANEOUS,"0, 0.03 MMOL/KG BW (5.5 MG/KG BW), SINGLE DOSE, OBSERVED 2 YR",INJECTION SITE: SPINDLE CELL SARCOMA; TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76][KNORRE,VON D; ZUR INDUKTION VON HODENSWISCHENZELLTUMOREN AN DER ALBINORATTE DURCH KADMIUMCHLORID; ARCH. GESCHWULSTFORSCH. 38:257-263, 1971, ]"
676,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR,SUBCUTANEOUS,"0.02-0.03 MMOL/KG BW (3.7-5.5 MG/KG BW), SINGLE DOSE",INJECTION SITE: FIBROSARCOMA; TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76][LUCIS,OJ, LUCIS,R AND ATERMAN,K; TUMORIGENES IS BY CADMIUM; ONCOLOGY 26:53-67, 1972, ]"
677,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
678,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 30 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
679,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 6 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
680,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 6 MO (STUDY DURATION: 29 MO),"LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
681,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 30 UMOL/KG IN DORSAL THORACIC MIDLINE AREA ONCE (STUDY DURATION: 90 WK),"INJECTION SITE: SARCOMA, FIBROSARCOMA",POSITIVE,"[WAALKES,MP, REHM,S, SASS,B, KONISHI,N AND WARD,JM; CHRONIC CARCINOGENIC AND TOXIC EFFECTS OF A SINGLE SUBCUTANEOUS DOSE OF CADMIUM IN THE MALE FISCHER RAT; ENVIRON. RES. 55(1):40-50, 1991]"
682,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 30 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
683,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 30 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
684,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 6 MO (STUDY DURATION: 30 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
685,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 6 MO (STUDY DURATION: 29 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
686,363898064,24947,Cl[Cd]Cl,Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 30 UG/M3 19 HR/D 5 D/WK FOR 65 WK FOR A TOTAL CADMIUM DOSE OF 0; 180 MG/M3 (STUDY DURATION: 113 WK),,NEGATIVE,"[AUFDERHEIDE,M, MOHR,U, THIEDERMANN,KU AND HEINRICH,U; QUANTIFICATION OF HYPERPLASTIC AREAS IN HAMSTER LUNGS AFTER CHRONIC INHALATION OF DIFFERENT CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 27(1-3):173-180, 1990]"
687,363898064,24947,Cl[Cd]Cl,Inactive,,,,HAMSTER,SYRIAN/FEMALE,INHALATION,0; 30 UG/M3 19 HR/D 5 D/WK FOR 65 WK FOR A TOTAL CADMIUM DOSE OF 0; 180 MG/M3 (STUDY DURATION: 76 WK),,NEGATIVE,"[AUFDERHEIDE,M, MOHR,U, THIEDERMANN,KU AND HEINRICH,U; QUANTIFICATION OF HYPERPLASTIC AREAS IN HAMSTER LUNGS AFTER CHRONIC INHALATION OF DIFFERENT CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 27(1-3):173-180, 1990]"
688,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 MG/M3 AEROSOL 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
689,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 30 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; SQUAMOUS CELL CARCINOMA,POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
690,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 6 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
691,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 6 MO (STUDY DURATION: 29 MO),"LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
692,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,CS/MALE,INTRAPROSTATIC,0; 0.04 ML OF 0.1 MOLAR SOLUTION (0.73 MG) ONCE (STUDY DURATION: 250 D),PROSTATE: CARCINOMA,POSITIVE,"[HOFFMANN,L, PUTZKE,HP, KAMPEHL,HJ, RUSSBUELT,R, GASE,P, SIMONN,C, ERDMANN,T AND HUCKSTORF,C; CARCINOGENIC EFFECTS OF CADMIUM ON THE PROSTATE OF THE RAT; J. CANCER RES. CLIN. ONCOL. 109(3):193-199, 1985]"
693,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 12.5; 25; 50 UG/M3 AEROSOL 23 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),"LUNG: ADENOMA, ADENOCARCINOMA, EPIDERMOID CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D, TAKENAKA,S, OBERDOERSTER,G AND KOENIG,H; LUNG CARCINOMAS IN RATS AFTER LOW-LEVEL CADMIUM INHALATION; TOXICOL. ENVIRON. CHEM. 9(1):41-51, 1984]"
694,363898064,24947,Cl[Cd]Cl,Inactive,,,,MOUSE,DBA/MALE,SUBCUTANEOUS,0; 40 UMOL/KG ONCE (STUDY DURATION: 104 WK),,NEGATIVE,"[WAALKES,MP AND REHM,S; CHRONIC TOXIC AND CARCINOGENIC EFFECTS OF CADMIUM CHLORIDE IN MALE DBA/2NCR AND NFS/NCR MICE: STRAIN-DEPENDENT ASSOCIATION WITH TUMORS OF THE HEMATOPOIETIC SYSTEM, INJECTION SITE, LIVER, AND LUNG; FUNDAM. APPL. TOXICOL. 23(1):21-31, 1994]"
695,363898064,24947,Cl[Cd]Cl,Active,,,,MOUSE,DBA/MALE,SUBCUTANEOUS,0; 40 UMOL/KG 1/WK FOR 16 WK (STUDY DURATION: 104 WK),HEMATOPOIETIC SYSTEM: LYMPHOMA,POSITIVE,"[WAALKES,MP AND REHM,S; CHRONIC TOXIC AND CARCINOGENIC EFFECTS OF CADMIUM CHLORIDE IN MALE DBA/2NCR AND NFS/NCR MICE: STRAIN-DEPENDENT ASSOCIATION WITH TUMORS OF THE HEMATOPOIETIC SYSTEM, INJECTION SITE, LIVER, AND LUNG; FUNDAM. APPL. TOXICOL. 23(1):21-31, 1994]"
696,363898064,24947,Cl[Cd]Cl,Active,,,,MOUSE,NFS/MALE,SUBCUTANEOUS,0; 40 UMOL/KG ONCE (STUDY DURATION: 104 WK),LUNG: ADENOMA OR CARCINOMA,POSITIVE,"[WAALKES,MP AND REHM,S; CHRONIC TOXIC AND CARCINOGENIC EFFECTS OF CADMIUM CHLORIDE IN MALE DBA/2NCR AND NFS/NCR MICE: STRAIN-DEPENDENT ASSOCIATION WITH TUMORS OF THE HEMATOPOIETIC SYSTEM, INJECTION SITE, LIVER, AND LUNG; FUNDAM. APPL. TOXICOL. 23(1):21-31, 1994]"
697,363898064,24947,Cl[Cd]Cl,Active,,,,MOUSE,NFS/MALE,SUBCUTANEOUS,0; 40 UMOL/KG 1/WK FOR 16 WK (STUDY DURATION: 104 WK),INJECTION SITE: TUMOR; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[WAALKES,MP AND REHM,S; CHRONIC TOXIC AND CARCINOGENIC EFFECTS OF CADMIUM CHLORIDE IN MALE DBA/2NCR AND NFS/NCR MICE: STRAIN-DEPENDENT ASSOCIATION WITH TUMORS OF THE HEMATOPOIETIC SYSTEM, INJECTION SITE, LIVER, AND LUNG; FUNDAM. APPL. TOXICOL. 23(1):21-31, 1994]"
698,363898064,24947,Cl[Cd]Cl,Inactive,,,,MOUSE,BALB/MALE,SUBCUTANEOUS,0; 20 UMOL/KG ONCE (STUDY DURATION: 104 WK),,NEGATIVE,"[WAALKES,MP AND REHM,S; CARCINOGENIC AND CHRONIC TOXIC EFFECTS OF SINGLE AND MULTIPLE SUBCUTANEOUS DOSES OF CADMIUM CHLORIDE IN MALE BALB/C MICE; TOXIC SUBST. J. 13(2):97-111, 1994]"
699,363898064,24947,Cl[Cd]Cl,Active,,,,MOUSE,BALB/MALE,SUBCUTANEOUS,0; 20 UMOL/KG 1/WK FOR 16 WK (STUDY DURATION: 104 WK),HEMATOPOIETIC SYSTEM: TUMOR,POSITIVE,"[WAALKES,MP AND REHM,S; CARCINOGENIC AND CHRONIC TOXIC EFFECTS OF SINGLE AND MULTIPLE SUBCUTANEOUS DOSES OF CADMIUM CHLORIDE IN MALE BALB/C MICE; TOXIC SUBST. J. 13(2):97-111, 1994]"
700,363898064,24947,Cl[Cd]Cl,Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 40 UMOL/KG ONCE AT 8 WK OF AGE (STUDY DURATION: 104 WK),ADRENAL GLAND: ADENOMA,POSITIVE,"[WAALKES,MP AND REHM,S; CARCINOGENIC AND CHRONIC TOXIC EFFECTS OF SINGLE OR MULTIPLE SUBCUTANEOUS DOSES OF CADMIUM CHLORIDE IN MALE SWISS [CR:NIH(S)] MICE; TOXIC SUBST. MECH. 14(2):79-92, 1995]"
701,363898064,24947,Cl[Cd]Cl,Inactive,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 40 UMOL/KG 1/WK FOR 16 WK BEGINNING AT 8 WK OF AGE (STUDY DURATION: 104 WK),,NEGATIVE,"[WAALKES,MP AND REHM,S; CARCINOGENIC AND CHRONIC TOXIC EFFECTS OF SINGLE OR MULTIPLE SUBCUTANEOUS DOSES OF CADMIUM CHLORIDE IN MALE SWISS [CR:NIH(S)] MICE; TOXIC SUBST. MECH. 14(2):79-92, 1995]"
702,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 10; 20; 30 UMOL/KG BW 1X/WK FOR 18 WK (STUDY DURATION: 18 WK),INJECTION SITE SARCOMA,POSITIVE,"[WAALKES,MP REHM,S AND CHERIAN,MG; REPEATED CADMIUM EXPOSURES ENHANCE THE MALIGNANT PROGRESSION OF ENSUING TUMORS IN RATS; TOXICOL. SCI. 54(1):110-120, 2000]"
703,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,"0; 3 UMOL/KG BW ONCE, THEN 30 UMOL/KG BW 1X/WK FOR 17 WK BEGINNING 1 WK POST INITIAL DOSE (STUDY DURATION: 18 WK)",INJECTION SITE SARCOMA,POSITIVE,"[WAALKES,MP REHM,S AND CHERIAN,MG; REPEATED CADMIUM EXPOSURES ENHANCE THE MALIGNANT PROGRESSION OF ENSUING TUMORS IN RATS; TOXICOL. SCI. 54(1):110-120, 2000]"
704,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 10; 20; 30 UMOL/KG BW 1X/WK FOR 18 WK (STUDY DURATION: 18 WK),INJECTION SITE SARCOMA,POSITIVE,"[WAALKES,MP REHM,S AND CHERIAN,MG; REPEATED CADMIUM EXPOSURES ENHANCE THE MALIGNANT PROGRESSION OF ENSUING TUMORS IN RATS; TOXICOL. SCI. 54(1):110-120, 2000]"
705,363898064,24947,Cl[Cd]Cl,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,"0; 3 UMOL/KG BW ONCE, THEN 30 UMOL/KG BW 1X/WK FOR 17 WK BEGINNING 1 WK POST INITIAL DOSE (STUDY DURATION: 18 WK)",INJECTION SITE SARCOMA,POSITIVE,"[WAALKES,MP REHM,S AND CHERIAN,MG; REPEATED CADMIUM EXPOSURES ENHANCE THE MALIGNANT PROGRESSION OF ENSUING TUMORS IN RATS; TOXICOL. SCI. 54(1):110-120, 2000]"
706,363898065,14782,O=[Cd],Active,,,,RAT,FEMALE,SUBCUTANEOUS,25 MG ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76]"
707,363898065,14782,O=[Cd],Active,,,,RAT,FEMALE,SUBCUTANEOUS,"25 MG, SINGLE DOSE",INJECTION SITE,POSITIVE,"[KAZANTZIS,G AND HANBURY,WJ; THE INDUCTION OF SARCOMA IN THE RAT BY CADMIUM SULPHIDE AND BY CADMIUM OXIDE; BR. J. CANCER 20:190-199, 1966]"
708,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 OF CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
709,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 30 UG/M3 OF CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
710,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 OF CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 7 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
711,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 OF CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 11 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
712,363898065,14782,O=[Cd],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 OF CADMIUM OXIDE DUST 40 HR/WK FOR 6 MO (STUDY DURATION: 31 MO),,NEGATIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
713,363898065,14782,O=[Cd],Inactive,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 OF CADMIUM OXIDE DUST 40 HR/WK FOR 6 MO (STUDY DURATION: 31 MO),,NEGATIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
714,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 OF CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 29 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
715,363898065,14782,O=[Cd],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 10 UG/M3 OF CADMIUM OXIDE FUME 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),,NEGATIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
716,363898065,14782,O=[Cd],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 OF CADMIUM OXIDE FUME 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),,NEGATIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
717,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
718,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 30 UG/M3 CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
719,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 7 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
720,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 4 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
721,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 CADMIUM OXIDE DUST DISCONTINOUS EXPOSURE FOR 40 HR/WK FOR 6 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
722,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 CADMIUM OXIDE DUST DISCONTINOUS EXPOSURE FOR 40 HR/WK FOR 6 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
723,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 18 MO ADMINISTERED TO RATS MAINTAINED ON ZINC REDUCED (24 PPM) DIET (STUDY DURATION: 29 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
724,363898065,14782,O=[Cd],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 10 UG/M3 CADMIUM OXIDE FUME 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),,NEGATIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
725,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 CADMIUM OXIDE FUME 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
726,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),LUNG: ADENOMA OR ADENOCARCINOMA OR SQUAMOUS CELL TUMOR OR ADENOSQUAMOUS CARCINOMA,POSITIVE,"[TAKENAKA,S, GLASER,U, OLDIGES,H AND MOHR,U;MORPHOLOGICAL EFFECTS OF CADMIUM OXIDE AEROSOLS ON THE RAT LUNG; TOXICOL. ENVIRON. CHEM. 27(1-3):163-172, 1990]"
727,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 CADMIUM OXIDE DUST 22 HR/D 7 D/WK FOR 7 MO (STUDY DURATION: 31 MO),LUNG: ADENOMA OR ADENOCARCINOMA OR SQUAMOUS CELL TUMOR,POSITIVE,"[TAKENAKA,S, GLASER,U, OLDIGES,H AND MOHR,U;MORPHOLOGICAL EFFECTS OF CADMIUM OXIDE AEROSOLS ON THE RAT LUNG; TOXICOL. ENVIRON. CHEM. 27(1-3):163-172, 1990]"
728,363898065,14782,O=[Cd],Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 10 UG/M3 19 HR/D 5 D/WK FOR 65 WK FOR A TOTAL CADMIUM DOSE OF 0; 63 MG/M3 (STUDY DURATION: 113 WK),,NEGATIVE,"[AUFDERHEIDE,M, MOHR,U, THIEDERMANN,KU AND HEINRICH,U; QUANTIFICATION OF HYPERPLASTIC AREAS IN HAMSTER LUNGS AFTER CHRONIC INHALATION OF DIFFERENT CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 27(1-3):173-180, 1990]"
729,363898065,14782,O=[Cd],Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 90 UG/M3 8 HR/D 5 D/WK FOR 65 WK FOR A TOTAL CADMIUM DOSE OF 0; 216 MG/M3 (STUDY DURATION: 113 WK),,NEGATIVE,"[AUFDERHEIDE,M, MOHR,U, THIEDERMANN,KU AND HEINRICH,U; QUANTIFICATION OF HYPERPLASTIC AREAS IN HAMSTER LUNGS AFTER CHRONIC INHALATION OF DIFFERENT CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 27(1-3):173-180, 1990]"
730,363898065,14782,O=[Cd],Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 270 UG/M3 8 HR/D 5 D/WK FOR 53 WK FOR A TOTAL CADMIUM DOSE OF 0; 522 MG/M3 (STUDY DURATION: 70 WK),,NEGATIVE,"[AUFDERHEIDE,M, MOHR,U, THIEDERMANN,KU AND HEINRICH,U; QUANTIFICATION OF HYPERPLASTIC AREAS IN HAMSTER LUNGS AFTER CHRONIC INHALATION OF DIFFERENT CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 27(1-3):173-180, 1990]"
731,363898065,14782,O=[Cd],Inactive,,,,RAT,WISTAR/FEMALE,INHALATION,"0; 30 UG/M3 8 HR/D,5D/WK FOR 18 MO (STUDY DURATION: 18 MO)",,NEGATIVE,"[OLDIGES,H, GLASER,U AND HOCHRAINER,D; TOXICITY AND CARCINOGENIC RISK AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS IN WISTAR RATS; ENVIRON. HYG., [EUR. MEET. ENVIRON. HYG.] 1:121-124, 1987]"
732,363898065,14782,O=[Cd],Inactive,,,,RAT,WISTAR/MALE,INHALATION,"0; 90 UG/M3, 8 HR/D, 5D/WK FOR 7.1 MO (STUDY DURATION: 7.1 MO)",,NEGATIVE,"[OLDIGES,H, GLASER,U AND HOCHRAINER,D; TOXICITY AND CARCINOGENIC RISK AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS IN WISTAR RATS; ENVIRON. HYG., [EUR. MEET. ENVIRON. HYG.] 1:121-124, 1987]"
733,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 DUST 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
734,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 30 UG/M3 DUST 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
735,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 DUST 22 HR/D 7 D/WK FOR 7 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
736,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 DUST 22 HR/D 7 D/WK FOR 11 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
737,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 DUST 8 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
738,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 DUST 8 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 31 MO),"LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
739,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 DUST 22 HR/D 7 D/WK FOR 18 MO MAINTAINED ON ZN REDUCED DIET (24 PPM) FOR STUDY DURATION (STUDY DURATION: 29 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
740,363898065,14782,O=[Cd],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 10 UG/M3 FUME 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),,NEGATIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
741,363898065,14782,O=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 30 UG/M3 FUME 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
742,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,ALBINO/MALE,SUBCUTANEOUS,0.5 MG IN WATER 1/WK FOR 10 WK,INJECTION SITE: SARCOMA; TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76]"
743,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,CB/MALE,SUBCUTANEOUS,"0.5 MG, 1/WK FOR 10 WK",INJECTION SITE: SARCOMA; TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76][HADDOW,A, ROE,FJC, DUKES,CE AND MITCHLEY,BCV; CADMIUM NEOPLASIA: SARCOMATA AT THE SITE OF INJECTION OF CADMIUM SULPHATE IN RATS AND MICE; BR. J. CANCER 18:667-673, 1964, ][ROE,FJC, DUKES,CE, CAMERON,KM, PUGH,RCB AND MITCHLEY,BCV; CADMIUM NEOPLASIA: TESTICULAR ATROPHY AND LEYDIG CELL HYPERPLASIA AND NEOPLASIA IN RATS AND MICE FOLLOWING SUBCUTANEOUS INJECTION OF CADMIUM SALTS; BR. J. CANCER 18:674-681, 1964, ]"
744,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 14 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
745,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 29 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
746,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 14 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
747,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 29 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
748,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 30 UG/M3 19 HR/D 5 D/WK FOR 65 WK FOR A TOTAL CADMIUM DOSE OF 0; 180 MG/M3 (STUDY DURATION: 113 WK),,NEGATIVE,"[AUFDERHEIDE,M, MOHR,U, THIEDERMANN,KU AND HEINRICH,U; QUANTIFICATION OF HYPERPLASTIC AREAS IN HAMSTER LUNGS AFTER CHRONIC INHALATION OF DIFFERENT CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 27(1-3):173-180, 1990]"
749,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Inactive,,,,HAMSTER,SYRIAN/FEMALE,INHALATION,0; 30 UG/M3 19 HR/D 5 D/WK FOR 65 WK FOR A TOTAL CADMIUM DOSE OF 0; 180 MG/M3 (STUDY DURATION: 77 WK),,NEGATIVE,"[AUFDERHEIDE,M, MOHR,U, THIEDERMANN,KU AND HEINRICH,U; QUANTIFICATION OF HYPERPLASTIC AREAS IN HAMSTER LUNGS AFTER CHRONIC INHALATION OF DIFFERENT CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 27(1-3):173-180, 1990]"
750,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 135 MO (STUDY DURATION: 13.5 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, GLASER,U AND HOCHRAINER,D; TOXICITY AND CARCINOGENIC RISK AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS IN WISTAR RATS; ENVIRON. HYG., [EUR. MEET. ENVIRON. HYG.] 1:121-124, 1987]"
751,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D WK FOR 18 MO (STUDY DURATION: 18 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, GLASER,U AND HOCHRAINER,D; TOXICITY AND CARCINOGENIC RISK AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS IN WISTAR RATS; ENVIRON. HYG., [EUR. MEET. ENVIRON. HYG.] 1:121-124, 1987]"
752,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 14 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
753,363898066,24962,[O-]S(=O)(=O)[O-].[Cd+2],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 29 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
754,363898067,14783,S=[Cd],Active,,,,RAT,,"INTRAMUSCULAR, SUBCUTANEOUS",,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76]"
755,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR,SUBCUTANEOUS,"25 MG, SINGLE DOSE",INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76][KANISAWA,M AND SCHROEDER,HA; LIFE TERM STUDIES ON THE EFFECT OF TRACE ELEMENTS ON SPONTANEOUS TUMORS IN MICE AND RATS; CANCER RES. 29:892-895, 1969, ][KAZANTZIS,G AND HANBURY,WJ; THE INDUCTION OF SARCOMA IN THE RAT BY CADMIUM SULPHIDE AND BY CADMIUM OXIDE; BR. J. CANCER 20:190-199, 1966, ]"
756,363898067,14783,S=[Cd],Active,,,,RAT,"MALE,FEMALE",INTRAMUSCULAR,"50 MG, SINGLE DOSE",INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 74 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 39 Y76][KAZANTZIS,G AND HANBURY,WJ; THE INDUCTION OF SARCOMA IN THE RAT BY CADMIUM SULPHIDE AND BY CADMIUM OXIDE; BR. J. CANCER 20:190-199, 1966, ]"
757,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL TUMOR",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
758,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 30 MO),"LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
759,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 270 UG/M3 22 HR/D 7 D/WK FOR 16 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
760,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 270 UG/M3 22 HR/D 7 D/WK FOR 16 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
761,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 810 UG/M3 22 HR/D 7 D/WK FOR 7 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
762,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 810 UG/M3 22 HR/D 7 D/WK FOR 10 MO (STUDY DURATION: 29 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
763,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 2430 UG/M3 22 HR/D 7 D/WK FOR 4 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
764,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 2430 UG/M3 22 HR/D 7 D/WK FOR 3 MO (STUDY DURATION: 31 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
765,363898067,14783,S=[Cd],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 270 UG/M3 40 HR/WK FOR 6 MO (STUDY DURATION: 27 MO),,NEGATIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
766,363898067,14783,S=[Cd],Inactive,,,,RAT,WISTAR/FEMALE,INHALATION,0; 270 UG/M3 40 HR/WK FOR 6 MO (STUDY DURATION: 29 MO),,NEGATIVE,"[OLDIGES,H, HOCHRAINER,D AND GLASER,U; LONG-TERM INHALATION STUDY WITH WISTAR RATS AND FOUR CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 19(3-4):217-22, 1989]"
767,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 30 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
768,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
769,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 270 UG/M3 22 HR/D 7 D/WK FOR 16 MO (STUDY DURATION: 30 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
770,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 270 UG/M3 22 HR/D 7 D/WK FOR 16 MO (STUDY DURATION: 30 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
771,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 810 UG/M3 22 HR/D 7 D/WK FOR 7 MO (STUDY DURATION: 30 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
772,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 810 UG/M3 22 HR/D 7 D/WK FOR 10 MO (STUDY DURATION: 29 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
773,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 2430 UG/M3 22 HR/D 7 D/WK FOR 4 MO (STUDY DURATION: 30 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
774,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 2430 UG/M3 22 HR/D 7 D/WK FOR 3 MO (STUDY DURATION: 31 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
775,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 270 UG/M3 DISCONTINOUS EXPOSURE FOR 40 HR/WK FOR 6 MO (STUDY DURATION: 27 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
776,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 270 UG/M3 DISCONTINOUS EXPOSURE FOR 40 HR/WK FOR 6 MO (STUDY DURATION: 29 MO),LUNG: TUMOR,POSITIVE,"[GLASER,U, HOCHRAINER,D, OTTO,FJ AND OLDIGES,H; CARCINOGENICITY AND TOXICITY OF FOUR CADMIUM COMPOUNDS INHALED BY RATS; TOXICOL. ENVIRON. CHEM. 27(1-3):153-162, 1990]"
777,363898067,14783,S=[Cd],Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 90 UG/M3 19 HR/D 5 D/WK FOR 65 WK FOR A TOTAL CADMIUM DOSE OF 0; 552 MG/M3 (STUDY DURATION: 111 WK),,NEGATIVE,"[AUFDERHEIDE,M, MOHR,U, THIEDERMANN,KU AND HEINRICH,U; QUANTIFICATION OF HYPERPLASTIC AREAS IN HAMSTER LUNGS AFTER CHRONIC INHALATION OF DIFFERENT CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 27(1-3):173-180, 1990]"
778,363898067,14783,S=[Cd],Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 270 UG/M3 8 HR/D 5 D/WK FOR 26 WK FOR A TOTAL CADMIUM DOSE OF 0; 278 MG/M3 (STUDY DURATION: 101 WK),,NEGATIVE,"[AUFDERHEIDE,M, MOHR,U, THIEDERMANN,KU AND HEINRICH,U; QUANTIFICATION OF HYPERPLASTIC AREAS IN HAMSTER LUNGS AFTER CHRONIC INHALATION OF DIFFERENT CADMIUM COMPOUNDS; TOXICOL. ENVIRON. CHEM. 27(1-3):173-180, 1990]"
779,363898067,14783,S=[Cd],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[OLDIGES,H, GLASER,U AND HOCHRAINER,D; TOXICITY AND CARCINOGENIC RISK AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS IN WISTAR RATS; ENVIRON. HYG., [EUR. MEET. ENVIRON. HYG.] 1:121-124, 1987]"
780,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 90 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
781,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 90 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 18 MO (STUDY DURATION: 31 MO),"LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
782,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 270 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 16 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
783,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 270 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 16 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
784,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 810 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 7 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA, COMBINED TUMOR",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
785,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 810 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 10 MO (STUDY DURATION: 29 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
786,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 2430 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 4 MO (STUDY DURATION: 30 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
787,363898067,14783,S=[Cd],Inactive,,,,RAT,WISTAR/FEMALE,INHALATION,0; 2430 UG/M3 AEROSOL 22 HR/D 7 D/WK FOR 3 MO (STUDY DURATION: 31 MO),,NEGATIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
788,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 270 UG/M3 AEROSOL 8 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 27 MO),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA,POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
789,363898067,14783,S=[Cd],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 270 UG/M3 AEROSOL 8 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 29 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[GLASER,U, HOCHRAINER,D AND OLDIGES,H; LUNG CANCER IN RODENTS AFTER LONG-TERM INHALATION OF CADMIUM COMPOUNDS; ED. PROC. 6TH INT CADMIUM CONF. (1989) PP. 143-146, 1990]"
790,363898068,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-163 Y79]"
791,363898068,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-163 Y79]"
792,363898068,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 100; 400 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-163 Y79]"
793,363898068,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 100; 200 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-163 Y79]"
794,363898069,7768,C1CCC(=O)NCC1,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 7500; 15000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-214 Y82]"
795,363898069,7768,C1CCC(=O)NCC1,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 7500; 15000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-214 Y82]"
796,363898069,7768,C1CCC(=O)NCC1,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-214 Y82]"
797,363898069,7768,C1CCC(=O)NCC1,Inactive,,,,RAT,F344/MALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-214 Y82]"
798,363898070,18594026,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 8000; 16000 PPM IN DIET,DUODENUM: ADENOMATOUS POLYP (NOS) OR ADENOCARCINOMA IN ADENOMATOUS POLYP,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-15 Y77]"
799,363898070,18594026,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(Cl)(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 2525; 6060 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-15 Y77]"
800,363898070,18594026,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(Cl)(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 2525; 6060 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-15 Y77]"
801,363898070,18594026,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(Cl)(Cl)Cl,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 450 UG IN 200 UL DMSO 3/WK FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[ANTONY,M, SHUKLA,Y AND MEHROTRA,NK; PRELIMINARY CARCINOGENIC AND COCARCINOGENIC STUDIES ON CAPTAN FOLLOWING TOPICAL EXPOSURE IN MICE; BULL. ENVIRON. CONTAM. TOXICOL. 52(2):203-211, 1994]"
802,363898070,18594026,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(Cl)(Cl)Cl,Active,,,,Rat,CD/Male (50/group),Oral,0; 25; 100; 250 mg/kg/day in diet for 2 yr,"KIDNEY: Renal tubular adenomas or carcinomas (1, 1, 3, 4)",Positive (Purity of 89%; Study details  not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CAPTAN (JULY 6, 1992)]"
803,363898070,18594026,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(Cl)(Cl)Cl,Inactive,,,,Rat,CD/Female (50/group),Oral,0; 25; 100; 250 mg/kg/day in diet for 2 yr,,Negative (Purity of 89%; Study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CAPTAN (JULY 6, 1992)]"
804,363898070,18594026,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(Cl)(Cl)Cl,Active,,,,Mouse,Swiss CD-1/Male (80/dose),Oral,"0; 2000/6000; 6000/10,000; 10,000/16,000 ppm in diet for 113 wk (lower dose first 4 wk, higher dose for remainder of study)",INTESTINE:  Adenomas and adenocarcinomas in jejunum,"Positive (10,000 ppm group) (Purity of 90.7%; Study details n ot given in source)","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CAPTAN (JULY 6, 1992)]"
805,363898070,18594026,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(Cl)(Cl)Cl,Inactive,,,,Mouse,Swiss CD-1/Female (80/dose),Oral,"0; 2000/6000; 6000/10,000; 10,000/16,000 ppm in diet for 113 wk (lower dose first 4 wk, higher dose for remainder of study)",,Negative (Purity of 90.7%; Study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CAPTAN (JULY 6, 1992)]"
806,363898071,6854,C1=CC=C2C(=C1)C3=CC=CC=C3N2,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0.15; 0.3; 0.6% IN DIET FOR 96 WK,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[TSUDA,H, HAGIWARA,A, SHIBATA,M, OHSHIMA,M AND ITO,N; CARCINOGENIC EFFECT OF CARBAZOLE IN THE LIVER OF (C57BL/6N X C3H/HEN)F1 MICE; J. NATL. CANCER INST. 69:1383-1389, 1982]"
807,363898071,6854,C1=CC=C2C(=C1)C3=CC=CC=C3N2,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0.15; 0.3; 0.6% IN DIET FOR 96 WK,"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA",POSITIVE,"[TSUDA,H, HAGIWARA,A, SHIBATA,M, OHSHIMA,M AND ITO,N; CARCINOGENIC EFFECT OF CARBAZOLE IN THE LIVER OF (C57BL/6N X C3H/HEN)F1 MICE; J. NATL. CANCER INST. 69:1383-1389, 1982]"
808,363898071,6854,C1=CC=C2C(=C1)C3=CC=CC=C3N2,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",,NEGATIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
809,363898071,6854,C1=CC=C2C(=C1)C3=CC=CC=C3N2,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",,NEGATIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
810,363898072,150131,CCCC(N(CCCC(=O)OC)N=O)OC(=O)C,Active,,,,RAT,"F344/MALE,FEMALE",SUBCUTANEOUS,38 UMOL/KG IN OLIVE OIL 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA,POSITIVE,"[TAKAHASHI,M, KUROKAWA,Y, MAEKAWA,A, KOKUBO,T, FURUKAWA,F, MOCHIZUKI,M, ANJO,T AND OKADA,M; COMPARATIVE CARCINOGENICITIES OF MODEL COMPOUNDS OF METABOLICALLY ACTIVATED N,N-DIBUTYLNITROSAMINE IN RATS; GANN 73:687-694, 1982]"
811,363898073,5943,C(Cl)(Cl)(Cl)Cl,Active,,,,MOUSE,,"ORAL, GAVAGE",,"LIVER: HEPATOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 53 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 371 Y79]"
812,363898073,5943,C(Cl)(Cl)(Cl)Cl,Active,,,,RAT,,SUBCUTANEOUS,,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 53 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 371 Y79]"
813,363898073,5943,C(Cl)(Cl)(Cl)Cl,Inactive,,,,FISH,RAINBOW TROUT,INTRAPERITONEAL,0; 1 ML/KG AT 21 D INTERVALS FOR A TOTAL OF 7 DOSES (STUDY DURATION: 6 MO),,NEGATIVE,"[KOTSANIS,N AND METCALFE,CD; ENHANCEMENT OF HEPATOCARCINOGENESIS IN RAINBOW TROUT WITH CARBON TETRACHLORIDE; BULL. ENVIRON. CONTAM. TOXICOL. 46(6):879-886, 1991]"
814,363898073,5943,C(Cl)(Cl)(Cl)Cl,Active,,,,Rat,F344/Male (50/group),Inhalation,"0; 5; 25; 125 ppm (v/v) 6 hr/d, 5 d/wk for 104 wk","Liver: hepatocellular carcinoma (1/50; 0/50; 0/50; 32/50), hepatocellular adenoma (0/50; 1/50; 1/50; 21/50)",Positive,"[NAGANO,K SASKI,T UMEDA,Y MISHIZAWA,T IKAWA,N OHBAYAHI,H ARITO,H YAMAMOTO,S AND FUKUSHIMA,S; INHALATION CARCINOGENICITY AND CHRONIC TOXICITY OF CARBON TETRACHLORIDE IN RATS AND MICE; INHALATION TOXICOLOGY 19(13):1089-1103, 2007]"
815,363898073,5943,C(Cl)(Cl)(Cl)Cl,Active,,,,Rat,F344/Female (50/group),Inhalation,"0; 5; 25; 125 ppm (v/v) 6 hr/d, 5 d/wk for 104 wk","Liver: hepatocellular carcinoma (0/50; 0/50; 3/50; 15/50), hepatocellular adenoma (0/50; 0/50; 0/50; 40/50)",Positive,"[NAGANO,K SASKI,T UMEDA,Y MISHIZAWA,T IKAWA,N OHBAYAHI,H ARITO,H YAMAMOTO,S AND FUKUSHIMA,S; INHALATION CARCINOGENICITY AND CHRONIC TOXICITY OF CARBON TETRACHLORIDE IN RATS AND MICE; INHALATION TOXICOLOGY 19(13):1089-1103, 2007]"
816,363898073,5943,C(Cl)(Cl)(Cl)Cl,Active,,,,Mouse,BDF1/Male (50/group),Inhalation,"0; 5; 25; 125 ppm (v/v) 6 hr/d, 5 d/wk for 104 wk","Liver: hepatocellular carcinoma (17/50; 12/50; 44/50; 47/50), hepatocellular adenoma (9/50; 10/50; 27/50; 16/50). Adrenal Gland: benign pheochromocytoma (0/50; 0/50; 16/50; 31/50)",Positive (Dose related metastasis of liver tumors to lung),"[NAGANO,K SASKI,T UMEDA,Y MISHIZAWA,T IKAWA,N OHBAYAHI,H ARITO,H YAMAMOTO,S AND FUKUSHIMA,S; INHALATION CARCINOGENICITY AND CHRONIC TOXICITY OF CARBON TETRACHLORIDE IN RATS AND MICE; INHALATION TOXICOLOGY 19(13):1089-1103, 2007]"
817,363898073,5943,C(Cl)(Cl)(Cl)Cl,Active,,,,Mouse,BDF1/Female (50/group),Inhalation,"0; 5; 25; 125 ppm (v/v) 6 hr/d, 5 d/wk for 104 wk","Liver: hepatocellular carcinoma (2/50; 1/49; 33/50; 48/49), hepatocellular adenoma (2/50; 8/49; 17/50; 5/49). Adrenal Gland: benign pheochromocytoma (0/50; 0/49; 0/50; 22/49)",Positive,"[NAGANO,K SASKI,T UMEDA,Y MISHIZAWA,T IKAWA,N OHBAYAHI,H ARITO,H YAMAMOTO,S AND FUKUSHIMA,S; INHALATION CARCINOGENICITY AND CHRONIC TOXICITY OF CARBON TETRACHLORIDE IN RATS AND MICE; INHALATION TOXICOLOGY 19(13):1089-1103, 2007]"
818,363898074,6488,CCC(CC)(C(=O)NC(=O)N)Br,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 2500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-173 Y79]"
819,363898074,6488,CCC(CC)(C(=O)NC(=O)N)Br,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1250; 2500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-173 Y79]"
820,363898074,6488,CCC(CC)(C(=O)NC(=O)N)Br,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1250; 2500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-173 Y79]"
821,363898074,6488,CCC(CC)(C(=O)NC(=O)N)Br,Inactive,,,,RAT,F344/MALE,ORAL,0; 1250; 2500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-173 Y79]"
822,363898075,8630,C1=C(C=C(C(=C1C(=O)O)Cl)N)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 80 WK (STUDY DURATION: 91-92 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-25 Y77]"
823,363898075,8630,C1=C(C=C(C(=C1C(=O)O)Cl)N)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 80 WK (STUDY DURATION: 112-113 WK ),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-25 Y77]"
824,363898075,8630,C1=C(C=C(C(=C1C(=O)O)Cl)N)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 80 WK (STUDY DURATION: 112-113 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-25 Y77]"
825,363898075,8630,C1=C(C=C(C(=C1C(=O)O)Cl)N)Cl,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 80 WK (STUDY DURATION: 91-92 WK),LIVER: HEPATOCELLULAR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-25 Y77]"
826,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,HUMAN,,ORAL,,HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 125 Y75][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 115 Y81]"
827,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,9.6; 37; 150; 420 MG/KG (TOTAL DOSES) IN 0.5% ACACIA OR 0.01% TRICAPRYLIN SOLN 3/WK FOR 4 WK,"LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 115 Y81]"
828,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,1.5; 3.0 MG/KG 3/WK FOR 6 MO,LUNG: ADENOMA; LYMPHATIC SYSTEM: LYMPHOSARCOMA; OVARIES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 125 Y75][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 115 Y81]"
829,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,1.5; 3.0 MG/KG 3/WK FOR 6 MO,HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOSARCOMA; LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 125 Y75][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 115 Y81]"
830,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,RAT,CD-1/MALE,INTRAPERITONEAL,2.2; 4.5 MG/KG 3/WK FOR 6 MO,"HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOSARCOMA, RETICULAR CELL SARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 125 Y75][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 115 Y81]"
831,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,MOUSE,BALB/FEMALE,INTRAGASTRIC,0; 1 MG/KG SUSPENDED IN WATER 5/WK FOR 12 WK (STUDY DURATION: 120 WK),LYMPHORETICULAR SYSTEM: TUMOR,POSITIVE,"[CAVALIERE,A, PIETROPAOLI,N, ALBERTI,PF AND VITALI,R; CHLORAMBUCIL CARCINOGENESIS IN BALB/C MICE; CANCER LETT. 55(2):115-120, 1990]"
832,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,MOUSE,BALB/MALE,INTRAGASTRIC,0; 1 MG/KG SUSPENDED IN WATER 5/WK FOR 12 WK (STUDY DURATION: 120 WK),LYMPHORETICULAR SYSTEM: TUMOR,POSITIVE,"[CAVALIERE,A, PIETROPAOLI,N, ALBERTI,PF AND VITALI,R; CHLORAMBUCIL CARCINOGENESIS IN BALB/C MICE; CANCER LETT. 55(2):115-120, 1990]"
833,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,MOUSE,BALB/MALE,INTRAGASTRIC,0; 1 MG/KG SUSPENDED IN WATER 5/WK FOR 12 WK (STUDY DURATION: 120 WK),LUNG: ADENOMA,POSITIVE,"[CAVALIERE,A, PIETROPAOLI,N, ALBERTI,PF AND VITALI,R; CHLORAMBUCIL CARCINOGENESIS IN BALB/C MICE; CANCER LETT. 55(2):115-120, 1990]"
834,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,MOUSE,BALB/FEMALE,INTRAGASTRIC,0; 1 MG/KG SUSPENDED IN WATER 5/WK FOR 12 WK (STUDY DURATION: 120 WK),LUNG: ADENOMA,POSITIVE,"[CAVALIERE,A, PIETROPAOLI,N, ALBERTI,PF AND VITALI,R; CHLORAMBUCIL CARCINOGENESIS IN BALB/C MICE; CANCER LETT. 55(2):115-120, 1990]"
835,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,MOUSE,BALB/FEMALE,INTRAGASTRIC,0; 1 MG/KG SUSPENDED IN WATER 5/WK FOR 12 WK (STUDY DURATION: 120 WK),MAMMARY GLAND: ADENOMA OR ADENOCANTHOMA,POSITIVE,"[CAVALIERE,A, PIETROPAOLI,N, ALBERTI,PF AND VITALI,R; CHLORAMBUCIL CARCINOGENESIS IN BALB/C MICE; CANCER LETT. 55(2):115-120, 1990]"
836,363898076,2708,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,"0; 3 MG/KG ADMINISTERED 1, 2, 4.5 OR 9 TIMES PER MO FOR 18 MO TO GIVE MEDIAN TOTAL DOSES OF 54; 108; 234; 425 MG/KG (STUDY DURATION: LIFETIME)",MAMMARY GLAND: TUMOR; NERVOUS SYSTEM: TUMOR; EAR CANAL: TUMOR,POSITIVE,"[BERGER,MR, HABS,M AND SCHMAHL,D; COMPARATIVE CARCINOGENIC ACTIVITY OF PREDNIMUSTINE, CHLORAMBUCIL, PREDNISOLONE AND CHLORAMBUCIL PLUS PREDNISOLONE IN SPRAGUE-DAWLEY RATS; ARCH. GESCHWULSTFORSCH. 55:429-442, 1985]"
837,363898077,11954021,C1C2C(C(C1Cl)Cl)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 30.1; 63.8 PPM IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-8 Y77][REUBER,MD AND WARD,JM; HISTOPATHOLOGY OF LIVER CARCINOMAS IN (C57BL/6N X C3H/HEN)F1 MICE INGESTING CHLORDANE; J. NATL. CANCER INST. 63:89-92, 1979, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 45 Y79]"
838,363898077,11954021,C1C2C(C(C1Cl)Cl)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 29.9; 56.2 PPM IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-8 Y77][REUBER,MD AND WARD,JM; HISTOPATHOLOGY OF LIVER CARCINOMAS IN (C57BL/6N X C3H/HEN)F1 MICE INGESTING CHLORDANE; J. NATL. CANCER INST. 63:89-92, 1979, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 45 Y79]"
839,363898077,11954021,C1C2C(C(C1Cl)Cl)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 120.8; 241.5PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-8 Y77]"
840,363898077,11954021,C1C2C(C(C1Cl)Cl)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 203.5; 407.0PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-8 Y77]"
841,363898077,11954021,C1C2C(C(C1Cl)Cl)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"CD-1/MALE,FEMALE",DIET,"0, 5, 25, 50 MG/KG FOR 18 MO",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 45 Y79][EPSTEIN,SS; CARCINOGENICITY OF HEPTACHLOR AND CHLORDANE; SCI. TOTAL ENVIRON. 6:103-154, 1976, ]"
842,363898077,11954021,C1C2C(C(C1Cl)Cl)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 55 PPM IN DIET BEGINNING AT 63 D OF AGE, AT 8 MO OF AGE DOSE WAS INCREASED TO 60 PPM FOR DURATION OF STUDY (STUDY DURATION: 696 D)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[MALARKEY,DE, DEVEREUX,TR, DINSE,GE, MANN,PC AND MARONPOT,RR; HEPATOCARCINOGENICITY OF CHLORDANE IN B6C3F1 AND B6D2F1 MALE MICE: EVIDENCE FOR REGRESSION IN B6C3F1 MICE AND CARCINOGENESIS INDEPENDENT OF RAS PROTO-ONCOGENE ACTIVATION; CARCINOGENESIS 16(11):2617-2625, 1995]"
843,363898077,11954021,C1C2C(C(C1Cl)Cl)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 55 PPM IN DIET BEGINNING AT 63 D OF AGE, AT 8 MO OF AGE DOSE INCREASED TO 60 PPM AND CONTINUED UNTIL 491 D OF AGE (STUDY DURATION: 696 D)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[MALARKEY,DE, DEVEREUX,TR, DINSE,GE, MANN,PC AND MARONPOT,RR; HEPATOCARCINOGENICITY OF CHLORDANE IN B6C3F1 AND B6D2F1 MALE MICE: EVIDENCE FOR REGRESSION IN B6C3F1 MICE AND CARCINOGENESIS INDEPENDENT OF RAS PROTO-ONCOGENE ACTIVATION; CARCINOGENESIS 16(11):2617-2625, 1995]"
844,363898077,11954021,C1C2C(C(C1Cl)Cl)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6D2F1/MALE,ORAL,"0; 55 PPM IN DIET BEGINNING AT 63 D OF AGE, AT 8 MO OF AGE DOSE WAS INCREASED TO 60 PPM FOR DURATION OF STUDY (STUDY DURATION: 696 D)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[MALARKEY,DE, DEVEREUX,TR, DINSE,GE, MANN,PC AND MARONPOT,RR; HEPATOCARCINOGENICITY OF CHLORDANE IN B6C3F1 AND B6D2F1 MALE MICE: EVIDENCE FOR REGRESSION IN B6C3F1 MICE AND CARCINOGENESIS INDEPENDENT OF RAS PROTO-ONCOGENE ACTIVATION; CARCINOGENESIS 16(11):2617-2625, 1995]"
845,363898077,11954021,C1C2C(C(C1Cl)Cl)[C@]3(C(=C([C@@]2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6D2F1/MALE,ORAL,"0; 55 PPM IN DIET BEGINNING AT 63 D OF AGE, AT 8 MO OF AGE DOSE INCREASED TO 60 PPM AND CONTINUED UNTIL 491 D OF AGE (STUDY DURATION: 696 D)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[MALARKEY,DE, DEVEREUX,TR, DINSE,GE, MANN,PC AND MARONPOT,RR; HEPATOCARCINOGENICITY OF CHLORDANE IN B6C3F1 AND B6D2F1 MALE MICE: EVIDENCE FOR REGRESSION IN B6C3F1 MICE AND CARCINOGENESIS INDEPENDENT OF RAS PROTO-ONCOGENE ACTIVATION; CARCINOGENESIS 16(11):2617-2625, 1995]"
846,363898078,299,C1(=O)C2(C3(C4(C1(C5(C2(C3(C(C45Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"20; 40 MG/KG IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 67 Y79]"
847,363898078,299,C1(=O)C2(C3(C4(C1(C5(C2(C3(C(C45Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"20; 23 MG/KG IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 67 Y79]"
848,363898078,299,C1(=O)C2(C3(C4(C1(C5(C2(C3(C(C45Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"18; 26 MG/KG IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 67 Y79]"
849,363898078,299,C1(=O)C2(C3(C4(C1(C5(C2(C3(C(C45Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"8; 24 MG/KG IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 67 Y79]"
850,363898079,9324,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C,Active,,,,DOG,,ORAL,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 365 Y79]"
851,363898080,8805,CC(=O)NC1=CC=C(C=C1)C(=O)CCl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-177 Y77]"
852,363898080,8805,CC(=O)NC1=CC=C(C=C1)C(=O)CCl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-177 Y77]"
853,363898080,8805,CC(=O)NC1=CC=C(C=C1)C(=O)CCl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1000; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-177 Y77]"
854,363898080,8805,CC(=O)NC1=CC=C(C=C1)C(=O)CCl,Inactive,,,,RAT,F344/MALE,ORAL,0; 1000; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-177 Y77]"
855,363898081,7812,C1=CC(=CC=C1N)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 250; 500 PPM IN DIET FOR 78 WK (STUDY DURATION: 102 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-189 Y79]"
856,363898081,7812,C1=CC(=CC=C1N)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 250; 500 PPM IN DIET FOR 78 WK (STUDY DURATION: 102 WK),SPLEEN OR PERITONEUM: SARCOMA,POSITIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
857,363898081,7812,C1=CC(=CC=C1N)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 250; 500 PPM IN DIET FOR 78 WK (STUDY DURATION: 102 WK),,NEGATIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
858,363898081,7812,C1=CC(=CC=C1N)Cl,Unspecified,,,,RAT,F344/MALE,ORAL,0; 250; 500 PPM IN DIET FOR 78 WK (STUDY DURATION: 102 WK),SPLEEN: FIBROMA AND SARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-189 Y79]"
859,363898081,7812,C1=CC(=CC=C1N)Cl,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 78 WK (STUDY DURATION: 91 WK),SPLEEN: HEMANGIOSARCOMA; LIVER: HEMANGIOMA AND HEMANGIOSARCOMA; KIDNEY: HEMANGIOSARCOMA; MULTIPLE ORGANS: HEMANGIOSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-189 Y79]"
860,363898081,7812,C1=CC(=CC=C1N)Cl,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 78 WK (STUDY DURATION: 91 WK),SPLEEN: HEMANGIOMA AND HEMANGIOSARCOMA; LIVER: HEMANGIOSARCOMA; MULTIPLE ORGANS: HEMANGIOSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-189 Y79]"
861,363898082,10522,CCOC(=O)C(C1=CC=C(C=C1)Cl)(C2=CC=C(C=C2)Cl)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3200; 5908 PPM IN DIET FOR 78 WK (STUDY DURATION: 90-91 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-75 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 75 Y74]"
862,363898082,10522,CCOC(=O)C(C1=CC=C(C=C1)Cl)(C2=CC=C(C=C2)Cl)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 4231; 7846 PPM IN DIET FOR 78 WK (STUDY DURATION: 90-91 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-75 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 75 Y74]"
863,363898082,10522,CCOC(=O)C(C1=CC=C(C=C1)Cl)(C2=CC=C(C=C2)Cl)O,Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 1600; 2995 PPM IN DIET FOR 78 WK (STUDY DURATION: 110-111 WK),ADRENAL GLAND: CORTICAL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-75 Y78]"
864,363898082,10522,CCOC(=O)C(C1=CC=C(C=C1)Cl)(C2=CC=C(C=C2)Cl)O,Unspecified,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 1175; 2229 PPM IN DIET FOR 78 WK (STUDY DURATION: 110-111 WK),ADRENAL GLAND: CORTICAL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-75 Y78]"
865,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,MOUSE,STRAIN-CS/MALE,ORAL,0.1% (W/W) IN DIET FOR 6 MO THEN 0.05% IN DIET FOR 8.5 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[REDDY,JK, RAO,MS, AZARNOFF,DL AND SELL,S; MITOGENIC AND CARCINOGENIC EFFECTS OF A HYPOLIPIDEMIC PEROXISOME PROLIFERATOR, (4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYL-THIO)ACETIC ACID (WY-14,643), IN RAT AND MOUSE LIVER; CANCER RES. 39:152-161, 1979]"
866,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0.2% (W/W) IN DIET FOR 65 WK,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[LALWANI,ND, REDDY,MK, QURESHI,SA AND REDDY,JK; DEVELOPMENT OF HEPATOCELLULAR CARCINOMAS AND INCREASED PEROXISOMAL FATTY ACID BETA-OXIDATION IN RATS FED (4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO)ACETIC ACID (WY-14,643) IN THE SEMIPURIFIED DIET; CARCINOGENESIS 2:645-650, 1981]"
867,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0.1% (W/W) IN DIET FOR 16 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[REDDY,JK, RAO,MS, AZARNOFF,DL AND SELL,S; MITOGENIC AND CARCINOGENIC EFFECTS OF A HYPOLIPIDEMIC PEROXISOME PROLIFERATOR, (4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYL-THIO)ACETIC ACID (WY-14,643), IN RAT AND MOUSE LIVER; CANCER RES. 39:152-161, 1979]"
868,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0.1% IN DIET FOR 54 WK (STUDY DURATION: 56 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[CATTLEY,RC AND POPP,JA; DIFFERENCES BETWEEN THE PROMOTING ACTIVITIES OF THE PEROXISOME PROLIFERATOR WY-14,643 AND PHENOBARBITAL IN RAT LIVER; CANCER RES. 49(12):3246-3251, 1989]"
869,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Inactive,,,,RAT,F344/MALE,ORAL,0.1% IN DIET FOR 11 WK FOLLOWED BY CONTROL DIET FOR DURATION OF STUDY (STUDY DURATION: 56 WK),,NEGATIVE,"[CATTLEY,RC AND POPP,JA; DIFFERENCES BETWEEN THE PROMOTING ACTIVITIES OF THE PEROXISOME PROLIFERATOR WY-14,643 AND PHENOBARBITAL IN RAT LIVER; CANCER RES. 49(12):3246-3251, 1989]"
870,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0.1% IN DIET FOR 43 WK (STUDY DURATION: 56 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[CATTLEY,RC AND POPP,JA; DIFFERENCES BETWEEN THE PROMOTING ACTIVITIES OF THE PEROXISOME PROLIFERATOR WY-14,643 AND PHENOBARBITAL IN RAT LIVER; CANCER RES. 49(12):3246-3251, 1989]"
871,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.05; 0.10% IN DIET STARTED AT 2 MO OF AGE FOR STUDY DURATION (STUDY DURATION: 22 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA",POSITIVE,"[CATTLEY,RC, MARSMAN,DS AND POPP,JA; AGE-RELATED SUSCEPTIBILITY TO THE CARCINOGENIC EFFECT OF THE PEROXISOME PROLIFERATOR WY-14,643 IN RAT LIVER; CARCINOGENESIS 12(3):469-473, 1991]"
872,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0.00; 0.05; 0.10% IN DIET STARTED AT 15 MO OF AGE FOR STUDY DURATION (STUDY DURATION: 22 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA",POSITIVE,"[CATTLEY,RC, MARSMAN,DS AND POPP,JA; AGE-RELATED SUSCEPTIBILITY TO THE CARCINOGENIC EFFECT OF THE PEROXISOME PROLIFERATOR WY-14,643 IN RAT LIVER; CARCINOGENESIS 12(3):469-473, 1991]"
873,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.1% IN DIET FOR 22 WK (STUDY DURATION: 22 WK),,NEGATIVE,"[MARSMAN,DS AND POPP,JA; BIOLOGICAL POTENTIAL OF BASOPHILIC HEPATOCELLULAR FOCI AND HEPATIC ADENOMA INDUCED BY THE PEROXISOME PROLIFERATOR, WY-14,643; CARCINOGENESIS 15(1):111-117, 1994]"
874,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.1% IN DIET FOR 37 WK (STUDY DURATION: 37 WK),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[MARSMAN,DS AND POPP,JA; BIOLOGICAL POTENTIAL OF BASOPHILIC HEPATOCELLULAR FOCI AND HEPATIC ADENOMA INDUCED BY THE PEROXISOME PROLIFERATOR, WY-14,643; CARCINOGENESIS 15(1):111-117, 1994]"
875,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.1% IN DIET FOR 52 WK (STUDY DURATION: 52 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[MARSMAN,DS AND POPP,JA; BIOLOGICAL POTENTIAL OF BASOPHILIC HEPATOCELLULAR FOCI AND HEPATIC ADENOMA INDUCED BY THE PEROXISOME PROLIFERATOR, WY-14,643; CARCINOGENESIS 15(1):111-117, 1994]"
876,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Inactive,,,,RAT,F344/MALE,ORAL,"0; 0.1% IN DIET FOR 22 WK FOLLOWED BY BASAL DIET UNTIL TERMINATION AT 37, 52, OR 104 WK, RESPECTIVELY (STUDY DURATION: 37, 52, OR 104 WK)",,NEGATIVE,"[MARSMAN,DS AND POPP,JA; BIOLOGICAL POTENTIAL OF BASOPHILIC HEPATOCELLULAR FOCI AND HEPATIC ADENOMA INDUCED BY THE PEROXISOME PROLIFERATOR, WY-14,643; CARCINOGENESIS 15(1):111-117, 1994]"
877,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.1% IN DIET FOR 37 WK FOLLOWED BY BASAL DIET UNTIL TERMINATION AT 52 OR 104 WK (STUDY DURATION: 52 OR 104 WK),,NEGATIVE,"[MARSMAN,DS AND POPP,JA; BIOLOGICAL POTENTIAL OF BASOPHILIC HEPATOCELLULAR FOCI AND HEPATIC ADENOMA INDUCED BY THE PEROXISOME PROLIFERATOR, WY-14,643; CARCINOGENESIS 15(1):111-117, 1994]"
878,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.1% IN DIET FOR 52 WK FOLLOWED BY BASAL DIET UNTIL TERMINATION AT 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[MARSMAN,DS AND POPP,JA; BIOLOGICAL POTENTIAL OF BASOPHILIC HEPATOCELLULAR FOCI AND HEPATIC ADENOMA INDUCED BY THE PEROXISOME PROLIFERATOR, WY-14,643; CARCINOGENESIS 15(1):111-117, 1994]"
879,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.1% IN DIET FOR 78 WK (STUDY DURATION: 78 WK),LIVER: NEOPLASM,POSITIVE,"[HAYASHI,F, TAMURA,H, YAMADA,J, KASAI,H AND SUGA,T; CHARACTERISTICS OF THE HEPATOCARCINOGENESIS CAUSED BY DEHYDROEPIANDROSTERONE, A PEROXISOME PROLIFERATOR, IN MALE F-344 RATS; CARCINOGENESIS 15(10):2215-2219, 1994]"
880,363898083,5694,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Active,,,,RAT,CD-1/MALE,ORAL,0; 50 PPM IN DIET FOR 43 WK FOLLOWED BY 25 PPM IN FEED FOR 61 WK (STUDY DURATION: 2 YR),"LIVER: ADENOMA, ADENOMA OR CARCINOMA; TESTES: LEYDIG CELL ADENOMA; PANCREAS: ACINAR CELL ADENOMA OR CARCINOMA",POSITIVE,"[BIEGEL,LB HURTT,ME FRAME,SR O'CONNOR,JC AND COOK,JC; MECHANISMS OF EXTRAHEPATIC TUMOR INDUCTION BY PEROXISOME PROLIFERATORS IN MALE CD RATS; TOXICOL. SCI. 60(1):44-55, 2001]"
881,363898084,68851,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)NCCO)Cl)C,Active,,,,MOUSE,STRAIN-CS/FEMALE,ORAL,0.2% IN DIET FOR 19 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[REDDY,JK, AZARNOFF,DL AND HIGNITE,CE; HYPOLIPIDAEMIC HEPATIC PEROXISOME PROLIFERATORS FORM A NOVEL CLASS OF CHEMICAL CARCINOGENS; NATURE 283:397-398, 1980]"
882,363898084,68851,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)NCCO)Cl)C,Active,,,,RAT,F344/MALE,ORAL,0.05; 0.2% IN DIET FOR 19 MO (LOW DOSE) OR 16 MO (HIGH DOSE),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[REDDY,JK, AZARNOFF,DL AND HIGNITE,CE; HYPOLIPIDAEMIC HEPATIC PEROXISOME PROLIFERATORS FORM A NOVEL CLASS OF CHEMICAL CARCINOGENS; NATURE 283:397-398, 1980]"
883,363898085,13836,C[N+](C)(C)CCCl.[Cl-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-158 Y79]"
884,363898085,13836,C[N+](C)(C)CCCl.[Cl-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-158 Y79]"
885,363898085,13836,C[N+](C)(C)CCCl.[Cl-],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1500; 3000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-158 Y79]"
886,363898085,13836,C[N+](C)(C)CCCl.[Cl-],Inactive,,,,RAT,F344/MALE,ORAL,0; 1500; 3000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-158 Y79]"
887,363898086,11643,C(F)Cl,Active,,,,RAT,"WISTAR/MALE,FEMALE",GAVAGE,300 MG/KG IN CORN OIL 5/WK FOR 52 WK,"STOMACH: SQUAMOUS CELL CARCINOMA, FIBROSARCOMA",POSITIVE,"[LONGSTAFF,E, ROBINSON,M, BRADBROOK,C, STYLES,JA AND PURCHASE,IFH; GENOTOXICITY AND CARCINOGENICITY OF FLUOROCARBONS: ASSESSMENT BY SHORT-TERM IN VITRO TESTS AND CHRONIC EXPOSURE IN RATS; TOXICOL. APPL. PHARMACOL. 72:15-31, 1984]"
888,363898087,6212,C(Cl)(Cl)Cl,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE,,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 401 Y79][NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-1 Y76][WINSLOW,SG AND GERSTNER,HB; HEALTH ASPECTS OF CHLOROFORM - A REVIEW; DRUG CHEM. TOXICOL. 1(3):259-275, 1978, ]"
889,363898087,6212,C(Cl)(Cl)Cl,Active,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,,"KIDNEY: ADENOMA, CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 401 Y79][NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-1 Y76][WINSLOW,SG AND GERSTNER,HB; HEALTH ASPECTS OF CHLOROFORM - A REVIEW; DRUG CHEM. TOXICOL. 1(3):259-275, 1978, ]"
890,363898087,6212,C(Cl)(Cl)Cl,Active,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 200; 400; 900; 1800 MG/L IN DRINKING WATER FOR 104 WK (STUDY DURATION: 24 MO),"KIDNEY: TUBULAR CELL CARCINOMA OR ADENOCARCINOMA, TUBULAR CELL CARCINOMA; ADRENAL GLAND: CORTICAL ADENOMA, PHEOCHROMOCYTOMA; THYROID GLAND: C-CELL ADENOMA",POSITIVE,"[JORGENSON,TA, MEIERHENRY,EF, RUSHBROOK,CJ, BULL,RJ AND ROBINSON,M; CARCINOGENICITY OF CHLOROFORM IN DRINKING WATER TO MALE OSBORNE- MENDEL RATS AND FEMALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 5:760-769, 1985]"
891,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 200; 400; 900; 1800 MG/L IN DRINKING WATER FOR 104 WK (STUDY DURATION: 24 MO),,NEGATIVE,"[JORGENSON,TA, MEIERHENRY,EF, RUSHBROOK,CJ, BULL,RJ AND ROBINSON,M; CARCINOGENICITY OF CHLOROFORM IN DRINKING WATER TO MALE OSBORNE- MENDEL RATS AND FEMALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 5:760-769, 1985]"
892,363898087,6212,C(Cl)(Cl)Cl,Active,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 200; 400; 900; 1800 ML/L IN DRINKING WATER FOR AN AVERAGE DOSE OF 0; 19; 38; 81; 160 MG/KG BW/D FOR 104 WK (STUDY DURATION: 104 WK),KIDNEY (TUBULAR CELL): ADENOMA OR ADENOCARCINOMA,POSITIVE,"[JORGENSON,TA, MEIERHENRY,EF, RUSHBROOK,CJ, BULL,RJ AND ROBINSON,M; CARCINOGENICITY OF CHLOROFORM IN DRINKING WATER TO MALE OSBORNE-MENDEL RATS AND FEMALE B6C3F1 MICE;FUNDAM. APPL. TOXICOL. 5(4):760-769, 1985]"
893,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 200; 400; 900; 1800 ML/L IN DRINKING WATER FOR AN AVERAGE DOSE OF 0; 34; 65; 130; 263 MG/KG BW/D FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[JORGENSON,TA, MEIERHENRY,EF, RUSHBROOK,CJ, BULL,RJ AND ROBINSON,M; CARCINOGENICITY OF CHLOROFORM IN DRINKING WATER TO MALE OSBORNE-MENDEL RATS AND FEMALE B6C3F1 MICE;FUNDAM. APPL. TOXICOL. 5(4):760-769, 1985]"
894,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 2 ML/L (24 MILLIMOLAR) IN DRINKING WATER FOR 72 WK THEN DOSE HALVED FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[TUMASONIS,CF, MCMARTIN,DN AND BUSH,B; LIFETIME TOXICITY OF CHLOROFORM AND BROMODICHLOROMETHANE WHEN ADMINISTERED OVER A LIFETIME IN RATS; ECOTOXICOL. ENVIRON. SAF. 9(2):233-240, 1985]"
895,363898087,6212,C(Cl)(Cl)Cl,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 2 ML/L (24 MILLIMOLAR) IN DRINKING WATER FOR 72 WK THEN DOSE HALVED FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),LIVER: NEOPLASTIC NODULES,POSITIVE,"[TUMASONIS,CF, MCMARTIN,DN AND BUSH,B; LIFETIME TOXICITY OF CHLOROFORM AND BROMODICHLOROMETHANE WHEN ADMINISTERED OVER A LIFETIME IN RATS; ECOTOXICOL. ENVIRON. SAF. 9(2):233-240, 1985]"
896,363898087,6212,C(Cl)(Cl)Cl,Active,,,,RAT,F344/DUCRJ/MALE,ORAL AND INHALATION,"0; 1,000 PPM IN DRINKING WATER AND 0; 25; 50; 100 PPM VAPOR CHAMBER 6 HR/D, 5 D/WK , BOTH FOR 104 WK (STUDY DURATION: 104 WK)","KIDNEY: ADENOMA, CARCINOMA; THYROID: ADENOMA, CARCINOMA",POSITIVE,"[YAMAMOTO,OS KANOH,H YAMAZAKI,K NISHIZAWA,T GOTOH,K NAGANO,K AND MATSUSHIMA,T; LONG-TERM TOXICOLOGY STUDY OF CHOLOROFORM IN F344 RATS BY PLURAL ROUTES (DRINKING WATER AND INHALATION); 276-277, 1999]"
897,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,RAT,F344/DUCRJ/MALE,ORAL,"0; 1,000 PPM IN DRINKING FOR 104 WK (STUDY DURATION: 104 WK)",,NEGATIVE,"[YAMAMOTO,OS KANOH,H YAMAZAKI,K NISHIZAWA,T GOTOH,K NAGANO,K AND MATSUSHIMA,T; LONG-TERM TOXICOLOGY STUDY OF CHOLOROFORM IN F344 RATS BY PLURAL ROUTES (DRINKING WATER AND INHALATION); 276-277, 1999]"
898,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,RAT,F344/DUCRJ/MALE,INHALATION,"0;25; 50; 100 PPM VAPOR CHAMBER 6 HR/D, 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK)",,NEGATIVE,"[YAMAMOTO,OS KANOH,H YAMAZAKI,K NISHIZAWA,T GOTOH,K NAGANO,K AND MATSUSHIMA,T; LONG-TERM TOXICOLOGY STUDY OF CHOLOROFORM IN F344 RATS BY PLURAL ROUTES (DRINKING WATER AND INHALATION); 276-277, 1999]"
899,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,FISH,ORYZIPIAS LATIPES/MALE,IMMERSION,0; 0.017; 0.151; 1.463 MG/L AQUEOUS SOLUTION FOR 6 MO (STUDY DURATION: 6 MO),,NEGATIVE,"[TOUSSAINT,MW ROSENCRANCE,AB BRENNAN,LM BEAMAN,JR WOLFE,MJ HOFFMAN,FJ AND GARDENER HS JR; CHRONIC TOXICITY OF CHLOROFORM TO JAPANESE MEDAKA FISH; ENVIRON. HEALTH PERSPECT. 109(1):35-40, 2001]"
900,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,FISH,ORYZIPIAS LATIPES/MALE,IMMERSION,0; 0.017; 0.151; 1.463 MG/L AQUEOUS SOLUTION FOR 9 MO (STUDY DURATION: 9 MO),,NEGATIVE,"[TOUSSAINT,MW ROSENCRANCE,AB BRENNAN,LM BEAMAN,JR WOLFE,MJ HOFFMAN,FJ AND GARDENER HS JR; CHRONIC TOXICITY OF CHLOROFORM TO JAPANESE MEDAKA FISH; ENVIRON. HEALTH PERSPECT. 109(1):35-40, 2001]"
901,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,FISH,ORYZIPIAS LATIPES/FEMALE,IMMERSION,0; 0.017; 0.151; 1.463 MG/L AQUEOUS SOLUTION FOR 6 MO (STUDY DURATION: 6 MO),,NEGATIVE,"[TOUSSAINT,MW ROSENCRANCE,AB BRENNAN,LM BEAMAN,JR WOLFE,MJ HOFFMAN,FJ AND GARDENER HS JR; CHRONIC TOXICITY OF CHLOROFORM TO JAPANESE MEDAKA FISH; ENVIRON. HEALTH PERSPECT. 109(1):35-40, 2001]"
902,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,FISH,ORYZIPIAS LATIPES/FEMALE,IMMERSION,0; 0.017; 0.151; 1.463 MG/L AQUEOUS SOLUTION FOR 9 MO (STUDY DURATION: 9 MO),,NEGATIVE,"[TOUSSAINT,MW ROSENCRANCE,AB BRENNAN,LM BEAMAN,JR WOLFE,MJ HOFFMAN,FJ AND GARDENER HS JR; CHRONIC TOXICITY OF CHLOROFORM TO JAPANESE MEDAKA FISH; ENVIRON. HEALTH PERSPECT. 109(1):35-40, 2001]"
903,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,RAT,F344/MALE,INHALATION,"0; 10; 30; 90 PPM IN AIR, 6 HR/D, 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK)",,NEGATIVE,"[YAMAMOTO,S KASAI,T MATSUMOTO,M NISHIZAWA,T ARITO,H NAGANO,K AND MATSUSHIMA,T;CARCINOGENICITY AND CHRONIC TOXICITY IN RATS AND MICE EXPOSED TO CHLOROFORM BY INHALATION; J. OCCUP. HEALTH 44(5):283-293, 2002]"
904,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,RAT,F344/FEMALE,INHALATION,"0; 10; 30; 90 PPM IN AIR, 6 HR/D, 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK)",,NEGATIVE,"[YAMAMOTO,S KASAI,T MATSUMOTO,M NISHIZAWA,T ARITO,H NAGANO,K AND MATSUSHIMA,T;CARCINOGENICITY AND CHRONIC TOXICITY IN RATS AND MICE EXPOSED TO CHLOROFORM BY INHALATION; J. OCCUP. HEALTH 44(5):283-293, 2002]"
905,363898087,6212,C(Cl)(Cl)Cl,Active,,,,MOUSE,BDF1/MALE,INHALATION,"0; 5; 30; 90 PPM IN AIR, 6 HR/D, 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK)","LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR CARCINOMA AND ADENOMA; KIDNEYS: RENAL CELL CARCINOMA, RENAL CELL ADENOMA AND CARCINOMA",POSITIVE,"[YAMAMOTO,S KASAI,T MATSUMOTO,M NISHIZAWA,T ARITO,H NAGANO,K AND MATSUSHIMA,T;CARCINOGENICITY AND CHRONIC TOXICITY IN RATS AND MICE EXPOSED TO CHLOROFORM BY INHALATION; J. OCCUP. HEALTH 44(5):283-293, 2002]"
906,363898087,6212,C(Cl)(Cl)Cl,Active,,,,MOUSE,BDF1/FEMALE,INHALATION,"0; 5; 30; 90 PPM IN AIR, 6 HR/D, 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK)","LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR CARCINOMA AND ADENOMA",POSITIVE,"[YAMAMOTO,S KASAI,T MATSUMOTO,M NISHIZAWA,T ARITO,H NAGANO,K AND MATSUSHIMA,T;CARCINOGENICITY AND CHRONIC TOXICITY IN RATS AND MICE EXPOSED TO CHLOROFORM BY INHALATION; J. OCCUP. HEALTH 44(5):283-293, 2002]"
907,363898087,6212,C(Cl)(Cl)Cl,Active,,,,Rat,F344/DuCrj/ Male (50 per group),Inhalation and oral (drinking water),"0; 25; 50; 100 ppm in air, 6 hr/d, 5 d/wk for 104 wk; each group also given chloroform-formulated drinking water (1000 ppm w/w) or water administered ad libitum 24 hr/d, 7 d/wk for 104 wk",KIDNEY: renal-cell adenomas and carcinomas,"Positive, Positive trend; significant increase in high dose group; exposure levels well above industrial exposures.","[NAGANO,K, KANO,H, ARITO,H, YAMAMOTO,S AND MATSUSHIMA,T; ENHANCEMENT OF RENAL CARCINOEGENICITY BY COMBINED INHALATION AND ORAL EXPOSURES TO CHLOROFORM IN MALE RATS; J. TOXICOL. ENVIRON. HEALTH, PART A 69(20): 1827-1842, 2006]"
908,363898087,6212,C(Cl)(Cl)Cl,Inactive,,,,Rat,F344/DuCrj/ Male (50 per group),Inhalation,"0; 25; 50; 100 ppm in air, 6 hr/d, 5 d/wk for 104 wk",KIDNEY: one renal-cell adenoma in the high dose group,Negative,"[NAGANO,K, KANO,H, ARITO,H, YAMAMOTO,S AND MATSUSHIMA,T; ENHANCEMENT OF RENAL CARCINOEGENICITY BY COMBINED INHALATION AND ORAL EXPOSURES TO CHLOROFORM IN MALE RATS; J. TOXICOL. ENVIRON. HEALTH, PART A 69(20): 1827-1842, 2006]"
909,363898088,7864,COCCl,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,300 UG IN 0.05 ML NUJOL 1/WK FOR 685 D,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 239 Y74]"
910,363898089,23392,C1=CC=NC(=C1)CCl.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 125; 250 MG/KG IN AQ SOLN,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-178 Y79]"
911,363898089,23392,C1=CC=NC(=C1)CCl.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 125; 250 MG/KG IN AQ SOLN,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-178 Y79]"
912,363898089,23392,C1=CC=NC(=C1)CCl.Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 75; 150 MG/KG IN AQ SOLN,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-178 Y79]"
913,363898089,23392,C1=CC=NC(=C1)CCl.Cl,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 75; 150 MG/KG IN AQ SOLN,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-178 Y79]"
914,363898090,23394,C1=CC(=CN=C1)CCl.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 200 MG/KG,"STOMACH: SQUAMOUS CELL PAPILLOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-95 Y78]"
915,363898090,23394,C1=CC(=CN=C1)CCl.Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 100; 200 MG/KG,"STOMACH: SQUAMOUS CELL PAPILLOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-95 Y78]"
916,363898090,23394,C1=CC(=CN=C1)CCl.Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 75; 150 MG/KG,STOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-95 Y78]"
917,363898090,23394,C1=CC(=CN=C1)CCl.Cl,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 75; 150 MG/KG FOR 83 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-95 Y78]"
918,363898091,6945,C1=CC=C(C(=C1)[N+](=O)[O-])Cl,Active,,,,MOUSE,CD-1/FEMALE,ORAL,3000; 6000 MG/KG IN DIET FOR 18 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[WEISBURGER,EK, RUSSFIELD,AB, HOMBURGER,F, WEISBURGER,JH, BOGER,E, VAN DONGEN,CG AND CHU,KC; TESTING OF TWENTY-ONE ENVIRONMENTAL AROMATIC AMINES OR DERIVATIVES FOR LONG-TERM TOXICITY OR CARCINOGENICITY; J. ENVIRON. PATHOL. TOXICOL. 2:325-356, 1978]"
919,363898092,7474,C1=CC(=CC=C1[N+](=O)[O-])Cl,Active,,,,MOUSE,"CD-1/MALE,FEMALE",ORAL,,BLOOD VESSELS,POSITIVE,"[WEISBURGER,EK, RUSSFIELD,AB, HOMBURGER,F, WEISBURGER,JH, BOGER,E, VAN DONGEN,CG AND CHU,KC; TESTING OF TWENTY-ONE ENVIRONMENTAL AROMATIC AMINES OR DERIVATIVES FOR LONG-TERM TOXICITY OR CARCINOGENICITY; J. ENVIRON. PATHOL. TOXICOL. 2:325-356, 1978]"
920,363898093,21209,C1=CC(=C(C=C1N)N)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.7; 1.4% OF DIET, TWA",LIVER: HEPATOCELLULAR ADENOMA OR HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-85 Y78]"
921,363898093,21209,C1=CC(=C(C=C1N)N)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.7; 1.4% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-85 Y78]"
922,363898093,21209,C1=CC(=C(C=C1N)N)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.2; 0.4% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-85 Y78]"
923,363898093,21209,C1=CC(=C(C=C1N)N)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 0.2; 0.4% OF DIET,ADRENAL GLAND: PHEOCHROMOCYTOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-85 Y78]"
924,363898094,7263,C1=CC(=C(C=C1Cl)N)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.7; 1.4% TWA, IN DIET FOR 78 WK (STUDY DURATION: 96-97 WK)","LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-63 Y78]"
925,363898094,7263,C1=CC(=C(C=C1Cl)N)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.7; 1.4% TWA, IN DIET FOR 78 WK (STUDY DURATION: 95-97 WK)","LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-63 Y78]"
926,363898094,7263,C1=CC(=C(C=C1Cl)N)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.5; 1.0% IN DIET FOR 78 WK (STUDY DURATION: 106 WK),"URINARY BLADDER: PAPILLARY CARCINOMA OR TRANSITIONAL CELL CARCINOMA, PAPILLARY CARCINOMA OR TRANSITIONAL CELL CARCINOMA OR PAPILLOMA (NOS) OR TRANSITIONAL CELL PAPILLOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-63 Y78]"
927,363898094,7263,C1=CC(=C(C=C1Cl)N)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.5; 1.0% IN DIET FOR 78 WK (STUDY DURATION: 105-106 WK),"URINARY BLADDER: TRANSITIONAL CELL CARCINOMA, PAPILLOMA (NOS) OR TRANSITIONAL CELL PAPILLOMA OR TRANSITIONAL CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-63 Y78]"
928,363898095,22584,C1=CC(=C(C=C1N)Cl)N.OS(=O)(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.3; 0.6% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-113 Y78]"
929,363898095,22584,C1=CC(=C(C=C1N)Cl)N.OS(=O)(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.3; 0.6% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-113 Y78]"
930,363898095,22584,C1=CC(=C(C=C1N)Cl)N.OS(=O)(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.15; 0.30% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-113 Y78]"
931,363898095,22584,C1=CC(=C(C=C1N)Cl)N.OS(=O)(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.15; 0.30% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-113 Y78]"
932,363898096,6423,C([N+](=O)[O-])(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 33; 66 MG/KG,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-65 Y78]"
933,363898096,6423,C([N+](=O)[O-])(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 33; 66 MG/KG,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-65 Y78]"
934,363898096,6423,C([N+](=O)[O-])(Cl)(Cl)Cl,Inactive,,,,Rat,"Sprague-Dawley Crl:CD BR, VAF/Plus /Male (30 per group)",Oral,0; 0.1; 1.0; 10 mg/kg/day by gavage in corn oil for 2 yr,,"Negative (1 stomach papilloma possibly treatment related; study details not given in source), Purity 99%","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROPICRIN (NOVEMBER 15, 2001)]"
935,363898096,6423,C([N+](=O)[O-])(Cl)(Cl)Cl,Active,,,,Rat,"Sprague-Dawley Crl:CD BR, VAF/Plus /Female (30 per group)",Oral,0; 0.1; 1.0; 10 mg/kg/day by gavage in corn oil for 2 yr,Mammary Gland: Fibroadenoma (14/30 at high dose),Positive (Study details not given in source) Purity 99%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROPICRIN (NOVEMBER 15, 2001)]"
936,363898096,6423,C([N+](=O)[O-])(Cl)(Cl)Cl,Inactive,,,,Rat,Sprague-Dawley/Female (50 per group),Inhalation,"0; 0.1; 0.5; 1.0 ppm, 6 hr/day, 5 day/wk for at least 107 wk",,Negative (Study details not given in source) Purity 99.6%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROPICRIN (NOVEMBER 15, 2001)]"
937,363898096,6423,C([N+](=O)[O-])(Cl)(Cl)Cl,Inactive,,,,Rat,Sprague-Dawley/Male (50 per group),Inhalation,"0; 0.1; 0.5; 1.0 ppm, 6 hr/day, 5 day/wk for at least 107 wk",,Negative (Study details not given in source) Purity 99.6%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROPICRIN (NOVEMBER 15, 2001)]"
938,363898096,6423,C([N+](=O)[O-])(Cl)(Cl)Cl,Inactive,,,,Mouse,CD-1 /Female/(50 per group),Inhalation,"0; 0.1; 0.5; 1.0 ppm, 6 hr/day, 5 day/wk for at least 78 wk",,Negative (Study details not given in report) Purity 99.6%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROPICRIN (NOVEMBER 15, 2001)]"
939,363898096,6423,C([N+](=O)[O-])(Cl)(Cl)Cl,Inactive,,,,Mouse,CD-1 /Male (50 per group),Inhalation,"0; 0.1; 0.5; 1.0 ppm, 6 hr/day, 5 day/wk for at least 78 wk",,Negative (Study details not given in source) Purity 99.6%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROPICRIN (NOVEMBER 15, 2001)]"
940,363898097,5284364,C/C=C/Cl,Active,,,,MOUSE,ICR/FEMALE,GAVAGE,1.0 MG IN 0.1 ML TRIOCTANOIN 1/WK,FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[VAN DUUREN,BL, GOLDSCHMIDT,BM, LOEWENGART,G, SMITH,AC, MELCHIONNE,S, SEIDMAN,I AND ROTH,D; CARCINOGENICITY OF HALOGENATED OLEFINIC AND ALIPHATIC HYDROCARBONS IN MICE; J. NATL. CANCER INST. 63:1433-1439, 1979]"
941,363898098,3036756,C[C@H]1[C@H](O1)Cl,Active,,,,MOUSE,ICR/FEMALE,DERMAL,10 MG IN 0.1 ML ACETONE 3/WK FOR LIFE,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[VAN DUUREN,BL, KLINE,SA, MELCHIONNE,S AND SEIDMAN,I; CHEMICAL STRUCTURE AND CARCINOGENICITY RELATIONSHIPS OF SOME CHLOROALKENE OXIDES AND THEIR PARENT OLEFINS; CANCER RES. 43:159-162, 1983]"
942,363898099,155623,C[C@@H]1[C@H](O1)Cl,Active,,,,MOUSE,ICR/FEMALE,DERMAL,10 MG IN 0.1 ML ACETONE 3/WK FOR LIFE,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[VAN DUUREN,BL, KLINE,SA, MELCHIONNE,S AND SEIDMAN,I; CHEMICAL STRUCTURE AND CARCINOGENICITY RELATIONSHIPS OF SOME CHLOROALKENE OXIDES AND THEIR PARENT OLEFINS; CANCER RES. 43:159-162, 1983]"
943,363898099,155623,C[C@@H]1[C@H](O1)Cl,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,1 MG IN 0.05 ML TRICAPRYLIN 1/WK FOR LIFE,"INJECTION SITE: FIBROSARCOMA, CARCINOMA",POSITIVE,"[VAN DUUREN,BL, KLINE,SA, MELCHIONNE,S AND SEIDMAN,I; CHEMICAL STRUCTURE AND CARCINOGENICITY RELATIONSHIPS OF SOME CHLOROALKENE OXIDES AND THEIR PARENT OLEFINS; CANCER RES. 43:159-162, 1983]"
944,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 3000; 6000 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-41 Y78]"
945,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 2688; 5375 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-41 Y78]"
946,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 5063; 10126 PPM IN DIET, TWA",KIDNEY: ADENOMA OR CARCINOMA (NOS) OR TUBULAR CELL ADENOMA OR TUBULAR CELL ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-41 Y78]"
947,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Active,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 5063; 10126 PPM IN DIET, TWA",KIDNEY: CARCINOMA (NOS) OR TUBULAR CELL ADENOMA OR TUBULAR CELL ADENOCARCINOMA OR ADENOCARCINOMA OR PAPILLARY ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-41 Y78]"
948,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Active,,,,Rat,Fischer 344/Female (55 per group),Oral,0; 1.8; 3.8; 15.2; 183 mg/kg/day in diet for 125 wks,"Kidney: Renal tubular adenomas and carcinomas (0, 0, 0, 0, 32 in 53-55 animals). Forestomach: Papillomas and carcinomas (1, 1, 2, 5, 9 in 53-55 animals)",Positive (Study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROTHALONIL (OCTOBER 27, 2006)]"
949,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Active,,,,Rat,Fischer 344/Male (55 per group),Oral,0; 1.8; 3.8; 15.2; 183 mg/kg/day in diet for 99 wks (high dose) or 111 wk (all others),"Kidney: Renal tubular adenomas and carcinomas (1, 1, 1, 4, 23 in 53-55 animals) Forestomach: Papillomas and carcinomas (0, 0, 3, 2, 5 in 53-55 animals)",Positive (Study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROTHALONIL (OCTOBER 27, 2006)]"
950,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Inactive,,,,Rat,Sprague-Dawley/Female (50 per group),Oral,"0; 15, 60, 240; 1,200 mg/kg/day in diet for 2 yr","Forestomach: Papillomas or carcinomas (0, 0, 0, 2, 1); Not significant",Negative (CA DPR describes as possible adverse effect; study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROTHALONIL (OCTOBER 27, 2006)]"
951,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Active,,,,Rat,Sprague-Dawley/Male (50 per group),Oral,"0; 15, 60, 240; 1,200 mg/kg/day in diet for 2 yr","Forestomach: Papillomas or carcinomas (0, 0, 0, 0, 3); Borderline significance",Positive at highest dose (CA DPR describes as possible adverse effect; study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROTHALONIL (OCTOBER 27, 2006)]"
952,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Active,,,,Mouse,CD-1/Female (60 per group),Oral,"0; 750; 1,500; 3,000 ppm in diet for 2 yr","Forestomach: Squamous cell papillomas or carcinomas (0, 2, 6, 5); No dose response",Positive (CA DPR describes as possible adverse effect; study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROTHALONIL (OCTOBER 27, 2006)]"
953,363898100,15910,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,Active,,,,Mouse,CD-1/Male (60 per group),Oral,"0; 750; 1,500; 3,000 ppm in diet for 2 yr","Kidney: renal tubular adenoma or carcinoma (0, 6, 4, 4). Forestomach: Squamous cell papillomas or carcinomas (0, 2, 5, 2)",Positive without dose response (CA DPR describes as possible adverse effect); study details not given in report,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLOROTHALONIL (OCTOBER 27, 2006)]"
954,363898101,7260,CC1=C(C=C(C=C1)Cl)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2000; 4000 PPM IN DIET,BLOOD VESSELS: HEMANGIOSARCOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-187 Y79]"
955,363898101,7260,CC1=C(C=C(C=C1)Cl)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2000; 4000 PPM IN DIET,BLOOD VESSELS: HEMANGIOSARCOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-187 Y79]"
956,363898101,7260,CC1=C(C=C(C=C1)Cl)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-187 Y79]"
957,363898101,7260,CC1=C(C=C(C=C1)Cl)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-187 Y79]"
958,363898102,7255,CC1=C(C=C(C=C1)N)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 300; 600 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-145 Y79]"
959,363898102,7255,CC1=C(C=C(C=C1)N)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 600; 1200 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-145 Y79]"
960,363898102,7255,CC1=C(C=C(C=C1)N)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 1635; 3269 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-145 Y79]"
961,363898102,7255,CC1=C(C=C(C=C1)N)Cl,Inactive,,,,RAT,F344/MALE,ORAL,"0; 1635; 3269 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-145 Y79]"
962,363898103,18487,CC1=C(C=CC(=C1)Cl)N.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 5000 PPM IN DIET,BLOOD VESSELS: HEMANGIOMA OR HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-165 Y79]"
963,363898103,18487,CC1=C(C=CC(=C1)Cl)N.Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3750; 15000 PPM IN DIET,BLOOD VESSELS: HEMANGIOMA OR HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-165 Y79]"
964,363898103,18487,CC1=C(C=CC(=C1)Cl)N.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1250; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-165 Y79]"
965,363898103,18487,CC1=C(C=CC(=C1)Cl)N.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 1250; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-165 Y79]"
966,363898104,6408,C(C(F)(F)F)Cl,Active,,,,RAT,WISTAR/FEMALE,GAVAGE,300 MG/KG IN CORN OIL 5/WK FOR 52 WK,UTERUS: ADENOCARCINOMA,POSITIVE,"[LONGSTAFF,E, ROBINSON,M, BRADBROOK,C, STYLES,JA AND PURCHASE,IFH; GENOTOXICITY AND CARCINOGENICITY OF FLUOROCARBONS: ASSESSMENT BY SHORT-TERM IN VITRO TESTS AND CHRONIC EXPOSURE IN RATS; TOXICOL. APPL. PHARMACOL. 72:15-31, 1984]"
967,363898104,6408,C(C(F)(F)F)Cl,Active,,,,RAT,WISTAR/MALE,GAVAGE,300 MG/KG IN CORN OIL 5/WK FOR 52 WK,TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[LONGSTAFF,E, ROBINSON,M, BRADBROOK,C, STYLES,JA AND PURCHASE,IFH; GENOTOXICITY AND CARCINOGENICITY OF FLUOROCARBONS: ASSESSMENT BY SHORT-TERM IN VITRO TESTS AND CHRONIC EXPOSURE IN RATS; TOXICOL. APPL. PHARMACOL. 72:15-31, 1984]"
968,363898105,2727,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3317; 6635 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-45 Y78]"
969,363898105,2727,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3317; 6635 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-45 Y78]"
970,363898105,2727,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-45 Y78]"
971,363898105,2727,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-45 Y78]"
972,363898106,26264,[O-][Cr](=O)(=O)[O-].[Ca+2],Active,,,,RAT,NIHBL,INTRAMUSCULAR IMPLANT,12.5 MG,IMPLANT SITE: MALIGNANT TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
973,363898106,26264,[O-][Cr](=O)(=O)[O-].[Ca+2],Active,,,,RAT,,INTRAMUSCULAR IMPLANT,25 MG,"IMPLANT SITE: SPINDLE CELL SARCOMA, FIBROSARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 100 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
974,363898106,26264,[O-][Cr](=O)(=O)[O-].[Ca+2],Active,,,,RAT,,BRONCHIAL IMPLANT,,"IMPLANT SITE: SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
975,363898106,26264,[O-][Cr](=O)(=O)[O-].[Ca+2],Active,,,,RAT,,PLEURAL IMPLANT,,IMPLANT SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
976,363898106,26264,[O-][Cr](=O)(=O)[O-].[Ca+2],Active,,,,MOUSE,"C57BL/MALE,FEMALE",INHALATION,"13 MG/M3, 5 HR/D, 5 D/WK FOR LIFE",LUNG: ADENOMA,POSITIVE,"[NETTESHEIM,P, HANNA,MG,JR, DOHERTY,DG, NEWELL,RF AND HELLMAN,A; EFFECT OF CALCIUM CHROMATE DUST, INFLUENZA VIRUS AND 100 R WHOLE-BODY X-RADIATION OF LUNG TUMOR INCIDENCE IN MICE; J. NATL. CANCER INST. 47:1129-1138, 1971]"
977,363898106,26264,[O-][Cr](=O)(=O)[O-].[Ca+2],Active,,,,RAT,STRAIN-CB/MALE,"INTRAMUSCULAR, SUBCUTANEOUS","0; 19 MG TOTAL DOSE, 1/WK FOR 20 WK",INJECTION SITE: SARCOMA,POSITIVE,"[ROE,FJC AND CARTER,RL; CHROMIUM CARCINOGENESIS: CALCIUM CHROMATE AS A POTENT CARCINOGEN FOR THE SUBCUTANEOUS TISSUES OF THE RAT; BR. J. CANCER 23:172-176, 1969]"
978,363898106,26264,[O-][Cr](=O)(=O)[O-].[Ca+2],Active,,,,MOUSE,"C57BL/MALE,FEMALE",INTRAMUSCULAR IMPLANT,10 MG OF SINTERED CALCIUM CHROMATE,IMPLANT SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 100 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
979,363898106,26264,[O-][Cr](=O)(=O)[O-].[Ca+2],Active,,,,RAT,,INTRAMUSCULAR IMPLANT,25 MG OF SINTERED CALCIUM CHROMATE,"IMPLANT SITE: SPINDLE CELL SARCOMA, FIBROSARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 100 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
980,363898106,26264,[O-][Cr](=O)(=O)[O-].[Ca+2],Active,,,,RAT,,PLEURAL IMPLANT,SINTERED CALCIUM CHROMATE,IMPLANT SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
981,363898108,32520,[O-][Cr](=O)(=O)[O-].[O-][Cr](=O)(=O)[O-].[O-][Cr](=O)(=O)[O-].[Cr+3].[Cr+3],Active,,,,RAT,,INTRAMUSCULAR IMPLANT,,IMPLANT SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 100 Y73]"
982,363898108,32520,[O-][Cr](=O)(=O)[O-].[O-][Cr](=O)(=O)[O-].[O-][Cr](=O)(=O)[O-].[Cr+3].[Cr+3],Active,,,,RAT,,PLEURAL IMPLANT,,IMPLANT SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 100 Y73]"
983,363898109,23976,[Cr],Active,,,,HUMAN,,"INHALATION, ORAL",,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 100 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 254 Y80]"
984,363898110,14915,O=[Cr](=O)=O,Active,,,,RAT,,INTRAMUSCULAR IMPLANT,25 MG,"INJECTION SITE: SPINDLE CELL SARCOMA, FIBROSARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 100 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
985,363898111,9171,C1=CC=C2C(=C1)C=CC3=C2C=CC4=CC=CC=C43,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[WOOD,AW, CHANG,RL, LEVIN,W, RYAN,DE, THOMAS,PE, MAH,HD, KARIE,J, YAGI,H, JERINA,DM AND CONNEY,AH; MUTAGENICITY AND TUMORIGENICITY OF PHENANTHRENE AND CHRYSENE EPOXIDES AND DIOL EPOXIDES; CANCER RES. 39:4069-4077, 1979]"
986,363898111,9171,C1=CC=C2C(=C1)C=CC3=C2C=CC4=CC=CC=C43,Active,,,,MOUSE,ICR/FEMALE,DERMAL,"0, 0.1 MG, 3/WK FOR 17 MO",INTEGUMENTARY SYSTEM (SKIN): CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V32 247 Y83][HECHT,SS, BONDINELL,WE AND HOFFMANN,D; CHRYSENE AND METHYLCHRYSENES. XXIX. PRESENCE IN TOBACCO SMOKE AND CARCINOGENICITY; J. NATL. CANCER INST. 53(4):1121-1133, 1974, ]"
987,363898111,9171,C1=CC=C2C(=C1)C=CC3=C2C=CC4=CC=CC=C43,Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 6.3 UG TOTAL DOSE (0.9 UG/5 UL, 1.8 UG/10 UL, 3.6 UG/20 UL DMSO ON DAYS 1, 8 AND 15); 210 UG TOTAL DOSE (30 UG/5 UL, 60 UG/10 UL, 120 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",,NEGATIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
988,363898111,9171,C1=CC=C2C(=C1)C=CC3=C2C=CC4=CC=CC=C43,Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 6.3 UG TOTAL DOSE (0.9 UG/5 UL, 1.8 UG/10 UL, 3.6 UG/20 UL DMSO ON DAYS 1, 8 AND 15); 210 UG TOTAL DOSE (30 UG/5 UL, 60 UG/10 UL, 120 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",,NEGATIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
989,363898111,9171,C1=CC=C2C(=C1)C=CC3=C2C=CC4=CC=CC=C43,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,INTRAPULMONARY IMPLANT,0; 1; 3 MG IN BEESWAX AND TRIOCTANOIN IMPLANTED IN LUNG (STUDY DURATION: 141 WK),LUNG: CARCINOMA,POSITIVE,"[WENZEL-HARTUNG,R, BRUNE,H, GRIMMER,G, GERMANN,P, TIMM,J AND WOSNIOK,W; EVALUATION OF THE CARCINOGENIC POTENCY OF 4 ENVIRONMENTAL POLYCYCLIC AROMATIC COMPOUNDS FOLLOWING INTRAPULMONARY APPLICATION IN RATS; EXP. PATHOL. 40(4):221-227, 1990]"
990,363898112,10771,C1=CC=C(C=C1)N=NC2=C(C=C(C=C2)N)N.Cl,Active,,,,MOUSE,,ORAL,,HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 91 Y75]"
991,363898113,19118,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-220 Y82]"
992,363898113,19118,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-220 Y82]"
993,363898113,19118,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 12500; 25000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-220 Y82]"
994,363898113,19118,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 6000; 12500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-220 Y82]"
995,363898113,19118,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,WISTAR/MALE,ORAL,"0; 100; 400; 1200 MG/KG/D IN BASAL DIET TO PUPS OF PARENTS EXPOSED TO THE SAME DOSE LEVELS FOR 9 WK PRIOR TO MATING AND CONTINUED THROUGHOUT MATING, PREGNANCY, LACTATION AND WEANING (STUDY DURATION: 115 WK)",,NEGATIVE,"[FORD,GP, STEVENSON,BI AND EVANS,JG; LONG-TERM TOXICITY STUDY OF CARMOISINE IN RATS USING ANIMALS EXPOSED IN UTERO; FOOD CHEM. TOXICOL. 25(12):919-925, 1987]"
996,363898113,19118,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,"0; 100; 400; 1200 MG/KG/D IN BASAL DIET TO PUPS OF PARENTS EXPOSED TO THE SAME DOSE LEVELS FOR 9 WK PRIOR TO MATING AND CONTINUED THROUGHOUT MATING, PREGNANCY, LACTATION AND WEANING (STUDY DURATION: 110 WK)",,NEGATIVE,"[FORD,GP, STEVENSON,BI AND EVANS,JG; LONG-TERM TOXICITY STUDY OF CARMOISINE IN RATS USING ANIMALS EXPOSED IN UTERO; FOOD CHEM. TOXICOL. 25(12):919-925, 1987]"
997,363898114,2724065,CC1=CC(=C(C=C1)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+],Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 189 Y75]"
998,363898114,2724065,CC1=CC(=C(C=C1)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+],Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 189 Y75]"
999,363898115,5359662,C1=CC=C(C=C1)N/N=C/2\C(=CC3=CC(=C(C(=C3C2=O)N)N=NC4=CC=C(C=C4)C5=CC=C(C=C5)N=NC6=C(C=C(C=C6)N)N)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],Active,,,,RAT,F344/FEMALE,ORAL,0; 190; 375; 750; 1500; 3000 PPM IN DIET FOR 91 D (STUDY DURATION:93 D),"LIVER: NEOPLASTIC NODULE, FOCI OF CELLULAR ALTERATION OR BASOPHILIC FOCI",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-108 Y78]"
1000,363898115,5359662,C1=CC=C(C=C1)N/N=C/2\C(=CC3=CC(=C(C(=C3C2=O)N)N=NC4=CC=C(C=C4)C5=CC=C(C=C5)N=NC6=C(C=C(C=C6)N)N)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],Active,,,,RAT,F344/MALE,ORAL,0; 190; 375; 750; 1500; 3000 PPM IN DIET FOR 91 D (STUDY DURATION: 93 D),"LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE, FOCI OF CELLULAR ALTERATION OR BASOPHILIC FOCI",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-108 Y78]"
1001,363898115,5359662,C1=CC=C(C=C1)N/N=C/2\C(=CC3=CC(=C(C(=C3C2=O)N)N=NC4=CC=C(C=C4)C5=CC=C(C=C5)N=NC6=C(C=C(C=C6)N)N)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],Active,,,,MOUSE,"ICR/MALE,FEMALE",ORAL,0; 0.3% IN DRINKING WATER FOR LIFE (STUDY DURATION: 50-60 WK),LIVER: HEPATOCELLULAR CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA,POSITIVE,"[ASADA,I, MATSUMOTO,Y, TOBE,T, YOSHIDA,O AND MIYAKAWA,M; INDUCTION OF HEPATOMA IN MICE BY DIRECT DEEP BLACK-EXTRA (DDB-EX) AND OCCURRENCE OF SERUM AFP; ARCH. JPN. CHIR. 50(1):44-55, 1981]"
1002,363898116,9570116,C1=CC(=CC=C1C2=CC=C(C=C2)N/N=C\3/C(=O)C4=C(C=C3S(=O)(=O)[O-])C=C(C=C4N)S(=O)(=O)[O-])N/N=C\5/C(=O)C6=C(C=C5S(=O)(=O)[O-])C=C(C=C6N)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],Active,,,,RAT,F344/FEMALE,ORAL,0; 190; 375; 750; 1500; 3000 PPM IN DIET FOR 91 D (STUDY DURATION: 93 D),"LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE, FOCI OF CELLULAR ALTERATION OR BASOPHILIC FOCI",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-108 Y78]"
1003,363898116,9570116,C1=CC(=CC=C1C2=CC=C(C=C2)N/N=C\3/C(=O)C4=C(C=C3S(=O)(=O)[O-])C=C(C=C4N)S(=O)(=O)[O-])N/N=C\5/C(=O)C6=C(C=C5S(=O)(=O)[O-])C=C(C=C6N)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],Active,,,,RAT,F344/MALE,ORAL,0; 190; 375; 750; 1500; 3000 PPM IN DIET FOR 91 D (STUDY DURATION: 93 D),"LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE, FOCI OF CELLULAR ALTERATION OR BASOPHILIC FOCI",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-108 Y78]"
1004,363898117,9566057,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N/N=C\3/C(=O)C4=C(C(=CC(=C4N)S(=O)(=O)[O-])S(=O)(=O)[O-])C=C3)C)N/N=C\5/C(=O)C6=C(C(=CC(=C6N)S(=O)(=O)[O-])S(=O)(=O)[O-])C=C5.[Na+].[Na+].[Na+].[Na+],Active,,,,RAT,,INTRAPERITONEAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 151 Y75]"
1005,363898118,9570322,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)[O-])C(=O)[O-])N/N=C\4/C(=O)C=C/C(=N\NC5=C(C=CC(=C5)S(=O)(=O)[O-])[O-])/C4=O.[Na+].[Na+].[Cu+2],Active,,,,RAT,F344/FEMALE,ORAL,0; 190; 375; 750; 1500; 3000 PPM IN DIET FOR 91 D (STUDY DURATION: 93 D),"LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE, FOCI OF CELLULAR ALTERATION OR BASOPHILIC FOCI",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-108 Y78]"
1006,363898118,9570322,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)[O-])C(=O)[O-])N/N=C\4/C(=O)C=C/C(=N\NC5=C(C=CC(=C5)S(=O)(=O)[O-])[O-])/C4=O.[Na+].[Na+].[Cu+2],Active,,,,RAT,F344/MALE,ORAL,0; 190; 375; 750; 1500; 3000 PPM IN DIET FOR 91 D (STUDY DURATION: 93 D),LIVER: FOCI OF CELLULAR ALTERATION OR BASOPHILIC FOCI,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-108 Y78]"
1007,363898119,17811,CC1=CC(=C(C=C1)O)N=NC2=CC=C(C=C2)NC(=O)C,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET,LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-222 Y82]"
1008,363898119,17811,CC1=CC(=C(C=C1)O)N=NC2=CC=C(C=C2)NC(=O)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-222 Y82]"
1009,363898119,17811,CC1=CC(=C(C=C1)O)N=NC2=CC=C(C=C2)NC(=O)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-222 Y82]"
1010,363898119,17811,CC1=CC(=C(C=C1)O)N=NC2=CC=C(C=C2)NC(=O)C,Active,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN DIET,LIVER: NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-222 Y82]"
1011,363898120,17730,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 12500; 25000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-208 Y81]"
1012,363898120,17730,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 12500; 25000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-208 Y81]"
1013,363898120,17730,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 12500; 25000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-208 Y81]"
1014,363898120,17730,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 12500; 25000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-208 Y81]"
1015,363898120,17730,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 19.5 MO (STUDY DURATION: 19.5 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
1016,363898120,17730,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 19.5 MO (STUDY DURATION: 19.5 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
1017,363898121,5284369,C1=CC=C(C=C1)/C=C/COC(=O)C2=CC=CC=C2N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 15000; 30000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105-107 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-196 Y80]"
1018,363898121,5284369,C1=CC=C(C=C1)/C=C/COC(=O)C2=CC=CC=C2N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 15000; 30000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105-107),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-196 Y80]"
1019,363898121,5284369,C1=CC=C(C=C1)/C=C/COC(=O)C2=CC=CC=C2N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 15000; 30000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105-107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-196 Y80]"
1020,363898121,5284369,C1=CC=C(C=C1)/C=C/COC(=O)C2=CC=CC=C2N,Active,,,,RAT,F344/MALE,ORAL,0; 15000; 30000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105-107),PANCREAS: ACINAR CELL ADENOMA OR CARCINOMA; KIDNEY (CORTEX): ADENOMA OR ADENOCARCINOMA (NOS),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-196 Y80]"
1021,363898122,21238,CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Ba+2],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-225 Y82]"
1022,363898122,21238,CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Ba+2],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-225 Y82]"
1023,363898122,21238,CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Ba+2],Active,,,,RAT,F344/MALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),SPLEEN: SARCOMA; LIVER: NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-225 Y82]"
1024,363898122,21238,CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Ba+2],Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 134.7 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
1025,363898122,21238,CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Ba+2],Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 134.7 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
1026,363898122,21238,CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Ba+2],Active,,,,RAT,F344/MALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),SPLEEN OR PERITONEUM: SARCOMA,POSITIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
1027,363898122,21238,CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Ba+2],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
1028,363898122,21238,CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Ba+2],Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),LIVER: NEOPLASTIC NODULE,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-225 Y82]"
1029,363898123,2763,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl,Active,,,,RAT,F344/MALE,ORAL,10 MG/KG IN DIET FOR 60 WK,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[RAO,MS, LALWANI,ND, WATANABE,TK AND REDDY,JK; INHIBITORY EFFECT OF ANTIOXIDANTS ETHOXYQUIN AND 2(3)-TERT-BUTYL-4-HYDROXYANISOLE ON HEPATIC TUMORIGENESIS IN RATS FED CIPROFIBRATE, A PEROXISOME PROLIFERATOR; CANCER RES. 44:1072-1076, 1984]"
1030,363898124,13297,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-226 Y82]"
1031,363898124,13297,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O,Active,,,,MOUSE,,SUBCUTANEOUS,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 225 Y75]"
1032,363898124,13297,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 250; 500 PPM IN DIET,LIVER: NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-226 Y82]"
1033,363898124,13297,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O,Active,,,,RAT,F344/MALE,ORAL,O; 250; 500 PPM IN DIET,LIVER: NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-226 Y82]"
1034,363898125,54680783,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C,Active,,,,RAT,F344/MALE,ORAL,0.1% IN DIET FOR 80 WK,KIDNEY: CLEAR CELL ADENOMA,POSITIVE,"[ARAI,M AND HIBINO,T; TUMORIGENICITY OF CITRININ IN MALE F344 RATS; CANCER LETT. 17:281-287, 1983]"
1035,363898125,54680783,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C,Active,,,,RAT,,DIET,"0, 0.1%, FOR 32 WK","KIDNEY: ADENOMA, ADENOCARCINOMA",POSITIVE,"[ARAI,M, SENBA,H, YOKOYAMA,K AND HIBINO,T; NEOPLASM FORMATION IN RAT KIDNEY AFTER A LONG-TERM ADMINISTRATION OF CITRININ; FUJITA GAKUEN IGAKKAISHI 5(1):77-80, 1981]"
1036,363898125,54680783,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C,Inactive,,,,MOUSE,DDD/MALE,ORAL,0; 100; 200 PPM IN DIET FOR 70 WK (STUDY DURATION: 70 WK),,NEGATIVE,"[KANISAWA,M; SYNERGISTIC EFFECT OF CITRININ ON HEPATORENAL CARCINOGENESIS OF OCHRATOXIN A IN MICE; DEV. FOOD SCI. 7(TOXIGENIC FUNGI):245-254, 1984]"
1037,363898126,31412,C1=CC=C2C(=C1)C3=C4C(=CC=C5C4=C(C=C3)C(=O)C6=CC=CC=C65)C2=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 12500; 25000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-134 Y79]"
1038,363898126,31412,C1=CC=C2C(=C1)C3=C4C(=CC=C5C4=C(C=C3)C(=O)C6=CC=CC=C65)C2=O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,LYMPHATIC SYSTEM: LYMPHOMA; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-134 Y79]"
1039,363898126,31412,C1=CC=C2C(=C1)C3=C4C(=CC=C5C4=C(C=C3)C(=O)C6=CC=CC=C65)C2=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3500; 7000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-134 Y79]"
1040,363898126,31412,C1=CC=C2C(=C1)C3=C4C(=CC=C5C4=C(C=C3)C(=O)C6=CC=CC=C65)C2=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 3500; 7000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-134 Y79]"
1041,363898127,2796,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,Active,,,,RAT,F344/MALE,ORAL,0.5% IN DIET FOR UP TO 28 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 39 Y80]"
1042,363898127,2796,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",ORAL,1500; 4500; 9000 PPM IN DIET,LIVER,POSITIVE,"[HARTIG,F, STEGMEIER,K, HEBOLD,G, OZEL,M AND FAHIMI,HD; STUDY OF LIVER ENZYMES: PEROXISOME PROLIFERATION AND TUMOR RATES IN RATS AT THE END OF CARCINOGENICITY STUDIES WITH BEZAFIBRATE AND CLOFIBRATE; ANN. NEW YORK ACAD. SCI. 386:464-467, 1982]"
1043,363898127,2796,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,Inactive,,,,MOUSE,"CD-1/MALE,FEMALE (NEONATAL) (24-28/GROUP)",ORAL (GAVAGE),"0, 100, 350, 500 MG/KG BW ON D 9 AND 16 OF LIFE (STUDY DURATION: 1 YR)",,NEGATIVE,"[NESFIELD,S, WILLIAMS,T, HOIVIK,D, MILLER,R, ALLEN,J,  SELINGER,K RICKERT,D AND SANTOSTEFANO,M; EVALUATION  OF THE CARCINOGENIC POTENTIAL OF CLOFIBRATE IN THE  NEONATAL MOUSE;  INT. J. TOXICOL. 24(5):341-348, 2005]"
1044,363898127,2796,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,Inactive,,,,Mouse,Nontransgenic rasH2/Male (15/group),Oral,"0; 200 mg/kg/day (Test material solvent: 0.5% (w/w) hydroxymethylcellulose in water), daily, by gavage for 27 wk; study duration 27 wk",Liver,"Negative (Hepatocellular neoplasms observed in matched study of male transgenic rasH2 mice exposed at  50, 150, and 200 mg.kg.day)","[ NESFIELD,SR CLARKE,CJ HOIVIK,DJ MILLER,RT ALLEN,JS SELINGER,K AND SANTOSTEFANO,MJ; EVALUATION OF THE CARCINOGENIC POTENTIAL OF CLOFIBRATE IN THE RAS(H2) MOUSE; INTERNATIONAL JOURNAL OF TOXICOLOGY 24(5):301-11, 2005]"
1045,363898127,2796,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,Inactive,,,,Mouse,Nontransgenic rasH2/Female (15/group),Oral,"0; 250 mg/kg/day (Test material solvent: 0.5% (w/w) hydroxymethylcellulose in water), daily, by gavage for 27 wk; study duration 27 wk",,"Negative (Slight increase in incidence of various neoplasms (harderian gland, lungs, skin, spleen, tail, thymus, and uterus) in female transgenic rasH2 mice similarly exposed at 50, 150, and 250 mg/kg/day.)","[ NESFIELD,SR CLARKE,CJ HOIVIK,DJ MILLER,RT ALLEN,JS SELINGER,K AND SANTOSTEFANO,MJ; EVALUATION OF THE CARCINOGENIC POTENTIAL OF CLOFIBRATE IN THE RAS(H2) MOUSE; INTERNATIONAL JOURNAL OF TOXICOLOGY 24(5):301-11, 2005]"
1046,363898128,14992,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 274; 549 PPM IN DIET FOR 78 WK (STUDY DURATION: 91-92 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-91 Y78]"
1047,363898128,14992,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 14216; 28433 PPM IN DIET FOR 78 WK (STUDY DURATION: 110-111 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-91 Y78]"
1048,363898128,14992,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,Unspecified,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 14216; 28433 PPM IN DIET FOR 78 WK (STUDY DURATION: 110-111 WK),MAMMARY GLAND: ADENOCARCINOMA; STOMACH: CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-91 Y78]"
1049,363898130,2871,CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(=C(C(=O)O2)Cl)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10; 20 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-96 Y79]"
1050,363898130,2871,CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(=C(C(=O)O2)Cl)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 10; 20 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-96 Y79]"
1051,363898130,2871,CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(=C(C(=O)O2)Cl)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 10; 20 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-96 Y79]"
1052,363898130,2871,CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(=C(C(=O)O2)Cl)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 10; 20 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-96 Y79]"
1053,363898130,2871,CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(=C(C(=O)O2)Cl)C,Inactive,,,,Rat,Wistar/Female (50/group),Oral,0 (1% peanut oil); 1; 5; 25 ppm in diet for 24 mo; test material purity 99.2%,,Negative. According to DPR evaluator; original data not presented. Cholinesterase inhibition at highest dose,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR COUMAPHOS (JUNE 5, 1992)]"
1054,363898130,2871,CCOP(=S)(OCC)OC1=CC2=C(C=C1)C(=C(C(=O)O2)Cl)C,Inactive,,,,Rat,Wistar/Male (50/group),Oral,0 (1% peanut oil); 1; 5; 25 ppm in diet for 24 mo; test material purity 99.2%,,Negative. According to DPR evaluator; original data not presented. Cholinesterase inhibition at highest dose,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR COUMAPHOS (JUNE 5, 1992)]"
1055,363898131,323,C1=CC=C2C(=C1)C=CC(=O)O2,Active,,,,RAT,,ORAL,,BILE DUCT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 113 Y76]"
1056,363898131,323,C1=CC=C2C(=C1)C=CC(=O)O2,Active,,,,RAT,F344/MALE,GAVAGE,0; 25; 50; 100 MG/KG BW IN CORN OIL 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),KIDNEY (RENAL TUBULE): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-422 Y93]"
1057,363898131,323,C1=CC=C2C(=C1)C=CC(=O)O2,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 50; 100; 200 MG/KG BW IN CORN OIL 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-422 Y93]"
1058,363898131,323,C1=CC=C2C(=C1)C=CC(=O)O2,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 50; 100; 200 MG/KG BW IN CORN OIL 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-422 Y93]"
1059,363898131,323,C1=CC=C2C(=C1)C=CC(=O)O2,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,"0; 333; 1000; 2000 PPM IN DIET FOR DURATION OF STUDY ADMINISTERED TO RATS EXPOSED TO THE SAME DOSES DURING GESTATION AND LACTATION PHASES, ADDITIONAL DOSES OF 3000 AND 5000 PPM IN DIET ADMINISTERED FOLLOWING WEANING FOR THE DURATION OF STUDY (STUDY DURATION: LIFE SPAN)","LIVER: CHOLANGIOCARCINOMA, PARENCHYMAL TUMORS",POSITIVE,"[CARLTON,BD, AUBRUN,JC AND SIMON,GS; EFFECTS OF COUMARIN FOLLOWING PERINATAL AND CHRONIC EXPOSURE IN SPRAGUE-DAWLEY RATS AND CD-1 MICE; FUNDAM. APPL. TOXICOL. 30(1):145-151, 1996]"
1060,363898131,323,C1=CC=C2C(=C1)C=CC(=O)O2,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 300; 1000; 3000 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 109 WK),,NEGATIVE,"[CARLTON,BD, AUBRUN,JC AND SIMON,GS; EFFECTS OF COUMARIN FOLLOWING PERINATAL AND CHRONIC EXPOSURE IN SPRAGUE-DAWLEY RATS AND CD-1 MICE; FUNDAM. APPL. TOXICOL. 30(1):145-151, 1996]"
1061,363898131,323,C1=CC=C2C(=C1)C=CC(=O)O2,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 300; 1000; 3000 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 101 WK),,NEGATIVE,"[CARLTON,BD, AUBRUN,JC AND SIMON,GS; EFFECTS OF COUMARIN FOLLOWING PERINATAL AND CHRONIC EXPOSURE IN SPRAGUE-DAWLEY RATS AND CD-1 MICE; FUNDAM. APPL. TOXICOL. 30(1):145-151, 1996]"
1062,363898131,323,C1=CC=C2C(=C1)C=CC(=O)O2,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,"0; 333; 1000; 2000 PPM IN DIET FOR DURATION OF STUDY ADMINISTERED TO RATS EXPOSED TO THE SAME DOSES DURING GESTATION AND LACTATION PHASES, ADDITIONAL DOSES OF 3000 AND 5000 PPM IN DIET ADMINISTERED FOLLOWING WEANING FOR THE DURATION OF STUDY (STUDY DURATION: LIFE SPAN)","LIVER: CHOLANGIOCARCINOMA, PARENCHYMAL TUMORS",POSITIVE,"[CARLTON,BD, AUBRUN,JC AND SIMON,GS; EFFECTS OF COUMARIN FOLLOWING PERINATAL AND CHRONIC EXPOSURE IN SPRAGUE-DAWLEY RATS AND CD-1 MICE; FUNDAM. APPL. TOXICOL. 30(1):145-151, 1996]"
1063,363898131,323,C1=CC=C2C(=C1)C=CC(=O)O2,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 25; 50; 100 MG/KG BW IN CORN OIL 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),KIDNEY (RENAL TUBULE): ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-422 Y93]"
1064,363898132,7610,CC1=C(C=CC(=C1)OC)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 0.06; 0.11 G/KG (FOR 53 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-105 Y78]"
1065,363898132,7610,CC1=C(C=CC(=C1)OC)N,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 0.08; 0.16 G/KG,URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-105 Y78]"
1066,363898132,7610,CC1=C(C=CC(=C1)OC)N,Active,,,,RAT,F344/MALE,GAVAGE,0; 0.08; 0.16 G/KG,URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-105 Y78]"
1067,363898133,8445,CC1=CC(=C(C=C1)OC)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.22; 0.44% TWA, IN DIET FOR 104 WK (STUDY DURATION: 97-106 WK)","LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR CARCINOMA OR ADENOMA; URINARY BLADDER: TRANSITIONAL CELL CARCINOMA OR CARCINOMA (NOS) OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-142 Y79]"
1068,363898133,8445,CC1=CC(=C(C=C1)OC)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.22; 0.46% TWA, IN DIET FOR 92-104 WK (STUDY DURATION: 92-106 WK)",URINARY BLADDER: SQUAMOUS CELL CARCINOMA OR TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-142 Y79]"
1069,363898133,8445,CC1=CC(=C(C=C1)OC)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.5; 1.0% IN DIET FOR 104 WK (STUDY DURATION: 106 WK),NASAL CAVITY: OLFACTORY NEUROBLASTOMA; URINARY BLADDER: NEOPLASM (NOS) OR PAPILLARY CARCINOMA OR SQUAMOUS CELL CARCINOMA OR TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-142 Y79]"
1070,363898133,8445,CC1=CC(=C(C=C1)OC)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.5; 1.0% IN DIET FOR 104 WK (STUDY DURATION: 105-106 WK),NASAL CAVITY: NEUROBLASTOMA OR OLFACTORY NEUROBLASTOMA; LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA OR MIXED HEPATO/CHOLANGIOCARCINOMA; URINARY BLADDER: CARCINOMA (UNDIFFERENTIATED) OR PAPILLARY CARCINOMA OR SQUAMOUS CELL CARCINOMA OR TRANSITIONAL CELL PAPILLOMA OR TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-142 Y79]"
1071,363898134,135465076,C1=CC=C(C=C1)/[N+](=N/[O-])/[O-].[NH4+],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.2; 0.4% TWA, IN DIET FOR 78 WK (STUDY DURATION: 95-98 WK)","CIRCULATORY SYSTEM: HEMANGIOSARCOMA OR HEMANGIOMA; LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA (NOS)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-100 Y78]"
1072,363898134,135465076,C1=CC=C(C=C1)/[N+](=N/[O-])/[O-].[NH4+],Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.2; 0.4% TWA, IN DIET FOR 78 WK (STUDY DURATION: 95-98 WK)",CIRCULATORY SYSTEM: HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-100 Y78]"
1073,363898134,135465076,C1=CC=C(C=C1)/[N+](=N/[O-])/[O-].[NH4+],Active,,,,RAT,F344/FEMALE,ORAL,0; 0.15; 0.30% IN DIET FOR 78 WK (STUDY DURATION: 106-110 WK),"CIRCULATORY SYSTEM: HEMANGIOSARCOMA; LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE; STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL CARCINOMA OR PAPILLOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-100 Y78]"
1074,363898134,135465076,C1=CC=C(C=C1)/[N+](=N/[O-])/[O-].[NH4+],Active,,,,RAT,F344/MALE,ORAL,0; 0.15; 0.30% IN DIET FOR 78 WK (STUDY DURATION: 97-110 WK),"CIRCULATORY SYSTEM: HEMANGIOSARCOMA; LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE; STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL CARCINOMA OR PAPILLOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-100 Y78]"
1075,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,GUINEA PIG,,ORAL,,LIVER; BILE DUCT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 121 Y76]"
1076,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,HAMSTER,,ORAL,,LIVER; LUNG; INTESTINES; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 121 Y76]"
1077,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,HAMSTER,,SUBCUTANEOUS,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 121 Y76]"
1078,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,MOUSE,,SUBCUTANEOUS,,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 157 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 121 Y76]"
1079,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,RABBIT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 121 Y76]"
1080,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,RAT,,ORAL,,INTESTINES; KIDNEY; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 157 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 121 Y76]"
1081,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,RAT,,SUBCUTANEOUS,,KIDNEY; INTESTINES; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 121 Y76]"
1082,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",GAVAGE,"3 ML/KG BW CYCAD EXTRACT, 1/WK FOR 12 WK",INTESTINES,POSITIVE,"[WATANABE,K, YOSHII,H, IWASHITA,H, MUTA,K, HAMADA,Y, HAMADA,Y, ISAKA,H AND NISHI,M; INTESTINAL TUMORS OF RATS BY GASTRIC OR INTESTINAL ADMINISTRATION OF CYCAD EXTRACT AND CYCASIN; GANN 66(4):449-454, 1975]"
1083,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",RECTAL,50 MG/KG BW INTO INTESTINE 1/WK FOR 12 WK,INTESTINES,POSITIVE,"[WATANABE,K, YOSHII,H, IWASHITA,H, MUTA,K, HAMADA,Y, HAMADA,Y, ISAKA,H AND NISHI,M; INTESTINAL TUMORS OF RATS BY GASTRIC OR INTESTINAL ADMINISTRATION OF CYCAD EXTRACT AND CYCASIN; GANN 66(4):449-454, 1975]"
1084,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,"80; 250 MG/KG, SINGLE DOSE",INTESTINES (COLON OR RECTUM); INTESTINES (JEJUNUM OR ILEUM); DUODENUM,POSITIVE,"[LAQUEUR,GL AND SPATZ,M; ONCOGENICITY OF CYCASIN AND METHYLAZOXYMETHANOL; GANN MONOGR. CANCER RES. 17 (RECENT TOP. CHEM. CARCINOG.):189-204, 1975]"
1085,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,"80 MG/KG, 1/WK FOR 15 WK",INTESTINES (COLON OR RECTUM); INTESTINES (JEJUNUM OR ILEUM),POSITIVE,"[LAQUEUR,GL AND SPATZ,M; ONCOGENICITY OF CYCASIN AND METHYLAZOXYMETHANOL; GANN MONOGR. CANCER RES. 17 (RECENT TOP. CHEM. CARCINOG.):189-204, 1975]"
1086,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,HAMSTER,,GAVAGE,"0.1; 0.15 MG/G BW, SINGLE DOSE","LIVER: HEPATOCELLULAR ADENOMA; BILE DUCT: CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; LUNG: ADENOMA; INTESTINES; KIDNEY: CARCINOMA, MALIGNANT LYMPHOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 121 Y76][HIRONO,I, HAYASHI,K, MORI,H AND MIWA,T; CARCINOGENIC EFFECTS OF CYCASIN IN SYRIAN GOLDEN HAMSTERS AND THE TRANSPLANTABILITY OF INDUCED TUMORS; CANCER RES. 31:283-287, 1971, ]"
1087,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,MONKEY,RHESUS,ORAL,"0; 3% (50-75 MG/KG) IN DIET OF CRUDE CYCAD MEAL, 5 D/WK FOR UP TO 11 YR",UNSPECIFIED: NEOPLASM,POSITIVE,"[SIEBER,SM, CORREA,P, DALGARD,DW, MCINTIRE,KR AND ADAMSON,RH; CARCINOGENICITY AND HEPATOTOXICITY OF CYCASIN AND ITS AGLYCONE METHYLAZOXYMETHANOLACETATE IN NONHUMAN PRIMATES; J. NATL. CANCER INST. 65(1):177-189, 1980]"
1088,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,GUINEA PIG,,ORAL,"0; 5% IN DIET OF CYCAD MEAL, 2-3 5-D PERIODS",LIVER: HEPATOCELLULAR CARCINOMA; BILE DUCT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 121 Y76][SPATZ,M; CARCINOGENIC EFFECT OF CYCAD MEAL IN GUINEA PIGS; FED. PROC. FED. AM. SOC. EXP. BIOL. 23:1384-1385, 1964, ]"
1089,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,MONKEY,CYNOMOLGUS,ORAL,"0; 3% (50-75 MG/KG) IN DIET OF CRUDE CYCAD MEAL, 5 D/WK FOR UP TO 11 YR",UNSPECIFIED: NEOPLASM,POSITIVE,"[SIEBER,SM, CORREA,P, DALGARD,DW, MCINTIRE,KR AND ADAMSON,RH; CARCINOGENICITY AND HEPATOTOXICITY OF CYCASIN AND ITS AGLYCONE METHYLAZOXYMETHANOLACETATE IN NONHUMAN PRIMATES; J. NATL. CANCER INST. 65(1):177-189, 1980]"
1090,363898135,5459896,C/[N+](=N/CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)/[O-],Active,,,,MONKEY,AFRICAN GREEN,ORAL,"0; 3% (50-75 MG/KG) IN DIET OF CRUDE CYCAD MEAL, 5 D/WK FOR UP TO 11 YR",UNSPECIFIED: NEOPLASM,POSITIVE,"[SIEBER,SM, CORREA,P, DALGARD,DW, MCINTIRE,KR AND ADAMSON,RH; CARCINOGENICITY AND HEPATOTOXICITY OF CYCASIN AND ITS AGLYCONE METHYLAZOXYMETHANOLACETATE IN NONHUMAN PRIMATES; J. NATL. CANCER INST. 65(1):177-189, 1980]"
1091,363898136,8752,C1CCC(CC1)NS(=O)(=O)[O-].C1CCC(CC1)NS(=O)(=O)[O-].[Ca+2],Active,,,,RAT,"ALBINO/MALE,FEMALE",SUBCUTANEOUS,5; 15% IN AQ SOLN 3/WK FOR 85 OR 107 WK,INJECTION SITE: FIBROSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V22 55 Y80]"
1092,363898137,23665706,C1CCC(CC1)NS(=O)(=O)[O-].[Na+],Inactive,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",ORAL,2; 5% IN DIET PRENATALLY AND FOR LIFE,,NEGATIVE,"[SCHMAHL,D AND HABS,M; INVESTIGATIONS ON THE CARCINOGENICITY OF THE ARTIFICIAL SWEETENERS SODIUM CYCLAMATE AND SODIUM SACCHARIN IN RATS IN A TWO-GENERATION EXPERIMENT; ARZNEIM.-FORSCH. 34:604-606, 1984]"
1093,363898137,23665706,C1CCC(CC1)NS(=O)(=O)[O-].[Na+],Inactive,,,,MONKEY,"CYNOMOLGUS, RHESUS, AFRICAN GREEN/MALE, FEMALE",ORAL,0; 100; 500 MG/KG IN DIET FOR 24 YR (STUDY DURATION: 24 YR),,NEGATIVE,"[TAKAYAMA,S RENWICK,AG JOHANSSON,SL THORGEIRSSON,UP TSUTSUMI,M DALGARD,DW AND SIEBER,SM; LONG-TERM TOXICITY AND CARCINOGENICITY STUDY OF CYCLAMATE IN NONHUMAN PRIMATES; TOXICOL. SCI. 53(1):33-39, 2000]"
1094,363898138,2907,C1CNP(=O)(OC1)N(CCCl)CCCl,Active,,,,HUMAN,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 165 Y81]"
1095,363898138,2907,C1CNP(=O)(OC1)N(CCCl)CCCl,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,26 MG/KG 1/WK FOR 52 WK,"MAMMARY GLAND: CARCINOMA; MULTIPLE SITES: CARCINOMA, SARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 165 Y81]"
1096,363898138,2907,C1CNP(=O)(OC1)N(CCCl)CCCl,Active,,,,RAT,BR46/MALE,INTRAVENOUS,15 MG/KG 1/WK OR 5 DOSES OF 33 MG/KG EVERY 2 WK,MULTIPLE SITES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 165 Y81]"
1097,363898138,2907,C1CNP(=O)(OC1)N(CCCl)CCCl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,13 MG/KG 1/WK,MULTIPLE SITES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 165 Y81]"
1098,363898138,2907,C1CNP(=O)(OC1)N(CCCl)CCCl,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",ORAL,0.31; 0.63; 1.25; 2.5 MG/KG 5/WK,"URINARY BLADDER: PAPILLOMA, TRANSITIONAL CELL CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 165 Y81]"
1099,363898138,2907,C1CNP(=O)(OC1)N(CCCl)CCCl,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,0; 13; 26 MG/KG IN SALINE 1/WK FOR LIFETIME (STUDY DURATION: LIFETIME),LYMPHATIC SYSTEM: MALIGNANT LEUKEMIA,POSITIVE,"[PETRU,E, BERGER,MR AND SCHMAHL,D; LONG-TERM CARCINOGENICITY OF CYCLOPHOSPHAMIDE IN TWO MOUSE STRAINS WITH DIFFERENT SPONTANEOUS LEUKEMIA INCIDENCE; CANCER LETT. 44:221-226, 1986]"
1100,363898138,2907,C1CNP(=O)(OC1)N(CCCl)CCCl,Inactive,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",ORAL,0; 200 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[HENDRICKS,JD, SHELTON,DW, LOVELAND,PM, PEREIRA,CB AND BAILEY,GS; CARCINOGENICITY OF DIETARY DIMETHYLNITROSOMORPHOLINE, N-METHYL-N'-NITRO-N-NITROSOGUANIDINE, AND DIBROMOETHANE IN RAINBOW TROUT; TOXICOL. PATHOL. 23(4):447-457, 1995]"
1101,363898139,23665583,COC1=CC=C(C=C1)C(=O)/C(=C\C(=O)[O-])/Br.[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,0; 12; 24 MG/KG 3/WK FOR 104 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-207 Y81]"
1102,363898139,23665583,COC1=CC=C(C=C1)C(=O)/C(=C\C(=O)[O-])/Br.[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 12; 24 MG/KG 3/WK FOR 104 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-207 Y81]"
1103,363898139,23665583,COC1=CC=C(C=C1)C(=O)/C(=C\C(=O)[O-])/Br.[Na+],Active,,,,RAT,F344/FEMALE,INTRAPERITONEAL,0; 7; 14 MG/KG 3/WK FOR 104 WK (STUDY DURATION: 104-105 WK),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-207 Y81]"
1104,363898139,23665583,COC1=CC=C(C=C1)C(=O)/C(=C\C(=O)[O-])/Br.[Na+],Active,,,,RAT,F344/MALE,INTRAPERITONEAL,0; 7; 14 MG/KG 3/WK FOR 104 WK (STUDY DURATION: 104-105 WK),MULTIPLE SITES: MALIGNANT MESOTHELIOMA; TUNICA VAGINALIS: MESOTHELIOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-207 Y81]"
1105,363898140,135398738,CN(C)/N=N/C1=C(NC=N1)C(=O)N,Active,,,,RAT,BUFFALO/FEMALE,ORAL,0; 500; MG/KG IN DIET FOR 11 WK,MAMMARY GLAND: ADENOCARCINOMA; THYMUS GLAND: LYMPHOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 203 Y81]"
1106,363898140,135398738,CN(C)/N=N/C1=C(NC=N1)C(=O)N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,346; 574; 740 MG/KG (TOTAL DOSE),"MAMMARY GLAND: ADENOCARCINOMA, CARCINOMA, ADENOFIBROMA; THYMUS GLAND: LYMPHOSARCOMA; SPLEEN: LYMPHOSARCOMA; BRAIN: EPENDYMOMA; LUNG: ALVEOLAR SARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 203 Y81]"
1107,363898140,135398738,CN(C)/N=N/C1=C(NC=N1)C(=O)N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 100; 250; 400 MG/RAT IN CITRATE-MANNITOL SOLN,MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 203 Y81]"
1108,363898140,135398738,CN(C)/N=N/C1=C(NC=N1)C(=O)N,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,608; 974 MG/KG (TOTAL DOSE),MAMMARY GLAND: ADENOCARCINOMA; THYMUS GLAND: LYMPHOSARCOMA; SPLEEN: LYMPHOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 203 Y81]"
1109,363898141,15331,CN(C)NC(=O)CCC(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-83 Y78]"
1110,363898141,15331,CN(C)NC(=O)CCC(=O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),ENDOMETRIUM: ADENOCARCINOMA; UTERUS: LEIOMYOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-83 Y78]"
1111,363898141,15331,CN(C)NC(=O)CCC(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-83 Y78]"
1112,363898141,15331,CN(C)NC(=O)CCC(=O)O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-83 Y78]"
1113,363898141,15331,CN(C)NC(=O)CCC(=O)O,Unspecified,,,,Rat,Fischer 344/Female (50/group),Oral,"0; 100; 500; 5,000; 10,000 ppm in diet for 2 yr","Uterus:  Adenocarcinoma (0, 1, 2, 1, 1); Leiomyocarcinoma (0, 0, 0, 2, 1)","Equivocal, CA DPR noted rarity of the tumors but that MTD not achieved","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAMINOZIDE (AUGUST 01, 1991)]"
1114,363898141,15331,CN(C)NC(=O)CCC(=O)O,Inactive,,,,Rat,Fischer 344/Male (50/group),Oral,"0; 100; 500; 5,000; 10,000 ppm in diet for 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAMINOZIDE (AUGUST 01, 1991)]"
1115,363898141,15331,CN(C)NC(=O)CCC(=O)O,Unspecified,,,,Rat,Fischer 344/Female (50/group),Oral,0; 1; 50; 100 ppm in diet for 2 yr,"Liver: increase at 50 and 100 ppm  (incidence not reported by CADPR) Uterus:  Adenocarcinoma (0, 0, 0, 2)","Equivocal, CA DPR described results as providing marginal evidence of treatment effects","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAMINOZIDE (AUGUST 01, 1991)]"
1116,363898141,15331,CN(C)NC(=O)CCC(=O)O,Unspecified,,,,Mouse,CD-1/Female (50/group),Oral,"0; 300; 3,000; 6,000; 10,000 ppm in diet for 2 yr","Uterus:  at 10,000 ppm",Equivocal,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAMINOZIDE (AUGUST 01, 1991)]"
1117,363898141,15331,CN(C)NC(=O)CCC(=O)O,Unspecified,,,,Mouse,CD-1/Male (50/group),Oral,"0; 300; 3,000; 6,000; 10,000 ppm in diet for 2 yr","Vascular tumor: hemangioma and hemangiosarcoma in liver at 10,000 ppm",Equivocal,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAMINOZIDE (AUGUST 01, 1991)]"
1118,363898141,15331,CN(C)NC(=O)CCC(=O)O,Unspecified,,,,Mouse,Swiss/Male and Female (100/group in controls; 50/group in treated group),Oral,0; 2% in drinking water (3000 mg/kg/day); 0.003% UDMH (40 ppm impurity) for 2 yr,Lung: adenomas and adenocarcinomas Vascular tumor: hemangioma and hemangiosarcoma predominantly in liver,"Equivocal, incidence of lung tumors may be from UDMH.","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAMINOZIDE (AUGUST 01, 1991)]"
1119,363898142,2955,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN DIET FOR 78 WK (STUDY DURATION: 105-108 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-20 Y77]"
1120,363898142,2955,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 1000 PPM IN DIET FOR 78 WK (STUDY DURATION: 105-106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-20 Y77]"
1121,363898142,2955,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,Active,,,,RAT,"BDIV/MALE,FEMALE",GAVAGE,100 MG/KG TO MOTHERS DURING PREGNANCY AND DURING WEANING; 52 G/KG (TOTAL DOSE) TO OFFSPRING AFTER WEANING,THYROID GLAND: MALIGNANT C CELL TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 59 Y80]"
1122,363898142,2955,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 600; 1200 PPM IN DIET FOR 78 WK (STUDY DURATION: 105-106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-20 Y77]"
1123,363898142,2955,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,Active,,,,RAT,F344/MALE,ORAL,0; 600; 1200 PPM IN DIET FOR 78 WK (STUDY DURATION: 104-106 WK),"SPLEEN: FIBROMA OR FIBROSARCOMA OR SARCOMA (NOS); PERITONEAL CAVITY: FIBROSARCOMA, SARCOMA (NOS)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-20 Y77]"
1124,363898142,2955,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,Active,,,,RAT,WISTAR/MALE,ORAL,0.025% INCREASED TO 0.3% BY THIRD MO,MULTIPLE SITES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 59 Y80]"
1125,363898142,2955,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,Active,,,,RAT,F344/MALE,ORAL,0; 600; 1200 PPM IN DIET FOR 78 WK (STUDY DURATION: 105 WK),SPLEEN OR PERITONEUM: SARCOMA,POSITIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
1126,363898142,2955,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 600; 1200 PPM IN DIET FOR 78 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
1127,363898143,3035,C1=CC(=CC=C1C(=C(Cl)Cl)C2=CC=C(C=C2)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 148; 261 PPM IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74]"
1128,363898143,3035,C1=CC(=CC=C1C(=C(Cl)Cl)C2=CC=C(C=C2)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 148; 261 PPM IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74]"
1129,363898143,3035,C1=CC(=CC=C1C(=C(Cl)Cl)C2=CC=C(C=C2)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,250 PPM IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74]"
1130,363898143,3035,C1=CC(=CC=C1C(=C(Cl)Cl)C2=CC=C(C=C2)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 242; 462 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
1131,363898143,3035,C1=CC(=CC=C1C(=C(Cl)Cl)C2=CC=C(C=C2)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 437; 839 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
1132,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,"B6AKF1/MALE,FEMALE",GAVAGE/ORAL,46.4 MG/KG FROM D 7-28 OF LIFE THEN 140 PPM IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74]"
1133,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE/ORAL,46.4 MG/KG FROM D 7-28 OF LIFE THEN 140 PPM IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74]"
1134,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 87; 175 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
1135,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 22; 90 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
1136,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 210; 420 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
1137,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 321; 642 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
1138,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[ROSSI,L, RAVERA,M, REPETTI,G AND SANTI,L; LONG-TERM ADMINISTRATION OF DDT OR PHENOBARBITAL-NA IN WISTAR RATS; INT. J. CANCER 19:179-185, 1977]"
1139,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",DIET,100 PPM FOR 110 WK,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74][THORPE,E AND WALKER,AIT; THE TOXICOLOGY OF DIELDRIN (HEOD). II. COMPARATIVE LONG-TERM ORAL TOXICITY STUDIES IN MICE WITH DIELDRIN, DDT, PHENOBARBITONE, BETA-BHC AND GAMMA-BHC; FOOD COSMET. TOXICOL. 11:433-442, 1973, ]"
1140,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",DIET,"0, 50, 100 PPM FOR 2 YR",LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74][WALKER,AIT, THORPE,E AND STEVENSON,DE; THE TOXICOLOGY OF DIELDRIN (HEOD). I. LONG-TERM ORAL TOXICITY STUDIES IN MICE; FOOD COSMET. TOXICOL. 11:415, 1973, ]"
1141,363898144,3036,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,BALB/MALE,ORAL,0; 175 PPM IN ACETONE ADDED TO DIET FOR 8 WK THEN BY 125 PPM FOR 8 WK AND 100 PPM FOR 59 WK (STUDY DURATION: 75 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[LIPSKY,MM, TRUMP,BF AND HINTON,DE; HISTOGENESIS OF DIELDRIN AND DDT-INDUCED HEPATOCELLULAR CARCINOMA IN BALB/C MICE; J. ENVIRON. PATHOL., TOXICOL. ONCOL. 9(1):79-93, 1989]"
1142,363898145,3000603,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=S)N)CO)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 3.5; 7 MG/KG FOR 52 WK (STUDY DURATION: 78 WK),"EAR (CANAL): CARCINOMA, NOS OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-57 Y78]"
1143,363898145,3000603,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=S)N)CO)O,Unspecified,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 3.5; 7 MG/KG FOR 52 WK (STUDY DURATION: 78 WK),EAR (CANAL): CARCINOMA OR SQUAMOUS CELL CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-57 Y78]"
1144,363898146,,,Active,,,,RAT,"ACI/MALE,FEMALE",ORAL,1% IN DIET FOR 660 D,"COLON: PAPILLOMA, SQUAMOUS CELL CARCINOMA, ADENOMA, ADENOCARCINOMA; RECTUM: PAPILLOMA, SQUAMOUS CELL CARCINOMA, ADENOMA, ADENOCARCINOMA",POSITIVE,"[HIRONO,I, KUHARA,K, YAMAJI,T, HOSAKA,S AND GOLBERG,L; INDUCTION OF COLORECTAL SQUAMOUS CELL CARCINOMAS IN RATS BY DEXTRAN SULFATE SODIUM; CARCINOGENESIS 3:353-355, 1982]"
1145,363898146,,,Inactive,,,,RAT,ACI/MALE,ORAL,0; 2.5% (MOL. WT. 9500 OR 520000) IN DIET FOR 480 DAYS (STUDY DURATION: 480 D),,NEGATIVE,"[HIRONO,I, KUHARA,K, YAMAJI,T, HOSAKA,S AND GOLBERG,L; CARCINOGENICITY OF DEXTRAN SULFATE SODIUM IN RELATION TO ITS MOLECULAR WEIGHT; CANCER LETT. 18:29-34, 1983]"
1146,363898146,,,Inactive,,,,RAT,ACI/FEMALE,ORAL,0; 2.5% (MOL. WT. 9500 OR 520000) IN DIET FOR 480 D (STUDY DURATION: 480 D),,NEGATIVE,"[HIRONO,I, KUHARA,K, YAMAJI,T, HOSAKA,S AND GOLBERG,L; CARCINOGENICITY OF DEXTRAN SULFATE SODIUM IN RELATION TO ITS MOLECULAR WEIGHT; CANCER LETT. 18:29-34, 1983]"
1147,363898146,,,Active,,,,RAT,ACI/MALE,ORAL,0; 2.5% (MOL. WT. 54000) IN DIET FOR 480 D (STUDY DURATION: 480 D),COLON OR RECTUM: PAPILLOMA OR SQUAMOUS CELL CARCINOMA OR ADENOCARCINOMA,POSITIVE,"[HIRONO,I, KUHARA,K, YAMAJI,T, HOSAKA,S AND GOLBERG,L; CARCINOGENICITY OF DEXTRAN SULFATE SODIUM IN RELATION TO ITS MOLECULAR WEIGHT; CANCER LETT. 18:29-34, 1983]"
1148,363898146,,,Active,,,,RAT,ACI/FEMALE,ORAL,0; 2.5% (MOL. WT. 54000) IN DIET FOR 480 D (STUDY DURATION: 480 D),"COLON OR RECTUM: PAPILLOMA, SQUAMOUS CELL CARCINOMA OR ADENOMA, ADENOCARCINOMA; CECUM: ADENOMA OR ADENOCARCINOMA",POSITIVE,"[HIRONO,I, KUHARA,K, YAMAJI,T, HOSAKA,S AND GOLBERG,L; CARCINOGENICITY OF DEXTRAN SULFATE SODIUM IN RELATION TO ITS MOLECULAR WEIGHT; CANCER LETT. 18:29-34, 1983]"
1149,363898147,11942,CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)C,Active,,,,RAT,,INTRAPERITONEAL,,EAR (CANAL); MAMMARY GLAND; INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V16 293 Y78]"
1150,363898147,11942,CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)C,Active,,,,RAT,,ORAL,,EAR (CANAL),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V16 293 Y78]"
1151,363898147,11942,CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)C,Active,,,,RAT,,SUBCUTANEOUS,,MAMMARY GLAND; LIVER; EAR (ZYMBAL GLAND),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V16 293 Y78]"
1152,363898148,5284376,CC(C)N(C(C)C)C(=O)SC/C(=C/Cl)/Cl,Active,,,,MOUSE,B6AKF1/MALE,GAVAGE/ORAL,215 MG/KG IN GELATIN FROM D 7-28 OF LIFE THEN 560 PPM IN DIET,LIVER: HEPATOMA,POSITIVE,"[INNES,JRM, ULLAND,B, VALERIO,MG, PETRUCELLI,L, FISHBEIN,L, HART,ER, PALLOTTA,AJ, BATES,RR, FALK,HL, GART,JJ, KLEIN,M, MITCHELL,I AND PETERS,J; BIOASSAY OF PESTICIDES AND INDUSTRIAL CHEMICALS FOR TUMORIGENICITY IN MICE: A PRELIMINARY NOTE;J. NATL. CANCER INST. 42:1101-1114, 1969, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 69 Y76]"
1153,363898148,5284376,CC(C)N(C(C)C)C(=O)SC/C(=C/Cl)/Cl,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE/ORAL,215 MG/KG IN GELATIN FROM D 7-28 OF LIFE THEN 560 PPM IN DIET,LIVER: HEPATOMA,POSITIVE,"[INNES,JRM, ULLAND,B, VALERIO,MG, PETRUCELLI,L, FISHBEIN,L, HART,ER, PALLOTTA,AJ, BATES,RR, FALK,HL, GART,JJ, KLEIN,M, MITCHELL,I AND PETERS,J; BIOASSAY OF PESTICIDES AND INDUSTRIAL CHEMICALS FOR TUMORIGENICITY IN MICE: A PRELIMINARY NOTE;J. NATL. CANCER INST. 42:1101-1114, 1969, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 69 Y76]"
1154,363898148,5284376,CC(C)N(C(C)C)C(=O)SC/C(=C/Cl)/Cl,Inactive,,,,RAT,"STRAIN-CD/MALE,FEMALE",ORAL,150; 300 PPM IN DIET FOR 78 WK,,NEGATIVE,"[WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
1155,363898149,21242,C=CCN(CC=C)N,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0.03125% IN DRINKING WATER FOR LIFE,"LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[TOTH,B, NAGEL,D, AND RAHA,C  TUMORIGENESIS WITH 1,1-DIALLYLHYDRAZINE IN MICE; ANTICANCER RES. 1:259-262, 1981]"
1156,363898149,21242,C=CCN(CC=C)N,Active,,,,MOUSE,SWISS/MALE,ORAL,0.03125% IN DRINKING WATER FOR LIFE,"LUNG: ADENOMA, ADENOCARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, CARCINOMA",POSITIVE,"[TOTH,B, NAGEL,D, AND RAHA,C  TUMORIGENESIS WITH 1,1-DIALLYLHYDRAZINE IN MICE; ANTICANCER RES. 1:259-262, 1981]"
1157,363898150,54680782,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 6300; 12500 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-315 Y87]"
1158,363898150,54680782,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 6300; 12500 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-315 Y87]"
1159,363898150,54680782,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 6300; 12500 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[DIETZ,DD, ABDO,KM, HASEMAN,JK, EUSTIS,SL AND HUFF,JE; COMPARATIVE TOXICITY AND CARCINOGENICITY STUDIES OF TETRACYCLINE AND OXYTETRACYCLINE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 17(2):335-346, 1991]"
1160,363898150,54680782,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 6300; 12500 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[DIETZ,DD, ABDO,KM, HASEMAN,JK, EUSTIS,SL AND HUFF,JE; COMPARATIVE TOXICITY AND CARCINOGENICITY STUDIES OF TETRACYCLINE AND OXYTETRACYCLINE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 17(2):335-346, 1991]"
1161,363898150,54680782,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O.Cl,Unspecified,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),ADRENAL GLAND: PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-315 Y87]"
1162,363898150,54680782,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O.Cl,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),PITUITARY GLAND: ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-315 Y87]"
1163,363898151,38221,COC1=C(C=C(C=C1)N)N.OS(=O)(=O)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.12; 0.24% IN DIET FOR 78 WK (STUDY DURATION: 96-97 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-84 Y78]"
1164,363898151,38221,COC1=C(C=C(C=C1)N)N.OS(=O)(=O)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.12; 0.24% IN DIET FOR 78 WK (STUDY DURATION: 96-97 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-84 Y78]"
1165,363898151,38221,COC1=C(C=C(C=C1)N)N.OS(=O)(=O)O,Active,,,,RAT,F344/FEMALE,ORAL,"0; 0.12; 0.5% TWA, IN DIET FOR 78 WK (STUDY DURATION: 107-110 WK)",THYROID GLAND: ADENOCARCINOMA (NOS) OR FOLLICULAR CELL CARCINOMA OR PAPILLARY CYSTADENOCARCINOMA (NOS); EAR (ZYMBAL GLAND): SEBACEOUS ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-84 Y78]"
1166,363898151,38221,COC1=C(C=C(C=C1)N)N.OS(=O)(=O)O,Active,,,,RAT,F344/MALE,ORAL,"0; 0.12; 0.5% TWA, IN DIET FOR 78 WK (STUDY DURATION: 107-109 WK)","THYROID GLAND: C CELL ADENOMA OR CARCINOMA, ADENOCARCINOMA (NOS), ADENOCARCINOMA (NOS) OR PAPILLARY ADENOCARCINOMA OR FOLLICULAR CELL CARCINOMA OR PAPILLARY CYSTADENOCARCINOMA; INTEGUMENTARY SYSTEM (SKIN (EXCLUDING SKIN OF EAR)): SQUAMOUS CELL CARCINOMA OR BASAL CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-84 Y78]"
1167,363898152,7261,CC1=C(C=C(C=C1)N)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 100; 200 PPM IN DIET FOR 101 WK,HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-162 Y79]"
1168,363898152,7261,CC1=C(C=C(C=C1)N)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 100; 200 PPM IN DIET FOR 101 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-162 Y79]"
1169,363898152,7261,CC1=C(C=C(C=C1)N)N,Active,,,,RAT,F344/FEMALE,ORAL,"0; 79; 171 PPM TWA, IN DIET FOR 84-103 WK","INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA, FIBROSARCOMA; LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE; MAMMARY GLAND: ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-162 Y79][CARDY,RH; CARCINOGENICITY AND CHRONIC TOXICITY OF 2,4-TOLUENEDIAMINE IN F344 RATS; J. NATL. CANCER INST. 62:1107-1116, 1979, ]"
1170,363898152,7261,CC1=C(C=C(C=C1)N)N,Active,,,,RAT,F344/MALE,ORAL,"0; 79; 176 PPM TWA, IN DIET FOR 79-103 WK","INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): SQUAMOUS CELL CARCINOMA, FIBROMA, LIPOMA; LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-162 Y79][CARDY,RH; CARCINOGENICITY AND CHRONIC TOXICITY OF 2,4-TOLUENEDIAMINE IN F344 RATS; J. NATL. CANCER INST. 62:1107-1116, 1979, ]"
1171,363898153,186342,CC(=O)C(C(=O)NC1=CC=CC=C1)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC(C(=O)C)C(=O)NC4=CC=CC=C4)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2.5; 5% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-30 Y78]"
1172,363898153,186342,CC(=O)C(C(=O)NC1=CC=CC=C1)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC(C(=O)C)C(=O)NC4=CC=CC=C4)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2.5; 5% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-30 Y78]"
1173,363898153,186342,CC(=O)C(C(=O)NC1=CC=CC=C1)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC(C(=O)C)C(=O)NC4=CC=CC=C4)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-30 Y78]"
1174,363898153,186342,CC(=O)C(C(=O)NC1=CC=CC=C1)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC(C(=O)C)C(=O)NC4=CC=CC=C4)Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-30 Y78]"
1175,363898154,3017,CCOP(=S)(OCC)OC1=NC(=NC(=C1)C)C(C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 100; 200 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-137 Y79]"
1176,363898154,3017,CCOP(=S)(OCC)OC1=NC(=NC(=C1)C)C(C)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 100; 200 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-137 Y79]"
1177,363898154,3017,CCOP(=S)(OCC)OC1=NC(=NC(=C1)C)C(C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 400; 800 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-137 Y79]"
1178,363898154,3017,CCOP(=S)(OCC)OC1=NC(=NC(=C1)C)C(C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 400; 800 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-137 Y79]"
1179,363898155,9550,C=[N+]=[N-],Active,,,,MOUSE,,"INHALATION, DERMAL",,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 223 Y74]"
1180,363898155,9550,C=[N+]=[N-],Active,,,,RAT,,INHALATION,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 223 Y74]"
1181,363898156,9183,C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC5=CC=CC=C5C4=N3,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 247 Y73]"
1182,363898156,9183,C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC5=CC=CC=C5C4=N3,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 247 Y73]"
1183,363898156,9183,C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC5=CC=CC=C5C4=N3,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.1; 0.3; 1.0 MG IN BEESWAX/TRICAPRYLIN (STUDY DURATION: LIFETIME),LUNG: EPIDERMOID CARCINOMA,POSITIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H AND GRIMMER,G; EXPERIMENTAL STUDIES ON THE CARCINOGENICITY OF FIVE NITROGEN CONTAINING POLYCYCLIC AROMATIC COMPOUNDS DIRECTLY INJECTED INTO RAT LUNGS; CANCER LETT. 20:97-101, 1983]"
1184,363898157,9177,C1=CC=C2C(=C1)C=CC3=NC4=C(C=C32)C5=CC=CC=C5C=C4,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 254 Y73]"
1185,363898157,9177,C1=CC=C2C(=C1)C=CC3=NC4=C(C=C32)C5=CC=CC=C5C=C4,Active,,,,MOUSE,,SUBCUTANEOUS,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 254 Y73]"
1186,363898157,9177,C1=CC=C2C(=C1)C=CC3=NC4=C(C=C32)C5=CC=CC=C5C=C4,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.1; 0.3; 1.0 MG IN BEESWAX/TRICAPRYLIN (STUDY DURATION: LIFETIME),,NEGATIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H AND GRIMMER,G; EXPERIMENTAL STUDIES ON THE CARCINOGENICITY OF FIVE NITROGEN CONTAINING POLYCYCLIC AROMATIC COMPOUNDS DIRECTLY INJECTED INTO RAT LUNGS; CANCER LETT. 20:97-101, 1983]"
1187,363898157,9177,C1=CC=C2C(=C1)C=CC3=NC4=C(C=C32)C5=CC=CC=C5C=C4,Active,,,,MOUSE,HSD:ICR(BR)/FEMALE,DERMAL,0; 50 NMOL IN 50 UL ACETONE 2/WK FOR 99 WK (STUDY DURATION: 99 WK),SKIN: TUMOR,POSITIVE,"[WARSHAWSKY,D, BARKLEY,W, MILLER,ML, LADOW,K AND ANDRINGA,A; CARCINOGENICITY OF 7H-DIBENZO[C,G]CARBAZOLE, DIBENZ[A,J]ACRIDINE AND BENZO[A]PYRENE IN MOUSE SKIN AND LIVER FOLLOWING TOPICAL APPLICATION; TOXICOLOGY 93(2,3):135-149, 1994]"
1188,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 178 Y73]"
1189,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,,ORAL,,FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 178 Y73]"
1190,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 178 Y73]"
1191,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,RAT,,INTRATRACHEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 178 Y73]"
1192,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,,DIET,9-19 MG TOTAL DOSE OVER 5-7 MO,FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 178 Y73][LARIONOW,LF AND SOBOLEVA,NG; GASTRIC TUMORS EXPERIMENTALLY PRODUCED IN MICE BY MEANS OF BENZOPYRENE AND DIBENZANTHRACENE; VESTN. RENTGENOL. RADIOL. 20:276, 1938, ]"
1193,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,0; 36; 40; 107; 308; 402 NMOL IN TRICAPRYLIN ONCE (STUDY DURATION: 112 WK),INJECTION SITE: FIBROSARCOMA,POSITIVE,"[PLATT,KL, PFEIFFER,E, PETROVIC,P, FRIESEL,H, BEERMANN,D, HECKER,E AND OESCH,F; COMPARATIVE TUMORIGENICITY OF PICENE AND DIBENZ[A,H]ANTHRACENE IN THE MOUSE; CARCINOGENESIS (LONDON) 11(10):1721-6, 1990]"
1194,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,NMRI/FEMALE,DERMAL,0; 136; 448; 1358 NMOL (TOTAL DOSE) APPLIED AS 1 DROP OF ACETONE SOLUTION 3/WK FOR DURATION OF STUDY (STUDY DURATION: 112 WK),SKIN: PAPILLOMA,POSITIVE,"[PLATT,KL, PFEIFFER,E, PETROVIC,P, FRIESEL,H, BEERMANN,D, HECKER,E AND OESCH,F; COMPARATIVE TUMORIGENICITY OF PICENE AND DIBENZ[A,H]ANTHRACENE IN THE MOUSE; CARCINOGENESIS (LONDON) 11(10):1721-6, 1990]"
1195,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,0; 40; 400 NMOL IN 0.05 ML OF AN AQUEOUS SOLUTION CONTAINING 1% (W/W) GELATIN 0.9% (W/W) SODIUM CHLORIDE AND 0.4% (W/W) TWEEN 20 ONCE ON DAY 2 OF LIFE (STUDY DURATION: 40 WK),LUNG: ADENOMA,POSITIVE,"[PLATT,KL, PFEIFFER,E, PETROVIC,P, FRIESEL,H, BEERMANN,D, HECKER,E AND OESCH,F; COMPARATIVE TUMORIGENICITY OF PICENE AND DIBENZ[A,H]ANTHRACENE IN THE MOUSE; CARCINOGENESIS (LONDON) 11(10):1721-6, 1990]"
1196,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,NMRI/MALE,SUBCUTANEOUS,0; 40; 400 NMOL IN 0.05 ML OF AN AQUEOUS SOLUTION CONTAINING 1% (W/W) GELATIN 0.9% (W/W) SODIUM CHLORIDE AND 0.4% TWEEN 20 ONCE ON DAY 2 OF LIFE (STUDY DURATION: 40 WK),LUNG: ADENOMA,POSITIVE,"[PLATT,KL, PFEIFFER,E, PETROVIC,P, FRIESEL,H, BEERMANN,D, HECKER,E AND OESCH,F; COMPARATIVE TUMORIGENICITY OF PICENE AND DIBENZ[A,H]ANTHRACENE IN THE MOUSE; CARCINOGENESIS (LONDON) 11(10):1721-6, 1990]"
1197,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,INTRAPULMONARY IMPLANT,0; 0.1 MG IN BEESWAX AND TRIOCTANOIN IMPLANTED IN LUNG (STUDY DURATION: 141 WK),LUNG: CARCINOMA,POSITIVE,"[WENZEL-HARTUNG,R, BRUNE,H, GRIMMER,G, GERMANN,P, TIMM,J AND WOSNIOK,W; EVALUATION OF THE CARCINOGENIC POTENCY OF 4 ENVIRONMENTAL POLYCYCLIC AROMATIC COMPOUNDS FOLLOWING INTRAPULMONARY APPLICATION IN RATS; EXP. PATHOL. 40(4):221-227, 1990]"
1198,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 1.25; 2.5; 5; 10 MG/KG BW ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[ROSS,JA, NELSON,GB, WILSON,KH, RABINOWITZ,JR, GALATI,A, STONER,GD, NESNOW,S AND MASS,MJ; ADENOMAS INDUCED BY POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MOUSE LUNG CORRELATE WITH TIME-INTEGRATED DNA ADDUCT LEVELS; CANCER RES. 55(5): 1039-1044, 1995]"
1199,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0-10 MG/KG IN TRICAPRYLIN ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[NESNOW,S, ROSS,JA, STONER,GD AND MASS,MJ; TUMORIGENESIS OF CARCINOGENIC ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MICE: LINKAGE TO DNA ADDUCTS AND MUTATIONS IN ONCOGENES; POLYCYCLIC AROMAT. COMPD. 10(1-4):259-266, 1996]"
1200,363898158,5889,C1=CC=C2C(=C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C32,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 353 UL DMSO (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 OF THE TOTAL DOSE ON DAYS 1, 8, AND 15 OF AGE, RESPECTIVELY (STUDY DURATION: 12 MO)","LIVER: ADENOMA, CARCINOMA; LUNG: ADENOMA",POSITIVE,"[FU,PP, VON TUNGELN,LS, CHIU,LH, ZHAN,DJ, DECK,J, BUCCI,T AND WANG,JC; STRUCTURE, TUMORIGENICITY, MICROSOMAL METABOLISM, AND DNA BINDING OF 7-NITRODIBENZ[A,H]ANTHRACENE; CHEM. RES. TOXICOL. 11(8):937-945, 1998]"
1201,363898159,9134,C1=CC=C2C(=C1)C=CC3=C2C4=C(N3)C=CC5=CC=CC=C54,Active,,,,HAMSTER,,INTRATRACHEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 260 Y73]"
1202,363898159,9134,C1=CC=C2C(=C1)C=CC3=C2C4=C(N3)C=CC5=CC=CC=C54,Active,,,,MOUSE,,INTRAVENOUS,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 260 Y73]"
1203,363898159,9134,C1=CC=C2C(=C1)C=CC3=C2C4=C(N3)C=CC5=CC=CC=C54,Active,,,,MOUSE,,ORAL,,FORESTOMACH; LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 260 Y73]"
1204,363898159,9134,C1=CC=C2C(=C1)C=CC3=C2C4=C(N3)C=CC5=CC=CC=C54,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 260 Y73]"
1205,363898159,9134,C1=CC=C2C(=C1)C=CC3=C2C4=C(N3)C=CC5=CC=CC=C54,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN); LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 260 Y73]"
1206,363898159,9134,C1=CC=C2C(=C1)C=CC3=C2C4=C(N3)C=CC5=CC=CC=C54,Active,,,,MOUSE,HSD:ICR(BR)/FEMALE,DERMAL,0; 50 NMOL IN 50 UL ACETONE 2/WK FOR 99 WK (STUDY DURATION: 99 WK),SKIN: TUMOR; LIVER: TUMOR,POSITIVE,"[WARSHAWSKY,D, BARKLEY,W, MILLER,ML, LADOW,K AND ANDRINGA,A; CARCINOGENICITY OF 7H-DIBENZO[C,G]CARBAZOLE, DIBENZ[A,J]ACRIDINE AND BENZO[A]PYRENE IN MOUSE SKIN AND LIVER FOLLOWING TOPICAL APPLICATION; TOXICOLOGY 93(2,3):135-149, 1994]"
1207,363898159,9134,C1=CC=C2C(=C1)C=CC3=C2C4=C(N3)C=CC5=CC=CC=C54,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 5; 10; 20; 40 MG/KG BW IN 0.2 ML TRICAPRYLIN ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[WARSHAWSKY,D, TALASKA,G, JAEGER,M, COLLINS,T, GALATI,A, YOU,L AND STONER,G; CARCINOGENICITY, DNA ADDUCT FORMATION AND K-RAS ACTIVATION BY 7H-DIBENZO[C,G]CARBAZOLE IN STRAIN A/J MOUSE LUNG; CARCINOGENESIS 17(4):865-871, 1996]"
1208,363898159,9134,C1=CC=C2C(=C1)C=CC3=C2C4=C(N3)C=CC5=CC=CC=C54,Active,,,,Mouse,XVIInc/Z homozygous/Female (50 or 162/Group),Subcutaneous,3 x 0.3 mg (162 animals) or 34 x 0.05 mg (50 animals) dissolved in olive oil,"Liver: Hepatoma (100%), Sarcoma (70%)",Positive (Historical controls only; reported incidence of liver tumors <2% at 2 yrs of age),"[TARAS-VALERO,D, PERIN-ROUSSEL,O, PLESSIS,M-J, ZAJDELA,F AND  PERIN,F; TISSUE-SPECIFIC ACTIVITIES OF METHYLATED  DIBENZO[c,g]CARBAZOLES IN MICE: CARCINOGENICITY, DNA ADDUCT  FORMATION, AND CYT1A INDUCTION IN LIVER AND SKIN; ENVIRON  MOL MUTAGEN. 35:139-149, 2000]"
1209,363898160,9119,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C6=CC=CC=C6C5=CC=C4,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 224 Y73][BLIZNAKOV,EG; EFFECT OF STIMULATION OF THE HOST DEFENSE SYSTEM BY COENZYME Q10 ON DIBENZPYRENE-INDUCED TUMORS AND INFECTION WITH FRIEND LEUKEMIA VIRUS IN MICE; PROC. NATL. ACAD. SCI. USA 70:390, 1973, ]"
1210,363898160,9119,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C6=CC=CC=C6C5=CC=C4,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[MASUDA,Y AND KAGAWA,R; NOVEL SYNTHESIS AND CARCINOGENICITY OF DIBENZO(A,L)PYRENE; CHEM. PHARM. BULL. 20(12):2736-2737, 1972]"
1211,363898160,9119,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C6=CC=CC=C6C5=CC=C4,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INJECTION,0; 0.25; 1 UMOL PER MAMMARY GLAND (STUDY DURATION: 24 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[CAVALIERI,EL, HIGGINBOTHAM,S, RAMAKRISHNA,NVS, DEVANESAN,PD, TODOROVIC,R, ROGAN,EG AND SALMASI,S; COMPARATIVE DOSE-RESPONSE TUMORIGENICITY STUDIES OF DIBENZO[A,L]PYRENE VERSUS 7,12-DIMETHYLBENZ[A]ANTHRACENE, BENZO[A]PYRENE AND TWO DIBENZO[A]PYRENE DIHYDRODIOLS IN MOUSE SKIN AND RAT MAMMARY GLAND; CARCINOGENESIS 12(10):1939-1944, 1991]"
1212,363898160,9119,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C6=CC=CC=C6C5=CC=C4,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 1; 4; 8 NMOL IN 100 UL ACETONE 2/WK FOR 40 WK (STUDY DURATION: 48 WK),SKIN: TUMORS,POSITIVE,"[HIGGINBOTHAM,S, RAMAKRISHNA,NVS, JOHANSSON,SL, ROGAN,EG AND CAVALIERI,EL; TUMOR-INITIATING ACTIVITY AND CARCINOGENICITY OF DIBENZO[A,L]PYRENE VERSUS 7,12-DIMETHYLBENZ[A]ANTHRACENE AND BENZO[A]PYRENE AT LOW DOSE IN MOUSE SKIN; CARCINOGENESIS 14(5):875-878, 1993]"
1213,363898160,9119,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C6=CC=CC=C6C5=CC=C4,Active,,,,Mouse,B6129SF1x129S1/Svlmj/Male and female (215 in 4 groups),"In utero, nursing, or in utero and nursing","15 mg/kg, gavage to pregnant B6129SF1 females, once on day 17 of pregnancy (Study duration 10 months from birth)",Lung,Positive (surviving offspring exhibited 100% incidence with multiplicity of approximately 15; offspring exposed only in utero had greater lung tumor multiplicity than those exposed only through nursing). Breeding to provide litters comprised of half ahr(b-1/d) and half ahr (d/d) siblings,"[CASTRO,DJ LOEHR,CV FISCHER,KA PEREIRA,CB AND WILLIAMS,DE; LYMPHOMA AND LUNG CANCER IN OFFSPRING BORN TO PREGNANT MICE DOSED WITH DIBENZO[A,L]PYRENE: THE IMPORTANCE OF IN UTERO VS. LACTATIONAL EXPOSURE; TOXICOLOGY AND APPLIED PHARMACOLOGY 233(3):454-458, 2008]"
1214,363898160,9119,C1=CC=C2C(=C1)C=C3C=CC4=C5C3=C2C6=CC=CC=C6C5=CC=C4,Active,,,,Mouse,B6129SF1/J v 129S1/SvImJ crosses,Transplacental,15 mg/kg bw in corn oil to dams on day 18 of gestation; study duration 10 months,Lung and liver tumors,Positive,"[YU,Z LOEHR,CV FISCHER,KA LOUDERBACK,MA KRUEGER,SK DASHWOOD,RH KERKVLIET,NI PEREIRA,CB JENNINGS-GEE,JE DANCE,ST MILLER,MS BAILEY,GS AND WILLIAMS,DE; IN UTERO EXPOSURE OF LICE TO DIBENZO[A,L]PYRENE PRODUCES LYMPHOME IN THE OFFSPRING: ROLE OF THE ARYL HYDROCARBON RECEPTOR; CANCER RESEARCH 66(2):755-762, 2006]"
1215,363898161,9216,C1=CC=C2C(=C1)OC3=CC=CC=C3O2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-122 Y79]"
1216,363898161,9216,C1=CC=C2C(=C1)OC3=CC=CC=C3O2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-122 Y79]"
1217,363898161,9216,C1=CC=C2C(=C1)OC3=CC=CC=C3O2,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-122 Y79]"
1218,363898161,9216,C1=CC=C2C(=C1)OC3=CC=CC=C3O2,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-122 Y79]"
1219,363898162,9126,C1=CC=C2C3=C4C(=CC2=C1)C5=CC=CC=C5C6=CC=CC(=C64)C=C3,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 201 Y73]"
1220,363898162,9126,C1=CC=C2C3=C4C(=CC2=C1)C5=CC=CC=C5C6=CC=CC(=C64)C=C3,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 201 Y73]"
1221,363898163,9108,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC6=CC=CC=C56)C=C3,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 207 Y73]"
1222,363898163,9108,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC6=CC=CC=C56)C=C3,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 207 Y73]"
1223,363898164,9106,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=CC6=CC=CC=C6C(=C54)C=C3,Active,,,,HAMSTER,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 215 Y73]"
1224,363898164,9106,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=CC6=CC=CC=C6C(=C54)C=C3,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 215 Y73]"
1225,363898164,9106,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=CC6=CC=CC=C6C(=C54)C=C3,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 215 Y73]"
1226,363898165,7280,C(C(CBr)Br)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 0.6; 3.0 PPM 6 HR/D, 5 D/WK FOR 76-103 WK","NASAL CAVITY: CARCINOMA (NOS), SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL CARCINOMA OR SQUAMOUS CELL PAPILLOMA, ADENOCARCINOMA (NOS); LUNG: BRONCHIOLAR PAPILLARY CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-206 Y82]"
1227,363898165,7280,C(C(CBr)Br)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 110; 209 MG/KG, TWA",STOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-28 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V15 139 Y77]"
1228,363898165,7280,C(C(CBr)Br)Cl,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 0.6; 3.0 PPM 6 HR/D, 5 D/WK FOR 76 WK","NASAL CAVITY: CARCINOMA (NOS), SQUAMOUS CELL CARCINOMA, ADENOMATOUS POLYP (NOS); LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-206 Y82]"
1229,363898165,7280,C(C(CBr)Br)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 114; 219 MG/KG, TWA",STOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-28 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V15 139 Y77]"
1230,363898165,7280,C(C(CBr)Br)Cl,Active,,,,RAT,F344/FEMALE,INHALATION,"0; 0.6; 3.0 PPM 6 HR/D, 5 D/WK FOR 84-103 WK","NASAL CAVITY: ADENOMATOUS POLYP (NOS), ADENOMA (NOS), SQUAMOUS CELL PAPILLOMA, CARCINOMA (NOS), ADENOCARCINOMA (NOS); NASAL TURBINATES: ADENOMATOUS POLYP (NOS); TONGUE: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA; PHARYNX: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA; ADRENAL GLAND: CORTICAL ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-206 Y82]"
1231,363898165,7280,C(C(CBr)Br)Cl,Active,,,,RAT,F344/MALE,INHALATION,"0; 0.6; 3.0 PPM 6 HR/D, 5 D/WK FOR 84-103 WK","NASAL CAVITY: ADENOMATOUS POLYP (NOS), ADENOMA (NOS), SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, CARCINOMA (NOS), ADENOCARCINOMA (NOS); NASAL TURBINATES: ADENOMATOUS POLYP; TONGUE: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA; TUNICA VAGINALIS: MESOTHELIOMA (NOS)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-206 Y82]"
1232,363898165,7280,C(C(CBr)Br)Cl,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,"0; 15; 29 MG/KG, TWA","STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA; MAMMARY GLAND: ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-28 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V15 139 Y77]"
1233,363898165,7280,C(C(CBr)Br)Cl,Active,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,"0; 15; 29 MG/KG, TWA",STOMACH: SQUAMOUS CELL CARCINOMA; MULTIPLE SITES: HEMANGIOSARCOMA OR HEMANGIOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-28 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V15 139 Y77]"
1234,363898166,154903,C1=CC2=C(C=C(C=C2Br)Br)N=C1,Inactive,,,,RAT,F344/FEMALE,ORAL,0.1% IN DIET FOR 2 YR,,NEGATIVE,"[FUKUSHIMA,S, ISHIHARA,Y, NISHIO,O, OGISO,T, SHIRAI,T AND ITO,N; CARCINOGENITIES  OF QUINOLINE DERIVATIVES IN F344 RATS; CANCER LETT. 14:115-123, 1981]"
1235,363898167,13542,CCCCN(CCCC)N=O,Active,,,,GUINEA PIG,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1236,363898167,13542,CCCCN(CCCC)N=O,Active,,,,HAMSTER,,GAVAGE,,LUNG; RESPIRATORY TRACT; TRACHEA; FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1237,363898167,13542,CCCCN(CCCC)N=O,Active,,,,HAMSTER,,INTRAPERITONEAL,,RESPIRATORY TRACT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1238,363898167,13542,CCCCN(CCCC)N=O,Active,,,,HAMSTER,,SUBCUTANEOUS,,TRACHEA; URINARY BLADDER; FORESTOMACH; RESPIRATORY TRACT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1239,363898167,13542,CCCCN(CCCC)N=O,Active,,,,MOUSE,,ORAL,,ESOPHAGUS; FORESTOMACH; LIVER; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1240,363898167,13542,CCCCN(CCCC)N=O,Active,,,,MOUSE,,INTRAVENOUS,,HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1241,363898167,13542,CCCCN(CCCC)N=O,Active,,,,MOUSE,,SUBCUTANEOUS,,URINARY BLADDER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1242,363898167,13542,CCCCN(CCCC)N=O,Active,,,,RABBIT,,SUBCUTANEOUS,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1243,363898167,13542,CCCCN(CCCC)N=O,Active,,,,RAT,,ORAL,,ESOPHAGUS; LIVER; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1244,363898167,13542,CCCCN(CCCC)N=O,Active,,,,RAT,,SUBCUTANEOUS,,URINARY BLADDER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 51 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 197 Y74]"
1245,363898168,16682740,CCCC[Sn](CCCC)(OC(=O)C)OC(=O)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 76; 152 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-183 Y79]"
1246,363898168,16682740,CCCC[Sn](CCCC)(OC(=O)C)OC(=O)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 76; 152 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-183 Y79]"
1247,363898168,16682740,CCCC[Sn](CCCC)(OC(=O)C)OC(=O)C,Inactive,,,,RAT,F344/MALE,ORAL,"0; 66.5; 133 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-183 Y79]"
1248,363898169,5284443,CNC[C@@H](C1=CC(=CC=C1)O)O.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 620; 1250 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-322 Y87]"
1249,363898169,5284443,CNC[C@@H](C1=CC(=CC=C1)O)O.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 620; 1250 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-322 Y87]"
1250,363898169,5284443,CNC[C@@H](C1=CC(=CC=C1)O)O.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1250; 2500 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-322 Y87]"
1251,363898169,5284443,CNC[C@@H](C1=CC(=CC=C1)O)O.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 2500 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-322 Y87]"
1252,363898170,7070,C1=CC(=C(C=C1C2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,HAMSTER,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 49 Y74]"
1253,363898170,7070,C1=CC(=C(C=C1C2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,RAT,,ORAL,,EAR (ZYMBAL GLAND); MAMMARY GLAND; INTEGUMENTARY SYSTEM (SKIN); HEMATOPOIETIC SYSTEM; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 49 Y74]"
1254,363898170,7070,C1=CC(=C(C=C1C2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,RAT,,SUBCUTANEOUS,,MAMMARY GLAND; INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 49 Y74]"
1255,363898171,,,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,54; 103; 108 UMOL/KG (TOTAL DOSES) IN NACL OR TRIOCTANOIN,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 151 Y81]"
1256,363898171,,,Active,,,,RAT,"F344/MALE, FEMALE",TRANSPLACENTAL,0; 5 MG/KG BW GIVEN INTRAPERITONEALLY TO FEMALE RATS ON DAY 18 OF GESTATION AND OFFSPRING OBSERVED TO 79 WK OF AGE (STUDY DURATION: 79 WK),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DIWAN,BA, ANDERSON,LM, WARD,JM, HENNEMAN,JR AND RICE,JM; TRANSPLACENTAL CARCINOGENESIS BY CISPLATIN IN F344/NCR RATS: PROMOTION OF KIDNEY TUMORS BY POSTNATAL ADMINISTRATION OF SODIUM BARBITAL; TOXICOL. APPL. PHARMACOL. 132(1): 115-121, 1995]"
1257,363898172,34239,C1=CC(=C(C=C1OC2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,RAT,,SUBCUTANEOUS,,EAR (CANAL),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V16 309 Y78]"
1258,363898173,36613,C1=CC2=C(C=C1Cl)OC3=C(O2)C=C(C=C3)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 5,000; 10,000 PPM IN DIET FOR 90 WK (STUDY DURATION: 91-98 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-123 Y79]"
1259,363898173,36613,C1=CC2=C(C=C1Cl)OC3=C(O2)C=C(C=C3)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 5,000; 10,000 PPM IN DIET FOR 110 WK (STUDY DURATION: 110-117 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-123 Y79]"
1260,363898173,36613,C1=CC2=C(C=C1Cl)OC3=C(O2)C=C(C=C3)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 5,000; 10,000 PPM IN DIET FOR 110 WK (STUDY DURATION: 110-112 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-123 Y79]"
1261,363898173,36613,C1=CC2=C(C=C1Cl)OC3=C(O2)C=C(C=C3)Cl,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 90 WK (STUDY DURATION: 92-101 WK),LIVER: HEPTOCELLULAR ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM: LYMPHOMA OR LEUKEMIA; SPLEEN: HEMANGIOMA OR HEMANGIOSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-123 Y79]"
1262,363898174,6365,CC(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 1,442; 2,885 MG/KG 5/WK FOR 78 WK (STUDY DURATION: 91 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-66 Y78]"
1263,363898174,6365,CC(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,0; 382; 764 MG/KG 5/WK FOR 78 WK (STUDY DURATION: 111 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-66 Y78]"
1264,363898174,6365,CC(Cl)Cl,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 1665; 3331 MG/KG 5/WK FOR 78 WK (STUDY DURATION: 91 WK),UTERUS: ENDOMETRIAL STROMAL POLYP,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-66 Y78]"
1265,363898174,6365,CC(Cl)Cl,Unspecified,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,0; 475; 950 MG/KG 5/WK FOR 78 WK (STUDY DURATION: 111 WK),MAMMARY GLAND: ADENOCARCINOMA; LUNG: HEMANGIOSARCOMA; SPLEEN: HEMANGIOSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-66 Y78]"
1266,363898175,11,C(CCl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 149; 299 MG/KG TWA,5 D/WK FOR 78 WK (STUDY DURATION: 91 WK)","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; UTERUS (ENDOMETRIUM): STROMAL POLYP, STROMAL SARCOMA; MAMMARY GLAND: ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-55 Y78]"
1267,363898175,11,C(CCl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 97; 195 MG/KG TWA, 5 D/WK FOR 78 WK (STUDY DURATION: 90-91 WK)",LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-55 Y78]"
1268,363898175,11,C(CCl)Cl,Active,,,,MOUSE,ICR/FEMALE,DERMAL,42; 126 MG/APPL/MOUSE IN 0.2 ML ACETONE 3/WK,LUNG: BENIGN PAPILLOMA,POSITIVE,"[VAN DUUREN,BL, GOLDSCHMIDT,BM, LOEWENGART,G, SMITH,AC, MELCHIONNE,S, SEIDMAN,I AND ROTH,D; CARCINOGENICITY OF HALOGENATED OLEFINIC AND ALIPHATIC HYDROCARBONS IN MICE; J. NATL. CANCER INST. 63:1433-1439, 1979]"
1269,363898175,11,C(CCl)Cl,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,"0; 47; 95 MG/KG TWA, 5 D/WK FOR 69 WK (STUDY DURATION: 93-110 WK)",MAMMARY GLAND: ADENOCARCINOMA OR FIBROADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-55 Y78]"
1270,363898175,11,C(CCl)Cl,Active,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,"0; 47; 95 MG/KG TWA, 5 D/WK FOR 69 WK (STUDY DURATION: 101-110 WK)",INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA; BLOOD VESSELS: HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-55 Y78]"
1271,363898175,11,C(CCl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 50 PPM 7 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHEEVER,KL, CHOLAKIS,JM, MONAEM EL-HAWARI,A, KOVATCH,RM AND WEISBURGER,EK; ETHYLENE DICHLORIDE: THE INFLUENCE OF DISULFIRAM OR ETHANOL ON ONCOGENICITY, METABOLISM, AND DNA COVALENT BINDING IN RATS; FUNDAM. APPL. TOXICOL. 14(2):243-261, 1990]"
1272,363898175,11,C(CCl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 50 PPM 7 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHEEVER,KL, CHOLAKIS,JM, MONAEM EL-HAWARI,A, KOVATCH,RM AND WEISBURGER,EK; ETHYLENE DICHLORIDE: THE INFLUENCE OF DISULFIRAM OR ETHANOL ON ONCOGENICITY, METABOLISM, AND DNA COVALENT BINDING IN RATS; FUNDAM. APPL. TOXICOL. 14(2):243-261, 1990]"
1273,363898175,11,C(CCl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 5; 10; 50; 150; 250 PPM IN AIR 7 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
1274,363898175,11,C(CCl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 5; 10; 50; 150; 250 PPM IN AIR 7 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
1275,363898175,11,C(CCl)Cl,Inactive,,,,MOUSE,EU-PIM-1/MALE,GAVAGE,0; 100; 300 MG/KG 1/D FOR 40 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[STORER,RD, CARTWRIGHT,ME, COOK,WO, SOPER,KA AND NICOLS,WW; SHORT-TERM CARCINOGENESIS BIOASSAY OF GENOTOXIC PROCARCINOGENS IN PM TRANSGENIC MICE; CARCINOGENESIS 16(2):285-293, 1995]"
1276,363898175,11,C(CCl)Cl,Active,,,,MOUSE,EU-PIM-1/FEMALE,GAVAGE,0; 100; 300 MG/KG 1/D FOR 40 WK (STUDY DURATION: 40 WK),LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[STORER,RD, CARTWRIGHT,ME, COOK,WO, SOPER,KA AND NICOLS,WW; SHORT-TERM CARCINOGENESIS BIOASSAY OF GENOTOXIC PROCARCINOGENS IN PM TRANSGENIC MICE; CARCINOGENESIS 16(2):285-293, 1995]"
1277,363898176,11860,C1=C(C=C(C(=C1Cl)N)Cl)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1000; 3000 PPM IN DIET,LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-219 Y82]"
1278,363898176,11860,C1=C(C=C(C(=C1Cl)N)Cl)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 3000 PPM IN DIET,LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-219 Y82]"
1279,363898176,11860,C1=C(C=C(C(=C1Cl)N)Cl)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-219 Y82]"
1280,363898176,11860,C1=C(C=C(C(=C1Cl)N)Cl)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 1000; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-219 Y82]"
1281,363898177,5280970,C(/C=C\Cl)Cl,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,3.0 MG/INJ IN 0.05 ML TRIOCTANOIN 1/WK,INJECTION SITE: FIBROSARCOMA,POSITIVE,"[VAN DUUREN,BL, GOLDSCHMIDT,BM, LOEWENGART,G, SMITH,AC, MELCHIONNE,S, SEIDMAN,I AND ROTH,D; CARCINOGENICITY OF HALOGENATED OLEFINIC AND ALIPHATIC HYDROCARBONS IN MICE; J. NATL. CANCER INST. 63:1433-1439, 1979]"
1282,363898178,119516,C([C@H]1[C@H](O1)Cl)Cl,Active,,,,MOUSE,ICR/FEMALE,DERMAL,10 MG IN 0.1 ML ACETONE 3/WK FOR LIFE,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[VAN DUUREN,BL, KLINE,SA, MELCHIONNE,S AND SEIDMAN,I; CHEMICAL STRUCTURE AND CARCINOGENICITY RELATIONSHIPS OF SOME CHLOROALKENE OXIDES AND THEIR PARENT OLEFINS; CANCER RES. 43:159-162, 1983]"
1283,363898178,119516,C([C@H]1[C@H](O1)Cl)Cl,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,500 UG IN 0.05 ML TRICAPRYLIN 1/WK FOR LIFE,INJECTION SITE: FIBROSARCOMA,POSITIVE,"[VAN DUUREN,BL, KLINE,SA, MELCHIONNE,S AND SEIDMAN,I; CHEMICAL STRUCTURE AND CARCINOGENICITY RELATIONSHIPS OF SOME CHLOROALKENE OXIDES AND THEIR PARENT OLEFINS; CANCER RES. 43:159-162, 1983]"
1284,363898179,149399,C([C@@H]1[C@H](O1)Cl)Cl,Active,,,,MOUSE,ICR/FEMALE,DERMAL,10 MG IN 0.1 ML ACETONE 3/WK FOR LIFE,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[VAN DUUREN,BL, KLINE,SA, MELCHIONNE,S AND SEIDMAN,I; CHEMICAL STRUCTURE AND CARCINOGENICITY RELATIONSHIPS OF SOME CHLOROALKENE OXIDES AND THEIR PARENT OLEFINS; CANCER RES. 43:159-162, 1983]"
1285,363898179,149399,C([C@@H]1[C@H](O1)Cl)Cl,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,500 UG IN 0.05 ML TRICAPRYLIN 1/WK FOR LIFE,INJECTION SITE: FIBROSARCOMA,POSITIVE,"[VAN DUUREN,BL, KLINE,SA, MELCHIONNE,S AND SEIDMAN,I; CHEMICAL STRUCTURE AND CARCINOGENICITY RELATIONSHIPS OF SOME CHLOROALKENE OXIDES AND THEIR PARENT OLEFINS; CANCER RES. 43:159-162, 1983]"
1286,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 317; 635 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-10 Y77]"
1287,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 317; 635 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-10 Y77]"
1288,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 318; 635 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-10 Y77]"
1289,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 150; 326 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-10 Y77]"
1290,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 4; 8 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),PANCREAS: ADENOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-342 Y89]"
1291,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 10; 20 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),FORESTOMACH: SQUAMOUS PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-342 Y89]"
1292,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 20; 40 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-342 Y89]"
1293,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Inactive,,,,RAT,BDIX/BLN/MALE,INTRAGASTRIC,0; 0.1 MG IN 0.2 ML WATER 2/WK FOR 60 WK (STUDY DURATION: 111 WK),,NEGATIVE,"[HORN,KH, TEICHMANN,B, SCHRAMM,T AND NISCHAN,P; INVESTIGATION OF DICHLORVOS (DDVP). PART II. TESTING OF DICHLORVOS FOR CARCINOGENIC ACTIVITY IN RATS; ARCH. GESCHWULSTFORSCH. 58(1):1-9, 1988]"
1294,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Inactive,,,,RAT,BDIX/BLN/FEMALE,INTRAGASTRIC,0; 0.1 MG IN 0.2 ML WATER 2/WK FOR 60 WK (STUDY DURATION: 111 WK),,NEGATIVE,"[HORN,KH, TEICHMANN,B, SCHRAMM,T AND NISCHAN,P; INVESTIGATION OF DICHLORVOS (DDVP). PART II. TESTING OF DICHLORVOS FOR CARCINOGENIC ACTIVITY IN RATS; ARCH. GESCHWULSTFORSCH. 58(1):1-9, 1988]"
1295,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Inactive,,,,RAT,BDIX/BLN/MALE,INTRAGASTRIC,0; 0.1 MG IN 0.2 ML WATER 3/WK FOR 60 WK (STUDY DURATION: 111 WK),,NEGATIVE,"[HORN,KH, TEICHMANN,B, SCHRAMM,T AND NISCHAN,P; INVESTIGATION OF DICHLORVOS (DDVP). PART II. TESTING OF DICHLORVOS FOR CARCINOGENIC ACTIVITY IN RATS; ARCH. GESCHWULSTFORSCH. 58(1):1-9, 1988]"
1296,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Inactive,,,,RAT,BDIX/BLN/FEMALE,INTRAGASTRIC,0; 0.1 MG IN 0.2 ML WATER 3/WK FOR 60 WK (STUDY DURATION: 111 WK),,NEGATIVE,"[HORN,KH, TEICHMANN,B, SCHRAMM,T AND NISCHAN,P; INVESTIGATION OF DICHLORVOS (DDVP). PART II. TESTING OF DICHLORVOS FOR CARCINOGENIC ACTIVITY IN RATS; ARCH. GESCHWULSTFORSCH. 58(1):1-9, 1988]"
1297,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 20; 40 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"FORESTOMACH: CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[CHAN,PC, HUFF,J, HASEMAN,JK, ALISON,R AND PREJEAN,JD; CARCINOGENESIS STUDIES OF DICHLORVOS IN FISCHER RATS AND B6C3F1 MICE;JPN. J. CANCER RES. 82(2):157-164, 1991]"
1298,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 10; 20 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA,POSITIVE,"[CHAN,PC, HUFF,J, HASEMAN,JK, ALISON,R AND PREJEAN,JD; CARCINOGENESIS STUDIES OF DICHLORVOS IN FISCHER RATS AND B6C3F1 MICE;JPN. J. CANCER RES. 82(2):157-164, 1991]"
1299,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 4; 8 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),PANCREAS: ACINAR CELL ADENOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[CHAN,PC, HUFF,J, HASEMAN,JK, ALISON,R AND PREJEAN,JD; CARCINOGENESIS STUDIES OF DICHLORVOS IN FISCHER RATS AND B6C3F1 MICE;JPN. J. CANCER RES. 82(2):157-164, 1991]"
1300,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 4; 8 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"PANCREAS: ACINAR CELL ADENOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA; MAMMARY GLAND: FIBROADENOMA, CARCINOMA",POSITIVE,"[CHAN,PC, HUFF,J, HASEMAN,JK, ALISON,R AND PREJEAN,JD; CARCINOGENESIS STUDIES OF DICHLORVOS IN FISCHER RATS AND B6C3F1 MICE;JPN. J. CANCER RES. 82(2):157-164, 1991]"
1301,363898180,3039,COP(=O)(OC)OC=C(Cl)Cl,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 4; 8 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),PANCREAS: ADENOMA; MAMMARY GLAND: FIBROADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-342 Y89]"
1302,363898181,8268,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)(C(Cl)(Cl)Cl)O)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 122; 243 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-90 Y78]"
1303,363898181,8268,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)(C(Cl)(Cl)Cl)O)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 264; 528 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA OR HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-90 Y78]"
1304,363898181,8268,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)(C(Cl)(Cl)Cl)O)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 380; 760 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-90 Y78]"
1305,363898181,8268,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)(C(Cl)(Cl)Cl)O)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 471; 942 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-90 Y78]"
1306,363898182,727200,C1CCC(CC1)NC(=S)NC2CCCCC2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-56 Y78]"
1307,363898182,727200,C1CCC(CC1)NC(=S)NC2CCCCC2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-56 Y78]"
1308,363898182,727200,C1CCC(CC1)NC(=S)NC2CCCCC2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-56 Y78]"
1309,363898182,727200,C1CCC(CC1)NC(=S)NC2CCCCC2,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-56 Y78]"
1310,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2.5; 5 PPM IN DIET FOR 80 WK (STUDY DURATION: 90-93 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-21 Y78]"
1311,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2.5; 5 PPM IN DIET FOR 80 WK (STUDY DURATION: 91-93 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-21 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 125 Y74]"
1312,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 29; 65 PPM TWA, IN DIET FOR 59-80 WK (STUDY DURATION: 110-111 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-21 Y78]"
1313,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 29; 65 PPM TWA, IN DIET FOR 59-80 WK (STUDY DURATION: 110-111 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-21 Y78]"
1314,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,0; 0.1; 1.0; 10 PPM IN DIET FOR 132 WK,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 125 Y74][WALKER,AIT, THORPE,E AND STEVENSON,DE; THE TOXICOLOGY OF DIELDRIN (HEOD). I. LONG-TERM ORAL TOXICITY STUDIES IN MICE; FOOD COSMET. TOXICOL. 11:415, 1973, ]"
1315,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,0; 10 PPM IN DIET FOR UP TO 110 WK,LIVER: HEPATOCELLULAR TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 125 Y74][THORPE,E AND WALKER,AIT; THE TOXICOLOGY OF DIELDRIN (HEOD). II. COMPARATIVE LONG-TERM ORAL TOXICITY STUDIES IN MICE WITH DIELDRIN, DDT, PHENOBARBITONE, BETA-BHC AND GAMMA-BHC; FOOD COSMET. TOXICOL. 11:433-442, 1973, ]"
1316,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,0; 1.25; 2.5; 5; 10; 20 PPM IN DIET FOR 128 WK,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 125 Y74][WALKER,AIT, THORPE,E AND STEVENSON,DE; THE TOXICOLOGY OF DIELDRIN (HEOD). I. LONG-TERM ORAL TOXICITY STUDIES IN MICE; FOOD COSMET. TOXICOL. 11:415, 1973, ]"
1317,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,0; 10 PPM IN DIET FOR 2 YR OR MORE,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 125 Y74][WALKER,AIT, THORPE,E AND STEVENSON,DE; THE TOXICOLOGY OF DIELDRIN (HEOD). I. LONG-TERM ORAL TOXICITY STUDIES IN MICE; FOOD COSMET. TOXICOL. 11:415, 1973, ]"
1318,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,"10 PPM IN DIET FOR 0, 2, 4, 8, 16, 32 OR 64 WK",LIVER: HEPATOCELLULAR TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 125 Y74][WALKER,AIT, THORPE,E AND STEVENSON,DE; THE TOXICOLOGY OF DIELDRIN (HEOD). I. LONG-TERM ORAL TOXICITY STUDIES IN MICE; FOOD COSMET. TOXICOL. 11:415, 1973, ]"
1319,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,0; 0.1; 1; 2.5; 5; 10; 20 PPM IN DIET CONTINUOUSLY,LIVER,POSITIVE,"[TENNEKES,HA, EDLER,L AND KUNZ,HW; DOSE-RESPONSE ANALYSIS OF THE ENHANCEMENT OF LIVER TUMOR FORMATION IN CF-1 MICE BY DIELDRIN; CARCINOGENESIS 3(8):941-946, 1982]"
1320,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,BALB/MALE,ORAL,0; 10 PPM (WT/WT) IN CORN OIL ADDED TO DIET FOR 75 WK (STUDY DURATION: 75 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[LIPSKY,MM, TRUMP,BF AND HINTON,DE; HISTOGENESIS OF DIELDRIN AND DDT-INDUCED HEPATOCELLULAR CARCINOMA IN BALB/C MICE; J. ENVIRON. PATHOL., TOXICOL. ONCOL. 9(1):79-93, 1989]"
1321,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,C57BL/MALE,ORAL,0; 10 PPM IN DIET FOR 85 WK (STUDY DURATION: 132 WK),LIVER: TUMORS,POSITIVE,"[RUEBNER,BH, GERSHWIN,ME, FRENCH,SW, MEIERHENRY,E, DUNN,P AND HSIEH,LS; MOUSE HEPATIC NEOPLASIA: DIFFERENCES AMONG STRAINS AND CARCINOGENS; MOUSE LIVER NEOPLASIA 115-143, 1984]"
1322,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,C3H/MALE,ORAL,0; 10 PPM IN DIET FOR 85 WK (STUDY DURATION: 132 WK),LIVER: TUMORS,POSITIVE,"[RUEBNER,BH, GERSHWIN,ME, FRENCH,SW, MEIERHENRY,E, DUNN,P AND HSIEH,LS; MOUSE HEPATIC NEOPLASIA: DIFFERENCES AMONG STRAINS AND CARCINOGENS; MOUSE LIVER NEOPLASIA 115-143, 1984]"
1323,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 10 PPM IN DIET FOR 85 WK (STUDY DURATION: 132 WK),LIVER: TUMORS,POSITIVE,"[RUEBNER,BH, GERSHWIN,ME, FRENCH,SW, MEIERHENRY,E, DUNN,P AND HSIEH,LS; MOUSE HEPATIC NEOPLASIA: DIFFERENCES AMONG STRAINS AND CARCINOGENS; MOUSE LIVER NEOPLASIA 115-143, 1984]"
1324,363898183,969491,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2.5; 5 PPM IN DIET FOR 80 WK (STUDY DURATION: 90-93 WK),LIVER: HEPATOCELLULAR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-21 Y78]"
1325,363898184,11254,C1C(O1)C2CO2,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 115 Y76]"
1326,363898184,11254,C1C(O1)C2CO2,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 115 Y76]"
1327,363898184,11254,C1C(O1)C2CO2,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 115 Y76]"
1328,363898184,11254,C1C(O1)C2CO2,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2.5; 5.0 PPM 6 HR/D 5 D/WK FOR 6 WK (STUDY DURATION: 18 MONTHS),HARDERIAN GLAND: TUMOR,POSITIVE,"[HENDERSON,RF BARR,EB BELINSKY,SA BENSON,JM HAHN,FF AND MENACHE,MG; 1,3-BUTADIENE: CANCER, MUTATIONS, AND ADDUCTS. PART I: CARCINOGENICITY OF 1,2,3,4-DIEPOXYBUTANE; RES. REP. -HEALTH EFF. INST. 92:11-43, 2000]"
1329,363898184,11254,C1C(O1)C2CO2,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 2.5; 5.0 PPM 6 HR/D 5 D/WK FOR 6 WK (STUDY DURATION: 18 MONTHS),NASAL MUCOSA: TUMOR,POSITIVE,"[HENDERSON,RF BARR,EB BELINSKY,SA BENSON,JM HAHN,FF AND MENACHE,MG; 1,3-BUTADIENE: CANCER, MUTATIONS, AND ADDUCTS. PART I: CARCINOGENICITY OF 1,2,3,4-DIEPOXYBUTANE; RES. REP. -HEALTH EFF. INST. 92:11-43, 2000]"
1330,363898184,11254,C1C(O1)C2CO2,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 115 Y76]"
1331,363898185,533728,CCN(CC)C(=S)[S-].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 4000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-172 Y79]"
1332,363898185,533728,CCN(CC)C(=S)[S-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 4000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-172 Y79]"
1333,363898185,533728,CCN(CC)C(=S)[S-].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1250; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-172 Y79]"
1334,363898185,533728,CCN(CC)C(=S)[S-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 1250; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-172 Y79]"
1335,363898186,7641,CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 12000; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105-106 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-212 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
1336,363898186,7641,CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 12000; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104-107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-212 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
1337,363898186,7641,CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC,Inactive,,,,RAT,F344/MALE,ORAL,0; 12000; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104-107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-212 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
1338,363898186,7641,CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 12000; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104-106 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-212 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
1339,363898186,7641,CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 12000; 25000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),LIVER: CARCINOMA OR ADENOMA,POSITIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
1340,363898186,7641,CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 12000; 25000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),"LIVER: CARCINOMA, CARCINOMA OR ADENOMA",POSITIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
1341,363898186,7641,CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC,Inactive,,,,RAT,F344/MALE,ORAL,0; 12000; 25000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),,NEGATIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
1342,363898186,7641,CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 12000; 25000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),,NEGATIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
1343,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-217 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
1344,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104-105 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-217 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
1345,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,RAT,F344/FEMALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-217 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
1346,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,RAT,F344/MALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104-105 WK),LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-217 Y82][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
1347,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),"LIVER: CARCINOMA, CARCINOMA OR ADENOMA",POSITIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
1348,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),"LIVER: CARCINOMA, CARCINOMA OR ADENOMA",POSITIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
1349,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,RAT,F344/MALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),"LIVER: CARCINOMA, CARCINOMA OR ADENOMA",POSITIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
1350,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,RAT,F344/FEMALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),LIVER: CARCINOMA; CARCINOMA OR ADENOMA,POSITIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
1351,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 108 WK (STUDY DURATION: 108 WK),LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA,POSITIVE,"[RAO,MS, YELDANDI,AV AND SUBBARAO,V; QUANTITATIVE ANALYSIS OF HEPATOCELLULAR LESIONS INDUCED BY DI(2-ETHYLHEXYL)PHTHALATE IN F-344 RATS; J. TOXICOL. ENVIRON. HEALTH 30(2):85-89, 1990]"
1352,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 78 WK (STUDY DURATION: 78 WK),LIVER: NEOPLASM,POSITIVE,"[HAYASHI,F, TAMURA,H, YAMADA,J, KASAI,H AND SUGA,T; CHARACTERISTICS OF THE HEPATOCARCINOGENESIS CAUSED BY DEHYDROEPIANDROSTERONE, A PEROXISOME PROLIFERATOR, IN MALE F-344 RATS; CARCINOGENESIS 15(10):2215-2219, 1994]"
1353,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,RAT,SPRAGUE-DAWLEY/MALE (31-167/GROUP),ORAL,0; 30; 95; 300 MG/KG/D IN DIET UP TO 159 WK (STUDY DURATION: LIFETIME),LIVER: CHOLANGIOCELLULAR TUMORS; TESTIS: LEYDIG CELL TUMORS (SIGNIFICANT DOSE RELATED TREND; INCIDENCE COMPARED TO CONTROLS NOT SIGNIFICANT),POSITIVE,"[VOSS,C ZERBAN,H BANNASCH,P AND BERGER,MR; LIFELONG EXPOSURE TO DI(2-ETHYLHEXYL)-PHTHALATE INDUCES TUMORS IN LIVER AND TESTES OF SPRAGUE-DAWLEY RATS; TOXICOLOGY 206(3): 359-371, 2004]"
1354,363898187,8343,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC,Active,,,,RAT,SPRAGUE-DAWLEY/MALE (31-167/GROUP),ORAL,0; 30; 95; 300 MG/KG/D IN DIET UP TO 159 WK (STUDY DURATION: LIFE TIME),TESTIS: LEYDIG CELL TUMORS,POSITIVE,"[VOSS,C ZERBAN,H BANNASCH,P AND BERGER,MR; LIFELONG EXPOSURE TO DI(2-ETHYLHEXYL)-PHTHALATE INDUCES TUMORS IN LIVER AND TESTES OF SPRAGUE-DAWLEY RATS; TOXICOLOGY 206(3): 359-371, 2004]"
1355,363898188,15374,CCNNCC,Active,,,,RAT,,PRE-NATAL EXP,,BRAIN; NERVOUS SYSTEM,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 153 Y74]"
1356,363898189,5921,CCN(CC)N=O,Active,,,,DOG,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1357,363898189,5921,CCN(CC)N=O,Active,,,,FISH,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1358,363898189,5921,CCN(CC)N=O,Active,,,,GUINEA PIG,,"ORAL, SUBCUTANEOUS",,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1359,363898189,5921,CCN(CC)N=O,Active,,,,HAMSTER,,ORAL,,TRACHEA; LUNG; NASAL CAVITY; BRONCHI; LIVER; FORESTOMACH; ESOPHAGUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1360,363898189,5921,CCN(CC)N=O,Active,,,,HAMSTER,,DERMAL,,NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1361,363898189,5921,CCN(CC)N=O,Active,,,,HAMSTER,,INHALATION,,TRACHEA; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1362,363898189,5921,CCN(CC)N=O,Active,,,,HAMSTER,,SUBCUTANEOUS,,NASAL CAVITY; BRONCHI; TRACHEA; LUNG; LIVER; FORESTOMACH; ESOPHAGUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1363,363898189,5921,CCN(CC)N=O,Active,,,,HAMSTER,,INTRAPERITONEAL,,TRACHEA; NASAL CAVITY; BRONCHI; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1364,363898189,5921,CCN(CC)N=O,Active,,,,MONKEY,,"ORAL, INTRAPERITONEAL",,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1365,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,,ORAL,,LIVER; ESOPHAGUS; LUNG; FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1366,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,,DERMAL,,NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1367,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,,"SUBCUTANEOUS, INTRAPERITONEAL",,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1368,363898189,5921,CCN(CC)N=O,Active,,,,RABBIT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1369,363898189,5921,CCN(CC)N=O,Active,,,,RAT,,ORAL,,LIVER; ESOPHAGUS; KIDNEY; NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1370,363898189,5921,CCN(CC)N=O,Active,,,,RAT,,"INTRAPERITONEAL, RECTAL",,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1371,363898189,5921,CCN(CC)N=O,Active,,,,RAT,,INTRAVENOUS,,KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 83 Y78]"
1372,363898189,5921,CCN(CC)N=O,Inactive,,,,MOUSE,C3H/MALE,TRANSPLACENTAL,0; 0.5 MMOL IN 0.9% STERILE SALINE (51 MG/KG) ON DAY 16 OF GESTATION (STUDY DURATION: LIFETIME),,NEGATIVE,"[ANDERSON,LM, HAGIWARA,A, KOVATCH,RM, REHM,S AND RICE,JM; TRANSPLACENTAL INITIATION OF LIVER, LUNG, NEUROGENIC, AND CONNECTIVE TISSUE TUMORS BY N-NITROSO COMPOUNDS IN MICE; FUNDAM. APPL. TOXICOL. 12(3):604-620, 1989]"
1373,363898189,5921,CCN(CC)N=O,Inactive,,,,MOUSE,C3H/FEMALE,TRANSPLACENTAL,0; 0.5 MMOL IN 0.9% STERILE SALINE (51 MG/KG) ON DAY 16 OF GESTATION (STUDY DURATION: LIFETIME),,NEGATIVE,"[ANDERSON,LM, HAGIWARA,A, KOVATCH,RM, REHM,S AND RICE,JM; TRANSPLACENTAL INITIATION OF LIVER, LUNG, NEUROGENIC, AND CONNECTIVE TISSUE TUMORS BY N-NITROSO COMPOUNDS IN MICE; FUNDAM. APPL. TOXICOL. 12(3):604-620, 1989]"
1374,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C3H/MALE,TRANSPLACENTAL,0; 0.5 MMOL IN 0.9% STERILE SALINE (51 MG/KG) ON DAY 19 OF GESTATION (STUDY DURATION: LIFETIME),LIVER: CARCINOMA; LUNG: CARCINOMA,POSITIVE,"[ANDERSON,LM, HAGIWARA,A, KOVATCH,RM, REHM,S AND RICE,JM; TRANSPLACENTAL INITIATION OF LIVER, LUNG, NEUROGENIC, AND CONNECTIVE TISSUE TUMORS BY N-NITROSO COMPOUNDS IN MICE; FUNDAM. APPL. TOXICOL. 12(3):604-620, 1989]"
1375,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C3H/FEMALE,TRANSPLACENTAL,0; 0.5 MMOL IN 0.9% STERILE SALINE (51 MG/KG) ON DAY 19 OF GESTATION (STUDY DURATION: LIFETIME),LIVER: CARCINOMA; LUNG: TUMOR,POSITIVE,"[ANDERSON,LM, HAGIWARA,A, KOVATCH,RM, REHM,S AND RICE,JM; TRANSPLACENTAL INITIATION OF LIVER, LUNG, NEUROGENIC, AND CONNECTIVE TISSUE TUMORS BY N-NITROSO COMPOUNDS IN MICE; FUNDAM. APPL. TOXICOL. 12(3):604-620, 1989]"
1376,363898189,5921,CCN(CC)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRATRACHEAL,0; 0.1; 0.5 MG IN PHOSPHATE BUFFER 1/WK FOR 15 WK (TOTAL DOSE; 1.5; 7.5 MG) (STUDY DURATION: LIFESPAN),"TRACHEA: PAPILLOMA; LUNG: ADENOMA, SQUAMOUS CARCINOMA, ADENOCARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA",POSITIVE,"[TANAKA,A, HISANAGA,A, INAMASU,T, HIRATA,M AND ISHINISHI,N; A COMPARISON OF THE CARCINOGENICITY OF N-NITROSODIETHYLAMINE AND N-NITROSODIMETHYLAMINE AFTER INTRATRACHEAL INSTILLATION INTO SYRIAN GOLDEN HAMSTERS; FOOD CHEM. TOXICOL. 26(10):847-850, 1988]"
1377,363898189,5921,CCN(CC)N=O,Active,,,,RAT,WISTAR/MALE,ORAL,"0; 0.033; 0.066; 0.132; 0.264; 0.528; 1.056; 1.584; 2.112; 2.640; 3.168; 4.224; 5.280; 6.336; 8.448; 16.896 PPM IN DRINKING WATER (10% SACRIFICED AT 12 MO, 10% SACRIFICED AT 18 MO) (STUDY DURATION: LIFESPAN)",ESOPHAGUS: TUMOR; LIVER HEPATOCELLULAR CARCINOMA,POSITIVE,"[PETO,R, GRAY,R, BRANTOM,P AND GRASSO,P; EFFECTS ON 4080 RATS OF CHRONIC INGESTION OF N-NITROSODIETHYLAMINE OR N-NITROSODIMETHYLAMINE: A DETAILED DOSE- RESPONSE STUDY; CANCER RES. 51(23, PT.2):6415-6451, 1991]"
1378,363898189,5921,CCN(CC)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 2.5 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 25 WK (TOTAL DOSE 1.2 MMOL) (STUDY DURATION: LIFESPAN),LIVER: HEMANGIOSARCOMA; ESOPHAGUS: TUMOR,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
1379,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,SWISS/MALE,INTRAGASTRIC,0; 80; 80; 40 MG/KG IN NORMAL SALINE ADMINISTERED WITH A 4 WK GAP BETWEEN EACH DOSE; (STUDY DURATION: 24 WK),LUNG: TUMOR,POSITIVE,"[KHANDUJA,KL, KOUL,IB, GANDHI,RK, SEHGAL,S AND SHARMA,RR; EFFECT OF COMBINED DEFICIENCY OF FAT AND VITAMIN A ON N-NITROSODIETHYLAMINE-INDUCED LUNG CARCINOGENESIS IN MICE; CANCER LETT. 62(1):57-62, 1992]"
1380,363898189,5921,CCN(CC)N=O,Active,,,,RAT,F344/FEMALE,ORAL,"0; 18 MG/L IN DEIONIZED DRINKING WATER DURING WK 1, 5, AND 9 (STUDY DURATION: 121 WK)",HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND THOMAS,BJ; THE CARCINOGENIC EFFECT OF METHAPYRILENE COMBINED WITH NITROSODIETHYLAMINE GIVEN TO RATS IN LOW DOSES; CARCINOGENESIS 13(7):1293-1297, 1992]"
1381,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 1 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1382,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 1 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1383,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 15 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1384,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 15 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1385,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 42 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1386,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 42 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1387,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C3AF1/MALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 1 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1388,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C3AF1/FEMALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 1 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1389,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C3AF1/MALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 15 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1390,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C3AF1/FEMALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 15 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1391,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C3AF1/MALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 42 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)","LIVER: ADENOMA, CARCINOMA; LUNG: TUMORS",POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1392,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C3AF1/FEMALE,INTRAPERITONEAL,"0; 1.5; 3 UG IN 0.01 ML TRIOCTANOIN/G BW INITIAL DOSE GIVEN ON DAY 42 OF AGE AND 3 SUBSEQUENT DOSES GIVEN 3, 9 AND 15 DAYS LATER (STUDY DURATION: LIFE-SPAN)",LUNG: TUMORS,POSITIVE,"[VESSELINOVITCH,SD, KOKA,M, MIHAILOVICH,N AND RAO,KVN; CARCINOGENICITY OF DIETHYLNITROSAMINE IN NEWBORN, INFANT, AND ADULT MICE; J. CANCER RES. CLIN. ONCOL. 108(1):60-65, 1984]"
1393,363898189,5921,CCN(CC)N=O,Inactive,,,,MOUSE,C57BL/MALE,INTRAPERITONEAL,"0; 12 UG ON DAYS 0, 3, 9 AND 15 (STUDY DURATION: 132 WK)",,NEGATIVE,"[RUEBNER,BH, GERSHWIN,ME, FRENCH,SW, MEIERHENRY,E, DUNN,P AND HSIEH,LS; MOUSE HEPATIC NEOPLASIA: DIFFERENCES AMONG STRAINS AND CARCINOGENS; MOUSE LIVER NEOPLASIA 115-143, 1984]"
1394,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C3H/MALE,INTRAPERITONEAL,"0; 12 UG ON DAYS 0, 3, 9 AND 15 (STUDY DURATION: 132 WK)",LIVER: TUMORS,POSITIVE,"[RUEBNER,BH, GERSHWIN,ME, FRENCH,SW, MEIERHENRY,E, DUNN,P AND HSIEH,LS; MOUSE HEPATIC NEOPLASIA: DIFFERENCES AMONG STRAINS AND CARCINOGENS; MOUSE LIVER NEOPLASIA 115-143, 1984]"
1395,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 12 UG ON DAYS 0, 3, 9 AND 15 (STUDY DURATION: 132 WK)",LIVER: TUMORS,POSITIVE,"[RUEBNER,BH, GERSHWIN,ME, FRENCH,SW, MEIERHENRY,E, DUNN,P AND HSIEH,LS; MOUSE HEPATIC NEOPLASIA: DIFFERENCES AMONG STRAINS AND CARCINOGENS; MOUSE LIVER NEOPLASIA 115-143, 1984]"
1396,363898189,5921,CCN(CC)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,INTRATRACHEAL,0; 1 MG IN 0.1 ML PHOSPHATE BUFFER 15/WK FOR 4 MO (STUDY DURATION: 237 D),LUNG: ADENOMA OR CARCINOMA; TRACHEA: PAPILLOMA,POSITIVE,"[YAMAMOTO,A, HISANAGA,A AND ISHINISHI,N; COMPARATIVE STUDY ON THE CARCINOGENICITY OF N-NITROSODIETHYLAMINE AND BENZO[A]PYRENE TO THE LUNG OF SYRIAN GOLDEN HAMSTERS INDUCED BY INTERMITTENT INSTILLATIONS TO THE TRACHEA; CANCER LETT. 25(3):271-276, 1985]"
1397,363898189,5921,CCN(CC)N=O,Active,,,,FISH,SHASTA RAINBOW TROUT/MALE,ORAL,0; 4; 70; 275; 550; 1100 PPM IN DIET FOR 12 MO (STUDY DURATION: 18 MO),LIVER: TUMOR,POSITIVE,"[HENDRICKS,JD, CHENG,R, SHELTON,DW, PEREIRA,CB AND BAILEY,GS; DOSE-DEPENDENT CARCINOGENICITY AND FREQUENT KI-RAS PROTO-ONCOGENE ACTIVATION BY DIETARY N-NITROSODIETHYLAMINE IN RAINBOW TROUT; FUNDAM. APPL. TOXICOL. 23(1):53-62, 1994]"
1398,363898189,5921,CCN(CC)N=O,Active,,,,FISH,SHASTA RAINBOW TROUT/FEMALE,ORAL,0; 4; 70; 275; 550; 1100 PPM IN DIET FOR 12 MO (STUDY DURATION: 18 MO),LIVER: TUMOR,POSITIVE,"[HENDRICKS,JD, CHENG,R, SHELTON,DW, PEREIRA,CB AND BAILEY,GS; DOSE-DEPENDENT CARCINOGENICITY AND FREQUENT KI-RAS PROTO-ONCOGENE ACTIVATION BY DIETARY N-NITROSODIETHYLAMINE IN RAINBOW TROUT; FUNDAM. APPL. TOXICOL. 23(1):53-62, 1994]"
1399,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,EU-PIM-1/MALE,GAVAGE,0; 1; 3 MG/KG 1/D FOR 38 WK (STUDY DURATION: 38 WK),LIVER: HEMANGIOSARCOMA,POSITIVE,"[STORER,RD, CARTWRIGHT,ME, COOK,WO, SOPER,KA AND NICOLS,WW; SHORT-TERM CARCINOGENESIS BIOASSAY OF GENOTOXIC PROCARCINOGENS IN PM TRANSGENIC MICE; CARCINOGENESIS 16(2):285-293, 1995]"
1400,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,EU-PIM-1/FEMALE,GAVAGE,0; 1; 3 MG/KG 1/D FOR 38 WK (STUDY DURATION: 38 WK),LIVER: HEMANGIOSARCOMA; LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[STORER,RD, CARTWRIGHT,ME, COOK,WO, SOPER,KA AND NICOLS,WW; SHORT-TERM CARCINOGENESIS BIOASSAY OF GENOTOXIC PROCARCINOGENS IN PM TRANSGENIC MICE; CARCINOGENESIS 16(2):285-293, 1995]"
1401,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.02; 0.07 UMOL/G BW IN 10 UL/G BW TRIOCTANOIN ONCE AT 12 D OF AGE (STUDY DURATION: 9 MO),LIVER: HEPATOMA,POSITIVE,"[LAI,CC, MILLER,JA, MILLER,EC AND LIEM,A; N-SULFOOXY-2-AMINOFLUORENE IS THE MAJOR ULTIMATE ELECTROPHILIC AND CARCINOGENIC METABOLITE OF N-HYDROXY-2-ACETYLAMINOFLUORENE IN THE LIVERS OF INFANT MALE C576BL/6J X C3H/HEJF1 (B6C3F1) MICE; CARCINOGENESIS 6(7):1037-1045, 1985]"
1402,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,B6C3F2 (BRACHYMORPHIC)/MALE,INTRAPERITONEAL,0; 0.02; 0.07 UMOL/G BW IN 10 UL/G BW TRIOCTANOIN ONCE AT 12 D OF AGE (STUDY DURATION: 9 MO),LIVER: HEPATOMA,POSITIVE,"[LAI,CC, MILLER,JA, MILLER,EC AND LIEM,A; N-SULFOOXY-2-AMINOFLUORENE IS THE MAJOR ULTIMATE ELECTROPHILIC AND CARCINOGENIC METABOLITE OF N-HYDROXY-2-ACETYLAMINOFLUORENE IN THE LIVERS OF INFANT MALE C576BL/6J X C3H/HEJF1 (B6C3F1) MICE; CARCINOGENESIS 6(7):1037-1045, 1985]"
1403,363898189,5921,CCN(CC)N=O,Active,,,,FISH,"MEDAKA/MALE,FEMALE",IMMERSION,0; 390 PPM IN AQUEOUS BATH FOR 48 HR (STUDY DURATION: 7 MO),LIVER: TUMOR,POSITIVE,"[TORTEN,M, LIU,Z, OKIHIRO,MS, TEH,SJ AND HINTON,DE; INDUCTION OF RAS ONCOGENE MUTATIONS AND HEPATOCARCINOGENESIS IN MEDAKA (ORYZIAS LATIPES) EXPOSED TO DIETHYLNITROSAMINE; MAR. ENVIRON. RES. 42(1-4):93-98, 1996]"
1404,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,AKR/MALE,ORAL,0; 100 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: 150 D),LUNG: TUMOR,POSITIVE,"[GIRI,RK, BARAL,RN AND DAS,BR; INDUCTION OF LUNG CARCINOGENESIS IN AKR-MICE BY N-NITROSODIETHYLAMINE/PHENOBARBITONE, ASSOCIATED WITH HIGH EXPRESSION OF C-MYC AND C-JUN ONCOPROTEINS; CANCER LETT. 112(1):57-63, 1997]"
1405,363898189,5921,CCN(CC)N=O,Active,,,,FISH,"GUPPY POECILIA RETICULATA/MALE, FEMALE",IMMERSION,0; 29.4 MG/L IN WATER FOR 28 D (STUDY DURATION: 6 MONTHS),"LIVER: MULTIFOCAL HEPATOMA, CHOLANGIOMA",POSITIVE,"[KOVRIZNYCH,JA AND URBANCIKOVA,M; TOXICITY OF N-NITROSODIETHYLAMINE FOR GUPPY POECILIA RETICULATA IN CARCINOGENICITY TESTS; J. TRACE MICROPROBE TECH. 18(2):227-233, 2000]"
1406,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,SWR/FEMALE,INTRAPERITONEAL,0; 15; 90 MG/KG ONCE (STUDY DURATION: 18 MONTHS),LUNG: TUMOR,POSITIVE,"[OREFFO,V SINGH,R RICH,KJ SHUKER,DEG CARTHEW,P CORDERO,R VAN DELFT,JHM AND FARMER,PB; DNA ADDUCTS IN RELATION TO LUNG TUMOUR OUTCOME ARE NOT MARKERS OF SUSCEPTIBILITY FOLLOWING A SINGLE DOSE TREATMENT OF SWR, BALB/C AND C57BL/6J MICE WITH N-NITROSODIETHYLAMINE; BIOMARKERS 5(5):323-340, 2000]"
1407,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,BALB/C/FEMALE,INTRAPERITONEAL,0; 15; 90 MG/KG ONCE (STUDY DURATION: 18 MONTHS),LUNG: TUMOR,POSITIVE,"[OREFFO,V SINGH,R RICH,KJ SHUKER,DEG CARTHEW,P CORDERO,R VAN DELFT,JHM AND FARMER,PB; DNA ADDUCTS IN RELATION TO LUNG TUMOUR OUTCOME ARE NOT MARKERS OF SUSCEPTIBILITY FOLLOWING A SINGLE DOSE TREATMENT OF SWR, BALB/C AND C57BL/6J MICE WITH N-NITROSODIETHYLAMINE; BIOMARKERS 5(5):323-340, 2000]"
1408,363898189,5921,CCN(CC)N=O,Active,,,,MOUSE,C57BL/6J/FEMALE,INTRAPERITONEAL,0; 15; 90 MG/KG ONCE (STUDY DURATION: 18 MONTHS),LUNG: TUMOR,POSITIVE,"[OREFFO,V SINGH,R RICH,KJ SHUKER,DEG CARTHEW,P CORDERO,R VAN DELFT,JHM AND FARMER,PB; DNA ADDUCTS IN RELATION TO LUNG TUMOUR OUTCOME ARE NOT MARKERS OF SUSCEPTIBILITY FOLLOWING A SINGLE DOSE TREATMENT OF SWR, BALB/C AND C57BL/6J MICE WITH N-NITROSODIETHYLAMINE; BIOMARKERS 5(5):323-340, 2000]"
1409,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,HAMSTER,,SUBCUTANEOUS,,KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 55 Y74]"
1410,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,HAMSTER,,SUBCUTANEOUS IMPLANT,,KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 173 Y79]"
1411,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,HAMSTER,,PRE-NATAL EXPOSURE,,UTERUS; ACCESSORY SEX ORGANS (M); VAGINA; CERVIX,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 173 Y79]"
1412,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,HUMAN,,DERMAL,,CERVIX OR VAGINA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 55 Y74]"
1413,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,MONKEY,,SUBCUTANEOUS,,UTERUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 55 Y74]"
1414,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,MOUSE,,ORAL,,MAMMARY GLAND; CERVIX; VAGINA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 55 Y74]"
1415,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,MOUSE,,SUBCUTANEOUS,,MAMMARY GLAND; GENITAL TRACT; OVARIES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 55 Y74]"
1416,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,MOUSE,,SUBCUTANEOUS IMPLANT,,TESTES; MAMMARY GLAND; LYMPHATIC SYSTEM,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 173 Y79]"
1417,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,MOUSE,,PRE-NATAL EXPOSURE,,CERVIX; VAGINA; OVARIES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 173 Y79]"
1418,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,MOUSE,,NEO-NATAL EXPOSURE,,CERVIX; VAGINA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 173 Y79]"
1419,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,RAT,,ORAL,,MAMMARY GLAND; PITUITARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 173 Y79]"
1420,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,RAT,,SUBCUTANEOUS,,MAMMARY GLAND; PITUITARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 55 Y74]"
1421,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,RAT,,SUBCUTANEOUS IMPLANT,,MAMMARY GLAND; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 173 Y79]"
1422,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,RAT,,NEO-NATAL EXPOSURE,,ACCESSORY SEX ORGANS (M),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 173 Y79]"
1423,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,RAT,ACI/FEMALE,SUBCUTANEOUS IMPLANT,"0; 1.25 MG/100 G ONCE IN A 20 MG PELLET AT AGES 75, 127 AND 177 D (STUDY DURATION: 347-365 D)",MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[SHELLABARGER,CJ, STONE,JP AND HOLTZMAN,S; EFFECT OF INTERVAL BETWEEN NEUTRON RADIATION AND DIETHYLSTILBESTROL ON MAMMARY CARCINOGENESIS IN FEMALE ACI RATS; ENVIRON. HEALTH PERSPECT. 50:227-232, 1983]"
1424,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,RAT,WISTAR/FEMALE,SUBCUTANEOUS,"0; 0.1; 0.5 MG/KG TO MOTHERS ON D 18, 19 AND 20 OF GESTATION (STUDY DURATION: 2 YR)",VAGINA: TUMOR,POSITIVE,"[BAGGS,RB, MILLER,RK AND ODOROFF,CL; CARCINOGENICITY OF DIETHYLSTILBESTROL IN THE WISTAR RAT: EFFECT OF POSTNATAL ORAL CONTRACEPTIVE STEROIDS; CANCER RES. 51(12):3311-3315, 1991]"
1425,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,RAT,WISTAR/FEMALE,SUBCUTANEOUS,0; 25; 50 MG/KG TO MOTHERS ON D 19 AND 20 OF GESTATION (STUDY DURATION: 2 YR),VAGINA: TUMOR,POSITIVE,"[BAGGS,RB, MILLER,RK AND ODOROFF,CL; CARCINOGENICITY OF DIETHYLSTILBESTROL IN THE WISTAR RAT: EFFECT OF POSTNATAL ORAL CONTRACEPTIVE STEROIDS; CANCER RES. 51(12):3311-3315, 1991]"
1426,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,MOUSE,C3H/FEMALE,ORAL,0; 2.5; 5; 10; 20; 40; 80; 160; 320; 640 PPB IN DIET (STUDY DURATION: 455 D),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[GREENMAN,DL AND HIGHMAN,B; CARCINOGENIC-ESTROGENIC BIOASSAY WITH C3H MICE GOV. REP. ANNOUNCE. INDEX (U.S) 84(15):80, 1984]"
1427,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 1 UG/G BW ADMINISTERED TO PREGNANT MICE AT 16 D AND 16 HR, 17 D, OR 17 D 16 HR POST CONCEPTION OR 2 UG/G BW AT 17 D 16 HR POST CONCEPTION THEN FEMALE OFFSPRING MAINTAINED FOR LIFE SPAN (STUDY DURATION: LIFETIME)",PITUITARY GLAND: TUMOR,POSITIVE,"[WALKER,BE AND KURTH,LA; PITUITARY TUMORS IN MICE EXPOSED PRENATALLY TO DIETHYLSTILBESTROL; CANCER RES. 53(7):1546-1549, 1993]"
1428,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),KIDNEY: TUMOR,POSITIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
1429,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Inactive,,,,MOUSE,"C57BL/6/MALE,FEMALE (WILD TYPE)",DIET,0; 1500 PPB IN DIET FOR 39 WKS (STUDY DURATION: 39 WKS),,NEGATIVE,"[MCANULTY,P AND SKYDSGAARD,M; DIETHYLSTILBESTROL (DES): CARCINOGENIC POTENTIAL IN XPA -/-, XPA-/-/P53/-, AND WILD-TYPE MICE DURING 9 MONTHS' DIETARY EXPOSURE; TOXICOL. PATHOL. 33 (5): 609-620, 2005]"
1430,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Active,,,,MOUSE,"C57BL/6/XPA/P53/MALE,FEMALE (TRANSGENIC)",DIET,0; 1500 PPB IN DIET FOR 39 WKS (STUDY DURATION: 39 WKS),"BONE: OSTEOSARCOMA (MALES ONLY); TESTICULAR INTERSTITIAL CELL ADENOMA (BENIGN), MALES",POSITIVE IN MALES ONLY,"[MCANULTY,P AND SKYDSGAARD,M; DIETHYLSTILBESTROL (DES): CARCINOGENIC POTENTIAL IN XPA -/-, XPA-/-/P53/-, AND WILD-TYPE MICE DURING 9 MONTHS' DIETARY EXPOSURE; TOXICOL. PATHOL. 33 (5): 609-620, 2005]"
1431,363898190,448537,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,Unspecified,,,,MOUSE,"C57BL/6XPA/MALE,FEMALE (TRANSGENIC)",DIET,0; 100; 300; 1500 PPB IN DIET FOR 39 WKS (STUDY DURATION: 39 WKS),PITUITARY: ADENOMA (BENIGN),SIGNIFICANT IN MALES AT 1500 PPB ONLY,"[MCANULTY,P AND SKYDSGAARD,M; DIETHYLSTILBESTROL (DES): CARCINOGENIC POTENTIAL IN XPA -/-, XPA-/-/P53/-, AND WILD-TYPE MICE DURING 9 MONTHS' DIETARY EXPOSURE; TOXICOL. PATHOL. 33 (5): 609-620, 2005]"
1432,363898191,657220,CC/C(=C(/CC)\C1=CC=C(C=C1)OC(=O)CC)/C2=CC=C(C=C2)OC(=O)CC,Active,,,,RAT,,SUBCUTANEOUS,,PITUITARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 173 Y79]"
1433,363898192,6163,CCOS(=O)(=O)OCC,Active,,,,RAT,,ORAL,,FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 277 Y74]"
1434,363898192,6163,CCOS(=O)(=O)OCC,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 277 Y74]"
1435,363898193,2735009,CCNC(=S)NCC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 250; 500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-149 Y79]"
1436,363898193,2735009,CCNC(=S)NCC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 250; 500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-149 Y79]"
1437,363898193,2735009,CCNC(=S)NCC,Active,,,,RAT,F344/FEMALE,ORAL,0; 125; 250 PPM IN DIET,THYROID GLAND: FOLLICULAR CELL CARCINOMA OR FOLLICULAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-149 Y79]"
1438,363898193,2735009,CCNC(=S)NCC,Active,,,,RAT,F344/MALE,ORAL,0; 125; 250 PPM IN DIET,THYROID GLAND: FOLLICULAR CELL CARCINOMA OR FOLLICULAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-149 Y79]"
1439,363898194,7197,CCCC1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,,ORAL,,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 170 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 233 Y76]"
1440,363898194,7197,CCCC1=CC2=C(C=C1)OCO2,Active,,,,RAT,,ORAL,,ESOPHAGUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 170 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 233 Y76]"
1441,363898195,3082,CNC(=O)CSP(=S)(OC)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 250; 500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-4 Y77]"
1442,363898195,3082,CNC(=O)CSP(=S)(OC)OC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 250; 500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-4 Y77]"
1443,363898195,3082,CNC(=O)CSP(=S)(OC)OC,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 192; 384 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-4 Y77]"
1444,363898195,3082,CNC(=O)CSP(=S)(OC)OC,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0, 155; 310 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-4 Y77]"
1445,363898195,3082,CNC(=O)CSP(=S)(OC)OC,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 2; 20; 200 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KNAPEK,R, KITA,K, KOBES,S, KITA,I AND POLKO,M; LATEST FINDINGS ON THE CARCINOGENICITY OF DIMETHOATE; TAGUNGSBER. - AKAD. LANDWIRTSCHAFTSWISS. D.D.R. 285(EXP. GRUNDLAGEN TOXIKOL. PRUEF. FREMDST.):77-81, 1990]"
1446,363898195,3082,CNC(=O)CSP(=S)(OC)OC,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 2; 20; 200 PPM IN DIET FOR 2 YR (STUDY DURATION 2 YR),,NEGATIVE,"[KNAPEK,R, KITA,K, KOBES,S, KITA,I AND POLKO,M; LATEST FINDINGS ON THE CARCINOGENICITY OF DIMETHOATE; TAGUNGSBER. - AKAD. LANDWIRTSCHAFTSWISS. D.D.R. 285(EXP. GRUNDLAGEN TOXIKOL. PRUEF. FREMDST.):77-81, 1990]"
1447,363898196,13232,CC1CC(OC(O1)C)OC(=O)C,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V15 177 Y77]"
1448,363898196,13232,CC1CC(OC(O1)C)OC(=O)C,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 62.5; 125 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-354 Y89]"
1449,363898196,13232,CC1CC(OC(O1)C)OC(=O)C,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-354 Y89]"
1450,363898196,13232,CC1CC(OC(O1)C)OC(=O)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-354 Y89]"
1451,363898196,13232,CC1CC(OC(O1)C)OC(=O)C,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),FORESTOMACH: SQUAMOUS PAPILLOMA OR SQUAMOUS CELL CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-354 Y89]"
1452,363898197,41023,COC1=CC(=C(C=C1)[NH3+])OC.[Cl-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-171 Y79]"
1453,363898197,41023,COC1=CC(=C(C=C1)[NH3+])OC.[Cl-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-171 Y79]"
1454,363898197,41023,COC1=CC(=C(C=C1)[NH3+])OC.[Cl-],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1500; 3000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-171 Y79]"
1455,363898197,41023,COC1=CC(=C(C=C1)[NH3+])OC.[Cl-],Inactive,,,,RAT,F344/MALE,ORAL,0; 1500; 3000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-171 Y79]"
1456,363898198,8821,CCOC(=O)C=C,Active,,,,RAT,F344/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL FOR 103 WK,"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-259 Y86]"
1457,363898198,8821,CCOC(=O)C=C,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL FOR 103 WK,"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-259 Y86]"
1458,363898198,8821,CCOC(=O)C=C,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL FOR 103 WK,"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-259 Y86]"
1459,363898198,8821,CCOC(=O)C=C,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL FOR 103 WK,FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-259 Y86]"
1460,363898198,8821,CCOC(=O)C=C,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 23 MG IN 25 UL ACETONE 3/WK FOR LIFESPAN (STUDY DURATION: LIFESPAN),,NEGATIVE,"[DEPASS,LR, FOWLER,EH, MECKLEY,DR AND WEIL,CS; DERMAL ONCOGENICITY BIOASSAYS OF ACRYLIC ACID, ETHYL ACRYLATE, AND BUTYL ACRYLATE; J. TOXICOL. ENVIRON. HEALTH 14(2-3):115-120, 1984]"
1461,363898198,8821,CCOC(=O)C=C,Inactive,,,,RAT,F344/MALE,INHALATION,0; 25; 75 PPM 6 HR/D 5 D/WK FOR 27 MO (STUDY DURATION: 27 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1462,363898198,8821,CCOC(=O)C=C,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 25; 75 PPM 6 HR/D 5 D/WK FOR 27 MO (STUDY DURATION: 27 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1463,363898198,8821,CCOC(=O)C=C,Inactive,,,,RAT,F344/MALE,INHALATION,0; 225 PPM 6 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 27 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1464,363898198,8821,CCOC(=O)C=C,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 225 PPM 6 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 27 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1465,363898198,8821,CCOC(=O)C=C,Inactive,,,,RAT,F344/MALE,INHALATION,0; 5 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1466,363898198,8821,CCOC(=O)C=C,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 5 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1467,363898198,8821,CCOC(=O)C=C,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 25; 75 PPM 6 HR/D 5 D/WK FOR 27 MO (STUDY DURATION: 27 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1468,363898198,8821,CCOC(=O)C=C,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 25; 75 PPM 6 HR/D 5 D/WK FOR 27 MO (STUDY DURATION: 27 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1469,363898198,8821,CCOC(=O)C=C,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 225 PPM 6 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 27 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1470,363898198,8821,CCOC(=O)C=C,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 225 PPM 6 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 27 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1471,363898198,8821,CCOC(=O)C=C,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 5 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1472,363898198,8821,CCOC(=O)C=C,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 5 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[MILLER,RR, YOUNG,JT, KOCIBA,RJ, KEYES,DG, BODNER,KM, CALHOUN,LL AND AYRES,JA; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY OF INHALED ETHYL ACRYLATE IN FISCHER 344 RATS AND B6C3F1 MICE; DRUG CHEM. TOXICOL. 8(1-2):1-42, 1985]"
1473,363898198,8821,CCOC(=O)C=C,Inactive,,,,MOUSE,TGAC/FEMALE,DERMAL,0; 60; 300; 600 UMOL IN 200 UL ACETONE 3/WK FOR 20 WK (STUDY DURATION: 20 WK),,NEGATIVE,"[NYLANDER-FRENCH,LA AND FRENCH,JE; TRIPROPYLENE GLYCOL DIACRYLATE BUT NOT ETHYL ACRYLATE INDUCES SKIN TUMORS IN A TWENTY-WEEK SHORT-TERM TUMORIGENESIS STUDY IN TG.AC (V-HA-RAS) MICE; TOXICOL. PATHOL. 26(4):476-483, 1998]"
1474,363898199,8411,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N)OC)N,Active,,,,HAMSTER,,ORAL,,FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 41 Y74]"
1475,363898199,8411,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N)OC)N,Active,,,,RAT,,ORAL,,EAR (ZYMBAL GLAND); URINARY BLADDER; INTESTINES; INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 41 Y74]"
1476,363898200,7069,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=C=O)OC)N=C=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 22000; 44000 PPM IN DIET FOR 78 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-128 Y79]"
1477,363898200,7069,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=C=O)OC)N=C=O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 22000; 44000 PPM IN DIET FOR 78 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-128 Y79]"
1478,363898200,7069,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=C=O)OC)N=C=O,Active,,,,RAT,F344/FEMALE,"GAVAGE, ORAL","0; 1500; 3000 MG/KG FOR 22 WK, THEN 22000; 44000 PPM IN DIET FOR 56 WK (STUDY DURATION: 104 WK)",HEMATOPOIETIC SYSTEM (LEUKEMIA); UTERUS: ENDOMETRIAL STROMAL POLYP; EAR (ZYMBAL GLAND AND SKIN OF EAR): SQUAMOUS CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA OR TRICHOEPITHELIOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-128 Y79]"
1479,363898200,7069,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=C=O)OC)N=C=O,Active,,,,RAT,F344/MALE,"GAVAGE, ORAL","0; 1500; 3000 MG/KG FOR 22 WK, THEN 22000; 44000 PPM IN DIET FOR 56 WK (STUDY DURATION: 104 WK)",INTEGUMENTARY SYSTEM (SKIN (EXCLUDING SKIN OF EAR)): PAPILLOMA (NOS) OR BASAL CELL TUMOR OR TRICHOEPITHELIOMA OR SEBACEOUS ADENOMA OR KERATOACANTHOMA OR SQUAMOUS CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA); EAR (ZYMBAL GLAND AND SKIN OF EAR): SQUAMOUS CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-128 Y79]"
1480,363898201,6053,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,DOG,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 125 Y75]"
1481,363898201,6053,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,MOUSE,,SUBCUTANEOUS,,LIVER; INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 125 Y75]"
1482,363898201,6053,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 125 Y75]"
1483,363898201,6053,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.3 UMOL/G IN TRIOCTANOIN ONCE ON DAY 1 FOLLOWED BY 0.4 UMOL/G ONCE ON DAY 8, 15 AND 22 (STUDY DURATION: 10 MO)",LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
1484,363898201,6053,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 0.3 UMOL/G IN TRIOCTANOIN ONCE ON DAY 1 FOLLOWED BY 0.4 UMOL/G ONCE ON DAY 8, 15 AND 22 (STUDY DURATION: 10 MO)",,NEGATIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
1485,363898201,6053,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.017; 0.05; 0.15; 0.45 UMOL/G ONCE IN TRIOCTANOIN (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
1486,363898201,6053,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2,Inactive,,,,RAT,F344/MALE,INTRAPERITONEAL,"0; 0.3 UMOL/G IN TRIOCTANOIN ONCE ON DAY 1 FOLLOWED BY 0.4 UMOL/G ONCE ON DAY 8, 15 AND 22 (STUDY DURATION: 10 MO)",,NEGATIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
1487,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0.15 MMOL/KG IN PEANUT OIL 1/WK FOR 37 WK (TOTAL DOSE: 5.6 MMOL/KG),"URINARY BLADDER: TRANSITIONAL CELL CARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[HECHT,SS, EL-BAYOUMY,K, RIVENSON,A AND FIALA,ES; BIOASSAY FOR CARCINOGENICITY OF 3,2'- DIMETHYL-4-NITROSOBIPHENYL, O-NITROSO-TOLUENE, NITROSOBENZENE AND THE CORRESPONDING AMINES IN SYRIAN GOLDEN HAMSTERS; CANCER LETT. 20:349-354, 1983]"
1488,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0.15 MMOL/KG IN PEANUT OIL 1/WK FOR 37 WK (TOTAL DOSE: 5.6 MMOL/KG),URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[HECHT,SS, EL-BAYOUMY,K, RIVENSON,A AND FIALA,ES; BIOASSAY FOR CARCINOGENICITY OF 3,2'- DIMETHYL-4-NITROSOBIPHENYL, O-NITROSO-TOLUENE, NITROSOBENZENE AND THE CORRESPONDING AMINES IN SYRIAN GOLDEN HAMSTERS; CANCER LETT. 20:349-354, 1983]"
1489,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",SUBCUTANEOUS,100 MG/KG 1/WK FOR 52 WK,"URINARY BLADDER: PAPILLOMA, CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 263]"
1490,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,RAT,ALBINO/MALE,SUBCUTANEOUS,2.8-3.5 G/KG,INTESTINES; SALIVARY GLAND; EAR (DUCT),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 345]"
1491,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,20 MG/KG 1/WK FOR 42 WK OR 50 MG/KG 1/WK FOR 20 WK,PROSTATE GLAND: CARCINOMA (IN SITU),POSITIVE,"[KATAYAMA,S, FIALA,E, REDDY,BS, RIVENSON,A, SILVERMAN,J, WILLIAMS,GM AND WEISBURGER,JH;PROSTATE ADENOCARCINOMA IN RATS: INDUCTION BY 3,2'-DIMETHYL-4-AMINOBIPHENYL;J. NATL. CANCER INST. 68(5):867-873, 1982]"
1492,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,RAT,WISTAR/FEMALE,SUBCUTANEOUS,2 MG/100 G 5/WK FOR 12 WK,MAMMARY GLAND: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 190]"
1493,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,RAT,"WISTAR/MALE,FEMALE",SUBCUTANEOUS,2 MG/100 G 5/WK FOR LIFE,INTESTINES (LARGE): POLYPLOID TUMOR (MULTIPLE),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 263]"
1494,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,"0; 100 MG/KG IN PEANUT OIL 1/WK FOR 8 WK, THEN ONCE EVERY 2 WK FOR 18 MO (TOTAL MAXIMUM DOSE: 555 MG)",URINARY BLADDER: TRANSITIONAL CELL CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA; INTESTINES (SMALL): ADENOCARCINOMA; COLON: ADENOCARCINOMA; LYMPHATIC SYSTEM: LYMPHOMA OR LEUKEMIA,POSITIVE,"[WILLIAMS,GM, CHANDRASEKARAN,V, KATAYAMA,S AND WEISBURGER,JH; CARCINOGENICITY OF 3-METHYL-2-NAPHTHYLAMINE AND 3,2'-DIMETHYL-4-AMINOBIPHENYL TO THE BLADDER AND GASTROINTESTINAL TRACT OF THE SYRIAN GOLDEN HAMSTER WITH ATYPICAL PROLIFERATIVE ENTERITIS; J. NATL. CANCER INST. 67(2):481-488, 1981]"
1495,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 150 MG/KG 1/WK FOR 3 WK FOLLOWED BY HIGH FAT DIET (20% CORN OIL) BEGINNING 12 WK POST LAST CARCINOGEN DOSE AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: 60 WK),PANCREAS: ADENOMA OR CARCINOMA,POSITIVE,"[SHIRAI,T, NAKAMURA,A, WADA,S AND ITO,N; PANCREATIC ACINAR CELL TUMORS IN RATS INDUCED BY 3,2'-DIMETHYL-4-AMINOBIPHENYL; CARCINOGENESIS 10(6):1127-1130, 1989]"
1496,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 150 MG/KG 1/WK FOR 3 WK FOLLOWED BY NORMAL FAT DIET (4.5% CORN OIL) BEGINNING 12 WK POST LAST CARCINOGEN DOSE AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: 60 WK),PANCREAS: ADENOMA OR CARCINOMA,POSITIVE,"[SHIRAI,T, NAKAMURA,A, WADA,S AND ITO,N; PANCREATIC ACINAR CELL TUMORS IN RATS INDUCED BY 3,2'-DIMETHYL-4-AMINOBIPHENYL; CARCINOGENESIS 10(6):1127-1130, 1989]"
1497,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 100 MG/KG BW 1/WK FOR 20 WK (STUDY DURATION: 50 WK),URINARY BLADDER: CARCINOMA,POSITIVE,"[CUI,L, HASEGAWA,R, OGAWA,K, YAMADA,Y, TAKAHASHI,S AND SHIRAI,T; HISTOPATHOLOGICAL ANALYSIS OF INVASIVE BLADDER CARCINOMAS INDUCED BY 3,2'-DIMETHYL-4-AMINOBIPHENYL IN HAMSTERS; JPN. J. CANCER RES. 87(1):37-43, 1996]"
1498,363898202,25948,CC1=CC=CC=C1C2=CC(=C(C=C2)N)C,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 100 MG/KG BW 1/WK FOR 20 WK (STUDY DURATION: 50 WK),URINARY BLADDER: CARCINOMA,POSITIVE,"[CUI,L, HASEGAWA,R, OGAWA,K, YAMADA,Y, TAKAHASHI,S AND SHIRAI,T; HISTOPATHOLOGICAL ANALYSIS OF INVASIVE BLADDER CARCINOMAS INDUCED BY 3,2'-DIMETHYL-4-AMINOBIPHENYL IN HAMSTERS; JPN. J. CANCER RES. 87(1):37-43, 1996]"
1499,363898203,9570442,CN(C)/C=N/C1=NN=C(O1)/C=C/C2=CC=C(O2)[N+](=O)[O-],Active,,,,RAT,,ORAL,,MAMMARY GLAND; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 147 Y74]"
1500,363898205,88898,CC1=CC(=C(C=C1)N)C.Cl,Active,,,,MOUSE,CD-1/FEMALE,ORAL,,LUNG,POSITIVE,"[WEISBURGER,EK, RUSSFIELD,AB, HOMBURGER,F, WEISBURGER,JH, BOGER,E, VAN DONGEN,CG AND CHU,KC; TESTING OF TWENTY-ONE ENVIRONMENTAL AROMATIC AMINES OR DERIVATIVES FOR LONG-TERM TOXICITY OR CARCINOGENICITY; J. ENVIRON. PATHOL. TOXICOL. 2:325-356, 1978]"
1501,363898206,8413,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N)C)N,Active,,,,RAT,,SUBCUTANEOUS,,EAR (ZYMBAL GLAND),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 87 Y72]"
1502,363898207,6598,CN(C)C(=O)Cl,Active,,,,MOUSE,,"INTRAPERITONEAL, SUBCUTANEOUS",,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 77 Y76]"
1503,363898207,6598,CN(C)C(=O)Cl,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 77 Y76]"
1504,363898208,5976,CN(C)N,Active,,,,MOUSE,,ORAL,,LUNG; BLOOD VESSELS; LIVER; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 137 Y74][TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975, ]"
1505,363898208,5976,CN(C)N,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 8; 17; 35 MG/KG BW IN 0.9% SALINE 1/WK FOR LIFE (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[JEONG,JY AND KAMINO,K; LACK OF TUMORIGENIC ACTIVITY OF 1,1-DIMETHYLHYDRAZINE IN SYRIAN GOLDEN HAMSTERS TREATED BY SUBCUTANEOUS INJECTION; EXP. TOXICOL. PATHOL. 45(1):61-63, 1993]"
1506,363898208,5976,CN(C)N,Inactive,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 8; 17; 35 MG/KG BW IN 0.9% SALINE 1/WK FOR LIFE (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[JEONG,JY AND KAMINO,K; LACK OF TUMORIGENIC ACTIVITY OF 1,1-DIMETHYLHYDRAZINE IN SYRIAN GOLDEN HAMSTERS TREATED BY SUBCUTANEOUS INJECTION; EXP. TOXICOL. PATHOL. 45(1):61-63, 1993]"
1507,363898209,1322,CNNC,Active,,,,HAMSTER,,ORAL,,BLOOD VESSELS; INTESTINES; LIVER,POSITIVE,"[TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 145 Y74]"
1508,363898209,1322,CNNC,Active,,,,HAMSTER,,INTRAMUSCULAR,,STOMACH; LIVER; INTESTINES,POSITIVE,"[TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 145 Y74]"
1509,363898209,1322,CNNC,Active,,,,MOUSE,,ORAL,,LUNG; BLOOD VESSELS,POSITIVE,"[TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 145 Y74]"
1510,363898209,1322,CNNC,Active,,,,MOUSE,,SUBCUTANEOUS,,COLON; INTESTINES,POSITIVE,"[TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 145 Y74]"
1511,363898209,1322,CNNC,Active,,,,RAT,,ORAL,,INTESTINES; LIVER,POSITIVE,"[TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 145 Y74]"
1512,363898209,1322,CNNC,Active,,,,RAT,,SUBCUTANEOUS,,COLON; INTESTINES; LIVER,POSITIVE,"[TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 145 Y74]"
1513,363898209,1322,CNNC,Inactive,,,,MONKEY,CEBUS APELLA/MALE,SUBCUTANEOUS,0; 25 MG/KG BW 1/WK FOR 16 WK (STUDY DURATION: 20 MO),,NEGATIVE,"[NEGRETTE,MS BORDA,JT MONTENEGRO,MA LERTORA,WJ AND GIMENO,EJ; FAILURE TO INDUCE TUMORS IN THE LARGE INTESTINE OF CAPUCHIN MONKEYS (CEBUS APELLA) BY USING 1,2-DIMETHYLHYDRAZINE; J. MED. PRIMATOL. 29(5):361-369, 2000]"
1514,363898210,9380,CNNC.Cl.Cl,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,30 MG/KG IN NACL-EDTA 1/WK FOR 10 OR 15 WK,"INTESTINES: CARCINOMA (INVASIVE, INCLUDING MUCIN AND NONMUCIN PRODUCING), CARCINOMA (NONINVASIVE)",POSITIVE,"[TAKEMIYA,M, MIYAYAMA,H AND TAKEUCHI,T; PATHOGENESIS OF 1,2-DIMETHYLHYDRAZINE- INDUCED CARCINOMAS IN RAT INTESTINE I. THE INDUCTION OF MUCIN PRODUCING CARCINOMAS IN RAT INTESTINE; ACTA PATHOL. JPN. 32(2):257-261, 1982]"
1515,363898210,9380,CNNC.Cl.Cl,Active,,,,RAT,WISTAR/FEMALE,SUBCUTANEOUS,0; 200 MG/KG BW ONCE (STUDY DURATION: 1 YR),KIDNEY: TUMOR,POSITIVE,"[SADRUDIN,AA, LEWIN,MR AND CRUSE,JP; INDUCTION OF NEPHROBLASTOMA-LIKE RENAL TUMORS IN RATS BY A SINGLE DOSE OF 1,2-DIMETHYLHYDRAZINE; J. PATHOL. 145(3):229-239, 1985]"
1516,363898211,6124,CN(C)N=O,Active,,,,DUCK,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1517,363898211,6124,CN(C)N=O,Active,,,,FISH,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1518,363898211,6124,CN(C)N=O,Active,,,,GUINEA PIG,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1519,363898211,6124,CN(C)N=O,Active,,,,HAMSTER,,SUBCUTANEOUS,,LIVER; KIDNEY; NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1520,363898211,6124,CN(C)N=O,Active,,,,HAMSTER,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1521,363898211,6124,CN(C)N=O,Active,,,,MOUSE,,ORAL,,LIVER; LUNG; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1522,363898211,6124,CN(C)N=O,Active,,,,MOUSE,,INHALATION,,LIVER; LUNG; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1523,363898211,6124,CN(C)N=O,Active,,,,MOUSE,,INTRAPERITONEAL,,LIVER; LUNG; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1524,363898211,6124,CN(C)N=O,Active,,,,MOUSE,,SUBCUTANEOUS,,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1525,363898211,6124,CN(C)N=O,Active,,,,RABBIT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1526,363898211,6124,CN(C)N=O,Active,,,,RAT,,INHALATION,,NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1527,363898211,6124,CN(C)N=O,Active,,,,RAT,,"SUBCUTANEOUS, INTRAPERITONEAL",,KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1528,363898211,6124,CN(C)N=O,Active,,,,RAT,,ORAL,,LIVER; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 125 Y78]"
1529,363898211,6124,CN(C)N=O,Inactive,,,,MOUSE,C3H/MALE,TRANSPLACENTAL,0; 0.1 MMOL IN 0.9% STERILE SALINE (7.4 MG/KG) ON DAY 16 OF GESTATION (STUDY DURATION: LIFETIME),,NEGATIVE,"[ANDERSON,LM, HAGIWARA,A, KOVATCH,RM, REHM,S AND RICE,JM; TRANSPLACENTAL INITIATION OF LIVER, LUNG, NEUROGENIC, AND CONNECTIVE TISSUE TUMORS BY N-NITROSO COMPOUNDS IN MICE; FUNDAM. APPL. TOXICOL. 12(3):604-620, 1989]"
1530,363898211,6124,CN(C)N=O,Active,,,,MOUSE,C3H/FEMALE,TRANSPLACENTAL,0; 0.1 MMOL IN 0.9% STERILE SALINE (7.4 MG/KG) ON DAY 16 OF GESTATION (STUDY DURATION: LIFETIME),LIVER: CARCINOMA,POSITIVE,"[ANDERSON,LM, HAGIWARA,A, KOVATCH,RM, REHM,S AND RICE,JM; TRANSPLACENTAL INITIATION OF LIVER, LUNG, NEUROGENIC, AND CONNECTIVE TISSUE TUMORS BY N-NITROSO COMPOUNDS IN MICE; FUNDAM. APPL. TOXICOL. 12(3):604-620, 1989]"
1531,363898211,6124,CN(C)N=O,Active,,,,MOUSE,C3H/MALE,TRANSPLACENTAL,0; 0.1 MMOL IN 0.9% STERILE SALINE (7.4 MG/KG) ON DAY 19 OF GESTATION (STUDY DURATION: LIFETIME),LIVER: CARCINOMA,POSITIVE,"[ANDERSON,LM, HAGIWARA,A, KOVATCH,RM, REHM,S AND RICE,JM; TRANSPLACENTAL INITIATION OF LIVER, LUNG, NEUROGENIC, AND CONNECTIVE TISSUE TUMORS BY N-NITROSO COMPOUNDS IN MICE; FUNDAM. APPL. TOXICOL. 12(3):604-620, 1989]"
1532,363898211,6124,CN(C)N=O,Active,,,,MOUSE,C3H/FEMALE,TRANSPLACENTAL,0; 0.1 MMOL IN 0.9% STERILE SALINE (7.4 MG/KG) ON DAY 19 OF GESTATION (STUDY DURATION: LIFETIME),LIVER: CARCINOMA,POSITIVE,"[ANDERSON,LM, HAGIWARA,A, KOVATCH,RM, REHM,S AND RICE,JM; TRANSPLACENTAL INITIATION OF LIVER, LUNG, NEUROGENIC, AND CONNECTIVE TISSUE TUMORS BY N-NITROSO COMPOUNDS IN MICE; FUNDAM. APPL. TOXICOL. 12(3):604-620, 1989]"
1533,363898211,6124,CN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRATRACHEAL,0; 0.05; 0.1 MG IN PHOSPHATE BUFFER 1/WK FOR 15 WK (TOTAL DOSE: 0; 0.75; 0.5 MG) (STUDY DURATION: LIFESPAN),"LIVER: HEMANGIOSARCOMA, TUMOR",POSITIVE,"[TANAKA,A, HISANAGA,A, INAMASU,T, HIRATA,M AND ISHINISHI,N; A COMPARISON OF THE CARCINOGENICITY OF N-NITROSODIETHYLAMINE AND N-NITROSODIMETHYLAMINE AFTER INTRATRACHEAL INSTILLATION INTO SYRIAN GOLDEN HAMSTERS; FOOD CHEM. TOXICOL. 26(10):847-850, 1988]"
1534,363898211,6124,CN(C)N=O,Inactive,,,,HAMSTER,SYRIAN/MALE,INTRATRACHEAL,0; 0.5 MG IN PHOSPHATE BUFFER ONCE (STUDY DURATION: LIFESPAN),,NEGATIVE,"[TANAKA,A, HISANAGA,A, INAMASU,T, HIRATA,M AND ISHINISHI,N; A COMPARISON OF THE CARCINOGENICITY OF N-NITROSODIETHYLAMINE AND N-NITROSODIMETHYLAMINE AFTER INTRATRACHEAL INSTILLATION INTO SYRIAN GOLDEN HAMSTERS; FOOD CHEM. TOXICOL. 26(10):847-850, 1988]"
1535,363898211,6124,CN(C)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 0.04; 0.2; 1 PPM 4-5 HR/D 4 D/WK FOR 207 D (ESTIMATED DAILY UPTAKE OF 0; 10; 40; 180 UG/KG) (STUDY DURATION: 207 D),NASAL CAVITY: TUMOR,POSITIVE,"[KLEIN,RG, JANOWSKY,I, POOL-ZOBEL,BL, SCHMEZER,P, HERMANN,R, AMELUNG,F, SPIEGELHALDER,B AND ZELLER,WJ; EFFECTS OF LONG-TERM INHALATION OF N-NITROSODIMETHYLAMINE IN RATS; IARC SCI. PUBL. 105(RELEVANCE HUM. CANCER N-NITROSO COMPD., TOB. MYCOTOXINS):322-328, 1991]"
1536,363898211,6124,CN(C)N=O,Active,,,,RAT,WISTAR/MALE,ORAL,"0; 0.033; 0.066; 0.132; 0.264; 0.528; 1.056; 1.584; 2.112; 2.640; 3.168; 4.224; 5.280; 6.336; 8.448; 16.896 PPM IN DRINKING WATER (10% SACRIFICED AT 12 MO, 10% SACRIFICED AT 18 MO) (STUDY DURATION: LIFESPAN)","LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOMA; BILE DUCT: TUMOR",POSITIVE,"[PETO,R, GRAY,R, BRANTOM,P AND GRASSO,P; EFFECTS ON 4080 RATS OF CHRONIC INGESTION OF N-NITROSODIETHYLAMINE OR N-NITROSODIMETHYLAMINE: A DETAILED DOSE- RESPONSE STUDY; CANCER RES. 51(23, PT.2):6415-6451, 1991]"
1537,363898211,6124,CN(C)N=O,Active,,,,RAT,WISTAR/FEMALE,ORAL,"0; 0.033; 0.066; 0.132; 0.264; 0.528; 1.056; 1.584; 2.112; 2.640; 3.168; 4.224; 5.280; 6.336; 8.448; 16.896 PPM IN DRINKING WATER (10% SACRIFICED AT 12 MO, 10% SACRIFICED AT 18 MO) (STUDY DURATION: LIFESPAN)","LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOMA; BILE DUCT: TUMOR",POSITIVE,"[PETO,R, GRAY,R, BRANTOM,P AND GRASSO,P; EFFECTS ON 4080 RATS OF CHRONIC INGESTION OF N-NITROSODIETHYLAMINE OR N-NITROSODIMETHYLAMINE: A DETAILED DOSE- RESPONSE STUDY; CANCER RES. 51(23, PT.2):6415-6451, 1991]"
1538,363898211,6124,CN(C)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 2 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 30 WK (TOTAL DOSE: 1.6 MMOL) (STUDY DURATION: LIFESPAN),KIDNEY: MESENCHYMAL NEOPLASM; LUNG: TUMOR,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
1539,363898211,6124,CN(C)N=O,Active,,,,RAT,WISTAR/FEMALE,INTRAPERITONEAL,0; 0.04% IN 0.1-0.2 ML PHYSIOLOGICAL SALINE 1/D FOR D 1-5 OF LIFE (TOTAL DOSE 0.2 MG) (STUDY DURATION: LIFESPAN OR 1 YR),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOMA, CHOLANGIOMA, ANGIOMA; KIDNEY: MESENCHYMAL TUMOR, EPITHELIAL TUMOR",POSITIVE,"[SYKORA,I, TRETINIK,P AND VORTEL,V; POSTNATAL CARCINOGENIC STUDY OF DIMETHYLNITROSAMINE IN RATS; NEOPLASMA 32(1):63-72, 1985]"
1540,363898211,6124,CN(C)N=O,Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 0.04% IN 0.1-0.2 ML PHYSIOLOGICAL SALINE 1/D FOR D 1-5 OF LIFE (TOTAL DOSE 0.2 MG) (STUDY DURATION: LIFESPAN OR 1 YR),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOMA, CHOLANGIOMA; KIDNEY: MESENCHYMAL TUMOR, EPITHELIAL TUMOR",POSITIVE,"[SYKORA,I, TRETINIK,P AND VORTEL,V; POSTNATAL CARCINOGENIC STUDY OF DIMETHYLNITROSAMINE IN RATS; NEOPLASMA 32(1):63-72, 1985]"
1541,363898211,6124,CN(C)N=O,Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 0.04% IN 0.1-0.2 ML PHYSIOLOGICAL SALINE 1/D FOR D 1-10 OF LIFE (TOTAL DOSE 0.4 MG) (STUDY DURATION: LIFESPAN OR 1 YR),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOMA, CHOLANGIOMA, ANGIOMA; KIDNEY: MESENCHYMAL TUMOR, EPITHELIAL TUMOR",POSITIVE,"[SYKORA,I, TRETINIK,P AND VORTEL,V; POSTNATAL CARCINOGENIC STUDY OF DIMETHYLNITROSAMINE IN RATS; NEOPLASMA 32(1):63-72, 1985]"
1542,363898211,6124,CN(C)N=O,Active,,,,RAT,WISTAR/FEMALE,INTRAPERITONEAL,0; 0.04% IN 0.1-0.2 ML PHYSIOLOGICAL SALINE 1/D FOR D 1-10 OF LIFE (TOTAL DOSE 0.4 MG) (STUDY DURATION: LIFESPAN OR 1 YR),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOMA, CHOLANGIOMA, ANGIOMA; KIDNEY: MESENCHYMAL TUMOR, EPITHELIAL TUMOR",POSITIVE,"[SYKORA,I, TRETINIK,P AND VORTEL,V; POSTNATAL CARCINOGENIC STUDY OF DIMETHYLNITROSAMINE IN RATS; NEOPLASMA 32(1):63-72, 1985]"
1543,363898211,6124,CN(C)N=O,Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 0.04% IN 0.1-0.2 ML PHYSIOLOGICAL SALINE 1/D FOR D 1-20 OF LIFE (TOTAL DOSE 0.5 MG) (STUDY DURATION: LIFESPAN OR 1 YR),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOMA, ANGIOMA; KIDNEY: MESENCHYMAL TUMOR",POSITIVE,"[SYKORA,I, TRETINIK,P AND VORTEL,V; POSTNATAL CARCINOGENIC STUDY OF DIMETHYLNITROSAMINE IN RATS; NEOPLASMA 32(1):63-72, 1985]"
1544,363898211,6124,CN(C)N=O,Active,,,,RAT,WISTAR/FEMALE,INTRAPERITONEAL,0; 0.04% IN 0.1-0.2 ML PHYSIOLOGICAL SALINE 1/D FOR D 1-20 OF LIFE (TOTAL DOSE 0.5 MG) (STUDY DURATION: LIFESPAN OR 1 YR),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOMA, ANGIOMA; KIDNEY: MESENCHYMAL TUMOR",POSITIVE,"[SYKORA,I, TRETINIK,P AND VORTEL,V; POSTNATAL CARCINOGENIC STUDY OF DIMETHYLNITROSAMINE IN RATS; NEOPLASMA 32(1):63-72, 1985]"
1545,363898211,6124,CN(C)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 5; 20 UMOL TOTAL DOSE ADMINISTERED IN SUBDOSES 3/WK FOR 7 WK (STUDY DURATION: 37 WK),LUNG: TUMOR,POSITIVE,"[HOFFMANN,D, DJORDJEVIC,MV, RIVENSON,A, ZANG,E, DESAI,D AND AMIN,S; A STUDY OF TOBACCO CARCINOGENESIS. LI. RELATIVE POTENCIES OF TOBACCO-SPECIFIC N-NITROSAMINES AS INDUCERS OF LUNG TUMORS IN A/J MICE; CANCER LETT. 71(1-3): 25-30, 1993]"
1546,363898212,51168,CC1=CC=CC=C1C2=CC(=C(C=C2)N=O)C,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0.15 MMOL/KG IN PEANUT OIL 1/WK FOR 37 WK (TOTAL DOSE 5.6 MMOL/KG),"INJECTION SITE: RHABDOMYOSARCOMA, SPINDLE CELL CARCINOMA, PLEIOMORPHIC SARCOMA",POSITIVE,"[HECHT,SS, EL-BAYOUMY,K, RIVENSON,A AND FIALA,ES; BIOASSAY FOR CARCINOGENICITY OF 3,2'- DIMETHYL-4-NITROSOBIPHENYL, O-NITROSO-TOLUENE, NITROSOBENZENE AND THE CORRESPONDING AMINES IN SYRIAN GOLDEN HAMSTERS; CANCER LETT. 20:349-354, 1983]"
1547,363898212,51168,CC1=CC=CC=C1C2=CC(=C(C=C2)N=O)C,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0.15 MMOL/KG IN PEANUT OIL 1/WK FOR 37 WK (TOTAL DOSE 5.6 MMOL/KG),"INJECTION SITE: RHABDOMYOSARCOMA, PLEIOMORPHIC SARCOMA",POSITIVE,"[HECHT,SS, EL-BAYOUMY,K, RIVENSON,A AND FIALA,ES; BIOASSAY FOR CARCINOGENICITY OF 3,2'- DIMETHYL-4-NITROSOBIPHENYL, O-NITROSO-TOLUENE, NITROSOBENZENE AND THE CORRESPONDING AMINES IN SYRIAN GOLDEN HAMSTERS; CANCER LETT. 20:349-354, 1983]"
1548,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",SUBCUTANEOUS,8; 16; 32 MG/KG 1/WK FOR LIFE,NASAL CAVITY; LARYNX; TRACHEA; LUNG; FORESTOMACH; PANCREAS; VAGINA,POSITIVE,"[ALTHOFF,J, GRANDJEAN,C AND GOLD,B; CARCINOGENIC EFFECT OF SUBCUTANEOUSLY ADMINISTERED N-NITROSO-2,6-DIMETHYLMORPHOLINE IN SYRIAN GOLDEN HAMSTERS; J. NATL. CANCER INST. 60(1):197-199, 1978]"
1549,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",GAVAGE,9-74 MG/KG 1/WK FOR LIFE,PANCREAS; TRACHEA; LUNG; LIVER; NASAL CAVITY; FORESTOMACH; GALL BLADDER; LARYNX,POSITIVE,"[REZNIK,G, MOHR,U, AND LIJINSKY,W; CARCINOGENIC EFFECT OF N-NITROSO-2,6-DIMETHYLMORPHOLINE IN SYRIAN GOLDEN HAMSTERS; J. NATL. CANCER INST. 60(2):371-378, 1978]"
1550,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,20 MG/L IN DRINKING WATER FOR 30 WK,"ESOPHAGUS: PAPILLOMA, CARCINOMA; TONGUE: PAPILLOMA, CARCINOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARATIVE CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOTETRAHYDROOXAZINE IN RATS; CARCINOGENESIS 3:911-915, 1982]"
1551,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,50 MG/L IN DRINKING WATER FOR 22 WK,"ESOPHAGUS: PAPILLOMA, CARCINOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARATIVE CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOTETRAHYDROOXAZINE IN RATS; CARCINOGENESIS 3:911-915, 1982]"
1552,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,50 MG/L IN DRINKING WATER (20 ML/D 5 D/WK) FOR 30 WK,"ESOPHAGUS: PAPILLOMA, SQUAMOUS CELL CARCINOMA; NASAL TURBINATES: ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 508]"
1553,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 6 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 18 WK (TOTAL DOSE 1.5 MMOL) (STUDY DURATION: LIFESPAN),ESOPHAGUS: TUMOR,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
1554,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",ORAL,0; 1556 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),LIVER: CARCINOMA; STOMACH: PAPILLOMA,POSITIVE,"[HENDRICKS,JD, SHELTON,DW, LOVELAND,PM, PEREIRA,CB AND BAILEY,GS; CARCINOGENICITY OF DIETARY DIMETHYLNITROSOMORPHOLINE, N-METHYL-N'-NITRO-N-NITROSOGUANIDINE, AND DIBROMOETHANE IN RAINBOW TROUT; TOXICOL. PATHOL. 23(4):447-457, 1995]"
1555,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",SUBCUTANEOUS,0; 1/100; 1/10 OF LD50 1/WK FOR LIFE (STUDY DURATION: LIFETIME),ESOPHAGUS: CARCINOMA,POSITIVE,"[CARDESA,A, BOMBI,JA, PERA,M, FERNANDEZ,PL, CAMPO,E, PERA,C AND MOHR,U; SPECTRUM OF GLANDULAR DIFFERENTIATION IN EXPERIMENTAL CARCINOMA OF THE ESOPHAGUS INDUCED BY 2,6-DIMETHYLNITROSOMORPHOLINE UNDER THE INFLUENCE OF ESOPHAGOJEJUNOSTOMY; EXP. TOXICOL. PATHOL. 46(1):41-49, 1994]"
1556,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",SUBCUTANEOUS,0; 1/100; 1/10 OF LD50 1/WK FOR LIFE TO RATS WITH ESOPHAGOJEJUNOSTOMY (STUDY DURATION: LIFETIME),ESOPHAGUS: CARCINOMA,POSITIVE,"[CARDESA,A, BOMBI,JA, PERA,M, FERNANDEZ,PL, CAMPO,E, PERA,C AND MOHR,U; SPECTRUM OF GLANDULAR DIFFERENTIATION IN EXPERIMENTAL CARCINOMA OF THE ESOPHAGUS INDUCED BY 2,6-DIMETHYLNITROSOMORPHOLINE UNDER THE INFLUENCE OF ESOPHAGOJEJUNOSTOMY; EXP. TOXICOL. PATHOL. 46(1):41-49, 1994]"
1557,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,HAMSTER,EUROPEAN/MALE,SUBCUTANEOUS,0; 85 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),NASAL CAVITY: TUMOR; LARYNX: TUMOR; TRACHEA: TUMOR; LUNG: TUMOR,POSITIVE,"[ALTHOFF,J, MOHR,U AND LIJINSKY,W; COMPARATIVE STUDY ON THE CARCINOGENICITY OF N-NITROSO-2,6-DIMETHYLMORPHOLINE IN THE EUROPEAN HAMSTER; J. CANCER RES. CLIN. ONCOL. 109(3):183-187, 1985]"
1558,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,HAMSTER,EUROPEAN/FEMALE,SUBCUTANEOUS,0; 85 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),NASAL CAVITY: TUMOR; LARYNX: TUMOR; TRACHEA: TUMOR; LUNG: TUMOR,POSITIVE,"[ALTHOFF,J, MOHR,U AND LIJINSKY,W; COMPARATIVE STUDY ON THE CARCINOGENICITY OF N-NITROSO-2,6-DIMETHYLMORPHOLINE IN THE EUROPEAN HAMSTER; J. CANCER RES. CLIN. ONCOL. 109(3):183-187, 1985]"
1559,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,HAMSTER,EUROPEAN/MALE,GAVAGE,0; 112 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),NASAL CAVITY: TUMOR; LUNG: TUMOR,POSITIVE,"[ALTHOFF,J, MOHR,U AND LIJINSKY,W; COMPARATIVE STUDY ON THE CARCINOGENICITY OF N-NITROSO-2,6-DIMETHYLMORPHOLINE IN THE EUROPEAN HAMSTER; J. CANCER RES. CLIN. ONCOL. 109(3):183-187, 1985]"
1560,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,HAMSTER,EUROPEAN/FEMALE,GAVAGE,0; 112 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),NASAL CAVITY: TUMOR; TRACHEA: TUMOR; LUNG: TUMOR,POSITIVE,"[ALTHOFF,J, MOHR,U AND LIJINSKY,W; COMPARATIVE STUDY ON THE CARCINOGENICITY OF N-NITROSO-2,6-DIMETHYLMORPHOLINE IN THE EUROPEAN HAMSTER; J. CANCER RES. CLIN. ONCOL. 109(3):183-187, 1985]"
1561,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,HAMSTER,EUROPEAN/MALE,GAVAGE,0; 37 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),NASAL CAVITY: TUMOR; LIVER: HEMANGIOENDOTHELIOMA,POSITIVE,"[ALTHOFF,J, MOHR,U AND LIJINSKY,W; COMPARATIVE STUDY ON THE CARCINOGENICITY OF N-NITROSO-2,6-DIMETHYLMORPHOLINE IN THE EUROPEAN HAMSTER; J. CANCER RES. CLIN. ONCOL. 109(3):183-187, 1985]"
1562,363898213,15081,CC1CN(CC(O1)C)N=O,Active,,,,HAMSTER,EUROPEAN/FEMALE,GAVAGE,0; 37 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),NASAL CAVITY: TUMOR; TRACHEA: TUMOR; LIVER: HEMANGIOENDOTHELIOMA,POSITIVE,"[ALTHOFF,J, MOHR,U AND LIJINSKY,W; COMPARATIVE STUDY ON THE CARCINOGENICITY OF N-NITROSO-2,6-DIMETHYLMORPHOLINE IN THE EUROPEAN HAMSTER; J. CANCER RES. CLIN. ONCOL. 109(3):183-187, 1985]"
1563,363898214,171407,CN(C)C(=O)NN=O,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,40 MG/KG 1/WK,FORESTOMACH: SQUAMOUS CELL CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA OR ADENOACANTHOMA; UTERUS: ADENOACANTHOMA,POSITIVE,"[HIRAKI,S; N,N'-DIMETHYLNITROSOUREA-INDUCED TUMORS IN MICE AND SYRIAN HAMSTERS; ACTA MED. OKAYAMA 28:333-351, 1974]"
1564,363898214,171407,CN(C)C(=O)NN=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,40 MG/KG 1/WK,FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[HIRAKI,S; N,N'-DIMETHYLNITROSOUREA-INDUCED TUMORS IN MICE AND SYRIAN HAMSTERS; ACTA MED. OKAYAMA 28:333-351, 1974]"
1565,363898214,171407,CN(C)C(=O)NN=O,Active,,,,MOUSE,C3H/FEMALE,SUBCUTANEOUS,80 MG/KG 1/WK (TOTAL AVE DOSE 1015 MG/KG),LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA,POSITIVE,"[HIRAKI,S; N,N'-DIMETHYLNITROSOUREA-INDUCED TUMORS IN MICE AND SYRIAN HAMSTERS; ACTA MED. OKAYAMA 28:333-351, 1974]"
1566,363898214,171407,CN(C)C(=O)NN=O,Active,,,,MOUSE,C3H/MALE,SUBCUTANEOUS,80 MG/KG 1/WK (TOTAL AVE DOSE 1073 MG/KG),LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA,POSITIVE,"[HIRAKI,S; N,N'-DIMETHYLNITROSOUREA-INDUCED TUMORS IN MICE AND SYRIAN HAMSTERS; ACTA MED. OKAYAMA 28:333-351, 1974]"
1567,363898215,6497,COS(=O)(=O)OC,Active,,,,RAT,,INHALATION,,NASAL CAVITY; BRAIN,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 271 Y74]"
1568,363898215,6497,COS(=O)(=O)OC,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 271 Y74]"
1569,363898216,8441,COC(=O)C1=CC=C(C=C1)C(=O)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-121 Y79]"
1570,363898216,8441,COC(=O)C1=CC=C(C=C1)C(=O)OC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105-106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-121 Y79]"
1571,363898216,8441,COC(=O)C1=CC=C(C=C1)C(=O)OC,Inactive,,,,RAT,F344/MALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105-106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-121 Y79]"
1572,363898216,8441,COC(=O)C1=CC=C(C=C1)C(=O)OC,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104-105 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-121 Y79]"
1573,363898217,23565,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C.O.O.O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 750; 1500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-318 Y87]"
1574,363898217,23565,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C.O.O.O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 1500; 3000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-318 Y87]"
1575,363898217,23565,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C.O.O.O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 1500; 3000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-318 Y87]"
1576,363898217,23565,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C.O.O.O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 1500; 3000 MG/KG IN CORN OIL 5 D/WK FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[DUNNICK,JK, EUSTIS,SL, HUFF,JE AND HASEMAN,JK; TWO-YEAR TOXICITY AND CARCINOGENICITY STUDIES OF AMPICILLIN TRIHYDRATE AND PENICILLIN VK IN RODENTS; FUNDAM. APPL. TOXICOL. 12(2):252-257, 1989]"
1577,363898217,23565,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C.O.O.O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 1500; 3000 MG/KG IN CORN OIL 5 D/WK FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[DUNNICK,JK, EUSTIS,SL, HUFF,JE AND HASEMAN,JK; TWO-YEAR TOXICITY AND CARCINOGENICITY STUDIES OF AMPICILLIN TRIHYDRATE AND PENICILLIN VK IN RODENTS; FUNDAM. APPL. TOXICOL. 12(2):252-257, 1989]"
1578,363898217,23565,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C.O.O.O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 750; 1500 MG/KG IN CORN OIL 5 D/WK FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[DUNNICK,JK, EUSTIS,SL, HUFF,JE AND HASEMAN,JK; TWO-YEAR TOXICITY AND CARCINOGENICITY STUDIES OF AMPICILLIN TRIHYDRATE AND PENICILLIN VK IN RODENTS; FUNDAM. APPL. TOXICOL. 12(2):252-257, 1989]"
1579,363898217,23565,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C.O.O.O,Unspecified,,,,RAT,F344/MALE,GAVAGE,0; 750; 1500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),ADRENAL MEDULLA: PHEOCHROMOCYTOMAS; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-318 Y87]"
1580,363898218,8461,CC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.008; 0.04% IN DIET FOR 78 WK (STUDY DURATION: 91 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-54 Y78]"
1581,363898218,8461,CC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.008; 0.04% IN DIET FOR 78 WK (STUDY DURATION: 91 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-54 Y78]"
1582,363898218,8461,CC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,ORAL,0; 0.008 (TWA); 0.02% IN DIET FOR 78 WK (STUDY DURATION: 104 WK),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-54 Y78]"
1583,363898218,8461,CC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 0.008 (TWA); 0.02% IN DIET FOR 78 WK (STUDY DURATION: 104 WK),INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE AND SKIN): FIBROMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-54 Y78]"
1584,363898219,31275,C1COCCO1,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.5; 1.0% (V/V) IN DRINKING WATER,LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-80 Y78]"
1585,363898219,31275,C1COCCO1,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1.0% (V/V) IN DRINKING WATER,LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-80 Y78]"
1586,363898219,31275,C1COCCO1,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 0.5; 1.0% (V/V) IN DRINKING WATER,NASAL TURBINATES: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-80 Y78]"
1587,363898219,31275,C1COCCO1,Active,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 0.5; 1.0% (V/V) IN DRINKING WATER,NASAL TURBINATES: SQUAMOUS CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-80 Y78]"
1588,363898219,31275,C1COCCO1,Active,,,,RAT,"SHERMAN/MALE,FEMALE",ORAL,0.01; 0.1; 1.0% IN DRINKING WATER FOR UP TO 716 D,"LIVER: HEPATOCELLULAR CARCINOMA, CHOLANGIOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 247 Y76]"
1589,363898219,31275,C1COCCO1,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0.75; 1.0; 1.4; 1.8% IN DRINKING WATER FOR 13 MO,"NASAL CAVITY: SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA; LIVER: HEPATOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 247 Y76]"
1590,363898219,31275,C1COCCO1,Active,,,,RAT,WISTAR/MALE,ORAL,1% IN DRINKING WATER FOR 63 WK,"LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 247 Y76]"
1591,363898219,31275,C1COCCO1,Active,,,,RAT,F344/MALE,ORAL,0; 200; 1000; 5000 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 105 WK),"NASAL CAVITY: TUMOR; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; PERITONEUM: MESOTHELIOMA; SUBCUTIS: FIBROMA",POSITIVE,"[YAMAZAKI,K, OHNO,H, ASAKURA,M, NARUMI,A, OHBAYASHI,H, FUJITA,H, OHNISHI,M, KAKAGIRI,T, SENOH,H, YAMANOUCHI,K, NAKAYAMA,E, YAMAMOTO,S, NOGUCHI,T, NAGANO,K, ENOMOTO,M AND SAKABE,H; TWO-YEAR TOXICOLOGICAL AND CARCINOGENESIS STUDIES OF 1,4-DIOXANE IN F344 RATS AND BDF1 MICE. DRINKING STUDIES; PROC. ICMR SEMIN. 193-198, 1994]"
1592,363898219,31275,C1COCCO1,Active,,,,RAT,F344/FEMALE,ORAL,0; 200; 1000; 5000 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 105 WK),"NASAL CAVITY: TUMOR; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; MAMMARY GLAND: TUMOR",POSITIVE,"[YAMAZAKI,K, OHNO,H, ASAKURA,M, NARUMI,A, OHBAYASHI,H, FUJITA,H, OHNISHI,M, KAKAGIRI,T, SENOH,H, YAMANOUCHI,K, NAKAYAMA,E, YAMAMOTO,S, NOGUCHI,T, NAGANO,K, ENOMOTO,M AND SAKABE,H; TWO-YEAR TOXICOLOGICAL AND CARCINOGENESIS STUDIES OF 1,4-DIOXANE IN F344 RATS AND BDF1 MICE. DRINKING STUDIES; PROC. ICMR SEMIN. 193-198, 1994]"
1593,363898219,31275,C1COCCO1,Active,,,,MOUSE,BDF1/MALE,ORAL,0; 500; 2000; 8000 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[YAMAZAKI,K, OHNO,H, ASAKURA,M, NARUMI,A, OHBAYASHI,H, FUJITA,H, OHNISHI,M, KAKAGIRI,T, SENOH,H, YAMANOUCHI,K, NAKAYAMA,E, YAMAMOTO,S, NOGUCHI,T, NAGANO,K, ENOMOTO,M AND SAKABE,H; TWO-YEAR TOXICOLOGICAL AND CARCINOGENESIS STUDIES OF 1,4-DIOXANE IN F344 RATS AND BDF1 MICE. DRINKING STUDIES; PROC. ICMR SEMIN. 193-198, 1994]"
1594,363898219,31275,C1COCCO1,Active,,,,MOUSE,BDF1/FEMALE,ORAL,0; 500; 2000; 8000 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[YAMAZAKI,K, OHNO,H, ASAKURA,M, NARUMI,A, OHBAYASHI,H, FUJITA,H, OHNISHI,M, KAKAGIRI,T, SENOH,H, YAMANOUCHI,K, NAKAYAMA,E, YAMAMOTO,S, NOGUCHI,T, NAGANO,K, ENOMOTO,M AND SAKABE,H; TWO-YEAR TOXICOLOGICAL AND CARCINOGENESIS STUDIES OF 1,4-DIOXANE IN F344 RATS AND BDF1 MICE. DRINKING STUDIES; PROC. ICMR SEMIN. 193-198, 1994]"
1595,363898220,6531,CCOP(=S)(OCC)SC1C(OCCO1)SP(=S)(OCC)OCC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 467; 935 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-125 Y78]"
1596,363898220,6531,CCOP(=S)(OCC)SC1C(OCCO1)SP(=S)(OCC)OCC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 284; 567 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-125 Y78]"
1597,363898220,6531,CCOP(=S)(OCC)SC1C(OCCO1)SP(=S)(OCC)OCC,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 45; 90 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-125 Y78]"
1598,363898220,6531,CCOP(=S)(OCC)SC1C(OCCO1)SP(=S)(OCC)OCC,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 90; 180 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-125 Y78]"
1599,363898221,12130,CCCN(CCC)N=O,Active,,,,HAMSTER,,SUBCUTANEOUS,,RESPIRATORY TRACT; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 177 Y78]"
1600,363898221,12130,CCCN(CCC)N=O,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 177 Y78]"
1601,363898221,12130,CCCN(CCC)N=O,Active,,,,RAT,,SUBCUTANEOUS,,NASAL CAVITY; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 177 Y78]"
1602,363898222,23674183,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].O.[Na+],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.125; 0.5% IN DRINKING WATER FOR 78 WK (STUDY DURATION: 86 WK),LIVER: ADENOMA,POSITIVE,"[KUMAGAI,H, KAWAURA,A, SHIBATA,M AND OTSUKA,H; CARCINOGENICITY OF DIPYRONE IN (C57BL/6 X C3H)F1 MICE; J. NATL. CANCER INST. 71(6):1295-1297, 1983]"
1603,363898222,23674183,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].O.[Na+],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.25; 1% IN DRINKING WATER FOR 78 WK (STUDY DURATION: 86 WK),LIVER: ADENOMA,POSITIVE,"[KUMAGAI,H, KAWAURA,A, SHIBATA,M AND OTSUKA,H; CARCINOGENICITY OF DIPYRONE IN (C57BL/6 X C3H)F1 MICE; J. NATL. CANCER INST. 71(6):1295-1297, 1983]"
1604,363898222,23674183,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].O.[Na+],Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 24 MO (STUDY DURATION: 30 MO),,NEGATIVE,"[DONAUBAUER,HH, KIEF,H, KRAMER,M, KRIEG,K, MAYER,D AND SCHUTZ,E; INVESTIGATIONS ON THE CARCINOGENICITY OF DIPYRONE IN RATS; TOXICOL. APPL. PHARMACOL. 81: 443-451, 1985]"
1605,363898222,23674183,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].O.[Na+],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 24 MO (STUDY DURATION: 30 MO),,NEGATIVE,"[DONAUBAUER,HH, KIEF,H, KRAMER,M, KRIEG,K, MAYER,D AND SCHUTZ,E; INVESTIGATIONS ON THE CARCINOGENICITY OF DIPYRONE IN RATS; TOXICOL. APPL. PHARMACOL. 81: 443-451, 1985]"
1606,363898223,2724564,C(=S)(N)NNC(=S)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1.0; 2.0% OF DIET FOR 78 WK (STUDY DURATION: 94 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-132 Y79]"
1607,363898223,2724564,C(=S)(N)NNC(=S)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.6; 1.2% OF DIET FOR 78 WK (STUDY DURATION: 109 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-132 Y79]"
1608,363898223,2724564,C(=S)(N)NNC(=S)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.6; 1.2% OF DIET OR 78 WK (STUDY DURATION: 109 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-132 Y79]"
1609,363898223,2724564,C(=S)(N)NNC(=S)N,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1.0; 2.0% OF DIET FOR 78 WK (STUDY DURATION: 94 WK),LIVER: HEPATOCELLULAR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-132 Y79]"
1610,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",SUBCUTANEOUS,0.005-20 MG IN 1 ML OLIVE OIL ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1611,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",DERMAL,80 UL OF 1% SOLN IN MINERAL OIL ONCE,INTEGUMENTARY SYSTEM (SKIN): AMELANOTIC DERMAL MELANOCYTOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1612,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",DERMAL,80 UL OF 1% SOLN IN MINERAL OIL ONCE OR 1/WK FOR 3 WK,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SQUAMOUS CELL CARCINOMA, ANGIOMA, MELANOTIC AND ADNEXAL TUMOR",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1613,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,ALBINO/MALE,DERMAL,"0.05% IN OLIVE OIL OR ACETONE, 0.2 ML 2/WK",INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1614,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,BALB,SUBCUTANEOUS,30 UG IN 0.02 ML OF 1% AQ GEL SUSPENDED ONCE,"LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1615,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,BALB/FEMALE,GAVAGE,0.5-2 MG IN ALMOND OIL 1/2 WK OR 2/WK FOR 8-10 WK,OVARIES: GRANULOSA CELL TUMOR,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1616,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,C57BL,DERMAL,0.5 ML OF 0.5% SOLN IN OLIVE OIL 1/2 WK FOR 6 WK,OVARIES,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1617,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,C57BL/FEMALE,DERMAL,2.5 MG OF 0.5% SOLN IN 0.5 ML OLIVE OIL 1/2 WK FOR LIFE,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1618,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,C57BL,DERMAL,0.5 ML OF 0.5% SOLN IN OLIVE OIL 1/2 WK FOR 6 WK,OVARIES; MAMMARY GLAND,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1619,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,CBA,SUBCUTANEOUS,30 UG IN 15 UL OF 1% AQ GEL ONCE,LUNG,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1620,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,ICR,SUBCUTANEOUS,0.001; 0.01; 0.1 MG IN 0.05 ML TRICAPRYLIN,"INJECTION SITE: FIBROSARCOMA, SQUAMOUS CELL CARCINOMA, SARCOMA",POSITIVE,"[VAN DUUREN,BL, LANGSETH,L, ORRIS,L, TEEBOR,G, NELSON,N AND KUSCHNER,M; CARCINOGENICITY OF EPOXIDES, LACTONES, AND PEROXY COMPOUNDS IV. TUMOR RESPONSE IN EPITHELIAL AND CONNECTIVE TISSUE IN MICE AND RATS; J. NATL. CANCER INST. 37:825-838, 1966]"
1621,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,"MALE,FEMALE",DERMAL,0.1 ML OF 0.1% SOLN IN ACETONE 1/WK FOR 9 WK,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, MALIGNANT PAPILLOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1622,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,"SWISS/MALE,FEMALE",SUBCUTANEOUS,0.9 MG SUSPENDED IN 0.45 ML 1% AQ GEL ONCE,"INJECTION SITE: FIBROSARCOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1623,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,"SWISS/MALE,FEMALE",SUBCUTANEOUS,30-40 UG IN 0.02 ML OF 1% AQ GEL,LUNG; LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1624,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,20-500 UG IN ACETONE ONCE,"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA, SARCOMA, EPITHELIOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1625,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,100; 200 UG IN 50 UL ACETONE ONCE,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, CARCINOMA, SARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1626,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,CD-1/FEMALE,SUBCUTANEOUS,20 MG/KG IN 1% GEL SOLN WITHIN 24 HR OF BIRTH,"LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[FUJII,K AND NOMOTO,K-I; TUMOR INDUCTION BY A SINGLE SUBCUTANEOUS INJECTION OF 1-BUTYL-1-NITROSOUREA OR 1-BUTYLUREA IN NEWBORN MICE; CANCER LETT. 18:321-328, 1983]"
1627,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,CD-1/MALE,SUBCUTANEOUS,20 MG/KG IN 1% GEL SOLN WITHIN 24 HR OF BIRTH,"LUNG: ADENOMA, ADENOCARCINOMA; LIVER: ADENOMA",POSITIVE,"[FUJII,K AND NOMOTO,K-I; TUMOR INDUCTION BY A SINGLE SUBCUTANEOUS INJECTION OF 1-BUTYL-1-NITROSOUREA OR 1-BUTYLUREA IN NEWBORN MICE; CANCER LETT. 18:321-328, 1983]"
1628,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,"ALBINO/MALE,FEMALE",SUBCUTANEOUS,5 MG IN 0.5 ML OLIVE OIL ONCE,INJECTION SITE: RHABDOMYOSARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1629,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,"BIRMINGHAM/ MALE, FEMALE",DERMAL,0.5; 1.6% SOLN IN OLIVE OIL ONCE EVERY 2 WK,"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS PAPILLOMA, KERATOACANTHOMA, SQUAMOUS CELL CARCINOMA; MAMMARY GLAND",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1630,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,STRAIN-CB/FEMALE,SUBCUTANEOUS,0.25 ML OF 1% SOLN IN DMSO ONCE,INJECTION SITE: SPINDLE CELL SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 309]"
1631,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,10 MG IN SESAME OIL 3 TIMES AT 14 D INTERVALS,"MAMMARY GLAND: ADENOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1632,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,20 MG IN SESAME OIL ONCE,"MAMMARY GLAND: ADENOMA, FIBROADENOMA, CARCINOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1633,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,20 MG IN 1 ML SESAME OIL ONCE,"MAMMARY GLAND: FIBROADENOMA, CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1634,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAVENOUS,5 MG IN 1 ML LIPID EMULSION ONCE,MAMMARY GLAND,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 406]"
1635,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,10 MG IN 0.5 ML SESAME OIL ONCE,MAMMARY GLAND,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 309]"
1636,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,WISTAR/FEMALE,GAVAGE,0.4 ML OF 0.5% SUNFLOWER SEED OIL SOLN 2/WK FOR 4.5 MO (TOTAL DOSE: 68 MG),HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1637,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,"OUTBRED/ MALE, FEMALE",DERMAL,0.5; 1.6% SOLN IN OLIVE OIL ONCE EVERY 2 WK,"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS PAPILLOMA, KERATOACANTHOMA, SQUAMOUS CELL CARCINOMA; MAMMARY GLAND",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1638,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,WISTAR/FEMALE,ORAL,10 MG IN SESAME OIL 3 TIMES AT 14 D INTERVALS,"MAMMARY GLAND: ADENOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 670]"
1639,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,FISH,"KING COBRA GUPPY/ MALE,  FEMALE",IMMERSION,"0; 0.86; 3.18; 0.90 PPB (LOW DOSE) GIVEN AS SEPARATE DOSES OVER A 4 WK PERIOD, EACH DOSE GIVEN 6 HR/D FOR 1 DAY; 0; 16.3; 30.0; 16.8; 11.3 PPB (INTERMEDIATE DOSE) 0; 23.7; 64.2; 28.1; 20.2 PPB (HIGH DOSE) (STUDY DURATION: 37 WK)",LIVER: HEPATOCELLULAR ADENOMA; HEPATOCELLULAR CARCINOMA,POSITIVE,"[HAWKINS,WE, WALKER,WW, LYTLE,JS, LYTLE,TF AND OVERSTREET,RM; CARCINOGENIC EFFECTS OF 7,12-DIMETHYLBENZ[A]ANTHRACENE ON THE GUPPY (POECILIA RETICULATA); AQUAT. TOXICOL. 15(1):63-82, 1989]"
1640,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,SHREW,JAPANESE/FEMALE,INTRAPERITONEAL,0; 1.25; 2.5 MG 1/WK FOR 8 WK (STUDY DURATION: 50 WK),HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[TSUBURA,A, SENZAKI,H, SHIKATA,N, OISHI,Y AND MORII,S; INDUCTION OF TUMORS IN THE JAPANESE HOUSE MUSK SHREW, SUNCUS MURINIS (INSECTIVORA), BY DIMETHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(8):1433-1436, 1991]"
1641,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,SHREW,JAPANESE/FEMALE,INTRAPERITONEAL,0; 1.25; 2.5 MG 1/WK FOR 4 WK (STUDY DURATION: 50 WK),HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[TSUBURA,A, SENZAKI,H, SHIKATA,N, OISHI,Y AND MORII,S; INDUCTION OF TUMORS IN THE JAPANESE HOUSE MUSK SHREW, SUNCUS MURINIS (INSECTIVORA), BY DIMETHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(8):1433-1436, 1991]"
1642,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,SHREW,JAPANESE/FEMALE,SUBCUTANEOUS,0; 1 MG INTO RIGHT INGUINAL SUBCUTANEOUS TISSUE OVER THE MAMMARY GLAND ONCE (STUDY DURATION: 50 WK),INJECTION SITE: SARCOMA,POSITIVE,"[TSUBURA,A, SENZAKI,H, SHIKATA,N, OISHI,Y AND MORII,S; INDUCTION OF TUMORS IN THE JAPANESE HOUSE MUSK SHREW, SUNCUS MURINIS (INSECTIVORA), BY DIMETHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(8):1433-1436, 1991]"
1643,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.003; 0.01; 0.03 UMOL/G IN 10 UL/G TRIOCTANOIN ONCE ON 12 D OF AGE (STUDY DURATION: 8.5 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
1644,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.00075; 0.0015; 0.003 UMOL/G IN 10 UL/G TRIOCTANOIN ONCE ON 12 D OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
1645,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.01 UMOL/G IN 10 UL/G TRIOCTANOIN ON D 12 OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
1646,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 2 UMOL IN 0.25 ML TRIOCTANOIN INTO LEFT HIND LEG AT ABOUT 40 D OF AGE FOLLOWED BY SECOND DOSE 6 D LATER (STUDY DURATION: 16 MO),INJECTION SITE: SARCOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
1647,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 2 UMOL IN 0.25 ML TRIOCTANOIN ONCE INTO LEFT HIND LEG AT ABOUT 40 D OF AGE (STUDY DURATION: 16 MO),INJECTION SITE: SARCOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
1648,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,FISH,"SHEEPSHEAD MINNOW/MALE, FEMALE",IMMERSION,0; 1; 30; 1200 PPB APPROXIMATE CONCENTRATIONS ADMINISTERED 1/WK FOR 6 OR 24 HR FOR 1 OR 2 WK (STUDY DURATION: 39 WK),"LIVER: ALTERED FOCI, HEPATOCELLULAR ADENOMA OR HEPATOCELLULAR CARCINOMA",POSITIVE,"[HAWKINS,WE, WALKER,WW, LYTLE,TF, LYTLE,JS AND OVERSTREET,RM; STUDIES ON THE CARCINOGENIC EFFECTS OF BENZO[A]PYRENE AND 7,12-DIMETHYLBENZ[A]ANTHRACENE ON THE SHEEPSHEAD MINNOW (CYPRINODON VARIEGATUS); ASTM SPEC. TECH. PUBL. 1124(AQUAT. TOXICOL. RISK ASSESS.: 14TH VOL.):97-104, 1991]"
1649,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INJECTION,0; 0.25; 1 UMOL PER MAMMARY GLAND (STUDY DURATION: 24 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[CAVALIERI,EL, HIGGINBOTHAM,S, RAMAKRISHNA,NVS, DEVANESAN,PD, TODOROVIC,R, ROGAN,EG AND SALMASI,S; COMPARATIVE DOSE-RESPONSE TUMORIGENICITY STUDIES OF DIBENZO[A,L]PYRENE VERSUS 7,12-DIMETHYLBENZ[A]ANTHRACENE, BENZO[A]PYRENE AND TWO DIBENZO[A]PYRENE DIHYDRODIOLS IN MOUSE SKIN AND RAT MAMMARY GLAND; CARCINOGENESIS 12(10):1939-1944, 1991]"
1650,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Inactive,,,,HAMSTER,SYRIAN/FEMALE,TONGUE,0; 0.10 ML OF A 0.5% ACETONE SOLUTION TO BORDER OF MIDDLE THIRD PORTION OF TONGUE 3/WK FOR 4 WK (STUDY DURATION: 11 WK),,NEGATIVE,"[MAREFAT,MP; THE EFFECT OF THE SHORT DOSE SCHEDULE OF DMBA APPLICATION IN INDUCING LINGUAL NEOPLASIA IN INBRED SYRIAN HAMSTERS; J. ORAL PATHOL. 14(5):383-389, 1985]"
1651,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,HAMSTER,SYRIAN/FEMALE,TONGUE,0; 0.10 ML OF A 0.5% ACETONE SOLUTION TO BORDER OF MIDDLE THIRD PORTION OF TONGUE 3/WK FOR 6 WK (STUDY DURATION: 11 WK),TONGUE: CARCINOMA,POSITIVE,"[MAREFAT,MP; THE EFFECT OF THE SHORT DOSE SCHEDULE OF DMBA APPLICATION IN INDUCING LINGUAL NEOPLASIA IN INBRED SYRIAN HAMSTERS; J. ORAL PATHOL. 14(5):383-389, 1985]"
1652,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,HAMSTER,SYRIAN/FEMALE,TONGUE,0; 0.10 ML OF A 0.5% ACETONE SOLUTION TO BORDER OF MIDDLE THIRD PORTION OF TONGUE 3/WK FOR 8 WK (STUDY DURATION: 11 WK),TONGUE: CARCINOMA,POSITIVE,"[MAREFAT,MP; THE EFFECT OF THE SHORT DOSE SCHEDULE OF DMBA APPLICATION IN INDUCING LINGUAL NEOPLASIA IN INBRED SYRIAN HAMSTERS; J. ORAL PATHOL. 14(5):383-389, 1985]"
1653,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 1; 4; 8 NMOL IN 100 UL ACETONE 2/WK FOR 40 WK (STUDY DURATION: 48 WK),SKIN: TUMORS,POSITIVE,"[HIGGINBOTHAM,S, RAMAKRISHNA,NVS, JOHANSSON,SL, ROGAN,EG AND CAVALIERI,EL; TUMOR-INITIATING ACTIVITY AND CARCINOGENICITY OF DIBENZO[A,L]PYRENE VERSUS 7,12-DIMETHYLBENZ[A]ANTHRACENE AND BENZO[A]PYRENE AT LOW DOSE IN MOUSE SKIN; CARCINOGENESIS 14(5):875-878, 1993]"
1654,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,WISTAR/FEMALE,INTRADUCTAL,0; 1 MG IN 0.05 ML OF SESAME OIL INJECTED INTO MAIN MAMMARY DUCT ON THE 10TH PUERPERAL DAY (STUDY DURATION: 20 WK),MAMMARY GLAND: DUCTAL CARCINOMA,POSITIVE,"[TERADA,S, UCHIDE,K, SUZUKI,N, AKASOFU,K AND NISHIDA,E; INDUCTION OF DUCTAL CARCINOMAS BY INTRADUCTAL ADMINISTRATION OF 7,12-DIMETHYLBENZ[A]ANTHRACENE IN WISTAR RATS; BREAST CANCER RES. TREAT. 34(1):35-43, 1995]"
1655,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,WISTAR/MALE,INJECTION,0; 0.05 ML OF A 1% SOLUTION IN ACETONE INJECTED INTO SUBMANDIBULAR SALIVARY GLANDS AFTER EXCISION OF A SMALL PORTION OF TISSUE (STUDY DURATION: 8 WK),SALIVARY GLAND: FIBROSARCOMA,POSITIVE,"[ZAMAN,A, KOHGO,T, SHINDOH,M, IIZUKA,T AND AMEMIYA,A; INDUCTION OF ADENOCARCINOMAS IN THE SUBMANDIBULAR SALIVARY GLANDS OF FEMALE WISTAR RATS TREATED WITH 7,12-DIMETHYLBENZ(A)ANTHRACENE; ARCH. ORAL BIOL. 41(2):221-224, 1996]"
1656,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,WISTAR/FEMALE,INJECTION,0; 0.05 ML OF A 1% SOLUTION IN ACETONE INJECTED INTO SUBMANDIBULAR SALIVARY GLANDS AFTER EXCISION OF A SMALL PORTION OF TISSUE (STUDY DURATION: 8 WK),SALIVARY GLAND: ADENOCARCINOMA,POSITIVE,"[ZAMAN,A, KOHGO,T, SHINDOH,M, IIZUKA,T AND AMEMIYA,A; INDUCTION OF ADENOCARCINOMAS IN THE SUBMANDIBULAR SALIVARY GLANDS OF FEMALE WISTAR RATS TREATED WITH 7,12-DIMETHYLBENZ(A)ANTHRACENE; ARCH. ORAL BIOL. 41(2):221-224, 1996]"
1657,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,MOUSE,SENCAR/FEMALE,GAVAGE,0; 20; 60; 200 UG IN 0.1 ML CORN OIL 1/D 5 D/WK FOR 6 WK (STUDY DURATION: 53 WK),LYMPHATIC SYSTEM: LYMPHOMA; MAMMARY GLAND: CARCINOMA,POSITIVE,"[QING,WG, CONTI,CJ, LABATE,M, JOHNSTON,D, SLAGA,TJ AND MACLEOD,MC; INDUCTION OF MAMMARY CANCER AND LYMPHOMA BY MULTIPLE, LOW ORAL DOSES OF 7,12-DIMETHYLBENZ[A]ANTHRACENE IN SENCAR MICE; CARCINOGENESIS 18(3):553-559, 1997]"
1658,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,WISTAR/FURTH/FEMALE,OVARIAN IMPLANTATION OF CARCINOGEN-COATED SUTURE AT 7 WKS OF AGE,200 UG IN SUTURE ONCE (STUDY DURATION: 1 YR),"OVARY: ADENOCARCINOMA, 77%",POSITIVE,"[CRIST,KA ZHANG,Z YOU,M GUNNING,WT CONRAN,PB STEELE,VE AND LUBET,RA; CHRACTERIZATION OF RAT OVARIAN ADENOCARCINOMAS DEVELOPED IN RESPONSE TO DIRECT INSTILLATION OF 7,12-DIMETHYLBENZ[A]ANTHRACENE (DMBA) COATED SUTURE; CARCINOGENESIS 26(5):951-957, 2005]"
1659,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,"ZUCKER/FEMALE, LEAN",ORAL (GAVAGE),65 MG/KG ONCE AT 50 D OF AGE (STUDY DURATION: 139 D),MAMMARY: TUMOR 32%; LATENCY 86 D,POSITIVE; LEAN RATS HAD LONGER LATENT PERIOD AND LOWER TUMOR INCIDENCE THAN OBESE RATS,"[HAKKAK,R HOLLEY,AW MACLEOD,SL SIMPSON,PM FUCHS,GJ JO,CH  KIEBER-EMMONS,T AND KOROURIAN,S; OBESITY PROMOTES  7,12-DIMETHYLBENZ(A)ANTHRACENE-INDUCED MAMMARY TUMOR  DEVELOPMENT IN FEMALE  ZUCKER RATS; BREAST CANCER RES.  7(5):R627-R633, 2005]"
1660,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Active,,,,RAT,"ZUCKER/FEMALE, OBESE",ORAL (GAVAGE),65 MG/KG ONCE AT 50 D OF AGE (STUDY DURATION: 139 D),MAMMARY: TUMOR 68%; LATENCY 49 D,POSITIVE; OBESE RATS HAD HIGHER TUMOR INCIDENCE AND SHORTER LATENT PERIOD THAN LEAN RATS,"[HAKKAK,R HOLLEY,AW MACLEOD,SL SIMPSON,PM FUCHS,GJ JO,CH  KIEBER-EMMONS,T AND KOROURIAN,S; OBESITY PROMOTES  7,12-DIMETHYLBENZ(A)ANTHRACENE-INDUCED MAMMARY TUMOR  DEVELOPMENT IN FEMALE  ZUCKER RATS; BREAST CANCER RES.  7(5):R627-R633, 2005]"
1661,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Unspecified,,,,RAT,"F344/FEMALE, 3 WKS OF AGE",GAVAGE,50 MG/KG ONCE (STUDY DURATION: 36 WKS),MAMMARY GLAND: CARCINOMA,20% TUMOR INCIDENCE; 0.23 CARCINOMAS/RAT; IMMATURE RATS LESS SUSCEPTIBLE,"[ARIAZI,JL, HAAG,JD, LINDSTROM,MJ AND GOULD,MN; MAMMARY GLANDS OF SEXUALLY IMMATURE RATS ARE MORE SUSCEPTIBLE THAN THOSE OF MATURE RATS TO THE CARCINOGENIC, LETHAL, AND MUTAGENIC EFFECTS OF N-NITROS-N-METHYLUREA; MOL. CARCINOG. 43(3):155-164, 2005]"
1662,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Unspecified,,,,RAT,"F344/FEMALE, 8 WKS OF AGE",GAVAGE,50 MG/KG ONCE (STUDY DURATION: 36 WKS),MAMMARY GLAND: CARCINOMA,69% TUMOR INCIDENCE; 1.27 CARCINOMAS/RAT; MATURE RATS MORE SUSCEPTIBLE,"[ARIAZI,JL, HAAG,JD, LINDSTROM,MJ AND GOULD,MN; MAMMARY GLANDS OF SEXUALLY IMMATURE RATS ARE MORE SUSCEPTIBLE THAN THOSE OF MATURE RATS TO THE CARCINOGENIC, LETHAL, AND MUTAGENIC EFFECTS OF N-NITROS-N-METHYLUREA; MOL. CARCINOG. 43(3):155-164, 2005]"
1663,363898224,6001,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)C,Inactive,,,,Rat,Fischer 344/Female,Direct application to ovary,"100 ug in sesame oil, once, study duration 5 months",,Negative,"[HOYER,PB DAVIS,JR BEDRNICEK,JB MARION,SL CHRISTIAN,PJ BARTON,JK AND BREWER,MA; OVARIAN NEOPLASM DEVELOPMENT BY7,12-DIMETHYLBENZ[A]ANTHRACENE (DMBA) IN A CHEMICALLY-INDUCED RAT MODEL OF OVARIAN FAILURE; GYNECOLOGIC ONCOLOGY 112(3):610-615, 2009]"
1664,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,Rat,Crl:CD (SD) BR/Male (50/Group),Oral,"0; 3.0; 7.5; 15.0; 75.0 ppm in corn oil in diet for 104 wk, study duration 104 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  ENDOSULFAN (November 28, 2006)]"
1665,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,Rat,Crl:CD (SD) BR/Female (50/Group),Oral,"0; 3.0; 7.5; 15.0; 75.0 ppm in corn oil in diet for 104 wk, study duration 104 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  ENDOSULFAN (November 28, 2006)]"
1666,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,Mouse,NMRI Hoe:NMRKf (SPF71)/Male (60/Group),Oral,"0 (sesame oil); 2; 6; 18 ppm 97.1% endosulfan in diet for 24 mo, study duration 24 mo.",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  ENDOSULFAN (November 28, 2006)]"
1667,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,Mouse,NMRI Hoe:NMRKf (SPF71)/Female (60/Group),Oral,"0 (sesame oil); 2; 6; 18 ppm 97.1% endosulfan in diet for 24 mo, study duration 24 mo.",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  ENDOSULFAN (November 28, 2006)]"
1668,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 2.0; 3.9 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-62 Y78]"
1669,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 223; 445 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-62 Y78]"
1670,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 3; 7.5; 15; 75 PPM IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HACK,R, EBERT,E AND LEIST,KH; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE INSECTICIDE ENDOSULFAN IN RATS AND MICE; FOOD CHEM. TOXICOL. 33(11):941-950, 1995]"
1671,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 3; 7.5; 15; 75 PPM IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HACK,R, EBERT,E AND LEIST,KH; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE INSECTICIDE ENDOSULFAN IN RATS AND MICE; FOOD CHEM. TOXICOL. 33(11):941-950, 1995]"
1672,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,NMRI/MALE,ORAL,0; 2; 6; 18 PPM IN THE DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[HACK,R, EBERT,E AND LEIST,KH; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE INSECTICIDE ENDOSULFAN IN RATS AND MICE; FOOD CHEM. TOXICOL. 33(11):941-950, 1995]"
1673,363898225,3224,C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,NMRI/FEMALE,ORAL,0; 2; 6; 18 PPM IN THE DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[HACK,R, EBERT,E AND LEIST,KH; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE INSECTICIDE ENDOSULFAN IN RATS AND MICE; FOOD CHEM. TOXICOL. 33(11):941-950, 1995]"
1674,363898226,12358480,C1[C@@H]2[C@@H]3[C@H]([C@H]1[C@H]4[C@@H]2O4)[C@@]5(C(=C([C@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 2.5; 5 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-12 Y79]"
1675,363898226,12358480,C1[C@@H]2[C@@H]3[C@H]([C@H]1[C@H]4[C@@H]2O4)[C@@]5(C(=C([C@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 1.6; 3.2 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-12 Y79]"
1676,363898226,12358480,C1[C@@H]2[C@@H]3[C@H]([C@H]1[C@H]4[C@@H]2O4)[C@@]5(C(=C([C@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 3; 6 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-12 Y79]"
1677,363898226,12358480,C1[C@@H]2[C@@H]3[C@H]([C@H]1[C@H]4[C@@H]2O4)[C@@]5(C(=C([C@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 2.5; 5 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-12 Y79]"
1678,363898227,7835,C1C(O1)CCl,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 131 Y76]"
1679,363898227,7835,C1C(O1)CCl,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 131 Y76]"
1680,363898227,7835,C1C(O1)CCl,Active,,,,RAT,WISTAR/MALE,GAVAGE,0; 2; 10 MG/KG IN WATER 5 D/WK FOR 104 WK (STUDY DURATION: 24 MO),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[WESTER,PW, VAN DER HEIJDEN,CA, BISSCHOP,A AND VAN ESCH,GJ; CARCINOGENICITY STUDY WITH EPICHLOROHYDRIN (CEP) BY GAVAGE IN RATS; TOXICOL. 36:325-339, 1985]"
1681,363898227,7835,C1C(O1)CCl,Active,,,,RAT,WISTAR/FEMALE,GAVAGE,0; 2; 10 MG/KG IN WATER 5 D/WK FOR 104 WK (STUDY DURATION: 24 MO),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[WESTER,PW, VAN DER HEIJDEN,CA, BISSCHOP,A AND VAN ESCH,GJ; CARCINOGENICITY STUDY WITH EPICHLOROHYDRIN (CEP) BY GAVAGE IN RATS; TOXICOL. 36:325-339, 1985]"
1682,363898228,7833,C1CC2C(O2)CC1C3CO3,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 141 Y76]"
1683,363898228,7833,C1CC2C(O2)CC1C3CO3,Active,,,,RAT,F344/MALE,DERMAL,0; 15; 30 MG/RAT IN ACETONE 5 D/WK FOR 105 WK (STUDY DURATION: 106 WK),"SKIN (APPLICATION SITE): BASAL CELL ADENOMA, BASAL CELL CARCINOMA, BASAL CELL ADENOMA OR SEBACEOUS GLAND ADENOMA, SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; SKIN (ALL SITES): BASAL CELL ADENOMA, BASAL CELL ADENOMA OR CARCINOMA, TRICHOEPITHELIOMA OR BASAL CELL ADENOMA OR SEBACEOUS GLAND ADENOMA, TRICHOEPITHELIOMA OR BASAL CELL ADENOMA OR SEBACEOUS GLAND ADENOMA OR BASAL CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-362 Y89]"
1684,363898228,7833,C1CC2C(O2)CC1C3CO3,Active,,,,RAT,F344/FEMALE,DERMAL,0; 15; 30 MG/RAT IN ACETONE 5 D/WK FOR 105 WK (STUDY DURATION: 106 WK),"SKIN (APPLICATION SITE): BASAL CELL CARCINOMA, SEBACEOUS GLAND ADENOMA OR BASAL CELL CARCINOMA, SQUAMOUS CELL CARCINOMA; SKIN (ALL SITES): BASAL CELL ADENOMA OR CARCINOMA, SEBACEOUS GLAND ADENOMA OR BASAL CELL ADENOMA OR BASAL CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-362 Y89]"
1685,363898228,7833,C1CC2C(O2)CC1C3CO3,Active,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 2.5; 5; 10 MG/MOUSE IN ACETONE 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"SKIN (APPLICATION SITE): BASOSQUAMOUS TUMOR MALIGNANT, BASOSQUAMOUS TUMOR MALIGNANT OR BASAL CELL CARCINOMA, SQUAMOUS CELL CARCINOMA; SKIN (ALL SITES): SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-362 Y89]"
1686,363898228,7833,C1CC2C(O2)CC1C3CO3,Active,,,,MOUSE,B6C3F1/FEMALE,DERMAL,"0; 2.5; 5; 10 MG/MOUSE IN ACETONE 5 D/WK FOR 103 WK, HIGH DOSE FEMALE MICE 85 WK (STUDY DURATION: 105 WK)","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; OVARY: GRANULOSA CELL TUMOR, GRANULOSA CELL TUMOR OR MALIGNANT GRANULOSA CELL TUMOR, BENIGN MIXED TUMOR, LUTEOMA OR GRANULOSA CELL TUMOR OR BENIGN MIXED TUMOR SKIN (APPLICATION SITE): SQUAMOUS CELL CARCINOMA; SKIN (ALL SITES): SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-362 Y89]"
1687,363898229,61094,CC1CC2C(O2)CC1COC(=O)C3CC4C(O4)CC3C,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 147 Y76]"
1688,363898230,5757,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,Active,,,,GUINEA PIG,,SUBCUTANEOUS IMPLANT,,UTERUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 99 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 279 Y79]"
1689,363898230,5757,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,Active,,,,HAMSTER,,SUBCUTANEOUS IMPLANT,,KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 99 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 279 Y79]"
1690,363898230,5757,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,,"ORAL, SUBCUTANEOUS IMPLANT",,CERVIX; THYMUS GLAND; MAMMARY GLAND; UTERUS; VAGINA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 99 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 279 Y79]"
1691,363898230,5757,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,,SUBCUTANEOUS,,LYMPHATIC SYSTEM,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 279 Y79]"
1692,363898230,5757,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,Active,,,,RAT,,SUBCUTANEOUS IMPLANT,,MAMMARY GLAND; PITUITARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 99 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 279 Y79]"
1693,363898230,5757,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),KIDNEY: TUMOR,POSITIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
1694,363898230,5757,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,BALB/CCRGL/FEMALE,SUBCUTANEOUS,5 UG DAILY FOR 5 D BEGINNING 16 HR AFTER BIRTH (STUDY DURATION: 20 MO),CERVICOVAGINAL TRACT: CARCINOMA (16/37),POSITIVE,"[MARTINEZ,J, STEPHENS,LC AND JONES,LA; LONG-TERM EFFECTS OF NEONATAL EXPOSURE TO HYDROXYLATED POLYCHLORINATED BIPHENYLS IN THE BALB/CCRGL MOUSE; ENVIRON. HEALTH PERSPECT. 113(8):1022-1025, 2005]"
1695,363898231,222757,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5,Active,,,,MOUSE,,SUBCUTANEOUS,,TESTES; PITUITARY GLAND; CERVIX; UTERUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 279 Y79]"
1696,363898231,222757,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5,Active,,,,RAT,,SUBCUTANEOUS IMPLANT,,PITUITARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 279 Y79]"
1697,363898232,8225,CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)OC(=O)CC)C,Active,,,,MOUSE,,SUBCUTANEOUS,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 279 Y79]"
1698,363898233,31586,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CC4=CC=C(C=C4)N(CCCl)CCCl)CCC5=C3C=CC(=C5)OC(=O)CC6=CC=C(C=C6)N(CCCl)CCCl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 15; 30 MG/KG 3/WK FOR 52 WKS,LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LYMPHATIC SYSTEM: LYMPHOMA; MYOCARDIUM: SARCOMA; STOMACH,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-59 Y78]"
1699,363898233,31586,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CC4=CC=C(C=C4)N(CCCl)CCCl)CCC5=C3C=CC(=C5)OC(=O)CC6=CC=C(C=C6)N(CCCl)CCCl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 15; 30 MG/KG 3/WK FOR 52 WKS,LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA): LYMPHOCYTIC LEUKEMIA; LYMPHATIC SYSTEM: LYMPHOMA; MYOCARDIUM: SARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-59 Y78]"
1700,363898233,31586,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CC4=CC=C(C=C4)N(CCCl)CCCl)CCC5=C3C=CC(=C5)OC(=O)CC6=CC=C(C=C6)N(CCCl)CCCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 0.62; 1.25 MG/KG IN 0.05% POLYSORB 80 IN PHOS BUFF SALINE 3/WK FOR 52 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-59 Y78]"
1701,363898233,31586,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CC4=CC=C(C=C4)N(CCCl)CCCl)CCC5=C3C=CC(=C5)OC(=O)CC6=CC=C(C=C6)N(CCCl)CCCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 0.62; 1.25 MG/KG IN 0.05% POLYSORB 80 IN PHOS BUFF SALINE 3/WK FOR 52 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-59 Y78]"
1702,363898234,5756,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O,Active,,,,HAMSTER,,SUBCUTANEOUS IMPLANT,,KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 327 Y79]"
1703,363898234,5756,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O,Active,,,,HUMAN,,,,UTERUS (ENDOMETRIUM),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 327 Y79]"
1704,363898234,5756,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,,SUBCUTANEOUS IMPLANT,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 327 Y79]"
1705,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,HAMSTER,,"SUBCUTANEOUS, SUBCUTANEOUS IMPLANT",,KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79]"
1706,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,HUMAN,,,,UTERUS (ENDOMETRIUM),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79]"
1707,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,,"ORAL, SUBCUTANEOUS, DERMAL, SUBCUTANEOUS IMPLANT",,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79]"
1708,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,RAT,,"SUBCUTANEOUS, SUBCUTANEOUS IMPLANT",,ADRENAL GLAND; KIDNEY; MAMMARY GLAND; PITUITARY GLAND; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79]"
1709,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,"C3H, C3HE(MTV-)/MALE",ORAL,"125, 2000 UG/L IN DRINKING WATER",MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79][BOOT,LM AND MUHLBOCK,O; THE MAMMARY TUMOUR INCIDENCE IN THE C3H MOUSE STRAIN WITH AND WITHOUT THE AGENT (C3H, C3H-F, C3H-E); ACTA UNIO INT. CANCRUM 12:569-581, 1956, ]"
1710,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,GRS/AFIB(MTV+)/FEMALE,ORAL,"0, 0.5 UG/ML FOR 14-25 WK IN DRINKING WATER",UTERUS,POSITIVE,"[BRIAND,P, HOU-JENSEN,K, THORPE,SM AND ROSE,C; HORMONE-DEPENDENT UTERINE SARCOMAS IN GR MICE; EUR. J. CANCER 17(6):635-641, 1981]"
1711,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,C3R3(MTV+)/MALE,DIET,"0, 0.06, 0.6, 6 UG/D",MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79][RUDALI,G, JULLIEN,P, VIVES,C AND APIOU,F; DOSE-EFFECT STUDIES ON ESTROGEN INDUCED MAMMARY CANCERS IN MICE; BIOMEDICINE 29:45-46, 1978, ]"
1712,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,,KIDNEY; PITUITARY GLAND: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79][DONTENWILL,W  EXPERIMENTAL PRODUCTION OF KIDNEY AND LIVER TUMOURS WITH FOLLICULAR HORMONE (GER.); VERH. DTSCH. GES. PATHOL. 42:458-461, 1958, ]"
1713,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,RAT,"AXC/MALE,FEMALE",SUBCUTANEOUS IMPLANT,"8-12 MG PELLET, SINGLE DOSE",MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79][DUNNING,WF, CURTIS,MR AND SEGALOFF,A; STRAIN DIFFERENCES IN RESPONSE TO ESTRONE AND THE INDUCTION OF MAMMARY GLAND, ADRENAL AND BLADDER CANCER IN RATS; CANCER RES. 13:147-152, 1953, ]"
1714,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,RAT,"COPENHAGEN/MALE,FEMALE",SUBCUTANEOUS IMPLANT,"8-12 MG PELLET, SINGLE DOSE",URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79]"
1715,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,"0, 20 MG PELLET, SINGLE DOSE",KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79][KIRKMAN,H; ESTROGEN-INDUCED TUMORS OF THE KIDNEY. IV. INCIDENCE IN FEMALE SYRIAN HAMSTERS; NATL. CANCER INST. MONOGR. 1:59-75, 1959, ]"
1716,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,RAT,"F344/MALE,FEMALE",SUBCUTANEOUS IMPLANT,"8-12 MG PELLET, SINGLE DOSE",MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79][DUNNING,WF, CURTIS,MR AND SEGALOFF,A; STRAIN DIFFERENCES IN RESPONSE TO ESTRONE AND THE INDUCTION OF MAMMARY GLAND, ADRENAL AND BLADDER CANCER IN RATS; CANCER RES. 13:147-152, 1953, ]"
1717,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,RAT,"AUGUST/MALE,FEMALE",SUBCUTANEOUS IMPLANT,"8-12 MG PELLET, SINGLE DOSE",MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 123 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 343 Y79][DUNNING,WF, CURTIS,MR AND SEGALOFF,A; STRAIN DIFFERENCES IN RESPONSE TO ESTRONE AND THE INDUCTION OF MAMMARY GLAND, ADRENAL AND BLADDER CANCER IN RATS; CANCER RES. 13:147-152, 1953, ]"
1718,363898235,5870,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),KIDNEY: TUMOR,POSITIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
1719,363898236,5991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,Inactive,,,,Rat,Sprague-Dawley/Male (50/Group),Oral,"0; 2; 10; 50 ppb in diet, continuous exposure from conception through 2 yr",,Negative,[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
1720,363898236,5991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,Inactive,,,,Rat,Sprague-Dawley/Male (50/Group),Oral,"0; 2; 10; 50 ppb in diet, continuous exposure from conception through PND 140, followed by control diet to 2 yr",,Negative,[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
1721,363898236,5991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,"0; 2; 10; 50 ppb in diet, continuous exposure from conception through PND 21, followed by control diet to 2 yr",,"Negative (Authors describe as equivocal evidence based on epithelial neoplasms (2/49, 4/49, 4/50, 8/49) in preputial gland and adenoma or adenocarcinoma (0/42, 0/42, 0/40, 3/45) in mammary gland)",[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
1722,363898236,5991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,"0; 2; 10; 50 ppb in diet, continuous exposure from conception through PND 21, followed by control diet to 2 yr",,"Negative (Authors describe as equivocal evidence based on stromal polyp (1/52, 7/50, 2/50, 5/50) in uterus)",[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
1723,363898236,5991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,"0; 2; 10; 50 ppb in diet, continuous exposure from conception through PND 140, followed by control diet to 2 yr",,"Negative (Authors describe as equivocal evidence based on stromal polyp (2/51, 5/50, 6/50, 7/50) in uterus)",[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
1724,363898236,5991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,"0; 2; 10; 50 ppb in diet, continuous exposure from conception through 2 yr",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-548 Y10]"
1725,363898236,5991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,,ORAL,,CERVIX; MAMMARY GLAND; PITUITARY GLAND; UTERUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 233 Y79][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 77 Y74]"
1726,363898236,5991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,Active,,,,RAT,,"ORAL, SUBCUTANEOUS",,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 233 Y79][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 77 Y74]"
1727,363898236,5991,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,Active,,,,MOUSE,CD-1/FEMALE,SUBCUTANEOUS,0; 2 UG/D IN CORN OIL ON DAYS 1-5 OF LIFE (STUDY DURATION: 12-18 WK),UTERUS: ADENOCARCINOMA,POSITIVE,"[NEWBOLD,RR AND LIEHR,JG; INDUCTION OF UTERINE ADENOCARCINOMA IN CD-1 MICE BY CATECHOL ESTROGENS; CANCER RES. 60(2):235-237, 2000]"
1728,363898237,2761171,CCC1=NC=CC(=C1)C(=S)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1000; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-46 Y78]"
1729,363898237,2761171,CCC1=NC=CC(=C1)C(=S)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-46 Y78]"
1730,363898237,2761171,CCC1=NC=CC(=C1)C(=S)N,Active,,,,MOUSE,,ORAL,,THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 83 Y77]"
1731,363898237,2761171,CCC1=NC=CC(=C1)C(=S)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1500; 3000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-46 Y78]"
1732,363898237,2761171,CCC1=NC=CC(=C1)C(=S)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 1500; 3000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-46 Y78]"
1733,363898238,6205,CCSCCC(C(=O)O)N,Active,,,,RAT,F344/MALE,ORAL,0.25% IN DIET FOR 24 WK,LIVER,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 41]"
1734,363898238,6205,CCSCCC(C(=O)O)N,Active,,,,RAT,"OSBORNE-MENDEL/MALE,FEMALE",ORAL,0.25% IN BASAL DIET FOR 8-9 MO,LIVER: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 121]"
1735,363898238,6205,CCSCCC(C(=O)O)N,Active,,,,RAT,SPRAGUE-DAWLEY,ORAL,0.25% IN DIET FOR 8 MO,LIVER: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 121]"
1736,363898238,6205,CCSCCC(C(=O)O)N,Active,,,,RAT,"WISTAR/MALE,FEMALE",ORAL,0.25% IN BASAL DIET FOR 8 MO THEN STOCK DIET FOR 2 MO,LIVER: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 2 155]"
1737,363898238,6205,CCSCCC(C(=O)O)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.05% IN METHYL-DEFICIENT DIET FOR 8 MO; STUDY DURATION: 20 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[LEOPOLD,WR, MILLER,JA AND MILLER EC; COMPARISON OF SOME CARCINOGENIC, MUTAGENIC, AND BIOCHEMICAL PROPERTIES OF S-VINYLHOMOCYSTEINE AND ETHIONINE; CANCER RES. 42:4364-4374, 1982]"
1738,363898239,25674,CCSCC[C@@H](C(=O)O)N,Active,,,,RAT,STRAIN-CD/MALE,ORAL,0.2% IN NONTOXIC PEANUT MEAL DIET FOR 380 D,LIVER,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 120]"
1739,363898239,25674,CCSCC[C@@H](C(=O)O)N,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",ORAL,0.25% IN DIET FOR 38 WK (AVE),LIVER: CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 44]"
1740,363898239,25674,CCSCC[C@@H](C(=O)O)N,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.05% IN CHOLINE-FREE DIET FOR 12 MO (STUDY DURATION: 12 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[TARSETTI,F, LENZI,R, SALVI,R, SCHULER,E, RIJHSINGHANI,K, LENZEN,R AND TAVOLONI, N; LIVER CARCINOGENESIS ASSOCIATED WITH FEEDING OF ETHIONINE IN A CHOLINE-FREE DIET: EVIDENCE AGAINST A ROLE OF OVAL CELLS IN THE EMERGENCE OF HEPATOCELLULAR CARCINOMA; HEPATOLOGY 18(3):596-603, 1993]"
1741,363898239,25674,CCSCC[C@@H](C(=O)O)N,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.1% IN CHOLINE-FREE DIET FOR 12 MO (STUDY DURATION: 12 MO),,NEGATIVE,"[TARSETTI,F, LENZI,R, SALVI,R, SCHULER,E, RIJHSINGHANI,K, LENZEN,R AND TAVOLONI, N; LIVER CARCINOGENESIS ASSOCIATED WITH FEEDING OF ETHIONINE IN A CHOLINE-FREE DIET: EVIDENCE AGAINST A ROLE OF OVAL CELLS IN THE EMERGENCE OF HEPATOCELLULAR CARCINOMA; HEPATOLOGY 18(3):596-603, 1993]"
1742,363898240,47793,CCN(COC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,5.5 MG/KG 1/WK FOR 10 WK,"INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; LUNG: ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, MOCHIZUKI,M, ANJO,T, OKADA,M AND ODASHIMA,S; CARCINOGENICITY OF N-ALKYL-N-(ACETOXYMETHYL)- NITROSAMINES AFTER SUBCUTANEOUS INJECTIONS IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 104:13-21, 1982]"
1743,363898240,47793,CCN(COC(=O)C)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,5.5 MG/KG 1/WK FOR 10 WK,"INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; LUNG: ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA; THYROID GLAND: C CELL ADENOMA, FOLLICULAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, MOCHIZUKI,M, ANJO,T, OKADA,M AND ODASHIMA,S; CARCINOGENICITY OF N-ALKYL-N-(ACETOXYMETHYL)- NITROSAMINES AFTER SUBCUTANEOUS INJECTIONS IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 104:13-21, 1982]"
1744,363898241,150695,CCCCN(C(=O)CCC(=O)OCC)N=O,Active,,,,RAT,"F344/MALE,FEMALE",SUBCUTANEOUS,38 UMOL/KG IN OLIVE OIL 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA,POSITIVE,"[TAKAHASHI,M, KUROKAWA,Y, MAEKAWA,A, KOKUBO,T, FURUKAWA,F, MOCHIZUKI,M, ANJO,T AND OKADA,M; COMPARATIVE CARCINOGENICITIES OF MODEL COMPOUNDS OF METABOLICALLY ACTIVATED N,N-DIBUTYLNITROSAMINE IN RATS; GANN 73:687-694, 1982]"
1745,363898242,6295,CCC1=CC=C(C=C1)C(C2=CC=C(C=C2)CC)C(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 2,500; 5,000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-156 Y79]"
1746,363898242,6295,CCC1=CC=C(C=C1)C(C2=CC=C(C=C2)CC)C(Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 3,500; 7,000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-156 Y79]"
1747,363898242,6295,CCC1=CC=C(C=C1)C(C2=CC=C(C=C2)CC)C(Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,"0; 3,500; 7,000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-156 Y79]"
1748,363898242,6295,CCC1=CC=C(C=C1)C(C2=CC=C(C=C2)CC)C(Cl)Cl,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5000 IN DIET FOR FIRST 48 WK FOLLOWED BY 1000 PPM IN DIET FOR LAST 57 WK; 10000 PPM IN DIET FOR 48 WK FOLLOWED BY 3000 PPM IN DIET FOR LAST 57 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-156 Y79]"
1749,363898243,7303,C1COC(=O)O1,Inactive,,,,RAT,STRAIN-CD/FEMALE,ORAL,25000; 50000 PPM IN DIET FOR 78 WK,,NEGATIVE,"[WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
1750,363898243,7303,C1COC(=O)O1,Inactive,,,,RAT,STRAIN-CD/MALE,ORAL,"25000; 44360 PPM IN DIET FOR 78 WK, TWA",,NEGATIVE,"[WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
1751,363898244,9008,C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-11 Y77]"
1752,363898244,9008,C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-11 Y77]"
1753,363898244,9008,C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-11 Y77]"
1754,363898244,9008,C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-11 Y77]"
1755,363898245,7839,C(CBr)Br,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 10; 40 PPM 6 HR/D, 5 D/WK FOR 90-103 WK (STUDY DURATION: 91-104 WK)","INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE OR RIB): FIBROSARCOMA; NASAL CAVITY: CARCINOMA (NOS), CARCINOMA (NOS) OR ADENOMA (NOS); LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA; LUNG (BRONCHUS): CARCINOMA (NOS) OR ADENOMA (NOS); MAMMARY GLAND: ADENOCARCINOMA (NOS); CIRCULATORY SYSTEM: HEMANGIOSARCOMA, HEMANGIOMA OR HEMANGIOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-210 Y82]"
1756,363898245,7839,C(CBr)Br,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 62; 107 MG/KG, TWA IN CORN OIL (STUDY DURATION: 78-90 WK)","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-86 Y78]"
1757,363898245,7839,C(CBr)Br,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 10; 40 PPM 6 HR/D, 5 D/WK FOR 78 WK (STUDY DURATION: 79 WK)","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-210 Y82]"
1758,363898245,7839,C(CBr)Br,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 62; 107 MG/KG, TWA IN CORN OIL (STUDY DURATION: 77-78 WK)","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; STOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-86 Y78]"
1759,363898245,7839,C(CBr)Br,Active,,,,RAT,F344/FEMALE,INHALATION,"0; 10; 40 PPM 6 HR/D, 5 D/WK FOR 91-103 WK (STUDY DURATION: 92-104 WK)","NASAL CAVITY: ADENOMA (NOS), CARCINOMA (NOS), ADENOCARCINOMA (NOS);LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA;SPLEEN: HEMANGIOSARCOMA; MAMMARY GLAND: FIBROADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-210 Y82]"
1760,363898245,7839,C(CBr)Br,Active,,,,RAT,F344/MALE,INHALATION,"0; 10; 40 PPM 6 HR/D, 5 D/WK FOR 88-103 WK (STUDY DURATION: 89-104 WK)","NASAL CAVITY: ADENOMA (NOS), ADENOCARCINOMA (NOS), CARCINOMA (NOS), ADENOMATOUS POLYP (NOS); CIRCULATORY SYSTEM: HEMANGIOSARCOMA; TUNICA VAGINALIS: MESOTHELIOMA (NOS)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-210 Y82]"
1761,363898245,7839,C(CBr)Br,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,"0; 37; 39 MG/KG, TWA IN CORN OIL (STUDY DURATION: 61 WK)","STOMACH: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-86 Y78]"
1762,363898245,7839,C(CBr)Br,Active,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,"0; 38; 41 MG/KG, TWA IN CORN OIL (STUDY DURATION: 49 WK)",BLOOD VESSELS: HEMANGIOSARCOMA; STOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-86 Y78]"
1763,363898245,7839,C(CBr)Br,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,"20 PPM 7 HR/D, 5 D/WK FOR 18 MO","SPLEEN: HEMANGIOSARCOMA; ADRENAL GLAND: PHEOCHROMOCYTOMA, CORTICAL ADENOMA, CARCINOMA; MAMMARY GLAND: ADENOMA, FIBROADENOMA, CARCINOMA, ADENOCARCINOMA",POSITIVE,"[WONG,LCK, WINSTON,JM, HONG,CB AND PLOTNICK,H; CARCINOGENICITY AND TOXICITY OF 1,2-DIBROMOETHANE IN THE RAT; TOXICOL. APPL. PHARMACOL. 63:155-165, 1982]"
1764,363898245,7839,C(CBr)Br,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,"20 PPM 7 HR/D, 5 D/WK FOR 18 MO","SPLEEN: HEMANGIOSARCOMA; ADRENAL GLAND: PHEOCHROMOCYTOMA, CORTICAL ADENOMA, CARCINOMA; INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): MESENCHYMAL TUMOR",POSITIVE,"[WONG,LCK, WINSTON,JM, HONG,CB AND PLOTNICK,H; CARCINOGENICITY AND TOXICITY OF 1,2-DIBROMOETHANE IN THE RAT; TOXICOL. APPL. PHARMACOL. 63:155-165, 1982]"
1765,363898245,7839,C(CBr)Br,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 10; 40 PPM 6 HR/D, 5 D/WK FOR 90-103 WK (STUDY DURATION: 91-104 WK)","NASAL CAVITY: SQUAMOUS CELL PAPILLOMA, CARCINOMA",POSITIVE,"[STINSON,SF, REZNIK,G AND WARD,JM; CHARACTERISTICS OF PROLIFERATIVE LESIONS IN THE NASAL CAVITIES OF MICE FOLLOWING CHRONIC INHALATION OF 1,2-DIBROMOETHANE CANCER LETT. 12:121-129, 1981]"
1766,363898245,7839,C(CBr)Br,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 10; 40 PPM 6 HR/D, 5 D/WK FOR 90-103 WK (STUDY DURATION: 91-104 WK)",NASAL CAVITY: SQUAMOUS CELL PAPILLOMA,POSITIVE,"[STINSON,SF, REZNIK,G AND WARD,JM; CHARACTERISTICS OF PROLIFERATIVE LESIONS IN THE NASAL CAVITIES OF MICE FOLLOWING CHRONIC INHALATION OF 1,2-DIBROMOETHANE CANCER LETT. 12:121-129, 1981]"
1767,363898245,7839,C(CBr)Br,Active,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",ORAL,0; 2000 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),STOMACH: PAPILLOMA,POSITIVE,"[HENDRICKS,JD, SHELTON,DW, LOVELAND,PM, PEREIRA,CB AND BAILEY,GS; CARCINOGENICITY OF DIETARY DIMETHYLNITROSOMORPHOLINE, N-METHYL-N'-NITRO-N-NITROSOGUANIDINE, AND DIBROMOETHANE IN RAINBOW TROUT; TOXICOL. PATHOL. 23(4):447-457, 1995]"
1768,363898245,7839,C(CBr)Br,Active,,,,FISH,"JAPANESE MEDAKA/MALE,FEMALE",IMMERSION,0; 0.133; 6.2; 18.58 MG/L IN WATER FOR UP TO 97 D (STUDY DURATION: 58 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, CHOLANGIOMA, CHOLANGIOCELLULAR CARCINOMA; GALL BLADDER: TUMOR",POSITIVE,"[HAWKINS,WE, WALKER,WW, JAMES,MO, MANNING,CS, BARNES,DH, HEARD,CS AND OVERSTREET,RM; CARCINOGENIC EFFECTS OF 1,2-DIBROMOETHANE (ETHYLENE DIBROMIDE; EDB) IN JAPANESE MEDAKA (ORYZIAS LATIPES); MUTAT. RES. 399(2):221-232, 1998]"
1769,363898246,9033,C1CN1,Active,,,,MOUSE,,ORAL,,LUNG; LIVER,POSITIVE,"[INNES,JRM, ULLAND,B, VALERIO,MG, PETRUCELLI,L, FISHBEIN,L, HART,ER, PALLOTTA,AJ, BATES,RR, FALK,HL, GART,JJ, KLEIN,M, MITCHELL,I AND PETERS,J; BIOASSAY OF PESTICIDES AND INDUSTRIAL CHEMICALS FOR TUMORIGENICITY IN MICE: A PRELIMINARY NOTE;J. NATL. CANCER INST. 42:1101-1114, 1969]"
1770,363898246,9033,C1CN1,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[WALPOLE,AL, ROBERTS,DC, ROSE,FL, HENDRY,JA AND HOMER,RF; CYTOTOXIC AGENTS IV. THE CARCINOGENIC ACTIONS OF SOME MONOFUNCTIONAL ETHYLENE IMINE DERIVATIVES; BR. J. PHARMACOL. 9:306-323, 1954]"
1771,363898247,6354,C1CO1,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,7.5; 30 MG/KG IN SALAD OIL 2/WK FOR UP TO 150 WK,FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[DUNKELBERG,H; CARCINOGENICITY OF ETHYLENE OXIDE AND 1,2-PROPYLENE OXIDE UPON INTRAGASTRIC ADMINISTRATION TO RATS; BR. J. CANCER 46:924-933, 1982]"
1772,363898247,6354,C1CO1,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 50; 100 PPM 6 HR/D 5 D/WK FOR 102 WK (STUDY DURATION: 105 WK),LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; HARDERIAN GLAND: PAPILLARY CYSTADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-326 Y87]"
1773,363898247,6354,C1CO1,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 50; 100 PPM 6 HR/D 5 D/WK FOR 102 WK (STUDY DURATION: 105 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM: LYMPHOMA, ALL MALIGNANT; UTERUS: ADENOCARCINOMA; UTERUS: ADENOMA OR ADENOCARCINOMA; HARDERIAN GLAND: PAPILLARY CYSTADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-326 Y87]"
1774,363898247,6354,C1CO1,Active,,,,RAT,F344/MALE,INHALATION,0; 50; 100 PPM 7 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 2 YR),BRAIN: GLIOMA (MIXED CELL); PERITONEUM: MESOTHELIOMA; PITUITARY GLAND: ADENOMA; SPLEEN: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[LYNCH,DW, LEWIS,TR, MOORMAN,WJ, BURG,JR, GROTH,DH, KHAN,A, ACKERMAN,LJ AND COCKRELL,BY; CARCINOGENIC AND TOXICOLOGIC EFFECTS OF INHALED ETHYLENE OXIDE AND PROPYLENE OXIDE IN F344 RATS; TOXICOL. APPL. PHARMACOL. 76:69-84, 1984]"
1775,363898247,6354,C1CO1,Active,,,,RAT,F344/MALE,INHALATION,0; 10; 33; 100 PPM 6 HR/D 5 D/WK FOR UP TO 2 YR (STUDY DURATION: 24 MO),BRAIN: GRANULAR CELL TUMOR OR GLIAL CELL TUMOR OR ASTROCYTOMA OR MALIGNANT RETICULOSIS,POSITIVE,"[GARMAN,RH AND SNELLINGS,WM; FREQUENCY, SIZE AND LOCATION OF BRAIN TUMOURS IN F-344 RATS CHRONICALLY EXPOSED TO ETHYLENE OXIDE; FOOD CHEM. TOXICOL. 24(2):145-153, 1986]"
1776,363898247,6354,C1CO1,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 10; 33; 100 PPM 6 HR/D 5 D/WK FOR UP TO 2 YR (STUDY DURATION: 24 MO),,NEGATIVE,"[GARMAN,RH AND SNELLINGS,WM; FREQUENCY, SIZE AND LOCATION OF BRAIN TUMOURS IN F-344 RATS CHRONICALLY EXPOSED TO ETHYLENE OXIDE; FOOD CHEM. TOXICOL. 24(2):145-153, 1986]"
1777,363898247,6354,C1CO1,Active,,,,RAT,F344/MALE,INHALATION,0; 50; 100 PPM 7 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: LIFETIME),HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA; PERITONEUM: MESOTHELIOMA; BRAIN: GLIOMA,POSITIVE,"[LYNCH,DW, LEWIS,TR, MOORMAN, WJ, BURG,JR, LAL,JB, SETZER,JV, GROTH,DH, GULATI,DK, ZAVOS,PM, SABHARWAL,PS, ACKERMAN,LJ, COCKRELL,BY AND SPRINZ,H; EFFECTS ON MONKEYS AND RATS OF LONG-TERM INHALATION EXPOSURE TO ETHYLENE OXIDE: MAJOR FINDINGS OF THE NIOSH STUDY; AAMI TECHNOL. ASSESS. REP. 8-84 (INHOSPITAL ETHYLENE OXIDE STERIL.):7-10, 1984]"
1778,363898247,6354,C1CO1,Active,,,,RAT,F344/MALE,INHALATION,0; 10; 33; 100 PPM 6 HR/D 5 D/WK FOR STUDY DURATION (STUDY DURATION: 2 YR),"BRAIN: GRANULAR CELL TUMOR, ASTROCYTOMA, MIXED GLIOMA, OLIGODENDROGLIOMA, MALIGNANT RETICULOSIS",POSITIVE,"[GARMAN,RH, SNELLINGS,WM AND MARONPOT,RR; BRAIN TUMORS IN F344 RATS ASSOCIATED WITH CHRONIC INHALATION EXPOSURE TO ETHYLENE OXIDE; NEUROTOXICOLOGY 6(1):117-137, 1985]"
1779,363898247,6354,C1CO1,Active,,,,RAT,F344/FEMALE,INHALATION,0; 10; 33; 100 PPM 6 HR/D 5 D/WK FOR STUDY DURATION (STUDY DURATION: 2 YR),"BRAIN: ASTROCYTOMA, MIXED GLIOMA, OLIGODENDROGLIOMA, MALIGNANT RETICULOSIS",POSITIVE,"[GARMAN,RH, SNELLINGS,WM AND MARONPOT,RR; BRAIN TUMORS IN F344 RATS ASSOCIATED WITH CHRONIC INHALATION EXPOSURE TO ETHYLENE OXIDE; NEUROTOXICOLOGY 6(1):117-137, 1985]"
1780,363898247,6354,C1CO1,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,0; 0.1; 0.3; 1 MG/MOUSE IN TRICAPRYLIN 1/WK FOR 95 WK (STUDY DURATION: 110 WK),INJECTION SITE: TUMOR,POSITIVE,"[DUNKELBERG,H; CARCINOGENIC ACTIVITY OF ETHYLENE OXIDE AND ITS REACTION PRODUCTS 2-CHLOROETHANOL, 2-BROMOETHANOL, ETHYLENE GLYCOL AND DIETHYLENE GLYCOL. I. CARCINOGENICITY OF ETHYLENE OXIDE IN COMPARISON WITH 1,2-PROPYLENE OXIDE AFTER SUBCUTANEOUS ADMINISTRATION IN MICE; ZBL. BAKT. HYG. I. ABT. ORIG. B 174:383-404, 1981]"
1781,363898248,2723650,C1CNC(=S)N1,Active,,,,MOUSE,"B6AKF1/MALE,FEMALE",GAVAGE/ORAL,215 MG/KG IN GELATIN FROM DAY 7-28 OF LIFE THEN 646 PPM IN DIET,LIVER: HEPATOMA; LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[INNES,JRM, ULLAND,B, VALERIO,MG, PETRUCELLI,L, FISHBEIN,L, HART,ER, PALLOTTA,AJ, BATES,RR, FALK,HL, GART,JJ, KLEIN,M, MITCHELL,I AND PETERS,J; BIOASSAY OF PESTICIDES AND INDUSTRIAL CHEMICALS FOR TUMORIGENICITY IN MICE: A PRELIMINARY NOTE;J. NATL. CANCER INST. 42:1101-1114, 1969]"
1782,363898248,2723650,C1CNC(=S)N1,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE/ORAL,215 MG/KG IN GELATIN FROM DAY 7-28 OF LIFE THEN 646 PPM IN DIET,LIVER: HEPATOMA; LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[INNES,JRM, ULLAND,B, VALERIO,MG, PETRUCELLI,L, FISHBEIN,L, HART,ER, PALLOTTA,AJ, BATES,RR, FALK,HL, GART,JJ, KLEIN,M, MITCHELL,I AND PETERS,J; BIOASSAY OF PESTICIDES AND INDUSTRIAL CHEMICALS FOR TUMORIGENICITY IN MICE: A PRELIMINARY NOTE;J. NATL. CANCER INST. 42:1101-1114, 1969]"
1783,363898248,2723650,C1CNC(=S)N1,Active,,,,RAT,"STRAIN-CD/MALE,FEMALE",ORAL,175; 350 PPM IN DIET FOR 78 WK,THYROID GLAND: FOLLICULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 45 Y74][WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981, ]"
1784,363898248,2723650,C1CNC(=S)N1,Active,,,,RAT,F344/MALE,ORAL,0; 83; 250 PPM IN FEED FOR 24 MO (STUDY DURATION: 2 YR),"THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-388 Y92]"
1785,363898248,2723650,C1CNC(=S)N1,Active,,,,RAT,F344/FEMALE,ORAL,0; 83; 250 PPM IN FEED FOR 24 MO (STUDY DURATION: 2 YR),"THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-388 Y92]"
1786,363898248,2723650,C1CNC(=S)N1,Active,,,,RAT,F344/MALE,ORAL,"0; 25; 83; 83; 250 PPM IN FEED FOR 24 MO, ADMINISTRATION BEGUN AT 8 WK OF AGE TO ANIMALS EXPOSED PERINATALLY BY DOSES TO MOTHERS OF 0; 9 (25 PPM GROUP); 30 (83 PPM GROUP); 90 (83 AND 250 PPM GROUPS) PPM (STUDY DURATION: 2 YR)","THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-388 Y92]"
1787,363898248,2723650,C1CNC(=S)N1,Active,,,,RAT,F344/FEMALE,ORAL,"0; 25; 83; 83; 250 PPM IN FEED FOR 24 MO, ADMINISTRATION BEGUN AT 8 WK OF AGE TO ANIMALS EXPOSED PERINATALLY BY ORAL DOSES TO MOTHERS OF 0; 9 (25 PPM GROUP); 30 (83 PPM GROUP); 90 (83 PPM GROUP); 90 (250 PPM GROUP) PPM (STUDY DURATION: 2 YR)","THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-388 Y92]"
1788,363898248,2723650,C1CNC(=S)N1,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 330; 1000 PPM IN FEED FOR 24 MO (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR CARCINOMA; PITUITARY GLAND, PARS DISTALIS: ADENOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-388 Y92]"
1789,363898248,2723650,C1CNC(=S)N1,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 330; 1000 PPM IN FEED FOR 24 MO (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; PITUITARY GLAND, PARS DISTALIS: ADENOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-388 Y92]"
1790,363898248,2723650,C1CNC(=S)N1,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 100; 330; 330; 1000 PPM IN FEED FOR 24 MO, ADMINISTRATION BEGUN AT 8 WK OF AGE TO ANIMALS EXPOSED PERINATALLY BY ORAL DOSES TO MOTHERS OF 0; 33 (100 PPM GROUP); 110 (330 PPM GROUP); 330 (330 PPM GROUP); 330 (1000 PPM GROUP) PPM (STUDY DURATION: 2 YR)","LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-388 Y92]"
1791,363898248,2723650,C1CNC(=S)N1,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 100; 330; 330; 1000 PPM IN FEED FOR 24 MO, ADMINISTRATION BEGUN AT 8 WK OF AGE TO ANIMALS EXPOSED PERINATALLY BY ORAL DOSES TO MOTHERS OF 0; 33 (100 PPM GROUP); 110 (330 PPM GROUP); 330 (330 PPM GROUP); 330 (1000 PPM GROUP) PPM (STUDY DURATION: 2 YR)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; PITUITARY GLAND, PARS DISTALIS: ADENOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-388 Y92]"
1792,363898249,6113,CCOS(=O)(=O)C,Active,,,,MOUSE,,SUBCUTANEOUS,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 245 Y74]"
1793,363898249,6113,CCOS(=O)(=O)C,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 245 Y74]"
1794,363898249,6113,CCOS(=O)(=O)C,Active,,,,RAT,,INTRAPERITONEAL,,LUNG; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 245 Y74]"
1795,363898249,6113,CCOS(=O)(=O)C,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,"0; 20 UMOL/MOUSE IN TRIOCTANOIN INTO LEFT FLANK, 1/WK FOR 52 WK (STUDY DURATION: 450 D)",THYMUS GLAND: LYMPHOMA; LUNG: ADENOMA,POSITIVE,"[SEGAL,A AND SELLAKUMAR,A; INDUCIBILITY OF THYMIC LYMPHOMAS IN FEMALE HSD: (ICR)BR MICE FOLLOWING SUBCUTANEOUS INJECTION OF ETHYL- AND ISOPROPYL METHANESULFONATE; CANCER LETT. 44(3):199-204, 1989]"
1796,363898250,5473908,CCN(/C(=N\[N+](=O)[O-])/N)N=O,Active,,,,HAMSTER,SYRIAN,ORAL,91 UG/ML IN DRINKING WATER FOR 12 MO,DUODENUM: ADENOCARCINOMA; STOMACH: ADENOCARCINOMA,POSITIVE,"[KAWACHI,T, KOGURE,K, TANAKA,N, TOKUNAGA,A, FUJIMURA,S AND SUGIMURA,T; INDUCTION OF TUMORS IN THE STOMACH AND DUODENUM OF HAMSTERS BY N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE; Z. KREBSFORSCH. 81:29-36, 1974]"
1797,363898250,5473908,CCN(/C(=N\[N+](=O)[O-])/N)N=O,Active,,,,MOUSE,"CBA/MALE,FEMALE",ORAL,50 MG/L FOR 10 MO IN DRINKING WATER,"ESOPHAGUS: PAPILLOMA, SQUAMOUS CELL CARCINOMA; DUODENUM: ADENOCARCINOMA",POSITIVE,"[NAKAMURA,T, MATSUYAMA,M AND KISHIMOTO,H; TUMORS OF THE ESOPHAGUS AND DUODENUM INDUCED IN MICE BY ORAL ADMINISTRATION OF N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE; J. NATL. CANCER INST. 52:519-521, 1974]"
1798,363898250,5473908,CCN(/C(=N\[N+](=O)[O-])/N)N=O,Active,,,,MOUSE,ICR/MALE,DERMAL,0.05 ML OF 0.5% SOLN 3/WK FOR 5 MO,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, CARCINOMA",POSITIVE,"[TAKAYAMA,S, KUWABARA,N, AZAMA,Y AND SUGIMURA,T; SKIN TUMORS IN MICE PAINTED WITH N-METHYL-N'-NITRO-N-NITROSOGUANIDINE AND N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE; J. NATL. CANCER INST. 46:973-980, 1971]"
1799,363898250,5473908,CCN(/C(=N\[N+](=O)[O-])/N)N=O,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0.25 ML OF 5.425; 50 MG/KG 1/WK,INJECTION SITE,POSITIVE,"[SANO,T, KAWACHI,T, MATSUKURA,N, NAKADATE,M, SUGIMURA,T AND MORIYAMA,M; COMPARISON OF CARCINOGENICITY OF N-ALKYL-N'-NITRO-N-NITROSOGUANIDINES; GANN 69:277-279, 1978]"
1800,363898250,5473908,CCN(/C(=N\[N+](=O)[O-])/N)N=O,Active,,,,RAT,DONRYU/FEMALE,INTRAUTERINE,0; 20 MG/KG IN POLYETHYLENE GLYCOL ONCE AT 10 WK OF AGE (STUDY DURATION: 12.5 MO),UTERUS: ENDOMETRIAL ADENOCARCINOMA,POSITIVE,"[ANDO-LU,J, TAKAHASHI,M, IMAI,S, ISHIHARA,R, KITAMURA,T, IIJIMA,T, TAKANO,S, NISHIYAMA,K, SUZUKI,K AND MAEKAWA,A; HIGH-YIELD INDUCTION OF UTERINE ENDOMETRIAL ADENOCARCINOMA IN DONRYU RATS BY A SINGLE INTRA-UTERINE ADMINISTRATION OF N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE VIA THE VAGINA; JPN. J. CANCER RES. 85(8):789-793, 1994]"
1801,363898250,5473908,CCN(/C(=N\[N+](=O)[O-])/N)N=O,Active,,,,RAT,DONRYU/FEMALE,INTRAUTERINE,0; 20 MG/KG BW ONCE ADMINISTERED TO PERSISTENT ESTROUS RATS (STUDY DURATION: 42 WK),UTERUS: ADENOCARCINOMA,POSITIVE,"[TAKAHASHI,M, ANDO-LU,J, IIJIMA,T, ISHIHARA,R, IMAI,S, KITAMURA,T, WAKABAYASHI, K AND MAEKAWA,A; INDUCTION OF ENDOMETRIAL ADENOCARCINOMAS IN PERSISTENT ESTROUS DONRYU RATS BY A SINGLE INTRA-UTERINE ADMINISTRATION OF N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE; IN VIVO 8(6):1047-1052, 1994]"
1802,363898251,20680,CCCCN(CC)N=O,Active,,,,MOUSE,"DBA/MALE,FEMALE",ORAL,10 MG/KG/D IN DRINKING WATER (TOTAL MEAN DOSE 2360 MG/KG),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 179]"
1803,363898251,20680,CCCCN(CC)N=O,Active,,,,RAT,"WISTAR/MALE, FEMALE",ORAL,0; 10 MG/KG/D FOR 4 WK THEN 5 MG/KG/D FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),"ESOPHAGUS: CARCINOMA, PAPILLOMA; PHARYNX: PAPILLOMA; ORAL CAVITY: PAPILLOMA; LIVER: ANGIOSARCOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[MANDARD,AM, MARNAY,J, HERLIN,P, ELIE,H, TUYNS,AJ AND LE TALAER,JY; TUMORS OF THE ESOPHAGUS INDUCED IN WISTAR RATS BY ORAL ADMINISTRATION OF N-ETHYL-N- BUTYL-NITROSAMINE; BULL. CANCER 71(5):419-424, 1984]"
1804,363898252,12967,CCN(C(=O)N)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAPERITONEAL,60; 274 MG/KG IN SODIUM CHLORIDE/SODIUM CITRATE ONCE,FORESTOMACH: SQUAMOUS CELL PAPILLOMA,POSITIVE,"[LIKHACHEV,AJ, IVANOV,MN, BRESIL,H, PLANCHE-MARTEL,G, MONTESANO,R AND MARGISON, GP; CARCINOGENICITY OF SINGLE DOSES OF N-NITROSO-N-METHYLUREA AND N-NITROSO-N-ETHYLUREA IN SYRIAN GOLDEN HAMSTERS AND THE PERSISTENCE OF ALKYLATED PURINES IN THE DNA OF VARIOUS TISSUES; CANCER RES. 43:829-833, 1983]"
1805,363898252,12967,CCN(C(=O)N)N=O,Active,,,,MOUSE,,SUBCUTANEOUS,,LIVER; LUNG; LYMPHATIC SYSTEM,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 191 Y78]"
1806,363898252,12967,CCN(C(=O)N)N=O,Active,,,,MOUSE,,INTRAPERITONEAL,,LIVER; KIDNEY; OVARIES; LUNG; HARDERIAN GLAND; LYMPHATIC SYSTEM; STOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 191 Y78]"
1807,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,,ORAL,,BRAIN; NERVOUS SYSTEM (PERIPHERAL); HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 191 Y78]"
1808,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,,SUBCUTANEOUS,,BRAIN; NERVOUS SYSTEM (PERIPHERAL),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 191 Y78]"
1809,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,,INTRAPERITONEAL,,LYMPHATIC SYSTEM: LYMPHOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 191 Y78]"
1810,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,,INTRAVENOUS,,BRAIN; NERVOUS SYSTEM (PERIPHERAL); HEMATOPOIETIC SYSTEM (LEUKEMIA); UTERUS; VAGINA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 191 Y78]"
1811,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,,PRE-NATAL EXPOSURE,,NERVOUS SYSTEM,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 191 Y78]"
1812,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 0.3; 1; 3; 10 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 111 WK),BRAIN: GLIOMA; MAMMARY GLAND: FIBROMA; LUNG: ADENOMA; LUNG: ADENOCARCINOMA; PERITONEUM: MESOTHELIOMA,POSITIVE,"[MAEKAWA,A, OGIU,T, MATSUOKA,C, ONODERA,H, FURUTA,K, KUROKAWA,Y, TAKAHASHI,M, KOKUBO,T, TANIGAWA,H, HAYASHI,Y, NAKADATE,M AND TANIMURA,A; CARCINOGENICITY OF LOW DOSES OF N-ETHYL-N-NITROSOUREA IN F344 RATS. A DOSE-RESPONSE STUDY; GANN. 75:117-125, 1984]"
1813,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.3; 1; 3; 10 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 111 WK),BRAIN: GLIOMA; UTERUS: ENDOMETRIAL STROMAL POLYP; MAMMARY GLAND: ADENOCARCINOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[MAEKAWA,A, OGIU,T, MATSUOKA,C, ONODERA,H, FURUTA,K, KUROKAWA,Y, TAKAHASHI,M, KOKUBO,T, TANIGAWA,H, HAYASHI,Y, NAKADATE,M AND TANIMURA,A; CARCINOGENICITY OF LOW DOSES OF N-ETHYL-N-NITROSOUREA IN F344 RATS. A DOSE-RESPONSE STUDY; GANN. 75:117-125, 1984]"
1814,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 6 MG/ML (TOTAL DOSE 0; 0.4 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 20 WK (STUDY DURATION: LIFETIME),"FORESTOMACH: SQUAMOUS CELL CARCINOMA; THYROID: C-CELL TUMOR, FOLLICULAR CELL TUMOR; LUNG: TUMOR; NERVOUS SYSTEM: TUMOR; COLON: TUMOR; BODY CAVITY: MESOTHELIOMA; ZYMBAL GLAND: TUMOR; SKIN: TUMOR",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
1815,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 12 MG/ML (TOTAL DOSE 0; 1.1 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 28 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: TUMOR; ILEUM/JEJUNUM: TUMOR; BODY CAVITY: MESOTHELIOMA; ZYMBAL GLAND: TUMOR; SKIN,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
1816,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 6; 12 MG/ML (TOTAL DOSE 0; 0.4; 0.8 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 20 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: TUMOR; MAMMARY GLAND: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
1817,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 1.2 MG 2/WK FOR 20 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
1818,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 2.4 MG 2/WK FOR 14 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
1819,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 2.4 MG IN 0.2 ML ETHYL ACETATE/CORN OIL (1:1) 2/WK FOR 28 WK (TOTAL DOSE: 135 MG) (STUDY DURATION: 80 WK),FORESTOMACH: CARCINOMA; LUNG: CARCINOMA OR ADENOMA,POSITIVE,"[LIJINSKY,W, SINGER,GM AND KOVATCH,RM; SIMILAR CARCINOGENIC EFFECTS IN RATS OF 1-ETHYL-1-NITROSO-3-HYDROXYETHYLUREA AND 1-HYDROXYETHYL-1-NITROSO-3- ETHYLUREA; CARCINOGENESIS 6(4):641-643, 1985]"
1820,363898252,12967,CCN(C(=O)N)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 12 MG/ML ((0.2 ML OF A SOLUTION IN ETHYL ACETATE/CORN OIL (1:2)) 1/WK FOR 20 WK (STUDY DURATION: LIFE SPAN),SPLEEN: HEMANGIOSARCOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA OR PAPILLOMA,POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
1821,363898252,12967,CCN(C(=O)N)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 12 MG/ML ((0.2 ML OF A SOLUTION IN ETHYL ACETATE/CORN OIL (1:2)) 1/WK FOR 20 WK (STUDY DURATION: 20 WK),SPLEEN: HEMANGIOSARCOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA OR PAPILLOMA,POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
1822,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,"WISTAR/MALE, FEMALE",TRANSPLACENTAL,0; 60 MG/KG BW INTRAVENOUS DOSE ADMINISTERED TO LATE GESTATIONAL RATS AND OFFSPRING OBSERVED FOR 12 MO (STUDY DURATION: 12 MO),CENTRAL NERVOUS SYSTEM: GLIOMA,POSITIVE,"[BIAN,X, SHI,J, TAO,H, YANG,G AND XIN,R; AN EXPERIMENTAL STUDY ON N-ETHYL-N-NITROSOUREA-INDUCED RAT BRAIN GLIOMAS; J. MED. COLL. PLA 9(4): 241-245, 1994]"
1823,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,"WISTAR/MALE, FEMALE",SUBCUTANEOUS,0; 60 MG/KG BW ADMINISTERED TO 3 DAY OLD RATS (STUDY DURATION: 12 MO),CENTRAL NERVOUS SYSTEM: GLIOMA,POSITIVE,"[BIAN,X, SHI,J, TAO,H, YANG,G AND XIN,R; AN EXPERIMENTAL STUDY ON N-ETHYL-N-NITROSOUREA-INDUCED RAT BRAIN GLIOMAS; J. MED. COLL. PLA 9(4): 241-245, 1994]"
1824,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 6 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 20 WK (STUDY DURATION: LIFESPAN),"FORESTOMACH: TUMOR; THYROID: C-CELL TUMOR, FOLLICULAR CELL TUMOR; LUNG: TUMOR; NERVOUS SYSTEM: TUMOR; COLON: TUMOR; PERITONEUM: MESOTHELIOMA; ZYMBAL GLAND: TUMOR; SKIN: TUMOR",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
1825,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 12 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 28 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LUNG: TUMOR; ILEUM/JEJUNUM: TUMOR; PERITONEUM: MESOTHELIOMA,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
1826,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 6; 12 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 20 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LUNG: TUMOR; MAMMARY GLAND: TUMOR; UTERUS: TUMOR; ZYMBAL GLAND: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
1827,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,IN UTERO,0; 2.5; 10 MG/KG BW ONCE ADMINISTERED INTRAVENOUSLY ON DAY 15 OF GESTATION (STUDY DURATION: 104 WK),BRAIN: GLIOMA,POSITIVE,"[ZOOK,BC SIMMENS,SJ AND JONES,RV; EVALUATION OF ENU-INDUCED GLIOAS RATS: NOMENCLATURE, IMMUNOCHEMISTRY, AND MALIGNANCY; TOXICOL. PATHOL. 28(1):193-201, 2000]"
1828,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,IN UTERO,0; 2.5; 10 MG/KG BW ONCE ADMINISTERED INTRAVENOUSLY ON DAY 15 OF GESTATION (STUDY DURATION: 104 WK),BRAIN: GLIOMA,POSITIVE,"[ZOOK,BC SIMMENS,SJ AND JONES,RV; EVALUATION OF ENU-INDUCED GLIOAS RATS: NOMENCLATURE, IMMUNOCHEMISTRY, AND MALIGNANCY; TOXICOL. PATHOL. 28(1):193-201, 2000]"
1829,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,300 MG/KG BW 1/WK FOR 45 WK (STUDY DURATION: 45 WK),INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): SPINDLE CELL SARCOMA,POSITIVE,"[OZDEMIR,O BARDAKCI,F EGILMEZ,H ANG EGILMEZ,R; SUBCUTANEOUS UNDIFFERENTIATED SARCOMA INDUCED BY N'-ETHYL-N'-NITROSOUREA IN RAT: RADIOLOGY, HISTOPATHOLOGY AND MUTAGENESIS; EXP. TOXICOL. PATHOL. 55(4):295-300, 2003]"
1830,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,SPRAGUE-DAWLEY,INTRAVENOUSLY TO MATERNAL RATS AT 15 D OF GESTATION; PROGENY OBSERVED,0; 2.5; 6.25; 10.0 MG/KG BW (STUDY DURATION: 24 MO),BRAIN: OLIGODENDRO-GLIOMA AND MIXED GLIOMA,POSITIVE,"[ZOOK,BC AND SIMMENS,SJ; NEUROGENIC TUMORS IN RATS INDUCED BY ETHYLNITROSOUREA; EXP. TOXICOL. PATHOL. 57(1):7-14, 2005]"
1831,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,SPRAGUE-DAWLEY,INTRAVENOUSLY TO MOTHERS AT 15 D OF GESTATION; PROGENY OBSERVED,0; 2.5; 6.25; 10.0 MG/KG BW (STUDY DURATION: 2 YRS),SPINAL NERVE: TUMORS,POSITIVE,"[ZOOK,BC AND SIMMENS,SJ; NEUROGENIC TUMORS IN RATS INDUCED BY ETHYLNITROSOUREA; EXP. TOXICOL. PATHOL. 57(1):7-14, 2005]"
1832,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,SPRAGUE-DAWLEY,INTRAVENOUSLY TO MOTHERS AT 15 D OF GESTATION; PROGENY OBSERVED,0; 2.5; 6.25; 10.0 MG/KG BW (STUDY DURATION: 24 MO),SPINAL CORD: TUMORS,POSITIVE,"[ZOOK,BC AND SIMMENS,SJ; NEUROGENIC TUMORS IN RATS INDUCED BY ETHYLNITROSOUREA; EXP. TOXICOL. PATHOL. 57(1):7-14, 2005]"
1833,363898252,12967,CCN(C(=O)N)N=O,Active,,,,RAT,SPRAGUE-DAWLEY,INTRAVENOUSLY TO MOTHERS AT 15 D OF GESTATION; PROGENY OBSERVED,0; 2.5; 6.25; 10.0 MG/KG BW (STUDY DURATION: 2 YRS),CRANIAL NERVE: TUMORS,POSITIVE,"[ZOOK,BC AND SIMMENS,SJ; NEUROGENIC TUMORS IN RATS INDUCED BY ETHYLNITROSOUREA; EXP. TOXICOL. PATHOL. 57(1):7-14, 2005]"
1834,363898253,25807,CCN(C=C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0.63-5 MG/KG IN OLIVE OIL 1/WK FOR LIFE,"NASAL CAVITY: PAPILLOMA, EPIDERMOID CARCINOMA, ADENOCARCINOMA; LARYNX: PAPILLOMA, EPIDERMOID CARCINOMA; TRACHEA: PAPILLOMA, EPIDERMOID CARCINOMA",POSITIVE,"[GREEN,U AND ALTHOFF,J; CARCINOGENICITY OF VINYLETHYLNITROSAMINE IN SYRIAN GOLDEN HAMSTERS; J. CANCER RES. CLIN. ONCOL. 102:227-233, 1982]"
1835,363898253,25807,CCN(C=C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0.63-5 MG/KG IN OLIVE OIL 1/WK FOR LIFE,"NASAL CAVITY: PAPILLOMA, EPIDERMOID CARCINOMA, ADENOCARCINOMA; LARYNX: PAPILLOMA, EPIDERMOID CARCINOMA; TRACHEA: PAPILLOMA, EPIDERMOID CARCINOMA",POSITIVE,"[GREEN,U AND ALTHOFF,J; CARCINOGENICITY OF VINYLETHYLNITROSAMINE IN SYRIAN GOLDEN HAMSTERS; J. CANCER RES. CLIN. ONCOL. 102:227-233, 1982]"
1836,363898253,25807,CCN(C=C)N=O,Active,,,,RAT,,ORAL,1.30; 2.50 MG/KG 7/WK (MEAN TOTAL DOSE 0.23; 0.42 G/KG),ESOPHAGUS,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 99]"
1837,363898253,25807,CCN(C=C)N=O,Active,,,,RAT,,INTRAVENOUS,10.0 MG/KG 1/WK(MEAN TOTAL DOSE 0.25 G/KG),ESOPHAGUS,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 99]"
1838,363898254,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 150; 300 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-152 Y79]"
1839,363898254,,,Unspecified,,,,RAT,F344/MALE,ORAL,0; 300; 600 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),BODY CAVITY: MESOTHELIOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-152 Y79]"
1840,363898254,,,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500 IN DIET FOR FIRST 40 WK FOLLOWED BY 500 PPM IN DIET FOR LAST 66 WK; 5000 PPM IN DIET FOR FIRST 40 WK FOLLOWED BY 2000 PPM IN DIET FOR LAST 66 WK (STUDY DURATION: 106 WK),HARDERIAN GLAND: ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-152 Y79]"
1841,363898254,,,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500 IN DIET FOR FIRST 37 WK FOLLOWED BY 500 PPM IN DIET FOR 3 WK FOLLOWED BY 2000 PPM IN DIET FOR LAST 66 WK; 5000 PPM IN DIET FOR FIRST 37 WK FOLLOWED BY 2000 PPM IN DIET FOR 3 WK FOLLOWED BY 5000 PPM IN DIET FOR LAST 66 WK (STUDY DURATION: 106 WK),HARDERIAN GLAND: ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-152 Y79]"
1842,363898255,9270,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,Active,,,,MOUSE,,ORAL,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 173 Y74]"
1843,363898255,9270,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,Active,,,,RAT,,ORAL,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 387 Y79][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 173 Y74]"
1844,363898256,3314,COC1=C(C=CC(=C1)CC=C)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 6000; 12500 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-223 Y83]"
1845,363898256,3314,COC1=C(C=CC(=C1)CC=C)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-223 Y83]"
1846,363898256,3314,COC1=C(C=CC(=C1)CC=C)O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-223 Y83]"
1847,363898256,3314,COC1=C(C=CC(=C1)CC=C)O,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-223 Y83]"
1848,363898257,4685,C1=CC(=CC=C1Cl)Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 150; 300 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"KIDNEY: TUBULAR CELL ADENOCARCINOMA, TUBULAR CELL ADENOMA OR ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-319 Y87]"
1849,363898257,4685,C1=CC(=CC=C1Cl)Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 300; 600 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-319 Y87]"
1850,363898257,4685,C1=CC(=CC=C1Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 300; 600 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-319 Y87]"
1851,363898257,4685,C1=CC(=CC=C1Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 300; 600 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-319 Y87]"
1852,363898257,4685,C1=CC(=CC=C1Cl)Cl,Active,,,,MOUSE,CRJ:BDF1/MALE,INHALATION,"0; 20; 75; 300 PPM 6 HR/D, 5 D/WK FOR 2 YRS (STUDY DURATION: 2 YRS)",LIVER: HEPATOCELLULAR CARCINOMA; LIVER: HEPATOBLASTOMA; HISTIOCYTIC SARCOMA,POSITIVE,"[AISO,S, TAKEUCHI,T, ARITO,H, NAGANO,K, YAMAMOTO,S AND MATSUSHIMA,T; CARCINOGENICITY AND CHRONIC TOXICOTY IN MICE AND RATS EXPOSED BY INHALATION TO PARA-DICHLOROBENZENE FOR TWO YEARS; J. VET. MED. SCI. 67(10):1019-1029, 2005]"
1853,363898257,4685,C1=CC(=CC=C1Cl)Cl,Active,,,,MOUSE,CRJ:BDF1/FEMALE,INHALATION,"0; 20; 75; 300 PPM 6 HR/D, 5 D/WK FOR 2 YRS (STUDY DURATION: 2 YRS)",LIVER: HEPATOCELLULAR ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA; LIVER: HEPATOBLASTOMA,POSITIVE,"[AISO,S, TAKEUCHI,T, ARITO,H, NAGANO,K, YAMAMOTO,S AND MATSUSHIMA,T; CARCINOGENICITY AND CHRONIC TOXICOTY IN MICE AND RATS EXPOSED BY INHALATION TO PARA-DICHLOROBENZENE FOR TWO YEARS; J. VET. MED. SCI. 67(10):1019-1029, 2005]"
1854,363898257,4685,C1=CC(=CC=C1Cl)Cl,Inactive,,,,RAT,"F344/MALE, FEMALE",INHALATION,"0; 20; 75; 300 PPM 6 HR/D, 5 D/WK FOR 2 YRS (STUDY DURATION: 2 YRS)",,NEGATIVE,"[AISO,S, TAKEUCHI,T, ARITO,H, NAGANO,K, YAMAMOTO,S AND MATSUSHIMA,T; CARCINOGENICITY AND CHRONIC TOXICOTY IN MICE AND RATS EXPOSED BY INHALATION TO PARA-DICHLOROBENZENE FOR TWO YEARS; J. VET. MED. SCI. 67(10):1019-1029, 2005]"
1855,363898258,32486,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,Active,,,,DOG,,ORAL,,URINARY BLADDER; GALL BLADDER,POSITIVE,"[GRUBBS,CJ, ETO,I, JULIANA,MM AND WHITAKER,LM; EFFECT OF CANTHAXANTHIN ON CHEMICALLY INDUCED MAMMARY CARCINOGENESIS; ONCOLOGY 48:239-245, 1991]"
1856,363898258,32486,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,Active,,,,MOUSE,,ORAL,,URINARY BLADDER,POSITIVE,"[GRUBBS,CJ, ETO,I, JULIANA,MM AND WHITAKER,LM; EFFECT OF CANTHAXANTHIN ON CHEMICALLY INDUCED MAMMARY CARCINOGENESIS; ONCOLOGY 48:239-245, 1991]"
1857,363898258,32486,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,Active,,,,RAT,F344/MALE,ORAL,0.001-0.2% IN DIET FOR 30 WK,URINARY BLADDER: CARCINOMA,POSITIVE,"[ARAI,M, ST. JOHN,M, FUKUSHIMA,S, FRIEDELL,GH AND COHEN,SM; LONG TERM DOSE RESPONSE STUDY OF N-(4-(5-NITRO-2-FURYL)-2-THIAZOLYL)FORMAMIDE-INDUCED URINARY BLADDER CARCINOGENESIS; CANCER LETT. 18:261-269, 1983]"
1858,363898258,32486,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0.188% IN DIET FOR 20 WK THEN BASAL DIET FOR 20 WK,URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[WANG,CY, CROFT,WA AND BRYAN,GT; TUMOR PRODUCTION IN GERM-FREE RATS FED 5-NITROFURANS; CANCER LETT. 21:303-308, 1984]"
1859,363898258,32486,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,Active,,,,RAT,,ORAL,,KIDNEY; MAMMARY GLAND,POSITIVE,"[GRUBBS,CJ, ETO,I, JULIANA,MM AND WHITAKER,LM; EFFECT OF CANTHAXANTHIN ON CHEMICALLY INDUCED MAMMARY CARCINOGENESIS; ONCOLOGY 48:239-245, 1991]"
1860,363898258,32486,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,Active,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.1% IN DIET FOR 36 WK (STUDY DURATION: 81 WK),"BLADDER: TRANSITIONAL CELL CARCINOMA, SPINDLE CELL TUMOR, SQUAMOUS CELL CARCINOMA",POSITIVE,"[DUNSFORD,HA, KEYSSER,CH, DOLAN,PM, SEED,JL AND BUEDING,E; CARCINOGENICITY OF THE ANTISCHISTOSOMAL NITROFURAN TRANS-5-AMINO-3-[2-(5-NITRO-2-FURYL)VINYL]-1,2,4- OXADIAZOLE; JNCI, J. NATL. CANCER INST. 73(1):151-160, 1984]"
1861,363898258,32486,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,Active,,,,MOUSE,CD-1/MALE,ORAL,0; 0.1% IN DIET FOR 40 WK (STUDY DURATION: 70 WK),"BLADDER: TRANSITIONAL CELL CARCINOMA, SPINDLE CELL TUMOR, SQUAMOUS CELL CARCINOMA",POSITIVE,"[DUNSFORD,HA, KEYSSER,CH, DOLAN,PM, SEED,JL AND BUEDING,E; CARCINOGENICITY OF THE ANTISCHISTOSOMAL NITROFURAN TRANS-5-AMINO-3-[2-(5-NITRO-2-FURYL)VINYL]-1,2,4- OXADIAZOLE; JNCI, J. NATL. CANCER INST. 73(1):151-160, 1984]"
1862,363898258,32486,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NC=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.188% IN DIET FOR 20 WK FOLLOWED BY CONTROL DIET FOR 20 WK (STUDY DURATION: 40 WK),BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[WANG,CY, CROFT,WA AND BRYAN,GT; TUMOR PRODUCTION IN GERM-FREE RATS FED 5-NITROFURANS; CANCER LETT. 21:303-308, 1984]"
1863,363898259,23668198,CN(C)C1=CC=C(C=C1)N=NS(=O)(=O)[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.05; 0.10% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-101 Y78]"
1864,363898259,23668198,CN(C)C1=CC=C(C=C1)N=NS(=O)(=O)[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.10; 0.19% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-101 Y78]"
1865,363898259,23668198,CN(C)C1=CC=C(C=C1)N=NS(=O)(=O)[O-].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 0.05; 0.10% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-101 Y78]"
1866,363898259,23668198,CN(C)C1=CC=C(C=C1)N=NS(=O)(=O)[O-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,"0; 0.05; 0.10% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-101 Y78]"
1867,363898260,3346,CC1=C(C=CC(=C1)OP(=S)(OC)OC)SC,Inactive,,,,Rat,Fischer 344/Male (50/Group),Oral,0 (corn oil); 5; 20; 100 ppm in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENTHION (December 2, 1997)]"
1868,363898260,3346,CC1=C(C=CC(=C1)OP(=S)(OC)OC)SC,Inactive,,,,Rat,Fischer 344/Female (50/Group),Oral,0 (corn oil); 5; 20; 100 ppm in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENTHION (December 2, 1997)]"
1869,363898260,3346,CC1=C(C=CC(=C1)OP(=S)(OC)OC)SC,Inactive,,,,Mouse,B6C3F1/Male (60/group),Oral,0; 0.1; 1; 5; 25 ppm in diet for up to 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENTHION (December 2, 1997)]"
1870,363898260,3346,CC1=C(C=CC(=C1)OP(=S)(OC)OC)SC,Inactive,,,,Mouse,B6C3F1/Female (60/group),Oral,0; 0.1; 1; 5; 25 ppm in diet for up to 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENTHION (December 2, 1997)]"
1871,363898260,3346,CC1=C(C=CC(=C1)OP(=S)(OC)OC)SC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10; 20 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-103 Y79]"
1872,363898260,3346,CC1=C(C=CC(=C1)OP(=S)(OC)OC)SC,Inactive,,,,RAT,F344/MALE,ORAL,0; 10; 20 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-103 Y79]"
1873,363898261,3347,CC(C)C(C1=CC=C(C=C1)Cl)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,Inactive,,,,Rat,Sprague-Dawley/Male and female (93/Experimental group and 183/Control group),Oral,0; 1; 5; 25; 250 ppm in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENVALERATE AND ESFENVALERATE (February 21, 2001)]"
1874,363898261,3347,CC(C)C(C1=CC=C(C=C1)Cl)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,Inactive,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",ORAL,1; 5; 25; 250; 1000 PPM (IN ACETONE OR HEXANE) IN DIET FOR 2 YR,,NEGATIVE,"[PARKER,CM, PATTERSON,DR, VAN GELDER,GA, GORDON,EB, VALERIO,MG AND HALL,WC; CHRONIC TOXICITY AND CARCINOGENICITY EVALUATION OF FENVALERATE IN RATS; J. TOXICOL. ENVIRON. HEALTH 13:83-97, 1984]"
1875,363898261,3347,CC(C)C(C1=CC=C(C=C1)Cl)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 10; 50; 250; 1250 PPM IN THE DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[PARKER,CM, MCCULLOUGH,CB, GELLATLY,JBM AND JOHNSTON,CD; TOXICOLOGIC AND CARCINOGENIC EVALUATION OF FENVALERATE IN THE B6C3F1 MOUSE; FUNDAM. APPL. TOXICOL. 3:114-120, 1983]"
1876,363898261,3347,CC(C)C(C1=CC=C(C=C1)Cl)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10; 50; 250; 1250 PPM IN THE DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[PARKER,CM, MCCULLOUGH,CB, GELLATLY,JBM AND JOHNSTON,CD; TOXICOLOGIC AND CARCINOGENIC EVALUATION OF FENVALERATE IN THE B6C3F1 MOUSE; FUNDAM. APPL. TOXICOL. 3:114-120, 1983]"
1877,363898261,3347,CC(C)C(C1=CC=C(C=C1)Cl)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,Inactive,,,,MOUSE,C57BL/MALE,INTRAGASTRIC,0; 40; 80 MG/KG IN ARACHIS OIL 5/WK FOR 104 WK (STUDY DURATION: 120 WK),,NEGATIVE,"[CABRAL,JRP AND GALENDO,D; CARCINOGENICITY STUDY OF THE PESTICIDE FENVALERATE IN MICE;CANCER LETT. 49(1):13-18, 1990]"
1878,363898261,3347,CC(C)C(C1=CC=C(C=C1)Cl)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,Inactive,,,,MOUSE,C57BL/FEMALE,INTRAGASTRIC,0; 40; 80 MG/KG IN ARACHIS OIL 5/WK FOR 104 WK (STUDY DURATION: 120 WK),,NEGATIVE,"[CABRAL,JRP AND GALENDO,D; CARCINOGENICITY STUDY OF THE PESTICIDE FENVALERATE IN MICE;CANCER LETT. 49(1):13-18, 1990]"
1879,363898262,,,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE,0.1; 0.3; 1.0; 3.0; 10.0 MG/KG IN CORN OIL 5/WK FOR 25 WK,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-244 Y83]"
1880,363898262,,,Active,,,,RAT,"F344/MALE,FEMALE",GAVAGE,0.1; 0.3; 1.0; 3.0; 10.0 MG/KG IN CORN OIL 5/WK FOR 25 WK,"LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA, CHOLANGIOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-244 Y83]"
1881,363898262,,,Active,,,,RAT,SHERMAN/FEMALE,GAVAGE,1000 MG/KG IN CORN OIL ONCE OR 100 MG/KG IN CORN OIL 2/WK EVERY 3 WK FOR 12 DOSES,"LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE",POSITIVE,"[KIMBROUGH,RD, GROCE,DF, KORVER,MP AND BURSE,VM; INDUCTION OF LIVER TUMORS IN FEMALE SHERMAN STRAIN RATS BY POLYBROMINATED BIPHENYLS; J. NATL. CANCER INST. 66:535-542, 1981]"
1882,363898262,,,Active,,,,RAT,F344/FEMALE,ORAL,0; 10; 30 PPM IN DIET BEGINNING AT 8 WK OF AGE AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1883,363898262,,,Active,,,,RAT,F344/MALE,ORAL,0; 10; 30 PPM IN DIET BEGINNING AT 8 WK OF AGE AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1884,363898262,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 10 PPM IN DIET FED TO MOTHERS BEGINNING 60 D PRIOR TO BREEDING AND CONTINUING THROUGH WEANING THEN SAME DOSES FED TO OFFSPRING FROM 4 TO 8 WK OF AGE (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1885,363898262,,,Active,,,,RAT,F344/MALE,ORAL,0; 1; 3; 10; 10 PPM IN DIET FED TO MOTHERS BEGINNING 60 D PRIOR TO BREEDING AND CONTINUING THROUGH WEANING THEN 0; 3; 10; 10; 30 PPM FED TO OFFSPRING FOR DURATION OF STUDY (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1886,363898262,,,Active,,,,RAT,F344/FEMALE,ORAL,0; 1; 3; 10; 10 PPM IN DIET FED TO MOTHERS BEGINNING 60 D PRIOR TO BREEDING AND CONTINUING THROUGH WEANING THEN 0; 3; 10; 10; 30 PPM FED TO OFFSPRING FOR DURATION OF STUDY (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1887,363898262,,,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 10; 30 PPM IN DIET BEGINNING AT 8 WK OF AGE AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1888,363898262,,,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10; 30 PPM IN DIET BEGINNING AT 8 WK OF AGE AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1889,363898262,,,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 30 PPM IN DIET TO MOTHERS BEGINNING 60 D PRIOR TO BREEDING AND CONTINUING THROUGH WEANING THEN SAME DOSES ADMINISTERED TO OFFSPRING FROM 4 TO 8 WK OF AGE (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1890,363898262,,,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 30 PPM IN DIET TO MOTHERS BEGINNING 60 D PRIOR TO BREEDING AND CONTINUING THROUGH WEANING THEN SAME DOSE FED TO OFFSPRING FROM 4 TO 8 WK OF AGE (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1891,363898262,,,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3; 10; 30; 30 PPM IN DIET FED TO MOTHERS BEGINNING 60 D PRIOR TO BREEDING AND CONTINUING THROUGH WEANING THEN 0; 3; 10; 10; 30 PPM FED TO OFFSPRING FOR DURATION OF STUDY (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1892,363898262,,,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3; 10; 30; 30 PPM IN DIET FED TO MOTHERS BEGINNING 60 D PRIOR TO BREEDING AND CONTINUING THROUGH WEANING THEN 0; 3; 10; 10; 30 PPM FED TO OFFSPRING FOR DURATION OF STUDY (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-398 Y93]"
1893,363898263,3356,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,Inactive,,,,MOUSE,"CD-1/MALE,FEMALE",ORAL,15; 30; 60 MG/KG/DAY IN DIET FOR 18 MO,,NEGATIVE,"[CASE,MT, SIBINSKI,LJ AND STEFFEN,GR; CHRONIC ORAL TOXICITY AND ONCOGENICITY STUDIES OF FLECAINIDE, AN ANTIARRHYTHMIC, IN RATS AND MICE; TOXICOL. APPL. PHARMACOL. 73:232-242, 1984]"
1894,363898263,3356,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,Inactive,,,,RAT,"WISTAR/MALE,FEMALE",ORAL,15; 30; 60 MG/KG/DAY IN DIET FOR 24 MO,,NEGATIVE,"[CASE,MT, SIBINSKI,LJ AND STEFFEN,GR; CHRONIC ORAL TOXICITY AND ONCOGENICITY STUDIES OF FLECAINIDE, AN ANTIARRHYTHMIC, IN RATS AND MICE; TOXICOL. APPL. PHARMACOL. 73:232-242, 1984]"
1895,363898264,16562,CN(C)C(=O)NC1=CC=CC(=C1)C(F)(F)F,Inactive,,,,Rat,Fischer 344 CD-F/Male (60/Group),Oral,0; 10; 300; 1000 ppm of 96.1% fluometuron in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUOMETURON (October 25, 1989)]"
1896,363898264,16562,CN(C)C(=O)NC1=CC=CC(=C1)C(F)(F)F,Inactive,,,,Rat,Fischer 344 CD-F/Female (60/Group),Oral,0; 10; 300; 1000 ppm of 96.1% fluometuron in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUOMETURON (October 25, 1989)]"
1897,363898264,16562,CN(C)C(=O)NC1=CC=CC(=C1)C(F)(F)F,Active,,,,Mouse,CR CD-1/Male (60/Group),Oral,0; 10; 500; 2000 ppm of 96.1% fluometuron in diet for 104 wk; study duration 104 wk,Lung: Primary pulmonary neoplasia,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUOMETURON (October 25, 1989)]"
1898,363898264,16562,CN(C)C(=O)NC1=CC=CC(=C1)C(F)(F)F,Active,,,,Mouse,CR CD-1/Female (60/Group),Oral,0; 10; 500; 2000 ppm of 96.1% fluometuron in diet for 104 wk; study duration 104 wk,Lymphocytic lymphoma (highest dose only),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUOMETURON (October 25, 1989)]"
1899,363898264,16562,CN(C)C(=O)NC1=CC=CC(=C1)C(F)(F)F,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-195 Y80]"
1900,363898264,16562,CN(C)C(=O)NC1=CC=CC(=C1)C(F)(F)F,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 125; 250 PPM IN DIET FOR 103 WK (STUDY DURATION: 103-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-195 Y80]"
1901,363898264,16562,CN(C)C(=O)NC1=CC=CC(=C1)C(F)(F)F,Inactive,,,,RAT,F344/MALE,ORAL,0; 125; 250 PPM IN DIET FOR 103 WK (STUDY DURATION: 103-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-195 Y80]"
1902,363898264,16562,CN(C)C(=O)NC1=CC=CC(=C1)C(F)(F)F,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103-105 WK),LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-195 Y80]"
1903,363898265,712,C=O,Active,,,,Mouse,"B6C3F1/Male (120/Group with sacrifices at 6, 12 and 24 mo)",Inhalation,"0; 2; 6; 15 ppm 6 hr/d, 5 d/wk for 24 mo; study duration 24 mo",Nasal passages,Positive. Dose-related non-neoplastic nasal lesions also observed.,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORMALDEHYDE (April 8, 1996)]"
1904,363898265,712,C=O,Inactive,,,,Mouse,"B6C3F1/Female (120/Group with sacrifices at 6, 12 and 24 mo)",Inhalation,"0; 2; 6; 15 ppm 6 hr/d, 5 d/wk for 24 mo; study duration 24 mo",,Negative. Dose-related non-neoplastic nasal lesions were observed.,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORMALDEHYDE (April 8, 1996)]"
1905,363898265,712,C=O,Inactive,,,,Hamster,Syrian golden/Male (132/Control group; 88/Experimental group),Inhalation,"10 ppm 5 hr/day, 5 d/wk for life; study duration was lifetime of the animal",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORMALDEHYDE (April 8, 1996)]"
1906,363898265,712,C=O,Active,,,,RAT,F344/FEMALE,INHALATION,0; 2; 6; 15 PPM,NASAL TURBINATES: SQUAMOUS CELL CARCINOMA,POSITIVE,"[FINAL REPORT ON A CHRONIC INHALATION TOXICOLOGY STUDY IN RATS AND MICE EXPOSED TO FORMALDEHYDE; SUBMITTED BY BATTELLE COLUMBUS LABORATORIES, COLUMBUS, OHIO, TO CHEMICAL INDUSTRY INSTITUTE OF TOXICOLOGY, SEPTEMBER 1981, REVISED, DECEMBER 1981, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V29 345 Y82]"
1907,363898265,712,C=O,Active,,,,RAT,F344/MALE,INHALATION,0; 2; 6; 15 PPM,NASAL TURBINATES: SQUAMOUS CELL CARCINOMA,POSITIVE,"[FINAL REPORT ON A CHRONIC INHALATION TOXICOLOGY STUDY IN RATS AND MICE EXPOSED TO FORMALDEHYDE; SUBMITTED BY BATTELLE COLUMBUS LABORATORIES, COLUMBUS, OHIO, TO CHEMICAL INDUSTRY INSTITUTE OF TOXICOLOGY, SEPTEMBER 1981, REVISED, DECEMBER 1981, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V29 345 Y82]"
1908,363898265,712,C=O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,"14.2 PPM 6 HR/DAY, 5 DAY/WK",NASAL CAVITY: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ALBERT,RE, SELLAKUMAR,AR, LASKIN,S, KUSCHNER,M, NELSON,N AND SNYDER,CA; GASEOUS FORMALDEHYDE AND HYDROGEN CHLORIDE INDUCTION OF NASAL CANCER IN THE RAT; J. NATL. CANCER INST. 68:597-603, 1982, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V29 345 Y82]"
1909,363898265,712,C=O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 1.8; 21 MG/KG IN DRINKING WATER FOR UP TO 24 MO (STUDY DURATION: 105 WK),,NEGATIVE,"[TIL,HP, WOUTERSEN,RA, FERON,VJ, HOLLANDERS,VHM AND FALKE, HE; TWO- YEAR DRINKING-WATER STUDY OF FORMALDEHYDE IN RATS; FOOD CHEM. TOXICOL. 27(2):77-87, 1989]"
1910,363898265,712,C=O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 1.2; 15 MG/KG IN DRINKING WATER FOR UP TO 24 MO (STUDY DURATION: 105 WK),,NEGATIVE,"[TIL,HP, WOUTERSEN,RA, FERON,VJ, HOLLANDERS,VHM AND FALKE, HE; TWO- YEAR DRINKING-WATER STUDY OF FORMALDEHYDE IN RATS; FOOD CHEM. TOXICOL. 27(2):77-87, 1989]"
1911,363898265,712,C=O,Inactive,,,,RAT,WISTAR/MALE,INHALATION,"0; 0.1; 1.0; 10 PPM 6HR/D, 5D/WK FOR 28 MO (STUDY DURATION: 29 MO)",,NEGATIVE,"[WOUTERSEN,RA, VAN GARDEREN-HOETMER,A, BRUIJNTJES,JP, ZWART,A AND FERON,VJ; NASAL TUMORS IN RATS AFTER SEVERE INJURY TO THE NASAL MUCOSA AND PROLONGED EXPOSURE TO 10 PPM FORMALDEHYDE; J. APPL. TOXICOL. 9(1):39-46, 1989]"
1912,363898265,712,C=O,Inactive,,,,RAT,WISTAR/MALE,INHALATION,"0; 0.1; 1.0; 10 PPM 6HR/D, 5D/WK FOR 3 MO (STUDY DURATION: 29 MO)",,NEGATIVE,"[WOUTERSEN,RA, VAN GARDEREN-HOETMER,A, BRUIJNTJES,JP, ZWART,A AND FERON,VJ; NASAL TUMORS IN RATS AFTER SEVERE INJURY TO THE NASAL MUCOSA AND PROLONGED EXPOSURE TO 10 PPM FORMALDEHYDE; J. APPL. TOXICOL. 9(1):39-46, 1989]"
1913,363898265,712,C=O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 10; 50; 100; 500; 1000; 1500 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: LIFETIME),LYMPHATIC SYSTEM: LEUKEMIA; GASTROINTESTINAL SYSTEM: TUMOR,POSITIVE,"[SOFFRITTI,M, MALTONI,C, MAFFEI,F AND BIAGI,R; FORMALDEHYDE: AN EXPERIMENTAL MULTIPOTENTIAL CARCINOGEN; TOXICOL. IND. HEALTH 5(5):699-730, 1989]"
1914,363898265,712,C=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 10; 50; 100; 500; 1000; 1500 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: LIFETIME),LYMPHATIC SYSTEM: LEUKEMIA; GASTROINTESTINAL SYSTEM: TUMOR,POSITIVE,"[SOFFRITTI,M, MALTONI,C, MAFFEI,F AND BIAGI,R; FORMALDEHYDE: AN EXPERIMENTAL MULTIPOTENTIAL CARCINOGEN; TOXICOL. IND. HEALTH 5(5):699-730, 1989]"
1915,363898265,712,C=O,Active,,,,RAT,F344/MALE,INHALATION,0; 0.3; 2; 15 PPM 6 HR/D 5 D/WK FOR 28 MO (STUDY DURATION: 28 MO),"NASAL CAVITY: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[KAMATA,E, NAKADATE,M, UCHIDA,O, OGAWA,Y, SUZUKI,S, KANEKO,T, SAITO,M AND KUROKAWA,Y;RESULTS OF A 28-MONTH CHRONIC INHALATION TOXICITY STUDY OF FORMALDEHYDE IN MALE FISHER-344 RATS; J. TOXICOL. SCI. 22(3):239-254, 1997]"
1916,363898266,41478,C(O)[P+](CO)(CO)CO.C(O)[P+](CO)(CO)CO.[O-]S(=O)(=O)[O-],Inactive,,,,RAT,F344/MALE,GAVAGE,0; 5; 10 MG/KG IN DISTILLED WATER 5 D/WK FOR 104 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-296 Y87]"
1917,363898266,41478,C(O)[P+](CO)(CO)CO.C(O)[P+](CO)(CO)CO.[O-]S(=O)(=O)[O-],Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 5; 10 MG/KG IN DISTILLED WATER 5 D/WK FOR 104 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-296 Y87]"
1918,363898266,41478,C(O)[P+](CO)(CO)CO.C(O)[P+](CO)(CO)CO.[O-]S(=O)(=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 5; 10 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-296 Y87]"
1919,363898266,41478,C(O)[P+](CO)(CO)CO.C(O)[P+](CO)(CO)CO.[O-]S(=O)(=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 5; 10 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-296 Y87]"
1920,363898267,31298,C(O)[P+](CO)(CO)CO.[Cl-],Inactive,,,,RAT,F344/MALE,GAVAGE,0; 3.75; 7.5 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-296 Y87]"
1921,363898267,31298,C(O)[P+](CO)(CO)CO.[Cl-],Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 3.75; 7.5 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-296 Y87]"
1922,363898267,31298,C(O)[P+](CO)(CO)CO.[Cl-],Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 7.5; 15 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-296 Y87]"
1923,363898267,31298,C(O)[P+](CO)(CO)CO.[Cl-],Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 15; 30 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-296 Y87]"
1924,363898268,3463,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,Active,,,,RAT,STRAIN-CD/MALE,ORAL,30; 300 MG/KG IN DIET FOR 2 YR,"LIVER: NEOPLASTIC NODULE, CARCINOMA; TESTES: INTERSTITIAL CELL TUMOR",POSITIVE,"[FITZGERALD,JE, SANYER,JL, SCHARDEIN,JL, LAKE,RS, MCGUIRE,EJ AND DE LA IGLESIA,FA; CARCINOGEN BIOASSAY AND MUTAGENICITY STUDIES WITH THE HYPOLIPIDEMIC AGENT GEMFIBROZIL; J. NATL. CANCER INST. 67:1105-1116, 1981]"
1925,363898269,13002,C1C(O1)C=O,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 175 Y76]"
1926,363898269,13002,C1C(O1)C=O,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 175 Y76]"
1927,363898270,441140,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,Active,,,,MOUSE,"CD-1/MALE,FEMALE",ORAL,1% IN DIET FOR 12 TO 16 MO,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 153 Y76]"
1928,363898270,441140,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,Active,,,,MOUSE,ICR/MALE,SUBCUTANEOUS,"0.5, 0.5, 1.0 OR 1.0 MG SUSPENDED IN TRICAPRYLIN (3 MG/ANIMAL, TOTAL DOSE) ON DAYS 1, 7, 14 AND 21 OF AGE",LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 153 Y76]"
1929,363898271,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-229 Y82]"
1930,363898271,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-229 Y82]"
1931,363898271,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-229 Y82]"
1932,363898271,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-229 Y82]"
1933,363898272,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-227 Y82]"
1934,363898272,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-227 Y82]"
1935,363898272,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-227 Y82]"
1936,363898272,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-227 Y82]"
1937,363898273,42540,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 2.5; 5.0; 10.0 UG/KG/WK (9:1 CORN OIL-ACETONE, 2 D/WK) FOR 104 WK (STUDY DURATION: 105-108 WK)",LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-198 Y80]"
1938,363898273,42540,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 1.25; 2.5; 5 UG/KG/WK (9:1 CORN OIL-ACETONE, 2 D/WK) FOR 104 WK (STUDY DURATION: 105-108 WK)","LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-198 Y80]"
1939,363898273,42540,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 0.01 UG (SUSPENDED IN 0.1 ML ACETONE APPLIED 3 DAYS/WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-202 Y80]"
1940,363898273,42540,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl,Inactive,,,,MOUSE,SWISS/MALE,DERMAL,0; 0.01 UG (SUSPENDED IN 0.1 ML ACETONE APPLIED 3 DAYS/WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-202 Y80]"
1941,363898273,42540,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,"0; 1.25; 2.5; 5 UG/KG/WK (9:1 CORN OIL-ACETONE, 2 D/WK) FOR 104 WK (STUDY DURATION: 105-108 WK)","LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-198 Y80]"
1942,363898273,42540,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=CC(=C(C(=C3O2)Cl)Cl)Cl,Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,"0; 1.25; 2.5; 5 UG/KG/WK (9:1 CORN OIL-ACETONE, 2 D/WK) FOR 104 WK (STUDY DURATION: 105-108 WK)","LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-198 Y80]"
1943,363898274,3589,C1=CC(C2C1C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 9; 18 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-9 Y77]"
1944,363898274,3589,C1=CC(C2C1C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 6.1; 13.8 PPM IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-9 Y77]"
1945,363898274,3589,C1=CC(C2C1C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 38.9; 77.9 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-9 Y77]"
1946,363898274,3589,C1=CC(C2C1C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Unspecified,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 25.7; 51.3 PPM IN DIET FOR 80 WK (STUDY DURATION: 111 WK),THYROID GLAND: FOLLICULAR CELL CARCINOMA OR ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-9 Y77]"
1947,363898275,8370,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,HAMSTER,,ORAL,,THYROID GLAND; LIVER,POSITIVE,"[CABRAL,JRP, SHUBIK,P, MOLLNER,T AND RAITANO,F; CARCINOGENIC ACTIVITY OF HEXACHLOROBENZENE IN HAMSTERS; NATURE 269:510-511, 1977]"
1948,363898275,8370,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[CABRAL,JRP, MOLLNER,T, RAITANO,F AND SHUBIK,P; CARCINOGENESIS OF HEXACHLOROBENZENE IN MICE; INT. J. CANCER 23:47-51, 1979][NOBUYUKI,I, NAGASAKI,H, ARAI,M, SUGIHARA,S AND MAKIURA,S; HISTOLOGIC AND ULTRASTRUCTURAL STUDIES ON THE HEPATOCARCINOGENICITY OF BENZENE HEXACHLORIDE IN MICE; J. NATL. CANCER INST. 51:817-826, 1973]"
1949,363898275,8370,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.02% IN DIET FOR 30 WK (STUDY DURATION: 35 WK),,NEGATIVE,"[STEWART,FP, MANSON,MM, CABRAL,JRP AND SMITH,AG; HEXACHLOROBENZENE AS A PROMOTER OF DIETHYLNITROSAMINE-INITIATED HEPATOCARCINOGENESIS IN RATS AND COMPARISON WITH INDUCTION OF PORPHYRIA; CARCINOGENESIS 10(7):1225-1230, 1989]"
1950,363898275,8370,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.02% IN DIET FOR 30 WK (STUDY DURATION: 35 WK),,NEGATIVE,"[STEWART,FP, MANSON,MM, CABRAL,JRP AND SMITH,AG; HEXACHLOROBENZENE AS A PROMOTER OF DIETHYLNITROSAMINE-INITIATED HEPATOCARCINOGENESIS IN RATS AND COMPARISON WITH INDUCTION OF PORPHYRIA; CARCINOGENESIS 10(7):1225-1230, 1989]"
1951,363898275,8370,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.02% OF DIET FOR 90 WK (STUDY DURATION: 90 WK),LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE,POSITIVE,"[SMITH,AG, FRANCIS,JE, DINSDALE,D, MANSON,MM AND CABRAL,JRP; HEPATOCARCINOGENICITY OF HEXACHLOROBENZENE IN RATS AND THE SEX DIFFERENCE IN HEPATIC IRON STATUS AND DEVELOPMENT OF PORPHYRIA; CARCINOGENESIS 6(4):631-636, 1985]"
1952,363898275,8370,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.02% OF DIET FOR 90 WK (STUDY DURATION: 90 WK),,NEGATIVE,"[SMITH,AG, FRANCIS,JE, DINSDALE,D, MANSON,MM AND CABRAL,JRP; HEPATOCARCINOGENICITY OF HEXACHLOROBENZENE IN RATS AND THE SEX DIFFERENCE IN HEPATIC IRON STATUS AND DEVELOPMENT OF PORPHYRIA; CARCINOGENESIS 6(4):631-636, 1985]"
1953,363898276,6901,C(=C(Cl)Cl)(C(=C(Cl)Cl)Cl)Cl,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",ORAL,0.2; 2.0; 20 MG/KG/DAY IN DIET,"KIDNEY: RENAL TUBULAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[BUSSIERE,JL, MATHER,GG AND EXON,JH; EFFECT OF CYCLOSPORINE ON 3-METHYLCHOLANTHRENE-INDUCED CARCINOGENESIS AND IMMUNE RESPONSES IN THE RAT; IMMUNOBIOL. 182:205-215, 1991, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 179 Y79]"
1954,363898277,727,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"MALE,FEMALE",ORAL,,LIVER: BENIGN TUMOR OR MALIGNANT TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 47 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 195 Y79]"
1955,363898278,727,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,200 MG/KG IN DIET,LIVER: BENIGN TUMOR OR MALIGNANT TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 47 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 195 Y79]"
1956,363898279,727,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,Rat,Wistar/Male (50/Group),Oral,0; 0.05; 0.45; 4.5; 18.7 mg/kg/day of 99.5-99.7% lindane in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR LINDANE (November 30, 1998)]"
1957,363898279,727,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,Rat,Wistar/Female (50/Group),Oral,0; 0.06; 0.57; 5.6; 23.1 mg/kg/day of 99.5-99.7% lindane in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR LINDANE (November 30, 1998)]"
1958,363898279,727,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 80; 160 PPM IN DIET FOR 80 WK (STUDY DURATION: 90-91 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-14 Y77]"
1959,363898279,727,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,400 MG/KG IN DIET,LIVER: BENIGN TUMOR OR MALIGNANT TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 47 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V20 195 Y79]"
1960,363898279,727,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 135; 270 PPM TWA, IN DIET FOR 80 WK (STUDY DURATION: 108-110 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-14 Y77]"
1961,363898279,727,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 236; 472 PPM TWA, IN DIET FOR 80 WK (STUDY DURATION: 109-110 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-14 Y77]"
1962,363898280,6214,C(C(Cl)(Cl)Cl)(Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 590; 1179 MG/KG, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-68 Y78]"
1963,363898280,6214,C(C(Cl)(Cl)Cl)(Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 590; 1179 MG/KG, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-68 Y78]"
1964,363898280,6214,C(C(Cl)(Cl)Cl)(Cl)(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,"0; 212; 423 MG/KG, TWA FOR 44 WK",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-68 Y78]"
1965,363898280,6214,C(C(Cl)(Cl)Cl)(Cl)(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,"0; 212; 423 MG/KG, TWA FOR 44 WK",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-68 Y78]"
1966,363898280,6214,C(C(Cl)(Cl)Cl)(Cl)(Cl)Cl,Active,,,,RAT,F344/M,GAVAGE,0; 10; 20 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),"ADRENAL MEDULLA: PHEOCHROMOCYTOMA; ADRENAL MEDULLA: PHEOCHROMOCYTOMA, BENIGN, COMPLEX OR MALIGNANT; KIDNEY: RENAL TUBULE CARCINOMA; KIDNEY: RENAL TUBULE ADENOMA OR RENAL TUBULE CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-361 Y89]"
1967,363898280,6214,C(C(Cl)(Cl)Cl)(Cl)(Cl)Cl,Inactive,,,,RAT,F344/F,GAVAGE,0; 80; 160 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-361 Y89]"
1968,363898281,3598,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 17; 50; 150 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-40 Y78]"
1969,363898281,3598,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 17; 50; 150 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-40 Y78]"
1970,363898282,12679,CN(C)P(=O)(N(C)C)N(C)C,Active,,,,RAT,,INHALATION,,NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V15 211 Y77]"
1971,363898282,12679,CN(C)P(=O)(N(C)C)N(C)C,Active,,,,RAT,"STRAIN-CD/MALE,FEMALE",INHALATION,0; 10; 50; 100; 400; 4000 PPB FOR 6-24 MO; STUDY DURATION: 24-25 MO,"NASAL CAVITY: SQUAMOUS CELL PAPILLOMA, EPIDERMOID CARCINOMA; NASAL CAVITY (ADENOID): SQUAMOUS CELL CARCINOMA",POSITIVE,"[LEE,KP AND TROCHIMOWICZ,HJ; INDUCTION OF NASAL TUMORS IN RATS EXPOSED TO HEXAMETHYLPHOSPHORAMIDE BY INHALATION; J. NATL. CANCER INST. 68(1):157-172, 1982]"
1972,363898282,12679,CN(C)P(=O)(N(C)C)N(C)C,Active,,,,RAT,"STRAIN-CD/MALE,FEMALE",INHALATION,0; 10; 50; 100; 400; 4000 PPB FOR 6-24 MO (STUDY DURATION: 2 YR),NASAL CAVITY: EPIDERMOID CARCINOMA,POSITIVE,"[LEE,KP AND TROCHIMOWICZ,HJ; METAPLASTIC CHANGES OF NASAL RESPIRATORY EPITHELIUM IN RATS EXPOSED TO HEXAMETHYLPHOSPHORAMIDE (HMPA) BY INHALATION; AM. J. PATHOL. 106(1):8-19, 1982]"
1973,363898283,31764,CC[NH+](CC)CCNC1=C2C(=C(C=C1)CO)SC3=CC=CC=C3C2=O.CS(=O)(=O)[O-],Active,,,,MOUSE,,INTRAMUSCULAR,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 91 Y77]"
1974,363898284,131709167,CNC1=NN=CC2=CC=CC=C21.Cl,Active,,,,MOUSE,"SWISS/MALE,FEMALE",ORAL,0.125% IN WATER,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 85 Y80]"
1975,363898284,131709167,CNC1=NN=CC2=CC=CC=C21.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.035% IN DIET FOR 68-87 WK (STUDY DURATION: 87 WK),,NEGATIVE,"[GERSHBEIN,LL AND RAO,KC; ACTION OF HYDRAZINE DRUGS IN TUMOR-FREE AND 1,2- DIMETHYLHYDRAZINE-TREATED MALE RATS; ONCOL. RES. 4(3):121-127, 1992]"
1976,363898284,131709167,CNC1=NN=CC2=CC=CC=C21.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 16.7 MG/KG 1/WK FOR 87 WK (STUDY DURATION: 87 WK),,NEGATIVE,"[GERSHBEIN,LL AND RAO,KC; ACTION OF HYDRAZINE DRUGS IN TUMOR-FREE AND 1,2- DIMETHYLHYDRAZINE-TREATED MALE RATS; ONCOL. RES. 4(3):121-127, 1992]"
1977,363898284,131709167,CNC1=NN=CC2=CC=CC=C21.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 16.7 MG/KG 1/WK FOR 87 WK ADMINISTERED TO PARTIALLY HEPATECTOMIZED RATS (STUDY DURATION: 87 WK),,NEGATIVE,"[GERSHBEIN,LL AND RAO,KC; ACTION OF HYDRAZINE DRUGS IN TUMOR-FREE AND 1,2- DIMETHYLHYDRAZINE-TREATED MALE RATS; ONCOL. RES. 4(3):121-127, 1992]"
1978,363898285,9321,NN,Active,,,,MOUSE,,"INTRAPERITONEAL, ORAL",,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 127 Y74]"
1979,363898285,9321,NN,Active,,,,MOUSE,,GAVAGE,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 127 Y74]"
1980,363898285,9321,NN,Inactive,,,,MOUSE,NMRI/MALE,ORAL,0; 2; 10; 50 PPM IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND SCHMIDT,WM; ON THE QUESTION OF THE CARCINOGENIC ACTION OF HYDRAZINE-EVALUATION ON THE BASIS OF NEW EXPERIMENTAL RESULTS; EXP. PATHOL. 39(1):1-9, 1990]"
1981,363898285,9321,NN,Inactive,,,,MOUSE,NMRI/FEMALE,ORAL,0; 2; 10; 50 PPM IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND SCHMIDT,WM; ON THE QUESTION OF THE CARCINOGENIC ACTION OF HYDRAZINE-EVALUATION ON THE BASIS OF NEW EXPERIMENTAL RESULTS; EXP. PATHOL. 39(1):1-9, 1990]"
1982,363898285,9321,NN,Active,,,,RAT,F344/MALE,INHALATION,0; 75; 750 PPM 1 HR/WK FOR 10 WK (STUDY DURATION: 28 MO),NOSE: ADENOMA,POSITIVE,"[LATENDRESSE,JR, MARIT,GB, VERNOT,EH, HAUN,CC AND FLEMMING,CD; ONCOGENIC POTENTIAL OF INHALED HYDRAZINE IN THE NOSE OF RATS AND HAMSTERS AFTER 1 OR 10 1-HR EXPOSURES; FUNDAM. APPL. TOXICOL. 27(1):33-48, 1995]"
1983,363898285,9321,NN,Active,,,,RAT,F344/FEMALE,INHALATION,0; 75; 750 PPM 1 HR/WK FOR 10 WK (STUDY DURATION: 30 MO),NOSE: ADENOMA,POSITIVE,"[LATENDRESSE,JR, MARIT,GB, VERNOT,EH, HAUN,CC AND FLEMMING,CD; ONCOGENIC POTENTIAL OF INHALED HYDRAZINE IN THE NOSE OF RATS AND HAMSTERS AFTER 1 OR 10 1-HR EXPOSURES; FUNDAM. APPL. TOXICOL. 27(1):33-48, 1995]"
1984,363898286,24842,NN.OS(=O)(=O)O,Active,,,,HAMSTER,SYRIAN/MALE,ORAL,0; 170; 340; 510 MG/L IN DRINKING WATER FOR 21 MO (STUDY DURATION: 21 MO),LIVER: TUMOR,POSITIVE,"[FITZGERALD,BE AND SHANK,RC; METHYLATION STATUS OF DNA CYTOSINE DURING THE COURSE OF INDUCTION OF LIVER CANCER IN HAMSTERS BY HYDRAZINE SULFATE; CARCINOGENESIS 17(12):2703-2709, 1996]"
1985,363898286,24842,NN.OS(=O)(=O)O,Active,,,,MOUSE,SWISS,GAVAGE,"1.1 MG/D, 5/WK FOR 15 MO",LUNG,POSITIVE,"[MARU,GB AND BHIDE,SV; EFFECT OF ANTIOXIDANTS AND ANTITOXICANTS OF ISONIAZID ON THE FORMATION OF LUNG TUMOURS IN MICE BY ISONIAZID AND HYDRAZINE SULPHATE; CANCER LETT. 17:75-80, 1982]"
1986,363898287,31222,C1=CC=C(C=C1)NNC2=CC=CC=C2,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.004; 0.04% TWA, IN DIET FOR 78 WK (STUDY DURATION: 95-96 WK)",LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-92 Y78]"
1987,363898287,31222,C1=CC=C(C=C1)NNC2=CC=CC=C2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.008; 0.04% TWA, IN DIET FOR 78 WK (STUDY DURATION: 85 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-92 Y78]"
1988,363898287,31222,C1=CC=C(C=C1)NNC2=CC=CC=C2,Active,,,,RAT,F344/FEMALE,ORAL,"0; 0.004; 0.01% TWA, IN DIET FOR 78 WK (STUDY DURATION: 107-108 WK)",LIVER: NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-92 Y78]"
1989,363898287,31222,C1=CC=C(C=C1)NNC2=CC=CC=C2,Active,,,,RAT,F344/MALE,ORAL,"0; 0.008; 0.03% TWA, IN DIET FOR 78 WK (STUDY DURATION: 106-107 WK)","LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; ADRENAL GLAND: PHEOCHROMOCYTOMA OR MALIGNANT PHEOCHROMOCYTOMA; EAR (INCLUDING EAR CANAL, ZYMBAL GLAND AND SKIN OF THE EAR): SQUAMOUS CELL CARCINOMA OR PAPILLOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-92 Y78]"
1990,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,GUINEA PIG,FEMALE,INTRAPERITONEAL,1.5 G/100 G SUSPENDED IN SALINE-GUM ACACIA 3/WK FOR 27 MO,INJECTION SITE: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
1991,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,GUINEA PIG,MALE,ORAL,0.024-0.064% IN DIET (AMOUNT VARIED BECAUSE OF TOXICITY),INTESTINES (SMALL): ADENOCARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
1992,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,HAMSTER,MALE,INTRAPERITONEAL,1.5 G/100 G SUSPENDED IN SALINE-GUM ACACIA 3/WK FOR 6-8 MO,PERITONEAL CAVITY: FIBROSARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
1993,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,HAMSTER,MALE,ORAL,0.032% IN DIET AS 5-10 G OF GLUCOSE TRITURATE/KG DIET FOR 7.5 MO,"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA; LIVER: BENIGN TUMOR",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
1994,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RABBIT,"NZW/MALE,FEMALE",INTRAPERITONEAL,32.3 MG/KG IN 3 ML/KG SALINE 3/WK FOR 40 WK,PERITONEAL CAVITY: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
1995,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,STRAIN-CD/FEMALE,ORAL,0.025% IN GRAIN DIET FOR 4 MO,"MAMMARY GLAND: CARCINOMA; LIVER: BENIGN TUMOR, NEOPLASM; EAR (DUCT): CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
1996,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,CRBL/FEMALE,INTRAPERITONEAL,4.O MG/100 G 3/WK FOR 2 WK THEN 3.0 MG/100 G 3/WK FOR 2 WK,"MAMMARY GLAND: BENIGN TUMOR, NEOPLASM",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
1997,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,F344/FEMALE,INTRAPERITONEAL,0.10 MMOL/RAT (TOTAL DOSE),"LIVER: CHOLANGIOMA, CARCINOMA",POSITIVE,"[GUTMANN,HR, MALEJKA-GIGANTI,D, BARRY,EF AND RYDELL,RE; ON THE CORRELATION BETWEEN THE HEPATOCARCINOGENICITY OF THE CARCINOGEN, N-2-FLUORENYLACETAMIDE, AND ITS METABOLIC ACTIVATION BY THE RAT; CANCER RES. 32:1554-1556, 1972]"
1998,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,F344/MALE,ORAL,160 UG/G IN DIET FOR 12 WK,LIVER: HEPATOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
1999,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,HOLTZMAN/FEMALE,INTRAPERITONEAL,2-AAF EQUIV OF 2.5 MG SUSPENDED IN SALINE-GUM ACACIA 3/WK FOR 3 WK THEN 3.5 MG FOR 2 WK THEN 3.0 MG FOR 9 WK,MAMMARY GLAND: NEOPLASM; PERITONEAL CAVITY: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
2000,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,HOLTZMAN/FEMALE,ORAL,0.032% IN GRAIN DIET FOR 4 MO,"MAMMARY GLAND: NEOPLASM; FORESTOMACH: PAPILLOMA, CARCINOMA; EAR (DUCT): NEOPLASM; INTESTINES (SMALL)",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
2001,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,HOLTZMAN/FEMALE,INTRAPERITONEAL,2-AAF EQUIV OF 4 MG IN 0.4 ML SALINE-GUM ACACIA 3/WK FOR 4 WK,MAMMARY GLAND: NEOPLASM,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
2002,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,HOLTZMAN/MALE,ORAL,0.032% IN GRAIN DIET FOR 3 MO,"LIVER: NEOPLASM; FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
2003,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,HOLTZMAN/MALE,INTRAPERITONEAL,2-AAF EQUIV OF 2.5 MG SUSPENDED IN SALINE-GUM ACACIA 3/WK FOR 3 WK THEN 3.5 MG 3/WK FOR 3 WK THEN 3.0 MG 3/WK FOR 9 WK,EAR (DUCT): NEOPLASM; PERITONEAL CAVITY: SARCOMA; INTESTINES (SMALL): NEOPLASM,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
2004,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,HOLTZMAN/MALE,SUBCUTANEOUS,3.2 MG IN 0.2 ML TRICAPRYLIN 2/WK FOR 4 WK,INJECTION SITE: SARCOMA; EAR (DUCT): CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
2005,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,"NIHBL/MALE,FEMALE",ORAL,80 UG/G IN DIET FOR 64 WK,"LIVER: HEPATOMA, CHOLANGIOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 585]"
2006,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0.10; 0.17 MMOL/RAT (TOTAL DOSE),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[GUTMANN,HR, MALEJKA-GIGANTI,D, BARRY,EF AND RYDELL,RE; ON THE CORRELATION BETWEEN THE HEPATOCARCINOGENICITY OF THE CARCINOGEN, N-2-FLUORENYLACETAMIDE, AND ITS METABOLIC ACTIVATION BY THE RAT; CANCER RES. 32:1554-1556, 1972]"
2007,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG BW IN DMSO 3/WK FOR 4 WK (STUDY DURATION: 61 WK),"MAMMARY GLAND: ADENOCARCINOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA, LYMPHOMA",POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
2008,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.025; 0.08; 0.23 UMOL/G BW IN 5 UL/G BW OF 80% DMSO ONCE AT 12 D OF AGE (STUDY DURATION: 9 MO),LIVER: HEPATOMA,POSITIVE,"[LAI,CC, MILLER,JA, MILLER,EC AND LIEM,A; N-SULFOOXY-2-AMINOFLUORENE IS THE MAJOR ULTIMATE ELECTROPHILIC AND CARCINOGENIC METABOLITE OF N-HYDROXY-2-ACETYLAMINOFLUORENE IN THE LIVERS OF INFANT MALE C576BL/6J X C3H/HEJF1 (B6C3F1) MICE; CARCINOGENESIS 6(7):1037-1045, 1985]"
2009,363898288,5896,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O,Active,,,,MOUSE,B6C3F2 (BRACHYMORPHOIC)/MALE,INTRAPERITONEAL,0; 0.025; 0.08; 0.23 UMOL/G BW IN 5 UL/G BW OF 80% DMSO ONCE AT 12 D OF AGE (STUDY DURATION: 9 MO),LIVER: HEPATOMA,POSITIVE,"[LAI,CC, MILLER,JA, MILLER,EC AND LIEM,A; N-SULFOOXY-2-AMINOFLUORENE IS THE MAJOR ULTIMATE ELECTROPHILIC AND CARCINOGENIC METABOLITE OF N-HYDROXY-2-ACETYLAMINOFLUORENE IN THE LIVERS OF INFANT MALE C576BL/6J X C3H/HEJF1 (B6C3F1) MICE; CARCINOGENESIS 6(7):1037-1045, 1985]"
2010,363898289,29539,CCOC1=CC=C(C=C1)N(C(=O)C)O,Active,,,,RAT,ALBINO/MALE,ORAL,0.05; 0.1; 0.5% IN DIET,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 135 Y80]"
2011,363898290,1923,C1=CC2=C(C(=C1)O)N=CC=C2,Inactive,,,,RAT,"F344/MALE,FEMALE",ORAL,0.1% IN DIET FOR 2 YR,,NEGATIVE,"[FUKUSHIMA,S, ISHIHARA,Y, NISHIO,O, OGISO,T, SHIRAI,T AND ITO,N; CARCINOGENITIES  OF QUINOLINE DERIVATIVES IN F344 RATS; CANCER LETT. 14:115-123, 1981]"
2012,363898290,1923,C1=CC2=C(C(=C1)O)N=CC=C2,Inactive,,,,RAT,F344/MALE,ORAL,0; 1500; 3000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-276 Y85]"
2013,363898290,1923,C1=CC2=C(C(=C1)O)N=CC=C2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1500; 3000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-276 Y85]"
2014,363898290,1923,C1=CC2=C(C(=C1)O)N=CC=C2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1500; 3000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-276 Y85]"
2015,363898290,1923,C1=CC2=C(C(=C1)O)N=CC=C2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1500; 3000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-276 Y85]"
2016,363898291,21268,C=CC(C1=CC2=C(C=C1)OCO2)O,Active,,,,MOUSE,CD-1/FEMALE,ORAL,"0.083% IN DIET FROM D 1 TO 10, 0.17% FROM D 11 TO 20, 0.55% THEREAFTER TO 12 MO",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[WISLOCKI,PG, MILLER,EC, MILLER,JA, MCCOY,EM AND ROSENKRANZ,HS; CARCINOGENIC AND MUTAGENIC ACTIVITIES OF SAFROLE, 1'-HYDROXYSAFROLE, AND SOME KNOWN OR POSSIBLE METABOLITES; CANCER RES. 37:1883-1891, 1977]"
2017,363898291,21268,C=CC(C1=CC2=C(C=C1)OCO2)O,Active,,,,MOUSE,CD-1/MALE,SUBCUTANEOUS,TOTAL DOSE: 3.18 UMOL IN TRIOCTANOIN OVER 22 D,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[WISLOCKI,PG, MILLER,EC, MILLER,JA, MCCOY,EM AND ROSENKRANZ,HS; CARCINOGENIC AND MUTAGENIC ACTIVITIES OF SAFROLE, 1'-HYDROXYSAFROLE, AND SOME KNOWN OR POSSIBLE METABOLITES; CANCER RES. 37:1883-1891, 1977]"
2018,363898291,21268,C=CC(C1=CC2=C(C=C1)OCO2)O,Active,,,,RAT,STRAIN-CD/MALE,ORAL,0.25% IN DIET FOR 17 MO; 0.55% IN DIET FOR 10 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[WISLOCKI,PG, MILLER,EC, MILLER,JA, MCCOY,EM AND ROSENKRANZ,HS; CARCINOGENIC AND MUTAGENIC ACTIVITIES OF SAFROLE, 1'-HYDROXYSAFROLE, AND SOME KNOWN OR POSSIBLE METABOLITES; CANCER RES. 37:1883-1891, 1977]"
2019,363898292,11510,CCOC(=O)NO,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,4000 NMOL/G,LUNG: ADENOMA,POSITIVE,"[DAHL,GA, MILLER,EC AND MILLER,JA; COMPARATIVE CARCINOGENICITIES AND MUTAGENICITIES OF VINYL CARBAMATE, ETHYL CARBAMATE, AND ETHYL N-HYDROXYCARBAMATE; CANCER RES. 40:1194-1203, 1980]"
2020,363898292,11510,CCOC(=O)NO,Active,,,,MOUSE,C57BL,INTRAPERITONEAL,1.18 MG/G 10X AT WEEKLY INTERVALS,THYMUS GLAND: LYMPHOSARCOMA; LUNG: ADENOMA,POSITIVE,"[BOIATO,L, MIRVISH,SS AND BERENBLUM,I; THE CARCINOGENIC ACTION AND METABOLISM OF N-HYDROXYURETHANE IN NEWBORN MICE; INT. J. CANCER 1:265-269, 1966]"
2021,363898293,83520,C1=NC2=C(N1)C(=O)NC(=O)N2O,Active,,,,RAT,WISTAR/MALE,ORAL,7 MG IN CARBOXYMETHYLCELLULOSE IN SALINE 1/WK FOR 22 WK,LIVER,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 546]"
2022,363898293,83520,C1=NC2=C(N1)C(=O)NC(=O)N2O,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 0.1; 1.0 MG IN CARBOXYMETHYLCELLULOSE 3/WK FOR 8 WK,"INJECTION SITE: SARCOMA, FIBROMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 631]"
2023,363898293,83520,C1=NC2=C(N1)C(=O)NC(=O)N2O,Active,,,,RAT,"WISTAR/MALE, FEMALE",SUBCUTANEOUS,3-7 MG/SUSPENDED IN CARBOXYMETHYLCELLULOSE IN SALINE 1/WK FOR 22-26 WK,INJECTION SITE; LIVER: HYPERPLASTIC NODULE OR HEPATOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 546]"
2024,363898293,83520,C1=NC2=C(N1)C(=O)NC(=O)N2O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 0.1; 1.0 MG IN CARBOXYMETHYLCELLULOSE 3/WK FOR 8 WK,"INJECTION SITE: SARCOMA, FIBROMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 631]"
2025,363898293,83520,C1=NC2=C(N1)C(=O)NC(=O)N2O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,3-7 MG/SUSPENDED IN CARBOXYMETHYLCELLULOSE IN SALINE 1/WK FOR 22-26 WK,INJECTION SITE; LIVER: HYPERPLASTIC NODULE OR HEPATOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 546]"
2026,363898294,30623,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,Active,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,0; 40; 80 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK,LYMPHATIC SYSTEM: HISTIOCYTIC LYMPHOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-78 Y78]"
2027,363898294,30623,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 40; 80 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-78 Y78]"
2028,363898294,30623,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 48; 96 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK,UTERUS: ADENOCARCINOMA (NOS),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-78 Y78]"
2029,363898294,30623,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 48; 96 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-78 Y78]"
2030,363898295,9131,C1=CC=C2C(=C1)C3=C4C2=CC5=CC=CC6=C5C4=C(C=C6)C=C3,Active,,,,MOUSE,ICR/FEMALE,DERMAL,,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 229 Y73]"
2031,363898295,9131,C1=CC=C2C(=C1)C3=C4C2=CC5=CC=CC6=C5C4=C(C=C6)C=C3,Active,,,,MOUSE,XVII-NC/Z/MALE,SUBCUTANEOUS,,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V3 229 Y73]"
2032,363898295,9131,C1=CC=C2C(=C1)C3=C4C2=CC5=CC=CC6=C5C4=C(C=C6)C=C3,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.16; 0.83; 4.15 MG IN BEESWAX/TRIOCTANOIN (STUDY DURATION: LIFETIME),LUNG: EPIDERMOID CARCINOMA,POSITIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G, DETTBARN,G AND MISFELD,J; EXPERIMENTAL STUDIES IN RAT LUNGS ON THE CARCINOGENICITY AND DOSE- RESPONSE RELATIONSHIPS OF EIGHT FREQUENTLY OCCURRING ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS; J. NATL. CANCER INST. 71(3):539-544, 1983]"
2033,363898296,6374,C(I)(I)I,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 47; 93 MG/KG, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-110 Y78]"
2034,363898296,6374,C(I)(I)I,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 47; 93 MG/KG, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-110 Y78]"
2035,363898296,6374,C(I)(I)I,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,"0; 27; 55 MG/KG, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-110 Y78]"
2036,363898296,6374,C(I)(I)I,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,"0; 71; 142 MG/KG, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-110 Y78]"
2037,363898297,,,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 161 Y73]"
2038,363898297,,,Active,,,,RAT,,"INTRAMUSCULAR, SUBCUTANEOUS",,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 161 Y73]"
2039,363898298,51153,CC(C)CN(COC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,6.6 MG/KG 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA,POSITIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, MOCHIZUKI,M, ANJO,T, OKADA,M AND ODASHIMA,S; CARCINOGENICITY OF N-ALKYL-N-(ACETOXYMETHYL)- NITROSAMINES AFTER SUBCUTANEOUS INJECTIONS IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 104:13-21, 1982]"
2040,363898299,6555,CC(C)CBr,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[POIRIER,LA, STONER,DK AND SHIMKIN,MB; BIOASSAY OF ALKYL HALIDES AND NUCLEOTIDE BASE ANALOGS BY PULMONARY TUMOR RESPONSE IN STRAIN A MICE; CANCER RES. 35:1411-1415, 1975]"
2041,363898300,69800,CC(C)CN(C(=O)N)N=O,Active,,,,RAT,DONRYU/FEMALE,ORAL,100; 200; 400 PPM IN DRINKING WATER,"DUODENUM: BENIGN HEMANGIOENDOTHELIOMA, MALIGNANT HEMANGIOENDOTHELIOMA",POSITIVE,"[OGIU,T, MATSUOKA,C, FURUTA,K, TAKEUCHI,M, MAEKAWA,A, NAKADATE,M AND ODASHIMA,S; INDUCTION OF ANGIOGENIC TUMORS IN THE DUODENUM OF FEMALE DONRYU RATS BY CONTINUOUS ORAL ADMINISTRATION OF N-ISOBUTYL-N-NITROSOUREA; GANN 74:342-350, 1983]"
2042,363898301,3767,C1=CN=CC=C1C(=O)NN,Active,,,,MOUSE,SWISS,GAVAGE,"1.1 MG/DAY, 5/WK FOR 25 MO",LUNG,POSITIVE,"[MARU,GB AND BHIDE,SV; EFFECT OF ANTIOXIDANTS AND ANTITOXICANTS OF ISONIAZID ON THE FORMATION OF LUNG TUMOURS IN MICE BY ISONIAZID AND HYDRAZINE SULPHATE; CANCER LETT. 17:75-80, 1982]"
2043,363898301,3767,C1=CN=CC=C1C(=O)NN,Active,,,,MOUSE,,"INTRAPERITONEAL, ORAL, SUBCUTANEOUS",,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 159 Y74]"
2044,363898301,3767,C1=CN=CC=C1C(=O)NN,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.030% IN DIET FOR 68-87 WK (STUDY DURATION: 87 WK),,NEGATIVE,"[GERSHBEIN,LL AND RAO,KC; ACTION OF HYDRAZINE DRUGS IN TUMOR-FREE AND 1,2- DIMETHYLHYDRAZINE-TREATED MALE RATS; ONCOL. RES. 4(3):121-127, 1992]"
2045,363898301,3767,C1=CN=CC=C1C(=O)NN,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 83.3 MG/KG 1/WK FOR 87 WK (STUDY DURATION: 87 WK),,NEGATIVE,"[GERSHBEIN,LL AND RAO,KC; ACTION OF HYDRAZINE DRUGS IN TUMOR-FREE AND 1,2- DIMETHYLHYDRAZINE-TREATED MALE RATS; ONCOL. RES. 4(3):121-127, 1992]"
2046,363898301,3767,C1=CN=CC=C1C(=O)NN,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 83.3 MG/KG 1/WK FOR 87 WK ADMINISTERED TO PARTIALLY HEPATECTOMIZED RATS (STUDY DURATION: 87 WK),,NEGATIVE,"[GERSHBEIN,LL AND RAO,KC; ACTION OF HYDRAZINE DRUGS IN TUMOR-FREE AND 1,2- DIMETHYLHYDRAZINE-TREATED MALE RATS; ONCOL. RES. 4(3):121-127, 1992]"
2047,363898302,3690,C1CN(P(=O)(OC1)NCCCl)CCCl,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,0; 18.8; 47 MG/KG IN WATER 3/WK FOR 8 WK,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V25 237 Y81]"
2048,363898302,3690,C1CN(P(=O)(OC1)NCCCl)CCCl,Active,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,0; 10; 20 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK (STUDY DURATION: 79-80 WK),LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-32 Y77]"
2049,363898302,3690,C1CN(P(=O)(OC1)NCCCl)CCCl,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 10; 20 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK (STUDY DURATION: 79-80 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-32 Y77]"
2050,363898302,3690,C1CN(P(=O)(OC1)NCCCl)CCCl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 6; 12 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK (STUDY DURATION: 79-83 WK),MAMMARY GLAND: CYSTADENOMA OR CYSTADENOCARCINOMA; UTERUS: LEIOMYOSARCOMA;ADRENAL GLAND: CORTICAL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-32 Y77]"
2051,363898302,3690,C1CN(P(=O)(OC1)NCCCl)CCCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 6; 12 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK (STUDY DURATION: 79-83 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-32 Y77]"
2052,363898303,637796,C/C=C/C1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE/ORAL,215 MG/KG FROM D 6= 28 OF LIFE THEN 517 MG/KG IN DIET,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 169 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 232 Y76]"
2053,363898303,637796,C/C=C/C1=CC2=C(C=C1)OCO2,Active,,,,RAT,,ORAL,1000; 2500; 5000; 10000 MG/KG IN DIET FOR 2 YR,"LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 169 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 232 Y76]"
2054,363898304,,,Inactive,,,,HAMSTER,SYRIAN/FEMALE,"IN UTERO, ORAL",1% IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-249 Y83]"
2055,363898304,,,Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,1% IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-249 Y83]"
2056,363898304,,,Active,,,,HAMSTER,,INTRAPLEURAL,1; 10 MG AMOSITE,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2057,363898304,,,Active,,,,RAT,WISTAR,INHALATION,"12 MG/M3 7 HR/D, 5 D/WK FOR 3, 6, 12, 24 MO OR ONCE","LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA, MESOTHELIOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2058,363898304,,,Active,,,,RAT,WISTAR,INTRAPLEURAL,20 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2059,363898304,,,Active,,,,RAT,CD-1,INHALATION,"5 MG/M3 4 HR/D, 4 D/WK FOR 2 YR",PLEURAL CAVITY: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2060,363898304,,,Active,,,,RAT,OSBORNE-MENDEL,INTRAPLEURAL,40 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2061,363898304,,,Active,,,,RAT,SPRAGUE-DAWLEY,INTRAPLEURAL,67 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2062,363898304,,,Active,,,,RAT,F344/MALE,INTRAPLEURAL,0; 20 MG/ANIMAL IN SALINE ONCE (STUDY DURATION: LIFESPAN),PLEURAL CAVITY: MESOTHELIOMA,POSITIVE,"[COFFIN,DL, PALEKAR,LD AND COOK,PM; TUMORIGENESIS BY A FERROACTINOLITE MINERAL;TOXICOL. LETT. 13:143-150, 1982]"
2063,363898304,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 1% IN DIET FOR LIFE (STUDY DURATION: LIFETIME),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-279 Y90]"
2064,363898304,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1% IN DIET FOR LIFE (STUDY DURATION: LIFETIME),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-279 Y90]"
2065,363898304,,,Active,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 25 MG IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2066,363898304,,,Active,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 25 MG IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2067,363898304,,,Active,,,,BABOON,SOUTH AFRICAN/MALE,INHALATION,1100-1200 FIBERS/ML 6 HR/D 5 D/WK FROM 242 TO 898 D (STUDY DURATION: LIFE SPAN),MESOTHELIUM: MESOTHELIOMA,POSITIVE,"[WEBSTER,I, GOLDSTEIN,B, COETZEE,FSJ AND VAN SITTERT,GCH; MALIGNANT MESOTHELIOMA INDUCED IN BABOONS BY INHALATION OF AMOSITE ASBESTOS; AM. J. IND. MED. 24(6):659-666, 1993]"
2068,363898304,,,Active,,,,RAT,AF/HAN,INHALATION,0; 1000 FIBERS/ML IN AIR 7 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: LIFESPAN),"LUNG: ADENOMA, CARCINOMA",POSITIVE,"[DAVIS,JMG, BROWN,DM, CULLEN,RT, DONALDSON,K, JONES,AD, MILLER,BG, MCINTOSH,C AND SEARL,A; A COMPARISON OF METHODS OF DETERMINING AND PREDICTING THE PATHOGENICITY OF MINERAL FIBERS; INHALATION TOXICOL. 8(8):747-77, 1996]"
2069,363898304,,,Active,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 25; 125; 300 FIBERS/CM3 6 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: 84 WK),LUNG: MESOTHELIOMA,POSITIVE,"[MCCONNELL,EE AXTEN,C HESTERBERG,TW CHEVALIER,J MIILLER,WC EVERITT,J OBERDORSTER,G CHASE,GR THEVENAZ,P AND KOTIN,P; STUDIES ON THE INHALATION TOXICOLOGY OF TWO FIBERGLASSES AND AMOSITE ASBESTOS IN THE SYRIAN GOLDEN HAMSTER. PART II. RESULTS OF CHRONIC EXPOSURE; INHALATION TOXICOL. 11(9):785-835, 1999]"
2070,363898305,5281735,C/C=C(/C)\C(=O)O[C@H]1CCN2[C@@H]1C(=CC2)COC(=O)[C@@]([C@H](C)OC)(C(C)(C)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 7; 15; 30 PPM IN DIET,"LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA (NOS), ANGIOSARCOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-39 Y78]"
2071,363898305,5281735,C/C=C(/C)\C(=O)O[C@H]1CCN2[C@@H]1C(=CC2)COC(=O)[C@@]([C@H](C)OC)(C(C)(C)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 7; 15; 30 PPM IN DIET,"LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA (NOS), ANGIOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-39 Y78]"
2072,363898305,5281735,C/C=C(/C)\C(=O)O[C@H]1CCN2[C@@H]1C(=CC2)COC(=O)[C@@]([C@H](C)OC)(C(C)(C)O)O,Active,,,,RAT,,INTRAPERITONEAL,,INTESTINES; LIVER; INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 281 Y76]"
2073,363898306,9317,CC(=O)[O-].CC(=O)[O-].[Pb+2],Active,,,,RAT,"WISTAR/MALE,FEMALE",ORAL,"3 MG/D FOR 2 MO, THEN 4 MG/D FOR 16 MO","KIDNEY: ADENOMA, CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 40 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 325 Y80]"
2074,363898306,9317,CC(=O)[O-].CC(=O)[O-].[Pb+2],Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 60 MG/KG ONCE OR TWICE A WK FOR 5-8 WK (STUDY DURATION: 80 WK),SUBCUTANEOUS TISSUE: TUMORS,POSITIVE,"[TERAKI,Y AND UCHIUMI,A; EXPERIMENTAL STUDIES ON METAL CARCINOGENESIS: A COMPARATIVE ASSESSMENT OF NICKEL AND LEAD; ADV. ENVIRON. SCI. TECHNOL. 25(NICKEL AND HUMAN HEALTH):527-535, 1992]"
2075,363898306,9317,CC(=O)[O-].CC(=O)[O-].[Pb+2],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 25 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
2076,363898306,9317,CC(=O)[O-].CC(=O)[O-].[Pb+2],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 25 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
2077,363898306,9317,CC(=O)[O-].CC(=O)[O-].[Pb+2],Active,,,,MOUSE,B6C3F1/MALE,TRANSPLACENTAL ; ORAL,0; 500; 750; 1000 PPM IN DRINKING WATER OF MOTHERS BEGINNING ON GESTATION DAY 12 AND CONTINUING TO 4 WK POSTPARTUM THEN PUPS OBSERVED FOR 112 WK (STUDY DURATION: 118 WK),KIDNEY: RENAL TUBULE CELL ADENOMA,POSITIVE,"[WAALKES,MP, DIWAN,BA, WARD,JM, DEVOR,DE AND GOYER,RA; RENAL TUBULAR TUMORS AND ATYPICAL HYPERPLASIA IN B6C3F1 MICE EXPOSED TO LEAD ACETATE DURING GESTATION AND LACTATION OCCUR WITH MINIMAL CHRONIC NEPHROPATHY; CANCER RES. 55(22):5265-5271, 1995]"
2078,363898306,9317,CC(=O)[O-].CC(=O)[O-].[Pb+2],Inactive,,,,MOUSE,B6C3F1/FEMALE,TRANSPLACENTAL ; ORAL,0; 500; 750; 1000 PPM IN DRINKING WATER OF MOTHERS BEGINNING ON GESTATION DAY 12 AND CONTINUING TO 4 WK POSTPARTUM THEN PUPS OBSERVED FOR 112 WK (STUDY DURATION: 118 WK),,NEGATIVE,"[WAALKES,MP, DIWAN,BA, WARD,JM, DEVOR,DE AND GOYER,RA; RENAL TUBULAR TUMORS AND ATYPICAL HYPERPLASIA IN B6C3F1 MICE EXPOSED TO LEAD ACETATE DURING GESTATION AND LACTATION OCCUR WITH MINIMAL CHRONIC NEPHROPATHY; CANCER RES. 55(22):5265-5271, 1995]"
2079,363898307,24460,[O-][Cr](=O)(=O)[O-].[Pb+2],Active,,,,RAT,"F344/MALE,FEMALE",INTRAMUSCULAR,8 MG SUSPENDED IN TRIOCTANOIN 1/M0 FOR 9 MO,"INJECTION SITE: RHABDOMYOSARCOMA, FIBROSARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
2080,363898307,24460,[O-][Cr](=O)(=O)[O-].[Pb+2],Active,,,,RAT,SPRAGUE-DAWLEY,SUBCUTANEOUS,30 MG ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
2081,363898308,,,Active,,,,RAT,SPRAGUE-DAWLEY,SUBCUTANEOUS,30 MG ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
2082,363898309,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25; 50 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-151 Y79]"
2083,363898309,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25; 50 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-151 Y79]"
2084,363898309,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25; 50 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-151 Y79]"
2085,363898309,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 25; 50 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-151 Y79]"
2086,363898310,24009,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Pb+2].[Pb+2].[Pb+2],Active,,,,RAT,ALBINO,SUBCUTANEOUS,20 MG 1/WK FOR UP TO 16 MO (TOTAL DOSE 40-760 MG/RAT),"KIDNEY: ADENOMA, PAPILLOMA, CYSTADENOMA, CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 325 Y80]"
2087,363898310,24009,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Pb+2].[Pb+2].[Pb+2],Active,,,,RAT,STRAIN-CB/MALE,SUBCUTANEOUS/INTRAPERITONEAL,TOTAL DOSES 29; 145; 450 MG,"KIDNEY: ADENOMA, ADENOCARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 40 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 325 Y80]"
2088,363898311,,,Active,,,,HAMSTER,,INTRAPLEURAL,10 MG ONCE,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2089,363898311,,,Active,,,,RAT,WISTAR,INHALATION,"12 MG/M3 7 HR/D, 5 D/WK FOR 3, 6, 12, 24 MO OR ONCE","LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA, MESOTHELIOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2090,363898311,,,Active,,,,RAT,WISTAR,INTRAPLEURAL,20 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2091,363898311,,,Active,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 25 MG IN 1 ML WATER ONCE (STUDY DURATION:; 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2092,363898311,,,Active,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 25 MG IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2093,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,HAMSTER,,INTRAPLEURAL,1; 10 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2094,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RABBIT,,INTRAPLEURAL,16 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2095,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,WISTAR,INHALATION,"12 MG/M3 7 HR/D, 5 D/WK FOR 3, 6, 12, 24 MO OR ONCE","LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA, MESOTHELIOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2096,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,WISTAR,INTRAPLEURAL,20 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2097,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,CD-1,INTRAPERITONEAL,20 MG,PERITONEAL CAVITY: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2098,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,CD-1,INHALATION,"5 MG/M3 4 HR/D, 4 D/WK FOR 2 YR",LUNG: CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2099,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,OSBORNE-MENDEL,INTRAPLEURAL,40 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2100,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,SPRAGUE-DAWLEY,INTRAPLEURAL,67 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2101,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",INTRAPERITONEAL,25 MG,PERITONEAL CAVITY: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2102,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,WISTAR/FEMALE,INTRAPERITONEAL,0; 0.05 MG/ANIMAL IN SALINE ONCE (AMORPHOUS TYPE) (STUDY DURATION: 862 D),PERITONEAL CAVITY: MESOTHELIOMA,POSITIVE,"[KOLEV,K; EXPERIMENTALLY INDUCED MESOTHELIOMA IN WHITE RATS IN RESPONSE TO INTRAPERITONEAL ADMINISTRATION OF AMORPHOUS CROCIDOLITE ASBESTOS: PRELIMINARY REPORT; ENVIRON. RES. 29:123-133, 1982]"
2103,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPLEURAL,0; 20 MG/ANIMAL IN SALINE ONCE (STUDY DURATION: LIFESPAN),BODY CAVITIES: MESOTHELIOMA,POSITIVE,"[MONCHAUX,G, BIGNON,J, JAURAND,MC, LAFUMA,J, SEBASTIEN,P, MASSE,R, HIRSCH,A AND GONI,J; MESOTHELIOMAS IN RATS FOLLOWING INOCULATION WITH ACID-LEACHED CHRYSOTILE ASBESTOS AND OTHER MINERAL FIBRES; CARCINOGENESIS 2(3):299-236, 1981]"
2104,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Inactive,,,,RAT,F344/MALE,ORAL,"0; 1% (10,000 PPM) IN FEED FOR LIFETIME",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-280 Y88]"
2105,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 1% (10,000 PPM) IN FEED FOR LIFETIME",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-280 Y88]"
2106,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,"WISTAR/MALE, FEMALE",INTRAPLEURAL,0; 20 MG/ML IN 2 ML SALINE ONCE (STUDY DURATION: 16 MO),BODY CAVITY: MESOTHELIOMA,POSITIVE,"[FANG,D, LIU,X, LUO,S AND WANG,C; TUMORIGENIC PROCESS OF MESOTHELIOMA INDUCED BY INTRAPLEURAL INJECTION OF CROCIDOLITE IN RATS; ZHONGHUA YIXUE ZAZHI 70(2):88-90, 1990]"
2107,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 25 MG IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2108,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 25 MG IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2109,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 2 MG IN OLIVE OIL 1/2 WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
2110,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 2 MG IN OLIVE OIL 1/2 WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
2111,363898312,86278622,O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.O[Si](=O)O.[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Fe+3].[Fe+3],Active,,,,RAT,F344/MALE,INHALATION,0; 10 MG/M3 6 HR/D 5 D/WK FOR 9-10 MO (STUDY DURATION: 24 MO),LUNG: BRONCHOALVEOLAR ADENOMA OR CARCINOMA,POSITIVE,"[MCCONNELL,EE, CHEVALIER,HJ, HESTERBERG,TW, HADLEY,JG AND MAST,RW; COMPARISON OF THE EFFECTS OF CHRYSOTILE AND CROCIDOLITE ASBESTOS IN RATS AFTER INHALATION FOR 24 MONTHS; IN: DUNGWORTH,DL, MAUDERLY,JL AND OBERDOERSTER,G (EDS.), TOXIC CARCINOG. EFF. SOLID PART. RESPIR. TRACT, ILSI PRESS, WASHINGTON, DC, 1994, PP. 361-365]"
2112,363898313,9903,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-175 Y79]"
2113,363898313,9903,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-175 Y79]"
2114,363898313,9903,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-175 Y79]"
2115,363898313,9903,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-175 Y79]"
2116,363898314,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-221 Y82]"
2117,363898314,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-221 Y82]"
2118,363898314,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-221 Y82]"
2119,363898314,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-221 Y82]"
2120,363898315,30840,CC1=CC(=C2C(=C1O)C(=O)C34C5C6C(C3C(=O)C7=C(C8=C(C=C(C(=C8C(=O)C67C(C5O)C(=O)C4=C2O)O)C)O)O)O)O,Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 163 Y76]"
2121,363898316,12447,CC1=CC(=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N)C=CC1=N.Cl,Active,,,,HUMAN,,"ORAL, INHALATION, DERMAL",,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 57 Y74]"
2122,363898316,12447,CC1=CC(=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N)C=CC1=N.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 200 MG/KG BW 2/WK FOR 8 WK WITH A 1 WK REST AFTER 2 WK THEN STARTING AT 9 WK 100 MG/KG BW 2/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[KETKAR,MB AND MOHR,U; THE CHRONIC EFFECTS OF MAGENTA, PARAMAGENTA AND PHENYL-BETA-NAPHTHYLAMINE IN RATS AFTER INTRAGASTRIC ADMINISTRATION; CANCER LETT. 16:203-206, 1982]"
2123,363898316,12447,CC1=CC(=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N)C=CC1=N.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 200 MG/KG BW 2/WK FOR 8 WK WITH A 1 WK REST AFTER 2 WK THEN STARTING AT 9 WK 100 MG/KG BW 2/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[KETKAR,MB AND MOHR,U; THE CHRONIC EFFECTS OF MAGENTA, PARAMAGENTA AND PHENYL-BETA-NAPHTHYLAMINE IN RATS AFTER INTRAGASTRIC ADMINISTRATION; CANCER LETT. 16:203-206, 1982]"
2124,363898317,15415,CCOC(=O)CC(C(=O)OCC)SP(=O)(OC)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-135 Y79]"
2125,363898317,15415,CCOC(=O)CC(C(=O)OCC)SP(=O)(OC)OC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-135 Y79]"
2126,363898317,15415,CCOC(=O)CC(C(=O)OCC)SP(=O)(OC)OC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-135 Y79]"
2127,363898317,15415,CCOC(=O)CC(C(=O)OCC)SP(=O)(OC)OC,Inactive,,,,RAT,F344/MALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-135 Y79]"
2128,363898318,4004,CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 8000; 16000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-24 Y78]"
2129,363898318,4004,CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 8000; 16000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-24 Y78]"
2130,363898318,4004,CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2000; 4000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-192 Y79]"
2131,363898318,4004,CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC,Inactive,,,,RAT,F344/MALE,ORAL,0; 2000; 4000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-192 Y79]"
2132,363898318,4004,CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 4700; 8150 PPM IN DIET, TWA FOR 80 WK",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-24 Y78]"
2133,363898318,4004,CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 4700; 8150 PPM IN DIET, TWA FOR 80 WK",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-24 Y78]"
2134,363898319,6251,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-236 Y82]"
2135,363898319,6251,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-236 Y82]"
2136,363898319,6251,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-236 Y82]"
2137,363898319,6251,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-236 Y82]"
2138,363898319,6251,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN THE DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[ABDO,KM, HASEMAN,JK AND BOORMAN,G; ABSENCE OF CARCINOGENIC RESPONSE IN F344 RATS AND B6C3F1 MICE GIVEN D-MANNITOL IN THE DIET FOR TWO YEARS; FOOD CHEM. TOXICOL. 21(3):259-262, 1983]"
2139,363898319,6251,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN THE DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[ABDO,KM, HASEMAN,JK AND BOORMAN,G; ABSENCE OF CARCINOGENIC RESPONSE IN F344 RATS AND B6C3F1 MICE GIVEN D-MANNITOL IN THE DIET FOR TWO YEARS; FOOD CHEM. TOXICOL. 21(3):259-262, 1983]"
2140,363898319,6251,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2.5; 5% IN THE DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[ABDO,KM, HASEMAN,JK AND BOORMAN,G; ABSENCE OF CARCINOGENIC RESPONSE IN F344 RATS AND B6C3F1 MICE GIVEN D-MANNITOL IN THE DIET FOR TWO YEARS; FOOD CHEM. TOXICOL. 21(3):259-262, 1983]"
2141,363898319,6251,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2.5; 5% IN THE DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[ABDO,KM, HASEMAN,JK AND BOORMAN,G; ABSENCE OF CARCINOGENIC RESPONSE IN F344 RATS AND B6C3F1 MICE GIVEN D-MANNITOL IN THE DIET FOR TWO YEARS; FOOD CHEM. TOXICOL. 21(3):259-262, 1983]"
2142,363898320,3033867,C(CCl)NC[C@H]([C@H]([C@@H]([C@@H](CNCCCl)O)O)O)O,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,2.2; 9; 36; 144 MG/KG IN 12 DOSES OVER 4 WK,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 157 Y75]"
2143,363898320,3033867,C(CCl)NC[C@H]([C@H]([C@@H]([C@@H](CNCCCl)O)O)O)O,Active,,,,MOUSE,"STRAIN-C3/MALE,FEMALE",INTRAPERITONEAL,2.5 MG/KG 1/WK FOR 52 WK,HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 157 Y75]"
2144,363898321,6279,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,Active,,,,DOG,,INTRAMUSCULAR,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 417 Y79]"
2145,363898321,6279,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,Inactive,,,,MONKEY,CYNOMOLGUS/FEMALE,ORAL,0; 2.5 MG/WOMAN/D HUMAN DOSE EQUIVALENT IN DIET FOR 36 MONTHS BEGINNING 3 MONTHS POST BILATERAL OVARIECTOMY (STUDY DURATION: 39 MONTHS),,NEGATIVE,"[CLINE,JM, SODERQVIST,G, VON SCHOULTZ,E, SKOOG,L AND VON SCHOULTZ,B; EFFECTS OF CONJUGATED ESTROGENS, MEDROXYPROGESTERONE ACETATE, AND TAMOXIFEN ON THE MAMMARY GLANDS OF MACAQUES; BREAST CANCER RES. TREAT. 48:221-229, 1998]"
2146,363898322,11683,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,Active,,,,DOG,,ORAL,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 431 Y79]"
2147,363898323,7955,C1(=NC(=NC(=N1)N)N)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2250; 4500 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-245 Y83][MELNICK,RL, BOORMAN,GA, HASEMAN,JK, MONTALI,RJ AND HUFF,J; UROLITHIASIS AND BLADDER CARCINOGENICITY OF MELAMINE IN RODENTS; TOXICOL. APPL. PHARMACOL. 72:292-303, 1984, ]"
2148,363898323,7955,C1(=NC(=NC(=N1)N)N)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2250; 4500 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-245 Y83][MELNICK,RL, BOORMAN,GA, HASEMAN,JK, MONTALI,RJ AND HUFF,J; UROLITHIASIS AND BLADDER CARCINOGENICITY OF MELAMINE IN RODENTS; TOXICOL. APPL. PHARMACOL. 72:292-303, 1984, ]"
2149,363898323,7955,C1(=NC(=NC(=N1)N)N)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 4500; 9000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-245 Y83][MELNICK,RL, BOORMAN,GA, HASEMAN,JK, MONTALI,RJ AND HUFF,J; UROLITHIASIS AND BLADDER CARCINOGENICITY OF MELAMINE IN RODENTS; TOXICOL. APPL. PHARMACOL. 72:292-303, 1984, ]"
2150,363898323,7955,C1(=NC(=NC(=N1)N)N)N,Active,,,,RAT,F344/MALE,ORAL,0; 2250; 4500 PPM IN DIET FOR 103 WK,URINARY BLADDER: TRANSITIONAL CELL PAPILLOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-245 Y83][MELNICK,RL, BOORMAN,GA, HASEMAN,JK, MONTALI,RJ AND HUFF,J; UROLITHIASIS AND BLADDER CARCINOGENICITY OF MELAMINE IN RODENTS; TOXICOL. APPL. PHARMACOL. 72:292-303, 1984, ]"
2151,363898323,7955,C1(=NC(=NC(=N1)N)N)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.3; 1; 3% IN DIET FOR 36 WK (STUDY DURATION: 40 WK),"BLADDER: PAPILLOMA, CARCINOMA",POSITIVE,"[OKUMURA,M, HASEGAWA,R, SHIRAI,T, ITO,M, YAMADA,S AND FUKUSHIMA,S; RELATIONSHIP BETWEEN CALCULUS FORMATION AND CARCINOGENESIS IN THE URINARY BLADDER OF RATS ADMINISTERED THE NON-GENOTOXIC AGENTS, THYMINE OR MELAMINE; CARCINOGENESIS 13(6):1043-1045, 1992]"
2152,363898323,7955,C1(=NC(=NC(=N1)N)N)N,Active,,,,RAT,F344/MALE,ORAL,0; 1; 3% IN DIET FOR 36 WK (STUDY DURATION: 40 WK),"URINARY BLADDER: PAPILLOMA, CARCINOMA",POSITIVE,"[OGASAWARA,H, IMAIDA,K, ISHIWATA,H, TOYODA,K, KAWANISHI,T, UNEYAMA,C, HAYASHI,S, TAKAHASHI,M AND HAYASHI,Y; URINARY BLADDER CARCINOGENESIS INDUCED BY MELANINE IN F344 MALE RATS: CORRELATION BETWEEN CARCINOGENICITY AND UROLITH FORMATION; CARCINOGENESIS 16(11):2773-2777, 1995]"
2153,363898323,7955,C1(=NC(=NC(=N1)N)N)N,Active,,,,RAT,F344/MALE,ORAL,0; 1; 3% IN DIET CONTAINING 5% SODIUM CHLORIDE FOR 36 WK (STUDY DURATION: 40 WK),"URAINARY BLADDER: PAPILLOMA, CARCINOMA",POSITIVE,"[OGASAWARA,H, IMAIDA,K, ISHIWATA,H, TOYODA,K, KAWANISHI,T, UNEYAMA,C, HAYASHI,S, TAKAHASHI,M AND HAYASHI,Y; URINARY BLADDER CARCINOGENESIS INDUCED BY MELANINE IN F344 MALE RATS: CORRELATION BETWEEN CARCINOGENICITY AND UROLITH FORMATION; CARCINOGENESIS 16(11):2773-2777, 1995]"
2154,363898323,7955,C1(=NC(=NC(=N1)N)N)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 1; 3% IN DIET CONTAINING 10% SODIUM CHLORIDE FOR 36 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[OGASAWARA,H, IMAIDA,K, ISHIWATA,H, TOYODA,K, KAWANISHI,T, UNEYAMA,C, HAYASHI,S, TAKAHASHI,M AND HAYASHI,Y; URINARY BLADDER CARCINOGENESIS INDUCED BY MELANINE IN F344 MALE RATS: CORRELATION BETWEEN CARCINOGENICITY AND UROLITH FORMATION; CARCINOGENESIS 16(11):2773-2777, 1995]"
2155,363898324,460612,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,Active,,,,HUMAN,,ORAL,,HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 167 Y75]"
2156,363898324,460612,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,0.27; 1.07; 4.27; 17.1 MG/KG IN 12 DOSES OVER 4 WK,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 167 Y75]"
2157,363898324,460612,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,0.75; 1.5 MG/KG 3/WK FOR 6 MO,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 167 Y75]"
2158,363898324,460612,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,0.75; 1.5 MG/KG 3/WK FOR 6 MO,LUNG: ADENOMA; LYMPHATIC SYSTEM: LYMPHOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 167 Y75]"
2159,363898324,460612,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,Active,,,,RAT,"STRAIN-CD/MALE,FEMALE",INTRAPERITONEAL,0.9; 1.8 MG/KG 3/WK FOR 6 MO,PERITONEAL CAVITY: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 167 Y75]"
2160,363898325,16666,C[C@@H]1CC[C@H]([C@@H](C1)O)C(C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2000; 4000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-98 Y79]"
2161,363898325,16666,C[C@@H]1CC[C@H]([C@@H](C1)O)C(C)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2000; 4000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-98 Y79]"
2162,363898325,16666,C[C@@H]1CC[C@H]([C@@H](C1)O)C(C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-98 Y79]"
2163,363898325,16666,C[C@@H]1CC[C@H]([C@@H](C1)O)C(C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-98 Y79]"
2164,363898326,4053,C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl,Active,,,,RAT,SWISS/FEMALE,INTRAPERITONEAL,10 MG/KG,MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 167 Y75]"
2165,363898327,6291,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC,Active,,,,MOUSE,,ORAL,,MAMMARY GLAND; PITUITARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 257 Y79][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 87 Y74]"
2166,363898327,6291,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC,Active,,,,RAT,,ORAL,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 257 Y79][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 87 Y74]"
2167,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,HAMSTER,,INTRAPLEURAL,1; 10; 25 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2168,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,WISTAR,INHALATION,"12 MG/M3 7 HR/D, 5 D/WK FOR 3, 6, 12, 24 MO OR ONCE","LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA, MESOTHELIOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2169,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,WISTAR,INHALATION,"12 MG/M3 7 HR/D, 5 D/WK FOR 3, 6, 12, 24 MO OR ONCE (RHODESIAN CHRYSOTILE)","LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2170,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,WISTAR,INTRAPLEURAL,20 MG (CANADIAN OR RHODESIAN CHRYSOTILE),LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2171,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,CD-1,INTRAPERITONEAL,20 MG,PERITONEAL CAVITY: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2172,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,CD-1,INHALATION,"5 MG/M3 4 HR/D, 4 D/WK FOR 2 YR",LUNG: CARCINOMA; PLEURAL CAVITY: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2173,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,OSBORNE-MENDEL,INTRAPLEURAL,40 MG (RHODESIAN CHRYSOTILE),LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2174,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,SPRAGUE-DAWLEY,INTRAPLEURAL,67 MG,LUNG: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2175,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,WISTAR,INTRAPERITONEAL,2-100 MG (RHODESIAN CHRYSOTILE),BODY CAVITIES: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2176,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,,INHALATION,80 MG/M3 30 HR/WK,"LUNG: ADENOCARCINOMA, FIBROSARCOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V14 42 Y77]"
2177,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPLEURAL,0; 20 MG/ANIMAL IN SALINE ONCE (CHRYSOTILE A) (STUDY DURATION: LIFESPAN),BODY CAVITIES: MESOTHELIOMA,POSITIVE,"[MONCHAUX,G, BIGNON,J, JAURAND,MC, LAFUMA,J, SEBASTIEN,P, MASSE,R, HIRSCH,A AND GONI,J; MESOTHELIOMAS IN RATS FOLLOWING INOCULATION WITH ACID-LEACHED CHRYSOTILE ASBESTOS AND OTHER MINERAL FIBRES; CARCINOGENESIS 2(3):299-236, 1981]"
2178,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Inactive,,,,RAT,LISTER/FEMALE,INTRATRACHEAL,0; 2 MG IN 0.4 ML STERILE TYRODE'S SOLUTION ONCE (STUDY DURATION: 104 WK),,NEGATIVE,"[HARRISON,PTC AND HEATH,JC; APPARENT SYNERGY BETWEEN CHRYSOTILE ASBESTOS AND N-NITROSOHEPTAMETHYLENEIMINE IN THE INDUCTION OF PULMONARY TUMOURS IN RATS; CARCINOGENESIS 9(12):2165-2171, 1988]"
2179,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Inactive,,,,HAMSTER,SYRIAN/MALE,ORAL,0; 1% SHORT RANGE OR INTERMEDIATE RANGE CHRYSOTILE IN PELLETED DIET FOR LIFE,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-246 Y90]"
2180,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Inactive,,,,HAMSTER,SYRIAN/FEMALE,ORAL,0; 1% SHORT RANGE OR INTERMEDIATE RANGE CHRYSOTILE IN PELLETED DIET FOR LIFE,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-246 Y90]"
2181,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Inactive,,,,RAT,F344/MALE,ORAL,0; 1% SHORT-RANGE FIBER LENGTH CHRYSOTILE IN PELLETED DIET FOR LIFE,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-295 Y85]"
2182,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1% SHORT-RANGE OR INTERMEDIATE RANGE CHRYSOTILE IN PELLETED DIET FOR LIFE,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-295 Y85]"
2183,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 25 MG IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2184,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 25 MG IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2185,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 25 MG CANADIAN ORE IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2186,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 25 MG CANADIAN ORE IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2187,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 25 MG CALIFORNIA ORE IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2188,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 25 MG CALIFORNIA ORE IN 1 ML WATER ONCE (STUDY DURATION: 2 YR),PERITONEUM: MESOTHELIOMA,POSITIVE,"[MINARDI,F AND MALTONI,C; RESULTS OF RECENT EXPERIMENTAL RESEARCH ON THE CARCINOGENICITY OF NATURAL AND MODIFIED ASBESTOS; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):754-761, 1988]"
2189,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,MOUSE,"ALBINO/MALE, FEMALE",INTRAPERITONEAL,0; 25 MG IN 0.5 ML SALINE ONCE AT 2 MO OF AGE AND ONCE AT 3 MO OF AGE (STUDY DURATION: LIFE SPAN),PERITONEUM: MESOTHELIOMA,POSITIVE,"[FRASH,VN, VANCHUGOVA,NN, RUKOLEEVA,SN, ZUKOVA,VA, GREBENNIKOV,SA AND SCHERBAKOV,SV; CARCINOGENIC EFFECTS OF SOME NONFIBROUS MINERAL DUSTS; BYULL. EKSP. BIOL. MED. 114(12):648-651, 1992]"
2190,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,MOUSE,"ALBINO/MALE, FEMALE",INTRAPERITONEAL,0; 10 MG IN 0.5 ML SALINE ONCE AT 1 MO OF AGE AND ONCE AT 2 MO OF AGE (STUDY DURATION: LIFE SPAN),PERITONEUM: MESOTHELIOMA,POSITIVE,"[FRASH,VN, VANCHUGOVA,NN, RUKOLEEVA,SN, ZUKOVA,VA, GREBENNIKOV,SA AND SCHERBAKOV,SV; CARCINOGENIC EFFECTS OF SOME NONFIBROUS MINERAL DUSTS; BYULL. EKSP. BIOL. MED. 114(12):648-651, 1992]"
2191,363898328,25477,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,F344/MALE,INHALATION,0; 10 MG/M3 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),LUNG: BRONCHOALVEOLAR ADENOMA OR CARCINOMA,POSITIVE,"[MCCONNELL,EE, CHEVALIER,HJ, HESTERBERG,TW, HADLEY,JG AND MAST,RW; COMPARISON OF THE EFFECTS OF CHRYSOTILE AND CROCIDOLITE ASBESTOS IN RATS AFTER INHALATION FOR 24 MONTHS; IN: DUNGWORTH,DL, MAUDERLY,JL AND OBERDOERSTER,G (EDS.), TOXIC CARCINOG. EFF. SOLID PART. RESPIR. TRACT, ILSI PRESS, WASHINGTON, DC, 1994, PP. 361-365]"
2192,363898329,8667,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2.Cl,Active,,,,RAT,"F344/MALE,FEMALE",ORAL,1000 PPM IN DIET FOR 64 WK (INITIAL DOSES AT 2000 PPM),"LIVER: HEPATOCELLULAR CARCINOMA, CHOLANGIOCARCINOMA",POSITIVE,"[LIJINSKY,W, REUBER,MD AND BLACKWELL,B-N; LIVER TUMORS INDUCED IN RATS BY ORAL ADMINISTRATION OF THE ANTIHISTAMINIC METHAPYRILENE HYDROCHLORIDE; SCIENCE 209:817-819, 1980][OHSHIMA,M, WARD,JM, BRENNAN,LM AND CREASIA,DA; A SEQUENTIAL STUDY OF METHAPYRILENE HYDROCHLORIDE-INDUCED LIVER CARCINOGENESIS IN MALE F344 RATS; J. NATL. CANCER INST. 72:759-768, 1984]"
2193,363898329,8667,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2.Cl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 500; 1000 PPM IN DRINKING WATER 5D/WK FOR LIFE (STUDY DURATION: 585-760 D),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[HABS,M, SHUBIK,P AND EISENBRAND,G; CARCINOGENICITY OF METHAPRILENE HYDROCHLORIDE, MEPYRAMINE HYDROCHLORIDE, THENYLDIAMINE HYDROCHLORIDE, AND PYRIBENZAMINE HYDROCHLORIDE IN SPRAGUE-DAWLEY RATS; J. CANCER RES. CLIN. ONCOL. 111:71-74, 1986]"
2194,363898329,8667,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2.Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 500; 1000 PPM IN DRINKING WATER 5D/WK FOR LIFE (STUDY DURATION: 576-709 D),LIVER: HEPATOCELLULAR CARCINOMA OR SARCOMA,POSITIVE,"[HABS,M, SHUBIK,P AND EISENBRAND,G; CARCINOGENICITY OF METHAPRILENE HYDROCHLORIDE, MEPYRAMINE HYDROCHLORIDE, THENYLDIAMINE HYDROCHLORIDE, AND PYRIBENZAMINE HYDROCHLORIDE IN SPRAGUE-DAWLEY RATS; J. CANCER RES. CLIN. ONCOL. 111:71-74, 1986]"
2195,363898329,8667,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 125; 250 MG/KG IN DIET (TOTAL DOSE: 0; 7; 14 G/KG) FOR 110 WK (STUDY DURATION: 133 WK),LIVER: CARCINOMA,POSITIVE,"[LIJINSKI,W; CHRONIC TOXICITY TESTS OF PYRILAMINE MALEATE AND METHAPYRILENE HYDROCHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 22(1):27-30, 1984]"
2196,363898329,8667,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 125; 250 MG/KG IN DIET (TOTAL DOSE: 0; 7; 15 MG/KG) FOR 110 WK (STUDY DURATION: 133 WK),LIVER: CARCINOMA,POSITIVE,"[LIJINSKI,W; CHRONIC TOXICITY TESTS OF PYRILAMINE MALEATE AND METHAPYRILENE HYDROCHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 22(1):27-30, 1984]"
2197,363898329,8667,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1 G/L IN DEIONIZED DRINKING WATER FOR 12 WK WITH NO TREATMENT DURING WK 5 AND 9 (STUDY DURATION: 121 WK),,NEGATIVE,"[LIJINSKY,W, KOVATCH,RM AND THOMAS,BJ; THE CARCINOGENIC EFFECT OF METHAPYRILENE COMBINED WITH NITROSODIETHYLAMINE GIVEN TO RATS IN LOW DOSES; CARCINOGENESIS 13(7):1293-1297, 1992]"
2198,363898330,4115,COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)C(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 997; 1994 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-35 Y78]"
2199,363898330,4115,COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)C(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 1746; 3491 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-35 Y78]"
2200,363898330,4115,COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)C(Cl)(Cl)Cl,Active,,,,MOUSE,BALB/MALE,ORAL,750 PPM IN DIET,TESTES: INTERSTITIAL CELL CARCINOMA,POSITIVE,"[REUBER,MD; INTERSTITIAL CELL CARCINOMAS OF THE TESTIS IN BALB/C MALE MICE INGESTING METHOXYCHLOR; J. CANCER RES. CLIN. ONCOL. 93:173-179, 1979]"
2201,363898330,4115,COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)C(Cl)(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 750; 1385 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-35 Y78]"
2202,363898330,4115,COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)C(Cl)(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 448; 845 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-35 Y78]"
2203,363898331,42016,CC(=O)OCN(C)N=O,Active,,,,RAT,"F344/MALE, FEMALE",SUBCUTANEOUS,5 MG/KG 1/WK FOR 10 WK,"INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; LUNG: ADENOMA, ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA; THYROID GLAND: CELL ADENOMA, FOLLICULAR ADENOMA OR ADENOCARCINOMA",POSITIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, MOCHIZUKI,M, ANJO,T, OKADA,M AND ODASHIMA,S; CARCINOGENICITY OF N-ALKYL-N-(ACETOXYMETHYL)- NITROSAMINES AFTER SUBCUTANEOUS INJECTIONS IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 104:13-21, 1982]"
2204,363898331,42016,CC(=O)OCN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,DERMAL,0; 2 MG/KG BW 1/2 WK APPLIED TO CHEEK POUCHES FOR DURATION OF STUDY (STUDY DURATION: LIFESPAN),ORAL MUCOSA: TUMOR,POSITIVE,"[BHIDE,SV, MUNIR,KM, WIESSLER,M, SARODE,AV AND SOMAN,CS; INDUCTION OF ORAL MUCOSAL TUMORS IN HAMSTERS AND RATS TREATED WITH METHYL(ACETOXYMETHYL)NITROSAMINE; JNCI, J. NATL. CANCER INST. 73(3):737-741, 1984]"
2205,363898331,42016,CC(=O)OCN(C)N=O,Inactive,,,,HAMSTER,SYRIAN/MALE,DERMAL,0; 2 MG/KG BW APPLIED TO CHEEK POUCH ONCE (STUDY DURATION: LIFESPAN),,NEGATIVE,"[BHIDE,SV, MUNIR,KM, WIESSLER,M, SARODE,AV AND SOMAN,CS; INDUCTION OF ORAL MUCOSAL TUMORS IN HAMSTERS AND RATS TREATED WITH METHYL(ACETOXYMETHYL)NITROSAMINE; JNCI, J. NATL. CANCER INST. 73(3):737-741, 1984]"
2206,363898331,42016,CC(=O)OCN(C)N=O,Active,,,,RAT,WISTAR/MALE,DERMAL,0; 2 MG/KG BW 1/2 WK APPLIED TO ORAL MUCOSA FOR DURATION OF STUDY (STUDY DURATION: LIFESPAN),ORAL MUCOSA: TUMOR,POSITIVE,"[BHIDE,SV, MUNIR,KM, WIESSLER,M, SARODE,AV AND SOMAN,CS; INDUCTION OF ORAL MUCOSAL TUMORS IN HAMSTERS AND RATS TREATED WITH METHYL(ACETOXYMETHYL)NITROSAMINE; JNCI, J. NATL. CANCER INST. 73(3):737-741, 1984]"
2207,363898331,42016,CC(=O)OCN(C)N=O,Active,,,,RAT,WISTAR/MALE,DERMAL,0; 2 MG/KG BW 1/2 WK APPLIED TO ORAL MUCOSA WHICH WAS SCRATCHED MILDLY ONCE EVERY 12 WK (STUDY DURATION: LIFESPAN),ORAL MUCOSA: TUMOR,POSITIVE,"[BHIDE,SV, MUNIR,KM, WIESSLER,M, SARODE,AV AND SOMAN,CS; INDUCTION OF ORAL MUCOSAL TUMORS IN HAMSTERS AND RATS TREATED WITH METHYL(ACETOXYMETHYL)NITROSAMINE; JNCI, J. NATL. CANCER INST. 73(3):737-741, 1984]"
2208,363898332,12137,CNC1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,RAT,SHERMAN,ORAL,0.056% IN DIET FOR 132 TO 250 D,LIVER: HEPATOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 653]"
2209,363898332,12137,CNC1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0.056% IN DIET FOR 4 MO,LIVER: HEPATOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 653]"
2210,363898332,12137,CNC1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.3 UMOL/G IN TRIOCTANOIN ONCE ON DAY 1 FOLLOWED BY 0.4 UMOL/G ONCE ON DAY 8, 15 AND 22 (STUDY DURATION: 10 MO)",LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
2211,363898332,12137,CNC1=CC=C(C=C1)N=NC2=CC=CC=C2,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 0.3 UMOL/G IN TRIOCTANOIN ONCE ON DAY 1 FOLLOWED BY 0.4 UMOL/G ONCE ON DAY 8, 15 AND 22 (STUDY DURATION: 10 MO)",,NEGATIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
2212,363898332,12137,CNC1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.017; 0.05; 0.15; 0.45 UMOL/G ONCE IN TRIOCTANOIN (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
2213,363898332,12137,CNC1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,MOUSE,C57BL/MALE,INTRAPERITONEAL,0; 0.45 UMOL/G ONCE IN TRIOCTANOIN (STUDY DURATION: 11 MO),LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
2214,363898332,12137,CNC1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,RAT,F344/MALE,INTRAPERITONEAL,"0; 0.3 UMOL/G IN TRIOCTANOIN ONCE ON DAY 1 FOLLOWED BY 0.4 UMOL/G ONCE ON DAY 8, 15 AND 22 (STUDY DURATION: 24 MO)",LIVER: HEPTOCELLULAR CARCINOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
2215,363898332,12137,CNC1=CC=C(C=C1)N=NC2=CC=CC=C2,Active,,,,MOUSE,C3H/MALE,INTRAPERITONEAL,0; 0.45 UMOL/G ONCE IN TRIOCTANOIN (STUDY DURATION: 11 MO),LIVER: HEPATOMA,POSITIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
2216,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,RAT,,"INTRAPERITONEAL, SUBCUTANEOUS",,BILE DUCT; INTESTINES; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 164 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 131 Y76]"
2217,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,RAT,,"INTRAVENOUS, ORAL",,INTESTINES; KIDNEY; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 164 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 131 Y76]"
2218,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,RAT,,RECTAL,,INTESTINES; KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 164 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 131 Y76]"
2219,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,RAT,DONRYU/MALE,RECTAL,"1 MG, 1/D FOR 7-26 D",INTESTINES (LARGE): ADENOCARCINOMA; KIDNEY: NEPHROBLASTOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 131 Y76][NARISAWA,T AND NAKANO,H; CARCINOMA OF THE LARGE INTESTINE OF RATS INDUCED BY RECTAL INFUSION OF METHYLAZOXYMETHANOL; GANN 64:93-95, 1973, ]"
2220,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,RAT,,SUBCUTANEOUS,"12.5 MG TOTAL DOSE, 4 DOSES OVER 3 WK",INTESTINES: NEOPLASMS; BILE DUCT: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 164 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 131 Y76][LAQUEUR,GL, MCDANIEL,EG AND MATSUMOTO,H; TUMOR INDUCTION IN GERM-FREE RATS WITH METHYLAZOXYMETHANOL (MAM) AND SYNTHETIC MAM ACETATE; J. NATL. CANCER INST. 39:355-371, 1967, ]"
2221,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,MOUSE,,SUBCUTANEOUS,"0.2-0.4 MG, SINGLE DOSE",UNSPECIFIED: TUMOR,POSITIVE,"[DASTUR,DK AND PALEKAR,RS; THE EXPERIMENTAL PATHOLOGY OF CYCAD TOXICITY WITH SPECIAL REFERENCE TO ONCOGENIC EFFECTS; IND. J. CANCER 11(1):33-49, 1974]"
2222,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,MONKEY,"RHESUS/MALE,FEMALE",INTRAPERITONEAL,"1.94-9.66 G TOTAL DOSE, 1/WK FOR UP TO 89 MO","LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOSARCOMA; KIDNEY: RENAL CELL CARCINOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA; CECUM: ADENOMATOUS POLYP; INTESTINES (SMALL): ADENOCARCINOMA",POSITIVE,"[SIEBER,SM, CORREA,P, DALGARD,DW, MCINTIRE,KR AND ADAMSON,RH; CARCINOGENICITY AND HEPATOTOXICITY OF CYCASIN AND ITS AGLYCONE METHYLAZOXYMETHANOLACETATE IN NONHUMAN PRIMATES; J. NATL. CANCER INST. 65(1):177-189, 1980]"
2223,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,MOUSE,BALB/MALE,DERMAL,0; 0.5 MG PAINTED ON ANAL REGION 3/WK FOR 24 WK (STUDY DURATION: 30 WK),PERIANAL SEBACEOUS GLAND: SQUAMOUS CELL CARCINOMA; BLOOD VESSELS: HEMANGIOMA OR HEMANGIOENDOTHELIOMA,POSITIVE,"[KAWAURA,A, KUMAGAI,H, SHIBATA,M, IZUMI,K, AND OTSUKA,H; TUMORS OF THE ANAL REGION INDUCED IN MICE PAINTED WITH METHYLAZOXYMETHANOL ACETATE; GANN 72(6): 886-890, 1981]"
2224,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,MOUSE,BALB/FEMALE,DERMAL,0; 0.5 MG PAINTED ON ANAL REGION 3/WK FOR 24 WK (STUDY DURATION: 24 WK),"PERIANAL SEBACEOUS GLAND: SQUAMOUS CELL CARCINOMA, ADENOMA",POSITIVE,"[KAWAURA,A, KUMAGAI,H, SHIBATA,M, IZUMI,K, AND OTSUKA,H; TUMORS OF THE ANAL REGION INDUCED IN MICE PAINTED WITH METHYLAZOXYMETHANOL ACETATE; GANN 72(6): 886-890, 1981]"
2225,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,MONKEY,"CYNOMOLGUS/MALE,FEMALE",INTRAPERITONEAL,"1.94-9.66 G TOTAL DOSE, 1/WK FOR UP TO 89 MO","LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOSARCOMA; KIDNEY: RENAL CELL CARCINOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA; CECUM: ADENOMATOUS POLYP; INTESTINES (SMALL): ADENOCARCINOMA",POSITIVE,"[SIEBER,SM, CORREA,P, DALGARD,DW, MCINTIRE,KR AND ADAMSON,RH; CARCINOGENICITY AND HEPATOTOXICITY OF CYCASIN AND ITS AGLYCONE METHYLAZOXYMETHANOLACETATE IN NONHUMAN PRIMATES; J. NATL. CANCER INST. 65(1):177-189, 1980]"
2226,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,MONKEY,"AFRICAN GREEN/MALE,FEMALE",INTRAPERITONEAL,"1.94-9.66 G TOTAL DOSE, 1/WK FOR UP TO 89 MO","LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOSARCOMA; KIDNEY: RENAL CELL CARCINOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA; CECUM: ADENOMATOUS POLYP; INTESTINES (SMALL): ADENOCARCINOMA",POSITIVE,"[SIEBER,SM, CORREA,P, DALGARD,DW, MCINTIRE,KR AND ADAMSON,RH; CARCINOGENICITY AND HEPATOTOXICITY OF CYCASIN AND ITS AGLYCONE METHYLAZOXYMETHANOLACETATE IN NONHUMAN PRIMATES; J. NATL. CANCER INST. 65(1):177-189, 1980]"
2227,363898333,5363199,CC(=O)OC/N=[N+](/C)\[O-],Active,,,,FISH,"MOSQUITOFISH/MALE, FEMALE",IMMERSION,0; 10 MG/L IN WATER FOR 2 HR EXPOSURE (STUDY DURATION: 40 WK),LIVER: TUMOR,POSITIVE,"[LAW,JM, HAWKINS,WE, OVERSTREET,RM AND WALKER,WW; HEPATOCARCINOGENESIS IN WESTERN MOSQUITOFISH (GAMBUSIA AFFINIS) EXPOSED TO METHYLAZOXYMETHANOL ACETATE; J. COMP. PATHOL. 110(2):117-127, 1994]"
2228,363898334,17347,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,Active,,,,MOUSE,ALBINO/FEMALE,SUBCUTANEOUS,0.1 ML OF 1 MG IN TRICAPRYLIN ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 2 511]"
2229,363898334,17347,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,Active,,,,MOUSE,ALBINO/FEMALE,DERMAL,70 UG IN 0.025 ML ACETONE 2/WK FOR 20 WK,INTEGUMENTARY SYSTEM (SKIN): CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 2 511]"
2230,363898334,17347,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,Active,,,,MOUSE,ALBINO/FEMALE,DERMAL,70 UG IN 0.025 ML ACETONE 2/WK FOR 20 WK,INTEGUMENTARY SYSTEM (SKIN): CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 697]"
2231,363898334,17347,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,Active,,,,MOUSE,ALBINO/FEMALE,SUBCUTANEOUS,0.25; 1.0 MG IN 0.1 ML TRICAPRYLIN ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 697]"
2232,363898334,17347,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,Active,,,,MOUSE,"C57BL/MALE,FEMALE",SUBCUTANEOUS,1 MG IN 0.1 ML ARACHIS OIL 1/WK FOR 10 WK,INJECTION SITE,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 697]"
2233,363898334,17347,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,Active,,,,RAT,HOLTZMAN/MALE,SUBCUTANEOUS,0.25 ML OF 2 MG IN TRICAPRYLIN ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 2 511]"
2234,363898334,17347,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,Active,,,,RAT,ALBINO/MALE,SUBCUTANEOUS,2.0 MG IN 0.25 ML TRICAPRYLIN ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 697]"
2235,363898334,17347,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,Active,,,,RAT,"F344/MALE,FEMALE",SUBCUTANEOUS,2 MG IN 0.2 ML PARAFFIN SOLN (TOTAL DOSE 4 MG/RAT),INJECTION SITE: FIBROSARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 2 511]"
2236,363898334,17347,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,Active,,,,RAT,LONG-EVANS/MALE,INTRAMUSCULAR,2.5 MG IN 0.5 ML SESAME OIL ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 416]"
2237,363898335,6323,CBr,Active,,,,RAT,WISTAR/FEMALE,GAVAGE,0.4; 2; 10; 50 MG/KG IN ARACHIS OIL 5/WK FOR 13 WK,FORESTOMACH: CARCINOMA,POSITIVE,"[DANSE,LHJC, VAN VELSEN,FL AND VAN DER HEIJDEN,CA; METHYLBROMIDE: CARCINOGENIC EFFECTS IN THE RAT FORESTOMACH; TOXICOL. APPL. PHARMACOL. 72:262-271, 1984]"
2238,363898335,6323,CBr,Active,,,,RAT,WISTAR/MALE,GAVAGE,0.4; 2; 10; 50 MG/KG IN ARACHIS OIL 5/WK FOR 13 WK,"FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[DANSE,LHJC, VAN VELSEN,FL AND VAN DER HEIJDEN,CA; METHYLBROMIDE: CARCINOGENIC EFFECTS IN THE RAT FORESTOMACH; TOXICOL. APPL. PHARMACOL. 72:262-271, 1984]"
2239,363898335,6323,CBr,Inactive,,,,RAT,F344/MALE,ORAL,0; 80; 200; 500 PPM OF TOTAL BROMINE FROM METHYL BROMIDE IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MITSUMORI,K, MAITA,K, KOSAKA,T, MIYAOKA,T AND SHIRASU,Y; TWO-YEAR ORAL CHRONIC TOXICITY AND CARCINOGENICITY STUDY IN RATS OF DIETS FUMIGATED WITH METHYL BROMIDE; FOOD CHEM. TOXICOL. 28(2):109-19, 1990]"
2240,363898335,6323,CBr,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 80; 200; 500 PPM OF TOTAL BROMINE FROM METHYL BROMIDE IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MITSUMORI,K, MAITA,K, KOSAKA,T, MIYAOKA,T AND SHIRASU,Y; TWO-YEAR ORAL CHRONIC TOXICITY AND CARCINOGENICITY STUDY IN RATS OF DIETS FUMIGATED WITH METHYL BROMIDE; FOOD CHEM. TOXICOL. 28(2):109-19, 1990]"
2241,363898335,6323,CBr,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 10; 33; 100 PPM 6 HR/D 5 D/WK FOR UP TO 103 WK, DOSING IN 100 PPM GROUP DISCONTINUED AFTER 20 WK (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-385 Y92]"
2242,363898335,6323,CBr,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 10; 33; 100 PPM 6 HR/D 5 D/WK FOR UP TO 103 WK, DOSING IN 100 PPM GROUP DISCONTINUED AFTER 20 WK (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-385 Y92]"
2243,363898335,6323,CBr,Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 3; 30; 90 PPM 6 HR/D 5 D/WK FOR 29 MO (STUDY DURATION: 29 MO),,NEGATIVE,"[REUZEL,PGJ, DREEF-VAN DER MEULEN,HC, HOLLANDERS,VMH, KUPER,CF, FERON,VJ AND VAN DER HEIJDEN,CA; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDY OF METHYL BROMIDE IN WISTAR RATS; FOOD CHEM. TOXICOL. 29(1):31-39, 1991]"
2244,363898335,6323,CBr,Inactive,,,,RAT,WISTAR/FEMALE,INHALATION,0; 3; 30; 90 PPM 6 HR/D 5 D/WK FOR 29 MO (STUDY DURATION: 29 MO),,NEGATIVE,"[REUZEL,PGJ, DREEF-VAN DER MEULEN,HC, HOLLANDERS,VMH, KUPER,CF, FERON,VJ AND VAN DER HEIJDEN,CA; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDY OF METHYL BROMIDE IN WISTAR RATS; FOOD CHEM. TOXICOL. 29(1):31-39, 1991]"
2245,363898335,6323,CBr,Inactive,,,,RAT,F344/MALE,INHALATION,0; 4; 20; 100 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[GOTOH,K, NISHIZAWA,T, YAMAGUCHI,T, KANOU,H, KASAI,T, OHSAWA,M, OHBAYASHI,H, AISO,S, IKAWA,N, YAMAMOTO,S, NOGUCHI,T, NAGANO,K, ENOMOTO,M, NOZAKI,K AND SAKABE,H;TWO-YEAR TOXICOLOGICAL AND CARCINOGENESIS STUDIES OF METHYL BROMIDE IN F344 RATS ANS BDF1 MICE. INHALATION STUDIES; PROC. ICMR SEMIN. 185-191, 1994]"
2246,363898335,6323,CBr,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 4; 20; 100 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[GOTOH,K, NISHIZAWA,T, YAMAGUCHI,T, KANOU,H, KASAI,T, OHSAWA,M, OHBAYASHI,H, AISO,S, IKAWA,N, YAMAMOTO,S, NOGUCHI,T, NAGANO,K, ENOMOTO,M, NOZAKI,K AND SAKABE,H;TWO-YEAR TOXICOLOGICAL AND CARCINOGENESIS STUDIES OF METHYL BROMIDE IN F344 RATS ANS BDF1 MICE. INHALATION STUDIES; PROC. ICMR SEMIN. 185-191, 1994]"
2247,363898335,6323,CBr,Inactive,,,,MOUSE,BDF1/MALE,INHALATION,0; 4; 16; 64 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[GOTOH,K, NISHIZAWA,T, YAMAGUCHI,T, KANOU,H, KASAI,T, OHSAWA,M, OHBAYASHI,H, AISO,S, IKAWA,N, YAMAMOTO,S, NOGUCHI,T, NAGANO,K, ENOMOTO,M, NOZAKI,K AND SAKABE,H;TWO-YEAR TOXICOLOGICAL AND CARCINOGENESIS STUDIES OF METHYL BROMIDE IN F344 RATS ANS BDF1 MICE. INHALATION STUDIES; PROC. ICMR SEMIN. 185-191, 1994]"
2248,363898335,6323,CBr,Inactive,,,,MOUSE,BDF1/FEMALE,INHALATION,0; 4; 16; 64 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[GOTOH,K, NISHIZAWA,T, YAMAGUCHI,T, KANOU,H, KASAI,T, OHSAWA,M, OHBAYASHI,H, AISO,S, IKAWA,N, YAMAMOTO,S, NOGUCHI,T, NAGANO,K, ENOMOTO,M, NOZAKI,K AND SAKABE,H;TWO-YEAR TOXICOLOGICAL AND CARCINOGENESIS STUDIES OF METHYL BROMIDE IN F344 RATS ANS BDF1 MICE. INHALATION STUDIES; PROC. ICMR SEMIN. 185-191, 1994]"
2249,363898335,6323,CBr,Inactive,,,,DOG,BEAGLE/MALE,ORAL,0; 0.06; 0.13; 0.28 MG/KG/D IN DIET FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[WILSON,NH, NEWTON,PE, RAHI,M, BOLTE,HF AND SUBER,RL; METHYL BROMIDE: 1-YEAR DIETARY STUDY IN DOGS; FOOD CHEM. TOXICOL. 36:575-584, 1998]"
2250,363898335,6323,CBr,Inactive,,,,DOG,BEAGLE/FEMALE,ORAL,0; 0.07; 0.12; 0.27 MG/KG/D IN DIET FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[WILSON,NH, NEWTON,PE, RAHI,M, BOLTE,HF AND SUBER,RL; METHYL BROMIDE: 1-YEAR DIETARY STUDY IN DOGS; FOOD CHEM. TOXICOL. 36:575-584, 1998]"
2251,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[DIPPLE,A; POLYNUCLEAR AROMATIC CARCINOGENS;IN: SEARLE,CE (ED.), CHEMICAL CARCINOGENS, ACS MONOGRAPH 173, AMERICAN CHEMICAL SOCIETY, WASHINGTON, D.C., 1976, PP. 245-314]"
2252,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,MOUSE,,"SUBCUTANEOUS, INTRAVENOUS",,INJECTION SITE,POSITIVE,"[DIPPLE,A; POLYNUCLEAR AROMATIC CARCINOGENS;IN: SEARLE,CE (ED.), CHEMICAL CARCINOGENS, ACS MONOGRAPH 173, AMERICAN CHEMICAL SOCIETY, WASHINGTON, D.C., 1976, PP. 245-314]"
2253,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,RAT,,"SUBCUTANEOUS, INTRAMUSCULAR",,INJECTION SITE,POSITIVE,"[DIPPLE,A; POLYNUCLEAR AROMATIC CARCINOGENS;IN: SEARLE,CE (ED.), CHEMICAL CARCINOGENS, ACS MONOGRAPH 173, AMERICAN CHEMICAL SOCIETY, WASHINGTON, D.C., 1976, PP. 245-314]"
2254,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRARECTAL,0; 2 MG/WK VIA A COTTON THREAD SOAKED WITH A 0.5% SOLUTION (1 MG CARCINOGEN IN 200 UL BENZENE) INSERTED INTO LUMEN OF THE LARGE INTESTINE THROUGH THE ANAL ORIFICE 2/WK (STUDY DURATION: 32 WK),LARGE INTESTINE: TUMOR,POSITIVE,"[BARAL,RN AND MAITY,P; INDUCTION OF COLORECTAL CANCER IN RATS BY 20-METHYLCHOLANTHRENE; CANCER LETT. 61(2):177-183, 1992]"
2255,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 3.25; 7.5; 15; 30 MG/KG BW ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[ROSS,JA, NELSON,GB, RABINOWITZ,JR, STONER,GD, NESNOW,S AND MASS,M; TIME-INTEGRATED DNA ADDUCT LEVELS AND RELATIVE TUMORIGENIC POTENCIES OF SIX POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MOUSE LUNG; POLYCYCLIC AROMAT. COMPD. 10(1-4):267-274, 1996]"
2256,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,MOUSE,"F2/MALE,FEMALE [D2XB6D2F1]",TRANSPLACENTAL,0; 10; 30 MG/KG BW IN OLIVE OIL BY INTRAPERITONEAL INJECTION ONCE ON DAY 17 OF GESTATION (STUDY DURATION: 1 YR),LUNG: TUMOR,POSITIVE,"[MILLER, MS GRESSANI,KM LEONE-KABLER,S TOWNSEND,AJ MALKINSON,AM AND O'SULLIVAN,MG;DIFFFERENTIAL SENSITIVITY TO LUNG TUMORIGENESIS FOLLOWING TRANSPLACENTAL EXPOSURE OF MICE TO POLYCYCLIC HYDROCARBONS, HETEROCYCLIC AMINES, AND LUNG TUMOR PROMOTERS; EXP. LUNG RES. 26(8):709-730, 2000]"
2257,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,Mouse,129 x MF1 wild type (15-16 males and females),Intraperitoneal,"100 mg/kg, once, study duration 5 mo","Lung: adenoma (incidence 80% vs 25% in controls, multiplicity 3.0 vs 0.3 in controls)",Positive,"[RITCHIE,KJ HENDERSON,CJ WANG,XJ VASSIEVA,O CARRIE,D FARMER,PB GASKILL,M PARK,K AND WOLF,RC; GLUTATHIONE TRANSFERASE PI PLAYS A CRITICAL ROLE IN THE DEVELOPMENT OF LUNG CARCINOGENESIS FOLLOWING EXPOSURE TO TOBACCO-RELATED CARCINOGENS AND URETHANE; CANCER RESEARCH 67(19):9248-9257, 2007]"
2258,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Inactive,,,,Mouse,129 x MF1 Gstp-null (12-15 males and females),Intraperitoneal,"100 mg/kg, once, study duration 5 mo","Lung: adenoma (incidence 75% vs 27% in controls, multiplicity 13.0 vs 0.3 in controls)",Negative,"[RITCHIE,KJ HENDERSON,CJ WANG,XJ VASSIEVA,O CARRIE,D FARMER,PB GASKILL,M PARK,K AND WOLF,RC; GLUTATHIONE TRANSFERASE PI PLAYS A CRITICAL ROLE IN THE DEVELOPMENT OF LUNG CARCINOGENESIS FOLLOWING EXPOSURE TO TOBACCO-RELATED CARCINOGENS AND URETHANE; CANCER RESEARCH 67(19):9248-9257, 2007]"
2259,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,Mouse,C57BL/6 x C57BL/6,Intraperitoneal in dams,"45 mg/kg once on 17th day of gestation, study duration for offspring 12-18 mo","Offspring: lung tumors, 11% incidence, <0.1 tumor/mouse",Positive,"[JENNINGS-GEE,JE, MOORE,JE, XU,M, DANCE,ST, KOCK,ND, MCCOY,TP, CARR,JJ, AND MILLER,MS; STRAIN-SPECIFIC INDUCTION OF MURINE LUNG TUMORS FOLLOWING IN UTERO EXPOSURE TO 3-METHYLCHOLANTHRENE; MOLECULAR CARCINOGENESIS 45:676-684, 2006]"
2260,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,Mouse,BALB/c x BALB/c,Intraperitoneal in dams,"45 mg/kg once on 17th day of gestation, study duration for offspring 12-18 mo","Offspring: lung tumors, 86% incidence, 3.3 tumors/mouse",Positive,"[JENNINGS-GEE,JE, MOORE,JE, XU,M, DANCE,ST, KOCK,ND, MCCOY,TP, CARR,JJ, AND MILLER,MS; STRAIN-SPECIFIC INDUCTION OF MURINE LUNG TUMORS FOLLOWING IN UTERO EXPOSURE TO 3-METHYLCHOLANTHRENE; MOLECULAR CARCINOGENESIS 45:676-684, 2006]"
2261,363898336,1674,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,Mouse,C57BL/6 x BALB/c,Intraperitoneal in dams,"45 mg/kg once on 17th day of gestation, study duration for offspring 12-18 mo","Offspring: lung tumors, 100% incidence, 5.8 tumors/mouse",Positive,"[JENNINGS-GEE,JE, MOORE,JE, XU,M, DANCE,ST, KOCK,ND, MCCOY,TP, CARR,JJ, AND MILLER,MS; STRAIN-SPECIFIC INDUCTION OF MURINE LUNG TUMORS FOLLOWING IN UTERO EXPOSURE TO 3-METHYLCHOLANTHRENE; MOLECULAR CARCINOGENESIS 45:676-684, 2006]"
2262,363898337,19427,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,C57BL/MALE,SUBCUTANEOUS,0.5 MG (TOTAL DOSE),INJECTION SITE: FIBROSARCOMA,POSITIVE,"[HECHT,SS, LOY,M AND HOFFMANN,D; ON THE STRUCTURE AND CARCINOGENICITY OF THE METHYLCHRYSENES; IN: FREUDENTHAL,RI AND JONES,PW (EDS.), CARCINOGENESIS, VOLUME 1, POLYNUCLEAR AROMATIC HYDROCARBONS: CHEMISTRY, METABOLISM, AND CARCINOGENESIS, RAVEN PRESS, NEW YORK, 1976, PP. 325-340]"
2263,363898337,19427,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,ICR/FEMALE,DERMAL,10.5 MG (TOTAL DOSE),INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[HECHT,SS, LOY,M AND HOFFMANN,D; ON THE STRUCTURE AND CARCINOGENICITY OF THE METHYLCHRYSENES; IN: FREUDENTHAL,RI AND JONES,PW (EDS.), CARCINOGENESIS, VOLUME 1, POLYNUCLEAR AROMATIC HYDROCARBONS: CHEMISTRY, METABOLISM, AND CARCINOGENESIS, RAVEN PRESS, NEW YORK, 1976, PP. 325-340]"
2264,363898337,19427,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED 1/7, 2/7 AND 4/7 ON DAY 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 32 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH, AMIN,S AND HECHT,SS; THE EFFECTS OF BAY-REGION METHYL SUBSTITUTION ON 6-NITROCHRYSENE MUTAGENICITY IN SALMONELLA TYPHIMURIUM AND TUMORIGENICITY IN NEWBORN MICE; CARCINOGENESIS (LONDON) 10(9):1685-9, 1989]"
2265,363898337,19427,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED 1/7, 2/7 AND 4/7 ON DAY 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH, AMIN,S AND HECHT,SS; THE EFFECTS OF BAY-REGION METHYL SUBSTITUTION ON 6-NITROCHRYSENE MUTAGENICITY IN SALMONELLA TYPHIMURIUM AND TUMORIGENICITY IN NEWBORN MICE; CARCINOGENESIS (LONDON) 10(9):1685-9, 1989]"
2266,363898337,19427,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
2267,363898337,19427,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
2268,363898337,19427,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 10; 50; 100; 200 MG/KG BW ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[ROSS,JA, NELSON,GB, WILSON,KH, RABINOWITZ,JR, GALATI,A, STONER,GD, NESNOW,S AND MASS,MJ; ADENOMAS INDUCED BY POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MOUSE LUNG CORRELATE WITH TIME-INTEGRATED DNA ADDUCT LEVELS; CANCER RES. 55(5): 1039-1044, 1995]"
2269,363898337,19427,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 10; 50; 100; 200 MG/KG IN TRICAPRYLIN ONCE (STUDY DURATION: 8 MO),LUNG: TUMOR,POSITIVE,"[YOU,L, WANG,D, GALATI,AJ, ROSS,JA, MASS,MJ, NELSON,GB, WILSON,KH, AMIN,S, STONER,JC, NESNOW,S AND STONER,GD; TUMOR MULTIPLICITY, DNA ADDUCTS AND K-RAS MUTATION PATTERN OF 5-METHYLCHRYSENE IN STRAIN A/J MOUSE LUNG; CARCINOGENESIS 15(11):2613-2618, 1994]"
2270,363898337,19427,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0-200 MG/KG IN TRICAPRYLIN ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[NESNOW,S, ROSS,JA, STONER,GD AND MASS,MJ; TUMORIGENESIS OF CARCINOGENIC ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MICE: LINKAGE TO DNA ADDUCTS AND MUTATIONS IN ONCOGENES; POLYCYCLIC AROMAT. COMPD. 10(1-4):259-266, 1996]"
2271,363898338,30602,CC(C)(C(=O)OC)OC1=CC=C(C=C1)C2=CC=C(C=C2)Cl,Active,,,,RAT,F344/MALE,ORAL,0.1% IN DIET FOR 75 WK,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[REDDY,JK, LALWANI,ND, REDDY,MK AND QURESHI,SA; EXCESSIVE ACCUMULATION OF AUTOFLUORESCENT LIPOFUSCIN IN THE LIVER DURING HEPATOCARCINOGENESIS BY METHYL CLOFENAPATE AND OTHER HYPOLIPIDEMIC PEROXISOME PROLIFERATORS; CANCER RES. 42:259-266, 1982]"
2272,363898339,7543,C1=CC(=C(C=C1CC2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,MOUSE,,ORAL,,BLOOD VESSELS; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 65 Y74]"
2273,363898339,7543,C1=CC(=C(C=C1CC2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,RAT,,ORAL,,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 65 Y74]"
2274,363898339,7543,C1=CC(=C(C=C1CC2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,RAT,,SUBCUTANEOUS,,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 65 Y74]"
2275,363898339,7543,C1=CC(=C(C=C1CC2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,RAT,STRAIN-CD/MALE,ORAL,0; 1000 PPM IN PROTEIN-ADEQUATE (23%) DIET FOR 2 YR (STUDY DURATION: 2 YR),LUNG: ADENOCARCINOMA,POSITIVE,"[STULA,EF, SHERMAN,H, ZAPP,JA,JR AND CLAYTON,JW,JR; EXPERIMENTAL NEOPLASIA IN RATS FROM ORAL ADMINISTRATION OF 3,3'-DICHLOROBENZIDINE, 4,4'-METHYLENE-BIS (2-CHLOROANILINE), AND 4,4'-METHYLENE-BIS(2-METHYLANILINE); TOXICOL. APPL. PHARMACOL. 31:159-176, 1975]"
2276,363898339,7543,C1=CC(=C(C=C1CC2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 1000 PPM IN PROTEIN-ADEQUATE (23%) DIET FOR 2 YR (STUDY DURATION: 2 YR),LUNG: ADENOCARCINOMA,POSITIVE,"[STULA,EF, SHERMAN,H, ZAPP,JA,JR AND CLAYTON,JW,JR; EXPERIMENTAL NEOPLASIA IN RATS FROM ORAL ADMINISTRATION OF 3,3'-DICHLOROBENZIDINE, 4,4'-METHYLENE-BIS (2-CHLOROANILINE), AND 4,4'-METHYLENE-BIS(2-METHYLANILINE); TOXICOL. APPL. PHARMACOL. 31:159-176, 1975]"
2277,363898339,7543,C1=CC(=C(C=C1CC2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,RAT,STRAIN-CD/MALE,ORAL,0; 1000 PPM IN PROTEIN-DEFICIENT (7%) DIET FOR 16 MO (STUDY DURATION: 16 MO),"LUNG: ADENOCARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[STULA,EF, SHERMAN,H, ZAPP,JA,JR AND CLAYTON,JW,JR; EXPERIMENTAL NEOPLASIA IN RATS FROM ORAL ADMINISTRATION OF 3,3'-DICHLOROBENZIDINE, 4,4'-METHYLENE-BIS (2-CHLOROANILINE), AND 4,4'-METHYLENE-BIS(2-METHYLANILINE); TOXICOL. APPL. PHARMACOL. 31:159-176, 1975]"
2278,363898339,7543,C1=CC(=C(C=C1CC2=CC(=C(C=C2)N)Cl)Cl)N,Active,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 1000 PPM IN PROTEIN-DEFICIENT (7%) DIET FOR 16 MO (STUDY DURATION: 16 MO),LUNG: ADENOCARCINOMA; MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[STULA,EF, SHERMAN,H, ZAPP,JA,JR AND CLAYTON,JW,JR; EXPERIMENTAL NEOPLASIA IN RATS FROM ORAL ADMINISTRATION OF 3,3'-DICHLOROBENZIDINE, 4,4'-METHYLENE-BIS (2-CHLOROANILINE), AND 4,4'-METHYLENE-BIS(2-METHYLANILINE); TOXICOL. APPL. PHARMACOL. 31:159-176, 1975]"
2279,363898340,7567,CN(C)C1=CC=C(C=C1)CC2=CC=C(C=C2)N(C)C,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 2500 PPM IN DIET FOR 78 WK (STUDY DURATION: 91 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-186 Y79]"
2280,363898340,7567,CN(C)C1=CC=C(C=C1)CC2=CC=C(C=C2)N(C)C,Active,,,,RAT,F344/FEMALE,ORAL,0; 375; 750 PPM IN DIET FOR 59 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-186 Y79]"
2281,363898340,7567,CN(C)C1=CC=C(C=C1)CC2=CC=C(C=C2)N(C)C,Active,,,,RAT,F344/MALE,ORAL,0; 375; 750 PPM IN DIET FOR 59 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-186 Y79]"
2282,363898340,7567,CN(C)C1=CC=C(C=C1)CC2=CC=C(C=C2)N(C)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.0375; 0.075% IN DIET FOR 59 WK (STUDY DURATION: 2 YR),THYROID GLAND: FOLLICULAR CARCINOMA,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
2283,363898340,7567,CN(C)C1=CC=C(C=C1)CC2=CC=C(C=C2)N(C)C,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.0375; 0.075% IN DIET FOR 59 WK (STUDY DURATION: 2 YR),THYROID GLAND: FOLLICULAR CARCINOMA,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
2284,363898340,7567,CN(C)C1=CC=C(C=C1)CC2=CC=C(C=C2)N(C)C,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1250; 2500 PPM IN DIET FOR 78 WK (STUDY DURATION: 91 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-186 Y79]"
2285,363898341,13283,CC1=C(C=CC(=C1)CC2=CC(=C(C=C2)N)C)N,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 73 Y74]"
2286,363898342,6344,C(Cl)Cl,Active,,,,RAT,F344/MALE,INHALATION,"0; 1000; 2000; 4000 PPM 6 HR/D, 5 D/WK FOR 102 WK","MAMMARY GLAND: FIBROADENOMA, ADENOMA OR FIBROADENOMA; TUNICA VAGINALIS: MESOTHELIOMA; MULTIPLE SITES: MESOTHELIOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-306 Y86]"
2287,363898342,6344,C(Cl)Cl,Active,,,,RAT,F344/FEMALE,INHALATION,"0; 1000; 2000; 4000 PPM 6 HR/D, 5 D/WK FOR 102 WK","MAMMARY GLAND: FIBROADENOMA, ADENOMA OR FIBROADENOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA): MONONUCLEAR CELL LEUKEMIA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-306 Y86]"
2288,363898342,6344,C(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 2000; 4000 PPM 6 HR/D, 5 D/WK FOR 102 WK","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; CIRCULATORY SYSTEM: HEMANGIOSARCOMA, HEMANGIOMA OR HEMANGIOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-306 Y86]"
2289,363898342,6344,C(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 2000; 4000 PPM 6 HR/D, 5 D/WK FOR 102 WK","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-306 Y86]"
2290,363898342,6344,C(Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 500; 1500; 3500 PPM IN AIR 6H/D 5D/WK FOR 104 WK (STUDY DURATION: 2 YR),SALIVARY GLAND: SARCOMA,POSITIVE,"[BUREK,JD, NITSCHKE,KD, BELL,TJ, WACKERLE,DL, CHILDS,RC, BEYER,JE, DITTENBER,DA, RAMPY,LW AND MCKENNA,MJ; METHYLENE CHLORIDE. A TWO-YEAR INHALATION TOXICITY AND ONCOGENICITY STUDY IN RATS AND HAMSTERS; FUNDAM. APPL. TOXICOL. 4:30-47, 1984]"
2291,363898342,6344,C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 500; 1500; 3500 PPM IN AIR 6H/D 5D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[BUREK,JD, NITSCHKE,KD, BELL,TJ, WACKERLE,DL, CHILDS,RC, BEYER,JE, DITTENBER,DA, RAMPY,LW AND MCKENNA,MJ; METHYLENE CHLORIDE. A TWO-YEAR INHALATION TOXICITY AND ONCOGENICITY STUDY IN RATS AND HAMSTERS; FUNDAM. APPL. TOXICOL. 4:30-47, 1984]"
2292,363898342,6344,C(Cl)Cl,Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 500; 1500; 3500 PPM IN AIR 6H/D 5D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[BUREK,JD, NITSCHKE,KD, BELL,TJ, WACKERLE,DL, CHILDS,RC, BEYER,JE, DITTENBER,DA, RAMPY,LW AND MCKENNA,MJ; METHYLENE CHLORIDE. A TWO-YEAR INHALATION TOXICITY AND ONCOGENICITY STUDY IN RATS AND HAMSTERS; FUNDAM. APPL. TOXICOL. 4:30-47, 1984]"
2293,363898342,6344,C(Cl)Cl,Inactive,,,,HAMSTER,SYRIAN/FEMALE,INHALATION,0; 500; 1500; 3500 PPM IN AIR 6H/D 5D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[BUREK,JD, NITSCHKE,KD, BELL,TJ, WACKERLE,DL, CHILDS,RC, BEYER,JE, DITTENBER,DA, RAMPY,LW AND MCKENNA,MJ; METHYLENE CHLORIDE. A TWO-YEAR INHALATION TOXICITY AND ONCOGENICITY STUDY IN RATS AND HAMSTERS; FUNDAM. APPL. TOXICOL. 4:30-47, 1984]"
2294,363898342,6344,C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 100; 500 MG/KG IN OLIVE OIL 1/D 5 D/WK FOR 64 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON METHYLENE CHLORIDE ADMINISTERED BY INGESTION TO SPRAGUE-DAWLEY RATS AND SWISS MICE AND BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):352-366, 1988]"
2295,363898342,6344,C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 100; 500 MG/KG IN OLIVE OIL 1/D 5 D/WK FOR 64 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON METHYLENE CHLORIDE ADMINISTERED BY INGESTION TO SPRAGUE-DAWLEY RATS AND SWISS MICE AND BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):352-366, 1988]"
2296,363898342,6344,C(Cl)Cl,Inactive,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 100; 500 MG/KG IN OLIVE OIL 1/D 5 D/WK FOR 64 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON METHYLENE CHLORIDE ADMINISTERED BY INGESTION TO SPRAGUE-DAWLEY RATS AND SWISS MICE AND BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):352-366, 1988]"
2297,363898342,6344,C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 100 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 97 WK BEGINNING WHEN RATS WERE 12 DAY OLD EMBRYOS (STUDY DURATION: 104 WK),,NEGATIVE,"[MALTONI,C, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON METHYLENE CHLORIDE ADMINISTERED BY INGESTION TO SPRAGUE-DAWLEY RATS AND SWISS MICE AND BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):352-366, 1988]"
2298,363898342,6344,C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 100 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 97 WK BEGINNING WHEN RATS WERE 12 DAY OLD EMBRYOS (STUDY DURATION: 104 WK),,NEGATIVE,"[MALTONI,C, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON METHYLENE CHLORIDE ADMINISTERED BY INGESTION TO SPRAGUE-DAWLEY RATS AND SWISS MICE AND BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):352-366, 1988]"
2299,363898342,6344,C(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2000 PPM 6 HR/D 5 D/WK FOR 26 WK FOLLOWED BY CHAMBER AIR EXPOSURE FOR 78 WK (STUDY DURATION: 104 WK),LUNG: ADENOMA OR CARCINOMA,POSITIVE,"[KARI,FW, FOLEY,JF, SEILKOP,SK, MARONPOT,RR AND ANDERSON,MW; EFFECT OF VARYING EXPOSURE REGIMENS ON METHYLENE CHLORIDE-INDUCED LUNG AND LIVER TUMORS IN FEMALE B6C3F1 MICE; CARCINOGENESIS 14(5):819-826, 1993]"
2300,363898342,6344,C(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2000 PPM 6 HR/D 5 D/WK FOR 26 WK FOLLOWING A 78 WK EXPOSURE TO CHAMBER AIR (STUDY DURATION: 104 WK),,NEGATIVE,"[KARI,FW, FOLEY,JF, SEILKOP,SK, MARONPOT,RR AND ANDERSON,MW; EFFECT OF VARYING EXPOSURE REGIMENS ON METHYLENE CHLORIDE-INDUCED LUNG AND LIVER TUMORS IN FEMALE B6C3F1 MICE; CARCINOGENESIS 14(5):819-826, 1993]"
2301,363898342,6344,C(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2000 PPM 6 HR/D 5 D/WK FOR 52 WK FOLLOWED BY CHAMBER AIR EXPOSURE FOR 52 WK (STUDY DURATION: 104 WK),LUNG: ADENOMA OR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[KARI,FW, FOLEY,JF, SEILKOP,SK, MARONPOT,RR AND ANDERSON,MW; EFFECT OF VARYING EXPOSURE REGIMENS ON METHYLENE CHLORIDE-INDUCED LUNG AND LIVER TUMORS IN FEMALE B6C3F1 MICE; CARCINOGENESIS 14(5):819-826, 1993]"
2302,363898342,6344,C(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2000 PPM 6 HR/D 5 D/WK FOR 52 WK FOLLOWING A 52 WK EXPOSURE TO CHAMBER AIR (STUDY DURATION: 104 WK),,NEGATIVE,"[KARI,FW, FOLEY,JF, SEILKOP,SK, MARONPOT,RR AND ANDERSON,MW; EFFECT OF VARYING EXPOSURE REGIMENS ON METHYLENE CHLORIDE-INDUCED LUNG AND LIVER TUMORS IN FEMALE B6C3F1 MICE; CARCINOGENESIS 14(5):819-826, 1993]"
2303,363898342,6344,C(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2000 PPM 6 HR/D 5 D/WK FOR 78 WK FOLLOWED BY CHAMBER AIR EXPOSURE FOR 26 WK (STUDY DURATION: 104 WK),LUNG: ADENOMA OR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[KARI,FW, FOLEY,JF, SEILKOP,SK, MARONPOT,RR AND ANDERSON,MW; EFFECT OF VARYING EXPOSURE REGIMENS ON METHYLENE CHLORIDE-INDUCED LUNG AND LIVER TUMORS IN FEMALE B6C3F1 MICE; CARCINOGENESIS 14(5):819-826, 1993]"
2304,363898342,6344,C(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2000 PPM 6 HR/D 5 D/WK FOR 78 WK FOLLOWING A 26 WK EXPOSURE TO CHAMBER AIR (STUDY DURATION: 104 WK),LUNG: ADENOMA OR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[KARI,FW, FOLEY,JF, SEILKOP,SK, MARONPOT,RR AND ANDERSON,MW; EFFECT OF VARYING EXPOSURE REGIMENS ON METHYLENE CHLORIDE-INDUCED LUNG AND LIVER TUMORS IN FEMALE B6C3F1 MICE; CARCINOGENESIS 14(5):819-826, 1993]"
2305,363898342,6344,C(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2000 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),LUNG: ADENOMA OR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[KARI,FW, FOLEY,JF, SEILKOP,SK, MARONPOT,RR AND ANDERSON,MW; EFFECT OF VARYING EXPOSURE REGIMENS ON METHYLENE CHLORIDE-INDUCED LUNG AND LIVER TUMORS IN FEMALE B6C3F1 MICE; CARCINOGENESIS 14(5):819-826, 1993]"
2306,363898342,6344,C(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2000 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: ADENOMA, CARCINOMA; LUNG: ADENOMA, CARCINOMA",POSITIVE,"[MARONPOT,RR, DEVEREUX,TR, HEGI,M, FOLEY,JF, KANNO,J, WISEMAN,R AND ANDERSON, MW; HEPATIC AND PULMONARY CARCINOGENICITY OF METHYLENE CHLORIDE IN MICE: A SEARCH FOR MECHANISMS; TOXICOLOGY 102(1-2):73-81, 1995]"
2307,363898343,26108,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N.Cl.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 150; 300 PPM IN DRINKING WATER,"THYROID GLAND: FOLLICULAR CELL ADENOMA, CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA; LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-248 Y83]"
2308,363898343,26108,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N.Cl.Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 150; 300 PPM IN DRINKING WATER,"THYROID GLAND: FOLLICULAR CELL ADENOMA; ADRENAL GLAND: PHEOCHROMOCYTOMA; LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-248 Y83]"
2309,363898343,26108,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N.Cl.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 150; 300 PPM IN DRINKING WATER,"THYROID GLAND: FOLLICULAR CELL ADENOMA, CARCINOMA, C CELL ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-248 Y83]"
2310,363898343,26108,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N.Cl.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 150; 300 PPM IN DRINKING WATER,"THYROID GLAND: FOLLICULAR CELL ADENOMA, CARCINOMA; LIVER: NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-248 Y83]"
2311,363898344,6061,CNN,Active,,,,HAMSTER,,ORAL,,LIVER,POSITIVE,"[TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975]"
2312,363898344,6061,CNN,Active,,,,MOUSE,,ORAL,,LUNG,POSITIVE,"[TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975]"
2313,363898344,6061,CNN,Active,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 0.2; 2; 5 PPM 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 1 YR),NASAL CAVITY: ADENOMA,POSITIVE,"[KINKEAD,ER, HAUN,CC, VERNOT,EH AND MACEWEN,JD; A CHRONIC INHALATION TOXICITY STUDY; AIR FORCE AEROSP. MED. RES. LAB. (TECH. REP. AFAMRL-TR-85-025), 31 PP., 1996]"
2314,363898344,6061,CNN,Inactive,,,,DOG,BEAGLE/MALE,INHALATION,0; 0.2; 2 PPM 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 6 YR),,NEGATIVE,"[KINKEAD,ER, HAUN,CC, VERNOT,EH AND MACEWEN,JD; A CHRONIC INHALATION TOXICITY STUDY; AIR FORCE AEROSP. MED. RES. LAB. (TECH. REP. AFAMRL-TR-85-025), 31 PP., 1996]"
2315,363898344,6061,CNN,Inactive,,,,DOG,BEAGLE/FEMALE,INHALATION,0; 0.2; 2 PPM 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 6 YR),,NEGATIVE,"[KINKEAD,ER, HAUN,CC, VERNOT,EH AND MACEWEN,JD; A CHRONIC INHALATION TOXICITY STUDY; AIR FORCE AEROSP. MED. RES. LAB. (TECH. REP. AFAMRL-TR-85-025), 31 PP., 1996]"
2316,363898344,6061,CNN,Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.02; 0.2; 2; 5 PPM 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KINKEAD,ER, HAUN,CC, VERNOT,EH AND MACEWEN,JD; A CHRONIC INHALATION TOXICITY STUDY; AIR FORCE AEROSP. MED. RES. LAB. (TECH. REP. AFAMRL-TR-85-025), 31 PP., 1996]"
2317,363898344,6061,CNN,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.02; 0.2; 2; 5 PPM 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KINKEAD,ER, HAUN,CC, VERNOT,EH AND MACEWEN,JD; A CHRONIC INHALATION TOXICITY STUDY; AIR FORCE AEROSP. MED. RES. LAB. (TECH. REP. AFAMRL-TR-85-025), 31 PP., 1996]"
2318,363898344,6061,CNN,Active,,,,MOUSE,C57BL/FEMALE,INHALATION,0; 0.02; 0.2; 2; 5 PPM 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),"LUNG: ADENOMA; LIVER: ADENOMA, CARCINOMA; HEMATOPOIETIC SYSTEM: HEMANGIOMA",POSITIVE,"[KINKEAD,ER, HAUN,CC, VERNOT,EH AND MACEWEN,JD; A CHRONIC INHALATION TOXICITY STUDY; AIR FORCE AEROSP. MED. RES. LAB. (TECH. REP. AFAMRL-TR-85-025), 31 PP., 1996]"
2319,363898345,6328,CI,Active,,,,Rat,Crl:CD(SD)IGS BR/Male (50/Group),Inhalation (whole body),0; 5; 20; 60 ppm for 2 yr; study duration 2 yr,Thyroid: follicular cell adenoma (60 ppm),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IODOMETHANE (June 16, 2009)]"
2320,363898345,6328,CI,Active,,,,Rat,Crl:CD(SD)IGS BR/Female (50/Group),Inhalation (whole body),0; 5; 20; 60 ppm for 2 yr; study duration 2 yr,Thyroid: follicular cell adenoma (60 ppm),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IODOMETHANE (June 16, 2009)]"
2321,363898345,6328,CI,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[POIRIER,LA, STONER,DK AND SHIMKIN,MB; BIOASSAY OF ALKYL HALIDES AND NUCLEOTIDE BASE ANALOGS BY PULMONARY TUMOR RESPONSE IN STRAIN A MICE; CANCER RES. 35:1411-1415, 1975, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V15 245 Y77]"
2322,363898345,6328,CI,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[POIRIER,LA, STONER,DK AND SHIMKIN,MB; BIOASSAY OF ALKYL HALIDES AND NUCLEOTIDE BASE ANALOGS BY PULMONARY TUMOR RESPONSE IN STRAIN A MICE; CANCER RES. 35:1411-1415, 1975, ][LAWLEY,P; CARCINOGENESIS BY ALKYLATING AGENTS; IN: SEARLE,CE (ED.), CHEMICAL CARCINOGENS, ACS MONOGRAPH 173, AMERICAN CHEMICAL SOCIETY, WASHINGTON, D.C., 1976, P. 156, ][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V15 245 Y77]"
2323,363898346,4156,COS(=O)(=O)C,Active,,,,MOUSE,,ORAL,,LUNG; THYMUS GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 253 Y74]"
2324,363898346,4156,COS(=O)(=O)C,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 253 Y74]"
2325,363898346,4156,COS(=O)(=O)C,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 50 PPM 6 HR/D 5 D/WK FOR 30 D (STUDY DURATION: LIFETIME),NASAL CAVITY: TUMORS,POSITIVE,"[SELLAKUMAR,AR, SNYDER,CA AND ALBERT,RE; INHALATION CARCINOGENESIS OF VARIOUS ALKYLATING AGENTS; 79:285-289, 1987]"
2326,363898347,31426,CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.03; 0.06% IN DIET,LIVER: HEMANGIOSARCOMA,POSITIVE,"[MURTHY,ASK, BAKER,JR, SMITH,ER AND WADE,GG;DEVELOPMENT OF HEMANGIOSARCOMAS IN B6C3F1 MICE FED 2-METHYL-1-NITROANTHRAQUINONE; INT. J. CANCER 19:117-121, 1977]"
2327,363898347,31426,CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.03; 0.06% IN DIET,LIVER: HEMANGIOSARCOMA,POSITIVE,"[MURTHY,ASK, BAKER,JR, SMITH,ER AND WADE,GG;DEVELOPMENT OF HEMANGIOSARCOMAS IN B6C3F1 MICE FED 2-METHYL-1-NITROANTHRAQUINONE; INT. J. CANCER 19:117-121, 1977]"
2328,363898347,31426,CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)[N+](=O)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 0.12; 0.06% IN DIET,LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE; INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-29 Y78]"
2329,363898348,62163,CN(CCC#N)N=O,Active,,,,RAT,"F344/MALE,FEMALE",SUBCUTANEOUS,2.13 MG 3/WK FOR 20 WK (TOTAL DOSE 129 MG),"ESOPHAGUS: PAPILLOMA, CARCINOMA; NASAL CAVITY: PAPILLOMA; TONGUE: PAPILLOMA, CARCINOMA",POSITIVE,"[YASUKAWA,K, TAKIDO,M, MATSUMOTO,T, TAKEUCHI,M AND NAKAGAWA,S; STEROL AND TRITERPENE DERIVATIVES FROM PLANTS INHIBIT THE EFFECTS OF A TUMOR PROMOTER, AND SITOSTEROL AND BETULINIC ACID INHIBIT TUMOR FORMATION IN MOUSE SKIN TWO-STAGE CARCINOGENESIS; ONCOLOGY 48:72-76, 1991]"
2330,363898348,62163,CN(CCC#N)N=O,Active,,,,RAT,F344/MALE,MUCOUS MEMBRANE,0; 0.3 ML OF A 15 MMOL WATER SOLUTION 1/D 3 D/WK FOR 1 WK THEN 1/D 5 D/WK FOR WK 2-4 THEN 2/D 5 D/WK FOR WK 5-6 (STUDY DURATION: 61 WK),"NASAL CAVITY: CARCINOMA, PAPILLOMA, ADENOMA; LUNG: ADENOCARCINOMA, ADENOMA; LIVER: CARCINOMA, ADENOMA; ESOPHAGUS: PAPILLOMA; ORAL CAVITY: PAPILLOMA",POSITIVE,"[PROKOPCZYK,B, RIVENSON,A AND HOFFMANN,D; A STUDY OF BETEL QUID CARCINOGENESIS. IX. COMPARATIVE CARCINOGENICITY OF 3-(METHYLNITROSAMINO)PROPIONITRILE AND 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE UPON LOCAL APPLICATION TO MOUSE SKIN AND RAT ORAL MUCOSA; CANCER LETT. 60(2):153-157, 1991]"
2331,363898348,62163,CN(CCC#N)N=O,Active,,,,RAT,"F344/MALE, FEMALE",SUBCUTANEOUS,0; 2.13 MG IN 0.3 ML SALINE 3/WK FOR 20 WK (TOTAL DOSE 127.8 MG) (STUDY DURATION: 24 WK),"ESOPHAGUS: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; TONGUE: PAPILLOMA, CARCINOMA; NASAL CAVITY: PAPILLOMA, ESTHESIONEUROEPITHELIOMA",POSITIVE,"[WENKE,G, RIVENSON,A, BRUNNEMANN,KD, HOFFMANN,D AND BHIDE,SV; A STUDY OF BETEL QUID CARCINOGENESIS. II. FORMATION OF N-NITROSAMINES DURING BETEL QUID CHEWING; IARC SCI. PUBL. 57(N-NITROSO COMPD: OCCURRENCE, BIOL. EFF. RELEVANCE HUM. CANCER):859-866, 1984]"
2332,363898348,62163,CN(CCC#N)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 0.019 MMOL 3/WK FOR 20 WK (STUDY DURATION: 24 WK),ESOPHAGUS: PAPILLOMA; NASAL CAVITY: PAPILLOMA; TONGUE: PAPILLOMA OR CARCINOMA,POSITIVE,"[INABA,S, SUZUKI,O, TAZAWA,T, TAKAHASHI,M, SEKI,H, KURAMOCHI,M, HIRANO,K AND IRIE,D; MUTAGENICITY STUDY OF HUMAN URINARY EPIDERMAL GROWTH FACTOR MG 111; YAKURI TO CHIRYO 20(SUPPL. 12):S3011-S3017, 1992]"
2333,363898348,62163,CN(CCC#N)N=O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,0; 0.019 MMOL 3/WK FOR 20 WK (STUDY DURATION: 24 WK),ESOPHAGUS: PAPILLOMA; NASAL CAVITY: PAPILLOMA; TONGUE: PAPILLOMA OR CARCINOMA,POSITIVE,"[INABA,S, SUZUKI,O, TAZAWA,T, TAKAHASHI,M, SEKI,H, KURAMOCHI,M, HIRANO,K AND IRIE,D; MUTAGENICITY STUDY OF HUMAN URINARY EPIDERMAL GROWTH FACTOR MG 111; YAKURI TO CHIRYO 20(SUPPL. 12):S3011-S3017, 1992]"
2334,363898349,107919,CN(C(=O)NCCC[C@@H](C(=O)O)N)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,INTRAPERITONEAL,218; 654 MG/KG 1/WK FOR 12 WK (LOW DOSE) OR 6 WK (HIGH DOSE),"PANCREAS: CARCINOMA, CARCINOMA (IN SITU); PERITONEAL CAVITY: MESOTHELIOMA;MAMMARY GLAND: CARCINOMA; STOMACH: PAPILLOMA, CARCINOMA; OVARIES (THECA): GRANULOSA CELL TUMOR",POSITIVE,"[LONGNECKER,DS, CURPHEY,TJ, KUHLMANN,ET AND SCHAEFFER,BK; EXPERIMENTAL INDUCTION OF PANCREATIC CARCINOMAS IN THE HAMSTER WITH N(DELTA)-(N-METHYL-N-NITROSOCARBAMOYL)-L-ORNITHINE; J. NATL. CANCER INST. 71:1327-1336, 1983]"
2335,363898349,107919,CN(C(=O)NCCC[C@@H](C(=O)O)N)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAPERITONEAL,218; 654 MG/KG 1/WK FOR 12 WK (LOW DOSE) OR 6 WK (HIGH DOSE),"PANCREAS: CARCINOMA, CARCINOMA (IN SITU); STOMACH: PAPILLOMA",POSITIVE,"[LONGNECKER,DS, CURPHEY,TJ, KUHLMANN,ET AND SCHAEFFER,BK; EXPERIMENTAL INDUCTION OF PANCREATIC CARCINOMAS IN THE HAMSTER WITH N(DELTA)-(N-METHYL-N-NITROSOCARBAMOYL)-L-ORNITHINE; J. NATL. CANCER INST. 71:1327-1336, 1983]"
2336,363898350,11957,CN(C1=CC=CC=C1)N=O,Active,,,,MOUSE,"SWISS/MALE,FEMALE",ORAL,0.070 G/L IN DRINKING WATER FOR 28 WK,LUNG: ADENOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 226]"
2337,363898350,11957,CN(C1=CC=CC=C1)N=O,Active,,,,RAT,"ALBINO/MALE,FEMALE",ORAL,2.0 MG IN 10 ML DRINKING WATER (AVE) 5/WK FOR 52 WK,"ESOPHAGUS: PAPILLOMA, SQUAMOUS CELL CARCINOMA; FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA; MOUTH: PAPILLOMA, SQUAMOUS CELL CARCINOMA; PHARYNX: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 226]"
2338,363898350,11957,CN(C1=CC=CC=C1)N=O,Active,,,,RAT,STRAIN-BD,ORAL,14 MG/KG/D IN DIET FOR 250 D (AVE TOTAL DOSE: 3.4 G/KG),ESOPHAGUS: SQUAMOUS CELL CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 443]"
2339,363898350,11957,CN(C1=CC=CC=C1)N=O,Active,,,,RAT,"STRAIN-CB/MALE,FEMALE",ORAL,"5 MG AS 0.2% FOR 7 MO THEN 2.5 MG AS 0.1% IN DRINKING WATER 1/D, 6/WK",ESOPHAGUS: BENIGN TUMOR OR MALIGNANT TUMOR,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 443]"
2340,363898350,11957,CN(C1=CC=CC=C1)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 5 MG/KG 1/WK FOR 50 WK (TOTAL DOSE: 0; 1.8 MMOL) (STUDY DURATION: LIFETIME),LIVER: CHOLANGIOMA,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
2341,363898351,92394,CC1COCCN1N=O,Active,,,,RAT,F344/FEMALE,ORAL,45 MG/L IN DRINKING WATER FOR 26 WK,"LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; ESOPHAGUS: PAPILLOMA, CARCINOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARATIVE CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOTETRAHYDROOXAZINE IN RATS; CARCINOGENESIS 3:911-915, 1982]"
2342,363898352,38357,CC1N(CCO1)N=O,Active,,,,RAT,F344/FEMALE,ORAL,40 MG/L IN DRINKING WATER FOR 50 WK,"LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARATIVE CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOTETRAHYDROOXAZINE IN RATS; CARCINOGENESIS 3:911-915, 1982]"
2343,363898353,147617,CC1CN(CO1)N=O,Active,,,,RAT,F344/FEMALE,ORAL,40 MG/L IN DRINKING WATER FOR 50 WK,"LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARATIVE CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOTETRAHYDROOXAZINE IN RATS; CARCINOGENESIS 3:911-915, 1982]"
2344,363898353,147617,CC1CN(CO1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAGASTRIC,0; 25 MG/ML IN 0.2 ML STERILIZED WATER 1/WK FOR 24 WK (TOTAL DOSE 120 MG) (STUDY DURATION: LIFESPAN),"LIVER: HEPATOCELLULAR CARCINOMA, ADENOMA, HEMANGIOSARCOMA, CHOLANGIOCARCINOMA; PANCREAS: DUCTAL CARCINOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOAZETIDINE GIVEN BY GAVAGE TO SYRIAN GOLDEN HAMSTERS; CARCINOGENESIS 5(7):875-878, 1984]"
2345,363898354,12699,CN(C(=O)N)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAPERITONEAL,30; 71 MG/KG IN SODIUM CHLORIDE- SODIUM CITRATE ONCE,FORESTOMACH: SQUAMOUS CELL PAPILLOMA,POSITIVE,"[LIKHACHEV,AJ, IVANOV,MN, BRESIL,H, PLANCHE-MARTEL,G, MONTESANO,R AND MARGISON, GP; CARCINOGENICITY OF SINGLE DOSES OF N-NITROSO-N-METHYLUREA AND N-NITROSO-N-ETHYLUREA IN SYRIAN GOLDEN HAMSTERS AND THE PERSISTENCE OF ALKYLATED PURINES IN THE DNA OF VARIOUS TISSUES; CANCER RES. 43:829-833, 1983]"
2346,363898354,12699,CN(C(=O)N)N=O,Active,,,,HAMSTER,,ORAL,,ORAL CAVITY; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2347,363898354,12699,CN(C(=O)N)N=O,Active,,,,HAMSTER,,INTRATRACHEAL,,TRACHEA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2348,363898354,12699,CN(C(=O)N)N=O,Active,,,,HAMSTER,,INTRAPERITONEAL,,INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2349,363898354,12699,CN(C(=O)N)N=O,Active,,,,HAMSTER,,INTRAVENOUS,,INTESTINES; ORAL CAVITY; STOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2350,363898354,12699,CN(C(=O)N)N=O,Active,,,,HAMSTER,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2351,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN); HEMATOPOIETIC SYSTEM (LEUKEMIA): LYMPHATIC LEUKEMIA; LYMPHATIC SYSTEM: LYMPHATIC LEUKEMIA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2352,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,,SUBCUTANEOUS,,LYMPHATIC SYSTEM: LYMPHOMA; LUNG; HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2353,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,,INTRAPERITONEAL,,LYMPHATIC SYSTEM; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2354,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,,INTRAVENOUS,,HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2355,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,,ORAL,,FORESTOMACH; BRAIN; NERVOUS SYSTEM (PERIPHERAL),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2356,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2357,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,,SUBCUTANEOUS,,NERVOUS SYSTEM,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2358,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,,INTRAVENOUS,,BRAIN; NERVOUS SYSTEM (PERIPHERAL),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2359,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,,INTRAPERITONEAL,,PERITONEAL CAVITY; NERVOUS SYSTEM,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 227 Y78]"
2360,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,FEMALE,INTRAVENOUS,0; 50 MG/KG BODY WT IN SODIUM CITRATE BUFFER 1/WK FOR 2 OR 4 WK (STUDY DURATION: 400-500 D),MAMMARY GLAND: ADENOCARCINOMA; KIDNEY; HEMATOPOIETIC SYSTEM (LEUKEMIA): GRANULOCYTIC LEUKEMIA,POSITIVE,"[ANISIMOV,VN; CARCINOGENESIS AND AGING. I. MODIFYING EFFECTS OF AGING ON N-METHYL-N-NITROSOUREA-INDUCED CARCINOGENESIS IN FEMALE RATS; EXP. PATHOL. 19(2):81-90, 1981]"
2361,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,FEMALE,INTRAVENOUS,0; 50 MG/KG BODY WT IN SODIUM CITRATE BUFFER 1/WK FOR 2 WK (STUDY DURATION: 750 D),VAGINA (CERVIX): LEIOMYOSARCOMA; KIDNEY; HEMATOPOIETIC SYSTEM (LEUKEMIA): GRANULOCYTIC LEUKEMIA,POSITIVE,"[ANISIMOV,VN; CARCINOGENESIS AND AGING. I. MODIFYING EFFECTS OF AGING ON N-METHYL-N-NITROSOUREA-INDUCED CARCINOGENESIS IN FEMALE RATS; EXP. PATHOL. 19(2):81-90, 1981]"
2362,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,CFLP/FEMALE,DERMAL,0; 12.5; 50; 200 UG IN ACETONE 2 D/WK FOR 104 WK (STUDY DURATION: 24 MO),SKIN: CARCINOMA,POSITIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G AND MISFELD,J; LOCAL APPLICATION TO MOUSE SKIN AS A CARCINOGEN SPECIFIC TEST SYSTEM FOR NON-VOLATILE NITROSO COMPOUNDS; CANCER LETT. 29:85-92, 1985]"
2363,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 5.25; 10.5 MG/ML (TOTAL DOSE 0; 0.4; 0.8 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 20 WKS (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
2364,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 5.25; 10.5 MG/ML (TOTAL DOSE 0; 0.4; 0.8 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 20 WKS (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
2365,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,WISTAR/MALE,INTRAVENOUS,0; 50 MG/KG ONCE INTO TAIL VEIN (STUDY DURATION: 79 WK),ZYMBAL GLAND: CARCINOMA,POSITIVE,"[BOSLAND,MC, PRINSEN,MK, RIVENSON,A AND WEISBURGER,JH; INDUCTION OF SKIN AND THYROID TUMORS IN MALE RATS BY N-METHYL-N-NITROSOUREA AFTER SEQUENTIAL TREATMENT WITH CYPROTERONE ACETATE AND TESTOSTERONE PROPIONATE: EFFECTS OF CASTRATION, RAT STRAIN AND TIME OF CARCINOGEN INJECTION; CARCINOGENESIS 13(4):669-674, 1992]"
2366,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,BALB/FEMALE,DERMAL,0; 25 UL OF A SOLUTION OF 4.1 MG/ML OF METHANOL 2/WK FOR 25 WK (TOTAL DOSE: 50 UMOL) (STUDY DURATION: 25 WK),"LUNG: ADENOMA, SKIN: TUMOR MALIGNANT TUMOR",POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; DIFFERENCES IN SKIN CARCINOGENESIS BY METHYLNITROSOUREA BETWEEN MICE OF SEVERAL STRAINS; CANCER LETT. 61(1):1-5, 1991]"
2367,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 25 UL OF A SOLUTION OF 4.1 MG/ML OF METHANOL 2/WK FOR 25 WK (TOTAL DOSE: 50 UMOL) (STUDY DURATION: 25 WK),"LUNG: ADENOMA, SKIN: TUMOR",POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; DIFFERENCES IN SKIN CARCINOGENESIS BY METHYLNITROSOUREA BETWEEN MICE OF SEVERAL STRAINS; CANCER LETT. 61(1):1-5, 1991]"
2368,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,SENCAR/FEMALE,DERMAL,0; 25 UL OF A SOLUTION OF 4.1 MG/ML OF METHANOL 2/WK FOR 25 WK (TOTAL DOSE: 50 UMOL) (STUDY DURATION: 25 WK),"SKIN: TUMOR, MALIGNANT TUMOR",POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; DIFFERENCES IN SKIN CARCINOGENESIS BY METHYLNITROSOUREA BETWEEN MICE OF SEVERAL STRAINS; CANCER LETT. 61(1):1-5, 1991]"
2369,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 25 UL OF A SOLUTION OF 4.1 MG/ML OF METHANOL 2/WK FOR 25 WK (TOTAL DOSE: 50 UMOL) (STUDY DURATION: 25 WK),"SKIN: TUMOR, MALIGNANT TUMOR",POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; DIFFERENCES IN SKIN CARCINOGENESIS BY METHYLNITROSOUREA BETWEEN MICE OF SEVERAL STRAINS; CANCER LETT. 61(1):1-5, 1991]"
2370,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 1.1 MG 2/WK FOR 3 TREATMENTS THEN 2 WK LATER 0.5 MG 2/WK FOR 17 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
2371,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,BUF/N/FEMALE,INTRAPERITONEAL,0; 30 MG/KG ADMINISTERED TO NEONATES ONCE (STUDY DURATION: 365 D),MAMMARY GLAND: TUMOR,POSITIVE,"[LU,S, LAROYE,G AND ARCHER,MC; MAMMARY TUMOR INDUCTION BY N-MEHTYL-N-NITROSOUREA IN GENETICALLY RESISTANT COPENHAGEN RATS; CANCER RES. 52(18):5037-5041, 1992]"
2372,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,BUF/N/FEMALE,INTRAPERITONEAL ; INJECTION,0; 30 MG/KG ADMINISTERED TO NEONATES FOLLOWED BY 30 MG/KG AT 50 DAYS OF AGE (STUDY DURATION: 365 D),MAMMARY GLAND: TUMOR,POSITIVE,"[LU,S, LAROYE,G AND ARCHER,MC; MAMMARY TUMOR INDUCTION BY N-MEHTYL-N-NITROSOUREA IN GENETICALLY RESISTANT COPENHAGEN RATS; CANCER RES. 52(18):5037-5041, 1992]"
2373,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,BUF/N/FEMALE,INJECTION,0; 30 MG/KG ADMINISTERED ONCE TO PUBESCENT ANIMALS AT 50 DAYS OF AGE (STUDY DURATION: 365 D),MAMMARY GLAND: TUMOR,POSITIVE,"[LU,S, LAROYE,G AND ARCHER,MC; MAMMARY TUMOR INDUCTION BY N-MEHTYL-N-NITROSOUREA IN GENETICALLY RESISTANT COPENHAGEN RATS; CANCER RES. 52(18):5037-5041, 1992]"
2374,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,COPENHAGEN/FEMALE,INTRAPERITONEAL,0; 30 MG/KG ADMINISTERED TO NEONATES ONCE (STUDY DURATION: 365 D),MAMMARY GLAND: TUMOR,POSITIVE,"[LU,S, LAROYE,G AND ARCHER,MC; MAMMARY TUMOR INDUCTION BY N-MEHTYL-N-NITROSOUREA IN GENETICALLY RESISTANT COPENHAGEN RATS; CANCER RES. 52(18):5037-5041, 1992]"
2375,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,COPENHAGEN/FEMALE,INTRAPERITONEAL ; INJECTION,0; 30 MG/KG ADMINISTERED TO NEONATES FOLLOWED BY 30 MG/KG AT 50 DAYS OF AGE (STUDY DURATION: 365 D),MAMMARY GLAND: TUMOR,POSITIVE,"[LU,S, LAROYE,G AND ARCHER,MC; MAMMARY TUMOR INDUCTION BY N-MEHTYL-N-NITROSOUREA IN GENETICALLY RESISTANT COPENHAGEN RATS; CANCER RES. 52(18):5037-5041, 1992]"
2376,363898354,12699,CN(C(=O)N)N=O,Active,,,,MOUSE,C3H/MALE,ORAL,0; 30; 60; 120 PPM IN DRINKING WATER FOR 30 WK (STUDY DURATION: 54 WK),GLANDULAR STOMACH: ADENOCARCINOMA; SPLEEN: HEMANGIOENDOTHELIAL SARCOMA; LUNG: ADENOMA,POSITIVE,"[TATEMATSU,M, YAMAMOTO,M, IWATA,H, FUKAMI,H, YUASA,H, TEZUKA,N, MASUI,T AND NAKANISHI,H; INDUCTION OF GLANDULAR STOMACH CANCERS IN C3H MICE TREATED WITH N-METHYL-N-NITROSOUREA IN THE DRINKING WATER;JPN. J. CANCER RES. 84(12): 1258-1264, 1993]"
2377,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,LIO/MALE,INTRAVENOUS,0; 20 MG/KG BW ONCE AT 3 MO OF AGE ADMINISTERED TO PROGENY OF 3 MONTH OLD MALE AND FEMALE RATS (STUDY DURATION: 18 MO),MAMMARY GLAND: FIBROADENOMA; THYROID GLAND: ADENOMA,POSITIVE,"[ANISIMOV,VN AND GVARDINA,OE; N-NITROSOMETHYLUREA-INDUCED CARCINOGENESIS IN THE PROGENY OF MALE RATS OF DIFFERENT AGES; MUTAT. RES. 316(3):139-145, 1995]"
2378,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,LIO/MALE,INTRAVENOUS,0; 20 MG/KG BW ONCE AT 3 MO OF AGE ADMINISTERED TO PROGENY OF 25 MONTH OLD MALE AND FEMALE RATS (STUDY DURATION: 18 MO),KIDNEY: MESENCHYMAL TUMOR,POSITIVE,"[ANISIMOV,VN AND GVARDINA,OE; N-NITROSOMETHYLUREA-INDUCED CARCINOGENESIS IN THE PROGENY OF MALE RATS OF DIFFERENT AGES; MUTAT. RES. 316(3):139-145, 1995]"
2379,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,LIO/FEMALE,INTRAVENOUS,0; 20 MG/KG BW ONCE AT 3 MO OF AGE ADMINISTERED TO PROGENY OF 3 MONTH OLD MALE AND FEMALE RATS (STUDY DURATION: 18 MO),MAMMARY GLAND: FIBROADENOMA; KIDNEY: MESENCHYMAL TUMOR; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[ANISIMOV,VN AND GVARDINA,OE; N-NITROSOMETHYLUREA-INDUCED CARCINOGENESIS IN THE PROGENY OF MALE RATS OF DIFFERENT AGES; MUTAT. RES. 316(3):139-145, 1995]"
2380,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,LIO/FEMALE,INTRAVENOUS,0; 20 MG/KG BW ONCE AT 3 MO OF AGE ADMINISTERED TO PROGENY OF 25 MONTH OLD MALE AND FEMALE RATS (STUDY DURATION: 18 MO),KIDNEY: MESENCHYMAL TUMOR,POSITIVE,"[ANISIMOV,VN AND GVARDINA,OE; N-NITROSOMETHYLUREA-INDUCED CARCINOGENESIS IN THE PROGENY OF MALE RATS OF DIFFERENT AGES; MUTAT. RES. 316(3):139-145, 1995]"
2381,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 50 MG/KG BW ONCE AT 21 D OF AGE (STUDY DURATION: 35 D),MAMMARY GLAND: CARCINOMA,POSITIVE,"[THOMPSON,HJ, MCGINLEY,JN, ROTHHAMMER,K AND SINGH,M; RAPID INDUCTION OF MAMMARY INTRADUCTAL PROLIFERATIONS, DUCTAL CARCINOMA IN SITU AND CARCINOMAS BY THE INJECTION OF SEXUALLY IMMATURE FEMALE RATS WITH 1-METHYL-1-NITROSOUREA; CARCINOGENESIS 16(10):2407-2411, 1995]"
2382,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,WHITE OUTBRED/MALE,DERMAL,0; 0.2 ML OF A 1% ACETONE SOLUTION 3/WK FOR 24 WK (STUDY DURATION: 48 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
2383,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,WHITE OUTBRED/FEMALE,DERMAL,0; 0.2 ML OF A 1% ACETONE SOLUTION 3/WK FOR 24 WK (STUDY DURATION: 48 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
2384,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,WHITE OUTBRED/MALE,DERMAL,0; 0.1 ML OF A 2% ACETONE SOLUTION 3/WK FOR 4 WK (STUDY DURATION: 40 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
2385,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,WHITE OUTBRED/MALE,DERMAL,0; 0.3 ML OF A 1% ACETONE SOLUTION 3/WK FOR 5 WK (STUDY DURATION: 40 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
2386,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 5.25; 10.5 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 20 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
2387,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 5.25; 10.5 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 20 WK (STUDY DURATION: LIFESPAN),THYMUS: TUMOR; FORESTOMACH: TUMOR; NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
2388,363898354,12699,CN(C(=O)N)N=O,Inactive,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 80; 160; 240 MG/KG 2/WK FOR 2 WK (STUDY DURATION: 12 WK),,NEGATIVE,"[FRANCHI,CADS BACCHI,MM PADOVANI,CR AND VIANA DE CAMARGO,JL; THYMIC LYMPHOMAS IN WISTAR RATS EXPOSED TO N-METHYL-N-NITROSOUREA (MNU); CANCER SCI. 94(3):240-243, 2003]"
2389,363898354,12699,CN(C(=O)N)N=O,Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 80; 160; 240 MG/KG 2/WK FOR 2 WK (STUDY DURATION: 20 WK),THYMUS: LYMPHOMA,POSITIVE,"[FRANCHI,CADS BACCHI,MM PADOVANI,CR AND VIANA DE CAMARGO,JL; THYMIC LYMPHOMAS IN WISTAR RATS EXPOSED TO N-METHYL-N-NITROSOUREA (MNU); CANCER SCI. 94(3):240-243, 2003]"
2390,363898354,12699,CN(C(=O)N)N=O,Unspecified,,,,RAT,"F344/FEMALE, 3 WKS OF AGE",INTRAVENOUS,50 MG/KG ONCE (STUDY DURATION: 36 WKS),MAMMARY GLAND: CARCINOMA,76% TUMOR INCIDENCE; 0.92 CARCINOMAS/RAT; IMMATURE RATS MORE SUSCEPTIBLE,"[ARIAZI,JL, HAAG,JD, LINDSTROM,MJ AND GOULD,MN; MAMMARY GLANDS OF SEXUALLY IMMATURE RATS ARE MORE SUSCEPTIBLE THAN THOSE OF MATURE RATS TO THE CARCINOGENIC, LETHAL, AND MUTAGENIC EFFECTS OF N-NITROS-N-METHYLUREA; MOL. CARCINOG. 43(3):155-164, 2005]"
2391,363898354,12699,CN(C(=O)N)N=O,Unspecified,,,,RAT,"F344/FEMALE, 8 WKS OF AGE",INTRAVENOUS,50 MG/KG ONCE (STUDY DURATION: 36 WKS),MAMMARY GLAND: CARCINOMA,46% TUMOR INCIDENCE; 0.54 CARCINOMAS/RAT; MATURE RATS LESS SUSCEPTIBLE,"[ARIAZI,JL, HAAG,JD, LINDSTROM,MJ AND GOULD,MN; MAMMARY GLANDS OF SEXUALLY IMMATURE RATS ARE MORE SUSCEPTIBLE THAN THOSE OF MATURE RATS TO THE CARCINOGENIC, LETHAL, AND MUTAGENIC EFFECTS OF N-NITROS-N-METHYLUREA; MOL. CARCINOG. 43(3):155-164, 2005]"
2392,363898354,12699,CN(C(=O)N)N=O,Active,,,,Rat,Wistar-Furth/Female (32/group),Injection,"Single dose given at 50 days of age, study duration to 46 wk of age",Mammary gland: Papillary cystic adenocarcinoma and 1 fibroadenoma; 84% (latency 13-15 wk),"Positive. In ancillary experiments, DNA damage was observed as early as 1 day after MNU injection; initial genomic instability was accompanied by a population of highly aneuploid cells.50 days post NMU treatment","[GOEPFERT,TM, MORENO-SMITH,M, EDWARDS,DG, PATHAK,S, MEDINA,D, AND BRINKLEY,WR; LOSS OF CHROMOSOMAL INTEGRITY DRIVES RAT MAMMARY TUMORIGENESIS; INT. J. CANCER 120:985-994, 2006]"
2393,363898355,4130,COP(=S)(OC)OC1=CC=C(C=C1)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 62.5; 125 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-157 Y79]"
2394,363898355,4130,COP(=S)(OC)OC1=CC=C(C=C1)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 35; 77 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-157 Y79]"
2395,363898355,4130,COP(=S)(OC)OC1=CC=C(C=C1)[N+](=O)[O-],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 20; 40 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-157 Y79]"
2396,363898355,4130,COP(=S)(OC)OC1=CC=C(C=C1)[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,ORAL,0; 20; 40 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-157 Y79]"
2397,363898356,13545,CCCN(C)N=O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",SUBCUTANEOUS,12.5; 25; 50 MG/KG 1/WK,"NASAL CAVITY: CARCINOMA, EPIDERMOID TUMOR, MUCOEPIDERMOID TUMOR; TRACHEA: PAPILLARY POLYP; LUNG: ADENOMA, CARCINOMA; LIVER: CHOLANGIOMA, CARCINOMA, HEMANGIOENDOTHELIOMA",POSITIVE,"[POUR,P, KRUGER,FW, CARDESA,A, ALTHOFF,J AND MOHR,U; TUMORIGENICITY OF METHYL-N-PROPYLNITROSAMINE IN SYRIAN GOLDEN HAMSTERS; J. NATL. CANCER INST. 52(2):457-462, 1974]"
2398,363898356,13545,CCCN(C)N=O,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,0.05; 0.1; 0.2 OF LD50 (77.1 MG/KG) 1/WK FOR LIFE,"NASAL CAVITY: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; LARYNX: PAPILLOMA, CARCINOMA (IN SITU), SQUAMOUS CELL CARCINOMA; TRACHEA: PAPILLOMA, SQUAMOUS CELL CARCINOMA; BRONCHI: PAPILLOMA; LIVER: HEMANGIOENDOTHELIAL SARCOMA; LUNG: ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[DICKHAUS,S, REZNIK,G, GREEN,U AND KETKAR,M;THE CARCINOGENIC EFFECT OF BETA-OXIDIZED DIPROPYLNITROSAMINE IN MICE; Z. KREBSFORSCH. 90:253-258, 1977]"
2399,363898356,13545,CCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 2.1 MG/KG 1/WK FOR 23-30 WK (TOTAL DOSE: 0; 0.6 MMOL) (STUDY DURATION: LIFETIME),"LIVER: HEPATOCELLULAR ADENOMA, HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIAL ADENOMA; NASAL MUCOSA: CARCINOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
2400,363898356,13545,CCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 2.1 MG/KG 1/WK FOR 23-30 WK (TOTAL DOSE: 0; 0.6 MMOL) (STUDY DURATION: LIFETIME),"LIVER: HEPATOCELLULAR ADENOMA, HEMANGIOSARCOMA; NASAL MUCOSA: CARCINOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
2401,363898357,7059,CC1=CC2=C(C=C1)N=CC=C2,Inactive,,,,RAT,"F344/MALE,FEMALE",ORAL,0.05% IN DIET FOR 2 YR,,NEGATIVE,"[FUKUSHIMA,S, ISHIHARA,Y, NISHIO,O, OGISO,T, SHIRAI,T AND ITO,N; CARCINOGENITIES  OF QUINOLINE DERIVATIVES IN F344 RATS; CANCER LETT. 14:115-123, 1981]"
2402,363898358,11910,CC1=C2C(=CC=C1)C=CC=N2,Inactive,,,,RAT,"F344/MALE,FEMALE",ORAL,0.05% IN DIET FOR 2 YR,,NEGATIVE,"[FUKUSHIMA,S, ISHIHARA,Y, NISHIO,O, OGISO,T, SHIRAI,T AND ITO,N; CARCINOGENITIES  OF QUINOLINE DERIVATIVES IN F344 RATS; CANCER LETT. 14:115-123, 1981]"
2403,363898358,11910,CC1=C2C(=CC=C1)C=CC=N2,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.25; 0.5; 1.0 UMOL IN DMSO TO NEWBORN MICE ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
2404,363898358,11910,CC1=C2C(=CC=C1)C=CC=N2,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.25; 0.5; 1.0 UMOL IN DMSO TO NEWBORN MICE ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
2405,363898358,11910,CC1=C2C(=CC=C1)C=CC=N2,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,"0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN 0; 200 UMOL/KG, ONCE AT WK 8 (STUDY DURATION: 78 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
2406,363898358,11910,CC1=C2C(=CC=C1)C=CC=N2,Inactive,,,,SPRAGUE-DAWLEY/MALE,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,"0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN 0; 200 UMOL/KG, ONCE AT WK 8 (STUDY DURATION: 78 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
2407,363898359,667493,CC1=CC(=O)NC(=S)N1,Active,,,,HAMSTER,,ORAL,,THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 53 Y74]"
2408,363898359,667493,CC1=CC(=O)NC(=S)N1,Active,,,,MOUSE,,ORAL,,THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 53 Y74]"
2409,363898359,667493,CC1=CC(=O)NC(=S)N1,Active,,,,RAT,,ORAL,,KIDNEY; THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 53 Y74]"
2410,363898360,4173,CC1=NC=C(N1CCO)[N+](=O)[O-],Active,,,,MOUSE,,ORAL,,LUNG; LYMPHATIC SYSTEM: LYMPHOMA (NOS),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 113 Y77]"
2411,363898360,4173,CC1=NC=C(N1CCO)[N+](=O)[O-],Active,,,,RAT,,ORAL,,MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 113 Y77]"
2412,363898361,9414,CC1=CC(=CC(=C1N(C)C)C)OC(=O)NC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 68; 135 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-147 Y78]"
2413,363898361,9414,CC1=CC(=CC(=C1N(C)C)C)OC(=O)NC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 327; 654 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-147 Y78]"
2414,363898361,9414,CC1=CC(=CC(=C1N(C)C)C)OC(=O)NC,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 339; 678 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-147 Y78]"
2415,363898361,9414,CC1=CC(=CC(=C1N(C)C)C)OC(=O)NC,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 209; 418 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-147 Y78]"
2416,363898362,7031,CN(C)C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)N(C)C,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 2500 PPM IN DIET,LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-181 Y79]"
2417,363898362,7031,CN(C)C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)N(C)C,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1250; 2500 PPM IN DIET,INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): HEMANGIOSARCOMA OR HEMANGIOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-181 Y79]"
2418,363898362,7031,CN(C)C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)N(C)C,Active,,,,RAT,F344/FEMALE,ORAL,0; 500; 1000 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-181 Y79]"
2419,363898362,7031,CN(C)C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)N(C)C,Active,,,,RAT,F344/MALE,ORAL,0; 250; 500 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-181 Y79]"
2420,363898363,16945,C12(C3(C4(C5(C3(C(C1(C5(C2(C4(Cl)Cl)Cl)Cl)Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"B6AKF1/MALE,FEMALE",GAVAGE/ORAL,10 MG/KG FROM D 7- 28 OF LIFE THEN 26 PPM IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 203 Y74]"
2421,363898363,16945,C12(C3(C4(C5(C3(C(C1(C5(C2(C4(Cl)Cl)Cl)Cl)Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE",GAVAGE/ORAL,10 MG/KG FROM D 7- 28 OF LIFE THEN 26 PPM IN DIET,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 203 Y74]"
2422,363898363,16945,C12(C3(C4(C5(C3(C(C1(C5(C2(C4(Cl)Cl)Cl)Cl)Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[ULLAND,BM, PAGE,NP, SQUIRE,RA, WEISBURGER,EK AND CYPHER,RL; A CARCINOGENICITY ASSAY OF MIREX IN CHARLES RIVER CD RATS; J. NATL. CANCER INST. 58:133-140, 1977]"
2423,363898363,16945,C12(C3(C4(C5(C3(C(C1(C5(C2(C4(Cl)Cl)Cl)Cl)Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 0.1; 1; 10; 25; 50 PPM IN FEED FOR 104 WK (STUDY DURATION: 105 WK),"LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; ADRENAL GLAND: PHEOCHROMOCYTOMA, PHEOCHROMOCYTOMA OR MALIGNANT PHEOCHROMOCYTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-313 Y90]"
2424,363898363,16945,C12(C3(C4(C5(C3(C(C1(C5(C2(C4(Cl)Cl)Cl)Cl)Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.1; 1; 10; 25; 50 PPM IN FEED FOR 104 WK (STUDY DURATION: 105 WK),HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-313 Y90]"
2425,363898363,16945,C12(C3(C4(C5(C3(C(C1(C5(C2(C4(Cl)Cl)Cl)Cl)Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 50; 100 PPM IN FEED FOR 104 WK (STUDY DURATION: 106 WK),"HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA; LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-313 Y90]"
2426,363898364,5746,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N,Active,,,,RAT,,INTRAPERITONEAL,,PERITONEAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 171 Y76]"
2427,363898364,5746,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N,Active,,,,RAT,,INTRAVENOUS,,PERITONEAL CAVITY; MAMMARY GLAND; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 171 Y76]"
2428,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,DOG,,ORAL,,STOMACH; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y74]"
2429,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,HAMSTER,,ORAL,,STOMACH; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y74]"
2430,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y74]"
2431,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,MOUSE,,INTRAPERITONEAL,,INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y74]"
2432,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,MOUSE,,ORAL,,FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y74]"
2433,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RABBIT,,ORAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y74]"
2434,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RAT,,ORAL,,STOMACH; FORESTOMACH; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y74][REDDY,BS, WEISBURGER,JH, NARISAWA,T AND WYNDER,EL; COLON CARCINOGENESIS IN GERM-FREE RATS WITH 1,2-DIMETHYLHYDRAZINE AND N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; CANCER RES. 34(9):2368-2372, 1974, ]"
2435,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RAT,,INTRAPERITONEAL,,STOMACH; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y75][REDDY,BS, WEISBURGER,JH, NARISAWA,T AND WYNDER,EL; COLON CARCINOGENESIS IN GERM-FREE RATS WITH 1,2-DIMETHYLHYDRAZINE AND N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; CANCER RES. 34(9):2368-2372, 1974, ]"
2436,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE; INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y74][REDDY,BS, WEISBURGER,JH, NARISAWA,T AND WYNDER,EL; COLON CARCINOGENESIS IN GERM-FREE RATS WITH 1,2-DIMETHYLHYDRAZINE AND N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; CANCER RES. 34(9):2368-2372, 1974, ]"
2437,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RAT,,RECTAL,,INTESTINES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 183 Y75][REDDY,BS, WEISBURGER,JH, NARISAWA,T AND WYNDER,EL; COLON CARCINOGENESIS IN GERM-FREE RATS WITH 1,2-DIMETHYLHYDRAZINE AND N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; CANCER RES. 34(9):2368-2372, 1974, ]"
2438,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 75 MG/L IN DRINKING WATER 5D/WK FOR 50 WK FOR A TOTAL DOSE OF 0; 375 MG (STUDY DURATION: 131 WK),GLANDULAR STOMACH: ADENOCARCINOMA; GLANDULAR STOMACH: ADENOMA; GLANDULAR STOMACH: SARCOMA,POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARISON OF NITROSOCIMETIDINE WITH NITROSOMETHYLNITROGUANIDINE IN CHRONIC FEEDING TESTS IN RATS; CANCER RES. 44:447-449, 1984]"
2439,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,FISH,RIVULUS,IMMERSION,0; 5; 15; 25 PPM IN WATER FOR 2 HR ADMINISTERED A 7 D OF AGE (STUDY DURATION: 4 MO),THYROID: TUMOR,POSITIVE,"[PARK,EH, CHANG,HH, LEE,KC, KWEON,HS, HEO,OS AND HA,KW; HIGH FREQUENCY OF THYROID TUMOR INDUCTION BY N-METHYL-N'-NITRO-N-NITROSO-GUANINE IN THE HERMAPHRODITIC FISH RIVULUS MARMORATUS; JPN. J. CANCER RES. 84(6):608-615, 1993]"
2440,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,SHREW,HOUSE MUSK/FEMALE,ORAL,0; 50 UG/ML IN DRINKING WATER FOR 30 WK (STUDY DURATION: 45 WK),ESOPHAGUS: PAPILLOMA OR CARCINOMA,POSITIVE,"[FUJITA,Y, OYAIZU,T, TAKAHASHI,H, OISHI,Y AND TSUBURA,A; MORPHOGENESIS OF ESOPHAGEAL CARCINOMA INDUCED BY N-METHYL-N'-NITRO-N-NITROSOGUANIDINE IN THE HOUSE MUSK SHREW, SUNCUS MURINUS (INSECTIVORA); JPN. J. CANCER RES. 85(12): 1208-1213, 1994]"
2441,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",ORAL,0; 500 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),STOMACH: PAPILLOMA,POSITIVE,"[HENDRICKS,JD, SHELTON,DW, LOVELAND,PM, PEREIRA,CB AND BAILEY,GS; CARCINOGENICITY OF DIETARY DIMETHYLNITROSOMORPHOLINE, N-METHYL-N'-NITRO-N-NITROSOGUANIDINE, AND DIBROMOETHANE IN RAINBOW TROUT; TOXICOL. PATHOL. 23(4):447-457, 1995]"
2442,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RAT,WISTAR/MALE,GAVAGE,0; 50; 125; 250 MG/KG ONCE (STUDY DURATION: 18 MO),"FORESTOMACH: BENIGN TUMOR, MALIGNANT TUMOR; STOMACH(PYLORUS): BENIGN TUMOR, MALIGNANT TUMOR; LIVER: CHOLANGIOMA",POSITIVE,"[ZAIDI,NH, CONNOR,PJO AND BUTLER,WH; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE- INDUCED CARCINOGENESIS: DIFFERENTIAL PATTERN OF UPPER GASTROINTESTINAL TRACT TUMORS IN WISTAR RATS AFTER SINGLE OR CHRONIC ORAL DOSES; CARCINOGENESIS 14(8):1561-1567, 1993]"
2443,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RAT,WISTAR/MALE,ORAL,0; 40; 80; 160 UG/ML IN DRINKING WATER FOR 28 WK (HIGH DOSE REDUCED TO 80 UG AFTER 8 WK)(STUDY DURATION: 52 WK),"FORESTOMACH: BENIGN TUMOR; STOMACH(CORPUS): BENIGN TUMOR, MALIGNANT TUMOR; STOMACH(PYLORUS): BENIGN TUMOR, MALIGNANT TUMOR; JEJUNUM: MALIGNANT TUMOR; LIVER: CHOLANGIOMA",POSITIVE,"[ZAIDI,NH, CONNOR,PJO AND BUTLER,WH; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE- INDUCED CARCINOGENESIS: DIFFERENTIAL PATTERN OF UPPER GASTROINTESTINAL TRACT TUMORS IN WISTAR RATS AFTER SINGLE OR CHRONIC ORAL DOSES; CARCINOGENESIS 14(8):1561-1567, 1993]"
2444,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RAT,WHITE OUTBRED/MALE,DERMAL,0; 0.2 ML OF A 0.5% ACETONE SOLUTION 3/WK FOR 60 WK (STUDY DURATION: 60 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
2445,363898365,9562060,CN(/C(=N/[N+](=O)[O-])/N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,20 MG/KG BW ONCE PER WK FOR 32 WK (STUDY DURATION: 104 WK),FORESTOMACH: PAPILLOMA; SQUAMOUS CELL CARCINOMA,POSITIVE,"[KANEKO,M MORIMURA,K NISHIKAWA,T WANIBUCHI,H TAKADA,N OSUGI,H KINOSHITA,H AND FUKUSHIMA,S; DIFFERENT GENETIC ALTERATIONS IN RAT FORESTOMACH TUMORS INDUCED BY GENOTOXIC AND ON-GENOTOXIC CARCINOGENS; CARCINOGENESIS 23(10):1729-1735, 2002]"
2446,363898366,9415,C[C@H]1C(=O)O[C@@H]2CCN3[C@@H]2C(=CC3)COC(=O)[C@]([C@]1(C)O)(C)O,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 291 Y76]"
2447,363898367,3005839,C1COCCN1C[C@H]2CN(C(=O)O2)N=CC3=CC=C(O3)[N+](=O)[O-],Active,,,,RAT,,ORAL,,LYMPHATIC SYSTEM: LYMPHOBLASTIC LYMPHOMA; MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 161 Y74]"
2448,363898368,2478,CS(=O)(=O)OCCCCOS(=O)(=O)C,Active,,,,MOUSE,,INTRAVENOUS,,OVARIES; THYMUS GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 247 Y74]"
2449,363898369,44437,CCCCCCCCCCCCCC(=O)ON(C1=CC2=C(C=C1)C3=CC=CC=C3C2)C(=O)C,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,10.6 UMOL IN 0.2 ML DMSO-TRIOCTANOIN 1/WK FOR 6 WK,INJECTION SITE: FIBROSARCOMA OR FIBROMYOSARCOMA OR FIBROLIPOSARCOMA,POSITIVE,"[FUCHS,RPP, LANG,MCE, MILLER,EC AND MILLER,JA; COMPARATIVE CARCINOGENICITIES AND REACTIVITIES OF N-MYRISTOYLOXY-N-ACETYL-2-AMINOFLUORENE AND ITS 7-IODO DERIVATIVE; CARCINOGENESIS 2:655-659, 1981]"
2450,363898370,54345,CCCCCCCCCCCCCC(=O)ON(C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)I)C(=O)C,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,10.6 UMOL IN 0.2 ML DMSO-TRIOCTANOIN 1/WK FOR 6 WK,INJECTION SITE: FIBROSARCOMA OR FIBROMYOSARCOMA OR FIBROLIPOSARCOMA,POSITIVE,"[FUCHS,RPP, LANG,MCE, MILLER,EC AND MILLER,JA; COMPARATIVE CARCINOGENICITIES AND REACTIVITIES OF N-MYRISTOYLOXY-N-ACETYL-2-AMINOFLUORENE AND ITS 7-IODO DERIVATIVE; CARCINOGENESIS 2:655-659, 1981]"
2451,363898371,19592,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,Active,,,,MOUSE,"STRAIN-CS/MALE,FEMALE",ORAL,0.1% IN DIET FOR 1 YR THEN 0.05% FOR 8 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 125 Y80]"
2452,363898371,19592,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,Active,,,,RAT,F344/MALE,ORAL,0.1% IN DIET FOR UP TO 25 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 125 Y80]"
2453,363898371,19592,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,Active,,,,RAT,WISTAR/MALE,ORAL,0; 100 MG/KG/BW/D IN DIET ADMINISTERED TO YOUNG RATS (13 WK OLD AT BEGINNING OF STUDY) FOR 13 MO (STUDY DURATION: 59 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[KRAUPP-GRASL,B, HUBER,W, TAPER,H AND SCHULTE-HERMANN,R; INCREASED SUSCEPTIBILITY OF AGED RATS TO HEPATOCARCINOGENESIS BY THE PEROXISOME PROLIFERATOR NAFENOPIN AND THE POSSIBLE INVOLVEMENT OF ALTERED LIVER FOCI OCCURRING SPONTANEOUSLY; CANCER RES. 51(2):666-671, 1991]"
2454,363898371,19592,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,Active,,,,RAT,WISTAR/MALE,ORAL,0; 100 MG/KG/BW/D IN DIET ADMINISTERED TO OLD RATS (57 WK AT BEGINNING OF STUDY) FOR 13 MO (STUDY DURATION: 59 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[KRAUPP-GRASL,B, HUBER,W, TAPER,H AND SCHULTE-HERMANN,R; INCREASED SUSCEPTIBILITY OF AGED RATS TO HEPATOCARCINOGENESIS BY THE PEROXISOME PROLIFERATOR NAFENOPIN AND THE POSSIBLE INVOLVEMENT OF ALTERED LIVER FOCI OCCURRING SPONTANEOUSLY; CANCER RES. 51(2):666-671, 1991]"
2455,363898372,16720,C1=CC2=C(C=CC=C2N)C(=C1)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.1; 0.2% IN DIET FOR 103 WK (STUDY DURATION: 105-109 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; THYROID GLAND: C CELL CARCINOMA, C CELL ADENOMA OR CARCINOMA, PAPILLARY ADENOMA OR FOLLICULAR CELL ADENOMA OR PAPILLARY CYSTADENOMA (NOS)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-143 Y78]"
2456,363898372,16720,C1=CC2=C(C=CC=C2N)C(=C1)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.1; 0.2% IN DIET FOR 103 WK (STUDY DURATION: 105-109 WK),THYROID GLAND: PAPILLARY ADENOMA OR FOLLICULAR CELL ADENOMA OR PAPILLARY CYSTADENOMA (NOS),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-143 Y78]"
2457,363898372,16720,C1=CC2=C(C=CC=C2N)C(=C1)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.05; 0.1% IN DIET FOR 103 WK (STUDY DURATION: 106-110 WK),CLITORAL GLAND: ADENOMA (NOS) OR CARCINOMA (NOS); UTERUS: ENDOMETRIAL STROMAL POLYP,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-143 Y78]"
2458,363898372,16720,C1=CC2=C(C=CC=C2N)C(=C1)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.05; 0.1% IN DIET FOR 103 WK (STUDY DURATION: 106-109 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-143 Y78]"
2459,363898373,8640,C1=CC=C2C(=C1)C=CC=C2N,Inactive,,,,DOG,BEAGLE/FEMALE,ORAL,22.0 MG/KG 5/WK,,NEGATIVE,"[PURCHASE,IFH, KALINOWSKI,AE, ISHMAEL,J, WILSON,J, GORE,CW AND CHART,IS; LIFETIME CARCINOGENICITY STUDY OF 1- AND 2-NAPHTHYLAMINE IN DOGS; BR. J. CANCER 44:892-901, 1981]"
2460,363898373,8640,C1=CC=C2C(=C1)C=CC=C2N,Inactive,,,,DOG,BEAGLE/MALE,ORAL,18.4 MG/KG 5/WK,,NEGATIVE,"[PURCHASE,IFH, KALINOWSKI,AE, ISHMAEL,J, WILSON,J, GORE,CW AND CHART,IS; LIFETIME CARCINOGENICITY STUDY OF 1- AND 2-NAPHTHYLAMINE IN DOGS; BR. J. CANCER 44:892-901, 1981]"
2461,363898374,7057,C1=CC=C2C=C(C=CC2=C1)N,Active,,,,DOG,BEAGLE/FEMALE,ORAL,21.3 MG/KG 5/WK,URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[PURCHASE,IFH, KALINOWSKI,AE, ISHMAEL,J, WILSON,J, GORE,CW AND CHART,IS; LIFETIME CARCINOGENICITY STUDY OF 1- AND 2-NAPHTHYLAMINE IN DOGS; BR. J. CANCER 44:892-901, 1981]"
2462,363898374,7057,C1=CC=C2C=C(C=CC2=C1)N,Active,,,,DOG,BEAGLE/MALE,ORAL,18.4 MG/KG 5/WK,URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[PURCHASE,IFH, KALINOWSKI,AE, ISHMAEL,J, WILSON,J, GORE,CW AND CHART,IS; LIFETIME CARCINOGENICITY STUDY OF 1- AND 2-NAPHTHYLAMINE IN DOGS; BR. J. CANCER 44:892-901, 1981]"
2463,363898374,7057,C1=CC=C2C=C(C=CC2=C1)N,Active,,,,DOG,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 97 Y74]"
2464,363898374,7057,C1=CC=C2C=C(C=CC2=C1)N,Active,,,,HAMSTER,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 97 Y74]"
2465,363898374,7057,C1=CC=C2C=C(C=CC2=C1)N,Active,,,,HUMAN,,"ORAL, INHALATION, DERMAL",,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 97 Y74]"
2466,363898374,7057,C1=CC=C2C=C(C=CC2=C1)N,Active,,,,MONKEY,,ORAL,,URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 97 Y74]"
2467,363898374,7057,C1=CC=C2C=C(C=CC2=C1)N,Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 97 Y74]"
2468,363898375,15106,C1=CC=C2C(=C1)C=CC=C2NCCN.Cl.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.2; 0.3% OF DIET, TWA FOR HIGH DOSE",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-168 Y79]"
2469,363898375,15106,C1=CC=C2C(=C1)C=CC=C2NCCN.Cl.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.05; 0.1% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-168 Y79]"
2470,363898375,15106,C1=CC=C2C(=C1)C=CC=C2NCCN.Cl.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.05; 0.1% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-168 Y79]"
2471,363898375,15106,C1=CC=C2C(=C1)C=CC=C2NCCN.Cl.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.05; 0.1% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-168 Y79]"
2472,363898376,69176,C1=CC=C2C=C(C=CC2=C1)NO,Active,,,,DOG,BEAGLE,INTRAVESICULAR,5 MG IN DMSO EVERY TWO WK FOR 30 MO,URINARY BLADDER: PAPILLARY TRANSITIONAL CELL CARCINOMA (INVASIVE),POSITIVE,"[RADOMSKI,JL, BRILL,E, DEICHMANN,WB AND GLASS,EM; CARCINOGENICITY TESTING OF N-HYDROXY AND OTHER OXIDATION AND DECOMPOSITION PRODUCTS OF 1- AND 2-NAPHTHYLAMINE; CANCER RES. 31:1461-1467, 1971]"
2473,363898376,69176,C1=CC=C2C=C(C=CC2=C1)NO,Active,,,,MOUSE,BALB,SUBCUTANEOUS,100 UG IN AQUEOUS GELATIN 1/D FOR 5 D,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 97 Y74]"
2474,363898376,69176,C1=CC=C2C=C(C=CC2=C1)NO,Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,"100 UG IN GELATIN ON D 1, 3 AND 5 OF LIFE","LUNG: ADENOMA, CARCINOMA",POSITIVE,"[RADOMSKI,JL, BRILL,E, DEICHMANN,WB AND GLASS,EM; CARCINOGENICITY TESTING OF N-HYDROXY AND OTHER OXIDATION AND DECOMPOSITION PRODUCTS OF 1- AND 2-NAPHTHYLAMINE; CANCER RES. 31:1461-1467, 1971]"
2475,363898376,69176,C1=CC=C2C=C(C=CC2=C1)NO,Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,"100 UG IN GELATIN ON D 1, 3 AND 5 OF LIFE",LIVER: HEPATOMA,POSITIVE,"[RADOMSKI,JL, BRILL,E, DEICHMANN,WB AND GLASS,EM; CARCINOGENICITY TESTING OF N-HYDROXY AND OTHER OXIDATION AND DECOMPOSITION PRODUCTS OF 1- AND 2-NAPHTHYLAMINE; CANCER RES. 31:1461-1467, 1971]"
2476,363898376,69176,C1=CC=C2C=C(C=CC2=C1)NO,Active,,,,RAT,STRAIN-CB/MALE,INTRAPERITONEAL,50 MG/KG IN ARACHIS OIL 2/WK FOR 3 MO,"PERITONEAL CAVITY: SARCOMA, CARCINOMA",POSITIVE,"[BOYLAND,E, DUKES,CE AND GROVER,PL; CARCINOGENICITY OF 2-NAPHTHYLHYDROXYLAMINE AND 2-NAPHTHYLAMINE; BR. J. CANCER 17:79-84, 1963]"
2477,363898377,935,[Ni],Active,,,,HUMAN,,INHALATION,,NASAL CAVITY; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 126 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2478,363898377,935,[Ni],Active,,,,RAT,"F344/MALE,FEMALE",INTRAPLEURAL,5 MG IN 0.2 ML SALINE 1/MO FOR 5 MO,PLEURAL CAVITY: MESOTHELIOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2479,363898377,935,[Ni],Active,,,,RAT,"F344/MALE,FEMALE",INTRAMUSCULAR,5 MG IN 0.2 ML TRIOCTANOIN 1/MO FOR 5 MO,INJECTION SITE: FIBROSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 126 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2480,363898377,935,[Ni],Active,,,,RAT,LONG-EVANS/FEMALE,INTRAMUSCULAR,28.3 MG IN 0.4 ML FOWL SERUM,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2481,363898377,935,[Ni],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL POWDER/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
2482,363898377,935,[Ni],Inactive,,,,Rat,Wistar Crl:WI(G1x/BRL/Han) IGS RR VAF/Plus / Male (50/group),Inhalation,"0; 0.1; 0.4, 1.0 mg Ni/cu m (MMAD=1.8 um); 6 hr/day, 5 d/wk for 104 wk, study duration 104 and 130 wk",Adrenal Gland: Pheochromocytomas (Benign and malignant),Positive at 0.4 mg/cu m only; Negative for lung tumors. Increase in pheochromocytomas was within the range for historical controls,"[OLLER,A KIRKPATRICK,DT RADOVSKY,A AND BATES,HK; INHALATION CARCINOGENICITY STUDY WITH NICKEL METAL POWDER IN WISTAR RATS; TOXICOLOGY AND APPLIED PHARMACOLOGY 233(2):262-275, 2008]"
2483,363898377,935,[Ni],Inactive,,,,Rat,Wistar Crl:WI(G1x/BRL/Han) IGS RR VAF/Plus / Female (50/group),Inhalation,"0; 0.1; 0.4, 1.0 mg Ni/cu m (MMAD=1.8 um); 6 hr/day, 5 d/wk for 104 wk, study duration 104 and 130 wk",Adrenal Cortex: Benign and malignant tumors combined,Positive at 0.4 mg/cu m only; Negative for lung tumors. Authors noted that these results were replicated in studies of nickel sulfate,"[OLLER,A KIRKPATRICK,DT RADOVSKY,A AND BATES,HK; INHALATION CARCINOGENICITY STUDY WITH NICKEL METAL POWDER IN WISTAR RATS; TOXICOLOGY AND APPLIED PHARMACOLOGY 233(2):262-275, 2008]"
2484,363898377,935,[Ni],Active,,,,Rat,F344/Male (36/Group),Intramuscular,10 pellets per hind leg; each pellet 1x2 mm (wt 14 mg); study duration 30 wk,Muscle: rhabdomyosarcoma,Positive,"[KALINICH,JF, EMOND,CA, DALTON,TK, MOG,SR, COLEMAN,GD, KORDELL,JE, MILLER,AC, AND MCCLAIN,DE; EMBEDDED WEAPONS-GRADE TUNGSTEN ALLOY SHARPNEL RAPIDLY INDUCES METASTATIC HIGH-GRADE RHABDOMYOSARCOMAS IN F344 RATS; ENVIRONMENTAL HEALTH PRESPECTIVES 113(6):729-734, 2005]"
2485,363898379,61534,[OH-].[OH-].[Ni+2],Active,,,,RAT,WISTAR,INTRAMUSCULAR IMPLANT,,IMPLANT SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2486,363898380,62390,[CH-]1C=CC=C1.[CH-]1C=CC=C1.[Ni+2],Active,,,,RAT,"F344/MALE,FEMALE",INTRAMUSCULAR,12; 25 MG IN 0.2 ML TRIOCTANOIN 1/MO FOR 12 MO,INJECTION SITE: FIBROSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 126 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2487,363898381,14805,O=[Ni],Active,,,,MOUSE,"SWISS, C3H",INTRAMUSCULAR,5 MG ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 126 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2488,363898381,14805,O=[Ni],Active,,,,RAT,,INTRAMUSCULAR,20 MG,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 126 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2489,363898381,14805,O=[Ni],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 1.1 MG/M3 DUST 6 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 12 MO),,NEGATIVE,"[HARATAKE,J, HORIE,A, KODAMA,Y AND TANAKA,I;HISTOPATHOLOGIC EXAMINATIONS OF RATS TREATED BY INHALATIONS OF VARIOUS TYPES OF NICKEL COMPOUNDS; INHALATION TOXICOL. 4(1):67-79, 1992]"
2490,363898381,14805,O=[Ni],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 1.3 MG/M3 DUST 6 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 12 MO),,NEGATIVE,"[HARATAKE,J, HORIE,A, KODAMA,Y AND TANAKA,I;HISTOPATHOLOGIC EXAMINATIONS OF RATS TREATED BY INHALATIONS OF VARIOUS TYPES OF NICKEL COMPOUNDS; INHALATION TOXICOL. 4(1):67-79, 1992]"
2491,363898381,14805,O=[Ni],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 0.96 MG/M3 6 HR/D 5 D/WK FOR 1 MO FOLLOWED BY INHALATION OF TOBACCO SMOKE FOR 1 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[HORIE,A, HARATAKE,J, TANAKA,I, KODAMA,Y, TSUCHIYA,K AND CHO,S; HISTOPATHOLOGICAL ASPECTS OF INHALATION EXPERIMENTS WITH NICKEL OXIDE (NIO) AEROSOLS AND CIGARET SMOKE; ADV. ENVIRON. SCI. TECHNOL. 25(NICKEL AND HUMAN HEALTH):517-525, 1992]"
2492,363898381,14805,O=[Ni],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 0.96 MG/M3 6 HR/D 5 D/WK FOR 6 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[HORIE,A, HARATAKE,J, TANAKA,I, KODAMA,Y, TSUCHIYA,K AND CHO,S; HISTOPATHOLOGICAL ASPECTS OF INHALATION EXPERIMENTS WITH NICKEL OXIDE (NIO) AEROSOLS AND CIGARET SMOKE; ADV. ENVIRON. SCI. TECHNOL. 25(NICKEL AND HUMAN HEALTH):517-525, 1992]"
2493,363898381,14805,O=[Ni],Active,,,,RAT,F344/MALE,INHALATION,0; 0.62; 1.25; 2.5 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),ADRENAL MEDULLA: MALIGNANT PHEOCHROMOCYTOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-451 Y96]"
2494,363898381,14805,O=[Ni],Active,,,,RAT,F344/FEMALE,INHALATION,0; 0.62; 1.25; 2.5 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-451 Y96]"
2495,363898381,14805,O=[Ni],Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 1.25; 2.5; 5 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-451 Y96]"
2496,363898381,14805,O=[Ni],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
2497,363898381,14805,O=[Ni],Unspecified,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 1.25; 2.5; 5 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-451 Y96]"
2498,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,MOUSE,"SWISS, C3H",INTRAMUSCULAR,5 MG ONCE,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 126 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2499,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,F344,INTRAMUSCULAR IMPLANT,10; 250; 500 MG,"IMPLANT SITE: SARCOMA, RHABDOMYOSARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 126 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2500,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,"F344/MALE,FEMALE",INHALATION,1 MG/M3 6 HR/DAY 5 DAY/WK FOR 78 WK,"LUNG: ADENOCARCINOMA, FIBROSARCOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2501,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,"F344/MALE,FEMALE","SUBCUTANEOUS, INTRAMUSCULAR",3.3; 10 MG IN 0.1 ML AQ PENICILLIN G PROCAINE ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2502,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0.63-20 MG IN AQ PENICILLIN G PROCAINE ONCE,INJECTION SITE: RHABDOMYOSARCOMA OR SARCOMA (UNDIFFERENTIATED) OR FIBROSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 126 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2503,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,NIHBL,INTRAMUSCULAR IMPLANT,,IMPLANT SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2504,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,WISTAR,INTRAMUSCULAR IMPLANT,,IMPLANT SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2505,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,,INTRAMUSCULAR,20 MG,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 126 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 75 Y76]"
2506,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 5 MG POWDER SUSPENDED IN 0.25 ML OF AQUEOUS PROCAIN G PENICILLIN (STUDY DURATION: 48 WK),INJECTION SITE: TUMOR,POSITIVE,"[SHIBATA,M, IZUMI,K, SANO,N, AKAGI,A AND OTSUKA,H; INDUCTION OF SOFT TISSUE TUMORS IN F344 RATS BY SUBCUTANEOUS, INTRAMUSCULAR, INTRA-ARTICULAR, AND RETROPERITONEAL INJECTION OF NICKEL SULPHIDE(NI3S2); J. PATHOL. 157(3):263-274, 1989]"
2507,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 5 MG POWDER SUSPENDED IN 0.25 ML OF AQUEOUS PROCAIN G PENICILLIN (STUDY DURATION: 48 WK),INJECTION SITE: TUMOR,POSITIVE,"[SHIBATA,M, IZUMI,K, SANO,N, AKAGI,A AND OTSUKA,H; INDUCTION OF SOFT TISSUE TUMORS IN F344 RATS BY SUBCUTANEOUS, INTRAMUSCULAR, INTRA-ARTICULAR, AND RETROPERITONEAL INJECTION OF NICKEL SULPHIDE(NI3S2); J. PATHOL. 157(3):263-274, 1989]"
2508,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,F344/MALE,INTRA-ARTICULAR,0; 5 MG POWDER SUSPENDED IN 0.25 ML OF AQUEOUS PROCAIN G PENICILLIN INJECTED INTO THE INTRA-ARTICULAR SPACE OF KNEE JOINT (STUDY DURATION: 48 WK),INJECTION SITE: TUMOR,POSITIVE,"[SHIBATA,M, IZUMI,K, SANO,N, AKAGI,A AND OTSUKA,H; INDUCTION OF SOFT TISSUE TUMORS IN F344 RATS BY SUBCUTANEOUS, INTRAMUSCULAR, INTRA-ARTICULAR, AND RETROPERITONEAL INJECTION OF NICKEL SULPHIDE(NI3S2); J. PATHOL. 157(3):263-274, 1989]"
2509,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,F344/MALE,INTRAFAT,0; 5 MG POWDER SUSPENDED IN 0.25 ML OF PROCAIN G PENICILLIN INJECTED INTO THE RETROPERITONEAL FATTY TISSUE (STUDY DURATION: 48 WK),INJECTION SITE: TUMOR,POSITIVE,"[SHIBATA,M, IZUMI,K, SANO,N, AKAGI,A AND OTSUKA,H; INDUCTION OF SOFT TISSUE TUMORS IN F344 RATS BY SUBCUTANEOUS, INTRAMUSCULAR, INTRA-ARTICULAR, AND RETROPERITONEAL INJECTION OF NICKEL SULPHIDE(NI3S2); J. PATHOL. 157(3):263-274, 1989]"
2510,363898382,22833473,S=S=[Ni].[Ni].[Ni],Inactive,,,,MOUSE,STRAIN-A,INTRAPERITONEAL,0; 0.053; 0.160 MG/KG 1/3 WK FOR 15 WK (STUDY DURATION: 45 WK),,NEGATIVE,"[MCNEILL,DA, CHRISP,CE AND FISHER,GL; TUMORIGENICITY OF NICKEL SUBSULFIDE IN STRAIN A/J MICE; DRUG CHEM. TOXICOL. 13(1):71-86, 1990]"
2511,363898382,22833473,S=S=[Ni].[Ni].[Ni],Inactive,,,,MOUSE,STRAIN-A,INTRAPERITONEAL,0; 0.053; 0.160 MG/KG 1/2 WK FOR 15 WK (STUDY DURATION: 45 WK),,NEGATIVE,"[MCNEILL,DA, CHRISP,CE AND FISHER,GL; TUMORIGENICITY OF NICKEL SUBSULFIDE IN STRAIN A/J MICE; DRUG CHEM. TOXICOL. 13(1):71-86, 1990]"
2512,363898382,22833473,S=S=[Ni].[Ni].[Ni],Inactive,,,,MOUSE,STRAIN-A,INTRAPERITONEAL,0; 0.053; 0.160 MG/KG 1 WK FOR 15 WK (STUDY DURATION: 45 WK),,NEGATIVE,"[MCNEILL,DA, CHRISP,CE AND FISHER,GL; TUMORIGENICITY OF NICKEL SUBSULFIDE IN STRAIN A/J MICE; DRUG CHEM. TOXICOL. 13(1):71-86, 1990]"
2513,363898382,22833473,S=S=[Ni].[Ni].[Ni],Inactive,,,,MOUSE,STRAIN-A,INTRATRACHEAL,0; 0.053; 0.160 MG/KG 1/3 WK FOR 15 WK (STUDY DURATION: 45 WK),,NEGATIVE,"[MCNEILL,DA, CHRISP,CE AND FISHER,GL; TUMORIGENICITY OF NICKEL SUBSULFIDE IN STRAIN A/J MICE; DRUG CHEM. TOXICOL. 13(1):71-86, 1990]"
2514,363898382,22833473,S=S=[Ni].[Ni].[Ni],Inactive,,,,MOUSE,STRAIN-A,INTRATRACHEAL,0; 0.053; 0.160 MG/KG 1/2 WK FOR 15 WK (STUDY DURATION: 45 WK),,NEGATIVE,"[MCNEILL,DA, CHRISP,CE AND FISHER,GL; TUMORIGENICITY OF NICKEL SUBSULFIDE IN STRAIN A/J MICE; DRUG CHEM. TOXICOL. 13(1):71-86, 1990]"
2515,363898382,22833473,S=S=[Ni].[Ni].[Ni],Inactive,,,,MOUSE,STRAIN-A,INTRATRACHEAL,0; 0.053; 0.160 MG/KG 1 WK FOR 15 WK (STUDY DURATION: 45 WK),,NEGATIVE,"[MCNEILL,DA, CHRISP,CE AND FISHER,GL; TUMORIGENICITY OF NICKEL SUBSULFIDE IN STRAIN A/J MICE; DRUG CHEM. TOXICOL. 13(1):71-86, 1990]"
2516,363898382,22833473,S=S=[Ni].[Ni].[Ni],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 0.5 MG/M3 DUST 6 H/D 5 D/WK FOR 6 MO (STUDY DURATION: 12 MO),,NEGATIVE,"[HARATAKE,J, HORIE,A, KODAMA,Y AND TANAKA,I;HISTOPATHOLOGIC EXAMINATIONS OF RATS TREATED BY INHALATIONS OF VARIOUS TYPES OF NICKEL COMPOUNDS; INHALATION TOXICOL. 4(1):67-79, 1992]"
2517,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,F344/MALE,INHALATION,0; 0.15; 1 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),"ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA, MALIGNANT PHEOCHROMOCYTOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-453 Y96]"
2518,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,RAT,F344/FEMALE,INHALATION,0; 0.15; 1 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),"ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA; LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-453 Y96]"
2519,363898382,22833473,S=S=[Ni].[Ni].[Ni],Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.6; 1.2 MG/M3 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-453 Y96]"
2520,363898382,22833473,S=S=[Ni].[Ni].[Ni],Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.6; 1.2 MG/M3 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-453 Y96]"
2521,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,MOUSE,C3H/MALE,INTRAMUSCULAR,0; 0.5; 1; 2.5; 5; 10 MG IN 0.05 ML OF GLYCEROL/WATER SUSPENSION ONCE INTO THIGH MUSCLES OF BOTH HIND LIMBS (STUDY DURATION: 78 WK),INJECTION SITE: SARCOMA,POSITIVE,"[RODRIGUEZ,RE, MISRA,M, DIWAN,BA, RIGGS,CW AND KASPRZAK,KS; RELATIVE SUSCEPTIBILITIES OF C57BL/6, (C57BL/6 X CH3/HE)F1, AND C3H/HE MICE TO ACUTE TOXICITY AND CARCINOGENICITY OF NICKEL SUBSULFIDE; TOXICOLOGY 107(2):131-140, 1996]"
2522,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,MOUSE,B6C3F1/MALE,INTRAMUSCULAR,0; 0.5; 1; 2.5; 5; 10 MG IN 0.05 ML OF GLYCEROL/WATER SUSPENSION ONCE INTO THIGH MUSCLES OF BOTH HIND LIMBS (STUDY DURATION: 78 WK),INJECTION SITE: SARCOMA,POSITIVE,"[RODRIGUEZ,RE, MISRA,M, DIWAN,BA, RIGGS,CW AND KASPRZAK,KS; RELATIVE SUSCEPTIBILITIES OF C57BL/6, (C57BL/6 X CH3/HE)F1, AND C3H/HE MICE TO ACUTE TOXICITY AND CARCINOGENICITY OF NICKEL SUBSULFIDE; TOXICOLOGY 107(2):131-140, 1996]"
2523,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,MOUSE,C57BL/MALE,INTRAMUSCULAR,0; 0.5; 1; 2.5; 5; 10 MG IN 0.05 ML OF GLYCEROL/WATER SUSPENSION ONCE INTO THIGH MUSCLES OF BOTH HIND LIMBS (STUDY DURATION: 78 WK),INJECTION SITE: SARCOMA,POSITIVE,"[RODRIGUEZ,RE, MISRA,M, DIWAN,BA, RIGGS,CW AND KASPRZAK,KS; RELATIVE SUSCEPTIBILITIES OF C57BL/6, (C57BL/6 X CH3/HE)F1, AND C3H/HE MICE TO ACUTE TOXICITY AND CARCINOGENICITY OF NICKEL SUBSULFIDE; TOXICOLOGY 107(2):131-140, 1996]"
2524,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,MOUSE,MT-NULL/MALE (METALLOTHIONEIN-I/II DOUBLE KNOCKOUT),INTRAMUSCULAR,0.5; 1.0 MG IN BOTH THIGHS ONCE (STUDY DURATION: 104 WKS),FIBROSARCOMA AT INJECTION SITE,POSITIVE,"[WAALKES,MP, LIU,J, KASPRZAK,KS AND DIWAN,BA; METALLOTHIONEIN-I/II DOUBLE KNOCKOUT MICE ARE NO MORE SENSITIVE TO THE CARCINOGENIC EFFECTS OF NICKEL SUBSULFIDE THAN WILD-TYPE MICE; INT. J. TOXICOL. 24(4):215-220, 2005]"
2525,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,MOUSE,MT-NULL/MALE,INTRAMUSCULAR INJECTION,0.5; 1.0 MG IN BOTH THIGHS ONCE (STUDY DURATION: 104 WKS),LUNG: PULMONARY ADENOMA,POSITIVE,"[WAALKES,MP, LIU,J, KASPRZAK,KS AND DIWAN,BA; METALLOTHIONEIN-I/II DOUBLE KNOCKOUT MICE ARE NO MORE SENSITIVE TO THE CARCINOGENIC EFFECTS OF NICKEL SUBSULFIDE THAN WILD-TYPE MICE; INT. J. TOXICOL. 24(4):215-220, 2005]"
2526,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,MOUSE,WILD-TYPE/MALE,INTRAMUSCULAR,0.5; 1.0 MG IN BOTH THIGHS ONCE (STUDY DURATION: 104 WKS),FIBROSARCOMA AT INJECTION SITE,POSITIVE,"[WAALKES,MP, LIU,J, KASPRZAK,KS AND DIWAN,BA; METALLOTHIONEIN-I/II DOUBLE KNOCKOUT MICE ARE NO MORE SENSITIVE TO THE CARCINOGENIC EFFECTS OF NICKEL SUBSULFIDE THAN WILD-TYPE MICE; INT. J. TOXICOL. 24(4):215-220, 2005]"
2527,363898382,22833473,S=S=[Ni].[Ni].[Ni],Active,,,,MOUSE,WILD-TYPE/MALE,INTRAMUSCULAR,0.5; 1.0 MG IN BOTH THIGHS ONCE,LUNG: PULMONARY ADENOCARCINOMA,POSITIVE,"[WAALKES,MP, LIU,J, KASPRZAK,KS AND DIWAN,BA; METALLOTHIONEIN-I/II DOUBLE KNOCKOUT MICE ARE NO MORE SENSITIVE TO THE CARCINOGENIC EFFECTS OF NICKEL SUBSULFIDE THAN WILD-TYPE MICE; INT. J. TOXICOL. 24(4):215-220, 2005]"
2528,363898383,3607071,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NNC=O,Active,,,,HAMSTER,,ORAL,,FORESTOMACH; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 151 Y74]"
2529,363898383,3607071,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NNC=O,Active,,,,MOUSE,,ORAL,,FORESTOMACH; HEMATOPOIETIC SYSTEM (LEUKEMIA); LUNG; STOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 151 Y74]"
2530,363898383,3607071,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NNC=O,Active,,,,RAT,,ORAL,,HEMATOPOIETIC SYSTEM (LEUKEMIA); KIDNEY; LIVER; MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 151 Y74]"
2531,363898384,6093,C1CN(C(=O)N1)C2=NC=C(S2)[N+](=O)[O-],Active,,,,HAMSTER,,ORAL,,FORESTOMACH; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 123 Y77]"
2532,363898384,6093,C1CN(C(=O)N1)C2=NC=C(S2)[N+](=O)[O-],Active,,,,MOUSE,,ORAL,,FORESTOMACH; MAMMARY GLAND; OVARIES; LUNG; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 123 Y77]"
2533,363898385,8776,CCNC(=O)NC1=NC=C(S1)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 94 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-146 Y79][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V31 179 Y83]"
2534,363898385,8776,CCNC(=O)NC1=NC=C(S1)[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,ORAL,0; 625; 1250 PPM IN DIET FOR 94 WK (STUDY DURATION: 104 WK),INTEGUMENTARY SYSTEM (SKIN AND SUBCUTANEOUS TISSUE) AND MAMMARY GLAND: FIBROADENOMA OR CYSTADENOMA (NOS),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-146 Y79][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V31 179 Y83]"
2535,363898385,8776,CCNC(=O)NC1=NC=C(S1)[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,ORAL,0; 625; 1250 PPM IN DIET FOR 94 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-146 Y79]"
2536,363898385,8776,CCNC(=O)NC1=NC=C(S1)[N+](=O)[O-],Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 94 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-146 Y79]"
2537,363898386,8758,C(C(=O)O)N(CC(=O)O)CC(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 7500; 15000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2538,363898386,8758,C(C(=O)O)N(CC(=O)O)CC(=O)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 7500; 15000 PPM IN DIET,KIDNEY: MALIGNANT TUMOR,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2539,363898386,8758,C(C(=O)O)N(CC(=O)O)CC(=O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 7500; 15000 PPM IN DIET,URINARY BLADDER: MALIGNANT TUMOR,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2540,363898386,8758,C(C(=O)O)N(CC(=O)O)CC(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 7500; 15000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2541,363898387,29194,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].O.[Na+].[Na+].[Na+],Active,,,,RAT,F344/FEMALE,ORAL,0; 200; 2000; 20000 PPM IN DIET (STUDY DURATION: 24 MO),URINARY BLADDER: TUMOR; URETER: TUMOR; KIDNEY: TUMOR,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2542,363898387,29194,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].O.[Na+].[Na+].[Na+],Active,,,,RAT,F344/MALE,ORAL,0; 200; 2000; 20000 PPM IN DIET (STUDY DURATION: 24 MO),KIDNEY: TUMOR; URETER: TUMOR,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2543,363898387,29194,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].O.[Na+].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET (STUDY DURATION: 18 MO),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2544,363898387,29194,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].O.[Na+].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET (STUDY DURATION: 18 MO),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2545,363898387,29194,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].O.[Na+].[Na+].[Na+],Unspecified,,,,RAT,F344/MALE,ORAL,0; 7500; 15000 PPM IN DIET (STUDY DURATION: 18 MO),KIDNEY: TUBULAR CELL ADENOCARCINOMA OR SARCOMA METASTATIC OR HAMARTOMA; RENAL PELVIS: TRANSIT CELL PAPILLOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2546,363898387,29194,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].O.[Na+].[Na+].[Na+],Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 7500; 1500 PPM IN DIET (STUDY DURATION: 18 MO),URINARY BLADDER: PAPILLOMA OR SQUAMOUS CELL CARCINOMA OR TRANSITIONAL CELL CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-6 Y77]"
2547,363898388,11769,C1CC2=CC=C(C3=CC=CC1=C23)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.05; 0.12% TWA, IN DIET FOR 78 WK (STUDY DURATION: 96 WK)","LIVER: HEPATOCELLULAR CARCINOMA; OVARIES: GRANULOSA CELL TUMOR, LUTEOMA OR TUBULAR CELL ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-118 Y78]"
2548,363898388,11769,C1CC2=CC=C(C3=CC=CC1=C23)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.06; 0.12% TWA, IN DIET FOR 78 WK (STUDY DURATION: 96 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-118 Y78]"
2549,363898388,11769,C1CC2=CC=C(C3=CC=CC1=C23)[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,ORAL,0; 0.12; 0.24% IN DIET FOR 78 WK (STUDY DURATION: 87-100 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR ALVEOLAR/BRONCHIOLAR CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA OR PAPILLARY CYSTADENOCARCINOMA, FIBROADENOMA; CLITORAL GLAND: CARCINOMA (NOS); EAR (CANAL): SQUAMOUS CELL CARCINOMA, CERUMINOUS CARCINOMA OR CARCINOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-118 Y78]"
2550,363898388,11769,C1CC2=CC=C(C3=CC=CC1=C23)[N+](=O)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 0.12; 0.24% IN DIET FOR 70-78 WK (STUDY DURATION: 70-100 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR ALVEOLAR/BRONCHIOLAR CARCINOMA; EAR (EAR CANAL OR SKIN OF EAR): SQUAMOUS CELL CARCINOMA, CERUMINOUS CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-118 Y78]"
2551,363898389,15685,CCOC1=C(C=C(C=C1)NC(=O)C)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.73; 1.46% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-133 Y79]"
2552,363898389,15685,CCOC1=C(C=C(C=C1)NC(=O)C)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.73; 1.46% OF DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-133 Y79]"
2553,363898389,15685,CCOC1=C(C=C(C=C1)NC(=O)C)[N+](=O)[O-],Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 0.18; 0.36% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-133 Y79]"
2554,363898389,15685,CCOC1=C(C=C(C=C1)NC(=O)C)[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,ORAL,"0; 0.18; 0.36% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-133 Y79]"
2555,363898390,7447,COC1=C(C=C(C=C1)[N+](=O)[O-])N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.8% IN DIET FOR 78 WK (STUDY DURATION: 97 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-127 Y78]"
2556,363898390,7447,COC1=C(C=C(C=C1)[N+](=O)[O-])N,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.4; 0.8% IN DIET FOR 78 WK (STUDY DURATION: 106-108 WK),"CLITORAL GLAND: CARCINOMA (NOS), CARCINOMA (NOS) OR SQUAMOUS CELL CARCINOMA, ADENOMA (NOS) OR PAPILLARY ADENOMA OR CARCINOMA (NOS) OR SQUAMOUS CELL CARCINOMA; EAR (ZYMBAL GLAND OR SKIN OF EAR): SEBACEOUS ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-127 Y78]"
2557,363898390,7447,COC1=C(C=C(C=C1)[N+](=O)[O-])N,Active,,,,RAT,F344/MALE,ORAL,0; 0.4; 0.8% IN DIET FOR 78 WK (STUDY DURATION: 102-109 WK),"INTEGUMENTARY SYSTEM (SKIN): BASAL CELL CARCINOMA, TRICHOEPITHELIOMA;INTEGUMENTARY SYSTEM (EXCLUDING SKIN OF EAR): SQUAMOUS CELL CARCINOMA, SEBACEOUS ADENOCARCINOMA, SEBACEOUS ADENOMA OR SEBACEOUS ADENOCARCINOMA; INTEGUMENTARY SYSTEM (SKIN OR ADNEXA (EXCLUDING SKIN OF EAR)): SQUAMOUS CELL CARCINOMA OR BASAL CELL CARCINOMA OR TRICHOEPITHELIOMA OR SEBACEOUS ADENOCARCINOMA OR SWEAT GLAND CARCINOMA; EAR (ZYMBAL GLAND OR SKIN OF EAR): SEBACEOUS ADENOCARCINOMA OR CERUMINOUS CARCINOMA OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-127 Y78]"
2558,363898390,7447,COC1=C(C=C(C=C1)[N+](=O)[O-])N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1.6% IN DIET FOR FIRST 15 WK FOLLOWING BY 0.4% FOR 63 WK (STUDY DURATION: 97 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-127 Y78]"
2559,363898390,7447,COC1=C(C=C(C=C1)[N+](=O)[O-])N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1.6% IN DIET FOR 15 WK FOLLOWING BY 0.4% FOR LAST 63 WK (STUDY DURATION: 97 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-127 Y78]"
2560,363898390,7447,COC1=C(C=C(C=C1)[N+](=O)[O-])N,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.8% IN DIET FOR 78 WK (STUDY DURATION: 97 WK),LIVER: HEPATOCELLULAR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-127 Y78]"
2561,363898391,12076,C1=CC(=C(C=C1[N+](=O)[O-])N)C(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.46; 1.0% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-109 Y78]"
2562,363898391,12076,C1=CC(=C(C=C1[N+](=O)[O-])N)C(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.46; 1.0% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-109 Y78]"
2563,363898391,12076,C1=CC(=C(C=C1[N+](=O)[O-])N)C(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 0.46; 1.5% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-109 Y78]"
2564,363898391,12076,C1=CC(=C(C=C1[N+](=O)[O-])N)C(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,"0; 0.46; 1.5% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-109 Y78]"
2565,363898392,7195,C1=CC2=C(C=C1[N+](=O)[O-])NC=N2,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.12; 0.24% OF DIET,LIVER: HEPATOCELLULAR CARCINOMA OR HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-117 Y79]"
2566,363898392,7195,C1=CC2=C(C=C1[N+](=O)[O-])NC=N2,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.12; 0.24% OF DIET,LIVER: HEPATOCELLULAR CARCINOMA OR HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-117 Y79]"
2567,363898392,7195,C1=CC2=C(C=C1[N+](=O)[O-])NC=N2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.12; 0.5% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-117 Y79]"
2568,363898392,7195,C1=CC2=C(C=C1[N+](=O)[O-])NC=N2,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.12; 0.5% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-117 Y79]"
2569,363898393,7114,C1=CC=C(C=C1)C2=CC=C(C=C2)[N+](=O)[O-],Active,,,,DOG,MONGREL/FEMALE,ORAL,300 MG 3/WK FOR LIFE,URINARY BLADDER: EPITHELIAL CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 113 Y74]"
2570,363898393,7114,C1=CC=C(C=C1)C2=CC=C(C=C2)[N+](=O)[O-],Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 50; 100 UMOL/KG IN DMSO 1/WK FOR 8 WK (STUDY DURATION: 62 WK),,NEGATIVE,"[HIROSE,M, LEE,M, WANG,CY AND KING,CM; INDUCTION OF RAT MAMMARY GLAND TUMORS BY 1-NITROPYRENE, A RECENTLY RECOGNIZED ENVIRONMENTAL MUTAGEN; CANCER RES. 44:1158-1162, 1984]"
2571,363898393,7114,C1=CC=C(C=C1)C2=CC=C(C=C2)[N+](=O)[O-],Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 50; 100 UMOL/KG IN DMSO 1/WK FOR 8 WK (STUDY DURATION: 62 WK),,NEGATIVE,"[HIROSE,M, LEE,M, WANG,CY AND KING,CM; INDUCTION OF RAT MAMMARY GLAND TUMORS BY 1-NITROPYRENE, A RECENTLY RECOGNIZED ENVIRONMENTAL MUTAGEN; CANCER RES. 44:1158-1162, 1984]"
2572,363898394,15787,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 2348; 4696 PPM IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-26 Y78]"
2573,363898394,15787,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET,LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-184 Y79]"
2574,363898394,15787,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 2348; 4696 PPM IN DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-26 Y78]"
2575,363898394,15787,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3000; 6000 PPM IN DIET,LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-184 Y79]"
2576,363898394,15787,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-26 Y78]"
2577,363898394,15787,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-26 Y78]"
2578,363898394,15787,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)Cl)Cl,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 1300; 2600 PPM IN DIET, TWA",PANCREAS: CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-26 Y78]"
2579,363898395,9568055,C1CN(C(=O)N1)/N=C/C2=CC=C(O2)[N+](=O)[O-],Active,,,,RAT,,ORAL,,LYMPHATIC SYSTEM: LYMPHOBLASTIC LYMPHOMA; MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 181 Y74]"
2580,363898396,10753,CC(=O)NC1=NC(=CS1)C2=CC=C(O2)[N+](=O)[O-],Active,,,,HAMSTER,,ORAL,,FORESTOMACH; URINARY BLADDER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 181 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 185 Y74]"
2581,363898396,10753,CC(=O)NC1=NC(=CS1)C2=CC=C(O2)[N+](=O)[O-],Active,,,,MOUSE,,ORAL,,FORESTOMACH; HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHATIC LEUKEMIA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 181 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 185 Y74]"
2582,363898396,10753,CC(=O)NC1=NC(=CS1)C2=CC=C(O2)[N+](=O)[O-],Active,,,,RAT,,ORAL,,MAMMARY GLAND; LUNG; SALIVARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 181 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 185 Y74]"
2583,363898398,5935,CN(CCCl)CCCl.Cl,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,3.85; 212; 866; 3369 UG/KG IN WATER IN 12 DOSES OVER 4 WK,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 193 Y75]"
2584,363898398,5935,CN(CCCl)CCCl.Cl,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAVENOUS,1 MG/KG IN WATER FOR 2-4 DOSES AT 2-DAY INTERVALS,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 193 Y75]"
2585,363898398,5935,CN(CCCl)CCCl.Cl,Active,,,,MOUSE,"C3H/MALE,FEMALE",SUBCUTANEOUS,,"LUNG; INJECTION SITE: SARCOMA, PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 193 Y75]"
2586,363898398,5935,CN(CCCl)CCCl.Cl,Active,,,,MOUSE,STRAIN-RF/FEMALE,INTRAVENOUS,2.4 MG/KG IN SALINE FOR 4 DOSES AT 2-WK INTERVALS,THYMUS GLAND: LYMPHOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 193 Y75]"
2587,363898398,5935,CN(CCCl)CCCl.Cl,Active,,,,RAT,BR46/MALE,INTRAVENOUS,0.11 MG/KG 1/WK FOR 52 WK,MULTIPLE SITES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 193 Y75]"
2588,363898399,9335,C[N+](CCCl)(CCCl)[O-],Active,,,,MOUSE,"STRAIN-DD/MALE,FEMALE",SUBCUTANEOUS,650 MG/KG,HARDERIAN GLAND: ADENOMA; LUNG: ADENOMA; THYMUS GLAND: LYMPHOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 209 Y75]"
2589,363898399,9335,C[N+](CCCl)(CCCl)[O-],Active,,,,RAT,BR46/MALE,INTRAVENOUS,4.2 MG/KG 1/WK FOR 52 WK,"LYMPHATIC SYSTEM: RETICULAR CELL TUMOR, SARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 209 Y75]"
2590,363898400,6849,C1=CC=C2C(=C1)C=CC=C2[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.06; 0.12% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-64 Y78]"
2591,363898400,6849,C1=CC=C2C(=C1)C=CC=C2[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.06; 0.12% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-64 Y78]"
2592,363898400,6849,C1=CC=C2C(=C1)C=CC=C2[N+](=O)[O-],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.06; 0.18% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-64 Y78]"
2593,363898400,6849,C1=CC=C2C(=C1)C=CC=C2[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,ORAL,0; 0.06; 0.18% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-64 Y78]"
2594,363898401,5111791,C1=CC(=C(C=C1[N+](=O)[O-])N)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-180 Y79]"
2595,363898401,5111791,C1=CC(=C(C=C1[N+](=O)[O-])N)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3750; 7500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-180 Y79]"
2596,363898401,5111791,C1=CC(=C(C=C1[N+](=O)[O-])N)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 375; 750 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-180 Y79]"
2597,363898401,5111791,C1=CC(=C(C=C1[N+](=O)[O-])N)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 375; 750 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-180 Y79]"
2598,363898402,4338370,C1=CC(=C(C=C1N)[N+](=O)[O-])N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2200; 4400 PPM IN DIET,LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-169 Y79]"
2599,363898402,4338370,C1=CC(=C(C=C1N)[N+](=O)[O-])N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2200; 4400 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-169 Y79]"
2600,363898402,4338370,C1=CC(=C(C=C1N)[N+](=O)[O-])N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1100; 2200 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-169 Y79]"
2601,363898402,4338370,C1=CC(=C(C=C1N)[N+](=O)[O-])N,Inactive,,,,RAT,F344/MALE,ORAL,0; 550; 1100 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-169 Y79]"
2602,363898403,398,CC(C)[N+](=O)[O-],Active,,,,RAT,,INHALATION,,LIVER,POSITIVE,"[NIOSH CURRENT INTELLIGENCE BULLETIN 17, 2-NITROPROPANE; U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH, CINCINNATI, OHIO, APRIL 25, 1977]"
2603,363898404,1678,C(C[N+](=O)[O-])C(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 0.375; 0.75 MG/ANIMAL/DAY FOR 104 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-52 Y78]"
2604,363898404,1678,C(C[N+](=O)[O-])C(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 0.375; 0.75 MG/ANIMAL/DAY FOR 104 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-52 Y78]"
2605,363898404,1678,C(C[N+](=O)[O-])C(=O)O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 0.6; 1.2 MG/ANIMAL/DAY FOR 110 WK (STUDY DURATION: 111 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-52 Y78]"
2606,363898404,1678,C(C[N+](=O)[O-])C(=O)O,Unspecified,,,,RAT,F344/MALE,GAVAGE,0; 0.425; 0.85 MG/ANIMAL/DAY FOR 110 WK (STUDY DURATION: 111 WK),LIVER: HEPATOCELLULAR NEOPLASM; PANCREAS: ISLET CELL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-52 Y78]"
2607,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,50; 100 UMOL/KG IN DMSO 1/WK FOR 8 WK,INJECTION SITE: FIBROSARCOMA; MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[HIROSE,M, LEE,M-S, WANG,CY AND KING,CM; INDUCTION OF RAT MAMMARY GLAND TUMORS BY 1-NITROPYRENE, A RECENTLY RECOGNIZED ENVIRONMENTAL MUTAGEN; CANCER RES. 44:1158-1162, 1984]"
2608,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/MALE,SUBCUTANEOUS,50; 100 UMOL/KG IN DMSO 1/WK FOR 8 WK,INJECTION SITE: FIBROSARCOMA,POSITIVE,"[HIROSE,M, LEE,M-S, WANG,CY AND KING,CM; INDUCTION OF RAT MAMMARY GLAND TUMORS BY 1-NITROPYRENE, A RECENTLY RECOGNIZED ENVIRONMENTAL MUTAGEN; CANCER RES. 44:1158-1162, 1984]"
2609,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,F344/MALE,SUBCUTANEOUS,2 MG IN DMSO 2/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA,POSITIVE,"[OHGAKI,HF, MATSUKURA,N, MORINO,K, KAWACHI,T, SUGIMURA,T, MORITA,K, TOKIWA,H AND HIROTA,T; CARCINOGENICITY IN RATS OF THE MUTAGENIC COMPOUNDS 1-NITROPYRENE AND 3-NITROFLUORANTHENE; CANCER LETT. 15:1-7, 1982]"
2610,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 50; 100 UMOL/KG IN DMSO 1/WK FOR 8 WK (STUDY DURATION: 62 WK),INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA,POSITIVE,"[HIROSE,M, LEE,M, WANG,CY AND KING,CM; INDUCTION OF RAT MAMMARY GLAND TUMORS BY 1-NITROPYRENE, A RECENTLY RECOGNIZED ENVIRONMENTAL MUTAGEN; CANCER RES. 44:1158-1162, 1984]"
2611,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 50; 100 UMOL/KG IN DMSO 1/WK FOR 8 WK (STUDY DURATION: 62 WK),"INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; MAMMARY GLAND: FIBROADENOMA, ADENOCARCINOMA",POSITIVE,"[HIROSE,M, LEE,M, WANG,CY AND KING,CM; INDUCTION OF RAT MAMMARY GLAND TUMORS BY 1-NITROPYRENE, A RECENTLY RECOGNIZED ENVIRONMENTAL MUTAGEN; CANCER RES. 44:1158-1162, 1984]"
2612,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 21 UG TOTAL DOSE (3 UG/5 UL, 6 UG/10 UL, 12 UG/20 UL DMSO ON DAYS 1,8 AND 15); 105 UG TOTAL DOSE (15 UG/5 UL, 30 UG/10 UL, 60 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",,NEGATIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
2613,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 21 UG TOTAL DOSE (3 UG/5 UL, 6 UG/10 UL, 12 UG/20 UL DMSO ON DAYS 1,8 AND 15); 105 UG TOTAL DOSE (15 UG/5 UL, 30 UG/10 UL, 60 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",,NEGATIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
2614,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,RAT,STRAIN CD/FEMALE,INTRAGASTRIC,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),,NEGATIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
2615,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),"MAMMARY GLAND: ADENOCARCINOMA, FIBROADENOMA",POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
2616,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),PITUITARY GLAND: CARCINOMA,POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
2617,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,HAMSTER,SYRIAN/MALE,INTRATRACHEAL,0; 1; 2 MG ADSORBED ONTO CARBON CARRIER PARTICLES IN 0.2 ML SALINE 2/WK FOR 92 WK (STUDY DURATION: 92 WK),,NEGATIVE,"[MOON,RC, RAO,KVN AND DETRISAC,CJ; RESPIRATORY CARCINOGENESIS OF NITROAROMATICS; RES. REP. - HEALTH EFF. INST. 32:1-36, 1990]"
2618,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,HAMSTER,SYRIAN/MALE,INTRATRACHEAL,0; 1; 2 MG ADSORBED ONTO CARBON CARRIER PARTICLES IN 0.2 ML SALINE 1/WK FOR 92 WK (STUDY DURATION: 92 WK),,NEGATIVE,"[MOON,RC, RAO,KVN AND DETRISAC,CJ; RESPIRATORY CARCINOGENESIS OF NITROAROMATICS; RES. REP. - HEALTH EFF. INST. 32:1-36, 1990]"
2619,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG/BW IN 25 UMOL/ML DMSO 3/WK FOR 4 WK (TOTAL DOSE: 0; 119 UMOL) ADMINISTERED TO WEANLING RATS (STUDY DURATION: 61 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
2620,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 100 UMOL/KG/BW IN 70 UMOL/ML DMSO 1/WK FOR 4 WK (TOTAL DOSE: 0; 77.3 UMOL) ADMINISTERED TO WEANLING RATS (STUDY DURATION: 87 WK),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
2621,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,0; 100 UMOL/KG/BW IN 70 UMOL/ML DMSO 1/WK FOR 4 WK (TOTAL DOSE: 0; 74.3 UMOL) ADMINISTERED TO WEANLING RATS (STUDY DURATION: 94 WK),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
2622,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 0.1 ML OF 20.3 UMOL/ML DMSO INJECTED INTO MAMMARY TISSUE OF THE 3 LEFT THORACIC NIPPLES FOLLOWED THE NEXT D BY SIMILAR TREATMENT OF THE INGUINAL NIPPLE AREA (TOTAL DOSE: 0; 12.3 UMOL) (STUDY DURATION: 77 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
2623,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,MOUSE,BALB/MALE,SUBCUTANEOUS,0; 0.1 MG IN DMSO 1/WK FOR 20 WK (STUDY DURATION: 60 WK),,NEGATIVE,"[TOKIWA,H, OTOFUJI,T, HORIKAWA,K, KITAMORI,S, OTSUKA,H, MANABE,Y, KINOUCHI,T AND OHNISHI,Y; 1,6-DINITROPYRENE: MUTAGENICITY IN SALMONELLA AND CARCINOGENICITY IN BALB/C MICE; JNCI, J. NATL. CANCER INST. 73(6):1359-1363, 1984]"
2624,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 0.71; 2.14; 6.44 MMOL/KG IN 0.1 ML TRIOCTANOIN TOTAL DOSE ADMINISTERED AS 3 INJECTIONS/WK FOR 17 INJECTIONS (STUDY DURATION: 24 WK),LUNG: ADENOMA,POSITIVE,"[EL-BAYOUMY,K, HECHT,SS, SACKL,T AND STONER,GD; TUMORIGENICITY AND METABOLISM OF 1-NITROPYRENE IN A/J MICE; CARCINOGENESIS 5(11):1449-1452, 1984]"
2625,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 0.71; 2.14; 6.44 MMOL/KG IN 0.1 ML TRIOCTANOIN TOTAL DOSE ADMINISTERED AS 3 INJECTIONS/WK FOR 17 INJECTIONS (STUDY DURATION: 24 WK),LUNG: ADENOMA,POSITIVE,"[EL-BAYOUMY,K, HECHT,SS, SACKL,T AND STONER,GD; TUMORIGENICITY AND METABOLISM OF 1-NITROPYRENE IN A/J MICE; CARCINOGENESIS 5(11):1449-1452, 1984]"
2626,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 0.2; 2 MG 2/WK FOR 10 WK (STUDY DURATION: 650 D),,NEGATIVE,"[OHGAKI,H, HASEGAWA,H, KATO,T, NEGISHI,C, SATO,S AND SUGIMURA,T; ABSENCE OF CARCINOGENICITY OF 1-NITROPYRENE, CORRECTION OF PREVIOUS RESULTS, AND NEW DEMONSTRATION OF CARCINOGENICITY OF 1,6-DINITROPYRENE IN RATS; CANCER LETT. 25(3):239-245, 1985]"
2627,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 7 NMOL (TOTAL DOSE), 1/7, 2/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED WITHIN 24 HR OF BIRTH AND AT 8 AND 15 D OF AGE, RESPECTIVELY (STUDY DURATION: 72 WK)",,NEGATIVE,"[MORI,H, MORISHITA,Y, SUGIE,S, TANAKA,T, KOJIMA,T, SUZUI,M, KATAOKA,K, KINOUCHI,T AND OHNISHI,Y; CARCINOGENICITY EXAMINATION OF 1-NITROPYRENE OXIDES AND RELATED CHEMICALS: LACK OF THEIR TUMORIGENIC EFFECTS IN A NEWBORN MICE ASSAY; J. TOXICOL. SCI. 17(4):235-241, 1992]"
2628,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 7 NMOL (TOTAL DOSE), 1/7, 2/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED WITHIN 24 HR OF BIRTH AND AT 8 AND 15 D OF AGE, RESPECTIVELY (STUDY DURATION: 72 WK)",,NEGATIVE,"[MORI,H, MORISHITA,Y, SUGIE,S, TANAKA,T, KOJIMA,T, SUZUI,M, KATAOKA,K, KINOUCHI,T AND OHNISHI,Y; CARCINOGENICITY EXAMINATION OF 1-NITROPYRENE OXIDES AND RELATED CHEMICALS: LACK OF THEIR TUMORIGENIC EFFECTS IN A NEWBORN MICE ASSAY; J. TOXICOL. SCI. 17(4):235-241, 1992]"
2629,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG BW IN DMSO 3/WK FOR 4 WK (STUDY DURATION: 61 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
2630,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 100 UMOL/KG BW IN DMSO 1/WK FOR 4 WK (STUDY DURATION: 90 WK),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
2631,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,0; 100 UMOL/KG BW IN DMSO 1/WK FOR 4 WK (STUDY DURATION: 90 WK),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
2632,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Inactive,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 0.1 ML OF A 20.3 UMOL/ML SOLUTION IN DMSO INJECTED INTO MAMMARY TISSUE UNDERLYING 3 LEFT THORACIC NIPPLES THE FOLLOWING DAY INGUINAL NIPPLE AREA TREATED SIMILARLY (STUDY DURATION: 77 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
2633,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,GAVAGE,0; 50 UMOL IN 0.5 ML TRIOCTANOIN 1/WK FOR 8 WK (STUDY DURATION: 49 WK),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[EL-BAYOUMY,K, CHAE,YH, UPADHYAYA,P, RIVENSON,A, KURTZKE,C, REDDY,B AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF BENZO[A]PYRENE, 1-NITROPYRENE AND 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE ADMINISTERED BY GAVAGE TO FEMALE CD RATS; CARCINOGENESIS 16(2):431-434, 1995]"
2634,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,0; 6.3 UMOL (TOTAL DOSE) ADMINISTERED OVER 8 WK BEGINNING ON DAY OF BIRTH (STUDY DURATION: 67 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[IMAIDA,K, LEE,MS, LAND,SJ, WANG,CY AND KING,CM; CARCINOGENICITY OF NITROPYRENES IN THE NEWBORN FEMALE RAT; CARCINOGENESIS 16(12):3027-3030, 1995]"
2635,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,0; 63 UMOL (TOTAL DOSE) ADMINISTERED OVER 8 WK BEGINNING WITHIN 24 HR OF BIRTH (STUDY DURATION: 86 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[IMAIDA,K, LEE,MS, LAND,SJ, WANG,CY AND KING,CM; CARCINOGENICITY OF NITROPYRENES IN THE NEWBORN FEMALE RAT; CARCINOGENESIS 16(12):3027-3030, 1995]"
2636,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,0; 40 UMOL (TOTAL DOSE) ADMINISTERED OVER 8 WK BEGINNING WITHIN 24 HR OF BIRTH (STUDY DURATION: 86 WK),HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[IMAIDA,K, LEE,MS, LAND,SJ, WANG,CY AND KING,CM; CARCINOGENICITY OF NITROPYRENES IN THE NEWBORN FEMALE RAT; CARCINOGENESIS 16(12):3027-3030, 1995]"
2637,363898405,21694,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,F344/DUCRJ FISCHER/MALE,SUBCUTANEOUS,2 MG TWICE WEEKLY FOR 10 WK (STUDY DURATION: 52 WK),INTEGUMENTARY SYSTEM: FIBROUS HISTIOCYTOMAS,POSITIVE,"[SUGIMURA,T AND TAKAYAMA,S; BIOLOGICAL ACTIONS OF NITROARENES  IN SHORT-TERM TESTS ON SALMONELLA, CULTURED MAMMALIAN CELLS  AND CULTURED HUMAN TRACHEAL TISSUES: POSSIBLE BASIS FOR  REGULATORY CONTROL. ENVIRON. HEALTH PERSPECT. 47:171-176,  1983]"
2638,363898406,11945,C1=CC2=C(C=CC(=C2)[N+](=O)[O-])N=C1,Inactive,,,,RAT,"F344/MALE,FEMALE",ORAL,0.05% IN DIET FOR 2 YR,,NEGATIVE,"[FUKUSHIMA,S, ISHIHARA,Y, NISHIO,O, OGISO,T, SHIRAI,T AND ITO,N; CARCINOGENITIES  OF QUINOLINE DERIVATIVES IN F344 RATS; CANCER LETT. 14:115-123, 1981]"
2639,363898407,11830,C1=CC2=C(C(=C1)[N+](=O)[O-])N=CC=C2,Active,,,,RAT,"F344/MALE,FEMALE",ORAL,0.1% IN DIET FOR 2 YR,"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, CARCINOMA",POSITIVE,"[FUKUSHIMA,S, ISHIHARA,Y, NISHIO,O, OGISO,T, SHIRAI,T AND ITO,N; CARCINOGENITIES  OF QUINOLINE DERIVATIVES IN F344 RATS; CANCER LETT. 14:115-123, 1981]"
2640,363898408,,,Active,,,,HAMSTER,SYRIAN,DERMAL,0.5 ML OF 0.5% IN ACETONE 2/WK FOR 36 WK,"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA, KERATOACANTHOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 1336]"
2641,363898408,,,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",SUBCUTANEOUS,0.015 OR 0.025 MG/10 G ONCE,LUNG; LYMPHATIC SYSTEM,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 578]"
2642,363898408,,,Active,,,,MOUSE,STRAIN-DD/FEMALE,SUBCUTANEOUS,0.5 MG IN OLIVE OIL-CHOLESTEROL (7:1) ONCE,LUNG: CYSTADENOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 1336]"
2643,363898408,,,Active,,,,MOUSE,STRAIN-DD/FEMALE,SUBCUTANEOUS,0.25 MG IN 0.1 ML OF 10% LECITHIN IN WATER 1/WK FOR 10 WK,"LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 1336]"
2644,363898408,,,Active,,,,MOUSE,"SWISS/MALE,FEMALE",DERMAL,0.3 ML OF 0.3% IN ACETONE 1/WK,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SQUAMOUS CELL CARCINOMA, SPINDLE CELL SARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 1336]"
2645,363898408,,,Active,,,,MOUSE,SWISS/MALE,DERMAL,0.6 ML OF 0.3% IN ACETONE 1/WK FOR 4 WK THEN 0.3 ML 1/WK FOR 15 WK,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 1336]"
2646,363898408,,,Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0.1 ML OF 0.25% SOLN IN OLIVE OIL-CHOLESTEROL (100:5) 1/WK FOR 10 WK (TOTAL DOSE: 2.5 MG),"LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 1336]"
2647,363898408,,,Active,,,,RAT,BUFFALO/FEMALE,SUBCUTANEOUS,0.5 MG IN 0.2 ML OF 10% LECITHIN IN WATER 1/WK FOR 20 WK,"LUNG: ADENOMA, ADENOCARCINOMA, EPIDERMOID CARCINOMA; INJECTION SITE: SARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 1336]"
2648,363898408,,,Active,,,,RAT,BUFFALO/FEMALE,SUBCUTANEOUS,0.25-0.5 MG AS 0.1-0.2 ML OF 0.25% SOLN IN OLIVE OIL-LECITHIN (100:5) 1/WK (TOTAL DOSE: 10 MG),"INJECTION SITE: SARCOMA; LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 1336]"
2649,363898408,,,Active,,,,RAT,BUFFALO/MALE,SUBCUTANEOUS,0.5 MG IN 0.2 ML OLIVE OIL-CHOLESTEROL (100:5) 1/WK FOR 20 WK (TOTAL DOSE: 10 MG),"INJECTION SITE: FIBROSARCOMA; LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 61-67 1336]"
2650,363898408,,,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 20 MG/KG 1/WK FOR 4 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[ITO,T, KITAMURA,H, INAYAMA,Y AND KANISAWA,M; PULMONARY ADENOMA AND ENDOCRINE CELL HYPERPLASIA IN SYRIAN GOLDEN HAMSTER TREATED WITH 4-NITROQUINOLINE 1-OXIDE; ACTA. PATHOL. JPN. 38(9):1097-1104, 1988]"
2651,363898408,,,Active,,,,RAT,DARK-AGOUTI/MALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2652,363898408,,,Active,,,,RAT,DARK-AGOUTI/FEMALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2653,363898408,,,Active,,,,RAT,LONG-EVANS/MALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2654,363898408,,,Active,,,,RAT,LONG-EVANS/FEMALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2655,363898408,,,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2656,363898408,,,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2657,363898408,,,Active,,,,RAT,ACI/MS/MALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA),POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2658,363898408,,,Active,,,,RAT,ACI/MS/FEMALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2659,363898408,,,Active,,,,RAT,F344/MALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2660,363898408,,,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2661,363898408,,,Active,,,,RAT,DONRYU/MALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2662,363898408,,,Active,,,,RAT,DONRYU/FEMALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2663,363898408,,,Active,,,,RAT,WISTAR/FURTH/MALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2664,363898408,,,Active,,,,RAT,WISTAR/FURTH/FEMALE,ORAL,0; 0.001% IN DRINKING WATER (APPROXIMATE DOSE 70 MG/100 G BW/D) FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),TONGUE: CARCINOMA,POSITIVE,"[KITANO,M, HATANO,H AND SHISA,H; STRAIN DIFFERENCE OF SUSCEPTIBILITY TO 4-NITRO- QUINOLINE 1-OXIDE-INDUCED TONGUE CARCINOMA IN RATS; JPN. J. CANCER RES. 83(8): 843-850, 1992]"
2665,363898408,,,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.001% IN DRINKING WATER FOR 28 WK (STUDY DURATION: 75 WK),PALATE: CARCINOMA,POSITIVE,"[SAKAI,K; EXPERIMENTAL INDUCTION OF PALATAL CARCINOMA IN RATS BY ORAL ADMINISTRATION OF AQUEOUS SOLUTION OF 4-NITROQUINOLINE-1-OXIDE (4NQO); MEIKAI DAIGAKU SHIGAKU ZASSHI 24(1):129-152, 1995]"
2666,363898408,,,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.001% IN DRINKING WATER FOR 28 WK (STUDY DURATION: 68 WK),TONGUE: CARCINOMA,POSITIVE,"[OHNE,M, SATOH,T, YAMADA,S AND TAKAI,H; EXPERIMENTAL TONGUE CARCINOMA OF RATS INDUCED BY ORAL ADMINISTRATION OF 4-NITROQUINOLINE 1-OXIDE (4NQO) IN DRINKING WATER; ORAL SURG., ORAL MED., ORAL PATHOL. 59(6):600-607, 1985]"
2667,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,250 MG/KG IN OLIVE OIL 1/WK FOR 25 WK,PANCREAS: ADENOCARCINOMA,POSITIVE,"[SINDELAR,WF AND KURMAN,CC; NITROSAMINE-INDUCED PANCREATIC CARCINOGENESIS IN OUTBRED AND INBRED SYRIAN HAMSTERS; CARCINOGENESIS 3:1021-1026, 1982]"
2668,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,250 MG/KG IN OLIVE OIL 1/WK FOR 25 WK,PANCREAS: ADENOCARCINOMA,POSITIVE,"[SINDELAR,WF AND KURMAN,CC; NITROSAMINE-INDUCED PANCREATIC CARCINOGENESIS IN OUTBRED AND INBRED SYRIAN HAMSTERS; CARCINOGENESIS 3:1021-1026, 1982]"
2669,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,250; 500; 1000 MG/KG IN OLIVE OIL 1/WK FOR 20 WK,PANCREAS: ADENOCARCINOMA,POSITIVE,"[SINDELAR,WF AND KURMAN,CC; NITROSAMINE-INDUCED PANCREATIC CARCINOGENESIS IN OUTBRED AND INBRED SYRIAN HAMSTERS; CARCINOGENESIS 3:1021-1026, 1982]"
2670,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,250 MG/KG IN OLIVE OIL 1/WK FOR 25 WK,PANCREAS: ADENOCARCINOMA,POSITIVE,"[SINDELAR,WF AND KURMAN,CC; NITROSAMINE-INDUCED PANCREATIC CARCINOGENESIS IN OUTBRED AND INBRED SYRIAN HAMSTERS; CARCINOGENESIS 3:1021-1026, 1982]"
2671,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,25; 125; 250 MG/KG 1/WK FOR LIFE,PANCREAS; NASAL CAVITY; LUNG; LIVER; TRACHEA; LARYNX,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 118]"
2672,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",SUBCUTANEOUS,40 MG/KG IN SALINE ONCE,"PANCREAS: ADENOMA, ADENOCARCINOMA, INTRADUCTAL CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 118]"
2673,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,MOUSE,STRAIN-DD/MALE,ORAL,100; 250; 500; 1000 PPM IN DRINKING WATER (DAILY INTAKE: 6.3-34.2 MG),"LUNG: ADENOMA, ADENOCARCINOMA; LIVER: HEMANGIOMA, HEMANGIOENDOTHELIOMA, HEMANGIOENDOTHELIAL SARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 118]"
2674,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,108 MG/L IN DRINKING WATER 5 DAY/WK FOR 50 WK (TOTAL DOSE 540 MG),"NASAL TURBINATES: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 118]"
2675,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,106 MG/L IN DRINKING WATER 5 DAY/WK FOR 30 WK (TOTAL DOSE: 318 MG),"LIVER: HEPATOCELLULAR CARCINOMA, CHOLANGIOCARCINOMA, HEMANGIOENDOTHELIAL SARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 118]"
2676,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,3; 4 G/KG ONCE,"LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 118]"
2677,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,RAT,WISTAR/MALE,ORAL,100; 500 PPM IN DRINKING WATER FOR 25 WK,"LUNG: ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 118]"
2678,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,RAT,WISTAR/MALE,ORAL,100; 500 PPM IN DRINKING WATER FOR 52 WK,"LUNG: ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA; LIVER: HEMANGIOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 118]"
2679,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,MOUSE,ICR/MALE,SUBCUTANEOUS,0; 25; 50; 100 MG/KG BW ONCE ON DAYS 1 AND 8 OF AGE (STUDY DURATION: 50 WK),LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[FUJII,K, HAYAKAWA,T AND KIKUCHI,M; TUMOR INDUCTION IN MICE ADMINISTERED NEONATALLY WITH N-BIS(2-HYDROXYPROPYL)NITROSAMINE (BHPN); SCI. REP. RES. INST. TOHOKU. UNIV. MED. 39(1-4):7-12, 1993]"
2680,363898409,40828,CC(CN(CC(C)O)N=O)O,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,0; 25; 50; 100 MG/KG BW ONCE ON DAYS 1 AND 8 OF AGE (STUDY DURATION: 50 WK),LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[FUJII,K, HAYAKAWA,T AND KIKUCHI,M; TUMOR INDUCTION IN MICE ADMINISTERED NEONATALLY WITH N-BIS(2-HYDROXYPROPYL)NITROSAMINE (BHPN); SCI. REP. RES. INST. TOHOKU. UNIV. MED. 39(1-4):7-12, 1993]"
2681,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,GUINEA PIG,STRAIN-13/MALE,SUBCUTANEOUS,70 MG/KG/WK FOR 2 WK FOLLOWED BY 1 WK NO TREATMENT THEN 20 MG/KG/WK FOR 2 WK,"LIVER: CHOLANGIOMA, CHOLANGIOCARCINOMA",POSITIVE,"[RAO,MS AND POUR,P; DEVELOPMENT OF BILIARY AND HEPATIC NEOPLASMS IN GUINEA PIGS TREATED WITH N-NITROSOBIS(2-OXOPROPYL)AMINE; CANCER LETT. 5:31-34, 1978]"
2682,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,5 MG/KG IN OLIVE OIL 1/WK FOR 15 WK,PANCREAS: ADENOCARCINOMA,POSITIVE,"[SINDELAR,WF AND KURMAN,CC; NITROSAMINE-INDUCED PANCREATIC CARCINOGENESIS IN OUTBRED AND INBRED SYRIAN HAMSTERS; CARCINOGENESIS 3:1021-1026, 1982]"
2683,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,5 MG/KG IN OLIVE OIL 1/WK FOR 15 WK,PANCREAS: ADENOCARCINOMA,POSITIVE,"[SINDELAR,WF AND KURMAN,CC; NITROSAMINE-INDUCED PANCREATIC CARCINOGENESIS IN OUTBRED AND INBRED SYRIAN HAMSTERS; CARCINOGENESIS 3:1021-1026, 1982]"
2684,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,5 MG/KG IN OLIVE OIL 1/WK FOR 15 WK,PANCREAS: ADENOCARCINOMA,POSITIVE,"[SINDELAR,WF AND KURMAN,CC; NITROSAMINE-INDUCED PANCREATIC CARCINOGENESIS IN OUTBRED AND INBRED SYRIAN HAMSTERS; CARCINOGENESIS 3:1021-1026, 1982]"
2685,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,5 MG/KG IN OLIVE OIL 1/WK FOR 15 WK,PANCREAS: ADENOCARCINOMA,POSITIVE,"[SINDELAR,WF AND KURMAN,CC; NITROSAMINE-INDUCED PANCREATIC CARCINOGENESIS IN OUTBRED AND INBRED SYRIAN HAMSTERS; CARCINOGENESIS 3:1021-1026, 1982]"
2686,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,5 MG/KG IN OLIVE OIL 1/WK FOR 15 WK,PANCREAS: ADENOCARCINOMA,POSITIVE,"[SINDELAR,WF AND KURMAN,CC; NITROSAMINE-INDUCED PANCREATIC CARCINOGENESIS IN OUTBRED AND INBRED SYRIAN HAMSTERS; CARCINOGENESIS 3:1021-1026, 1982]"
2687,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",ORAL,0.35; 0.7; 1.4% IN DRINKING WATER,"LIVER: CHOLANGIOMA, INTRADUCTAL CARCINOMA, CHOLANGIOCARCINOMA; GALL BLADDER: POLYP; COMMON BILE DUCT: POLYP; COMMON DUCT: POLYP",POSITIVE,"[POUR,P AND ALTHOFF,J; THE EFFECT OF N-NITROSOBIS(2-OXOPROPYL)AMINE AFTER ORAL ADMINISTRATION TO HAMSTERS; CANCER LETT. 2:323-326, 1977]"
2688,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,2.5; 5; 10 MG/KG,"PANCREAS: DUCTAL ADENOMA, INTRADUCTAL CARCINOMA, ADENOCARCINOMA; LUNG: ADENOMA, ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA; LIVER: CHOLANGIOMA, HEMANGIOENDOTHELIOMA, CHOLANGIOCARCINOMA; GALL BLADDER: PAPILLARY POLYP",POSITIVE,"[POUR,P, ALTHOFF,J, KRUGER,FW AND MOHR,U; A POTENT PANCREATIC CARCINOGEN IN SYRIAN HAMSTERS: N-NITROSOBIS(2-OXOPROPYL)AMINE; J. NATL. CANCER INST. 58(5):1449-1453, 1977]"
2689,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,2.5; 5; 10 MG/KG,"PANCREAS: DUCTAL ADENOMA, INTRADUCTAL CARCINOMA, ADENOCARCINOMA; LUNG: ADENOMA, ADENOCARCINOMA; GALL BLADDER: PAPILLARY POLYP",POSITIVE,"[POUR,P, ALTHOFF,J, KRUGER,FW AND MOHR,U; A POTENT PANCREATIC CARCINOGEN IN SYRIAN HAMSTERS: N-NITROSOBIS(2-OXOPROPYL)AMINE; J. NATL. CANCER INST. 58(5):1449-1453, 1977]"
2690,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,RAT,"MRC/MALE,FEMALE",SUBCUTANEOUS,2.5; 5; 10 MG/KG,"THYROID GLAND: FOLLICULAR ADENOMA, CARCINOMA",POSITIVE,"[POUR,P AND SALMASIZADEH,S; INDUCTION OF THYROID FOLLICULAR ADENOMAS AND CARCINOMAS BY N-NITROSOBIS(2-OXOPROPYL)AMINE; CANCER LETT. 5:13-18, 1978]"
2691,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 0.8 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 30 WK (TOTAL DOSE 0.3 MMOL) (STUDY DURATION: LIFESPAN),"BLADDER: TRANSITIONAL CELL CARCINOMA, TRANSITIONAL CELL PAPILLOMA; LUNG: TUMOR; KIDNEY: MESENCHYMAL NEOPLASM; LIVER: TUMOR",POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
2692,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,RAT,CD-1/MALE,SUBCUTANEOUS,0; 6.15; 12.3; 24.6 MG/KG 1/WK FOR LIFE (STUDY DURATION: LIFE),NASAL CAVITY: TUMOR,POSITIVE,"[CARDESA,A, TRASERRA,J, BOMBI,JA AND MOHR,U;TUMORS OF THE NASAL CAVITIES INDUCED IN RATS BY 2,2-DIOXOPROPYL-N-PROPYLNITROSAMINE. COMPARATIVE ASPECTS WITH MAN; J. CANCER RES. CLIN. ONCOL. 108(1):114-120, 1984]"
2693,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,RAT,CD-1/FEMALE,SUBCUTANEOUS,0; 5.35; 10.7; 21.4 MG/KG 1/WK FOR LIFE (STUDY DURATION: LIFE),NASAL CAVITY: TUMOR,POSITIVE,"[CARDESA,A, TRASERRA,J, BOMBI,JA AND MOHR,U;TUMORS OF THE NASAL CAVITIES INDUCED IN RATS BY 2,2-DIOXOPROPYL-N-PROPYLNITROSAMINE. COMPARATIVE ASPECTS WITH MAN; J. CANCER RES. CLIN. ONCOL. 108(1):114-120, 1984]"
2694,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 10 MG/KG/BW 2/WK FOR A TOTAL OF 11 DOSES BEGINNING AT 2 D OF AGE (STUDY DURATION: 26 WK),LIVER: HEPATOCELLULAR CARCINOMA; KIDNEY: NEPHROBLASTOMA; TESTIS: GONADAL STROMAL TUMOR,POSITIVE,"[RAO,MS, SUBBARAO,V AND SCARPELLI,DG; CARCINOGENIC EFFECT OF N-NITROSOBIS (2-OXOPROPYL)AMINE IN NEWBORN RATS; CARCINOGENESIS 6(9):1395-1397, 1985]"
2695,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,0; 10 MG/KG/BW 2/WK FOR A TOTAL OF 11 DOSES BEGINNING AT 2 D OF AGE (STUDY DURATION: 26 WK),LIVER: HEPATOCELLULAR CARCINOMA; KIDNEY: NEPHROBLASTOMA,POSITIVE,"[RAO,MS, SUBBARAO,V AND SCARPELLI,DG; CARCINOGENIC EFFECT OF N-NITROSOBIS (2-OXOPROPYL)AMINE IN NEWBORN RATS; CARCINOGENESIS 6(9):1395-1397, 1985]"
2696,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 55 MG/L DRINKING WATER 5 D/WK FOR 50 WK (TOTAL DOSE 275 MG) (STUDY DURATION: LIFESPAN),"LIVER: CARCINOMA, ANGIOSARCOMA; LUNG: TUMOR",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; CARCINOGENESIS IN F-344 RATS BY NITROSOBIS(2-OXOPROPYL)AMINE AND RELATED COMPOUNDS ADMINISTERED IN DRINKING WATER; J. CANCER RES. CLIN. ONCOL. 107(3):178-182, 1984]"
2697,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 6.15; 12.3; 24.6 MG/KG BW IN 0.9% SALINE 1/WK FOR DURATION OF STUDY (STUDY DURATION: 96 WK),KIDNEY (RENAL PELVIS): TUMOR; URINARY BLADDER: TUMOR,POSITIVE,"[SOLE,M, CARDESA,A, DOMINGO,J AND MOHR,U; THE CARCINOGENIC EFFECT OF 2,2-DIOXOPROPYLNITROSAMINE ON THE RENAL PELVIC EPITHELIUM OF SPRAGUE-DAWLEY RATS, AFTER CHRONIC SUBCUTANEOUS INJECTIONS; J. CANCER RES. CLIN. ONCOL. 118(3):222-227, 1992]"
2698,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 5.35; 10.7; 21.4 MG/KG BW IN 0.9% SALINE 1/WK FOR DURATION OF STUDY (STUDY DURATION: 96 WK),KIDNEY (RENAL PELVIS): TUMOR; URETER: TUMOR; URINARY BLADDER: TUMOR,POSITIVE,"[SOLE,M, CARDESA,A, DOMINGO,J AND MOHR,U; THE CARCINOGENIC EFFECT OF 2,2-DIOXOPROPYLNITROSAMINE ON THE RENAL PELVIC EPITHELIUM OF SPRAGUE-DAWLEY RATS, AFTER CHRONIC SUBCUTANEOUS INJECTIONS; J. CANCER RES. CLIN. ONCOL. 118(3):222-227, 1992]"
2699,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,MOUSE,ICR/MALE,SUBCUTANEOUS,"0; 10; 20; 40 MG/KG BW IN 1% GELATIN SOLUTION ON DAYS 1, 8, 15 AND 22 OF AGE (STUDY DURATION: 1 YR)",NASAL CAVITY: TUMOR; LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[FUJII,K, HAYAKAWA,T AND KIKUCHI,M; TUMOR INDUCTION IN MICE ADMINISTERED NEONATALLY WITH BIS(2-OXOPROPYL)NITROSAMINE; TOHOKU J. EXP. MED. 174(4): 361-368, 1994]"
2700,363898410,43371,CC(=O)CN(CC(=O)C)N=O,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,"0; 10; 20; 40 MG/KG BW IN 1% GELATIN SOLUTION ON DAYS 1, 8, 15 AND 22 OF AGE (STUDY DURATION: 1 YR)",NASAL CAVITY: TUMOR; LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[FUJII,K, HAYAKAWA,T AND KIKUCHI,M; TUMOR INDUCTION IN MICE ADMINISTERED NEONATALLY WITH BIS(2-OXOPROPYL)NITROSAMINE; TOHOKU J. EXP. MED. 174(4): 361-368, 1994]"
2701,363898411,54990,C(CC(F)(F)F)CN(CCCC(F)(F)F)N=O,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",GAVAGE,1.5; 7.5% IN VEGETABLE OIL 2/WK FOR UP TO 32 WK,"LIVER: HEPATOCELLULAR CARCINOMA; LUNG: SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA",POSITIVE,"[MATHEWS-ROTH,MM, LAUSEN,N, DROUIN,G, RICHTER,A AND KRINSKY,NI; EFFECTS OF CAROTENOID ADMINISTRATION ON BLADDER CANCER PREVENTION; ONCOLOGY 48:177-179, 1991]"
2702,363898412,149617,CCCCN(C(=O)CCC)N=O,Active,,,,RAT,"F344/MALE,FEMALE",SUBCUTANEOUS,38 UMOL/KG IN OLIVE OIL 1/WK FOR 10 WK,INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; LUNG: ADENOMA,POSITIVE,"[TAKAHASHI,M, KUROKAWA,Y, MAEKAWA,A, KOKUBO,T, FURUKAWA,F, MOCHIZUKI,M, ANJO,T AND OKADA,M; COMPARATIVE CARCINOGENICITIES OF MODEL COMPOUNDS OF METABOLICALLY ACTIVATED N,N-DIBUTYLNITROSAMINE IN RATS; GANN 73:687-694, 1982]"
2703,363898413,14223,C(CO)N(CCO)N=O,Active,,,,HAMSTER,,SUBCUTANEOUS,,LIVER; INJECTION SITE; NASAL CAVITY; TRACHEA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 77 Y78]"
2704,363898413,14223,C(CO)N(CCO)N=O,Active,,,,RAT,,ORAL,,KIDNEY; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 77 Y78]"
2705,363898413,14223,C(CO)N(CCO)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 250; 500; 1000 MG/KG IN SALINE 1/WK FOR DURATION OF STUDY (STUDY DURATION: 41-59 WK),NASAL CAVITY: ADENOCARCINOMA; TRACHEA: PAPILLARY POLYP; LARYNX: PAPILLARY POLYP,POSITIVE,"[POUR,P AND WALLCAVE,L; THE CARCINOGENICITY OF N-NITROSODIETHANOLAMINE, AN ENVIRONMENTAL POLLUTANT, IN SYRIAN HAMSTERS; CANCER LETT. 14:23-27, 1981]"
2706,363898413,14223,C(CO)N(CCO)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 250; 500; 1000 MG/KG IN SALINE 1/WK FOR DURATION OF STUDY (STUDY DURATION: 45-54 WK),NASAL CAVITY: ADENOCARCINOMA; TRACHEA: PAPILLARY POLYP; LARYNX: PAPILLARY POLYP,POSITIVE,"[POUR,P AND WALLCAVE,L; THE CARCINOGENICITY OF N-NITROSODIETHANOLAMINE, AN ENVIRONMENTAL POLLUTANT, IN SYRIAN HAMSTERS; CANCER LETT. 14:23-27, 1981]"
2707,363898413,14223,C(CO)N(CCO)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,ORAL,"0; 0.2 UMOL/ML IN DRINKING WATER FOR 10 WK (TOTAL DOSE: 0, 55 UMOL) FOLLOWED BY TAP WATER FOR 20 WK (STUDY DURATION: 30 WK)",LUNG: TUMORS,POSITIVE,"[HECHT,SS, LIJINSKY,W, KOVATCH,RM, CHUNG,FL AND SAAVEDRA,JE; COMPARATIVE TUMORIGENICITY OF N-NITROSO-2-HYDROXYMORPHOLINE, N-NITROSODIETHANOLAMINE AND N-NITROSOMORPHOLINE IN A/J MICE AND F344 RATS; CARCINOGENESIS 10(8): 1475-1477, 1989]"
2708,363898413,14223,C(CO)N(CCO)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 150 MG/L IN DRINKING WATER 5 D/WK FOR 50 WK (TOTAL DOSE: 0; 5.6 MMOL) (STUDY DURATION: 124 WK),LIVER: HEPATOCELLULAR TUMOR,POSITIVE,"[HECHT,SS, LIJINSKY,W, KOVATCH,RM, CHUNG,FL AND SAAVEDRA,JE; COMPARATIVE TUMORIGENICITY OF N-NITROSO-2-HYDROXYMORPHOLINE, N-NITROSODIETHANOLAMINE AND N-NITROSOMORPHOLINE IN A/J MICE AND F344 RATS; CARCINOGENESIS 10(8): 1475-1477, 1989]"
2709,363898414,6838,C1=CC=C(C=C1)N(C2=CC=CC=C2)N=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 2315; 5741 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-164 Y79]"
2710,363898414,6838,C1=CC=C(C=C1)N(C2=CC=CC=C2)N=O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 10000; 20000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-164 Y79]"
2711,363898414,6838,C1=CC=C(C=C1)N(C2=CC=CC=C2)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 1000; 4000 PPM IN DIET,URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-164 Y79]"
2712,363898414,6838,C1=CC=C(C=C1)N(C2=CC=CC=C2)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 1000; 4000 PPM IN DIET,INTEGUMENTARY SYSTEM: FIBROMA; URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-164 Y79]"
2713,363898415,9074,C1=CC=C(C=C1)NC2=CC=C(C=C2)N=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 4254; 9000 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-190 Y79]"
2714,363898415,9074,C1=CC=C(C=C1)NC2=CC=C(C=C2)N=O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 4254; 9000 PPM IN DIET, TWA",LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-190 Y79]"
2715,363898415,9074,C1=CC=C(C=C1)NC2=CC=C(C=C2)N=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-190 Y79]"
2716,363898415,9074,C1=CC=C(C=C1)NC2=CC=C(C=C2)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 2500; 5000 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-190 Y79]"
2717,363898416,135565414,C1=CC(=CC=C1C(=O)N([C@@H](CCC(=O)O)C(=O)O)N=O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 217 Y78]"
2718,363898417,30360,C1CCCN(CCC1)N=O,Active,,,,HAMSTER,EUROPEAN/FEMALE,SUBCUTANEOUS,11; 22; 44 MG/KG 3/WK,"LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA; NASAL CAVITY: SQUAMOUS CELL CARCINOMA",POSITIVE,"[REZNIK,G, MOHR,U AND LIJINSKY,W; CARCINOGENICITY OF SUBCUTANEOUSLY INJECTED N-NITROSOHEPTAMETHYLENEIMINE IN EUROPEAN HAMSTERS; J. NATL. CANCER INST. 61:239-243, 1978]"
2719,363898417,30360,C1CCCN(CCC1)N=O,Active,,,,HAMSTER,EUROPEAN/MALE,SUBCUTANEOUS,16.5; 33; 66 MG/KG 3/WK,"LUNG: ADENOCARCINOMA, SQUAMOUS CELL CARCINOMA; NASAL CAVITY: SQUAMOUS CELL CARCINOMA",POSITIVE,"[REZNIK,G, MOHR,U AND LIJINSKY,W; CARCINOGENICITY OF SUBCUTANEOUSLY INJECTED N-NITROSOHEPTAMETHYLENEIMINE IN EUROPEAN HAMSTERS; J. NATL. CANCER INST. 61:239-243, 1978]"
2720,363898417,30360,C1CCCN(CCC1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,ORAL,50; 200 MG/L 5 NIGHT/WK FOR 50 WK IN DRINKING WATER,NASAL CAVITY; LARYNX; PHARYNX; TRACHEA; ESOPHAGUS; FORESTOMACH,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 586]"
2721,363898417,30360,C1CCCN(CCC1)N=O,Active,,,,RAT,"MRC/MALE,FEMALE",ORAL,100 MG/L 5 D/WK FOR 30 WK IN DRINKING WATER,ESOPHAGUS; TRACHEA: SQUAMOUS CELL PAPILLOMA; LUNG: SQUAMOUS CELL CARCINOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 773]"
2722,363898417,30360,C1CCCN(CCC1)N=O,Inactive,,,,RAT,LISTER/FEMALE,SUBCUTANEOUS,0; 1 MG 1/WK FOR 10 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HARRISON,PTC AND HEATH,JC; APPARENT SYNERGY BETWEEN CHRYSOTILE ASBESTOS AND N-NITROSOHEPTAMETHYLENEIMINE IN THE INDUCTION OF PULMONARY TUMOURS IN RATS; CARCINOGENESIS 9(12):2165-2171, 1988]"
2723,363898418,13613,C1CCCN(CC1)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0.9 MM (112 MG/L) IN DRINKING WATER 5/WK FOR 28 WK,"LIVER: CARCINOMA, SARCOMA; ESOPHAGUS: PAPILLOMA, CARCINOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; CARCINOGENIC EFFECT OF NITROSOPYRROLIDINE, NITROSOPIPERIDINE AND NITROSOHEXAMETHYLENEIMINE IN FISCHER RATS; CANCER LETT. 12:99-103, 1981]"
2724,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZO/MALE,ORAL,0; 1.56 NMOL IN DRINKING WATER 5D/WK FOR 8 WK FOR A TOTAL DOSE OF 0; 6.1 MILLIMOLAR/KG (STUDY DURATION: 600-800 D),OROPHARYNX: PAPILLOMA OR CARCINOMA; ESOPHAGUS: PAPILLOMA OR CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR TUMOR; RETICULOENDOTHELIAL SYSTEM: LYMPHOMA,POSITIVE,"[GOODALL,CM AND LIJINSKY,W; STRAIN AND SEX DIFFERENCES IN N-NITROSOHEXAMETHYLENEIMINE CARCINOGENESIS IN NZB, NZC, NZO, AND NZY MICE; J. NATL. CANCER INST. 73(5):1215-1218, 1984]"
2725,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZO/FEMALE,ORAL,0; 1.56 NMOL IN DRINKING WATER 5D/WK FOR 8 WK FOR A TOTAL DOSE OF 0: 6.3 MILLIMOLAR/KG (STUDY DURATION: 600-800 D),OROPHARYNX: PAPILLOMA OR CARCINOMA; ESOPHAGUS: PAPILLOMA OR CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR TUMOR; LUNG: ALVEOLAR ADENOMA OR ADENOCARCINOMA; RETICULOENDOTHELIAL SYSTEM: LYMPHOMA,POSITIVE,"[GOODALL,CM AND LIJINSKY,W; STRAIN AND SEX DIFFERENCES IN N-NITROSOHEXAMETHYLENEIMINE CARCINOGENESIS IN NZB, NZC, NZO, AND NZY MICE; J. NATL. CANCER INST. 73(5):1215-1218, 1984]"
2726,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZC/MALE,ORAL,0; 1.56 NMOL IN DRINKING WATER 5D/WK FOR 8 WK FOR A TOTAL DOSE OF 0; 6 MILLIMOLAR/KG (STUDY DURATION: 600-800 D),OROPHARYNX: PAPILLOMA OR CARCINOMA; ESOPHAGUS: PAPILLOMA OR CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR TUMOR; LUNG: ALVEOLAR ADENOMA OR ADENOCARCINOMA,POSITIVE,"[GOODALL,CM AND LIJINSKY,W; STRAIN AND SEX DIFFERENCES IN N-NITROSOHEXAMETHYLENEIMINE CARCINOGENESIS IN NZB, NZC, NZO, AND NZY MICE; J. NATL. CANCER INST. 73(5):1215-1218, 1984]"
2727,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZC/FEMALE,ORAL,0; 1.56 NMOL IN DRINKING WATER 5D/WK FOR 8 WK FOR A TOTAL DOSE OF 0; 5.3 MILLIMOLAR/KG (STUDY DURATION: 600-800 D),ESOPHAGUS: CARCINOMA OR PAPILLOMA; STOMACH: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR TUMOR,POSITIVE,"[GOODALL,CM AND LIJINSKY,W; STRAIN AND SEX DIFFERENCES IN N-NITROSOHEXAMETHYLENEIMINE CARCINOGENESIS IN NZB, NZC, NZO, AND NZY MICE; J. NATL. CANCER INST. 73(5):1215-1218, 1984]"
2728,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZB/MALE,ORAL,0; 1.56 NMOL IN DRINKING WATER 5D/WK FOR 8 WK FOR A TOTAL DOSE OF 0; 5.4 MILLIMOLAR/KG (STUDY DURATION: 400-600 D),ESOPHAGUS: PAPILLOMA OR CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR TUMOR; LUNG: ALVEOLAR ADENOMA OR ADENOCARCINOMA,POSITIVE,"[GOODALL,CM AND LIJINSKY,W; STRAIN AND SEX DIFFERENCES IN N-NITROSOHEXAMETHYLENEIMINE CARCINOGENESIS IN NZB, NZC, NZO, AND NZY MICE; J. NATL. CANCER INST. 73(5):1215-1218, 1984]"
2729,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZB/FEMALE,ORAL,0; 1.56 NMOL IN DRINKING WATER 5D/WK FOR 8 WK FOR A TOTAL DOSE OF 0; 6.4 MILLIMOLAR/KG (STUDY DURATION: 400-600 D),OROPHARYNX: PAPILLOMA OR CARCINOMA; ESOPHAGUS: PAPILLOMA OR CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR TUMOR; LUNG: ALVEOLAR ADENOMA OR ADENOCARCINOMA; RETICULOENDOTHELIAL SYSTEM: LYMPHOMA,POSITIVE,"[GOODALL,CM AND LIJINSKY,W; STRAIN AND SEX DIFFERENCES IN N-NITROSOHEXAMETHYLENEIMINE CARCINOGENESIS IN NZB, NZC, NZO, AND NZY MICE; J. NATL. CANCER INST. 73(5):1215-1218, 1984]"
2730,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZY/MALE,ORAL,0; 1.56 NMOL IN DRINKING WATER 5D/WK FOR 8 WK FOR A TOTAL DOSE OF 0; 5.4 MILLIMOLAR/KG (STUDY DURATION: 600-800 D),ESOPHAGUS: PAPILLOMA OR CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR TUMOR,POSITIVE,"[GOODALL,CM AND LIJINSKY,W; STRAIN AND SEX DIFFERENCES IN N-NITROSOHEXAMETHYLENEIMINE CARCINOGENESIS IN NZB, NZC, NZO, AND NZY MICE; J. NATL. CANCER INST. 73(5):1215-1218, 1984]"
2731,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZY/FEMALE,ORAL,0; 1.56 NMOL IN DRINKING WATER 5D/WK FOR 8 WK FOR A TOTAL DOSE OF 0; 5.2 MILLIMOLAR/KG (STUDY DURATION: 600-800 D),ESOPHAGUS: PAPILLOMA OR CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[GOODALL,CM AND LIJINSKY,W; STRAIN AND SEX DIFFERENCES IN N-NITROSOHEXAMETHYLENEIMINE CARCINOGENESIS IN NZB, NZC, NZO, AND NZY MICE; J. NATL. CANCER INST. 73(5):1215-1218, 1984]"
2732,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZO/MALE,ORAL,0; 200 MG/L IN DRINKING WATER 5 D/WK FOR 8 WK (TOTAL DOSE: 52 MG) (STUDY DURATION: 2 YR),"OROPHARYNX: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA; RETICULOENDOTHELIAL SYSTEM: LYMPHOMA; LUNG: ALVEOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[GOODALL,CM AND LIJINSKY,W; CARCINOGENESIS BY N-NITROSOHEXAMETHYLENEIMINE IN NZO INBRED MICE; TOXICOLOGY 33(3-4):251-259, 1984]"
2733,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZO/FEMALE,ORAL,0; 200 MG/L IN DRINKING WATER 5 D/WK FOR 8 WK (TOTAL DOSE: 52 MG) (STUDY DURATION: 2 YR),"OROPHARYNX: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA; RETICULOENDOTHELIAL SYSTEM: LYMPHOMA; LUNG: ALVEOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[GOODALL,CM AND LIJINSKY,W; CARCINOGENESIS BY N-NITROSOHEXAMETHYLENEIMINE IN NZO INBRED MICE; TOXICOLOGY 33(3-4):251-259, 1984]"
2734,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZO/FEMALE,ORAL,0; 50 MG/L IN DRINKING WATER 5 D/WK FOR 32 WK (TOTAL DOSE: 52 MG) (STUDY DURATION: 1.5 YR),"OROPHARYNX: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA",POSITIVE,"[GOODALL,CM AND LIJINSKY,W; CARCINOGENESIS BY N-NITROSOHEXAMETHYLENEIMINE IN NZO INBRED MICE; TOXICOLOGY 33(3-4):251-259, 1984]"
2735,363898418,13613,C1CCCN(CC1)N=O,Active,,,,MOUSE,NZO/MALE,ORAL,0; 50 MG/L IN DRINKING WATER 5 D/WK FOR 52 WK (TOTAL DOSE: 52 MG) (STUDY DURATION: 1.5 YR),"OROPHARYNX: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL ADENOMA; LUNG: ALVEOLAR ADENOMA, ADENOCARCINOMA",POSITIVE,"[GOODALL,CM AND LIJINSKY,W; CARCINOGENESIS BY N-NITROSOHEXAMETHYLENEIMINE IN NZO INBRED MICE; TOXICOLOGY 33(3-4):251-259, 1984]"
2736,363898419,128951,CCC(=O)CNCN=O,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,4; 8; 16 MG/KG 1/WK FOR LIFE,"NASAL CAVITY: ADENOCARCINOMA, PAPILLOMA, MUCOEPIDERMOID TUMOR; LARYNX OR PHARYNX: PAPILLARY POLYP, PAPILLOMA; ORAL CAVITY (LIPS): TRICHOEPITHELIOMA, PAPILLOMA, SQUAMOUS CELL CARCINOMA; INTESTINES (COLON OR RECTUM): CARCINOMA, ADENOCARCINOMA; LIVER: CHOLANGIOMA, CHOLANGIOCARCINOMA; URETER: PAPILLOMA; VAGINA: PAPILLOMA",POSITIVE,"[POUR,PM, NAGEL,D AND LAWSON,T; CARCINOGENICITY OF NITROSOMETHYL(2-OXOBUTYL)AMINE AND N-NITROSOMETHYL(3-OXOBUTYL)AMINE IN SYRIAN HAMSTERS WITH SPECIAL REFERENCE TO THE PANCREAS; CANCER RES. 43:4885-4890, 1983]"
2737,363898419,128951,CCC(=O)CNCN=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,2.3; 4.6; 9.2 MG/KG 1/WK FOR LIFE,"NASAL CAVITY: ADENOCARCINOMA, PAPILLOMA, MUCOEPIDERMOID TUMOR; LARYNX OR PHARYNX: PAPILLARY POLYP, PAPILLOMA; ORAL CAVITY (LIPS): TRICHOEPITHELIOMA, PAPILLOMA, SQUAMOUS CELL CARCINOMA; LIVER: CHOLANGIOMA, CHOLANGIOCARCINOMA; KIDNEY: TUBULAR ADENOMA, TUBULAR ADENOCARCINOMA, HEMANGIOMA; URETER: PAPILLOMA",POSITIVE,"[POUR,PM, NAGEL,D AND LAWSON,T; CARCINOGENICITY OF NITROSOMETHYL(2-OXOBUTYL)AMINE AND N-NITROSOMETHYL(3-OXOBUTYL)AMINE IN SYRIAN HAMSTERS WITH SPECIAL REFERENCE TO THE PANCREAS; CANCER RES. 43:4885-4890, 1983]"
2738,363898420,128952,CC(=O)CCNCN=O,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,20.25; 40.5; 81MG/KG 1/WK FOR LIFE,"NASAL CAVITY: ADENOCARCINOMA; ORAL CAVITY (CHEEK POUCH): SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; COLON: CARCINOMA",POSITIVE,"[POUR,PM, NAGEL,D AND LAWSON,T; CARCINOGENICITY OF NITROSOMETHYL(2-OXOBUTYL)AMINE AND N-NITROSOMETHYL(3-OXOBUTYL)AMINE IN SYRIAN HAMSTERS WITH SPECIAL REFERENCE TO THE PANCREAS; CANCER RES. 43:4885-4890, 1983]"
2739,363898420,128952,CC(=O)CCNCN=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,17.63; 35.25; 70.5 MG/KG 1/WKFOR LIFE,"NASAL CAVITY: ADENOCARCINOMA; ORAL CAVITY (CHEEK POUCH): SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; COLON: CARCINOMA",POSITIVE,"[POUR,PM, NAGEL,D AND LAWSON,T; CARCINOGENICITY OF NITROSOMETHYL(2-OXOBUTYL)AMINE AND N-NITROSOMETHYL(3-OXOBUTYL)AMINE IN SYRIAN HAMSTERS WITH SPECIAL REFERENCE TO THE PANCREAS; CANCER RES. 43:4885-4890, 1983]"
2740,363898421,12001,CCOC(=O)N(C)N=O,Active,,,,MOUSE,,ORAL,,ESOPHAGUS; FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 211 Y74]"
2741,363898421,12001,CCOC(=O)N(C)N=O,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 211 Y74]"
2742,363898421,12001,CCOC(=O)N(C)N=O,Active,,,,RAT,,ORAL,,FORESTOMACH,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 211 Y74]"
2743,363898421,12001,CCOC(=O)N(C)N=O,Active,,,,RAT,,INTRAVENOUS,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 211 Y74]"
2744,363898421,12001,CCOC(=O)N(C)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 0.35; 1.4 MG/ANIMAL IN CORN OIL 1/WK FOR 20 WK (STUDY DURATION: 114 WK),"FORESTOMACH: CARCINOMA; ESOPHAGUS: CARCINOMA, PAPILLOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; STUDIES OF A DEUTERIUM ISOTOPE EFFECT IN CARCINOGENESIS BY N-NITROSO-N-ALKYLURETHANES IN RATS; CANCER LETT. 16:273-279, 1982]"
2745,363898421,12001,CCOC(=O)N(C)N=O,Active,,,,RAT,F344/MALE,ORAL,20 PPM IN DRINKING WATER FOR 48 WK (STUDY DURATION: 104 WK),FORESTOMACH: PAPILLOMA; SQUAMOUS CELL CARCINOMA,POSITIVE,"[KANEKO,M MORIMURA,K NISHIKAWA,T WANIBUCHI,H TAKADA,N OSUGI,H KINOSHITA,H AND FUKUSHIMA,S; DIFFERENT GENETIC ALTERATIONS IN RAT FORESTOMACH TUMORS INDUCED BY GENOTOXIC AND ON-GENOTOXIC CARCINOGENS; CARCINOGENESIS 23(10):1729-1735, 2002]"
2746,363898422,20678,CN(C=C)N=O,Active,,,,RAT,,ORAL,,ESOPHAGUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 257 Y78]"
2747,363898422,20678,CN(C=C)N=O,Active,,,,RAT,,INHALATION,,NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 257 Y78]"
2748,363898423,6046,C1COCCN1N=O,Active,,,,FISH,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 263 Y78]"
2749,363898423,6046,C1COCCN1N=O,Active,,,,HAMSTER,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 263 Y78]"
2750,363898423,6046,C1COCCN1N=O,Active,,,,HAMSTER,,SUBCUTANEOUS,,TRACHEA; NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 263 Y78]"
2751,363898423,6046,C1COCCN1N=O,Active,,,,MOUSE,,ORAL,,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 263 Y78]"
2752,363898423,6046,C1COCCN1N=O,Active,,,,RAT,F344/FEMALE,ORAL,40 MG/L IN DRINKING WATER FOR 50 WK,"LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; ESOPHAGUS: PAPILLOMA, CARCINOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARATIVE CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOTETRAHYDROOXAZINE IN RATS; CARCINOGENESIS 3:911-915, 1982]"
2753,363898423,6046,C1COCCN1N=O,Active,,,,RAT,F344/MALE,ORAL,16; 40 MG/L IN DRINKING WATER FOR 50 WK,"LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA; ESOPHAGUS: PAPILLOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARATIVE CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOTETRAHYDROOXAZINE IN RATS; CARCINOGENESIS 3:911-915, 1982]"
2754,363898423,6046,C1COCCN1N=O,Active,,,,RAT,,ORAL,,KIDNEY; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 263 Y78]"
2755,363898423,6046,C1COCCN1N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,ORAL,"0; 0.2 UMOL/ML IN DRINKING WATER FOR 10 WK (TOTAL DOSE: 0, 54 UMOL) FOLLOWED BY TAP WATER FOR 20 WK (STUDY DURATION: 30 WK)",LUNG: TUMORS,POSITIVE,"[HECHT,SS, LIJINSKY,W, KOVATCH,RM, CHUNG,FL AND SAAVEDRA,JE; COMPARATIVE TUMORIGENICITY OF N-NITROSO-2-HYDROXYMORPHOLINE, N-NITROSODIETHANOLAMINE AND N-NITROSOMORPHOLINE IN A/J MICE AND F344 RATS; CARCINOGENESIS 10(8): 1475-1477, 1989]"
2756,363898423,6046,C1COCCN1N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 26.5 MG/L IN DRINKING WATER 5 D/WK FOR 50 WK (TOTAL DOSE: 0; 1.1 MMOL) (STUDY DURATION: 124 WK),"LIVER: HEPATOCELLULAR TUMOR, HEMANGIOSARCOMA",POSITIVE,"[HECHT,SS, LIJINSKY,W, KOVATCH,RM, CHUNG,FL AND SAAVEDRA,JE; COMPARATIVE TUMORIGENICITY OF N-NITROSO-2-HYDROXYMORPHOLINE, N-NITROSODIETHANOLAMINE AND N-NITROSOMORPHOLINE IN A/J MICE AND F344 RATS; CARCINOGENESIS 10(8): 1475-1477, 1989]"
2757,363898423,6046,C1COCCN1N=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 7.7 MG/M3 4 HR/D 4-5 D/WK FOR 6 WK FOR A DAILY DOSE OF 0; 0.5 MG/KG (STUDY DURATION: 124 WK),"LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE",POSITIVE,"[KLEIN,RG, SPIEGELHALDER,B AND PREUSSMANN,R;INHALATION CARCINOGENESIS OF N-NITROSOMORPHOLINE (NMOR) IN RATS AND HAMSTERS; EXP. PATHOL. 40(4):189-195, 1990]"
2758,363898423,6046,C1COCCN1N=O,Active,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 14.4 MG/M3 4 HR/D 4-5 D/WK FOR 5 WK FOR A DAILY DOSE OF 0; 1.8 MG/KG (STUDY DURATION: 91 WK),LIVER: HEPATOCELLULAR CARCINOMA OR HEMANGIOENDOTHELIOMA OR CARCINOMA; FORESTOMACH: PAPILLOMA; TRACHEA: PAPILLOMA,POSITIVE,"[KLEIN,RG, SPIEGELHALDER,B AND PREUSSMANN,R;INHALATION CARCINOGENESIS OF N-NITROSOMORPHOLINE (NMOR) IN RATS AND HAMSTERS; EXP. PATHOL. 40(4):189-195, 1990]"
2759,363898423,6046,C1COCCN1N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 5 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 30 WK (TOTAL DOSE 2.6 MMOL) (STUDY DURATION: LIFESPAN),LIVER: TUMOR; NASAL MUCOSA: TUMOR; ESOPHAGUS: TUMOR,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
2760,363898423,6046,C1COCCN1N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 10 MG/WK FOR A TOTAL DOSE OF 1.9 MMOL (STUDY DYRATION: 30 WK),ESOPHAGUS: TUMOR; LIVER: TUMOR; THYROID: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
2761,363898423,6046,C1COCCN1N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAGASTRIC,0; 26 MG/ML IN 0.2 ML STERILIZED WATER 1/WK FOR 26 WK (TOTAL DOSE 135 MG) (STUDY DURATION: LIFESPAN),NASAL CAVITY: CARCINOMA; TRACHEA: ADENOMA,POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOAZETIDINE GIVEN BY GAVAGE TO SYRIAN GOLDEN HAMSTERS; CARCINOGENESIS 5(7):875-878, 1984]"
2762,363898423,6046,C1COCCN1N=O,Active,,,,RAT,WS/MALE,ORAL,0; 0.02% IN DRINKING WATER FOR 8 WK (STUDY DURATION: 20 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[MURAI,T MORI,S HOSONO,M IWAKURA,Y TAKASHIMA,A OOHARA,T MAKINO,S TAKEDA,R AND FUKUSHIMA,S; INDUCTION OF HEPATOCELLULAR CARCINOMA WITH HIGHT METASTATIC POTENTIAL IN WS/SHI RATS: DISCOVERY OF AN INBRED STRAIN HIGHLY SUSCEPTIBLE TO THE LIVER CARCINOGEN N-NITROSOMORPHOLINE; ONCOL. RES. 12(3):121-126, 2000]"
2763,363898423,6046,C1COCCN1N=O,Active,,,,RAT,F344/MALE,ORAL,0; 0.02% IN DRINKING WATER FOR 8 WK (STUDY DURATION: 20 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[MURAI,T MORI,S HOSONO,M IWAKURA,Y TAKASHIMA,A OOHARA,T MAKINO,S TAKEDA,R AND FUKUSHIMA,S; INDUCTION OF HEPATOCELLULAR CARCINOMA WITH HIGHT METASTATIC POTENTIAL IN WS/SHI RATS: DISCOVERY OF AN INBRED STRAIN HIGHLY SUSCEPTIBLE TO THE LIVER CARCINOGEN N-NITROSOMORPHOLINE; ONCOL. RES. 12(3):121-126, 2000]"
2764,363898423,6046,C1COCCN1N=O,Inactive,,,,RAT,SD/G/MALE,ORAL,0; 0.02% IN DRINKING WATER FOR 8 WK (STUDY DURATION: 20 WK),,NEGATIVE,"[MURAI,T MORI,S HOSONO,M IWAKURA,Y TAKASHIMA,A OOHARA,T MAKINO,S TAKEDA,R AND FUKUSHIMA,S; INDUCTION OF HEPATOCELLULAR CARCINOMA WITH HIGHT METASTATIC POTENTIAL IN WS/SHI RATS: DISCOVERY OF AN INBRED STRAIN HIGHLY SUSCEPTIBLE TO THE LIVER CARCINOGEN N-NITROSOMORPHOLINE; ONCOL. RES. 12(3):121-126, 2000]"
2765,363898424,23098,C1=CC=C2C=C(C=CC2=C1)N=O,Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,"100 UG IN GELATIN ON FIRST, THIRD AND FIFTH D OF LIFE",LIVER: HEPATOMA,POSITIVE,"[RADOMSKI,JL, BRILL,E, DEICHMANN,WB AND GLASS,EM; CARCINOGENICITY TESTING OF N-HYDROXY AND OTHER OXIDATION AND DECOMPOSITION PRODUCTS OF 1- AND 2-NAPHTHYLAMINE; CANCER RES. 31:1461-1467, 1971]"
2766,363898425,,,Inactive,,,,RAT,"F344/N/MALE, FEMALE (50/GROUP)",ORAL,0; 2500; 10000; 40000 PPM IN DRINKING WATER FOR UP TO 105 WK; NO MALE SURVIVORS AT 40000 PPM AFTER WK 98 (STUDY DURATION: 104 OR 105 WK),NONE,NEGATIVE,"[KIRKLAND,D, AARDEMA,M, MUELLER,L AND HAYASHI,M; EVALUATION OF THE ABILITY OF A BATTERY OF THREE IN VITRO GENOTOXICITY TESTS TO DISCRIMINATE RODENT CARCINOGENS AND NON-CARCINOGENS; MUTAT. RES. 608(1):29-42, 2006]"
2767,363898425,,,Inactive,,,,MOUSE,"B6C3F1/MALE, FEMALE (50/GROUP)",ORAL,0; 10000; 20000; 40000 PPM IN DRINKING WATER FOR UP TO 105 WK;  (STUDY DURATION: 104 OR 105 WK),NONE,NEGATIVE,"[KIRKLAND,D, AARDEMA,M, MUELLER,L AND HAYASHI,M; EVALUATION OF THE ABILITY OF A BATTERY OF THREE IN VITRO GENOTOXICITY TESTS TO DISCRIMINATE RODENT CARCINOGENS AND NON-CARCINOGENS; MUTAT. RES. 608(1):29-42, 2006]"
2768,363898426,114957,C1COCN1N=O,Active,,,,RAT,F344/FEMALE,ORAL,35 MG/L IN DRINKING WATER FOR 50 WK,"LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARATIVE CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOTETRAHYDROOXAZINE IN RATS; CARCINOGENESIS 3:911-915, 1982]"
2769,363898426,114957,C1COCN1N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAGASTRIC,0; 23 MG/ML IN 0.2 ML STERILIZED WATER 1/WK FOR 35 WK (TOTAL DOSE 161 MG) (STUDY DURATION: LIFESPAN),"LIVER: HEPATOCELLULAR CARCINOMA, ADENOMA, HEMANGIOSARCOMA, CHOLANGIOCARCINOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOAZETIDINE GIVEN BY GAVAGE TO SYRIAN GOLDEN HAMSTERS; CARCINOGENESIS 5(7):875-878, 1984]"
2770,363898427,7526,C1CCN(CC1)N=O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",ORAL,0.006; 0.025; 0.05% IN DRINKING WATER FOR LIFE,"RESPIRATORY TRACT (LARYNX, PHARYNX, TRACHEA): PAPILLOMA, EPIDERMOID CARCINOMA, PAPILLARY POLYP; FORESTOMACH: PAPILLOMA, EPIDERMOID CARCINOMA; LIVER: ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[KETKAR,MB, FUHST,R, PREUSSMANN,R AND MOHR,U; THE CARCINOGENIC EFFECT OF NITROSOPIPERIDINE ADMINISTERED IN THE DRINKING WATER OF SYRIAN GOLDEN HAMSTERS; CANCER LETT. 21:219-224, 1983]"
2771,363898427,7526,C1CCN(CC1)N=O,Active,,,,HAMSTER,,SUBCUTANEOUS,,TRACHEA; NASAL CAVITY; ESOPHAGUS; FORESTOMACH; LUNG; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 287 Y78]"
2772,363898427,7526,C1CCN(CC1)N=O,Active,,,,MONKEY,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 287 Y78]"
2773,363898427,7526,C1CCN(CC1)N=O,Active,,,,MOUSE,,ORAL,,FORESTOMACH; LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 287 Y78]"
2774,363898427,7526,C1CCN(CC1)N=O,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 287 Y78]"
2775,363898427,7526,C1CCN(CC1)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0.9 MILLIMOLAR SOLUTION (100 MG/L) IN DRINKING WATER 5/WK FOR 28 WK,"ESOPHAGUS: PAPILLOMA, CARCINOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; CARCINOGENIC EFFECT OF NITROSOPYRROLIDINE, NITROSOPIPERIDINE AND NITROSOHEXAMETHYLENEIMINE IN FISCHER RATS; CANCER LETT. 12:99-103, 1981]"
2776,363898427,7526,C1CCN(CC1)N=O,Active,,,,RAT,,SUBCUTANEOUS,,ESOPHAGUS; NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 287 Y78]"
2777,363898427,7526,C1CCN(CC1)N=O,Active,,,,RAT,,INTRAVENOUS,,ESOPHAGUS; PHARYNX,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 287 Y78]"
2778,363898427,7526,C1CCN(CC1)N=O,Active,,,,RAT,,ORAL,,ESOPHAGUS; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 287 Y78]"
2779,363898428,13591,C1CCN(C1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,ORAL,0.00042; 0.0016; 0.0033% IN DRINKING WATER FOR LIFE,"LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA",POSITIVE,"[KETKAR,MB, SCHNEIDER,P, PREUSSMANN,R, PLASS,C AND MOHR,U; CARCINOGENIC EFFECT OF LOW DOSES OF NITROSOPYRROLIDINE ADMINISTERED IN DRINKING WATER TO SYRIAN GOLDEN HAMSTERS; J. CANCER RES. CLIN. ONCOL. 104:75-79, 1982]"
2780,363898428,13591,C1CCN(C1)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0.9 MM (90 MG/L) IN DRINKING WATER 5/WK FOR 50 WK,LIVER: CARCINOMA,POSITIVE,"[LIJINSKY,W AND REUBER,MD; CARCINOGENIC EFFECT OF NITROSOPYRROLIDINE, NITROSOPIPERIDINE AND NITROSOHEXAMETHYLENEIMINE IN FISCHER RATS; CANCER LETT. 12:99-103, 1981]"
2781,363898428,13591,C1CCN(C1)N=O,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 313 Y78]"
2782,363898428,13591,C1CCN(C1)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 20; 100 UMOL TOTAL DOSE ADMINISTERED IN SUBDOSES 3/WK FOR 7 WK (STUDY DURATION: 37 WK),LUNG: TUMOR,POSITIVE,"[HOFFMANN,D, DJORDJEVIC,MV, RIVENSON,A, ZANG,E, DESAI,D AND AMIN,S; A STUDY OF TOBACCO CARCINOGENESIS. LI. RELATIVE POTENCIES OF TOBACCO-SPECIFIC N-NITROSAMINES AS INDUCERS OF LUNG TUMORS IN A/J MICE; CANCER LETT. 71(1-3): 25-30, 1993]"
2783,363898428,13591,C1CCN(C1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAPERITONEAL,0; 0.5 MMOL TWICE ON ALTERNATE DAYS (TOTAL DOSE 1 MMOL) (STUDY DURATION: 19 MO),LARYNX/TRACHEA: TUMOR; NASAL CAVITY: TUMOR; LUNG: TUMOR,POSITIVE,"[MCCOY,GD, DEMARCO,GJ, HAXHIU,L, ROGGERO,E, SUDILOVSKY,EC AND SUDILOVSKY,O; EFFECT OF ACUTE ADMINISTRATION OF N-NITROSOPYRROLIDINE TO MALE SYRIAN GOLDEN HAMSTERS; CANCER LETT. 79(2):161-165, 1994]"
2784,363898428,13591,C1CCN(C1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAPERITONEAL,0; 0.33 MMOL FOR 3 DOSES ON ALTERNATE DAYS (TOTAL DOSE 1 MMOL) (STUDY DURATION: 19 MO),LARYNX/TRACHEA: TUMOR; LUNG: TUMOR,POSITIVE,"[MCCOY,GD, DEMARCO,GJ, HAXHIU,L, ROGGERO,E, SUDILOVSKY,EC AND SUDILOVSKY,O; EFFECT OF ACUTE ADMINISTRATION OF N-NITROSOPYRROLIDINE TO MALE SYRIAN GOLDEN HAMSTERS; CANCER LETT. 79(2):161-165, 1994]"
2785,363898428,13591,C1CCN(C1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAPERITONEAL,0; 0.5 MMOL ONCE (STUDY DURATION: 19 MO),LARYNX/TRACHEA: TUMOR,POSITIVE,"[MCCOY,GD, DEMARCO,GJ, HAXHIU,L, ROGGERO,E, SUDILOVSKY,EC AND SUDILOVSKY,O; EFFECT OF ACUTE ADMINISTRATION OF N-NITROSOPYRROLIDINE TO MALE SYRIAN GOLDEN HAMSTERS; CANCER LETT. 79(2):161-165, 1994]"
2786,363898428,13591,C1CCN(C1)N=O,Inactive,,,,HAMSTER,SYRIAN/MALE,INTRAPERITONEAL,0; 0.25 MMOL ONCE (STUDY DURATION: 19 MO),,NEGATIVE,"[MCCOY,GD, DEMARCO,GJ, HAXHIU,L, ROGGERO,E, SUDILOVSKY,EC AND SUDILOVSKY,O; EFFECT OF ACUTE ADMINISTRATION OF N-NITROSOPYRROLIDINE TO MALE SYRIAN GOLDEN HAMSTERS; CANCER LETT. 79(2):161-165, 1994]"
2787,363898429,25811,CN(CC(=O)O)N=O,Active,,,,MOUSE,,ORAL,,NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 327 Y78]"
2788,363898429,25811,CN(CC(=O)O)N=O,Active,,,,MOUSE,,INTRAPERITONEAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 327 Y78]"
2789,363898429,25811,CN(CC(=O)O)N=O,Active,,,,RAT,,ORAL,,ESOPHAGUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 327 Y78]"
2790,363898430,11909,CC1=CC=CC=C1N=O,Active,,,,RAT,F344/MALE,ORAL,3.38 G/KG- DIET FOR 72 WK (TOTAL DOSE 0.21 MOL/RAT),"LIVER: HEPATOMA; URINARY BLADDER: PAPILLOMA; PERITONEAL CAVITY: MESOTHELIOMA, SARCOMA; SPLEEN: FIBROMA; INTEGUMENTARY SYSTEM (SKIN): FIBROMA",POSITIVE,"[HECHT,SS, EL-BAYOUMY,K, RIVENSON,A AND FIALA,E; COMPARATIVE CARCINOGENICITY OF O-TOLUIDINE HYDROCHLORIDE AND O-NITROSOTOLUENE IN F-344 RATS; CANCER LETT. 16:103-108, 1982]"
2791,363898431,54806,CCN(CC(F)(F)F)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,7.5; 15; 30; 60 MG/KG IN VEGETABLE OIL 2/WK,ESOPHAGUS: CARCINOMA; NASAL CAVITY: SQUAMOUS CELL CARCINOMA,POSITIVE,"[PREUSSMANN,R, HABS,M, HABS,H AND STUMMEYER,D; FLUORO-SUBSTITUTED N-NITROSAMINES. 6. CARCINOGENICITY OF N-NITROSO-(2,2,2-TRIFLUOROETHYL)-ETHYLAMINE IN RATS; CARCINOGENESIS 4:755-757, 1983]"
2792,363898433,7444,CC1=C(C=C(C=C1)[N+](=O)[O-])N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.12; 0.23% OF DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA; BLOOD VESSELS: HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-107 Y78]"
2793,363898433,7444,CC1=C(C=C(C=C1)[N+](=O)[O-])N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.12; 0.23% OF DIET, TWA",LIVER: HEPATOCELLULAR CARCINOMA; BLOOD VESSELS: HEMANGIOSARCOMA OR HEMANGIOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-107 Y78]"
2794,363898433,7444,CC1=C(C=C(C=C1)[N+](=O)[O-])N,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 0.005; 0.01% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-107 Y78]"
2795,363898433,7444,CC1=C(C=C(C=C1)[N+](=O)[O-])N,Inactive,,,,RAT,F344/MALE,ORAL,"0; 0.005; 0.01% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-107 Y78]"
2796,363898434,6230,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,Active,,,,MOUSE,,ORAL,,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 179 Y74]"
2797,363898435,5832,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,Active,,,,MOUSE,,ORAL,,LIVER; PITUITARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 179 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 441 Y79]"
2798,363898435,5832,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 179 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 441 Y79]"
2799,363898436,6231,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3CCC(=O)C4,Active,,,,MOUSE,,ORAL,,MAMMARY GLAND; PITUITARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 191 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 461 Y79]"
2800,363898436,6231,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3CCC(=O)C4,Active,,,,RAT,,ORAL,,LIVER; MAMMARY GLAND; PITUITARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 191 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 461 Y79]"
2801,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Active,,,,MOUSE,"SWISS/MALE,FEMALE",ORAL,0.05; 0.15% IN DIET FOR 9 MO,LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 58 Y77]"
2802,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Active,,,,MOUSE,SWISS-WEBSTER/MALE,ORAL,0; 2500; 5000 PPM IN FEED FOR 57 WK (STUDY DURATION: 57 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-443 Y93]"
2803,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Active,,,,MOUSE,SWISS-WEBSTER/FEMALE,ORAL,0; 2500; 5000 PPM IN FEED FOR 57 WK (STUDY DURATION: 57 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-443 Y93]"
2804,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 125; 2500; 5000 PPM IN FEED FOR 104-105 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOBLASTOMA, HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-443 Y93]"
2805,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 125; 2500; 5000 PPM IN FEED FOR 104-105 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOBLASTOMA, HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; THYROID: FOLLICULAR CELL ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-443 Y93]"
2806,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Unspecified,,,,RAT,F344/MALE,ORAL,0; 625; 2500; 5000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),KIDNEY: RENAL TUBULE ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-468  Y98]"
2807,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 625; 2500; 5000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-468  Y98]"
2808,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 10000 PPM IN DIET FOR 26 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-468  Y98]"
2809,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 10,000 PPM FOR 26 WK (STUDY DURATION: 105 WK)",,NEGATIVE,"[BUCHER,JR, HASEMAN,JK, HERBERT,RA, HEJTMANCIK,M AND RYAN,MJ; TOXICITY AND CARCINOGENICITY STUDIES OF OXAZEPAM IN THE FISCHER F344 RAT; TOXICOL. SCI. 42:1-12, 1998]"
2810,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Active,,,,RAT,F344/MALE,ORAL,"0; 10,000 PPM FOR 26 WK (STUDY DURATION: 105 WK)",KIDNEY: RENAL TUBULE ADENOMA,POSITIVE,"[BUCHER,JR, HASEMAN,JK, HERBERT,RA, HEJTMANCIK,M AND RYAN,MJ; TOXICITY AND CARCINOGENICITY STUDIES OF OXAZEPAM IN THE FISCHER F344 RAT; TOXICOL. SCI. 42:1-12, 1998]"
2811,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 625; 2500; 5000 PPM FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[BUCHER,JR, HASEMAN,JK, HERBERT,RA, HEJTMANCIK,M AND RYAN,MJ; TOXICITY AND CARCINOGENICITY STUDIES OF OXAZEPAM IN THE FISCHER F344 RAT; TOXICOL. SCI. 42:1-12, 1998]"
2812,363898438,4616,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,Unspecified,,,,RAT,F344/MALE,ORAL,0; 10000; PPM IN DIET FOR 26 WK (STUDY DURATION: 105 WK),KIDNEY: RENAL TUBULE ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-468  Y98]"
2813,363898439,33770,CS(=O)CC(=O)C1=CC=CC=N1,Active,,,,RAT,WISTAR/MALE,ORAL,0; 40; 240; 600 MG/KG IN DIET FOR 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DE LA IGLESIA,FA AND MCGUIRE,EJ; RODENT CARCINOGENESIS BIOASSAY WITH OXISURAN, A SELECTIVE IMMUNOSUPPRESIVE AGENT; TOXICOLOGY 28:17-28, 1983]"
2814,363898439,33770,CS(=O)CC(=O)C1=CC=CC=N1,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 40; 240; 600 MG/KG IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[DE LA IGLESIA,FA AND MCGUIRE,EJ; RODENT CARCINOGENESIS BIOASSAY WITH OXISURAN, A SELECTIVE IMMUNOSUPPRESIVE AGENT; TOXICOLOGY 28:17-28, 1983]"
2815,363898439,33770,CS(=O)CC(=O)C1=CC=CC=N1,Inactive,,,,MOUSE,CF1/MALE,ORAL,0; 40; 240; 600 MG/KG IN DIET FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[DE LA IGLESIA,FA AND MCGUIRE,EJ; RODENT CARCINOGENESIS BIOASSAY WITH OXISURAN, A SELECTIVE IMMUNOSUPPRESIVE AGENT; TOXICOLOGY 28:17-28, 1983]"
2816,363898439,33770,CS(=O)CC(=O)C1=CC=CC=N1,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 40; 240; 600 MG/KG IN DIET FOR 80 WK (STUDY DURATION: 80 WK),LUNG: ALVEOLOGENIC ADENOCARCINOMA,POSITIVE,"[DE LA IGLESIA,FA AND MCGUIRE,EJ; RODENT CARCINOGENESIS BIOASSAY WITH OXISURAN, A SELECTIVE IMMUNOSUPPRESIVE AGENT; TOXICOLOGY 28:17-28, 1983]"
2817,363898440,91630,CCCN(CC(=O)C)N=O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",SUBCUTANEOUS,50-200 MG/KG 1/WK FOR LIFE,RESPIRATORY TRACT; LIVER; KIDNEY,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 192]"
2818,363898440,91630,CCCN(CC(=O)C)N=O,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,0.05; 0.1; 0.2% OF 603 MG/KG IN SALINE 1/WK FOR LIFE,"LIVER: HEMANGIOENDOTHELIAL SARCOMA; NASAL CAVITY: PAPILLOMA, ADENOCARCINOMA; NASAL TURBINATES: PAPILLOMA, ADENOCARCINOMA; LUNG: INTRABRONCHIAL PAPILLOMA, ALVEOGENIC ADENOMA, ADENOCARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Y78 123]"
2819,363898440,91630,CCCN(CC(=O)C)N=O,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",SUBCUTANEOUS,0.12; 0.42; 0.85 MG/KG 1/WK FOR LIFE,"LIVER: HEPATOMA, CARCINOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 72-73 192]"
2820,363898441,7579,C1=CC(=CC=C1N)OC2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 150; 300; 800 PPM IN DIET,"LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA; HARDERIAN GLAND: ADENOMA, NOS",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-205 Y80]"
2821,363898441,7579,C1=CC(=CC=C1N)OC2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 150; 300; 800 PPM IN DIET,"LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA, NOS",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-205 Y80]"
2822,363898441,7579,C1=CC(=CC=C1N)OC2=CC=C(C=C2)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 200; 400; 500 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-205 Y80]"
2823,363898441,7579,C1=CC(=CC=C1N)OC2=CC=C(C=C2)N,Active,,,,RAT,F344/MALE,ORAL,0; 200; 400; 500 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-205 Y80]"
2824,363898441,7579,C1=CC(=CC=C1N)OC2=CC=C(C=C2)N,Active,,,,RAT,,SUBCUTANEOUS,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V16 301 Y78]"
2825,363898441,7579,C1=CC(=CC=C1N)OC2=CC=C(C=C2)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.02; 0.04; 0.05% IN DIET FOR 103 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR CARCINOMA; THYROID GLAND: FOLLICULAR ADENOMA; LIVER: NEOPLASTIC NODULE; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
2826,363898441,7579,C1=CC(=CC=C1N)OC2=CC=C(C=C2)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.02; 0.04; 0.05% IN DIET FOR 103 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR CARCINOMA; THYROID GLAND: FOLLICULAR ADENOMA; LIVER: NEOPLASTIC NODULE; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
2827,363898441,7579,C1=CC(=CC=C1N)OC2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.015; 0.03; 0.08% IN DIET FOR 103 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR HYPERPLASIA; HARDERIAN GLAND: ADENOMA,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
2828,363898441,7579,C1=CC(=CC=C1N)OC2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.015; 0.03; 0.08% IN DIET FOR 103 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR ADENOMA; LIVER: ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA; HARDERIAN GLAND: ADENOMA,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
2829,363898442,5281034,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,Active,,,,HUMAN,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 131 Y77]"
2830,363898442,5281034,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,Unspecified,,,,RAT,F344/N/MALE,GAVAGE,0; 3; 30; 150 MG/KG IN 0.5% METHYLCELLULOSE FOR 104 WK (STUDY DURATION: 104 WK),"SKIN (SUBCUTANEOUS TISSUE): FIBROMA, FIBROMA OR FIBROSARCOMA; ADRENAL GLAND: BENIGN PHEOCHROMOCYTOMA, BENIGN PHEOCHROMOCYTOMA OR MALIGNANT PHEOCHROMOCYTOMA; KIDNEY (RENAL TUBULE): ADENOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-485 Y99]"
2831,363898442,5281034,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,Active,,,,RAT,F344/N/FEMALE,GAVAGE,0; 3; 30; 100 MG/KG IN 0.5% METHYLCELLULOSE FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; SKIN: SQUAMOUS CELL PAPILLOMA, KERATOACANTHOMA, BASAL CELL ADENOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-485 Y99]"
2832,363898443,991,CCOP(=S)(OCC)OC1=CC=C(C=C1)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 80; 160 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-70 Y79]"
2833,363898443,991,CCOP(=S)(OCC)OC1=CC=C(C=C1)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 80; 160 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-70 Y79]"
2834,363898443,991,CCOP(=S)(OCC)OC1=CC=C(C=C1)[N+](=O)[O-],Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 32; 63 PPM IN DIET FOR 80 WK (STUDY DURATION: 112-113 WK),ADRENAL GLAND: CORTICAL ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-70 Y79]"
2835,363898443,991,CCOP(=S)(OCC)OC1=CC=C(C=C1)[N+](=O)[O-],Unspecified,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 23; 45 PPM IN DIET FOR 80 WK (STUDY DURATION: 112-113 WK),ADRENAL GLAND: CORTICAL ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-70 Y79]"
2836,363898444,6419,C(C(Cl)(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,250; 500 MG/KG IN CORN OIL FOR 41-103 WK (STUDY DURATION: 41-103 WK),"LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-232 Y83][MENNEAR,JH, HASEMAN,JK, SULLIVAN,DJ, BERNAL,E AND HILDEBRANDT,PK; STUDIES ON THE CARCINOGENICITY OF PENTACHLOROETHANE IN RATS AND MICE; FUND. APPL. TOXICOL. 2:82-87, 1982, ]"
2837,363898444,6419,C(C(Cl)(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,250; 500 MG/KG IN CORN OIL FOR 41-103 WK (STUDY DURATION: 41-103 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-232 Y83][MENNEAR,JH, HASEMAN,JK, SULLIVAN,DJ, BERNAL,E AND HILDEBRANDT,PK; STUDIES ON THE CARCINOGENICITY OF PENTACHLOROETHANE IN RATS AND MICE; FUND. APPL. TOXICOL. 2:82-87, 1982, ]"
2838,363898444,6419,C(C(Cl)(Cl)Cl)(Cl)Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 75; 150 MG/KG IN CORN OIL FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-232 Y83]"
2839,363898444,6419,C(C(Cl)(Cl)Cl)(Cl)Cl,Unspecified,,,,RAT,F344/MALE,GAVAGE,0; 75; 150 MG/KG IN CORN OIL FOR 103 WK (STUDY DURATION: 103 WK),KIDNEY: TUBULAR CELL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-232 Y83]"
2840,363898445,6720,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 4093; 8187 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-61 Y78]"
2841,363898445,6720,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 2606; 5213 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-61 Y78]"
2842,363898445,6720,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[N+](=O)[O-],Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[INNES,JRM, ULLAND,B, VALERIO,MG, PETRUCELLI,L, FISHBEIN,L, HART,ER, PALLOTTA,AJ, BATES,RR, FALK,HL, GART,JJ, KLEIN,M, MITCHELL,I AND PETERS,J; BIOASSAY OF PESTICIDES AND INDUSTRIAL CHEMICALS FOR TUMORIGENICITY IN MICE: A PRELIMINARY NOTE;J. NATL. CANCER INST. 42:1101-1114, 1969]"
2843,363898445,6720,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[N+](=O)[O-],Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[SEARLE,CE; TUMOR INITIATORY ACTIVITY OF SOME CHLOROMONONITROBENZENES AND OTHER COMPOUNDS; CANCER RES. 26:12-17, 1966]"
2844,363898445,6720,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[N+](=O)[O-],Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 7875; 14635 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-61 Y78]"
2845,363898445,6720,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[N+](=O)[O-],Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 5417; 10064 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-61 Y78]"
2846,363898445,6720,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION = 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-325 Y87]"
2847,363898446,4754,CCOC1=CC=C(C=C1)NC(=O)C,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0.6; 1.25% IN DIET,"KIDNEY: RENAL CELL ADENOMA, RENAL CELL CARCINOMA",POSITIVE,"[NAKANISHI,K, KURATA,Y, OSHIMA,M, FUKUSHIMA,S AND ITO,N; CARCINOGENICITY OF PHENACETIN: LONG-TERM FEEDING STUDY IN B6C3F1 MICE; INT. J. CANCER 29:439-444, 1982]"
2848,363898446,4754,CCOC1=CC=C(C=C1)NC(=O)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,1.25; 2.5% IN DIET FOR 18 MO,NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 135 Y80]"
2849,363898446,4754,CCOC1=CC=C(C=C1)NC(=O)C,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,1.25; 2.5% IN DIET FOR 18 MO,NASAL CAVITY; URINARY TRACT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 135 Y80]"
2850,363898446,4754,CCOC1=CC=C(C=C1)NC(=O)C,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.535% IN DIET FOR 117 WK,KIDNEY; NASAL CAVITY: SQUAMOUS CELL CARCINOMA,POSITIVE,"[JOHANSSON,SL; CARCINOGENICITY OF ANALGESICS: LONG-TERM TREATMENT OF SPRAGUE-DAWLEY RATS WITH PHENACETIN, PHENAZONE, CAFFEINE AND PARACETAMOL (ACETAMIDOPHEN); INT. J. CANCER 27:521-529, 1981]"
2851,363898446,4754,CCOC1=CC=C(C=C1)NC(=O)C,Active,,,,RAT,SD/CSHI/MALE,ORAL,0; 2% IN DIET FOR 85 WK (STUDY DURATION: 85 WK),"RENAL PELVIS: CARCINOMA, PAPILLOMA; URINARY BLADDER: PAPILLOMA",POSITIVE,"[MURAI,T, MORI,S, MACHINO,S, HOSONO,M, TAKEUCHI,M, OHARA,T, MAKINO,S AND TAKEDA,R;INDUCTION OF RENAL PELVIC CARCINOMA BY PHENACETIN IN HYDRONEPHROSIS- BEARING RATS OF THE SC/CSHI STRAIN; CANCER RES. 53(18):4218-4223, 1993]"
2852,363898447,8691,C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 600; 1200 PPM IN DIET,LIVER: HEPATOCELLULAR ADENOMA OR HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-99 Y78]"
2853,363898447,8691,C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N.Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 600; 1200 PPM IN DIET,,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-99 Y78]"
2854,363898447,8691,C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 3700; 7500 PPM IN DIET,COLON: ADENOCARCINOMA (NOS),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-99 Y78]"
2855,363898447,8691,C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 3700; 7500 PPM IN DIET,"INTESTINES (COLON OR RECTUM): ADENOCARCINOMA (NOS), ADENOCARCINOMA (NOS) OR ADENOMA (NOS)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-99 Y78]"
2856,363898448,61100,C1=CC=C(C=C1)CCNN.OS(=O)(=O)O,Active,,,,MOUSE,SWISS/MALE,ORAL,0; 0.15% IN WATER,"BLOOD VESSELS: ANGIOMA, ANGIOSARCOMA; LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 175 Y80]"
2857,363898448,61100,C1=CC=C(C=C1)CCNN.OS(=O)(=O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.02% IN DIET FOR 68-87 WK (STUDY DURATION: 87 WK),,NEGATIVE,"[GERSHBEIN,LL AND RAO,KC; ACTION OF HYDRAZINE DRUGS IN TUMOR-FREE AND 1,2- DIMETHYLHYDRAZINE-TREATED MALE RATS; ONCOL. RES. 4(3):121-127, 1992]"
2858,363898449,266461,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CC5=CC=C(C=C5)N(CCCl)CCCl)C)C,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 7; 15; 30 MG/KG 3/WK FOR 52-88 WK (STUDY DURATION: 62-104 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA; MYOCARDIUM: SARCOMA; OVARIES: TUBULAR ADENOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-60 Y78]"
2859,363898449,266461,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CC5=CC=C(C=C5)N(CCCl)CCCl)C)C,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 7; 15; 30 MG/KG 3/WK FOR 52-102 WK (STUDY DURATION: 74-104 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA; MYOCARDIUM: SARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-60 Y78]"
2860,363898449,266461,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CC5=CC=C(C=C5)N(CCCl)CCCl)C)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 5; 10 MG/KG 3/WK FOR 52 WKS (STUDY DURATION: 84-85 WK),"MAMMARY GLAND: ADENOCARCINOMA, FIBROADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-60 Y78]"
2861,363898449,266461,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CC5=CC=C(C=C5)N(CCCl)CCCl)C)C,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 5; 10 MG/KG 3/WK FOR 52 WK (STUDY DURATION: 84-85 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-60 Y78]"
2862,363898450,8249,C1=CC=C(C=C1)CCN=C(N)N=C(N)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1200; 2500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-7 Y77]"
2863,363898450,8249,C1=CC=C(C=C1)CCN=C(N)N=C(N)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1200; 2500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-7 Y77]"
2864,363898450,8249,C1=CC=C(C=C1)CCN=C(N)N=C(N)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 15000; 30000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-7 Y77]"
2865,363898450,8249,C1=CC=C(C=C1)CCN=C(N)N=C(N)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 15000; 30000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-7 Y77]"
2866,363898451,170220,C1=CC=C(C=C1)N(C(=O)N)N,Active,,,,MOUSE,,ORAL,,LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 177 Y76]"
2867,363898452,4763,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,Active,,,,MOUSE,6HF1/MALE,ORAL,0; 0.05% IN BASAL DIET FOR 104 WK (STUDY DURATION: 104 WK),LIVER: TUMOR,POSITIVE,"[NITTA,Y, KAMIYA,K, TANIMOTO,M, KAGIMOTO,O, NIWA,O AND YOKORO,K; EFFECTS OF ADMINISTRATION OF NATURAL VITAMIN E ON SPONTANEOUS HEPATOCARCINOGENESIS AND N- NITROSODIETHYLAMINE INITIATED TUMORS IN MICE; J. TOXICOL. PATHOL. 4(1):55-61, 1991]"
2868,363898453,23674889,CCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 159 Y77]"
2869,363898453,23674889,CCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 159 Y77]"
2870,363898453,23674889,CCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],Inactive,,,,MOUSE,C3H/HE/MALE,ORAL,0; 85 MG/KG/D IN DIET FOR DURATION OF STUDY (STUDY DURATION: 91 WK),,NEGATIVE,"[EVANS,JG, COLLINS,MA, LAKE,BG AND BUTLER,WH; THE HISTOLOGY AND DEVELOPMENT OF HEPATIC NODULES AND CARCINOMA IN C3H/HE AND C57BL/6 MICE FOLLOWING CHRONIC PHENOBARBITONE ADMINISTRATION; TOXICOL. PATHOL. 20(4):585-594, 1992]"
2871,363898453,23674889,CCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],Inactive,,,,MOUSE,C57BL/MALE,ORAL,0; 85 MG/KG/D IN DIET FOR DURATION OF STUDY (STUDY DURATION: 100 WK),,NEGATIVE,"[EVANS,JG, COLLINS,MA, LAKE,BG AND BUTLER,WH; THE HISTOLOGY AND DEVELOPMENT OF HEPATIC NODULES AND CARCINOMA IN C3H/HE AND C57BL/6 MICE FOLLOWING CHRONIC PHENOBARBITONE ADMINISTRATION; TOXICOL. PATHOL. 20(4):585-594, 1992]"
2872,363898453,23674889,CCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 8; 30; 125; 500 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HAGIWARA,A MIYATA,E TAMANO,S SANO,M MASUDA,C FUNAE,Y ITO,N FUKUSHIMA,S AND SHIRAI,T; NON-CARCINOGENICITY, BUT DOSE-RELATED INCREASE IN PRENEOPLASTIC HEPATOCELLULAR LESIONS, IN A TWO-YEAR FEEDING STUDY OF PHENOBARBITAL SODIUM IN MALE F344 RATS; FOOD CHEM. TOXICOL. 37(8):869-879, 1999]"
2873,363898454,996,C1=CC=C(C=C1)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-203 Y80]"
2874,363898454,996,C1=CC=C(C=C1)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-203 Y80]"
2875,363898454,996,C1=CC=C(C=C1)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-203 Y80]"
2876,363898454,996,C1=CC=C(C=C1)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-203 Y80]"
2877,363898455,4768,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,40; 100; 200 MG/KG IN TRICAPRYLIN,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 223 Y75][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 185 Y80]"
2878,363898456,6141,CC(COC1=CC=CC=C1)[NH+](CCCl)CC2=CC=CC=C2.[Cl-],Active,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,0; 12.5; 25 MG/KG 3/WK FOR 50 OR 52 WK,PERITONEAL CAVITY: SARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-72 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 185 Y80]"
2879,363898456,6141,CC(COC1=CC=CC=C1)[NH+](CCCl)CC2=CC=CC=C2.[Cl-],Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 12.5; 25 MG/KG 3/WK FOR 50 OR 52 WK,PERITONEAL CAVITY: SARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-72 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 185 Y80]"
2880,363898456,6141,CC(COC1=CC=CC=C1)[NH+](CCCl)CC2=CC=CC=C2.[Cl-],Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 5; 10 MG/KG 3/WK FOR 52 WKS,PERITONEAL CAVITY: SARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-72 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 185 Y80]"
2881,363898456,6141,CC(COC1=CC=CC=C1)[NH+](CCCl)CC2=CC=CC=C2.[Cl-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 5; 10 MG/KG 3/WK FOR 52 WK,PERITONEAL CAVITY: SARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-72 Y78][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 185 Y80]"
2882,363898457,23654,CN(C)N=NC1=CC=CC=C1,Active,,,,RAT,STRAIN-BD,"ORAL, SUBCUTANEOUS",24.8; 43.4 MG/KG 1/WK (MEAN TOTAL DOSE 1.5 G/KG),BRAIN; NERVOUS SYSTEM,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 519]"
2883,363898457,23654,CN(C)N=NC1=CC=CC=C1,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",SUBCUTANEOUS,50 MG/KG 1/WK FOR LIFE,BRAIN; NERVOUS SYSTEM (CENTRAL),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 378]"
2884,363898457,23654,CN(C)N=NC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL ; TRANSPLACENTAL,0; 10; 30; 60 MG/KG ADMINISTERED TO PREGNANT RATS ON DAY 20 OF GESTATION (STUDY DURATION: 1 YR),,NEGATIVE,"[FRANK,AA, HEIDEL,JR, THOMPSON,DJ, CARLTON,WW AND BECKWITH,JB; RENAL TRANSPLACENTAL CARCINOGENICITY OF 3,3-DIMETHYL-1-PHENYLTRIAZENE IN RATS: RELATIONSHIP OF RENAL MESENCHYMAL TUMOR TO CONGENITAL MESOBLASTIC NEPHROMA AND INTRALOBAR NEPHROGENIC RESTS; TOXICOL. PATHOL. 20(3, PT. 1):313-322, 1992]"
2885,363898457,23654,CN(C)N=NC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL ; TRANSPLACENTAL,0; 10; 30; 60 MG/KG ADMINISTERED TO PREGNANT RATS ON DAY 20 OF GESTATION (STUDY DURATION: 1 YR),,NEGATIVE,"[FRANK,AA, HEIDEL,JR, THOMPSON,DJ, CARLTON,WW AND BECKWITH,JB; RENAL TRANSPLACENTAL CARCINOGENICITY OF 3,3-DIMETHYL-1-PHENYLTRIAZENE IN RATS: RELATIONSHIP OF RENAL MESENCHYMAL TUMOR TO CONGENITAL MESOBLASTIC NEPHROMA AND INTRALOBAR NEPHROGENIC RESTS; TOXICOL. PATHOL. 20(3, PT. 1):313-322, 1992]"
2886,363898457,23654,CN(C)N=NC1=CC=CC=C1,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL ; TRANSPLACENTAL,"0; 1 MG/KG ADMINISTERED TO PREGNANT RATS ON DAY 16, 18 AND 20 OF GESTATION (STUDY DURATION: 1 YR)",BRAIN: TUMOR; DENTITIOUS TISSUE: ODONTOMA,POSITIVE,"[FRANK,AA, HEIDEL,JR, THOMPSON,DJ, CARLTON,WW AND BECKWITH,JB; RENAL TRANSPLACENTAL CARCINOGENICITY OF 3,3-DIMETHYL-1-PHENYLTRIAZENE IN RATS: RELATIONSHIP OF RENAL MESENCHYMAL TUMOR TO CONGENITAL MESOBLASTIC NEPHROMA AND INTRALOBAR NEPHROGENIC RESTS; TOXICOL. PATHOL. 20(3, PT. 1):313-322, 1992]"
2887,363898457,23654,CN(C)N=NC1=CC=CC=C1,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL ; TRANSPLACENTAL,"0; 1 MG/KG ADMINISTERED TO PREGNANT RATS ON DAY 16, 18 AND 20 OF GESTATION (STUDY DURATION: 1 YR)",KIDNEY: RENAL MESENCHYMAL TUMOR,POSITIVE,"[FRANK,AA, HEIDEL,JR, THOMPSON,DJ, CARLTON,WW AND BECKWITH,JB; RENAL TRANSPLACENTAL CARCINOGENICITY OF 3,3-DIMETHYL-1-PHENYLTRIAZENE IN RATS: RELATIONSHIP OF RENAL MESENCHYMAL TUMOR TO CONGENITAL MESOBLASTIC NEPHROMA AND INTRALOBAR NEPHROGENIC RESTS; TOXICOL. PATHOL. 20(3, PT. 1):313-322, 1992]"
2888,363898458,7243,C1=CC=C(C(=C1)N)N,Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[WEISBURGER,EK, RUSSFIELD,AB, HOMBURGER,F, WEISBURGER,JH, BOGER,E, VAN DONGEN,CG AND CHU,KC; TESTING OF TWENTY-ONE ENVIRONMENTAL AROMATIC AMINES OR DERIVATIVES FOR LONG-TERM TOXICITY OR CARCINOGENICITY; J. ENVIRON. PATHOL. TOXICOL. 2:325-356, 1978]"
2889,363898458,7243,C1=CC=C(C(=C1)N)N,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[WEISBURGER,EK, RUSSFIELD,AB, HOMBURGER,F, WEISBURGER,JH, BOGER,E, VAN DONGEN,CG AND CHU,KC; TESTING OF TWENTY-ONE ENVIRONMENTAL AROMATIC AMINES OR DERIVATIVES FOR LONG-TERM TOXICITY OR CARCINOGENICITY; J. ENVIRON. PATHOL. TOXICOL. 2:325-356, 1978]"
2890,363898460,12205,C1=CC(=CC=C1N)N.Cl.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 625; 1250 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-174 Y79]"
2891,363898460,12205,C1=CC(=CC=C1N)N.Cl.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 625; 1250 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-174 Y79]"
2892,363898460,12205,C1=CC(=CC=C1N)N.Cl.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 625; 1250 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-174 Y79]"
2893,363898460,12205,C1=CC(=CC=C1N)N.Cl.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 625; 1250 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-174 Y79]"
2894,363898461,7516,C1=CC=C(C=C1)NN,Active,,,,MOUSE,,ORAL,,BLOOD VESSELS; LUNG,POSITIVE,"[TOTH,B; SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS; CANCER RES. 35:3693-3697, 1975][TOTH,B AND SHIMIZU,H; TUMORIGENIC EFFECTS OF CHRONIC ADMINISTRATION OF BENZYLHYDRAZINE DIHYDROCHLORIDE AND PHENYLHYDRAZINE HYDROCHLORIDE IN SWISS MICE; Z. KREBSFORSCH. 87:267-273, 1976]"
2895,363898462,4021,CC1=NN(C(=O)C1)C2=CC=CC=C2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 7500; 15000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-141 Y78]"
2896,363898462,4021,CC1=NN(C(=O)C1)C2=CC=CC=C2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 7500; 15000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-141 Y78]"
2897,363898462,4021,CC1=NN(C(=O)C1)C2=CC=CC=C2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-141 Y78]"
2898,363898462,4021,CC1=NN(C(=O)C1)C2=CC=CC=C2,Inactive,,,,RAT,F344/MALE,ORAL,0; 2500; 5000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-141 Y78]"
2899,363898463,7564,C1=CC=C(C=C1)NC2=CC=C(C=C2)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 3672; 8170 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-82 Y78]"
2900,363898463,7564,C1=CC=C(C=C1)NC2=CC=C(C=C2)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 2057; 4114 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-82 Y78]"
2901,363898463,7564,C1=CC=C(C=C1)NC2=CC=C(C=C2)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 600; 1200 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-82 Y78]"
2902,363898463,7564,C1=CC=C(C=C1)NC2=CC=C(C=C2)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 600; 1200 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-82 Y78]"
2903,363898464,676454,C1=CC=C(C=C1)NC(=S)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 150; 300 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-148 Y78]"
2904,363898464,676454,C1=CC=C(C=C1)NC(=S)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 150; 300 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-148 Y78]"
2905,363898464,676454,C1=CC=C(C=C1)NC(=S)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 60; 120 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-148 Y78]"
2906,363898464,676454,C1=CC=C(C=C1)NC(=S)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 60; 120 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-148 Y78]"
2907,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Active,,,,MOUSE,,"INTRAPERITONEAL, ORAL",,HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 201 Y77]"
2908,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,RAT,F344/DUCRJ/MALE,ORAL,0; 0.025; 0.05% IN BASAL DIET FOR 2 YR (STUDY DURATION: 112 WK),,NEGATIVE,"[JANG,JJ, TAKAHASHI,M, FURUKAWA,F, TOYODA,K, HASEGAWA,R, SATO,H AND HAYASHI,Y;LONG-TERM IN VIVO CARCINOGENICITY STUDY OF PHENYTOIN (5,5-DIPHENYLHYDANTOIN) IN F344 RATS; FOOD CHEM. TOXICOL. 25(9):697-702, 1987]"
2909,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,RAT,F344/DUCRJ/FEMALE,ORAL,0; 0.025; 0.05% IN BASAL DIET FOR 2 YR (STUDY DURATION: 112 WK),,NEGATIVE,"[JANG,JJ, TAKAHASHI,M, FURUKAWA,F, TOYODA,K, HASEGAWA,R, SATO,H AND HAYASHI,Y;LONG-TERM IN VIVO CARCINOGENICITY STUDY OF PHENYTOIN (5,5-DIPHENYLHYDANTOIN) IN F344 RATS; FOOD CHEM. TOXICOL. 25(9):697-702, 1987]"
2910,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Unspecified,,,,RAT,F344/MALE,ORAL,0; 800; 2400 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2911,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 800; 2400 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2912,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,RAT,F344/MALE,"IN UTERO, ORAL","0; 630 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 0, 800, OR 2400 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2913,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,RAT,F344/FEMALE,"IN UTERO, ORAL","0; 630 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 0, 800, OR 2400 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2914,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,RAT,F344/MALE,"IN UTERO, ORAL","0; 63 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 240 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2915,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,RAT,F344/MALE,"IN UTERO, ORAL","0; 210 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 800 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2916,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,RAT,F344/FEMALE,"IN UTERO, ORAL","0; 210 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 800 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2917,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,RAT,F344/FEMALE,"IN UTERO, ORAL","0; 63 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 240 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2918,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 100; 300 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2919,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 200; 600 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2920,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,MOUSE,B6C3F1/MALE,"IN UTERO, ORAL","0; 210 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 0, 100, OR 300 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2921,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Active,,,,MOUSE,B6C3F1/FEMALE,"IN UTERO, ORAL","0; 210 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 0, 200, OR 600 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2922,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,MOUSE,B6C3F1/MALE,"IN UTERO, ORAL","0; 70 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 100 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2923,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,MOUSE,B6C3F1/MALE,"IN UTERO, ORAL","0; 21 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 30 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2924,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,MOUSE,B6C3F1/FEMALE,"IN UTERO, ORAL","0; 21 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 60 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2925,363898465,1775,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,Inactive,,,,MOUSE,B6C3F1/FEMALE,"IN UTERO, ORAL","0; 70 PPM IN DIET FED TO MOTHERS 1 WK BEFORE BREEDING, THROUGH BREEDING, GESTATION AND LACTATION, THEN DIETS WITH 200 PPM WERE FED TO PUPS 8 WK OF AGE FOR 2 YR (STUDY DURATION: 116 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-404 Y93]"
2926,363898466,3032604,CCN(CC)C(=O)/C(=C(\C)/OP(=O)(OC)OC)/Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 80; 160 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-16 Y77]"
2927,363898466,3032604,CCN(CC)C(=O)/C(=C(\C)/OP(=O)(OC)OC)/Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 80; 160 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-16 Y77]"
2928,363898466,3032604,CCN(CC)C(=O)/C(=C(\C)/OP(=O)(OC)OC)/Cl,Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 80; 160 PPM IN DIET FOR 80 WK (STUDY DURATION: 111 WK),SPLEEN: HEMANGIOMA OR HEMANGIOSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-16 Y77]"
2929,363898466,3032604,CCN(CC)C(=O)/C(=C(\C)/OP(=O)(OC)OC)/Cl,Unspecified,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 80; 160 PPM IN DIET FOR 80 WK (STUDY DURATION: 111 WK),THYROID GLAND: C-CELL ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-16 Y77]"
2930,363898467,122361661,[C@@H]12[C@@H]3[C@@H](O3)C4[C@@H]1[C@@]5([C@@H](C6(C4C2[C@]5(C6(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.32; 0.64 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-17 Y77]"
2931,363898467,122361661,[C@@H]12[C@@H]3[C@@H](O3)C4[C@@H]1[C@@]5([C@@H](C6(C4C2[C@]5(C6(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.32; 0.64 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-17 Y77]"
2932,363898467,122361661,[C@@H]12[C@@H]3[C@@H](O3)C4[C@@H]1[C@@]5([C@@H](C6(C4C2[C@]5(C6(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 3.4; 7.5 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-17 Y77]"
2933,363898467,122361661,[C@@H]12[C@@H]3[C@@H](O3)C4[C@@H]1[C@@]5([C@@H](C6(C4C2[C@]5(C6(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 5; 10 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-17 Y77]"
2934,363898468,6956,C1=CC=C(C(=C1)C(=O)N)C(=O)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 6200; 12500; 25000 PPM IN DIET FOR 103-105 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-161 Y79][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
2935,363898468,6956,C1=CC=C(C(=C1)C(=O)N)C(=O)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 105 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-161 Y79][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
2936,363898468,6956,C1=CC=C(C(=C1)C(=O)N)C(=O)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 106 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-161 Y79][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
2937,363898468,6956,C1=CC=C(C(=C1)C(=O)N)C(=O)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 15000; 30000 PPM IN DIET FOR 106 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-161 Y79][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
2938,363898469,6811,C1=CC=C2C(=C1)C(=O)OC2=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 12019; 24038 PPM IN DIET, TWA (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-159 Y79][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
2939,363898469,6811,C1=CC=C2C(=C1)C(=O)OC2=O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 16346; 32692 PPM IN DIET, TWA (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-159 Y79][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
2940,363898469,6811,C1=CC=C2C(=C1)C(=O)OC2=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 7500; 15000 PPM IN DIET FOR 105 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-159 Y79][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
2941,363898469,6811,C1=CC=C2C(=C1)C(=O)OC2=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 7500; 15000 PPM IN DIET FOR 105 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-159 Y79][KLUWE,WM, MCCONNELL,EE, HUFF,JE, HASEMAN,JK, DOUGLAS,JF AND HARTWELL,WV; CARCINOGENICITY TESTING OF PHTHALATE ESTERS AND RELATED COMPOUNDS BY THE NATIONAL TOXICOLOGY PROGRAM AND THE NATIONAL CANCER INSTITUTE; ENVIRON. HEALTH PERSPECT. 45:129-133, 1982, ]"
2942,363898470,15965,C1(=C(C(=NC(=C1Cl)Cl)C(=O)O)Cl)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2531; 5062 PPM IN DIET FOR 80 WK (STUDY DURATION: 90 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-23 Y78]"
2943,363898470,15965,C1(=C(C(=NC(=C1Cl)Cl)C(=O)O)Cl)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2531; 5062 PPM IN DIET FOR 80 WK (STUDY DURATION: 90 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-23 Y78]"
2944,363898470,15965,C1(=C(C(=NC(=C1Cl)Cl)C(=O)O)Cl)N,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 7437; 14875 PPM IN DIET FOR 80 WK (STUDY DURATION: 113 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-23 Y78]"
2945,363898470,15965,C1(=C(C(=NC(=C1Cl)Cl)C(=O)O)Cl)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 20; 60; 200 MG/KG/D OF TECHNICAL GRADE PICLORAM IN FEED FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[STOTT,WT, JOHNSON,KA, LANDRY,TD, GORZINSKI,SJ AND CIESZLAK,FS; CHRONIC TOXICITY AND ONCOGENICITY OF PICLORAM IN FISCHER 344 RATS; J. TOXICOL. ENVIRON. HEALTH 30(2):91-104, 1990]"
2946,363898470,15965,C1(=C(C(=NC(=C1Cl)Cl)C(=O)O)Cl)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 20; 60; 200 MG/KG/D OF TECHNICAL GRADE PICLORAM IN FEED FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[STOTT,WT, JOHNSON,KA, LANDRY,TD, GORZINSKI,SJ AND CIESZLAK,FS; CHRONIC TOXICITY AND ONCOGENICITY OF PICLORAM IN FISCHER 344 RATS; J. TOXICOL. ENVIRON. HEALTH 30(2):91-104, 1990]"
2947,363898470,15965,C1(=C(C(=NC(=C1Cl)Cl)C(=O)O)Cl)N,Unspecified,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 7437; 14875 PPM IN DIET FOR 80 WK (STUDY DURATION: 113 WK),LIVER: NEOPLASTIC NODULE,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-23 Y78]"
2948,363898471,151324,CC(CN(C)C1=NN=C(C=C1)NN)O.Cl.Cl,Inactive,,,,MOUSE,"B6C3F1/MALE,FEMALE",ORAL,100; 200; 400 PPM IN DRINKING WATER FOR 80 WK,,NEGATIVE,"[DELLA PORTA,G AND DRAGANI,TA; CARCINOGENICITY STUDY IN MICE ON PILDRALAZINE, A HYDRALAZINELIKE ANTIHYPERTENSIVE COMPOUND; J. CANCER RES. CLIN. ONCOL. 106: 97-101, 1983]"
2949,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 1036; 2804 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-120 Y79]"
2950,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 1036; 2804 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-120 Y79]"
2951,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-120 Y79]"
2952,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Inactive,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-120 Y79]"
2953,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.5; 1% IN DIET FOR 2 YR (STUDY DURATION: 110 WK),,NEGATIVE,"[MAEKAWA,A, ONODERA,H, FURUTA,K, TANIGAWA,H, OGIU,T AND HAYASHI,Y; LACK OF EVIDENCE OF CARCINOGENICITY OF TECHNICAL GRADE PIPERONYL BUTOXIDE IN F344 RATS: SELECTIVE INDUCTION OF ILEOCAECAL ULCERS; FOOD CHEM. TOXICOL. 23(7):675-682, 1985]"
2954,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.5; 1% IN DIET FOR 2 YR (STUDY DURATION: 110 WK),,NEGATIVE,"[MAEKAWA,A, ONODERA,H, FURUTA,K, TANIGAWA,H, OGIU,T AND HAYASHI,Y; LACK OF EVIDENCE OF CARCINOGENICITY OF TECHNICAL GRADE PIPERONYL BUTOXIDE IN F344 RATS: SELECTIVE INDUCTION OF ILEOCAECAL ULCERS; FOOD CHEM. TOXICOL. 23(7):675-682, 1985]"
2955,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Active,,,,MOUSE,CD-1/MALE,ORAL,0; 0.6; 1.2% IN DIET FOR 12 MO (STUDY DURATION: 12 MO),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA (SMALL), HEMANGIOENDOTHELIAL SARCOMA (LARGE)",POSITIVE,"[TAKAHASHI,O, OISHI,S, FUJITANI,T, TANAKA,T AND YONEYAMA,M; PIPERONYL BUTOXIDE HEPATOCELLULAR CARCINOMA IN MALE CD-1 MICE;ARCH. TOXICOL. 68(7):467-469, 1994]"
2956,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Active,,,,RAT,F344/MALE,ORAL,0; 0.6; 1.2; 2.4% IN DIET FOR 95 WK (STUDY DURATION: 95 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[TAKAHASHI,O, OISHI,S, FUJITANI,T, TANAKA,T AND YONEYAMA,M; CHRONIC TOXICITY STUDIES OF PIPERONYL BUTOXIDE IN F344 RATS: INDUCTION OF HEPATOCELLULAR CARCINOMA; FUNDAM. APPL. TOXICOL. 22(2):293-303, 1994]"
2957,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.6; 1.2; 2.4% IN DIET FOR 96 WK (STUDY DURATION: 96 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[TAKAHASHI,O, OISHI,S, FUJITANI,T, TANAKA,T AND YONEYAMA,M; CHRONIC TOXICITY STUDIES OF PIPERONYL BUTOXIDE IN F344 RATS: INDUCTION OF HEPATOCELLULAR CARCINOMA; FUNDAM. APPL. TOXICOL. 22(2):293-303, 1994]"
2958,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Active,,,,MOUSE,CD-1/MALE,ORAL,0; 0.6; 1.2% IN DIET FOR 52 WK (STUDY DURATION: 52 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[TAKAHASHI,O, OISHI,S, FUJITANI,T, TANAKA,T AND YONEYAMA,M; CHRONIC TOXICITY STUDIES OF PIPERONYL BUTOXIDE IN CD-1 MICE: INDUCTION OF HEPATOCELLULAR CARCINOMA; TOXICOLOGY 124(2):95-103, 1997]"
2959,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Active,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.6; 1.2% IN DIET FOR 52 WK (STUDY DURATION: 52 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[TAKAHASHI,O, OISHI,S, FUJITANI,T, TANAKA,T AND YONEYAMA,M; CHRONIC TOXICITY STUDIES OF PIPERONYL BUTOXIDE IN CD-1 MICE: INDUCTION OF HEPATOCELLULAR CARCINOMA; TOXICOLOGY 124(2):95-103, 1997]"
2960,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 30; 100; 500 MG/KG/D IN DIET FOR 104-105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[BUTLER,WH, GABRIEL,KL, OSIMITZ,TG AND PREISS,FJ; ONCOGENICITY STUDIES OF PIPERONYL BUTOXIDE IN RATS AND MICE; HUM. EXP. TOXICOL. 17(6):323-330, 1998]"
2961,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 30; 100; 500 MG/KG/D IN DIET FOR 104-105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[BUTLER,WH, GABRIEL,KL, OSIMITZ,TG AND PREISS,FJ; ONCOGENICITY STUDIES OF PIPERONYL BUTOXIDE IN RATS AND MICE; HUM. EXP. TOXICOL. 17(6):323-330, 1998]"
2962,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Active,,,,MOUSE,CD-1/MALE,ORAL,0; 30; 100; 300 MG/KG/D IN DIET FOR 79 WK (STUDY DURATION: 79 WK),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[BUTLER,WH, GABRIEL,KL, OSIMITZ,TG AND PREISS,FJ; ONCOGENICITY STUDIES OF PIPERONYL BUTOXIDE IN RATS AND MICE; HUM. EXP. TOXICOL. 17(6):323-330, 1998]"
2963,363898472,5794,CCCCOCCOCCOCC1=CC2=C(C=C1CCC)OCO2,Active,,,,MOUSE,CD-1/FEMALE,ORAL,0; 30; 100; 300 MG/KG/D IN DIET FOR 79 WK (STUDY DURATION: 79 WK),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[BUTLER,WH, GABRIEL,KL, OSIMITZ,TG AND PREISS,FJ; ONCOGENICITY STUDIES OF PIPERONYL BUTOXIDE IN RATS AND MICE; HUM. EXP. TOXICOL. 17(6):323-330, 1998]"
2964,363898473,8442,CCCCCCCCS(=O)C(C)CC1=CC2=C(C=C1)OCO2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 295; 754 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-124 Y79]"
2965,363898473,8442,CCCCCCCCS(=O)C(C)CC1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 350; 700 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-124 Y79]"
2966,363898473,8442,CCCCCCCCS(=O)C(C)CC1=CC2=C(C=C1)OCO2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-124 Y79]"
2967,363898473,8442,CCCCCCCCS(=O)C(C)CC1=CC2=C(C=C1)OCO2,Inactive,,,,RAT,F344/MALE,ORAL,0; 1500; 3000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-124 Y79]"
2968,363898474,16059,CC1(COC1=O)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 75; 150 MG/KG,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-140 Y78]"
2969,363898474,16059,CC1(COC1=O)C,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 75; 150 MG/KG,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-140 Y78]"
2970,363898474,16059,CC1(COC1=O)C,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 150; 300 MG/KG,STOMACH: SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA; UTERUS: ENDOMETRIAL STROMAL POLYP,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-140 Y78]"
2971,363898474,16059,CC1(COC1=O)C,Active,,,,RAT,F344/MALE,GAVAGE,0; 150; 300 MG/KG,STOMACH: SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA; TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-140 Y78]"
2972,363898477,19095,CC1=CC(=C(C=C1C)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+],Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 199 Y75]"
2973,363898479,23673461,[O-]Br(=O)=O.[K+],Active,,,,RAT,F344/FEMALE,ORAL,250; 500 PPM IN DRINKING WATER FOR 110 WK,"KIDNEY: RENAL CELL ADENOMA, RENAL CELL ADENOCARCINOMA",POSITIVE,"[KUROKAWA,Y, HAYASHI,Y, MAEKAWA,A, TAKAHASHI,M AND KOKUBO,T; INDUCTION OF RENAL CELL TUMORS IN F-344 RATS BY ORAL ADMINISTRATION OF POTASSIUM BROMATE, A FOOD ADDITIVE; GANN 73:335-338, 1982][KUROKAWA,Y, HAYASHI,Y, MAEKAWA,A, TAKAHASHI,M, KOKUBO,T AND ODASHIMA,S; CARCINOGENICITY OF POTASSIUM BROMATE ADMINISTERED ORALLY TO F344 RATS; J. NATL. CANCER INST. 71:965-972, 1983]"
2974,363898479,23673461,[O-]Br(=O)=O.[K+],Active,,,,RAT,F344/MALE,ORAL,250; 500 PPM IN DRINKING WATER (HIGH DOSE REDUCED TO 400 PPM AT WK 60),"KIDNEY: RENAL CELL ADENOMA, RENAL CELL ADENOCARCINOMA; PERITONEAL CAVITY: MESOTHELIOMA",POSITIVE,"[KUROKAWA,Y, HAYASHI,Y, MAEKAWA,A, TAKAHASHI,M AND KOKUBO,T; INDUCTION OF RENAL CELL TUMORS IN F-344 RATS BY ORAL ADMINISTRATION OF POTASSIUM BROMATE, A FOOD ADDITIVE; GANN 73:335-338, 1982][KUROKAWA,Y, HAYASHI,Y, MAEKAWA,A, TAKAHASHI,M, KOKUBO,T AND ODASHIMA,S; CARCINOGENICITY OF POTASSIUM BROMATE ADMINISTERED ORALLY TO F344 RATS; J. NATL. CANCER INST. 71:965-972, 1983]"
2975,363898479,23673461,[O-]Br(=O)=O.[K+],Active,,,,RAT,F344/MALE,ORAL,"0; 0.02; 0.1; 0.2; 0.4 G/L IN DRINKING WATER FOR 52, 78, OR 100 WK (STUDY DURATION: 100 WK)",TESTICLE: MESOTHELIOMA; KIDNEY: RENAL CELL TUMOR; THYROID: TUMOR,POSITIVE,"[WOLF,DC, CROSBY,LM, GEORGE,MH, KILBURN,SR, MOORE,TM, MILLER,RT AND DEANGELO,AB; TIME- AND DOSE-DEPENDENT DEVELOPMENT OF POTASSIUM BROMATE-INDUCED TUMORS IN MALE FISCHER F344 RATS; TOXICOL. PATHOL. 26(6):724-729, 1998]"
2976,363898479,23673461,[O-]Br(=O)=O.[K+],Inactive,,,,Mouse,Ogg1 wild type/Female (15/15)/(13/15),Oral,2 g/l in drinking water for 18 wk followed by 1 g/l in drinking water for 11 wk (Study duration: 52 wk),,"Negative (kidney, liver, lung, spleen, thymus, stomach, and intestine examined); similar results in female Ogg1 knockout mouse.","[ARAI,T, KELLY,VP, MINOWA,O, NODA,T, AND NISHIMURA,S; THE STUDY USING WILD-TYPE AND OGGL KNOCKOUT MICE EXPOSED TO POTASSIUM BROMATE SHOWS NO TUMOR INDUCTION DESPITE AN EXTENSIVE ACCUMULATION OF 8-HYDROXYGUANINE IN KIDNEY DNA; TOXICOLOGY 221(2-3):179-186, 2006]"
2977,363898479,23673461,[O-]Br(=O)=O.[K+],Inactive,,,,Mouse,Ogg1 wild type/Male (13/15)/(15/15),Oral,2 g/l in drinking water for 18 wk followed by 1 g/l in drinking water for 11 wk (Study duration: 52 wk),,"Negative (kidney, liver, lung, spleen, thymus, stomach and intestine examined); similar results in male Ogg1 knockout mouse.","[ARAI,T, KELLY,VP, MINOWA,O, NODA,T, AND NISHIMURA,S; THE STUDY USING WILD-TYPE AND OGGL KNOCKOUT MICE EXPOSED TO POTASSIUM BROMATE SHOWS NO TUMOR INDUCTION DESPITE AN EXTENSIVE ACCUMULATION OF 8-HYDROXYGUANINE IN KIDNEY DNA; TOXICOLOGY 221(2-3):179-186, 2006]"
2978,363898479,23673461,[O-]Br(=O)=O.[K+],Inactive,,,,Rat,Fischer 344/Female (50/group),Oral,0; 10; 30; 50 mg/kg/day by gavage once daily for 104 wk,,Negative,"[HEIM,KE BATES,HK RUSH,RE AND OLLER,AR; ORAL CARCINOGENICITY STUDY WITH NICKEL SULFATE HEXAHYDRATE IN FISCHER 344 RATS; TOXICOLOGY AND APPLIED PHARMACOLOGY 224(2):126-37, 2007]"
2979,363898479,23673461,[O-]Br(=O)=O.[K+],Inactive,,,,Rat,Fischer 344/Male (50/group),Oral,0; 10; 30; 50 mg/kg/day by gavage once daily for 104 wk,,Negative,"[HEIM,KE BATES,HK RUSH,RE AND OLLER,AR; ORAL CARCINOGENICITY STUDY WITH NICKEL SULFATE HEXAHYDRATE IN FISCHER 344 RATS; TOXICOLOGY AND APPLIED PHARMACOLOGY 224(2):126-37, 2007]"
2980,363898479,23673461,[O-]Br(=O)=O.[K+],Active,,,,Rat,F344/Male (20-24/group),Oral,0; 15; 30; 60; 125; 250; 500 ppm in drinking water for 104 wk,"Kidney: Renal adenoma (0/19, 0/19, 0/20, 1/24, 5/24, 5/20, 6/20) and adenocarcinoma (0/19, 0/19, 0/20, 0/24, 0/24, 0/20, 3/20). Thyroid: Follicular adenomas and adenocarcinomas (0/19, 0/20, 0/20, 1/24, 0/24, 3/20, 7/20). Peritoneum: Mesothelioma (0/19. 0/20, 3/20, 4/24, 2/24, 3/20, 15/20)",Positive,"[KUROKAWA,,Y, MAEKAWA,A, TAKAHASHI,M, AND HAYASHI,Y; TOXICITY AND CARCINOGENICITY OF POTASSIUM BROMATE --- A NEW RENAL CARCINOGEN; ENVIRON HEALTH PERSPECT. 87:309-335, 1990]"
2981,363898479,23673461,[O-]Br(=O)=O.[K+],Active,,,,Rat,F344/Male (14-20/group),Oral,"500 ppm in drinking water for 13, 26, 39, and 52 wk followed by drinking water for a study duration of 104 wk","Kidney: Adenoma (10/20, 9/19,13/19, 8/14), Adenocarcinoma (2/20, 1/19, 6/19, 3/14). Peritoneum: Mesothelioma (6/20, 8/19, 7/19, 5/14); Thyroid: Follicular adenoma and adenocarcinoma (2/20, 6/19, 1/19, 5/14)",Positive,"[KUROKAWA,,Y, MAEKAWA,A, TAKAHASHI,M, AND HAYASHI,Y; TOXICITY AND CARCINOGENICITY OF POTASSIUM BROMATE --- A NEW RENAL CARCINOGEN; ENVIRON HEALTH PERSPECT. 87:309-335, 1990]"
2982,363898479,23673461,[O-]Br(=O)=O.[K+],Active,,,,Hamster,Syrian golden/Male (20/group),Oral,0; 125; 250; 500; 2000 ppm in drinking water for 89 wk; study duration 89 wk,"Kidney: Renal adenoma (0/20, 0/20, 1/20, 2/20, 4/20)",Positive,"[KUROKAWA,,Y, MAEKAWA,A, TAKAHASHI,M, AND HAYASHI,Y; TOXICITY AND CARCINOGENICITY OF POTASSIUM BROMATE --- A NEW RENAL CARCINOGEN; ENVIRON HEALTH PERSPECT. 87:309-335, 1990]"
2983,363898479,23673461,[O-]Br(=O)=O.[K+],Active,,,,Rat,F344 (20-41/group),Oral,"0; 300; 600 mg/kg single intragastric administration, study duration 87 wk","Kidney: Renal adenoma and carcinoma (0/20, 0/20, 4/41)",Positive,"[KUROKAWA,,Y, MAEKAWA,A, TAKAHASHI,M, AND HAYASHI,Y; TOXICITY AND CARCINOGENICITY OF POTASSIUM BROMATE --- A NEW RENAL CARCINOGEN; ENVIRON HEALTH PERSPECT. 87:309-335, 1990]"
2984,363898479,23673461,[O-]Br(=O)=O.[K+],Inactive,,,,Mouse,B6C3F1/Female (25/ group),Oral,"0; 500; 1000 ppm in drinking water for 78 wk, followed by tap water for 26 wk; study duration 104 wk",,Negative,"[KUROKAWA,,Y, MAEKAWA,A, TAKAHASHI,M, AND HAYASHI,Y; TOXICITY AND CARCINOGENICITY OF POTASSIUM BROMATE --- A NEW RENAL CARCINOGEN; ENVIRON HEALTH PERSPECT. 87:309-335, 1990]"
2985,363898479,23673461,[O-]Br(=O)=O.[K+],Active,,,,Mouse,"B6C3F1, BDF1, and CDF1/Male (27/experimental group, 15/control group)",Oral,"0; 750 ppm in drinking water for 88 wk, study duration 88 wk","Kidney: Renal adenoma and carcinoma - B6C3F1: 0/15 (controls), 3/26 (750 ppm); BDF1: 0/15 (controls),1/27 (750 ppm); CDF1: 0/15 (controls), 1/27 (750 ppm). Small intestine: Adenocarcinoma and adenoma - CDF1:1/15 (controls), 14/27 (750 ppm); Liver, Adenocarcinoma or adenoma - B6C3F1 (3/15 (controls), 13/26 (750 ppm); others not significant",Positive,"[KUROKAWA,,Y, MAEKAWA,A, TAKAHASHI,M, AND HAYASHI,Y; TOXICITY AND CARCINOGENICITY OF POTASSIUM BROMATE --- A NEW RENAL CARCINOGEN; ENVIRON HEALTH PERSPECT. 87:309-335, 1990]"
2986,363898481,9703,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,0; 6; 12 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK (STUDY DURATION: 67-85 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA; UTERUS: ADENOCARCINOMA (NOS); BRAIN: OLFACTORY NEUROBLASTOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-19 Y79]"
2987,363898481,9703,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 6; 12 MG/KG IN BUFFERED SALINE 3/WK FOR 52 WK (STUDY DURATION: 67-85 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA; BRAIN: OLFACTORY NEUROBLASTOMA OR CARCINOMA (UNDIFFERENTIATED),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-19 Y79]"
2988,363898481,9703,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,Active,,,,RAT,BR46/MALE,INTRAVENOUS,24 MG/KG 1/WK FOR 52 WK,MULTIPLE SITES: BENIGN TUMOR OR MALIGNANT TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V26 311 Y81]"
2989,363898481,9703,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 15; 30 MG/KG IN BUFFERED SALINE 3/WK FOR 26 WK (STUDY DURATION: 31-86 WK),LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA; MAMMARY GLAND: ADENOMA (NOS) OR ADENOCARCINOMA (NOS); BRAIN (CEREBRUM): OLFACTORY NEUROBLASTOMA OR MUCINOUS ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-19 Y79]"
2990,363898481,9703,CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 15; 30 MG/KG IN BUFFERED SALINE 3/WK FOR 26 WK (STUDY DURATION: 43-86 WK),"HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA; MAMMARY GLAND: ADENOMA (NOS) OR ADENOSARCOMA (NOS); BRAIN (OLFACTORY BULB): CARCINOMA (NOS), NEUROBLASTOMA OR ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-19 Y79]"
2991,363898482,44581885,C1=CC(=CC2=[NH+]C3=C(C=CC(=C3)N)C=C21)N.[Cl-],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 300; 600 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-5 Y77]"
2992,363898482,44581885,C1=CC(=CC2=[NH+]C3=C(C=CC(=C3)N)C=C21)N.[Cl-],Unspecified,,,,RAT,F344/MALE,ORAL,0; 300; 600 PPM IN DIET FOR 109 WK (STUDY DURATION: 109 WK),INTESTINE: LEIOMYOSARCOMA OR ADENOCARCINOMA OR SARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-5 Y77]"
2993,363898482,44581885,C1=CC(=CC2=[NH+]C3=C(C=CC(=C3)N)C=C21)N.[Cl-],Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 200; 400 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-5 Y77]"
2994,363898482,44581885,C1=CC(=CC2=[NH+]C3=C(C=CC(=C3)N)C=C21)N.[Cl-],Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 200; 400 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-5 Y77]"
2995,363898483,5994,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,Active,,,,MOUSE,,SUBCUTANEOUS,,MAMMARY GLAND; OVARIES; UTERUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 135 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 491 Y79]"
2996,363898484,60975,CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O.Cl,Active,,,,MOUSE,,ORAL,,THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V13 227 Y77]"
2997,363898485,14264,C1COS(=O)(=O)C1,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,0.3 MG IN WATER 1/WK FOR 63 WK,"INJECTION SITE: ADENOACANTHOMA, SARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 253 Y74]"
2998,363898485,14264,C1COS(=O)(=O)C1,Active,,,,RAT,STRAIN-BD,SUBCUTANEOUS,15; 30 MG/KG IN ARACHIS OIL 1/WK FOR 1 YR,"INJECTION SITE: MYOSARCOMA, FIBROSARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 253 Y74]"
2999,363898485,14264,C1COS(=O)(=O)C1,Active,,,,RAT,STRAIN-BD,SUBCUTANEOUS,15; 30 MG/KG IN WATER 1/WK FOR 1 YR,INJECTION SITE: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 253 Y74]"
3000,363898485,14264,C1COS(=O)(=O)C1,Active,,,,RAT,STRAIN-CD/FEMALE,GAVAGE,28; 56 MG/KG IN WATER 2/WK FOR 78 WK (LOW DOSE) OR 32 WK (HIGH DOSE),"BRAIN (CEREBELLUM, CEREBRUM): MALIGNANT GLIOMA; MAMMARY GLAND: ADENOCARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 253 Y74][WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981, ]"
3001,363898485,14264,C1COS(=O)(=O)C1,Active,,,,RAT,STRAIN-CD/MALE,GAVAGE,28; 56 MG/KG IN WATER 2/WK FOR 78 WK (LOW DOSE) OR 32 WK (HIGH DOSE),"BRAIN (CEREBELLUM, CEREBRUM): MALIGNANT GLIOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 253 Y74][WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981, ]"
3002,363898486,2365,C1COC1=O,Active,,,,MOUSE,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 259 Y74]"
3003,363898486,2365,C1COC1=O,Active,,,,MOUSE,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 259 Y74]"
3004,363898486,2365,C1COC1=O,Active,,,,MOUSE,,INTRAPERITONEAL,,LIVER; LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 259 Y74]"
3005,363898486,2365,C1COC1=O,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 259 Y74]"
3006,363898486,2365,C1COC1=O,Active,,,,MOUSE,CF1/MALE,DERMAL,0; 2% IN ACETONE 2D/WK FOR 104 WK (STUDY DURATION: 2 YR),SKIN: SQUAMOUS CELL CARCINOMA; SKIN: DERMAL FIBROSARCOMA; SKIN: CARCINOSARCOMA,POSITIVE,"[ZAKOVA,N, ZAK,F, FROEHLICH,E AND HESS,R; EVALUATION OF SKIN CARCINOGENICITY OF TECHNICAL 2,2-BIS-(P-GLYCIDYLOXYPHENYL)PROPANE; FOOD CHEM. TOXICOL. 23(12): 1081-1089, 1985]"
3007,363898486,2365,C1COC1=O,Active,,,,MOUSE,CF1/FEMALE,DERMAL,0; 2% IN ACETONE 2D/WK FOR 2 YR (STUDY DURATION: 2 YR),SKIN: SQUAMOUS CELL CARCINOMA; SKIN: CARCINOSARCOMA,POSITIVE,"[ZAKOVA,N, ZAK,F, FROEHLICH,E AND HESS,R; EVALUATION OF SKIN CARCINOGENICITY OF TECHNICAL 2,2-BIS-(P-GLYCIDYLOXYPHENYL)PROPANE; FOOD CHEM. TOXICOL. 23(12): 1081-1089, 1985]"
3008,363898486,2365,C1COC1=O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 5; 10; 20 PPM 6 HR/D 5 D/WK FOR 30 D EXCEPT 20 PPM GROUP WHICH WAS EXPOSED FOR 5 D (STUDY DURATION: LIFETIME),NASAL CAVITY: TUMORS,POSITIVE,"[SELLAKUMAR,AR, SNYDER,CA AND ALBERT,RE; INHALATION CARCINOGENESIS OF VARIOUS ALKYLATING AGENTS; 79:285-289, 1987]"
3009,363898487,47807,CCCN(COC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,6.1 MG/KG 1/WK FOR 10 WK,"INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; LUNG: ADENOMA, ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA; THYROID GLAND: C CELL ADENOMA, FOLLICULAR ADENOMA OR ADENOCARCINOMA",POSITIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, MOCHIZUKI,M, ANJO,T, OKADA,M AND ODASHIMA,S; CARCINOGENICITY OF N-ALKYL-N-(ACETOXYMETHYL)- NITROSAMINES AFTER SUBCUTANEOUS INJECTIONS IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 104:13-21, 1982]"
3010,363898487,47807,CCCN(COC(=O)C)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,6.1 MG/KG 1/WK FOR 10 WK,"INJECTION SITE: MALIGNANT FIBROUS HISTIOCYTOMA; LUNG: ADENOMA, ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, MOCHIZUKI,M, ANJO,T, OKADA,M AND ODASHIMA,S; CARCINOGENICITY OF N-ALKYL-N-(ACETOXYMETHYL)- NITROSAMINES AFTER SUBCUTANEOUS INJECTIONS IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 104:13-21, 1982]"
3011,363898488,12306,CCCOC(=O)N,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 201 Y76]"
3012,363898489,6377,CC1CN1,Active,,,,RAT,STRAIN-CD/FEMALE,GAVAGE,10.5; 20.7 MG/KG (AVE DOSE) IN WATER 2/WK FOR 58 WK (LOW DOSE) OR 27 WK (HIGH DOSE),INTESTINES: ADENOCARCINOMA; BRAIN (CEREBRUM): GLIOMA; EAR (DUCT): SQUAMOUS CELL CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[ULLAND,B, FINKELSTEIN,M, WEISBURGER,EK, RICE,JM AND WEISBURGER,JH; CARCINOGENICITY OF INDUSTRIAL CHEMICALS PROPYLENE IMINE AND PROPANE SULTONE; NATURE 230:460-461, 1971][WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
3013,363898489,6377,CC1CN1,Active,,,,RAT,STRAIN-CD/MALE,GAVAGE,10.5; 20.7 MG/KG (AVE DOSE) IN WATER 2/WK FOR 58 WK (LOW DOSE) OR 27 WK (HIGH DOSE),HEMATOPOIETIC SYSTEM (LEUKEMIA): GRANULOCYTIC LEUKEMIA; BRAIN (CEREBRUM): GLIOMA; EAR (DUCT): SQUAMOUS CELL CARCINOMA; INTESTINES: ADENOCARCINOMA,POSITIVE,"[ULLAND,B, FINKELSTEIN,M, WEISBURGER,EK, RICE,JM AND WEISBURGER,JH; CARCINOGENICITY OF INDUSTRIAL CHEMICALS PROPYLENE IMINE AND PROPANE SULTONE; NATURE 230:460-461, 1971][WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
3014,363898490,6378,CC1CO1,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,15; 60 MG/KG IN SALAD OIL 2/WK FOR UP TO 150 WK,FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[DUNKELBERG,H; CARCINOGENICITY OF ETHYLENE OXIDE AND 1,2-PROPYLENE OXIDE UPON INTRAGASTRIC ADMINISTRATION TO RATS; BR. J. CANCER 46:924-933, 1982]"
3015,363898490,6378,CC1CO1,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 191 Y76]"
3016,363898490,6378,CC1CO1,Active,,,,RAT,F344/MALE,INHALATION,"0; 200; 400 PPM 6 HR/D, 5 D/WK FOR 103 WK",NASAL TURBINATES: PAPILLARY ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-267 Y85]"
3017,363898490,6378,CC1CO1,Active,,,,RAT,F344/FEMALE,INHALATION,"0; 200; 400 PPM 6 HR/D, 5 D/WK FOR 103 WK",NASAL TURBINATES: PAPILLARY ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-267 Y85]"
3018,363898490,6378,CC1CO1,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 200; 400 PPM 6 HR/D, 5 D/WK FOR 103 WK","NASAL TURBINATES: HEMANGIOMA, HEMANGIOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-267 Y85]"
3019,363898490,6378,CC1CO1,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 200; 400 PPM 6 HR/D, 5 D/WK FOR 103 WK",NASAL TURBINATES: HEMANGIOMA OR HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-267 Y85]"
3020,363898490,6378,CC1CO1,Active,,,,RAT,F344/MALE,INHALATION,0; 100; 300 PPM IN AIR 7 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 2 YR),ADRENAL GLAND: PHEOCHROMOCYTOMA; PITUITARY GLAND: ADENOMA,POSITIVE,"[LYNCH,DW, LEWIS,TR, MOORMAN,WJ, BURG,JR, GROTH,DH, KHAN,A, ACKERMAN,LJ AND COCKRELL,BY; CARCINOGENIC AND TOXICOLOGIC EFFECTS OF INHALED ETHYLENE OXIDE AND PROPYLENE OXIDE IN F344 RATS; TOXICOL. APPL. PHARMACOL. 76:69-84, 1984]"
3021,363898490,6378,CC1CO1,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,0; 0.1; 0.3; 1; 2.5 MG/MOUSE IN TRICAPRYLIN 1/WK FOR 95 WK (STUDY DURATION: 110 WK),INJECTION SITE: TUMOR,POSITIVE,"[DUNKELBERG,H; CARCINOGENIC ACTIVITY OF ETHYLENE OXIDE AND ITS REACTION PRODUCTS 2-CHLOROETHANOL, 2-BROMOETHANOL, ETHYLENE GLYCOL AND DIETHYLENE GLYCOL. I. CARCINOGENICITY OF ETHYLENE OXIDE IN COMPARISON WITH 1,2-PROPYLENE OXIDE AFTER SUBCUTANEOUS ADMINISTRATION IN MICE; ZBL. BAKT. HYG. I. ABT. ORIG. B 174:383-404, 1981]"
3022,363898490,6378,CC1CO1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 435; 870; 1740 PPM 6 HR/D 5 D/WK FOR 30 D EXCEPT 1740 PPM GROUP WHICH WAS EXPOSED FOR 5 D (STUDY DURATION: LIFETIME),,NEGATIVE,"[SELLAKUMAR,AR, SNYDER,CA AND ALBERT,RE; INHALATION CARCINOGENESIS OF VARIOUS ALKYLATING AGENTS; 79:285-289, 1987]"
3023,363898491,4947,CCCOC(=O)C1=CC(=C(C(=C1)O)O)O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-240 Y82][ABDO,KM, HUFF,JE, HASEMAN,JK, DIETER,MP, BOORMAN,GA, HILDEBRANDT,P, PREJEAN,JD AND FARNELL,DR; CARCINOGENESIS BIOASSAY OF PROPYL GALLATE IN F344 RATS AND B6C3F1 MICE; J. AM. COLL. TOXICOL. 2:425-433, 1983, ]"
3024,363898491,4947,CCCOC(=O)C1=CC(=C(C(=C1)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-240 Y82]"
3025,363898491,4947,CCCOC(=O)C1=CC(=C(C(=C1)O)O)O,Unspecified,,,,RAT,F344/MALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),PREPUTIAL GLAND: CARCINOMA OR ADENOMA OR ADENOCARCINOMA; PANCREAS: ISLET CELL ADENOMA OR CARCINOMA; ADRENAL GLAND: PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-240 Y82]"
3026,363898491,4947,CCCOC(=O)C1=CC(=C(C(=C1)O)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 6000; 12000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-240 Y82]"
3027,363898492,33643,CCCI,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[POIRIER,LA, STONER,DK AND SHIMKIN,MB; BIOASSAY OF ALKYL HALIDES AND NUCLEOTIDE BASE ANALOGS BY PULMONARY TUMOR RESPONSE IN STRAIN A MICE; CANCER RES. 35:1411-1415, 1975]"
3028,363898493,13157,CCCN(C(=O)N)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,ORAL,100; 400 PPM IN DRINKING WATER FOR 42 WK,"SPLEEN: HEMANGIOENDOTHELIOMA; LIVER: HEMANGIOENDOTHELIOMA; ESOPHAGUS: SQUAMOUS CELL PAPILLOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; DUODENUM: ADENOCARCINOMA; VAGINA: SQUAMOUS CELL PAPILLOMA",POSITIVE,"[TAKAHASHI,M, FURUKAWA,F, KURATA,Y, NAGANO,K, KOKUBO,T, HAYASHI,Y AND NAKADATE,M; VASCULAR TUMORS OF THE SPLEEN AND OTHER NEOPLASMS INDUCED IN SYRIAN GOLDEN HAMSTERS BY 1-PROPYL-1-NITROSOUREA; GANN 73:695-703, 1982]"
3029,363898493,13157,CCCN(C(=O)N)N=O,Active,,,,HAMSTER,SYRIAN/MALE,ORAL,100; 400 PPM IN DRINKING WATER FOR 42 WK,"SPLEEN: HEMANGIOENDOTHELIOMA; LIVER: HEMANGIOENDOTHELIOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; DUODENUM: ADENOCARCINOMA; STOMACH: SARCOMA",POSITIVE,"[TAKAHASHI,M, FURUKAWA,F, KURATA,Y, NAGANO,K, KOKUBO,T, HAYASHI,Y AND NAKADATE,M; VASCULAR TUMORS OF THE SPLEEN AND OTHER NEOPLASMS INDUCED IN SYRIAN GOLDEN HAMSTERS BY 1-PROPYL-1-NITROSOUREA; GANN 73:695-703, 1982]"
3030,363898493,13157,CCCN(C(=O)N)N=O,Active,,,,RAT,BUF/MNA/FEMALE,ORAL,0; 400 PPM SOLUTION AS DRINKING WATER DAILY (STUDY DURATION: 22 WK),THYMUS: LYMPHOMA,POSITIVE,"[OGIU,T, FUKAMI,H, MATSUYAMA,M AND MAEKAWA,A; THYMIC LYMPHOMAS INDUCED BY N-PROPYL-N-NITROSOUREA (PNU) IN THE BUF/MNA RAT, AN INBRED STRAIN WITH A HIGH INCIDENCE OF SPONTANEOUS THYMOMA; ACTA PATHOL. JPN. 39(11):706-711, 1989]"
3031,363898493,13157,CCCN(C(=O)N)N=O,Active,,,,RAT,BUF/MNA/MALE,ORAL,0; 400 PPM SOLUTION AS DRINKING WATER DAILY (STUDY DURATION: 22 WK),THYMUS: LYMPHOMA; DUODENUM: TUMOR,POSITIVE,"[OGIU,T, FUKAMI,H, MATSUYAMA,M AND MAEKAWA,A; THYMIC LYMPHOMAS INDUCED BY N-PROPYL-N-NITROSOUREA (PNU) IN THE BUF/MNA RAT, AN INBRED STRAIN WITH A HIGH INCIDENCE OF SPONTANEOUS THYMOMA; ACTA PATHOL. JPN. 39(11):706-711, 1989]"
3032,363898494,657298,CCCC1=CC(=O)NC(=S)N1,Active,,,,HAMSTER,,ORAL,,THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 67 Y74]"
3033,363898494,657298,CCCC1=CC(=O)NC(=S)N1,Active,,,,MOUSE,,ORAL,,PITUITARY GLAND; THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 67 Y74]"
3034,363898494,657298,CCCC1=CC(=O)NC(=S)N1,Active,,,,RAT,,ORAL,,THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 67 Y74]"
3035,363898495,1046,C1=CN=C(C=N1)C(=O)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-48 Y78]"
3036,363898495,1046,C1=CN=C(C=N1)C(=O)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-48 Y78]"
3037,363898495,1046,C1=CN=C(C=N1)C(=O)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-48 Y78]"
3038,363898496,4993,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-77 Y78]"
3039,363898496,4993,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 200; 400 PPM IN DIET 5 D/WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-77 Y78]"
3040,363898496,4993,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 200; 400 PPM IN DIET 5 D/WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-77 Y78]"
3041,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[SHINOHARA,Y, OGISO,T, HANANOUCHI,M, NAKANISHI,K, YOSHIMURA,T AND ITO,N; EFFECTS OF VARIOUS FACTORS ON THE INDUCTION OF LIVER TUMORS IN ANIMALS BY QUINOLINE; GANN 68:785, 1977][KINOSHITA,H; CARCINOGENICITY OF QUINOLINE AND EXPERIMENTAL ANALYSIS OF VARIOUS FACTORS ON QUINOLINE-INDUCED LIVER TUMORIGENESIS; NAGOYA-SHIRITSU DAIGAKU IGAKKI ZASSHI 29(1):93-111, 1979]"
3042,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[HIRAO,K, SHINOHARA,Y, TSUDA,H, FUKUSHIMA,S, TAKAHASHI,M AND ITO,N; CARCINOGENIC ACTIVITY OF QUINOLINE ON RAT LIVER; CANCER RES. 36:329-335, 1976][KINOSHITA,H; CARCINOGENICITY OF QUINOLINE AND EXPERIMENTAL ANALYSIS OF VARIOUS FACTORS ON QUINOLINE-INDUCED LIVER TUMORIGENESIS; NAGOYA-SHIRITSU DAIGAKU IGAKKI ZASSHI 29(1):93-111, 1979][SHINOHARA,Y, OGISO,T, HANANOUCHI,M, NAKANISHI,K, YOSHIMURA,T AND ITO,N; EFFECTS OF VARIOUS FACTORS ON THE INDUCTION OF LIVER TUMORS IN ANIMALS BY QUINOLINE; GANN 68:785, 1977]"
3043,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 0.25% IN DIET FOR 4 WK (STUDY DURATION: 20 WK),,NEGATIVE,"[HASEGAWA,R, FURUKAWA,F, TOYODA,K, SATO,H, IMAIDA,K AND TAKAHASHI,M; SEQUENTIAL ANALYSIS OF QUINOLINE-INDUCED HEPATIC HEMANGIOENDOTHELIOMA DEVELOPMENT IN RATS; CARCINOGENESIS 10(4):711-716, 1989]"
3044,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 0.25% IN DIET FOR 8 WK (STUDY DURATION: 20 WK),,NEGATIVE,"[HASEGAWA,R, FURUKAWA,F, TOYODA,K, SATO,H, IMAIDA,K AND TAKAHASHI,M; SEQUENTIAL ANALYSIS OF QUINOLINE-INDUCED HEPATIC HEMANGIOENDOTHELIOMA DEVELOPMENT IN RATS; CARCINOGENESIS 10(4):711-716, 1989]"
3045,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Active,,,,RAT,WISTAR/MALE,ORAL,0; 0.25% IN DIET FOR 12 WK (STUDY DURATION: 20 WK),LIVER: HEMANGIOENDOTHELIOMA,POSITIVE,"[HASEGAWA,R, FURUKAWA,F, TOYODA,K, SATO,H, IMAIDA,K AND TAKAHASHI,M; SEQUENTIAL ANALYSIS OF QUINOLINE-INDUCED HEPATIC HEMANGIOENDOTHELIOMA DEVELOPMENT IN RATS; CARCINOGENESIS 10(4):711-716, 1989]"
3046,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Active,,,,RAT,WISTAR/MALE,ORAL,0; 0.25% IN DIET FOR 16 WK (STUDY DURATION: 20 WK),LIVER: HEMANGIOENDOTHELIOMA,POSITIVE,"[HASEGAWA,R, FURUKAWA,F, TOYODA,K, SATO,H, IMAIDA,K AND TAKAHASHI,M; SEQUENTIAL ANALYSIS OF QUINOLINE-INDUCED HEPATIC HEMANGIOENDOTHELIOMA DEVELOPMENT IN RATS; CARCINOGENESIS 10(4):711-716, 1989]"
3047,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Active,,,,RAT,WISTAR/MALE,ORAL,0; 0.25% IN DIET FOR 20 WK (STUDY DURATION: 20 WK),LIVER: HEMANGIOENDOTHELIOMA,POSITIVE,"[HASEGAWA,R, FURUKAWA,F, TOYODA,K, SATO,H, IMAIDA,K AND TAKAHASHI,M; SEQUENTIAL ANALYSIS OF QUINOLINE-INDUCED HEPATIC HEMANGIOENDOTHELIOMA DEVELOPMENT IN RATS; CARCINOGENESIS 10(4):711-716, 1989]"
3048,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,"0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN 0; 200 UMOL/KG, ONCE (STUDY DURATION: 78 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
3049,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,"0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN 0; 200 UMOL/KG, ONCE (STUDY DURATION: 78 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
3050,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.25; 0.5; 1.0 UMOL IN DMSO TO NEWBORN MICE ON DAY 1,8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1,75 UMOL) (STUDY DURATION: 52 WK)","LIVER: HEPATOMA, ADENOMA",POSITIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
3051,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.25; 0.5; 1.0 UMOL IN DMSO TO NEWBORN MICE ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
3052,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",,NEGATIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
3053,363898497,7047,C1=CC=C2C(=C1)C=CC=N2,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
3054,363898499,7737,C1=CC(=CC=C1NO)N=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 750; 1500 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-179 Y79]"
3055,363898499,7737,C1=CC(=CC=C1NO)N=O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 750; 1500 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-179 Y79]"
3056,363898499,7737,C1=CC(=CC=C1NO)N=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 375; 750 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-179 Y79]"
3057,363898499,7737,C1=CC(=CC=C1NO)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 375; 750 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),"URINARY BLADDER: TRANSITIONAL CELL CARCINOMA, TRANSITIONAL CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-179 Y79]"
3058,363898500,5770,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5; 10 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),MAMMARY GLAND: MALIGNANT TUMOR,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-193 Y80]"
3059,363898500,5770,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5; 10 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),SEMINAL VESICLES: CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-193 Y80]"
3060,363898500,5770,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5; 10 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-193 Y80]"
3061,363898500,5770,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,Active,,,,RAT,F344/MALE,ORAL,0; 5; 10 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),ADRENAL GLAND: MALIGNANT PHEOCHROMOCYTOMA OR PHEOCHROMOCYTOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-193 Y80]"
3062,363898501,135550179,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N\N5CCN(CC5)C)/C,Active,,,,MOUSE,C3F/FEMALE,ORAL,0.01; 0.03 0.06% IN DRINKING WATER WITH 0.05% SODIUM ASCORBATE FOR 60 WK,LIVER: BENIGN TUMOR OR MALIGNANT TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 243 Y80]"
3063,363898502,33474,CCN1C2=C(C(=N1)C)NC(=O)CN=C2C3=CC=CC=C3,Inactive,,,,RAT,CD/MALE,ORAL,0; 15; 150 MG/KG IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[FITZGERALD,JE, DE LA IGLESIA,FA AND MCGUIRE,EJ; CARCINOGENICITY STUDIES IN RODENTS WITH RIPAZEPAM, A MINOR TRANQUILIZING AGENT; FUNDAM. APPL. TOXICOL. 4:178-190, 1984]"
3064,363898502,33474,CCN1C2=C(C(=N1)C)NC(=O)CN=C2C3=CC=CC=C3,Inactive,,,,RAT,CD/FEMALE,ORAL,0; 15; 150 MG/KG IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[FITZGERALD,JE, DE LA IGLESIA,FA AND MCGUIRE,EJ; CARCINOGENICITY STUDIES IN RODENTS WITH RIPAZEPAM, A MINOR TRANQUILIZING AGENT; FUNDAM. APPL. TOXICOL. 4:178-190, 1984]"
3065,363898502,33474,CCN1C2=C(C(=N1)C)NC(=O)CN=C2C3=CC=CC=C3,Active,,,,MOUSE,CD-1/MALE,ORAL,0; 15; 150; MG/KG IN DIET FOR 78 WK (STUDY DURATION: 78 WK),LIVER: ADENOMA,POSITIVE,"[FITZGERALD,JE, DE LA IGLESIA,FA AND MCGUIRE,EJ; CARCINOGENICITY STUDIES IN RODENTS WITH RIPAZEPAM, A MINOR TRANQUILIZING AGENT; FUNDAM. APPL. TOXICOL. 4:178-190, 1984]"
3066,363898502,33474,CCN1C2=C(C(=N1)C)NC(=O)CN=C2C3=CC=CC=C3,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 15; 150; MG/KG IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[FITZGERALD,JE, DE LA IGLESIA,FA AND MCGUIRE,EJ; CARCINOGENICITY STUDIES IN RODENTS WITH RIPAZEPAM, A MINOR TRANQUILIZING AGENT; FUNDAM. APPL. TOXICOL. 4:178-190, 1984]"
3067,363898503,5144,C=CCC1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,"B6AKF1/MALE,FEMALE","GAVAGE, ORAL",464 MG/KG FROM D 7-28 OF LIFE THEN 1112 MG/KG IN DIET,LIVER: HEPATOCELLULAR TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 169 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 231 Y76]"
3068,363898503,5144,C=CCC1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,"B6C3F1/MALE,FEMALE","GAVAGE, ORAL",464 MG/KG FROM D 7-28 OF LIFE THEN 1112 MG/KG IN DIET,LIVER: HEPATOCELLULAR TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 169 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 231 Y76]"
3069,363898503,5144,C=CCC1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,CD-1/MALE,ORAL,4000; 5000 MG/KG IN DIET FOR 13 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 169 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 231 Y76]"
3070,363898503,5144,C=CCC1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,CD-1/MALE,SUBCUTANEOUS,0.66; 6.6 MG (TOTAL DOSES) IN TRICAPRYLIN IN 3 WK,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 169 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 231 Y76]"
3071,363898503,5144,C=CCC1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0.66; 6.6 MG (TOTAL DOSES) IN TRICAPRYLIN IN 3 WK,"LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 169 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 231 Y76]"
3072,363898503,5144,C=CCC1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0.66; 6.6 MG (TOTAL DOSES) IN TRICAPRYLIN IN 3 WK,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 169 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 231 Y76]"
3073,363898503,5144,C=CCC1=CC2=C(C=C1)OCO2,Active,,,,RAT,"OSBORNE-MENDEL/MALE,FEMALE",ORAL,100; 500; 1000; 5000 MG/KG IN DIET FOR 2 YR,"LIVER: HEPATOCELLULAR CARCINOMA, CHOLANGIOCARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 169 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 231 Y76]"
3074,363898503,5144,C=CCC1=CC2=C(C=C1)OCO2,Active,,,,MOUSE,BALB/MALE,ORAL,0; 4000 PPM IN DIET FOR 52 WK (STUDY DURATION: 75 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA",POSITIVE,"[LIPSKY,MM, HINTON,DE, KLAUNIG,JE AND TRUMP,BF; BIOLOGY OF HEPATOCELLULAR NEOPLASIA IN THE MOUSE. I. HISTOGENESIS OF SAFROLE-INDUCED HEPATOCELLULAR CARCINOMA; J. NATL. CANCER INST. 67(2):365-376, 1981]"
3075,363898504,24011,S=[Se],Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 20; 100 MG/KG IN 0.5% AQ CMC,LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-194 Y80]"
3076,363898504,24011,S=[Se],Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 20; 100 MG/KG IN 0.5% AQ CMC,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-194 Y80]"
3077,363898504,24011,S=[Se],Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 0.5; 1.0 MG/KG IN SALINE SOLN CONT 0.5% CMC 3/WK FOR 86 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-197 Y80]"
3078,363898504,24011,S=[Se],Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 0.5; 1.0 MG/KG IN SALINE SOLN CONT 0.5% CMC 3/WK FOR 86 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-197 Y80]"
3079,363898504,24011,S=[Se],Active,,,,RAT,F344/FEMALE,GAVAGE,0; 3; 15 MG/KG IN 0.5% AQ CMC,LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-194 Y80]"
3080,363898504,24011,S=[Se],Active,,,,RAT,F344/MALE,GAVAGE,0; 3; 15 MG/KG IN 0.5% AQ CMC,LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-194 Y80]"
3081,363898506,11236,C(=O)(N)NN.Cl,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0.0625% IN DRINKING WATER FOR LIFE,"BLOOD VESSELS: ANGIOMA, ANGIOSARCOMA; LUNG",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 209 Y76]"
3082,363898506,11236,C(=O)(N)NN.Cl,Inactive,,,,RAT,STRAIN-CD/FEMALE,ORAL,500; 1000 PPM IN DIET FOR 78 WK (LOW DOSE) OR 32 WK (HIGH DOSE),,NEGATIVE,"[WEISBURGER,EK, ULLAND,BM, NAM,J-M, GART,JJ AND WEISBURGER,JH; CARCINOGENICITY TESTS OF CERTAIN ENVIRONMENTAL AND INDUSTRIAL CHEMICALS; J. NATL. CANCER INST. 67:75-88, 1981]"
3083,363898507,5281752,C/C=C\1/C[C@H]([C@@](C(=O)OC/C/2=C/CN(CC[C@H](C2=O)OC1=O)C)(C)O)C,Active,,,,RAT,ACI/MALE,INTRAPERITONEAL,"22 MG/KG IN SALINE 2/WK FOR 4 WK, THEN 1/WK FOR 52 WK",LIVER: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V31 231 Y83]"
3084,363898508,24268,[N+](=O)([O-])[O-].[Na+],Inactive,,,,RAT,"F344/MALE,FEMALE",ORAL,2.5; 5% IN DRINKING WATER FOR 2 YR,,NEGATIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, OHNO,Y AND ODASHIMA,S; CARCINOGENICITY STUDIES OF SODIUM NITRITE AND SODIUM NITRATE IN F-344 RATS; FOOD CHEM. TOXICOL. 20:25-33, 1982]"
3085,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,RAT,"F344/MALE,FEMALE",ORAL,0.125; 0.25% IN DRINKING WATER FOR 2 YR,,NEGATIVE,"[MAEKAWA,A, OGIU,T, ONODERA,H, FURUTA,K, MATSUOKA,C, OHNO,Y AND ODASHIMA,S; CARCINOGENICITY STUDIES OF SODIUM NITRITE AND SODIUM NITRATE IN F-344 RATS; FOOD CHEM. TOXICOL. 20:25-33, 1982]"
3086,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,MOUSE,VM/MALE,ORAL,0; 0.2% IN DRINKING WATER BEGINNING AT WEANING AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[HAWKES,CH, CAVANAGH,JB, DARLING,JL, WATKINS,BA AND THOMAS,DGT; CHRONIC LOW- DOSE EXPOSURE OF SODIUM NITRITE IN VM-STRAIN MICE: CENTRAL NERVOUS SYSTEM CHANGES; HUM. EXP. TOXICOL. 11(4):279-281, 1992]"
3087,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,MOUSE,VM/FEMALE,ORAL,0; 0.2% IN DRINKING WATER BEGINNING AT WEANING AND CONTINUING FOR DURATION STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[HAWKES,CH, CAVANAGH,JB, DARLING,JL, WATKINS,BA AND THOMAS,DGT; CHRONIC LOW- DOSE EXPOSURE OF SODIUM NITRITE IN VM-STRAIN MICE: CENTRAL NERVOUS SYSTEM CHANGES; HUM. EXP. TOXICOL. 11(4):279-281, 1992]"
3088,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,MOUSE,VM/MALE,ORAL,0; 0.2% IN DRINKING WATER BEGINNING IN UTERO AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[HAWKES,CH, CAVANAGH,JB, DARLING,JL, WATKINS,BA AND THOMAS,DGT; CHRONIC LOW- DOSE EXPOSURE OF SODIUM NITRITE IN VM-STRAIN MICE: CENTRAL NERVOUS SYSTEM CHANGES; HUM. EXP. TOXICOL. 11(4):279-281, 1992]"
3089,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,MOUSE,VM/FEMALE,ORAL,0; 0.2% IN DRINKING WATER BEGINNING IN UTERO AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[HAWKES,CH, CAVANAGH,JB, DARLING,JL, WATKINS,BA AND THOMAS,DGT; CHRONIC LOW- DOSE EXPOSURE OF SODIUM NITRITE IN VM-STRAIN MICE: CENTRAL NERVOUS SYSTEM CHANGES; HUM. EXP. TOXICOL. 11(4):279-281, 1992]"
3090,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,MOUSE,C57BL/FEMALE,ORAL,0; 30.7; 310 MG/D IN DRINKING WATER BEGINNING AT 7-8 WK OF AGE AND CONTINUING FOR STUDY DURATION (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[ANDERSON,LM, GINER-SOROLLA,A, HALLER,IM AND BUDINGER,JM; EFFECTS OF CIMETIDINE, NITRITE, CIMETIDINE PLUS NITRITE, AND NITROSOCIMETIDINE ON TUMORS IN MICE FOLLOWING TRANSPLACENTAL PLUS CHRONIC LIFETIME EXPOSURE; CANCER RES. 45(8): 3561-3566, 1985]"
3091,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 30.7; 310 MG/D IN DRINKING WATER FOR LIFE ADMINISTERED TO MICE OF MOTHERS EXPOSED TO SAME DOSES THROUGH PREGNANCY AND LACTATION (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[ANDERSON,LM, GINER-SOROLLA,A, HALLER,IM AND BUDINGER,JM; EFFECTS OF CIMETIDINE, NITRITE, CIMETIDINE PLUS NITRITE, AND NITROSOCIMETIDINE ON TUMORS IN MICE FOLLOWING TRANSPLACENTAL PLUS CHRONIC LIFETIME EXPOSURE; CANCER RES. 45(8): 3561-3566, 1985]"
3092,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 30.7; 310 MG/D IN DRINKING WATER FOR LIFE ADMINISTERED TO MICE OF MOTHERS EXPOSED TO SAME DOSES THROUGH PREGNANCY AND LACTATION (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[ANDERSON,LM, GINER-SOROLLA,A, HALLER,IM AND BUDINGER,JM; EFFECTS OF CIMETIDINE, NITRITE, CIMETIDINE PLUS NITRITE, AND NITROSOCIMETIDINE ON TUMORS IN MICE FOLLOWING TRANSPLACENTAL PLUS CHRONIC LIFETIME EXPOSURE; CANCER RES. 45(8): 3561-3566, 1985]"
3093,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 0.2; 0.5% IN DIET FOR 115 WK (STUDY DURATION: 115 WK),,NEGATIVE,"[GRANT,D AND BUTLER,WH; CHRONIC TOXICITY OF SODIUM NITRITE IN THE MALE F344 RAT; FOOD CHEM. TOXICOL. 27(9):565-571, 1989]"
3094,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,"0; 750; 1,500; 3,000 PPM IN DRINKING WATER FOR 105 WK (STUDY DURATION: 105 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-495 Y01][TOXICOLOGY AND CARINOGENESIS STUDIES OF SODIUMNITRITE (CAS NO. 7632-00-0) IN F344/N RATS AND B6C3F1 MICE (DRINKING WATER STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 495:1-274, 2001, ]"
3095,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 750; 1,500; 3,000 PPM IN DRINKING WATER FOR 105 WK (STUDY DURATION: 105 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-495 Y01][TOXICOLOGY AND CARINOGENESIS STUDIES OF SODIUMNITRITE (CAS NO. 7632-00-0) IN F344/N RATS AND B6C3F1 MICE (DRINKING WATER STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 495:1-274, 2001, ]"
3096,363898509,23668193,N(=O)[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 750; 1,500; 3,000 PPM IN DRINKING WATER FOR 104-105 WK (STUDY DURATION: 104-105 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-495 Y01][TOXICOLOGY AND CARINOGENESIS STUDIES OF SODIUMNITRITE (CAS NO. 7632-00-0) IN F344/N RATS AND B6C3F1 MICE (DRINKING WATER STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 495:1-274, 2001, ]"
3097,363898509,23668193,N(=O)[O-].[Na+],Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 750; 1500; 3000 PPM IN DRINKING WATER FOR 104-105 WK (STUDY DURATION: 104-105 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-495 Y01]"
3098,363898510,24479,Cl[Sn]Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-231 Y82]"
3099,363898510,24479,Cl[Sn]Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-231 Y82]"
3100,363898510,24479,Cl[Sn]Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-231 Y82]"
3101,363898510,24479,Cl[Sn]Cl,Unspecified,,,,RAT,F344/MALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),"THYROID GLAND: C-CELL ADENOMA, C-CELL ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-231 Y82]"
3102,363898511,5280389,COC1=C2C(=C3[C@@H]4C=CO[C@@H]4OC3=C1)OC5=CC=CC(=C5C2=O)O,Active,,,,MOUSE,,ORAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 175 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 245 Y76]"
3103,363898511,5280389,COC1=C2C(=C3[C@@H]4C=CO[C@@H]4OC3=C1)OC5=CC=CC(=C5C2=O)O,Active,,,,RAT,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 175 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 245 Y76]"
3104,363898511,5280389,COC1=C2C(=C3[C@@H]4C=CO[C@@H]4OC3=C1)OC5=CC=CC(=C5C2=O)O,Active,,,,RAT,,SUBCUTANEOUS,,INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 175 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 245 Y76]"
3105,363898511,5280389,COC1=C2C(=C3[C@@H]4C=CO[C@@H]4OC3=C1)OC5=CC=CC(=C5C2=O)O,Active,,,,RAT,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 175 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 245 Y76]"
3106,363898511,5280389,COC1=C2C(=C3[C@@H]4C=CO[C@@H]4OC3=C1)OC5=CC=CC(=C5C2=O)O,Active,,,,MOUSE,DBF1/FEMALE,ORAL,0; 30; 120 PPM IN DIET FOR 55 OR 51 WK; STUDY DURATION: 73 WK,"LIVER: HEMANGIOENDOTHELIOMA, ANGIOSARCOMA; LUNG: ADENOMA; INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): ANGIOSARCOMA",POSITIVE,"[ENOMOTO,M, HATANAKA,J, IGARASHI,S, UWANUMA,Y, ITO,H, ASAOKA,S, IYATOMI,A, KUYAMA,S, HARADA,T, AND HAMASAKI,T; HIGH INCIDENCE OF ANGIOSARCOMAS IN BROWN-FAT TISSUE AND LIVERS OF MICE FED STERIGMATOCYSTIN; FOOD CHEM. TOXICOL. 20:547-556, 1982]"
3107,363898512,23615975,CN(C(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O)N=O,Active,,,,HAMSTER,,"INTRAPERITONEAL, INTRAVENOUS",,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 221 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 337 Y78]"
3108,363898512,23615975,CN(C(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O)N=O,Active,,,,MOUSE,,INTRAPERITONEAL,,KIDNEY; LUNG; UTERUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 221 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 337 Y78]"
3109,363898512,23615975,CN(C(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O)N=O,Active,,,,RAT,,INTRAPERITONEAL,,KIDNEY; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 221 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 337 Y78]"
3110,363898512,23615975,CN(C(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O)N=O,Active,,,,RAT,,INTRAVENOUS,,KIDNEY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V4 221 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 337 Y78]"
3111,363898512,23615975,CN(C(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O)N=O,Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 100; 125; 137.5; 150 MG/KG INJECTED ONCE (STUDY DURATION: 12 M0),LIVER: HEPATOMA; KIDNEY: NEPHROBLASTOMA,POSITIVE,"[IWASE,M, NUNOI,K, SADOSHIMA,S, KIKUCHI,M AND FUJISHIMA,M; LIVER, KIDNEY, AND ISLET CELL TUMORS IN SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS TREATED NEONATALLY WITH STREPTOZOTOCIN; TOHOKU J. EXP. MED. 159(2):83-90, 1989]"
3112,363898512,23615975,CN(C(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O)N=O,Active,,,,RAT,SHR/MALE,INTRAPERITONEAL,0; 37.5; 50; 62.5; 75 MG/KG INJECTED ONCE (STUDY DURATION: 12 MO),LIVER: HEPATOMA; KIDNEY: NEPHROBLASTOMA; PANCREATIC ISLETS: TUMOR,POSITIVE,"[IWASE,M, NUNOI,K, SADOSHIMA,S, KIKUCHI,M AND FUJISHIMA,M; LIVER, KIDNEY, AND ISLET CELL TUMORS IN SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS TREATED NEONATALLY WITH STREPTOZOTOCIN; TOHOKU J. EXP. MED. 159(2):83-90, 1989]"
3113,363898513,24599,[O-][Cr](=O)(=O)[O-].[Sr+2],Active,,,,RAT,,"INTRAMUSCULAR IMPLANT, PLEURAL IMPLANT",,IMPLANT SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V2 100 Y73][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 205 Y80]"
3114,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 150; 300 MG/KG FOR 78 WK (STUDY DURATION: 91 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-185 Y79]"
3115,363898514,7501,C=CC1=CC=CC=C1,Active,,,,MOUSE,"O20/MALE,FEMALE",GAVAGE,,"LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 231 Y79]"
3116,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,F344/FEMALE,GAVAGE,"0; 500 MG/KG FOR 103 WK (STUDY DURATION: 104 WK); 1,000; 2,000 MG/KG FOR 78 WK (STUDY DURATION: 105 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-185 Y79]"
3117,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,F344/MALE,GAVAGE,"0; 500 MG/KG FOR 103 WK (STUDY DURATION: 104 WK); 1,000; 2,000 MG/KG FOR 78 WK (STUDY DURATION: 105 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-185 Y79]"
3118,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 50 MG/RAT IN OLIVE OIL ONCE (STUDY DURATION: LIFESPAN),,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
3119,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 50 MG/RAT IN OLIVE OIL ONCE (STUDY DURATION: LIFESPAN),,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
3120,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,"0; 50 MG/RAT IN OLIVE OIL, 1/2 MO FOR 8 MO (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
3121,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,"0; 50 MG/RAT IN OLIVE OIL, 1/2 MO FOR 8 MO (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
3122,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAGASTRIC,"0; 50; 250 MG/KG IN OLIVE OIL 1/D, 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
3123,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAGASTRIC,"0; 50; 250 MG/KG IN OLIVE OIL 1/D, 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
3124,363898514,7501,C=CC1=CC=CC=C1,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,"0; 25; 50; 100; 200; 300 PPM 4 HR/D, 5 D/WK FOR 52 WK (STUDY DURATION: LIFESPAN)","MAMMARY GLAND: BENIGN TUMOR, MALIGNANT TUMOR",POSITIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
3125,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,"0; 25; 50; 100; 200; 300 PPM 4 HR/D, 5 D/WK FOR 52 WK (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
3126,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN 0.1 ML OLIVE OIL 3/WK FOR 20 DOSES (TOTAL DOSE: 200 UMOL) (STUDY DURATION: 27 WK),,NEGATIVE,"[BRUNNEMANN,KD, RIVENSON,A, CHENG,SC, SAA,V AND HOFFMANN,D; A STUDY OF TOBACCO CARCINOGENESIS XLVII. BIOASSAYS OF VINYLPYRIDINES FOR GENOTOXICITY AND FOR TUMORIGENICITY IN A/J MICE; CANCER LETT. 65(2):107-113, 1992]"
3127,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,MOUSE,O20/FEMALE,GAVAGE,0; 1350 MG/KG BW IN 0.1 ML OLIVE OIL ONCE ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),,NEGATIVE,"[PONOMARKOV,V AND TOMATIS,L; EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF STYRENE TO MICE AND RATS; SCAND. J. WORK ENVIRON. HEALTH. 4(SUPPL. 2):127-135, 1978]"
3128,363898514,7501,C=CC1=CC=CC=C1,Active,,,,MOUSE,O20/MALE,GAVAGE,0; 1350 MG/KG BW IN 0.1 ML OLIVE OIL FOR 16 WK POST WEANING ADMINISTERED TO OFFSPRING OF FEMALES GIVEN 1350 MG/KG ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),LUNG: ADENOMA OR CARCINOMA,POSITIVE,"[PONOMARKOV,V AND TOMATIS,L; EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF STYRENE TO MICE AND RATS; SCAND. J. WORK ENVIRON. HEALTH. 4(SUPPL. 2):127-135, 1978]"
3129,363898514,7501,C=CC1=CC=CC=C1,Active,,,,MOUSE,O20/FEMALE,GAVAGE,0; 1350 MG/KG BW IN 0.1 ML OLIVE OIL FOR 16 WK POST WEANING ADMINISTERED TO OFFSPRING OF FEMALES GIVEN 1350 MG/KG ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 D),LUNG: ADENOMA OR CARCINOMA,POSITIVE,"[PONOMARKOV,V AND TOMATIS,L; EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF STYRENE TO MICE AND RATS; SCAND. J. WORK ENVIRON. HEALTH. 4(SUPPL. 2):127-135, 1978]"
3130,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,MOUSE,C57BL/FEMALE,GAVAGE,0; 300 MG/KG BW IN 0.1 ML OLIVE OIL ONCE ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),,NEGATIVE,"[PONOMARKOV,V AND TOMATIS,L; EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF STYRENE TO MICE AND RATS; SCAND. J. WORK ENVIRON. HEALTH. 4(SUPPL. 2):127-135, 1978]"
3131,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,MOUSE,C57BL/MALE,GAVAGE,0; 300 MG/KG BW IN 0.1 ML OLIVE OIL FOR LIFE BEGINNING POST WEANING ADMINISTERED TO OFFSPRING OF FEMALES GIVEN 300 MG/KG ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),,NEGATIVE,"[PONOMARKOV,V AND TOMATIS,L; EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF STYRENE TO MICE AND RATS; SCAND. J. WORK ENVIRON. HEALTH. 4(SUPPL. 2):127-135, 1978]"
3132,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,MOUSE,C57BL/FEMALE,GAVAGE,0; 300 MG/KG BW IN 0.1 ML OLIVE OIL FOR LIFE BEGINNING POST WEANING ADMINISTERED TO OFFSPRING OF FEMALES GIVEN 1350 MG/KG ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),,NEGATIVE,"[PONOMARKOV,V AND TOMATIS,L; EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF STYRENE TO MICE AND RATS; SCAND. J. WORK ENVIRON. HEALTH. 4(SUPPL. 2):127-135, 1978]"
3133,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,BDIV/FEMALE,GAVAGE,0; 1350 MG/KG BW IN 0.3 ML OLIVE OIL ONCE ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),,NEGATIVE,"[PONOMARKOV,V AND TOMATIS,L; EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF STYRENE TO MICE AND RATS; SCAND. J. WORK ENVIRON. HEALTH. 4(SUPPL. 2):127-135, 1978]"
3134,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,BDIV/MALE,GAVAGE,0; 500 MG/KG BW IN 0.3 ML OLIVE OIL FOR LIFE BEGINNING POST WEANING ADMINISTERED TO OFFSPRING OF FEMALES GIVEN 1350 MG/KG ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),,NEGATIVE,"[PONOMARKOV,V AND TOMATIS,L; EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF STYRENE TO MICE AND RATS; SCAND. J. WORK ENVIRON. HEALTH. 4(SUPPL. 2):127-135, 1978]"
3135,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,BDIV/FEMALE,GAVAGE,0; 500 MG/KG BW IN 0.3 ML OLIVE OIL FOR LIFE BEGINNING POST WEANING ADMINISTERED TO OFFSPRING OF FEMALES GIVEN 1350 MG/KG ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),,NEGATIVE,"[PONOMARKOV,V AND TOMATIS,L; EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF STYRENE TO MICE AND RATS; SCAND. J. WORK ENVIRON. HEALTH. 4(SUPPL. 2):127-135, 1978]"
3136,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 25; 50; 100; 200; 300 PPM IN AIR 4 HR/D 5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3137,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 25; 50; 100; 200; 300 PPM IN AIR 4 HR/D 5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3138,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 50; 250 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3139,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 50; 250 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3140,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,STRAIN-CD/MALE,INHALATION,0; 50; 200; 500; 1000 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION:107 WK),,NEGATIVE,"[CRUZAN,G, CUSHMAN,JR, ANDREWS,LS, GRANVILLE,GC, JOHNSON,KA, HARDY,CJ, COOMBS,DW, MULLIN,PA AND BROWN,WR; CHRONIC TOXICITY/ONCOGENICITY STUDY OF STYRENE IN CD RATS BY INHALATION EXPOSURE FOR 104 WK; TOXICOL. SCI. 46(2):266-281, 1998]"
3141,363898514,7501,C=CC1=CC=CC=C1,Inactive,,,,RAT,STRAIN-CD/FEMALE,INHALATION,0; 50; 200; 500; 1000 PPM 6HR/D 5 D/WK FOR 104 WK (STUDY DURATION:107 WK),,NEGATIVE,"[CRUZAN,G, CUSHMAN,JR, ANDREWS,LS, GRANVILLE,GC, JOHNSON,KA, HARDY,CJ, COOMBS,DW, MULLIN,PA AND BROWN,WR; CHRONIC TOXICITY/ONCOGENICITY STUDY OF STYRENE IN CD RATS BY INHALATION EXPOSURE FOR 104 WK; TOXICOL. SCI. 46(2):266-281, 1998]"
3142,363898514,7501,C=CC1=CC=CC=C1,Active,,,,MOUSE,CD-1/MALE,INHALATION,0; 20; 40; 80; 160 PPM IN CHAMBER FOR 6 HR/D 5D/WK FOR 104 WK (STUDY DURATION: 104 WK),LUNG: BRONCHIOLOALVEOLAR ADENOMA,POSITIVE,"[CRUZAN,G CUSHMAN,JR ANDREWS,LS GRANVILLE,GC JOHNSON,KA BEVAN,C HARDY,CJ COOMBS,DW MULLINS,PA AND BROWN,WR; CHRONIC TOXICITY/ONCOGENICITY STUDY OF STYRENE IN CD-1 MICE BY INHALATION EXPOSURE FOR 104 WEEKS; J. APPL. TOXICOL. 21(3):185-198, 2001]"
3143,363898514,7501,C=CC1=CC=CC=C1,Active,,,,MOUSE,CD-1/FEMALE,INHALATION,0; 20; 40; 80; 160 PPM IN CHAMBER FOR 6 HR/D 5D/WK FOR 98 WK (STUDY DURATION: 98 WK),"LUNG: BRONCHIOLOALVEOLAR ADENOMA, BRONCHIOLOALVEOLAR CARCINOMA",POSITIVE,"[CRUZAN,G CUSHMAN,JR ANDREWS,LS GRANVILLE,GC JOHNSON,KA BEVAN,C HARDY,CJ COOMBS,DW MULLINS,PA AND BROWN,WR; CHRONIC TOXICITY/ONCOGENICITY STUDY OF STYRENE IN CD-1 MICE BY INHALATION EXPOSURE FOR 104 WEEKS; J. APPL. TOXICOL. 21(3):185-198, 2001]"
3144,363898514,7501,C=CC1=CC=CC=C1,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 150; 300 MG/KG FOR 78 WK (STUDY DURATION: 91 WK),"LUNG: ADENOMA, CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-185 Y79]"
3145,363898516,7216,CCN(CC)C(=S)SCC(=C)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 908; 1815 PPM TWA, IN DIET FOR 74 WK (STUDY DURATION: 90-91 WK)",MAMMARY GLAND: ADENOCARCINOMA OR SQUAMOUS METAPLASIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-115 Y78]"
3146,363898516,7216,CCN(CC)C(=S)SCC(=C)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 949; 1897 PPM TWA, IN DIET FOR 74 WK (STUDY DURATION: 91 WK)",LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR ALVEOLAR/BRONCHIOLAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-115 Y78]"
3147,363898516,7216,CCN(CC)C(=S)SCC(=C)Cl,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 250; 404 PPM TWA, IN DIET FOR 63-78 WK (STUDY DURATION: 104-111 WK)",MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-115 Y78]"
3148,363898516,7216,CCN(CC)C(=S)SCC(=C)Cl,Active,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 250; 410 PPM TWA, IN DIET FOR 64-78 WK (STUDY DURATION: 103-111 WK)","STOMACH: PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-115 Y78]"
3149,363898517,5329,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,Active,,,,RAT,"CD-1/MALE,FEMALE",ORAL,25; 50; 150; 300; 600 MG/KG/D IN DIET FOR 60 WK,THYROID GLAND: ADENOMA OR NODULES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V24 285 Y80]"
3150,363898518,5344,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 2000 MG/KG IN 0.5% AQ CMC,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-138 Y79]"
3151,363898518,5344,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 2000 MG/KG IN 0.5% AQ CMC,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-138 Y79]"
3152,363898518,5344,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 100; 400 MG/KG IN 0.5% AQ CMC,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-138 Y79]"
3153,363898518,5344,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 100; 400 MG/KG IN 0.5% AQ CMC,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-138 Y79]"
3154,363898519,6498,C1C=CCS1(=O)=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 384; 768 MG/KG,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-102 Y78]"
3155,363898519,6498,C1C=CCS1(=O)=O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 311; 622 MG/KG,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-102 Y78]"
3156,363898519,6498,C1C=CCS1(=O)=O,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,0; 120; 240 MG/KG,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-102 Y78]"
3157,363898519,6498,C1C=CCS1(=O)=O,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,0; 197; 372 MG/KG,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-102 Y78]"
3158,363898520,10461,C(CCl)SCCCl,Active,,,,HUMAN,,INHALATION,,RESPIRATORY TRACT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 181 Y75]"
3159,363898520,10461,C(CCl)SCCCl,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INHALATION,100 CM3/8 L FOR 15 MIN,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 181 Y75]"
3160,363898520,10461,C(CCl)SCCCl,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAVENOUS,0.06-0.07% IN WATER IN 4 DOSES OF 0.25 ML OVER 8 D,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 181 Y75]"
3161,363898521,16133892,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,Active,,,,MOUSE,,SUBCUTANEOUS,,LIVER; INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 253 Y76]"
3162,363898521,16133892,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,Active,,,,RAT,,SUBCUTANEOUS,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 253 Y76]"
3163,363898521,16133892,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.25; 0.5% IN DISTILLED WATER AS DRINKING WATER FOR 2 YR (STUDY DURATION: 114 WK),,NEGATIVE,"[ONODERA,H, KITAURA,K, MITSUMORI,K, YOSHIDA,J, YASUHARA,K, SHIMO,T, TAKAHASHI, M AND HAYASHI,Y; STUDY ON THE CARCINOGENICITY OF TANNIC ACID IN F344 RATS; FOOD CHEM. TOXICOL. 32(12):1101-1106, 1994]"
3164,363898521,16133892,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.25; 0.5% IN DISTILLED WATER AS DRINKING WATER FOR 2 YR (STUDY DURATION: 114 WK),,NEGATIVE,"[ONODERA,H, KITAURA,K, MITSUMORI,K, YOSHIDA,J, YASUHARA,K, SHIMO,T, TAKAHASHI, M AND HAYASHI,Y; STUDY ON THE CARCINOGENICITY OF TANNIC ACID IN F344 RATS; FOOD CHEM. TOXICOL. 32(12):1101-1106, 1994]"
3165,363898522,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-224 Y82]"
3166,363898522,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-224 Y82]"
3167,363898522,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-224 Y82]"
3168,363898522,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-224 Y82]"
3169,363898523,6294,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 411; 822 PPM IN DIET FOR 78 WK (STUDY DURATION: 93 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
3170,363898523,6294,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 411; 822 PPM IN DIET FOR 78 WK (STUDY DURATION: 93 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
3171,363898523,6294,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",ORAL,250 PPM IN DIET,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74]"
3172,363898523,6294,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 850; 1700 PPM IN DIET FOR 78 WK (STUDY DURATION: 113 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
3173,363898523,6294,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 1647; 3294 PPM IN DIET FOR 78 WK (STUDY DURATION: 113 WK),THYROID GLAND: FOLLICULAR CELL CARCINOMA OR ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-131 Y78]"
3174,363898524,6013,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,Active,,,,MOUSE,,SUBCUTANEOUS IMPLANT,,MAMMARY GLAND; VAGINA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V6 209 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 519 Y79]"
3175,363898524,6013,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,Active,,,,MOUSE,,SUBCUTANEOUS,,GENITAL TRACT,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 519 Y79]"
3176,363898525,5995,CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,Active,,,,MOUSE,,SUBCUTANEOUS IMPLANT,,CERVIX; UTERUS,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 519 Y79]"
3177,363898525,5995,CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,Active,,,,RAT,,SUBCUTANEOUS IMPLANT,,PROSTATE GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V21 519 Y79]"
3178,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 0.04; 0.2; 2.0 UG/KG SUSPENDED IN 9:1 CORN OIL-ACETONE,LIVER: HEPATOCELLULAR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-209 Y82]"
3179,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 0.01; 0.05; 0.5 UG/KG SUSPENDED IN 9:1 CORN OIL-ACETONE,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-209 Y82]"
3180,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0.005 UG IN ACETONE SUSPENSION 3/WK FOR 99 OR 104 WK (STUDY DURATION: 99 OR 104 WK),INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-201 Y82]"
3181,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,0; 0.01; 0.05; 0.5 UG/KG SUSPENDED IN 9:1 CORN OIL-ACETONE,LIVER: NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-209 Y82]"
3182,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,0; 0.01; 0.05; 0.5 UG/KG SUSPENDED IN 9:1 CORN OIL-ACETONE,THYROID GLAND: FOLLICULAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-209 Y82]"
3183,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,MOUSE,B6C3/MALE,INTRAPERITONEAL,0; 1; 30; 60; UG/KG 1/WK FOR 5 WK BEGINNING AT 10 D OF AGE (STUDY DURATION: 78 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPTOCELLULAR CARCINOMA; THYMUS: LYMPHOMA",POSITIVE,"[DELLA PORTA,G, DRAGANI,TA AND SOZZI,G; CARCINOGENIC EFFECTS OF INFANTILE AND LONG-TERM 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TREATMENT IN THE MOUSE; TUMORI 73(2):99-107, 1987]"
3184,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,MOUSE,B6C3/FEMALE,INTRAPERITONEAL,0; 1; 30; 60; UG/KG 1/WK FOR 5 WK BEGINNING AT 10 D OF AGE (STUDY DURATION: 78 WK),LIVER: HEPATOCELLULAR ADENOMA; THYMUS: LYMPHOMA,POSITIVE,"[DELLA PORTA,G, DRAGANI,TA AND SOZZI,G; CARCINOGENIC EFFECTS OF INFANTILE AND LONG-TERM 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TREATMENT IN THE MOUSE; TUMORI 73(2):99-107, 1987]"
3185,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,MOUSE,B6C3/MALE,GAVAGE,0; 2.5; 5 UG/KG IN CORN OIL 1/WK FOR 52 WK (STUDY DURATION: 110 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[DELLA PORTA,G, DRAGANI,TA AND SOZZI,G; CARCINOGENIC EFFECTS OF INFANTILE AND LONG-TERM 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TREATMENT IN THE MOUSE; TUMORI 73(2):99-107, 1987]"
3186,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,MOUSE,B6C3/FEMALE,GAVAGE,0; 2.5; 5 UG/KG IN CORN OIL 1/WK FOR 52 WK (STUDY DURATION: 110 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPTOCELLULAR CARCINOMA",POSITIVE,"[DELLA PORTA,G, DRAGANI,TA AND SOZZI,G; CARCINOGENIC EFFECTS OF INFANTILE AND LONG-TERM 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TREATMENT IN THE MOUSE; TUMORI 73(2):99-107, 1987]"
3187,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Unspecified,,,,MOUSE,SWISS/MALE,DERMAL,0.001 UG IN ACETONE SUSPENSION 3/WK FOR 99 OR 104 WK (STUDY DURATION: 99 OR 104 WK),INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-201 Y82]"
3188,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 3; 10; 22; 46; 100 NG/KG/D (STUDY DURATION: 2 YRS),ORAL MUCOSA: SQUAMOUS CELL CARCINOMA,POSITIVE; HIGHEST DOSE ONLY,"[YOSHIZAWA,K, WALKER,NJ, JOKINEN,MP, BRIX,AE, SELLS,DM,  MARSH,T, WYDE,ME, ORZECH,D, HASEMAN,JK, AND NYSKA,A;  GINGIVAL CARCINOGENICITY IN FEMALE HARLAN SPRAGUE-DAWLEY  RATS FOLLOWING TWO YEAR ORAL TREATMENT WITH  2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN AND DIOXIN-LIKE  COMPOUNDS. [ERRATUM TO DOCUMENT CITED IN CA142:234804];  TOXICOL. SCI. 83(2):405-406, 2005]"
3189,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,Rat,Harlan Sprague-Dawley/Female,Gavage,0; 3; 10; 22; 46; 100 ng/kg (Test material solvent: corn oil: acetone (99:1)),"Liver: Hepatocellular adenoma (0/53, 0/54, 0/53, 1/53, 13/53, 2/50); Cholangiocarcinoma (0/53, 0/54, 0/53, 1/53, 4/53, 25/53, 2/50); Hepatocholangioma (0/53, 0/54, 0/53, 0/53, 0/53, 2/53, 0/50); Cholangioma (0/53, 0/54, 0/53, 0/53, 0/53, 1/50); Lung: Cystic keratinizing epithelioma (0/53, 0/54, 0/53, 0/52, 0/53, 9/52, 0/50); Oral mucosa: Gingival squamous cell carcinoma (1/53, 2/54, 1/53, 0/53, 4/53, 10/53, 5/50); Uterus: Squamous cell carcinoma (0/53, 0/54, 0/53, 5/53, 0/53, 2/50); Pancreas: Acinar adenoma or carcinoma (0/51, 0/54, 0/52, 0/53, 0/52, 3/51, 1/49)",Positive; Findings in pancreas and in liver for hepatocholangioma and cholangioma considered equivocal by NTP,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-521 Y06]"
3190,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Inactive,,,,Rat,Harlan Sprague-Dawley/Female (50 dosed animals),Gavage,0; 100 ng/kg (Test material solvent: corn oil: acetone (99:1)),,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-521 Y06]"
3191,363898526,15625,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Active,,,,Rat,Spartan Sprague Dawley/Female (50/Experimental Group; 86 Controls),Oral,"0; 1; 10; 100 ng/kg in food, 7 days a wk for 2 yr","Liver: Hepatocellular adenoma (2/86, 1/50, 9/50, 14/49); hepatocellular carcinoma (0/86, 0/50, 0/50, 4/49). Lungs: Keratinizing squamous cell carcinoma (0/86), 0/50, 0/50, 7/49). Oral mucosa: Gingival squamous cell carcinoma ( 0/86, 0/50, 1/50, 4/49), tongue squamous cell carcinoma (1/86, 0/50, 0/50, 2/49). Pancreas: Acinar cell adenoma and carcinoma (0/86, 1/50, 0/50, 1/49). Thyroid: C-cell adenoma and carcinoma (16/86, 3/50, 2/50, 6/49). Uterus: Endommetrial polyp ((28/86, 12/50, 11/50, 7/49). Mammary gland: Benign and/or malignant neoplasms (73/86, 39/50, 40/50, 24/49). Pituitary: Adenoma (43/86, 12/50, 12/50, 18/49).",Positive,"[WALKER,NJ, WYDE,ME, FISCHER,LJ, NYSKA,A, AND BUCHER,JR; COMPARISON OF CHRONIC TOXICITY AND CARCINOGENICITY OF 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN (TCDD) IN 2-YEAR BIOASSAY IN FEMALE SPRAGUE-DAWLEY RATS; MOL. NUTR.FOOD RES. 50(10):934-944, 2006]"
3192,363898527,12418,C(C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL,LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-237 Y83]"
3193,363898527,12418,C(C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL,LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-237 Y83]"
3194,363898527,12418,C(C(Cl)(Cl)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-237 Y83]"
3195,363898527,12418,C(C(Cl)(Cl)Cl)Cl,Unspecified,,,,RAT,F344/MALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-237 Y83]"
3196,363898528,6591,C(C(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 142; 282 MG/KG N CORN OIL 5 D/WK FOR 78 WK (STUDY DURATION: 90 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-27 Y78]"
3197,363898528,6591,C(C(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 142; 282 MG/KG IN CORN OIL 5 D/WK FOR 78 WK (STUDY DURATION: 90 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-27 Y78]"
3198,363898528,6591,C(C(Cl)Cl)(Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,0; 43; 76 MG/KG IN CORN OIL 5 D/WK FOR 78 WK (STUDY DURATION: 110 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-27 Y78]"
3199,363898528,6591,C(C(Cl)Cl)(Cl)Cl,Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,0; 62; 108 MG/KG IN CORN OIL 5 D/WK FOR 78 WK (STUDY DURATION: 110 WK),"LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-27 Y78]"
3200,363898529,31373,C(=C(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 386; 772 MG/KG, TWA FOR 78 WKS",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-13 Y77]"
3201,363898529,31373,C(=C(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 536; 1072 MG/KG, TWA FOR 78 WKS",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-13 Y77]"
3202,363898529,31373,C(=C(Cl)Cl)(Cl)Cl,Active,,,,RAT,F344/MALE,INHALATION,"0; 200; 400 PPM 6 HR/D, 5 D/WK FOR 103 WK",HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-311 Y86]"
3203,363898529,31373,C(=C(Cl)Cl)(Cl)Cl,Active,,,,RAT,F344/FEMALE,INHALATION,"0; 200; 400 PPM 6 HR/D, 5 D/WK FOR 103 WK",HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-311 Y86]"
3204,363898529,31373,C(=C(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 100; 200 PPM 6 HR/D, 5 D/WK FOR 103 WK","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-311 Y86]"
3205,363898529,31373,C(=C(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 100; 200 PPM 6 HR/D, 5 D/WK FOR 103 WK","LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-311 Y86]"
3206,363898530,17107,COC1=C(C(=C(C(=C1Cl)Cl)[N+](=O)[O-])Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.006; 0.012% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-114 Y78]"
3207,363898530,17107,COC1=C(C(=C(C(=C1Cl)Cl)[N+](=O)[O-])Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.006; 0.012% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-114 Y78]"
3208,363898530,17107,COC1=C(C(=C(C(=C1Cl)Cl)[N+](=O)[O-])Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.006; 0.012% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-114 Y78]"
3209,363898530,17107,COC1=C(C(=C(C(=C1Cl)Cl)[N+](=O)[O-])Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.006; 0.012% OF DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-114 Y78]"
3210,363898531,13745,COP(=O)(OC)OC(=CCl)C1=CC(=C(C=C1Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 8000; 16000 PPM IN DIET,LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-33 Y78]"
3211,363898531,13745,COP(=O)(OC)OC(=CCl)C1=CC(=C(C=C1Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 4250; 8500 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-33 Y78]"
3212,363898532,3117,CCN(CC)C(=S)SSC(=S)N(CC)CC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 100; 500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-166 Y79]"
3213,363898532,3117,CCN(CC)C(=S)SSC(=S)N(CC)CC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 2000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-166 Y79]"
3214,363898532,3117,CCN(CC)C(=S)SSC(=S)N(CC)CC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 300; 600 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-166 Y79]"
3215,363898532,3117,CCN(CC)C(=S)SSC(=S)N(CC)CC,Inactive,,,,RAT,F344/MALE,ORAL,0; 300; 600 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-166 Y79]"
3216,363898533,93185,C1CN(COC1)N=O,Active,,,,RAT,F344/FEMALE,ORAL,40 MG/L IN DRINKING WATER FOR 50 WK,"LIVER: HEPATOCELLULAR CARCINOMA, HEMANGIOENDOTHELIAL SARCOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; COMPARATIVE CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOTETRAHYDROOXAZINE IN RATS; CARCINOGENESIS 3:911-915, 1982]"
3217,363898534,2723949,CC(=S)N,Active,,,,MOUSE,SWISS,ORAL,0.03% IN DIET,LIVER: CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 77 Y74]"
3218,363898534,2723949,CC(=S)N,Active,,,,RAT,"WISTAR/MALE,FEMALE",ORAL,0.032% IN DIET,"LIVER: BILE DUCT TUMOR, NOS",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 77 Y74]"
3219,363898535,8765,C1=CC(=CC=C1N)SC2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-47 Y78]"
3220,363898535,8765,C1=CC(=CC=C1N)SC2=CC=C(C=C2)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET,LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-47 Y78]"
3221,363898535,8765,C1=CC(=CC=C1N)SC2=CC=C(C=C2)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 1500; 3000 PPM IN DIET,"THYROID GLAND: FOLLICULAR CELL CARCINOMA; UTERUS: ADENOCARCINOMA, NOS",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-47 Y78]"
3222,363898535,8765,C1=CC(=CC=C1N)SC2=CC=C(C=C2)N,Active,,,,RAT,F344/MALE,ORAL,0; 1500; 3000 PPM IN DIET (68-72 WEEKS),"LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; COLON: ADENOCARCINOMA, NOS; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA; EAR (CANAL): SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-47 Y78]"
3223,363898536,5453,C1CN1P(=S)(N2CC2)N3CC3,Active,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,0; 1.15; 2.3 MG/KG 3/WK FOR 43-52 WK (STUDY DURATION: 86-87 WK),HEMATOPOIETIC SYSTEM (LEUKEMIA): LYMPHOCYTIC LEUKEMIA; LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-58 Y78]"
3224,363898536,5453,C1CN1P(=S)(N2CC2)N3CC3,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 1.15; 2.3 MG/KG 3/WK FOR 52 WK (STUDY DURATION: 56-87 WK),INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA; EAR (CANAL): SQUAMOUS CELL CARCINOMA; PREPUTIAL GLAND: SQUAMOUS CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-58 Y78]"
3225,363898536,5453,C1CN1P(=S)(N2CC2)N3CC3,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 0.7; 1.4; 2.8 MG/KG 3/WK FOR 21-52 WK (STUDY DURATION: 21-87 WK),MAMMARY GLAND: ADENOCARCINOMA; PITUITARY GLAND: CHROMOPHOBE ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-58 Y78]"
3226,363898536,5453,C1CN1P(=S)(N2CC2)N3CC3,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 0.7; 1.4; 2.8 MG/KG 3/WK FOR 19-52 WK (STUDY DURATION: 19-87 WK),INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA; INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): SARCOMA; HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA; EAR (ZYMBAL GLAND): SQUAMOUS CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-58 Y78]"
3227,363898537,1269845,C1=CNC(=S)NC1=O,Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 85 Y74]"
3228,363898537,1269845,C1=CNC(=S)NC1=O,Active,,,,RAT,,ORAL,,THYROID GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 85 Y74]"
3229,363898538,2723790,C(=S)(N)N,Active,,,,RAT,,ORAL,,LIVER; THYROID GLAND; EAR (ZYMBAL GLAND),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 95 Y74]"
3230,363898539,32335,C[C@@H]1C[C@@H](CN(C1)S(=O)(=O)C2=CC(=C(C=C2)Cl)C(=O)O)C,Active,,,,RAT,F344/MALE,ORAL,"0.2% IN DIET FOR 7.5 MO, THEN 0.1% FOR 4 MO, THEN 0.05% FOR 4 MO",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[REDDY,JK, AZARNOFF,DL AND HIGNITE,CE; HYPOLIPIDAEMIC HEPATIC PEROXISOME PROLIFERATORS FORM A NOVEL CLASS OF CHEMICAL CARCINOGENS; NATURE 283:397-398, 1980]"
3231,363898540,26042,O=[Ti]=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-97 Y79]"
3232,363898540,26042,O=[Ti]=O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-97 Y79]"
3233,363898540,26042,O=[Ti]=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-97 Y79]"
3234,363898540,26042,O=[Ti]=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-97 Y79]"
3235,363898540,26042,O=[Ti]=O,Active,,,,RAT,STRAIN CD/MALE,INHALATION,0; 10; 50; 250 MG/M3 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA,POSITIVE,"[LEE,KP, TROCHIMOWICZ,HJ AND REINHARDT,CF; PULMONARY RESPONSE OF RATS EXPOSED TO TITANIUM DIOXIDE BY INHALATION FOR TWO YEARS; TOXICOL. APPL. PHARMACOL. 79:179-192, 1985]"
3236,363898540,26042,O=[Ti]=O,Active,,,,RAT,STRAIN CD/FEMALE,INHALATION,0; 10; 50; 250 MG/M3 6 HR/D 5 D/WK FOR 85 WK (STUDY DURATION: 24 MO),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[LEE,KP, TROCHIMOWICZ,HJ AND REINHARDT,CF; PULMONARY RESPONSE OF RATS EXPOSED TO TITANIUM DIOXIDE BY INHALATION FOR TWO YEARS; TOXICOL. APPL. PHARMACOL. 79:179-192, 1985]"
3237,363898540,26042,O=[Ti]=O,Active,,,,RAT,"STRAIN CD/MALE, FEMALE",INHALATION,"0; 10; 50; 250 MG/M3, 6HR/D, 5D/WK FOR 104 WK (STUDY DURATION: 24 MO)",LUNG: BRONCHIOALVEOLAR ADENOMA,POSITIVE,"[TROCHIMOWICZ,HJ, LEE,KP AND REINHARDT,CF; CHRONIC INHALATION EXPOSURE OF RATS TO TITANIUM DIOXIDE DUST; J. APPL. TOXICOL. 8(6):383-5, 1988]"
3238,363898540,26042,O=[Ti]=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1; 2; 5% IN DIET AS A COATING ON MICA FOR STUDY DURATION (STUDY DURATION: 130 WK),,NEGATIVE,"[BERNARD,BK, OSHEROFF,MR, HOFMAN,A AND MENNEAR,JH; TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIETARY TITANIUM DIOXIDE-COATED MICA IN MALE AND FEMALE FISCHER 344 RATS; J. TOXICOL. ENVIRON. HEALTH 28(4):415-426, 1989]"
3239,363898540,26042,O=[Ti]=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 1; 2; 5% IN DIET AS A COATING ON MICA FOR STUDY DURATION (STUDY DURATION: 130 WK),,NEGATIVE,"[BERNARD,BK, OSHEROFF,MR, HOFMAN,A AND MENNEAR,JH; TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIETARY TITANIUM DIOXIDE-COATED MICA IN MALE AND FEMALE FISCHER 344 RATS; J. TOXICOL. ENVIRON. HEALTH 28(4):415-426, 1989]"
3240,363898540,26042,O=[Ti]=O,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 7.2 MG/M3 18 HR/D 5 D/WK FOR 4 MO INCREASED TO 14.8 MG/M3 FOR THE NEXT 4 MO THEN 9.4 MG/M3 FOR 16 MO FOLLOWED BY CLEAN AIR FOR 6 MO (STUDY DURATION: 30 MO),LUNG: TUMOR,POSITIVE,"[HEINRICH,U, FUHST,R, RITTINGHAUSEN,S, CREUTZENBERG,O, BELLMANN,B, KOCH,W AND LEVSEN,K; CHRONIC INHALATION EXPOSURE OF WISTAR RATS AND TWO DIFFERENT STRAINS OF MICE TO DIESEL ENGINE EXHAUST, CARBON BLACK, AND TITANIUM DIOXIDE; INHALATION TOXICOL. 7(4):533-556, 1995]"
3241,363898540,26042,O=[Ti]=O,Inactive,,,,MOUSE,NMRI/FEMALE,INHALATION,0; 7.2 MG/M3 18 HR/D 5 D/WK FOR 4 MO INCREASED TO 14.8 MG/M3 FOR THE NEXT 4 MO THEN 9.4 MG/M3 FOR 5.5 MO FOLLOWED BY CLEAN AIR FOR 9.5 MO (STUDY DURATION: 23 MO),,NEGATIVE,"[HEINRICH,U, FUHST,R, RITTINGHAUSEN,S, CREUTZENBERG,O, BELLMANN,B, KOCH,W AND LEVSEN,K; CHRONIC INHALATION EXPOSURE OF WISTAR RATS AND TWO DIFFERENT STRAINS OF MICE TO DIESEL ENGINE EXHAUST, CARBON BLACK, AND TITANIUM DIOXIDE; INHALATION TOXICOL. 7(4):533-556, 1995]"
3242,363898540,26042,O=[Ti]=O,Inactive,,,,RAT,"F344/MALE,FEMALE",INHALATION,0; 5 MG/M3 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 25.5 MO),,NEGATIVE,"[MUHLE,H, KITTEL,B, ERNST,H, MOHR,U AND MERMELSTEIN,R; NEOPLASTIC LUNG LESIONS IN RAT AFTER CHRONIC EXPOSURE TO CRYSTALLINE SILICA; SCAND. J. WORK, ENVIRON. HEALTH 21(SUPPL. 2):27-29, 1995]"
3243,363898540,26042,O=[Ti]=O,Active,,,,Rat,Wistar/Female (48/group),Intratracheal,"6 mg of 0.09-0.2 um particles given as 10 instillations before wk 26, study duration 108 wk or no treatment","Lung: Bronchiolo-alveolar adenoma (7/44 experimental animals vs 0/46 control animals), bronchiolo-alveolar carcinoma (2/44 vs 0/46), squamous cell carcinoma (4/44 vs 0/46), cystic keratinizing epithelioma (5/44 vs 0/46), >1 tumor type (5/44 vs 0/46)",Positive,"[MOHR,U, ERNST,H, ROLLER,M, AND POTT,F; PULMONARY TUMOR TYPES INDUCED IN WISTAR RATS OF THE SO-CALLED 19-DUST STUDY; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 58:13-20, 2006]"
3244,363898540,26042,O=[Ti]=O,Active,,,,Rat,Wistar/Female (48/group),Intratracheal,"5 instillations of 3 mg hydrophilic P25 titanium dioxide as 0.01-0.03 um  particles given before wk 26, study duration 104-114 wk or no treatment","Lung: Bronchiolo-alveolar adenoma (12/42, 16/46, and 17/46 in experimental groups vs 0/46 in control), bronchiolo-alveolar carcinoma (12/42, 18/48, 14/46 vs 0/46), adenosquamous cell carcinoma (0/42, 0/46, 1/46 vs 0/46), squamous cell carcinoma (2/42, 8/46, 12/46 vs 0/46), cystic keratinizing epithelioma (12/44, 13/46, 19/46 vs 0/46), non-keratinizing epithelioma (1/44, 2/46, 0/46 vs 0/46), >1 tumor type (11/42, 20/46, 19/46 vs 0/46)",Positive,"[MOHR,U, ERNST,H, ROLLER,M, AND POTT,F; PULMONARY TUMOR TYPES INDUCED IN WISTAR RATS OF THE SO-CALLED 19-DUST STUDY; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 58:13-20, 2006]"
3245,363898540,26042,O=[Ti]=O,Active,,,,Rat,Wistar/Female (48/group),Intratracheal,"5 instillations of 6 mg hydrophilic P25 titanium dioxide as 0.01-0.03 um  particles given before wk 26, study duration 104-114 wk","Lung: Bronchiolo-alveolar adenoma (12/42, 16/46, and 17/46 in experimental groups vs 0/46 in control), bronchiolo-alveolar carcinoma (12/42, 18/48, 14/46 vs 0/46), adenosquamous cell carcinoma (0/42, 0/46, 1/46 vs 0/46), squamous cell carcinoma (2/42, 8/46, 12/46 vs 0/46), cystic keratinizing epithelioma (12/44, 13/46, 19/46 vs 0/46), non-keratinizing epithelioma (1/44, 2/46, 0/46 vs 0/46), >1 tumor type (11/42, 20/46, 19/46 vs 0/46)",Positive,"[MOHR,U, ERNST,H, ROLLER,M, AND POTT,F; PULMONARY TUMOR TYPES INDUCED IN WISTAR RATS OF THE SO-CALLED 19-DUST STUDY; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 58:13-20, 2006]"
3246,363898540,26042,O=[Ti]=O,Active,,,,Rat,Wistar/Female (48/group),Intratracheal,"10 instillations of 6 mg hydrophilic P25 titanium dioxide as 0.01-0.03 um  particles given before wk 26, study duration 104-114 wk","Lung: Bronchiolo-alveolar adenoma (12/42, 16/46, and 17/46 in experimental groups vs 0/46 in control), bronchiolo-alveolar carcinoma (12/42, 18/48, 14/46 vs 0/46), adenosquamous cell carcinoma (0/42, 0/46, 1/46 vs 0/46), squamous cell carcinoma (2/42, 8/46, 12/46 vs 0/46), cystic keratinizing epithelioma (12/44, 13/46, 19/46 vs 0/46), non-keratinizing epithelioma (1/44, 2/46, 0/46 vs 0/46), >1 tumor type (11/42, 20/46, 19/46 vs 0/46)",Positive,"[MOHR,U, ERNST,H, ROLLER,M, AND POTT,F; PULMONARY TUMOR TYPES INDUCED IN WISTAR RATS OF THE SO-CALLED 19-DUST STUDY; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 58:13-20, 2006]"
3247,363898541,5503,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-51 Y78]"
3248,363898541,5503,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-51 Y78]"
3249,363898541,5503,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-51 Y78]"
3250,363898541,5503,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,Inactive,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-51 Y78]"
3251,363898542,5505,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-31 Y77]"
3252,363898542,5505,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-31 Y77]"
3253,363898542,5505,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 12000; 24000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-31 Y77]"
3254,363898542,5505,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 12000; 24000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-31 Y77]"
3255,363898544,27324,CC1=C(C=CC=C1N)N.Cl.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 50; 100 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-200 Y80]"
3256,363898544,27324,CC1=C(C=CC=C1N)N.Cl.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 50; 100 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-200 Y80]"
3257,363898544,27324,CC1=C(C=CC=C1N)N.Cl.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 250; 500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-200 Y80]"
3258,363898544,27324,CC1=C(C=CC=C1N)N.Cl.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 250; 500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-200 Y80]"
3259,363898545,22856,CC1=C(C=CC(=C1)N)N.OS(=O)(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 0.06; 0.1% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-126 Y78]"
3260,363898545,22856,CC1=C(C=CC(=C1)N)N.OS(=O)(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 0.06; 0.1% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-126 Y78]"
3261,363898545,22856,CC1=C(C=CC(=C1)N)N.OS(=O)(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 0.06; 0.2% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-126 Y78]"
3262,363898545,22856,CC1=C(C=CC(=C1)N)N.OS(=O)(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,"0; 0.06; 0.2% OF DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-126 Y78]"
3263,363898546,,,Active,,,,RAT,F344/MALE,GAVAGE,0; 30; 60 MG/KG IN CORN OIL 5 D/WK FOR 106 WK,INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA OR FIBROSARCOMA; PANCREAS: ACINAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-251 Y86]"
3264,363898546,,,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR 106 WK,INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA OR FIBROSARCOMA; LIVER: NEOPLASTIC NODULE; PANCREAS: ISLET CELL ADENOMA; MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-251 Y86]"
3265,363898546,,,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 120; 240 MG/KG IN CORN OIL 5 D/WK FOR 105 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-251 Y86]"
3266,363898546,,,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR 105 WK,BLOOD VESSELS: HEMANGIOMA OR HEMANGIOSARCOMA; LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-251 Y86]"
3267,363898546,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 0.05; 0.15 PPM IN AIR 6H/D 5D/WK FOR 110 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[LOESER,E; LONG-TERM TOXICITY AND CARCINOGENICITY STUDIES WITH 2,4/2,6-TOLUENE-DIISOCYANATE (80/20) IN RATS AND MICE; TOXICOL. LETT. 15:71-81, 1983]"
3268,363898546,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 0.05; 0.15 PPM IN AIR 6H/D 5D/WK FOR 108 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[LOESER,E; LONG-TERM TOXICITY AND CARCINOGENICITY STUDIES WITH 2,4/2,6-TOLUENE-DIISOCYANATE (80/20) IN RATS AND MICE; TOXICOL. LETT. 15:71-81, 1983]"
3269,363898546,,,Inactive,,,,MOUSE,CD-1/MALE,INHALATION,0; 0.05; 0.15 PPM IN AIR 6H/D 5D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[LOESER,E; LONG-TERM TOXICITY AND CARCINOGENICITY STUDIES WITH 2,4/2,6-TOLUENE-DIISOCYANATE (80/20) IN RATS AND MICE; TOXICOL. LETT. 15:71-81, 1983]"
3270,363898546,,,Inactive,,,,MOUSE,CD-1/FEMALE,INHALATION,0; 0.05; 0.15 PPM IN AIR 6H/D 5D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[LOESER,E; LONG-TERM TOXICITY AND CARCINOGENICITY STUDIES WITH 2,4/2,6-TOLUENE-DIISOCYANATE (80/20) IN RATS AND MICE; TOXICOL. LETT. 15:71-81, 1983]"
3271,363898548,7813,CC1=CC=C(C=C1)N,Active,,,,MOUSE,,ORAL,,LIVER,POSITIVE,"[WEISBURGER,EK, RUSSFIELD,AB, HOMBURGER,F, WEISBURGER,JH, BOGER,E, VAN DONGEN,CG AND CHU,KC; TESTING OF TWENTY-ONE ENVIRONMENTAL AROMATIC AMINES OR DERIVATIVES FOR LONG-TERM TOXICITY OR CARCINOGENICITY; J. ENVIRON. PATHOL. TOXICOL. 2:325-356, 1978]"
3272,363898549,12484,CC1=CC=CC=C1N.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK,LIVER: HEPATOCELLULAR CARCINOMA OR HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-153 Y79]"
3273,363898549,12484,CC1=CC=CC=C1N.Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 102-103 WK,BLOOD VESSELS: HEMANGIOMA OR HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-153 Y79]"
3274,363898549,12484,CC1=CC=CC=C1N.Cl,Active,,,,MOUSE,"CD-1/MALE,FEMALE",ORAL,"0; 16000; 32000 MG/KG FOR 3 MO, THEN 0; 8000; 16000 MG/KG FOR 15 MO","BLOOD VESSELS: HEMANGIOMA, HEMANGIOSARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V27 155 Y82]"
3275,363898549,12484,CC1=CC=CC=C1N.Cl,Active,,,,RAT,CD-1/MALE,ORAL,"0; 8000; 16000 MG/KG FOR 3 MO, THEN 0; 4000; 8000 MG/KG FOR 15 MO","INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA, FIBROSARCOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V27 155 Y82]"
3276,363898549,12484,CC1=CC=CC=C1N.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 104 WK,"SPLEEN: ANGIOSARCOMA, SARCOMA (NOS) OR ANGIOSARCOMA OR OSTEOSARCOMA; URINARY BLADDER: TRANSITIONAL CELL CARCINOMA, TRANSITIONAL CELL CARCINOMA OR PAPILLOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-153 Y79]"
3277,363898549,12484,CC1=CC=CC=C1N.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 101-104 WK,"INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA; SPLEEN: FIBROMA, ANGIOSARCOMA; MULTIPLE ORGANS OR TUNICA VAGINALIS: MESOTHELIOMA; MULTIPLE ORGANS: SARCOMA (NOS), FIBROSARCOMA, OSTEOSARCOMA, SARCOMA (NOS) OR FIBROSARCOMA OR ANGIOSARCOMA OR OSTEOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-153 Y79]"
3278,363898549,12484,CC1=CC=CC=C1N.Cl,Active,,,,RAT,F344/MALE,ORAL,4.0 G/KG IN DIET FOR 72 WK (TOTAL DOSE 0.22 MOL/RAT),"SPLEEN: FIBROMA; INTEGUMENTARY SYSTEM (SKIN): FIBROMA; MAMMARY GLAND: FIBROADENOMA, ADENOCARCINOMA; PERITONEAL CAVITY: MESOTHELIOMA, SARCOMA",POSITIVE,"[HECHT,SS, EL-BAYOUMY,K, RIVENSON,A AND FIALA,E; COMPARATIVE CARCINOGENICITY OF O-TOLUIDINE HYDROCHLORIDE AND O-NITROSOTOLUENE IN F-344 RATS; CANCER LETT. 16:103-108, 1982]"
3279,363898549,12484,CC1=CC=CC=C1N.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),SPLEEN OR PERITONEUM: SARCOMA,POSITIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
3280,363898549,12484,CC1=CC=CC=C1N.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 3000; 6000; PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),SPLEEN OR PERITONEUM: SARCOMA,POSITIVE,"[GOODMAN,DG, WARD,JM AND REICHARDT,WD; SPLENIC FIBROSIS AND SARCOMAS IN F344 RATS FED DIETS CONTAINING ANILINE HYDROCHLORIDE, P-CHLOROANILINE, AZOBENZENE, OTOLUIDINE HYDROCHLORIDE, 4,4'-SULFONYLDIANILINE, OR D & C RED NO. 9; JNCI, J. NATL. CANCER INST. 73(1):265-273, 1984]"
3281,363898550,,,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 99; 198 PPM IN DIET FOR 80 WK (STUDY DURATION: 90-91 WK),"LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-37 Y79][REUBER,MD; CARCINOGENICITY OF TOXAPHENE: A REVIEW; J. TOXICOL. ENVIRON. HEALTH 5(4):729-748, 1979, ]"
3282,363898550,,,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 99; 198 PPM IN DIET FOR 80 WK (STUDY DURATION: 90-91 WK),"LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-37 Y79][REUBER,MD; CARCINOGENICITY OF TOXAPHENE: A REVIEW; J. TOXICOL. ENVIRON. HEALTH 5(4):729-748, 1979, ]"
3283,363898550,,,Unspecified,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,0; 540; 1080 PPM IN DIET FOR 80 WK (STUDY DURATION: 108-110 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-37 Y79][REUBER,MD; CARCINOGENICITY OF TOXAPHENE: A REVIEW; J. TOXICOL. ENVIRON. HEALTH 5(4):729-748, 1979, ]"
3284,363898550,,,Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,0; 556; 1112 PPM IN DIET FOR 80 WK (STUDY DURATION: 108-110 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-37 Y79][REUBER,MD; CARCINOGENICITY OF TOXAPHENE: A REVIEW; J. TOXICOL. ENVIRON. HEALTH 5(4):729-748, 1979, ]"
3285,363898551,12471,C1=C(C=C(C(=C1Cl)N)Cl)Cl,Active,,,,MOUSE,CD-1/MALE,ORAL,6000; 12000 PPM IN DIET,BLOOD VESSELS,POSITIVE,"[WEISBURGER,EK, RUSSFIELD,AB, HOMBURGER,F, WEISBURGER,JH, BOGER,E, VAN DONGEN,CG AND CHU,KC; TESTING OF TWENTY-ONE ENVIRONMENTAL AROMATIC AMINES OR DERIVATIVES FOR LONG-TERM TOXICITY OR CARCINOGENICITY; J. ENVIRON. PATHOL. TOXICOL. 2:325-356, 1978]"
3286,363898552,6574,C(C(Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 195; 390 MG/KG/D, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-74 Y78]"
3287,363898552,6574,C(C(Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 195; 390 MG/KG/D, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-74 Y78]"
3288,363898552,6574,C(C(Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,GAVAGE,"0; 46; 92 MG/KG/D, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-74 Y78]"
3289,363898552,6574,C(C(Cl)Cl)Cl,Inactive,,,,RAT,OSBORNE-MENDEL/MALE,GAVAGE,"0; 46; 92 MG/KG/D, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-74 Y78]"
3290,363898553,6575,C(=C(Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 869; 1739 MG/KG/D, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 263 Y76][NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-2 Y76]"
3291,363898553,6575,C(=C(Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 1169; 2339 MG/KG/D, TWA",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V11 263 Y76][NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-2 Y76]"
3292,363898553,6575,C(=C(Cl)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-243 Y90]"
3293,363898553,6575,C(=C(Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 107 WK),"LIVER: ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-243 Y90]"
3294,363898553,6575,C(=C(Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 107 WK),"LIVER: ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-243 Y90]"
3295,363898553,6575,C(=C(Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 100; 300; 600 PPM 7 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),TESTIS: LEYDIG CELL TUMOR,POSITIVE,"[MALTONI,C, LEFEMINE,G, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON TRICHLOROETHYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS AND B6C3F1 MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD): 316-342, 1988]"
3296,363898553,6575,C(=C(Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 100; 300; 600 PPM 7 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON TRICHLOROETHYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS AND B6C3F1 MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD): 316-342, 1988]"
3297,363898553,6575,C(=C(Cl)Cl)Cl,Active,,,,MOUSE,SWISS/MALE,INHALATION,0; 100; 300; 600 PPM 7 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; LIVER: HEPATOMA,POSITIVE,"[MALTONI,C, LEFEMINE,G, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON TRICHLOROETHYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS AND B6C3F1 MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD): 316-342, 1988]"
3298,363898553,6575,C(=C(Cl)Cl)Cl,Inactive,,,,MOUSE,SWISS/FEMALE,INHALATION,0; 100; 300; 600 PPM 7 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON TRICHLOROETHYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS AND B6C3F1 MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD): 316-342, 1988]"
3299,363898553,6575,C(=C(Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 100; 300; 600 PPM 7 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON TRICHLOROETHYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS AND B6C3F1 MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD): 316-342, 1988]"
3300,363898553,6575,C(=C(Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 100; 300; 600 PPM 7 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR,POSITIVE,"[MALTONI,C, LEFEMINE,G, COTTI,G AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON TRICHLOROETHYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS AND B6C3F1 MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD): 316-342, 1988]"
3301,363898553,6575,C(=C(Cl)Cl)Cl,Inactive,,,,MOUSE,"ICR/MALE, FEMALE",GAVAGE,0; 10 MG/KG IN CORN OIL 5 D/WK FOR 18 MO (DOSES REDUCED BY FACTOR OF 2 FROM 40TH WEEK)(STUDY DURATION: 24 MO),,NEGATIVE,"[HENSCHLER,D, ELSAESSER,H, ROMEN,W AND EDER,E; CARCINOGENICITY STUDY OF TRICHLOROETHYLENE, WITH AND WITHOUT EPOXIDE STABILIZERS, IN MICE; J. CANCER RES. CLIN. ONCOL. 107(3):149-156, 1984]"
3302,363898553,6575,C(=C(Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 50; 250 MG/KG BW IN OLIVE OIL 1/D 4-6 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3303,363898553,6575,C(=C(Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 50; 250 MG/KG BW IN OLIVE OIL 1/D 4-6 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3304,363898554,6389,C(F)(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 1962; 3925 MG/KG, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-106 Y78]"
3305,363898554,6389,C(F)(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 1962; 3925 MG/KG, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-106 Y78]"
3306,363898554,6389,C(F)(Cl)(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
3307,363898554,6389,C(F)(Cl)(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
3308,363898554,6389,C(F)(Cl)(Cl)Cl,Inactive,,,,MOUSE,SWISS/MALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
3309,363898554,6389,C(F)(Cl)(Cl)Cl,Inactive,,,,MOUSE,SWISS/FEMALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
3310,363898554,6389,C(F)(Cl)(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 1000; 5000 PPM IN AIR 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3311,363898554,6389,C(F)(Cl)(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 1000; 5000 PPM IN AIR 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3312,363898555,6914,C1=C(C=C(C(=C1Cl)O)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5214; 10428 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-155 Y79]"
3313,363898555,6914,C1=C(C=C(C(=C1Cl)O)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET,LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-155 Y79]"
3314,363898555,6914,C1=C(C=C(C(=C1Cl)O)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-155 Y79]"
3315,363898555,6914,C1=C(C=C(C(=C1Cl)O)Cl)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN DIET,HEMATOPOIETIC SYSTEM (LEUKEMIA): MONOCYTIC LEUKEMIA; LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-155 Y79]"
3316,363898556,7618,C(CO)N(CCO)CCO,Active,,,,MOUSE,,ORAL,,LYMPHATIC SYSTEM,POSITIVE,"[HOSHINO,H AND TANOOKA,H; CARCINOGENICITY OF TRIETHANOLAMINE IN MICE AND ITS MUTAGENICITY AFTER REACTION WITH SODIUM NITRITE IN BACTERIA; CANCER RES. 38:3918-3921, 1978]"
3317,363898556,7618,C(CO)N(CCO)CCO,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1; 2% IN DRINKING WATER FOR 82 WK (STUDY DURATION: 82 WK),,NEGATIVE,"[KONISHI,Y, DENDA,A, UCHIDA,K, EMI,Y, URA,H, YOKOSE,Y, SHIRAIWA,K AND TSUTSUMI, M; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF TRIETHANOLAMINE IN B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 18(1):25-29, 1992]"
3318,363898556,7618,C(CO)N(CCO)CCO,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1; 2% IN DRINKING WATER FOR 82 WK (STUDY DURATION: 82 WK),,NEGATIVE,"[KONISHI,Y, DENDA,A, UCHIDA,K, EMI,Y, URA,H, YOKOSE,Y, SHIRAIWA,K AND TSUTSUMI, M; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF TRIETHANOLAMINE IN B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 18(1):25-29, 1992]"
3319,363898556,7618,C(CO)N(CCO)CCO,Inactive,,,,RAT,F344/FEMALE,DERMAL,0; 32; 63; 125 MG/KG 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-449  Y99]"
3320,363898556,7618,C(CO)N(CCO)CCO,Unspecified,,,,RAT,F344/MALE,DERMAL,0; 32; 63; 125 MG/KG 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),KIDNEY: RENAL TUBULE ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-449  Y99]"
3321,363898556,7618,C(CO)N(CCO)CCO,Unspecified,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 200; 630; 2000 MG/KG 5D/WK FOR 104 WKS (STUDY DURATION: 104 WKS),LIVER: HEMANGIOSARCOMA AT MEDIAN DOSE LEVEL,EQUIVOCAL; P=0.047 AT MEDIAN DOSE FOR HEMANGIOSARCOMA,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF TRIETHANOLOLAMINE  (CAS NO. 102-71-6) IN B6C3F1 MICE (DERMAL  STUDY); NATL. TOXICOL. PROGRAM TECH. REP. SER. 518:1-163, 2004]"
3322,363898556,7618,C(CO)N(CCO)CCO,Active,,,,MOUSE,B6C3F1/FEMALE,DERMAL,0; 100; 300; 1000 MG/KG 5 D/WK FOR 104 -105 WKS (STUDY DURATION: 105 WKS),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF TRIETHANOLOLAMINE  (CAS NO. 102-71-6) IN B6C3F1 MICE (DERMAL  STUDY); NATL. TOXICOL. PROGRAM TECH. REP. SER. 518:1-163, 2004]"
3323,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 2740; 5192 PPM IN DIET, TWA",LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-34 Y78]"
3324,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 2000; 3744 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-34 Y78]"
3325,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,ORAL,"0; 4125; 7917 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-34 Y78]"
3326,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,RAT,OSBORNE-MENDEL/MALE,ORAL,"0; 4125; 8000 PPM IN DIET, TWA",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-34 Y78]"
3327,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 563; 2250; 4500 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[FRANCIS,PC, EMMERSON,JL, ADAMS,ER AND OWEN,NV; ONCOGENICITY STUDY OF TRIFLURALIN IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 29(3):549-555, 1991]"
3328,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 563; 2250; 4500 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[FRANCIS,PC, EMMERSON,JL, ADAMS,ER AND OWEN,NV; ONCOGENICITY STUDY OF TRIFLURALIN IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 29(3):549-555, 1991]"
3329,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 200; 800; 3200 MG/KG IN DIET FOR 122 WK (STUDY DURATION: WK),,NEGATIVE,"[EBERT,E, LEIST,KH, HACK,R AND EHLING,G; TOXICOLOGY AND HAZARD POTENTIAL OF TRIFLURALIN; FOOD CHEM. TOXICOL. 30(12):1031-1044, 1992]"
3330,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 200; 800; 3200 MG/KG IN DIET FOR 122 WK (STUDY DURATION: 122 WK),,NEGATIVE,"[EBERT,E, LEIST,KH, HACK,R AND EHLING,G; TOXICOLOGY AND HAZARD POTENTIAL OF TRIFLURALIN; FOOD CHEM. TOXICOL. 30(12):1031-1044, 1992]"
3331,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,MOUSE,NMRI/MALE,ORAL,0; 50; 200; 800 MG/KG IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[EBERT,E, LEIST,KH, HACK,R AND EHLING,G; TOXICOLOGY AND HAZARD POTENTIAL OF TRIFLURALIN; FOOD CHEM. TOXICOL. 30(12):1031-1044, 1992]"
3332,363898557,5569,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,MOUSE,NMRI/FEMALE,ORAL,0; 50; 200; 800 MG/KG IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[EBERT,E, LEIST,KH, HACK,R AND EHLING,G; TOXICOLOGY AND HAZARD POTENTIAL OF TRIFLURALIN; FOOD CHEM. TOXICOL. 30(12):1031-1044, 1992]"
3333,363898558,8717,CC1=CC(=C(C=C1C)N)C,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 50; 100 PPM IN DIET FOR 101 WK (STUDY DURATION: 101 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-160 Y79]"
3334,363898558,8717,CC1=CC(=C(C=C1C)N)C,Active,,,,RAT,F344/FEMALE,ORAL,0; 200; 800 PPM IN DIET FOR 101 WK (STUDY DURATION: 101 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-160 Y79]"
3335,363898558,8717,CC1=CC(=C(C=C1C)N)C,Active,,,,RAT,F344/MALE,ORAL,0; 200; 800 PPM IN DIET FOR 101 WK (STUDY DURATION: 101 WK),"LIVER: BILE DUCT CARCINOMA, HEPATOCELLULAR CARCINOMA OR NEOPLASTIC NODULE",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-160 Y79]"
3336,363898558,8717,CC1=CC(=C(C=C1C)N)C,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 50; 100 PPM IN DIET FOR 101 WK (STUDY DURATION: 101 WK),LIVER: HEPATOCELLULAR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-160 Y79]"
3337,363898559,83363,CC1=C2C(=C3C=CC4=CC=CC=C4C3=C(C2=CC=C1)C)C,Active,,,,MOUSE,"C57BL/MALE,FEMALE",DERMAL,0.06% IN BENZENE 2/WK,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, EPITHELIOMA, SARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 566]"
3338,363898559,83363,CC1=C2C(=C3C=CC4=CC=CC=C4C3=C(C2=CC=C1)C)C,Active,,,,MOUSE,"DBF1/MALE,FEMALE",DERMAL,0.06% IN BENZENE 2/WK,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, EPITHELIOMA, SARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 566]"
3339,363898559,83363,CC1=C2C(=C3C=CC4=CC=CC=C4C3=C(C2=CC=C1)C)C,Active,,,,MOUSE,"DBA/MALE,FEMALE",DERMAL,0.06% IN BENZENE 2/WK,"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, EPITHELIOMA, SARCOMA",POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. Suppl 1 566]"
3340,363898559,83363,CC1=C2C(=C3C=CC4=CC=CC=C4C3=C(C2=CC=C1)C)C,Active,,,,RAT,LONG-EVANS/FEMALE,INTRAVENOUS,"35 MG/KG, 0.5% IN DMSO DILUTED WITH COTTONSEED OIL-WATER EMULSION, 1/2 WK OR 1/10 D FOR 3-5 DOSES",HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 330]"
3341,363898559,83363,CC1=C2C(=C3C=CC4=CC=CC=C4C3=C(C2=CC=C1)C)C,Active,,,,RAT,LONG-EVANS/MALE,INTRAMUSCULAR,2.5 MG IN 0.5 ML SESAME OIL ONCE,INJECTION SITE: SARCOMA,POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 68-69 425]"
3342,363898559,83363,CC1=C2C(=C3C=CC4=CC=CC=C4C3=C(C2=CC=C1)C)C,Active,,,,RAT,LONG-EVANS/MALE,INTRAVENOUS,"35 MG/KG, 0.5% IN DMSO DILUTED WITH COTTONSEED OIL-WATER EMULSION, 1/2 WK FOR 4 DOSES",HEMATOPOIETIC SYSTEM (LEUKEMIA),POSITIVE,"[U.S. PUBLIC HEALTH SERVICE PUBLICATION 149;SURVEY OF COMPOUNDS WHICH HAVE BEEN TESTED FOR CARCINOGENIC ACTIVITY; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT PRINTING OFFICE, WASHINGTON, D.C., p. 70-71 330]"
3343,363898560,10541,COP(=O)(OC)OC,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 250; 500 MG/KG 3/WK FOR 103 WK,UTERUS (ENDOMETRIUM): ADENOCARCINOMA (NOS),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-81 Y78]"
3344,363898560,10541,COP(=O)(OC)OC,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 250; 500 MG/KG 3/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-81 Y78]"
3345,363898560,10541,COP(=O)(OC)OC,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 50; 100 MG/KG 3/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-81 Y78]"
3346,363898560,10541,COP(=O)(OC)OC,Inactive,,,,RAT,WISTAR/MALE,ORAL,"0; 1; 10; 100 MG/KG/D IN DRINKING WATER FOR DURATION OF STUDY, HIGH DOSE REDUCED TO 50 MG/KG IN WK 54 (STUDY DURATION: 30 MO)",,NEGATIVE,"[BOMHARD,EM, KRINKE,GJ, ROSSBERG,WM AND SKRIPSKY,T; TRIMETHYLPHOSPHATE: A 30-MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY IN WISTAR RATS WITH ADMINISTRATION IN DRINKING WATER; FUNDAM. APPL. TOXICOL. 40(1):75-89, 1997]"
3347,363898560,10541,COP(=O)(OC)OC,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,"0; 1; 10; 100 MG/KG/D IN DRINKING WATER FOR DURATION OF STUDY, HIGH DOSE REDUCED TO 50 MG/KG IN WK 54 (STUDY DURATION: 30 MO)",,NEGATIVE,"[BOMHARD,EM, KRINKE,GJ, ROSSBERG,WM AND SKRIPSKY,T; TRIMETHYLPHOSPHATE: A 30-MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY IN WISTAR RATS WITH ADMINISTRATION IN DRINKING WATER; FUNDAM. APPL. TOXICOL. 40(1):75-89, 1997]"
3348,363898561,2779938,CNC(=S)N(C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-129 Y79]"
3349,363898561,2779938,CNC(=S)N(C)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 1000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-129 Y79]"
3350,363898561,2779938,CNC(=S)N(C)C,Active,,,,RAT,F344/FEMALE,ORAL,0; 250; 500 PPM IN DIET,THYROID GLAND: FOLLICULAR CELL CARCINOMA OR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-129 Y79]"
3351,363898561,2779938,CNC(=S)N(C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 250; 500 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-129 Y79]"
3352,363898562,6327657,C1=CC=C(C=C1)[Sn](C2=CC=CC=C2)C3=CC=CC=C3.O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 37.5; 75 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-139 Y78]"
3353,363898562,6327657,C1=CC=C(C=C1)[Sn](C2=CC=CC=C2)C3=CC=CC=C3.O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 37.5; 75 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-139 Y78]"
3354,363898562,6327657,C1=CC=C(C=C1)[Sn](C2=CC=CC=C2)C3=CC=CC=C3.O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 37.5; 75 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-139 Y78]"
3355,363898562,6327657,C1=CC=C(C=C1)[Sn](C2=CC=CC=C2)C3=CC=CC=C3.O,Inactive,,,,RAT,F344/MALE,ORAL,0; 37.5; 75 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-139 Y78]"
3356,363898563,5799,C1CN1C2=NC(=NC(=N2)N3CC3)N4CC4,Active,,,,MOUSE,,INTRAPERITONEAL,,OVARIES; LUNG; THYMUS GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 95 Y75]"
3357,363898564,31356,C(C(CBr)Br)OP(=O)(OCC(CBr)Br)OCC(CBr)Br,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN DIET,STOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-76 Y78]"
3358,363898564,31356,C(C(CBr)Br)OP(=O)(OCC(CBr)Br)OCC(CBr)Br,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 1000 PPM IN DIET,STOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-76 Y78]"
3359,363898564,31356,C(C(CBr)Br)OP(=O)(OCC(CBr)Br)OCC(CBr)Br,Active,,,,RAT,F344/FEMALE,ORAL,0; 50; 100 PPM IN DIET,KIDNEY: TUBULAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-76 Y78]"
3360,363898564,31356,C(C(CBr)Br)OP(=O)(OCC(CBr)Br)OCC(CBr)Br,Active,,,,RAT,F344/MALE,ORAL,0; 50; 100 PPM IN DIET,KIDNEY: TUBULAR CELL ADENOMA OR ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-76 Y78]"
3361,363898565,6537,CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5/WK FOR 103 WK (STUDY DURATION: 104 WK),"LIVER: ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-274 Y84]"
3362,363898565,6537,CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-274 Y84]"
3363,363898565,6537,CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 1000; 2000 MG/KG IN CORN OIL 5/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-274 Y84]"
3364,363898565,6537,CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 1/D 5 D/WK FOR 102-104 WK (STUDY DURATION: 102-104 WK),,NEGATIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
3365,363898565,6537,CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 1/D 5 D/WK FOR 102-104 WK (STUDY DURATION: 102-104 WK),"LIVER: CARCINOMA, CARCINOMA OR ADENOMA",POSITIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
3366,363898565,6537,CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 2000; 4000 MG/KG IN CORN OIL 5 D/WK FOR 102-104 WK (STUDY DURATION: 102-104 WK),,NEGATIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
3367,363898565,6537,CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 1000; 2000 MG/KG IN CORN OIL 5 D/WK FOR 102-104 WK (STUDY DURATION: 102-104 WK),,NEGATIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
3368,363898565,6537,CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC,Unspecified,,,,RAT,F344/MALE,GAVAGE,0; 2000; 4000 MG/KG IN CORN OIL 5/WK FOR 103 WK (STUDY DURATION: 104 WK),ADRENAL GLAND: PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-274 Y84]"
3369,363898566,9562061,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N/N=C\3/C(=O)C4=C(C=C3S(=O)(=O)[O-])C=C(C=C4N)S(=O)(=O)[O-])C)N/N=C\5/C(=O)C6=C(C=C5S(=O)(=O)[O-])C=C(C=C6N)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],Active,,,,RAT,,"INTRAPERITONEAL, SUBCUTANEOUS",,LIVER; INJECTION SITE,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V8 267 Y75]"
3370,363898567,6305,C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-71 Y78]"
3371,363898567,6305,C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-71 Y78]"
3372,363898567,6305,C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-71 Y78]"
3373,363898567,6305,C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-71 Y78]"
3374,363898568,6194,C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,8; 20; 40 MG/KG FOR 7 DOSES OVER 24 WK,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 235 Y75]"
3375,363898568,6194,C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAPERITONEAL,0.18-12 MG/KG IN 12 DOSES OVER 4 WK,LUNG: ADENOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 235 Y75]"
3376,363898568,6194,C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0.15; 0.3 MG/KG 3/WK FOR 6 MO,LYMPHATIC SYSTEM: LYMPHOMA; PERITONEAL CAVITY: SARCOMA; MAMMARY GLAND: CARCINOMA; OVARIES: CARCINOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 235 Y75]"
3377,363898568,6194,C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl,Active,,,,RAT,STRAIN-CD/MALE,INTRAPERITONEAL,0.15; 0.3 MG/KG 3/WK FOR 6 MO,LYMPHATIC SYSTEM: LYMPHOMA; PANCREAS; PERITONEAL CAVITY: SARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V9 235 Y75]"
3378,363898569,5641,CCOC(=O)N,Active,,,,HAMSTER,,ORAL,,FORESTOMACH; INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3379,363898569,5641,CCOC(=O)N,Active,,,,HAMSTER,,DERMAL,,INTEGUMENTARY SYSTEM (SKIN); MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3380,363898569,5641,CCOC(=O)N,Active,,,,HAMSTER,,SUBCUTANEOUS,,ADRENAL GLAND; FORESTOMACH; INTESTINES; INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3381,363898569,5641,CCOC(=O)N,Active,,,,HAMSTER,,INTRAPERITONEAL,,INTEGUMENTARY SYSTEM (SKIN),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3382,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,,ORAL,,HEMATOPOIETIC SYSTEM (LEUKEMIA): LYMPHOCYTIC LEUKEMIA; LYMPHATIC SYSTEM: LYMPHOSARCOMA; MAMMARY GLAND; LUNG; LIVER; THYMUS GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3383,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,,INHALATION,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3384,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3385,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,C57BL,INTRAPERITONEAL,1.00 MG/G 10 TIMES AT WEEKLY INTERVALS,THYMUS GLAND: LYMPHOSARCOMA; LUNG: ADENOMA,POSITIVE,"[BOIATO,L, MIRVISH,SS AND BERENBLUM,I; THE CARCINOGENIC ACTION AND METABOLISM OF N-HYDROXYURETHANE IN NEWBORN MICE; INT. J. CANCER 1:265-269, 1966]"
3386,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,,SUBCUTANEOUS,,HARDERIAN GLAND; HEMATOPOIETIC SYSTEM (LEUKEMIA); LIVER; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3387,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,,INTRAPERITONEAL,,HEMATOPOIETIC SYSTEM (LEUKEMIA); LYMPHATIC SYSTEM: LYMPHOMA; LUNG; LIVER; HARDERIAN GLAND; OVARIES,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3388,363898569,5641,CCOC(=O)N,Active,,,,RAT,,"INTRAPERITONEAL, ORAL",,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3389,363898569,5641,CCOC(=O)N,Active,,,,RAT,,SUBCUTANEOUS,,EYE (IRIS),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3390,363898569,5641,CCOC(=O)N,Active,,,,RAT,,INTRAPERITONEAL,,LIVER; NERVOUS SYSTEM,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 111 Y74]"
3391,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,"SWISS/MALE,FEMALE",ORAL,0; 0.4% IN DRINKING WATER; 2 10-D TREATMENTS,"LUNG: ADENOMA, LYMPHOMA; LIVER: HEMANGIOMA; INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SEBACEOUS CARCINOMA",POSITIVE,"[TOTH,B, DELLA PORTA,G AND SHUBIK,P; THE OCCURRENCE OF MALIGNANT LYMPHOMAS IN URETHAN-TREATED SWISS MICE; BR. J. CANCER 15:322-326, 1961]"
3392,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,"CTM/MALE,FEMALE",ORAL,"0; 0.4% IN DRINKING WATER; 1 OR 2 10-D TREATMENTS OR 1, 2 OR 3 5-D TREATMENTS WITH 10-D INTERVALS BETWEEN TREATMENTS","LUNG: ADENOMA, LYMPHOSARCOMA",POSITIVE,"[DELLA PORTA,G, CAPITANO,J, MONTIPO,W AND PARMI,L; STUDIO SULL' AZIONE CANCEROGENA DELL' URETANO NEL TOPO; TUMORI 49:413-428, 1963]"
3393,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.6; 3; 6; 60; 600 PPM IN DRINKING WATER FOR 70 WK (STUDY DURATION: 70 WK),"LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA; LIVER: ANGIOSARCOMA, HEMANGIOMA",POSITIVE,"[INAI,K, ARIHIRO,K, TAKESHIMA,Y, YONEHARA,S, TACHIYAMA,Y, KHATUN,N AND NISHISAKA,T; QUANTITATIVE RISK ASSESSMENT OF CARCINOGENICITY OF URETHANE (ETHYL CARBAMATE) ON THE BASIS OF LONG-TERM ORAL ADMINISTRATION TO B6C3F1 MICE; JPN. J. CANCER RES. 82(4):380-385, 1991]"
3394,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 1.29 UG/ML AIR FOR 0.25 D (TOTAL DOSE 0.32 UG/ML/D) (STUDY DURATION: 5 MO),LUNG: TUMOR; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3395,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 1.29 UG/ML AIR FOR 1 D (TOTAL DOSE 1.29 UG/ML/D) (STUDY DURATION; 5 MO),LUNG: TUMOR; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3396,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 1.29 UG/ML AIR FOR 2 D (TOTAL DOSE 2.58 UG/ML/D) (STUDY DURATION: 5 MO),LUNG: TUMOR; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3397,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 1.29 UG/ML AIR FOR 4 D (TOTAL DOSE 5.16 UG/ML/D) (STUDY DURATION: 5 MO),LUNG: TUMOR; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3398,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 1.29 UG/ML AIR FOR 5 D (TOTAL DOSE 6.45 UG/ML/D) (STUDY DURATION: 5 MO),LUNG: TUMOR; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3399,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 0.25 UG/ML AIR FOR 0.25 D (TOTAL DOSE 0.25 UG/ML/D) (STUDY DURATION: 5 MO),LUNG: TUMOR; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3400,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 0.25 UG/ML AIR FOR 3 D (TOTAL DOSE 0.75 UG/ML/D) (STUDY DURATION: 5 MO),LUNG: TUMOR; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3401,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 0.25 UG/ML AIR FOR 5 D (TOTAL DOSE 1.25 UG/ML/D) (STUDY DURATION: 5 MO),LUNG: TUMOR; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3402,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 0.25 UG/ML AIR FOR 10 D (TOTAL DOSE 2.5 UG/ML/D) (STUDY DURATION: 5 MO),LUNG: TUMOR,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3403,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/MALE,INHALATION,0; 0.25 UG/ML AIR FOR 10 D (TOTAL DOSE 2.5 UG/ML/D) (STUDY DURATION: 12 MO),LUNG: ADENOCARCINOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA; LIVER: HEPATOMA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3404,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,ICR/MALE,INHALATION,0; 1.29 UG/ML AIR FOR 4 D (TOTAL DOSE 5.16 UG/ML/D) (STUDY DURATION: 12 MO),LUNG: ADENOCARCINOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA; LIVER: HEPATOMA,POSITIVE,"[NOMURA,T, HAYASHI,T, MASUYAMA,T, TANAKA,S, NAKAJIMA,H, KUROKAWA,N AND ISA,Y; CARCINOGENICITY OF SUBLIMED URETHANE IN MICE THROUGH THE RESPIRATORY TRACT; JPN. J. CANCER RES. 81(8):742-746, 1990]"
3405,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,"HR/HR/MALE, FEMALE",DERMAL,0; 15; 30; 75% IN PROPYLENE GLYCOL 2/WK FOR STUDY DURATION (STUDY DURATION: 56-60 WK),"SKIN: CARCINOMA, PAPILLOMA; LUNG: ADENOMA",POSITIVE,"[IVERSEN,OH; URETHAN (ETHYL CARBAMATE) ALONE IS CARCINOGENIC FOR MOUSE SKIN; CARCINOGENESIS 5(7):911-915, 1984]"
3406,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,"HR/HR/MALE, FEMALE",DERMAL,0; 10; 20; 40% IN 200 UL ACETONE 2/WK FOR STUDY DURATION (STUDY DURATION: 56-60 WK),"SKIN: CARCINOMA, PAPILLOMA; LUNG: ADENOMA",POSITIVE,"[IVERSEN,OH; URETHAN (ETHYL CARBAMATE) ALONE IS CARCINOGENIC FOR MOUSE SKIN; CARCINOGENESIS 5(7):911-915, 1984]"
3407,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 125 UG/G BW IN 10 UL TRIOCTANOIN ONCE (STUDY DURATION: 9 MO),LIVER: HEPATOMA,POSITIVE,"[PARK,KK, LIEM,A, STEWART,BC AND MILLER,JA; VINYL CARBAMATE EPOXIDE, A MAJOR STRONG ELECTROPHILIC, MUTAGENIC AND CARCINOGENIC METABOLITE OF VINYL CARBAMATE AND ETHYL CARBAMATE (URETHANE); CARCINOGENESIS 14(3):441-450, 1993]"
3408,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 1.12; 4.6 MMOL/KG IN ISOTONIC SALINE ONCE AT 6 WK OF AGE (STUDY DURATION: 16 WK),LUNG: ADENOMA,POSITIVE,"[MIRVISH,SS, SMYRK,T, PAYNE,S, TUATOO,H AND CHEN,SC; WEAK CARCINOGENICITY OF 2-HYDROXYETHYL CARBAMATE IN STRAIN A MICE: INDICATION THAT THIS IS NOT A PROXIMAL METABOLITE OF ETHYL CARBAMATE; CANCER LETT. 77(1):1-5, 1994]"
3409,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,SWISS WEBSTER/FEMALE,INTRAVENOUS,0; 3.3 MMOL/KG ONCE ADMINISTERED TO MOTHERS ON GESTATIONAL DAY 14 (STUDY DURATION: 6 MO),LUNG: ADENOMA,POSITIVE,"[NEEPER-BRADLEY,TL AND CONNER,MK; TUMOR FORMATION AND SISTER CHROMATID EXCHANGE INDUCTION BY ETHYL CARBAMATE: RELATIONSHIPS AMONG NON-PREGNANT MURINE FEMALES, GRAVID DAMS, AND TRANSPLACENTALLY EXPOSED OFFSPRING; TERATOG., CARCINOG., MUTAGEN. 12(4):167-177, 1992]"
3410,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,SWISS WEBSTER/FEMALE,TRANSPLACENTAL,0; 3.3 MMOL/KG ONCE BY INTRAVENOUS ADMINISTRATION TO MOTHERS ON GESTATIONAL DAY 14 (STUDY DURATION: 6 MO),LUNG: ADENOMA,POSITIVE,"[NEEPER-BRADLEY,TL AND CONNER,MK; TUMOR FORMATION AND SISTER CHROMATID EXCHANGE INDUCTION BY ETHYL CARBAMATE: RELATIONSHIPS AMONG NON-PREGNANT MURINE FEMALES, GRAVID DAMS, AND TRANSPLACENTALLY EXPOSED OFFSPRING; TERATOG., CARCINOG., MUTAGEN. 12(4):167-177, 1992]"
3411,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,SWISS WEBSTER/MALE,TRANSPLACENTAL,0; 3.3 MMOL/KG ONCE BY INTRAVENOUS ADMINISTRATION TO MOTHERS ON GESTATIONAL DAY 14 (STUDY DURATION: 6 Mo),LUNG: ADENOMA,POSITIVE,"[NEEPER-BRADLEY,TL AND CONNER,MK; TUMOR FORMATION AND SISTER CHROMATID EXCHANGE INDUCTION BY ETHYL CARBAMATE: RELATIONSHIPS AMONG NON-PREGNANT MURINE FEMALES, GRAVID DAMS, AND TRANSPLACENTALLY EXPOSED OFFSPRING; TERATOG., CARCINOG., MUTAGEN. 12(4):167-177, 1992]"
3412,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,SWISS WEBSTER/FEMALE,INTRAVENOUS,0; 3.3 MMOL ONCE ADMINISTERED TO VIRGIN FEMALES AT 12 WK OF AGE (STUDY DURATION: 6 MO),LUNG: ADENOMA,POSITIVE,"[NEEPER-BRADLEY,TL AND CONNER,MK; TUMOR FORMATION AND SISTER CHROMATID EXCHANGE INDUCTION BY ETHYL CARBAMATE: RELATIONSHIPS AMONG NON-PREGNANT MURINE FEMALES, GRAVID DAMS, AND TRANSPLACENTALLY EXPOSED OFFSPRING; TERATOG., CARCINOG., MUTAGEN. 12(4):167-177, 1992]"
3413,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,"B6C3F1/MALE, FEMALE (48/GROUP)",ORAL,10; 30; 90 PPM IN DRINKING WATER (STUDY DURATION: 2 YRS),"LIVER: HEMANGIOSARCOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA (COMBINED); LUNG: ADENOMA OR CARCINOMA (COMBINED): HARDERIAN GLAND: ADENOMA OR CARCINOMA (COMBINED)",POSITIVE,"[BUCHER,JR, CASCIANO,DA,  ALLABEN,WT, CHAMBERLAIN,PL,  DENNIS,DA, DUNNICK,JK, FARRELLY,JG, FORBES,PD, GREENLESS,KJ,  LORENTZEN,RJ, MILLER,MA, NEWBOLD,RR, POIRIER,M, SISTARE,FD,  YETLEY,EA, WAMER,WG, CARSON,J, DURRETT,JH, MATSON,A,  MOORE,M, NICHOLS,ML, SMITH,ES, BELAND,FA, ALLABEN,WT,  APPLEGET,BS, BENSON,RW, CHURCHWELL,MI, DOERGE,DR, FANG,LJ,  JACKSON,CD, KODELL,RL, REED,JM, ROBERTS,DW, WITT,KL,  WITT,WM, COOPER,WM, EVANS,FE, FREEMENA,JP, GEHRING,TA,  HEINZE,TM, SIITONEN,PH, MELLICK,PW, KOVATCH,RM, HARDISTY,JK,  SHACKELFORD,CC, HAILEY,JR, HARDISTRY,JF, HERBERT,RA,  WARD,JM, ARMSTONG,J, AUSTEN,M, BARTON,DL, BRYANT,B  CARROLL,K, DING, X, GOLDMAN,S, GOSSETT,JM, MCCARTY,CC,  MCCRACKEN,WA, SPADONI,B, THORN, BT, GUNNELS,SR, HARPER,LM,  SERBUS,DC AND WILLIS,RA; NTP TECHNICAL REPORT ON THE  TOXICOLOGY AND CARCINOGENESIS: STUDIES OF URETHANE, ETHANOL,  AND URETHANE/ETHANOL (URETHANE, CASE NO. 51-79-6; ETHANOL,  CAS NO. 64-17-5) IN B6C3F1 MICE (DRINKING WATER STUDIES);  NATL. TOXICOL. PROGRAM. TECH. REP. SER. 510: 1-346, 2004]"
3414,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,B6C3F1/MALE (48/GROUP),ORAL,10; 30; 90 PPM IN DRINKING WATER (STUDY DURATION: 2 YRS),HEART: HEMANGIOSARCOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA (COMBINED); SKIN: SQUAMOUS CELL PAPILLOMA OR CARCINOMA (COMBINED),POSITIVE,"[BUCHER,JR, CASCIANO,DA,  ALLABEN,WT, CHAMBERLAIN,PL,  DENNIS,DA, DUNNICK,JK, FARRELLY,JG, FORBES,PD, GREENLESS,KJ,  LORENTZEN,RJ, MILLER,MA, NEWBOLD,RR, POIRIER,M, SISTARE,FD,  YETLEY,EA, WAMER,WG, CARSON,J, DURRETT,JH, MATSON,A,  MOORE,M, NICHOLS,ML, SMITH,ES, BELAND,FA, ALLABEN,WT,  APPLEGET,BS, BENSON,RW, CHURCHWELL,MI, DOERGE,DR, FANG,LJ,  JACKSON,CD, KODELL,RL, REED,JM, ROBERTS,DW, WITT,KL,  WITT,WM, COOPER,WM, EVANS,FE, FREEMENA,JP, GEHRING,TA,  HEINZE,TM, SIITONEN,PH, MELLICK,PW, KOVATCH,RM, HARDISTY,JK,  SHACKELFORD,CC, HAILEY,JR, HARDISTRY,JF, HERBERT,RA,  WARD,JM, ARMSTONG,J, AUSTEN,M, BARTON,DL, BRYANT,B  CARROLL,K, DING, X, GOLDMAN,S, GOSSETT,JM, MCCARTY,CC,  MCCRACKEN,WA, SPADONI,B, THORN, BT, GUNNELS,SR, HARPER,LM,  SERBUS,DC AND WILLIS,RA; NTP TECHNICAL REPORT ON THE  TOXICOLOGY AND CARCINOGENESIS: STUDIES OF URETHANE, ETHANOL,  AND URETHANE/ETHANOL (URETHANE, CASE NO. 51-79-6; ETHANOL,  CAS NO. 64-17-5) IN B6C3F1 MICE (DRINKING WATER STUDIES);  NATL. TOXICOL. PROGRAM. TECH. REP. SER. 510: 1-346, 2004]"
3415,363898569,5641,CCOC(=O)N,Active,,,,MOUSE,B6C3F1/FEMALE (48/GROUP),ORAL,10; 30; 90 PPM IN DRINKING WATER (STUDY DURATION: 2 YRS),"MAMMARY GLAND: ADENOACANTHOMA, ADENOCARCINOMA; OVARY: GRANULOSA CELL TUMOR (BENIGN OR MALIGNANT); SPLEEN: HEMANGIOSARCOMA",POSITIVE ; MARGINAL BUT NOT SIGNIFICANT INCREASES OF HEMANGIOSARCOMAS OCCURRED IN THE UTERUS AND SKIN,"[BUCHER,JR, CASCIANO,DA,  ALLABEN,WT, CHAMBERLAIN,PL,  DENNIS,DA, DUNNICK,JK, FARRELLY,JG, FORBES,PD, GREENLESS,KJ,  LORENTZEN,RJ, MILLER,MA, NEWBOLD,RR, POIRIER,M, SISTARE,FD,  YETLEY,EA, WAMER,WG, CARSON,J, DURRETT,JH, MATSON,A,  MOORE,M, NICHOLS,ML, SMITH,ES, BELAND,FA, ALLABEN,WT,  APPLEGET,BS, BENSON,RW, CHURCHWELL,MI, DOERGE,DR, FANG,LJ,  JACKSON,CD, KODELL,RL, REED,JM, ROBERTS,DW, WITT,KL,  WITT,WM, COOPER,WM, EVANS,FE, FREEMENA,JP, GEHRING,TA,  HEINZE,TM, SIITONEN,PH, MELLICK,PW, KOVATCH,RM, HARDISTY,JK,  SHACKELFORD,CC, HAILEY,JR, HARDISTRY,JF, HERBERT,RA,  WARD,JM, ARMSTONG,J, AUSTEN,M, BARTON,DL, BRYANT,B  CARROLL,K, DING, X, GOLDMAN,S, GOSSETT,JM, MCCARTY,CC,  MCCRACKEN,WA, SPADONI,B, THORN, BT, GUNNELS,SR, HARPER,LM,  SERBUS,DC AND WILLIS,RA; NTP TECHNICAL REPORT ON THE  TOXICOLOGY AND CARCINOGENESIS: STUDIES OF URETHANE, ETHANOL,  AND URETHANE/ETHANOL (URETHANE, CASE NO. 51-79-6; ETHANOL,  CAS NO. 64-17-5) IN B6C3F1 MICE (DRINKING WATER STUDIES);  NATL. TOXICOL. PROGRAM. TECH. REP. SER. 510: 1-346, 2004]"
3416,363898569,5641,CCOC(=O)N,Inactive,,,,Mouse,129 x MF1 wild type (14-16 males and females),Intraperitoneal,"10 mg/kg, once, study duration 5 mo","Lung: adenoma (incidence 29% vs 25% in controls, multiplicity 0.4 vs 0.3 in controls)",Negative,"[RITCHIE,KJ HENDERSON,CJ WANG,XJ VASSIEVA,O CARRIE,D FARMER,PB GASKILL,M PARK,K AND WOLF,RC; GLUTATHIONE TRANSFERASE PI PLAYS A CRITICAL ROLE IN THE DEVELOPMENT OF LUNG CARCINOGENESIS FOLLOWING EXPOSURE TO TOBACCO-RELATED CARCINOGENS AND URETHANE; CANCER RESEARCH 67(19):9248-9257, 2007]"
3417,363898569,5641,CCOC(=O)N,Inactive,,,,Mouse,129 x MF1 Gstp-null (12-16 males and females),Intraperitoneal,"10 mg/kg, once, study duration 5 mo","Lung: adenoma (incidence 92% vs 27% in controls, multiplicity 3.8 vs 0.3 in controls)",Negative,"[RITCHIE,KJ HENDERSON,CJ WANG,XJ VASSIEVA,O CARRIE,D FARMER,PB GASKILL,M PARK,K AND WOLF,RC; GLUTATHIONE TRANSFERASE PI PLAYS A CRITICAL ROLE IN THE DEVELOPMENT OF LUNG CARCINOGENESIS FOLLOWING EXPOSURE TO TOBACCO-RELATED CARCINOGENS AND URETHANE; CANCER RESEARCH 67(19):9248-9257, 2007]"
3418,363898570,11641,C=CBr,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,10; 50; 250; 1250 PPM 6 HR/D 5/WK FOR 24 MO,LIVER: ANGIOSARCOMA; EAR (ZYMBAL GLAND): SQUAMOUS CELL CARCINOMA,POSITIVE,"[BENYA,TJ, BUSEY,WM, DORATO,MA AND BERTEAU,PE; INHALATION CARCINOGENICITY BIOASSAY OF VINYL BROMIDE IN RATS; TOXICOL. APPL. PHARMACOL. 64:367-379, 1982]"
3419,363898570,11641,C=CBr,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,10; 50; 250; 1250 PPM 6 HR/D 5/WK FOR 24 MO,"LIVER: ANGIOSARCOMA; EAR (ZYMBAL GLAND): PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[BENYA,TJ, BUSEY,WM, DORATO,MA AND BERTEAU,PE; INHALATION CARCINOGENICITY BIOASSAY OF VINYL BROMIDE IN RATS; TOXICOL. APPL. PHARMACOL. 64:367-379, 1982]"
3420,363898571,6338,C=CCl,Active,,,,HAMSTER,SYRIAN,INHALATION,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 377 Y79]"
3421,363898571,6338,C=CCl,Active,,,,HUMAN,,INHALATION,,LIVER; BRAIN; LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 291 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 377 Y79]"
3422,363898571,6338,C=CCl,Active,,,,MOUSE,SWISS,INHALATION,,LIVER; LUNG; MAMMARY GLAND,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 291 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 377 Y79]"
3423,363898571,6338,C=CCl,Active,,,,RAT,SPRAGUE-DAWLEY,ORAL,,LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 377 Y79]"
3424,363898571,6338,C=CCl,Active,,,,RAT,,INHALATION,,LIVER; LUNG; KIDNEY; EAR (ZYMBAL GLAND),POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V7 291 Y74][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 377 Y79]"
3425,363898571,6338,C=CCl,Active,,,,MOUSE,ICR/MALE,INHALATION,0; 50; 500; 5000; 50000 PPM ONCE FOR 1 HR (STUDY DURATION: 18 MO),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,POSITIVE,"[HEHIR,RM, MCNAMARA,BP, MCLAUGHLIN,J, WILLIGAN,DA, BIERBOWER,G AND HARDISTY,JF; CANCER INDUCTION FOLLOWING SINGLE AND MULTIPLE EXPOSURES TO A CONSTANT AMOUNT OF VINYL CHLORIDE MONOMER; ENVIRON. HEALTH PERSPECT. 41:63-72, 1982]"
3426,363898571,6338,C=CCl,Active,,,,MOUSE,ICR/FEMALE,INHALATION,0; 50; 500; 5000; 50000 PPM ONCE FOR 1 HR (STUDY DURATION: 18 MO),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,POSITIVE,"[HEHIR,RM, MCNAMARA,BP, MCLAUGHLIN,J, WILLIGAN,DA, BIERBOWER,G AND HARDISTY,JF; CANCER INDUCTION FOLLOWING SINGLE AND MULTIPLE EXPOSURES TO A CONSTANT AMOUNT OF VINYL CHLORIDE MONOMER; ENVIRON. HEALTH PERSPECT. 41:63-72, 1982]"
3427,363898571,6338,C=CCl,Active,,,,RAT,WISTAR/MALE,INHALATION,"0; 1; 50; 250; 500; 2500; 6000; 10000 PPM 4 HR/D, 5 D/WK FOR 52 WK (STUDY DURATION: 134-165 WK)",LIVER: ANGIOSARCOMA; NERVOUS SYSTEM: NEUROBLASTOMA,POSITIVE,"[MALTONI,C, LEFEMINE,G, CILIBERTI,A, COTTI,G AND CARRETTI,D; CARCINOGENICITY BIOASSAYS OF VINYL CHLORIDE MONOMER: A MODEL OF RISK ASSESSMENT ON AN EXPERIMENTAL BASIS; ENVIRON. HEALTH PERSPECT. 41:3-29, 1981]"
3428,363898571,6338,C=CCl,Active,,,,HAMSTER,SYRIAN/MALE,INHALATION,"0; 50; 250; 500; 2500; 6000; 10000 PPM 4 HR/D, 5 D/WK FOR (STUDY DURATION: 109 WK)",INTEGUMENTARY SYSTEM (SKIN): EPITHELIOMA; FORESTOMACH: PAPILLOMA OR ACANTHOMA; LIVER: ANGIOMA OR ANGIOSARCOMA,POSITIVE,"[MALTONI,C, LEFEMINE,G, CILIBERTI,A, COTTI,G AND CARRETTI,D; CARCINOGENICITY BIOASSAYS OF VINYL CHLORIDE MONOMER: A MODEL OF RISK ASSESSMENT ON AN EXPERIMENTAL BASIS; ENVIRON. HEALTH PERSPECT. 41:3-29, 1981]"
3429,363898571,6338,C=CCl,Active,,,,MOUSE,"SWISS/MALE,FEMALE",INHALATION,"0; 50; 250; 500; 2500; 6000; 10000 PPM 4 HR/D, 5 D/WK FOR 30 WK (STUDY DURATION: 81 WK)","LIVER: ANGIOMA, ANGIOSARCOMA; LUNG: TUMOR (NOS); MAMMARY GLAND: CARCINOMA",POSITIVE,"[MALTONI,C, LEFEMINE,G, CILIBERTI,A, COTTI,G AND CARRETTI,D; CARCINOGENICITY BIOASSAYS OF VINYL CHLORIDE MONOMER: A MODEL OF RISK ASSESSMENT ON AN EXPERIMENTAL BASIS; ENVIRON. HEALTH PERSPECT. 41:3-29, 1981]"
3430,363898571,6338,C=CCl,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",INHALATION,"0; 50-10000 PPM 4 HR/D, 5 D/WK FOR 52 WK (STUDY DURATION: 135 WK)",LIVER: ANGIOSARCOMA; NERVOUS SYSTEM: NEUROBLASTOMA; EAR (ZYMBAL GLAND): CARCINOMA; KIDNEY: NEPHROBLASTOMA,POSITIVE,"[MALTONI,C, LEFEMINE,G, CILIBERTI,A, COTTI,G AND CARRETTI,D; CARCINOGENICITY BIOASSAYS OF VINYL CHLORIDE MONOMER: A MODEL OF RISK ASSESSMENT ON AN EXPERIMENTAL BASIS; ENVIRON. HEALTH PERSPECT. 41:3-29, 1981]"
3431,363898571,6338,C=CCl,Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",GAVAGE,"0; 3.33; 16.65; 50.0 MG/KG IN OLIVE OIL 1/D, 4-5 D/WK FOR 52 WK (STUDY DURATION: 136 WK)",LIVER: ANGIOSARCOMA,POSITIVE,"[MALTONI,C, LEFEMINE,G, CILIBERTI,A, COTTI,G AND CARRETTI,D; CARCINOGENICITY BIOASSAYS OF VINYL CHLORIDE MONOMER: A MODEL OF RISK ASSESSMENT ON AN EXPERIMENTAL BASIS; ENVIRON. HEALTH PERSPECT. 41:3-29, 1981]"
3432,363898571,6338,C=CCl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,"0; 600 PPM 4 HR/D, 5 D/WK FOR 1 YR (STUDY DURATION: 2.5 YR)","LIVER: HEPATOCELLULAR CARCINOMA, ANGIOSARCOMA",POSITIVE,"[RADIKE,MJ, STEMMER,KL AND BINGHAM,E; EFFECT OF ETHANOL ON VINYL CHLORIDE CARCINOGENESIS; ENVIRON. HEALTH PERSPECT. 41:59-62, 1981]"
3433,363898571,6338,C=CCl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 2500 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 69 WK ADMINISTERED TO BREEDER RATS (STUDY DURATION: 76 WK),"BRAIN: NEUROBLASTOMA; LIVER; HEPATOCARCINOMA, ANGIOSARCOMA",POSITIVE,"[MALTONI,C AND COTTI,G; CARCINOGENICITY OF VINYL CHLORIDE IN SPRAGUE-DAWLEY RATS AFTER PRENATAL AND POSTNATAL EXPOSURE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):145-159, 1988]"
3434,363898571,6338,C=CCl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 2500 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 69 WK ADMINISTERED TO RAT EMBRYOS BEGINNING ON 12TH DAY OF GESTATION (STUDY DURATION: 76 WK),"BRAIN: NEUROBLASTOMA; LIVER; HEPATOCARCINOMA, ANGIOSARCOMA",POSITIVE,"[MALTONI,C AND COTTI,G; CARCINOGENICITY OF VINYL CHLORIDE IN SPRAGUE-DAWLEY RATS AFTER PRENATAL AND POSTNATAL EXPOSURE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):145-159, 1988]"
3435,363898571,6338,C=CCl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 2500 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 69 WK ADMINISTERED TO RAT EMBRYOS BEGINNING ON 12TH DAY OF GESTATION (STUDY DURATION: 76 WK),"BRAIN: NEUROBLASTOMA; LIVER; HEPATOCARCINOMA, ANGIOSARCOMA",POSITIVE,"[MALTONI,C AND COTTI,G; CARCINOGENICITY OF VINYL CHLORIDE IN SPRAGUE-DAWLEY RATS AFTER PRENATAL AND POSTNATAL EXPOSURE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):145-159, 1988]"
3436,363898571,6338,C=CCl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 2500 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 8 WK ADMINISTERED TO RAT EMBRYOS BEGINNING ON 12TH DAY OF GESTATION (STUDY DURATION: LIFETIME),"LIVER: HEPATOMA, ANGIOSARCOMA; BRAIN: NEUROBLASTOMA",POSITIVE,"[MALTONI,C AND COTTI,G; CARCINOGENICITY OF VINYL CHLORIDE IN SPRAGUE-DAWLEY RATS AFTER PRENATAL AND POSTNATAL EXPOSURE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):145-159, 1988]"
3437,363898571,6338,C=CCl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 2500 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 8 WK ADMINISTERED TO RAT EMBRYOS BEGINNING ON 12TH DAY OF GESTATION (STUDY DURATION: LIFETIME),"LIVER: HEPATOMA, ANGIOSARCOMA; BRAIN: NEUROBLASTOMA",POSITIVE,"[MALTONI,C AND COTTI,G; CARCINOGENICITY OF VINYL CHLORIDE IN SPRAGUE-DAWLEY RATS AFTER PRENATAL AND POSTNATAL EXPOSURE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):145-159, 1988]"
3438,363898571,6338,C=CCl,Active,,,,RAT,WISTAR/MALE,ORAL,0; 0.014; 0.13; 1.3 MG/KG/BW/D IN DIET FOR DURATION OF STUDY (STUDY DURATION: 149 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[TIL,HP, FERON,VJ AND IMMEL,HR; LIFETIME (149-WEEK) ORAL CARCINOGENICITY STUDY OF VINYL CHLORIDE IN RATS; FOOD CHEM. TOXICOL. 29(10):713-718, 1991]"
3439,363898571,6338,C=CCl,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 0.014; 0.13; 1.3 MG/KG/BW/D IN DIET FOR DURATION OF STUDY (STUDY DURATION: 150 WK),LIVER: NEOPLASTIC NODULES,POSITIVE,"[TIL,HP, FERON,VJ AND IMMEL,HR; LIFETIME (149-WEEK) ORAL CARCINOGENICITY STUDY OF VINYL CHLORIDE IN RATS; FOOD CHEM. TOXICOL. 29(10):713-718, 1991]"
3440,363898571,6338,C=CCl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 50; 250; 500; 2500; 6000; 10000 PPM IN AIR 4 HR/D 5 D/WK FOR 17 WK (STUDY DURATION: LIFETIME),BRAIN: NEUROBLASTOMA [ONLY SITE EVALUATED],POSITIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3441,363898571,6338,C=CCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 6000; 10000 PPM IN AIR 4 HR/D 1 D/WK FOR 25 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3442,363898571,6338,C=CCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 6000; 10000 PPM IN AIR 4 HR/D 1 D/WK FOR 25 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3443,363898571,6338,C=CCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 6000; 10000 PPM IN AIR 1 HR/D 4 D/WK FOR 25 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3444,363898571,6338,C=CCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 6000; 10000 PPM IN AIR 1 HR/D 4 D/WK FOR 25 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3445,363898571,6338,C=CCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 6000; 10000 PPM IN AIR 4 HR/D 5 D/WK FOR 5 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3446,363898571,6338,C=CCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 6000; 10000 PPM IN AIR 4 HR/D 5 D/WK FOR 5 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3447,363898571,6338,C=CCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 0.03; 0.3; 1; 3.33; 16.65; 50 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52-59 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3448,363898571,6338,C=CCl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 0.03; 0.3; 1; 3.33; 16.65; 50 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52-59 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3449,363898572,6366,C=C(Cl)Cl,Active,,,,MOUSE,,INHALATION,,KIDNEY; LUNG; LIVER,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 439 Y79]"
3450,363898572,6366,C=C(Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY,INHALATION,,"MAMMARY GLAND: FIBROADENOMA, CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V19 439 Y79]"
3451,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 50; 100; 200 PPM IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[QUAST,JF, HUMISTON,CG, WADE,CE, BALLARD,J, BEYER,JE, SCHWETZ,RW AND NORRIS,JM; A CHRONIC TOXICITY AND ONCOGENICITY STUDY IN RATS AND SUBCHRONIC TOXICITY STUDY IN DOGS ON INGESTED VINYLIDENE CHLORIDE; FUNDAM. APPL. TOXICOL. 3:55-62, 1983]"
3452,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 50; 100; 200 PPM IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[QUAST,JF, HUMISTON,CG, WADE,CE, BALLARD,J, BEYER,JE, SCHWETZ,RW AND NORRIS,JM; A CHRONIC TOXICITY AND ONCOGENICITY STUDY IN RATS AND SUBCHRONIC TOXICITY STUDY IN DOGS ON INGESTED VINYLIDENE CHLORIDE; FUNDAM. APPL. TOXICOL. 3:55-62, 1983]"
3453,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 100 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 97 WK ADMINISTERED TO BREEDER RATS (STUDY DURATION: 104 WK),,NEGATIVE,"[COTTI,G, MALTONI,C AND LEFEMINE,G; LONG-TERM CARCINOGENICITY BIOASSAY ON VINYLIDENE CHLORIDE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):160-168, 1988]"
3454,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 100 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 97 WK ADMINISTERED TO RAT EMBRYOS BEGINNING ON 12TH DAY OF GESTATION (STUDY DURATION: 104 WK),,NEGATIVE,"[COTTI,G, MALTONI,C AND LEFEMINE,G; LONG-TERM CARCINOGENICITY BIOASSAY ON VINYLIDENE CHLORIDE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):160-168, 1988]"
3455,363898572,6366,C=C(Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 100 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 97 WK ADMINISTERED TO RAT EMBRYOS BEGINNING ON 12TH DAY OF GESTATION (STUDY DURATION: 104 WK),HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[COTTI,G, MALTONI,C AND LEFEMINE,G; LONG-TERM CARCINOGENICITY BIOASSAY ON VINYLIDENE CHLORIDE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):160-168, 1988]"
3456,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 100 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 8 WK ADMINISTERED TO RAT EMBRYOS BEGINNING ON THE 12TH DAY OF GESTATION (STUDY DURATION: LIFETIME),,NEGATIVE,"[COTTI,G, MALTONI,C AND LEFEMINE,G; LONG-TERM CARCINOGENICITY BIOASSAY ON VINYLIDENE CHLORIDE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):160-168, 1988]"
3457,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 100 PPM 4 HR/D 5 D/WK FOR 7 WK THEN 7 HR/D 5 D/WK FOR 8 WK ADMINISTERED TO RAT EMBRYOS BEGINNING ON THE 12TH DAY OF GESTATION (STUDY DURATION: LIFETIME),,NEGATIVE,"[COTTI,G, MALTONI,C AND LEFEMINE,G; LONG-TERM CARCINOGENICITY BIOASSAY ON VINYLIDENE CHLORIDE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):160-168, 1988]"
3458,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 10; 25; 50; 100; 150 PPM IN AIR 4 HR/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3459,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 10; 25; 50; 100; 150 PPM IN AIR 4 HR/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3460,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 0.5; 5; 10; 20 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52-59 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3461,363898572,6366,C=C(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 0.5; 5; 10; 20 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52-59 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3462,363898572,6366,C=C(Cl)Cl,Inactive,,,,FISH,"SHASTA RAINBOW TROUT/MALE, FEMALE",ORAL,0; 2000 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[HENDRICKS,JD, SHELTON,DW, LOVELAND,PM, PEREIRA,CB AND BAILEY,GS; CARCINOGENICITY OF DIETARY DIMETHYLNITROSOMORPHOLINE, N-METHYL-N'-NITRO-N-NITROSOGUANIDINE, AND DIBROMOETHANE IN RAINBOW TROUT; TOXICOL. PATHOL. 23(4):447-457, 1995]"
3463,363898573,5281576,C[C@H]1CCCC(=O)CCC/C=C/C2=C(C(=CC(=C2)O)O)C(=O)O1,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 50; 100 PPM IN DIET,"LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA; PITUITARY GLAND: ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-235 Y82]"
3464,363898573,5281576,C[C@H]1CCCC(=O)CCC/C=C/C2=C(C(=CC(=C2)O)O)C(=O)O1,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 50; 100 PPM IN DIET,"PITUITARY GLAND: ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-235 Y82]"
3465,363898573,5281576,C[C@H]1CCCC(=O)CCC/C=C/C2=C(C(=CC(=C2)O)O)C(=O)O1,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25; 50 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-235 Y82]"
3466,363898573,5281576,C[C@H]1CCCC(=O)CCC/C=C/C2=C(C(=CC(=C2)O)O)C(=O)O1,Inactive,,,,RAT,F344/MALE,ORAL,0; 25; 50 PPM IN DIET,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-235 Y82]"
3467,363898574,22748686,[Be+2].[O-][Si]([O-])([O-])[O-].[Zn+2],Active,,,,RABBIT,,INTRAVENOUS,"1 G/RABBIT (TOTAL), 20 INJ OVER 6 WK",BONE: OSTEOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V1 17 Y72][IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 173 Y80]"
3468,363898574,22748686,[Be+2].[O-][Si]([O-])([O-])[O-].[Zn+2],Active,,,,RABBIT,,INTRAVENOUS,1% SUSPENDED IN SALINE,BONE: OSTEOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 173 Y80]"
3469,363898574,22748686,[Be+2].[O-][Si]([O-])([O-])[O-].[Zn+2],Active,,,,RABBIT,,INTRAOSSEOUS,33 MG IN 0.5 ML GELATIN,BONE: OSTEOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 173 Y80]"
3470,363898574,22748686,[Be+2].[O-][Si]([O-])([O-])[O-].[Zn+2],Active,,,,RABBIT,,INTRAVENOUS,"1-2.1 G TOTAL DOSE, REPEATED ADMINISTRATION",BONE: OSTEOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80][BARNES,JM; EXPERIMENTAL PRODUCTION OF MALIGNANT TUMOURS BY BERYLLIUM; LANCET i:463, 1950, ][BARNES,JM, DENZ,FA AND SISSONS,HA; BERYLLIUM BONE SARCOMA IN RABBITS; BR. J. CANCER 4:212-222, 1950, ][SISSONS,HA; BONE SARCOMAS PRODUCED EXPERIMENTALLY IN THE RABBIT, USING COMPOUNDS OF BERYLLIUM; ACTA UNIO. INT. CANCRUM 7:171-172, 1950, ]"
3471,363898574,22748686,[Be+2].[O-][Si]([O-])([O-])[O-].[Zn+2],Active,,,,RABBIT,"MIXED BREEDS/MALE,FEMALE",INTRAMEDULLARY,20 MG INTO RIGHT TIBIA,BONE: OSTEOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80][TAPP,E; BERYLLIUM INDUCED SARCOMAS OF THE RABBIT TIBIA; BR. J. CANCER 20:778-783, 1966, ]"
3472,363898575,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 600; 1200 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-238 Y83]"
3473,363898575,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 300; 600 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-238 Y83]"
3474,363898575,,,Active,,,,RAT,F344/MALE,ORAL,0; 300; 600 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),THYROID GLAND: C CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-238 Y83]"
3475,363898575,,,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 600; 1200 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-238 Y83]"
3476,363898579,3102,C1=CC=C(C=C1)C(=O)C2=CC=CC=C2,Active,,,,Rat,F344/N/Male,Oral,0; 312; 625; 1250 ppm in feed for 105 wks,"Kidney: Renal tubule adenoma (1/50, 1/10, 2/50, 4/50); Mononuclear cell leukemia: (27/50, 41/50, 39/50, 24/50)",Positive Trend for Renal tubule adenoma (NTP describes as Some Evidence); Mononuclear cell leukemia findings described by NTP as equivocal,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-533 Y06]"
3477,363898579,3102,C1=CC=C(C=C1)C(=O)C2=CC=CC=C2,Unspecified,,,,Rat,F344/N/Female,Oral,0; 312; 625; 1250 ppm in feed for 105 wks,"Mononuclear cell leukemia: (19/50, 25/50, 30/50, 29/50) Histiocytic sarcoma: (0/50, 0/50, 1/50, 2/50) Mammary gland: fibroadenoma (27/50, 24/50, 15/50, 7/50) (decreased incidence)",Equivocal; Mononuclear cell leukemia and histiocytic sarcoma incidences described by NTP as equivocal.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-533 Y06]"
3478,363898579,3102,C1=CC=C(C=C1)C(=O)C2=CC=CC=C2,Active,,,,Mouse,B6C3F1/Male,Oral,0; 312; 625; 1250 ppm in feed for 105 wks,"Liver: Hepatocellular adenoma (11/50, 15/50, 23/50, 23/50); Hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma (18/50, 20/50, 25/50, 29/50)",Positive (NTP describes as Some Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-533 Y06]"
3479,363898579,3102,C1=CC=C(C=C1)C(=O)C2=CC=CC=C2,Active,,,,Mouse,B6C3F1/Female,Oral,0; 312; 625; 1250 ppm in feed for 105 wks,"Histiocytic sarcoma: (0/50, 0/50, 5/50, 3/50) Liver: Hepatocellular adenoma (5/50, 4/50, 10/50, 8/50)",Positive (NTP describes as Some Evidence); NTP describes results in liver as equivocal evidence,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-533 Y06]"
3480,363898580,7187,C1=CC=C(C=C1)C(=O)OOC(=O)C2=CC=CC=C2,Active,,,,MOUSE,SENCAR/FEMALE,DERMAL,0; 0.2 ML OF 100 MG/ML SOLUTION IN ACETONE 2 D/WK FOR 51 WK (STUDY DURATION: 52 WK),SKIN: SQUAMOUS CELL CARCINOMA OR EPIDERMAL HYPERPLASIA,POSITIVE,"[KUROKAWA,Y, TAKAMURU,N, MATSUSHIMA,Y, IMAZAWA,T AND HAYASHI,Y; STUDIES ON THE PROMOTING AND COMPLETE CARCINOGENIC ACTIVITIES OF SOME OXIDIZING CHEMICALS IN SKIN CARCINOGENESIS; CANCER LETT. 24:299-304, 1984]"
3481,363898584,,,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,10 X 20 X 0.3 MM SHEETS IMPLANTED INTO 2 SITES IN LATERAL ABDOMINAL REGION AND 1 SITE ON THE BACK (STUDY DURATION: 741 D),IMPLANT SITE: MALIGNANT HISTIOCYTOMA,POSITIVE,"[HATANAKA,S, ONEDA,S, OKAZAKI,K, SHONG,L, YOSHIDA,A, ISAKA,H AND YOSHIDA,H; INDUCTION OF MALIGNANT FIBROUS HISTIOCYTOMA IN FEMALE FISHER RATS BY IMPLANTATION OF CYANOACRYLATE, ZIRCONIA, POLYVINYL CHLORIDE OR SILICONE; IN VIVO 7(2):111-115, 1993]"
3482,363898584,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 2 MG IN OLIVE OIL (EMULSION OR SUSPENSION) 1/2 WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3483,363898584,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 2 MG IN OLIVE OIL (EMULSION OR SUSPENSION 1/2 WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3484,363898599,6780,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2=O,Active,,,,RAT,F344/N/MALE,DIET,0; 469; 938; 1875; 3750 PPM FOR 2 YRS (STUDY DURATION: 2YRS),KIDNEY: RENAL TUBULE ADENOMA; BLADDER: PAPILLOMA,"POSITIVE; NO TRUE DOSE RESPONSE, P VALUES = 0.01 IN THESE 2 CASES; ALL OTHERS NOT SIGNIFICANT","[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS    STUDIES OF ANTHRAQUINONE (CAS NO. 84-65-1) IN F344/N RATS  AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL.   PROGRAM  TECH. REP. SER. 494:1-358, 2005]"
3485,363898599,6780,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2=O,Active,,,,RAT,F344/N/MALE,DIET,0; 469; 938; 1875; 3750 PPM FOR 2 YRS (STUDY DURATION: 2YRS),KIDNEY: RENAL TUBULE ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS    STUDIES OF ANTHRAQUINONE (CAS NO. 84-65-1) IN F344/N RATS  AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL.   PROGRAM  TECH. REP. SER. 494:1-358, 2005]"
3486,363898599,6780,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2=O,Active,,,,MOUSE,B6C3F1/MALE,DIET,0; 833; 2500; 7500 PPM FOR 2 YR (STUDY DURATION: 2 YRS),"LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA OR HEPATOBLASTOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS    STUDIES OF ANTHRAQUINONE (CAS NO. 84-65-1) IN F344/N RATS  AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL.   PROGRAM  TECH. REP. SER. 494:1-358, 2005]"
3487,363898599,6780,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2=O,Active,,,,MOUSE,B6C3F1/MALE,DIET,0; 833; 2500; 7500 PPM FOR 2 YR (STUDY DURATION: 2 YRS),"LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA OR HEPATOBLASTOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS    STUDIES OF ANTHRAQUINONE (CAS NO. 84-65-1) IN F344/N RATS  AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL.   PROGRAM  TECH. REP. SER. 494:1-358, 2005]"
3488,363898601,444041,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 25; 75; 225; 675 MG/KG/D IN DIET FOR 122 WK (STUDY DURATION: 122 WK),,NEGATIVE,"[WANER,T, BORELLI,G, CADEL,S, PRIVMAN,I AND NYSKA,A; INVESTIGATION OF POTENTIAL ONCOGENETIC EFFECTS OF B-CYCLODEXTRIN IN THE RAT AND MOUSE; ARCH. TOXICOL. 69(9):631-639, 1995]"
3489,363898601,444041,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25; 75; 225; 675 MG/KG/D IN DIET FOR 130 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[WANER,T, BORELLI,G, CADEL,S, PRIVMAN,I AND NYSKA,A; INVESTIGATION OF POTENTIAL ONCOGENETIC EFFECTS OF B-CYCLODEXTRIN IN THE RAT AND MOUSE; ARCH. TOXICOL. 69(9):631-639, 1995]"
3490,363898601,444041,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 25; 75; 225; 675 MG/KG/D IN DIET FOR 93 WK (STUDY DURATION: 93 WK),,NEGATIVE,"[WANER,T, BORELLI,G, CADEL,S, PRIVMAN,I AND NYSKA,A; INVESTIGATION OF POTENTIAL ONCOGENETIC EFFECTS OF B-CYCLODEXTRIN IN THE RAT AND MOUSE; ARCH. TOXICOL. 69(9):631-639, 1995]"
3491,363898601,444041,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 25; 75; 225; 675 MG/KG/D IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[WANER,T, BORELLI,G, CADEL,S, PRIVMAN,I AND NYSKA,A; INVESTIGATION OF POTENTIAL ONCOGENETIC EFFECTS OF B-CYCLODEXTRIN IN THE RAT AND MOUSE; ARCH. TOXICOL. 69(9):631-639, 1995]"
3492,363898601,444041,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN DIET FOR 104 WK (STUDY DURATION: 109 WK),,NEGATIVE,"[TOYODA,K, SHODA,T, UNEYAMA,C, TAKADA,K AND TAKAHASHI,M; CARCINOGENICITY STUDY OF BETA-CYCLODEXTRIN IN F344 RATS; FOOD CHEM. TOXICOL. 35(3/4):331-336, 1997]"
3493,363898601,444041,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN DIET FOR 104 WK (STUDY DURATION: 109 WK),,NEGATIVE,"[TOYODA,K, SHODA,T, UNEYAMA,C, TAKADA,K AND TAKAHASHI,M; CARCINOGENICITY STUDY OF BETA-CYCLODEXTRIN IN F344 RATS; FOOD CHEM. TOXICOL. 35(3/4):331-336, 1997]"
3494,363898607,8449,C1=CC(=C(C=C1Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-353 Y89]"
3495,363898607,8449,C1=CC(=C(C=C1Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5000; 10000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-353 Y89]"
3496,363898607,8449,C1=CC(=C(C=C1Cl)Cl)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-353 Y89]"
3497,363898607,8449,C1=CC(=C(C=C1Cl)Cl)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2500; 5000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-353 Y89]"
3498,363898621,440917,CC1=CC[C@@H](CC1)C(=C)C,Active,,,,RAT,F344/MALE,GAVAGE,0; 75; 150 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),"KIDNEY: TUBULAR CELL ADENOMA, TUBULAR CELL ADENOMA OR ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-347 Y90]"
3499,363898621,440917,CC1=CC[C@@H](CC1)C(=C)C,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 300; 600 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-347 Y90]"
3500,363898621,440917,CC1=CC[C@@H](CC1)C(=C)C,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-347 Y90]"
3501,363898621,440917,CC1=CC[C@@H](CC1)C(=C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-347 Y90]"
3502,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG/D FOR 13 WK (STUDY DURATION: 13 WK),,NEGATIVE,"[SANDERS,VM, ELWELL,MR, HEATH,JE, COLLINS,BJ, DUNNICK,JK, RAO,GN, PREJEAN,D, LINDAMOOD,C,III AND IRWIN,RD; INDUCTION OF THYMIC LYMPHOMA IN MICE ADMINISTERED THE DIDEOXYNUCLEOSIDE DDC; FUNDAM. APPL. TOXICOL. 27(2):263-269, 1995]"
3503,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG/D FOR 13 WK (STUDY DURATION: 13 WK),,NEGATIVE,"[SANDERS,VM, ELWELL,MR, HEATH,JE, COLLINS,BJ, DUNNICK,JK, RAO,GN, PREJEAN,D, LINDAMOOD,C,III AND IRWIN,RD; INDUCTION OF THYMIC LYMPHOMA IN MICE ADMINISTERED THE DIDEOXYNUCLEOSIDE DDC; FUNDAM. APPL. TOXICOL. 27(2):263-269, 1995]"
3504,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG/D FOR 13 WK FOLLOWED BY 4 WK OF RECOVERY (STUDY DURATION: 17 WK),,NEGATIVE,"[SANDERS,VM, ELWELL,MR, HEATH,JE, COLLINS,BJ, DUNNICK,JK, RAO,GN, PREJEAN,D, LINDAMOOD,C,III AND IRWIN,RD; INDUCTION OF THYMIC LYMPHOMA IN MICE ADMINISTERED THE DIDEOXYNUCLEOSIDE DDC; FUNDAM. APPL. TOXICOL. 27(2):263-269, 1995]"
3505,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG/D FOR 13 WK FOLLOWED BY 13 WK FOR RECOVERY (STUDY DURATION: 26 WK),THYMUS: LYMPHOMA,POSITIVE,"[SANDERS,VM, ELWELL,MR, HEATH,JE, COLLINS,BJ, DUNNICK,JK, RAO,GN, PREJEAN,D, LINDAMOOD,C,III AND IRWIN,RD; INDUCTION OF THYMIC LYMPHOMA IN MICE ADMINISTERED THE DIDEOXYNUCLEOSIDE DDC; FUNDAM. APPL. TOXICOL. 27(2):263-269, 1995]"
3506,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG BW A DAY FOR 6 MO (STUDY DURATION: 6 MO),THYMUS: LYMPHOMA,POSITIVE,"[RAO,GN, COLLINS,BJ, GILES,HD, HEATH,JE, FOLEY,JF, MAY,RD AND BUCKLEY,LA; CARCINOGENICITY OF 2',3'-DIDEOXYCYTIDINE IN MICE; CANCER RES. 56(20):4666-4672, 1996]"
3507,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG BW A DAY FOR 6 MO (STUDY DURATION: 6 MO),THYMUS: LYMPHOMA,POSITIVE,"[RAO,GN, COLLINS,BJ, GILES,HD, HEATH,JE, FOLEY,JF, MAY,RD AND BUCKLEY,LA; CARCINOGENICITY OF 2',3'-DIDEOXYCYTIDINE IN MICE; CANCER RES. 56(20):4666-4672, 1996]"
3508,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Active,,,,MOUSE,NIH SWISS/MALE,GAVAGE,0; 500; 1000 MG/KG BW A DAY FOR 6 MO (STUDY DURATION: 6 MO),THYMUS: LYMPHOMA,POSITIVE,"[RAO,GN, COLLINS,BJ, GILES,HD, HEATH,JE, FOLEY,JF, MAY,RD AND BUCKLEY,LA; CARCINOGENICITY OF 2',3'-DIDEOXYCYTIDINE IN MICE; CANCER RES. 56(20):4666-4672, 1996]"
3509,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Active,,,,MOUSE,NIH SWISS/FEMALE,GAVAGE,0; 500; 1000 MG/KG BW A DAY FOR 6 MO (STUDY DURATION: 6 MO),THYMUS: LYMPHOMA; SPLEEN: LYMPHOMA; LYMPH NODE: LYMPHOMA,POSITIVE,"[RAO,GN, COLLINS,BJ, GILES,HD, HEATH,JE, FOLEY,JF, MAY,RD AND BUCKLEY,LA; CARCINOGENICITY OF 2',3'-DIDEOXYCYTIDINE IN MICE; CANCER RES. 56(20):4666-4672, 1996]"
3510,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 1000 MG/KG BW A DAY FOR 3 MO FOLLOWED BY A 3 MO RECOVERY PERIOD (STUDY DURATION: 6 MO),THYMUS: LYMPHOMA,POSITIVE,"[RAO,GN, COLLINS,BJ, GILES,HD, HEATH,JE, FOLEY,JF, MAY,RD AND BUCKLEY,LA; CARCINOGENICITY OF 2',3'-DIDEOXYCYTIDINE IN MICE; CANCER RES. 56(20):4666-4672, 1996]"
3511,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 1000 MG/KG BW A DAY FOR 3 MO FOLLOWED BY A 3-MO RECOVERY PERIOD (STUDY DURATION: 6 MO),THYMUS: LYMPHOMA; SPLEEN: LYMPHOMA,POSITIVE,"[RAO,GN, COLLINS,BJ, GILES,HD, HEATH,JE, FOLEY,JF, MAY,RD AND BUCKLEY,LA; CARCINOGENICITY OF 2',3'-DIDEOXYCYTIDINE IN MICE; CANCER RES. 56(20):4666-4672, 1996]"
3512,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Active,,,,MOUSE,NIH SWISS/MALE,GAVAGE,0; 1000 MG/KG BW A DAY FOR 3 MO FOLLOWED BY A 3-MO RECOVERY PERIOD (STUDY DURATION: 6 MO),THYMUS: LYMPHOMA,POSITIVE,"[RAO,GN, COLLINS,BJ, GILES,HD, HEATH,JE, FOLEY,JF, MAY,RD AND BUCKLEY,LA; CARCINOGENICITY OF 2',3'-DIDEOXYCYTIDINE IN MICE; CANCER RES. 56(20):4666-4672, 1996]"
3513,363898642,24066,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,Active,,,,MOUSE,NIH SWISS/FEMALE,GAVAGE,0; 1000 MG/KG BW A DAY FOR 3 MO FOLLOWED BY A 3-MO RECOVERY PERIOD (STUDY DURATION: 6 MO),THYMUS: LYMPHOMA; SPLEEN: LYMPHOMA; LYMPH NODE: LYMPHOMA,POSITIVE,"[RAO,GN, COLLINS,BJ, GILES,HD, HEATH,JE, FOLEY,JF, MAY,RD AND BUCKLEY,LA; CARCINOGENICITY OF 2',3'-DIDEOXYCYTIDINE IN MICE; CANCER RES. 56(20):4666-4672, 1996]"
3514,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Active,,,,RAT,F344/MALE,ORAL,0; 0.125; 0.25; 0.5; 1.0; 2.0; 4.0% IN DIET FOR 91 WK,KIDNEY: TRANSITIONAL CELL CARCINOMA; URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[HIRAGA,K AND FUJII,T; INDUCTION OF TUMOURS OF THE URINARY SYSTEM IN F344 RATS BY DIETARY ADMINISTRATION OF SODIUM O-PHENYLPHENATE; FOOD COSMET. TOXICOL. 19:303-310, 1981]"
3515,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1; 2% IN THE DIET FOR 96 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HAGIWARA,A, SHIBATA,M, HIROSE,M, FUKUSHIMA,S AND ITO,N; LONG-TERM TOXICITY AND CARCINOGENICITY STUDY OF SODIUM O-PHENYLPHENATE IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 22(10):809-814, 1984]"
3516,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.5; 1; 2% IN THE DIET FOR 96 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HAGIWARA,A, SHIBATA,M, HIROSE,M, FUKUSHIMA,S AND ITO,N; LONG-TERM TOXICITY AND CARCINOGENICITY STUDY OF SODIUM O-PHENYLPHENATE IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 22(10):809-814, 1984]"
3517,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET (STUDY DURATION: 48 WK),,NEGATIVE,"[HASEGAWA,R, TAKAHASHI,S, ASAMOTO,M, SHIRAI,T AND FUKUSHIMA,S; SPECIES DIFFERENCES IN SODIUM O-PHENYLPHENATE INDUCTION OF URINARY BLADDER LESIONS; CANCER LETT. 50(2):87-91, 1990]"
3518,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2% IN DIET (STUDY DURATION: 48 WK),,NEGATIVE,"[HASEGAWA,R, TAKAHASHI,S, ASAMOTO,M, SHIRAI,T AND FUKUSHIMA,S; SPECIES DIFFERENCES IN SODIUM O-PHENYLPHENATE INDUCTION OF URINARY BLADDER LESIONS; CANCER LETT. 50(2):87-91, 1990]"
3519,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Inactive,,,,HAMSTER,SYRIAN/MALE,ORAL,0; 2% IN DIET (STUDY DURATION: 48 WK),,NEGATIVE,"[HASEGAWA,R, TAKAHASHI,S, ASAMOTO,M, SHIRAI,T AND FUKUSHIMA,S; SPECIES DIFFERENCES IN SODIUM O-PHENYLPHENATE INDUCTION OF URINARY BLADDER LESIONS; CANCER LETT. 50(2):87-91, 1990]"
3520,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Inactive,,,,GUINEA PIG,HARTLEY/MALE,ORAL,0; 2% IN DIET (STUDY DURATION: 48 WK),,NEGATIVE,"[HASEGAWA,R, TAKAHASHI,S, ASAMOTO,M, SHIRAI,T AND FUKUSHIMA,S; SPECIES DIFFERENCES IN SODIUM O-PHENYLPHENATE INDUCTION OF URINARY BLADDER LESIONS; CANCER LETT. 50(2):87-91, 1990]"
3521,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),BLADDER: CARCINOMA,POSITIVE,"[FUKUSHIMA,S, INOUE,T, UWAGAWA,S, SHIBATA,M AND ITO,N; CO-CARCINOGENIC EFFECTS OF NAHCO3 ON O-PHENYLPHENOL-INDUCED RAT BLADDER CARCINOGENESIS; CARCINOGENESIS 10(9):1635-1640, 1989]"
3522,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1; 2% IN DIET FOR 96 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HAGIWARA,A, SHIBATA,M, HIROSE,M, FUKUSHIMA,S AND ITO,N; LONG-TERM TOXICITY AND CARCINOGENICITY STUDY OF SODIUM O-PHENYLPHENATE IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 22(10):809-814, 1984]"
3523,363898643,23675735,C1=CC=C(C=C1)C2=CC=CC=C2[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.5; 1; 2% IN DIET FOR 96 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HAGIWARA,A, SHIBATA,M, HIROSE,M, FUKUSHIMA,S AND ITO,N; LONG-TERM TOXICITY AND CARCINOGENICITY STUDY OF SODIUM O-PHENYLPHENATE IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 22(10):809-814, 1984]"
3524,363898650,5281955,CCCCCCCC/C=C/CCCCCCCC(=O)OCCOCC(C1C(C(CO1)OCCO)OCCO)OCCO,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN FEED 7 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-415 Y92]"
3525,363898650,5281955,CCCCCCCC/C=C/CCCCCCCC(=O)OCCOCC(C1C(C(CO1)OCCO)OCCO)OCCO,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN FEED 7 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-415 Y92]"
3526,363898650,5281955,CCCCCCCC/C=C/CCCCCCCC(=O)OCCOCC(C1C(C(CO1)OCCO)OCCO)OCCO,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN FEED 7 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-415 Y92]"
3527,363898650,5281955,CCCCCCCC/C=C/CCCCCCCC(=O)OCCOCC(C1C(C(CO1)OCCO)OCCO)OCCO,Unspecified,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN FEED 7 D/WK FOR 103 WK (STUDY DURATION: 103 WK),ADRENAL MEDULLA: PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-415 Y92]"
3528,363898656,656582,C1=CC=C2C(=C1)C(=O)[N-]S2(=O)=O.[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 5% IN DIET FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[HOMMA,Y,, KONDO,Y, KAKIZOE,T, ASO,Y AND NAGASE,S; LACK OF BLADDER CARCINOGENICITY OF DIETARY SODIUM SACCHARIN IN ANALBUMINEMIC RATS, WHICH ARE HIGHLY SUSCEPTIBLE TO N-NITROSO-N-BUTYL-(4-HYDROXYBUTYL)AMINE; FOOD CHEM. TOXICOL. 29(6):373-376, 1991]"
3529,363898656,656582,C1=CC=C2C(=C1)C(=O)[N-]S2(=O)=O.[Na+],Inactive,,,,RAT,ANALBUMINEMIC/MALE,ORAL,0; 5% IN DIET FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[HOMMA,Y,, KONDO,Y, KAKIZOE,T, ASO,Y AND NAGASE,S; LACK OF BLADDER CARCINOGENICITY OF DIETARY SODIUM SACCHARIN IN ANALBUMINEMIC RATS, WHICH ARE HIGHLY SUSCEPTIBLE TO N-NITROSO-N-BUTYL-(4-HYDROXYBUTYL)AMINE; FOOD CHEM. TOXICOL. 29(6):373-376, 1991]"
3530,363898656,656582,C1=CC=C2C(=C1)C(=O)[N-]S2(=O)=O.[Na+],Inactive,,,,MONKEY,"AFRICAN GREEN, RHESUS, CYNOMOLGUS, HYBRID/MALE, FEMALE",ORAL,0; 25 MG/KG BW IN FOOD 5 D/WK FOR DURATION OF STUDY (STUDY DURATION: 24 YR),,NEGATIVE,"[TAKAYAMA,S, SIEBER,SM, ADAMSON,RH, THORGEIRSSON,UP, DALGARD,DW, ARNOLD,LL, CANO,M, EKLUND,S AND COHEN,SM; LONG-TERM FEEDING OF SODIUM SACCHARIN TO NONHUMAN PRIMATES: IMPLICATIONS FOR URINARY TRACT CANCER; J. NATL. CANCER INST. 90(1):19-25, 1998]"
3531,363898658,23665760,[O-]Cl.[Na+],Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 100; 500; 750 MG/L IN DRINKING WATER FOR 104 WK (STUDY DURATION: LIFETIME),LYMPHATIC SYSTEM: LYMPHOMA OR LEUKEMIA,POSITIVE,"[SOFFRITTI,M, BELPOGGI,F, LENZI,A AND MALTONI,C; RESULTS OF LONG-TERM CARCINOGENICITY STUDIES OF CHLORINE IN RATS; ANN. N.Y. ACAD. SCI. 837(PREVENTIVE STRATEGIES FOR LIVING IN A CHEMICAL WORLD):189-208, 1997]"
3532,363898658,23665760,[O-]Cl.[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 100; 500; 750 MG/L IN DRINKING WATER FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[SOFFRITTI,M, BELPOGGI,F, LENZI,A AND MALTONI,C; RESULTS OF LONG-TERM CARCINOGENICITY STUDIES OF CHLORINE IN RATS; ANN. N.Y. ACAD. SCI. 837(PREVENTIVE STRATEGIES FOR LIVING IN A CHEMICAL WORLD):189-208, 1997]"
3533,363898666,27924,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)C)O)C,Active,,,,MOUSE,"BALB/MALE, FEMALE",DERMAL,0; 18 NMOL IN ACETONE 1/WK FOR 17 MO (STUDY DURATION: 24 MO),SKIN: SQUAMOUS CELL PAPILLOMA,POSITIVE,"[ASTRUP,EG AND IVERSEN,OH; THE TUMOURIGENIC AND CARCINOGENIC EFFECT OF 12-0-TETRADECANOYLPHORBOL-13-ACETATE WHEN APPLIED TO THE SKIN OF BALB/CA AND HAIRLESS (HR/HR) MICE; ACTA PATH. MICROBIOL. IMMUNOL. SCAND. SECT. A 91:103-113, 1983]"
3534,363898666,27924,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)C)O)C,Inactive,,,,MOUSE,"HR-HR/MALE, FEMALE",DERMAL,0; 18 NMOL IN ACETONE 1/WK FOR 18 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[ASTRUP,EG AND IVERSEN,OH; THE TUMOURIGENIC AND CARCINOGENIC EFFECT OF 12-0-TETRADECANOYLPHORBOL-13-ACETATE WHEN APPLIED TO THE SKIN OF BALB/CA AND HAIRLESS (HR/HR) MICE; ACTA PATH. MICROBIOL. IMMUNOL. SCAND. SECT. A 91:103-113, 1983]"
3535,363898666,27924,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)C)O)C,Active,,,,MOUSE,"HR/HR/MALE, FEMALE",DERMAL,0; 20; 40; 100; 1000; 1200; 1394 NMOL TOTAL DOSE WITH RESPECTIVE ADMINISTRATIONS OF 20 NMOL ONCE; 2 NMOL TWICE; 20 NMOL 2/WK FOR 5 DOSES; 20 NMOL 2/WK FOR 50 DOSES; 10 NMOL 2/WK FOR 60 WK; 17 NMOL 2/WK FOR 41 WK (STUDY DURATION: 20 MO),SKIN: TUMOR,POSITIVE,"[IVERSEN,OH; TPA (12-0-TETRADECANOYLPHORBOL 13-ACETATE) AS A CARCINOGEN FOR MOUSE SKIN. A POSITIVE DOSE-RESPONSE RELATIONSHIP; VIRCHOWS ARCH. B 49(2):129-135, 1985]"
3536,363898687,6581,C=CC(=O)O,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 0.20 MG IN 25 UL ACETONE 3/WK FOR LIFESPAN (STUDY DURATION: LIFESPAN),,NEGATIVE,"[DEPASS,LR, FOWLER,EH, MECKLEY,DR AND WEIL,CS; DERMAL ONCOGENICITY BIOASSAYS OF ACRYLIC ACID, ETHYL ACRYLATE, AND BUTYL ACRYLATE; J. TOXICOL. ENVIRON. HEALTH 14(2-3):115-120, 1984]"
3537,363898687,6581,C=CC(=O)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 120; 400; 1200 PPM IN DRINKING WATER FOR 26 MO (STUDY DURATION: 26 MO),,NEGATIVE,"[HELLWIG,J, DECKARDT,K AND FREISBERG,KO; SUBCHRONIC AND CHRONIC STUDIES OF THE EFFECTS OF ORAL ADMINISTRATION OF ACRYLIC ACID TO RATS; FOOD CHEM. TOXICOL. 31(1):1-18, 1993]"
3538,363898687,6581,C=CC(=O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 120; 400; 1200 PPM IN DRINKING WATER FOR 28 MO (STUDY DURATION: 28 MO),,NEGATIVE,"[HELLWIG,J, DECKARDT,K AND FREISBERG,KO; SUBCHRONIC AND CHRONIC STUDIES OF THE EFFECTS OF ORAL ADMINISTRATION OF ACRYLIC ACID TO RATS; FOOD CHEM. TOXICOL. 31(1):1-18, 1993]"
3539,363898689,31703,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAVENOUS,0; 5; 10 MG/KG IN SALINE SOLUTION ONCE (STUDY DURATION: 1 YR),"MAMMARY GLAND: FIBROADENOMA, ADENOCARCINOMA",POSITIVE,"[BUCCIARELLI,E; MAMMARY TUMOR INDUCTION IN MALE AND FEMALE SPRAGUE-DAWLEY RATS BY ADRIAMYCIN AND DAUNOMYCIN; J. NATL. CANCER INST. 66(1):81-84, 1981]"
3540,363898689,31703,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,0; 5; 10 MG/KG IN SALINE SOLUTION ONCE (STUDY DURATION: 1 YR),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[BUCCIARELLI,E; MAMMARY TUMOR INDUCTION IN MALE AND FEMALE SPRAGUE-DAWLEY RATS BY ADRIAMYCIN AND DAUNOMYCIN; J. NATL. CANCER INST. 66(1):81-84, 1981]"
3541,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 0.8% IN POWDERED BASAL DIET FOR 104 WK (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOCARCINOMA,POSITIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
3542,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.8% IN POWDERED BASAL DIET FOR 104 WK (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOCARCINOMA,POSITIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
3543,363898691,289,C1=CC=C(C(=C1)O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.8% IN POWDERED BASAL DIET FOR 96 WK (STUDY DURATION: 96 WK),,NEGATIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
3544,363898691,289,C1=CC=C(C(=C1)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.8% IN POWDERED BASAL DIET FOR 96 WK (STUDY DURATION: 96 WK),,NEGATIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
3545,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOCARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369(CHEM. INDUCED CELL PROLIFERATION):43-52, 1991]"
3546,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOCARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369(CHEM. INDUCED CELL PROLIFERATION):43-52, 1991]"
3547,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/MALE,ORAL,"0; 0.8% IN DIET FOR 12, 24, 48, 72, OR 96 WK FOLLOWED BY BASAL DIET FOR 84, 72, 48, 24, AND 0 WK RESPECTIVELY (STUDY DURATION: 96 WK)","STOMACH: ADENOMA, ADENOCARCINOMA",POSITIVE,"[HIROSE,M, WAKA,S, YAMAGUCHI,S, MASUDA,A, OKAZAKI,S AND ITO,N; REVERSIBILITY OF CATECHOL-INDUCED RAT GLANDULAR STOMACH LESIONS; CANCER RES. 52(4):787-790, 1992]"
3548,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 0.8% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"GLANDULAR STOMACH: ADENOMA, ADENOCARCINOMA",POSITIVE,"[HIROSE,M, FUKUSHIMA,S, TANAKA,H, ASAKAWA,E, TAKAHASHI,S AND ITO,N; CARCINOGENICITY OF CATECHOL IN F344 RATS AND B6C3F1 MICE; CARCINOGENESIS 14(3):525-529, 1993]"
3549,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.8% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"GLANDULAR STOMACH: ADENOMA, ADENOCARCINOMA",POSITIVE,"[HIROSE,M, FUKUSHIMA,S, TANAKA,H, ASAKAWA,E, TAKAHASHI,S AND ITO,N; CARCINOGENICITY OF CATECHOL IN F344 RATS AND B6C3F1 MICE; CARCINOGENESIS 14(3):525-529, 1993]"
3550,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.8% IN DIET FOR 96 WK (STUDY DURATION: 96 WK),GLANDULAR STOMACH: ADENOMA,POSITIVE,"[HIROSE,M, FUKUSHIMA,S, TANAKA,H, ASAKAWA,E, TAKAHASHI,S AND ITO,N; CARCINOGENICITY OF CATECHOL IN F344 RATS AND B6C3F1 MICE; CARCINOGENESIS 14(3):525-529, 1993]"
3551,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.8% IN DIET FOR 96 WK (STUDY DURATION: 96 WK),GLANDULAR STOMACH: ADENOMA,POSITIVE,"[HIROSE,M, FUKUSHIMA,S, TANAKA,H, ASAKAWA,E, TAKAHASHI,S AND ITO,N; CARCINOGENICITY OF CATECHOL IN F344 RATS AND B6C3F1 MICE; CARCINOGENESIS 14(3):525-529, 1993]"
3552,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,WISTAR/MALE,ORAL,0; 0.8% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"GLANDULAR STOMACH: ADENOMA, ADENOCARCINOMA",POSITIVE,"[TANAKA,H, HIROSE,M, HAGIWARA,K, IMAIDA,T, SHIRAI,T AND ITO,N; RAT STRAIN DIFFERENCES IN CATECHOL CARCINOGENICITY TO THE STOMACH;FOOD CHEM. TOXICOL. 33(2):93-98, 1995]"
3553,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,WKY/MALE,ORAL,0; 0.8% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOMA,POSITIVE,"[TANAKA,H, HIROSE,M, HAGIWARA,K, IMAIDA,T, SHIRAI,T AND ITO,N; RAT STRAIN DIFFERENCES IN CATECHOL CARCINOGENICITY TO THE STOMACH;FOOD CHEM. TOXICOL. 33(2):93-98, 1995]"
3554,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,LEWIS/MALE,ORAL,0; 0.8% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"GLANDULAR STOMACH: ADENOMA, ADENOCARCINOMA",POSITIVE,"[TANAKA,H, HIROSE,M, HAGIWARA,K, IMAIDA,T, SHIRAI,T AND ITO,N; RAT STRAIN DIFFERENCES IN CATECHOL CARCINOGENICITY TO THE STOMACH;FOOD CHEM. TOXICOL. 33(2):93-98, 1995]"
3555,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.8% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"GLANDULAR STOMACH: ADENOMA, ADENOCARCINOMA; FORESTOMACH: PAPILLOMA",POSITIVE,"[TANAKA,H, HIROSE,M, HAGIWARA,K, IMAIDA,T, SHIRAI,T AND ITO,N; RAT STRAIN DIFFERENCES IN CATECHOL CARCINOGENICITY TO THE STOMACH;FOOD CHEM. TOXICOL. 33(2):93-98, 1995]"
3556,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 0.16% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOMA,POSITIVE,"[HIROSE,M, TAKESADA,Y, TANAKA,H, TAMANO,S, KATO,T AND SHIRAI,T; CARCINOGENICITY OF ANTIOXIDANTS BHA, CAFFEIC ACID, SESAMOL, 4-METHOXYPHENOL AND CATECHOL AT LOW DOSES, EITHER ALONE OR IN COMBINATION, AND MODULATION OF THEIR EFFECTS IN A RAT MEDIUM-TERM MULTI-ORGAN CARCINOGENESIS MODEL; CARCINOGENESIS 19(1):207-212, 1998]"
3557,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 0.1; 0.2; 0.4; 0.8% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOMA; PANCREAS: ACINAR CELL ADENOMA,POSITIVE,"[HAGIWARA,A TAKESADA,Y TANAKA,H TAMANO,S HIROSE,M ITO,N AND SHIRAI,T; DOSE-DEPENDENT INDUCTION OF GLANDULAR STOMACH PRENEOPLASTIC AND NEOPLASTIC LESIONS IN MALE F344 RATS TREATED WITH CATECHOL CHRONICALLY; TOXICOL. PATHOL. 29(2):180-186, 2001]"
3558,363898691,289,C1=CC=C(C(=C1)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 0.1; 0.2; 0.4; 0.8% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOMA; PANCREAS: ACINAR CELL ADENOMA,POSITIVE,"[HAGIWARA,A TAKESADA,Y TANAKA,H TAMANO,S HIROSE,M ITO,N AND SHIRAI,T; DOSE-DEPENDENT INDUCTION OF GLANDULAR STOMACH PRENEOPLAST AND NEOPLASTIC LESIONS IN MALE F344 RATS TREATED WITH CATECHNOOL CHRONICALLY; TOXICOL. PATHOL. 29(2):180-186, 2001]"
3559,363898694,853433,C/C=C/C1=CC(=C(C=C1)O)OC,Inactive,,,,Rat,F344/N / Male (50/Group),Oral,"0; 75; 150; 300 mg/kg in corn oil, by gavage, 5 d/wk for 2 yr",,"Negative. (Authors describe as equivocal evidence based on incidence of thymoma, benign or malignant (0/47, 0/43, 0/49, 2/48) in thymus and carcinoma (0/50, 0/50, 0/50, 2/50) in mammary gland)",[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
3560,363898694,853433,C/C=C/C1=CC(=C(C=C1)O)OC,Inactive,,,,Rat,F344/N / Female (50/Group),Oral,"0; 75; 150; 300 mg/kg in corn oil, by gavage, 5 d/wk for 2 yr",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-551 Y10]"
3561,363898694,853433,C/C=C/C1=CC(=C(C=C1)O)OC,Active,,,,Mouse,B6C3F1 /Male (50/Group),Oral,"0; 75; 150; 300 mg/kg in corn oil, by gavage, 5 d/wk for 2 yr","Liver: hepatocellular adenoma (24/50, 35/50, 37/50, 33/50); hepatocellular carcinoma (8/50, 18/50, 19/50, 18/50); hepatocellular adenoma or carcinoma (28/50, 43/50, 43/50, 43/50)",Positive. (Authors describe as clear evidence),[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
3562,363898694,853433,C/C=C/C1=CC(=C(C=C1)O)OC,Inactive,,,,Mouse,B6C3F1 /Female (50/Group),Oral,"0; 75; 150; 300 mg/kg in corn oil, by gavage, 5 d/wk for 2 yr",,"Negative. (Authors describe as equivocal evidence based on incidence of histiocytic sarcoma (0/49, 1/50, 1/50, 4/50) in all organs)","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-551 Y10]"
3563,363898696,7127,COC1=C(C=C(C=C1)CC=C)OC,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 37; 75; 150 MG/KG BW IN 0.5% METHYLCELLULOSE 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),LIVER: TUMOR,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-491 Y00]"
3564,363898696,7127,COC1=C(C=C(C=C1)CC=C)OC,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 37; 75; 150 MG/KG BW IN 0.5% METHYLCELLULOSE 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-491 Y00]"
3565,363898696,7127,COC1=C(C=C(C=C1)CC=C)OC,Active,,,,RAT,F344/N/MALE,GAVAGE,0; 37; 75; 150 MG/KG BW IN 0.5% METHYLCELLULOSE 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; GLANDULAR STOMACH: MALIGNANT NEUROENDOCRINE TUMOR; KIDNEY: ADENOMA; MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-491 Y00]"
3566,363898696,7127,COC1=C(C=C(C=C1)CC=C)OC,Active,,,,RAT,F344/N/MALE,GAVAGE,0; 300 MG/KG BW IN 0.5% METHYLCELLULOSE 5 D/WK FOR 52 WK (STUDY DURATION: 105 WK),"KIDNEY: RENAL TUBULE ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA, HEPATOCHOLANGIOMA OR HEPATOCHOLANDGIOCARCINOMA; GLANDULAR STOMACH: BENIGN OR MALIGNANT NEUROENDOCRINE TUMOR",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-491 Y00]"
3567,363898696,7127,COC1=C(C=C(C=C1)CC=C)OC,Active,,,,RAT,F344/N/FEMALE,GAVAGE,0; 37; 75; 150 MG/KG BW IN 0.5% METHYLCELLULOSE 5D/WK FOR 105 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; GLANDULAR STOMACH: BENIGN OR MALIGNANT NEUROENDOCRINE TUMOR,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-491 Y00]"
3568,363898696,7127,COC1=C(C=C(C=C1)CC=C)OC,Active,,,,RAT,F344/N/FEMALE,GAVAGE,0; 300 MG/KG BW IN 0.5% METHYLCELLULOSE 5D/WK FOR 52 WK (STUDY DURATION: 105 WK),"ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA, HEPATOCHOLANGIOMA OR HEPATOCHOLANGIOCARCINOMA; GLANDULAR STOMACH: BENIGN OR MALIGNANT NEUROENDOCRINE TUMOR",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-491 Y00]"
3569,363898697,7858,C=CCO,Inactive,,,,RAT,F344/MALE,ORAL,0; 300 MG/L IN DRINKING WATER 5 D/WK FOR 100 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
3570,363898697,7858,C=CCO,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 300 MG/L IN DRINKING WATER 5 D/WK FOR 100 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
3571,363898697,7858,C=CCO,Inactive,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 2 MG/WK FOR 60 WK (STUDY DURATION: 92 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
3572,363898700,23676814,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+],Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5D/WK FOR 104 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-336 Y88]"
3573,363898700,23676814,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+],Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5D/WK FOR 104 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-336 Y88]"
3574,363898700,23676814,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+],Inactive,,,,RAT,F344/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-336 Y88]"
3575,363898700,23676814,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+],Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-336 Y88]"
3576,363898700,23676814,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+],Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[DUNNICK,JK, EUSTIS,SL, HUFF,JE AND HASEMAN,JK; TWO-YEAR TOXICITY AND CARCINOGENICITY STUDIES OF AMPICILLIN TRIHYDRATE AND PENICILLIN VK IN RODENTS; FUNDAM. APPL. TOXICOL. 12(2):252-257, 1989]"
3577,363898700,23676814,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+],Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[DUNNICK,JK, EUSTIS,SL, HUFF,JE AND HASEMAN,JK; TWO-YEAR TOXICITY AND CARCINOGENICITY STUDIES OF AMPICILLIN TRIHYDRATE AND PENICILLIN VK IN RODENTS; FUNDAM. APPL. TOXICOL. 12(2):252-257, 1989]"
3578,363898700,23676814,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+],Inactive,,,,RAT,F344/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[DUNNICK,JK, EUSTIS,SL, HUFF,JE AND HASEMAN,JK; TWO-YEAR TOXICITY AND CARCINOGENICITY STUDIES OF AMPICILLIN TRIHYDRATE AND PENICILLIN VK IN RODENTS; FUNDAM. APPL. TOXICOL. 12(2):252-257, 1989]"
3579,363898700,23676814,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+],Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[DUNNICK,JK, EUSTIS,SL, HUFF,JE AND HASEMAN,JK; TWO-YEAR TOXICITY AND CARCINOGENICITY STUDIES OF AMPICILLIN TRIHYDRATE AND PENICILLIN VK IN RODENTS; FUNDAM. APPL. TOXICOL. 12(2):252-257, 1989]"
3580,363898704,4984721,C1=CC(=C(C=C1[N+](=O)[O-])O)N,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 400; 800 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-334 Y88]"
3581,363898704,4984721,C1=CC(=C(C=C1[N+](=O)[O-])O)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 400; 800 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-334 Y88]"
3582,363898704,4984721,C1=CC(=C(C=C1[N+](=O)[O-])O)N,Active,,,,RAT,F344/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),PANCREAS: ACINAR CELL ADENOMA; PANCREAS: ACINAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-334 Y88]"
3583,363898704,4984721,C1=CC(=C(C=C1[N+](=O)[O-])O)N,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-334 Y88]"
3584,363898705,17534,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)N,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",,NEGATIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
3585,363898705,17534,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)N,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",,NEGATIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
3586,363898723,28780,CCCCNC(=O)N1C2=CC=CC=C2N=C1NC(=O)OC,Active,,,,Mouse,CD-1/Male (80/group),Oral,0; 500; 1500; 7500 for 37 wk reduced to 5000 ppm in feed for 2 yr,"Liver: Hepatocellular adenoma (9/60, 9/75, 11/73, 10/76); Hepatocellular carcinoma (16/60, 26/75, 41/73, 17/76); Combined (25/60, 35/75, 52/73, 27/76)",Positive; Purity 99%; Additional study details in California EPA Department of Pesticide Regulation Risk Characterization Document RCD-99-01,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENOMYL AND METHYL 2-BENZIMIDAZOL CARBAMATE (MBC) (PRINCIPAL BENOMYL METABOLITE) (OCTOBER 1, 1997)]"
3587,363898723,28780,CCCCNC(=O)N1C2=CC=CC=C2N=C1NC(=O)OC,Active,,,,Mouse,CD-1/Female (80/group),Oral,0; 500; 1500; 7500 for 37 wk reduced to 5000 ppm in feed for 2 yr,"Liver: Hepatocellular adenoma (2/64, 2/60, 7/73, 7/68); Hepatocellular carcinoma (2/64, 7/60, 6/73, 14/68); Combined (4/64, 9/60, 13/73, 21/68)",Positive; Purity 99%; Additional study details in California EPA Department of Pesticide Regulation Risk Characterization Document RCD-99-01,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENOMYL AND METHYL 2-BENZIMIDAZOL CARBAMATE (MBC) (PRINCIPAL BENOMYL METABOLITE) (OCTOBER 1, 1997)]"
3588,363898734,9117,C1=CC2=C3C(=C1)C4=CC=CC5=C4C6=C(C=C5)C=CC(=C36)C=C2,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.16; 0.83; 4.15 MG IN BEESWAX/TRIOCTANOIN (STUDY DURATION: LIFETIME),,NEGATIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G, DETTBARN,G AND MISFELD,J; EXPERIMENTAL STUDIES IN RAT LUNGS ON THE CARCINOGENICITY AND DOSE- RESPONSE RELATIONSHIPS OF EIGHT FREQUENTLY OCCURRING ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS; J. NATL. CANCER INST. 71(3):539-544, 1983]"
3589,363898736,9128,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=CC=C25)C=C4,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.2; 1.0; 5.0 MG IN BEESWAX/TRIOCTANOIN (STUDY DURATION: LIFETIME),,NEGATIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G, DETTBARN,G AND MISFELD,J; EXPERIMENTAL STUDIES IN RAT LUNGS ON THE CARCINOGENICITY AND DOSE- RESPONSE RELATIONSHIPS OF EIGHT FREQUENTLY OCCURRING ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS; J. NATL. CANCER INST. 71(3):539-544, 1983]"
3590,363898741,104889,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=C[C@H]([C@@H]5O)O)C=C2,Active,,,,FISH,"RAINBOW TROUT/MALE,FEMALE",INJECTION,0; 0.5; 2; 5 UG INJECTED INTO NEWLY HATCHED SAC-FRY (STUDY DURATION: 9 MO),LIVER: TUMOR,POSITIVE,"[KELLY,JD, DUTCHUK,M, HENDRICKS,JD AND WILLIAMS,DE; HEPATOCARCINOGENIC POTENCY OF MIXED AND PURE ENANTIOMERS OF TRANS-7,8-DIHYDROBENZO[A]PYRENE-7,8-DIOL IN TROUT; CANCER LETT. 68(2-3):225-229, 1993]"
3591,363898742,104853,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=C[C@@H]([C@H]5O)O)C=C2,Active,,,,FISH,"RAINBOW TROUT/MALE,FEMALE",INJECTION,0; 0.5; 2; 5 UG INJECTED INTO NEWLY HATCHED SAC-FRY (STUDY DURATION: 9 MO),LIVER: TUMOR,POSITIVE,"[KELLY,JD, DUTCHUK,M, HENDRICKS,JD AND WILLIAMS,DE; HEPATOCARCINOGENIC POTENCY OF MIXED AND PURE ENANTIOMERS OF TRANS-7,8-DIHYDROBENZO[A]PYRENE-7,8-DIOL IN TROUT; CANCER LETT. 68(2-3):225-229, 1993]"
3592,363898745,44461,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]6[C@@H](O6)[C@H]([C@@H]5O)O)C=C2,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 25 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
3593,363898745,44461,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]6[C@@H](O6)[C@H]([C@@H]5O)O)C=C2,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 25 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
3594,363898745,44461,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]6[C@@H](O6)[C@H]([C@@H]5O)O)C=C2,Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 2.04 UMOL IN 0.1 ML DMSO 3 INJECTIONS INTO MAMMARY TISSUE BENEATH THE 3 LEFT THORACIC NIPPLES ON THE NEXT DAY PROCEDURE REPEATED ON THE 3 LEFT INGUINAL NIPPLES (STUDY DURATION: 38 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[HECHT,SS, EL-BAYOUMY,K, RIVENSON,A AND AMIN,S; POTENT MAMMARY CARCINOGENICITY IN FEMALE CD RATS OF A FJORD REGION DIOL-EPOXIDE OF BENZO[C]PHENANTHRENE COMPARED TO A BAY REGION DIOL-EPOXIDE OF BENZO[A]PYRENE; CANCER RES. 54(1): 21-24, 1994]"
3595,363898745,44461,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]6[C@@H](O6)[C@H]([C@@H]5O)O)C=C2,Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 2.04 UMOL IN 0.1 ML DMSO INJECTED BENEATH EACH THE THREE LEFT THORACIC NIPPLES THEN ON THE NEXT DAY BENEATH EACH OF THE THREE LEFT INGUINAL NIPPLES (STUDY DURATION: 38 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
3596,363898745,44461,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]6[C@@H](O6)[C@H]([C@@H]5O)O)C=C2,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0, 25 NMOL TOTAL DOSE INJECTED IN DOSES OF 1/7 ON DAY 1, 2/7 ON DAY 8, AND 4/7 ON DAY 15 OF LIFE (STUDY DURATION: 35 WK)",LUNG:TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
3597,363898745,44461,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4[C@@H]6[C@@H](O6)[C@H]([C@@H]5O)O)C=C2,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0;25 NMOL TOTAL DOSE INJECTED IN DOSES OF 1/7 ON DAY 1, 2.7 ON DAY 8, AND 4/7 ON DAY 15 OF LIFE (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
3598,363898750,6796,C1=CC=C2C(=C1)C=CC3=C2C=CC=N3,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN O; 200 UMOL/KG ONCE AT 8 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
3599,363898750,6796,C1=CC=C2C(=C1)C=CC3=C2C=CC=N3,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN O; 200 UMOL/KG ONCE AT 8 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
3600,363898751,9191,C1=CC=C2C(=C1)C=CC3=C2N=CC=C3,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN O; 200 UMOL/KG ONCE (STUDY DURATION: 78 WK),,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
3601,363898751,9191,C1=CC=C2C(=C1)C=CC3=C2N=CC=C3,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN O; 200 UMOL/KG ONCE (STUDY DURATION: 78 WK),,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
3602,363898768,6035,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Br)CO)O,Active,,,,RAT,LIO/MALE,SUBCUTANEOUS,"0; 3.2 MG ON DAY 1 OR ON DAYS 1 AND 3 OR ON DAYS 1, 3, 7, AND 21 FOLLOWING BIRTH FOR TOTAL DOSES OF 3.2, 6.4, OR 12.8 MG (STUDY DURATION: LIFESPAN)",TESTES: LEYDIGOMA,POSITIVE,"[ANISIMOV,VN; CARCINOGENESIS INDUCED BY NEONATAL EXPOSURE TO VARIOUS DOSES OF 5-BROMO-2'-DEOXYURIDINE IN RATS; CANCER LETT. 91(1):63-71, 1995]"
3603,363898768,6035,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Br)CO)O,Active,,,,RAT,LIO/FEMALE,SUBCUTANEOUS,"0; 3.2 MG ON DAY 1 OR ON DAYS 1 AND 3 OR ON DAYS 1, 3, 7, AND 21 FOLLOWING BIRTH FOR TOTAL DOSES OF 3.2, 6.4, OR 12.8 MG (STUDY DURATION: LIFESPAN)",THYROID: ADENOMA; KIDNEY: MESENCHYMAL TUMORS,POSITIVE,"[ANISIMOV,VN; CARCINOGENESIS INDUCED BY NEONATAL EXPOSURE TO VARIOUS DOSES OF 5-BROMO-2'-DEOXYURIDINE IN RATS; CANCER LETT. 91(1):63-71, 1995]"
3604,363898769,6359,C(Cl)(Cl)Br,Active,,,,RAT,F344/MALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5D/WK FOR 102 WK (STUDY DURATION: 104 WK),LARGE INTESTINE: ADENOCARCINOMA; LARGE INTESTINE: ADENOMATOUS POLYP; LARGE INTESTINE: ADENOMATOUS POLYP OR ADENOCARCINOMA; KIDNEY: TUBULAR CELL ADENOCARCINOMA; KIDNEY: TUBULAR CELL ADENOMA OR ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-321 Y87]"
3605,363898769,6359,C(Cl)(Cl)Br,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5D/WK FOR 102 WK (STUDY DURATION: 104 WK),LARGE INTESTINE: ADENOMATOUS POLYP; LARGE INTESTINE: ADENOCARCINOMA; LARGE INTESTINE: ADENOMATOUS POLYP OR ADENOCARCINOMA; KIDNEY: TUBULAR CELL ADENOMA;KIDNEY: TUBULAR CELL ADENOCARCINOMA; KIDNEY: TUBULAR CELL ADENOMA OR ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-321 Y87]"
3606,363898769,6359,C(Cl)(Cl)Br,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 25; 50 MG/KG IN CORN OIL 5D/WK FOR 102 WK (STUDY DURATION: 105 WK),KIDNEY: TUBULAR CELL ADENOMA OR ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-321 Y87]"
3607,363898769,6359,C(Cl)(Cl)Br,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 75; 150 MG/KG IN CORN OIL 5D/WK FOR 102 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-321 Y87]"
3608,363898769,6359,C(Cl)(Cl)Br,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 1.2 ML/L (15 MILLIMOLAR) IN DRINKING WATER FOR 72 WK THEN DOSE HALVED FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[TUMASONIS,CF, MCMARTIN,DN AND BUSH,B; LIFETIME TOXICITY OF CHLOROFORM AND BROMODICHLOROMETHANE WHEN ADMINISTERED OVER A LIFETIME IN RATS; ECOTOXICOL. ENVIRON. SAF. 9(2):233-240, 1985]"
3609,363898769,6359,C(Cl)(Cl)Br,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 1.2 ML/L (15 MILLIMOLAR) IN DRINKING WATER FOR 72 WK THEN DOSE HALVED FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),LIVER: NEOPLASTIC NODULES; LYMPHOID TISSUE: LYMPHOSARCOMA,POSITIVE,"[TUMASONIS,CF, MCMARTIN,DN AND BUSH,B; LIFETIME TOXICITY OF CHLOROFORM AND BROMODICHLOROMETHANE WHEN ADMINISTERED OVER A LIFETIME IN RATS; ECOTOXICOL. ENVIRON. SAF. 9(2):233-240, 1985]"
3610,363898769,6359,C(Cl)(Cl)Br,Inactive,,,,FISH,ORYZIAS LATIPES/FEMALE,IMMERSION,0; 0.018; 0.143; 1.424 MG/L AQUEOUS SOLUTION FOR 6 MO (STUDY DURATION: 6 MO),,NEGATIVE,"[TOUSSAINT,MW ROSENCRANCE,AB BRENNAN,LM DENNIS,WE BEAMAN,JR WOLFE,MJ HOFFMANN,FJ AND GARDNER,HS JR; CHRONIC TOXICITY OF BROMODICHLOROMETHANE TO THE JAPANESE MEDAKA (ORYZIAS LATIPES); TOXICOL. PATHOL. 29(6):662-669, 2001]"
3611,363898769,6359,C(Cl)(Cl)Br,Inactive,,,,FISH,ORYZIAS LATIPES/MALE,IMMERSION,0; 0.018; 0.143; 1.424 MG/L AQUEOUS SOLUTION FOR 6 MO (STUDY DURATION: 6 MO),,NEGATIVE,"[TOUSSAINT,MW ROSENCRANCE,AB BRENNAN,LM DENNIS,WE BEAMAN,JR WOLFE,MJ HOFFMANN,FJ AND GARDNER,HS JR; CHRONIC TOXICITY OF BROMODICHLOROMETHANE TO THE JAPANESE MEDAKA (ORYZIAS LATIPES); TOXICOL. PATHOL. 29(6):662-669, 2001]"
3612,363898769,6359,C(Cl)(Cl)Br,Inactive,,,,FISH,ORYZIAS LATIPES/MALE,IMMERSION,0; 0.018; 0.143; 1.424 MG/L AQUEOUS SOLUTION FOR 9 MO (STUDY DURATION: 9 MO),,NEGATIVE,"[TOUSSAINT,MW ROSENCRANCE,AB BRENNAN,LM DENNIS,WE BEAMAN,JR WOLFE,MJ HOFFMANN,FJ AND GARDNER,HS JR; CHRONIC TOXICITY OF BROMODICHLOROMETHANE TO THE JAPANESE MEDAKA (ORYZIAS LATIPES); TOXICOL. PATHOL. 29(6):662-669, 2001]"
3613,363898769,6359,C(Cl)(Cl)Br,Inactive,,,,FISH,ORYZIAS LATIPES/FEMALE,IMMERSION,0; 0.018; 0.143; 1.424 MG/L AQUEOUS SOLUTION FOR 9 MO (STUDY DURATION: 9 MO),,NEGATIVE,"[TOUSSAINT,MW ROSENCRANCE,AB BRENNAN,LM DENNIS,WE BEAMAN,JR WOLFE,MJ HOFFMANN,FJ AND GARDNER,HS JR; CHRONIC TOXICITY OF BROMODICHLOROMETHANE TO THE JAPANESE MEDAKA (ORYZIAS LATIPES); TOXICOL. PATHOL. 29(6):662-669, 2001]"
3614,363898769,6359,C(Cl)(Cl)Br,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 8.1; 27.2; 43.4 MG/KG/D IN 0.25% EMULPHOR IN DRINKING WATER FOR 100 WK (STUDY DURATION: 100 WK),,NEGATIVE,"[GEORGE,MH OLSON,GR, DOERFLER,D, MOORE,T, KILBURN,S AND  DEANGELO,AB; CARCINOGENICITY OF BROMODICHLOROMETHANE  ADMINISTERED IN DRINKING WATER TO MALE F344/N RATS AND  B6C3F1 MICE; INT. J. TOXICOL. 21(3): 219-230, 2002]"
3615,363898769,6359,C(Cl)(Cl)Br,Active,,,,RAT,F344/MALE,ORAL,0; 3.9; 20.6; 36.3 MG/KG/D IN 0.25% EMULPHOR IN DRINKING WATER FOR 100 WK (STUDY DURATION: 100 WK),LIVER: HEPATOCELLULAR ADENOMA; HEPATOCELLULAR ADENOMA OR HEPATOCELLULAR CARCINOMA,POSITIVE,"[GEORGE,MH OLSON,GR, DOERFLER,D, MOORE,T, KILBURN,S AND  DEANGELO,AB; CARCINOGENICITY OF BROMODICHLOROMETHANE  ADMINISTERED IN DRINKING WATER TO MALE F344/N RATS AND  B6C3F1 MICE; INT. J. TOXICOL. 21(3): 219-230, 2002]"
3616,363898769,6359,C(Cl)(Cl)Br,Inactive,,,,Rat,F344/N/male,Oral,"0; 175; 350; 700 mg/L (about 0, 6, 12, and 25 mg/kg, respectively) in drinking water for 104 wk",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-532 Y06]"
3617,363898769,6359,C(Cl)(Cl)Br,Inactive,,,,Mouse,B6C3F1/female,Oral,"0; 175; 350; 700 mg/L (about 0, 9, 18, and 36 mg/kg, respectively) in drinking water for 104 wk",,negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-532 Y06]"
3618,363898780,6437067,CC/C=C/C=C/C=C/C=C/C=C/OC[C@H](CO)O,Inactive,,,,RAT,F344/MALE,INTRARECTAL,0; 14 MG/KG IN DMSO: EMULPHOR-SALINE 34WK FOR 9 WK THEN 2/WK FOR 12 WK AND 1/WK FOR 50 WK (STUDY DURATION: 92 WK),,NEGATIVE,"[WEISBURGER,JH, JONES,RC, WANG,CX, BACKLUND,JYC, WILLIAMS,GM, KINGSTON,DGI, VAN TASSELL,RL, KEYES,RF, WILKINS,TD, DEWIT,PP, VAN DER STEEG,M, VAN DER GEN,A; CARCINOGENICITY TESTS OF FECAPENTAENE-12 IN MICE AND RATS; CANCER LETT. 49(2): 89-98, 1990]"
3619,363898780,6437067,CC/C=C/C=C/C=C/C=C/C=C/OC[C@H](CO)O,Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 2.6 MG/KG IN DMSO ON D 1 AND D 3 THEN 0; 5.2 MG/KG IN DMSO ON D 7, 10, 14 AND (STUDY DURATION: 21 MO)",,NEGATIVE,"[WEISBURGER,JH, JONES,RC, WANG,CX, BACKLUND,JYC, WILLIAMS,GM, KINGSTON,DGI, VAN TASSELL,RL, KEYES,RF, WILKINS,TD, DEWIT,PP, VAN DER STEEG,M, VAN DER GEN,A; CARCINOGENICITY TESTS OF FECAPENTAENE-12 IN MICE AND RATS; CANCER LETT. 49(2): 89-98, 1990]"
3620,363898780,6437067,CC/C=C/C=C/C=C/C=C/C=C/OC[C@H](CO)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 2.6 MG/KG IN DMSO ON D 1 AND D 3 THEN 0; 5.2 MG/KG IN DMSO ON D 7, 10, 14 AND (STUDY DURATION: 21 MO)","LIVER: ADENOMA, CARCINOMA; LUNG: ADENOMA, CARCINOMA; GLANDULAR STOMACH: ADENOCARCINOMA; SUBCUTANEOUS TISSUE: FIBROSARCOMA",POSITIVE,"[WEISBURGER,JH, JONES,RC, WANG,CX, BACKLUND,JYC, WILLIAMS,GM, KINGSTON,DGI, VAN TASSELL,RL, KEYES,RF, WILKINS,TD, DEWIT,PP, VAN DER STEEG,M, VAN DER GEN,A; CARCINOGENICITY TESTS OF FECAPENTAENE-12 IN MICE AND RATS; CANCER LETT. 49(2): 89-98, 1990]"
3621,363898780,6437067,CC/C=C/C=C/C=C/C=C/C=C/OC[C@H](CO)O,Inactive,,,,RAT,F344/MALE,INTRARECTAL,0; 5; 10 NANOMOLAR IN 0.5 ML T-E BUFFER AND METHANOL SATURATED WITH ARGON 1/WK FOR 85 WK (STUDY DURATION: 28 MO),,NEGATIVE,"[SHAMSUDDIN,AM, ULLAH,A, BATEN,A AND HALE,E;STABILITY OF FECAPENTAENE-12 AND ITS CARCINOGENICITY IN F-344 RATS; CARCINOGENESIS 12(4):601-607, 1991]"
3622,363898785,37993,CCCCN(CCCC(=O)O)N=O,Active,,,,MOUSE,B6D2F1/MALE,ORAL,0; 565 MG/L IN DRINKING WATER FOR 13 WK (STUDY DURATION: 28 WK),URINARY BLADDER: TUMOR,POSITIVE,"[IRVING,CC, MURPHY,WM AND DANIEL,DS; COMPARATIVE CARCINOGENICITY OF N-BUTYL-N-(3-CARBOXYPROPYL)NITROSAMINE AND N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE FOR THE URINARY BLADDER OF (C57BL/6 X DBA/2)F1 MICE; JNCI, J. NATL. CANCER INST. 73(3):753-756, 1984]"
3623,363898785,37993,CCCCN(CCCC(=O)O)N=O,Active,,,,MOUSE,B6D2F1/FEMALE,ORAL,0; 565 MG/L IN DRINKING WATER FOR 13 WK (STUDY DURATION: 28 WK),URINARY BLADDER: TUMOR,POSITIVE,"[IRVING,CC, MURPHY,WM AND DANIEL,DS; COMPARATIVE CARCINOGENICITY OF N-BUTYL-N-(3-CARBOXYPROPYL)NITROSAMINE AND N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE FOR THE URINARY BLADDER OF (C57BL/6 X DBA/2)F1 MICE; JNCI, J. NATL. CANCER INST. 73(3):753-756, 1984]"
3624,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,RAT,ACI/MALE,ORAL,0; 0.05% IN DRINKING WATER FOR 4-24 WK,"URINARY BLADDER: PAPILLOMA, TRANSITIONAL CELL CARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[FUJII,M, MORI,H, KATO,K AND TAKAHASHI,M; CYTOCHEMICAL STUDIES OF LDH ISOENZYMES IN EXPERIMENTAL BLADDER TUMORS; J. UROL. 128:1349-1352, 1982]"
3625,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,MOUSE,DS/SHI/MALE,ORAL,0; 0.05% IN DRINKING WATER FOR 12 WK (STUDY DURATION: 20 WK),BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
3626,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.05% IN DRINKING WATER FOR 12 WK (STUDY DURATION: 20 WK),BLADDER: SQUAMOUS CELL CARCINOMA,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
3627,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,MOUSE,NON/SHI/MALE,ORAL,0; 0.05% IN DRINKING WATER FOR 12 WK (STUDY DURATION: 20 WK),"KIDNEY: TRANSITIONAL CELL CARCINOMA, SQUAMOUS CELL CARCINOMA; BLADDER: TRANSITIONAL CELL CARCINOMA",POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
3628,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,MOUSE,NON/SHI/MALE,ORAL,0; 0.05% IN DRINKING WATER FOR 4 WK (STUDY DURATION: 36 WK),KIDNEY: TRANSITIONAL CELL CARCINOMA PAPILLOMA; BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
3629,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 1; 5; 10; 50 PPM IN DRINKING WATER FOR 112 WK (STUDY DURATION: 112 WK),"BLADDER: CARCINOMA, PAPILLOMA",POSITIVE,"[ITO,N, SHIRAI,T, FUKUSHIMA,S AND HIROSE,M; DOSE-RESPONSE STUDY OF URINARY BLADDER CARCINOGENESIS IN RATS BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE; J. CANCER RES. CLIN. ONCOL. 108(1):169-173, 1984]"
3630,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,MOUSE,B6D2F1/MALE,ORAL,0; 523 MG/L IN DRINKING WATER FOR 13 WK (STUDY DURATION: 28 WK),URINARY BLADDER: TUMOR,POSITIVE,"[IRVING,CC, MURPHY,WM AND DANIEL,DS; COMPARATIVE CARCINOGENICITY OF N-BUTYL-N-(3-CARBOXYPROPYL)NITROSAMINE AND N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE FOR THE URINARY BLADDER OF (C57BL/6 X DBA/2)F1 MICE; JNCI, J. NATL. CANCER INST. 73(3):753-756, 1984]"
3631,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,MOUSE,B6D2F1/FEMALE,ORAL,0; 523 MG/L IN DRINKING WATER FOR 13 WK (STUDY DURATION: 28 WK),URINARY BLADDER: TUMOR,POSITIVE,"[IRVING,CC, MURPHY,WM AND DANIEL,DS; COMPARATIVE CARCINOGENICITY OF N-BUTYL-N-(3-CARBOXYPROPYL)NITROSAMINE AND N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE FOR THE URINARY BLADDER OF (C57BL/6 X DBA/2)F1 MICE; JNCI, J. NATL. CANCER INST. 73(3):753-756, 1984]"
3632,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 0.05% IN DRINKING WATER FOR 10 WK (STUDY DURATION: 20 WK),URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[OGAWA,K ST. JOHN,M DE OLIVEIRA,ML ARNOLD,L SHIRAI,T SUN,T AND COHEN,SM; COMPARISON OF UROPLAKIN EXPRESSION DURING UROTHELIAL CARCINOGENESIS INDUCED BY N-BUTYL-N-(4-HYROXYBUTYL)NITROSAMINE IN RATS AND MICE; TOXICOL. PATHOL. 27(6):645-651, 2000]"
3633,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,MOUSE,B6D2F1/MALE,ORAL,0; 5 MG TWICE/WK BY GAVAGE FOR 10 WK (STUDY DURATION: 30 WK),URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[OGAWA,K ST. JOHN,M DE OLIVEIRA,ML ARNOLD,L SHIRAI,T SUN,T AND COHEN,SM; COMPARISON OF UROPLAKIN EXPRESSION DURING UROTHELIAL CARCINOGENESIS INDUCED BY N-BUTYL-N-(4-HYROXYBUTYL)NITROSAMINE IN RATS AND MICE; TOXICOL. PATHOL. 27(6):645-651, 2000]"
3634,363898786,19665,CCCCN(CCCCO)N=O,Active,,,,MOUSE,B6D2F1/MALE,ORAL,0; 0.05% IN DRINKING WATER FOR 26 WK (STUDY DURATION: 26 WK),URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[OGAWA,K ST. JOHN,M DE OLIVEIRA,ML ARNOLD,L SHIRAI,T SUN,T AND COHEN,SM; COMPARISON OF UROPLAKIN EXPRESSION DURING UROTHELIAL CARCINOGENESIS INDUCED BY N-BUTYL-N-(4-HYROXYBUTYL)NITROSAMINE IN RATS AND MICE; TOXICOL. PATHOL. 27(6):645-651, 2000]"
3635,363898786,19665,CCCCN(CCCCO)N=O,Unspecified,,,,Mouse,"Nrf2-/-, p53+/-, Nrf2-/-::p53+/-, and wild type",Oral,0.05% in drinking water for 8 wk; study duration 8 wk,,"Urinary bladder: Carcinoma, 63.0% in Nrf2-/- mice, 75.8% in p53+/- mice, 89.6% in Nrf2-/-::p53 +/- mice, and 37.9% in wild-type mice. Muscle: Invasive carcinoma, 38.0% in p53 +/-mice, 3.7% in Nrf2-/- mice, 62.0% in Nrf2 -/-::p53+/- mice, 6.9% in wild-type mice","[IIDA,K ITOH,K MAHER,JM KUMAGAI,Y OYASU,R MORI,Y SHIMAZUI,T AKAZA,H AND YAMAMOTO,M; NRF2 AND P53 COORPERATIVELY PROTECT AGAINST BBN-INDUCED URINARY BLADDER CARCINOGENESIS; CARCINOGENESIS 28(11):2398-2403, 2007]"
3636,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN POWDERED BASAL DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
3637,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN POWDERED BASAL DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
3638,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2% IN POWDERED BASAL DIET FOR 96 WK (STUDY DURATION: 96 WK),,NEGATIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
3639,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2% IN POWDERED BASAL DIET FOR 96 WK (STUDY DURATION: 96 WK),,NEGATIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
3640,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369(CHEM. INDUCED CELL PROLIFERATION):43-52, 1991]"
3641,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369(CHEM. INDUCED CELL PROLIFERATION):43-52, 1991]"
3642,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[HAGIWARA,A, HIROSE,M, TAKAHASHI,S, OGAWA,K, SHIRAI,T AND ITO,N; FORESTOMACH AND KIDNEY CARCINOGENICITY OF CAFFEIC ACID IN F344 RATS AND C57BL/6N X C3H/HEN F1 MICE; CANCER RES. 51:5655-5660, 1991]"
3643,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[HAGIWARA,A, HIROSE,M, TAKAHASHI,S, OGAWA,K, SHIRAI,T AND ITO,N; FORESTOMACH AND KIDNEY CARCINOGENICITY OF CAFFEIC ACID IN F344 RATS AND C57BL/6N X C3H/HEN F1 MICE; CANCER RES. 51:5655-5660, 1991]"
3644,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2% IN DIET FOR 96 WK (STUDY DURATION: 96 WK),LUNG (ALVEOLAR CELL): ADENOMA OR ADENOCARCINOMA,POSITIVE,"[HAGIWARA,A, HIROSE,M, TAKAHASHI,S, OGAWA,K, SHIRAI,T AND ITO,N; FORESTOMACH AND KIDNEY CARCINOGENICITY OF CAFFEIC ACID IN F344 RATS AND C57BL/6N X C3H/HEN F1 MICE; CANCER RES. 51:5655-5660, 1991]"
3645,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2% IN DIET FOR 96 WK (STUDY DURATION: 96 WK),KIDNEY (TUBULAR CELL): ADENOMA,POSITIVE,"[HAGIWARA,A, HIROSE,M, TAKAHASHI,S, OGAWA,K, SHIRAI,T AND ITO,N; FORESTOMACH AND KIDNEY CARCINOGENICITY OF CAFFEIC ACID IN F344 RATS AND C57BL/6N X C3H/HEN F1 MICE; CANCER RES. 51:5655-5660, 1991]"
3646,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369:43-52, 1991]"
3647,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369:43-52, 1991]"
3648,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 0.4% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),FORESTOMACH: PAPILLOMA,POSITIVE,"[HIROSE,M, TAKESADA,Y, TANAKA,H, TAMANO,S, KATO,T AND SHIRAI,T; CARCINOGENICITY OF ANTIOXIDANTS BHA, CAFFEIC ACID, SESAMOL, 4-METHOXYPHENOL AND CATECHOL AT LOW DOSES, EITHER ALONE OR IN COMBINATION, AND MODULATION OF THEIR EFFECTS IN A RAT MEDIUM-TERM MULTI-ORGAN CARCINOGENESIS MODEL; CARCINOGENESIS 19(1):207-212, 1998]"
3649,363898797,689043,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,Active,,,,RAT,F344/MALE,ORAL,2% IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: PAPILLOMA; SQUAMOUS CELL CARCINOMA,POSITIVE,"[KANEKO,M MORIMURA,K NISHIKAWA,T WANIBUCHI,H TAKADA,N OSUGI,H KINOSHITA,H AND FUKUSHIMA,S; DIFFERENT GENETIC ALTERATIONS IN RAT FORESTOMACH TUMORS INDUCED BY GENOTOXIC AND ON-GENOTOXIC CARCINOGENS; CARCINOGENESIS 23(10):1729-1735, 2002]"
3650,363898798,16760159,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(C(Cl)Cl)(Cl)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 750; 1500 PPM IN DIET FOR 104 WK (STUDY DURATION: 112 WK),"KIDNEY: RENAL CELL CARCINOMA, RENAL CELL ADENOMA; LIVER: HYPERPLASTIC NODULE",POSITIVE,"[TAMANO,S, KURATA,Y, KAWABE,M, YAMAMOTO,A, HAGIWARA,A, CABRAL,R AND ITO,N; CARCINOGENICITY OF CAPTAFOL IN F344/DUCRJ RATS; JPN. J. CANCER RES. 81(12):1222-1231, 1990]"
3651,363898798,16760159,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(C(Cl)Cl)(Cl)Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 750; 1500 PPM IN DIET FOR 104 WK (STUDY DURATION: 112 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HYPERPLASTIC NODULE; KIDNEY: RENAL CELL ADENOMA",POSITIVE,"[TAMANO,S, KURATA,Y, KAWABE,M, YAMAMOTO,A, HAGIWARA,A, CABRAL,R AND ITO,N; CARCINOGENICITY OF CAPTAFOL IN F344/DUCRJ RATS; JPN. J. CANCER RES. 81(12):1222-1231, 1990]"
3652,363898798,16760159,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(C(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.075; 0.15; 0.3% IN DIET FOR 96 WK (STUDY DURATION: 104 WK),"HEART: HEMANGIOENDOTHELIOMA; SMALL INTESTINE: ADENOMA, ADENOCARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA; SPLEEN: HEMANGIOMA; FORESTOMACH: PAPILLOMA OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[ITO,N, OGISO,T, FUKUSHIMA,S, SHIBATA,M AND HAGIWARA,A; CARCINOGENICITY OF CAPTAFOL IN B6C3F1 MICE; GANN 75(10):853-865, 1984]"
3653,363898798,16760159,C1C=CC[C@H]2[C@@H]1C(=O)N(C2=O)SC(C(Cl)Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.075; 0.15; 0.3% IN DIET FOR 96 WK (STUDY DURATION: 104 WK),"HEART: HEMANGIOENDOTHELIOMA; FORESTOMACH: PAPILLOMA; SMALL INTESTINE: ADENOMA, ADENOCARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA; SPLEEN: HEMANGIOMA",POSITIVE,"[ITO,N, OGISO,T, FUKUSHIMA,S, SHIBATA,M AND HAGIWARA,A; CARCINOGENICITY OF CAPTAFOL IN B6C3F1 MICE; GANN 75(10):853-865, 1984]"
3654,363898800,6129,CNC(=O)OC1=CC=CC2=CC=CC=C21,Active,,,,RAT,SWISS,GAVAGE,"0; 30 MG/KG BW, 1/D FOR UP TO 22 MO",INTESTINES: FIBROSARCOMA; BONE: OSTEOSARCOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V12 37 Y76][ANDRIANOVA,MM AND ALEKSEEV,IV; ON THE CARC INOGENIC PROPERTIES OF THE PESTICIDES SEVINE, MANEB, CIRAM AND CINEB; VOPR. PITAN. 29:71-74, 1970, ]"
3655,363898800,6129,CNC(=O)OC1=CC=CC2=CC=CC=C21,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 100 MG/KG IN 100 UL ACETONE 3/WK FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[SHUKLA,Y, ANTONY,M AND MEHROTRA,NK; CARCINOGENIC AND COCARCINOGENIC STUDIES WITH CARBARYL FOLLOWING TOPICAL EXPOSURE IN MICE; CANCER LETT. 62(2):133-140, 1992]"
3656,363898800,6129,CNC(=O)OC1=CC=CC2=CC=CC=C21,Active,,,,Rat,Sprague-Dawley/Male (50/control and high-dose group and 40 per low-and mid-dose group),Oral,"0; 250; 1,500; 7,500 ppm in feed for 104 wk",URINARY BLADDER: papilloma and carcinoma at highest dose. KIDNEY: one transitional cell carcinoma. LIVER: adenoma. THYROID: adenoma and one carcinoma.,Positive at the high dose level (Purity 99%; Study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CARBARYL (MARCH 29, 2006)]"
3657,363898800,6129,CNC(=O)OC1=CC=CC2=CC=CC=C21,Active,,,,Mouse,CD-1/Male (70/group),Oral,"0; 100; 1,000; 8,000 ppm in feed for 104 wk",BLOOD VESSELS: Hemangiosarcoma and hemangioma (all doses). KIDNEY: Renal tubular cell adenoma and carcinoma (high dose only).,Positive (Purity 99.3%; Study details not given in source; Neoplastic lesions could not be duplicated in a study using p53 knockout mice; Bigot-Lasserre et al; Fd Chem Toxicol 14 (2003) 99-106),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CARBARYL (MARCH 29, 2006)]"
3658,363898800,6129,CNC(=O)OC1=CC=CC2=CC=CC=C21,Active,,,,Mouse,CD-1/Female (70/group),Oral,"0; 100; 1,000; 8,000 ppm in feed for 104 wk",BLOOD VESSELS: Hemangiosarcoma and hemangioma (high dose only). LIVER: Hepatocellular adenoma and carcinoma (high dose only).,Positive (Purity 99.3%; Study details not given in source; MTD may have been exceeded),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CARBARYL (MARCH 29, 2006)]"
3659,363898803,8679,C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2,Inactive,,,,RAT,F344/MALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-333 Y88]"
3660,363898803,8679,C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-333 Y88]"
3661,363898803,8679,C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-333 Y88]"
3662,363898803,8679,C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 600 MG/KG BW 2/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[KETKAR,MB AND MOHR,U; THE CHRONIC EFFECTS OF MAGENTA, PARAMAGENTA AND PHENYL-BETA-NAPHTHYLAMINE IN RATS AFTER INTRAGASTRIC ADMINISTRATION; CANCER LETT. 16:203-206, 1982]"
3663,363898803,8679,C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 600 MG/KG BW 2/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[KETKAR,MB AND MOHR,U; THE CHRONIC EFFECTS OF MAGENTA, PARAMAGENTA AND PHENYL-BETA-NAPHTHYLAMINE IN RATS AFTER INTRAGASTRIC ADMINISTRATION; CANCER LETT. 16:203-206, 1982]"
3664,363898803,8679,C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),"KIDNEY: RENAL TUBULAR CELL ADENOMA, RENAL TUBULAR CELL ADENOCARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-333 Y88]"
3665,363898804,5993,C1C2C(C(C1Cl)Cl)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 1; 5; 25 PPM IN DIET FOR 130 WK (STUDY DURATION: 130 WK),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[KHASAWINAH,AM AND GRUTSCH,JF; CHLORDANE: THIRTY-MONTH TUMORIGENICITY AND CHRONIC TOXICITY TEST IN RATS; REGUL. TOXICOL. PHARMACOL. 10(2):95-109, 1989]"
3666,363898804,5993,C1C2C(C(C1Cl)Cl)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 1; 5; 25 PPM IN DIET FOR 130 WK (STUDY DURATION: 130 WK),LIVER: NODULE,POSITIVE,"[KHASAWINAH,AM AND GRUTSCH,JF; CHLORDANE: THIRTY-MONTH TUMORIGENICITY AND CHRONIC TOXICITY TEST IN RATS; REGUL. TOXICOL. PHARMACOL. 10(2):95-109, 1989]"
3667,363898804,5993,C1C2C(C(C1Cl)Cl)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,ICR/MALE,ORAL,0; 1; 5; 12.5 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: ADENOMA, HEMANGIOMA",POSITIVE,"[KHASAWINAH,AM AND GRUTSCH,JF; CHLORDANE: 24-MONTH TUMORIGENICITY AND CHRONIC TOXICITY TEST IN MICE; REGUL. TOXICOL. PHARMACOL. 10(3):244-254, 1989]"
3668,363898804,5993,C1C2C(C(C1Cl)Cl)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 1; 5; 12.5 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KHASAWINAH,AM AND GRUTSCH,JF; CHLORDANE: 24-MONTH TUMORIGENICITY AND CHRONIC TOXICITY TEST IN MICE; REGUL. TOXICOL. PHARMACOL. 10(3):244-254, 1989]"
3669,363898804,5993,C1C2C(C(C1Cl)Cl)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,C57B1/MALE,ORAL,0; 50 PPM IN DIET FOR 24 MO (STUDY DURATION: 24 MO),LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[BARRASS,N, STEWART,M, WARBURTON,S, AITCHISON,J, JACKSON,D, WADSWORTH,P, MARSDEN,A AND ORTON,T; CELL PROLIFERATION IN THE LIVER AND THYROID OF C57B1/10J MICE AFTER DIETARY ADMINISTRATION OF CHLORDANE; ENVIRON. HEALTH PERSPECT. 101(SUPPL. 5):219-223, 1993]"
3670,363898805,7628,B(O)(O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-324 Y87]"
3671,363898805,7628,B(O)(O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-324 Y87]"
3672,363898806,33,C(C=O)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.1 G/L DISTILLED DRINKING WATER FOR STUDY DURATION (17 MG/KG/D) (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA",POSITIVE,"[DANIEL,FB, DEANGELO,AB, STOBER,JA, OLSON,GR AND PAGE,NP; HEPATOCARCINOGENICITY OF CHLORAL HYDRATE, 2-CHLOROACETALDEHYDE, AND DICHLOROACETIC ACID IN THE MALE B6C3F1 MOUSE; FUNDAM. APPL. TOXICOL. 19(2):159-168, 1992]"
3673,363898808,6372,C(F)(F)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
3674,363898808,6372,C(F)(F)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
3675,363898808,6372,C(F)(F)Cl,Inactive,,,,MOUSE,SWISS/MALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
3676,363898808,6372,C(F)(F)Cl,Inactive,,,,MOUSE,SWISS/FEMALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
3677,363898808,6372,C(F)(F)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 1000; 5000 PPM IN AIR 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3678,363898808,6372,C(F)(F)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 1000; 5000 PPM IN AIR 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
3679,363898809,34,C(CCl)O,Inactive,,,,RAT,F344/MALE,DERMAL,0; 50; 100 MG/KG IN 70% ETHANOL IN WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-275 Y85]"
3680,363898809,34,C(CCl)O,Inactive,,,,RAT,F344/FEMALE,DERMAL,0; 50; 100 MG/KG IN 70% ETHANOL IN WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-275 Y85]"
3681,363898809,34,C(CCl)O,Inactive,,,,MOUSE,CD-1/MALE,DERMAL,0; 7.5; 15 MG/ANIMAL IN 70% ETHANOL IN WATER 5 D/WK FOR 104 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-275 Y85]"
3682,363898809,34,C(CCl)O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 7.5; 15 MG/ANIMAL IN 70% ETHANOL IN WATER 5 D/WK FOR 104 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-275 Y85]"
3683,363898819,11241,CC(=C)CCl,Active,,,,RAT,F344/MALE,GAVAGE,0; 75; 150 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,FORESTOMACH: PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-300 Y86]"
3684,363898819,11241,CC(=C)CCl,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 75; 150 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,FORESTOMACH: PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-300 Y86]"
3685,363898819,11241,CC(=C)CCl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-300 Y86]"
3686,363898819,11241,CC(=C)CCl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-300 Y86]"
3687,363898819,11241,CC(=C)CCl,Active,,,,RAT,F344/MALE,GAVAGE,0; 75; 150 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),"FORESTOMACH: BASAL CELL OR EPITHELIAL HYPERPLASIA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[CHAN,PC, HASEMAN,JK, BOORMAN,GA, HUFF,J, MANUS,AG AND CARDY,RH; FORESTOMACH LESIONS IN RATS AND MICE ADMINISTERED 3-CHLORO-2- METHYLPROPENE BY GAVAGE FOR TWO YEARS; CANCER RES. 46:6349-6352, 1986]"
3688,363898819,11241,CC(=C)CCl,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 75; 150 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),"FORESTOMACH: BASAL CELL HYPERPLASIA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[CHAN,PC, HASEMAN,JK, BOORMAN,GA, HUFF,J, MANUS,AG AND CARDY,RH; FORESTOMACH LESIONS IN RATS AND MICE ADMINISTERED 3-CHLORO-2- METHYLPROPENE BY GAVAGE FOR TWO YEARS; CANCER RES. 46:6349-6352, 1986]"
3689,363898819,11241,CC(=C)CCl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),"FORESTOMACH: EPITHELIAL HYPERPLASIA, SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[CHAN,PC, HASEMAN,JK, BOORMAN,GA, HUFF,J, MANUS,AG AND CARDY,RH; FORESTOMACH LESIONS IN RATS AND MICE ADMINISTERED 3-CHLORO-2- METHYLPROPENE BY GAVAGE FOR TWO YEARS; CANCER RES. 46:6349-6352, 1986]"
3690,363898819,11241,CC(=C)CCl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),"FORESTOMACH: EPITHELIAL HYPERPLASIA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[CHAN,PC, HASEMAN,JK, BOORMAN,GA, HUFF,J, MANUS,AG AND CARDY,RH; FORESTOMACH LESIONS IN RATS AND MICE ADMINISTERED 3-CHLORO-2- METHYLPROPENE BY GAVAGE FOR TWO YEARS; CANCER RES. 46:6349-6352, 1986]"
3691,363898819,11241,CC(=C)CCl,Inactive,,,,MOUSE,BDF1/MALE,INHALATION,0; 50; 100; 200 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KATAGIRI,T TAKEUCHI,T MINE,T NOGUCHI,T NISHIZAWA,T YAMAMOTAO,S OKUDAIRA,M AND MATSUSHIMA,T; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDIES OF 3-CHLORO-2-METHYLPROPENE IN BDF1 MICE; IND. HEALTH 38(3):309-318, 2000]"
3692,363898819,11241,CC(=C)CCl,Active,,,,MOUSE,BDF1/FEMALE,INHALATION,0; 50; 100; 200 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),HARDERIAN GLAND: ADENOMA,POSITIVE,"[KATAGIRI,T TAKEUCHI,T MINE,T NOGUCHI,T NISHIZAWA,T YAMAMOTAO,S OKUDAIRA,M AND MATSUSHIMA,T; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDIES OF 3-CHLORO-2-METHYLPROPENE IN BDF1 MICE; IND. HEALTH 38(3):309-318, 2000]"
3693,363898823,31369,C=CC(=C)Cl,Active,,,,MOUSE,"ALBINO/MALE, FEMALE",INHALATION,0; 2.9; 19.18; 189 MG/M3 4 HR/D 6 D/WK FOR 7 MO (STUDY DURATION: 8 MO),LUNG: TUMOR,POSITIVE,"[DONG,Q, XIAO,B, HU,Y AND LI,S; LUNG TUMORS INDUCTION SHORT-TERM TEST OF CHLOROPRENE IN MICE; HUAXI YIKE DAXUE XUEBAO 20(3):299-302, 1989]"
3694,363898823,31369,C=CC(=C)Cl,Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 10; 50 PPM 6 HR/D 5D/WK FOR 24 MO AT 72 WK 82 MALE RATS IN LOW DOSE GROUP DIED DUE TO MALFUNCTION IN EXPOSURE APPARATUS (STUDY DURATION: 24 MO),,NEGATIVE,"[TROCHIMOWICZ,HJ, LOSER,E, FERON,VJ, CLARY,JJ AND VALENTINE,R; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDIES ON BETA-CHLOROPRENE IN RATS AND HAMSTERS; INHALATION TOXICOL. 10(5):443-472, 1998]"
3695,363898823,31369,C=CC(=C)Cl,Inactive,,,,HAMSTER,SYRIAN/FEMALE,INHALATION,0; 10; 50 PPM 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[TROCHIMOWICZ,HJ, LOSER,E, FERON,VJ, CLARY,JJ AND VALENTINE,R; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDIES ON BETA-CHLOROPRENE IN RATS AND HAMSTERS; INHALATION TOXICOL. 10(5):443-472, 1998]"
3696,363898823,31369,C=CC(=C)Cl,Inactive,,,,HAMSTER,SYRIAN/MALE,INHALATION,0; 10; 50 PPM 6HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[TROCHIMOWICZ,HJ, LOSER,E, FERON,VJ, CLARY,JJ AND VALENTINE,R; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDIES ON BETA-CHLOROPRENE IN RATS AND HAMSTERS; INHALATION TOXICOL. 10(5):443-472, 1998]"
3697,363898823,31369,C=CC(=C)Cl,Inactive,,,,RAT,WISTAR/FEMALE,INHALATION,0; 10; 50 PPM 6 HR/D 5D/WK FOR 24 MO AT 72 WK 73 FEMALE RATS IN LOW DOSE GROUP DIED DUE TO MALFUNCTION IN EXPOSURE APPARATUS (STUDY DURATION : 24 MO),,NEGATIVE,"[TROCHIMOWICZ,HJ, LOSER,E, FERON,VJ, CLARY,JJ AND VALENTINE,R; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDIES ON BETA-CHLOROPRENE IN RATS AND HAMSTERS; INHALATION TOXICOL. 10(5):443-472, 1998]"
3698,363898823,31369,C=CC(=C)Cl,Active,,,,RAT,F344/MALE,INHALATION,0; 12.8; 32; 80 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 106 WK),"ORAL CAVITY: SQUAMOUS CELL PAPILLOMA, SQUAMOUS PAPILLOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; KIDNEY: RENAL TUBULE ADENOMA, RENAL TUBULE ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-467 Y98]"
3699,363898823,31369,C=CC(=C)Cl,Active,,,,RAT,F344/FEMALE,INHALATION,0; 12.8; 32; 80 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 106 WK),"ORAL CAVITY: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA; MAMMARY GLAND: FIBROADENOMA; KIDNEY: RENAL TUBULE ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-467 Y98]"
3700,363898823,31369,C=CC(=C)Cl,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 12.8; 32; 80 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 106 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA; CIRCULATORY SYSTEM: HEMANGIOSARCOMA, HEMANGIOSARCOMA OR HEMANGIOMA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA; KIDNEY: RENAL TUBULE ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-467 Y98]"
3701,363898823,31369,C=CC(=C)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 12.8; 32; 80 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 106 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA; CIRCULATORY SYSTEM: HEMANGIOMA, HEMANGIOSARCOMA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA; MAMMARY GLAND: CARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR CARCINOMA OR ADENOMA; SKIN: SARCOMA; MESENTERY: SARCOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA; ZYMBAL'S GLAND: CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-467 Y98]"
3702,363898826,12958,COP(=O)(C)OC,Active,,,,RAT,F344/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),KIDNEY: TRANSITIONAL CELL PAPILLOMA; KIDNEY: TRANSITIONAL CELL PAPILLOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-323 Y87]"
3703,363898826,12958,COP(=O)(C)OC,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-323 Y87]"
3704,363898826,12958,COP(=O)(C)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 1000 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-323 Y87]"
3705,363898827,1549026,CC(=CCC/C(=C/COC(=O)C)/C)C,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 1000 MG/KG OF FOOD GRADE (29% CITRONELLYL ACETATE) IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-252 Y87]"
3706,363898827,1549026,CC(=CCC/C(=C/COC(=O)C)/C)C,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 1000; 2000 MG/KG OF FOOD GRADE (29% CITRONELLYL ACETATE) IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-252 Y87]"
3707,363898827,1549026,CC(=CCC/C(=C/COC(=O)C)/C)C,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500 MG/KG OF FOOD GRADE (29% CITRONELLYL ACETATE) IN CORN OIL 5D/WK FOR 102 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-252 Y87]"
3708,363898830,227037,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@H]4[C@@]5([C@@]3(CC[C@@H](C5)O)C)O4)C,Inactive,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 12.3 UMOL (TOTAL DOSE) 1/6 INJECTED UNDER EACH OF 3 THORACIC AND 3 INGUINAL NIPPLES ONCE (STUDY DURATION: 44 WK),,NEGATIVE,"[EL-BAYOUMY,K, JI,BY, UPADHYAYA,P, CHAE,YH, KURTZKE,C, RIVENSON,A, REDDY,BS, AMIN,S AND HECHCT,SS; LACK OF TUMORIGENICITY OF CHOLESTEROL EPOXIDES AND ESTRONE-3,4-QUINONE IN THE RAT MAMMARY GLAND; CANCER RES. 56(9):1970-197 3, 1996]"
3709,363898831,16015,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC(=CC(=C32)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-211 Y87]"
3710,363898831,16015,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC(=CC(=C32)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1000; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-211 Y87]"
3711,363898831,16015,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC(=CC(=C32)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-211 Y87]"
3712,363898831,16015,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC(=CC(=C32)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-211 Y87]"
3713,363898835,11722,COC(=O)N,Active,,,,RAT,F344/MALE,GAVAGE,"0; 100; 200 MG/KG IN DISTILLED WATER 5D/WK FOR 103 WK (STUDY DURATION: 105 WK); 400 MG/KG IN DISTILLED WATER 5D/WK FOR 6, 12, OR 18 MO (STUDY DURATION: 83 WK)",LIVER: NEOPLASTIC NODULES; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-328 Y87]"
3714,363898835,11722,COC(=O)N,Active,,,,RAT,F344/FEMALE,GAVAGE,"0; 100; 200 MG/KG IN DISTILLED WATER 5D/WK FOR 103 WK (STUDY DURATION: 105 WK); 400 MG/KG IN DISTILLED WATER 5D/WK FOR 6, 12 OR 18 MO (STUDY DURATION: 83 WK)",LIVER: NEOPLASTIC NODULE; LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-328 Y87]"
3715,363898835,11722,COC(=O)N,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 500; 1000 MG/KG IN DISTILLED WATER 5D/WK FOR 103 WK (STUDY DURATION: 105 WK);1000 MG/KG IN DISTILLED WATER 5D/WK FOR 6, 12 OR 18 MO (STUDY DURATION: 81 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-328 Y87]"
3716,363898835,11722,COC(=O)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 500; 1000 MG/KG IN DISTILLED WATER 5D/WK FOR 103 WK (STUDY DURATION: 105 WK); 1000 MG/KG IN DISTILLED WATER 5D/WK FOR 6, 12 OR 18 MO (STUDY DURATION: 81 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-328 Y87]"
3717,363898838,3610,CCCCCCC1=C(C=C(C=C1)O)O,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 62.5; 125 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-330 Y88]"
3718,363898838,3610,CCCCCCC1=C(C=C(C=C1)O)O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 62.5; 125 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-330 Y88]"
3719,363898838,3610,CCCCCCC1=C(C=C(C=C1)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 62.5; 125 MG/KG IN CORN OIL 5D/WK FOR 102 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-330 Y88]"
3720,363898838,3610,CCCCCCC1=C(C=C(C=C1)O)O,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 62.5; 125 MG/KG IN CORN OIL 5D/WK FOR 102 WK (STUDY DURATION: 104 WK),ADRENAL GLAND: PHEOCHROMOCYTOMA; HARDERIAN GLAND: ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-330 Y88]"
3721,363898840,3613389,C1=CC(=C(C=C1[N+](=O)[O-])N)O,Active,,,,RAT,F344/MALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),PREPUTIAL GLAND: ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-339 Y88]"
3722,363898840,3613389,C1=CC(=C(C=C1[N+](=O)[O-])N)O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-339 Y88]"
3723,363898840,3613389,C1=CC(=C(C=C1[N+](=O)[O-])N)O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-339 Y88]"
3724,363898840,3613389,C1=CC(=C(C=C1[N+](=O)[O-])N)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-339 Y88]"
3725,363898841,697993,C1=CC=C2C(=C1)NC(=S)S2,Active,,,,RAT,F344/MALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA; PANCREAS: ACINAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-332 Y88]"
3726,363898841,697993,C1=CC=C2C(=C1)NC(=S)S2,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 188; 375 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),PITUITARY GLAND: ADENOMA; PITUITARY GLAND: ADENOMA OR ADENOCARCINOMA; ADRENAL GLAND: PHEOCHROMOCYTOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-332 Y88]"
3727,363898841,697993,C1=CC=C2C(=C1)NC(=S)S2,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-332 Y88]"
3728,363898841,697993,C1=CC=C2C(=C1)NC(=S)S2,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-332 Y88]"
3729,363898842,12961638,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)I)[O-])I)I)[O-])I.[Na+].[Na+],Inactive,,,,RAT,CD-1/MALE,ORAL,0; 0.1; 0.5; 1% IN DIET FOR 30 MO BEGINNING IN UTERO WITH PARENTS GIVEN THE SAME DIETARY DOSES (STUDY DURATION: 30 MO),,NEGATIVE,"[BORZELLECA,JF, CAPEN,CC AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDY OF FD&C RED NO. 3 (ERYTHROSINE) IN RATS; FOOD CHEM. TOXICOL. 25(10): 723-733, 1987]"
3730,363898842,12961638,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)I)[O-])I)I)[O-])I.[Na+].[Na+],Inactive,,,,RAT,CD-1/FEMALE,ORAL,0; 0.1; 0.5; 1% IN DIET FOR 30 MO BEGINNING IN UTERO WITH PARENTS GIVEN THE SAME DIETARY DOSES (STUDY DURATION: 30 MO),,NEGATIVE,"[BORZELLECA,JF, CAPEN,CC AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDY OF FD&C RED NO. 3 (ERYTHROSINE) IN RATS; FOOD CHEM. TOXICOL. 25(10): 723-733, 1987]"
3731,363898842,12961638,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)I)[O-])I)I)[O-])I.[Na+].[Na+],Active,,,,RAT,CD-1/MALE,ORAL,0; 4% IN DIET FOR 30 MO BEGINNING IN UTERO WITH PARENTS GIVEN THE SAME DIETARY DOSES (STUDY DURATION: 30 MO),THYROID: ADENOMA,POSITIVE,"[BORZELLECA,JF, CAPEN,CC AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDY OF FD&C RED NO. 3 (ERYTHROSINE) IN RATS; FOOD CHEM. TOXICOL. 25(10): 723-733, 1987]"
3732,363898842,12961638,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)I)[O-])I)I)[O-])I.[Na+].[Na+],Inactive,,,,RAT,CD-1/FEMALE,ORAL,0; 4% IN DIET FOR 30 MO BEGINNING IN UTERO WITH PARENTS GIVEN THE SAME DIETARY DOSES (STUDY DURATION: 30 MO),,NEGATIVE,"[BORZELLECA,JF, CAPEN,CC AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDY OF FD&C RED NO. 3 (ERYTHROSINE) IN RATS; FOOD CHEM. TOXICOL. 25(10): 723-733, 1987]"
3733,363898842,12961638,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)I)[O-])I)I)[O-])I.[Na+].[Na+],Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 0.3; 1.0; 3.0% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BORZELLECA,JF AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDY OF FD&C RED NO. 3 (ERYTHROSINE) IN MICE; FOOD CHEM. TOXICOL. 25(10):735-737, 1987]"
3734,363898842,12961638,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)I)[O-])I)I)[O-])I.[Na+].[Na+],Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.3; 1.0; 3.0% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BORZELLECA,JF AND HALLAGAN,JB; LIFETIME TOXICITY/CARCINOGENICITY STUDY OF FD&C RED NO. 3 (ERYTHROSINE) IN MICE; FOOD CHEM. TOXICOL. 25(10):735-737, 1987]"
3735,363898842,12961638,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)I)[O-])I)I)[O-])I.[Na+].[Na+],Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 133 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
3736,363898842,12961638,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)I)[O-])I)I)[O-])I.[Na+].[Na+],Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 133 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
3737,363898845,6758,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 38; 75 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-320 Y88]"
3738,363898845,6758,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 600; 1200 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-320 Y88]"
3739,363898845,6758,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 600; 1200 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-320 Y88]"
3740,363898845,6758,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,Inactive,,,,RAT,WISTAR/FEMALE,INTRAPERITONEAL,0; 1; 2 MG/KG IN SUNFLOWER OIL/CHLOROFORM (9:1) 5 D/WK FOR 8 WK (STUDY DURATION: 18 MO),,NEGATIVE,"[GREENMAN,DL, ALLABEN,WT, BURGER,GT AND KODELL,RL; BIOASSAY FOR CARCINOGENICITY OF ROTENONE IN FEMALE WISTAR RATS; FUNDAM. APPL. TOXICOL. 20(3):383-390, 1993]"
3741,363898845,6758,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,Inactive,,,,RAT,WISTAR/FEMALE,INTRAPERITONEAL,0; 1; 2 MG/KG IN SUNFLOWER OIL 5 D/WK FOR 8 WK (STUDY DURATION: 18 MO),,NEGATIVE,"[GREENMAN,DL, ALLABEN,WT, BURGER,GT AND KODELL,RL; BIOASSAY FOR CARCINOGENICITY OF ROTENONE IN FEMALE WISTAR RATS; FUNDAM. APPL. TOXICOL. 20(3):383-390, 1993]"
3742,363898845,6758,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,Unspecified,,,,RAT,F344/MALE,ORAL,0; 38; 75 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),PARATHYROID GLAND: ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-320 Y88]"
3743,363898846,8266,C1(C(C2(C(=C(C1(C2(Cl)Cl)Cl)Cl)Cl)Cl)C(=O)O)C(=O)O,Active,,,,RAT,F344/MALE,ORAL,0; 620; 1250 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: NEOPLASTIC NODULE; LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; PANCREAS: ACINAR CELL ADENOMA; PREPUTIAL GLAND: CARCINOMA; PREPUTIAL GLAND: ADENOMA, CARCINOMA OR SQUAMOUS CELL PAPILLOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-304 Y87]"
3744,363898846,8266,C1(C(C2(C(=C(C1(C2(Cl)Cl)Cl)Cl)Cl)Cl)C(=O)O)C(=O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 620; 1250 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),LIVER: NEOPLASTIC NODULE; LIVER: HEPATOCELLULAR CARCINOMA; LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; UTERUS: ENDROMETRIAL STROMAL POLYP,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-304 Y87]"
3745,363898846,8266,C1(C(C2(C(=C(C1(C2(Cl)Cl)Cl)Cl)Cl)Cl)C(=O)O)C(=O)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 620; 1250 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-304 Y87]"
3746,363898846,8266,C1(C(C2(C(=C(C1(C2(Cl)Cl)Cl)Cl)Cl)Cl)C(=O)O)C(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 620; 1250 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-304 Y87]"
3747,363898848,8800,CN(C)C(=O)NC1=CC=C(C=C1)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 750; 1500 PPM IN DIET FOR 103 WK (STUDY DURATION: 106 WK),"LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR CARCINOMA; KIDNEY: TUBULAR CELL ADENOMA, TUBULAR CELL ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-266 Y88]"
3748,363898848,8800,CN(C)C(=O)NC1=CC=C(C=C1)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 750; 1500 PPM IN DIET FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-266 Y88]"
3749,363898848,8800,CN(C)C(=O)NC1=CC=C(C=C1)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 103 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-266 Y88]"
3750,363898848,8800,CN(C)C(=O)NC1=CC=C(C=C1)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 103 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-266 Y88]"
3751,363898849,61532,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]Cl.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG IN DEIONIZED WATER 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-294 Y86]"
3752,363898849,61532,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]Cl.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN DEIONIZED WATER 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-294 Y86]"
3753,363898850,40470,C1=CC(=C(C(=C1)Cl)Cl)C2=C(C(=C(C=C2)Cl)Cl)Cl,Active,,,,MOUSE,BALB/MALE,ORAL,300 MG/KG IN DIET FOR 6 OR 11 MO,LIVER: HEPATOMA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V18 43 Y78]"
3754,363898850,40470,C1=CC(=C(C(=C1)Cl)Cl)C2=C(C(=C(C=C2)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 25; 50; 100 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 24 MO),THYROID GLAND: ADENOMA OR CARCINOMA,POSITIVE,"[MAYES,BA, MCCONNELL,EE, NEAL,BH, BRUNNER,MJ, HAMILTON,SB, SULLIVAN,TM, PETERS,AC, RYAN,MJ, TOFT,JD, SINGER,AW, BROWN,JF,JR, MENTON,RG AND MOORE,JA; COMPARATIVE CARCINOGENICITY IN SPRAGUE-DAWLEY RATS OF THE POLYCHLORINATED BIPHENYL MIXTURES AROCLORS 1016, 1242, 1254, AND 1260; TOXICOL. SCI. 41(1):62-76, 1998]"
3755,363898850,40470,C1=CC(=C(C(=C1)Cl)Cl)C2=C(C(=C(C=C2)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 25; 50; 100 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 24 MO),LIVER: TUMOR,POSITIVE,"[MAYES,BA, MCCONNELL,EE, NEAL,BH, BRUNNER,MJ, HAMILTON,SB, SULLIVAN,TM, PETERS,AC, RYAN,MJ, TOFT,JD, SINGER,AW, BROWN,JF,JR, MENTON,RG AND MOORE,JA; COMPARATIVE CARCINOGENICITY IN SPRAGUE-DAWLEY RATS OF THE POLYCHLORINATED BIPHENYL MIXTURES AROCLORS 1016, 1242, 1254, AND 1260; TOXICOL. SCI. 41(1):62-76, 1998]"
3756,363898850,40470,C1=CC(=C(C(=C1)Cl)Cl)C2=C(C(=C(C=C2)Cl)Cl)Cl,Unspecified,,,,RAT,F344/MALE,ORAL,0; 25; 50; 100 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 104-105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; GASTROINTESTINAL SYSTEM: ADENOCARCINOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-38 Y78]"
3757,363898850,40470,C1=CC(=C(C(=C1)Cl)Cl)C2=C(C(=C(C=C2)Cl)Cl)Cl,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 25; 50; 100 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 104-105 WK),"LIVER: ADENOMA; STOMACH: ADENOMA, ADENOCARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-38 Y78]"
3758,363898851,38018,C1=CC(=C(C(=C1C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,SHERMAN/FEMALE,ORAL,100 MG/KG IN DIET,"LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V18 43 Y78]"
3759,363898851,38018,C1=CC(=C(C(=C1C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,WISTAR/MALE,ORAL,0; 50; 100 PPM IN A 10% PROTEIN DIET FOR 4 MO (STUDY DURATION: 4 MO),THYMUS: NEOPLASM; SPLEEN: NEOPLASM,POSITIVE,"[RAO,CV AND BANERJI,SA; INDUCTION OF NEOPLASIA IN THYMUS AND SPLEEN OF POLYCHLORINATED BIPHENYL FED MALE WISTAR RATS; J. ENVIRON. BIOL. 11(SUPPL. 2):241-246, 1990]"
3760,363898851,38018,C1=CC(=C(C(=C1C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 100 PPM IN DIET FOR 16 MO AND 50 PPM FOR AN ADDITIONAL 8 MO FOLLOWED BY CONTROL DIET FOR 5 MO (STUDY DURATION: 29 MO),,NEGATIVE,"[NORBACK,DH AND WELTMAN,RH; POLYCHLORINATEDBIPHENYL INDUCTION OF HEPATOCELLULAR CARCINOMA IN THE SPRAGUE-DAWLEY RAT; ENVIRON. HEALTH PERSPECT. 60:97-105, 1985]"
3761,363898851,38018,C1=CC(=C(C(=C1C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 100 PPM IN DIET FOR 16 MO AND 50 PPM FOR AN ADDITIONAL 8 MO FOLLOWED BY CONTROL DIET FOR 5 MO (STUDY DURATION: 29 MO),"LIVER: TRABECULAR CARCINOMA, ADENOCARCINOMA",POSITIVE,"[NORBACK,DH AND WELTMAN,RH; POLYCHLORINATEDBIPHENYL INDUCTION OF HEPATOCELLULAR CARCINOMA IN THE SPRAGUE-DAWLEY RAT; ENVIRON. HEALTH PERSPECT. 60:97-105, 1985]"
3762,363898851,38018,C1=CC(=C(C(=C1C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 25; 50; 100 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 24 MO),THYROID GLAND: ADENOMA OR CARCINOMA; LIVER: TUMOR,POSITIVE,"[MAYES,BA, MCCONNELL,EE, NEAL,BH, BRUNNER,MJ, HAMILTON,SB, SULLIVAN,TM, PETERS,AC, RYAN,MJ, TOFT,JD, SINGER,AW, BROWN,JF,JR, MENTON,RG AND MOORE,JA; COMPARATIVE CARCINOGENICITY IN SPRAGUE-DAWLEY RATS OF THE POLYCHLORINATED BIPHENYL MIXTURES AROCLORS 1016, 1242, 1254, AND 1260; TOXICOL. SCI. 41(1):62-76, 1998]"
3763,363898851,38018,C1=CC(=C(C(=C1C2=C(C(=C(C=C2)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 25; 50; 100 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 24 MO),LIVER: TUMOR,POSITIVE,"[MAYES,BA, MCCONNELL,EE, NEAL,BH, BRUNNER,MJ, HAMILTON,SB, SULLIVAN,TM, PETERS,AC, RYAN,MJ, TOFT,JD, SINGER,AW, BROWN,JF,JR, MENTON,RG AND MOORE,JA; COMPARATIVE CARCINOGENICITY IN SPRAGUE-DAWLEY RATS OF THE POLYCHLORINATED BIPHENYL MIXTURES AROCLORS 1016, 1242, 1254, AND 1260; TOXICOL. SCI. 41(1):62-76, 1998]"
3764,363898852,,,Active,,,,MOUSE,STRAIN-DD/MALE,ORAL,100; 250; 500 MG/KG FOR 32 WK IN DIET,"LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V18 43 Y78]"
3765,363898853,,,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-327 Y86]"
3766,363898853,,,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-327 Y86]"
3767,363898853,,,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-327 Y86]"
3768,363898853,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-327 Y86]"
3769,363898859,447466,C/C=C/C=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 1500 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 15 MO OF AGE (STUDY DURATION: 15 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
3770,363898859,447466,C/C=C/C=O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1500 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 15 MO OF AGE (STUDY DURATION: 15 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
3771,363898859,447466,C/C=C/C=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 3000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 12 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
3772,363898859,447466,C/C=C/C=O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 3000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 12 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
3773,363898863,6253,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,"0; 500; 1500 MG/KG IN PHYSIOLOGICAL SALINE ON D 1, 3, 5 WITHIN 3 MO, CYCLE REPEATED 6 TIMES (STUDY DURATION: LIFETIME)",,NEGATIVE,"[BERGER,MR AND SCHMAEHL,D; STUDY ON THE LONG-TERM EFFICACY OF CYTOSINE- ARABINOSIDE IN SPRAGUE-DAWLEY RATS; CANCER LETTERS 43(1-2):59-64, 1988]"
3774,363898863,6253,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,"0; 500; 1500 MG/KG IN PHYSIOLOGICAL SALINE ON D 1, 3, 5 WITHIN 3 MO, CYCLE REPEATED 6 TIMES (STUDY DURATION: LIFETIME)",,NEGATIVE,"[BERGER,MR AND SCHMAEHL,D; STUDY ON THE LONG-TERM EFFICACY OF CYTOSINE- ARABINOSIDE IN SPRAGUE-DAWLEY RATS; CANCER LETTERS 43(1-2):59-64, 1988]"
3775,363898863,6253,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 5; 25 MG/KG IN PHYSIOLOGICAL SALINE 5/WK FOR 72 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[BERGER,MR AND SCHMAEHL,D; STUDY ON THE LONG-TERM EFFICACY OF CYTOSINE- ARABINOSIDE IN SPRAGUE-DAWLEY RATS; CANCER LETTERS 43(1-2):59-64, 1988]"
3776,363898863,6253,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 5; 25 MG/KG IN PHYSIOLOGICAL SALINE 5/WK FOR 72 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[BERGER,MR AND SCHMAEHL,D; STUDY ON THE LONG-TERM EFFICACY OF CYTOSINE- ARABINOSIDE IN SPRAGUE-DAWLEY RATS; CANCER LETTERS 43(1-2):59-64, 1988]"
3777,363898864,30323,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAVENOUS,0; 10 MG/KG IN SALINE SOLUTION ONCE (STUDY DURATION: 1 YR),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[BUCCIARELLI,E; MAMMARY TUMOR INDUCTION IN MALE AND FEMALE SPRAGUE-DAWLEY RATS BY ADRIAMYCIN AND DAUNOMYCIN; J. NATL. CANCER INST. 66(1):81-84, 1981]"
3778,363898864,30323,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,0; 10 MG/KG IN SALINE SOLUTION ONCE (STUDY DURATION: 1 YR),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[BUCCIARELLI,E; MAMMARY TUMOR INDUCTION IN MALE AND FEMALE SPRAGUE-DAWLEY RATS BY ADRIAMYCIN AND DAUNOMYCIN; J. NATL. CANCER INST. 66(1):81-84, 1981]"
3779,363898864,30323,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 2; 4; 8 UG IN 100 UL SALINE INTO THORACIC AND ABDOMINAL MAMMARY GLANDS ONCE (STUDY DURATION: 6.5 MO),MAMMARY GLAND: TUMOR,POSITIVE,"[HOWELL,SK, STEPHENS,LC AND WANG,YM; DAUNORUBICIN-INDUCED MAMMARY TUMORS IN THE RAT; EUR. J. CANCER CLIN. ONCOL. 25(11):1549-1554, 1989]"
3780,363898864,30323,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAVENOUS,0; 10 MG/KG IN SALINE ONCE (STUDY DURATION: 244 D) (STUDY DURATION: 244 D),MAMMARY GLAND: TUMOR,POSITIVE,"[HOWELL,SK, STEPHENS,LC AND WANG,YM; DAUNORUBICIN-INDUCED MAMMARY TUMORS IN THE RAT; EUR. J. CANCER CLIN. ONCOL. 25(11):1549-1554, 1989]"
3781,363898866,7500,CCC1=CC=CC=C1,Inactive,,,,RAT,STRAIN-CD/MALE,INTRAGASTRIC,0; 500 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
3782,363898866,7500,CCC1=CC=CC=C1,Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAGASTRIC,0; 500 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
3783,363898866,7500,CCC1=CC=CC=C1,Active,,,,RAT,F344/MALE,INHALATION,0; 75; 250; 750 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),KIDNEY (RENAL TUBULE): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-466 Y99]"
3784,363898866,7500,CCC1=CC=CC=C1,Active,,,,RAT,F344/FEMALE,INHALATION,0; 75; 250; 750 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),KIDNEY (RENAL TUBULE): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-466 Y99]"
3785,363898866,7500,CCC1=CC=CC=C1,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 75; 250; 750 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-466 Y99]"
3786,363898866,7500,CCC1=CC=CC=C1,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 75; 250; 750 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-466 Y99]"
3787,363898884,9164,C1=CC=C2C=C3C4=CC=CC=C4C5=CC=CC=C5C3=CC2=C1,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",,NEGATIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
3788,363898885,7095,C1=CC=C(C=C1)C2=CC=CC=C2,Active,,,,RAT,F344/MALE,ORAL,0; 500; 1500; 4500 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK ),"URINARY BLADDER: TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA",POSITIVE,"[UMEDA,Y ARITO,H KANO,H OHNISHI,M MATSUMOTO,M NAGANO,K YAMAMOTO,S AND MATSUSHIMA,T; TWO-YEAR STUDY OF CARCINOGENICITY AND CHRONIC TOXICITY OF BIPHENYL IN RATS; J. OCCUP. HEALTH 44(3):176-183, 2002]"
3789,363898885,7095,C1=CC=C(C=C1)C2=CC=CC=C2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 500; 1500; 4500 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK ),,NEGATIVE,"[UMEDA,Y ARITO,H KANO,H OHNISHI,M MATSUMOTO,M NAGANO,K YAMAMOTO,S AND MATSUSHIMA,T; TWO-YEAR STUDY OF CARCINOGENICITY AND CHRONIC TOXICITY OF BIPHENYL IN RATS; J. OCCUP. HEALTH 44(3):176-183, 2002]"
3790,363898885,7095,C1=CC=C(C=C1)C2=CC=CC=C2,Inactive,,,,MOUSE,CRJ:BDF1/MALE,ORAL,0; 667; 2000; 6000 PPM IN DIET FOR 2 YRS (STUDY DURATION: 2 YRS),,NEGATIVE,"[UMEDA,Y, AISO,S, YAMAZAKI,K, OHNISHI,M, ARITO,H, NAGANO,K, YAMAMOTO,S AND MATSUSHIMA,T; CARCINOGENICITY OF BIPHENYL IN MICE BY TWO YEARS FEEDING; J. VET. MED. SCI. 67(4):417-424, 2005]"
3791,363898885,7095,C1=CC=C(C=C1)C2=CC=CC=C2,Active,,,,MOUSE,CRJ:BDF1/FEMALE,ORAL,667; 2000; 6000 PPM IN DIET FOR 2 YRS (STUDY DURATION: 2 YRS),LIVER: HEPATOCELLULAR ADENOMA AND CARCINOMA,POSITIVE,"[UMEDA,Y, AISO,S, YAMAZAKI,K, OHNISHI,M, ARITO,H, NAGANO,K, YAMAMOTO,S AND MATSUSHIMA,T; CARCINOGENICITY OF BIPHENYL IN MICE BY TWO YEARS FEEDING; J. VET. MED. SCI. 67(4):417-424, 2005]"
3792,363898888,31296,C(Cl)(Br)Br,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 40; 80 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-282 Y85]"
3793,363898888,31296,C(Cl)(Br)Br,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 40; 80 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-282 Y85]"
3794,363898888,31296,C(Cl)(Br)Br,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-282 Y85]"
3795,363898888,31296,C(Cl)(Br)Br,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-282 Y85]"
3796,363898890,7281,C(C(CBr)Br)O,Active,,,,RAT,F344/MALE,DERMAL,0; 188; 375 MG/KG IN ETHANOL APPLIED TO SUBSCAPULAR SKIN 5 D/WK FOR 48-51 WK (STUDY DURATION: 56 WK),"SKIN: SQUAMOUS CELL PAPILLOMA OR CARCINOMA, BASAL CELL TUMOR, SEBACEOUS ADENOMA, KERATOACANTHOMA; ORAL MUCOSA: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; ESOPHAGUS: SQUAMOUS CELL PAPILLOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR ADENOMA POLYP; SMALL INTESTINE: ADENOCARCINOMA; NOSE: ADENOMA; ZYMBAL GLAND: ADENOMA, ADENOCARCINOMA; KIDNEY (RENAL TUBULE): ADENOMA; TUNICA VAGINALIS: MESOTHELIOMA; SPLEEN: HEMANGIOMA OR HEMANGIOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-400 Y93]"
3797,363898890,7281,C(C(CBr)Br)O,Active,,,,RAT,F344/FEMALE,DERMAL,0; 188; 375 MG/KG IN ETHANOL APPLIED TO SUBSCAPULAR SKIN 5 D/WK FOR 52-55 WK (STUDY DURATION: 56 WK),"SKIN: SQUAMOUS CELL PAPILLOMA OR CARCINOMA, BASAL CELL TUMOR, KERATOACANTHOMA; ORAL MUCOSA: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; ESOPHAGUS: SQUAMOUS CELL PAPILLOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA; SMALL INTESTINE: ADENOCARCINOMA; NOSE: ADENOMA; ZYMBAL GLAND: ADENOMA, ADENOCARCINOMA; KIDNEY (RENAL TUBULE): ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA; CLITORAL GLAND: ADENOMA OR ADENOCARCINOMA; MAMMARY GLAND: ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-400 Y93]"
3798,363898890,7281,C(C(CBr)Br)O,Active,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 188; 375 MG/KG IN ETHANOL APPLIED TO SUBSCAPULAR SKIN 5 D/WK FOR 36-39 WK (STUDY DURATION: 42 WK),SKIN: SQUAMOUS CELL PAPILLOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-400 Y93]"
3799,363898890,7281,C(C(CBr)Br)O,Active,,,,MOUSE,B6C3F1/FEMALE,DERMAL,0; 188; 375 MG/KG IN ETHANOL APPLIED TO SUBSCAPULAR SKIN 5 D/WK FOR 39-42 WK (STUDY DURATION: 42 WK),"SKIN: SQUAMOUS CELL PAPILLOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-400 Y93]"
3800,363898895,702,CCO,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 1; 3% IN LIQUID DIET FOR 104 WK (STUDY DURATION: 120 WK),,NEGATIVE,"[HOLMBERG,B AND EKSTROEM,T; THE EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF ETHANOL ON SPRAGUE-DAWLEY RATS - A CONDENSED REPORT; TOXICOLOGY 96(2):133-145, 1995]"
3801,363898895,702,CCO,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 1; 3% IN LIQUID DIET FOR 104 WK (STUDY DURATION: 120 WK),,NEGATIVE,"[HOLMBERG,B AND EKSTROEM,T; THE EFFECTS OF LONG-TERM ORAL ADMINISTRATION OF ETHANOL ON SPRAGUE-DAWLEY RATS - A CONDENSED REPORT; TOXICOLOGY 96(2):133-145, 1995]"
3802,363898895,702,CCO,Active,,,,MOUSE,B6C3F1/MALE (48/GROUP),ORAL,2.5% OR 5% IN DRINKING WATER (STUDY DURATION: 2 YRS),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA (COMBINED),POSITIVE; INADEQUATE STUDY TO DETERMINE CARCINOGENIC ACTIVITY,"[BUCHER,JR, CASCIANO,DA,  ALLABEN,WT, CHAMBERLAIN,PL,  DENNIS,DA, DUNNICK,JK, FARRELLY,JG, FORBES,PD, GREENLESS,KJ,  LORENTZEN,RJ, MILLER,MA, NEWBOLD,RR, POIRIER,M, SISTARE,FD,  YETLEY,EA, WAMER,WG, CARSON,J, DURRETT,JH, MATSON,A,  MOORE,M, NICHOLS,ML, SMITH,ES, BELAND,FA, ALLABEN,WT,  APPLEGET,BS, BENSON,RW, CHURCHWELL,MI, DOERGE,DR, FANG,LJ,  JACKSON,CD, KODELL,RL, REED,JM, ROBERTS,DW, WITT,KL,  WITT,WM, COOPER,WM, EVANS,FE, FREEMENA,JP, GEHRING,TA,  HEINZE,TM, SIITONEN,PH, MELLICK,PW, KOVATCH,RM, HARDISTY,JK,  SHACKELFORD,CC, HAILEY,JR, HARDISTRY,JF, HERBERT,RA,  WARD,JM, ARMSTONG,J, AUSTEN,M, BARTON,DL, BRYANT,B  CARROLL,K, DING, X, GOLDMAN,S, GOSSETT,JM, MCCARTY,CC,  MCCRACKEN,WA, SPADONI,B, THORN, BT, GUNNELS,SR, HARPER,LM,  SERBUS,DC AND WILLIS,RA; NTP TECHNICAL REPORT ON THE  TOXICOLOGY AND CARCINOGENESIS: STUDIES OF URETHANE, ETHANOL,  AND URETHANE/ETHANOL (URETHANE, CASE NO. 51-79-6; ETHANOL,  CAS NO. 64-17-5) IN B6C3F1 MICE (DRINKING WATER STUDIES);  NATL. TOXICOL. PROGRAM. TECH. REP. SER. 510: 1-346, 2004]"
3803,363898895,702,CCO,Inactive,,,,MOUSE,B6C3F1/FEMALE (48/GROUP),ORAL,2.5% OR 5% IN DRINKING WATER (STUDY DURATION: 2 YRS),,NEGATIVE; INADEQUATE STUDY TO DETERMINE CARCINOGENIC ACTIVITY,"[BUCHER,JR, CASCIANO,DA,  ALLABEN,WT, CHAMBERLAIN,PL,  DENNIS,DA, DUNNICK,JK, FARRELLY,JG, FORBES,PD, GREENLESS,KJ,  LORENTZEN,RJ, MILLER,MA, NEWBOLD,RR, POIRIER,M, SISTARE,FD,  YETLEY,EA, WAMER,WG, CARSON,J, DURRETT,JH, MATSON,A,  MOORE,M, NICHOLS,ML, SMITH,ES, BELAND,FA, ALLABEN,WT,  APPLEGET,BS, BENSON,RW, CHURCHWELL,MI, DOERGE,DR, FANG,LJ,  JACKSON,CD, KODELL,RL, REED,JM, ROBERTS,DW, WITT,KL,  WITT,WM, COOPER,WM, EVANS,FE, FREEMENA,JP, GEHRING,TA,  HEINZE,TM, SIITONEN,PH, MELLICK,PW, KOVATCH,RM, HARDISTY,JK,  SHACKELFORD,CC, HAILEY,JR, HARDISTRY,JF, HERBERT,RA,  WARD,JM, ARMSTONG,J, AUSTEN,M, BARTON,DL, BRYANT,B  CARROLL,K, DING, X, GOLDMAN,S, GOSSETT,JM, MCCARTY,CC,  MCCRACKEN,WA, SPADONI,B, THORN, BT, GUNNELS,SR, HARPER,LM,  SERBUS,DC AND WILLIS,RA; NTP TECHNICAL REPORT ON THE  TOXICOLOGY AND CARCINOGENESIS: STUDIES OF URETHANE, ETHANOL,  AND URETHANE/ETHANOL (URETHANE, CASE NO. 51-79-6; ETHANOL,  CAS NO. 64-17-5) IN B6C3F1 MICE (DRINKING WATER STUDIES);  NATL. TOXICOL. PROGRAM. TECH. REP. SER. 510: 1-346, 2004]"
3804,363898899,1486,C1=CC(=C(C=C1Cl)Cl)OCC(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 5; 75; 150 MG/KG BW DAILY FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHARLES,JM, BOND,DM, JEFFRIES,TK, YANO,BL, STOTT,WT, JOHNSON,KA, CUNNY,HC, WILSON,RD AND BUS,JS; CHRONIC DIETARY TOXICITY/ONCOGENICITY STUDIES ON 2,4-DICHLOROPHENOXYACETIC ACID IN RODENTS; FUNDAM. APPL. TOXICOL. 33(2):166-172, 1996]"
3805,363898899,1486,C1=CC(=C(C=C1Cl)Cl)OCC(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5; 75; 150 MG/KG BW DAILY FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHARLES,JM, BOND,DM, JEFFRIES,TK, YANO,BL, STOTT,WT, JOHNSON,KA, CUNNY,HC, WILSON,RD AND BUS,JS; CHRONIC DIETARY TOXICITY/ONCOGENICITY STUDIES ON 2,4-DICHLOROPHENOXYACETIC ACID IN RODENTS; FUNDAM. APPL. TOXICOL. 33(2):166-172, 1996]"
3806,363898899,1486,C1=CC(=C(C=C1Cl)Cl)OCC(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5; 62.5; 125 MG/KG BW DAILY FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHARLES,JM, BOND,DM, JEFFRIES,TK, YANO,BL, STOTT,WT, JOHNSON,KA, CUNNY,HC, WILSON,RD AND BUS,JS; CHRONIC DIETARY TOXICITY/ONCOGENICITY STUDIES ON 2,4-DICHLOROPHENOXYACETIC ACID IN RODENTS; FUNDAM. APPL. TOXICOL. 33(2):166-172, 1996]"
3807,363898899,1486,C1=CC(=C(C=C1Cl)Cl)OCC(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5; 150; 300 MG/KG BW DAILY FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHARLES,JM, BOND,DM, JEFFRIES,TK, YANO,BL, STOTT,WT, JOHNSON,KA, CUNNY,HC, WILSON,RD AND BUS,JS; CHRONIC DIETARY TOXICITY/ONCOGENICITY STUDIES ON 2,4-DICHLOROPHENOXYACETIC ACID IN RODENTS; FUNDAM. APPL. TOXICOL. 33(2):166-172, 1996]"
3808,363898901,6564,CC(CCl)Cl,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 62; 125 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-263 Y86]"
3809,363898901,6564,CC(CCl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LIVER: ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-263 Y86]"
3810,363898901,6564,CC(CCl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LIVER: ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-263 Y86]"
3811,363898901,6564,CC(CCl)Cl,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 125; 150 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),MAMMARY GLAND: ADENOCARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-263 Y86]"
3812,363898902,7860,C(=O)C=O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 50 UMOL/O.1 ML DMSO 2/WK FOR 5 WK FOLLOWED 1 WK LATER BY 0.1 ML ACETONE 2/WK FOR 47 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MIYAKAWA,Y, NISHI,Y, KATO,K, SATO,K, TAKAHASHI,M AND HAYASHI,Y; INITIATING ACTIVITY OF EIGHT PYROLYSATES OF CARBOHYDRATES IN A TWO-STAGE MOUSE SKIN TUMORIGENESIS MODEL; CARCINOGENESIS 12(7):1169-1173, 1991]"
3813,363898905,24726,C(/C=C/Cl)Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 25; 50 MG/KG BODY WT (TELONE II) IN CORN OIL 3 D/WK FOR 104 WK,"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA; LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-269 Y85]"
3814,363898905,24726,C(/C=C/Cl)Cl,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 25; 50 MG/KG BODY WT (TELONE II) IN CORN OIL 3 D/WK FOR 104 WK,FORESTOMACH: SQUAMOUS CELL PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-269 Y85]"
3815,363898905,24726,C(/C=C/Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 50; 100 MG/KG BODY WT (TELONE II) IN CORN OIL 3 D/WK FOR 104 WK,"URINARY BLADDER: TRANSITIONAL CELL CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-269 Y85]"
3816,363898905,24726,C(/C=C/Cl)Cl,Inactive,,,,RAT,F344/MALE,INHALATION,0; 5; 20; 60 PPM TECHNICAL GRADE 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[LOMAX,LG, STOTT,WT, JOHNSON,KA, CALHOUN,LL, YANO,BL AND QUAST,JF; THE CHRONIC TOXICITY AND ONCOGENICITY OF INHALED TECHNICAL-GRADE 1,3-DICHLOROPROPENE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 12(3):418-431, 1989]"
3817,363898905,24726,C(/C=C/Cl)Cl,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 5; 20; 60 PPM TECHNICAL GRADE 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[LOMAX,LG, STOTT,WT, JOHNSON,KA, CALHOUN,LL, YANO,BL AND QUAST,JF; THE CHRONIC TOXICITY AND ONCOGENICITY OF INHALED TECHNICAL-GRADE 1,3-DICHLOROPROPENE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 12(3):418-431, 1989]"
3818,363898905,24726,C(/C=C/Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 5; 20; 60 PPM TECHNICAL GRADE 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),LUNG: BRONCHIOALVEOLAR ADENOMA,POSITIVE,"[LOMAX,LG, STOTT,WT, JOHNSON,KA, CALHOUN,LL, YANO,BL AND QUAST,JF; THE CHRONIC TOXICITY AND ONCOGENICITY OF INHALED TECHNICAL-GRADE 1,3-DICHLOROPROPENE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 12(3):418-431, 1989]"
3819,363898905,24726,C(/C=C/Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 5; 20; 60 PPM TECHNICAL GRADE 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[LOMAX,LG, STOTT,WT, JOHNSON,KA, CALHOUN,LL, YANO,BL AND QUAST,JF; THE CHRONIC TOXICITY AND ONCOGENICITY OF INHALED TECHNICAL-GRADE 1,3-DICHLOROPROPENE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 12(3):418-431, 1989]"
3820,363898905,24726,C(/C=C/Cl)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 2.5; 12.5; 25 MG/KG BW IN DIET FOR 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[STEBBINS, JOHNSON, KA JEFFRIES,TK REDMOND,JM HAUT,KT SHABRANG,SN AND STOTT,WT; CHRONIC TOXICITY AND ONCOGENICITY STUDIES OF INGESTED 1,3-DICHLOROPROPENE IN RATS AND MICE; REGUL. TOXICOL. PHARMACOL. 32(1):1-13, 2000]"
3821,363898905,24726,C(/C=C/Cl)Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 12.5; 25 MG/KG BW IN DIET FOR 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[STEBBINS, JOHNSON, KA JEFFRIES,TK REDMOND,JM HAUT,KT SHABRANG,SN AND STOTT,WT; CHRONIC TOXICITY AND ONCOGENICITY STUDIES OF INGESTED 1,3-DICHLOROPROPENE IN RATS AND MICE; REGUL. TOXICOL. PHARMACOL. 32(1):1-13, 2000]"
3822,363898905,24726,C(/C=C/Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2.5; 25; 50 MG/KG BW IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[STEBBINS, JOHNSON, KA JEFFRIES,TK REDMOND,JM HAUT,KT SHABRANG,SN AND STOTT,WT; CHRONIC TOXICITY AND ONCOGENICITY STUDIES OF INGESTED 1,3-DICHLOROPROPENE IN RATS AND MICE; REGUL. TOXICOL. PHARMACOL. 32(1):1-13, 2000]"
3823,363898905,24726,C(/C=C/Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2.5; 25; 50 MG/KG BW IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[STEBBINS, JOHNSON, KA JEFFRIES,TK REDMOND,JM HAUT,KT SHABRANG,SN AND STOTT,WT; CHRONIC TOXICITY AND ONCOGENICITY STUDIES OF INGESTED 1,3-DICHLOROPROPENE IN RATS AND MICE; REGUL. TOXICOL. PHARMACOL. 32(1):1-13, 2000]"
3824,363898909,7411,C1=CC=C(C=C1)C(Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.1; 0.5; 2% IN FEED FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[LEUNG,H-W BALLANTYNE,B HERMANSKY,S AND FRANTZ,S; PERORAL SUBCHRONIC, CHRONIC TOXICITY, AND PHARMACOKINETIC STUDIES OF A 100-KILODALTON POLYMER OF ETHYLENE OXIDE (POLYOX N-10) IN THE FISCHER 344 RAT; INT. J. TOXICOL. 19:305-312, 2000]"
3825,363898909,7411,C1=CC=C(C=C1)C(Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.1; 0.5; 2% IN FEED FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[LEUNG,H-W BALLANTYNE,B HERMANSKY,S AND FRANTZ,S; PERORAL SUBCHRONIC, CHRONIC TOXICITY, AND PHARMACOKINETIC STUDIES OF A 100-KILODALTON POLYMER OF ETHYLENE OXIDE (POLYOX N-10) IN THE FISCHER 344 RAT; INT. J. TOXICOL. 19:305-312, 2000]"
3826,363898922,3034752,CC1=CC2=C(CCC2=O)C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,"TO/MALE, FEMALE",DERMAL,0; 50 UG (10 UL OF A 0.5% W/V TOLUENE SOLUTION) 2/WK FOR 70 WK (STUDY DURATION: 70 WK),SKIN: CARCINOMA,POSITIVE,
3827,363898929,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.1; 0.5; 2% IN FEED FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[LEUNG,H-W BALLANTYNE,B HERMANSKY,S AND FRANTZ,S; PERORAL SUBCHRONIC, CHRONIC TOXICITY, AND PHARMACOKINETIC STUDIES OF A 100-KILODALTON POLYMER OF ETHYLENE OXIDE (POLYOX N-10) IN THE FISCHER 344 RAT; INT. J. TOXICOL. 19:305-312, 2000]"
3828,363898929,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.1; 0.5; 2% IN FEED FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[LEUNG,H-W BALLANTYNE,B HERMANSKY,S AND FRANTZ,S; PERORAL SUBCHRONIC, CHRONIC TOXICITY, AND PHARMACOKINETIC STUDIES OF A 100-KILODALTON POLYMER OF ETHYLENE OXIDE (POLYOX N-10) IN THE FISCHER 344 RAT; INT. J. TOXICOL. 19:305-312, 2000]"
3829,363898930,5755,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 40 UG/ML IN DRINKING WATER FOR AN AVERAGE DAILY DOSE OF 368 UG/KG FOR 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[RYRFELDT,A, SQUIRE,RA AND EKMAN,L; LIVER TUMORS IN MALE RATS FOLLOWING TREATMENT WITH GLUCOCORTICOSTEROIDS; TOXICOL. PATHOL. 20(1):115-117, 1992]"
3830,363898930,5755,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,"0; 3 MG/KG ADMINISTERED 1, 2, 4.5 OR 9 TIMES PER MO FOR 18 MO TO GIVE MEDIAN TOTAL DOSES OF 54; 108; 234; 468 MG/KG (STUDY DURATION: LIFETIME)",,NEGATIVE,"[BERGER,MR, HABS,M AND SCHMAHL,D; COMPARATIVE CARCINOGENIC ACTIVITY OF PREDNIMUSTINE, CHLORAMBUCIL, PREDNISOLONE AND CHLORAMBUCIL PLUS PREDNISOLONE IN SPRAGUE-DAWLEY RATS; ARCH. GESCHWULSTFORSCH. 55:429-442, 1985]"
3831,363898942,156317,CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=C[C@@H]([C@H]3O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE (8/GROUP),SUBCUTANEOUS,0.1 UMOL 3X A WK FOR 20 DOSES (STUDY DURATION: 38 WK),MAMMARY: ADENOCARCINOMA,POSITIVE (100%); NO TUMORS AT INJECTION SITE,"[HORN,J LEHNER,AF AND FLESHER,JW; RAPID INDUCTION OF MAMMARY CANCER BY REPEATED SUBCUTANEOUS INJECTION OF THE TRANS-A3,4-DIHYDRODIOL OF 7,12-DIMETHYLBENZ[A]ANTHRACENE IN THE FEMALE SPRAGUE-DAWLEY RAT; CANCER LETT. 220(2):155-160, 2005]"
3832,363898942,156317,CC1=C2C=CC3=C(C2=C(C4=CC=CC=C14)C)C=C[C@@H]([C@H]3O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE (8/GROUP),SUBCUTANEOUS,0.2 UMOL 3X A WK FOR 20 DOSES (STUDY DURATION: 30 WK),MAMMARY: ADENOCARCINOMA,POSITIVE (100%); NO TUMORS AT INJECTION SITE,"[HORN,J LEHNER,AF AND FLESHER,JW; RAPID INDUCTION OF MAMMARY CANCER BY REPEATED SUBCUTANEOUS INJECTION OF THE TRANS-A3,4-DIHYDRODIOL OF 7,12-DIMETHYLBENZ[A]ANTHRACENE IN THE FEMALE SPRAGUE-DAWLEY RAT; CANCER LETT. 220(2):155-160, 2005]"
3833,363898948,62311,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N)OC)N.Cl.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 80; 170; 330 PPM IN DRINKING WATER FOR 21 MO (STUDY DURATION: 93 WK),"BRAIN: MALIGNANT ASTROCYTOMA; PREPUTIAL GLAND: CARCINOMA, ADENOMA OR CARCINOMA; LARGE INTESTINE: ADENOMATOUS POLYP OR ADENOCARCINOMA; SMALL INTESTINE: ADENOCARCINOMA; LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; ORAL CAVITY: SQUAMOUS PAPILLOMA OR SQUAMOUS CELL CARCINOMA; SKIN: BASAL CELL ADENOMA OR BASAL CELL CARCINOMA OR SEBACEOUS GLAND ADENOMA OR SEBACEOUS GLAND CARCINOMA; ZYMBAL GLAND: ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-372 Y90]"
3834,363898948,62311,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N)OC)N.Cl.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 80; 170; 330 PPM IN DRINKING WATER FOR 21 MO ( STUDY DURATION: 93 WK),CLITORAL GLAND: ADENOMA OR CARCINOMA; LARGE INTESTINE: ADENOMATOUS POLYP OR ADENOCARCINOMA; LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA; ORAL CAVITY: SQUAMOUS PAPILLOMA OR SQUAMOUS CELL CARCINOMA; SKIN: BASAL CELL ADENOMA OR CARCINOMA; UTERUS: ADENOMA OR CARCINOMA; ZYMBAL GLAND: ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-372 Y90]"
3835,363898948,62311,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N)OC)N.Cl.Cl,Inactive,,,,MOUSE,BALB/MALE,ORAL,0; 20; 40; 80; 160; 315; 630 PPM IN DRINKING WATER (STUDY DURATION: 112 WK),,NEGATIVE,"[SCHIEFERSTEIN,GJ; SHELDON,WG; ALLEN,RR, GREENMAN,DL AND ALLABEN,WT; ONCOGENIC EVALUATION OF 3,3'-DIMETHOXYBENZIDINE DIHYDROCHLORIDE IN BALB/C MICE; J. AM. COLL. TOXICOL. 9(1):71-77, 1990]"
3836,363898948,62311,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N)OC)N.Cl.Cl,Inactive,,,,MOUSE,BALB/FEMALE,ORAL,0; 20; 40; 80; 160; 315; 630 PPM IN DRINKING WATER (STUDY DURATION: 112 WK),,NEGATIVE,"[SCHIEFERSTEIN,GJ; SHELDON,WG; ALLEN,RR, GREENMAN,DL AND ALLABEN,WT; ONCOGENIC EVALUATION OF 3,3'-DIMETHOXYBENZIDINE DIHYDROCHLORIDE IN BALB/C MICE; J. AM. COLL. TOXICOL. 9(1):71-77, 1990]"
3837,363898948,62311,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N)OC)N.Cl.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 80; 170; 330 PPM IN DRINKING WATER FOR 21 MO (STUDY DURATION: 21 MO),"ZYMBAL GLAND: ADENOMA, CARCINOMA; PREPUTIAL GLAND: CARCINOMA; SKIN: BASAL CELL ADENOMA, BASAL CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; LARGE INTESTINE: ADENOMATOUS POLYP OR ADENOCARCINOMA; SMALL INTESTINE: ADENOCARCINOMA; OVAL CAVITY: PAPILLOMA; LIVER: NEOPLASTIC NODULE OR CARCINOMA",POSITIVE,"[MORGAN,DL, BUCHER,JR, HUFF,JE, HASEMAN,JK, EUSTIS,SL, LEMEN,JK, ULLAND,BM AND MENNEAR,JH; MULTI-ORGAN CARCINOGENICITY OF 3,3'-DIMETHOXYBENZIDINE DIHYDROCHLORIDE GIVEN IN DRINKING WATER TO F344/N RATS; J. AM. COLL. TOXICOL. 9(1):79-91, 1990]"
3838,363898948,62311,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N)OC)N.Cl.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 80; 170; 330 PPM IN DRINKING WATER FOR 21 MO (STUDY DURATION: 21 MO),"ZYMBAL GLAND: ADENOMA, CARCINOMA; CLITORAL GLAND: ADENOMA, CARCINOMA; LARGE INTESTINE: ADENOMATOUS POLYP OR ADENOCARCINOMA; MAMMARY GLAND: ADENOCARCINOMA",POSITIVE,"[MORGAN,DL, BUCHER,JR, HUFF,JE, HASEMAN,JK, EUSTIS,SL, LEMEN,JK, ULLAND,BM AND MENNEAR,JH; MULTI-ORGAN CARCINOGENICITY OF 3,3'-DIMETHOXYBENZIDINE DIHYDROCHLORIDE GIVEN IN DRINKING WATER TO F344/N RATS; J. AM. COLL. TOXICOL. 9(1):79-91, 1990]"
3839,363898952,10555,CC(=CCl)C,Active,,,,RAT,F344/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"NASAL CAVITY: CARCINOMA (NOS), SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA; ESOPHAGUS: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; ORAL CAVITY: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-316 Y86]"
3840,363898952,10555,CC(=CCl)C,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"NASAL CAVITY: CARCINOMA (NOS), CARCINOMA (NOS) OR SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; ORAL CAVITY: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-316 Y86]"
3841,363898952,10555,CC(=CCl)C,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 102 WK,"FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA; PREPUTIAL GLAND: SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-316 Y86]"
3842,363898952,10555,CC(=CCl)C,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 102 WK,"FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-316 Y86]"
3843,363898957,252237,CCCCCN(CCCCC)N=O,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 62.5; 125; 250 MG/KG BW 1/WK FOR 25 WK (STUDY DURATION: 1 YR),"NASAL CAVITY: POLYPOID ADENOMA; LUNG: BRONCHIOALVEOLAR ADENOCARCINOMA, BRONCHIOALVEOLAR ADENOMA",POSITIVE,"[KAMINO,K AND MOHR,U; EFFECTS OF DIPENTYLNITROSAMINE (DPNA) ON THE RESPIRATORY TRACT OF RATS; EXP. TOXICOL. PATHOL. 44(5):217-221, 1992]"
3844,363898957,252237,CCCCCN(CCCCC)N=O,Active,,,,RAT,WISTAR/FEMALE,SUBCUTANEOUS,0; 62.5; 125; 250 MG/KG BW 1/WK FOR 25 WK (STUDY DURATION: 1 YR),NASAL CAVITY: POLYPOID ADENOMA; LUNG: BRONCHIOALVEOLAR ADENOMA,POSITIVE,"[KAMINO,K AND MOHR,U; EFFECTS OF DIPENTYLNITROSAMINE (DPNA) ON THE RESPIRATORY TRACT OF RATS; EXP. TOXICOL. PATHOL. 44(5):217-221, 1992]"
3845,363898960,7577,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.15; 0.03% IN DIET FOR 103 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR CARCINOMA; LIVER: NEOPLASTIC NODULE,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
3846,363898960,7577,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.015; 0.03% IN DIET FOR 103 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR ADENOMA,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
3847,363898960,7577,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.015; 0.03% IN DIET FOR 103 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
3848,363898960,7577,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.015; 0.03% IN DIET FOR 103 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR ADENOMA; LIVER: HEPATOCELLULAR ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[WEISBURGER,EK, MURTHY,ASK, LILJA,HS AND LAMB,JC; NEOPLASTIC RESPONSE OF F344 RATS AND B6C3F1 MICE TO THE POLYMER AND DYESTUFF INTERMEDIATES 4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE, 4,4'-OXYDIANILINE AND 4,4'-METHYLENEDIANILINE; J. NATL. CANCER INST. 72(6):1457-1463, 1984]"
3849,363898961,3118,CCOP(=S)(OCC)SCCSCC,Inactive,,,,Rat,F344/Male (50/Group),Oral,"0; 1; 4; 16 ppm 97.6% disulfoton in diet for 105 wks, study duration 105 wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  DISULFOTON  (June 2, 2000)]"
3850,363898961,3118,CCOP(=S)(OCC)SCCSCC,Inactive,,,,Rat,F344/Female (50/Group),Oral,"0; 1; 4; 16 ppm 97.6% disulfoton in diet for 105 wks, study duration 105 wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  DISULFOTON  (June 2, 2000)]"
3851,363898961,3118,CCOP(=S)(OCC)SCCSCC,Inactive,,,,Mouse,CD/Male (60/Group with 10 used as replacements),Oral,"0; 1; 4; 16 ppm 98.2% disulfoton in diet for 99 wks, study duration 99 wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  DISULFOTON  (June 2, 2000)]"
3852,363898961,3118,CCOP(=S)(OCC)SCCSCC,Inactive,,,,Mouse,CD/Female (60/Group with 10 used as replacements),Oral,"0; 1; 4; 16 ppm 98.2% disulfoton in diet for 99 wks, study duration 99 wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  DISULFOTON  (June 2, 2000)]"
3853,363898962,3120,CN(C)C(=O)NC1=CC(=C(C=C1)Cl)Cl,Active,,,,Rat,Wistar/Male (50/Group),Oral,0; 25; 250; 2500 ppm 98.7% diuron in diet for 2 yr; study duration 2 yr,Urinary bladder: Transitional epithelial cell carcinoma (highest dose only). Kidney: Epithelial cell tumors in renal pelvis (highest dose only),Positive. (CA Department of Pesticide Regulation reviewer evaluates as a possible adverse effect.),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DIURON  (February 18, 2010)]"
3854,363898962,3120,CN(C)C(=O)NC1=CC(=C(C=C1)Cl)Cl,Active,,,,Rat,Wistar/Female (50/Group),Oral,0; 25; 250; 2500 ppm 98.7% diuron in diet for 2 yr; study duration 2 yr,Urinary bladder: Transitional epithelial cell carcinoma (highest dose only),Positive. (CA Department of Pesticide Regulation reviewer evaluates as a possible adverse effect.),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DIURON  (February 18, 2010)]"
3855,363898962,3120,CN(C)C(=O)NC1=CC(=C(C=C1)Cl)Cl,Inactive,,,,Mouse,Bor strain NMRI SPF HAN/Male (60/Group),Oral,0; 25; 250; 2500 ppm 98.7% diuron in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DIURON  (February 18, 2010)]"
3856,363898962,3120,CN(C)C(=O)NC1=CC(=C(C=C1)Cl)Cl,Active,,,,Mouse,Bor strain NMRI SPF HAN/Female (60/Group),Oral,0; 25; 250; 2500 ppm 98.7% diuron in diet for 24 mo; study duration 24 mo,Mammary gland: Adenocarcinoma (highest dose only),Positive. (CA Department of Pesticide Regulation reviewer evaluates as a possible adverse effect.),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DIURON  (February 18, 2010)]"
3857,363898962,3120,CN(C)C(=O)NC1=CC(=C(C=C1)Cl)Cl,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 250 MG/KG IN 100 UL DMSO TO INTERSCAPULAR REGION 3/WK FOR 3 WK FOLLOWED 1 WK LATER BY 100 UL ACETONE 3/WK FOR DURATION OF STUDY (STUDY DURATION: 52 WK),,NEGATIVE,"[ANTONY,M, SHUKLA,Y AND MEHROTRA,NK; TUMOR INITIATORY ACTIVITY OF A HERBICIDE DIURON ON MOUSE SKIN; CANCER LETT. 48(2):125-8, 1989]"
3858,363898965,7834,CCC1CO1,Active,,,,RAT,F344/MALE,INHALATION,0; 200; 400 PPM 6 HR/D 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),NASAL CAVITY: PAPILLARY ADENOMA; LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-329 Y88]"
3859,363898965,7834,CCC1CO1,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 50; 100 PPM 6 HR/D 5D/WK FOR 102 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-329 Y88]"
3860,363898965,7834,CCC1CO1,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 50; 100 PPM 6 HR/D 5D/WK FOR 102 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-329 Y88]"
3861,363898965,7834,CCC1CO1,Unspecified,,,,RAT,F344/FEMALE,INHALATION,0; 200; 400 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),NASAL CAVITY: PAPILLARY ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-329 Y88]"
3862,363898971,1489,C1=CC(=C(C=C1Cl)Cl)OCCCC(=O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 60; 600; 1800 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[CHARLES,JM AND LEEMING,NM; CHRONIC DIETARY TOXICITY/ONCOGENICITY STUDIES ON 2,4-DICHLOROPHENOXYBUTYRIC ACID IN RODENTS; TOXICOL. SCI. 46(1):21-30, 1998]"
3863,363898971,1489,C1=CC(=C(C=C1Cl)Cl)OCCCC(=O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 60; 600; 1800 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[CHARLES,JM AND LEEMING,NM; CHRONIC DIETARY TOXICITY/ONCOGENICITY STUDIES ON 2,4-DICHLOROPHENOXYBUTYRIC ACID IN RODENTS; TOXICOL. SCI. 46(1):21-30, 1998]"
3864,363898971,1489,C1=CC(=C(C=C1Cl)Cl)OCCCC(=O)O,Inactive,,,,MOUSE,ICR/MALE,ORAL,0; 25; 250; 750 PPM IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[CHARLES,JM AND LEEMING,NM; CHRONIC DIETARY TOXICITY/ONCOGENICITY STUDIES ON 2,4-DICHLOROPHENOXYBUTYRIC ACID IN RODENTS; TOXICOL. SCI. 46(1):21-30, 1998]"
3865,363898971,1489,C1=CC(=C(C=C1Cl)Cl)OCCCC(=O)O,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 25; 250; 750 PPM IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[CHARLES,JM AND LEEMING,NM; CHRONIC DIETARY TOXICITY/ONCOGENICITY STUDIES ON 2,4-DICHLOROPHENOXYBUTYRIC ACID IN RODENTS; TOXICOL. SCI. 46(1):21-30, 1998]"
3866,363898972,7204,CC1=C(C=CC(=C1)Cl)OCC(=O)O,Inactive,,,,NEWT,,IMMERSION,0; 100; 200; 400 PPM 4 D/WK FOR 12 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[ZAVANELLA,T, PACCES ZAFFARONI,N AND ARIAS,E; EVALUATION OF THE CARCINOGENIC RISK OF THE PHENOXYHERBICIDE MCPA TO AN URODELE AMPHIBIAN; ECOTOXICOL. ENVIRON. SAF. 16(2):114-22, 1988]"
3867,363898972,7204,CC1=C(C=CC(=C1)Cl)OCC(=O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 20; 80; 320 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BELLET,EM VAN RAVENZWAAY,B PIGOTT,G AND LEEMING,N; CHRONIC DIETARY TOXICITY AND ONCOGENICITY EVALUATION OF MCPA (4-CHLORO-2-METHYLPHENOXYACETIC ACID) IN RODENTS; REGUL. TOXICOL. PHARMACOL. 30(3):223-232, 1999]"
3868,363898972,7204,CC1=C(C=CC(=C1)Cl)OCC(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 20; 100; 500 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BELLET,EM VAN RAVENZWAAY,B PIGOTT,G AND LEEMING,N; CHRONIC DIETARY TOXICITY AND ONCOGENICITY EVALUATION OF MCPA (4-CHLORO-2-METHYLPHENOXYACETIC ACID) IN RODENTS; REGUL. TOXICOL. PHARMACOL. 30(3):223-232, 1999]"
3869,363898972,7204,CC1=C(C=CC(=C1)Cl)OCC(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 20; 100; 500 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BELLET,EM VAN RAVENZWAAY,B PIGOTT,G AND LEEMING,N; CHRONIC DIETARY TOXICITY AND ONCOGENICITY EVALUATION OF MCPA (4-CHLORO-2-METHYLPHENOXYACETIC ACID) IN RODENTS; REGUL. TOXICOL. PHARMACOL. 30(3):223-232, 1999]"
3870,363898972,7204,CC1=C(C=CC(=C1)Cl)OCC(=O)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 20; 80; 320 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BELLET,EM VAN RAVENZWAAY,B PIGOTT,G AND LEEMING,N; CHRONIC DIETARY TOXICITY AND ONCOGENICITY EVALUATION OF MCPA (4-CHLORO-2-METHYLPHENOXYACETIC ACID) IN RODENTS; REGUL. TOXICOL. PHARMACOL. 30(3):223-232, 1999]"
3871,363898974,25742,CCN(CCO)N=O,Active,,,,RAT,WISTAR/MALE,ORAL,0; 1000 PPM IN DIET FOR 2 WK (STUDY DURATION: 30 WK),KIDNEY: RENAL CELL TUMOR; LIVER: TUMOR,POSITIVE,"[KONISHI,N, HAYASHI,I, NAKAOKA,S, KITAHORI,Y, TSUZUKI,T, MATSUDA,H, KITAMURA,M, HIASA,Y AND OHSHIMA,M; RODENT SPECIES AND STRAIN DIFFERENCE IN KIDNEY AND LUNG PATHOLOGY INDUCED BY N-ETHYL-N-HYDROXYETHYLNITROSAMINE; J. TOXICOL. PATHOL. 7(1):67-71, 1994]"
3872,363898974,25742,CCN(CCO)N=O,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 1000 PPM IN DIET FOR 2 WK (STUDY DURATION: 30 WK),KIDNEY: RENAL CELL TUMOR,POSITIVE,"[KONISHI,N, HAYASHI,I, NAKAOKA,S, KITAHORI,Y, TSUZUKI,T, MATSUDA,H, KITAMURA,M, HIASA,Y AND OHSHIMA,M; RODENT SPECIES AND STRAIN DIFFERENCE IN KIDNEY AND LUNG PATHOLOGY INDUCED BY N-ETHYL-N-HYDROXYETHYLNITROSAMINE; J. TOXICOL. PATHOL. 7(1):67-71, 1994]"
3873,363898974,25742,CCN(CCO)N=O,Active,,,,RAT,WISTAR/MALE,ORAL,0; 1000 PPM IN DRINKING WATER FOR 2 WK (STUDY DURATION: 30 WK),KIDNEY: RENAL CELL TUMOR,POSITIVE,"[KONISHI,N, HAYASHI,I, NAKAOKA,S, KITAHORI,Y, TSUZUKI,T, MATSUDA,H, KITAMURA,M, HIASA,Y AND OHSHIMA,M; RODENT SPECIES AND STRAIN DIFFERENCE IN KIDNEY AND LUNG PATHOLOGY INDUCED BY N-ETHYL-N-HYDROXYETHYLNITROSAMINE; J. TOXICOL. PATHOL. 7(1):67-71, 1994]"
3874,363898974,25742,CCN(CCO)N=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 1000 PPM IN DIET FOR 2 WK (STUDY DURATION: 30 WK),,NEGATIVE,"[KONISHI,N, HAYASHI,I, NAKAOKA,S, KITAHORI,Y, TSUZUKI,T, MATSUDA,H, KITAMURA,M, HIASA,Y AND OHSHIMA,M; RODENT SPECIES AND STRAIN DIFFERENCE IN KIDNEY AND LUNG PATHOLOGY INDUCED BY N-ETHYL-N-HYDROXYETHYLNITROSAMINE; J. TOXICOL. PATHOL. 7(1):67-71, 1994]"
3875,363898974,25742,CCN(CCO)N=O,Active,,,,MOUSE,BALB/MALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 2 WK (STUDY DURATION: 30 WK),LUNG: TUMOR,POSITIVE,"[KONISHI,N, HAYASHI,I, NAKAOKA,S, KITAHORI,Y, TSUZUKI,T, MATSUDA,H, KITAMURA,M, HIASA,Y AND OHSHIMA,M; RODENT SPECIES AND STRAIN DIFFERENCE IN KIDNEY AND LUNG PATHOLOGY INDUCED BY N-ETHYL-N-HYDROXYETHYLNITROSAMINE; J. TOXICOL. PATHOL. 7(1):67-71, 1994]"
3876,363898974,25742,CCN(CCO)N=O,Active,,,,MOUSE,STRAIN-A/MALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 2 WK (STUDY DURATION: 30 WK),LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[KONISHI,N, HAYASHI,I, NAKAOKA,S, KITAHORI,Y, TSUZUKI,T, MATSUDA,H, KITAMURA,M, HIASA,Y AND OHSHIMA,M; RODENT SPECIES AND STRAIN DIFFERENCE IN KIDNEY AND LUNG PATHOLOGY INDUCED BY N-ETHYL-N-HYDROXYETHYLNITROSAMINE; J. TOXICOL. PATHOL. 7(1):67-71, 1994]"
3877,363898974,25742,CCN(CCO)N=O,Inactive,,,,HAMSTER,SYRIAN/MALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 2 WK (STUDY DURATION: 30 WK),,NEGATIVE,"[KONISHI,N, HAYASHI,I, NAKAOKA,S, KITAHORI,Y, TSUZUKI,T, MATSUDA,H, KITAMURA,M, HIASA,Y AND OHSHIMA,M; RODENT SPECIES AND STRAIN DIFFERENCE IN KIDNEY AND LUNG PATHOLOGY INDUCED BY N-ETHYL-N-HYDROXYETHYLNITROSAMINE; J. TOXICOL. PATHOL. 7(1):67-71, 1994]"
3878,363898974,25742,CCN(CCO)N=O,Active,,,,RAT,WISTAR/MALE,ORAL,0; 1000; 2000 PPM IN DRINKING WATER FOR 2 WK (STUDY DURATION: 52 WK),KIDNEY: TUMOR,POSITIVE,"[HIASA,Y PAUL,M HAYASHI,I MOCHIZUKI,M TSUTSUMI,H KUWASHIMA,S KITAHORI,Y AND KONISHI,N; CARCINOGENIC EFFECTS OF N-ETHYL-N-HYDROXYETHYLNITROSAMINE AND ITS METABOLITES IN RATS AND MICE; CANCER LETT. (SHANNON, IREL.) 145(1-2):143-149, 1999]"
3879,363898974,25742,CCN(CCO)N=O,Active,,,,MOUSE,BALB/C/MALE,ORAL,0; 1000; 2000 PPM IN DRINKING WATER FOR 2 WK (STUDY DURATION: 52 WK),LUNG: TUMOR,POSITIVE,"[HIASA,Y PAUL,M HAYASHI,I MOCHIZUKI,M TSUTSUMI,H KUWASHIMA,S KITAHORI,Y AND KONISHI,N; CARCINOGENIC EFFECTS OF N-ETHYL-N-HYDROXYETHYLNITROSAMINE AND ITS METABOLITES IN RATS AND MICE; CANCER LETT. (SHANNON, IREL.) 145(1-2):143-149, 1999]"
3880,363898975,2256,CCNC1=NC(=NC(=N1)Cl)NC(C)C,Active,,,,RAT,F344/LATI/MALE,ORAL,0; 500; 1000 PPM TECHNICAL GRADE IN FEED FOR 8 WK THEN 0; 375; 750 PPM FOR LIFE SPAN (STUDY DURATION: LIFE SPAN),MAMMARY GLAND: BENIGN TUMOR,POSITIVE,"[PINTER,A, TOROK,G, BORZSONYI,M, SURJAN,A, CSIK,M, KELECSENYI,Z AND KOCSIS,Z; LONG-TERM CARCINOGENICITY BIOASSAY OF THE HERBICIDE ATRAZINE IN F344 RATS; NEOPLASMA 37(5):533-544, 1990]"
3881,363898975,2256,CCNC1=NC(=NC(=N1)Cl)NC(C)C,Active,,,,RAT,F344/LATI/FEMALE,ORAL,0; 500; 1000 PPM TECHNICAL GRADE IN FEED FOR 8 WK THEN 0; 375; 750 PPM FOR LIFE SPAN (STUDY DURATION: LIFE SPAN),UTERUS: ADENOCARCINOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA OR LYMPHOMA,POSITIVE,"[PINTER,A, TOROK,G, BORZSONYI,M, SURJAN,A, CSIK,M, KELECSENYI,Z AND KOCSIS,Z; LONG-TERM CARCINOGENICITY BIOASSAY OF THE HERBICIDE ATRAZINE IN F344 RATS; NEOPLASMA 37(5):533-544, 1990]"
3882,363898975,2256,CCNC1=NC(=NC(=N1)Cl)NC(C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 10; 70; 200; 400 PPM IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[WETZEL,LT, LUEMPERT,LG,III, BRECKENRIDGE,CB, TISDEL,MO, STEVENS,JT, THAKUR, AK, EXTROM,PJ AND ELDRIDGE,JC; CHRONIC EFFECTS OF ATRAZINE ON ESTRUS AND MAMMARY TUMOR FORMATION IN FEMALE SPRAGUE-DAWLEY AND FISCHER 344 RATS; J. TOXICOL. ENVIRON. HEALTH 43(2):169-182, 1994]"
3883,363898975,2256,CCNC1=NC(=NC(=N1)Cl)NC(C)C,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 70; 400 PPM IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[WETZEL,LT, LUEMPERT,LG,III, BRECKENRIDGE,CB, TISDEL,MO, STEVENS,JT, THAKUR, AK, EXTROM,PJ AND ELDRIDGE,JC; CHRONIC EFFECTS OF ATRAZINE ON ESTRUS AND MAMMARY TUMOR FORMATION IN FEMALE SPRAGUE-DAWLEY AND FISCHER 344 RATS; J. TOXICOL. ENVIRON. HEALTH 43(2):169-182, 1994]"
3884,363898977,2179,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,Inactive,,,,MOUSE,"STRAIN-A/MALE, FEMALE",INTRAPERITONEAL,0; 2; 5; 10 MG/KG 1/WK FOR 7 WK (STUDY DURATION: 24 WK),,NEGATIVE,"[DE LA IGLESIA,FA, FITZGERALD,JE, MCGUIRE,EJ, KIM,SN, HEIFETZ,CL AND STONER,GD; BACTERIAL AND MAMMALIAN CELL MUTAGENESIS, SISTER-CHROMATID EXCHANGE, AND MOUSE LUNG ADENOMA BIOASSAY WITH THE ANTINEOPLASTIC ACRIDINE DERIVATIVE AMSACRINE; J. TOXICOL. ENVIRON. HEALTH 14(5-6):667-681, 1984]"
3885,363898977,2179,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,Active,,,,RAT,WISTAR/MALE,INTRAVENOUS,"0; 0.25; 1; 3 MG/KG 1/D FOR 5 D FOLLOWED BY A 23-D RECOVERY PERIOD, CYCLE OF DOSING REPEATED 6 TIMES (STUDY DURATION: 2 YR)",LARGE INTESTINE: ADENOMA OR ADENOCARCINOMA; SMALL INTESTINE: ADENOMA OR ADENOCARCINOMA OR LEIOMYOSARCOMA; SKIN: TUMOR; THYMUS: THYMOMA; BONE: OSTEOSARCOMA,POSITIVE,"[GRAZIANO,MJ, COURTNEY,CL, MEIERHENRY,EF, KHEOH,T, PEGG,DG AND GOUGH,AW; CARCINOGENICITY OF THE ANTICANCER TOPOISOMERASE INHIBITOR, AMSACRINE, IN WISTAR RATS; FUMDAM. APPL. TOXICOL. 32(1):53-65, 1996]"
3886,363898977,2179,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42,Active,,,,RAT,WISTAR/FEMALE,INTRAVENOUS,"0; 0.25; 1; 3 MG/KG 1/D FOR 5 D FOLLOWED BY A 23-D RECOVERY PERIOD, CYCLE OF DOSING REPEATED 6 TIMES (STUDY DURATION: 2 YR)",SMALL INTESTINE: ADENOCARCINOMA OR ADENOMA OR LEIOMYOSARCOMA; INTEGUMENTARY SYSTEM: TUMOR; SKIN: TUMOR; UTERUS (UTERINE HORN): TUMOR; KIDNEY: TUMOR,POSITIVE,"[GRAZIANO,MJ, COURTNEY,CL, MEIERHENRY,EF, KHEOH,T, PEGG,DG AND GOUGH,AW; CARCINOGENICITY OF THE ANTICANCER TOPOISOMERASE INHIBITOR, AMSACRINE, IN WISTAR RATS; FUMDAM. APPL. TOXICOL. 32(1):53-65, 1996]"
3887,363898982,23683747,CC1=CC(=NS(=O)(=O)O1)[O-].[K+],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 3000; 10000; 30000 PPM IN DIET FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[BEEMS,RB, TIL,HP, NEWMAN,J AND MAYER,DG; CARCINOGENICITY STUDY WITH ACESULFAME-K IN MICE; FOOD SCI. TECHNOL. 47(ACESULFAME-K):59-70, 1991]"
3888,363898982,23683747,CC1=CC(=NS(=O)(=O)O1)[O-].[K+],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 3000; 10000; 30000 PPM IN DIET FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[BEEMS,RB, TIL,HP, NEWMAN,J AND MAYER,DG; CARCINOGENICITY STUDY WITH ACESULFAME-K IN MICE; FOOD SCI. TECHNOL. 47(ACESULFAME-K):59-70, 1991]"
3889,363898982,23683747,CC1=CC(=NS(=O)(=O)O1)[O-].[K+],Inactive,,,,RAT,CPB-WK SPF/MALE,ORAL,0; 3000; 10000; 30000 PPM IN DIET FOR 120 WK (STUDY DURATION: 120 WK),,NEGATIVE,"[SINKELDAM,EJ, KUPER,CF, BEEMS,RB, NEWMAN,AJ AND FERON,VJ; COMBINED CHRONIC TOXICITY AND CARCINOGENICITY STUDY WITH ACESULFAME-K IN RATS; FOOD SCI. TECHNOL. 47(ACESULFAME-K):43-58, 1991]"
3890,363898982,23683747,CC1=CC(=NS(=O)(=O)O1)[O-].[K+],Inactive,,,,RAT,CPB-WK SPF/FEMALE,ORAL,0; 3000; 10000; 30000 PPM IN DIET FOR 113 WK (STUDY DURATION: 113 WK),,NEGATIVE,"[SINKELDAM,EJ, KUPER,CF, BEEMS,RB, NEWMAN,AJ AND FERON,VJ; COMBINED CHRONIC TOXICITY AND CARCINOGENICITY STUDY WITH ACESULFAME-K IN RATS; FOOD SCI. TECHNOL. 47(ACESULFAME-K):43-58, 1991]"
3891,363898984,9154,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC=C4,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 257.6 UG TOTAL DOSE (36.8 UG/5 UL, 73.6 UG/10 UL, 147.2 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
3892,363898984,9154,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC=C4,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 257.6 UG TOTAL DOSE (36.8 UG/5 UL, 73.6 UG/10 UL, 147.2 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
3893,363898984,9154,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC=C4,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,0; 100; 500 UG IN DMSO ON DAY 1 OF STUDY FOLLOWED BY 0; 200; 1000 UG ON DAY 8 THEN 0; 400; 2000 UG ON DAY 15 ADMINISTERED TO NEWBORN MICE (STUDY DURATION: 24 WK),LUNG: ADENOMA OR CARCINOMA,POSITIVE,"[BUSBY,WF,JR, GOLDMAN,ME, NEWBERNE,PM  AND WOGAN,GN; TUMORIGENICITY OF FLUORANTHENE IN A NEWBORN MOUSE LUNG ADENOMA BIOASSAY; CARCINOGENESIS 5(10):1311-1316, 1984]"
3894,363898984,9154,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC=C4,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,0; 100; 500 UG IN DMSO ON DAY 1 OF STUDY FOLLOWED BY 0; 200; 1000 UG ON DAY 8 THEN 0; 400; 2000 UG ON DAY 15 ADMINISTERED TO NEWBORN MICE (STUDY DURATION: 24 WK),LUNG: ADENOMA OR CARCINOMA,POSITIVE,"[BUSBY,WF,JR, GOLDMAN,ME, NEWBERNE,PM  AND WOGAN,GN; TUMORIGENICITY OF FLUORANTHENE IN A NEWBORN MOUSE LUNG ADENOMA BIOASSAY; CARCINOGENESIS 5(10):1311-1316, 1984]"
3895,363898984,9154,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC=C4,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 3.46; 17.3 UMOL (TOTAL DOSE) IN DMSO ADMINISTERED ON DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",LUNG: TUMOR,POSITIVE,"[LAVOIE,EJ, CAI,ZW, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF FLUORANTHENE, 2-METHYLFLUORANTHENE AND 3-METHYLFLUORANTHENE IN NEWBORN CD-1 MICE. CARCINOGENESIS 15(10):2131-2135, 1994]"
3896,363898984,9154,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC=C4,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 3.46; 17.3 UMOL (TOTAL DOSE) IN DMSO ADMINISTERED ON DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[LAVOIE,EJ, CAI,ZW, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF FLUORANTHENE, 2-METHYLFLUORANTHENE AND 3-METHYLFLUORANTHENE IN NEWBORN CD-1 MICE. CARCINOGENESIS 15(10):2131-2135, 1994]"
3897,363898984,9154,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC=C4,Active,,,,MOUSE,"CD-1/MALE, FEMALE",INTRAPERITONEAL,"0; 0.7; 1.75; 3.5 (TOTAL DOSE) ADMINISTERED TO NEWBORN MICE ON DAYS 1, 8, AND 15 OF AGE IN 1/7, 2/7, AND 4/7 DOSES, RESPECTIVELY (STUDY DURATION: 6 MO)",LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[WANG,JS AND BUSBY,WF,JR; INDUCTION OF LUNG AND LIVER TUMORS BY FLUORANTHENE IN A PREWEANLING CD-1 MOUSE BIOASSAY; CARCINOGENESIS 14(9):1871-1874, 1993]"
3898,363898984,9154,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC=C4,Active,,,,MOUSE,"CD-1/MALE, FEMALE",INTRAPERITONEAL,"0; 0.7; 1.75; 3.5 (TOTAL DOSE) ADMINISTERED TO NEWBORN MICE ON DAYS 1, 8, AND 15 OF AGE IN 1/7, 2/7, AND 4/7 DOSES, RESPECTIVELY (STUDY DURATION: 9 MO)",LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[WANG,JS AND BUSBY,WF,JR; INDUCTION OF LUNG AND LIVER TUMORS BY FLUORANTHENE IN A PREWEANLING CD-1 MOUSE BIOASSAY; CARCINOGENESIS 14(9):1871-1874, 1993]"
3899,363898984,9154,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=CC=C4,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",,NEGATIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
3900,363898986,8607,C1=CC=C2C(=C1)C(=O)N(C2=O)SC(Cl)(Cl)Cl,Inactive,,,,Rat,Strain not specified in Department of Pesticides Regulation report /Male (60/Group),Oral,0; 200; 800; 3200 ppm of 89.5% folpet in diet for 105 wk; study duration 105 wk,,Negative. Increased incidence of thyroid tumors judged by reviewers as equivocal evidence of oncogenic effect.,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FOLPET (December 1, 1988)]"
3901,363898986,8607,C1=CC=C2C(=C1)C(=O)N(C2=O)SC(Cl)(Cl)Cl,Inactive,,,,Rat,Strain not specified in Department of Pesticides Regulation report /Female (60/Group),Oral,0; 200; 800; 3200 ppm of 89.5% folpet in diet for 105 wk; study duration 105 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FOLPET (December 1, 1988)]"
3902,363898986,8607,C1=CC=C2C(=C1)C(=O)N(C2=O)SC(Cl)(Cl)Cl,Active,,,,Mouse,B6C3F1/Male (52/Group),Oral,"0; 1000, 5000/3500; 10,000/7000 ppm (doses reduced at wk 21) of 88-89% folpet in diet for 2 yr; study duration 2 yr","Stomach: papilloma and squamous cell carcinoma combined (0, 2, 6, 3).  Duodenum: adenomas and carcinomas (0, 4, 17, 25)",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FOLPET (December 1, 1988)]"
3903,363898986,8607,C1=CC=C2C(=C1)C(=O)N(C2=O)SC(Cl)(Cl)Cl,Active,,,,Mouse,B6C3F1/Female (52/Group),Oral,"0; 1000, 5000/3500; 10,000/7000 ppm (doses reduced at wk 21) of 88-89% folpet in diet for 2 yr; study duration 2 yr","Stomach: papilloma and squamous cell carcinoma combined (2, 2, 5, 7).  Duodenum: adenomas and carcinomas (1, 2, 10, 19). Malignant lymphoma (16, 16, 19, 26)",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FOLPET (December 1, 1988)]"
3904,363898986,8607,C1=CC=C2C(=C1)C(=O)N(C2=O)SC(Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 5000; 10000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),NON-GLANDULAR STOMACH: PAPILLOMA OR SQUAMOUS CELL CARCINOMA; DUODENUM: CARCINOMA OR ADENOMA,POSITIVE,"[NYSKA,A, WANER,T, PASTER,Z, BRACHA,P, GORDON,EB AND KLEIN,B; INDUCTION OF GASTROINTESTINAL TUMORS IN MICE FED THE FUNGICIDE FOLPET: POSSIBLE MECHANISMS; JPN. J. CANCER RES. 81(6-7):545-9, 1990]"
3905,363898986,8607,C1=CC=C2C(=C1)C(=O)N(C2=O)SC(Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1000; 5000; 10000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),DUODENUM: CARCINOMA OR ADENOMA,POSITIVE,"[NYSKA,A, WANER,T, PASTER,Z, BRACHA,P, GORDON,EB AND KLEIN,B; INDUCTION OF GASTROINTESTINAL TUMORS IN MICE FED THE FUNGICIDE FOLPET: POSSIBLE MECHANISMS; JPN. J. CANCER RES. 81(6-7):545-9, 1990]"
3906,363898993,638011,CC(=CCC/C(=C/C=O)/C)C,Inactive,,,,MOUSE,B6C3F1/MALE (50),ORAL,0; 500; 1000; 2000 PPM IN MICROCAPSULES IN THE DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[RESS,NB HAILEY,JR MARONPOT,RR BUCHER,JR TRAVLOS,GS, HASEMAN,JK ORZECH,DP JOHNSON,JD AND HEJTMANCIK,MR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF MICROENCAPSULATED CITRAL IN RATS AND MICE; TOXICOL. SCI. 71(2):198-206, 2003]"
3907,363898993,638011,CC(=CCC/C(=C/C=O)/C)C,Unspecified,,,,MOUSE,B3C3F1/FEMALE (50),ORAL,0; 500; 1000; 2000 PPM IN MICROCAPSULES IN THE DIET FOR 2 YR (STUDY DURATION: 2 YR),LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA,EQUIVOCAL,"[RESS,NB HAILEY,JR MARONPOT,RR BUCHER,JR TRAVLOS,GS, HASEMAN,JK ORZECH,DP JOHNSON,JD AND HEJTMANCIK,MR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF MICROENCAPSULATED CITRAL IN RATS AND MICE; TOXICOL. SCI. 71(2):198-206, 2003]"
3908,363898993,638011,CC(=CCC/C(=C/C=O)/C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1000; 2000; 4000 PPM IN MICROCAPSULES IN THE DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[RESS,NB HAILEY,JR MARONPOT,RR BUCHER,JR TRAVLOS,GS, HASEMAN,JK ORZECH,DP JOHNSON,JD AND HEJTMANCIK,MR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF MICROENCAPSULATED CITRAL IN RATS AND MICE; TOXICOL. SCI. 71(2):198-206, 2003]"
3909,363898993,638011,CC(=CCC/C(=C/C=O)/C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 1000; 2000; 4000 PPM IN MICROCAPSULES IN THE DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[RESS,NB HAILEY,JR MARONPOT,RR BUCHER,JR TRAVLOS,GS, HASEMAN,JK ORZECH,DP JOHNSON,JD AND HEJTMANCIK,MR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF MICROENCAPSULATED CITRAL IN RATS AND MICE; TOXICOL. SCI. 71(2):198-206, 2003]"
3910,363898994,7362,C1=COC(=C1)C=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 30; 60 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),BILE DUCT: CHOLANGIOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-382 Y90]"
3911,363898994,7362,C1=COC(=C1)C=O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 30; 60 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-382 Y90]"
3912,363898994,7362,C1=COC(=C1)C=O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 50; 100; 175 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-382 Y90]"
3913,363898994,7362,C1=COC(=C1)C=O,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 50; 100; 175 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS PAPILLOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-382 Y90]"
3914,363898994,7362,C1=COC(=C1)C=O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 50 UMOL/0.1 ML DMSO 2/WK FOR 5 WK FOLLOWED 1 WK LATER BY 0.1 ML ACETONE 2/WK FOR 47 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MIYAKAWA,Y, NISHI,Y, KATO,K, SATO,K, TAKAHASHI,M AND HAYASHI,Y; INITIATING ACTIVITY OF EIGHT PYROLYSATES OF CARBOHYDRATES IN A TWO-STAGE MOUSE SKIN TUMORIGENESIS MODEL; CARCINOGENESIS 12(7):1169-1173, 1991]"
3915,363899002,11164,C1C(O1)CO,Active,,,,RAT,F344/MALE,GAVAGE,0; 37.5; 75 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"SKIN: SEBACEOUS GLAND ADENOMA OR BASAL CELL TUMOR OR SEBACEOUS GLAND ADENOCARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA; MAMMARY GLAND: FIBROADENOMA; BRAIN: GLIOMA; ZYMBAL GLAND: CARCINOMA; TUNICA VAGINALIS: MESOTHELIOMA (NOS), MALIGNANT MESOTHELIOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-374 Y90]"
3916,363899002,11164,C1C(O1)CO,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 37.5; 75 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA; ORAL CAVITY (MOUTH OR TONGUE): SQUAMOUS CELL PAPILLOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA; MAMMARY GLAND: FIBROADENOMA, ADENOCARCINOMA; CLITORAL GLAND: ADENOMA OR CARCINOMA OR ADENOCARCINOMA; BRAIN: GLIOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-374 Y90]"
3917,363899002,11164,C1C(O1)CO,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 25; 50 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"SKIN: SQUAMOUS CELL PAPILLOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA, ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-374 Y90]"
3918,363899002,11164,C1C(O1)CO,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 25; 50 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"SUBCUTANEOUS TISSUE: SARCOMA, SARCOMA OR FIBROSARCOMA; MAMMARY GLAND: ADENOCARCINOMA, ADENOMA OR FIBROADENOMA OR ADENOCARCINOMA; HARDERIAN GLAND: ADENOMA, ADENOMA OR ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-374 Y90]"
3919,363899010,784,OO,Active,,,,MOUSE,"C57BL/MALE,FEMALE",ORAL,0; 0.1%; 0.4% IN DRINKING WATER (STUDY DURATION: 108 WK),"DUODENUM: ADENOMA, ADENOCARCINOMA",POSITIVE,"[ITO,A, WATANABE,H, NAITO,M AND NAITO,Y; INDUCTION OF DUODENAL TUMORS IN MICE BY ORAL ADMINISTRATION OF HYDROGEN PEROXIDE; GANN 72(1):174-175, 1981]"
3920,363899011,20527,CC(=O)N(C1=CC=C(C=C1)C2=CC=CC=C2)O,Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 100 UMOL/KG BW 2/WK FOR 6 WK (STUDY DURATION: 62 WK),,NEGATIVE,"[HIROSE,M, SHIRAI,T, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF THE N-ACYL DERIVATIVES OF N-HYDROXY-TRANS-4-AMINOSTILBENE IN CD RATS; CHEM.-BIOL. INTERACT. 106(2):123-132, 1997]"
3921,363899029,30544,C1=CC=C2C(=C1)C3=C4C(=C2CO)C=CC5=CC=CC(=C54)C=C3,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.0025; 0.005; 0.015 UMOL/G ONCE AT 12 DAYS OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; THE STRONG HEPATOCARCINOGENICITY OF THE ELECTROPHILIC AND MUTAGENIC METABOLITE 6-SULFOOXYMETHYLBENZO[A]PYRENE AND ITS FORMATION OF BENZYLIC DNA ADDUCTS IN THE LIVERS OF INFANT MALE B6C3F1 MICE; BIOCHEM. BIOPHYS. RES. COMMUN. 172(1):85-91, 1990]"
3922,363899029,30544,C1=CC=C2C(=C1)C3=C4C(=C2CO)C=CC5=CC=CC(=C54)C=C3,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL 3/WK FOR 20 DOSES (STUDY DURATION: 52 WK),INJECTION SITE: SARCOMA,POSITIVE,"[FLESHER,JW, HORN,J AND LEHNER,AF; 6-SULFOOXYMETHYLBENZO[A]PYRENE IS AN ULTIMATE ELECTROPHILIC AND CARCINOGENIC FORM OF THE INTERMEDIARY METABOLITE 6-HYDROXYMETHYLBENZO[A]PYRENE; BIOCHEM. BIOPHYS. RES. COMMUN. 234(3):554-558, 1997]"
3923,363899030,18759,CC1=C2CC(C3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL IN 0.1 ML SESAME OIL:DMSO (9:1) 3/WK FOR 20 DOSES (STUDY DURATION: 52 WK),INJECTION SITE: SARCOMA,POSITIVE,"[FLESHER,JW, HORN,J AND LEHNER,AF; CARCINOGENICITY OF 1-HYDROXY-3-METHYLCHOLANTHRENE AND ITS ELECTROPHILIC SULFATE ESTER 1-SULFOOXY-3-METHYLCHOLANTHRENE IN SPRAGUE-DAWLEY RATS; BIOCHEM. BIOPHYS. RES. COMMUN. 243(1):30-35, 1998]"
3924,363899032,11285,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 2 UMOL IN 0.25 ML TRIOCTANOIN INTO LEFT HIND LEG AT ABOUT 40 D OF AGE FOLLOWED BY A SECOND DOSE 6 D LATER (STUDY DURATION: 16 MO),,NEGATIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
3925,363899032,11285,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 2 UMOL IN 0.25 ML TRIOCTANOIN ONCE INTO LEFT HIND LEG AT ABOUT 40 D OF AGE (STUDY DURATION: 16 MO),,NEGATIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
3926,363899032,11285,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 0.01; 0.03; 0.06 UMOL/G IN 5 UL DMSO/G ONCE AT 4-6 WK OF AGE (STUDY DURATION: 6 MO),LUNG: ADENOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
3927,363899032,11285,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.0025 UMOL/G IN 10 UL TRIOCTANOIN ON D 12, 16, 20 AND 24 OF AGE (STUDY DURATION: 12 MO)",LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
3928,363899032,11285,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.0025; 0.01; 0.03 UMOL/G IN 10 UL/G TRIOCTANOIN D 12 OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
3929,363899032,11285,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.0075; 0.015; 0.03 UMOL/G IN 10 UL/G TRIOCTANOIN ONCE ON D 12 OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
3930,363899032,11285,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.03; 0.08; 0.25 UMOL/G IN 10 UL/G TRIOCTANOIN ONCE AT 12 D OF AGE (STUDY DURATION: 8.5 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
3931,363899032,11285,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.01; 0.03; 0.06; UMOL/G IN 5 UL/G DMSO ONCE ON D 12 AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
3932,363899032,11285,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL 3/WK FOR 20 DOSES (STUDY DURATION: 52 WK),INJECTION SITE: SARCOMA,POSITIVE,"[FLESHER,JW, HORN,J AND LEHNER,AF; 7-SULFOOXYMETHYL-12-METHYLBENZ[A]ANTHRACENE IS AN EXCEPTIONALLY REACTIVE ELECTROPHILIC MUTAGEN AND ULTIMATE CARCINOGEN; BIOCHEM. BIOPHYS. RES. COMMUN. 231(1):144-148, 1997]"
3933,363899045,42373,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 100; 300; 900 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[MARKIEWICZ,V, TOMPKINS,C, MEHDI,N, HUBMER,S, PAYNE,BJ AND SUMI,N; RANGEFINDING TOXICITY AND CARCINOGENICITY STUDIES OF NEW BETA-ADRENOCEPTOR BLOCKING AGENT CELIPROLOL IN MICE; OYO YAKURI 38(5):421-434, 1989]"
3934,363899045,42373,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 100; 300; 900 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[MARKIEWICZ,V, TOMPKINS,C, MEHDI,N, HUBMER,S, PAYNE,BJ AND SUMI,N; RANGEFINDING TOXICITY AND CARCINOGENICITY STUDIES OF NEW BETA-ADRENOCEPTOR BLOCKING AGENT CELIPROLOL IN MICE; OYO YAKURI 38(5):421-434, 1989]"
3935,363899045,42373,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 100; 300; 900 MG/KG IN DIET FOR 316 D THEN 0; 30; 100; 300 MG/KG FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[MARKIEWICZ,V, TOMPKINS,C, MEHDI,N, HUBMER,S, PAYNE,BJ AND SUMI,N; RANGEFINDING TOXICITY AND CARCINOGENICITY STUDIES OF A NEW BETA-ADRENOCEPTORS BLOCKING AGENT CELIPROLOL IN RATS; OYO YAKURI 38(5):407-420, 1989]"
3936,363899045,42373,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 100; 300; 900 MG/KG IN DIET FOR 316 D THEN 0; 30; 100; 300 MG/KG FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[MARKIEWICZ,V, TOMPKINS,C, MEHDI,N, HUBMER,S, PAYNE,BJ AND SUMI,N; RANGEFINDING TOXICITY AND CARCINOGENICITY STUDIES OF A NEW BETA-ADRENOCEPTORS BLOCKING AGENT CELIPROLOL IN RATS; OYO YAKURI 38(5):407-420, 1989]"
3937,363899049,10958,CC(C)CON=O,Active,,,,RAT,F344/MALE,INHALATION,0; 158; 315; 630 MG/M3 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-448 Y96]"
3938,363899049,10958,CC(C)CON=O,Active,,,,RAT,F344/FEMALE,INHALATION,0; 158; 315; 630 MG/M3 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA OR ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-448 Y96]"
3939,363899049,10958,CC(C)CON=O,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 158; 315; 630 MG/M3 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-448 Y96]"
3940,363899049,10958,CC(C)CON=O,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 158; 315; 630 MG/M3 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-448 Y96]"
3941,363899051,6561,CC(C)C=O,Inactive,,,,RAT,F344/MALE,INHALATION,0; 500; 1000; 2000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-472 Y99]"
3942,363899051,6561,CC(C)C=O,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 500; 1000; 2000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-472 Y99]"
3943,363899051,6561,CC(C)C=O,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 500; 1000; 2000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-472 Y99]"
3944,363899051,6561,CC(C)C=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 500; 1000; 2000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-472 Y99]"
3945,363899053,13551,CC(C)OS(=O)(=O)C,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,"0; 10 UMOL/MOUSE IN TRIOCTANOIN INTO LEFT FLANK, 1/WK FOR 139 D (STUDY DURATION: 139 D)",THYMUS GLAND: LYMPHOMA,POSITIVE,"[SEGAL,A AND SELLAKUMAR,A; INDUCIBILITY OF THYMIC LYMPHOMAS IN FEMALE HSD: (ICR)BR MICE FOLLOWING SUBCUTANEOUS INJECTION OF ETHYL- AND ISOPROPYL METHANESULFONATE; CANCER LETT. 44(3):199-204, 1989]"
3946,363899057,,,Inactive,,,,Rat,Sprague-Dawley/Male (90/Group),Oral,"0; 30; 100; 300; 1000 ppm of 90% maneb in diet for up to 31 mo with interim sacrifice at 3, 6, and 12 mo); study duration 31 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANEB (August 18, 1986)]"
3947,363899057,,,Inactive,,,,Rat,Sprague-Dawley/Female (90/Group),Oral,"0; 30; 100; 300; 1000 ppm of 90% maneb in diet for up to 31 mo with interim sacrifice at 3, 6, and 12 mo); study duration 31 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANEB (August 18, 1986)]"
3948,363899057,,,Active,,,,Mouse,Crl:CD-1(ICR)/Male (75/Group),Oral,0; 60; 240; 2400 ppm of 89.5% maneb in diet for 18 mo; study duration 18 mo,Lung: Alveologenic adenoma. Liver: hepatocellular adenoma (high dose only),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANEB (August 18, 1986)]"
3949,363899057,,,Active,,,,Mouse,Crl:CD-1(ICR)/Female (75/Group),Oral,0; 60; 240; 2400 ppm of 89.5% maneb in diet for 18 mo; study duration 18 mo,Lung: Alveologenic adenoma. Liver: hepatocellular adenoma (high dose only),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANEB (August 18, 1986)]"
3950,363899063,6433205,C/[N+](=N/CO)/[O-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,"25 MG/KG, SINGLE DOSE",INTESTINES (JEJUNUM OR ILEUM); INTESTINES (COLON OR RECTUM),POSITIVE,"[HIRONO,I, SHIBUYA,C AND FUSHIMI,K; EXPERIMENTAL STUDIES ON SITES OF TUMOR DEVELOPMENT IN THE INTESTINE BY CHEMICAL CARCINOGENS.; IN: PATHOPHYSIOLOGY OF CARCINOGENESIS IN DIGESTIVE ORGANS, PROCEEDINGS OF THE 7TH INTERNATIONAL SYMPOSIUM OF THE PRINCESS.  TAKAMATSU CANCER RESEARCH FUND, 441 PP., 1977]"
3951,363899063,6433205,C/[N+](=N/CO)/[O-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,25 MG/KG 1/WK FOR 5 WK,INTESTINES (JEJUNUM OR ILEUM); INTESTINES (COLON OR RECTUM); CECUM; DUODENUM,POSITIVE,"[HIRONO,I, SHIBUYA,C AND FUSHIMI,K; EXPERIMENTAL STUDIES ON SITES OF TUMOR DEVELOPMENT IN THE INTESTINE BY CHEMICAL CARCINOGENS.; IN: PATHOPHYSIOLOGY OF CARCINOGENESIS IN DIGESTIVE ORGANS, PROCEEDINGS OF THE 7TH INTERNATIONAL SYMPOSIUM OF THE PRINCESS.  TAKAMATSU CANCER RESEARCH FUND, 441 PP., 1977]"
3952,363899063,6433205,C/[N+](=N/CO)/[O-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,25 MG/KG 1/WK FOR 15 WK,INTESTINES (JEJUNUM OR ILEUM); INTESTINES (COLON OR RECTUM); CECUM; DUODENUM,POSITIVE,"[HIRONO,I, SHIBUYA,C AND FUSHIMI,K; EXPERIMENTAL STUDIES ON SITES OF TUMOR DEVELOPMENT IN THE INTESTINE BY CHEMICAL CARCINOGENS.; IN: PATHOPHYSIOLOGY OF CARCINOGENESIS IN DIGESTIVE ORGANS, PROCEEDINGS OF THE 7TH INTERNATIONAL SYMPOSIUM OF THE PRINCESS.  TAKAMATSU CANCER RESEARCH FUND, 441 PP., 1977]"
3953,363899063,6433205,C/[N+](=N/CO)/[O-],Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAVENOUS,"20 MG/KG BW, SINGLE DOSE","LIVER: ADENOCARCINOMA, HEPATOCELLULAR CARCINOMA, VASCULAR TUMOR, CYSTADENOMA AND CYSTIC LESIONS; INTESTINES (LARGE): ADENOMA, ADENOCARCINOMA",POSITIVE,"[LAQUEUR,GL AND SPATZ,M; ONCOGENICITY OF CYCASIN AND METHYLAZOXYMETHANOL; GANN MONOGR. CANCER RES. 17 (RECENT TOP. CHEM. CARCINOG.):189-204, 1975]"
3954,363899063,6433205,C/[N+](=N/CO)/[O-],Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAVENOUS,"20 MG/KG BW, 3 INJ",LIVER: CYSTADENOMA AND CYSTIC LESIONS; GALL BLADDER: ADENOCARCINOMA; INTESTINES (LARGE): ADENOCARCINOMA,POSITIVE,"[LAQUEUR,GL AND SPATZ,M; ONCOGENICITY OF CYCASIN AND METHYLAZOXYMETHANOL; GANN MONOGR. CANCER RES. 17 (RECENT TOP. CHEM. CARCINOG.):189-204, 1975]"
3955,363899063,6433205,C/[N+](=N/CO)/[O-],Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAVENOUS,"15 MG/KG BW, 4-5 INJ","LIVER: CYSTADENOMA AND CYSTIC LESIONS, VASCULAR TUMOR, HEPATOCELLULAR CARCINOMA; INTESTINES (LARGE): ADENOMA, ADENOCARCINOMA",POSITIVE,"[LAQUEUR,GL AND SPATZ,M; ONCOGENICITY OF CYCASIN AND METHYLAZOXYMETHANOL; GANN MONOGR. CANCER RES. 17 (RECENT TOP. CHEM. CARCINOG.):189-204, 1975]"
3956,363899063,6433205,C/[N+](=N/CO)/[O-],Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAVENOUS,"10 MG/KG BW, 4-5 INJ","LIVER: CYSTADENOMA AND CYSTIC LESIONS, VASCULAR TUMOR, HEPATOCELLULAR CARCINOMA; INTESTINES (LARGE): ADENOMA, ADENOCARCINOMA",POSITIVE,"[LAQUEUR,GL AND SPATZ,M; ONCOGENICITY OF CYCASIN AND METHYLAZOXYMETHANOL; GANN MONOGR. CANCER RES. 17 (RECENT TOP. CHEM. CARCINOG.):189-204, 1975]"
3957,363899064,53665,C1(C(=C(C(=O)O1)Cl)C(Cl)Cl)O,Active,,,,RAT,WISTAR/MALE,ORAL,0; 0.4; 1.3; 5 MG/KG BW IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),"SKIN (SUBCUTANEOUS TISSUE): BASAL CELL TUMOR; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; LIVER: CHOLANGIOMA,ADENOMA; PANCREAS (LANGERHAN'S CELL): ADENOMA; ADRENAL GLAND: CORTICAL ADENOMA; THYROID GLAND: FOLLICULAR CARCINOMA, FOLLICULAR ADENOMA",POSITIVE,"[KOMULAINEN,H, KOSMA,VM, VAITTINEN,SL, VARTIAINEN,T, KALISTE-KORHONEN,E, LOTJONEN,S, TUOMINEN,RK AND TUOMISTO,J; CARCINOGENICITY OF THE DRINKING WATER MUTAGEN 3-CHLORO-4-(DICHLOROMETHYL)-5-HYDROXY-2(5H)-FURANONE IN THE RAT; J. NATL. CANCER INST. 89(12):848-856, 1997]"
3958,363899064,53665,C1(C(=C(C(=O)O1)Cl)C(Cl)Cl)O,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 0.6; 1.9; 6.6 MG/KG BW IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),"MAMMARY GLAND: ADENOCARCINOMA, FIBROADENOMA; HEMATOPOIETIC SYSTEM: LYMPHOMA OR LEUKEMIA; LIVER: CHOLANGIOMA, ADENOMA; ADRENAL GLAND: CORTICAL ADENOMA; THYROID GLAND: FOLLICULAR CARCINOMA, FOLLICULAR ADENOMA",POSITIVE,"[KOMULAINEN,H, KOSMA,VM, VAITTINEN,SL, VARTIAINEN,T, KALISTE-KORHONEN,E, LOTJONEN,S, TUOMINEN,RK AND TUOMISTO,J; CARCINOGENICITY OF THE DRINKING WATER MUTAGEN 3-CHLORO-4-(DICHLOROMETHYL)-5-HYDROXY-2(5H)-FURANONE IN THE RAT; J. NATL. CANCER INST. 89(12):848-856, 1997]"
3959,363899070,13643,CN(CC1=CC=CC=C1)N=O,Active,,,,MOUSE,"CD-1/MALE, FEMALE",INTRAPERITONEAL,0; 4 MG/KG 2/WK FOR 12 WK; 8 MG/KG 2/WK FOR 6 WK; 16 MG/KG 2/WK FOR 3 WK FOR TOTAL DOSES OF 96 MG/KG (STUDY DURATION: 40 WK),"FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[SCHNEIDER,P, HINRICHS,S, ZULIM,R, TOWERY,R, MORRIS,C AND MIRVISH,SS; CARCINOGENESIS BY METHYLBENZYLNITROSAMINE NEAR THE SQUAMOCOLUMNAR JUNCTION AND METHYLAMYLNITROSAMINE METABOLISM IN THE MOUSE FORESTOMACH; CANCER LETT. 102(1,2):125-131, 1996]"
3960,363899070,13643,CN(CC1=CC=CC=C1)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 0.5; 2 MG/KG IN SALINE ONCE ADMINISTERED TO RATS MAINTAINED ON ZINC-DEFICIENT DIET (STUDY DURATION: 14 WK),ESOPHAGUS: TUMOR,POSITIVE,"[FONG,LYY, LAU,KM, HUEBNER,K AND MAGEE,PN; INDUCTION OF ESOPHAGEAL TUMORS IN ZINC-DEFICIENT RATS BY SINGLE LOW DOSES OF N-NITROSOMETHYLBENZYLAMINE (NMBA): ANALYSIS OF CELL PROLIFERATION, AND MUTATIONS IN H-RAS AND P53 GENES; CARCINOGENESIS 18(8):1477-1484, 1997]"
3961,363899072,23471,CCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 2.5; 5 MG/KG 1/WK FOR 23-30 WK (TOTAL DOSE: 0; 0.65; 1.0 MMOL) (STUDY DURATION: LIFETIME),"LIVER: HEPATOCELLULAR ADENOMA, HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIAL ADENOMA; NASAL MUCOSA: CARCINOMA, ADENOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
3962,363899072,23471,CCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 2.5; 5 MG/KG 1/WK FOR 23-30 WK (TOTAL DOSE: 0; 0.65; 1.0 MMOL) (STUDY DURATION: LIFETIME),"LIVER: HEPATOCELLULAR ADENOMA; LUNG: ALVEOLAR/BRONCHIAL ADENOMA; NASAL MUCOSA: CARCINOMA, ADENOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
3963,363899072,23471,CCCCN(C)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 3 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 17 WK (TOTAL DOSE 0.9 MMOL) (STUDY DURATION: LIFESPAN),ESOPHAGUS: TUMOR; LIVER: HEMANGIOSARCOMA,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
3964,363899082,41320,CCCCCCCCCCCCN(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,60 MG/ML IN CORN OIL 2/WK FOR 30 WK; STUDY DURATION: 112 WK,LUNG: ADENOCARCINOMA; FORESTOMACH: CARCINOMA; BLADDER,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; INDUCTION OF CARCINOGENESIS IN FISCHER RATS BY METHYLALKYLNITROSAMINES; CANCER RES. 41(4):1288-1292, 1981]"
3965,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Inactive,,,,MOUSE,STRAIN-A/MALE,TRANSPLACENTAL,"0; 100 MG/KG (0.5 MMOL) IN 0.9% STERILE SALINE ADMINISTERED INTRAPERITONEALLY ON DAYS 14, 16 AND 18 OF GESTATION (STUDY DURATION: 24 WK OF AGE)",,NEGATIVE,"[ANDERSON,LM, HECHT,SS, DIXON,DE, DOVE,LF, KOVATCH,RM, AMIN,S, HOFFMANN,D AND RICE,JM;EVALUATION OF THE TRANSPLACENTAL TUMORIGENICITY OF THE TOBACCO-SPECIFIC CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE IN MICE; CANCER RES. 49(14):3770-3775, 1989]"
3966,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,TRANSPLACENTAL,"0; 100 MG/KG (0.5 MMOL) IN 0.9% STERILE SALINE ADMINISTERED INTRAPERITONEALLY ON DAYS 14, 16 AND 18 OF GESTATION (STUDY DURATION: 24 WK OF AGE)",LUNG: TUMOR,POSITIVE,"[ANDERSON,LM, HECHT,SS, DIXON,DE, DOVE,LF, KOVATCH,RM, AMIN,S, HOFFMANN,D AND RICE,JM;EVALUATION OF THE TRANSPLACENTAL TUMORIGENICITY OF THE TOBACCO-SPECIFIC CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE IN MICE; CANCER RES. 49(14):3770-3775, 1989]"
3967,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,MOUSE,C3B6F1/MALE,TRANSPLACENTAL,"0; 100 MG/KG (0.5 MMOL) IN 0.9% STERILE SALINE ADMINISTERED INTRAPERITONEALLY ON DAYS 14, 16 AND 18 OF GESTATION (STUDY DURATION: 72 WK OF AGE)",LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[ANDERSON,LM, HECHT,SS, DIXON,DE, DOVE,LF, KOVATCH,RM, AMIN,S, HOFFMANN,D AND RICE,JM;EVALUATION OF THE TRANSPLACENTAL TUMORIGENICITY OF THE TOBACCO-SPECIFIC CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE IN MICE; CANCER RES. 49(14):3770-3775, 1989]"
3968,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Inactive,,,,MOUSE,C3B6F1/FEMALE,TRANSPLACENTAL,"0; 100 MG/KG (0.5 MMOL) IN 0.9% STERILE SALINE ADMINISTERED INTRAPERITONEALLY ON DAYS 14, 16 AND 18 OF GESTATION (STUDY DURATION: 70 WK)",,NEGATIVE,"[ANDERSON,LM, HECHT,SS, DIXON,DE, DOVE,LF, KOVATCH,RM, AMIN,S, HOFFMANN,D AND RICE,JM;EVALUATION OF THE TRANSPLACENTAL TUMORIGENICITY OF THE TOBACCO-SPECIFIC CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE IN MICE; CANCER RES. 49(14):3770-3775, 1989]"
3969,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Inactive,,,,MOUSE,SWISS/MALE,TRANSPLACENTAL,"0; 100 MG/KG (0.5 MMOL) IN 0.9% STERILE SALINE ADMINISTERED INTRAPERITONEALLY ON DAYS 15, 17 AND 19 OF GESTATION (STUDY DURATION: 72 WK OF AGE)",,NEGATIVE,"[ANDERSON,LM, HECHT,SS, DIXON,DE, DOVE,LF, KOVATCH,RM, AMIN,S, HOFFMANN,D AND RICE,JM;EVALUATION OF THE TRANSPLACENTAL TUMORIGENICITY OF THE TOBACCO-SPECIFIC CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE IN MICE; CANCER RES. 49(14):3770-3775, 1989]"
3970,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Inactive,,,,MOUSE,SWISS/FEMALE,TRANSPLACENTAL,"0; 100 MG/KG (0.5 MMOL) IN 0.9% STERILE SALINE ADMINISTERED INTRAPERITONEALLY ON DAYS 15, 17 AND 19 OF GESTATION (STUDY DURATION: 72 WK OF AGE)",,NEGATIVE,"[ANDERSON,LM, HECHT,SS, DIXON,DE, DOVE,LF, KOVATCH,RM, AMIN,S, HOFFMANN,D AND RICE,JM;EVALUATION OF THE TRANSPLACENTAL TUMORIGENICITY OF THE TOBACCO-SPECIFIC CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE IN MICE; CANCER RES. 49(14):3770-3775, 1989]"
3971,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,MOUSE,C3H/HE/FEMALE,INTRAPERITONEAL,"0; 100 MG/KG (0.5 MMOL) IN 0.9% STERILE SALINE ONCE ON DAYS 14, 16 AND 18 OF PREGNANCY (STUDY DURATION: 24 WK)",LUNG: TUMOR,POSITIVE,"[ANDERSON,LM, HECHT,SS, DIXON,DE, DOVE,LF, KOVATCH,RM, AMIN,S, HOFFMANN,D AND RICE,JM;EVALUATION OF THE TRANSPLACENTAL TUMORIGENICITY OF THE TOBACCO-SPECIFIC CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE IN MICE; CANCER RES. 49(14):3770-3775, 1989]"
3972,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 20 UMOL MOUSE (TOTAL DOSE) ADMINISTERED IN 0.1 ML SALINE 3/WK (TOTAL 20 INJECTIONS) (STUDY DURATION: 37 WK),"LUNG: ADENOCARCINOMA, ADENOMA",POSITIVE,"[RIVENSON,A, DJORDJEVIC,MV, AMIN,S AND HOFFMANN,R; A STUDY OF TOBACCO CARCINOGENESIS. XLIV. BIOASSAY IN A/J MICE OF SOME N-NITROSAMINES; CANCER LETT. 47(1-2):111-114, 1989]"
3973,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 50 MG/KG IN STERILE SALINE ADMINISTERED ON POSTNATAL D 1, 3, 5, 7 AND 10 (STUDY DURATION: 15 MO)",LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: TUMOR,POSITIVE,"[ANDERSON,LM, HECHT,SS, KOVATCH,RM, AMIN,S, HOFFMANN,D AND RICE,JM; TUMORIGENICIT OF THE TOBACCO-SPECIFIC CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1- BUTANONE IN INFANT MICE; CANCER LETT. 58(3):177-181, 1991]"
3974,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 50 MG/KG IN STERILE SALINE ADMINISTERED ON POSTNATAL D 1, 3, 5, 7 AND 10 (STUDY DURATION: 15 MO)",LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: TUMOR,POSITIVE,"[ANDERSON,LM, HECHT,SS, KOVATCH,RM, AMIN,S, HOFFMANN,D AND RICE,JM; TUMORIGENICIT OF THE TOBACCO-SPECIFIC CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1- BUTANONE IN INFANT MICE; CANCER LETT. 58(3):177-181, 1991]"
3975,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 5.5 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 30 WK (TOTAL DOSE 1.5 MMOL) (STUDY DURATION: LIFESPAN),LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
3976,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,RAT,F344/MALE,MUCOUS MEMBRANE,0; 0.3 ML OF A 15 MMOL WATER SOLUTION 1/D 3 D/WK FOR 1 WK THEN 1/D 5 D/WK FOR WK 2-4 THEN 2/D 5 D/WK FOR WK 5-61 (STUDY DURATION: 61 WK),"LUNG: ADENOSQUAMOUS CARCINOMA, ADENOCARCINOMA, ADENOMA; NASAL CAVITY: CARCINOMA, PAPILLOMA, ADENOMA; ORAL CAVITY: PAPILLOMA; LIVER: CARCINOMA, ADENOMA",POSITIVE,"[PROKOPCZYK,B, RIVENSON,A AND HOFFMANN,D; A STUDY OF BETEL QUID CARCINOGENESIS. IX. COMPARATIVE CARCINOGENICITY OF 3-(METHYLNITROSAMINO)PROPIONITRILE AND 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE UPON LOCAL APPLICATION TO MOUSE SKIN AND RAT ORAL MUCOSA; CANCER LETT. 60(2):153-157, 1991]"
3977,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 11 MG/WK FOR A TOTAL DOSE OF 1.3 MMOL (STUDY DYRATION: 50 WK),LIVER: TUMOR; LUNG: TUMOR; NASAL MUCOSA: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
3978,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 1; 3; 9 MMOL/KG BW (TOTAL DOSE) WITH SUBDOSES GIVEN 3/WK FOR 20 WK WITH A 2 WK INTERRUPTION AFTER 7 WK (STUDY DURATION: LIFE SPAN),NASAL CAVITY: TUMORS; LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[HOFFMANN,D, RIVENSON,A, AMIN,S AND HECHT,SS; DOSE-RESPONSE STUDY OF THE CARCINOGENICITY OF TOBACCO-SPECIFIC N-NITROSAMINES IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 108(1):81-86, 1984]"
3979,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,0; 1; 3; 9 MMOL/KG BW (TOTAL DOSE) WITH SUBDOSES GIVEN 3/WK FOR 20 WK WITH A 2 WK INTERRUPTION AFTER 7 WK (STUDY DURATION: LIFE SPAN),NASAL CAVITY: TUMORS; LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[HOFFMANN,D, RIVENSON,A, AMIN,S AND HECHT,SS; DOSE-RESPONSE STUDY OF THE CARCINOGENICITY OF TOBACCO-SPECIFIC N-NITROSAMINES IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 108(1):81-86, 1984]"
3980,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,TRANSPLACENTAL,0; 50 MG/KG IN DISTILLED WATER ADMINISTERED INTRATRACHEALLY TO MOTHERS ON DAY 15 OF GESTATION (STUDY DURATION: 48 WK),NASAL CAVITY: TUMOR,POSITIVE,"[SCHULLER,HM, JORQUERA,R, REICHERT,A AND CASTONGUAY,A; TRANSPLACENTAL INDUCTION OF PANCREAS TUMORS IN HAMSTERS BY ETHANOL AND THE TOBACCO-SPECIFIC NITROSAMINE 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; CANCER RES. 53(11):2498-2501, 1993]"
3981,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,TRANSPLACENTAL,0; 50 MG/KG IN DISTILLED WATER ADMINISTERED INTRATRACHEALLY TO MOTHERS ON DAY 15 OF GESTATION (STUDY DURATION: 48 WK),ADRENAL GLAND: TUMOR; COLON: TUMOR; LYMPHOID TISSUE: LYMPHOMA,POSITIVE,"[SCHULLER,HM, JORQUERA,R, REICHERT,A AND CASTONGUAY,A; TRANSPLACENTAL INDUCTION OF PANCREAS TUMORS IN HAMSTERS BY ETHANOL AND THE TOBACCO-SPECIFIC NITROSAMINE 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; CANCER RES. 53(11):2498-2501, 1993]"
3982,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 5; 20 UMOL TOTAL DOSE ADMINISTERED IN SUBDOSES 3/WK FOR 7 WK (STUDY DURATION: 37 WK),LUNG: TUMOR,POSITIVE,"[HOFFMANN,D, DJORDJEVIC,MV, RIVENSON,A, ZANG,E, DESAI,D AND AMIN,S; A STUDY OF TOBACCO CARCINOGENESIS. LI. RELATIVE POTENCIES OF TOBACCO-SPECIFIC N-NITROSAMINES AS INDUCERS OF LUNG TUMORS IN A/J MICE; CANCER LETT. 71(1-3): 25-30, 1993]"
3983,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 1; 5; 10; 20 MG/KG ONCE ADMINISTERED TO MOTHERS ON DAY 15 OF GESTATION (STUDY DURATION: 59 WK),NASAL CAVITY: ADENOCARCINOMA; ADRENAL GLAND: TUMOR,POSITIVE,"[SCHULLER,HM, JORQUERA,R, LU,X, RIECHERT,A AND CASTONGUAY,A; TRANSPLACENTAL CARCINOGENICITY OF LOW DOSES OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE ADMINISTERED SUBCUTANEOUSLY OR INTRATRACHEALLY TO HAMSTERS; J. CANCER RES. CLIN. ONCOL. 120(4):200-203, 1994]"
3984,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 1; 5; 10; 20 MG/KG ONCE ADMINISTERED TO MOTHERS ON DAY 15 OF GESTATION (STUDY DURATION: 59 WK),NASAL CAVITY: ADENOCARCINOMA; ADRENAL GLAND: TUMOR,POSITIVE,"[SCHULLER,HM, JORQUERA,R, LU,X, RIECHERT,A AND CASTONGUAY,A; TRANSPLACENTAL CARCINOGENICITY OF LOW DOSES OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE ADMINISTERED SUBCUTANEOUSLY OR INTRATRACHEALLY TO HAMSTERS; J. CANCER RES. CLIN. ONCOL. 120(4):200-203, 1994]"
3985,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRATRACHEAL,0; 0.05; 5; 50 MG/KG ONCE ADMINISTERED TO MOTHERS ON DAY 15 OF GESTATION (STUDY DURATION: 59 WK),NASAL CAVITY: ADENOCARCINOMA; ADRENAL GLAND: TUMOR,POSITIVE,"[SCHULLER,HM, JORQUERA,R, LU,X, RIECHERT,A AND CASTONGUAY,A; TRANSPLACENTAL CARCINOGENICITY OF LOW DOSES OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE ADMINISTERED SUBCUTANEOUSLY OR INTRATRACHEALLY TO HAMSTERS; J. CANCER RES. CLIN. ONCOL. 120(4):200-203, 1994]"
3986,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,INTRATRACHEAL,0; 0.05; 5; 50 MG/KG ONCE ADMINISTERED TO MOTHERS ON DAY 15 OF GESTATION (STUDY DURATION: 59 WK),NASAL CAVITY: ADENOCARCINOMA; ADRENAL GLAND: TUMOR; PANCREAS: ADENOMA,POSITIVE,"[SCHULLER,HM, JORQUERA,R, LU,X, RIECHERT,A AND CASTONGUAY,A; TRANSPLACENTAL CARCINOGENICITY OF LOW DOSES OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE ADMINISTERED SUBCUTANEOUSLY OR INTRATRACHEALLY TO HAMSTERS; J. CANCER RES. CLIN. ONCOL. 120(4):200-203, 1994]"
3987,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,GAVAGE,0; 1; 2; 3 UMOL IN 0.1 ML COTTONSEED OIL 1/WK FOR 8 WK (STUDY DURATION: 26 WK),LUNG: ADENOMA,POSITIVE,"[HECHT,SS, ISAACS,S AND THRUSHIN,N; LUNG TUMOR INDUCTION IN A/J MICE BY THE TOBACCO SMOKE CARCINOGENS 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE AND BENZO[A]PYRENE: A POTENTIALLY USEFUL MODEL FOR EVALUATION OF CHEMOPREVENTIVE AGENTS; CARCINOGENESIS 15(12):2721-2725, 1994]"
3988,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 1; 2; 3 UMOL IN 0.1 ML COTTONSEED OIL 1/WK FOR 8 WK (STUDY DURATION: 26 WK),LUNG: ADENOMA,POSITIVE,"[HECHT,SS, ISAACS,S AND THRUSHIN,N; LUNG TUMOR INDUCTION IN A/J MICE BY THE TOBACCO SMOKE CARCINOGENS 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE AND BENZO[A]PYRENE: A POTENTIALLY USEFUL MODEL FOR EVALUATION OF CHEMOPREVENTIVE AGENTS; CARCINOGENESIS 15(12):2721-2725, 1994]"
3989,363899100,47289,CN(CCCC(=O)C1=CN=CC=C1)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 0.5; 1; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (TOTAL DOSE: 0; 0.073; 0.17; 0.68 MMOL/KG) (STUDY DURATION: 128 WK),"NASAL CAVITY: TUMOR; LIVER: ADENOMA, HEPATOMA; LUNG: ADENOMA, ADENOCARCINOMA, ADENOSQUAMOUS CARCINOMA, SQUAMOUS CELL CARCINOMA; EXOCRINE PANCREAS: ACINAR ADENOMA",POSITIVE,"[RIVENSON,A, HOFFMANN,D, PROKOPCZYK,B, AMIN,S AND HECHT,SS; INDUCTION OF LUNG AND EXOCRINE PANCREAS TUMORS IN F344 RATS BY TOBACCO-SPECIFIC AND ARECA-DERIVED N-NITROSAMINES; CANCER RES. 48(23):6912-6917, 1988]"
3990,363899101,27826,CN1CCN(CC1)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 2.4 PPM 14.5 HR/D FOR 74 D OVER 7.5 MONTHS (STUDY DURATION: 350 D),NASAL CAVITY: TUMOR,POSITIVE,"[KLEIN,RG, SCHMEZER,P, HERMANN,R, WASS,P, SPIEGELHALDER,B AND BARTSCH,H; STRONG NASAL CARCINOGENICITY AND GENOTOXICITY OF 1-NITROSO-4-METHYLPIPERAZINE AFTER LOW DOSE INHALATION IN RATS; CARCINOGENESIS 20(8):1629-1631, 1999]"
3991,363899113,14802,O=[Mo](=O)=O,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 10; 30; 100 MG/M3 6 HR/D 5 D/WK FOR 106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-462 Y97]"
3992,363899113,14802,O=[Mo](=O)=O,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 10; 30; 100 MG/M3 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-462 Y97]"
3993,363899113,14802,O=[Mo](=O)=O,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 10; 30; 100 MG/M3 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-462 Y97]"
3994,363899113,14802,O=[Mo](=O)=O,Unspecified,,,,RAT,F344/MALE,INHALATION,0; 10; 30; 100 MG/M3 6 HR/D 5 D/WK FOR 106 WK (STUDY DURATION: 106 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-462 Y97]"
3995,363899132,12962,CN(C=O)N,Active,,,,MOUSE,SWISS/MALE,ORAL,0; 0.0078% SOLUTION IN DRINKING WATER STARTING AT 6 WK OF AGE FOR LIFE FOR AVERAGE DAILY INTAKE OF 0 OR 0.99 MG (STUDY DURATION: 130 WK),LIVER: HEPATOMA OR CARCINOMA; LUNG: ADENOMA OR ADENOCARCINOMA; GALLBLADDER: ADENOMA; BILE DUCT: CHOLANGIOMA OR CHOLANGIOCARCINOMA,POSITIVE,"[TOTH,B AND NAGEL,D; TUMORS INDUCED IN MICE BY N-METHYL-N-FORMYLHYDRAZINE OF THE FALSE MOREL GYROMITRA ESCULENTA; J. NATL. CANCER INST. 60(1):201-204, 1978]"
3996,363899132,12962,CN(C=O)N,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 0.0078% SOLUTION IN DRINKING WATER STARTING AT 6 WK OF AGE FOR LIFE FOR AVERAGE DAILY INTAKE OF 0 OR 0.80 MG (STUDY DURATION: 130 WK),LIVER: HEPATOMA OR CARCINOMA; LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[TOTH,B AND NAGEL,D; TUMORS INDUCED IN MICE BY N-METHYL-N-FORMYLHYDRAZINE OF THE FALSE MOREL GYROMITRA ESCULENTA; J. NATL. CANCER INST. 60(1):201-204, 1978]"
3997,363899134,7475,C1=CC(=CC=C1N)[N+](=O)[O-],Inactive,,,,RAT,"STRAIN CD/MALE, FEMALE",GAVAGE,0; 0.25; 1.5; 9 MG/KG IN CORN OIL 1/D 7 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[NAIR,RS, AULETTA,CS, SCHROEDER,RE AND JOHANNSEN,FR; CHRONIC TOXICITY, ONCOGENIC POTENTIAL, AND REPRODUCTIVE TOXICITY OF P-NITROANILINE IN RATS; FUNDAM. APPL. TOXICOL. 15(3):607-621, 1990]"
3998,363899134,7475,C1=CC(=CC=C1N)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 3; 30; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-418 Y93]"
3999,363899134,7475,C1=CC(=CC=C1N)[N+](=O)[O-],Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 3; 30; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),LIVER: HEMANGIOSARCOMA; ALL ORGANS: HEMANGIOMA OR HEMANGIOSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-418 Y93]"
4000,363899135,6108,C1=CC(=CC=C1C(=O)O)[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-442 Y94]"
4001,363899135,6108,C1=CC(=CC=C1C(=O)O)[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),"CLITORAL GLAND: ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-442 Y94]"
4002,363899135,6108,C1=CC(=CC=C1C(=O)O)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-442 Y94]"
4003,363899135,6108,C1=CC(=CC=C1C(=O)O)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-442 Y94]"
4004,363899139,11831,C1C2=CC=CC=C2C3=C1C=C(C=C3)[N+](=O)[O-],Active,,,,RAT,WISTAR/MALE,ORAL,0; 0.24; 0.95; 2.37 MMOL/KG DIET FOR 11 MO FOLLOWED BY BASAL DIET FOR 13 MO (STUDY DURATION: 24 MO),LIVER: HEPATOCELLULAR CARCINOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA; KIDNEY: CARCINOMA,POSITIVE,"[CUI,XS, TORNDAL,UB, ERIKSSON,LC AND MOELLER,L; EARLY FORMATION OF DNA ADDUCTS COMPARED WITH TUMOR FORMATION IN A LONG-TERM TUMOR STUDY IN RATS AFTER ADMINISTRATION OF 2-NITROFLUORENE; CARCINOGENESIS 16(9): 2135-2141, 1995]"
4005,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 1300; 2500 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),"KIDNEY: TUBULAR ADENOMA OR CARCINOMA; SUBCUTANEOUS TISSUE: FIBROMA, FIBROMA OR FIBROSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-341 Y89]"
4006,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 600; 1300 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-341 Y89]"
4007,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1300; 2500 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-341 Y89]"
4008,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1300; 2500 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),"OVARY: TUBULAR ADENOMA, MIXED TUMOR (BENIGN)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-341 Y89]"
4009,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,RAT,STRAIN-CD/MALE,ORAL,0; 12; 24; 48 MG/KG BW IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BUTLER,WH, GRAHAM,TC AND SUTTON,ML; CHRONIC TOXICITY AND ONCOGENICITY STUDIES OF MACRODANTIN IN SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 28(4):269-77, 1990]"
4010,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 12; 24; 48 MG/KG BW IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BUTLER,WH, GRAHAM,TC AND SUTTON,ML; CHRONIC TOXICITY AND ONCOGENICITY STUDIES OF MACRODANTIN IN SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 28(4):269-77, 1990]"
4011,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 0.03% IN DIET FOR 441 D; THEN 0.04% IN DIET FOR DURATION OF STUDY (TOTAL AVERAGE DOSE: 58.76 MG/KG) (STUDY DURATION: 22 MO),,NEGATIVE,"[BUTLER,WH, GRAHAM,TC AND SUTTON,ML; ONCOGENICITY STUDY OF MACRODANTIN IN SWISS MICE; FOOD CHEM. TOXICOL. 28(1):49-54, 1990]"
4012,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 0.03% IN DIET FOR 441 D; THEN 0.04% IN DIET FOR DURATION OF STUDY (TOTAL AVERAGE DOSE: 43.63 MG/KG) (STUDY DURATION: 22 MO),,NEGATIVE,"[BUTLER,WH, GRAHAM,TC AND SUTTON,ML; ONCOGENICITY STUDY OF MACRODANTIN IN SWISS MICE; FOOD CHEM. TOXICOL. 28(1):49-54, 1990]"
4013,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 0.06% IN DIET FOR 441 D; THEN 0.075% IN DIET FOR DURATION OF STUDY (TOTAL AVERAGE DOSE: 83.59 MG/KG) (STUDY DURATION: 22 MO),,NEGATIVE,"[BUTLER,WH, GRAHAM,TC AND SUTTON,ML; ONCOGENICITY STUDY OF MACRODANTIN IN SWISS MICE; FOOD CHEM. TOXICOL. 28(1):49-54, 1990]"
4014,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 0.06% IN DIET FOR 441 D; THEN 0.075% IN DIET FOR DURATION OF STUDY (TOTAL AVERAGE DOSE: 115.59 MG/KG) (STUDY DURATION: 22 MO),,NEGATIVE,"[BUTLER,WH, GRAHAM,TC AND SUTTON,ML; ONCOGENICITY STUDY OF MACRODANTIN IN SWISS MICE; FOOD CHEM. TOXICOL. 28(1):49-54, 1990]"
4015,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 0.13% IN DIET FOR 441 D; THEN 0.155% IN DIET FOR DURATION OF STUDY (TOTAL AVERAGE DOSE: 224.07 MG/KG) (STUDY DURATION: 22 MO),,NEGATIVE,"[BUTLER,WH, GRAHAM,TC AND SUTTON,ML; ONCOGENICITY STUDY OF MACRODANTIN IN SWISS MICE; FOOD CHEM. TOXICOL. 28(1):49-54, 1990]"
4016,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Active,,,,MOUSE,SWISS/MALE,ORAL,0; 0.13% IN DIET FOR 441 D; THEN 0.155% IN DIET FOR DURATION OF STUDY (TOTAL AVERAGE DOSE: 181.14 MG/KG) (STUDY DURATION: 22 MO),HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA,POSITIVE,"[BUTLER,WH, GRAHAM,TC AND SUTTON,ML; ONCOGENICITY STUDY OF MACRODANTIN IN SWISS MICE; FOOD CHEM. TOXICOL. 28(1):49-54, 1990]"
4017,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,ORAL,0; 0.187% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HASEGAWA,R, MURASAKI,G, ST. JOHN,MK, ZENSER,TV AND COHEN,SM; EVALUATION OF NITROFURANTOIN ON THE TWO STAGES OF URINARY BLADDER CARCINOGENESIS IN THE RAT; TOXICOLOGY 62(3):333-347, 1990]"
4018,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.188% IN DIET FOR 2 YR (STUDY DURATION: 2 YR),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[WANG,CY, CROFT,WA AND BRYAN,GT; TUMOR PRODUCTION IN GERM-FREE RATS FED 5-NITROFURANS; CANCER LETT. 21:303-308, 1984]"
4019,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,MOUSE,BDF1/MALE,ORAL,0; 0.075; 0.3% IN DIET BEGINNING AT 9 WK OF AGE AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[ITO,A, NAITO,M, NAITO,Y AND WATANABE,H; TUMORIGENICITY TEST OF N-(5-NITRO-2-FURFURYLIDINE)-1-AMINOHYDANTOIN BY DIETARY ADMINISTRATION IN BDF1 MICE; HIROSHIMA J. MED. SCI. 32:99-102, 1983]"
4020,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Inactive,,,,MOUSE,BDF1/FEMALE,ORAL,0; 0.075; 0.3% IN DIET BEGINNING AT 9 WK OF AGE AND CONTINUING FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[ITO,A, NAITO,M, NAITO,Y AND WATANABE,H; TUMORIGENICITY TEST OF N-(5-NITRO-2-FURFURYLIDINE)-1-AMINOHYDANTOIN BY DIETARY ADMINISTRATION IN BDF1 MICE; HIROSHIMA J. MED. SCI. 32:99-102, 1983]"
4021,363899142,6604200,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],Active,,,,MOUSE,"ICR/MALE, FEMALE",TRANSPLACENTAL,"0; 75 UG/G ADMINISTERED SUBCUTANEOUSLY TO MOTHERS ON DAYS 13, 15 AND 17 OF GESTATION (STUDY DURATION: 33 WK)",LUNG: PAPILLARY ADENOMA,POSITIVE,"[NOMURA,T, KIMURA,S, KANZAKI,T, TANAKA,H, SHIBATA,K, NAKAJIMA,H, ISA,T, KUROKAWA,N, HATANAKA,T, KINUTA,M, MASADA,K AND SAKAMOTO,Y; INDUCTION OF TUMORS AND MALFORMATIONS IN MICE AFTER PRENATAL TREATMENT WITH SOME ANTIBIOTIC DRUGS; MED. J. OSAKA UNIV. 35:13-17, 1984]"
4022,363899145,5447130,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 150; 310 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-337 Y88]"
4023,363899145,5447130,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 150; 310 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),"OVARY: GRANULOSA CELL TUMOR; OVARY: GRANULOSA CELL TUMOR OR LUTEOMA;OVARY: MIXED TUMOR,BENIGN; OVARY: TUBULAR CELL ADENOMA OR MIXED TUMOR,BENIGN",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-337 Y88]"
4024,363899145,5447130,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 310; 620 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-337 Y88]"
4025,363899145,5447130,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N,Active,,,,RAT,F344 INBRED/FEMALE,ORAL,0; 310; 620 PPM IN DIET (STUDY DURATION: 2 YR),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[KARI,FW, HUFF,JE, LEININGER,J, HASEMAN,JK AND EUSTIS,SL; TOXICITY AND CARCINOGENICITY OF NITROFURAZONE IN F344/N RATS AND B6C3F1 MICE; FOOD CHEM. TOXICOL. 27(2):129-137, 1989]"
4026,363899145,5447130,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 150; 310 PPM IN DIET (STUDY DURATION: 2 YR),,NEGATIVE,"[KARI,FW, HUFF,JE, LEININGER,J, HASEMAN,JK AND EUSTIS,SL; TOXICITY AND CARCINOGENICITY OF NITROFURAZONE IN F344/N RATS AND B6C3F1 MICE; FOOD CHEM. TOXICOL. 27(2):129-137, 1989]"
4027,363899145,5447130,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 150; 310 PPM IN DIET (STUDY DURATION: 2 YR),OVARIES: GRANULOSA CELL TUMOR,POSITIVE,"[KARI,FW, HUFF,JE, LEININGER,J, HASEMAN,JK AND EUSTIS,SL; TOXICITY AND CARCINOGENICITY OF NITROFURAZONE IN F344/N RATS AND B6C3F1 MICE; FOOD CHEM. TOXICOL. 27(2):129-137, 1989]"
4028,363899145,5447130,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N,Active,,,,MOUSE,"ICR/MALE, FEMALE",SUBCUTANEOUS,"0; 75 UG/G ONCE WITHIN 12 HR OF BIRTH AND ONCE ON DAYS 7,14 AND 21 OF AGE (STUDY DURATION: 32 WK)",LUNG: PAPILLARY ADENOMA,POSITIVE,"[NOMURA,T, KIMURA,S, KANZAKI,T, TANAKA,H, SHIBATA,K, NAKAJIMA,H, ISA,T, KUROKAWA,N, HATANAKA,T, KINUTA,M, MASADA,K AND SAKAMOTO,Y; INDUCTION OF TUMORS AND MALFORMATIONS IN MICE AFTER PRENATAL TREATMENT WITH SOME ANTIBIOTIC DRUGS; MED. J. OSAKA UNIV. 35:13-17, 1984]"
4029,363899145,5447130,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N,Inactive,,,,MOUSE,"ICR/MALE, FEMALE",TRANSPLACENTAL,"0; 75 UG/G ADMINISTERED SUBCUTANEOUSLY TO MOTHERS ON DAYS 13, 15 AND 17 OF GESTATION (STUDY DURATION: 33 WK)",,NEGATIVE,"[NOMURA,T, KIMURA,S, KANZAKI,T, TANAKA,H, SHIBATA,K, NAKAJIMA,H, ISA,T, KUROKAWA,N, HATANAKA,T, KINUTA,M, MASADA,K AND SAKAMOTO,Y; INDUCTION OF TUMORS AND MALFORMATIONS IN MICE AFTER PRENATAL TREATMENT WITH SOME ANTIBIOTIC DRUGS; MED. J. OSAKA UNIV. 35:13-17, 1984]"
4030,363899145,5447130,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N,Unspecified,,,,RAT,F344/MALE,ORAL,0; 310; 620 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),"SEBACEOUS GLAND: ADENOMA; SKIN: TRICHOEPITHELIOMA; TUNICA VAGINALIS: MESOTHELIOMA; PREPUTIAL GLAND: ADENOMA, CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-337 Y88]"
4031,363899151,107987,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC=N2,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 1540 PPM IN DIET FOR 46 WK (TOTAL DOSE: 42 MMOL/RAT) (STUDY DURATION: 68 WK),MAMMARY GLAND: FIBROADENOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[SWAMINATHAN,S, ERTURK,E AND BRYAN,GT; MUTAGENICITY, CARCINOGENICITY, DISTRIBUTION, AND NITROREDUCTION OF 4-(5-NITRO-2-FURYL)THIAZOLE IN THE RAT; CANCER RES. 41(7):2648-2653, 1981]"
4032,363899154,25113282,CC1=C2C(=CC(=C1C(=O)O)O)C(=O)C3=C(C2=O)C(=C(C(=C3O)O)[C@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)CO)O)O)O)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 50; 150; 500 MG/KG/D IN BASAL DIET TO PUPS OF PARENTS GIVEN THE SAME DIETARY DOSE LEVELS FOR 60 D PRIOR TO MATING AND CONTINUED THROUGHOUT PREGNANCY (STUDY DURATION: 107 WK),,NEGATIVE,"[FORD,GP, GOPAL,T, GRANT,D, GAUNT,IF, EVANS,JG AND BUTLER,WH; CHRONIC TOXICITY/ CARCINOGENICITY STUDY OF CARMINE OF COCHINEAL IN THE RAT; FOOD CHEM. TOXICOL. 25(12):897-902, 1987]"
4033,363899154,25113282,CC1=C2C(=CC(=C1C(=O)O)O)C(=O)C3=C(C2=O)C(=C(C(=C3O)O)[C@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)CO)O)O)O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 50; 150; 500 MG/KG/D IN BASAL DIET TO PUPS OF PARENTS GIVEN THE SAME DIETARY DOSE LEVELS FOR 60 D PRIOR TO MATING AND CONTINUED THROUGHOUT PREGNANCY (STUDY DURATION: 108 WK),,NEGATIVE,"[FORD,GP, GOPAL,T, GRANT,D, GAUNT,IF, EVANS,JG AND BUTLER,WH; CHRONIC TOXICITY/ CARCINOGENICITY STUDY OF CARMINE OF COCHINEAL IN THE RAT; FOOD CHEM. TOXICOL. 25(12):897-902, 1987]"
4034,363899155,6375,C[N+](=O)[O-],Inactive,,,,RAT,LONG-EVANS/MALE,INHALATION,0; 100; 200 PPM 7 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[GRIFFIN,TB, COULSTON,F AND STEIN,AA; CHRONIC INHALATION EXPOSURE OF RATS TO NITROMETHANE; ECOTOXICOL. ENVIRON. SAF. 34(2):109-117, 1996]"
4035,363899155,6375,C[N+](=O)[O-],Inactive,,,,RAT,LONG-EVANS/FEMALE,INHALATION,0; 100; 200 PPM 7 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[GRIFFIN,TB, COULSTON,F AND STEIN,AA; CHRONIC INHALATION EXPOSURE OF RATS TO NITROMETHANE; ECOTOXICOL. ENVIRON. SAF. 34(2):109-117, 1996]"
4036,363899155,6375,C[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,INHALATION,0; 94; 188; 375 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-461 Y97]"
4037,363899155,6375,C[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,INHALATION,0; 94; 188; 375 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"MAMMARY GLAND: FIBROADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-461 Y97]"
4038,363899155,6375,C[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 188; 375; 750 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"HARDERIAN GLAND: CARCINOMA, ADENOMA; LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-461 Y97]"
4039,363899155,6375,C[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 188; 375; 750 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"HARDERIAN GLAND: ADENOMA; LIVER: HEPATOCELLULAR ADENOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-461 Y97]"
4040,363899155,6375,C[N+](=O)[O-],Inactive,,,,GUPPIE,FEMALE,AQUARIUM WATER,0; 10; 30; 70 MG/L FOR 16 MO (STUDY DURATION: 16 MO),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
4041,363899155,6375,C[N+](=O)[O-],Inactive,,,,MEDAKA,MALE,AQUARIUM WATER,0; 10; 20; 40 MG/L FOR 13 MO (STUDY DURATION: 13 MO),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
4042,363899155,6375,C[N+](=O)[O-],Inactive,,,,MEDAKA,FEMALE,AQUARIUM WATER,0; 10; 20; 40 MG/L FOR 13 MO (STUDY DURATION: 13 MO),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
4043,363899167,23493,CN(C(=O)OC1=CC=CC2=CC=CC=C21)N=O,Active,,,,MOUSE,CFLP/FEMALE,DERMAL,0; 12.5; 50; 200 UG IN ACETONE 2 D/WK FOR 104 WK (STUDY DURATION: 24 MO),SKIN: CARCINOMA,POSITIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G AND MISFELD,J; LOCAL APPLICATION TO MOUSE SKIN AS A CARCINOGEN SPECIFIC TEST SYSTEM FOR NON-VOLATILE NITROSO COMPOUNDS; CANCER LETT. 29:85-92, 1985]"
4044,363899168,12613538,C1C[C@H](N(C1)N=O)C2=CN=CC=C2,Active,,,,HAMSTER,,SUBCUTANEOUS,,TRACHEA,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 281 Y78]"
4045,363899168,12613538,C1C[C@H](N(C1)N=O)C2=CN=CC=C2,Active,,,,MOUSE,,INTRAPERITONEAL,,LUNG,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 281 Y78]"
4046,363899168,12613538,C1C[C@H](N(C1)N=O)C2=CN=CC=C2,Active,,,,RAT,,ORAL,,ESOPHAGUS; NASAL CAVITY,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V17 281 Y78]"
4047,363899168,12613538,C1C[C@H](N(C1)N=O)C2=CN=CC=C2,Inactive,,,,MOUSE,CFLP/FEMALE,DERMAL,0; 12.5; 50; 200 UG IN ACETONE 2 D/WK FOR 104 WK (STUDY DURATION: 24 MO),,NEGATIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H, GRIMMER,G AND MISFELD,J; LOCAL APPLICATION TO MOUSE SKIN AS A CARCINOGEN SPECIFIC TEST SYSTEM FOR NON-VOLATILE NITROSO COMPOUNDS; CANCER LETT. 29:85-92, 1985]"
4048,363899168,12613538,C1C[C@H](N(C1)N=O)C2=CN=CC=C2,Active,,,,MINK,"MALE, FEMALE",SUBCUTANEOUS,0; 11.9 MILLIMOLAR (TOTAL DOSE) GIVEN IN SUBDOSES 2/WK FOR 38 WK (STUDY DURATION: 185 WK),NASAL CAVITY: TUMORS,POSITIVE,"[KOPPANG,N, RIVENSON,A, REITH,A, DAHLE,HK, EVENSEN,O AND HOFFMANN,D; A STUDY OF TOBACCO CARCINOGENESIS. XLVIII. CARCINOGENICITY OF N'-NITROSONORNICOTINE IN MINK (MUSTELA VISON); CARCINOGENESIS 13(11):1957-1960, 1992]"
4049,363899168,12613538,C1C[C@H](N(C1)N=O)C2=CN=CC=C2,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 1; 3; 9 MMOL/KG BW (TOTAL DOSE) WITH SUBDOSES GIVEN 3/WK FOR 20 WK WITH A 2 WK INTERRUPTION AFTER 7 WK (STUDY DURATION: LIFE SPAN),NASAL CAVITY: TUMORS; LUNG: TUMORS; ESOPHAGUS: BENIGN TUMORS,POSITIVE,"[HOFFMANN,D, RIVENSON,A, AMIN,S AND HECHT,SS; DOSE-RESPONSE STUDY OF THE CARCINOGENICITY OF TOBACCO-SPECIFIC N-NITROSAMINES IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 108(1):81-86, 1984]"
4050,363899168,12613538,C1C[C@H](N(C1)N=O)C2=CN=CC=C2,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS,0; 1; 3; 9 MMOL/KG BW (TOTAL DOSE) WITH SUBDOSES GIVEN 3/WK FOR 20 WK WITH A 2 WK INTERRUPTION AFTER 7 WK (STUDY DURATION: LIFE SPAN),NASAL CAVITY: TUMORS; ESOPHAGUS: BENIGN TUMORS,POSITIVE,"[HOFFMANN,D, RIVENSON,A, AMIN,S AND HECHT,SS; DOSE-RESPONSE STUDY OF THE CARCINOGENICITY OF TOBACCO-SPECIFIC N-NITROSAMINES IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 108(1):81-86, 1984]"
4051,363899168,12613538,C1C[C@H](N(C1)N=O)C2=CN=CC=C2,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 40; 200 UMOL TOTAL DOSE ADMINISTERED IN SUBDOSES 3/WK FOR 7 WK (STUDY DURATION: 37 WK),LUNG: TUMOR,POSITIVE,"[HOFFMANN,D, DJORDJEVIC,MV, RIVENSON,A, ZANG,E, DESAI,D AND AMIN,S; A STUDY OF TOBACCO CARCINOGENESIS. LI. RELATIVE POTENCIES OF TOBACCO-SPECIFIC N-NITROSAMINES AS INDUCERS OF LUNG TUMORS IN A/J MICE; CANCER LETT. 71(1-3): 25-30, 1993]"
4052,363899169,11294,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=CC=C3.[Cl-],Unspecified,,,,RAT,F344/N/FEMALE,ORAL (DIET),0; 100; 300; 600 PPM IN DIET FOR 2 YRS,THYROID: FOLLICULAR CELL ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA; MAMMARY GLAND: CARCINOMA,EQUIVOCAL; NONE OF THE TUMOR INCIDENCES REACHED STATISTICAL SIGNIFICANCE; IN SOME CASES THE INCREASES IN TUMORS WERE MINIMAL,"[CULP,SJ; NTP TECHNICAL REPORT ON THE TOXICITY STUDIES OF MALACHITE GREEN CHLORIDE AND LEUCOMALACHITE GREEN (CAS NOS. 569-64-2 AND 129-73-7) ADMINISTERED IN FEED TO F344/N RATS AND B6C3F1 MICE; NATL. TOXICOL. PROG. TOXI. REP. SER. 71:1-5, 7-9, 11-49, A1-A7, B1-B7, C1-C9, D1-D5, E1-E6, F1-F10, 2004]"
4053,363899169,11294,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=CC=C3.[Cl-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL (DIET),0; 100; 225; 450 PPM IN DIET FOR 2 YRS,,NEGATIVE,"[CULP,SJ; NTP TECHNICAL REPORT ON THE TOXICITY STUDIES OF MALACHITE GREEN CHLORIDE AND LEUCOMALACHITE GREEN (CAS NOS. 569-64-2 AND 129-73-7) ADMINISTERED IN FEED TO F344/N RATS AND B6C3F1 MICE; NATL. TOXICOL. PROG. TOXI. REP. SER. 71:1-5, 7-9, 11-49, A1-A7, B1-B7, C1-C9, D1-D5, E1-E6, F1-F10, 2004]"
4054,363899174,6944,CC1=CC=CC=C1[N+](=O)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 625; 1250; 2000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),"MESOTHELIUM: MALIGNANT MESOTHELIOMA; SKIN (SUBCUTANEOUS): LIPOMA, FIBROMA, FIBROSARCOMA, FIBROMA OR FIBROSARCOMA; MAMMARY GLAND: FIBROADENOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-504 Y02]"
4055,363899174,6944,CC1=CC=CC=C1[N+](=O)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 2000; 5000 PPM IN DIET FOR FIRST 3 MO (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA, CHOLANGIOCARCINOMA: LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-504 Y02]"
4056,363899174,6944,CC1=CC=CC=C1[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,ORAL,0; 625; 1250; 2000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),"SKIN (SUBCUTANEOUS): FIBROMA, FIBROMA OR FIBROSARCOMA; MAMMARY GLAND: FIBROADENOMA: LIVER: HEPATOCELLULAR ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-504 Y02]"
4057,363899174,6944,CC1=CC=CC=C1[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),CIRCULATORY SYSTEM: HEMANGIOSARCOMA; LARGE INTESTINE (CECUM): CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-504 Y02]"
4058,363899174,6944,CC1=CC=CC=C1[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),"CIRCULATORY SYSTEM: HEMANGIOSARCOMA; LARGE INTESTINE (CECUM): CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-504 Y02]"
4059,363899183,995,C1=CC=C2C(=C1)C=CC3=CC=CC=C32,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,INTRAPULMONARY IMPLANT,0; 1; 3; 10 MG IN BEESWAX AND TRIOCTANOIN IMPLANTED IN LUNG (STUDY DURATION: 141 WK),,NEGATIVE,"[WENZEL-HARTUNG,R, BRUNE,H, GRIMMER,G, GERMANN,P, TIMM,J AND WOSNIOK,W; EVALUATION OF THE CARCINOGENIC POTENCY OF 4 ENVIRONMENTAL POLYCYCLIC AROMATIC COMPOUNDS FOLLOWING INTRAPULMONARY APPLICATION IN RATS; EXP. PATHOL. 40(4):221-227, 1990]"
4060,363899184,9189,C1=CC=C2C(=C1)C=NC3=CC=CC=C23,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,"0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN 0; 200 UMOL/KG, ONCE (STUDY DURATION: 78 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
4061,363899184,9189,C1=CC=C2C(=C1)C=NC3=CC=CC=C23,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,"0; 200 UMOL/KG IN DMSO INTO SUPRASCAPULAR AREA ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN 0; 200 UMOL/KG, ONCE (STUDY DURATION: 78 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
4062,363899186,7935,C1=CC(=CC(=C1)N)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.02; 0.04% IN THE DRINKING WATER FOR 78 WK; TOTAL INTAKE 10.9; 21.0 G/KG BODY WEIGHT (STUDY DURATION: 85 WK),,NEGATIVE,"[MATSUYAMA,M, AMANO,H, YAMADA,C, KAWAI,M, MIYATA,N AND NAKADATE,M; CARCIOGENICITY AND TOXICITY STUDY OF M-PHENYLENEDIAMINE ADMINISTERED IN THE DRINKING-WATER TO (C57BL/6 X C3H/HE)F1 MICE; FOOD CHEM. TOXICOL. 26(11-12): 893-897, 1988]"
4063,363899186,7935,C1=CC(=CC(=C1)N)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.02; 0.04% IN DRINKING WATER FOR 78 WK; TOTAL INTAKE 13.0; 22.9 G/KG (STUDY DURATION: 85 WK),,NEGATIVE,"[MATSUYAMA,M, AMANO,H, YAMADA,C, KAWAI,M, MIYATA,N AND NAKADATE,M; CARCIOGENICITY AND TOXICITY STUDY OF M-PHENYLENEDIAMINE ADMINISTERED IN THE DRINKING-WATER TO (C57BL/6 X C3H/HE)F1 MICE; FOOD CHEM. TOXICOL. 26(11-12): 893-897, 1988]"
4064,363899206,31423,C1=CC2=C3C(=C1)C=CC4=CC=CC(=C43)C=C2,Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 86.1 UG TOTAL DOSE (12.3 UG/5 UL, 24.6 UG/10 UL, 49.2 UG/20 UL DMSO ON DAYS 1, 8 AND 15); 1750 UG TOTAL DOSE (250 UG/5 UL, 500 UG/10 UL, 1000 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",,NEGATIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
4065,363899206,31423,C1=CC2=C3C(=C1)C=CC4=CC=CC(=C43)C=C2,Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 86.1 UG TOTAL DOSE (12.3 UG/5 UL, 24.6 UG/10 UL, 49.2 UG/20 UL DMSO ON DAYS 1, 8 AND 15); 1750 UG TOTAL DOSE (250 UG/5 UL, 500 UG/10 UL, 1000 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",,NEGATIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
4066,363899206,31423,C1=CC2=C3C(=C1)C=CC4=CC=CC(=C43)C=C2,Inactive,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 10; 50; 100; 200 MG/KG BW ONCE (STUDY DURATION: 8 MO),,NEGATIVE,"[ROSS,JA, NELSON,GB, WILSON,KH, RABINOWITZ,JR, GALATI,A, STONER,GD, NESNOW,S AND MASS,MJ; ADENOMAS INDUCED BY POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MOUSE LUNG CORRELATE WITH TIME-INTEGRATED DNA ADDUCT LEVELS; CANCER RES. 55(5): 1039-1044, 1995]"
4067,363899211,33557,[N-]=[N+]=[N-].[Na+],Inactive,,,,RAT,F344/MALE,GAVAGE,0; 5; 10 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-389 Y91]"
4068,363899211,33557,[N-]=[N+]=[N-].[Na+],Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 5; 10 MG/KG IN DISTILLED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-389 Y91]"
4069,363899217,75230,CC(C)NC(=O)C1=CC=C(C=C1)CN=NC,Active,,,,MOUSE,CDF1/MALE,GAVAGE,0; 300 MG/KG IN 0.01 ML OF 0.5% AQUEOUS SOLUTION OF SODIUM CARBOXYMETHYL CELLULOSE 1/WK FOR 4 WK THEN 0; 400 MG/KG 1/WK FOR 4 WK (STUDY DURATION: 53 WK),PULMONARY SYSTEM: TUMOR; KIDNEY: CYSTADENOMA,POSITIVE,"[KELLY,MG, O'GARA,RW, YANCEY,ST, GADEKAR,K, BOTKIN,C AND OLIVERIO,VT; COMPARATIVE CARCINOGENICITY OF N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HCL (PROCARBAZINE HYDROCHLORIDE), ITS DEGRADATION PRODUCTS, OTHER HYDRAZINES, AND ISONICOTINIC ACID HYDRAZIDE; J. NATL. CANCER INST. 42(2):337-344, 1969]"
4070,363899218,7276,C1C(O1)C2=CC=CC=C2,Active,,,,RAT,F344/MALE,GAVAGE,0; 275; 550 MG/KG IN CORN OIL 3 D/WK FOR 104 WK (STUDY DURATION: 24 MO),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[LIJINSKY,W; RAT AND MOUSE FORESTOMACH TUMORS INDUCED BY CHRONIC ORAL ADMINISTRATION OF STYRENE OXIDE; J. NATL. CANCER INST. 77(2):471-476, 1986]"
4071,363899218,7276,C1C(O1)C2=CC=CC=C2,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 275; 550 MG/KG IN CORN OIL 3 D/WK FOR 104 WK (STUDY DURATION: 24 MO),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[LIJINSKY,W; RAT AND MOUSE FORESTOMACH TUMORS INDUCED BY CHRONIC ORAL ADMINISTRATION OF STYRENE OXIDE; J. NATL. CANCER INST. 77(2):471-476, 1986]"
4072,363899218,7276,C1C(O1)C2=CC=CC=C2,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 3 D/WK FOR UP TO 104 WK (STUDY DURATION: 24 MO),"LIVER: CARCINOMA OR ADENOMA; FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[LIJINSKY,W; RAT AND MOUSE FORESTOMACH TUMORS INDUCED BY CHRONIC ORAL ADMINISTRATION OF STYRENE OXIDE; J. NATL. CANCER INST. 77(2):471-476, 1986]"
4073,363899218,7276,C1C(O1)C2=CC=CC=C2,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 3 D/WK FOR UP TO 104 WK (STUDY DURATION: 24 MO),"FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[LIJINSKY,W; RAT AND MOUSE FORESTOMACH TUMORS INDUCED BY CHRONIC ORAL ADMINISTRATION OF STYRENE OXIDE; J. NATL. CANCER INST. 77(2):471-476, 1986]"
4074,363899218,7276,C1C(O1)C2=CC=CC=C2,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAGASTRIC,"0; 50; 250 MG/KG IN OLIVE OIL 1/D, 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFESPAN","FORESTOMACH: PAPILLOMA OR ACANTHOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
4075,363899218,7276,C1C(O1)C2=CC=CC=C2,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAGASTRIC,"0; 50; 250 MG/KG IN OLIVE OIL 1/D, 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFESPAN","FORESTOMACH: PAPILLOMA OR ACANTHOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
4076,363899218,7276,C1C(O1)C2=CC=CC=C2,Inactive,,,,RAT,BDIV/FEMALE,GAVAGE,0; 200 MG/KG ONCE IN OLIVE OIL ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),,NEGATIVE,"[PONOMARKOV,V, CABRAL,JRP, WAHRENDORF,J AND GALENDO,D; A CARCINOGENICITY STUDY OF STYRENE-7,8-OXIDE IN RATS; CANCER LETT. 24:95-101, 1984]"
4077,363899218,7276,C1C(O1)C2=CC=CC=C2,Active,,,,RAT,BDIV/FEMALE,GAVAGE,0; 100-150 MG/KG IN OLIVE OIL 1/WK FOR 96 WK ADMINISTERED TO OFFSPRING OF FEMALE RATS GIVEN 200 MG/KG ONCE ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),"FORESTOMACH: CARCINOMA IN SITU, CARCINOMA",POSITIVE,"[PONOMARKOV,V, CABRAL,JRP, WAHRENDORF,J AND GALENDO,D; A CARCINOGENICITY STUDY OF STYRENE-7,8-OXIDE IN RATS; CANCER LETT. 24:95-101, 1984]"
4078,363899218,7276,C1C(O1)C2=CC=CC=C2,Active,,,,RAT,BDIV/MALE,GAVAGE,0; 100-150 MG/KG IN OLIVE OIL 1/WK FOR 96 WK ADMINISTERED TO OFFSPRING OF FEMALE RATS GIVEN 200 MG/KG ONCE ON DAY 17 OF PREGNANCY (STUDY DURATION: 120 WK),"FORESTOMACH: PAPILLOMA, CARCINOMA IN SITU, CARCINOMA",POSITIVE,"[PONOMARKOV,V, CABRAL,JRP, WAHRENDORF,J AND GALENDO,D; A CARCINOGENICITY STUDY OF STYRENE-7,8-OXIDE IN RATS; CANCER LETT. 24:95-101, 1984]"
4079,363899218,7276,C1C(O1)C2=CC=CC=C2,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 50; 250 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
4080,363899218,7276,C1C(O1)C2=CC=CC=C2,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 50; 250 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
4081,363899231,9058,C1CCC2=C(C1)C=CC3=CC4=C(C=CC5=CC=CC=C54)C=C23,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 32 UG AS 0.2% SOLUTION IN ACETONE APPLIED TO INTERSCAPULAR REGION 2/WK FOR 50 WK (STUDY DURATION: 60 WK),SKIN: CARCINOMA,POSITIVE,"[LIJINSKY,W, GARCIA,H, TERRACINI,B AND SAFFIOTTI,U; TUMORIGENIC ACTIVITY OF HYDROGENATED DERIVATIVES OF DIBENZ[A,H]ANTHRACENE; J. NATL. CANCER INST. 34(1): 1-6, 1965]"
4082,363899232,5455,CN(C)C(=S)SSC(=S)N(C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.05; 0.1% IN DIET FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[HASEGAWA,R, TAKAHASHI,M, FURUKAWA,F, TOYODA,K, SATO,H, JANG,JJ AND HAYASHI,Y; CARCINOGENICITY STUDY OF TETRAMETHYLTHIURAM DISULFIDE (THIRAM) IN F344 RATS; TOXICOLOGY 51(2-3), 1988]"
4083,363899232,5455,CN(C)C(=S)SSC(=S)N(C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.05; 0.1% IN DIET FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[HASEGAWA,R, TAKAHASHI,M, FURUKAWA,F, TOYODA,K, SATO,H, JANG,JJ AND HAYASHI,Y; CARCINOGENICITY STUDY OF TETRAMETHYLTHIURAM DISULFIDE (THIRAM) IN F344 RATS; TOXICOLOGY 51(2-3), 1988]"
4084,363899232,5455,CN(C)C(=S)SSC(=S)N(C)C,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 3; 30; 300 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MAITA,K, TSUDA,S AND SHIRASU,Y; CHRONIC TOXICITY STUDIES WITH THIRAM IN WISTAR RATS AND BEAGLE DOGS; FUNDAM. APPL. TOXICOL. 16:667-686, 1991]"
4085,363899232,5455,CN(C)C(=S)SSC(=S)N(C)C,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 3; 30; 300 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MAITA,K, TSUDA,S AND SHIRASU,Y; CHRONIC TOXICITY STUDIES WITH THIRAM IN WISTAR RATS AND BEAGLE DOGS; FUNDAM. APPL. TOXICOL. 16:667-686, 1991]"
4086,363899232,5455,CN(C)C(=S)SSC(=S)N(C)C,Inactive,,,,DOG,BEAGLE/MALE,ORAL,0; 0.4; 4; 40 MG/KG/D ADMINISTERED IN GELATIN CAPSULES 7 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MAITA,K, TSUDA,S AND SHIRASU,Y; CHRONIC TOXICITY STUDIES WITH THIRAM IN WISTAR RATS AND BEAGLE DOGS; FUNDAM. APPL. TOXICOL. 16:667-686, 1991]"
4087,363899232,5455,CN(C)C(=S)SSC(=S)N(C)C,Inactive,,,,DOG,BEAGLE/FEMALE,ORAL,0; 0.4; 4; 40 MG/KG/D ADMINISTERED IN GELATIN CAPSULES 7 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MAITA,K, TSUDA,S AND SHIRASU,Y; CHRONIC TOXICITY STUDIES WITH THIRAM IN WISTAR RATS AND BEAGLE DOGS; FUNDAM. APPL. TOXICOL. 16:667-686, 1991]"
4088,363899232,5455,CN(C)C(=S)SSC(=S)N(C)C,Inactive,,,,MOUSE,SWISS/MALE,0; 100 MG/KG BW IN 100 UL DMSO 3/WK FOR 52 WK (STUDY DURATION: 52 WK),,,NEGATIVE,"[SHUKLA,Y, BAQAR,SM AND MEHROTRA,NK; CARCINOGENIC AND CO-CARCINOGENIC STUDIES OF THIRAM ON MOUSE SKIN; FOOD CHEM. TOXICOL. 34(3):283-289, 1996]"
4089,363899232,5455,CN(C)C(=S)SSC(=S)N(C)C,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 100 MG/KG BW IN 100 UL DMSO 3/WK FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[SHUKLA,Y, BAQAR,SM AND MEHROTRA,NK; CARCINOGENIC AND CO-CARCINOGENIC STUDIES OF THIRAM ON MOUSE SKIN; FOOD CHEM. TOXICOL. 34(3):283-289, 1996]"
4090,363899234,,,Unspecified,,,,RAT,F344/MALE,GAVAGE,0; 25; 50 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, BASOSQUAMOUS TUMOR BENIGN",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-399 Y91]"
4091,363899234,,,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 25; 50 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-399 Y91]"
4092,363899235,9056,C1CCC2=C(C1)C=CC3=CC4=C(CCC5=CC=CC=C54)C=C23,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 38 UG AS A 0.2% SOLUTION IN ACETONE APPLIED TO INTERSCAPULAR REGION 2/WK FOR 50 WK (STUDY DURATION: 60 WK),SKIN: CARCINOMA,POSITIVE,"[LIJINSKY,W, GARCIA,H, TERRACINI,B AND SAFFIOTTI,U; TUMORIGENIC ACTIVITY OF HYDROGENATED DERIVATIVES OF DIBENZ[A,H]ANTHRACENE; J. NATL. CANCER INST. 34(1): 1-6, 1965]"
4093,363899237,11955,C1=CC=C(C=C1)C(=O)NN,Active,,,,MOUSE,SWISS/MALE,ORAL,0; 0.01% SOLUTION IN DRINKING WATER STARTING AT 6 WK OF AGE AND CONTINUED FOR LIFE FOR AN AVERAGE DAILY INTAKE OF 0; 0.85 MG (STUDY DURATION: 130 WK),LUNG: ADENOMA; LUNG: ADENOMA AND ADENOCARCINOMA,POSITIVE,"[TOTH,B; BENZOYLHYDRAZINE CARCINOGENESIS IN LUNGS AND LYMPHORETICULAR TISSUES OF SWISS MICE; EUR. J. CANCER 8:341-345, 1972]"
4094,363899237,11955,C1=CC=C(C=C1)C(=O)NN,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 0.1% SOLUTION IN DRINKING WATER STARTING AT 6 WK OF AGE AND CONTINUED FOR LIFE FOR AN AVERAGE DAILY INTAKE OF 0; 0.57 MG (STUDY DURATION: 130 WK),LUNG: ADENOMA; LUNG: ADENOMA AND ADENOCARCINOMA,POSITIVE,"[TOTH,B; BENZOYLHYDRAZINE CARCINOGENESIS IN LUNGS AND LYMPHORETICULAR TISSUES OF SWISS MICE; EUR. J. CANCER 8:341-345, 1972]"
4095,363899240,6278,CC(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 150; 500; 1500 PPM IN AIR 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[QUAST,JF, CALHOUN,LL AND FRAUSON,LE; 1,1,1-TRICHLOROETHANE FORMULATION: A CHRONIC INHALATION TOXICITY AND ONCOGENICITY STUDY IN FISCHER 344 RATS AND B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 11(4):611-625, 1988]"
4096,363899240,6278,CC(Cl)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 150; 500; 1500 PPM IN AIR 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[QUAST,JF, CALHOUN,LL AND FRAUSON,LE; 1,1,1-TRICHLOROETHANE FORMULATION: A CHRONIC INHALATION TOXICITY AND ONCOGENICITY STUDY IN FISCHER 344 RATS AND B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 11(4):611-625, 1988]"
4097,363899240,6278,CC(Cl)(Cl)Cl,Inactive,,,,RAT,F344/MALE,INHALATION,0; 150; 500; 1500 PPM IN AIR 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[QUAST,JF, CALHOUN,LL AND FRAUSON,LE; 1,1,1-TRICHLOROETHANE FORMULATION: A CHRONIC INHALATION TOXICITY AND ONCOGENICITY STUDY IN FISCHER 344 RATS AND B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 11(4):611-625, 1988]"
4098,363899240,6278,CC(Cl)(Cl)Cl,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 150; 500; 1500 PPM IN AIR 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[QUAST,JF, CALHOUN,LL AND FRAUSON,LE; 1,1,1-TRICHLOROETHANE FORMULATION: A CHRONIC INHALATION TOXICITY AND ONCOGENICITY STUDY IN FISCHER 344 RATS AND B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 11(4):611-625, 1988]"
4099,363899241,93308,CCCCNN.Cl,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 0.0125% SOLUTION IN DRINKING WATER DAILY FOR LIFE FOR AN AVERAGE DAILY INTAKE OF 0; 1.3 MG (STUDY DURATION: 130 WK),LUNG: ADENOMA; LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[NAGEL,D, SHIMIZU,H AND TOTH,B; TUMOR INDUCTION STUDIES WITH N-BUTYL- AND N-PROPYLHYDRAZINE HYDROCHLORIDES IN SWISS MICE; EUR. J. CANCER 11:473-478, 1975]"
4100,363899241,93308,CCCCNN.Cl,Active,,,,MOUSE,SWISS/MALE,ORAL,0; 0.0125% SOLUTION IN DRINKING WATER DAILY FOR LIFE FOR AN AVERAGE DAILY INTAKE OF 0; 2.1 MG (STUDY DURATION: 130 WK),LUNG: ADENOMA; LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[NAGEL,D, SHIMIZU,H AND TOTH,B; TUMOR INDUCTION STUDIES WITH N-BUTYL- AND N-PROPYLHYDRAZINE HYDROCHLORIDES IN SWISS MICE; EUR. J. CANCER 11:473-478, 1975]"
4101,363899242,7367,C1=CC=C(C=C1)C(Cl)(Cl)Cl,Active,,,,MOUSE,ICR/FEMALE,GAVAGE,0; 0.0315; 0.125; 0.5; 2 UL IN STERILIZED SESAME OIL 2/WK FOR 25 WK (STUDY DURATION: 18 MO),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: ADENOCARCINOMA OR ADENOMA; HEMATOPOIETIC SYSTEM: TUMORS,POSITIVE,"[FUKUDA,K, MATSUSHITA,H, TAKEMOTO,K AND TOYA,T; CARCINOGENICITY OF BENZOTRICHLORIDE ADMINISTERED TO MICE BY GASTRIC INTUBATION; IND. HEALTH 31(3):127-131, 1993]"
4102,363899252,8295,C(CCl)OP(=O)(OCCCl)OCCCl,Active,,,,RAT,F344/MALE,GAVAGE,0; 44; 88 MG/KG IN CORN OIL 5 D/WK FOR 103 (STUDY DURATION: 104 WK),KIDNEY (RENAL TUBULE): ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA (MONONUCLEAR),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-391 Y91]"
4103,363899252,8295,C(CCl)OP(=O)(OCCCl)OCCCl,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 44; 88 MG/KG IN CORN OIL 5 D/WK FOR 103 (STUDY DURATION: 104 WK),KIDNEY (RENAL TUBULE): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-391 Y91]"
4104,363899252,8295,C(CCl)OP(=O)(OCCCl)OCCCl,Active,,,,MOUSE,DDY/MALE,ORAL,"0; 0.012; 0.06, 0.3, 1.5% IN DIET FOR 18 MO (STUDY DURATION: 18 MO)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; KIDNEY: RENAL CELL ADENOMA, RENAL CELL CARCINOMA",POSITIVE,"[TAKADA,K, YASUHARA,K, NAKAJI,Y, YOSHIMOTO,H, MOMMA,J, KUROKAWA,Y, AIDA,Y AND TOBE,M; CARCINOGENICITY STUDY OF TRIS(2-CHLOROETHYL)PHOSPHATE IN DDY MICE; J. TOXICOL. PATHOL. 2(2):213-222, 1989]"
4105,363899252,8295,C(CCl)OP(=O)(OCCCl)OCCCl,Active,,,,MOUSE,DDY/FEMALE,ORAL,0; 0.012; 0.06; 0.3; 1.5% IN DIET FOR 18 MO (STUDY DURATION: 18 MO),"HEMATOPOIETIC SYSTEM: LEUKEMIA; FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[TAKADA,K, YASUHARA,K, NAKAJI,Y, YOSHIMOTO,H, MOMMA,J, KUROKAWA,Y, AIDA,Y AND TOBE,M; CARCINOGENICITY STUDY OF TRIS(2-CHLOROETHYL)PHOSPHATE IN DDY MICE; J. TOXICOL. PATHOL. 2(2):213-222, 1989]"
4106,363899252,8295,C(CCl)OP(=O)(OCCCl)OCCCl,Inactive,,,,MOUSE,SLC:DDY/FEMALE,DERMAL,0; 5; 50% IN ETHANOL 2/WK FOR 79 WK (STUDY DURATION: 18 MO),,NEGATIVE,"[TAKADA,K, YOSHIMOTO,H, YASUHARA,K, MOMMA,J, AIDA,Y, SAITO,M, KUROKAWA,Y AND TOBE,M; COMBINED CHRONIC TOXICITY/CARCINOGENICITY TEST OF TRIS(2-CHLOROETHYL) PHOSPHATE (TCEP) APPLIED TO FEMALE MOUSE SKIN; EISEI SHIKENSHO HOKOKU 109:18-24, 1991]"
4107,363899252,8295,C(CCl)OP(=O)(OCCCl)OCCCl,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 175; 350 MG/KG IN CORN OIL 5 D/WK FOR 103 (STUDY DURATION: 104 WK),"KIDNEY (RENAL TUBULE): ADENOMA, CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-391 Y91]"
4108,363899252,8295,C(CCl)OP(=O)(OCCCl)OCCCl,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 175; 350 MG/KG IN CORN OIL 5 D/WK FOR 103 (STUDY DURATION: 104 WK),HARDERIAN GLAND: ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-391 Y91]"
4109,363899253,42006,CCCN[NH3+].[Cl-],Active,,,,MOUSE,SWISS/MALE,ORAL,0; 0.025% SOLUTION IN DRINKING WATER DAILY FOR LIFE FOR AN AVERAGE DAILY INTAKE OF 0; 2.9 MG (STUDY DURATION: 100 WK),LUNG: ADENOMA; LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[NAGEL,D, SHIMIZU,H AND TOTH,B; TUMOR INDUCTION STUDIES WITH N-BUTYL- AND N-PROPYLHYDRAZINE HYDROCHLORIDES IN SWISS MICE; EUR. J. CANCER 11:473-478, 1975]"
4110,363899253,42006,CCCN[NH3+].[Cl-],Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 0.025% SOLUTION IN DRINKING WATER DAILY FOR LIFE FOR AND AVERAGE DAILY INTAKE OF 0; 3.0 MG (STUDY DURATION: 100 WK),LUNG: ADENOMA; LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[NAGEL,D, SHIMIZU,H AND TOTH,B; TUMOR INDUCTION STUDIES WITH N-BUTYL- AND N-PROPYLHYDRAZINE HYDROCHLORIDES IN SWISS MICE; EUR. J. CANCER 11:473-478, 1975]"
4111,363899256,7904,CC(=O)OC=C,Inactive,,,,RAT,F344/MALE,ORAL,0; 1000; 2500 MG/L IN DRINKING WATER 5 D/WK FOR 100 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
4112,363899256,7904,CC(=O)OC=C,Active,,,,RAT,F344/FEMALE,ORAL,0; 1000; 2500 MG/L IN DRINKING WATER 5 D/WK FOR 100 WK (STUDY DURATION: 130 WK),UTERUS: CARCINOMA; THYROID: C-CELL ADENOMA; LIVER: NEOPLASTIC NODULE,POSITIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
4113,363899256,7904,CC(=O)OC=C,Active,,,,RAT,CRL:CD(SD)BR/MALE,INHALATION,0; 50; 200; 600 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),NASAL CAVITY: TUMOR,POSITIVE,"[BOGDANFFY,MS, DREEF-VAN DER MUELEN,HC, BEEMS,RB, FERON,VJ, CASCIERI,TC, TYLER, TR, VINEGAR,MB AND RICKARD,RW; CHRONIC TOXICITY AND ONCOGENICITY INHALATION STUDY WITH VINYL ACETATE IN THE RAT AND MOUSE; FUNDAM. APPL. TOXICOL. 23(2): 215-229, 1994]"
4114,363899256,7904,CC(=O)OC=C,Inactive,,,,RAT,CRL:CD(SD)BR/FEMALE,INHALATION,0; 50; 200; 600 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BOGDANFFY,MS, DREEF-VAN DER MUELEN,HC, BEEMS,RB, FERON,VJ, CASCIERI,TC, TYLER, TR, VINEGAR,MB AND RICKARD,RW; CHRONIC TOXICITY AND ONCOGENICITY INHALATION STUDY WITH VINYL ACETATE IN THE RAT AND MOUSE; FUNDAM. APPL. TOXICOL. 23(2): 215-229, 1994]"
4115,363899256,7904,CC(=O)OC=C,Inactive,,,,MOUSE,CRL:CD-1(ICR)BR/MALE,INHALATION,0; 50; 200; 600 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BOGDANFFY,MS, DREEF-VAN DER MUELEN,HC, BEEMS,RB, FERON,VJ, CASCIERI,TC, TYLER, TR, VINEGAR,MB AND RICKARD,RW; CHRONIC TOXICITY AND ONCOGENICITY INHALATION STUDY WITH VINYL ACETATE IN THE RAT AND MOUSE; FUNDAM. APPL. TOXICOL. 23(2): 215-229, 1994]"
4116,363899256,7904,CC(=O)OC=C,Inactive,,,,MOUSE,CRL:CD-1(ICR)BR/FEMALE,INHALATION,0; 50; 200; 600 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BOGDANFFY,MS, DREEF-VAN DER MUELEN,HC, BEEMS,RB, FERON,VJ, CASCIERI,TC, TYLER, TR, VINEGAR,MB AND RICKARD,RW; CHRONIC TOXICITY AND ONCOGENICITY INHALATION STUDY WITH VINYL ACETATE IN THE RAT AND MOUSE; FUNDAM. APPL. TOXICOL. 23(2): 215-229, 1994]"
4117,363899256,7904,CC(=O)OC=C,Inactive,,,,RAT,CRL:CD(SD)BR/MALE,ORAL,0; 200; 1000; 5000 PPM IN DRINKING WATER FOR 104 WK ADMINISTERED TO OFFSPRING OF RATS ADMINISTERED THE SAME DOSES BEGINNING 10 WK PRIOR TO MATING (STUDY DURATION: >104 WK),,NEGATIVE,"[BOGDANFFY,MS, TYLER,TR, VINEGAR,MB, RICKARD,RW, CARPANINI,FMB AND CASCIERI,TC; CHRONIC TOXICITY AND ONCOGENICITY STUDY WITH VINYL ACETATE IN THE RAT: IN UTERO EXPOSURE IN DRINKING WATER; FUNDAM. APPL. TOXICOL. 23(2):206-214, 1994]"
4118,363899256,7904,CC(=O)OC=C,Inactive,,,,RAT,CRL:CD(SD)BR/FEMALE,ORAL,0; 200; 1000; 5000 PPM IN DRINKING WATER FOR 104 WK ADMINISTERED TO OFFSPRING OF RATS ADMINISTERED THE SAME DOSES BEGINNING 10 WK PRIOR TO MATING (STUDY DURATION: >104 WK),,NEGATIVE,"[BOGDANFFY,MS, TYLER,TR, VINEGAR,MB, RICKARD,RW, CARPANINI,FMB AND CASCIERI,TC; CHRONIC TOXICITY AND ONCOGENICITY STUDY WITH VINYL ACETATE IN THE RAT: IN UTERO EXPOSURE IN DRINKING WATER; FUNDAM. APPL. TOXICOL. 23(2):206-214, 1994]"
4119,363899256,7904,CC(=O)OC=C,Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 1000; 5000 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[MALTONI,C, CILIBERTI,A, LEFEMINE,G AND SOFFRITTI,M; RESULTS OF A LONG-TERM EXPERIMENTAL STUDY ON THE CARCINOGENICITY OF VINYL ACETATE MONOMER IN MICE; ANN. N.Y. ACAD. SCI. 837(PREVENTIVE STRATEGIES FOR LIVING IN A CHEMICAL WORLD):209-238, 1997]"
4120,363899256,7904,CC(=O)OC=C,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 1000; 5000 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION:LIFE SPAN),TONGUE: SQUAMOUS CELL CARCINOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA; LUNG: ADENOMA OR ADENOCARCINOMA; UTERUS: TUMOR,POSITIVE,"[MALTONI,C, CILIBERTI,A, LEFEMINE,G AND SOFFRITTI,M; RESULTS OF A LONG-TERM EXPERIMENTAL STUDY ON THE CARCINOGENICITY OF VINYL ACETATE MONOMER IN MICE; ANN. N.Y. ACAD. SCI. 837(PREVENTIVE STRATEGIES FOR LIVING IN A CHEMICAL WORLD):209-238, 1997]"
4121,363899256,7904,CC(=O)OC=C,Active,,,,SWISS/MALE,ORAL,ORAL,0; 1000; 5000 PPM IN DRINKING WATER ADMINISTERED FOR DURATION OF STUDY TO OFFSPRING OF MOTHERS EXPOSED TO THE SAME DOSES FROM THE 12TH DAY OF GESTATION (STUDY DURATION:LIFE SPAN),ZYMBAL GLAND: CARCINOMA; ORAL CAVITY: SQUAMOUS CELL CARCINOMA; TONGUE: SQUAMOUS CELL CARCINOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA; LUNG: ADENOMA OR CARCINOMA,POSITIVE,"[MALTONI,C, CILIBERTI,A, LEFEMINE,G AND SOFFRITTI,M; RESULTS OF A LONG-TERM EXPERIMENTAL STUDY ON THE CARCINOGENICITY OF VINYL ACETATE MONOMER IN MICE; ANN. N.Y. ACAD. SCI. 837(PREVENTIVE STRATEGIES FOR LIVING IN A CHEMICAL WORLD):209-238, 1997]"
4122,363899256,7904,CC(=O)OC=C,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 1000; 5000 PPM IN DRINKING WATER ADMINISTERED FOR DURATION OF STUDY TO OFFSPRING OF MOTHERS EXPOSED TO THE SAME DOSES FROM THE 12TH DAY OF GESTATION (STUDY DURATION:LIFE SPAN),ZYMBAL GLAND: CARCINOMA; ORAL CAVITY: SQUAMOUS CELL CARCINOMA; TONGUE: SQUAMOUS CELL CARCINOMA; ESOPHAGUS: SQUAMOUS CELL CARCINOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: ADENOMA OR ADENOCARCINOMA; UTERUS: TUMOR,POSITIVE,"[MALTONI,C, CILIBERTI,A, LEFEMINE,G AND SOFFRITTI,M; RESULTS OF A LONG-TERM EXPERIMENTAL STUDY ON THE CARCINOGENICITY OF VINYL ACETATE MONOMER IN MICE; ANN. N.Y. ACAD. SCI. 837(PREVENTIVE STRATEGIES FOR LIVING IN A CHEMICAL WORLD):209-238, 1997]"
4123,363899262,91560,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl.C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,"BALB/MALE,FEMALE",DIET,0; 2; 20; 250 PPM,LIVER: HEPATOCELLULAR TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74][TERRACINI,B, TESTA,MC, CABRAL,JR AND DAY,N;THE EFFECTS OF LONG-TERM FEEDING OF DDT TO BALB/C MICE; INT. J. CANCER 11:747, 1973, ]"
4124,363899262,91560,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl.C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,CF-1,DIET,0; 2; 10; 50; 250 PPM,LIVER: HEPATOCELLULAR TUMOR,POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V5 83 Y74][TOMATIS,L, TURUSOV,V, DAY,N AND CHARLES,RT;THE EFFECT OF LONG-TERM EXPOSURE TO DDT ON CF-1 MICE; INT. J. CANCER 10:489, 1972, ]"
4125,363899262,91560,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl.C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,Active,,,,MOUSE,"CF-1/MALE,FEMALE",DIET,0; 250 PPM FOR 30 WK,LIVER: HEPATOMA,POSITIVE,"[TOMATIS,L, TURUSOV,V, CHARLES,RT, BOIOCCHI,M AND GATI,E; LIVER TUMOURS IN CF-1 MICE EXPOSED FOR LIMITED PERIODS TO TECHNICAL DDT; Z. KREBSFORSCH. 82(1):25-35, 1974]"
4126,363899263,518753,[Be+2].[OH-].[OH-],Active,,,,RAT,WISTAR/FEMALE,INTRATRACHEAL,50 UG THEN 25 UG AFTER 10 MO,"LUNG: ADENOMA, ADENOCARCINOMA, ALVEOLAR/BRONCHIOLAR TUMOR",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V23 143 Y80][GROTH,DH, KOMMINENI,C AND MACKAY,GR; CARCINOGENICITY OF BERYLLIUM HYDROXIDE AND ALLOYS; ENVIRON. RES. 21:63-84, 1980, ]"
4127,363899264,2519,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Inactive,,,,RAT,"WISTAR/MALE,FEMALE",ORAL,0; 0.1; 0.2% SOLN. IN DRINKING WATER FOR 78 WK,,NEGATIVE,"[TAKAYAMA,S AND KUWABARA,N; LONG-TERM STUDY ON THE EFFECT OF CAFFEINE IN WISTAR RATS; GANN 73(3):365-371, 1982]"
4128,363899264,2519,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 200; 430; 930; 2000 MG/L IN DRINKING WATER FOR 24 MO (STUDY DURATION: 2 YR),,NEGATIVE,"[MOHR,U, ALTOFF,J, KETKAR,MB, CONRADT,P AND MORGAREIDGE,K; THE INFLUENCE OF CAFFEINE ON TUMOUR INCIDENCE IN SPRAGUE-DAWLEY RATS;FOOD CHEM. TOXICOL. 22(5):377-382, 1984]"
4129,363899264,2519,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 200; 430; 930; 2000 MG/L IN DRINKING WATER FOR 24 MO (STUDY DURATION: 2 YR),,NEGATIVE,"[MOHR,U, ALTOFF,J, KETKAR,MB, CONRADT,P AND MORGAREIDGE,K; THE INFLUENCE OF CAFFEINE ON TUMOUR INCIDENCE IN SPRAGUE-DAWLEY RATS;FOOD CHEM. TOXICOL. 22(5):377-382, 1984]"
4130,363899265,26089,[O-][Cr](=O)(=O)[O-].[Zn+2],Active,,,,MOUSE,STRAIN-A,INTRATRACHEAL,"0.03 ML OF A 2% SUSPENSION, 6 INJ AT 6 WK INTERVALS",LUNG: ADENOMA,POSITIVE,"[STEFFE,CH AND BAETJER,AM; HISTOPATHOLOGIC EFFECTS OF CHROMATE CHEMICALS. REPORT OF STUDIES IN RABBITS, GUINEA PIGS, RATS AND MICE; ARCH. ENVIRON. HEALTH 11:66-75, 1965]"
4131,363899266,77098495,CC[C@@H]1C(=O)N[C@H](C(=O)N[C@H](CC(=O)N[C@@H](C(=O)N2C[C@H]([C@H]([C@H]2C(=O)N1)Cl)Cl)CO)C3=CC=CC=C3)CO,Active,,,,MOUSE,DDNI/MALE,ORAL,"0; 40; 60 UG IN DIET, 1/D FOR LIFE","HEMATOPOIETIC SYSTEM: RETICULOENDOTHELIOMA; LIVER: CARCINOMA, HEPATOCELLULAR ADENOMA",POSITIVE,"[IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS, INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, LYON, FRANCE, p. V10 139 Y76][URAGUCHI,K, SAITO,M, NOGUCHI,Y, TAKAHASI,K, ENOMOTO,M AND TATSUNO,T; CHRONIC TOXICITY AND CARCINOGENICITY IN MICE OF THE PURIFIED MYCOTOXINS, LUTEOSKYRIN AND CYCLOCHLOROTINE; FOOD COSMET. TOXICOL. 10:193-207, 1972, ]"
4132,363899267,8815,COC1=CC=C(C=C1)CC=C,Active,,,,Mouse,ICR/Female (30 324 day survivors/Group),Intraperitoneal injection,"150 mg/kg bw a wk for 17 wks, study duration 537 days",Liver: Hepatocellular adenoma and carcinoma,Positive (80% incidence). Apparent lack of concurrent controls.,"[KALEDIN,VI, PAKHARUKOVA,MY, PIVOVAROVA,EN, KROPACHEV,KY, BAGINSKAYA,NV, VASILIEVA,ED, ILNITSKAYA,SI, NIKITENKO,EV, KOBZEV,VK, MERKULOVA,TI; CORRELATION BETWEEN HEPATOCARCINOGENIC EFFECT OF ESTRAGOLE AND ITS INFLUENCE ON GLUCOCORTICOID INDUCTION OF LIVER-SPECIFIC ENZYMES AND ACTIVITIES OF FOXA AND HNF4 TRANSCRIPTION FACTORS IN MOUSE AND RAT LIVER. BIOCHEMISTRY (MOSCOW). 74(4): 377-384, 2009]"
4133,363899267,8815,COC1=CC=C(C=C1)CC=C,Active,,,,MOUSE,"CD-1/MALE,FEMALE",GAVAGE,0; 25 UMOL/G TOTAL DOSE; 2/WK FOR 5 WK BEGINNING ON D 4 AFTER BIRTH; AUTOPSIED AT 11-14 MO,LIVER: HEPATOMA,POSITIVE,"[MILLER,EC, SWANSON,AB, PHILLIPS,DH, FLETCHER,TL, LIEM,A AND MILLER,JA; STRUCTURE-ACTIVITY STUDIES OF THE CARCINOGENICITIES IN THE MOUSE AND RAT OF SOME NATURALLY OCCURRING AND SYNTHETIC ALKENYLBENZENE DERIVATIVES RELATED TO SAFROLE AND ESTRAGOLE; CANCER RES. 43(3):1124-1134, 1983]"
4134,363899267,8815,COC1=CC=C(C=C1)CC=C,Active,,,,MOUSE,CD-1/FEMALE,ORAL,"0; 0.23; 0.46% IN DIET, FOR 12 MO",LIVER: HEPATOMA,POSITIVE,"[MILLER,EC, SWANSON,AB, PHILLIPS,DH, FLETCHER,TL, LIEM,A AND MILLER,JA; STRUCTURE-ACTIVITY STUDIES OF THE CARCINOGENICITIES IN THE MOUSE AND RAT OF SOME NATURALLY OCCURRING AND SYNTHETIC ALKENYLBENZENE DERIVATIVES RELATED TO SAFROLE AND ESTRAGOLE; CANCER RES. 43(3):1124-1134, 1983]"
4135,363899267,8815,COC1=CC=C(C=C1)CC=C,Active,,,,MOUSE,C3H/MALE,INTRAPERITONEAL,"0; 9.45 UMOL TOTAL DOSE; D 1,8,15 AND 22 AFTER BIRTH; AUTOPSIED AT 12 MO",LIVER: HEPATOMA,POSITIVE,"[MILLER,EC, SWANSON,AB, PHILLIPS,DH, FLETCHER,TL, LIEM,A AND MILLER,JA; STRUCTURE-ACTIVITY STUDIES OF THE CARCINOGENICITIES IN THE MOUSE AND RAT OF SOME NATURALLY OCCURRING AND SYNTHETIC ALKENYLBENZENE DERIVATIVES RELATED TO SAFROLE AND ESTRAGOLE; CANCER RES. 43(3):1124-1134, 1983]"
4136,363899267,8815,COC1=CC=C(C=C1)CC=C,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 4.75 UMOL TOTAL DOSE; D 1,8,15 AND 22 AFTER BIRTH; AUTOPSIED AT 13-18 MO",LIVER: HEPATOMA,POSITIVE,"[MILLER,EC, SWANSON,AB, PHILLIPS,DH, FLETCHER,TL, LIEM,A AND MILLER,JA; STRUCTURE-ACTIVITY STUDIES OF THE CARCINOGENICITIES IN THE MOUSE AND RAT OF SOME NATURALLY OCCURRING AND SYNTHETIC ALKENYLBENZENE DERIVATIVES RELATED TO SAFROLE AND ESTRAGOLE; CANCER RES. 43(3):1124-1134, 1983]"
4137,363899267,8815,COC1=CC=C(C=C1)CC=C,Active,,,,MOUSE,CD-1/MALE,SUBCUTANEOUS,"0; 4.43; 5.19 UMOL TOTAL DOSE; D 1,8,15 AND 22 AFTER BIRTH",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[DRINKWATER,NR, MILLER,EC, MILLER,JA AND PITOT,HC; HEPATOCARCINOGENICITY OF ESTRAGOLE, (1-ALLYL-4-METHOXYBENZENE) AND 1'-HYDROXYESTRAGOLE IN THE MOUSE AND MUTAGENICITY OF 1'-ACETOXYESTRAGOLE IN BACTERIA; J. NATL. CANCER INST. 57(6):1323-1331, 1977]"
4138,363899267,8815,COC1=CC=C(C=C1)CC=C,Active,,,,MOUSE,CD-1/MALE,SUBCUTANEOUS,"0; 0.17; 0.35 UMOL IN 0.025 ML TRIOCTANOIN WITHIN 24 HR AFTER BIRTH THEN 0; 0.47; 0.69 UMOL IN 0.05 ML TRIOCTANOIN ON D 8, 0; 0.95; 1.38 UMOL IN 0.05 ML TRIOCTANOIN ON D 15 AND 0; 2.84; 2.77 UMOL IN 0.1 ML TRIOCTANOIN ON D 22 FOR A TOTAL DOSE OF 0; 4.43; 5.19 UMOL (STUDY DURATION: 15 MO)",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[DRINKWATER,NR, MILLER,EC, MILLER,JA AND PITOT,HC; HEPATOCARCINOGENICITY OF ESTRAGOLE (1-ALLYL-4-METHOXYBENZENE) AND 1'-HYDROXYESTRAGOLE IN THE MOUSE AND MUTAGENICITY OF 1'-ACETOXYESTRAGOLE IN BACTERIA; J. NATL. CANCER INST. 57(6):1323-1331, 1976]"
4139,363899280,5284451,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,O; 2000 PPM IN DIET (TOTAL DOSE: 110 G/KG) FOR 110 WK (STUDY DURATION: 133 WK),,NEGATIVE,"[LIJINSKI,W; CHRONIC TOXICITY TESTS OF PYRILAMINE MALEATE AND METHAPYRILENE HYDROCHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 22(1):27-30, 1984]"
4140,363899280,5284451,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2000 PPM IN DIET (TOTAL DOSE: 120 G/KG) FOR 110 WK (STUDY DURATION: 133 WK),,NEGATIVE,"[LIJINSKI,W; CHRONIC TOXICITY TESTS OF PYRILAMINE MALEATE AND METHAPYRILENE HYDROCHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 22(1):27-30, 1984]"
4141,363899280,5284451,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 2000 PPM (0.2%) IN DRINKING WATER 5 D/WK FOR 110 WK (TOTAL DOSE: 55 G/KG) (STUDY DURATION: 133 WK),,NEGATIVE,"[LIJINSKI,W; CHRONIC TOXICITY TESTS OF PYRILAMINE MALEATE AND METHAPYRILENE HYDROCHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 22(1):27-30, 1984]"
4142,363899280,5284451,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2000 PPM IN DRINKING WATER (0.2%) 5 D/WK FOR 110 WK (TOTAL DOSE: 88 G/KG) (STUDY DURATION: 133 WK),,NEGATIVE,"[LIJINSKI,W; CHRONIC TOXICITY TESTS OF PYRILAMINE MALEATE AND METHAPYRILENE HYDROCHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 22(1):27-30, 1984]"
4143,363899280,5284451,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 300; 1500; 3000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[GREENMAN,DL, CRONIN,GM, DAHLGREN,R, ALLEN,R AND ALLABEN,W; CHRONIC FEEDING STUDY OF PYRILAMINE IN FISCHER 344 RATS; FUNDAM. APPL. TOXICOL. 25(1):1-8, 1995]"
4144,363899280,5284451,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 300; 1500; 3000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[GREENMAN,DL, CRONIN,GM, DAHLGREN,R, ALLEN,R AND ALLABEN,W; CHRONIC FEEDING STUDY OF PYRILAMINE IN FISCHER 344 RATS; FUNDAM. APPL. TOXICOL. 25(1):1-8, 1995]"
4145,363899280,5284451,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 150; 750; 1500 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[GREENMAN,DL, ALLEN,R, DAHLGREN,R, CRONIN,GM AND ALLABEN,WT; CHRONIC TOXICITY/CARCINOGENICITY STUDY OF PYRILAMINE IN B6C3F1 MICE; J. AM. COLL. TOXICOL. 14(2):148-157, 1995]"
4146,363899280,5284451,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 150; 750; 1500 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[GREENMAN,DL, ALLEN,R, DAHLGREN,R, CRONIN,GM AND ALLABEN,WT; CHRONIC TOXICITY/CARCINOGENICITY STUDY OF PYRILAMINE IN B6C3F1 MICE; J. AM. COLL. TOXICOL. 14(2):148-157, 1995]"
4147,363899300,11292,C1=CC(=N)C=CC1=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN DIET FOR 103 WK (STUDY DURATION: 110-113 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA;LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; ADRENAL GLAND: PHEOCHROMOCYTOMA, PHEOCHROMOCYTOMA OR MALIGNANT PHEOCHROMOCYTOMA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CYSTADENOMA, ADENOMA OR CYSTADENOMA OR CARCINOMA;HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-285 Y86]"
4148,363899300,11292,C1=CC(=N)C=CC1=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N.Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 1000 PPM IN DIET FOR 103 WK (STUDY DURATION: 113-115 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-285 Y86]"
4149,363899300,11292,C1=CC(=N)C=CC1=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 500; 1000 PPM IN DIET FOR 103 WK (STUDY DURATION: 110-113 WK),"INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA, FIBROMA OR FIBROSARCOMA, FIBROMA OR SARCOMA OR FIBROSARCOMA; MAMMARY GLAND: FIBROADENOMA, ADENOMA OR FIBROADENOMA, ADENOMA OR FIBROADENOMA OR ADENOCARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL ADENOMA OR CARCINOMA; EAR (ZYMBAL GLAND): CARCINOMA; UTERUS: ENDOMETRIAL STROMAL SARCOMA, ENDOMETRIAL STROMAL POLYP OR SARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-285 Y86]"
4150,363899300,11292,C1=CC(=N)C=CC1=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 1000; 2000 PPM IN DIET FOR 103 WK (STUDY DURATION: 110-113 WK),"INTEGUMENTARY SYSTEM (SKIN): SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA, TRICHOEPITHELIOMA, SEBACEOUS ADENOMA; INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA, FIBROMA OR FIBROSARCOMA, FIBROMA OR SARCOMA OR FIBROSARCOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL CARCINOMA; EAR (ZYMBAL GLAND): CARCINOMA; LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA, BILE DUCT ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-285 Y86]"
4151,363899300,11292,C1=CC(=N)C=CC1=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 300 MG/KG BW 2/WK FOR 18 WK WITH A 1 WK REST AFTER 12 WK THEN STARTING AT 19 WK 150 MG/KG BW 2/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[KETKAR,MB AND MOHR,U; THE CHRONIC EFFECTS OF MAGENTA, PARAMAGENTA AND PHENYL-BETA-NAPHTHYLAMINE IN RATS AFTER INTRAGASTRIC ADMINISTRATION; CANCER LETT. 16:203-206, 1982]"
4152,363899300,11292,C1=CC(=N)C=CC1=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 300 MG/KG BW 2/WK FOR 18 WK WITH A 1 WK REST AFTER 12 WK THEN STARTING AT 19 WK 150 MG/KG BW 2/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[KETKAR,MB AND MOHR,U; THE CHRONIC EFFECTS OF MAGENTA, PARAMAGENTA AND PHENYL-BETA-NAPHTHYLAMINE IN RATS AFTER INTRAGASTRIC ADMINISTRATION; CANCER LETT. 16:203-206, 1982]"
4153,363899301,5359318,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 125; 250 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-307 Y86]"
4154,363899301,5359318,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 125; 250 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-307 Y86]"
4155,363899301,5359318,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 125; 250 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-307 Y86]"
4156,363899301,5359318,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 125; 250 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-307 Y86]"
4157,363899302,11698,COP(=O)(N1CCOCC1)OC,Active,,,,RAT,F344/MALE,GAVAGE,0; 150; 300; 600 MG/KG BODY WT IN CORN OIL 5 D/WK FOR 103 WK,HEMATOPOIETIC SYSTEM (LEUKEMIA): MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-298 Y86]"
4158,363899302,11698,COP(=O)(N1CCOCC1)OC,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 150; 300; 600 MG/KG BODY WT IN CORN OIL 5 D/WK FOR 103 WK,HEMATOPOIETIC SYSTEM (LEUKEMIA): MONONUCLEAR CELL LEUKEMIA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-298 Y86]"
4159,363899302,11698,COP(=O)(N1CCOCC1)OC,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 150; 300 MG/KG BODY WT IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-298 Y86]"
4160,363899302,11698,COP(=O)(N1CCOCC1)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 300; 600 MG/KG BODY WT IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-298 Y86]"
4161,363899303,6544,CC1=CC(=O)CC(C1)(C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-291 Y86]"
4162,363899303,6544,CC1=CC(=O)CC(C1)(C)C,Active,,,,RAT,F344/MALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),PREPUTIAL GLAND: CARCINOMA; KIDNEY: TUBULAR CELL ADENOMA OR ADENOCARCINOMA; PANCREAS: ACINAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-291 Y86]"
4163,363899303,6544,CC1=CC(=O)CC(C1)(C)C,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-291 Y86]"
4164,363899303,6544,CC1=CC(=O)CC(C1)(C)C,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; INTEGUMENTARY SYSTEM: MESENCHYMAL TUMOR; HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-291 Y86]"
4165,363899304,6327114,CO[P+](=O)OC,Active,,,,RAT,F344/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"LUNG: SQUAMOUS CELL CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-287 Y85]"
4166,363899304,6327114,CO[P+](=O)OC,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-287 Y85]"
4167,363899304,6327114,CO[P+](=O)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-287 Y85]"
4168,363899304,6327114,CO[P+](=O)OC,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),LUNG:ALVEOLAR/BRONCHIOLAR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-287 Y85]"
4169,363899306,8252,CC=C,Inactive,,,,RAT,F344/MALE,INHALATION,0; 5000; 10000 PPM IN AIR 6H/D 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-272 Y85][QUEST,JA, TOMASZEWSKI,JE, HASEMAN,JK, BOORMAN,GA, DOUGLAS,JF AND CLARKE,WJ; TWO-YEAR INHALATION STUDY OF PROPYLENE IN F344/N RATS AND B6C3F1 MICE; TOXICOL. APPL. PHARMACOL. 76:288-295, 1984, ]"
4170,363899306,8252,CC=C,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 5000; 10000 PPM IN AIR 6H/D 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-272 Y85][QUEST,JA, TOMASZEWSKI,JE, HASEMAN,JK, BOORMAN,GA, DOUGLAS,JF AND CLARKE,WJ; TWO-YEAR INHALATION STUDY OF PROPYLENE IN F344/N RATS AND B6C3F1 MICE; TOXICOL. APPL. PHARMACOL. 76:288-295, 1984, ]"
4171,363899306,8252,CC=C,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 5000; 10000 PPM IN AIR 6H/D 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-272 Y85][QUEST,JA, TOMASZEWSKI,JE, HASEMAN,JK, BOORMAN,GA, DOUGLAS,JF AND CLARKE,WJ; TWO-YEAR INHALATION STUDY OF PROPYLENE IN F344/N RATS AND B6C3F1 MICE; TOXICOL. APPL. PHARMACOL. 76:288-295, 1984, ]"
4172,363899306,8252,CC=C,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 5000; 10000 PPM IN AIR 6H/D 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-272 Y85][QUEST,JA, TOMASZEWSKI,JE, HASEMAN,JK, BOORMAN,GA, DOUGLAS,JF AND CLARKE,WJ; TWO-YEAR INHALATION STUDY OF PROPYLENE IN F344/N RATS AND B6C3F1 MICE; TOXICOL. APPL. PHARMACOL. 76:288-295, 1984, ]"
4173,363899306,8252,CC=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,"0; 200; 1000; 5000 PPM 7 HR/D, 5D/WK FOR 104 WK (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[CILIBERTI,A, MALTONI,C AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON PROPYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):235-245, 1988]"
4174,363899306,8252,CC=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,"0; 200; 1000; 5000 PPM 7 HR/D, 5D/WK FOR 104 WK (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[CILIBERTI,A, MALTONI,C AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON PROPYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):235-245, 1988]"
4175,363899306,8252,CC=C,Inactive,,,,MOUSE,SWISS/FEMALE,INHALATION,"0; 200; 1000; 5000 PPM 7 HR/D, 5D/WK FOR 78 WK (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[CILIBERTI,A, MALTONI,C AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON PROPYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):235-245, 1988]"
4176,363899306,8252,CC=C,Inactive,,,,MOUSE,SWISS/MALE,INHALATION,"0; 200; 1000; 5000 PPM 7 HR/D, 5D/WK FOR 78 WK (STUDY DURATION: LIFESPAN)",,NEGATIVE,"[CILIBERTI,A, MALTONI,C AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON PROPYLENE ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):235-245, 1988]"
4177,363899306,8252,CC=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 200; 1000; 5000 PPM IN AIR 7 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
4178,363899306,8252,CC=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 200; 1000; 5000 PPM IN AIR 7 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
4179,363899307,7964,C1=CC=C(C=C1)Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-261 Y85]"
4180,363899307,7964,C1=CC=C(C=C1)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 30; 60 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-261 Y85]"
4181,363899307,7964,C1=CC=C(C=C1)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-261 Y85]"
4182,363899307,7964,C1=CC=C(C=C1)Cl,Unspecified,,,,RAT,F344/MALE,GAVAGE,0; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-261 Y85]"
4183,363899308,36383,C1=CC(=C(C=C1N(CCO)CCO)[N+](=O)[O-])NCCO,Inactive,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-293 Y85]"
4184,363899308,36383,C1=CC(=C(C=C1N(CCO)CCO)[N+](=O)[O-])NCCO,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-293 Y85]"
4185,363899308,36383,C1=CC(=C(C=C1N(CCO)CCO)[N+](=O)[O-])NCCO,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 104 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-293 Y85]"
4186,363899308,36383,C1=CC(=C(C=C1N(CCO)CCO)[N+](=O)[O-])NCCO,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 104 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-293 Y85]"
4187,363899309,,,Inactive,,,,RAT,F344/MALE,INHALATION,0; 1000; 5000 MG/M3 JP-4 JET FUEL VAPOR 6 HR/D 5 D/WK FOR 12 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BRUNER,RH, KINKEAD,ER, O'NEILL,TP, FLEMMING,CD, MATTIE,DR, RUSSELL,CA AND WALL, HG; THE TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 JET FUEL VAPORS IN RATS AND MICE: 12-MONTH INTERMITTENT INHALATION EXPOSURES; FUNDAM. APPL. TOXICOL. 20(1):97-110, 1993]"
4188,363899309,,,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 1000; 5000 MG/M3 JP-4 JET FUEL VAPOR 6 HR/D 5 D/WK FOR 12 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BRUNER,RH, KINKEAD,ER, O'NEILL,TP, FLEMMING,CD, MATTIE,DR, RUSSELL,CA AND WALL, HG; THE TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 JET FUEL VAPORS IN RATS AND MICE: 12-MONTH INTERMITTENT INHALATION EXPOSURES; FUNDAM. APPL. TOXICOL. 20(1):97-110, 1993]"
4189,363899309,,,Inactive,,,,MOUSE,C57BL/MALE,INHALATION,0; 1000; 5000 MG/M3 JP-4 JET FUEL VAPOR 6 HR/D 5 D/WK FOR 12 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BRUNER,RH, KINKEAD,ER, O'NEILL,TP, FLEMMING,CD, MATTIE,DR, RUSSELL,CA AND WALL, HG; THE TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 JET FUEL VAPORS IN RATS AND MICE: 12-MONTH INTERMITTENT INHALATION EXPOSURES; FUNDAM. APPL. TOXICOL. 20(1):97-110, 1993]"
4190,363899309,,,Inactive,,,,MOUSE,C57BL/FEMALE,INHALATION,0; 1000; 5000 MG/M3 JP-4 JET FUEL VAPOR 6 HR/D 5 D/WK FOR 12 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BRUNER,RH, KINKEAD,ER, O'NEILL,TP, FLEMMING,CD, MATTIE,DR, RUSSELL,CA AND WALL, HG; THE TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 JET FUEL VAPORS IN RATS AND MICE: 12-MONTH INTERMITTENT INHALATION EXPOSURES; FUNDAM. APPL. TOXICOL. 20(1):97-110, 1993]"
4191,363899309,,,Inactive,,,,RAT,F344/MALE,INHALATION,0; 200; 1000 MG/M3 (JP-TS JET FUEL) IN AIR 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HARRIS,RK, WITT,WM, DAVIS,H AND SCHMIDT,RE;TUMORIGENIC EVALUATION OF JET FUELS JP-TS AND JP-7; ARMSTRONG AEROSPACE MEDICAL RESEARCH LABORATORY, WRIGHT- PATTERSON AIR FORCE BASE, REPORT NO. AL-TR-1991-0020, NTIS AD-A252012, 1991]"
4192,363899309,,,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 200; 1000 MG/M3 (JP-TS JET FUEL) IN AIR 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HARRIS,RK, WITT,WM, DAVIS,H AND SCHMIDT,RE;TUMORIGENIC EVALUATION OF JET FUELS JP-TS AND JP-7; ARMSTRONG AEROSPACE MEDICAL RESEARCH LABORATORY, WRIGHT- PATTERSON AIR FORCE BASE, REPORT NO. AL-TR-1991-0020, NTIS AD-A252012, 1991]"
4193,363899309,,,Inactive,,,,RAT,F344/MALE,INHALATION,0; 150; 750 MG/M3 (JP-7 JET FUEL) IN AIR 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HARRIS,RK, WITT,WM, DAVIS,H AND SCHMIDT,RE;TUMORIGENIC EVALUATION OF JET FUELS JP-TS AND JP-7; ARMSTRONG AEROSPACE MEDICAL RESEARCH LABORATORY, WRIGHT- PATTERSON AIR FORCE BASE, REPORT NO. AL-TR-1991-0020, NTIS AD-A252012, 1991]"
4194,363899309,,,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 150; 750 MG/M3 (JP-7 JET FUEL) IN AIR 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HARRIS,RK, WITT,WM, DAVIS,H AND SCHMIDT,RE;TUMORIGENIC EVALUATION OF JET FUELS JP-TS AND JP-7; ARMSTRONG AEROSPACE MEDICAL RESEARCH LABORATORY, WRIGHT- PATTERSON AIR FORCE BASE, REPORT NO. AL-TR-1991-0020, NTIS AD-A252012, 1991]"
4195,363899309,,,Inactive,,,,MOUSE,C57BL/MALE,INHALATION,0; 200; 1000 MG/M3 (JP-TS JET FUEL) IN AIR 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HARRIS,RK, WITT,WM, DAVIS,H AND SCHMIDT,RE;TUMORIGENIC EVALUATION OF JET FUELS JP-TS AND JP-7; ARMSTRONG AEROSPACE MEDICAL RESEARCH LABORATORY, WRIGHT- PATTERSON AIR FORCE BASE, REPORT NO. AL-TR-1991-0020, NTIS AD-A252012, 1991]"
4196,363899309,,,Inactive,,,,MOUSE,C57BL/FEMALE,INHALATION,0; 200; 1000 MG/M3 IN AIR 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HARRIS,RK, WITT,WM, DAVIS,H AND SCHMIDT,RE;TUMORIGENIC EVALUATION OF JET FUELS JP-TS AND JP-7; ARMSTRONG AEROSPACE MEDICAL RESEARCH LABORATORY, WRIGHT- PATTERSON AIR FORCE BASE, REPORT NO. AL-TR-1991-0020, NTIS AD-A252012, 1991]"
4197,363899309,,,Inactive,,,,MOUSE,C57BL/MALE,INHALATION,0; 150; 750 MG/M3 (JP-7 JET FUEL) IN AIR 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HARRIS,RK, WITT,WM, DAVIS,H AND SCHMIDT,RE;TUMORIGENIC EVALUATION OF JET FUELS JP-TS AND JP-7; ARMSTRONG AEROSPACE MEDICAL RESEARCH LABORATORY, WRIGHT- PATTERSON AIR FORCE BASE, REPORT NO. AL-TR-1991-0020, NTIS AD-A252012, 1991]"
4198,363899309,,,Inactive,,,,MOUSE,C57BL/FEMALE,INHALATION,0; 150; 750 MG/M3 (JP-7 JET FUEL) IN AIR 6 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HARRIS,RK, WITT,WM, DAVIS,H AND SCHMIDT,RE;TUMORIGENIC EVALUATION OF JET FUELS JP-TS AND JP-7; ARMSTRONG AEROSPACE MEDICAL RESEARCH LABORATORY, WRIGHT- PATTERSON AIR FORCE BASE, REPORT NO. AL-TR-1991-0020, NTIS AD-A252012, 1991]"
4199,363899309,,,Inactive,,,,RAT,F344/MALE,INHALATION,0; 500; 1000 MG/M3 (JP-4 JET FUEL) 23 HR/D 7 D/WK FOR 90 D (STUDY DURATION: 24 MO),,NEGATIVE,"[KINKEAD,ER, WOLFE,RE, FLEMMING,CD, SOLOMON,RA, MATTIE,DR, GRABAU,JH AND MARIT, GB; TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 VAPOR: 90-DAY CONTINUOUS INHALATION EXPOSURE; INHALATION TOXICOL. 7(2):239-253, 1995]"
4200,363899309,,,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 500; 1000 MG/M3 (JP-4 JET FUEL) 23 HR/D 7 D/WK FOR 90 D (STUDY DURATION: 24 MO),,NEGATIVE,"[KINKEAD,ER, WOLFE,RE, FLEMMING,CD, SOLOMON,RA, MATTIE,DR, GRABAU,JH AND MARIT, GB; TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 VAPOR: 90-DAY CONTINUOUS INHALATION EXPOSURE; INHALATION TOXICOL. 7(2):239-253, 1995]"
4201,363899309,,,Inactive,,,,MOUSE,C57BL/6/MALE,INHALATION,0; 500; 1000 MG/M3 (JP-4 JET FUEL) 23 HR/D 7 D/WK FOR 90 D (STUDY DURATION: 24 MO),,NEGATIVE,"[KINKEAD,ER, WOLFE,RE, FLEMMING,CD, SOLOMON,RA, MATTIE,DR, GRABAU,JH AND MARIT, GB; TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 VAPOR: 90-DAY CONTINUOUS INHALATION EXPOSURE; INHALATION TOXICOL. 7(2):239-253, 1995]"
4202,363899309,,,Inactive,,,,MOUSE,C57BL/6/FEMALE,INHALATION,0; 500; 1000 MG/M3 (JP-4 JET FUEL) 23 HR/D 7 D/WK FOR 90 D (STUDY DURATION: 24 MO),,NEGATIVE,"[KINKEAD,ER, WOLFE,RE, FLEMMING,CD, SOLOMON,RA, MATTIE,DR, GRABAU,JH AND MARIT, GB; TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 VAPOR: 90-DAY CONTINUOUS INHALATION EXPOSURE; INHALATION TOXICOL. 7(2):239-253, 1995]"
4203,363899309,,,Inactive,,,,DOG,BEAGLE/MALE,INHALATION,0; 500; 1000 MG/M3 (JP-4 JET FUEL) 23 HR/D 7 D/WK FOR 90 D (STUDY DURATION: 90 D),,NEGATIVE,"[KINKEAD,ER, WOLFE,RE, FLEMMING,CD, SOLOMON,RA, MATTIE,DR, GRABAU,JH AND MARIT, GB; TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 VAPOR: 90-DAY CONTINUOUS INHALATION EXPOSURE; INHALATION TOXICOL. 7(2):239-253, 1995]"
4204,363899309,,,Inactive,,,,DOG,BEAGLE/FEMALE,INHALATION,0; 500; 1000 MG/M3 (JP-4 JET FUEL) 23 HR/D 7 D/WK FOR 90 D (STUDY DURATION: 90 D),,NEGATIVE,"[KINKEAD,ER, WOLFE,RE, FLEMMING,CD, SOLOMON,RA, MATTIE,DR, GRABAU,JH AND MARIT, GB; TOXICOLOGIC AND ONCOGENIC POTENTIAL OF JP-4 VAPOR: 90-DAY CONTINUOUS INHALATION EXPOSURE; INHALATION TOXICOL. 7(2):239-253, 1995]"
4205,363899309,,,Active,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 24 MO),SKIN: TUMOR,POSITIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
4206,363899309,,,Inactive,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 250; 500 MG/KG IN ACETONE 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-310 Y86]"
4207,363899309,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,DERMAL,0; 250 IN ACETONE 5 D/WK FOR 103 WK; 500 MG/KG IN ACETONE 5 D/WK FOR 90 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-310 Y86]"
4208,363899310,7239,C1=CC=C(C(=C1)Cl)Cl,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 60; 120 MG/KG BODY WT IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-255 Y85]"
4209,363899310,7239,C1=CC=C(C(=C1)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 60; 120 MG/KG BODY WT IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-255 Y85]"
4210,363899310,7239,C1=CC=C(C(=C1)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 60; 120 MG/KG BODY WT IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-255 Y85]"
4211,363899310,7239,C1=CC=C(C(=C1)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 60; 120 MG/KG BODY WT IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-255 Y85]"
4212,363899311,8560,C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-284 Y85]"
4213,363899311,8560,C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 150; 300 MG/KG IN CORN OIL FOR 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA; HEMATOPOIETIC SYSTEM: LYMPHOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-242 Y83]"
4214,363899311,8560,C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 150; 300 MG/KG IN CORN OIL FOR 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-242 Y83]"
4215,363899311,8560,C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-284 Y85]"
4216,363899312,17734,CNC1=C(C=C(C=C1)N(CCO)CCO)[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,ORAL,0; 1500; 3000 PPM IN DIET FOR 103 WK FOR 103 WK (STUDY DURATION: 105 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; UTERUS: ENDOMETRIAL STROMAL POLYP,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-271 Y85]"
4217,363899312,17734,CNC1=C(C=C(C=C1)N(CCO)CCO)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1500; 3000 PPM IN DIET FOR 103 WK FOR 103 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-271 Y85]"
4218,363899312,17734,CNC1=C(C=C(C=C1)N(CCO)CCO)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3000; 6000 PPM IN DIET FOR 103 WK FOR 103 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-271 Y85]"
4219,363899312,17734,CNC1=C(C=C(C=C1)N(CCO)CCO)[N+](=O)[O-],Unspecified,,,,RAT,F344/MALE,ORAL,0; 1500; 3000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR NEOPLASTIC NODULE OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-271 Y85]"
4220,363899313,3465817,C1=CC(=C(C=C1N)[N+](=O)[O-])NCCO,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-281 Y86]"
4221,363899313,3465817,C1=CC(=C(C=C1N)[N+](=O)[O-])NCCO,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-281 Y86]"
4222,363899313,3465817,C1=CC(=C(C=C1N)[N+](=O)[O-])NCCO,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-281 Y86]"
4223,363899314,6658,CC(=C)C(=O)OC,Inactive,,,,RAT,F344/MALE,INHALATION,"0; 500; 1,000 PPM 6 HR/D, 5 D/WK FOR 102 WK",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-314 Y86]"
4224,363899314,6658,CC(=C)C(=O)OC,Inactive,,,,RAT,F344/FEMALE,INHALATION,"0; 250; 500 PPM 6 HR/D, 5 D/WK FOR 102 WK",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-314 Y86]"
4225,363899314,6658,CC(=C)C(=O)OC,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 500; 1000 PPM 6 HR/D, 5 D/WK FOR 102 WK",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-314 Y86]"
4226,363899314,6658,CC(=C)C(=O)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 500; 1000 PPM 6 HR/D, 5 D/WK FOR 102 WK",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-314 Y86]"
4227,363899314,6658,CC(=C)C(=O)OC,Inactive,,,,RAT,F344/MALE,INHALATION,0; 25; 100; 400 PPM IN AIR 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 104-106 WK),,NEGATIVE,"[LOMAX,LG, KRIVANEK,ND AND FRAME,SR; CHRONIC INHALATION TOXICITY AND ONCOGENICITY OF METHYL METHACRYLATE IN RATS AND HAMSTERS; FOOD CHEM. TOXICOL. 35(3/4):393-407, 1997]"
4228,363899314,6658,CC(=C)C(=O)OC,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 25; 100; 400 PPM IN AIR 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 104-106 WK),,NEGATIVE,"[LOMAX,LG, KRIVANEK,ND AND FRAME,SR; CHRONIC INHALATION TOXICITY AND ONCOGENICITY OF METHYL METHACRYLATE IN RATS AND HAMSTERS; FOOD CHEM. TOXICOL. 35(3/4):393-407, 1997]"
4229,363899314,6658,CC(=C)C(=O)OC,Inactive,,,,HAMSTER,GOLDEN/FEMALE,INHALATION,0; 25; 100; 400 PPM IN AIR 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 78 WK),,NEGATIVE,"[LOMAX,LG, KRIVANEK,ND AND FRAME,SR; CHRONIC INHALATION TOXICITY AND ONCOGENICITY OF METHYL METHACRYLATE IN RATS AND HAMSTERS; FOOD CHEM. TOXICOL. 35(3/4):393-407, 1997]"
4230,363899314,6658,CC(=C)C(=O)OC,Inactive,,,,HAMSTER,GOLDEN/MALE,INHALATION,0; 25; 100; 400 PPM IN AIR 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 78 WK),,NEGATIVE,"[LOMAX,LG, KRIVANEK,ND AND FRAME,SR; CHRONIC INHALATION TOXICITY AND ONCOGENICITY OF METHYL METHACRYLATE IN RATS AND HAMSTERS; FOOD CHEM. TOXICOL. 35(3/4):393-407, 1997]"
4231,363899315,115083,CCCCCCCCCCCCCCN(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 140 MG/ML IN CORN OIL 2/WK FOR 30 WK; STUDY DURATION: 110 WK,BLADDER,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; INDUCTION OF CARCINOGENESIS IN FISCHER RATS BY METHYLALKYLNITROSAMINES; CANCER RES. 41(4):1288-1292, 1981]"
4232,363899316,53394,CCCCCCCCCCN(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 108 MG/ML IN CORN OIL 2/WK FOR 30 WK; STUDY DURATION: 110 WK,LUNG: ADENOCARCINOMA; BLADDER,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; INDUCTION OF CARCINOGENESIS IN FISCHER RATS BY METHYLALKYLNITROSAMINES; CANCER RES. 41(4):1288-1292, 1981]"
4233,363899317,53393,CCCCCCCCCN(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 100 MG/ML IN CORN OIL 2/WK FOR 30 WK; STUDY DURATION: 60 WK,"LUNG: ADENOCARCINOMA; NASAL CAVITY: CARCINOMA, PAPILLOMA; LIVER: CHOLANGIOCARCINOMA, HEPATOCELLULAR TUMOR",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; INDUCTION OF CARCINOGENESIS IN FISCHER RATS BY METHYLALKYLNITROSAMINES; CANCER RES. 41(4):1288-1292, 1981]"
4234,363899318,36828,CCCCCCCCN(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 93 MG/ML IN CORN OIL 2/WK FOR 30 WK; STUDY DURATION: 50 WK,"LUNG: ADENOCARCINOMA, ADENOMA; NASAL CAVITY: CARCINOMA; LIVER: HEPATOCELLULAR TUMOR; BLADDER",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; INDUCTION OF CARCINOGENESIS IN FISCHER RATS BY METHYLALKYLNITROSAMINES; CANCER RES. 41(4):1288-1292, 1981]"
4235,363899318,36828,CCCCCCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 7.4 MG/KG 1/WK FOR 40 WK (TOTAL DOSE: 0; 2.1 MMOL) (STUDY DURATION: LIFETIME),"LIVER: HEPATOCELLULAR ADENOMA, CHOLANGIOMA, HEMANGIOSARCOMA; LUNG: ALVEOLAR/ BRONCHIAL ADENOMA; NASAL MUCOSA: ADENOMA; URINARY BLADDER: TRANSITIONAL CELL PAPILLOMA, HEMANGIOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
4236,363899318,36828,CCCCCCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 7.4 MG/KG 1/WK FOR 40 WK (TOTAL DOSE: 0; 2.1 MMOL) (STUDY DURATION: LIFETIME),"LIVER: HEPATOCELLULAR ADENOMA; LUNG: ALVEOLAR/BRONCHIAL ADENOMA; NASAL MUCOSA: ADENOMA; URINARY BLADDER: SARCOMA, UNDIFFERENTIATED; FORESTOMACH: SQUAMOUS CELL PAPILLOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
4237,363899319,2206,CC1=CC(=O)N(N1C)C2=CC=CC=C2,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.535% IN DIET FOR 117 WK,KIDNEY,POSITIVE,"[JOHANSSON,SL; CARCINOGENICITY OF ANALGESICS: LONG-TERM TREATMENT OF SPRAGUE-DAWLEY RATS WITH PHENACETIN, PHENAZONE, CAFFEINE AND PARACETAMOL (ACETAMIDOPHEN); INT. J. CANCER 27:521-529, 1981]"
4238,363899320,149740,CC1CN(CC(N1C(=O)C2=CC=CC=C2)C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 172 MG/L IN DRINKING WATER 5 D/WK FOR 50 WK; STUDY DURATION: 120-130 WK,FORESTOMACH: PAPILLOMA OR CARCINOMA,POSITIVE,"[SINGER,SS, SINGER,GM, SAAVEDRA,JE, REUBER,MD AND LIJINSKY,W; CARCINOGENESIS BY DERIVATIVES OF 1-NITROSO-3,5-DIMETHYLPIPERAZINE IN RATS; CANCER RES. 41:1034-1038, 1981]"
4239,363899321,135652,CC1CN(CC(N1C(=O)C)C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 130 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK; STUDY DURATION: 30-40 WK,ESOPHAGUS: CARCINOMA; TONGUE: PAPILLOMA OR CARCINOMA,POSITIVE,"[SINGER,SS, SINGER,GM, SAAVEDRA,JE, REUBER,MD AND LIJINSKY,W; CARCINOGENESIS BY DERIVATIVES OF 1-NITROSO-3,5-DIMETHYLPIPERAZINE IN RATS; CANCER RES. 41:1034-1038, 1981]"
4240,363899322,92376,CC1CN(CC(N1)C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 100 MG/L IN DRINKING WATER 5 D/WK FOR 29 WK; STUDY DURATION: 40-50 WK,THYMUS GLAND: LYMPHOMA OR LEUKEMIA; MULTIPLE SITES: LYMPHOMA OR LEUKEMIA,POSITIVE,"[SINGER,SS, SINGER,GM, SAAVEDRA,JE, REUBER,MD AND LIJINSKY,W; CARCINOGENESIS BY DERIVATIVES OF 1-NITROSO-3,5-DIMETHYLPIPERAZINE IN RATS; CANCER RES. 41:1034-1038, 1981]"
4241,363899323,150692,CC1CN(CC(N1C)C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 110 MG/L IN DRINKING WATER 5 D/WK FOR 26 WK; STUDY DURATION: 40-50 WK,THYMUS GLAND: LYMPHOMA OR LEUKEMIA; MULTIPLE SITES: LYMPHOMA OR LEUKEMIA; NASAL CAVITY: CARCINOMA,POSITIVE,"[SINGER,SS, SINGER,GM, SAAVEDRA,JE, REUBER,MD AND LIJINSKY,W; CARCINOGENESIS BY DERIVATIVES OF 1-NITROSO-3,5-DIMETHYLPIPERAZINE IN RATS; CANCER RES. 41:1034-1038, 1981]"
4242,363899324,11112,C1=CC(=CN=C1)C(=O)NN,Active,,,,MOUSE,SWISS/MALE,ORAL,0; 0.125% IN DRINKING WATER FOR LIFE; STUDY DURATION: 90-100 WK,LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[TOTH,B; NICOTINIC ACID HYDRAZIDE CARCINOGENESIS IN MICE; ONCOLOGY 38:106-109, 1981]"
4243,363899324,11112,C1=CC(=CN=C1)C(=O)NN,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 0.125% IN DRINKING WATER FOR LIFE; STUDY DURATION: 100-110 WK,"LUNG: ADENOMA, ADENOMA OR ADENOCARCINOMA",POSITIVE,"[TOTH,B; NICOTINIC ACID HYDRAZIDE CARCINOGENESIS IN MICE; ONCOLOGY 38:106-109, 1981]"
4244,363899325,46335,CCCCCN(C(=O)OCC)N=O,Active,,,,RAT,DONRYU/FEMALE,ORAL,0; 100; 200; 400 PPM IN DRINKING WATER FOR 60 WK,"ORAL CAVITY: PAPILLOMA, CARCINOMA; ESOPHAGUS: PAPILLOMA, CARCINOMA; FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[ONODERA,H, FURUTA,K, MATSUOKA,C, KAMIYA,S AND MAEKAWA,A; CARCINOGENICITIES OF 1-ETHYL- AND 1-AMYL-1-NITROSOURETHANS IN FEMALE DONRYU RATS: DOSE-EFFECT RELATIONS; GANN 73:48-54, 1982]"
4245,363899326,11977,CCN(C(=O)OCC)N=O,Active,,,,RAT,DONRYU/FEMALE,ORAL,0; 25; 50; 100 PPM IN DRINKING WATER FOR 60 WK,"ORAL CAVITY: PAPILLOMA, CARCINOMA; ESOPHAGUS: PAPILLOMA, CARCINOMA; FORESTOMACH: PAPILLOMA, CARCINOMA; DUODENUM: ADENOMA OR CARCINOMA, CARCINOMA",POSITIVE,"[ONODERA,H, FURUTA,K, MATSUOKA,C, KAMIYA,S AND MAEKAWA,A; CARCINOGENICITIES OF 1-ETHYL- AND 1-AMYL-1-NITROSOURETHANS IN FEMALE DONRYU RATS: DOSE-EFFECT RELATIONS; GANN 73:48-54, 1982]"
4246,363899326,11977,CCN(C(=O)OCC)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 0.36; 1.6 MG/ANIMAL IN CORN OIL 1/WK FOR 20 WK (STUDY DURATION: 114 WK),"FORESTOMACH: CARCINOMA, PAPILLOMA OR CARCINOMA",POSITIVE,"[LIJINSKY,W AND REUBER,MD; STUDIES OF A DEUTERIUM ISOTOPE EFFECT IN CARCINOGENESIS BY N-NITROSO-N-ALKYLURETHANES IN RATS; CANCER LETT. 16:273-279, 1982]"
4247,363899326,11977,CCN(C(=O)OCC)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.15; 0.6; 2.5; 10 PPM IN DISTILLED WATER FOR 2 YRS (STUDY DURATION: 112 WK),"ORAL CAVITY: PAPILLOMA, CARCINOMA; ESOPHAGUS: PAPILLOMA, CARCINOMA; FORESTOMACH: PAPILLOMA, CARCINOMA",POSITIVE,"[MAEKAWA,A, ONODERA,H, MATSUSHIMA,Y, NAGAOKA,T, TODATE,A, SHIBUTANI,M, KODAMA,Y AND HAYASHI,Y; DOSE-RESPONSE CARCINOGENICITY IN RATS ON LOW-DOSE LEVELS OF N-ETHYL-N-NITROSOURETHANE; JPN. J. CANCER RES. 80(7):632-636, 1989]"
4248,363899326,11977,CCN(C(=O)OCC)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 0.8 MG 2/WK FOR 14 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
4249,363899326,11977,CCN(C(=O)OCC)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 14 MG/ML ((0.2 ML OF A SOLUTION IN ETHYL ACETATE/CORN OIL (1:2)) 1/WK FOR 28 WK (STUDY DURATION: LIFE SPAN),PANCREAS: CARCINOMA OR ADENOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA OR PAPILLOMA,POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
4250,363899327,55145,C=CSCCC(C(=O)O)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.05% IN METHYL-DEFICIENT DIET FOR 20 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[LEOPOLD,WR, MILLER,JA AND MILLER EC; COMPARISON OF SOME CARCINOGENIC, MUTAGENIC, AND BIOCHEMICAL PROPERTIES OF S-VINYLHOMOCYSTEINE AND ETHIONINE; CANCER RES. 42:4364-4374, 1982]"
4251,363899327,55145,C=CSCCC(C(=O)O)N,Active,,,,RAT,F344/MALE,INTRAPERITONEAL,0; 50-100 MG/KG 5 D/WK FOR 12 WK; STUDY DURATION: 25 MO,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[LEOPOLD,WR, MILLER,JA AND MILLER EC; COMPARISON OF SOME CARCINOGENIC, MUTAGENIC, AND BIOCHEMICAL PROPERTIES OF S-VINYLHOMOCYSTEINE AND ETHIONINE; CANCER RES. 42:4364-4374, 1982]"
4252,363899332,5324276,CC/C(=N\O)/C,Active,,,,RAT,F344/MALE,INHALATION,0; 15; 75; 374 PPM 6 HR/D 5 D/WK FOR 26 MO (STUDY DURATION: 26 MO),"LIVER: ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NEWTON,PE WOODING,WL BOLTE,HF DERELANKO,MJ HARDISTY,JF AND RINEHART,WE; A CHRONIC INHALATION TOXICITY/ONCOGENICTY STUDY OF METHYLETHYLKETOXIME IN RATS AND MICE; INHALATION TOXICOL. 13(12):1093-1116, 2001]"
4253,363899332,5324276,CC/C(=N\O)/C,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 15; 75; 374 PPM 6 HR/D 5 D/WK FOR 26 MO (STUDY DURATION: 26 MO),,NEGATIVE,"[NEWTON,PE WOODING,WL BOLTE,HF DERELANKO,MJ HARDISTY,JF AND RINEHART,WE; A CHRONIC INHALATION TOXICITY/ONCOGENICTY STUDY OF METHYLETHYLKETOXIME IN RATS AND MICE; INHALATION TOXICOL. 13(12):1093-1116, 2001]"
4254,363899332,5324276,CC/C(=N\O)/C,Active,,,,MOUSE,CD-1/MALE,INHALATION,0; 15; 75; 374 PPM 6 HR/D 5 D/WK FOR 26 MO (STUDY DURATION: 26 MO),"LIVER: CARCINOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NEWTON,PE WOODING,WL BOLTE,HF DERELANKO,MJ HARDISTY,JF AND RINEHART,WE; A CHRONIC INHALATION TOXICITY/ONCOGENICTY STUDY OF METHYLETHYLKETOXIME IN RATS AND MICE; INHALATION TOXICOL. 13(12):1093-1116, 2001]"
4255,363899332,5324276,CC/C(=N\O)/C,Inactive,,,,MOUSE,CD-1/FEMALE,INHALATION,0; 15; 75; 374 PPM 6 HR/D 5 D/WK FOR 26 MO (STUDY DURATION: 26 MO),,NEGATIVE,"[NEWTON,PE WOODING,WL BOLTE,HF DERELANKO,MJ HARDISTY,JF AND RINEHART,WE; A CHRONIC INHALATION TOXICITY/ONCOGENICTY STUDY OF METHYLETHYLKETOXIME IN RATS AND MICE; INHALATION TOXICOL. 13(12):1093-1116, 2001]"
4256,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN POWDERED BASAL DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
4257,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN POWDERED BASAL DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: PAPILLOMA,POSITIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
4258,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2% IN POWDERED BASAL DIET FOR 96 WK (STUDY DURATION: 96 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
4259,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2% IN POWDERED BASAL DIET FOR 96 WK (STUDY DURATION: 96 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[HIROSE,M, FUKUSHIMA,S, SHIRAI,T, HASEGAWA,R, KATO,T, TANAKA,H, ASAKAWA,E AND ITO,N; STOMACH CARCINOGENICITY OF CAFFEIC ACID, SESAMOL AND CATECHOL IN RATS AND MICE; JPN.J. CANCER RES. 81(3):207-12, 1990]"
4260,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369(CHEM. INDUCED CELL PROLIFERATION):43-52, 1991]"
4261,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369(CHEM. INDUCED CELL PROLIFERATION):43-52, 1991]"
4262,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369:43-52, 1991]"
4263,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369:43-52, 1991]"
4264,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[TAMANO,S, HIROSE,M, TANAKA,H, ASAKAWA,E, OGAWA,K AND ITO,N; FORESTOMACH NEOPLASM INDUCTION IN F344/DUCRJ RATS AND B6C3F1 MICE EXPOSED TO SESAMOL; JPN. J. CANCER RES. 83(12):1279-1285, 1992]"
4265,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: PAPILLOMA,POSITIVE,"[TAMANO,S, HIROSE,M, TANAKA,H, ASAKAWA,E, OGAWA,K AND ITO,N; FORESTOMACH NEOPLASM INDUCTION IN F344/DUCRJ RATS AND B6C3F1 MICE EXPOSED TO SESAMOL; JPN. J. CANCER RES. 83(12):1279-1285, 1992]"
4266,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2% IN DIET FOR 96 WK (STUDY DURATION: 96 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[TAMANO,S, HIROSE,M, TANAKA,H, ASAKAWA,E, OGAWA,K AND ITO,N; FORESTOMACH NEOPLASM INDUCTION IN F344/DUCRJ RATS AND B6C3F1 MICE EXPOSED TO SESAMOL; JPN. J. CANCER RES. 83(12):1279-1285, 1992]"
4267,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2% IN DIET FOR 96 WK (STUDY DURATION: 96 WK),FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[TAMANO,S, HIROSE,M, TANAKA,H, ASAKAWA,E, OGAWA,K AND ITO,N; FORESTOMACH NEOPLASM INDUCTION IN F344/DUCRJ RATS AND B6C3F1 MICE EXPOSED TO SESAMOL; JPN. J. CANCER RES. 83(12):1279-1285, 1992]"
4268,363899336,68289,C1OC2=C(O1)C=C(C=C2)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.4% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[HIROSE,M, TAKESADA,Y, TANAKA,H, TAMANO,S, KATO,T AND SHIRAI,T; CARCINOGENICITY OF ANTIOXIDANTS BHA, CAFFEIC ACID, SESAMOL, 4-METHOXYPHENOL AND CATECHOL AT LOW DOSES, EITHER ALONE OR IN COMBINATION, AND MODULATION OF THEIR EFFECTS IN A RAT MEDIUM-TERM MULTI-ORGAN CARCINOGENESIS MODEL; CARCINOGENESIS 19(1):207-212, 1998]"
4269,363899338,7017,C1=CC=C(C=C1)C2=CC=CC=C2O,Inactive,,,,MOUSE,CD-1/MALE,DERMAL,0; 55.5 MG/ANIMAL IN 0.1 ML ACETONE 3 D/WK FOR 102 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-301 Y86]"
4270,363899338,7017,C1=CC=C(C=C1)C2=CC=CC=C2O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 55.5 MG/ANIMAL IN 0.1 ML ACETONE 3 D/WK FOR 102 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-301 Y86]"
4271,363899338,7017,C1=CC=C(C=C1)C2=CC=CC=C2O,Active,,,,RAT,F344/MALE,ORAL,0; 0.625; 1.25; 2.5% IN PELLET DIET FOR STUDY DURATION (STUDY DURATION: 91 WK),"BLADDER: TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA",POSITIVE,"[HIRAGA,K AND FUJII,T; INDUCTION OF TUMORS OF THE URINARY BLADDER IN F344 RATS BY DIETARY ADMINISTRATION OF O-PHENYLPHENOL; FOOD CHEM. TOXICOL. 22(11): 865-870, 1984]"
4272,363899339,8005,CCCCCl,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-312 Y86]"
4273,363899339,8005,CCCCCl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-312 Y86]"
4274,363899339,8005,CCCCCl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-312 Y86]"
4275,363899339,8005,CCCCCl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-312 Y86]"
4276,363899342,4944,CC(C)OC1=CC=CC=C1OC(=O)NC,Inactive,,,,MOUSE,SWISS/MALE,DERMAL,0; 100 MG/KG BW IN 100 UL ACETONE 3/WK FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[SHUKLA,Y, BAQAR,SM AND MEHROTRA,NK; CARCINOGENICITY AND CO-CARCINOGENICITY STUDIES ON PROPOXUR IN MOUSE SKIN; FOOD CHEM. TOXICOL. 36(12):1125-1130, 1998]"
4277,363899342,4944,CC(C)OC1=CC=CC=C1OC(=O)NC,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 100 MG/KG BW IN 100 UL ACETONE 3/WK FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[SHUKLA,Y, BAQAR,SM AND MEHROTRA,NK; CARCINOGENICITY AND CO-CARCINOGENICITY STUDIES ON PROPOXUR IN MOUSE SKIN; FOOD CHEM. TOXICOL. 36(12):1125-1130, 1998]"
4278,363899346,177,CC=O,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 750; 1500; 3000 PPM 6 HR/D 5 D/WK AFTER 4 MO HIGH DOSE REDUCED TO 2150 PPM THEN 1500 PPM AT 6 MO AND 1000 PPM AT 12 MO (STUDY DURATION: 15 MO),NASAL CAVITY: TUMOR,POSITIVE,"[WOUTERSEN,RA, APPELMAN,LM, FERON,VJ AND VAN DER HEIJDEN,CA; INHALATION TOXICITY OF ACETALDEHYDE IN RATS. II. CARCINOGENICITY STUDY: INTERIM RESULTS AFTER 15 MONTHS; TOXICOLOGY 31(2):123-133, 1984]"
4279,363899346,177,CC=O,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 750; 1500; 3000 PPM 6 HR/D 5 D/WK AFTER 4 MO HIGH DOSE REDUCED TO 2150 PPM THEN 1500 PPM AT 6 MO AND 1000 PPM AT 12 MO (STUDY DURATION: 15 MO),NASAL CAVITY: TUMOR,POSITIVE,"[WOUTERSEN,RA, APPELMAN,LM, FERON,VJ AND VAN DER HEIJDEN,CA; INHALATION TOXICITY OF ACETALDEHYDE IN RATS. II. CARCINOGENICITY STUDY: INTERIM RESULTS AFTER 15 MONTHS; TOXICOLOGY 31(2):123-133, 1984]"
4280,363899353,12192,CCOC(=O)C=[N+]=[N-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,0; 100 MG/KG IN ISOTONIC SALINE ONCE (STUDY DURATION: 843-880 D),"INTEGUMENTARY SYSTEM (SKIN): PAPILLOMA, SEBACEOUS GLAND ADENOMA, SQUAMOUS CELL CARCINOMA, BASAL CELL EPITHELIOMA",POSITIVE,"[SCHWEIZER,J, LOEHRKE,H, HESSE,B AND GOERTTLER,K; 7,12-DIMETHYLBENZ(A)ANTHRACENE /12-O-TETRADECANOYL-PHORBOL-13-ACETATE-MEDIATED SKIN TUMOR INITIATION AND PROMOTION IN MALE SPRAGUE-DAWLEY RATS; CARCINOGENESIS 3(7):785-789, 1982]"
4281,363899353,12192,CCOC(=O)C=[N+]=[N-],Active,,,,RAT,WHITE OUTBRED/MALE,DERMAL,0; 0.1 ML OF A 10% ETHER SOLUTION 2/WK FOR 48 WK (STUDY DURATION: 68 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
4282,363899353,12192,CCOC(=O)C=[N+]=[N-],Active,,,,RAT,WHITE OUTBRED/MALE,DERMAL,0; 0.1 ML OF A 50% ETHER SOLUTION 5/WK FOR 40 WK (STUDY DURATION: 100 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
4283,363899353,12192,CCOC(=O)C=[N+]=[N-],Active,,,,RAT,WHITE OUTBRED/MALE,INTRAVENOUS,0; 25 MG/KG ONCE EVERY 7 TO 10 D FOR 30 WK (STUDY DURATION: 104 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
4284,363899353,12192,CCOC(=O)C=[N+]=[N-],Active,,,,RAT,WHITE OUTBRED/MALE,INTRAPERITONEAL,0; 10 MG/KG ONCE EVERY 7 TO 10 D FOR 30 WK (STUDY DURATION: 100 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
4285,363899353,12192,CCOC(=O)C=[N+]=[N-],Inactive,,,,RAT,WHITE OUTBRED/FEMALE,INTRAVENOUS,0; 25 MG/KG ONCE EVERY 7 TO 10 D FOR 30 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
4286,363899353,12192,CCOC(=O)C=[N+]=[N-],Inactive,,,,RAT,WHITE OUTBRED/FEMALE,INTRAPERITONEAL,0; 10 MG/KG ONCE EVERY 7 TO 10 D FOR 30 WK (STUDY DURATION: 100 WK),,NEGATIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
4287,363899353,12192,CCOC(=O)C=[N+]=[N-],Inactive,,,,RAT,WHITE OUTBRED/FEMALE,SUBCUTANEOUS,0; 10 MG/KG ONCE EVERY 7 TO 10 D FOR 30 WK (STUDY DURATION: 43 WK),,NEGATIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
4288,363899353,12192,CCOC(=O)C=[N+]=[N-],Inactive,,,,RAT,WHITE OUTBRED/MALE,SUBCUTANEOUS,0; 10 MG/KG ONCE EVERY 7 TO 10 D FOR 30 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
4289,363899353,12192,CCOC(=O)C=[N+]=[N-],Active,,,,RAT,WHITE OUTBRED/MALE,DERMAL,0; 0.2 ML OF A 50% ETHER SOLUTION 2/WK FOR 48 WK (STUDY DURATION: 48 WK),SKIN: TUMOR,POSITIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
4290,363899354,21152,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Na+],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 1000 PPM (PURITY NOT REPORTED) IN DRINKING WATER FOR 2 YR,KIDNEY: TUBULAR CELL ADENOMA OR ADENOCARCINOMA,POSITIVE,"[GOYER,RA, FALK,HL, HOGAN,M, FELDMAN,DD AND RICHTER,W; RENAL TUMORS IN RATS GIVEN TRISODIUM NITRILOTRIACETIC ACID IN DRINKNG WATER FOR 2 YEARS; J. NATL. CANCER INST. 66(5):869-880, 1981]"
4291,363899355,5284417,CN1C=C(C(=O)C2=C1N=C(C=C2)/C=C/C3=CC=C(O3)[N+](=O)[O-])C(=O)[O-].[K+],Active,,,,MOUSE,ICR/MALE,ORAL,0; 0.012% IN DIET FOR 14 WK (STUDY DURATION: 53 WK),"FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA; LUNG: PAPILLARY ADENOCARCINOMA",POSITIVE,"[KURODA,K, KANISAWA,M AND AKAO,M; INHIBITORY EFFECT OF FUMARIC ACID ON FORESTOMACH AND LUNG CARCINOGENESIS BY A 5-NITROFURAN NAPHTHYRIDINE DERIVATIVE IN MICE; J. NATL. CANCER INST. 69(6):1317-1320, 1982]"
4292,363899356,73456703,[H+].[H+].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[Ca+2].[Ca+2].[Fe+2].[Fe+2].[Fe+2].[Fe+2].[Fe+2],Active,,,,RAT,F344/MALE,INTRAPLEURAL,0; 20 MG/ANIMAL IN SALINE ONCE (STUDY DURATION: LIFESPAN),PLEURAL CAVITY: MESOTHELIOMA,POSITIVE,"[COFFIN,DL, PALEKAR,LD AND COOK,PM; TUMORIGENESIS BY A FERROACTINOLITE MINERAL;TOXICOL. LETT. 13:143-150, 1982]"
4293,363899357,51665,CC1=C(C(=CC=C1)OCC(CNC(C)(C)C)O)[N+](=O)[O-],Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 25; 50; 100 MG/KG DAILY BY GAVAGE FOR 3 OR 6 MO,"LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA",POSITIVE,"[RAGNOTTI,G, PRESTA,M, RIBONI,L AND ZAVANELLA,T; LIVER TUMORS INDUCED BY A NEW BETA-ADRENORECEPTOR BLOCKING AGENT IN FEMALE RATS; J. NATL. CANCER INST. 68(4):669-672, 1982]"
4294,363899358,5284475,CC1=C2C3=CC=CC=C3NC2=CC(=N1)N.CC(=O)O,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 200 PPM IN DIET FOR 621 D,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[MATSUKURA,N, KAWACHI,T, MORINO,K, OHGAKI,H, SUGIMURA,T, AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM A TRYPTOPHAN PYROLYZATE; SCIENCE 213:346-347, 1981]"
4295,363899359,5284473,CC1=C2C(=C(N=C1N)C)C3=CC=CC=C3N2.CC(=O)O,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 200 PPM IN DIET FOR 621 D,LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[MATSUKURA,N, KAWACHI,T, MORINO,K, OHGAKI,H, SUGIMURA,T, AND TAKAYAMA,S; CARCINOGENICITY IN MICE OF MUTAGENIC COMPOUNDS FROM A TRYPTOPHAN PYROLYZATE; SCIENCE 213:346-347, 1981]"
4296,363899360,,,Active,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 400 UG/G BW IN 0.01 ML OF 0.9% SALINE ONCE (STUDY DURATION: 120 WK),GLANDULAR STOMACH: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[TOTH,B, NAGEL,D AND ROSS,A; GASTRIC TUMORIGENESIS BY A SINGLE DOSE OF 4-(HYDROXYMETHYL)BENZENEDIAZONIUM ION OF AGARICUS BISPORUS; BR. J. CANCER 46:417-422, 1982]"
4297,363899360,,,Active,,,,MOUSE,SWISS/MALE,GAVAGE,0; 400 UG/G BW IN 0.01 ML OF 0.9% SALINE ONCE (STUDY DURATION: 88 WK),GLANDULAR STOMACH: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[TOTH,B, NAGEL,D AND ROSS,A; GASTRIC TUMORIGENESIS BY A SINGLE DOSE OF 4-(HYDROXYMETHYL)BENZENEDIAZONIUM ION OF AGARICUS BISPORUS; BR. J. CANCER 46:417-422, 1982]"
4298,363899360,,,Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 50 UG/G/WK IN 0.9% SALINE FOR 26 WK (STUDY DURATION: 110 WK),SKIN: TUMOR; SUBCUTIS: TUMOR,POSITIVE,"[TOTH,B, PATIL,K AND JAE,HS; CARCINOGENESIS OF 4-(HYDROXYMETHYL)BENZENEDIAZONIUM ION(TETRAFLUOROBORATE) OF AGARICUS BISPORUS; CANCER RES. 41:2444-2449, 1981]"
4299,363899360,,,Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 50 UG/G/WK IN 0.9% SALINE FOR 26 WK (STUDY DURATION: 100 WK),SKIN: TUMOR; SUBCUTIS: TUMOR,POSITIVE,"[TOTH,B, PATIL,K AND JAE,HS; CARCINOGENESIS OF 4-(HYDROXYMETHYL)BENZENEDIAZONIUM ION(TETRAFLUOROBORATE) OF AGARICUS BISPORUS; CANCER RES. 41:2444-2449, 1981]"
4300,363899361,51366,CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)N(C(=O)C)O,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,"0; 10; 30 UMOL/KG IN TRIOCTANOIN 2/WK FOR 4 WK (TOTAL DOSES: 13.2, 40.0 UMOL) (STUDY DURATION: 46 WK)","MAMMARY GLAND: FIBROADENOMA, ADENOCARCINOMA; EAR (ZYMBAL GLAND): ADENOMA OR CARCINOMA",POSITIVE,"[MORTON,KC, WANG,CY, GARNER,CD AND SHIRAI,T;CARCINOGENICITY OF BENZIDINE, N,N'-DIACETYLBENZIDINE, AND N-HYDROXY-N,N'-DIACETYLBENZIDINE FOR FEMALE CD RATS; CARCINOGENESIS 2(8):747-752, 1981]"
4301,363899362,10754,C1=CC(=CC=C1C2=CC=C(C=C2)N)N.Cl.Cl,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,"0; 10; 30 UMOL/KG IN TRIOCTANOIN 2/WK FOR 4 WK (TOTAL DOSES: 13.5, 40.1 UMOL) (STUDY DURATION: 46 WK)","MAMMARY GLAND: FIBROADENOMA, ADENOCARCINOMA; EAR (ZYMBAL GLAND): ADENOMA OR CARCINOMA",POSITIVE,"[MORTON,KC, WANG,CY, GARNER,CD AND SHIRAI,T;CARCINOGENICITY OF BENZIDINE, N,N'-DIACETYLBENZIDINE, AND N-HYDROXY-N,N'-DIACETYLBENZIDINE FOR FEMALE CD RATS; CARCINOGENESIS 2(8):747-752, 1981]"
4302,363899363,32154,CC(C)(C#C)NC(=O)C1=CC(=CC(=C1)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 20; 100; 500; 2500 PPM IN DIET FOR 12, 18 OR 24 MO (STUDY DURATION: 24 MO)",LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA,POSITIVE,"[ESSIGMANN,EM AND NEWBERNE,PM; ENZYMATIC ALTERATIONS IN MOUSE HEPATIC NODULES INDUCED BY A CHLORINATED HYDROCARBON PESTICIDE; CANCER RES. 41:2823-2831, 1981]"
4303,363899364,5284474,CC1=C2C(=C(N=C1N)C)C3=CC=CC=C3N2,Active,,,,MOUSE,DDY/FEMALE,BLADDER IMPLANT,0; 5% IN PARAFFIN PELLET (STUDY DURATION: 40 WK),URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[HASHIDA,C, NAGAYAMA,K AND TAKEMURA,N; INDUCTION OF BLADDER CANCER IN MICE BY IMPLANTING PELLETS CONTAINING TRYPTOPHAN PYROLYSIS PRODUCTS; CANCER LETT. 17:101-105, 1982]"
4304,363899364,5284474,CC1=C2C(=C(N=C1N)C)C3=CC=CC=C3N2,Active,,,,RAT,F344/MALE,ORAL,0; 0.015% IN PELLET DIET FOR DURATION OF STUDY (STUDY DURATION: 365 D),"LIVER: TRABECULAR CARCINOMA, ADENOCARCINOMA",POSITIVE,"[TAKAYAMA,S, NAKATSURU,Y, OHGAKI,H, SATO,S AND SUGIMURA,T; CARCINOGENICITY IN RATS OF A MUTAGENIC COMPOUND, 3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-B]INDOLE, FROM TRYPTOPHAN PYROLYSATE; JPN. J. CANCER RES. (GANN) 76(9):815-817, 1985]"
4305,363899364,5284474,CC1=C2C(=C(N=C1N)C)C3=CC=CC=C3N2,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.02% IN PELLET DIET FOR DURATION OF STUDY (STUDY DURATION: 365 D),"LIVER: TRABECULAR CARCINOMA, ADENOCARCINOMA",POSITIVE,"[TAKAYAMA,S, NAKATSURU,Y, OHGAKI,H, SATO,S AND SUGIMURA,T; CARCINOGENICITY IN RATS OF A MUTAGENIC COMPOUND, 3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-B]INDOLE, FROM TRYPTOPHAN PYROLYSATE; JPN. J. CANCER RES. (GANN) 76(9):815-817, 1985]"
4306,363899365,5284476,CC1=C2C3=CC=CC=C3NC2=CC(=N1)N,Active,,,,MOUSE,DDY/FEMALE,BLADDER IMPLANT,0; 5% IN PARAFFIN PELLET (STUDY DURATION: 40 WK),URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[HASHIDA,C, NAGAYAMA,K AND TAKEMURA,N; INDUCTION OF BLADDER CANCER IN MICE BY IMPLANTING PELLETS CONTAINING TRYPTOPHAN PYROLYSIS PRODUCTS; CANCER LETT. 17:101-105, 1982]"
4307,363899365,5284476,CC1=C2C3=CC=CC=C3NC2=CC(=N1)N,Active,,,,RAT,F344/MALE,ORAL,0; 30; 100 PPM IN DIET FOR 112 WK (STUDY DURATION: 112 WK),LIVER: HEPATOCELLULAR ADENOMA; URINARY BLADDER: TRANSITIONAL CELL PAPILLOMA; MAMMARY GLAND: FIBROADENOMA OR FIBROMA,POSITIVE,"[TAKAHASHI,M, TOYODA,K, AZE,Y, FURUTA,K, MITSUMORI,K AND HAYASHI,Y; THE RAT URINARY BLADDER AS A NEW TARGET OF HETEROCYCLIC AMINE CARCINOGENICITY: TUMOR INDUCTION BY 3-AMINO-1-METHYL-5H-PYRIDO[4,3-B]INDOLE ACETATE; JPN. J. CANCER RES. 84(8):852-858, 1993]"
4308,363899365,5284476,CC1=C2C3=CC=CC=C3NC2=CC(=N1)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 30; 100 PPM IN DIET FOR 112 WK (STUDY DURATION: 112 WK),MAMMARY GLAND: FIBROADENOMA OR FIBROMA; HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA; CLITORAL GLAND: ADENOMA,POSITIVE,"[TAKAHASHI,M, TOYODA,K, AZE,Y, FURUTA,K, MITSUMORI,K AND HAYASHI,Y; THE RAT URINARY BLADDER AS A NEW TARGET OF HETEROCYCLIC AMINE CARCINOGENICITY: TUMOR INDUCTION BY 3-AMINO-1-METHYL-5H-PYRIDO[4,3-B]INDOLE ACETATE; JPN. J. CANCER RES. 84(8):852-858, 1993]"
4309,363899366,2723789,C(=S)(N)NN,Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 156; 312 PPM IN DRINKING WATER DAILY FOR LIFE (STUDY DURATION: 130-140 WK),,NEGATIVE,"[TOTH,B; EFFECTS OF LIFELONG ADMINISTRATION OF BETA-PHENYLISOPROPYLHYDRAZINE HYDROCHLORIDE AND THIOCARBAMYLHYDRAZINE IN MICE; FUNDAM. APPL. TOXICOL. 2:173-176, 1982]"
4310,363899366,2723789,C(=S)(N)NN,Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 156; 312 PPM IN DRINKING WATER DAILY FOR LIFE (STUDY DURATION: 130-140 WK),,NEGATIVE,"[TOTH,B; EFFECTS OF LIFELONG ADMINISTRATION OF BETA-PHENYLISOPROPYLHYDRAZINE HYDROCHLORIDE AND THIOCARBAMYLHYDRAZINE IN MICE; FUNDAM. APPL. TOXICOL. 2:173-176, 1982]"
4311,363899367,6182,CC(CNN)C1=CC=CC=C1.Cl,Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 156; 312 PPM IN DRINKING WATER DAILY FOR LIFE (STUDY DURATION: 120-140 WK),,NEGATIVE,"[TOTH,B; EFFECTS OF LIFELONG ADMINISTRATION OF BETA-PHENYLISOPROPYLHYDRAZINE HYDROCHLORIDE AND THIOCARBAMYLHYDRAZINE IN MICE; FUNDAM. APPL. TOXICOL. 2:173-176, 1982]"
4312,363899367,6182,CC(CNN)C1=CC=CC=C1.Cl,Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 156; 312 PPM IN DRINKING WATER DAILY FOR LIFE (STUDY DURATION: 120-140 WK),,NEGATIVE,"[TOTH,B; EFFECTS OF LIFELONG ADMINISTRATION OF BETA-PHENYLISOPROPYLHYDRAZINE HYDROCHLORIDE AND THIOCARBAMYLHYDRAZINE IN MICE; FUNDAM. APPL. TOXICOL. 2:173-176, 1982]"
4313,363899368,5281068,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 1000 PPM IN DIET FOR 106 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; INDUCTION OF TUMOURS IN RATS BY FEEDING NITROSATABLE AMINES TOGETHER WITH SODIUM NITRITE; FOOD CHEM. TOXICOL. 22(9):715-720, 1984]"
4314,363899368,5281068,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1000 PPM IN DIET FOR 106 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; INDUCTION OF TUMOURS IN RATS BY FEEDING NITROSATABLE AMINES TOGETHER WITH SODIUM NITRITE; FOOD CHEM. TOXICOL. 22(9):715-720, 1984]"
4315,363899368,5281068,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 15; 30 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-317 Y86]"
4316,363899368,5281068,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 30; 60 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-317 Y86]"
4317,363899368,5281068,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 25; 50 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-317 Y86]"
4318,363899368,5281068,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 200 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-317 Y86]"
4319,363899369,17190,C1=CC(=C2C(=C1N)C(=O)C3=C(C=CC(=C3C2=O)N)N)N,Active,,,,RAT,F344/MALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),"URINARY BLADDER: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA, TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA, LEIOMYOSARCOMA, LEIOMYOMA OR LEIOMYOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-299 Y86]"
4320,363899369,17190,C1=CC(=C2C(=C1N)C(=O)C3=C(C=CC(=C3C2=O)N)N)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),"URINARY BLADDER: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA, LEIOMYOMA, LEIOMYOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-299 Y86]"
4321,363899369,17190,C1=CC(=C2C(=C1N)C(=O)C3=C(C=CC(=C3C2=O)N)N)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 600; 1200; 2500 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-299 Y86]"
4322,363899369,17190,C1=CC(=C2C(=C1N)C(=O)C3=C(C=CC(=C3C2=O)N)N)N,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 600; 1200; 2500 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-299 Y86]"
4323,363899370,22833489,CCC(C(C(CC(C(C(C)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 312; 625 MG/KG IN CORN OIL 5 D/WK FOR 104 WK,"LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; KIDNEY: TUBULAR CELL ADENOMA OR ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-308 Y86]"
4324,363899370,22833489,CCC(C(C(CC(C(C(C)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 312; 625 MG/KG IN CORN OIL 5 D/WK FOR 104 WK,"LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-308 Y86]"
4325,363899370,22833489,CCC(C(C(CC(C(C(C)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-308 Y86]"
4326,363899370,22833489,CCC(C(C(CC(C(C(C)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA, FOLLICULAR CELL ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-308 Y86]"
4327,363899371,14410,C1(=C(C(=C(C(=C1Br)Br)Br)Br)Br)OC2=C(C(=C(C(=C2Br)Br)Br)Br)Br,Active,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-309 Y86]"
4328,363899371,14410,C1(=C(C(=C(C(=C1Br)Br)Br)Br)Br)OC2=C(C(=C(C(=C2Br)Br)Br)Br)Br,Active,,,,RAT,F344/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-309 Y86]"
4329,363899371,14410,C1(=C(C(=C(C(=C1Br)Br)Br)Br)Br)OC2=C(C(=C(C(=C2Br)Br)Br)Br)Br,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-309 Y86]"
4330,363899371,14410,C1(=C(C(=C(C(=C1Br)Br)Br)Br)Br)OC2=C(C(=C(C(=C2Br)Br)Br)Br)Br,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-309 Y86]"
4331,363899372,7499,C=CC1CCC=CC1,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 200; 400 MG/KG IN CORN OIL 5 D/WK FOR 103 WK,"OVARIES: BENIGN MIXED TUMOR, GRANULOSA CELL TUMOR, GRANULOSA CELL TUMOR OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-303 Y86]"
4332,363899373,8785,CC(=O)OCC1=CC=CC=C1,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-250 Y86]"
4333,363899373,8785,CC(=O)OCC1=CC=CC=C1,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR ADENOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-250 Y86]"
4334,363899373,8785,CC(=O)OCC1=CC=CC=C1,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 500; 1000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-250 Y86]"
4335,363899373,8785,CC(=O)OCC1=CC=CC=C1,Active,,,,RAT,F344/MALE,ORAL,0; 0.8% IN DIET FOR 2 YR (STUDY DURATION: 2 YR),PANCREAS: CARCINOMA IN SITU,POSITIVE,"[LONGNECKER,DS, ROEBUCK,BD, CURPHEY,TJ AND MACMILLAN,DL; EVALUATIN OF PROMOTION OF PANCREATIC CARCINOGENESIS IN RATS BY BENZYL ACETATE; FOOD CHEM. TOXICOL. 28(10):665-668, 1990]"
4336,363899373,8785,CC(=O)OCC1=CC=CC=C1,Inactive,,,,RAT,F344/MALE,ORAL,0; 3000; 6000 PPM IN FEED FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-431 Y93]"
4337,363899373,8785,CC(=O)OCC1=CC=CC=C1,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3000; 6000 PPM IN FEED FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-431 Y93]"
4338,363899373,8785,CC(=O)OCC1=CC=CC=C1,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 330; 1000; 3000 PPM IN FEED FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-431 Y93]"
4339,363899373,8785,CC(=O)OCC1=CC=CC=C1,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 330; 1000; 3000 PPM IN FEED FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-431 Y93]"
4340,363899373,8785,CC(=O)OCC1=CC=CC=C1,Unspecified,,,,RAT,F344/MALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),PANCREAS: ACINAR CELL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-250 Y86]"
4341,363899374,7586,C1C(O1)COC2=CC(=CC=C2)OCC3CO3,Active,,,,RAT,F344/MALE,GAVAGE,0; 12; 25; 50 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104-105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-257 Y86]"
4342,363899374,7586,C1C(O1)COC2=CC(=CC=C2)OCC3CO3,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 12; 25; 50 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104-105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-257 Y86]"
4343,363899374,7586,C1C(O1)COC2=CC(=CC=C2)OCC3CO3,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104-105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-257 Y86]"
4344,363899374,7586,C1C(O1)COC2=CC(=CC=C2)OCC3CO3,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104-105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-257 Y86]"
4345,363899374,7586,C1C(O1)COC2=CC(=CC=C2)OCC3CO3,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 12; 25; 50 MG/KG BW IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[MURTHY,ASK, MCCONNELL,EE, HUFF,JE, RUSSFIELD,AB AND GOOD,AE; FORESTOMACH NEOPLASMS IN FISCHER F344/N RATS AND B6C3F1 MICE EXPOSED TO DIGLYCIDYL RESORCINOL ETHER-AN EPOXY RESIN; FOOD CHEM. TOXICOL. 28(10):723-729, 1990]"
4346,363899374,7586,C1C(O1)COC2=CC(=CC=C2)OCC3CO3,Active,,,,RAT,F344/MALE,GAVAGE,0; 12; 25; 50 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[MURTHY,ASK, MCCONNELL,EE, HUFF,JE, RUSSFIELD,AB AND GOOD,AE; FORESTOMACH NEOPLASMS IN FISCHER F344/N RATS AND B6C3F1 MICE EXPOSED TO DIGLYCIDYL RESORCINOL ETHER-AN EPOXY RESIN; FOOD CHEM. TOXICOL. 28(10):723-729, 1990]"
4347,363899374,7586,C1C(O1)COC2=CC(=CC=C2)OCC3CO3,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 50; 100 MG/KG BW IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[MURTHY,ASK, MCCONNELL,EE, HUFF,JE, RUSSFIELD,AB AND GOOD,AE; FORESTOMACH NEOPLASMS IN FISCHER F344/N RATS AND B6C3F1 MICE EXPOSED TO DIGLYCIDYL RESORCINOL ETHER-AN EPOXY RESIN; FOOD CHEM. TOXICOL. 28(10):723-729, 1990]"
4348,363899374,7586,C1C(O1)COC2=CC(=CC=C2)OCC3CO3,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 50; 100 MG/KG BW IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[MURTHY,ASK, MCCONNELL,EE, HUFF,JE, RUSSFIELD,AB AND GOOD,AE; FORESTOMACH NEOPLASMS IN FISCHER F344/N RATS AND B6C3F1 MICE EXPOSED TO DIGLYCIDYL RESORCINOL ETHER-AN EPOXY RESIN; FOOD CHEM. TOXICOL. 28(10):723-729, 1990]"
4349,363899376,23668197,[O-]Cl=O.[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 0.03; 0.06% IN DRINKING WATER FOR 85 WK (STUDY DURATION: 85 WK),,NEGATIVE,"[SHIMOYAMA,T, HIASA,Y, KITAHORI,Y, KONISHI,N AND MURATA,Y; ABSENCE OF CARCINOGENIC EFFECT OF SODIUM CHLORITE IN RATS; J. NARA. MED. ASSOC. 36:710-718, 1985]"
4350,363899376,23668197,[O-]Cl=O.[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.03; 0.06% IN DRINKING WATER FOR 85 WK (STUDY DURATION: 85 WK),,NEGATIVE,"[SHIMOYAMA,T, HIASA,Y, KITAHORI,Y, KONISHI,N AND MURATA,Y; ABSENCE OF CARCINOGENIC EFFECT OF SODIUM CHLORITE IN RATS; J. NARA. MED. ASSOC. 36:710-718, 1985]"
4351,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,RAT,F344/MALE,ORAL,"0; 5000 PPM IN DIET FOR 102 WK, CONTROL AND DOSED GROUPS FED AD LIBITUM (STUDY DURATION; 122 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
4352,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,RAT,F344/MALE,ORAL,"0; 5000 PPM IN DIET FOR 122 WK, CONTROL GROUP WAS WEIGHT-MATCHED TO DOSED GROUP (STUDY DURATION: 122 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
4353,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,RAT,F344/MALE,ORAL,"0; 5000 PPM IN DIET FOR 130 WK, CONTROL GROUP DIET RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUPS (STUDY DURATION: 30 MO)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
4354,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 5000 PPM IN DIET FOR 128 WK, CONTROL AND DOSED GROUPS FED AD LIBITUM (STUDY DURATION: 128 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
4355,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 5000 PPM IN DIET FOR 128 WK, CONTROL GROUP WAS WEIGHT-MATCHED TO DOSED GROUP (STUDY DURATION: 128 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
4356,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 123 WK ADMINISTERED TO RATS ALSO EXPOSED IN UTERO THROUGH MOTHERS THAT RECEIVED THE SAME DOSES IN DIET FOR 12 WK (STUDY DURATION: 135 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-459 Y97]"
4357,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 129 WK ADMINISTERED TO RATS ALSO EXPOSED IN UTERO THROUGH MOTHERS THAT RECEIVED THE SAME DOSES IN DIET FOR 12 WK (STUDY DURATION: 141 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-459 Y97]"
4358,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-459 Y97]"
4359,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1250; 2500; 5000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-459 Y97]"
4360,363899397,16043,CC(C)(C)C1=C(C=CC(=C1)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 5000 PPM IN DIET FOR 130 WK, CONTROL GROUP DIET RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUPS (STUDY DURATION: 30 MO)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
4361,363899398,6731,C1=CC=C2C(=C1)C=CC(=N2)C3C(=O)C4=CC=CC=C4C3=O,Active,,,,RAT,F344/MALE,ORAL,0; 500; 1700; 5000 PPM IN DIET FOR 105 WK (STUDY DURATION: 110 WK),"KIDNEY(RENAL TUBULE): ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA; ORAL CAVITY: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-463 Y97]"
4362,363899398,6731,C1=CC=C2C(=C1)C=CC(=N2)C3C(=O)C4=CC=CC=C4C3=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 500; 1700; 5000 PPM IN DIET FOR 106 WK (STUDY DURATION: 111 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-463 Y97]"
4363,363899399,727,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,DD/MALE,ORAL,0; 6.6; 66; 660 PPM IN BASAL DIET UNTIL SACRIFICE AT 24 WK (STUDY DURATION: 24 WK),LIVER: HEPATOMA,POSITIVE,"[NAGASAKI,H, TOMII,S, MEGA,T, MARUGAMI,M AND ITO,N; DEVELOPMENT OF HEPATOMAS IN MICE TREATED WITH BENZENE HEXACHLORIDE; GANN 62(5):431, 1971]"
4364,363899400,6414792,C1=C(OC(=C1)[N+](=O)[O-])/C=C/C2=CN=C(N=N2)N(CO)CO,Active,,,,RAT,WISTAR/MALE,ORAL,0; 350; 1750; 3500 PPM IN POWDERED BASAL DIET (STUDY DURATION: 35 WK),FORESTOMACH; SQUAMOUS CELL PAPILLOMA; DUODENUM: ADENOCARCINOMA; SMALL INTESTINE: ADENOCARCINOMA,POSITIVE,"[KONISHI,Y, DENDA,A, TAKAHASHI,S, INUI,S AND KOJIMA,K; CARCINOGENIC ACTIVITY OF 3-DI(HYDROXYMETHYL)AMINO-6-(5-NITRO-2-FURYLETHENYL)-1,2,4-TRIAZINE (PANFURAN-S) IN MALE RATS; GANN 68:371-372, 1977]"
4365,363899420,3031,C1=CC(=C(C(=C1)Cl)C#N)Cl,Active,,,,MICE,SWISS/MALE,INTRAPERITONEAL,2 PPM (0.0005MG) 1/3 D FOR 13 TIMES (STUDY DURATION: 375 D),"LYMPHATIC SYSTEM: HISTIOCYTIC LYMPHOMA, PLASMA CELL LYMPHOMA; LIVER: HEPATOCELLULAR CARCINOMA",POSITIVE,"[DONNA,A, BETTA,PG, ROBUTTI,F AND BELLINGERI,D; A ONE-YEAR CARCINOGENICITY STUDY WITH 2,6-DICHLOROBENZONITRILE (DICHLOBENIL) IN MALE SWISS MICE: PRELIMINARY NOTE; CANCER DETECT. PREV. 15(1):41-44, 1991]"
4366,363899420,3031,C1=CC(=C(C(=C1)Cl)C#N)Cl,Active,,,,MICE,SWISS/MALE,SUBCUTANEOUS,2 PPM (0.0005MG) 1/3 D FOR 13 TIMES (STUDY DURATION: 375 D),LYMPHATIC SYSTEM: PLASMA CELL LYMPHOMA; LUNG: CARCINOMA; BODY CAVITY: MESOTHELIOMA; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[DONNA,A, BETTA,PG, ROBUTTI,F AND BELLINGERI,D; A ONE-YEAR CARCINOGENICITY STUDY WITH 2,6-DICHLOROBENZONITRILE (DICHLOBENIL) IN MALE SWISS MICE: PRELIMINARY NOTE; CANCER DETECT. PREV. 15(1):41-44, 1991]"
4367,363899453,23712862,[CH-](C=O)C=O.[Na+],Active,,,,RAT,F344/MALE,GAVAGE,0; 50; 100 MG/KG IN DISTILLED WATER 5D/WK FOR 102 WK (STUDY DURATION: 104 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA; PANCREATIC ISLETS: ISLET CELL ADENOMA; PANCREATIC ISLETS: ISLET CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-331 Y88]"
4368,363899453,23712862,[CH-](C=O)C=O.[Na+],Active,,,,RAT,F344/FEMALE,GAVAGE,0; 50; 100 MG/KG IN DISTILLED WATER 5D/WK FOR 102 WK (STUDY DURATION: 105 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-331 Y88]"
4369,363899453,23712862,[CH-](C=O)C=O.[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 60; 120 MG/KG IN DISTILLED WATER 5D/WK FOR 102 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-331 Y88]"
4370,363899453,23712862,[CH-](C=O)C=O.[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 60; 120 MG/KG IN DISTILLED WATER 5D/WK FOR 102 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-331 Y88]"
4371,363899454,12559,CCCCCCCCCCCCCCCCCC(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-338 Y88]"
4372,363899454,12559,CCCCCCCCCCCCCCCCCC(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-338 Y88]"
4373,363899454,12559,CCCCCCCCCCCCCCCCCC(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-338 Y88]"
4374,363899454,12559,CCCCCCCCCCCCCCCCCC(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-338 Y88]"
4375,363899455,5284435,C1=CC=C(C=C1)NC2=C(C=C(C=C2)NC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-])S(=O)(=O)[O-].[Na+],Inactive,,,,RAT,F344/MALE,GAVAGE,0; 375 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-335 Y88]"
4376,363899455,5284435,C1=CC=C(C=C1)NC2=C(C=C(C=C2)NC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-])S(=O)(=O)[O-].[Na+],Active,,,,RAT,F344/FEMALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),KIDNEY: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-335 Y88]"
4377,363899455,5284435,C1=CC=C(C=C1)NC2=C(C=C(C=C2)NC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-])S(=O)(=O)[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 125; 250 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-335 Y88]"
4378,363899455,5284435,C1=CC=C(C=C1)NC2=C(C=C(C=C2)NC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-])S(=O)(=O)[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 250; 500 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-335 Y88]"
4379,363899478,114893,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=C4)C=CC(=C25)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",,NEGATIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
4380,363899494,2236,COC1=CC=CC2=C3C(=C(C=C21)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,"ORAL, GAVAGE",50 MG/KG BW/D FOR 3 D (STUDY DURATION: 6 MO),"KIDNEY: TUMORS, 29% (THERE WERE 3 MESENCHYMAL TUMORS AND 1 RENAL ONCOCYTOMA IN 14 ANIMALS)",POSITIVE,"[CUI,M LIU,ZH QIU,Q LI,H AND LI,LS; TUMOUR INDUCTION IN RATS FOLLWOING EXPOSURE TO SHORT-TERM HIGH DOSE ARISTOLOCHIC ACID I; MUTAGENESIS 20(1): 45-49, 2005]"
4381,363899502,36324,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,Inactive,,,,Rat,Wistar/Male,Oral (diet),0; 15; 50; 200 ppm in feed for 104 wks,,Negative; Purity 97.8 and 99.8%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR AMITRAZ (DECEMBER 22, 1998)]"
4382,363899502,36324,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,Inactive,,,,Rat,Wistar/Female,Oral (diet),0; 15; 50; 200 ppm in feed for 104 wks,,Negative; Purity 97.8 and 99.8%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR AMITRAZ (DECEMBER 22, 1998)]"
4383,363899502,36324,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,Inactive,,,,Mouse,B6C3F1/Male,Oral (diet),0; 25; 100; 400 ppm in feed for 104 wks,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR AMITRAZ (DECEMBER 22, 1998)]"
4384,363899502,36324,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,Active,,,,Mouse,B6C3F1/Female,Oral (diet),0; 25; 100; 400 ppm in feed for 104 wks,"Liver: Hepatocellular adenoma/carcinoma (5/80, 1/61, 3/62, 24/56)",Positive (At highest dose),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR AMITRAZ (DECEMBER 22, 1998)]"
4385,363899503,25429,COC(=O)NC1=NC2=CC=CC=C2N1,Inactive,,,,Mouse,CD-1/Male (80/sex/dose),Oral,0; 500; 1500; 7500 ppm  in feed for 2 yr except for highest dose where  animals terminated at week 73 with 29% survival),,Negative: Purity 99.3%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENOMYL AND METHYL 2-BENZIMIDAZOL CARBAMATE (MBC) (PRINCIPAL BENOMYL METABOLITE) (OCTOBER 1, 1997)]"
4386,363899503,25429,COC(=O)NC1=NC2=CC=CC=C2N1,Active,,,,Mouse,CD-1/Female (80/sex/dose),Oral,0; 500; 1500; 7500 ppm  in feed for 2 yr,"Liver: Hepatocellular adenoma (0/68, 5/62, 5/66, 3/71); Hepatocellular carcinoma (2/68, 4/62, 15/66, 12/71); Combined (2/68, 9/62, 20/66, 15/71)",Positive: Purity 99.3%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENOMYL AND METHYL 2-BENZIMIDAZOL CARBAMATE (MBC) (PRINCIPAL BENOMYL METABOLITE) (OCTOBER 1, 1997)]"
4387,363899512,29061,CCNN.Cl,Active,,,,MOUSE,SWISS/MALE,ORAL,0; 0.0125% IN DRINKING WATER FOR LIFE FOR AN AVERAGE DAILY DOSE OF 0; 1.52 MG (STUDY DURATION: 130 WK),LUNG: ADENOMA OR ADENOCARCINOMA; BLOOD VESSEL: ANGIOSARCOMA OR ANGIOMA,POSITIVE,"[SHIMIZU,H, NAGEL,D AND TOTH,B; ETHYLHYDRAZINE HYDROCHLORIDE AS A TUMOR INDUCER IN MICE; INT. J. CANCER 13:500-505, 1974]"
4388,363899512,29061,CCNN.Cl,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 0.0125% IN DRINKING WATER FOR LIFE FOR AN AVERAGE DAILY DOSE OF 0; 0.92 MG (STUDY DURATION: 130 WK),LUNG: ADENOMA OR ADENOCARCINOMA; BLOOD VESSEL: ANGIOSARCOMA OR ANGIOMA,POSITIVE,"[SHIMIZU,H, NAGEL,D AND TOTH,B; ETHYLHYDRAZINE HYDROCHLORIDE AS A TUMOR INDUCER IN MICE; INT. J. CANCER 13:500-505, 1974]"
4389,363899513,85598,C1CN(C(=O)NC1=O)N=O,Active,,,,RAT,WISTAR/MALE,ORAL,0; 450 MG/L CITRATE BUFFER SOLUTION IN DRINKING WATER 5D/WK FOR AN AVERAGE TOTAL DOSE OF 0; 1250 MG (STUDY DURATION: 32 WK),LIVER: CARCINOMA; KIDNEY: ADENOMA,POSITIVE,"[MIRVISH,SS AND GARCIA,H; 1-NITROSO-5,6-DIHYDROURACIL. INDUCTION OF LIVER CELL CARCINOMAS AND KIDNEY ADENOMAS IN THE RAT; Z. KREBSFORSCH. 79:304-308, 1973]"
4390,363899513,85598,C1CN(C(=O)NC1=O)N=O,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 450 MG/L CITRATE BUFFER SOLUTION IN DRINKING WATER 5D/WK FOR AN AVERAGE TOTAL DOSE OF 0; 950 MG (STUDY DURATION: 28 WK),LIVER: CARCINOMA,POSITIVE,"[MIRVISH,SS AND GARCIA,H; 1-NITROSO-5,6-DIHYDROURACIL. INDUCTION OF LIVER CELL CARCINOMAS AND KIDNEY ADENOMAS IN THE RAT; Z. KREBSFORSCH. 79:304-308, 1973]"
4391,363899514,36618,CN(C#N)N=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 6.9 MG/KG IN 25 ML DRINKING WATER DAILY (STUDY DURATION: >11 MO),FORESTOMACH: SQUAMOUS CELL CARCINOMA; ESOPHAGUS: SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA,POSITIVE,"[ENDO,H, TAKAHASHI,K, KINOSHITA,N AND BABA,T; PRODUCTION OF GASTRIC AND ESOPHAGEAL TUMORS IN RATS BY METHYLNITROSOCYANAMIDE, A POSSIBLE CANIDATE OF ETIOLOGIC FACTORS FOR HUMAN GASTRIC CANCER; PROC. JAPAN ACAD. 50:497-502, 1974]"
4392,363899515,6511,CC[Pb](CC)(CC)CC,Active,,,,MOUSE,ICR/FEMALE,SUBCUTANEOUS,0; 0.1 MG IN TRICAPRYLIN AT DAYS 1 AND 7 OF AGE AND 0; 0.2 MG AT DAYS 14 AND 21 OF AGE FOR A TOTAL DOSE OF 0; 0.6 MG (STUDY DURATION: 49-51 WK),HEMATOPOIETIC SYSTEM: LYMPHOMA,POSITIVE,"[EPSTEIN,SS AND MANTEL,N; CARCINOGENICITY OF TETRAETHYL LEAD; EXPERIENTIA 24(6):580-581, 1968]"
4393,363899515,6511,CC[Pb](CC)(CC)CC,Inactive,,,,MOUSE,ICR/MALE,SUBCUTANEOUS,0; 0.1 MG IN TRICAPRYLIN ON DAYS 1 AND 7 OF AGE AND 0; 0.2 MG ON DAYS 14 AND 21 OF AGE FOR A TOTAL DOSE OF 0; 0.6 MG (STUDY DURATION: 49-51 WK),,NEGATIVE,"[EPSTEIN,SS AND MANTEL,N; CARCINOGENICITY OF TETRAETHYL LEAD; EXPERIENTIA 24(6):580-581, 1968]"
4394,363899516,13296,CCS(=O)(=O)C1=CC=C(C2=CC=CC=C21)S(=O)(=O)N,Active,,,,MOUSE,A X 1F/FEMALE,ORAL,0; 0.01% IN POWDERED OXOID DIET (STUDY DURATION: 333-701 D),BLADDER: CARCINOMA; LUNG: ADENOMA,POSITIVE,"[FLAKS,A, HAMILTON,JM, CLAYSON,DB AND BURCH,PRJ; THE COMBINED EFFECT OF RADIATION AND CHEMICAL CARCINOGENS IN FEMALE A X IF MICE; BR. J. CANCER 28:227-231, 1973]"
4395,363899516,13296,CCS(=O)(=O)C1=CC=C(C2=CC=CC=C21)S(=O)(=O)N,Active,,,,MOUSE,A X 1F/FEMALE,ORAL,0; 0.01% IN POWDERED OXOID DIET PRECEDED BY IRRADIATION OF 1000 RAD WITH UPPER BODY SHIELDED 48H PRIOR TO DOSING (STUDY DURATION: 266-723 D),BLADDER: CARCINOMA; LUNG: ADENOMA,POSITIVE,"[FLAKS,A, HAMILTON,JM, CLAYSON,DB AND BURCH,PRJ; THE COMBINED EFFECT OF RADIATION AND CHEMICAL CARCINOGENS IN FEMALE A X IF MICE; BR. J. CANCER 28:227-231, 1973]"
4396,363899519,9462,C1=CC(=CC=C1C2=CC=C(C=C2)F)N,Active,,,,MOUSE,CBA/FEMALE,GAVAGE,0; 0.05 ML OF 1% IN ARACHIS OIL 2/WK FOR 6 MO FOR AN ESTIMATED TOTAL DOSE OF 0; 13 MG (STUDY DURATION: 119 WK),LIVER: HEPATOMA,POSITIVE,"[CLAYSON,DB, LAWSON,TA, SANTANA,S AND BONSER,GM; CORRELATION BETWEEN THE CHEMICAL INDUCTION OF HYPERPLASIA AND OF MALIGNANCY IN THE BLADDER EPITHELIUM; BR. J. CANCER 19:297-310, 1965]"
4397,363899519,9462,C1=CC(=CC=C1C2=CC=C(C=C2)F)N,Active,,,,MOUSE,CBA/MALE,GAVAGE,0; 0.05 ML OF 1% IN ARACHIS OIL 2/WK FOR 6 MO FOR AN ESTIMATED TOTAL DOSE OF 0; 13 MG (STUDY DURATION: 109 WK),LIVER: HEPATOMA,POSITIVE,"[CLAYSON,DB, LAWSON,TA, SANTANA,S AND BONSER,GM; CORRELATION BETWEEN THE CHEMICAL INDUCTION OF HYPERPLASIA AND OF MALIGNANCY IN THE BLADDER EPITHELIUM; BR. J. CANCER 19:297-310, 1965]"
4398,363899520,,,Active,,,,RAT,WISTAR/MALE,ORAL,0; 1; 10 MG/KG BW IN DIET FOR 18 MO FOLLOWED BY CONTROL DIET FOR 6 MO (STUDY DURATION: 24 MO),NASAL CAVITY: MALIGNANT TUMOR; LIVER: TUMOR,POSITIVE,"[TUCKER,MJ; CARCINOGENIC ACTION OF QUINOXALINE 1,4-DIOXIDE IN RATS; J. NATL. CANCER INST. 55(1):137-145, 1975]"
4399,363899520,,,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 1; 10 MG/KG BW IN DIET FOR 18 MO FOLLOWED BY CONTROL DIET FOR 6 MO (STUDY DURATION: 24 MO),NASAL CAVITY: MALIGNANT TUMOR; LIVER: TUMOR,POSITIVE,"[TUCKER,MJ; CARCINOGENIC ACTION OF QUINOXALINE 1,4-DIOXIDE IN RATS; J. NATL. CANCER INST. 55(1):137-145, 1975]"
4400,363899521,198077,CC1=CC2=C(C=C1)N=C3C4=CC=CC=C4N=C5N3C2=NC6=CC=CC=C65,Active,,,,MOUSE,"ALBINO/MALE, FEMALE",DERMAL,0; 0.3 ML OF A 1 MG/ML BENZENE SOLUTION 2/WK FOR 12 MO FOR A TOTAL DOSE OF 0; 31 MG (STUDY DURATION: 516 D),SKIN: TUMOR,POSITIVE,"[BALDWIN,RW, CUNNINGHAM,GJ, PARTRIDGE,MW AND VIPOND,HJ; STUDIES ON THE CARCINOGENICITY OF TRICYCLOQUINAZOLINE. THE EFFECT OF SUBSTITUTION IN THE PERIPHERAL CARBOCYCLIC RINGS ON THE CARCINOGENIC ACTIVITY; BR. J. CANCER 16:275-282, 1962]"
4401,363899522,4021704,C1=C(OC(=C1)[N+](=O)[O-])C2=CSC(=N2)NN,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.089% OF DIET FOR 46 WK FOLLOWED BY CONTROL DIET FOR 20 WK FOR A TOTAL DOSE OF 0; 4.2 G (STUDY DURATION: 66 WK),MAMMARY GLAND: ADENOCARCINOMA; MAMMARY GLAND: ADENOFIBROMA OR FIBROADENOMA,POSITIVE,"[COHEN,SM, ERTURK,E, PRICE,JM AND BRYAN,T; COMPARATIVE CARCINOGENICITY IN THE RAT OF 2-HYDRAZINOTHIAZOLES WITH NITROFURYL, NITROPHENYL, OR AMINOPHENYL SUBSTITUENTS IN THE 4-POSITION; CANCER RES. 30:897-901, 1970]"
4402,363899523,5235,[F-].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 25; 100; 175 PPM IN DRINKING WATER FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-393 Y90]"
4403,363899523,5235,[F-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25; 100; 175 PPM IN DRINKING WATER FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-393 Y90]"
4404,363899523,5235,[F-].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25; 100; 175 PPM IN DRINKING WATER FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-393 Y90]"
4405,363899523,5235,[F-].[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 4; 10; 25 MG/KG/D ADDED TO LOW-FLUORIDE DIET FOR DURATION OF STUDY (STUDY DURATION: 95 WK),,NEGATIVE,"[MAURER,JK, CHENG,MC, BOYSEN,BG AND ANDERSON,RL; TWO-YEAR CARCINOGENICITY STUDY OF SODIUM FLUORIDE IN RATS; J. NATL. CANCER INST. 82(13):1118-26, 1990]"
4406,363899523,5235,[F-].[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 4; 10; 25 MG/KG/D ADDED TO LOW-FLUORIDE DIET FOR DURATION OF STUDY (STUDY DURATION: 99 WK),,NEGATIVE,"[MAURER,JK, CHENG,MC, BOYSEN,BG AND ANDERSON,RL; TWO-YEAR CARCINOGENICITY STUDY OF SODIUM FLUORIDE IN RATS; J. NATL. CANCER INST. 82(13):1118-26, 1990]"
4407,363899523,5235,[F-].[Na+],Unspecified,,,,MOUSE,F344/MALE,ORAL,0; 25; 100; 175 PPM IN DRINKING WATER FOR 103 WK (STUDY DURATION: 103 WK),BONE: OSTEOSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-393 Y90]"
4408,363899537,3496,C(C(=O)O)NCP(=O)(O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 300; 900; 2700 MG/L IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHRUSCIELSKA,K, BRZENZINSKI,J, KITA,K, KALHORN,D, KITA,I,  GRAFFSTEIN,B, AND KORZENIOWSKI,P; GLYPHOSATE. EVALUATION OF  CHRONIC ACTIVITY AND POSSIBLE FAR-REACHING EFFECTS. PART 1.  STUDIES ON CHRONIC TOXICITY. PEESTYCYDY 3-4: 11-20, 2000]"
4409,363899537,3496,C(C(=O)O)NCP(=O)(O)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 300; 900; 2700 MG/L IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHRUSCIELSKA,K, BRZENZINSKI,J, KITA,K, KALHORN,D, KITA,I,  GRAFFSTEIN,B, AND KORZENIOWSKI,P; GLYPHOSATE. EVALUATION OF  CHRONIC ACTIVITY AND POSSIBLE FAR-REACHING EFFECTS. PART 1.  STUDIES ON CHRONIC TOXICITY. PEESTYCYDY 3-4: 11-20, 2000]"
4410,363899540,5284373,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,Inactive,,,,DOG,BEAGLE/MALE,GAVAGE,0; 5; 15; 45 MG/KG/D IN OLIVE OIL FOR 52 WK (STUDY DURATION: 64 WK),,NEGATIVE,"[RYFFEL,B, DONATSCH,P, MADORIN,M, MATTER,BE, RUTTIMANN,G, SCHON,H, STOLL,R AND WILSON,J; TOXICOLOGICAL EVALUATION OF CYCLOSPORIN A; ARCH. TOXICOL. 53:107-141, 1983]"
4411,363899540,5284373,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,Inactive,,,,DOG,BEAGLE/FEMALE,GAVAGE,0; 5; 15; 45 MG/KG/D IN OLIVE OIL FOR 52 WK (STUDY DURATION: 64 WK),,NEGATIVE,"[RYFFEL,B, DONATSCH,P, MADORIN,M, MATTER,BE, RUTTIMANN,G, SCHON,H, STOLL,R AND WILSON,J; TOXICOLOGICAL EVALUATION OF CYCLOSPORIN A; ARCH. TOXICOL. 53:107-141, 1983]"
4412,363899540,5284373,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,Inactive,,,,MOUSE,OF 1/MALE,ORAL,0; 1; 4; 16 MG/KG/D IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[RYFFEL,B, DONATSCH,P, MADORIN,M, MATTER,BE, RUTTIMANN,G, SCHON,H, STOLL,R AND WILSON,J; TOXICOLOGICAL EVALUATION OF CYCLOSPORIN A; ARCH. TOXICOL. 53:107-141, 1983]"
4413,363899540,5284373,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,Inactive,,,,MOUSE,OF 1/FEMALE,ORAL,0; 1; 4; 16 MG/KG/D IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[RYFFEL,B, DONATSCH,P, MADORIN,M, MATTER,BE, RUTTIMANN,G, SCHON,H, STOLL,R AND WILSON,J; TOXICOLOGICAL EVALUATION OF CYCLOSPORIN A; ARCH. TOXICOL. 53:107-141, 1983]"
4414,363899540,5284373,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,Inactive,,,,RAT,OFA/MALE,ORAL,0; 0.5; 2; 8 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[RYFFEL,B, DONATSCH,P, MADORIN,M, MATTER,BE, RUTTIMANN,G, SCHON,H, STOLL,R AND WILSON,J; TOXICOLOGICAL EVALUATION OF CYCLOSPORIN A; ARCH. TOXICOL. 53:107-141, 1983]"
4415,363899540,5284373,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,Inactive,,,,RAT,OFA/FEMALE,ORAL,0; 0.5; 2; 8 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[RYFFEL,B, DONATSCH,P, MADORIN,M, MATTER,BE, RUTTIMANN,G, SCHON,H, STOLL,R AND WILSON,J; TOXICOLOGICAL EVALUATION OF CYCLOSPORIN A; ARCH. TOXICOL. 53:107-141, 1983]"
4416,363899541,13962857,C[C@@H]1C[C@]2(C=C(C3(CC3)[C@@]([C@H]2C1=O)(C)O)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,Active,,,,RAT,CD-1/FEMALE,INTRAGASTRIC,0; 100-150 MG/KG BW IN SALINE 2/WK FOR 8 WK THEN ONCE ON WK 9 (TOTAL DOSE: 0; 339 MG) (STUDY DURATION: 300 D),"MAMMARY GLAND: ADENOCARCINOMA, CARCINOMA; SMALL INTESTINE: ADENOCARCINOMA; BLADDER: PAPILLOMA",POSITIVE,"[HIRONO,I, AISO,S, YAMAJI,T, MORI,H, YAMADA,K, NIWA,H, OJIKA,M, WAKAMATSU,K KIGOSHI,H, NIIYAMA,K AND UOSAKI,Y; CARCINOGENICITY IN RATS OF PTAQUILOSIDE ISOLATED FROM BRACKEN; GANN 75(10):833-836, 1984]"
4417,363899541,13962857,C[C@@H]1C[C@]2(C=C(C3(CC3)[C@@]([C@H]2C1=O)(C)O)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,Active,,,,RAT,CD-1/FEMALE,INTRAGASTRIC,0; 780 MG/KG BW IN SALINE ONCE THEN 0; 100-200 MG/KG 1/WK FOR 8 WK (TOTAL DOSE: 0; 300 MG) (STUDY DURATION: 300 D),"MAMMARY GLAND: ADENOCARCINOMA, CARCINOMA; SMALL INTESTINE: ADENOCARCINOMA",POSITIVE,"[HIRONO,I, AISO,S, YAMAJI,T, MORI,H, YAMADA,K, NIWA,H, OJIKA,M, WAKAMATSU,K KIGOSHI,H, NIIYAMA,K AND UOSAKI,Y; CARCINOGENICITY IN RATS OF PTAQUILOSIDE ISOLATED FROM BRACKEN; GANN 75(10):833-836, 1984]"
4418,363899546,636822,C/C=C/C1=CC(=C(C=C1OC)OC)OC,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,"0; 5 UMOL 1X/WK FOR 3 WK BEGINNING 24 HR POST FIRST TPA DOSE (2.5 UG IN 0.1 ML ACETONE), FOLLOWED BY 2.5 UG TPA IN 0.1 ML ACETONE 2X/WK FOR 20 WK (STUDY DURATION: 20 WK)",,NEGATIVE,"[KIM,SG, LIEM,A, STEWART,BC AND MILLER,JA; NEW STUDIES ON TRANS-ANETHOLE OXIDE AND TRANS-ASARONE OXIDE; CARCINOGENESIS 20(7):1303-1307, 1999]"
4419,363899546,636822,C/C=C/C1=CC(=C(C=C1OC)OC)OC,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.25; 0.5 UMOL/G BW ONCE (STUDY DURATION: 10-11 MONTHS),LIVER: HEPATOMA,POSITIVE,"[KIM,SG, LIEM,A, STEWART,BC AND MILLER,JA; NEW STUDIES ON TRANS-ANETHOLE OXIDE AND TRANS-ASARONE OXIDE; CARCINOGENESIS 20(7):1303-1307, 1999]"
4420,363899578,6342,CC#N,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 100; 200; 400 PPM 6/HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-447  Y96]"
4421,363899578,6342,CC#N,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 50; 100; 200 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-447 Y96]"
4422,363899578,6342,CC#N,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 50; 100; 200 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-447  Y96]"
4423,363899578,6342,CC#N,Unspecified,,,,RAT,F344/MALE,INHALATION,0; 100; 200; 400 PPM 6/HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-447  Y96]"
4424,363899583,13387,CN1CCCC1=O,Inactive,,,,RAT,CD-1/MALE,INHALATION,0; 0.04; 0.4 MG/L 6 HR/D 5D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[LEE,KP, CHROMEY,NC, CULIK,R, BARNES,JR AND SCHNEIDER,PW; TOXICITY OF N-METHYL-2-PYRROLIDONE (NMP): TERATOGENIC, SUBCHRONIC, AND TWO-YEAR INHALATION STUDIES; FUNDAM. APPL. TOXICOL. 9:222-235, 1987]"
4425,363899583,13387,CN1CCCC1=O,Inactive,,,,RAT,CD-1/FEMALE,INHALATION,0; 0.04; 0.4 MG/L 6 HR/D 5D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[LEE,KP, CHROMEY,NC, CULIK,R, BARNES,JR AND SCHNEIDER,PW; TOXICITY OF N-METHYL-2-PYRROLIDONE (NMP): TERATOGENIC, SUBCHRONIC, AND TWO-YEAR INHALATION STUDIES; FUNDAM. APPL. TOXICOL. 9:222-235, 1987]"
4426,363899583,13387,CN1CCCC1=O,Inactive,,,,RAT,CD-1/FEMALE,ORAL,0; 1600; 5000; 15000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MALLEY,LA KENNEDY,GL ELLIOTT,GS SLONE,TW MELLERT,W DECKARDT,K KUTTLER,K HILDEBRAND,B BANTON,MI PAROD,RJ AND GRIFFITHS,JC; CHRONIC TOXICITY AND ONCOGENICITY OF N-METHYLPYRROLIDONE (NMP) IN RATS AND MICE BY DIETARY ADMINISTRATION;DRUG CHEM. TOXICOL. 24(4):315-338, 2001]"
4427,363899583,13387,CN1CCCC1=O,Inactive,,,,RAT,CD-1/MALE,ORAL,0; 1600; 5000; 15000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MALLEY,LA KENNEDY,GL ELLIOTT,GS SLONE,TW MELLERT,W DECKARDT,K KUTTLER,K HILDEBRAND,B BANTON,MI PAROD,RJ AND GRIFFITHS,JC; CHRONIC TOXICITY AND ONCOGENICITY OF N-METHYLPYRROLIDONE (NMP) IN RATS AND MICE BY DIETARY ADMINISTRATION;DRUG CHEM. TOXICOL. 24(4):315-338, 2001]"
4428,363899583,13387,CN1CCCC1=O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 600; 1200; 7200 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[MALLEY,LA KENNEDY,GL ELLIOTT,GS SLONE,TW MELLERT,W DECKARDT,K KUTTLER,K HILDEBRAND,B BANTON,MI PAROD,RJ AND GRIFFITHS,JC; CHRONIC TOXICITY AND ONCOGENICITY OF N-METHYLPYRROLIDONE (NMP) IN RATS AND MICE BY DIETARY ADMINISTRATION;DRUG CHEM. TOXICOL. 24(4):315-338, 2001]"
4429,363899583,13387,CN1CCCC1=O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 600; 1200; 7200 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[MALLEY,LA KENNEDY,GL ELLIOTT,GS SLONE,TW MELLERT,W DECKARDT,K KUTTLER,K HILDEBRAND,B BANTON,MI PAROD,RJ AND GRIFFITHS,JC; CHRONIC TOXICITY AND ONCOGENICITY OF N-METHYLPYRROLIDONE (NMP) IN RATS AND MICE BY DIETARY ADMINISTRATION;DRUG CHEM. TOXICOL. 24(4):315-338, 2001]"
4430,363899586,9215,C1=CC=C2C(=C1)C=C3C=CC=CC3=N2,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.2; 1.0; 5.0 MG IN BEESWAX/TRICAPRYLIN (STUDY DURATION: LIFETIME),,NEGATIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H AND GRIMMER,G; EXPERIMENTAL STUDIES ON THE CARCINOGENICITY OF FIVE NITROGEN CONTAINING POLYCYCLIC AROMATIC COMPOUNDS DIRECTLY INJECTED INTO RAT LUNGS; CANCER LETT. 20:97-101, 1983]"
4431,363899587,89594,CN1CCC[C@H]1C2=CN=CC=C2,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 500 UG/M3 20 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[WALDUM,HL, NILSEN,OG, NILSEN,T, ROERVIK,H, SYVERSEN,U, SANDVIK,AK, HAUGEN,OA, TORP,SH AND BRENNA,E; LONG-TERM EFFECTS OF INHALED NICOTINE; LIFE SCI. 58(16):1339-1346, 1996]"
4432,363899588,6228,CN(C)C=O,Inactive,,,,RAT,CRL:CD BR/MALE,INHALATION,0; 25; 100; 400 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[MALLEY,LA, SLONE,TW,JR, VAN PELT,C, ELLIOTT,GS, ROSS,PE, STADLER,JC AND KENNEDY,GL,JR; CHRONIC TOXICITY/ONCOGENICITY OF DIMETHYLFORMAMIDE IN RATS AND MICE FOLLOWING INHALATION EXPOSURE; FUNDAM. APPL. TOXICOL. 23(2):268-279, 1994]"
4433,363899588,6228,CN(C)C=O,Inactive,,,,RAT,CRL:CD BR/FEMALE,INHALATION,0; 25; 100; 400 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[MALLEY,LA, SLONE,TW,JR, VAN PELT,C, ELLIOTT,GS, ROSS,PE, STADLER,JC AND KENNEDY,GL,JR; CHRONIC TOXICITY/ONCOGENICITY OF DIMETHYLFORMAMIDE IN RATS AND MICE FOLLOWING INHALATION EXPOSURE; FUNDAM. APPL. TOXICOL. 23(2):268-279, 1994]"
4434,363899588,6228,CN(C)C=O,Inactive,,,,MOUSE,CRL:CD-1(ICR)BR/MALE,INHALATION,0; 25; 100; 400 PPM 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[MALLEY,LA, SLONE,TW,JR, VAN PELT,C, ELLIOTT,GS, ROSS,PE, STADLER,JC AND KENNEDY,GL,JR; CHRONIC TOXICITY/ONCOGENICITY OF DIMETHYLFORMAMIDE IN RATS AND MICE FOLLOWING INHALATION EXPOSURE; FUNDAM. APPL. TOXICOL. 23(2):268-279, 1994]"
4435,363899588,6228,CN(C)C=O,Inactive,,,,MOUSE,CRL:CD-1(ICR)BR/FEMALE,INHALATION,0; 25; 100; 400 PPM 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[MALLEY,LA, SLONE,TW,JR, VAN PELT,C, ELLIOTT,GS, ROSS,PE, STADLER,JC AND KENNEDY,GL,JR; CHRONIC TOXICITY/ONCOGENICITY OF DIMETHYLFORMAMIDE IN RATS AND MICE FOLLOWING INHALATION EXPOSURE; FUNDAM. APPL. TOXICOL. 23(2):268-279, 1994]"
4436,363899589,5280343,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1.25; 5.0% IN DIET FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[ITO,N, HAGIWARA,A, TAMANO,S, KAGAWA,M, SHIBATA,MA, KURATA,Y AND FUKUSHIMA,S; LACK OF CARCINOGENICITY OF QUERCETIN IN F344/DUCRJ RATS; JPN. J. CANCER RES. 80(4):317-325, 1989]"
4437,363899589,5280343,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 1.25; 5.0% IN DIET FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[ITO,N, HAGIWARA,A, TAMANO,S, KAGAWA,M, SHIBATA,MA, KURATA,Y AND FUKUSHIMA,S; LACK OF CARCINOGENICITY OF QUERCETIN IN F344/DUCRJ RATS; JPN. J. CANCER RES. 80(4):317-325, 1989]"
4438,363899589,5280343,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,Active,,,,RAT,F344/MALE,ORAL,"0; 1,000; 10,000; 40,000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK)",KIDNEY (RENAL TUBULE): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-409 Y92]"
4439,363899589,5280343,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,"0; 1,000; 10,000; 40,000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-409 Y92]"
4440,363899589,5280343,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.1; 0.2% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 64 WK),,NEGATIVE,"[STOEWSAND,GS, ANDERSON,JL, BOYD,JN, HRAZDINA,G, BABISH,JG, WALSH,KM AND LOSCO,P; QUERCETIN: A MUTAGEN, NOT A CARCINOGEN, IN FISCHER RATS; J. TOXICOL. ENVIRON. HEALTH 14(2-3):105-114, 1984]"
4441,363899589,5280343,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.1; 0.2% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 64 WK),,NEGATIVE,"[STOEWSAND,GS, ANDERSON,JL, BOYD,JN, HRAZDINA,G, BABISH,JG, WALSH,KM AND LOSCO,P; QUERCETIN: A MUTAGEN, NOT A CARCINOGEN, IN FISCHER RATS; J. TOXICOL. ENVIRON. HEALTH 14(2-3):105-114, 1984]"
4442,363899611,5104,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 50; 100 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-345 Y89]"
4443,363899611,5104,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 100; 200 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-345 Y89]"
4444,363899611,5104,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 100; 200 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-345 Y89]"
4445,363899611,5104,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O,Unspecified,,,,RAT,F344/MALE,ORAL,0; 50; 100 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),EXOCRINE PANCREAS: ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-345 Y89]"
4446,363899612,38852,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.O.O.O,Inactive,,,,RAT,F344/MALE,ORAL,0; 3100; 6300 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-348 Y89]"
4447,363899612,38852,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.O.O.O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3100; 6300 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-348 Y89]"
4448,363899612,38852,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.O.O.O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 6300; 12500 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-348 Y89]"
4449,363899612,38852,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N.O.O.O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 6300; 12500 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),KIDNEY: RENAL TUBULAR CELL ADENOMA OR ADENOCARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-348 Y89]"
4450,363899613,992,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 100; 200 PPM TECHNICAL GRADE PENTACHLOROPHENOL IN FEED FOR 103 WK (STUDY DURATION: 103 WK),ADRENAL GLAND/MEDULLA: PHEOCHROMOCYTOMA; LIVER: HEPATOCELLULAR ADENOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-349 Y89]"
4451,363899613,992,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 100; 200 PPM TECHNICAL GRADE PENTACHLOROPHENOL IN FEED FOR 103 WK (STUDY DURATION: 103 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; CIRCULATORY SYSTEM: HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-349 Y89]"
4452,363899613,992,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 100; 200; 600 PPM DOWCIDE EC-7 IN FEED FOR 103 WK (STUDY DURATION: 103 WK),ADRENAL GLAND/MEDULLA: PHEOCHROMOCYTOMA; ADRENAL GLAND/MEDULLA: PHEOCHROMOCYTOMA OR MALIGNANT PHEOCHROMOCYTOMA; LIVER: HEPATOCELLULAR ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-349 Y89]"
4453,363899613,992,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 100; 200; 600 PPM DOWCIDE EC-7 IN FEED FOR 103 WK (STUDY DURATION: 103 WK),ADRENAL GLAND/MEDULLA: PHEOCHROMOCYTOMA: ADRENAL GLAND/MEDULLA: PHEOCHROMOCYTOMA OR MALIGNANT PHEOCHROMOCYTOMA; CIRCULATORY SYSTEM: HEMANGIOSARCOMA; CIRCULATORY SYSTEM: HEMANGIOMA OR HEMANGIOSARCOMA; LIVER: HEPATOCELLULAR ADENOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-349 Y89]"
4454,363899613,992,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,Inactive,,,,RAT,F344/N/MALE,ORAL,0; 200; 400; 600 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-483 Y99]"
4455,363899613,992,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,Active,,,,RAT,F344/N/MALE,ORAL,0; 1000 PPM IN DIET FOR 52 WK (STUDY DURATION: 105 WK),SKIN: KERATOACANTHOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-483 Y99]"
4456,363899613,992,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,Inactive,,,,RAT,F344/N/FEMALE,ORAL,0; 200; 400; 600 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-483 Y99]"
4457,363899613,992,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,Inactive,,,,RAT,F344/N/FEMALE,ORAL,0; 1000 PPM IN DIET FOR 52 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-483 Y99]"
4458,363899613,992,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1200 PPM IN DIET FOR 13 WK (STUDY DURATION: 42 WK),,NEGATIVE,"[UMEMURA,T, KAI,S, HASEGAWA,R, SAI,K, KUROKAWA,Y AND WILLIAMS,GM; PENTACHLOROPHENOL (PCP) PRODUCES LIVER OXIDATIVE STRESS AND PROMOTES BUT DOES NOT INITIATE HEPATOCARCINOGENESIS IN B6C3F1 MICE; CARCINOGENESIS 20(6):1115-1120, 1999]"
4459,363899644,14046,CC(C)COC(=O)C(=C)C#N,Active,,,,RAT,F344/FEMALE,IMPLANT,0; 10; 100 UL INTO VENTRAL LIVER CAPSULE ONCE (STUDY DURATION: 2 YR),BODY CAVITY: SARCOMA,POSITIVE,"[BROWN,LD, MELLICK,PW, SMITH,CD AND KORTE,DW; CARCINOGENICITY BIOASSAY OF ISOBUTYL 2-CYANOACRYLATE (IBC) IN FISCHER-344 RATS; U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND, NTIS AD-A222000, 1990]"
4460,363899644,14046,CC(C)COC(=O)C(=C)C#N,Active,,,,RAT,F344/MALE,IMPLANT,0; 10; 100 UL INTO VENTRAL LIVER CAPSULE ONCE (STUDY DURATION: 2 YR),BODY CAVITY: SARCOMA,POSITIVE,"[BROWN,LD, MELLICK,PW, SMITH,CD AND KORTE,DW; CARCINOGENICITY BIOASSAY OF ISOBUTYL 2-CYANOACRYLATE (IBC) IN FISCHER-344 RATS; U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND, NTIS AD-A222000, 1990]"
4461,363899691,880,CC(=O)C=O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 50 UMOL/0.1 ML DMSO 2/WK FOR 5 WK FOLLOWED 1 WK LATER BY 0.1 ML ACETONE 2/WK FOR 47 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MIYAKAWA,Y, NISHI,Y, KATO,K, SATO,K, TAKAHASHI,M AND HAYASHI,Y; INITIATING ACTIVITY OF EIGHT PYROLYSATES OF CARBOHYDRATES IN A TWO-STAGE MOUSE SKIN TUMORIGENESIS MODEL; CARCINOGENESIS 12(7):1169-1173, 1991]"
4462,363899693,55786,CC1=CC2=C(C3=CC=CC=C13)C4=C(N2)C=C(C5=CC=CC=C54)C,Active,,,,MOUSE,A/J/MALE,INTRAPERITONEAL,0; 2; 10 MG/KG BW IN TRICAPRYLIN ONCE AT 4-5 WK OF AGE (STUDY DURATION: 7-8 MO),LUNG: TUMOR,POSITIVE,"[GRAY,DL WARSHAWSKY,D XUE,W NINES,R WANG,Y YAO,R AND STONER,GD; THE EFFECTS OF A BINARY MIXTURE OF BENZO(A)PYRENE AND 7H-DIBENZO(C,G)CARBAZOLE ON LUNG TUMORS AND K-RAS ONCOGENE MUTATIONS IN STRAIN A/J MICE; EXP. LUNG RES. 27(3):245-253, 2001]"
4463,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,RAT,WISTAR/MALE,INTRAGASTRIC,0; 10 MG/KG IN ACIDIFIED WATER 1/D FOR 2 WK (STUDY DURATION: 58 WK),,NEGATIVE,"[KRISTIANSEN,E, CLEMMENSEN,S AND OLSEN,P; CARCINOGENIC POTENTIAL OF COOKED FOOD MUTAGENS (IQ AND MEIQ) IN WISTAR RATS AFTER SHORT-TERM EXPOSURE; PHARMACOL. TOXICOL. (COPENHAGEN) 65(5):332-335, 1989]"
4464,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
4465,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
4466,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
4467,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
4468,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MOUSE,CDF1/MALE,ORAL,0; 0.03% IN DIET FOR UP TO 675 D (STUDY DURATION: 675 D),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA OR HEMANGIOENDOTHELIOMA; FORESTOMACH: PAPILLOMA OR SQUAMOUS CELL CARCINOMA; LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[OHGAKI,H, KUSAMA,K, MATSUKURA,N, MORINO,K, HASEGAWA,H, SATO,S, TAKAYAMA,S AND SUGIMURA,T; CARCINOGENICITY IN MICE OF A MUTAGENIC COMPOUND, 2-AMINO-3- METHYLIMIDAZO[4,5-F]QUINOLINE, FROM BROILED SARDINE, COOKED BEEF AND BEEF EXTRACT; CARCINOGENESIS 5(7):921-924, 1984]"
4469,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 0.03% IN DIET FOR UP TO 675 D (STUDY DURATION: 675 D),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA OR HEMANGIOENDOTHELIOMA; FORESTOMACH: PAPILLOMA OR SQUAMOUS CELL CARCINOMA; LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[OHGAKI,H, KUSAMA,K, MATSUKURA,N, MORINO,K, HASEGAWA,H, SATO,S, TAKAYAMA,S AND SUGIMURA,T; CARCINOGENICITY IN MICE OF A MUTAGENIC COMPOUND, 2-AMINO-3- METHYLIMIDAZO[4,5-F]QUINOLINE, FROM BROILED SARDINE, COOKED BEEF AND BEEF EXTRACT; CARCINOGENESIS 5(7):921-924, 1984]"
4470,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,RAT,F344/MALE,INTRARECTAL,0; 50.5 MG/KG IN 1.7 ML/KG DMSO INFUSED 3/WK FOR 2 MO THEN 2/WK FOR DURATION OF STUDY (STUDY DURATION: 18 MO),COLON: CARCINOMA; SKIN: SEBACEOUS SQUAMOUS CELL CARCINOMA,POSITIVE,"[WEISBURGER,JH, RIVENSON,A, REINHARDT,J, ALIAGA,C, BRALEY,J, DOLAN,LM, WILLIAMS, GM, ZANG,E, KINGSTON,DGI, BASHLR,M, SHU,YZ, WILKINS,TD AND VAN TASSELL,RL; GENOTOXICITY AND CARCINOGENICITY IN RATS AND MICE OF 2-AMINO-3,6-DIHYDRO-3-METHYL-7H-IMIDAZOLO[4,5-F]QUINOLIN-7-ONE: AN INTESTINAL BACTERIAL METABOLITE OF 2-AMINO-3-METHYL-3H-IMIDAZO[4,5-F]QUINOLINE; J. NATL. CANCER INST. 86(1):25-30, 1994]"
4471,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL ; ORAL,"0; 5 UL OF A 14 MG/ML SOLUTION IN DMSO ON DAYS 1, 3, 5, 7, 10, 13, 17, 21, 24 AND 28 OF LIFE THEN 2/WK TO WK 10 FOLLOWED BY 300 PPM IN DIET 5 D/WK FOR 56 WK (STUDY DURATION: 76 WK)",LIVER: CARCINOMA,POSITIVE,"[WEISBURGER,JH, RIVENSON,A, REINHARDT,J, ALIAGA,C, BRALEY,J, DOLAN,LM, WILLIAMS, GM, ZANG,E, KINGSTON,DGI, BASHLR,M, SHU,YZ, WILKINS,TD AND VAN TASSELL,RL; GENOTOXICITY AND CARCINOGENICITY IN RATS AND MICE OF 2-AMINO-3,6-DIHYDRO-3-METHYL-7H-IMIDAZOLO[4,5-F]QUINOLIN-7-ONE: AN INTESTINAL BACTERIAL METABOLITE OF 2-AMINO-3-METHYL-3H-IMIDAZO[4,5-F]QUINOLINE; J. NATL. CANCER INST. 86(1):25-30, 1994]"
4472,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL ; ORAL,"0; 5 UL OF A 14 MG/ML SOLUTION IN DMSO ON DAYS 1, 3, 5, 7, 10, 13, 17, 21, 24 AND 28 OF LIFE THEN 2/WK TO WK 10 FOLLOWED BY 300 PPM IN DIET 5 D/WK FOR 56 WK (STUDY DURATION: 76 WK)",LIVER: CARCINOMA; LUNG: ADENOMA,POSITIVE,"[WEISBURGER,JH, RIVENSON,A, REINHARDT,J, ALIAGA,C, BRALEY,J, DOLAN,LM, WILLIAMS, GM, ZANG,E, KINGSTON,DGI, BASHLR,M, SHU,YZ, WILKINS,TD AND VAN TASSELL,RL; GENOTOXICITY AND CARCINOGENICITY IN RATS AND MICE OF 2-AMINO-3,6-DIHYDRO-3-METHYL-7H-IMIDAZOLO[4,5-F]QUINOLIN-7-ONE: AN INTESTINAL BACTERIAL METABOLITE OF 2-AMINO-3-METHYL-3H-IMIDAZO[4,5-F]QUINOLINE; J. NATL. CANCER INST. 86(1):25-30, 1994]"
4473,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MONKEY,"MACAQUE/MALE,FEMALE",GAVAGE,0; 10; 20 MG/KG 5/D/WK FOR DURATION OF STUDY (STUDY DURATION: 91 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[ADAMSON,RH, TAKAYAMA,S, SUGIMURA,T AND THORGEIRSSON,UP; INDUCTION OF HEPATOCELLULAR CARCINOMA IN NONHUMAN PRIMATES BY THE FOOD MUTAGEN 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE; ENVIRON. HEALTH PERSPECT. 102(2): 190-193, 1994]"
4474,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 0.35 MMOL/KG BW IN 0.25 ML OF 5% EMULPHOR IN WATER 3/WK FOR WK 1-4 THEN 2/WK FOR WK 5-8 FOLLOWED BY 1/WK FOR 23 WK (STUDY DURATION: 52 WK),MAMMARY GLAND: CARCINOMA; LIVER: TUMOR; EAR DUCT: TUMOR,POSITIVE,"[TANAKA,T, BARNES,WS, WILLIAMS,GM AND WEISBURGER,JH; MULTIPOTENTIAL CARCINOGENICITY OF THE FRIED FOOD MUTAGEN 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE IN RATS; JPN. J. CANCER RES. (GANN) 76(7):570-576, 1985]"
4475,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,MOUSE,TRANSGENIC EU-PIM-1/MALE,ORAL,0; 0.03% IN DIET FOR 24 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SOERENSEN,IK, MORTENSEN,A, KRISTIANSEN,E, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; SHORT-TERM CARCINOGENICITY TESTING OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) AND 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE (IQ) IN EU-PIM-1 TRANSGENIC MICE; CARCINOGENESIS 17(10):2221-2227, 1996]"
4476,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,MOUSE,TRANSGENIC EU-PIM-1/FEMALE,ORAL,0; 0.03% IN DIET FOR 24 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SOERENSEN,IK, MORTENSEN,A, KRISTIANSEN,E, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; SHORT-TERM CARCINOGENICITY TESTING OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) AND 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE (IQ) IN EU-PIM-1 TRANSGENIC MICE; CARCINOGENESIS 17(10):2221-2227, 1996]"
4477,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,MOUSE,NON-TRANSGENIC WILD-TYPE/MALE,ORAL,0; 0.03% IN DIET FOR 24 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SOERENSEN,IK, MORTENSEN,A, KRISTIANSEN,E, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; SHORT-TERM CARCINOGENICITY TESTING OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) AND 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE (IQ) IN EU-PIM-1 TRANSGENIC MICE; CARCINOGENESIS 17(10):2221-2227, 1996]"
4478,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,MOUSE,NON-TRANSGENIC WILD-TYPE/FEMALE,ORAL,0; 0.03% IN DIET FOR 24 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SOERENSEN,IK, MORTENSEN,A, KRISTIANSEN,E, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; SHORT-TERM CARCINOGENICITY TESTING OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) AND 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE (IQ) IN EU-PIM-1 TRANSGENIC MICE; CARCINOGENESIS 17(10):2221-2227, 1996]"
4479,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,MOUSE,WILD-TYPE/MALE,ORAL,0; 0.03% IN DIET FOR 24 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SOERENSEN,IK, KRISTIANSEN,E, MORTENSEN,A, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; LYMPHOMA INDUCTION BY HETEROCYCLIC AMINES IN EU-PIM-1 TRANSGENIC MICE; ARCH. TOXICOL., SUPPL. 19(APPLIED TOXICOLOGY: APPROACHES THROUGH BASIC SCIENCE):377-386, 1997]"
4480,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,MOUSE,WILD-TYPE/FEMALE,ORAL,0; 0.03% IN DIET FOR 24 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SOERENSEN,IK, KRISTIANSEN,E, MORTENSEN,A, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; LYMPHOMA INDUCTION BY HETEROCYCLIC AMINES IN EU-PIM-1 TRANSGENIC MICE; ARCH. TOXICOL., SUPPL. 19(APPLIED TOXICOLOGY: APPROACHES THROUGH BASIC SCIENCE):377-386, 1997]"
4481,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,MOUSE,EU-PIM-1/MALE,ORAL,0; 0.03% IN DIET FOR 24 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SOERENSEN,IK, KRISTIANSEN,E, MORTENSEN,A, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; LYMPHOMA INDUCTION BY HETEROCYCLIC AMINES IN EU-PIM-1 TRANSGENIC MICE; ARCH. TOXICOL., SUPPL. 19(APPLIED TOXICOLOGY: APPROACHES THROUGH BASIC SCIENCE):377-386, 1997]"
4482,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,MOUSE,EU-PIM-1/FEMALE,ORAL,0; 0.03% IN DIET FOR 24 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SOERENSEN,IK, KRISTIANSEN,E, MORTENSEN,A, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; LYMPHOMA INDUCTION BY HETEROCYCLIC AMINES IN EU-PIM-1 TRANSGENIC MICE; ARCH. TOXICOL., SUPPL. 19(APPLIED TOXICOLOGY: APPROACHES THROUGH BASIC SCIENCE):377-386, 1997]"
4483,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,MOUSE,SEVERE COMBINED IMMUNODEFICIENT/FEMALE,ORAL,0; 300 PPM IN THE DIET FOR 78 WK (STUDY DURATION: 78 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[HOSHI,M WANIBUCHI,H SALIM,EI MORIMURA,K MURAI,T NOMURA,T TAKAOKA,K AND FUKUSHIMA,S; CARCINOGENIC POTENTIAL OF 2-AMINO-3-METHYL-IMIDAZO[4,5-F]QUINOLINE (IQ) IN SEVERE COMBINED IMMUNODEFICIENT (SCID) MICE; J. TOXICOL. PATHOL. 17(1):17-23, 2004]"
4484,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,Mouse,Non transgenic rasH2 Wild-type/ Female (10/10)/(15/15),Oral,300 ppm in the diet starting at 7 weeks of age (Study duration: 26 weeks),,"Negative: Although only hyperplasia observed in wild-type mouse,  forestomach papillomas and squamous cell carcinomas were observed in low incidence in rasH2 animals.","[OKAMURA,M, MOTO,M, MUGURUMA,M, ITO,T, JIN,M, KASHIDA,Y, AND MITSUMORI,K; A 26-WEEK CARCINOGENICITY STUDY OF 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE IN RASH2 MICE; TOXICOLOGIC PATHOLOGY 34(2):199-205, 2006]"
4485,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Inactive,,,,Mouse,Non transgenic rasH2 Wild-type/ Male (10/10)/(15/15),Oral,300 ppm in the diet starting at 7 weeks of age (Study duration: 26 wks),,"Negative; Although only hyperplasia observed in wild-type mouse,  forestomach papillomas (significant) and squamous cell carcinomas (nonsignificant) were observed  in rasH2 animals.","[OKAMURA,M, MOTO,M, MUGURUMA,M, ITO,T, JIN,M, KASHIDA,Y, AND MITSUMORI,K; A 26-WEEK CARCINOGENICITY STUDY OF 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE IN RASH2 MICE; TOXICOLOGIC PATHOLOGY 34(2):199-205, 2006]"
4486,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,Mouse,Parp-1+/+ C57BL/6/Male,Oral,300 ppm in diet for 60 wk; study duration 60 wk,Spleen: Malignant lymphoma (3/18),Positive (No lung adenomas or forestomach papillomas found). Parp-1 deficiency (Parp-1-/- or Parp-1+/-) did not affect susceptibility of the mice to IQ carcinogenicity.,"[OGAWA,K MASUTANI,M KATO,K TANG,M KAMADA,N SUZUKI,H NAKAGAMA,H SUGIMURA,T AND SHIRAI,T; PARP-1 DEFICIENCY DOES NOT ENHANCE LIVER ARCINOGENESIS INDUCED BY 2-AMINO-3METHYLIMIDAZO[4,5-F]QUINOLINE IN MICE; CANCER LETTERS 236(1):32-38, 2006]"
4487,363899717,53462,CN1C2=C(C3=C(C=C2)N=CC=C3)N=C1N,Active,,,,Mouse,Parp-1+/+ C57BL/6/Male,Oral,300 ppm in diet for 60 wk; study duration 60 wk,Spleen: Malignant lymphoma (3/18),"Positive (However, no lung adenomas or forestomach papillomas found. Parp-1 deficiency (Parp-1-/- or Parp-1+/-) did not affect susceptibility of the mice to IQ carcinogenicity)","[OGAWA,K MASUTANI,M KATO,K TANG,M KAMADA,N SUZUKI,H NAKAGAMA,H SUGIMURA,T AND SHIRAI,T; PARP-1 DEFICIENCY DOES NOT ENHANCE LIVER ARCINOGENESIS INDUCED BY 2-AMINO-3METHYLIMIDAZO[4,5-F]QUINOLINE IN MICE; CANCER LETTERS 236(1):32-38, 2006]"
4488,363899718,62274,CC1=CC2=C(C=CC=N2)C3=C1N(C(=N3)N)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.03% IN DIET (DAILY INTAKE: 5.6 MG) FOR 286 D (STUDY DURATION: 286 D),ZYMBAL GLAND: SQUAMOUS CELL CARCINOMA; ORAL CAVITY: SQUAMOUS CELL CARCINOMA OR SEBACEOUS SQUAMOUS CELL CARCINOMA; COLON: ADENOMA OR ADENOCARCINOMA; SKIN: SQUAMOUS CELL CARCINOMA,POSITIVE,"[KATO,T, MIGITA,H, OHGAKI,H, SATO,S, TAKAYAMA,S AND SUGIMURA,T; INDUCTION OF TUMORS IN THE ZYMBAL GLAND, ORAL CAVITY, COLON, SKIN AND MAMMARY GLAND OF F344 RATS BY A MUTAGENIC COMPOUND, 2-AMINO-3,4-DIMETHYLIMIDAZO[4,5-F]QUINOLINE; CARCINOGENESIS 10(3):601-603, 1989]"
4489,363899718,62274,CC1=CC2=C(C=CC=N2)C3=C1N(C(=N3)N)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.03% IN DIET (DAILY INTAKE: 3.8 MG) FOR 286 D (STUDY DURATION: 286 D),ZYMBAL GLAND: SQUAMOUS CELL CARCINOMA; ORAL CAVITY: SQUAMOUS CELL CARCINOMA OR SEBACEOUS SQUAMOUS CELL CARCINOMA; COLON: ADENOMA OR ADENOCARCINOMA; MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[KATO,T, MIGITA,H, OHGAKI,H, SATO,S, TAKAYAMA,S AND SUGIMURA,T; INDUCTION OF TUMORS IN THE ZYMBAL GLAND, ORAL CAVITY, COLON, SKIN AND MAMMARY GLAND OF F344 RATS BY A MUTAGENIC COMPOUND, 2-AMINO-3,4-DIMETHYLIMIDAZO[4,5-F]QUINOLINE; CARCINOGENESIS 10(3):601-603, 1989]"
4490,363899718,62274,CC1=CC2=C(C=CC=N2)C3=C1N(C(=N3)N)C,Active,,,,RAT,WISTAR/MALE,INTRAGASTRIC,0; 10 MG/KG IN ACIDIFIED WATER 1/D FOR 2 WK (STUDY DURATION: 58 WK),ZYMBAL GLAND: CARCINOMA,POSITIVE,"[KRISTIANSEN,E, CLEMMENSEN,S AND OLSEN,P; CARCINOGENIC POTENTIAL OF COOKED FOOD MUTAGENS (IQ AND MEIQ) IN WISTAR RATS AFTER SHORT-TERM EXPOSURE; PHARMACOL. TOXICOL. (COPENHAGEN) 65(5):332-335, 1989]"
4491,363899718,62274,CC1=CC2=C(C=CC=N2)C3=C1N(C(=N3)N)C,Active,,,,MOUSE,CDF1/MALE,ORAL,0; 0.04% IN THE DIET FOR STUDY DURATION (STUDY DURATION: LIFESPAN),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA; LIVER: CHOLANGIOCARCINOMA",POSITIVE,"[OHGAKI,H, HASEGAWA,H, KATO,T, SUENAGA,M, UBUKATA,M, SATO,S, TAKAYAMA,S AND SUGIMURA,T; INDUCTION OF TUMORS IN THE FORESTOMACH AND LIVER OF MICE BY FEEDING 2-AMINO-3,4-DIMETHYLIMIDAZO[4,5-F]QUINOLINE (MEIQ); PROC. JPN. ACAD., SER. B 61(3):137-139, 1985]"
4492,363899718,62274,CC1=CC2=C(C=CC=N2)C3=C1N(C(=N3)N)C,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 0.04% IN THE DIET FOR STUDY DURATION (STUDY DURATION: LIFESPAN),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[OHGAKI,H, HASEGAWA,H, KATO,T, SUENAGA,M, UBUKATA,M, SATO,S, TAKAYAMA,S AND SUGIMURA,T; INDUCTION OF TUMORS IN THE FORESTOMACH AND LIVER OF MICE BY FEEDING 2-AMINO-3,4-DIMETHYLIMIDAZO[4,5-F]QUINOLINE (MEIQ); PROC. JPN. ACAD., SER. B 61(3):137-139, 1985]"
4493,363899718,62274,CC1=CC2=C(C=CC=N2)C3=C1N(C(=N3)N)C,Active,,,,MOUSE,C57BL/6N/FEMALE,ORAL,0; 300 PPM IN DIET FOR 92 WK (STUDY DURATION: 92 WK),"COLON: ADENOCARCINOMA; CECUM: ADENOCARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, OR FIBROSARCOMA",POSITIVE,"[FUJITA,H NAGANO,K OCHIAI,M USHIJIMA,T SUGIMURA,T NAGAO,M AND MATSUSHIMA,T; DIFFERENCE IN TARGET ORGANS IN CARCINOGENESIS WITH A HETEROCYCLIC AMINE, 2-AMINO-3,4-DIMETHYLIMIDAZO-[4,5-F]QUINOLINE, IN DIFFERENT STRAINS OF MICE; JPN. J. CANCER RES. 90(11):1203-1206, 1999]"
4494,363899731,5283344,CCCCCC(/C=C/C=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 750 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 15 MO OF AGE (STUDY DURATION: 15 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
4495,363899731,5283344,CCCCCC(/C=C/C=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 750 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 15 MO OF AGE (STUDY DURATION: 15 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
4496,363899731,5283344,CCCCCC(/C=C/C=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 1500 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 12 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
4497,363899731,5283344,CCCCCC(/C=C/C=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1500 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 12 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
4498,363899737,60025,CC1=C(C2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3)[N+](=O)[O-],Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED 1/7, 2/7 AND 4/7 ON DAY 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 32 WK)",LIVER: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH, AMIN,S AND HECHT,SS; THE EFFECTS OF BAY-REGION METHYL SUBSTITUTION ON 6-NITROCHRYSENE MUTAGENICITY IN SALMONELLA TYPHIMURIUM AND TUMORIGENICITY IN NEWBORN MICE; CARCINOGENESIS (LONDON) 10(9):1685-9, 1989]"
4499,363899737,60025,CC1=C(C2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3)[N+](=O)[O-],Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED 1/7, 2/7 AND 4/7 ON DAY 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 32 WK)",,NEGATIVE,"[EL-BAYOUMY,K, SHIUE,GH, AMIN,S AND HECHT,SS; THE EFFECTS OF BAY-REGION METHYL SUBSTITUTION ON 6-NITROCHRYSENE MUTAGENICITY IN SALMONELLA TYPHIMURIUM AND TUMORIGENICITY IN NEWBORN MICE; CARCINOGENESIS (LONDON) 10(9):1685-9, 1989]"
4500,363899788,931,C1=CC=C2C=CC=CC2=C1,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.25; O.5; 1.0 UMOL IN DMSO TO NEWBORN MICE ON DAY 1,8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
4501,363899788,931,C1=CC=C2C=CC=CC2=C1,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.25; 0.5; 1.0 UMOL IN DMSO TO NEWBORN MICE ON DAY 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
4502,363899788,931,C1=CC=C2C=CC=CC2=C1,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 10; 30 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-410 Y92]"
4503,363899788,931,C1=CC=C2C=CC=CC2=C1,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 10; 30 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-410 Y92]"
4504,363899788,931,C1=CC=C2C=CC=CC2=C1,Active,,,,RAT,F344/N/MALE,INHALATION,0; 10; 30; 60 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),NOSE: ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-500 Y00]"
4505,363899788,931,C1=CC=C2C=CC=CC2=C1,Active,,,,RAT,F344/N/FEMALE,INHALATION,0; 10; 30; 60 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),NOSE: NEUROBLASTOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-500 Y00]"
4506,363899789,7294,COC(=O)C=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 15; 45; 135 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 130 WK),,NEGATIVE,"[REININGHAUS,W, KOESTNER,A AND KLIMISCH,HJ; CHRONIC TOXICITY AND ONCOGENICITY OF INHALED METHYL ACRYLATE AND N-BUTYL ACRYLATE IN SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 29(5):329-339, 1991]"
4507,363899789,7294,COC(=O)C=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 15; 45; 135 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 130 WK),,NEGATIVE,"[REININGHAUS,W, KOESTNER,A AND KLIMISCH,HJ; CHRONIC TOXICITY AND ONCOGENICITY OF INHALED METHYL ACRYLATE AND N-BUTYL ACRYLATE IN SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 29(5):329-339, 1991]"
4508,363899797,82746,CCCCCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 16 MG/ML (TOTAL DOSE 0; 2 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 50 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: TUMOR; BODY CAVITY: MESOTHELIOMA,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
4509,363899797,82746,CCCCCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 16 MG/ML (TOTAL DOSE 0; 2 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 50 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
4510,363899797,82746,CCCCCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 16 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 50 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LUNG: TUMOR: PERITONEUM: MESOTHELIOMA; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
4511,363899797,82746,CCCCCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 16 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 50 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LUNG: TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
4512,363899798,135419,C(CF)N(C(=O)N)N=O,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 1.75 MG/ML (TOTAL DOSE 0; 0.2 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 40 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
4513,363899798,135419,C(CF)N(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 1.75 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 40 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
4514,363899800,83695,C(CO)N(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 2.4 MG IN 0.2 ML ETHYL ACETATE/CORN OIL (1:1) 2/WK FOR 30 WK (TOTAL DOSE: 168 MG) (STUDY DURATION: 80 WK),LUNG: CARCINOMA OR ADENOMA; THYROID: CARCINOMA OR ADENOMA,POSITIVE,"[LIJINSKY,W, SINGER,GM AND KOVATCH,RM; SIMILAR CARCINOGENIC EFFECTS IN RATS OF 1-ETHYL-1-NITROSO-3-HYDROXYETHYLUREA AND 1-HYDROXYETHYL-1-NITROSO-3- ETHYLUREA; CARCINOGENESIS 6(4):641-643, 1985]"
4515,363899800,83695,C(CO)N(C(=O)N)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 14 MG/ML ((0.2 ML OF A SOLUTION IN ETHYL ACETATE/CORN OIL (1:2)) 1/WK FOR 22 WK (STUDY DURATION: LIFE SPAN),LIVER: HEMANGIOSARCOMA; SPLEEN: HEMANGIOSARCOMA,POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
4516,363899800,83695,C(CO)N(C(=O)N)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 14 MG/ML ((0.2 ML OF A SOLUTION IN ETHYL ACETATE/CORN OIL (1:2)) 1/WK FOR 22 WK (STUDY DURATION: 20 WK),LIVER: HEMANGIOSARCOMA; PANCREAS: CARCINOMA OR ADENOMA; SPLEEN: HEMANGIOSARCOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA OR PAPILLOMA,POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
4517,363899801,123019,C(CN(C(=O)N)N=O)CO,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 8 MG/ML (TOTAL DOSE 0; 0.9 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 40 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
4518,363899801,123019,C(CN(C(=O)N)N=O)CO,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 8 MG/ML (TOTAL DOSE 0; 0.9 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 40 WK (STUDY DURATION: LIFETIME),THYROID: C-CELL TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
4519,363899801,123019,C(CN(C(=O)N)N=O)CO,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 16 MG/ML (TOTAL DOSE 0; 1.3 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
4520,363899801,123019,C(CN(C(=O)N)N=O)CO,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 16 MG/ML (TOTAL DOSE 0; 1.3 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
4521,363899801,123019,C(CN(C(=O)N)N=O)CO,Active,,,,RAT,F344/MALE,GAVAGE,0; 8 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 40 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
4522,363899801,123019,C(CN(C(=O)N)N=O)CO,Active,,,,RAT,F344/MALE,GAVAGE,0; 16 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 30 WK (STUDY DURATION: LIFESPAN),LUNG: TUMOR; GLANDULAR STOMACH: TUMOR; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
4523,363899801,123019,C(CN(C(=O)N)N=O)CO,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 8 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 40 WK (STUDY DURATION: LIFESPAN),THYROID: C-CELL TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
4524,363899801,123019,C(CN(C(=O)N)N=O)CO,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 16 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 30 WK (STUDY DURATION: LIFESPAN),LIVER: TUMOR; FORESTOMACH: TUMOR; THYROID: C-CELL TUMOR; UTERUS: TUMOR; DUODENUM: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
4525,363899803,114735,CC(CN(C(=O)N)N=O)O,Active,,,,RAT,F344/MALE,GAVAGE,0; 8 MG/ML (TOTAL DOSE 0; 0.4 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 18 WK (STUDY DURATION: LIFETIME),THYMUS: LYMPHOMA,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
4526,363899803,114735,CC(CN(C(=O)N)N=O)O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 8 MG/ML (TOTAL DOSE 0; 0.4 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 18 WK (STUDY DURATION: LIFETIME),THYMUS: LYMPHOMA,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
4527,363899803,114735,CC(CN(C(=O)N)N=O)O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 3.2 MG 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
4528,363899803,114735,CC(CN(C(=O)N)N=O)O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 16 MG/ML ((0.2 ML OF A SOLUTION IN ETHYL ACETATE/CORN OIL (1:2)) 1/WK FOR 24 WK (STUDY DURATION: LIFE SPAN),LIVER: HEMANGIOSARCOMA; SPLEEN: HEMANGIOSARCOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA OR PAPILLOMA,POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
4529,363899803,114735,CC(CN(C(=O)N)N=O)O,Active,,,,RAT,F344/MALE,GAVAGE,0; 8 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 18 WK (STUDY DURATION: LIFESPAN),THYMUS: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
4530,363899803,114735,CC(CN(C(=O)N)N=O)O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 8 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 18 WK (STUDY DURATION: LIFESPAN),THYMUS: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
4531,363899804,130063,COCCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 3.2 MG 2/WK FOR 17 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
4532,363899812,105037,C1CN2C=CC(=C2[C@@H]1O)CO,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 20 MG/KG IN 0.2 ML ACETONE 1/WK FOR 4 WK AFTER 6 MO ANIMALS WITHOUT TUMORS TREATED AGAIN 1/WK FOR 2 WK (STUDY DURATION: 63 WK),SKIN: BASAL CELL CARCINOMA,POSITIVE,"[JOHNSON,WD, ROBERTSON,KA, POUNDS,JG AND ALLEN,JR; DEHYDRORETRONECINE-INDUCED SKIN TUMORS IN MICE; J. NATL. CANCER INST. 61(1):85-89, 1978]"
4533,363899812,105037,C1CN2C=CC(=C2[C@@H]1O)CO,Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 20 MG/KG IN 0.1 ML PHOSPHATE BUFFER 1/WK FOR 4 WK AFTER 6 MO ANIMALS WITHOUT TUMORS TREATED AGAIN 1/WK FOR 2 WK (STUDY DURATION: 63 WK),SKIN: BASAL CELL CARCINOMA,POSITIVE,"[JOHNSON,WD, ROBERTSON,KA, POUNDS,JG AND ALLEN,JR; DEHYDRORETRONECINE-INDUCED SKIN TUMORS IN MICE; J. NATL. CANCER INST. 61(1):85-89, 1978]"
4534,363899812,105037,C1CN2C=CC(=C2[C@@H]1O)CO,Active,,,,MOUSE,SWISS/FEMALE,DERMAL/SUBCUTANEOUS,"0; 20 MG/KG IN 0.2 ML ACETONE TO SHAVED MID-BACK REGION AND 0; 20 MG/KG IN 0.1 ML PHOSPHATE BUFFER TO INTERSCAPULAR REGION 1/WK FOR 4 WK, AFTER 6 MO ANIMALS WITHOUT TUMORS TREATED AGAIN 1/WK FOR 2 WK (STUDY DURATION: 63 WK)",SKIN: BASAL CELL CARCINOMA,POSITIVE,"[JOHNSON,WD, ROBERTSON,KA, POUNDS,JG AND ALLEN,JR; DEHYDRORETRONECINE-INDUCED SKIN TUMORS IN MICE; J. NATL. CANCER INST. 61(1):85-89, 1978]"
4535,363899813,12342,C(=O)NNC=O,Active,,,,MOUSE,SWISS/MALE,ORAL,0; 2% SOLUTION IN DRINKING WATER FROM AGE 6 WK FOR LIFE FOR AN AVERAGE DAILY INTAKE OF 0; 146 MG,LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[TOTH,B AND ERICKSON,J; LUNG TUMORIGENESIS BY 1,2-DIFORMYLHYDRAZINE IN MICE; Z. KREBSFORSCH. 92:11-16, 1978]"
4536,363899813,12342,C(=O)NNC=O,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 2% SOLUTION IN DRINKING WATER FROM AGE 6 WK FOR LIFE FOR AN AVERAGE DAILY INTAKE OF 0; 144 MG,LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[TOTH,B AND ERICKSON,J; LUNG TUMORIGENESIS BY 1,2-DIFORMYLHYDRAZINE IN MICE; Z. KREBSFORSCH. 92:11-16, 1978]"
4537,363899814,77082,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O.Cl,Active,,,,MOUSE,AB/JENA/FEMALE,ORAL,0; 62.5 MG/KG IN 0.25 ML WATER 1/D FOR 4 D FOR A TOTAL DOSE OF 0; 250 MG/KG,LUNG: ADENOMA,POSITIVE,"[GUTTNER,VJ, BRUNS,G AND JUNGSTAND,W; ONCOGENICITY OF GAMMA-[1-METHYL-5-BIS-(BETA-CHLOROETHYL)-AMINOBENZIMIDAZOLYL-(2)]-BUTYRIC ACID HYDROCHLORIDE (CYTOSTASAN) IN MICE; ARCH. GESCHWULSTFORSCH. 43:16-21, 1974]"
4538,363899814,77082,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O.Cl,Active,,,,MOUSE,AB/JENA/FEMALE,INTRAPERITONEAL,0; 12.5; 25 MG/KG IN 2 ML SALINE 1/D FOR 4 D FOR A TOTAL DOSE OF 0; 50; 100 MG/KG,PERITONEUM: SARCOMA,POSITIVE,"[GUTTNER,VJ, BRUNS,G AND JUNGSTAND,W; ONCOGENICITY OF GAMMA-[1-METHYL-5-BIS-(BETA-CHLOROETHYL)-AMINOBENZIMIDAZOLYL-(2)]-BUTYRIC ACID HYDROCHLORIDE (CYTOSTASAN) IN MICE; ARCH. GESCHWULSTFORSCH. 43:16-21, 1974]"
4539,363899815,2723854,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,"OSBORNE-MENDEL/MALE, FEMALE",ORAL,0; 0.5; 1.0; 2.0; 5.0% IN DIET FOR 2 YR,,NEGATIVE,"[HANSEN,WH, FITZHUGH,OG, NELSON,AA AND DAVIS,KJ; CHRONIC TOXICITY OF TWO FOOD COLORS BRILLIANT BLUE FCF AND INDIGOTINE; TOXICOL. APPL. PHARMACOL. 8:29-36, 1966]"
4540,363899815,2723854,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)[O-])O.[Na+].[Na+],Active,,,,RAT,"OSBORNE-MENDEL/MALE, FEMALE",SUBCUTANEOUS,0; 20 MG AS A 2% AQUEOUS SOLUTION 1/WK FOR 2 YR,INJECTION SITE: FIBROSARCOMA,POSITIVE,"[HANSEN,WH, FITZHUGH,OG, NELSON,AA AND DAVIS,KJ; CHRONIC TOXICITY OF TWO FOOD COLORS BRILLIANT BLUE FCF AND INDIGOTINE; TOXICOL. APPL. PHARMACOL. 8:29-36, 1966]"
4541,363899815,2723854,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,"C3H AND C57/MALE, FEMALE",SUBCUTANEOUS,0; 2.5 MG AS A 1% AQUEOUS SOLUTION 1/WK FOR 2 YR,,NEGATIVE,"[HANSEN,WH, FITZHUGH,OG, NELSON,AA AND DAVIS,KJ; CHRONIC TOXICITY OF TWO FOOD COLORS BRILLIANT BLUE FCF AND INDIGOTINE; TOXICOL. APPL. PHARMACOL. 8:29-36, 1966]"
4542,363899815,2723854,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,DOG,"BEAGLE/MALE, FEMALE",ORAL,0; 1; 2% IN DIET FOR 2 YR,,NEGATIVE,"[HANSEN,WH, FITZHUGH,OG, NELSON,AA AND DAVIS,KJ; CHRONIC TOXICITY OF TWO FOOD COLORS BRILLIANT BLUE FCF AND INDIGOTINE; TOXICOL. APPL. PHARMACOL. 8:29-36, 1966]"
4543,363899815,2723854,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 0.5; 1.5; 5% IN DIET FOR 22 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BORZELLECA,JF AND HOGAN,GK; CHRONIC TOXICITY/CARCINOGENICITY STUDY OF FD & C BLUE NO. 2 IN MICE; FOOD CHEM. TOXICOL. 23(8):719-722, 1985]"
4544,363899815,2723854,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.5; 1.5; 5% IN DIET FOR 23 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BORZELLECA,JF AND HOGAN,GK; CHRONIC TOXICITY/CARCINOGENICITY STUDY OF FD & C BLUE NO. 2 IN MICE; FOOD CHEM. TOXICOL. 23(8):719-722, 1985]"
4545,363899815,2723854,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,STRAIN-CD/MALE,ORAL,0; 0.5; 1; 2% IN DIET FOR 29 MO TO ANIMALS ALSO EXPOSED IN UTERO THROUGH THE SAME DOSES ADMINISTERED TO PARENTS BEGINNING 2 MO PRIOR TO MATING (STUDY DURATION: 31 MO),,NEGATIVE,"[BORZELLECA,JF, HOGAN,GK AND KOESTNER,A; CHRONIC TOXICITY/CARCINOGENICITY STUDY OF FD AND C BLUE NO. 2 IN RATS; FOOD CHEM. TOXICOL. 23(6):551-558, 1985]"
4546,363899815,2723854,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 0.5; 1; 2% IN DIET FOR 30 MO TO ANIMALS ALSO EXPOSED IN UTERO THROUGH THE SAME DOSES ADMINISTERED TO PARENTS BEGINNING 2 MO PRIOR TO MATING (STUDY DURATION: 32 MO),,NEGATIVE,"[BORZELLECA,JF, HOGAN,GK AND KOESTNER,A; CHRONIC TOXICITY/CARCINOGENICITY STUDY OF FD AND C BLUE NO. 2 IN RATS; FOOD CHEM. TOXICOL. 23(6):551-558, 1985]"
4547,363899816,20376,C1=CC=C(C=C1)C2=CC(=C(C=C2)N)O,Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 200 UG IN 0.02 ML 3% AQUEOUS GELATIN 1/D FOR 3 D (STUDY DURATION: 52 WK),LIVER: HEPATOMA,POSITIVE,"[GORROD,JW, CARTER,RL AND ROE,FJC; INDUCTION OF HEPATOMAS BY 4-AMINOBIPHENYL AND THREE OF ITS HYDROXYLATED DERIVATIVES ADMINISTERED TO NEWBORN MICE; J. NATL. CANCER INST. 41(2):403-410, 1968]"
4548,363899816,20376,C1=CC=C(C=C1)C2=CC(=C(C=C2)N)O,Inactive,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 200 UG IN 0.02 ML 3% AQUEOUS GELATIN 1/D FOR 3 D (STUDY DURATION: 52 WK),,NEGATIVE,"[GORROD,JW, CARTER,RL AND ROE,FJC; INDUCTION OF HEPATOMAS BY 4-AMINOBIPHENYL AND THREE OF ITS HYDROXYLATED DERIVATIVES ADMINISTERED TO NEWBORN MICE; J. NATL. CANCER INST. 41(2):403-410, 1968]"
4549,363899817,16887,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=C(C=C(C=C5)O)S(=O)(=O)[O-].[Na+].[Na+],Active,,,,RAT,FISCHER/FEMALE,SUBCUTANEOUS,0; 0.5 ML OF 6% SOLUTION IN DISTILLED WATER (0; 30 MG) 2/WK FOR 19 WK THEN 3% SOLUTION (0; 15 MG) 2/WK FOR 9 WK FOLLOWED BY 3% SOLUTION 1/WK FOR 22 WK (STUDY DURATION: 11 MO),INJECTION SITE: FIBROSARCOMA,POSITIVE,"[HESSELBACH,ML AND O'GARA,RW; FAST GREEN- AND LIGHT GREEN-INDUCED TUMORS. INDUCTION, MORPHOLOGY, AND EFFECT ON HOST; J. NATL. CANCER INST. 24(4):769-793, 1960]"
4550,363899817,16887,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=C(C=C(C=C5)O)S(=O)(=O)[O-].[Na+].[Na+],Active,,,,RAT,FISCHER/FEMALE,SUBCUTANEOUS,0; 0.5 ML OF 3% SOLUTION IN DISTILLED WATER (0; 15 MG) 2/WK FOR 26 WK THEN 1/WK FOR 22 WK (STUDY DURATION: 11 MO),INJECTION SITE: FIBROSARCOMA,POSITIVE,"[HESSELBACH,ML AND O'GARA,RW; FAST GREEN- AND LIGHT GREEN-INDUCED TUMORS. INDUCTION, MORPHOLOGY, AND EFFECT ON HOST; J. NATL. CANCER INST. 24(4):769-793, 1960]"
4551,363899817,16887,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=C(C=C(C=C5)O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 19.5 MO (STUDY DURATION: 19.5 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
4552,363899817,16887,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=C(C=C(C=C5)O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 19.5 MO (STUDY DURATION: 19.5 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
4553,363899818,6913060,[2H]C1=C(C(=C2C(=C1[2H])C(=C(C3=C(C4=C(C(=C(C(=C4C(=C32)C([2H])([2H])[2H])[2H])[2H])[2H])[2H])C([2H])([2H])[2H])[2H])[2H])[2H])[2H],Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,IN OLIVE OIL 1/MO FOR 3 MO FOR A TOTAL DOSE OF 0; 1.5 MG (STUDY DURATION: 395 D),INJECTION SITE: FIBROBLASTIC SARCOMA,POSITIVE,"[BUU-HOI,NP AND GIAO,NB; ENHANCEMENT OF THE CARCINOGENICITY OF 7,12-DIMETHYLBENZ[A]ANTHRACENE THROUGH REPLACEMENT OF HYDROGEN BY DEUTERIUM. A NEW BIOLOGICAL ISOTOPE EFFECT; NATURWISSENSCHAFTEN 58:371, 1971]"
4554,363899818,6913060,[2H]C1=C(C(=C2C(=C1[2H])C(=C(C3=C(C4=C(C(=C(C(=C4C(=C32)C([2H])([2H])[2H])[2H])[2H])[2H])[2H])C([2H])([2H])[2H])[2H])[2H])[2H])[2H],Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,IN OLIVE OIL 1/MO FOR 3 MO FOR A TOTAL DOSE OF 0; 1.5 MG (STUDY DURATION: 395 D),INJECTION SITE: FIBROBLASTIC SARCOMA,POSITIVE,"[BUU-HOI,NP AND GIAO,NB; ENHANCEMENT OF THE CARCINOGENICITY OF 7,12-DIMETHYLBENZ[A]ANTHRACENE THROUGH REPLACEMENT OF HYDROGEN BY DEUTERIUM. A NEW BIOLOGICAL ISOTOPE EFFECT; NATURWISSENSCHAFTEN 58:371, 1971]"
4555,363899819,62123,C1=CC(=CC=C1COCCl)COCCl,Active,,,,MOUSE,ICR/HA SWISS/FEMALE,DERMAL,0; 0.3 MG IN 0.1 ML CYCLOHEXANE 3/WK FOR 502 D (STUDY DURATION: 570 D),SKIN: PAPILLOMA; SKIN: CARCINOMA,POSITIVE,"[VAN DUUREN,BL, GOLDSCHMIDT,BM AND SEIDMAN,I; CARCINOGENIC ACTIVITY OF DI- AND TRIFUNCTIONAL ALPHA-CHLORO ETHERS AND OF 1,4-DICHLOROBUTENE-2 IN ICR/HA SWISS MICE; CANCER RES. 35:2553-2557, 1975]"
4556,363899819,62123,C1=CC(=CC=C1COCCl)COCCl,Active,,,,MOUSE,ICR/HA SWISS/FEMALE,SUBCUTANEOUS,0; 0.3 MG IN 0.05 ML TRICAPRYLIN 1/WK FOR 569 D (STUDY DURATION: 570 D),INJECTION SITE: SARCOMA,POSITIVE,"[VAN DUUREN,BL, GOLDSCHMIDT,BM AND SEIDMAN,I; CARCINOGENIC ACTIVITY OF DI- AND TRIFUNCTIONAL ALPHA-CHLORO ETHERS AND OF 1,4-DICHLOROBUTENE-2 IN ICR/HA SWISS MICE; CANCER RES. 35:2553-2557, 1975]"
4557,363899820,61632,C(COCCl)OCCl,Active,,,,MOUSE,ICR/HA SWISS/FEMALE,DERMAL,0; 1 MG IN 0.1 ML CYCLOHEXANE 3/WK FOR 502 D (STUDY DURATION: 570 D),SKIN: PAPILLOMA; SKIN: SQUAMOUS CARCINOMA,POSITIVE,"[VAN DUUREN,BL, GOLDSCHMIDT,BM AND SEIDMAN,I; CARCINOGENIC ACTIVITY OF DI- AND TRIFUNCTIONAL ALPHA-CHLORO ETHERS AND OF 1,4-DICHLOROBUTENE-2 IN ICR/HA SWISS MICE; CANCER RES. 35:2553-2557, 1975]"
4558,363899820,61632,C(COCCl)OCCl,Active,,,,MOUSE,ICR/HA SWISS/FEMALE,SUBCUTANEOUS,0; 0.3 MG IN 0.05 ML TRICAPRYLIN 1/WK FOR 569 D (STUDY DURATION: 570 D),INJECTION SITE: SARCOMA,POSITIVE,"[VAN DUUREN,BL, GOLDSCHMIDT,BM AND SEIDMAN,I; CARCINOGENIC ACTIVITY OF DI- AND TRIFUNCTIONAL ALPHA-CHLORO ETHERS AND OF 1,4-DICHLOROBUTENE-2 IN ICR/HA SWISS MICE; CANCER RES. 35:2553-2557, 1975]"
4559,363899820,61632,C(COCCl)OCCl,Active,,,,MOUSE,ICR/HA SWISS/FEMALE,INTRAPERITONEAL,0; 0.3 MG IN 0.05 ML TRICAPRYLIN 1/WK FOR 546 D (STUDY DURATION: 570 D),PERITONEUM: SARCOMA,POSITIVE,"[VAN DUUREN,BL, GOLDSCHMIDT,BM AND SEIDMAN,I; CARCINOGENIC ACTIVITY OF DI- AND TRIFUNCTIONAL ALPHA-CHLORO ETHERS AND OF 1,4-DICHLOROBUTENE-2 IN ICR/HA SWISS MICE; CANCER RES. 35:2553-2557, 1975]"
4560,363899821,786655,CC(=O)NC1=CC=C(C=C1)/C=C/C2=CC=CC=C2,Active,,,,RAT,HOLTZMAN/MALE,ORAL,0; 0.0046% IN DIET FOR WK 0-13 (STUDY DURATION: 40 WK),EAR DUCT GLAND: CARCINOMA,POSITIVE,"[ANDERSON,RA, ENOMOTO,M, MILLER,EC AND MILLER,JA; CARCINOGENESIS AND INHIBITION OF THE WALKER 256 TUMOR IN THE RAT BY TRANS-4-ACETYLAMINOSTILBENE, ITS N-HYDROXY METABOLITE, AND RELATED COMPOUNDS; CANCER RES. 24:128-143, 1964]"
4561,363899822,1272788,C1=CC=C(C=C1)/C=C/C2=CC=C(C=C2)N,Active,,,,RAT,HOLTZMAN/FEMALE,SUBCUTANEOUS,0. 5.3 UMOL SUSPENDED IN 0.2 ML TRICAPRYLIN 1/WK FOR 5 WK (STUDY DURATION: 10 MO),MAMMARY GLAND: CARCINOMA,POSITIVE,"[ANDERSON,RA, ENOMOTO,M, MILLER,EC AND MILLER,JA; CARCINOGENESIS AND INHIBITION OF THE WALKER 256 TUMOR IN THE RAT BY TRANS-4-ACETYLAMINOSTILBENE, ITS N-HYDROXY METABOLITE, AND RELATED COMPOUNDS; CANCER RES. 24:128-143, 1964]"
4562,363899822,1272788,C1=CC=C(C=C1)/C=C/C2=CC=C(C=C2)N,Active,,,,RAT,HOLTZMAN/FEMALE,ORAL,0; 0.0038% IN DIET FOR 13 WK BEGINNING AT WEANING (STUDY DURATION: 40 WK),EAR DUCT GLAND: CARCINOMA,POSITIVE,"[ANDERSON,RA, ENOMOTO,M, MILLER,EC AND MILLER,JA; CARCINOGENESIS AND INHIBITION OF THE WALKER 256 TUMOR IN THE RAT BY TRANS-4-ACETYLAMINOSTILBENE, ITS N-HYDROXY METABOLITE, AND RELATED COMPOUNDS; CANCER RES. 24:128-143, 1964]"
4563,363899823,40003,COC1=CC=C(C=C1)C(C=C)O,Active,,,,MOUSE,CD-1/MALE,SUBCUTANEOUS,"0; 0.17 UMOL IN 0.025 ML TRIOCTANOIN WITHIN 24 H AFTER BIRTH THEN 0; 0.47 UMOL IN 0.05 ML TRIOCTANOIN ON D 8, 0; 0.95 UMOL IN 0.05 ML TRIOCTANOIN ON D 15 AND 0; 2.84 UMOL IN 0.1 ML TRIOCTANOIN ON D 22 FOR A TOTAL DOSE OF 0; 4.43 UMOL (STUDY DURATION: 15 MO)",LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[DRINKWATER,NR, MILLER,EC, MILLER,JA AND PITOT,HC; HEPATOCARCINOGENICITY OF ESTRAGOLE (1-ALLYL-4-METHOXYBENZENE) AND 1'-HYDROXYESTRAGOLE IN THE MOUSE AND MUTAGENICITY OF 1'-ACETOXYESTRAGOLE IN BACTERIA; J. NATL. CANCER INST. 57(6):1323-1331, 1976]"
4564,363899824,88617,CC1=CC(N(C2=CC=CC=C12)N=O)(C)C,Active,,,,RAT,CB/MALE,INTRAPERITONEAL,0; 25 MG IN POLYETHYLENE GLYCOL 400 1/WK FOR 6 MO FOR A TOTAL DOSE OF 0; 650 MG (STUDY DURATION: 24 MO),PERITONEUM: SARCOMA,POSITIVE,"[BOYLAND,E, CARTER,RL, GORROD,JW AND ROE,FJC; CARCINOGENIC PROPERTIES OF CERTAIN RUBBER ADDITIVES; EUR. J. CANCER 4:233-239, 1968]"
4565,363899825,22830,COC1=CC(=C(C=C1)OC)N=NC2=C(C=CC3=CC=CC=C32)O,Active,,,,MOUSE,C57 X 1F F1,BLADDER IMPLANT,0; 12.5% SUSPENSION IN PARAFFIN WAX (STUDY DURATION: 40 WK),BLADDER: CARCINOMA,POSITIVE,"[CLAYSON,DB, PRINGLE,JAS, BONSER,GM AND WOOD,M; THE TECHNIQUE OF BLADDER IMPLANTATION. FURTHER RESULTS AND AN ASSESSMENT; BR. J. CANCER 22:825-832, 1968]"
4566,363899826,33012,CC1=C2C=CC3=CC=CC=C3C2=C(C4=C1CCCC4)C,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 41 UG IN ACETONE (0.2%) 2/WK FOR 65 WK FOR A TOTAL DOSE OF 0; 5.3 MG (STUDY DURATION: 80 WK),SKIN: CARCINOMA; SKIN: PAPILLOMA,POSITIVE,"[LIJINSKY,W, GARCIA,H AND SAFFIOTTI,U; STRUCTURE-ACTIVITY RELATIONSHIPS AMONG SOME POLYNUCLEAR HYDROCARBONS AND THEIR HYDROGENATED DERIVATIVES; J. NATL. CANCER INST. 44:641-649, 1970]"
4567,363899827,9176,C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)C5=CC=CC=C5C=C4,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 78 UG IN ACETONE (0.4%) 2/WK FOR 60 WK FOR A TOTAL DOSE OF 0; 9.4 MG (STUDY DURATION: 80 WK),SKIN: CARCINOMA,POSITIVE,"[LIJINSKY,W, GARCIA,H AND SAFFIOTTI,U; STRUCTURE-ACTIVITY RELATIONSHIPS AMONG SOME POLYNUCLEAR HYDROCARBONS AND THEIR HYDROGENATED DERIVATIVES; J. NATL. CANCER INST. 44:641-649, 1970]"
4568,363899828,27810,C1CCC2=C(C1)C=CC3=C2C=C4C(=C3)C=CC5=CC=CC=C54,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 37 UG IN ACETONE (0.2%) 2/WK FOR 70 WK FOR A TOTAL DOSE OF 0; 5.2 MG (STUDY DURATION: 100 WK),SKIN: CARCINOMA; SKIN: PAPILLOMA,POSITIVE,"[NISHIZUKA,Y; LYMPHOMA INDUCTION IN MICE BY SYNTHETIC ESTROGENS OF TRIPHENYLETHYLENE TYPE; MIE. MED. J. 11:96-104, 1961]"
4569,363899829,21954,C1=CC(=O)NNC1=O,Active,,,,MOUSE,ICR/HA SWISS/MALE,SUBCUTANEOUS,"0; 5 MG IN 0.1 ML TRICAPRYLIN SUSPENSION ON D 1 OF AGE THEN 0; 10 MG IN 0.1 ML ON D 7, 0; 20 MG IN 0.2 ML ON D 14 AND 21 FOR A TOTAL DOSE OF 0; 55 MG (STUDY DURATION: 49 WK)",LIVER: HEPATOMA,POSITIVE,"[EPSTEIN,SS AND MANTEL,N; HEPATOCARCINOGENICITY OF THE HERBICIDE MALEIC HYDRAZINE FOLLOWING PARENTERAL ADMINISTRATION TO INFANT SWISS MICE; INT. J. CANCER 3:325-335, 1968]"
4570,363899829,21954,C1=CC(=O)NNC1=O,Inactive,,,,MOUSE,ICR/HA SWISS/FEMALE,SUBCUTANEOUS,0; 0.5 MG IN 0.1 ML WATER ON D 1 AND 7 OF AGE THEN 0; 1 MG IN 0.2 ML ON D 14 AND 21 FOR A TOTAL DOSE OF 0; 3 MG (STUDY DURATION: 49 WK),,NEGATIVE,"[EPSTEIN,SS AND MANTEL,N; HEPATOCARCINOGENICITY OF THE HERBICIDE MALEIC HYDRAZINE FOLLOWING PARENTERAL ADMINISTRATION TO INFANT SWISS MICE; INT. J. CANCER 3:325-335, 1968]"
4571,363899829,21954,C1=CC(=O)NNC1=O,Inactive,,,,MOUSE,ICR/HA SWISS/FEMALE,SUBCUTANEOUS,"0; 5 MG IN 0.1 ML TRICAPRYLIN SUSPENSION ON D 1 OF AGE THEN 0; 10 MG IN 0.1 ML ON D 7, 0; 20 MG IN 0.2 ML ON D 14 AND 21 FOR A TOTAL DOSE OF 0; 55 MG (STUDY DURATION: 49 WK)",,NEGATIVE,"[EPSTEIN,SS AND MANTEL,N; HEPATOCARCINOGENICITY OF THE HERBICIDE MALEIC HYDRAZINE FOLLOWING PARENTERAL ADMINISTRATION TO INFANT SWISS MICE; INT. J. CANCER 3:325-335, 1968]"
4572,363899842,9178,C1=CC=C2C(=C1)C=CC3=C2N=C4C(=C3)C=CC5=CC=CC=C54,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4573,363899842,9178,C1=CC=C2C(=C1)C=CC3=C2N=C4C(=C3)C=CC5=CC=CC=C54,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4574,363899849,644160,C([C@H]([C@@H]([C@H](C=O)O)O)O)O,Inactive,,,,RAT,"FISCHER 344/MALE, FEMALE (50/GROUP)",DIET,0; 2.5; 5% IN DIET FOR 104 WKS (STUDY DURATION: 104 WKS),,NEGATIVE,"[KUROIWA,Y, NISHIKAWA,A, IMAZAWA,T, KITAMURA,Y, KANKI,K, UMEMURA,T AND HIROSE,M; LACK OF CARCINOGENICITY OF D-XYLOSE GIVEN IN THE DIET TO F344 RATS FOR TWO YEARS; FOOD CHEM. TOXICOL. 43(9):1399-1404, 2005]"
4575,363899857,638034,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/COC(=O)C)/C)/C,Active,,,,RAT,F344/MALE,ORAL,0; 0.125; 0.25% IN DRINKING WATER (TOTAL DOSE: 0; 50; 95 G/KG) FOR 104 WK (STUDY DURATION: 108 WK),"ADRENAL GLAND: MALIGNANT PHEOCHROMOCYTOMA, BENIGN PHEOCHROMOCYTOMA, BILATERAL LESIONS",POSITIVE,"[KUROKAWA,Y, HAYASHI,Y, MAEKAWA,A, TAKAHASHI,M AND KUKUBO,T; HIGH INCIDENCES OF PHEOCHROMOCYTOMAS AFTER LONG-TERM ADMINISTRATION OF RETINOL ACETATE TO F344/DUCRJ RATS; J. NATL. CANCER INST. 74(3):715-723, 1985]"
4576,363899857,638034,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/COC(=O)C)/C)/C,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.125; 0.25% IN DRINKING WATER (TOTAL DOSE: 0; 50; 95 G/KG) FOR 104 WK (STUDY DURATION: 108 WK),"ADRENAL GLAND: MALIGNANT OR BENIGN PHEOCHROMOCYTOMA, BENIGN PHEOCHROMOCYTOMA, BILATERAL LESIONS; CLITORAL GLAND: ADENOMA",POSITIVE,"[KUROKAWA,Y, HAYASHI,Y, MAEKAWA,A, TAKAHASHI,M AND KUKUBO,T; HIGH INCIDENCES OF PHEOCHROMOCYTOMAS AFTER LONG-TERM ADMINISTRATION OF RETINOL ACETATE TO F344/DUCRJ RATS; J. NATL. CANCER INST. 74(3):715-723, 1985]"
4577,363899858,91525,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+],Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 0.033; 0.33; 0.66% IN DIET TO PUPS OF PARENTS GIVEN THE SAME DIETARY DOSES FOR 9 WK PRIOR TO MATING. FROM 2 TO 5 WK OF AGE DOSES WERE REDUCED TO 0; 0.0165; 0.165; 0.33% FOR PUPS AND MOTHERS AFTER WHICH THE HIGHER DOSES WERE RESUMED (STUDY DURATION: 106 WK),,NEGATIVE,"[BRANTOM,PG, CREASY,DM AND GAUNT,IF; LONG-TERM TOXICITY STUDY OF GREEN S IN MICE; FOOD CHEM. TOXICOL. 25(12):977-983, 1987]"
4578,363899858,91525,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+],Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.033; 0.33; 0.66% IN DIET TO PUPS OF PARENTS GIVEN THE SAME DIETARY DOSES FOR 9 WK PRIOR TO MATING. FROM 2 TO 5 WK OF AGE DOSES WERE REDUCED TO 0; 0.0165; 0.165; 0.33% AFTER WHICH THE HIGHER DOSES WERE RESUMED (STUDY DURATION: 106 WK),,NEGATIVE,"[BRANTOM,PG, CREASY,DM AND GAUNT,IF; LONG-TERM TOXICITY STUDY OF GREEN S IN MICE; FOOD CHEM. TOXICOL. 25(12):977-983, 1987]"
4579,363899901,3440,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 700; 1400 PPM IN FEED FOR 104 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-356 Y89]"
4580,363899901,3440,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 700; 1400 PPM IN FEED FOR 104 WK (STUDY DURATION: 107 WK),"MAMMARY GLAND: MIXED TUMOR, MALIGNANT; MAMMARY GLAND: MIXED TUMOR, MALIGNANT OR ACINAR CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-356 Y89]"
4581,363899901,3440,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 350; 700 PPM IN FEED FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-356 Y89]"
4582,363899901,3440,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,Unspecified,,,,RAT,F344/MALE,ORAL,0; 350; 700 PPM IN FEED FOR 103 WK (STUDY DURATION: 106 WK),KIDNEY: RENAL TUBULE CELL ADENOMA OR ADENOCARCINOMA; BRAIN: MENINGIOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-356 Y89]"
4583,363899902,52445,CC1=C(N=CN1)CSCCN=C(NC#N)N(C)N=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 150 MG/L IN DRINKING WATER 5D/WK FOR 106 WK FOR A TOTAL DOSE OF 0; 1600 MG (STUDY DURATION: 131 WK),,NEGATIVE,"[LIJINSKY,W AND REUBER,MD; COMPARISON OF NITROSOCIMETIDINE WITH NITROSOMETHYLNITROGUANIDINE IN CHRONIC FEEDING TESTS IN RATS; CANCER RES. 44:447-449, 1984]"
4584,363899902,52445,CC1=C(N=CN1)CSCCN=C(NC#N)N(C)N=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 150 MG/L IN DRINKING WATER 5D/WK FOR 106 WK FOR A TOTAL DOSE OF 0; 1600 MG (STUDY DURATION: 131 WK),,NEGATIVE,"[LIJINSKY,W AND REUBER,MD; COMPARISON OF NITROSOCIMETIDINE WITH NITROSOMETHYLNITROGUANIDINE IN CHRONIC FEEDING TESTS IN RATS; CANCER RES. 44:447-449, 1984]"
4585,363899902,52445,CC1=C(N=CN1)CSCCN=C(NC#N)N(C)N=O,Inactive,,,,MOUSE,C57BL/FEMALE,ORAL,0; 18.8; 190 MG/D IN DRINKING WATER BEGINNING AT 7-8 WK OF AGE AND CONTINUING FOR STUDY DURATION (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[ANDERSON,LM, GINER-SOROLLA,A, HALLER,IM AND BUDINGER,JM; EFFECTS OF CIMETIDINE, NITRITE, CIMETIDINE PLUS NITRITE, AND NITROSOCIMETIDINE ON TUMORS IN MICE FOLLOWING TRANSPLACENTAL PLUS CHRONIC LIFETIME EXPOSURE; CANCER RES. 45(8): 3561-3566, 1985]"
4586,363899902,52445,CC1=C(N=CN1)CSCCN=C(NC#N)N(C)N=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 18.8; 190 MG/D IN DRINKING WATER FOR LIFE ADMINISTERED TO MICE OF MOTHERS EXPOSED TO SAME DOSES THROUGH PREGNANCY AND LACTATION (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[ANDERSON,LM, GINER-SOROLLA,A, HALLER,IM AND BUDINGER,JM; EFFECTS OF CIMETIDINE, NITRITE, CIMETIDINE PLUS NITRITE, AND NITROSOCIMETIDINE ON TUMORS IN MICE FOLLOWING TRANSPLACENTAL PLUS CHRONIC LIFETIME EXPOSURE; CANCER RES. 45(8): 3561-3566, 1985]"
4587,363899902,52445,CC1=C(N=CN1)CSCCN=C(NC#N)N(C)N=O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 18.8; 190 MG/D IN DRINKING WATER FOR LIFE ADMINISTERED TO MICE OF MOTHERS EXPOSED TO SAME DOSES THROUGH PREGNANCY AND LACTATION (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[ANDERSON,LM, GINER-SOROLLA,A, HALLER,IM AND BUDINGER,JM; EFFECTS OF CIMETIDINE, NITRITE, CIMETIDINE PLUS NITRITE, AND NITROSOCIMETIDINE ON TUMORS IN MICE FOLLOWING TRANSPLACENTAL PLUS CHRONIC LIFETIME EXPOSURE; CANCER RES. 45(8): 3561-3566, 1985]"
4588,363899902,52445,CC1=C(N=CN1)CSCCN=C(NC#N)N(C)N=O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 50; 500 MG/KG 2/WK FOR 1 YR (STUDY DURATION: LIFETIME),,NEGATIVE,"[HABS,M, SCHMAHL,D, EISENBRAND,G AND PREUSSMANN,R; CARCINOGENESIS STUDIES WITH N-NITROSOCIMETIDINE. PART II: ORAL ADMINISTRATION TO SPRAGUE-DAWLEY RATS; IN: MAGEE,PN (ED.), NITROSAMINES IN HUMAN CANCER (BANBURY REPORT NO. 12), COLD SPRING HARBOR, NY, CSH PRESS, 1982, PP. 403-405][HABS,M, EISENBRAND,G, HABS,H AND SCHMAHL,D;NO EVIDENCE OF CARCINOGENICITY OF N-NITROSOCIMETIDINE IN RATS; HEPATO-GASTROENTEROLOGY 29:265-266, 1982]"
4589,363899902,52445,CC1=C(N=CN1)CSCCN=C(NC#N)N(C)N=O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 50; 500 MG/KG 2/WK FOR 1 YR (STUDY DURATION: LIFETIME),,NEGATIVE,"[HABS,M, SCHMAHL,D, EISENBRAND,G AND PREUSSMANN,R; CARCINOGENESIS STUDIES WITH N-NITROSOCIMETIDINE. PART II: ORAL ADMINISTRATION TO SPRAGUE-DAWLEY RATS; IN: MAGEE,PN (ED.), NITROSAMINES IN HUMAN CANCER (BANBURY REPORT NO. 12), COLD SPRING HARBOR, NY, CSH PRESS, 1982, PP. 403-405][HABS,M, EISENBRAND,G, HABS,H AND SCHMAHL,D;NO EVIDENCE OF CARCINOGENICITY OF N-NITROSOCIMETIDINE IN RATS; HEPATO-GASTROENTEROLOGY 29:265-266, 1982]"
4590,363899903,135398513,C1=NC2=C(N1COCCO)N=C(NC2=O)N,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 50; 150; 450 MG/KG IN STERILE AGAR 1/D (STUDY DURATION: 110 WK),,NEGATIVE,"[TUCKER,WE, KRANSNY,HC, DE MIRANDA,P, GOLDENTHAL,EI, ELION,GB, HAJIAN,G AND SZCZECH,GM; PRECLINICAL TOXICOLOGY STUDIES WITH ACYCLOVIR. CARCINOGENICITY BIOASSAYS AND CHRONIC TOXICITY TESTS; FUNDAM. APPL. TOXICOL. 3:579-586, 1983]"
4591,363899903,135398513,C1=NC2=C(N1COCCO)N=C(NC2=O)N,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 50; 150; 450 MG/KG IN STERILE AGAR 1/D (STUDY DURATION: 122 WK),,NEGATIVE,"[TUCKER,WE, KRANSNY,HC, DE MIRANDA,P, GOLDENTHAL,EI, ELION,GB, HAJIAN,G AND SZCZECH,GM; PRECLINICAL TOXICOLOGY STUDIES WITH ACYCLOVIR. CARCINOGENICITY BIOASSAYS AND CHRONIC TOXICITY TESTS; FUNDAM. APPL. TOXICOL. 3:579-586, 1983]"
4592,363899903,135398513,C1=NC2=C(N1COCCO)N=C(NC2=O)N,Inactive,,,,MOUSE,SWISS/MALE,GAVAGE,0; 50; 150; 450 MG/KG IN STERILE AGAR 1/D (STUDY DURATION: 126 WK),,NEGATIVE,"[TUCKER,WE, KRANSNY,HC, DE MIRANDA,P, GOLDENTHAL,EI, ELION,GB, HAJIAN,G AND SZCZECH,GM; PRECLINICAL TOXICOLOGY STUDIES WITH ACYCLOVIR. CARCINOGENICITY BIOASSAYS AND CHRONIC TOXICITY TESTS; FUNDAM. APPL. TOXICOL. 3:579-586, 1983]"
4593,363899903,135398513,C1=NC2=C(N1COCCO)N=C(NC2=O)N,Inactive,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 50; 150; 450 MG/KG IN STERILE AGAR 1/D (STUDY DURATION: 111 WK),,NEGATIVE,"[TUCKER,WE, KRANSNY,HC, DE MIRANDA,P, GOLDENTHAL,EI, ELION,GB, HAJIAN,G AND SZCZECH,GM; PRECLINICAL TOXICOLOGY STUDIES WITH ACYCLOVIR. CARCINOGENICITY BIOASSAYS AND CHRONIC TOXICITY TESTS; FUNDAM. APPL. TOXICOL. 3:579-586, 1983]"
4594,363899904,5391,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3,Inactive,,,,RAT,STRAIN-CD/MALE,ORAL,0; 10; 40; 160 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[ROBISON,RL, VAN RYZIN,RJ, STOLL,RE, JENSEN,RD AND BAGDON,RE; CHRONIC TOXICITY/ CARCINOGENESIS STUDY OF TEMAZEPAM IN MICE AND RATS; FUNDAM. APPL. TOXICOL. 4(3, PT. 1):394-405, 1984]"
4595,363899904,5391,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3,Inactive,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 10; 40; 160 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[ROBISON,RL, VAN RYZIN,RJ, STOLL,RE, JENSEN,RD AND BAGDON,RE; CHRONIC TOXICITY/ CARCINOGENESIS STUDY OF TEMAZEPAM IN MICE AND RATS; FUNDAM. APPL. TOXICOL. 4(3, PT. 1):394-405, 1984]"
4596,363899904,5391,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 10; 80; 160 MG/KG/D IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ROBISON,RL, VAN RYZIN,RJ, STOLL,RE, JENSEN,RD AND BAGDON,RE; CHRONIC TOXICITY/ CARCINOGENESIS STUDY OF TEMAZEPAM IN MICE AND RATS; FUNDAM. APPL. TOXICOL. 4(3, PT. 1):394-405, 1984]"
4597,363899904,5391,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 10; 80; 160 MG/KG/D IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ROBISON,RL, VAN RYZIN,RJ, STOLL,RE, JENSEN,RD AND BAGDON,RE; CHRONIC TOXICITY/ CARCINOGENESIS STUDY OF TEMAZEPAM IN MICE AND RATS; FUNDAM. APPL. TOXICOL. 4(3, PT. 1):394-405, 1984]"
4598,363899905,3261,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.5; 2; 10 MG/KG IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KIMURA,ET, FORT,FL, BURATTO,B, TEKELI,S, KESTERSON,JW, HEYMAN,IA AND CUSICK,PK; CARCINOGENIC EVALUATION OF ESTAZOLAM VIA DIET IN CD STRAIN SPRAGUE-DAWLEY RATS AND B6C3F1 MICE FOR 2 YEARS; FUNDAM. APPL. TOXICOL. 4:827-842, 1984]"
4599,363899905,3261,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.5; 2; 10 MG/KG IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KIMURA,ET, FORT,FL, BURATTO,B, TEKELI,S, KESTERSON,JW, HEYMAN,IA AND CUSICK,PK; CARCINOGENIC EVALUATION OF ESTAZOLAM VIA DIET IN CD STRAIN SPRAGUE-DAWLEY RATS AND B6C3F1 MICE FOR 2 YEARS; FUNDAM. APPL. TOXICOL. 4:827-842, 1984]"
4600,363899905,3261,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.8; 3; 10 MG/KG IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KIMURA,ET, FORT,FL, BURATTO,B, TEKELI,S, KESTERSON,JW, HEYMAN,IA AND CUSICK,PK; CARCINOGENIC EVALUATION OF ESTAZOLAM VIA DIET IN CD STRAIN SPRAGUE-DAWLEY RATS AND B6C3F1 MICE FOR 2 YEARS; FUNDAM. APPL. TOXICOL. 4:827-842, 1984]"
4601,363899905,3261,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.8; 3; 10 MG/KG IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KIMURA,ET, FORT,FL, BURATTO,B, TEKELI,S, KESTERSON,JW, HEYMAN,IA AND CUSICK,PK; CARCINOGENIC EVALUATION OF ESTAZOLAM VIA DIET IN CD STRAIN SPRAGUE-DAWLEY RATS AND B6C3F1 MICE FOR 2 YEARS; FUNDAM. APPL. TOXICOL. 4:827-842, 1984]"
4602,363899905,3261,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,Inactive,,,,RAT,STRAIN-CD/MALE,ORAL,0; 0.5; 2; 10 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KIMURA,ET, FORT,FL, BURATTO,B, TEKELI,S, KETERSON,JW, HEYMAN,IA AND CUSICK,PK; CARCINOGENIC EVALUATION OF ESTAZOLAM VIA DIET IN CD STRAIN SPRAGUE-DAWLEY RATS AND B6C3F1 MICE FOR 2 YEARS; FUNDAM. APPL. TOXICOL. 4(5):827-842, 1984]"
4603,363899905,3261,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,Inactive,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 0.5; 2; 10 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KIMURA,ET, FORT,FL, BURATTO,B, TEKELI,S, KETERSON,JW, HEYMAN,IA AND CUSICK,PK; CARCINOGENIC EVALUATION OF ESTAZOLAM VIA DIET IN CD STRAIN SPRAGUE-DAWLEY RATS AND B6C3F1 MICE FOR 2 YEARS; FUNDAM. APPL. TOXICOL. 4(5):827-842, 1984]"
4604,363899905,3261,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.8; 3; 10 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KIMURA,ET, FORT,FL, BURATTO,B, TEKELI,S, KETERSON,JW, HEYMAN,IA AND CUSICK,PK; CARCINOGENIC EVALUATION OF ESTAZOLAM VIA DIET IN CD STRAIN SPRAGUE-DAWLEY RATS AND B6C3F1 MICE FOR 2 YEARS; FUNDAM. APPL. TOXICOL. 4(5):827-842, 1984]"
4605,363899905,3261,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.8; 3; 10 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KIMURA,ET, FORT,FL, BURATTO,B, TEKELI,S, KETERSON,JW, HEYMAN,IA AND CUSICK,PK; CARCINOGENIC EVALUATION OF ESTAZOLAM VIA DIET IN CD STRAIN SPRAGUE-DAWLEY RATS AND B6C3F1 MICE FOR 2 YEARS; FUNDAM. APPL. TOXICOL. 4(5):827-842, 1984]"
4606,363899906,76958463,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=C(C3=O)C(=CC(=C4)OS(=O)(=O)[O-])OS(=O)(=O)[O-])C5=CC(=C(C=C5)O)O)O)O)O)O)O)O.[Na+].[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 10; 27; 71; 188; 500 MG/KG 3/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HABS,M, HABS,H, BERGER,MR AND SCHMAEHL,D; NEGATIVE DOSE-RESPONSE STUDY FOR CARCINOGENICITY OF ORALLY ADMINISTERED RUTIN SULFATE IN SPRAGUE-DAWLEY RATS; CANCER LETT. 23(1):103-108, 1984]"
4607,363899906,76958463,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=C(C3=O)C(=CC(=C4)OS(=O)(=O)[O-])OS(=O)(=O)[O-])C5=CC(=C(C=C5)O)O)O)O)O)O)O)O.[Na+].[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 10; 27; 71; 188; 500 MG/KG 3/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HABS,M, HABS,H, BERGER,MR AND SCHMAEHL,D; NEGATIVE DOSE-RESPONSE STUDY FOR CARCINOGENICITY OF ORALLY ADMINISTERED RUTIN SULFATE IN SPRAGUE-DAWLEY RATS; CANCER LETT. 23(1):103-108, 1984]"
4608,363899907,124937,CC1CN(C(=O)NC1=O)N=O,Inactive,,,,RAT,MRC-WISTAR/MALE,ORAL,0; 1 G TOTAL DOSE IN CITRATE BUFFER IN DRINKING WATER 5D/WK FOR 12 MO (STUDY DURATION: 2 YR),,NEGATIVE,"[LAWSON,TA, MIRVISH,SS, POUR,P AND WILLIAMS,G; PERSISTENCE OF DNA SINGLE-STRAND BREAKS AND OTHER TESTS AS INDICATORS OF THE LIVER CARCINOGENICITY OF 1-NITROSO-5,6-DIHYDROURACIL AND THE NONCARCINOGENICITY OF 1-NITROSO-5,6-DIHYDROTHYMINE; J. NATL. CANCER INST. 73(2):515-519, 1984]"
4609,363899907,124937,CC1CN(C(=O)NC1=O)N=O,Inactive,,,,RAT,MRC-WISTAR/FEMALE,ORAL,0; 10 G TOTAL DOSE IN CITRATE BUFFER IN DRINKING WATER 5D/WK FOR 12 MO (STUDY DURATION: 2 YR),,NEGATIVE,"[LAWSON,TA, MIRVISH,SS, POUR,P AND WILLIAMS,G; PERSISTENCE OF DNA SINGLE-STRAND BREAKS AND OTHER TESTS AS INDICATORS OF THE LIVER CARCINOGENICITY OF 1-NITROSO-5,6-DIHYDROURACIL AND THE NONCARCINOGENICITY OF 1-NITROSO-5,6-DIHYDROTHYMINE; J. NATL. CANCER INST. 73(2):515-519, 1984]"
4610,363899908,204,C1(C(=O)NC(=O)N1)NC(=O)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 2000 PPM IN DIET FOR 106 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; INDUCTION OF TUMOURS IN RATS BY FEEDING NITROSATABLE AMINES TOGETHER WITH SODIUM NITRITE; FOOD CHEM. TOXICOL. 22(9):715-720, 1984]"
4611,363899908,204,C1(C(=O)NC(=O)N1)NC(=O)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2000 PPM IN DIET FOR 106 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; INDUCTION OF TUMOURS IN RATS BY FEEDING NITROSATABLE AMINES TOGETHER WITH SODIUM NITRITE; FOOD CHEM. TOXICOL. 22(9):715-720, 1984]"
4612,363899909,3100,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,Inactive,,,,RAT,F344/MALE,ORAL,0; 2000 PPM IN DIET FOR 106 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; INDUCTION OF TUMOURS IN RATS BY FEEDING NITROSATABLE AMINES TOGETHER WITH SODIUM NITRITE; FOOD CHEM. TOXICOL. 22(9):715-720, 1984]"
4613,363899909,3100,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2000 PPM IN DIET FOR 106 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; INDUCTION OF TUMOURS IN RATS BY FEEDING NITROSATABLE AMINES TOGETHER WITH SODIUM NITRITE; FOOD CHEM. TOXICOL. 22(9):715-720, 1984]"
4614,363899910,29231,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC4=C(C=C(C=C4[O+]=C3C5=CC(=C(C=C5)O)O)O)O)O)O)O)O)O)O.[Cl-],Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 1.5; 3.7 G/KG/D DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[TSUBURA,Y, OHNO,Y, IMAI,S, MORIMOTO,J, OKUYAMA,T AND NAKAMORI,K; CHRONIC ORAL TOXICITY TEST OF KERACYANIN IS SLC:WISTAR RATS; J. NARA. MED. ASSOC. 34:728-744, 1983]"
4615,363899910,29231,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC4=C(C=C(C=C4[O+]=C3C5=CC(=C(C=C5)O)O)O)O)O)O)O)O)O)O.[Cl-],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 1.7; 4.1 G/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[TSUBURA,Y, OHNO,Y, IMAI,S, MORIMOTO,J, OKUYAMA,T AND NAKAMORI,K; CHRONIC ORAL TOXICITY TEST OF KERACYANIN IS SLC:WISTAR RATS; J. NARA. MED. ASSOC. 34:728-744, 1983]"
4616,363899912,4873,[Cl-].[K+],Inactive,,,,RAT,F344/MALE,ORAL,0; 0.25; 1; 4% IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[IMAI,S, MORIMOTO,J, SEKIYA,N, SHIMA,M, KIYOZUKA,Y, NAKAMORI,K AND TSUBURA,Y; CHRONIC TOXICITY TEST OF KCL AND NACL IN F344/SLC RATS; J. NARA. MED. ASSOC. 37:115-127, 1986]"
4617,363899913,31657,CNC(=O)ON=C(C(=O)N(C)C)SC,Inactive,,,,RAT,CRL:CD/MALE,ORAL,0; 50; 100; 150 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KENNEDY,GL; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES WITH OXAMYL; FUNDAM. APPL. TOXICOL. 7:106-118, 1986]"
4618,363899913,31657,CNC(=O)ON=C(C(=O)N(C)C)SC,Inactive,,,,RAT,CRL:CD/FEMALE,ORAL,0; 50; 100; 150 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KENNEDY,GL; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES WITH OXAMYL; FUNDAM. APPL. TOXICOL. 7:106-118, 1986]"
4619,363899913,31657,CNC(=O)ON=C(C(=O)N(C)C)SC,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 25; 50; 75 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KENNEDY,GL; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES WITH OXAMYL; FUNDAM. APPL. TOXICOL. 7:106-118, 1986]"
4620,363899913,31657,CNC(=O)ON=C(C(=O)N(C)C)SC,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 25; 50; 75 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KENNEDY,GL; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES WITH OXAMYL; FUNDAM. APPL. TOXICOL. 7:106-118, 1986]"
4621,363899914,23665730,CCCCCCCC/C=C\CCCCCCCC(=O)[O-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN DRINKING WATER FOR 108 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[HIASA,Y, KONISHI,N, KITAHORI,Y AND SHIMOYAMA,T; CARCINOGENICITY STUDY OF A COMMERCIAL SODIUM OLEATE IN FISCHER RATS; FOOD CHEM. TOXICOL. 23(6):619-623, 1985]"
4622,363899914,23665730,CCCCCCCC/C=C\CCCCCCCC(=O)[O-].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN DRINKING WATER FOR 108 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[HIASA,Y, KONISHI,N, KITAHORI,Y AND SHIMOYAMA,T; CARCINOGENICITY STUDY OF A COMMERCIAL SODIUM OLEATE IN FISCHER RATS; FOOD CHEM. TOXICOL. 23(6):619-623, 1985]"
4623,363899915,2286,CC(C)(C1=CC=C(C=C1)OCC2CO2)C3=CC=C(C=C3)OCC4CO4,Inactive,,,,MOUSE,CF1/MALE,DERMAL,0; 1; 10% IN ACETONE 2D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[ZAKOVA,N, ZAK,F, FROEHLICH,E AND HESS,R; EVALUATION OF SKIN CARCINOGENICITY OF TECHNICAL 2,2-BIS-(P-GLYCIDYLOXYPHENYL)PROPANE; FOOD CHEM. TOXICOL. 23(12): 1081-1089, 1985]"
4624,363899915,2286,CC(C)(C1=CC=C(C=C1)OCC2CO2)C3=CC=C(C=C3)OCC4CO4,Inactive,,,,MOUSE,CF1/FEMALE,DERMAL,0; 1; 10% IN ACETONE 2D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[ZAKOVA,N, ZAK,F, FROEHLICH,E AND HESS,R; EVALUATION OF SKIN CARCINOGENICITY OF TECHNICAL 2,2-BIS-(P-GLYCIDYLOXYPHENYL)PROPANE; FOOD CHEM. TOXICOL. 23(12): 1081-1089, 1985]"
4625,363899915,2286,CC(C)(C1=CC=C(C=C1)OCC2CO2)C3=CC=C(C=C3)OCC4CO4,Inactive,,,,MOUSE,CF-1/FEMALE,DERMAL,0; 1; 10% IN ACETONE (TOTAL DOSE 0.2 ML) 2/WK APPLIED TO DORSAL SKIN FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[PERISTIANIS,GC, DOAK,SMA, COLE,PN AND HEND,RW; TWO-YEAR CARCINOGENICITY STUDY ON THREE AROMATIC EPOXY RESINS APPLIED CUTANEOUSLY TO CF1 MICE; FOOD CHEM. TOXICOL. 26(7):611-624, 1988]"
4626,363899915,2286,CC(C)(C1=CC=C(C=C1)OCC2CO2)C3=CC=C(C=C3)OCC4CO4,Inactive,,,,MOUSE,CF-1/MALE,DERMAL,0; 1; 10% IN ACETONE (TOTAL DOSE 0.2 ML) 2/WK APPLIED TO DORSAL SKIN FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[PERISTIANIS,GC, DOAK,SMA, COLE,PN AND HEND,RW; TWO-YEAR CARCINOGENICITY STUDY ON THREE AROMATIC EPOXY RESINS APPLIED CUTANEOUSLY TO CF1 MICE; FOOD CHEM. TOXICOL. 26(7):611-624, 1988]"
4627,363899916,118984432,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)[O-])O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)[O-])O)O)O)C)(C)C(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.04; 0.08; 0.15% IN DRINKING WATER FOR 96 WK (STUDY DURATION: 110 WK),,NEGATIVE,"[KOBUKE,T, INAI,K, NAMBU,S, OHE,K, TAKEMOTO,T, MATSUKI,K, NISHINA,H, HUANG,IB AND TOKUOKA,S; TUMORIGENICITY STUDY OF DISODIUM GLYCYRRHIZINATE ADMINISTERED ORALLY TO MICE; FOOD CHEM. TOXICOL. 23(11):979-983, 1985]"
4628,363899916,118984432,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)[O-])O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)[O-])O)O)O)C)(C)C(=O)[O-].[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.08; 0.15; 0.3% IN DRINKING WATER FOR 96 WK (STUDY DURATION: 110 WK),,NEGATIVE,"[KOBUKE,T, INAI,K, NAMBU,S, OHE,K, TAKEMOTO,T, MATSUKI,K, NISHINA,H, HUANG,IB AND TOKUOKA,S; TUMORIGENICITY STUDY OF DISODIUM GLYCYRRHIZINATE ADMINISTERED ORALLY TO MICE; FOOD CHEM. TOXICOL. 23(11):979-983, 1985]"
4629,363899917,13734,C[NH+](C)CCN(CC1=CSC=C1)C2=CC=CC=N2.[Cl-],Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 500; 1000 PPM IN DRINKING WATER 5D/WK FOR LIFE (STUDY DURATION: 515-576 D),,NEGATIVE,"[HABS,M, SHUBIK,P AND EISENBRAND,G; CARCINOGENICITY OF METHAPRILENE HYDROCHLORIDE, MEPYRAMINE HYDROCHLORIDE, THENYLDIAMINE HYDROCHLORIDE, AND PYRIBENZAMINE HYDROCHLORIDE IN SPRAGUE-DAWLEY RATS; J. CANCER RES. CLIN. ONCOL. 111:71-74, 1986]"
4630,363899917,13734,C[NH+](C)CCN(CC1=CSC=C1)C2=CC=CC=N2.[Cl-],Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 500; 1000 PPM IN DRINKING WATER 5D/WK FOR LIFE (STUDY DURATION: 572-731 D),,NEGATIVE,"[HABS,M, SHUBIK,P AND EISENBRAND,G; CARCINOGENICITY OF METHAPRILENE HYDROCHLORIDE, MEPYRAMINE HYDROCHLORIDE, THENYLDIAMINE HYDROCHLORIDE, AND PYRIBENZAMINE HYDROCHLORIDE IN SPRAGUE-DAWLEY RATS; J. CANCER RES. CLIN. ONCOL. 111:71-74, 1986]"
4631,363899918,80139,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 500; 1000 PPM IN DRINKING WATER 5D/WK FOR LIFE (STUDY DURATION: 496-611 D),,NEGATIVE,"[HABS,M, SHUBIK,P AND EISENBRAND,G; CARCINOGENICITY OF METHAPRILENE HYDROCHLORIDE, MEPYRAMINE HYDROCHLORIDE, THENYLDIAMINE HYDROCHLORIDE, AND PYRIBENZAMINE HYDROCHLORIDE IN SPRAGUE-DAWLEY RATS; J. CANCER RES. CLIN. ONCOL. 111:71-74, 1986]"
4632,363899918,80139,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 500; 1000 PPM IN DRINKING WATER 5D/WK FOR LIFE (STUDY DURATION: 549-745 D),,NEGATIVE,"[HABS,M, SHUBIK,P AND EISENBRAND,G; CARCINOGENICITY OF METHAPRILENE HYDROCHLORIDE, MEPYRAMINE HYDROCHLORIDE, THENYLDIAMINE HYDROCHLORIDE, AND PYRIBENZAMINE HYDROCHLORIDE IN SPRAGUE-DAWLEY RATS; J. CANCER RES. CLIN. ONCOL. 111:71-74, 1986]"
4633,363899919,9066,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 500; 1000 PPM IN DRINKING WATER 5D/WK FOR LIFE (STUDY DURATION: 529-600 D),,NEGATIVE,"[HABS,M, SHUBIK,P AND EISENBRAND,G; CARCINOGENICITY OF METHAPRILENE HYDROCHLORIDE, MEPYRAMINE HYDROCHLORIDE, THENYLDIAMINE HYDROCHLORIDE, AND PYRIBENZAMINE HYDROCHLORIDE IN SPRAGUE-DAWLEY RATS; J. CANCER RES. CLIN. ONCOL. 111:71-74, 1986]"
4634,363899919,9066,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 500; 1000 PPM IN DRINKING WATER 5D/WK FOR LIFE (STUDY DURATION: 493-754 D),,NEGATIVE,"[HABS,M, SHUBIK,P AND EISENBRAND,G; CARCINOGENICITY OF METHAPRILENE HYDROCHLORIDE, MEPYRAMINE HYDROCHLORIDE, THENYLDIAMINE HYDROCHLORIDE, AND PYRIBENZAMINE HYDROCHLORIDE IN SPRAGUE-DAWLEY RATS; J. CANCER RES. CLIN. ONCOL. 111:71-74, 1986]"
4635,363899948,107781,C1=CC=C2C3=C4C(=CC=CC4=CC2=C1)C=C3,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175; 437.5; 875 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",LUNG: ADENOMA OR ADENOCARCINOMA; LIVER: TUMOR,POSITIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
4636,363899948,107781,C1=CC=C2C3=C4C(=CC=CC4=CC2=C1)C=C3,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175; 437.5; 875 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
4637,363899948,107781,C1=CC=C2C3=C4C(=CC=CC4=CC2=C1)C=C3,Active,,,,MOUSE,BLU:HA/MALE,INTRAPERITONEAL,"0; 175; 437.5; 875 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",LUNG: ADENOMA,POSITIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
4638,363899948,107781,C1=CC=C2C3=C4C(=CC=CC4=CC2=C1)C=C3,Active,,,,MOUSE,BLU:HA/FEMALE,INTRAPERITONEAL,"0; 175; 437.5; 875 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",LUNG: ADENOMA,POSITIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
4639,363899949,9143,C1=CC=C2C(=C1)C=C3C=CC4=C3C2=CC=C4,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175; 437.5; 875 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",LUNG: ADENOMA OR ADENOCARCINOMA; LIVER: TUMOR,POSITIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
4640,363899949,9143,C1=CC=C2C(=C1)C=C3C=CC4=C3C2=CC=C4,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175; 437.5; 875 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",,NEGATIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
4641,363899949,9143,C1=CC=C2C(=C1)C=C3C=CC4=C3C2=CC=C4,Active,,,,MOUSE,BLU:HA/MALE,INTRAPERITONEAL,"0; 175; 437.5 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",LUNG: ADENOMA,POSITIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
4642,363899949,9143,C1=CC=C2C(=C1)C=C3C=CC4=C3C2=CC=C4,Inactive,,,,MOUSE,BLU:HA/FEMALE,INTRAPERITONEAL,"0; 175; 437.5 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",,NEGATIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
4643,363899963,43677,CC(CN(CC(=O)C)N=O)O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 2.5 MG IN 0.2 ML ETHANOL:DEIONIZED WATER (1:3) 2/WK FOR 22 WK (TOTAL DOSE 0.7 MMOL) (STUDY DURATION: LIFESPAN),BLADDER: TUMOR; LIVER: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; LOCAL AND SYSTEMIC CARCINOGENIC EFFECTS OF ALKYLATING CARCINOGENS IN RATS TREATED BY INTRAVESICULAR ADMINISTRATION; JPN. J. CANCER RES. 82(9):980-986, 1991]"
4644,363899963,43677,CC(CN(CC(=O)C)N=O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 55; 220 MG/L DRINKING WATER 5 D/WK FOR 40; 21 WK (TOTAL DOSE 220; 460 MG) (STUDY DURATION: LIFESPAN),"LIVER: CARCINOMA, ANGIOSARCOMA; LUNG: TUMOR; ESOPHAGUS: CARCINOMA, PAPILLOMA; NASAL CAVITY: TUMOR",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; CARCINOGENESIS IN F-344 RATS BY NITROSOBIS(2-OXOPROPYL)AMINE AND RELATED COMPOUNDS ADMINISTERED IN DRINKING WATER; J. CANCER RES. CLIN. ONCOL. 107(3):178-182, 1984]"
4645,363899965,107719,CC(CN(C)N=O)O,Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 4.4; 8.8; 17.6 MG/KG IN 0.9% SALINE 1/WK FOR 12 WK (STUDY DURATION: 26 WK),"NASAL CAVITY: CARCINOMA, PAPILLOMA",POSITIVE,"[YAMAMOTO,K, NAKAJIMA,A, EIMOTO, TAKASHIMA,Y, TSUJIUCHI,T, SUGIMURA,M AND KONISHI,Y; DOSE-RESPONSE STUDY OF N-NITROSOMETHYL(2-HYDROXYPROPYL)AMINE-INDUCED NASAL CAVITY CARCINOGENESIS IN RATS; EXP. PATHOL. 38(1):53-59, 1990]"
4646,363899965,107719,CC(CN(C)N=O)O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 4; 10 MG/WK FOR A TOTAL DOSE OF 0.6; 0.4 MMOL (STUDY DURATION: 50 WK),ESOPHAGUS: TUMOR; KIDNEY: TUMOR; THYROID: TUMOR; LUNG: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
4647,363899965,107719,CC(CN(C)N=O)O,Active,,,,RAT,F344/MALE,GAVAGE,0; 4 MG/WK FOR A TOTAL DOSE OF 0.6 MMOL (STUDY DURATION: 50 WK),ESOPHAGUS: TUMOR; NASAL MUCOSA: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
4648,363899965,107719,CC(CN(C)N=O)O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 5 MG IN 0.2 ML WATER FOR 4 WK THEN 2 MG 1/WK FOR 14 WK FOR A TOTAL DOSE OF 48 MG (STUDY DURATION: 45 WK),"LIVER: HEMANGIOSARCOMA, HEPATOCELLULAR ADENOMA, CHOLANGIOCELLULAR CARCINOMA, CHOLANGIOCELLULAR ADENOMA; PANCREAS: DUCTAL CARCINOMA, DUCTAL ADENOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; NASAL MUCOSA: CARCINOMA OR ADENOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY OXYGENATED NITROSOMETHYLPROPYLAMINES IN SYRIAN HAMSTERS; J. CANCER RES. CLIN. ONCOL. 109(1):1-4, 1985]"
4649,363899965,107719,CC(CN(C)N=O)O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 1 MG IN 0.2 ML WATER 1/WK FOR 21 WK FOR A TOTAL DOSE OF 21 MG (STUDY DURATION: 45 WK),LIVER: HEMANGIOSARCOMA OR HEMANGIOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; NASAL MUCOSA: CARCINOMA,POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY OXYGENATED NITROSOMETHYLPROPYLAMINES IN SYRIAN HAMSTERS; J. CANCER RES. CLIN. ONCOL. 109(1):1-4, 1985]"
4650,363899966,104910,CC(=O)CN(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 2; 4; 10 MG/WK FOR A TOTAL DOSE OF 0.5; 0.5; 0.9 MMOL (STUDY DURATION: 70 WK),ESOPHAGUS: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
4651,363899966,104910,CC(=O)CN(C)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 4 MG/WK FOR A TOTAL DOSE OF 0.5 MMOL (STUDY DURATION: 40 WK),ESOPHAGUS: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
4652,363899966,104910,CC(=O)CN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 2 MG IN 0.2 ML WATER 1/WK FOR 14 WK FOR A TOTAL DOSE OF 28 MG (STUDY DURATION: 17 WK),"LIVER: HEPATOCELLULAR ADENOMA, CHOLANGIOCELLULAR CARCINOMA OR ADENOMA; NASAL MUCOSA: CARCINOMA OR ADENOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY OXYGENATED NITROSOMETHYLPROPYLAMINES IN SYRIAN HAMSTERS; J. CANCER RES. CLIN. ONCOL. 109(1):1-4, 1985]"
4653,363899966,104910,CC(=O)CN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 1 MG IN 0.1 ML WATER 2/WK FOR 11 WK FOR A TOTAL DOSE OF 22 MG (STUDY DURATION: 45 WK),LIVER: TUMOR; NASAL MUCOSA: CARCINOMA,POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY OXYGENATED NITROSOMETHYLPROPYLAMINES IN SYRIAN HAMSTERS; J. CANCER RES. CLIN. ONCOL. 109(1):1-4, 1985]"
4654,363899966,104910,CC(=O)CN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 0.5 MG IN 0.1 ML WATER 2/WK FOR 22 WK FOR A TOTAL DOSE OF 22 MG (STUDY DURATION: 45 WK),"LIVER: HEMANGIOSARCOMA, CHOLANGIOCELLULAR CARCINOMA, CHOLANGIOCELLULAR ADENOMA; NASAL MUCOSA: CARCINOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY OXYGENATED NITROSOMETHYLPROPYLAMINES IN SYRIAN HAMSTERS; J. CANCER RES. CLIN. ONCOL. 109(1):1-4, 1985]"
4655,363899968,128823,CN(CC(CO)O)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 2.4 MG IN 0.2 ML OF WATER 1/WK FOR 41 WK FOR A TOTAL DOSE OF 98 MG (STUDY DURATION: 45 WK),"NASAL MUCOSA: CARCINOMA, ADENOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY OXYGENATED NITROSOMETHYLPROPYLAMINES IN SYRIAN HAMSTERS; J. CANCER RES. CLIN. ONCOL. 109(1):1-4, 1985]"
4656,363899983,51545,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3[C@@H]5[C@@H](O5)[C@H]([C@@H]4O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 500 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7 AND 15 OF LIFE , RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
4657,363899983,51545,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3[C@@H]5[C@@H](O5)[C@H]([C@@H]4O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 500 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
4658,363899983,51545,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3[C@@H]5[C@@H](O5)[C@H]([C@@H]4O)O,Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 8 NMOL IN 5 UL DMSO ON D 1, 16 NMOL IN 10 UL ON D 8 AND 32 NMOL IN 20 UL ON D 15 OF LIFE (STUDY DURATION: 35 WK)",,NEGATIVE,"[AMIN,S, MISRA,B, BRALEY,J AND HECHT,SS; COMPARATIVE TUMORIGENICITY IN NEWBORN MICE OF CHRYSENE- AND 5-ALKYLCHRYSENE-1,2-DIOL 3,4-EPOXIDES; CANCER LETT. 58(1-2):115-118, 1991]"
4659,363899983,51545,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3[C@@H]5[C@@H](O5)[C@H]([C@@H]4O)O,Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 8 NMOL IN 5 UL DMSO ON D 1, 16 NMOL IN 10 UL ON D 8 AND 32 NMOL IN 20 UL ON D 15 OF LIFE (STUDY DURATION: 35 WK)",,NEGATIVE,"[AMIN,S, MISRA,B, BRALEY,J AND HECHT,SS; COMPARATIVE TUMORIGENICITY IN NEWBORN MICE OF CHRYSENE- AND 5-ALKYLCHRYSENE-1,2-DIOL 3,4-EPOXIDES; CANCER LETT. 58(1-2):115-118, 1991]"
4660,363900002,7909,CC(C)CC(=O)C,Active,,,,Rat,F344/N/Male,Inhalation,"0; 450; 900; 1800 ppm 6 hr and 12 min/d, 5 d/wk for 104 wks","Kidney: Renal tubule adenoma (2/50, 3/50, 3/50, 10/50); Renal tubule carcinoma (0/50, 1/50, 0/50, 2/50); Renal tubule adenoma or carcinoma (2/50), 4/50, 3/50, 11/50) Mononuclear cell leukemia (25/50, 26/50, 32/50, 35/50) (Positive trend, significant at highest dose)",Positive (NTP describes as Some Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-538 Y07]"
4661,363900002,7909,CC(C)CC(=O)C,Unspecified,,,,Rat,F344/N/Female,Inhalation,"0; 450; 900; 1800 ppm 6 hr and 12 min/d, 5 d/wk for 104 wks","Mesenchymal tumor malignant: (0/50, 0/50, 0/50, 2/50)",Equivocal,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-538 Y07]"
4662,363900002,7909,CC(C)CC(=O)C,Active,,,,Mouse,B6C3F1/N/Male,Inhalation,"0; 450; 900; 1800 ppm 6 hr and 12 min/day, 5 d/wk for 105 wks","Liver: Hepatocellular adenoma (17/50, 25/50, 23/50, 34/50); Hepatocellular carcinoma (12/50, 12/50, 10/50, 9/50); Hepatocellular adenoma or carcinoma (27/50, 34/50, 28/50, 37/50)",Positive (NTP describes as Some Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-538 Y07]"
4663,363900002,7909,CC(C)CC(=O)C,Unspecified,,,,Mouse,B6C3F1/N/Female,Inhalation,"0; 450; 900; 1800 ppm 6 hr and 12 min/day, 5 d/wk for 105 wks","Liver: Hepatocellular adenoma (13/50, 15/50, 20/50, 23/50); Hepatocellular carcinoma (6/50, 5/50, 6/50, 11/50); Hepatocellular adenoma or carcinoma (17/50, 17/50, 22/50, 27/50)",Equivocal,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-538 Y07]"
4664,363900004,13462,C1=CC=C2C(=C1)C3=C4C2=CC=CC4=C(C=C3)[N+](=O)[O-],Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 63 UG TOTAL DOSE (9 UG/5 UL, 18 UG/10 UL, 36 UG/20 UL DMSO ON DAYS 1, 8 AND 15); 315 UG TOTAL DOSE (45 UG/5 UL, 90 UG/10 UL, 180 UG/20 UL DMSO ON DAYS 1,8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
4665,363900004,13462,C1=CC=C2C(=C1)C3=C4C2=CC=CC4=C(C=C3)[N+](=O)[O-],Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 63 UG TOTAL DOSE (9 UG/5 UL, 18 UG/10 UL, 36 UG/20 UL DMSO ON DAYS 1, 8 AND 15); 315 UG TOTAL DOSE (45 UG/5 UL, 90 UG/10 UL, 180 UG/20 UL DMSO ON DAYS 1,8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
4666,363900004,13462,C1=CC=C2C(=C1)C3=C4C2=CC=CC4=C(C=C3)[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,LUNG IMPLANT,0; 1000 UG SUSPENDED IN BEESWAX/TRICAPRYLIN INTO LOWER LEFT LUNG ONCE (STUDY DURATION: 100 WK),,NEGATIVE,"[HORIKAWA,K, SERA,N, OTOFUJI,T, MURAKAMI,K, TOKIWA,H, IWAGAWA,M, IZUMI,K AND OTSUKA,H; PULMONARY CARCINOGENICITY OF 3,9- AND 3,7-DINITROFLUORANTHENE, 3-NITROFLUORANTHENE AND BENZO[A]PYRENE IN F344 RATS; CARCINOGENESIS 12(6):1003-1007, 1991]"
4667,363900004,13462,C1=CC=C2C(=C1)C3=C4C2=CC=CC4=C(C=C3)[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,PULMONARY IMPLANT,0; 1000 UG IN 50 UL BEESWAX/TRICAPRYLIN IMPLANTED FOR UP TO 100 WK (STUDY DURATION: 100 WK),,NEGATIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, OTOFUJI,T, TOKIWA,H, IZUMI,K AND OTSUKA,H; CARCINOGENICITY OF DINITROBENZO[A]PYRENES AND DINITROFLUORANTHENES IN F344 RATS; IN: DAI,Q, ARMOUR,MA AND ZHENG,Q (EDS.), RECENT ADV. CHEM. MOL. BIOL. CANCER RES., INT. SYMP., SCIENCE PRESS, BEIJING, CHINA, 1991, PP. 319-325]"
4668,363900004,13462,C1=CC=C2C(=C1)C3=C4C2=CC=CC4=C(C=C3)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",,NEGATIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
4669,363900004,13462,C1=CC=C2C(=C1)C3=C4C2=CC=CC4=C(C=C3)[N+](=O)[O-],Active,,,,RAT,F344/DUCRJ FISCHER/MALE,SUBCUTANEOUS,2 MG TWICE WEEKLY FOR A TOTAL OF 15 INJECTIONS (STUDY DURATION: 52 WK),INTEGUMENTARY SYSTEM: FIBROUS HISTIOCYTOMAS,POSITIVE,"[SUGIMURA,T AND TAKAYAMA,S; BIOLOGICAL ACTIONS OF NITROARENES  IN SHORT-TERM TESTS ON SALMONELLA, CULTURED MAMMALIAN CELLS  AND CULTURED HUMAN TRACHEAL TISSUES: POSSIBLE BASIS FOR  REGULATORY CONTROL. ENVIRON. HEALTH PERSPECT. 47:171-176,  1983]"
4670,363900006,60018,C1=CC2=C(C=CC3=C2C(=C1)C4=C3C=CC=C4[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/DUCRJ/MALE,PULMONARY IMPLANT,0; 0.2 MG AS A SUSPENSION IN EQUAL VOL OF BEESWAX AND TRICAPRYLIN IMPLANTED IN LEFT LUNG (STUDY DURATION: 70 WK),LUNG: TUMOR,POSITIVE,"[TOKIWA,H, HORIKAWA,K, SERA,N, IZUMI,K, IWAGAWA,M, OTSUKA,H, OHNISHI,Y, NAKASHIMA,A AND NAKASHIMA,K; CARCINOGENICITY OF DINITROARENES IN RAT LUNG; ENVIRON. SCI. RES. 40(NITROARENES):29-37, 1990]"
4671,363900006,60018,C1=CC2=C(C=CC3=C2C(=C1)C4=C3C=CC=C4[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/MALE,LUNG IMPLANT,0; 200 UG IN BEESWAX/TRICAPRYLIN INTO LOWER LEFT LUNG ONCE (STUDY DURATION: 100 WK),LUNG: SQUAMOUS CELL CARCINOMA,POSITIVE,"[HORIKAWA,K, SERA,N, OTOFUJI,T, MURAKAMI,K, TOKIWA,H, IWAGAWA,M, IZUMI,K AND OTSUKA,H; PULMONARY CARCINOGENICITY OF 3,9- AND 3,7-DINITROFLUORANTHENE, 3-NITROFLUORANTHENE AND BENZO[A]PYRENE IN F344 RATS; CARCINOGENESIS 12(6):1003-1007, 1991]"
4672,363900006,60018,C1=CC2=C(C=CC3=C2C(=C1)C4=C3C=CC=C4[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/MALE,PULMONARY IMPLANT,0; 200 UG IN 50 UL BEESWAX/TRICAPRYLIN IMPLANTED FOR UP TO 100 WK (STUDY DURATION: 100 WK),LUNG: TUMOR,POSITIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, OTOFUJI,T, TOKIWA,H, IZUMI,K AND OTSUKA,H; CARCINOGENICITY OF DINITROBENZO[A]PYRENES AND DINITROFLUORANTHENES IN F344 RATS; IN: DAI,Q, ARMOUR,MA AND ZHENG,Q (EDS.), RECENT ADV. CHEM. MOL. BIOL. CANCER RES., INT. SYMP., SCIENCE PRESS, BEIJING, CHINA, 1991, PP. 319-325]"
4673,363900007,31186,C1=CC2=C(C=CC3=C2C(=C1)C4=C3C=C(C=C4)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/DUCRJ/MALE,PULMONARY IMPLANT,0; 0.05; 0.1; 0.2 MG AS A SUSPENSION IN EQUAL VOL OF BEESWAX AND TRICAPRYLIN IMPLANTED IN LEFT LUNG (STUDY DURATION: 70 WK),LUNG: TUMOR,POSITIVE,"[TOKIWA,H, HORIKAWA,K, SERA,N, IZUMI,K, IWAGAWA,M, OTSUKA,H, OHNISHI,Y, NAKASHIMA,A AND NAKASHIMA,K; CARCINOGENICITY OF DINITROARENES IN RAT LUNG; ENVIRON. SCI. RES. 40(NITROARENES):29-37, 1990]"
4674,363900007,31186,C1=CC2=C(C=CC3=C2C(=C1)C4=C3C=C(C=C4)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/MALE,LUNG IMPLANT,0; 50; 100; 200 UG IN BEESWAX/TRICAPRYLIN INTO LOWER LEFT LUNG ONCE (STUDY DURATION: 100 WK),"LUNG: SQUAMOUS CELL CARCINOMA, ADENOSQUAMOUS CARCINOMA, TUMOR",POSITIVE,"[HORIKAWA,K, SERA,N, OTOFUJI,T, MURAKAMI,K, TOKIWA,H, IWAGAWA,M, IZUMI,K AND OTSUKA,H; PULMONARY CARCINOGENICITY OF 3,9- AND 3,7-DINITROFLUORANTHENE, 3-NITROFLUORANTHENE AND BENZO[A]PYRENE IN F344 RATS; CARCINOGENESIS 12(6):1003-1007, 1991]"
4675,363900007,31186,C1=CC2=C(C=CC3=C2C(=C1)C4=C3C=C(C=C4)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/MALE,PULMONARY IMPLANT,0; 50; 100; 200 UG IN 50 UL BEESWAX/TRICAPRYLIN IMPLANTED FOR UP TO 100 WK (STUDY DURATION: 100 WK),LUNG: TUMOR,POSITIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, OTOFUJI,T, TOKIWA,H, IZUMI,K AND OTSUKA,H; CARCINOGENICITY OF DINITROBENZO[A]PYRENES AND DINITROFLUORANTHENES IN F344 RATS; IN: DAI,Q, ARMOUR,MA AND ZHENG,Q (EDS.), RECENT ADV. CHEM. MOL. BIOL. CANCER RES., INT. SYMP., SCIENCE PRESS, BEIJING, CHINA, 1991, PP. 319-325]"
4676,363900009,23605,CN(C)N=NC1=CC=C(C=C1)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,0; 0.1 NMOL/KG (18.4 MG/KG) IN CREMOPHOR EL/ETHANOL/WATER 1/2 WK FOR A TOTAL OF 20 INJECTIONS (368 MG/KG) (STUDY DURATION: LIFETIME),,NEGATIVE,"[KOLAR,GF AND HABS,M; COMPARATIVE METABOLISM AND CARCINOGENICITY OF RING-HALOGENATED 3,3-DIMETHYL-1-PHENYLTRIAZENES;J. CANCER RES. CLIN. ONCOL. 108:71-75, 1984]"
4677,363900013,81652,CN(C)N=NC1=CC=C(C=C1)Br,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,0; 0.1 NMOL/KG (22.8 MG/KG) IN CREMOPHOR EL/ETHANOL/WATER 1/2 WK FOR A TOTAL OF 20 INJECTIONS (456 MG/KG) (STUDY DURATION: LIFETIME),,NEGATIVE,"[KOLAR,GF AND HABS,M; COMPARATIVE METABOLISM AND CARCINOGENICITY OF RING-HALOGENATED 3,3-DIMETHYL-1-PHENYLTRIAZENES;J. CANCER RES. CLIN. ONCOL. 108:71-75, 1984]"
4678,363900031,244,C1=CC=C(C=C1)CO,Inactive,,,,RAT,F344/M,GAVAGE,0; 200; 400 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-343 Y89]"
4679,363900031,244,C1=CC=C(C=C1)CO,Inactive,,,,RAT,F344/F,GAVAGE,0; 200; 400 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-343 Y89]"
4680,363900031,244,C1=CC=C(C=C1)CO,Inactive,,,,MOUSE,B6C3F1/M,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-343 Y89]"
4681,363900031,244,C1=CC=C(C=C1)CO,Inactive,,,,MOUSE,B6C3F1/F,GAVAGE,0; 100; 200 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-343 Y89]"
4682,363900032,3639,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 250; 500; 2000 PPM IN FEED FOR 105-106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-357 Y89]"
4683,363900032,3639,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 250; 500; 2000 PPM IN FEED FOR 105-106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-357 Y89]"
4684,363900032,3639,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2500; 5000 PPM IN FEED FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-357 Y89]"
4685,363900032,3639,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.1% IN DIET FOR 104 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W AND REUBER,MD; PATHOLOGIC EFFECTS OF CHRONIC ADMINISTRATION OF HYDROCHLOROTHIAZIDE, WITH AND WITHOUT SODIUM NITRITE, TO F344 RATS; TOXICOL. IND. HEALTH 3:413-422, 1987]"
4686,363900032,3639,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.1% IN DIET FOR 104 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W AND REUBER,MD; PATHOLOGIC EFFECTS OF CHRONIC ADMINISTRATION OF HYDROCHLOROTHIAZIDE, WITH AND WITHOUT SODIUM NITRITE, TO F344 RATS; TOXICOL. IND. HEALTH 3:413-422, 1987]"
4687,363900032,3639,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2500; 5000 PPM IN FEED FOR 103-104 WK (STUDY DURATION: 106 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-357 Y89]"
4688,363900033,4114,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,Active,,,,RAT,F344/M,GAVAGE,0; 37.5; 75 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 106 WK),SUBCUTANEOUS TISSUE: FIBROMA; SUBCUTANEOUS TISSUE: FIBROMA OR SARCOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA; KIDNEY: TUBULAR CELL ADENOMA; KIDNEY: TUBULAR CELL ADENOMA OR ADENOCARCINOMA; ZYMBAL GLAND: CARCINOMA OR SQUAMOUS CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-359 Y89]"
4689,363900033,4114,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,Inactive,,,,RAT,F344/F,GAVAGE,0; 37.5; 75 MG/KG IN CORN OIL 5D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-359 Y89]"
4690,363900034,5284363,C1=CC(=CC=C1N)Cl.Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 2; 6; 18 MG/KG IN ACIDIFIED WATER 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),"ADRENAL MEDULLA: PHEOCHROMOCYTOMA; ADRENAL MEDULLA: PHEOCHROMOCYTOMA OR MALIGNANT PHEOCHROMOCYTOMA; SPLEEN: FIBROSARCOMA; SPLEEN: FIBROMA OR FIBROSARCOMA; SPLEEN: OSTEOSARCOMA; SPLEEN: FIBROSARCOMA OR OSTEOSARCOMA; SPLEEN: FIBROSARCOMA, OSTEOSARCOMA OR HEMANGIOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-351 Y89]"
4691,363900034,5284363,C1=CC(=CC=C1N)Cl.Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 3; 10; 30 MG/KG IN ACIDIFIED WATER 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; CIRCULATORY SYSTEM: HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-351 Y89]"
4692,363900034,5284363,C1=CC(=CC=C1N)Cl.Cl,Inactive,,,,MOUSE,B6C3F1/F,GAVAGE,0; 3; 10; 30 MG/KG IN ACIDIFIED WATER 5D/WK FOR 103 WK (STUDY DURATION: 104 WK,,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-351 Y89]"
4693,363900034,5284363,C1=CC(=CC=C1N)Cl.Cl,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 2; 6; 18 MG/KG IN ACIDIFIED WATER 5D/WK FOR 103 WK (STUDY DURATION: 104 WK),SPLEEN: SARCOMA; ADRENAL GLAND: PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-351 Y89]"
4694,363900035,57175,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@@H]([C@H]5[C@@H]4O5)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
4695,363900035,57175,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@@H]([C@H]5[C@@H]4O5)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LIVER: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
4696,363900036,57139,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,0; 8 NMOL IN 5 UL DMSO TO PUPS ON D 1/OF LIFE THEN 16 NMOL IN 10 UL ON D 8 AND 3 NMOL IN 20 UL ON D 15 (STUDY DURATION: 35 WK),LUNG: TUMOR,POSITIVE,"[MISRA,B, AMIN,S AND HECHT,SS; DIMETHYLCHRYSENEDIOL EPOXIDES: MUTAGENICITY IN SALMONELLA TYPHIMURIUM, TUMORIGENICITY IN NEWBORN MICE, AND REACTIVITY WITH DEOXYADENOSINE IN DNA; CHEM. RES. TOXICOL. 5(2):248-254, 1992]"
4697,363900036,57139,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,0; 8 NMOL IN 5 UL DMSO TO PUPS ON D 1/OF LIFE THEN 16 NMOL IN 10 UL ON D 8 AND 3 NMOL IN 20 UL ON D 15 (STUDY DURATION: 35 WK),LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[MISRA,B, AMIN,S AND HECHT,SS; DIMETHYLCHRYSENEDIOL EPOXIDES: MUTAGENICITY IN SALMONELLA TYPHIMURIUM, TUMORIGENICITY IN NEWBORN MICE, AND REACTIVITY WITH DEOXYADENOSINE IN DNA; CHEM. RES. TOXICOL. 5(2):248-254, 1992]"
4698,363900036,57139,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 8 NMOL IN 5 UL DMSO ON D 1, 16 NMOL IN 10 UL ON D 8 AND 32 NMOL IN 20 UL ON D 15 OF LIFE (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, MISRA,B, BRALEY,J AND HECHT,SS; COMPARATIVE TUMORIGENICITY IN NEWBORN MICE OF CHRYSENE- AND 5-ALKYLCHRYSENE-1,2-DIOL 3,4-EPOXIDES; CANCER LETT. 58(1-2):115-118, 1991]"
4699,363900036,57139,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 8 NMOL IN 5 UL DMSO ON D 1, 16 NMOL IN 10 UL ON D 8 AND 32 NMOL IN 20 UL ON D 15 OF LIFE (STUDY DURATION: 35 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[AMIN,S, MISRA,B, BRALEY,J AND HECHT,SS; COMPARATIVE TUMORIGENICITY IN NEWBORN MICE OF CHRYSENE- AND 5-ALKYLCHRYSENE-1,2-DIOL 3,4-EPOXIDES; CANCER LETT. 58(1-2):115-118, 1991]"
4700,363900036,57139,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
4701,363900036,57139,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
4702,363900067,300,C(C(=O)O)Cl,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 15; 30 MG/KG IN DEIONIZED WATER 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-396 Y92]"
4703,363900067,300,C(C(=O)O)Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 15; 30 MG/KG IN DEIONIZED WATER 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-396 Y92]"
4704,363900067,300,C(C(=O)O)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 50; 100 MG/KG IN DEIONIZED WATER 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-396 Y92]"
4705,363900067,300,C(C(=O)O)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 50; 100 MG/KG IN DEIONIZED WATER 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-396 Y92]"
4706,363900067,300,C(C(=O)O)Cl,Inactive,,,,RAT,F344/MALE,ORAL,"O; 0.05; 0.5; 2 G/L IN DRINKING WATER FOR 104 WK, THE 2.5 G/L CONCENTRATION WAS LOWERED TO 1.5 G/L AT 8 WK THEN TO 1 G/L AT 24 WK ( STUDY DURATION: 104 WK)",,NEGATIVE,"[DEANGELO,AB, DANIEL,FB, MOST,BM AND OLSON,GR; FAILURE OF MONOCHLOROACETIC ACID AND TRICHLOROACETIC ACID ADMINISTERED IN THE DRINKING WATER TO PRODUCE LIVER CANCER IN MALE F344/N RATS; J. TOXICOL. ENVIRON. HEALTH 52(5):425-445, 1997]"
4707,363900068,8715,C1=CC(=C(C=C1N)N)O.Cl.Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 12.5; 25 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-401 Y92]"
4708,363900068,8715,C1=CC(=C(C=C1N)N)O.Cl.Cl,Inactive,,,,RAT,F344/MALE,GAVAGE,"0; 12.5, 25 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-401 Y92]"
4709,363900068,8715,C1=CC(=C(C=C1N)N)O.Cl.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 19; 38 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-401 Y92]"
4710,363900069,15767,COC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 10; 20; 40 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-414 Y93]"
4711,363900069,15767,COC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 20; 40 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA; LIVER: HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-414 Y93]"
4712,363900069,15767,COC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 20; 40 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-414 Y93]"
4713,363900069,15767,COC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 20; 40 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-414 Y93]"
4714,363900076,121492632,C1=CC2=C3C(=C1)[C@H]4[C@H](O4)C5=C3C(=C(C=C5)[N+](=O)[O-])C=C2,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 7 NMOL (TOTAL DOSE), 1/7, 2/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED WITHIN 24 HR OF BIRTH AND AT 8 AND 15 D OF AGE, RESPECTIVELY (STUDY DURATION: 72 WK)",,NEGATIVE,"[MORI,H, MORISHITA,Y, SUGIE,S, TANAKA,T, KOJIMA,T, SUZUI,M, KATAOKA,K, KINOUCHI,T AND OHNISHI,Y; CARCINOGENICITY EXAMINATION OF 1-NITROPYRENE OXIDES AND RELATED CHEMICALS: LACK OF THEIR TUMORIGENIC EFFECTS IN A NEWBORN MICE ASSAY; J. TOXICOL. SCI. 17(4):235-241, 1992]"
4715,363900076,121492632,C1=CC2=C3C(=C1)[C@H]4[C@H](O4)C5=C3C(=C(C=C5)[N+](=O)[O-])C=C2,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 7 NMOL (TOTAL DOSE), 1/7, 2/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED WITHIN 24 HR OF BIRTH AND AT 8 AND 15 D OF AGE, RESPECTIVELY (STUDY DURATION: 72 WK)",,NEGATIVE,"[MORI,H, MORISHITA,Y, SUGIE,S, TANAKA,T, KOJIMA,T, SUZUI,M, KATAOKA,K, KINOUCHI,T AND OHNISHI,Y; CARCINOGENICITY EXAMINATION OF 1-NITROPYRENE OXIDES AND RELATED CHEMICALS: LACK OF THEIR TUMORIGENIC EFFECTS IN A NEWBORN MICE ASSAY; J. TOXICOL. SCI. 17(4):235-241, 1992]"
4716,363900077,107809,C1=CC2=C3C(=C1)C4C(O4)C5=C(C=CC(=C53)C=C2)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 7 NMOL (TOTAL DOSE), 1/7, 2/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED WITHIN 24 HR OF BIRTH AND AT 8 AND 15 D OF AGE, RESPECTIVELY (STUDY DURATION: 72 WK)",,NEGATIVE,"[MORI,H, MORISHITA,Y, SUGIE,S, TANAKA,T, KOJIMA,T, SUZUI,M, KATAOKA,K, KINOUCHI,T AND OHNISHI,Y; CARCINOGENICITY EXAMINATION OF 1-NITROPYRENE OXIDES AND RELATED CHEMICALS: LACK OF THEIR TUMORIGENIC EFFECTS IN A NEWBORN MICE ASSAY; J. TOXICOL. SCI. 17(4):235-241, 1992]"
4717,363900077,107809,C1=CC2=C3C(=C1)C4C(O4)C5=C(C=CC(=C53)C=C2)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 7 NMOL (TOTAL DOSE), 1/7, 2/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED WITHIN 24 HR OF BIRTH AND AT 8 AND 15 D OF AGE, RESPECTIVELY (STUDY DURATION: 72 WK)",,NEGATIVE,"[MORI,H, MORISHITA,Y, SUGIE,S, TANAKA,T, KOJIMA,T, SUZUI,M, KATAOKA,K, KINOUCHI,T AND OHNISHI,Y; CARCINOGENICITY EXAMINATION OF 1-NITROPYRENE OXIDES AND RELATED CHEMICALS: LACK OF THEIR TUMORIGENIC EFFECTS IN A NEWBORN MICE ASSAY; J. TOXICOL. SCI. 17(4):235-241, 1992]"
4718,363900111,50958,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=C(C=C5)[N+](=O)[O-])C=C3,Inactive,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 500; 1000 UG SUSPENDED IN BEESWAX/TRICAPRYLIN (1:1) ONCE (STUDY DURATION: LIFETIME),,NEGATIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, SANO,N, IZUMI,K AND TOKIWA,H; COMPARATIVE TUMORIGENICITY OF 1- AND 3-NITROBENZO[A]PYRENES, AND 3,6- AND 1,6-DINITROBENZO[A]PYRENES IN F344/DUCRJ RATS; TOXICOL. LETT. 98(1-2):51-58, 1998]"
4719,363900111,50958,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=C(C=C5)[N+](=O)[O-])C=C3,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",,NEGATIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
4720,363900124,9939943,CC1=CNC2=C1[C@@]34C[C@@H]3CN(C4=CC2=O)C(=O)C5=CC6=C7CCN(C7=C(C(=C6N5)OC)O)C(=O)C8=CC9=C1CCN(C1=C(C(=C9N8)OC)O)C(=O)N,Active,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAVENOUS,0; 2; 4; 8 UG/KG ONCE (STUDY DURATION: 24 WK),LUNG: ADENOMA,POSITIVE,"[LINSEMAN,DA, BRANSTETTER,DG, YU,RL AND AARON,CS; LUNG TUMOR INDUCTION IN A/J MICE AND CLASTOGENIC EFFECTS IN CD-1 MICE OF THE SEQUENCE-SELECTIVE DNA ALKYLATING AGENTS (+)-CC-1065 AND (-)-CC-1065; NAT. TOXINS 3(1):32-40, 1995]"
4721,363900132,157895,C1=CC=C2C(=C1)C3=C4[C@@]25[C@@H](O5)C(C(C4=CC=C3)O)O,Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 2; 10 UMOL IN 0.1 ML DMSO INJECTED INTO MAMMARY TISSUE UNDER EACH OF THE 3 LEFT THORACIC NIPPLES FOLLOWED BY SIMILAR INJECTIONS UNDER THE 3 LEFT INGUINAL NIPPLES THE NEXT DAY (STUDY DURATION: 41 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[HECHT,SS, AMIN,S, LIN,JM, RIVENSON,A, KURTZKE,C AND EL-BAYOUMY,K; MAMMARY CARCINOGENICITY IN FEMALE CD RATS OF A DIOL EPOXIDE METABOLITE OF FLUORANTHENE, A COMMONLY OCCURRING ENVIRONMENTAL POLLUTANT;CARCINOGENESIS 16(6):1433-1435, 1995]"
4722,363900132,157895,C1=CC=C2C(=C1)C3=C4[C@@]25[C@@H](O5)C(C(C4=CC=C3)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 500 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7 AND 15 OF LIFE , RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
4723,363900132,157895,C1=CC=C2C(=C1)C3=C4[C@@]25[C@@H](O5)C(C(C4=CC=C3)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 500 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
4724,363900143,8117,C(COCCO)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 1.25; 2.5% IN DRINKING WATER FOR 108 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[HIASA,Y, KITAHORI,Y, MORIMOTO,J, KONISHI,N AND OHSHIMA,M; ABSENCE OF CARCINOGENIC OR PROMOTING EFFECTS OF DIETHYLENE GLYCOL ON RENAL TUMORIGENESIS IN RATS; J. TOXICOL. PATHOL. 3(1):97-104, 1990]"
4725,363900143,8117,C(COCCO)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1.25; 2.5% IN DRINKING WATER FOR 108 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[HIASA,Y, KITAHORI,Y, MORIMOTO,J, KONISHI,N AND OHSHIMA,M; ABSENCE OF CARCINOGENIC OR PROMOTING EFFECTS OF DIETHYLENE GLYCOL ON RENAL TUMORIGENESIS IN RATS; J. TOXICOL. PATHOL. 3(1):97-104, 1990]"
4726,363900150,31593,C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,0; 8 UG/G BW 1/D FOR 60 DAYS (STUDY DURATION: LIFETIME),LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[TEIXEIRA,ARL, CALIXTO,MA AND TEIXEIRA,ML; CHAGAS' DISEASE: CARCINOGENIC ACTIVITY OF THE ANTITRYPANOSOMAL NITROARENES IN MICE; MUTAT. RES. 305(2): 189-196, 1994]"
4727,363900150,31593,C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,0; 8 UG/G BW 1/D FOR 30 DAYS (STUDY DURATION: LIFETIME),LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[TEIXEIRA,ARL, CALIXTO,MA AND TEIXEIRA,ML; CHAGAS' DISEASE: CARCINOGENIC ACTIVITY OF THE ANTITRYPANOSOMAL NITROARENES IN MICE; MUTAT. RES. 305(2): 189-196, 1994]"
4728,363900151,6842999,CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,0; 8 UG/G BW 1/D FOR 60 DAYS (STUDY DURATION: LIFETIME),LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[TEIXEIRA,ARL, CALIXTO,MA AND TEIXEIRA,ML; CHAGAS' DISEASE: CARCINOGENIC ACTIVITY OF THE ANTITRYPANOSOMAL NITROARENES IN MICE; MUTAT. RES. 305(2): 189-196, 1994]"
4729,363900151,6842999,CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,0; 8 UG/G BW 1/D FOR 30 DAYS (STUDY DURATION: LIFETIME),LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[TEIXEIRA,ARL, CALIXTO,MA AND TEIXEIRA,ML; CHAGAS' DISEASE: CARCINOGENIC ACTIVITY OF THE ANTITRYPANOSOMAL NITROARENES IN MICE; MUTAT. RES. 305(2): 189-196, 1994]"
4730,363900162,39184,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/NS1C/MALE,PULMONARY IMPLANT,0; 0.003; 0.01; 0.03; 0.1; 0.15 MG AS A SUSPENSION IN EQUAL VOL OF BEESWAX AND TRICAPRYLIN IMPLANTED IN LEFT LUNG (STUDY DURATION: 104 WK),LUNG: TUMOR,POSITIVE,"[TOKIWA,H, HORIKAWA,K, SERA,N, IZUMI,K, IWAGAWA,M, OTSUKA,H, OHNISHI,Y, NAKASHIMA,A AND NAKASHIMA,K; CARCINOGENICITY OF DINITROARENES IN RAT LUNG; ENVIRON. SCI. RES. 40(NITROARENES):29-37, 1990]"
4731,363900162,39184,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAGASTRIC,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),PITUITARY GLAND: CARCINOMA,POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
4732,363900162,39184,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE; 16 UMOL/RAT) (STUDY DURATION; 78 WK),HEMATOPOIETIC SYSTEM: HISTIOCYTOMA,POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
4733,363900162,39184,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)[N+](=O)[O-])[N+](=O)[O-],Active,,,,MOUSE,BALB/MALE,SUBCUTANEOUS,0; 0.1 MG IN DMSO 1/WK FOR 20 WK (STUDY DURATION: 60 WK),INJECTION SITE: TUMOR,POSITIVE,"[TOKIWA,H, OTOFUJI,T, HORIKAWA,K, KITAMORI,S, OTSUKA,H, MANABE,Y, KINOUCHI,T AND OHNISHI,Y; 1,6-DINITROPYRENE: MUTAGENICITY IN SALMONELLA AND CARCINOGENICITY IN BALB/C MICE; JNCI, J. NATL. CANCER INST. 73(6):1359-1363, 1984]"
4734,363900162,39184,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 0.2 MG 2/WK FOR 10 WK (STUDY DURATION: 320 D),INJECTION SITE: SARCOMA,POSITIVE,"[OHGAKI,H, HASEGAWA,H, KATO,T, NEGISHI,C, SATO,S AND SUGIMURA,T; ABSENCE OF CARCINOGENICITY OF 1-NITROPYRENE, CORRECTION OF PREVIOUS RESULTS, AND NEW DEMONSTRATION OF CARCINOGENICITY OF 1,6-DINITROPYRENE IN RATS; CANCER LETT. 25(3):239-245, 1985]"
4735,363900162,39184,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)[N+](=O)[O-])[N+](=O)[O-],Active,,,,HAMSTER,SYRIAN/MALE,INTRAPERITONEAL,0; 0.5 MG IN 0.2 ML OF SALINE 1/WK FOR 26 WK (STUDY DURATION: 48 WK),LUNG: ADENOCARCINOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[TAKAYAMA,S, ISHIKAWA,T, NAKAJIMA,H AND SATO,S; LUNG CARCINOMA INDUCTION IN SYRIAN GOLDEN HAMSTERS BY INTRATRACHEAL INSTILLATION OF 1,6-DINITROPYRENE; JPN. J. CANCER RES. (GANN) 76(6):457-461, 1985]"
4736,363900162,39184,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)[N+](=O)[O-])[N+](=O)[O-],Active,,,,HAMSTER,SYRIAN/FEMALE,INTRATRACHEAL,0; 0.5 MG IN 0.2 ML OF SALINE 1/WK FOR 26 WK (STUDY DURATION: 48 WK),LUNG: ADENOCARCINOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[TAKAYAMA,S, ISHIKAWA,T, NAKAJIMA,H AND SATO,S; LUNG CARCINOMA INDUCTION IN SYRIAN GOLDEN HAMSTERS BY INTRATRACHEAL INSTILLATION OF 1,6-DINITROPYRENE; JPN. J. CANCER RES. (GANN) 76(6):457-461, 1985]"
4737,363900162,39184,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,0; 6.3 UMOL (TOTAL DOSE) ADMINISTERED OVER 8 WK BEGINNING ON DAY OF BIRTH (STUDY DURATION: 67 WK),INTEGUMENTARY SYSTEM: MALIGNANT FIBROUS HISTIOCYTOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[IMAIDA,K, LEE,MS, LAND,SJ, WANG,CY AND KING,CM; CARCINOGENICITY OF NITROPYRENES IN THE NEWBORN FEMALE RAT; CARCINOGENESIS 16(12):3027-3030, 1995]"
4738,363900230,24526,ClCl,Inactive,,,,RAT,F344/MALE,ORAL,"0; 70; 140; 275 PPM (BASED ON AVAILABLE ATOMIC CHLORINE) IN BUFFERED, CHARCOAL- FILTERED, DEIONIZED WATER FOR 103 WK (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-392 Y92]"
4739,363900230,24526,ClCl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 70; 140; 275 PPM (BASED ON AVAILABLE ATOMIC CHLORINE) IN BUFFERED, CHARCOAL- FILTERED, DEIONIZED WATER FOR 104 WK (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-392 Y92]"
4740,363900230,24526,ClCl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 70; 140; 275 PPM (BASED ON AVAILABLE ATOMIC CHLORINE) IN BUFFERED, CHARCOAL- FILTERED, DEIONIZED WATER FOR 104 WK (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-392 Y92]"
4741,363900230,24526,ClCl,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.4; 1; 2.5 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[WOLF,DC, MORGAN,KT, GROSS,EA, BARROW,C, MOSS,OR, JAMES,RA AND POPP,JA; TWO-YEAR INHALATION EXPOSURE OF FEMALE AND MALE B6C3F1 MICE AND F344 RATS TO CHLORINE GAS INDUCES LESIONS CONFINED TO THE NOSE; FUNDAM. APPL. TOXICOL. 24(1):111-131, 1995]"
4742,363900230,24526,ClCl,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.4; 1; 2.5 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[WOLF,DC, MORGAN,KT, GROSS,EA, BARROW,C, MOSS,OR, JAMES,RA AND POPP,JA; TWO-YEAR INHALATION EXPOSURE OF FEMALE AND MALE B6C3F1 MICE AND F344 RATS TO CHLORINE GAS INDUCES LESIONS CONFINED TO THE NOSE; FUNDAM. APPL. TOXICOL. 24(1):111-131, 1995]"
4743,363900230,24526,ClCl,Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.4; 1; 2.5 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[WOLF,DC, MORGAN,KT, GROSS,EA, BARROW,C, MOSS,OR, JAMES,RA AND POPP,JA; TWO-YEAR INHALATION EXPOSURE OF FEMALE AND MALE B6C3F1 MICE AND F344 RATS TO CHLORINE GAS INDUCES LESIONS CONFINED TO THE NOSE; FUNDAM. APPL. TOXICOL. 24(1):111-131, 1995]"
4744,363900230,24526,ClCl,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.4; 1; 2.5 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[WOLF,DC, MORGAN,KT, GROSS,EA, BARROW,C, MOSS,OR, JAMES,RA AND POPP,JA; TWO-YEAR INHALATION EXPOSURE OF FEMALE AND MALE B6C3F1 MICE AND F344 RATS TO CHLORINE GAS INDUCES LESIONS CONFINED TO THE NOSE; FUNDAM. APPL. TOXICOL. 24(1):111-131, 1995]"
4745,363900231,8255,CC(=C)C,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 500; 2000; 8000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-487 Y98]"
4746,363900231,8255,CC(=C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 500; 2000; 8000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-487 Y98]"
4747,363900231,8255,CC(=C)C,Unspecified,,,,RAT,F344/N/MALE,INHALATION,0; 500; 2000;8000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),THYROID GLAND: FOLLICULAR CELL CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-487 Y98]"
4748,363900231,8255,CC(=C)C,Inactive,,,,RAT,F344/N/FEMALE,INHALATION,0; 500; 2000; 8000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-487 Y98]"
4749,363900241,31237,CCCCCCCCCCCCC1=CC=CC=C1,Active,,,,MOUSE,"HR/HR OSLO/MALE, FEMALE",DERMAL,0; 16; 80% IN ACETONE 2/WK FOR 78 WK (STUDY DURATION: 80 WK),SKIN: TUMOR,POSITIVE,"[IVERSEN,OH; STUDIES OF THE CARCINOGENESIS AND TUMORIGENESIS OF SKIN APPLICATIONS OF DODECYLBENZENE ON HAIRLESS MICE; BR. J. IND. MED. 46(9):608-616, 1989]"
4750,363900242,7720,CCCCC(CC)CO,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 50; 150; 500 MG/KG/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[ASTIL,BD, GINGELL,R, GUEST,D, HELLWIG,J, HOGDSON,JR, KUETTLER,K, MELLERT,W, MURPHY,SR, SIELKEN,RL AND TYLER,TR; ONCOGENICITY TESTING OF 2-ETHYLHEXANOL IN FISCHER 344 RATS AND B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(1):29-41, 1996]"
4751,363900242,7720,CCCCC(CC)CO,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 50; 150; 500 MG/KG/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[ASTIL,BD, GINGELL,R, GUEST,D, HELLWIG,J, HOGDSON,JR, KUETTLER,K, MELLERT,W, MURPHY,SR, SIELKEN,RL AND TYLER,TR; ONCOGENICITY TESTING OF 2-ETHYLHEXANOL IN FISCHER 344 RATS AND B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(1):29-41, 1996]"
4752,363900242,7720,CCCCC(CC)CO,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 50; 200; 750 MG/KG/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ASTIL,BD, GINGELL,R, GUEST,D, HELLWIG,J, HOGDSON,JR, KUETTLER,K, MELLERT,W, MURPHY,SR, SIELKEN,RL AND TYLER,TR; ONCOGENICITY TESTING OF 2-ETHYLHEXANOL IN FISCHER 344 RATS AND B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(1):29-41, 1996]"
4753,363900242,7720,CCCCC(CC)CO,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 50; 200; 750 MG/KG/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ASTIL,BD, GINGELL,R, GUEST,D, HELLWIG,J, HOGDSON,JR, KUETTLER,K, MELLERT,W, MURPHY,SR, SIELKEN,RL AND TYLER,TR; ONCOGENICITY TESTING OF 2-ETHYLHEXANOL IN FISCHER 344 RATS AND B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(1):29-41, 1996]"
4754,363900249,24380,Cl[Fe](Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.25; 0.5% IN DRINKING WATER FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[SATO,M, FURUKAWA,F, TOYODA,K, MITSUMORI,K, NISHIKAWA,A AND TAKAHASHI,M; LACK OF CARCINOGENICITY OF FERRIC CHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 30(10): 837-842, 1992]"
4755,363900249,24380,Cl[Fe](Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.25; 0.5% IN DRINKING WATER FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[SATO,M, FURUKAWA,F, TOYODA,K, MITSUMORI,K, NISHIKAWA,A AND TAKAHASHI,M; LACK OF CARCINOGENICITY OF FERRIC CHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 30(10): 837-842, 1992]"
4756,363900258,3776,CC(C)O,Inactive,,,,MOUSE,CD-1/MALE,INHALATION,0; 500; 2500; 5000 PPM 6 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[BURLEIGH-FLAYER,H, GARMAN,R, NEPTUN,D, BEVAN,C, GARDINER,T, KAPP,R, TYLER,T AND WRIGHT,G; ISOPROPANOL VAPOR INHALATION ONCOGENICITY STUDY IN FISCHER 344 RATS AND CD-1 MICE; FUNDAM. APPL. TOXICOL. 36(2):95-111, 1997]"
4757,363900258,3776,CC(C)O,Inactive,,,,MOUSE,CD-1/FEMALE,INHALATION,0; 500; 2500; 5000 PPM 6 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[BURLEIGH-FLAYER,H, GARMAN,R, NEPTUN,D, BEVAN,C, GARDINER,T, KAPP,R, TYLER,T AND WRIGHT,G; ISOPROPANOL VAPOR INHALATION ONCOGENICITY STUDY IN FISCHER 344 RATS AND CD-1 MICE; FUNDAM. APPL. TOXICOL. 36(2):95-111, 1997]"
4758,363900258,3776,CC(C)O,Inactive,,,,RAT,F344/MALE,INHALATION,0; 500; 2500; 5000 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BURLEIGH-FLAYER,H, GARMAN,R, NEPTUN,D, BEVAN,C, GARDINER,T, KAPP,R, TYLER,T AND WRIGHT,G; ISOPROPANOL VAPOR INHALATION ONCOGENICITY STUDY IN FISCHER 344 RATS AND CD-1 MICE; FUNDAM. APPL. TOXICOL. 36(2):95-111, 1997]"
4759,363900258,3776,CC(C)O,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 500; 2500; 5000 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BURLEIGH-FLAYER,H, GARMAN,R, NEPTUN,D, BEVAN,C, GARDINER,T, KAPP,R, TYLER,T AND WRIGHT,G; ISOPROPANOL VAPOR INHALATION ONCOGENICITY STUDY IN FISCHER 344 RATS AND CD-1 MICE; FUNDAM. APPL. TOXICOL. 36(2):95-111, 1997]"
4760,363900263,7473,CC1=CC=C(C=C1)[N+](=O)[O-],Unspecified,,,,RAT,F344/MALE,ORAL,0; 1250; 2500; 5000 PPM FOR 105-106 WK (STUDY DURATION: 105-106 WK),"SKIN (SUBCUTANEOUS):FIBROMA, FIBROMA OR FIBROSARCOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-498 Y02]"
4761,363900263,7473,CC1=CC=C(C=C1)[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,ORAL,0; 1250; 2500; 5000 PPM FOR 105-106 WK (STUDY DURATION: 105-106 WK),CLITORAL GLAND: ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-498 Y02]"
4762,363900263,7473,CC1=CC=C(C=C1)[N+](=O)[O-],Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1250; 2500; 5000 PPM FOR 105-106 WK (STUDY DURATION: 105-106 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-498 Y02]"
4763,363900263,7473,CC1=CC=C(C=C1)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1250; 2500; 5000 PPM FOR 105-106 WK (STUDY DURATION: 105-106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-498 Y02]"
4764,363900266,980,C1=CC(=CC=C1[N+](=O)[O-])O,Inactive,,,,MOUSE,SWISS/MALE,DERMAL,0; 40; 80; 160 MG/KG IN ACETONE 3 D/WK FOR 78 WK (STUDY DURATION: 18 MO),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-417 Y93]"
4765,363900266,980,C1=CC(=CC=C1[N+](=O)[O-])O,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 40; 80; 160 MG/KG IN ACETONE 3 D/WK FOR 78 WK (STUDY DURATION: 18 MO),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-417 Y93]"
4766,363900269,7048,COC1=CC=CC=C1[N+](=O)[O-],Inactive,,,,RAT,F344/N/MALE,ORAL,0; 222; 666; 2000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-416 Y93]"
4767,363900269,7048,COC1=CC=CC=C1[N+](=O)[O-],Inactive,,,,RAT,F344/N/FEMALE,ORAL,0; 222; 666; 2000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-416 Y93]"
4768,363900269,7048,COC1=CC=CC=C1[N+](=O)[O-],Active,,,,RAT,F344/N/MALE,ORAL,"0; 6000; 18,000 PPM IN DIET FOR 27 WK (STUDY DURATION: 104 WK)","COLON: ADENOMATOUS POLYP; KIDNEY: CARCINOMA; URINARY BLADDER: CARCINOMA, SARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-416 Y93]"
4769,363900269,7048,COC1=CC=CC=C1[N+](=O)[O-],Active,,,,RAT,F344/N/FEMALE,ORAL,"0; 6000; 18,000 PPM IN DIET FOR 27 WK (STUDY DURATION: 104 WK)","COLON: ADENOMATOUS POLYP; URINARY BLADDER: CARCINOMA, SARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-416 Y93]"
4770,363900269,7048,COC1=CC=CC=C1[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 666; 2000; 6000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: HEPATOBLASTOMA, HEPATOCELLULAR ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-416 Y93]"
4771,363900301,54704426,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 12500; 25000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-344 Y89]"
4772,363900301,54704426,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 12500; 25000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-344 Y89]"
4773,363900301,54704426,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 12500; 25000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-344 Y89]"
4774,363900301,54704426,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 12500; 25000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-344 Y89]"
4775,363900301,54704426,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 12500; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[DIETZ,DD, ABDO,KM, HASEMAN,JK, EUSTIS,SL AND HUFF,JE; COMPARATIVE TOXICITY AND CARCINOGENICITY STUDIES OF TETRACYCLINE AND OXYTETRACYCLINE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 17(2):335-346, 1991]"
4776,363900301,54704426,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 12500; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[DIETZ,DD, ABDO,KM, HASEMAN,JK, EUSTIS,SL AND HUFF,JE; COMPARATIVE TOXICITY AND CARCINOGENICITY STUDIES OF TETRACYCLINE AND OXYTETRACYCLINE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 17(2):335-346, 1991]"
4777,363900301,54704426,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 12500; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[DIETZ,DD, ABDO,KM, HASEMAN,JK, EUSTIS,SL AND HUFF,JE; COMPARATIVE TOXICITY AND CARCINOGENICITY STUDIES OF TETRACYCLINE AND OXYTETRACYCLINE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 17(2):335-346, 1991]"
4778,363900301,54704426,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 12500; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[DIETZ,DD, ABDO,KM, HASEMAN,JK, EUSTIS,SL AND HUFF,JE; COMPARATIVE TOXICITY AND CARCINOGENICITY STUDIES OF TETRACYCLINE AND OXYTETRACYCLINE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 17(2):335-346, 1991]"
4779,363900303,151977,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@H]([C@@H]([C@H]6[C@@H]5O6)O)O)N=C32,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 28 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 35-36 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4780,363900303,151977,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@H]([C@@H]([C@H]6[C@@H]5O6)O)O)N=C32,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 28 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 35-36 WK)",LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4781,363900303,151977,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@H]([C@@H]([C@H]6[C@@H]5O6)O)O)N=C32,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 70; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4782,363900303,151977,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@H]([C@@H]([C@H]6[C@@H]5O6)O)O)N=C32,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 70; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4783,363900304,151984,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@@H]([C@H]([C@H]6[C@@H]5O6)O)O)N=C32,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4784,363900304,151984,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@@H]([C@H]([C@H]6[C@@H]5O6)O)O)N=C32,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4785,363900305,151982,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@H]([C@@H]([C@@H]6[C@H]5O6)O)O)N=C32,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4786,363900305,151982,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@H]([C@@H]([C@@H]6[C@H]5O6)O)O)N=C32,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4787,363900306,151979,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@@H]([C@H]([C@@H]6[C@H]5O6)O)O)N=C32,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 28 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 35-36 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4788,363900306,151979,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@@H]([C@H]([C@@H]6[C@H]5O6)O)O)N=C32,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 28 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 35-36 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4789,363900306,151979,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@@H]([C@H]([C@@H]6[C@H]5O6)O)O)N=C32,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4790,363900306,151979,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@@H]([C@H]([C@@H]6[C@H]5O6)O)O)N=C32,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
4791,363900310,6054491,CC(=O)N(C1=CC=C(C=C1)/C=C/C2=CC=CC=C2)O,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 10 UMOL/KG BW 2/WK FOR 6 WK (STUDY DURATION: 62 WK),LIVER: NEOPLASTIC NODULE; MAMMARY GLAND: TUMOR; EAR DUCT: TUMOR; PITUITARY GLAND: CARCINOMA,POSITIVE,"[HIROSE,M, SHIRAI,T, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF THE N-ACYL DERIVATIVES OF N-HYDROXY-TRANS-4-AMINOSTILBENE IN CD RATS; CHEM.-BIOL. INTERACT. 106(2):123-132, 1997]"
4792,363900310,6054491,CC(=O)N(C1=CC=C(C=C1)/C=C/C2=CC=CC=C2)O,Active,,,,RAT,STRAIN-CD/MALE,INTRAPERITONEAL,0; 10 UMOL/KG BW 2/WK FOR 6 WK (STUDY DURATION: 62 WK),TESTICLE: MESOTHELIOMA; PANCREAS(ACINUS): ADENOMA; EAR DUCT: CARCINOMA,POSITIVE,"[HIROSE,M, SHIRAI,T, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF THE N-ACYL DERIVATIVES OF N-HYDROXY-TRANS-4-AMINOSTILBENE IN CD RATS; CHEM.-BIOL. INTERACT. 106(2):123-132, 1997]"
4793,363900311,85290,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)CO,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL IN SESAME OIL:DMSO (9:1) 3/WK FOR 20 DOSES (STUDY DURATION: 52 WK),INJECTION SITE: SARCOMA,POSITIVE,"[FLESHER,JW, HORN,J AND LEHNER,AF; 7-SULFOOXYMETHYLBENZ[A]ANTHRACENE IS AN ULTIMATE ELECTROPHILIC AND CARCINOGENIC FORM OF 7-HYDROXYMETHYLBENZ[A]ANTHRACENE; BIOCHEM. BIOPHYS. RES. COMMUN. 231(3):712-716, 1997]"
4794,363900312,137372,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)COS(=O)(=O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL IN SESAME OIL:DMSO (9:1) 3/WK FOR 20 DOSES (STUDY DURATION: 52 WK),INJECTION SITE: SARCOMA,POSITIVE,"[FLESHER,JW, HORN,J AND LEHNER,AF; 7-SULFOOXYMETHYLBENZ[A]ANTHRACENE IS AN ULTIMATE ELECTROPHILIC AND CARCINOGENIC FORM OF 7-HYDROXYMETHYLBENZ[A]ANTHRACENE; BIOCHEM. BIOPHYS. RES. COMMUN. 231(3):712-716, 1997]"
4795,363900315,4421,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,Active,,,,RAT,F344/MALE,ORAL,0; 2000; 4000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),"PREPUTIAL GLAND: ADENOMA, ADENOMA OR PAPILLOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-368 Y89]"
4796,363900315,4421,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2000; 4000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),"CLITORAL GLAND: ADENOMA, ADENOMA OR PAPILLOMA, ADENOMA OR PAPILLOMA OR CARCINOMA OR PAPILLARY CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-368 Y89]"
4797,363900315,4421,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2000; 4000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-368 Y89]"
4798,363900315,4421,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2000; 4000 PPM IN FEED FOR 103 WK (STUDY DURATION: 104 WK),INTEGUMENTARY SYSTEM (SUBCUTANEOUS TISSUE): FIBROMA OR FIBROSARCOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-368 Y89]"
4799,363900316,1140,CC1=CC=CC=C1,Inactive,,,,RAT,F344/MALE,INHALATION,0; 600; 1200 PPM 6.5 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-371 Y90]"
4800,363900316,1140,CC1=CC=CC=C1,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 600; 1200 PPM 6.5 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-371 Y90]"
4801,363900316,1140,CC1=CC=CC=C1,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 120; 600; 1200 PPM 6.5 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-371 Y90]"
4802,363900316,1140,CC1=CC=CC=C1,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 120; 600; 1200 PPM 6.5 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-371 Y90]"
4803,363900316,1140,CC1=CC=CC=C1,Inactive,,,,RAT,STRAIN-CD/MALE,INTRAGASTRIC,0; 500 MG/KG IN OLIVE OIL 1/D 4-5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MALTONI,C, CONTI,B, COTTI,G AND BELPOGGI,F;EXPERIMENTAL STUDIES ON BENZENE CARCINOGENICITY AT THE BOLOGNA INSTITUTE OF ONCOLOGY: CURRENT RESULTS AND ONGOING RESEARCH; AM. J. IND. MED. 7(5-6):415-446, 1985]"
4804,363900317,7409,CC(C1=CC=CC=C1)O,Active,,,,RAT,F344/MALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"KIDNEY: TUBULAR CELL ADENOMA, TUBULAR CELL ADENOMA OR ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-369 Y90]"
4805,363900317,7409,CC(C1=CC=CC=C1)O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-369 Y90]"
4806,363900317,7409,CC(C1=CC=CC=C1)O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-369 Y90]"
4807,363900317,7409,CC(C1=CC=CC=C1)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-369 Y90]"
4808,363900319,,,Inactive,,,,RAT,F344/MALE,INHALATION,0; 100; 300 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-375 Y90]"
4809,363900319,,,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 100; 300 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-375 Y90]"
4810,363900319,,,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 10; 25 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-375 Y90]"
4811,363900319,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 10; 25 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-375 Y90]"
4812,363900320,10757,C1=CC=C(C=C1)C(=O)CCl,Inactive,,,,RAT,F344/MALE,INHALATION,0; 1; 2 MG/M3 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-379 Y90]"
4813,363900320,10757,C1=CC=C(C=C1)C(=O)CCl,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 2; 4 MG/M3 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-379 Y90]"
4814,363900320,10757,C1=CC=C(C=C1)C(=O)CCl,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2; 4 MG/M3 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-379 Y90]"
4815,363900320,10757,C1=CC=C(C=C1)C(=O)CCl,Unspecified,,,,RAT,F344/FEMALE,INHALATION,0; 1; 2 MG/M3 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),MAMMARY GLAND: FIBROADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-379 Y90]"
4816,363900321,10509,C([N+](=O)[O-])([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/MALE,INHALATION,"0; 2; 5 PPM 6 HR/D, 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK)","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-386 Y90]"
4817,363900321,10509,C([N+](=O)[O-])([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,INHALATION,"0; 2; 5 PPM, 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK)","LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA OR ADENOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-386 Y90]"
4818,363900321,10509,C([N+](=O)[O-])([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 0.5; 2 PPM 6 HR/D, 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK)","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-386 Y90]"
4819,363900321,10509,C([N+](=O)[O-])([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 0.5; 2 PPM 6 HR/D, 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK)","LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-386 Y90]"
4820,363900322,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 1% (10000 PPM) IN PELLETED FEED FOR LIFETIME BEGINNING WITH MOTHERS OF THE STUDY ANIMALS 15-16 WK PRIOR TO DELIVERY (STUDY DURATION: LIFETIME),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-277 Y90]"
4821,363900322,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1% (10000 PPM) IN PELLETED FEED FOR LIFETIME BEGINNING WITH MOTHERS OF THE STUDY ANIMALS 15-16 WK PRIOR TO DELIVERY (STUDY DURATION: LIFETIME),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-277 Y90]"
4822,363900322,,,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 10 MG/M3 OF RESPIRABLE DUST 7 HR/D 5 D/WK FOR 224 DAYS DURING A PERIOD OF 12 MO (STUDY DURATION: 29 MO),LUNG: CARCINOMA,POSITIVE,"[DAVIS,JMG, ADDISON,J, BOLTON,RE, DONALDSON,K, JONES,AD AND MILLER,BG; INHALATION STUDIES ON THE EFFECTS OF TREMOLITE AND BRUCITE DUST IN RATS; CARCINOGENESIS 6(5):667-674, 1985]"
4823,363900322,,,Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 25 MG OF DUST SUSPENDED IN 2 ML PHOSPHATE BUFFERED SALINE (STUDY DURATION: >352 D),LUNG: MESOTHELIOMA,POSITIVE,"[DAVIS,JMG, ADDISON,J, BOLTON,RE, DONALDSON,K, JONES,AD AND MILLER,BG; INHALATION STUDIES ON THE EFFECTS OF TREMOLITE AND BRUCITE DUST IN RATS; CARCINOGENESIS 6(5):667-674, 1985]"
4824,363900323,6896,CC1=C(C(=CC=C1)C)N,Active,,,,RAT,CD/MALE,ORAL,0; 300; 1000; 3000 PPM IN FEED FOR 102 WK (STUDY DURATION: 104 WK),"SUBCUTANEOUS TISSUE: FIBROMA, FIBROMA OR NEUROFIBROMA, FIBROMA OR FIBROSARCOMA; NASAL CAVITY: PAPILLARY ADENOMA, CARCINOMA, ADENOMA OR ADENOCARCINOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-278 Y90]"
4825,363900323,6896,CC1=C(C(=CC=C1)C)N,Active,,,,RAT,CD/FEMALE,ORAL,0; 300; 1000; 3000 PPM IN FEED FOR 102 WK (STUDY DURATION: 104 WK),"SUBCUTANEOUS TISSUE: FIBROMA, FIBROMA OR FIBROSARCOMA; NASAL CAVITY: PAPILLARY ADENOMA, ADENOMA OR PAPILLARY ADENOMA, CARCINOMA; LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-278 Y90]"
4826,363900324,4781,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"KIDNEY: TRANSITIONAL EPITHELIAL CARCINOMA, TUBULAR CELL ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-367 Y90]"
4827,363900324,4781,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 150; 300 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 107 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-367 Y90]"
4828,363900324,4781,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 150; 300 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-367 Y90]"
4829,363900324,4781,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,Unspecified,,,,RAT,F344/MALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"KIDNEY: TUBULAR CELL ADENOMA, TUBULAR CELL ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-367 Y90]"
4830,363900325,7838,C=CCOCC1CO1,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,INHALATION,0; 5; 10 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-376 Y90]"
4831,363900325,7838,C=CCOCC1CO1,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 5; 10 PPM 6 HR/D 5 D/WK FOR 102 WK (STUDY DURATION: 105 WK),NOSE (RESPIRATORY EPITHELIUM): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-376 Y90]"
4832,363900325,7838,C=CCOCC1CO1,Unspecified,,,,RAT,OSBORNE-MENDEL/MALE,INHALATION,0; 5; 10 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),"NOSE (RESPIRATORY OR OLFACTORY EPITHELIUM): PAPILLARY ADENOMA, SQUAMOUS CELL CARCINOMA, POORLY DIFFERENTIATED ADENOCARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-376 Y90]"
4833,363900325,7838,C=CCOCC1CO1,Unspecified,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 5; 10 PPM 6 HR/D 5 D/WK FOR 102 WK (STUDY DURATION: 105 WK),NOSE (RESPIRATORY EPITHELIUM): ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-376 Y90]"
4834,363900326,240,C1=CC=C(C=C1)C=O,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 200; 400 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-378 Y90]"
4835,363900326,240,C1=CC=C(C=C1)C=O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 200; 400 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-378 Y90]"
4836,363900326,240,C1=CC=C(C=C1)C=O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 200; 400 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),FORESTOMACH: SQUAMOUS PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-378 Y90]"
4837,363900326,240,C1=CC=C(C=C1)C=O,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 300; 600 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-378 Y90]"
4838,363900327,17604,C1=CC=C(C(=C1)C=C(C#N)C#N)Cl,Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.075; 0.25; 0.75 MG/M3 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-377 Y90]"
4839,363900327,17604,C1=CC=C(C(=C1)C=C(C#N)C#N)Cl,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.075; 0.25; 0.75 MG/M3 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-377 Y90]"
4840,363900327,17604,C1=CC=C(C(=C1)C=C(C#N)C#N)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.75; 1.5 MG/M3 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-377 Y90]"
4841,363900327,17604,C1=CC=C(C(=C1)C=C(C#N)C#N)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.75; 1.5 MG/M3 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-377 Y90]"
4842,363900328,21852,CC(C1OCC(O1)CO)I,Active,,,,RAT,F344/MALE,GAVAGE,0; 125; 250 MG/KG IN WATER 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA; THYROID GLAND: FOLLICULAR CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-340 Y90]"
4843,363900328,21852,CC(C1OCC(O1)CO)I,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 62; 125 MG/KG IN WATER 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-340 Y90]"
4844,363900328,21852,CC(C1OCC(O1)CO)I,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 125; 250 MG/KG IN WATER 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-340 Y90]"
4845,363900328,21852,CC(C1OCC(O1)CO)I,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 62; 125 MG/KG IN WATER 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA; ANTERIOR PITUTARY GLAND: ADENOMA; HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-340 Y90]"
4846,363900330,13543,C=CC(=O)NCO,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 6; 12 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-352 Y89]"
4847,363900330,13543,C=CC(=O)NCO,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 6; 12 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-352 Y89]"
4848,363900330,13543,C=CC(=O)NCO,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 25; 50 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-352 Y89]"
4849,363900330,13543,C=CC(=O)NCO,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 25; 50 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; OVARY: GRANULOSA CELL TUMOR",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-352 Y89]"
4850,363900331,949,CN(C)C1=CC=CC=C1,Active,,,,RAT,F344/MALE,GAVAGE,0; 3; 30 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"SPLEEN: SARCOMA, SARCOMA OR OSTEOSARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-360 Y89]"
4851,363900331,949,CN(C)C1=CC=CC=C1,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 3; 30 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-360 Y89]"
4852,363900331,949,CN(C)C1=CC=CC=C1,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 15; 30 MG/KG IN CORN OIL FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-360 Y89]"
4853,363900331,949,CN(C)C1=CC=CC=C1,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 15; 30 MG/KG IN CORN OIL FOR 103 WK (STUDY DURATION: 105 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-360 Y89]"
4854,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 21; 70; 210 UG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"KIDNEY TUBULE: ADENOMA, CARCINOMA; MAMMARY GLAND: FIBROADENOMA, ADENOMA OR FIBROADENOMA OR ADENOCARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-358 Y89]"
4855,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 21; 70; 210 UG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),"KIDNEY TUBULE: ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-358 Y89]"
4856,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Active,,,,MOUSE,DDY/MALE,ORAL,"0; 7.05; 17.24; 26.27; 33.16; 35.86; 42.67 MG/MOUSE (TOTAL DOSE) ADMINISTERED AT A DOSE OF 50 PPM IN DIET FOR 0, 5, 10, 15, 20, 25 OR 30 WK, RESPECTIVELY (STUDY DURATION: 70 WK)",LIVER: HEPATOMA; KIDNEY: RENAL CELL TUMOR,POSITIVE,"[KANISAWA,M; SYNERGISTIC EFFECT OF CITRININ ON HEPATORENAL CARCINOGENESIS OF OCHRATOXIN A IN MICE; DEV. FOOD SCI. 7(TOXIGENIC FUNGI):245-254, 1984]"
4857,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Active,,,,MOUSE,DDD/MALE,ORAL,0; 25 PPM IN DIET FOR 70 WK (STUDY DURATION: 70 WK),KIDNEY: RENAL CELL TUMOR; LIVER: HEPATOMA,POSITIVE,"[KANISAWA,M; SYNERGISTIC EFFECT OF CITRININ ON HEPATORENAL CARCINOGENESIS OF OCHRATOXIN A IN MICE; DEV. FOOD SCI. 7(TOXIGENIC FUNGI):245-254, 1984]"
4858,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Active,,,,MOUSE,"ALBINO/MALE,FEMALE",GAVAGE,0; 0.25 ML OF 50 PPM SOLUTION 2/WK FOR 20 WK (STUDY DURATION: 20 WK),KIDNEY: CARCINOMA,POSITIVE,"[JESWAL,P; CUMULATIVE EFFECT OF OCHRATOXIN A AND CITRININ ON INDUCTION OF HEPATORENAL CARCINOGENESIS IN MICE (MUS MUSCULUS); BIOMED. LETT. 52(208):269-275, 1995]"
4859,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Active,,,,MOUSE,"SWISS/MALE,FEMALE",GAVAGE,0; 0.25 ML OF A 50 PPM SOLUTION 2/WK FOR 20 WK (STUDY DURATION: 20 WK),KIDNEY: CARCINOMA,POSITIVE,"[JESWAL,P; OCHRATOXIN A INDUCED HEPATORENAL CARCINOGENESIS IN MICE (MUS MUSCULUS); PROC. INDIAN NATL. SCI. ACAD., PART B 62(5):339-343, 1996]"
4860,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Active,,,,RAT,DA/MALE,GAVAGE,0; 0.4 MG/KG BW IN SODIUM BICARBONATE 3/WK FOR DURATION OF STUDY (STUDY DURATION: LIFESPAN),"KIDNEY: ADENOCARCINOMA, ADENOMA",POSITIVE,"[CASTEGNARO,M, MOHR,U, PFOHL-LESZKOWICZ,A, ESTEVE,J, STEINMANN,J, TILLMANN,T, MICHELON,J AND BARTSCH,H; SEX- AND STRAIN-SPECIFIC INDUCTION OF RENAL TUMORS BY OCHRATOXIN A IN RATS CORRELATES WITH DNA ADDUCTION; INT. J. CANCER 77(1):70-75, 1998]"
4861,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Inactive,,,,RAT,DA/FEMALE,GAVAGE,0; 0.4 MG/KG BW IN SODIUM BICARBONATE 3/WK FOR DURATION OF STUDY (STUDY DURATION: LIFESPAN),,NEGATIVE,"[CASTEGNARO,M, MOHR,U, PFOHL-LESZKOWICZ,A, ESTEVE,J, STEINMANN,J, TILLMANN,T, MICHELON,J AND BARTSCH,H; SEX- AND STRAIN-SPECIFIC INDUCTION OF RENAL TUMORS BY OCHRATOXIN A IN RATS CORRELATES WITH DNA ADDUCTION; INT. J. CANCER 77(1):70-75, 1998]"
4862,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Active,,,,RAT,LEWIS/MALE,GAVAGE,0; 0.4 MG/KG BW IN SODIUM BICARBONATE 3/WK FOR DURATION OF STUDY (STUDY DURATION: LIFESPAN),KIDNEY: ADENOCARCINOMA,POSITIVE,"[CASTEGNARO,M, MOHR,U, PFOHL-LESZKOWICZ,A, ESTEVE,J, STEINMANN,J, TILLMANN,T, MICHELON,J AND BARTSCH,H; SEX- AND STRAIN-SPECIFIC INDUCTION OF RENAL TUMORS BY OCHRATOXIN A IN RATS CORRELATES WITH DNA ADDUCTION; INT. J. CANCER 77(1):70-75, 1998]"
4863,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Active,,,,RAT,LEWIS/FEMALE,GAVAGE,0; 0.4 MG/KG BW IN SODIUM BICARBONATE 3/WK FOR DURATION OF STUDY (STUDY DURATION: LIFESPAN),KIDNEY: ADENOCARCINOMA,POSITIVE,"[CASTEGNARO,M, MOHR,U, PFOHL-LESZKOWICZ,A, ESTEVE,J, STEINMANN,J, TILLMANN,T, MICHELON,J AND BARTSCH,H; SEX- AND STRAIN-SPECIFIC INDUCTION OF RENAL TUMORS BY OCHRATOXIN A IN RATS CORRELATES WITH DNA ADDUCTION; INT. J. CANCER 77(1):70-75, 1998]"
4864,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 0.031; 0.125; 0.5% IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[TADA,Y FUJITANI,T YANO,N YUZAWA,K NAGASAWA,A AOKI,N OGATA,A  AND YONEYAMA,M; CHRONIC TOXICITY OF THIABENDAZOLE (TBZ) IN CD-1 MICE;  TOXICOLOGY 169(3): 163-176, 2001]"
4865,363900332,9344,C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)NC(CC3=CC=CC=C3)C(=O)O)Cl,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.031; 0.125; 0.5% IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[TADA,Y FUJITANI,T YANO,N YUZAWA,K NAGASAWA,A AOKI,N OGATA,A  AND YONEYAMA,M; CHRONIC TOXICITY OF THIABENDAZOLE (TBZ) IN CD-1 MICE;  TOXICOLOGY 169(3): 163-176, 2001]"
4866,363900333,8980,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 156; 313 PPM IN FEED FOR 105 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-355 Y89]"
4867,363900333,8980,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 156; 313 PPM IN FEED FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-355 Y89]"
4868,363900333,8980,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.Cl,Unspecified,,,,RAT,F344/MALE,ORAL,0; 313; 625 PPM IN FEED FOR 103 WK (STUDY DURATION: 106 WK),BRAIN: ASTROCYTOMA OR GLIOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-355 Y89]"
4869,363900333,8980,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.Cl,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 156; 313 PPM IN FEED FOR 103 WK (STUDY DURATION: 106 WK),PITUITARY GLAND: ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-355 Y89]"
4870,363900334,9223,C1=CC=C2C(=C1)C=CO2,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 30; 60 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-370 Y89]"
4871,363900334,9223,C1=CC=C2C(=C1)C=CO2,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),KIDNEY: TUBULAR CELL ADENOCARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-370 Y89]"
4872,363900334,9223,C1=CC=C2C(=C1)C=CO2,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA, HEPATOBLASTOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-370 Y89]"
4873,363900334,9223,C1=CC=C2C(=C1)C=CO2,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 120; 240 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-370 Y89]"
4874,363900335,16724,CC1=CC[C@@H](CC1=O)C(=C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-381 Y90]"
4875,363900335,16724,CC1=CC[C@@H](CC1=O)C(=C)C,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 375; 750 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),KIDNEY: TUBULAR CELL ADENOCARCINOMA,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-381 Y90]"
4876,363900336,7922,C1CC(=O)OC1=O,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-373 Y90]"
4877,363900336,7922,C1CC(=O)OC1=O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 50; 100 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-373 Y90]"
4878,363900336,7922,C1CC(=O)OC1=O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 38; 75 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-373 Y90]"
4879,363900336,7922,C1CC(=O)OC1=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 75; 150 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-373 Y90]"
4880,363900337,6518,C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 25000; 50000 PPM PENTAERYTHRITOL TETRANITRATE (FORMULATED WITH 80% D-LACTOSE MONOHYDRATE) IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-365 Y89]"
4881,363900337,6518,C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 25000; 50000 PPM PENTAERYTHRITOL TETRANITRATE (FORMULATED WITH 80% D-LACTOSE MONOHYDRATE) IN FEED FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-365 Y89]"
4882,363900337,6518,C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O[N+](=O)[O-],Unspecified,,,,RAT,F344/MALE,ORAL,0; 25000; 50000 PPM PENTAERYTHRITOL TETRANITRATE (FORMULATED WITH 80% D-LACTOSE MONOHYDRATE) IN FEED FOR 103 WK (STUDY DURATION: 104 WK),"ZYMBAL GLAND: ADENOMA, CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-365 Y89]"
4883,363900337,6518,C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O[N+](=O)[O-],Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 6200; 12500 PPM PENTAERYTHRITOL TETRANITRATE (FORMULATED WITH 80% D-LACTOSE MONOHYDRATE) IN FEED FOR 103 WK (STUDY DURATTION: 104 WK),"ZYMBAL GLAND: ADENOMA, CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-365 Y89]"
4884,363900338,13806,CCNC1=CC2=C(C=C1C)C(=C3C=C(C(=[NH+]CC)C=C3O2)C)C4=CC=CC=C4C(=O)OCC.[Cl-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 2000 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-364 Y89]"
4885,363900338,13806,CCNC1=CC2=C(C=C1C)C(=C3C=C(C(=[NH+]CC)C=C3O2)C)C4=CC=CC=C4C(=O)OCC.[Cl-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1000 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-364 Y89]"
4886,363900338,13806,CCNC1=CC2=C(C=C1C)C(=C3C=C(C(=[NH+]CC)C=C3O2)C)C4=CC=CC=C4C(=O)OCC.[Cl-],Unspecified,,,,RAT,F344/MALE,ORAL,0; 120; 250 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),INTEGUMENTARY SYSTEM: KERATOACANTHOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-364 Y89]"
4887,363900338,13806,CCNC1=CC2=C(C=C1C)C(=C3C=C(C(=[NH+]CC)C=C3O2)C)C4=CC=CC=C4C(=O)OCC.[Cl-],Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 120; 250 PPM IN FEED FOR 103 WK (STUDY DURATION: 105 WK),ADRENAL GLAND: PHEOCHROMOCYTOMA OR MALIGNANT PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-364 Y89]"
4888,363900341,62329,CC1=C(C(=C(C(=C1[N+](=O)[O-])C(C)(C)C)[N+](=O)[O-])C)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.075; 0.15% IN DIET FOR 80 WK (STUDY DURATION: 80 WK),LIVER: ADENOMA,POSITIVE,"[MATSUSHIMA,Y, MAEKAWA,A, ONODERA,H, SHIBUTANI,M, YOSHIDA,J, KUROKAWA,Y AND HAYASHI,Y; TOXICITY AND CARCINOGENICITY STUDIES OF MUSK XYLOL IN B6C3F1 MOUSE; EISEI SHIKENSHO HOKOKU (108):89-94, 1990]"
4889,363900341,62329,CC1=C(C(=C(C(=C1[N+](=O)[O-])C(C)(C)C)[N+](=O)[O-])C)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.075; 0.15% IN DIET FOR 80 WK (STUDY DURATION: 80 WK),"LIVER: ADENOMA, CARCINOMA; HARDERIAN GLAND: ADENOMA",POSITIVE,"[MATSUSHIMA,Y, MAEKAWA,A, ONODERA,H, SHIBUTANI,M, YOSHIDA,J, KUROKAWA,Y AND HAYASHI,Y; TOXICITY AND CARCINOGENICITY STUDIES OF MUSK XYLOL IN B6C3F1 MOUSE; EISEI SHIKENSHO HOKOKU (108):89-94, 1990]"
4890,363900369,6321380,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N/N=C\3/C(=O)C4=C(C=C3S(=O)(=O)[O-])C=C(C=C4N)S(=O)(=O)[O-])OC)N/N=C\5/C(=O)C6=C(C=C5S(=O)(=O)[O-])C=C(C=C6N)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],Active,,,,RAT,F344/MALE,ORAL,0; 630; 1250; 2500 PPM IN DRINKING WATER FOR 22 MO (STUDY DURATION: 22 MO),"LARGE INTESTINE: ADENOMATOUS POLYP OR ADENOCARCINOMA; LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; ORAL CAVITY (TONGUE OR PHARYNX): SQUAMOUS PAPILLOMA, SQUAMOUS PAPILLOMA OR SQUAMOUS CELL CARCINOMA; PHARYNX: SQUAMOUS PAPILLOMA; PREPUTIAL GLAND: ADENOMA OR CARCINOMA; SKIN: BASAL CELL ADENOMA, BASAL CELL CARCINOMA, SEBACEOUS GLAND ADENOMA, SQUAMOUS PAPILLOMA, SQUAMOUS CARCINOMA; ZYMBAL GLAND: ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-397 Y92]"
4891,363900369,6321380,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N/N=C\3/C(=O)C4=C(C=C3S(=O)(=O)[O-])C=C(C=C4N)S(=O)(=O)[O-])OC)N/N=C\5/C(=O)C6=C(C=C5S(=O)(=O)[O-])C=C(C=C6N)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],Active,,,,RAT,F344/FEMALE,ORAL,0; 630; 1250; 2500 PPM IN DRINKING WATER FOR 22 MO (STUDY DURATION: 22 MO),"CLITORAL GLAND: ADENOMA, CARCINOMA; LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; ORAL CAVITY (TONGUE OR PHARYNX): SQUAMOUS PAPILLOMA: SQUAMOUS CELL CARCINOMA; PHARYNX: SQUAMOUS PAPILLOMA; SKIN: SQUAMOUS PAPILLOMA, SQUAMOUS PAPILLOMA OR SQUAMOUS CELL CARCINOMA; SMALL INTESTINE: ADENOCARCINOMA; TONGUE: SQUAMOUS PAPILLOMA OR SQUAMOUS CELL CARCINOMA; UTERUS: ADENOMA OR ADENOCARCINOMA; ZYMBAL'S GLAND: CARCINOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-397 Y92]"
4892,363900373,22960,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=C(C=C(C=C3)C4=CC(=C(C=C4)N=NC5=C(C=CC6=CC(=CC(=C65)S(=O)(=O)[O-])S(=O)(=O)[O-])O)C)C.[Na+].[Na+],Active,,,,RAT,F344/MALE,ORAL,0; 70; 150; 300 PPM IN DRINKING WATER 7 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; SKIN: BASAL CELL ADENOMA, BASAL CELL CARCINOMA, KERATOACANTHOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA, SEBACEOUS GLAND ADENOMA OR CARCINOMA; ZYMBAL'S GLAND: ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-405 Y91]"
4893,363900373,22960,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=C(C=C(C=C3)C4=CC(=C(C=C4)N=NC5=C(C=CC6=CC(=CC(=C65)S(=O)(=O)[O-])S(=O)(=O)[O-])O)C)C.[Na+].[Na+],Active,,,,RAT,F344/FEMALE,ORAL,0; 150; 300; 600 PPM IN DRINKING WATER 7 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"CLITORAL GLAND: ADENOMA OR CARCINOMA; LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; ORAL CAVITY (PHARYNX AND TONGUE): SQUAMOUS CELL PAPILLOMA OR CARCINOMA; SKIN: BASAL CELL ADENOMA OR CARCINOMA; ZYMBAL'S GLAND: ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-405 Y91]"
4894,363900377,135442941,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)S(=O)(=O)[O-])O.[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
4895,363900377,135442941,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)S(=O)(=O)[O-])O.[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
4896,363900378,135487615,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C4=CC=CC=C4C=C3)S(=O)(=O)[O-])O.[Na+],Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 128.1 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
4897,363900378,135487615,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C4=CC=CC=C4C=C3)S(=O)(=O)[O-])O.[Na+],Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 128.1 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
4898,363900383,50961,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C(C=CC(=C54)C=C3)[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 500; 1000 UG SUSPENDED IN BEESWAX/TRICAPRYLIN (1:1) ONCE (STUDY DURATION: LIFETIME),,NEGATIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, SANO,N, IZUMI,K AND TOKIWA,H; COMPARATIVE TUMORIGENICITY OF 1- AND 3-NITROBENZO[A]PYRENES, AND 3,6- AND 1,6-DINITROBENZO[A]PYRENES IN F344/DUCRJ RATS; TOXICOL. LETT. 98(1-2):51-58, 1998]"
4899,363900383,50961,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C(C=CC(=C54)C=C3)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",,NEGATIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
4900,363900384,44374,C1=CC=C2C(=C1)C3=C4C(=C2[N+](=O)[O-])C=CC5=CC=CC(=C54)C=C3,Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 14 UG TOTAL DOSE (2 UG/5 UL, 4 UG/10 UL, 8 UG/20 UL DMSO ON DAYS 1,8 AND 15); 70 UG TOTAL DOSE (10 UG/5 UL, 20 UG/10 UL, 40 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",,NEGATIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
4901,363900384,44374,C1=CC=C2C(=C1)C3=C4C(=C2[N+](=O)[O-])C=CC5=CC=CC(=C54)C=C3,Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 14 UG TOTAL DOSE (2 UG/5 UL, 4 UG/10 UL, 8 UG/20 UL DMSO ON DAYS 1,8 AND 15); 70 UG TOTAL DOSE (10 UG/5 UL, 20 UG/10 UL, 40 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)",,NEGATIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
4902,363900396,9916275,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN DIET FOR 106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[KONISHI,N, KITAHORI,Y, NISHIOKA,H, YANE,K AND HIASA,Y; CARCINOGENICITY TESTING OF FOOD RED NO. 106 (ACID RED) IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 5(2): 157-165, 1992]"
4903,363900396,9916275,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN DIET FOR 106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[KONISHI,N, KITAHORI,Y, NISHIOKA,H, YANE,K AND HIASA,Y; CARCINOGENICITY TESTING OF FOOD RED NO. 106 (ACID RED) IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 5(2): 157-165, 1992]"
4904,363900397,15531,C1=C(C=C(C(=C1Br)O)Br)C#N,Active,,,,Mouse,Crl:CD-1 (ICR)BR VAF/Plus/Male (60/sex/group),Oral,0; 20; 75; 300 ppm in feed for 78-80 wk,Liver: Hepatocellular adenoma and carcinoma combined (5/60; 16/60; 12/60; 23/60),Positive; Purity 94.4%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMOXYNIL OCTANOATE, BROMOXYNIL (AUGUST 11, 2005)]"
4905,363900397,15531,C1=C(C=C(C(=C1Br)O)Br)C#N,Active,,,,Mouse,Crl:CD-1 (ICR)BR VAF/Plus/Female (60/sex/group),Oral,0; 20; 75; 300 ppm in feed for 78-80 wk,"Liver: Hepatocellular adenoma and carcinoma combined (0 ppm, 2/60; 300 ppm, 7/59)",Positive at high dose only; Purity 94.4%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMOXYNIL OCTANOATE, BROMOXYNIL (AUGUST 11, 2005)]"
4906,363900409,12749,CC1=NC=CN1,Inactive,,,,RAT,F344/N/MALE,ORAL (DIET),0; 300; 1000; 3000 PPM FOR 106 WKS (STUDY DURATION: 106 WKS),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2-METHYLIMIDAZOLE (CAS NO. 693-98-1) IN F344/N  RATS AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 516:1-292, 2004][CHAN,PC, SILLS, RC, KISSLING,GE, NYSKA,A, RICHTER, W; INDUCTION OF THYROID AND LIVER TUMORS BY CHRONIC EXPOSURE TO 2-METHYLIMIDAZOLE IN F344/N RATS AND B6C3F1 MICE. ARCH. TOXICOL. 82(6): 399-412, 2008]"
4907,363900409,12749,CC1=NC=CN1,Active,,,,RAT,F344/N/FEMALE,ORAL (DIET),0; 1000; 2500; 5000 PPM FOR 106 WKS (STUDY DURATION: 106 WKS),THYROID: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2-METHYLIMIDAZOLE (CAS NO. 693-98-1) IN F344/N  RATS AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 516:1-292, 2004][CHAN,PC, SILLS, RC, KISSLING,GE, NYSKA,A, RICHTER, W; INDUCTION OF THYROID AND LIVER TUMORS BY CHRONIC EXPOSURE TO 2-METHYLIMIDAZOLE IN F344/N RATS AND B6C3F1 MICE. ARCH. TOXICOL. 82(6): 399-412, 2008]"
4908,363900409,12749,CC1=NC=CN1,Active,,,,MOUSE,B6C3F1/MALE,ORAL (DIET),0; 625; 1250; 2500 PPM FOR 105 WKS (STUDY DURATION: 105 WKS),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; THYROID: FOLLICULAR CELL ADENOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2-METHYLIMIDAZOLE (CAS NO. 693-98-1) IN F344/N  RATS AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 516:1-292, 2004][CHAN,PC, SILLS, RC, KISSLING,GE, NYSKA,A, RICHTER, W; INDUCTION OF THYROID AND LIVER TUMORS BY CHRONIC EXPOSURE TO 2-METHYLIMIDAZOLE IN F344/N RATS AND B6C3F1 MICE. ARCH. TOXICOL. 82(6): 399-412, 2008]"
4909,363900409,12749,CC1=NC=CN1,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL (DIET),0; 625; 1250; 2500 PPM FOR 105 WKS (STUDY DURATION: 105 WKS),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2-METHYLIMIDAZOLE (CAS NO. 693-98-1) IN F344/N  RATS AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 516:1-292, 2004][CHAN,PC, SILLS, RC, KISSLING,GE, NYSKA,A, RICHTER, W; INDUCTION OF THYROID AND LIVER TUMORS BY CHRONIC EXPOSURE TO 2-METHYLIMIDAZOLE IN F344/N RATS AND B6C3F1 MICE. ARCH. TOXICOL. 82(6): 399-412, 2008]"
4910,363900411,23662383,CCCCC(CC)COS(=O)(=O)[O-].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),,NEGATIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
4911,363900411,23662383,CCCCC(CC)COS(=O)(=O)[O-].[Na+],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),"LIVER: CARCINOMA, CARCINOMA OR ADENOMA",POSITIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
4912,363900411,23662383,CCCCC(CC)COS(=O)(=O)[O-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),,NEGATIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
4913,363900411,23662383,CCCCC(CC)COS(=O)(=O)[O-].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 102-104 WK (STUDY DURATION: 102-104 WK),,NEGATIVE,"[KLUWE,WM, HUFF,JE, MATTHEWS,HB, IRWIN,R AND HASEMAN,JK; COMPARATIVE CHRONIC TOXICITIES AND CARCINOGENIC POTENTIALS OF 2-ETHYLHEXYL- CONTAINING COMPOUNDS IN RATS AND MICE; CARCINOGENESIS 6(11):1577-1583, 1985]"
4914,363900412,7184,CCCCOC(=O)C1=CC=C(C=C1)O,Inactive,,,,MOUSE,ICR/MALE,ORAL,0; O.15; 0.3; 0.6% IN DIET FOR 102 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[INAI,K, AOKI,Y, AKAMIZU,H, ETO,R, NISHIDA,T AND TOKUOKA,S; TUMORIGENICITY STUDY OF BUTYL AND ISOBUTYL P-HYDOXYBENZOATES ADMINISTERED ORALLY TO MICE; FOOD CHEM. TOXICOL. 23(6):575-578, 1985]"
4915,363900412,7184,CCCCOC(=O)C1=CC=C(C=C1)O,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 0.15; 0.3; 0.6% IN DIET FOR 102 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[INAI,K, AOKI,Y, AKAMIZU,H, ETO,R, NISHIDA,T AND TOKUOKA,S; TUMORIGENICITY STUDY OF BUTYL AND ISOBUTYL P-HYDOXYBENZOATES ADMINISTERED ORALLY TO MICE; FOOD CHEM. TOXICOL. 23(6):575-578, 1985]"
4916,363900413,20240,CC(C)COC(=O)C1=CC=C(C=C1)O,Inactive,,,,MOUSE,ICR/MALE,ORAL,0; 0.15; 0.3; 0.6% IN DIET FOR 102 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[INAI,K, AOKI,Y, AKAMIZU,H, ETO,R, NISHIDA,T AND TOKUOKA,S; TUMORIGENICITY STUDY OF BUTYL AND ISOBUTYL P-HYDOXYBENZOATES ADMINISTERED ORALLY TO MICE; FOOD CHEM. TOXICOL. 23(6):575-578, 1985]"
4917,363900413,20240,CC(C)COC(=O)C1=CC=C(C=C1)O,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 0.15; 0.3; 0.6% IN DIET FOR 102 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[INAI,K, AOKI,Y, AKAMIZU,H, ETO,R, NISHIDA,T AND TOKUOKA,S; TUMORIGENICITY STUDY OF BUTYL AND ISOBUTYL P-HYDOXYBENZOATES ADMINISTERED ORALLY TO MICE; FOOD CHEM. TOXICOL. 23(6):575-578, 1985]"
4918,363900414,11057,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 100; 300; 600 PPM IN DIET FOR 104 WK (STUDY DURATION: 2 YR),LIVER: MALIGNANT NEOPLASM; HARDERIAN GLAND: ADENOMA,POSITIVE,"[LITTLEFIELD,NA, BLACKWELL,B, HEWITT,CC AND GAYLOR,DW; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF GENTIAN VIOLET IN MICE; FUNDAM. APPL. TOXICOL. 5:902-912, 1985]"
4919,363900414,11057,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 100; 300; 600 PPM IN DIET FOR 104 WK (STUDY DURATION: 2 YR),LIVER: MALIGNANT NEOPLASM; HARDERIAN GLAND: ADENOMA; UTERUS: TYPE-A RETICULUM CELL SARCOMA; OVARIES: TYPE-A RETICULUM CELL SARCOMA; VAGINA: TYPE-A RETICULUM CELL SARCOMA; URINARY BLADDER: TYPE-A RETICULUM CELL SARCOMA,POSITIVE,"[LITTLEFIELD,NA, BLACKWELL,B, HEWITT,CC AND GAYLOR,DW; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF GENTIAN VIOLET IN MICE; FUNDAM. APPL. TOXICOL. 5:902-912, 1985]"
4920,363900414,11057,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],Active,,,,RAT,F344/MALE,ORAL,0; 100; 300; 600 PPM IN FEED FOR 24 MO (STUDY DURATION: 24 MO),LIVER: HEPATOCELLULAR ADENOMA; THYROID GLAND: FOLLICULAR CELL ADENOCARCINOMA,POSITIVE,"[LITTLEFIELD,NA, GAYLOR,DW, BLACKWELL,BN AND ALLEN,RR; CHRONIC TOXICITY/ CARCINOGENICITY STUDIES OF GENTIAN VIOLET IN FISCHER 344 RATS: TWO-GENERATION EXPOSURE; FOOD CHEM. TOXICOL. 27(4):239-247, 1989]"
4921,363900414,11057,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],Active,,,,RAT,F344/FEMALE,ORAL,0; 100; 300; 600 PPM IN FEED FOR 24 MO (STUDY DURATION: 24 MO),LIVER: HEPATOCELLULAR ADENOMA; THYROID GLAND: FOLLICULAR CELL ADENOCARCINOMA,POSITIVE,"[LITTLEFIELD,NA, GAYLOR,DW, BLACKWELL,BN AND ALLEN,RR; CHRONIC TOXICITY/ CARCINOGENICITY STUDIES OF GENTIAN VIOLET IN FISCHER 344 RATS: TWO-GENERATION EXPOSURE; FOOD CHEM. TOXICOL. 27(4):239-247, 1989]"
4922,363900415,9181,C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4N=C32,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.1; 0.3; 1.0 MG IN BEESWAX/TRICAPRYLIN (STUDY DURATION: LIFETIME),,NEGATIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H AND GRIMMER,G; EXPERIMENTAL STUDIES ON THE CARCINOGENICITY OF FIVE NITROGEN CONTAINING POLYCYCLIC AROMATIC COMPOUNDS DIRECTLY INJECTED INTO RAT LUNGS; CANCER LETT. 20:97-101, 1983]"
4923,363900415,9181,C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4N=C32,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
4924,363900415,9181,C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4N=C32,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA; LIVER: NEOPLASTIC NODULE,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
4925,363900416,9180,C1=CC=C2C(=C1)C=CC3=NC4=CC=CC=C4C=C32,Inactive,,,,RAT,OSBORNE-MENDEL/FEMALE,LUNG IMPLANT,0; 0.2; 1.0; 5.0 MG IN BEESWAX/TRICAPRYLIN (STUDY DURATION: LIFETIME),,NEGATIVE,"[DEUTSCH-WENZEL,RP, BRUNE,H AND GRIMMER,G; EXPERIMENTAL STUDIES ON THE CARCINOGENICITY OF FIVE NITROGEN CONTAINING POLYCYCLIC AROMATIC COMPOUNDS DIRECTLY INJECTED INTO RAT LUNGS; CANCER LETT. 20:97-101, 1983]"
4926,363900417,79373,CNC1=CC=C(C=C1)N.Cl.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.15 UMOL/G ONCE IN SODIUM ACETATE BUFFER (STUDY DURATION: 10 MO),,NEGATIVE,"[DELCLOS,KB, TARPLEY,WG, MILLER,EC AND MILLER,JA; 4-AMINOAZOBENZENE AND N,N-DIMETHYL-4-AMINOAZOBENZENE AS EQUIPOTENT HEPATIC CARCINOGENS IN MALE C57BL/6 X C3H/HEF1 MICE AND CHARACTERIZATION OF N-(DEOXYGUANOSIN-8-YL)-4- AMINOAZOBENZENE AS THE MAJOR PERSISTENT HEPATIC DNA-BOUND DYE IN THESE MICE; CANCER RES. 44:2540-2550, 1984]"
4927,363900419,4125253,C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(C=O)O)O)O)O)O)O)O)O)O)O)O,Inactive,,,,RAT,ACI/MALE,ORAL,0; 2.5% (MOL. WT. 21500) IN DIET FOR 480 D (STUDY DURATION: 480 D),,NEGATIVE,"[HIRONO,I, KUHARA,K, YAMAJI,T, HOSAKA,S AND GOLBERG,L; CARCINOGENICITY OF DEXTRAN SULFATE SODIUM IN RELATION TO ITS MOLECULAR WEIGHT; CANCER LETT. 18:29-34, 1983]"
4928,363900419,4125253,C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(C=O)O)O)O)O)O)O)O)O)O)O)O,Inactive,,,,RAT,ACI/FEMALE,ORAL,0; 2.5% (MOL. WT. 21500) IN DIET FOR 480 D (STUDY DURATION: 480 D),,NEGATIVE,"[HIRONO,I, KUHARA,K, YAMAJI,T, HOSAKA,S AND GOLBERG,L; CARCINOGENICITY OF DEXTRAN SULFATE SODIUM IN RELATION TO ITS MOLECULAR WEIGHT; CANCER LETT. 18:29-34, 1983]"
4929,363900420,72466,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.OS(=O)(=O)[O-],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 0.35; 0.70; 1.40; 2.8 MG/KG IN SALINE 1/WK FOR 10 WK THEN 1/2 WK FOR 52 WK OR FOR LIFETIME (STUDY DURATION: 650 D),KIDNEY: MALIGNANT OR BENIGN TUMOR; INJECTION SITE: MALIGNANT TUMOR,POSITIVE,"[HABS,M AND SCHMAHL,D; CARCINOGENICITY OF BLEOMYCIN SULFATE AND PEPLOMYCIN SULFATE AFTER REPEATED SUBCUTANEOUS APPLICATION TO RATS; ONCOLOGY 41:114-119, 1984]"
4930,363900420,72466,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.OS(=O)(=O)[O-],Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.35; 0.7; 1.40; 2.8 MG/KG IN SALINE 1/WK FOR 10 WK THEN 1/2 WK FOR 52 WK OR FOR LIFETIME (STUDY DURATION: 650 D),KIDNEY: MALIGNANT OR BENIGN TUMOR; INJECTION SITE: MALIGNANT TUMOR,POSITIVE,"[HABS,M AND SCHMAHL,D; CARCINOGENICITY OF BLEOMYCIN SULFATE AND PEPLOMYCIN SULFATE AFTER REPEATED SUBCUTANEOUS APPLICATION TO RATS; ONCOLOGY 41:114-119, 1984]"
4931,363900421,6321297,CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCN[C@@H](C)C7=CC=CC=C7)O.OS(=O)(=O)O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,"0; 0.32; 0.63; 1.25; 2.50; 5.0 MG/KG IN SALINE 1/WK FOR 10 WK THEN 1/2 WK FOR 12 WK, 19 WK OR LIFETIME (STUDY DURATION: 650 D)",KIDNEY: MALIGNANT OR BENIGN TUMOR; INJECTION SITE: MALIGNANT TUMOR,POSITIVE,"[HABS,M AND SCHMAHL,D; CARCINOGENICITY OF BLEOMYCIN SULFATE AND PEPLOMYCIN SULFATE AFTER REPEATED SUBCUTANEOUS APPLICATION TO RATS; ONCOLOGY 41:114-119, 1984]"
4932,363900421,6321297,CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCN[C@@H](C)C7=CC=CC=C7)O.OS(=O)(=O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,"0; 0.32; 0.63; 1.25; 2.50; 5.0 MG/KG IN SALINE 1/WK FOR 10 WK THEN 1/2 WK FOR 12 WK, 19 WK OR LIFETIME (STUDY DURATION: 650 D)",KIDNEY: MALIGNANT OR BENIGN TUMOR; INJECTION SITE: MALIGNANT TUMOR,POSITIVE,"[HABS,M AND SCHMAHL,D; CARCINOGENICITY OF BLEOMYCIN SULFATE AND PEPLOMYCIN SULFATE AFTER REPEATED SUBCUTANEOUS APPLICATION TO RATS; ONCOLOGY 41:114-119, 1984]"
4933,363900422,149027,CN=NNC1=C(C=C(C=C1Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,0; 0.1 NMOL/KG (25.3 MG/KG) IN CREMOPHOR EL/ETHANOL/WATER 1/2 WK FOR A TOTAL OF 20 INJECTIONS (506 MG/KG) (STUDY DURATION: LIFETIME),,NEGATIVE,"[KOLAR,GF AND HABS,M; COMPARATIVE METABOLISM AND CARCINOGENICITY OF RING-HALOGENATED 3,3-DIMETHYL-1-PHENYLTRIAZENES;J. CANCER RES. CLIN. ONCOL. 108:71-75, 1984]"
4934,363900423,99637,CN(C)N=NC1=C(C=C(C=C1Br)Br)Br,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAVENOUS,0; 0.1 NMOL/KG (38.6 MG/KG) IN CREMOPHOR EL/ETHANOL/WATER 1/2 WK FOR A TOTAL OF 20 INJECTIONS (772 MG/KG) (STUDY DURATION: LIFETIME),,NEGATIVE,"[KOLAR,GF AND HABS,M; COMPARATIVE METABOLISM AND CARCINOGENICITY OF RING-HALOGENATED 3,3-DIMETHYL-1-PHENYLTRIAZENES;J. CANCER RES. CLIN. ONCOL. 108:71-75, 1984]"
4935,363900424,126355,C1CC(=O)C2=C1C3=C4C(=C2)CC5=CC=CC(=C54)C=C3,Active,,,,MOUSE,"T.O./MALE, FEMALE",DERMAL,0; 50 UG IN TOLUENE SOLUTION 2 D/WK FOR 39 OR 50 WK (STUDY DURATION: 2 YR),SKIN: PAPILLOMA OR CARCINOMA,POSITIVE,"[HADFIELD,ST, BHATT,TS AND COOMBS,MM; THE BIOLOGICAL ACTIVITY AND ACTIVATION OF 15,16-DIHYDRO-1,11-METHANOCYCLOPENTA[A]PHENANTHREN-17-ONE, A CARCINOGEN WITH AN OBSTRUCTED BAY REGION; CARCINOGENESIS 5(11): 1485-1491, 1984]"
4936,363900425,24261,O=[Si]=O,Active,,,,RAT,"INBRED-W/MALE, FEMALE",INTRAPERITONEAL,"20 MG ALKALINE-WASHED MIN-U-SIL CRYSTALS (A COMMERCIAL FINE QUARTZ, 99% PURE) IN 0.4 ML SALINE AUTOCLAVED SUSPENSION (STUDY DURATION: 120 WK)","HEMATOPOIETIC SYSTEM: THYMOMA OR LYMPHOSARCOMA, LYMPHOMA",POSITIVE,"[WAGNER,MMF; PATHOGENESIS OF MALIGNANT HISTIOCYTIC LYMPHOMA INDUCED BY SILICA IN A COLONY OF SPECIFIC-PATHOGEN-FREE WISTAR RATS; J. NATL. CANCER INST. 57(3):509-518, 1976]"
4937,363900425,24261,O=[Si]=O,Active,,,,RAT,"INBRED-W/MALE, FEMALE",INTRAPLEURAL,"20 MG ALKALINE-WASHED MIN-U-SIL CRYSTALS (A COMMERCIAL FINE QUARTZ, 99% PURE) IN 0.4 ML SALINE AUTOCLAVED SUSPENSION INTO RIGHT AXILLA (STUDY DURATION: 120 WK)",HEMATOPOIETIC SYSTEM: LYMPHOMA,POSITIVE,"[WAGNER,MMF; PATHOGENESIS OF MALIGNANT HISTIOCYTIC LYMPHOMA INDUCED BY SILICA IN A COLONY OF SPECIFIC-PATHOGEN-FREE WISTAR RATS; J. NATL. CANCER INST. 57(3):509-518, 1976]"
4938,363900425,24261,O=[Si]=O,Active,,,,RAT,"INBRED-W/MALE, FEMALE",INTRAPLEURAL,20 MG ALKALINE-WASHED CRYSTALS (CRISTABOLITE FROM QUARTZ EXPOSED TO HIGH TEMPERATURE) IN A 0.4 ML SALINE AUTOCLAVED SUSPENSION INTO RIGHT AXILLA (STUDY DURATION: 120 WK),"HEMATOPOIETIC SYSTEM: MALIGNANT HISTIOCYTIC LYMPHOMA, THYMOMA OR LYMPHOSARCOMA, LYMPHOMA",POSITIVE,"[WAGNER,MMF; PATHOGENESIS OF MALIGNANT HISTIOCYTIC LYMPHOMA INDUCED BY SILICA IN A COLONY OF SPECIFIC-PATHOGEN-FREE WISTAR RATS; J. NATL. CANCER INST. 57(3):509-518, 1976]"
4939,363900425,24261,O=[Si]=O,Active,,,,RAT,"INBRED-W/MALE, FEMALE",INTRAPLEURAL,20 MG ALKALINE-WASHED CRYSTALS <5 UM IN SIZE IN A 0.4 ML SALINE AUTOCLAVED SUSPENSION INTO RIGHT AXILLA (STUDY DURATION: 120 WK),"HEMATOPOIETIC SYSTEM: MALIGNANT HISTIOCYTIC LYMPHOMA, MALIGNANT TUMOR",POSITIVE,"[WAGNER,MMF; PATHOGENESIS OF MALIGNANT HISTIOCYTIC LYMPHOMA INDUCED BY SILICA IN A COLONY OF SPECIFIC-PATHOGEN-FREE WISTAR RATS; J. NATL. CANCER INST. 57(3):509-518, 1976]"
4940,363900426,9571066,C1=CC=C2C(=C1)/C(=N/O)/C=CN2O.Cl,Active,,,,RAT,BUFFALO/FEMALE,GAVAGE,1 MG/0.1 ML OR 2 MG/0.2 ML IN 60% ETHANOL SOLUTION 1/3 WK (TOTAL DOSE: 30 MG) (STUDY DURATION: 610 D),GLANDULAR STOMACH: MUCOSAL CARCINOMA; MAMMARY GLAND: TUMOR; THYMUS GLAND: THYMOMA,POSITIVE,"[MORI,K, OHTA,A, MURAKAMI,T, TAMURA,M, KONDO,M AND ICHIMURA,H; CARCINOMAS OF THE GLANDULAR STOMACH AND OTHER ORGANS OF RATS BY 4-HYDROXYAMINOQUINOLINE 1-OXIDE HYDROCHLORIDE; GANN 60:627-630, 1969]"
4941,363900426,9571066,C1=CC=C2C(=C1)/C(=N/O)/C=CN2O.Cl,Active,,,,MOUSE,DDD/FEMALE,SUBCUTANEOUS,53 NMOL IN 0.1 ML OLIVE OIL WITHIN 24 HR AFTER BIRTH (STUDY DURATION: 400 D),LUNG: ADENOMA; INJECTION SITE: SARCOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA OR LYMPHOSARCOMA,POSITIVE,"[SATO,K, SAITO,T AND ENOMOTO,M; DEVELPOMENT OF SARCOMAS IN MICE AT SITE OF INJECTION WITH A NEW CARCINOGEN, MONOACETYL DERIVATIVE OF 4-HYDROXYAMINOQUINOLINE; JAPAN. J. EXP. MED. 40(6):475-478, 1970]"
4942,363900427,146310,C1=NC2=C(N1[O-])C(=O)NC(=O)[NH2+]2,Active,,,,RAT,WISTAR OR SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 1.0 MG HOMOGENIZED IN 0.5% CARBOXYMETHYLCELLULOSE IN 0.85% SALINE SOLUTION 3/WK FOR 8 WK (STUDY DURATION: 18 MO),LIVER: CARCINOMA OR ADENOMA; INJECTION SITE: FIBROMA OR LIPOMA,POSITIVE,"[TELLER,MN, BUDINGER,JM, ZVILICHOVSKY,G, WATSON,AA, MCDONALD,JJ, STOHRER,G AND BROWN,GBB; COMPARISON OF THE ONCOGENICITIES OF FOUR STRUCTURALLY ISOMERIC N-HYDROXYXANTHINES; CANCER RES. 38:2038-2042, 1978]"
4943,363900427,146310,C1=NC2=C(N1[O-])C(=O)NC(=O)[NH2+]2,Active,,,,RAT,WISTAR OR SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 0.1; 1.0 MG HOMOGENIZED IN 0.85% SALINE SOLUTION 3/WK FOR 8 WK (STUDY DURATION: 18 MO),LIVER: CARCINOMA,POSITIVE,"[TELLER,MN, BUDINGER,JM, ZVILICHOVSKY,G, WATSON,AA, MCDONALD,JJ, STOHRER,G AND BROWN,GBB; COMPARISON OF THE ONCOGENICITIES OF FOUR STRUCTURALLY ISOMERIC N-HYDROXYXANTHINES; CANCER RES. 38:2038-2042, 1978]"
4944,363900428,9323,CN[NH3+].OS(=O)(=O)[O-],Active,,,,MOUSE,SWISS/MALE,ORAL,0.001% SOLUTION IN DRINKING WATER FOR LIFE (DAILY INTAKE: 0.102 MG) (STUDY DURATION: LIFETIME),"LUNG: ADENOMA, ADENOCARCINOMA; HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA",POSITIVE,"[TOTH,B; HYDRAZINE, METHYLHYDRAZINE AND METHYLHYDRAZINE SULFATE CARCINOGENESIS IN SWISS MICE. FAILURE OF AMMONIUM HYDROXIDE TO INTERFERE IN THE DEVELOPMENT OF TUMORS; INT. J. CANCER 9:109-118, 1972]"
4945,363900428,9323,CN[NH3+].OS(=O)(=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,ORAL,0.001% SOLUTION IN DRINKING WATER FOR LIFE (DAILY INTAKE: 0.078 MG) (STUDY DURATION: LIFETIME),"LUNG: ADENOMA, ADENOCARCINOMA; HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA; MAMMARY GLAND: ADENOCARCINOMA",POSITIVE,"[TOTH,B; HYDRAZINE, METHYLHYDRAZINE AND METHYLHYDRAZINE SULFATE CARCINOGENESIS IN SWISS MICE. FAILURE OF AMMONIUM HYDROXIDE TO INTERFERE IN THE DEVELOPMENT OF TUMORS; INT. J. CANCER 9:109-118, 1972]"
4946,363900429,18761,CC1=C2C=CC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0.2 UMOL IN 33.4 UL ACETONE TO SHAVED DORSAL SKIN 2/WK FOR 20 WK (STUDY DURATION: 52 WK),"SKIN: PAPILLOMA, KERATOACANTHOMA, EPIDERMAL CARCINOMA",POSITIVE,"[CAVALIERI,E, ROTH,R, ALTHOFF,J, GRANDJEAN,C, PATIL,K, MAR,S AND MCLAUGHIN,D; CARCINOGENICITY AND METABOLIC PROFILES OF 3-METHYLCHOLANTHRENE OXYGENATED DERIVATIVE AT THE 1 AND 2 POSITIONS; CHEM. BIOL. INTERACT. 22:69-81, 1978]"
4947,363900431,637563,C/C=C/C1=CC=C(C=C1)OC,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.25; 0.5; 1.0% IN DIET FOR 117 WK (STUDY DURATION: 121 WK),,NEGATIVE,"[TRUHAUT,R, LE BOURHIS,B, ATTIA,M, GLOMOT,R, NEWMAN,J AND CALDWELL,J; CHRONIC TOXICITY/CARCINOGENICITY STUDY OF TRANS-ANETHOLE IN RATS; FOOD CHEM. TOXICOL. 27(1):11-20, 1989][NEWBERNE,PM, CARLTON,WW AND BROWN,WR; HISTOPATHOLOGICAL EVALUATION OF PROLIFERATIVE LIVER LESIONS IN RATS FED TRANS-ANETHOLE IN CHRONIC STUDIES; FOOD CHEM. TOXICOL. 27(1):21-26, 1989]"
4948,363900431,637563,C/C=C/C1=CC=C(C=C1)OC,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.25; 0.5; 1% IN DIET FOR 117 WK (STUDY DURATION: 121 WK),LIVER: HEPTOCELLULAR CARCINOMA,POSITIVE,"[TRUHAUT,R, LE BOURHIS,B, ATTIA,M, GLOMOT,R, NEWMAN,J AND CALDWELL,J; CHRONIC TOXICITY/CARCINOGENICITY STUDY OF TRANS-ANETHOLE IN RATS; FOOD CHEM. TOXICOL. 27(1):11-20, 1989][NEWBERNE,PM, CARLTON,WW AND BROWN,WR; HISTOPATHOLOGICAL EVALUATION OF PROLIFERATIVE LIVER LESIONS IN RATS FED TRANS-ANETHOLE IN CHRONIC STUDIES; FOOD CHEM. TOXICOL. 27(1):21-26, 1989]"
4949,363900431,637563,C/C=C/C1=CC=C(C=C1)OC,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,"0; 5 UMOL 1X/WK FOR 3 WK BEGINNING 24 HR POST FIRST TPA DOSE (2.5 UG IN 0.1 ML ACETONE), FOLLOWED BY 2.5 UG TPA IN 0.1 ML ACETONE 2X/WK FOR 20 WK (STUDY DURATION: 20 WK)",SKIN: PAPILLOMA,NEGATIVE,"[KIM,SG, LIEM,A, STEWART,BC AND MILLER,JA; NEW STUDIES ON TRANS-ANETHOLE OXIDE AND TRANS-ASARONE OXIDE; CARCINOGENESIS 20(7):1303-1307, 1999]"
4950,363900431,637563,C/C=C/C1=CC=C(C=C1)OC,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.5 UMOL/G BW ONCE (STUDY DURATION: 10-11 MONTHS),,NEGATIVE,"[KIM,SG, LIEM,A, STEWART,BC AND MILLER,JA; NEW STUDIES ON TRANS-ANETHOLE OXIDE AND TRANS-ASARONE OXIDE; CARCINOGENESIS 20(7):1303-1307, 1999]"
4951,363900432,8083,C1COCCN1,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 10; 50; 150 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[HARBISON,RD, MARINO,DJ, CONAWAY,CC, RUBIN,LF AND GANDY J; CHRONIC MORPHOLINE EXPOSURE OF RATS; FUNDAM. APPL. TOXICOL. 12(3):491-507, 1989]"
4952,363900432,8083,C1COCCN1,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 10; 50; 150 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[HARBISON,RD, MARINO,DJ, CONAWAY,CC, RUBIN,LF AND GANDY J; CHRONIC MORPHOLINE EXPOSURE OF RATS; FUNDAM. APPL. TOXICOL. 12(3):491-507, 1989]"
4953,363900445,,,Inactive,,,,Rat,Sprague-Dawley CD/Male (50/Group),Oral,0; 25; 100; 400 ppm of 88.2-88.5% mancozeb in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANCOZEB (February 10, 2000)]"
4954,363900445,,,Inactive,,,,Rat,Sprague-Dawley CD/Female (50/Group),Oral,0; 25; 100; 400 ppm of 88.2-88.5% mancozeb in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANCOZEB (February 10, 2000)]"
4955,363900445,,,Inactive,,,,Mouse,CD-1/Male (94/Group),Oral,0; 30; 100; 1000 ppm of 77-82.2% mancozeb in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANCOZEB (February 10, 2000)]"
4956,363900445,,,Inactive,,,,Mouse,CD-1/Female (94/Group),Oral,0; 30; 100; 1000 ppm of 77-82.2% mancozeb in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANCOZEB (February 10, 2000)]"
4957,363900445,,,Inactive,,,,Mouse,CD-1/Male (50/Group),Oral,0; 100; 1000; 7000 ppm of 88.6% mancozeb in diet for 78 wk (7000 ppm group terminated and 25 ppm group added at wk 60); study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANCOZEB (February 10, 2000)]"
4958,363900445,,,Inactive,,,,Mouse,CD-1/Female (50/Group),Oral,0; 100; 1000; 7000 ppm of 88.6% mancozeb in diet for 78 wk (7000 ppm group terminated and 25 ppm group added at wk 60); study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANCOZEB (February 10, 2000)]"
4959,363900445,,,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 100 MG/KG IN 0.1 ML DMSO 3/WK (STUDY DURATION: 60 WK),SKIN: BENIGN TUMOR,POSITIVE,"[SHUKLA,Y, ANTONY,M, KUMAR,S AND MEHROTRA,NK; CARCINOGENIC ACTIVITY OF A CARBAMATE FUNGICIDE, MANCOZEB, ON MOUSE SKIN; CANCER LETT. 53(2-3):191-195, 1990]"
4960,363900445,,,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 100 MG/KG BW IN 100 UL DMSO 3/WK FOR 60 WK (STUDY DURATION: 60 WK),SKIN: PAPILLOMA OR KERATOACANTHOMA,POSITIVE,"[MEHROTA,NK, SHUKIA,Y, KUMAR,S AND ANWER,J; CARCINOGENIC, COCARCINOGENIC AND TERATOGENIC ACTIVITY OF A CARBAMATE FUNGICIDE MANCOZEB; ENVIRON. MUTAGEN. CARCINOG. (PROC. SYMP.) 2:52-63, 1996]"
4961,363900450,5284484,C(CNC(=S)[S-])NC(=S)[S-].[Zn+2],Inactive,,,,RAT,CD/MALE,ORAL,0; 5; 20; 80; 320 PPM IN DIET FOR 119 WK (STUDY DURATION: 119 WK),,NEGATIVE,"[CHARLES,JM TOBIA,A AND VAN RAVENZWAAY,B; SUBCHRONIC AND CHRONIC TOXICOLOGICAL INVESTIGATIONS ON METIRAM: THE LACK OF A CARCINOGENIC RESPONSE IN RODENTS; TOXICOL. SCI. 54(2):481-492, 2000]"
4962,363900450,5284484,C(CNC(=S)[S-])NC(=S)[S-].[Zn+2],Inactive,,,,RAT,CD/FEMALE,ORAL,0; 5; 20; 80; 320 PPM IN DIET FOR 112 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[CHARLES,JM TOBIA,A AND VAN RAVENZWAAY,B; SUBCHRONIC AND CHRONIC TOXICOLOGICAL INVESTIGATIONS ON METIRAM: THE LACK OF A CARCINOGENIC RESPONSE IN RODENTS; TOXICOL. SCI. 54(2):481-492, 2000]"
4963,363900450,5284484,C(CNC(=S)[S-])NC(=S)[S-].[Zn+2],Inactive,,,,MOUSE,CD/MALE,ORAL,0; 100; 300; 1000 PPM IN DIET FOR 95 WK (STUDY DURATION: 96 WK),,NEGATIVE,"[CHARLES,JM TOBIA,A AND VAN RAVENZWAAY,B; SUBCHRONIC AND CHRONIC TOXICOLOGICAL INVESTIGATIONS ON METIRAM: THE LACK OF A CARCINOGENIC RESPONSE IN RODENTS; TOXICOL. SCI. 54(2):481-492, 2000]"
4964,363900450,5284484,C(CNC(=S)[S-])NC(=S)[S-].[Zn+2],Inactive,,,,MOUSE,CD/FEMALE,ORAL,0; 100; 300 PPM IN DIET FOR 89 WK (STUDY DURATION: 94 WK),,NEGATIVE,"[CHARLES,JM TOBIA,A AND VAN RAVENZWAAY,B; SUBCHRONIC AND CHRONIC TOXICOLOGICAL INVESTIGATIONS ON METIRAM: THE LACK OF A CARCINOGENIC RESPONSE IN RODENTS; TOXICOL. SCI. 54(2):481-492, 2000]"
4965,363900450,5284484,C(CNC(=S)[S-])NC(=S)[S-].[Zn+2],Inactive,,,,MOUSE,CD/FEMALE,ORAL,0; 1000 PPM IN DIET FOR 88 WK (STUDY DURATION: 88 WK),,NEGATIVE,"[CHARLES,JM TOBIA,A AND VAN RAVENZWAAY,B; SUBCHRONIC AND CHRONIC TOXICOLOGICAL INVESTIGATIONS ON METIRAM: THE LACK OF A CARCINOGENIC RESPONSE IN RODENTS; TOXICOL. SCI. 54(2):481-492, 2000]"
4966,363900454,6332,CCBr,Active,,,,RAT,F344/MALE,INHALATION,0; 100; 200; 400 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 106 WK),"ADRENAL MEDULLA: PHEOCHROMOCYTOMA, PHEOCHROMOCYTOMA OR MALIGNANT PHEOCHROMOCYTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-363 Y89]"
4967,363900454,6332,CCBr,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 100; 200; 400 PPM 6 HR/D 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),"UTERUS: ADENOMA, ADENOCARCINOMA, ADENOMA OR ADENOCARCINOMA, ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-363 Y89]"
4968,363900454,6332,CCBr,Unspecified,,,,RAT,F344/FEMALE,INHALATION,0; 100; 200; 400 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 106 WK),BRAIN: GLIOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-363 Y89]"
4969,363900454,6332,CCBr,Unspecified,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 100; 200; 400 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 106 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-363 Y89]"
4970,363900467,23683938,C([C@H]([C@@H]1C(=C(C(=O)O1)O)[O-])O)O.[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1.25; 2.5% IN DRINKING WATER FOR 96 WK (STUDY DURATION: 110 WK),,NEGATIVE,"[INAI,K, AKAMIZU,H, ETO,R, NISHIDA,T, OHE,K, KOBUKE,T, NAMBU,S, MATSUKI,K AND TOKUOKA,S; TUMORIGENICITY STUDY OF SODIUM ERYTHROBATE ADMINISTERED ORALLY TO MICE; HIROSHIMA J. MED. SCI. 38(3):135-139, 1989]"
4971,363900467,23683938,C([C@H]([C@@H]1C(=C(C(=O)O1)O)[O-])O)O.[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2.5; 5% IN DRINKING WATER FOR 96 WK (STUDY DURATION: 110 WK),,NEGATIVE,"[INAI,K, AKAMIZU,H, ETO,R, NISHIDA,T, OHE,K, KOBUKE,T, NAMBU,S, MATSUKI,K AND TOKUOKA,S; TUMORIGENICITY STUDY OF SODIUM ERYTHROBATE ADMINISTERED ORALLY TO MICE; HIROSHIMA J. MED. SCI. 38(3):135-139, 1989]"
4972,363900467,23683938,C([C@H]([C@@H]1C(=C(C(=O)O1)O)[O-])O)O.[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 1.25%; 2.5% IN TAP DRINKING WATER FOR 104 WK (STUDY DURATION: LIFESPAN),,NEGATIVE,"[ABE,I, SAITO,S, HORI,K, SUZUKI,M AND SATO,H; SODIUM ERYTHORBATE IS NOT CARCINOGENIC IN F344 RATS; EXP. MOL. PATHOL. 41(1):35-43, 1984]"
4973,363900467,23683938,C([C@H]([C@@H]1C(=C(C(=O)O1)O)[O-])O)O.[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1.25%; 2.5% IN TAP DRINKING WATER FOR 104 WK (STUDY DURATION: LIFESPAN),,NEGATIVE,"[ABE,I, SAITO,S, HORI,K, SUZUKI,M AND SATO,H; SODIUM ERYTHORBATE IS NOT CARCINOGENIC IN F344 RATS; EXP. MOL. PATHOL. 41(1):35-43, 1984]"
4974,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",,NEGATIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
4975,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",,NEGATIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
4976,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
4977,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
4978,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Active,,,,RAT,F344/MALE,ORAL,0; 100; 200; 400 PPM IN DIET FOR 56 WK (STUDY DURATION: 56 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; ZYMBAL GLAND: SQUAMOUS CELL CARCINOMA; SKIN: TUMOR",POSITIVE,"[KUSHIDA,H, WAKABAYASHI,K, SATO,H, KATAMI,M, KUROSAKA,R AND NAGAO,M; DOSE-RESPONSE STUDY OF MEIQX CARCINOGENICITY IN F344 MALE RATS; CANCER LETT. 83(1-2):31-35, 1994]"
4979,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Active,,,,MOUSE,CDF1/MALE,ORAL,0; 0.06% IN DIET FOR 84 WK (STUDY DURATION: 84 WK),LIVER: TUMOR; LYMPHATIC SYSTEM: LYMPHOMA OR LEUKEMIA,POSITIVE,"[OHGAKI,H, HASEGAWA,H, SUENAGA,M, SATO,S, TAKAYAMA,S AND SUGIMURA,T; CARCINOGENICITY IN MICE OF A MUTAGENIC COMPOUND, 2-AMINO-3,8-DIMETHYLIMIDAZO [4,5-F]QUINOXALINE (MEIQX) FROM COOKED FOODS; CARCINOGENESIS 8:665-668, 1987]"
4980,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 0.06% IN DIET FOR 84 WK (STUDY DURATION: 84 WK),LIVER: TUMOR; LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[OHGAKI,H, HASEGAWA,H, SUENAGA,M, SATO,S, TAKAYAMA,S AND SUGIMURA,T; CARCINOGENICITY IN MICE OF A MUTAGENIC COMPOUND, 2-AMINO-3,8-DIMETHYLIMIDAZO [4,5-F]QUINOXALINE (MEIQX) FROM COOKED FOODS; CARCINOGENESIS 8:665-668, 1987]"
4981,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Active,,,,RAT,F344/MALE,ORAL,0; 0.04% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 429 D),LIVER: TUMOR; ZYMBAL GLAND: TUMOR; SKIN: TUMOR,POSITIVE,"[KATO,T, OHGAKI,H, HASEGAWA,H, SATO,S, TAKAYAMA,S AND SUGIMURA,T; CARCINOGENICITY IN RATS OF A MUTAGENIC COMPOUND, 2-AMINO-3,8-DIMETHYLIMIDAZO [4,5-F]QUINOXALINE; CARCINOGENESIS 9:71-73, 1988]"
4982,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 0.04% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 429 D),LIVER: TUMOR; ZYMBAL GLAND: TUMOR; CLITORAL GLAND: TUMOR,POSITIVE,"[KATO,T, OHGAKI,H, HASEGAWA,H, SATO,S, TAKAYAMA,S AND SUGIMURA,T; CARCINOGENICITY IN RATS OF A MUTAGENIC COMPOUND, 2-AMINO-3,8-DIMETHYLIMIDAZO [4,5-F]QUINOXALINE; CARCINOGENESIS 9:71-73, 1988]"
4983,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Active,,,,RAT,LEC/MALE,ORAL,0; 40 PPM IN DIET FOR 40 WK (STUDY DURATION: 40 WK),LIVER: TUMOR,POSITIVE,"[SONE,H, WAKABAYASHI,K, KUSHIDA,H, ENOMOTO,K, MORI,M, TAKEICHI,N, TSUDA,H, SUGIMURA,T AND NAGAO,M; HEPATOCELLULAR CARCINOMA INDUCTION IN LEC RATS BY A LOW DOSE OF 2-AMIMO-3,8-DIMETHYLIMIDAZO[4,5-F]QUINOXALINE; JPN. J. CANCER RES. 87(1):25-29, 1996]"
4984,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Inactive,,,,RAT,LEA/MALE,ORAL,0; 40 PPM IN DIET FOR 40 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SONE,H, WAKABAYASHI,K, KUSHIDA,H, ENOMOTO,K, MORI,M, TAKEICHI,N, TSUDA,H, SUGIMURA,T AND NAGAO,M; HEPATOCELLULAR CARCINOMA INDUCTION IN LEC RATS BY A LOW DOSE OF 2-AMIMO-3,8-DIMETHYLIMIDAZO[4,5-F]QUINOXALINE; JPN. J. CANCER RES. 87(1):25-29, 1996]"
4985,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Inactive,,,,MONKEY,CYNOMOLGUS/MALE,GAVAGE,0; 10; 20 MG/KG BW FOR 84 MONTHS (STUDY DURATION: 92 MONTHS),,NEGATIVE,"[OGAWA,K, TSUDA,H, SHIRAI,T, OGISO,T, WAKABAYASHI,K, DALGARD,DW, THORGEIRSSON,UP, THORGEIRSSON,SS, ADAMSON,RH AND SUGIMURA,T; LACK OF CARCINOGENICITY OF 2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-F]QUINOXALINE (MEIQX) IN CYNOMOLGUS MONKEYS; JPN. J. CANCER RES. 90(6):622-628, 1999]"
4986,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Inactive,,,,MONKEY,CYNOMOLGUS/FEMALE,GAVAGE,0; 10; 20 MG/KG BW FOR 84 MONTHS (STUDY DURATION: 92 MONTHS),,NEGATIVE,"[OGAWA,K, TSUDA,H, SHIRAI,T, OGISO,T, WAKABAYASHI,K, DALGARD,DW, THORGEIRSSON,UP, THORGEIRSSON,SS, ADAMSON,RH AND SUGIMURA,T; LACK OF CARCINOGENICITY OF 2-AMINO-3,8-DIMETHYLIMIDAZO[4,5-F]QUINOXALINE (MEIQX) IN CYNOMOLGUS MONKEYS; JPN. J. CANCER RES. 90(6):622-628, 1999]"
4987,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,"75 MG/KG/D FOR 10 D, THEN PLACED ON A HIGH-FAT DIET (STUDY DURATION: 46 WK)","MAMMARY GLAND: CARCINOMA, ADENOMA",POSITIVE,"[SNYDERWINE,EG VENUGOPAL,M AND YU,M; MAMMARY GLAND CARCINOGENESIS BY FOOD-DERIVED HETEROCYCLIC AMINES AND STUDIES ON THE MECHANISMS OF CARCINOGENESIS OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDIDINE (PHIP); MUTAT. RES. 506-507:145-152, 2002]"
4988,363900486,62275,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)N,Inactive,,,,MOUSE,C57BL/6J/MALE (20/GROUP),DIET,0; 30; 300 PPM FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[NISHIKAWA,A IMAZAWA,T KUROIWA,Y KITAMURA,Y KANKI,K ISHII,Y UMEMURA,T AND HIROSE,M; INDUCTION OF COLON TUMORS IN C57BL/6J MICE FED MEIQX, IQ, OR PHIP FOLLOWED BY DEXTRAN SULFATE SODIUM TREATMENT; TOXICOL. SCI. 84(2):243-248, 2005]"
4989,363900532,3385,C1=C(C(=O)NC(=O)N1)F,Active,,,,MOUSE,BALB/MALE,INTRAPERITONEAL,0; 30 MG/KG IN STERILE SALINE 1/WK FOR 50 WK (STUDY DURATION: 105 WK),LUNG: TUMOR,POSITIVE,"[CAVALIERE,A, ALBERT,PF AND VITALI,R; 5-FLUOROURACIL CARCINOGENESIS IN BALB/C MICE;TUMORI 76(2):179-181, 1990]"
4990,363900532,3385,C1=C(C(=O)NC(=O)N1)F,Active,,,,MOUSE,BALB/FEMALE,INTRAPERITONEAL,0; 30 MG/KG IN STERILE SALINE 1/WK FOR 50 WK (STUDY DURATION: 105 WK),LUNG: TUMOR; LYMPHORETICULAR SYSTEM: LYMPHOMA OR LEUKEMIA,POSITIVE,"[CAVALIERE,A, ALBERT,PF AND VITALI,R; 5-FLUOROURACIL CARCINOGENESIS IN BALB/C MICE;TUMORI 76(2):179-181, 1990]"
4991,363900532,3385,C1=C(C(=O)NC(=O)N1)F,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 30; 60 PPM IN DRINKING WATER FOR 82 WK (STUDY DURATION: 86 WK),,NEGATIVE,"[IWAGAWA,M, NAKAMURA,M, IZUMI,K AND OTSUKA,H; CARCINOGENICITY TESTING OF 5-FLUOROURACIL IN (C57BL/6 X C3H) F1 MICE; J. TOXICOL. PATHOL. 4(2):129-135, 1991]"
4992,363900532,3385,C1=C(C(=O)NC(=O)N1)F,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 30; 60 PPM IN DRINKING WATER FOR 82 WK (STUDY DURATION: 86 WK),,NEGATIVE,"[IWAGAWA,M, NAKAMURA,M, IZUMI,K AND OTSUKA,H; CARCINOGENICITY TESTING OF 5-FLUOROURACIL IN (C57BL/6 X C3H) F1 MICE; J. TOXICOL. PATHOL. 4(2):129-135, 1991]"
4993,363900532,3385,C1=C(C(=O)NC(=O)N1)F,Inactive,,,,RAT,F344/MALE,ORAL,0; 62; 125 PPM IN DRINKING WATER FOR 111 WK (STUDY DURATION: 111 WK),,NEGATIVE,"[TOYODA,K SHIBUTANI,M SATO,H UNEYAMA,C TAKAHASHI,M HAYASHI,Y AND HIROSE,M; LACK OF CARCINOGENICITY AND INCREASED SURVIVAL IN F344 RATS TREATED WITH 5-FLUOROURACIL FOR TWO YEARS; FOOD CHEM. TOXICOL. 38(2-3):187-193, 2000]"
4994,363900532,3385,C1=C(C(=O)NC(=O)N1)F,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 62; 125 PPM IN DRINKING WATER FOR 111 WK (STUDY DURATION: 111 WK),,NEGATIVE,"[TOYODA,K SHIBUTANI,M SATO,H UNEYAMA,C TAKAHASHI,M HAYASHI,Y AND HIROSE,M; LACK OF CARCINOGENICITY AND INCREASED SURVIVAL IN F344 RATS TREATED WITH 5-FLUOROURACIL FOR TWO YEARS; FOOD CHEM. TOXICOL. 38(2-3):187-193, 2000]"
4995,363900535,39185,C1=CC2=C3C(=C(C=C2)[N+](=O)[O-])C=CC4=C(C=CC1=C43)[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAGASTRIC,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),"ADRENAL GLAND: PHEOCHROMOCYTOMA, CORTICAL ADENOMA; PITUITARY GLAND: CARCINOMA; LIVER: HYPERPLASTIC NODULES",POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
4996,363900535,39185,C1=CC2=C3C(=C(C=C2)[N+](=O)[O-])C=CC4=C(C=CC1=C43)[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
4997,363900535,39185,C1=CC2=C3C(=C(C=C2)[N+](=O)[O-])C=CC4=C(C=CC1=C43)[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAGASTRIC,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),"MAMMARY GLAND: ADENOCARCINOMA, FIBROADENOMA",POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
4998,363900535,39185,C1=CC2=C3C(=C(C=C2)[N+](=O)[O-])C=CC4=C(C=CC1=C43)[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),"HEMATOPOIETIC SYSTEM: HISTIOCYTOMA, LEUKEMIA",POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
4999,363900535,39185,C1=CC2=C3C(=C(C=C2)[N+](=O)[O-])C=CC4=C(C=CC1=C43)[N+](=O)[O-],Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 0.002; 0.02 MG 2/WK FOR 10 WK (STUDY DURATION: 320 D),INJECTION SITE: SARCOMA,POSITIVE,"[OHGAKI,H, HASEGAWA,H, KATO,T, NEGISHI,C, SATO,S AND SUGIMURA,T; ABSENCE OF CARCINOGENICITY OF 1-NITROPYRENE, CORRECTION OF PREVIOUS RESULTS, AND NEW DEMONSTRATION OF CARCINOGENICITY OF 1,6-DINITROPYRENE IN RATS; CANCER LETT. 25(3):239-245, 1985]"
5000,363900535,39185,C1=CC2=C3C(=C(C=C2)[N+](=O)[O-])C=CC4=C(C=CC1=C43)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,0; 6.3 UMOL (TOTAL DOSE) ADMINISTERED OVER 8 WK BEGINNING ON DAY OF BIRTH (STUDY DURATION: 67 WK),INTEGUMENTARY SYSTEM: MALIGNANT FIBROUS HISTIOCYTOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[IMAIDA,K, LEE,MS, LAND,SJ, WANG,CY AND KING,CM; CARCINOGENICITY OF NITROPYRENES IN THE NEWBORN FEMALE RAT; CARCINOGENESIS 16(12):3027-3030, 1995]"
5001,363900596,5865,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 0.25; 0.5; 1; 5 MG/KG/D FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[DILLBERGER,JE, CRONIN,NS AND CARR,GJ; PREDNISONE IS NOT A MOUSE CARCINOGEN; TOXICOL. PATHOL. 20(1):18-26, 1992]"
5002,363900596,5865,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,Inactive,,,,MOUSE,ICR/MALE,ORAL,0; 0.25; 0.5; 1; 5 MG/KG/D FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[DILLBERGER,JE, CRONIN,NS AND CARR,GJ; PREDNISONE IS NOT A MOUSE CARCINOGEN; TOXICOL. PATHOL. 20(1):18-26, 1992]"
5003,363900602,17466,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C=CC4=CC(=CC(=C43)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+],Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 50; 500; 1250 MG/KG/D IN DIET TO PUPS OF PARENTS GIVEN THE SAME DIETARY DOSE LEVELS FOR 60 D PRIOR TO MATING (STUDY DURATION: 114 WK),,NEGATIVE,"[BRANTOM,PG, STEVENSON,BI AND WRIGHT,MG; LONG-TERM TOXICITY STUDY OF PONCEAU 4R IN RATS USING ANIMALS EXPOSED IN UTERO; FOOD CHEM. TOXICOL. 25(12):955-962, 1988]"
5004,363900602,17466,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C=CC4=CC(=CC(=C43)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 50; 500; 1250 MG/KG/D IN DIET TO PUPS OF PARENTS GIVEN THE SAME DIETARY DOSE LEVELS FOR 60 D PRIOR TO MATING (STUDY DURATION: 118 WK),,NEGATIVE,"[BRANTOM,PG, STEVENSON,BI AND WRIGHT,MG; LONG-TERM TOXICITY STUDY OF PONCEAU 4R IN RATS USING ANIMALS EXPOSED IN UTERO; FOOD CHEM. TOXICOL. 25(12):955-962, 1988]"
5005,363900603,13506,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,RAT,WISTAR/MALE,ORAL,"0; 50; 250; 1250 MG/KG IN THE DIET TO PUPS OF PARENTS EXPOSED TO THE SAME DOSE LEVELS FOR 60 D PRIOR TO MATING AND CONTINUED THROUGHOUT MATING, PREGNANCY, LACTATION AND WEANING (STUDY DURATION: 111 WK)",,NEGATIVE,"[CLODE,SA, HOOSON,J, GRANT,D AND BUTLER,WH; LONG-TERM TOXICITY STUDY OF AMARANTH IN RATS USING ANIMALS EXPOSED IN UTERO; FOOD CHEM. TOXICOL. 25(12):937-946, 1987]"
5006,363900603,13506,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,"0; 50; 250; 1250 MG/KG IN THE DIET TO PUPS OF PARENTS EXPOSED TO THE SAME DOSE LEVELS FOR 60 D PRIOR TO MATING AND CONTINUED THROUGHOUT MATING, PREGNANCY, LACTATION AND WEANING (STUDY DURATION: 112 WK)",,NEGATIVE,"[CLODE,SA, HOOSON,J, GRANT,D AND BUTLER,WH; LONG-TERM TOXICITY STUDY OF AMARANTH IN RATS USING ANIMALS EXPOSED IN UTERO; FOOD CHEM. TOXICOL. 25(12):937-946, 1987]"
5007,363900603,13506,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 19.5 MO (STUDY DURATION: 19.5 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
5008,363900603,13506,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 19.5 MO (STUDY DURATION: 19.5 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
5009,363900604,14130,CCOC1=CC=C(C=C1)NC(=O)CC(C)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.75; 1.5% IN BASAL DIET FOR 76 WK FOLLOWED BY BASAL DIET ONLY FOR 8 WK (STUDY DURATION: 84 WK),"KIDNEY: RENAL CELL ADENOMA, RENAL CELL CARCINOMA",POSITIVE,"[TOGEI,K, SANO,N, MAEDA,T, SHIBATA,M AND OTSUKA,H; CARCINOGENICITY OF BUCETIN IN (C57BL/6 X C3H)F1 MICE; J. NATL. CANCER INST. 79(5):1151-1158, 1987]"
5010,363900604,14130,CCOC1=CC=C(C=C1)NC(=O)CC(C)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.75; 1.5% IN BASAL DIET FOR 76 WK FOLLOWED BY BASAL DIET ONLY FOR 8 WK (STUDY DURATION: 84 WK),,NEGATIVE,"[TOGEI,K, SANO,N, MAEDA,T, SHIBATA,M AND OTSUKA,H; CARCINOGENICITY OF BUCETIN IN (C57BL/6 X C3H)F1 MICE; J. NATL. CANCER INST. 79(5):1151-1158, 1987]"
5011,363900605,52195,CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.02; 0.04; 0.08% IN DIET FOR APPROXIMATE DAILY DOSES OF 0; 9; 18; 37 MG/KG (STUDY DURATION: 2 YR),,NEGATIVE,"[SANDUSKY,GE, USHER,RW AND TAMURA,RN; CHRONIC DIETARY ONCOGENICITY STUDIES OF INDECAINIDE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 9(3):436-477, 1987]"
5012,363900605,52195,CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.02; 0.04; 0.08% IN DIET FOR APPROXIMATE DAILY DOSES OF 0; 9; 18; 37 MG/KG (STUDY DURATION: 2 YR),,NEGATIVE,"[SANDUSKY,GE, USHER,RW AND TAMURA,RN; CHRONIC DIETARY ONCOGENICITY STUDIES OF INDECAINIDE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 9(3):436-477, 1987]"
5013,363900605,52195,CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.02; 0.04; 0.08% IN DIET FOR APPROXIMATE DAILY DOSES OF 0; 27; 53; 113 MG/KG (STUDY DURATION: 2 YR),,NEGATIVE,"[SANDUSKY,GE, USHER,RW AND TAMURA,RN; CHRONIC DIETARY ONCOGENICITY STUDIES OF INDECAINIDE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 9(3):436-477, 1987]"
5014,363900605,52195,CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.02; 0.04; 0.08% IN DIET FOR APPROXIMATE DAILY DOSES OF 0; 27; 53; 113 MG/KG (STUDY DURATION: 2 YR),,NEGATIVE,"[SANDUSKY,GE, USHER,RW AND TAMURA,RN; CHRONIC DIETARY ONCOGENICITY STUDIES OF INDECAINIDE IN RATS AND MICE; FUNDAM. APPL. TOXICOL. 9(3):436-477, 1987]"
5015,363900606,164825,C1=CC(=CC=C1N=NC2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)[O-])C(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 1; 2% IN DRINKING WATER FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[MAEKAWA,A, MATSUOKA,C, ONODERA,H, TANIGAWA,H, FURUTA,K, KANNO,J, JANG,JJ AND HAYASHI,Y; LACK OF CARCINOGENICITY OF TARTRAZINE (FD&C YELLOW NO. 5) IN THE F344 RAT; FOOD CHEM. TOXICOL. 25(12):891-896, 1987]"
5016,363900606,164825,C1=CC(=CC=C1N=NC2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)[O-])C(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1; 2% IN DRINKING WATER FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[MAEKAWA,A, MATSUOKA,C, ONODERA,H, TANIGAWA,H, FURUTA,K, KANNO,J, JANG,JJ AND HAYASHI,Y; LACK OF CARCINOGENICITY OF TARTRAZINE (FD&C YELLOW NO. 5) IN THE F344 RAT; FOOD CHEM. TOXICOL. 25(12):891-896, 1987]"
5017,363900606,164825,C1=CC(=CC=C1N=NC2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)[O-])C(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 133.4 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5018,363900606,164825,C1=CC(=CC=C1N=NC2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)[O-])C(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 133.4 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5019,363900607,50225,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6,Inactive,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 0.0002; 0.0006; 0.0018 MG/KG 1/D FOR 24 MO (STUDY DURATION: 30 MO),,NEGATIVE,"[DONAUBAUER,HH, KRAMER,M, KRIEG,K, MAYER,D, VON RECHENBERG,W, SANDOW,J AND SCHUTZ,E; INVESTIGATIONS OF THE CARCINOGENICITY OF THE LH-RH ANALOG BUSERELIN (HOE 766) IN RATS USING THE SUBCUTANEOUS ROUTE OF ADMINISTRATION; FUNDAM. APPL. TOXICOL. 9(4):738-752, 1987]"
5020,363900607,50225,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6,Inactive,,,,RAT,WISTAR/FEMALE,SUBCUTANEOUS,0; 0.0002; 0.0006; 0.0018 MG/KG 1/D FOR 24 MO (STUDY DURATION: 30 MO),,NEGATIVE,"[DONAUBAUER,HH, KRAMER,M, KRIEG,K, MAYER,D, VON RECHENBERG,W, SANDOW,J AND SCHUTZ,E; INVESTIGATIONS OF THE CARCINOGENICITY OF THE LH-RH ANALOG BUSERELIN (HOE 766) IN RATS USING THE SUBCUTANEOUS ROUTE OF ADMINISTRATION; FUNDAM. APPL. TOXICOL. 9(4):738-752, 1987]"
5021,363900608,20838052,CCCCCCCC/C=C\CCCCCCCC(=O)O.C1COCCN1,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.25; 1.0% IN DRINKING WATER FOR 96 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[SHIBATA,MA, KURATA,Y, OGISO,T, TAMANO,S, FUKUSHIMA,S AND ITO,N; COMBINED CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF MORPHOLINE OLEIC ACID SALT IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 25(8):569-574, 1987]"
5022,363900608,20838052,CCCCCCCC/C=C\CCCCCCCC(=O)O.C1COCCN1,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.25; 1.0% IN DRINKING WATER FOR 96 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[SHIBATA,MA, KURATA,Y, OGISO,T, TAMANO,S, FUKUSHIMA,S AND ITO,N; COMBINED CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF MORPHOLINE OLEIC ACID SALT IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 25(8):569-574, 1987]"
5023,363900623,18617,C(#N)C(Br)Br,Active,,,,Rat,F344/N / Female (50/group),Oral,0; 50; 100; 200 mg/l in drinking water for 2 yr,"Oral Cavity (oral mucosa or tongue): squamous cell papilloma (1/50, 0/50, 4/50, 0/50). Skin: squamous cell papilloma, keratoacanthoma, basal cell adenoma, and basal cell carcinoma combined (0/50, 0/50, 3/50, 4/50)",Positive (NTP describes as Some Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-544 Y10]"
5024,363900623,18617,C(#N)C(Br)Br,Active,,,,Rat,F344/N / Male (50/group),Oral,0; 50; 100; 200 mg/l in drinking water for 2 yr,"Oral Cavity (oral mucosa or tongue): squamous cell papilloma and carcinoma combined (0/50, 0/50, 2/50, 5/50) (Statistically significant). Glandular Stomach: adenoma (0/50, 0/50, 0/50, 2/50) (Not statistically significant)",Positive (NTP describes as Clear Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-544 Y10]"
5025,363900623,18617,C(#N)C(Br)Br,Active,,,,Mouse,B6C3F1/Female (50/group),Oral,0; 50; 100; 200 mg/l in drinking water for 2 yr,"Forestomach: squamous cell papilloma and squamous cell carcinoma combined (1/50, 0/50, 5/50, 14/50)",Positive (NTP describes as Clear Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-544 Y10]"
5026,363900623,18617,C(#N)C(Br)Br,Active,,,,Mouse,B6C3F1/Male (50/group),Oral,0; 50; 100; 200 mg/l in drinking water for 2 yr,"Forestomach: squamous cell papilloma and squamous cell carcinoma combined (0/50, 1/50, 0/50, 5/50). Liver: hepatoblastoma (1/50, 7/50, 3/50, 2/50); hepatocellular adenoma and carcinoma or hepatoblastoma combined (37/50, 46/50, 43/50, 42/50)",Positive (NTP describes as Clear Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-544 Y10]"
5027,363900625,6781,CCOC(=O)C1=CC=CC=C1C(=O)OCC,Inactive,,,,RAT,F344/MALE,DERMAL,0; 100; 300 UL IN ACETONE 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-429 Y95]"
5028,363900625,6781,CCOC(=O)C1=CC=CC=C1C(=O)OCC,Inactive,,,,RAT,F344/FEMALE,DERMAL,0; 100; 300 UL IN ACETONE 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-429 Y95]"
5029,363900625,6781,CCOC(=O)C1=CC=CC=C1C(=O)OCC,Unspecified,,,,MOUSE,B6C3F1/FEMALE,DERMAL,"0; 7.5; 15, 30 UL/100 UL IN ACETONE 5 D/WK FOR 104-105 WK (STUDY DURATION: 104-105 WK)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-429 Y95]"
5030,363900625,6781,CCOC(=O)C1=CC=CC=C1C(=O)OCC,Unspecified,,,,MOUSE,B6C3F1/MALE,DERMAL,"0; 7.5; 15, 30 UL/100 UL IN ACETONE 5 D/WK FOR 104-105 WK (STUDY DURATION: 104-105 WK)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-429 Y95]"
5031,363900712,5386,C1CC(OC1)N2C=C(C(=O)NC2=O)F,Inactive,,,,MOUSE,C57BL/CBA/MALE,GAVAGE,0; 40 MG/KG IN 0.2 ML OF A STARCH/WATER SUSPENSION 2/WK FOR 12 MO (STUDY DURATION: LIFETIME),,NEGATIVE,"[GRICIUTE,L AND DOMKIENE,V; EXPERIMENTAL STUDY ON THE CARCINOGENICITY OF THE CYTOSTATIC DRUG FTORAFUR (TEGAFUR); PATHOL. ONCOL. RES. 2(1-2):69-70, 1996]"
5032,363900712,5386,C1CC(OC1)N2C=C(C(=O)NC2=O)F,Inactive,,,,MOUSE,C57BL/CBA/FEMALE,GAVAGE,0; 40 MG/KG IN 0.2 ML OF A STARCH/WATER SUSPENSION 2/WK FOR 12 MO (STUDY DURATION: LIFETIME),,NEGATIVE,"[GRICIUTE,L AND DOMKIENE,V; EXPERIMENTAL STUDY ON THE CARCINOGENICITY OF THE CYTOSTATIC DRUG FTORAFUR (TEGAFUR); PATHOL. ONCOL. RES. 2(1-2):69-70, 1996]"
5033,363900712,5386,C1CC(OC1)N2C=C(C(=O)NC2=O)F,Inactive,,,,RAT,WISTAR/MALE,GAVAGE,0; 60 MG/KG IN 0.5 ML OF A STARCH/WATER SUSPENSION 2/WK FOR 12 MO (STUDY DURATION: LIFETIME),,NEGATIVE,"[GRICIUTE,L AND DOMKIENE,V; EXPERIMENTAL STUDY ON THE CARCINOGENICITY OF THE CYTOSTATIC DRUG FTORAFUR (TEGAFUR); PATHOL. ONCOL. RES. 2(1-2):69-70, 1996]"
5034,363900712,5386,C1CC(OC1)N2C=C(C(=O)NC2=O)F,Inactive,,,,RAT,WISTAR/FEMALE,GAVAGE,0; 60 MG/KG IN 0.5 ML OF A STARCH/WATER SUSPENSION 2/WK FOR 12 MO (STUDY DURATION: LIFETIME),,NEGATIVE,"[GRICIUTE,L AND DOMKIENE,V; EXPERIMENTAL STUDY ON THE CARCINOGENICITY OF THE CYTOSTATIC DRUG FTORAFUR (TEGAFUR); PATHOL. ONCOL. RES. 2(1-2):69-70, 1996]"
5035,363900739,39363,CC(=O)OCC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C5=CC=CC=C51,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.0025; 0.005 UMOL/G ONCE AT 12 DAYS OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; THE STRONG HEPATOCARCINOGENICITY OF THE ELECTROPHILIC AND MUTAGENIC METABOLITE 6-SULFOOXYMETHYLBENZO[A]PYRENE AND ITS FORMATION OF BENZYLIC DNA ADDUCTS IN THE LIVERS OF INFANT MALE B6C3F1 MICE; BIOCHEM. BIOPHYS. RES. COMMUN. 172(1):85-91, 1990]"
5036,363900785,108109,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H]4[C@]5([C@@]3(CC[C@@H](C5)O)C)O4)C,Inactive,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 12.3 UMOL (TOTAL DOSE) 1/6 INJECTED UNDER EACH OF 3 THORACIC AND 3 INGUINAL NIPPLES ONCE (STUDY DURATION: 44 WK),,NEGATIVE,"[EL-BAYOUMY,K, JI,BY, UPADHYAYA,P, CHAE,YH, KURTZKE,C, RIVENSON,A, REDDY,BS, AMIN,S AND HECHCT,SS; LACK OF TUMORIGENICITY OF CHOLESTEROL EPOXIDES AND ESTRONE-3,4-QUINONE IN THE RAT MAMMARY GLAND; CANCER RES. 56(9):1970-197 3, 1996]"
5037,363900791,7416,C1=CC=C(C=C1)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 5; 25; 50 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),"LUNG: ADENOMA, ADENOMA OR CARCINOMA; THYROID GLAND: FOLLICULAR CELL ADENOMA",POSITIVE,"[CATTLEY,RC, EVERITT,JI, GROSS,EA, MOSS,OR, HAMM,TE,JR AND POPP,JA; CARCINOGENICITY AND TOXICITY OF INHALED NITROBENZENE IN B6C3F1 MICE AND F344 AND CD RATS; FUNDAM. APPL. TOXICOL. 22(3):328-340, 1994]"
5038,363900791,7416,C1=CC=C(C=C1)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 5; 25; 50 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[CATTLEY,RC, EVERITT,JI, GROSS,EA, MOSS,OR, HAMM,TE,JR AND POPP,JA; CARCINOGENICITY AND TOXICITY OF INHALED NITROBENZENE IN B6C3F1 MICE AND F344 AND CD RATS; FUNDAM. APPL. TOXICOL. 22(3):328-340, 1994]"
5039,363900791,7416,C1=CC=C(C=C1)[N+](=O)[O-],Active,,,,RAT,F344/MALE,INHALATION,0; 1; 5; 25 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; KIDNEY: TUBULAR ADENOMA, TUBULAR ADENOMA OR CARCINOMA",POSITIVE,"[CATTLEY,RC, EVERITT,JI, GROSS,EA, MOSS,OR, HAMM,TE,JR AND POPP,JA; CARCINOGENICITY AND TOXICITY OF INHALED NITROBENZENE IN B6C3F1 MICE AND F344 AND CD RATS; FUNDAM. APPL. TOXICOL. 22(3):328-340, 1994]"
5040,363900791,7416,C1=CC=C(C=C1)[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,INHALATION,0; 1; 5; 25 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),UTERUS: ENDOMETRIAL STROMAL POLYP,POSITIVE,"[CATTLEY,RC, EVERITT,JI, GROSS,EA, MOSS,OR, HAMM,TE,JR AND POPP,JA; CARCINOGENICITY AND TOXICITY OF INHALED NITROBENZENE IN B6C3F1 MICE AND F344 AND CD RATS; FUNDAM. APPL. TOXICOL. 22(3):328-340, 1994]"
5041,363900791,7416,C1=CC=C(C=C1)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/MALE,INHALATION,0; 1; 5; 25 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[CATTLEY,RC, EVERITT,JI, GROSS,EA, MOSS,OR, HAMM,TE,JR AND POPP,JA; CARCINOGENICITY AND TOXICITY OF INHALED NITROBENZENE IN B6C3F1 MICE AND F344 AND CD RATS; FUNDAM. APPL. TOXICOL. 22(3):328-340, 1994]"
5042,363900792,147468,CCC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 8 NMOL IN 5 UL DMSO ON D 1, 16 NMOL IN 10 UL ON D 8 AND 32 NMOL IN 20 UL ON D 15 OF LIFE (STUDY DURATION: 35 WK)",,NEGATIVE,"[AMIN,S, MISRA,B, BRALEY,J AND HECHT,SS; COMPARATIVE TUMORIGENICITY IN NEWBORN MICE OF CHRYSENE- AND 5-ALKYLCHRYSENE-1,2-DIOL 3,4-EPOXIDES; CANCER LETT. 58(1-2):115-118, 1991]"
5043,363900792,147468,CCC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@@H]([C@H]([C@@H]5[C@H]4O5)O)O,Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 8 NMOL IN 5 UL DMSO ON D 1, 16 NMOL IN 10 UL ON D 8 AND 32 NMOL IN 20 UL ON D 15 OF LIFE (STUDY DURATION: 35 WK)",,NEGATIVE,"[AMIN,S, MISRA,B, BRALEY,J AND HECHT,SS; COMPARATIVE TUMORIGENICITY IN NEWBORN MICE OF CHRYSENE- AND 5-ALKYLCHRYSENE-1,2-DIOL 3,4-EPOXIDES; CANCER LETT. 58(1-2):115-118, 1991]"
5044,363900793,147448,CCCC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)C(C(C5C4O5)O)O,Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 8 NMOL IN 5 UL DMSO ON D 1, 16 NMOL IN 10 UL ON D 8 AND 32 NMOL IN 20 UL ON D 15 OF LIFE (STUDY DURATION: 35 WK)",,NEGATIVE,"[AMIN,S, MISRA,B, BRALEY,J AND HECHT,SS; COMPARATIVE TUMORIGENICITY IN NEWBORN MICE OF CHRYSENE- AND 5-ALKYLCHRYSENE-1,2-DIOL 3,4-EPOXIDES; CANCER LETT. 58(1-2):115-118, 1991]"
5045,363900793,147448,CCCC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)C(C(C5C4O5)O)O,Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 8 NMOL IN 5 UL DMSO ON D 1, 16 NMOL IN 10 UL ON D 8 AND 32 NMOL IN 20 UL ON D 15 OF LIFE (STUDY DURATION: 35 WK)",,NEGATIVE,"[AMIN,S, MISRA,B, BRALEY,J AND HECHT,SS; COMPARATIVE TUMORIGENICITY IN NEWBORN MICE OF CHRYSENE- AND 5-ALKYLCHRYSENE-1,2-DIOL 3,4-EPOXIDES; CANCER LETT. 58(1-2):115-118, 1991]"
5046,363900819,149804,C1=CC=C2C(=C1)C3=C4C(=C(C=C3)[N+](=O)[O-])C=CC5=C4C2=CC=C5,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",,NEGATIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
5047,363900840,115243,C1=CC2=C(C=CC=N2)C(=C1)F,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",,NEGATIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
5048,363900840,115243,C1=CC2=C(C=CC=N2)C(=C1)F,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",LIVER: CARCINOMA,POSITIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
5049,363900844,10285,CC1=CC=NC2=CC=CC=C12,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.25; 0.5; 1.0 UMOL IN DMSO TO NEWBORN MICE ON DAY 1,8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)","LIVER: ADENOMA, HEPATOMA",POSITIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
5050,363900844,10285,CC1=CC=NC2=CC=CC=C12,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.25; 0.5; 1.0 UMOL IN DMSO TO NEWBORN MICE ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
5051,363900844,10285,CC1=CC=NC2=CC=CC=C12,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 200 UMOL/KG INTO SUPRASCAPULAR REGION ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN 0; 200 UMOL ONCE AT WK 8 (STUDY DURATION: 78 WK),,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
5052,363900844,10285,CC1=CC=NC2=CC=CC=C12,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 200 UMOL/KG INTO SUPRASCAPULAR REGION ON DAY 1 OF LIFE FOLLOWED BY 0; 100 UMOL 1/WK AT WK 2-7 THEN 0; 200 UMOL ONCE AT WK 8 (STUDY DURATION: 78 WK),,NEGATIVE,"[LAVOIE,EJ, DOLAN,S, LITTLE,P, WANG,CX, SUGIE,S AND RIVENSON,A; CARCINOGENICITY OF QUINOLINE, 4- AND 8-METHYLQUINOLINE AND BENZOQUINOLINES IN NEWBORN MICE AND RATS; FOOD CHEM. TOXICOL. 26(7):625-629, 1988]"
5053,363900847,119042,C=COC1=CC=C(C=C1)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 60; 300 NMOL/G BW IN 10 UL TRIOCTANOIN ONCE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[PARK,KK, SOHN,Y, LIEM,A, KIM,HJ, STEWART,BC AND MILLER,JA; THE ELECTROPHILIC, MUTAGENIC AND TUMORIGENIC ACTIVITIES OF PHENYL AND 4-NITROPHENYL VINYL ETHERS AND THEIR EPOXIDE METABOLITES;CARCINOGENESIS 18(2):431-437, 1997]"
5054,363900857,6009,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.04; 0.08% IN DRINKING WATER FOR 100 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[INAI,K, KOBUKE,T, FUJIHARA,M, YONEHARA,S, TAKEMOTO,T, TSUYA,T, YAMAMOTO,A, TACHIYAMA,Y, IZUMI,K AND TOKUOKA,S; LACK OF TUMORIGENICITY OF AMINOPYRINE ORALLY ADMINISTERED TO B6C3F1 MICE; JPN. J. CANCER RES. 81(2):122-128, 1990]"
5055,363900857,6009,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.04; 0.08% IN DRINKING WATER FOR 100 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[INAI,K, KOBUKE,T, FUJIHARA,M, YONEHARA,S, TAKEMOTO,T, TSUYA,T, YAMAMOTO,A, TACHIYAMA,Y, IZUMI,K AND TOKUOKA,S; LACK OF TUMORIGENICITY OF AMINOPYRINE ORALLY ADMINISTERED TO B6C3F1 MICE; JPN. J. CANCER RES. 81(2):122-128, 1990]"
5056,363900859,21502,C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=C1C=C(C=C3)[N+](=O)[O-],Inactive,,,,Rat,Sprague-Dawley/Female (17/group),Oral,10 umol/kg 3 times a wk for 4 wk (avg total dose 18.0 umol/rat); animals retained for up to 90 wk after last dosing (Test material solvent: 12% DMSO in olive oil),"Mammary Gland: % of rats with tumors (malignant 29, benign 53 vs 12 malignant, 53 benign in vehicle controls)",Negative. DNA adducts observed in mammary gland DNA collected 24 hr after last dosing.,"[MALEJKA-GIGANTI,D PARKIN,DR DECKER,RW NIEHANS,GA BLISS,RL CHURCHWELL,MI AND BELAND,FA; TUMORIGENICITY AND GENOTOXICITY OF AN ENVIRONMENTAL POLLUTANT 2,7-DINITROFLUORENE AFTER SYSTEMIC ADMINISTRATION AT A LOW DOSE LEVEL TO FEMALE RATS; INTERNATIONAL JOURNAL OF CANCER 122(9):1958-65, 2008]"
5057,363900859,21502,C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=C1C=C(C=C3)[N+](=O)[O-],Active,,,,Rat,Sprague-Dawley/Female (16/group),Intraperitoneal,10 umol/kg 3 times a wk for 4 wk (avg total dose 16.0 umol/rat); animals retained for up to 90 wk after last dosing (Test material solvent: 12% DMSO in olive oil),"Mammary Gland: % of rats with tumors (malignant 44, benign 38 vs 6 malignant, 53 benign in vehicle controls)",Positive for malignant tumors only (p=0.02). DNA adducts observed in mammary gland DNA collected 24 hr after last dosing.,"[MALEJKA-GIGANTI,D PARKIN,DR DECKER,RW NIEHANS,GA BLISS,RL CHURCHWELL,MI AND BELAND,FA; TUMORIGENICITY AND GENOTOXICITY OF AN ENVIRONMENTAL POLLUTANT 2,7-DINITROFLUORENE AFTER SYSTEMIC ADMINISTRATION AT A LOW DOSE LEVEL TO FEMALE RATS; INTERNATIONAL JOURNAL OF CANCER 122(9):1958-65, 2008]"
5058,363900863,115222,CN1C2=C(C3=C(C=C2)NC(=O)C=C3)N=C1N,Inactive,,,,RAT,F344/MALE,INTRARECTAL,0; 54.8 MG/KG IN 1.7 ML/KG DMSO INFUSED 3/WK FOR 2 MO THEN 2/WK FOR DURATION OF STUDY (STUDY DURATION: 21 MO),,NEGATIVE,"[WEISBURGER,JH, RIVENSON,A, REINHARDT,J, ALIAGA,C, BRALEY,J, DOLAN,LM, WILLIAMS, GM, ZANG,E, KINGSTON,DGI, BASHLR,M, SHU,YZ, WILKINS,TD AND VAN TASSELL,RL; GENOTOXICITY AND CARCINOGENICITY IN RATS AND MICE OF 2-AMINO-3,6-DIHYDRO-3-METHYL-7H-IMIDAZOLO[4,5-F]QUINOLIN-7-ONE: AN INTESTINAL BACTERIAL METABOLITE OF 2-AMINO-3-METHYL-3H-IMIDAZO[4,5-F]QUINOLINE; J. NATL. CANCER INST. 86(1):25-30, 1994]"
5059,363900863,115222,CN1C2=C(C3=C(C=C2)NC(=O)C=C3)N=C1N,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL ; ORAL,"0; 5 UL OF A 21.7 MG/ML SOLUTION IN DMSO ON DAYS 1, 3, 5, 7, 10, 13, 17, 21, 24 AND 28 OF LIFE THEN 2/WK TO WK 10 FOLLOWED BY 465 PPM IN DIET 5 D/WK FOR 56 WK (STUDY DURATION: 76 WK)",,NEGATIVE,"[WEISBURGER,JH, RIVENSON,A, REINHARDT,J, ALIAGA,C, BRALEY,J, DOLAN,LM, WILLIAMS, GM, ZANG,E, KINGSTON,DGI, BASHLR,M, SHU,YZ, WILKINS,TD AND VAN TASSELL,RL; GENOTOXICITY AND CARCINOGENICITY IN RATS AND MICE OF 2-AMINO-3,6-DIHYDRO-3-METHYL-7H-IMIDAZOLO[4,5-F]QUINOLIN-7-ONE: AN INTESTINAL BACTERIAL METABOLITE OF 2-AMINO-3-METHYL-3H-IMIDAZO[4,5-F]QUINOLINE; J. NATL. CANCER INST. 86(1):25-30, 1994]"
5060,363900863,115222,CN1C2=C(C3=C(C=C2)NC(=O)C=C3)N=C1N,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL ; ORAL,"0; 5 UL OF A 21.7 MG/ML SOLUTION IN DMSO ON DAYS 1, 3, 5, 7, 10, 13, 17, 21, 24 AND 28 OF LIFE THEN 2/WK TO WK 10 FOLLOWED BY 465 PPM IN DIET 5 D/WK FOR 56 WK (STUDY DURATION: 76 WK)",LIVER: CARCINOMA,POSITIVE,"[WEISBURGER,JH, RIVENSON,A, REINHARDT,J, ALIAGA,C, BRALEY,J, DOLAN,LM, WILLIAMS, GM, ZANG,E, KINGSTON,DGI, BASHLR,M, SHU,YZ, WILKINS,TD AND VAN TASSELL,RL; GENOTOXICITY AND CARCINOGENICITY IN RATS AND MICE OF 2-AMINO-3,6-DIHYDRO-3-METHYL-7H-IMIDAZOLO[4,5-F]QUINOLIN-7-ONE: AN INTESTINAL BACTERIAL METABOLITE OF 2-AMINO-3-METHYL-3H-IMIDAZO[4,5-F]QUINOLINE; J. NATL. CANCER INST. 86(1):25-30, 1994]"
5061,363900864,107887,C1COC(CN1N=O)O,Active,,,,MOUSE,STRAIN-A/FEMALE,ORAL,0; 0.2 UMOL/ML IN DRINKING WATER FOR 10 WK (TOTAL DOSE: 0; 53 UMOL) FOLLOWED BY TAP WATER FOR 20 WK (STUDY DURATION: 30 WK),LUNG: TUMORS,POSITIVE,"[HECHT,SS, LIJINSKY,W, KOVATCH,RM, CHUNG,FL AND SAAVEDRA,JE; COMPARATIVE TUMORIGENICITY OF N-NITROSO-2-HYDROXYMORPHOLINE, N-NITROSODIETHANOLAMINE AND N-NITROSOMORPHOLINE IN A/J MICE AND F344 RATS; CARCINOGENESIS 10(8): 1475-1477, 1989]"
5062,363900864,107887,C1COC(CN1N=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 15; 30 MG/L IN DRINKING WATER 5 D/WK FOR 50 WK (TOTAL DOSE: 0; 0.6; 1.2 MMOL) (STUDY DURATION: 124 WK),,NEGATIVE,"[HECHT,SS, LIJINSKY,W, KOVATCH,RM, CHUNG,FL AND SAAVEDRA,JE; COMPARATIVE TUMORIGENICITY OF N-NITROSO-2-HYDROXYMORPHOLINE, N-NITROSODIETHANOLAMINE AND N-NITROSOMORPHOLINE IN A/J MICE AND F344 RATS; CARCINOGENESIS 10(8): 1475-1477, 1989]"
5063,363900864,107887,C1COC(CN1N=O)O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 22 MG/WK FOR A TOTAL DOSE OF 8.5 MMOL (STUDY DYRATION: 110 WK),LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
5064,363900872,7361,C1=COC(=C1)CO,Active,,,,RAT,F344/MALE,INHALATION,0; 2; 8; 32 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"NOSE: ADENOMA, CARCINOMA, OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-482  Y99]"
5065,363900872,7361,C1=COC(=C1)CO,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 2; 8; 32 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"KIDNEY: RENAL TUBULE ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-482  Y99]"
5066,363900872,7361,C1=COC(=C1)CO,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2; 8; 32 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-482  Y99]"
5067,363900872,7361,C1=COC(=C1)CO,Unspecified,,,,RAT,F344/FEMALE,INHALATION,0; 2; 8; 32 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"NOSE: LATERAL WALL, ADENOMA, RESPIRATORY EPITHELIUM ADENOMA; KIDNEY (RENAL TUBULE): ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-482  Y99]"
5068,363900874,7302,C1CC(=O)OC1,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 112; 225 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-406 Y92]"
5069,363900874,7302,C1CC(=O)OC1,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 225; 450 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-406 Y92]"
5070,363900874,7302,C1CC(=O)OC1,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 262; 525 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-406 Y92]"
5071,363900874,7302,C1CC(=O)OC1,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 262; 525 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),ADRENAL MEDULLA: BENIGN OR MALIGNANT PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-406 Y92]"
5072,363900876,1049,C1=CC=NC=C1,Active,,,,RAT,F344/MALE,ORAL,0; 100; 200; 400 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),"KIDNEY: RENAL TUBULE ADENOMA, RENAL TUBULE ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-470 Y00]"
5073,363900876,1049,C1=CC=NC=C1,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 125; 250; 500 PPM IN DRINKING WATER FOR 105 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, OR HEPATOBLASTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-470 Y00]"
5074,363900876,1049,C1=CC=NC=C1,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 250; 500; 1000 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, OR HEPATOBLASTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-470 Y00]"
5075,363900876,1049,C1=CC=NC=C1,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 100; 200; 400 PPM IN DRINKING WATER FOR 105 WK (STUDY DURATION: 105 WK),MULTIPLE ORGANS: MONONUCLEAR CELL LEUKEMIA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-470 Y00]"
5076,363900876,1049,C1=CC=NC=C1,Unspecified,,,,RAT,WISTAR/MALE,ORAL,0; 100; 200; 400 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),TESTIS: INTERSTITIAL CELL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-470 Y00]"
5077,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,MOUSE,CDF1/MALE,ORAL,0; 0.04% IN THE DIET FOR DURATION OF STUDY (STUDY DURATION: 579 D),HEMATOPOIETIC SYSTEM: LYMPHOMA,POSITIVE,"[ESUMI,H, OHGAKI,H, KOHZEN,E, TAKAYAMA,S AND SUGIMURA,T; INDUCTION OF LYMPHOMA IN CDF1 MICE BY THE FOOD MUTAGEN, 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE; JPN. J. CANCER RES. 80(12):1176-1178, 1989]"
5078,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,MOUSE,CDF1/FEMALE,ORAL,0; 0.04% IN THE DIET FOR DURATION OF STUDY (STUDY DURATION: 579 D),HEMATOPOIETIC SYSTEM: LYMPHOMA,POSITIVE,"[ESUMI,H, OHGAKI,H, KOHZEN,E, TAKAYAMA,S AND SUGIMURA,T; INDUCTION OF LYMPHOMA IN CDF1 MICE BY THE FOOD MUTAGEN, 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE; JPN. J. CANCER RES. 80(12):1176-1178, 1989]"
5079,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,F344/MALE,ORAL,0; 400 PPM IN DIET FOR 52 WK (STUDY DURATION: 52 WK),COLON: ADENOCARCINOMA,POSITIVE,"[ITO,N, HASEGAWA,R, SANO,M, TAMANO,S, ESUMI,H, TAKAYAMA,S AND SUGIMURA,T; A NEW COLON AND MAMMARY CARCINOGEN IN COOKED FOOD, 2-AMINO-1-METHYL-6- PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP); CARCINOGENESIS 12(8):1503-1506, 1991]"
5080,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,F344/FEMALE,ORAL,0; 400 PPM IN DIET FOR 52 WK (STUDY DURATION: 52 WK),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[ITO,N, HASEGAWA,R, SANO,M, TAMANO,S, ESUMI,H, TAKAYAMA,S AND SUGIMURA,T; A NEW COLON AND MAMMARY CARCINOGEN IN COOKED FOOD, 2-AMINO-1-METHYL-6- PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP); CARCINOGENESIS 12(8):1503-1506, 1991]"
5081,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",,NEGATIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
5082,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 8 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
5083,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.625 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
5084,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1.25 UMOL IN 35 UL DMSO ON D 1, 8, AND 15 AFTER BIRTH (STUDY DURATION: 12 MO)","LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[DOOLEY,KL, VON TUNGELN,LS, BUCCI,T, FU,PP AND KADLUBAR,FF; COMPARATIVE CARCINOGENICITY OF 4-AMINOBIPHENYL AND THE FOOD PYROLYZATES, GLU-P-1, 1Q, PHIP, AND MEIQX IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 62(3):205-209, 1992]"
5085,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,F344/MALE,ORAL,0; 25; 100 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),COLON: CARCINOMA,POSITIVE,"[HASEGAWA,R, SANO,M, TAMANO,S, IMAIDA,K, SHIRAI,T, NAGAO,M, SUGIMURA,T AND ITO,N; DOSE-DEPENDENCE OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) CARCINOGENICITY IN RATS; CARCINOGENESIS 14(12):2553-2557, 1993]"
5086,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,F344/FEMALE,ORAL,0; 25; 100 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[HASEGAWA,R, SANO,M, TAMANO,S, IMAIDA,K, SHIRAI,T, NAGAO,M, SUGIMURA,T AND ITO,N; DOSE-DEPENDENCE OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) CARCINOGENICITY IN RATS; CARCINOGENESIS 14(12):2553-2557, 1993]"
5087,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,TRANSPLACENTAL ; ORAL,0; 100 PPM IN DIET OF MOTHERS BEGINNING 4 WK BEFORE MATING AND CONTINUING THROUGH LACTATION THEN OFFSPRING ADMINISTERED 0; 25; 100 PPM IN DIET FROM WEANING TO 47 WK OF AGE (STUDY DURATION: 54 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[HASEGAWA,R, KIMURA,J, YAONO,M, TAKAHASHI,S, KATO,T, FUTAKUCHI,M, FUKUTAKE,M, FUKUTOME,K, WAKABAYASHI,K, SUGIMURA,T, ITO,N AND SHIRAI,T; INCREASED RISK OF MAMMARY CARCINOMA DEVELOPMENT FOLLOWING TRANSPLACENTAL AND TRANS-BREAST MILK EXPOSURE TO A FOOD-DERIVED CARCINOGEN, 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP), IN SPRAGUE-DAWLEY RATS; CANCER RES. 55(19):4333-4338, 1995]"
5088,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,TRANSPLACENTAL ; ORAL,0; 100 PPM IN DIET OF MOTHERS BEGINNING 4 WK BEFORE MATING AND CONTINUING THROUGH LACTATION THEN OFFSPRING ADMINISTERED 0; 25; 100 PPM IN DIET FROM WEANING TO 47 WK OF AGE (STUDY DURATION: 54 WK),,NEGATIVE,"[HASEGAWA,R, KIMURA,J, YAONO,M, TAKAHASHI,S, KATO,T, FUTAKUCHI,M, FUKUTAKE,M, FUKUTOME,K, WAKABAYASHI,K, SUGIMURA,T, ITO,N AND SHIRAI,T; INCREASED RISK OF MAMMARY CARCINOMA DEVELOPMENT FOLLOWING TRANSPLACENTAL AND TRANS-BREAST MILK EXPOSURE TO A FOOD-DERIVED CARCINOGEN, 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP), IN SPRAGUE-DAWLEY RATS; CANCER RES. 55(19):4333-4338, 1995]"
5089,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 25; 100 PPM IN DIET FROM WEANING TO 47 WK OF AGE (STUDY DURATION: 47 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[HASEGAWA,R, KIMURA,J, YAONO,M, TAKAHASHI,S, KATO,T, FUTAKUCHI,M, FUKUTAKE,M, FUKUTOME,K, WAKABAYASHI,K, SUGIMURA,T, ITO,N AND SHIRAI,T; INCREASED RISK OF MAMMARY CARCINOMA DEVELOPMENT FOLLOWING TRANSPLACENTAL AND TRANS-BREAST MILK EXPOSURE TO A FOOD-DERIVED CARCINOGEN, 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP), IN SPRAGUE-DAWLEY RATS; CANCER RES. 55(19):4333-4338, 1995]"
5090,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 25; 100 PPM IN DIET FROM WEANING TO 47 WK OF AGE (STUDY DURATION: 47 WK),,NEGATIVE,"[HASEGAWA,R, KIMURA,J, YAONO,M, TAKAHASHI,S, KATO,T, FUTAKUCHI,M, FUKUTAKE,M, FUKUTOME,K, WAKABAYASHI,K, SUGIMURA,T, ITO,N AND SHIRAI,T; INCREASED RISK OF MAMMARY CARCINOMA DEVELOPMENT FOLLOWING TRANSPLACENTAL AND TRANS-BREAST MILK EXPOSURE TO A FOOD-DERIVED CARCINOGEN, 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP), IN SPRAGUE-DAWLEY RATS; CANCER RES. 55(19):4333-4338, 1995]"
5091,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 25; 100; 200 PPM IN DIET FOR 48 WK (STUDY DURATION: 48 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[SHIRAI,T, TAMANO,S, SANO,M, MASUI,T, HASEGAWA,R AND ITO,N; CARCINOGENICITY OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) IN RATS: DOSE-RESPONSE STUDIES; PROC. INT. SYMP. PRINCESS TAKAMATSU CANCER RES. FUND 23RD (HETEROCYCLIC AMINES IN COOKED FOODS: POSSIBLE HUMAN CARCINOGENS):232-239, 1995]"
5092,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,STRAIN-CD/FEMALE,GAVAGE,0; 50 UMOL IN 0.5 ML TRIOCTANOIN 1/WK FOR 8 WK (STUDY DURATION: 49 WK),"MAMMARY GLAND: FIBROADENOMA, ADENOCARCINOMA",POSITIVE,"[EL-BAYOUMY,K, CHAE,YH, UPADHYAYA,P, RIVENSON,A, KURTZKE,C, REDDY,B AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF BENZO[A]PYRENE, 1-NITROPYRENE AND 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE ADMINISTERED BY GAVAGE TO FEMALE CD RATS; CARCINOGENESIS 16(2):431-434, 1995]"
5093,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 75 MG/KG IN 5 ML CORN OIL 1/D ON DAYS 1-5 AND 8-12 OF STUDY FOLLOWED 2 DAYS LATER BY A HIGH-FAT DIET FOR DURATION OF STUDY (STUDY DURATION: 27 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[GHOSHAL,A, PREISEGGER,KH, TAKAYAMA,S, THORGEIRSSON,SS AND SNYDERWINE,EG; INDUCTION OF MAMMARY TUMORS IN FEMALE SPRAGUE-DAWLEY RATS BY THE FOOD- DERIVED CARCINOGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE AND EFFECT OF DIETARY FAT; CARCINOGENESIS 15(11):2429-2433, 1994]"
5094,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,MOUSE,TRANSGENIC EU-PIM-1/MALE,ORAL,0; 0.03% IN DIET FOR 31 WK (STUDY DURATION: 31 WK),,NEGATIVE,"[SOERENSEN,IK, MORTENSEN,A, KRISTIANSEN,E, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; SHORT-TERM CARCINOGENICITY TESTING OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) AND 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE (IQ) IN EU-PIM-1 TRANSGENIC MICE; CARCINOGENESIS 17(10):2221-2227, 1996]"
5095,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,MOUSE,TRANSGENIC EU-PIM-1/FEMALE,ORAL,0; 0.03% IN DIET FOR 31 WK (STUDY DURATION: 31 WK),LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[SOERENSEN,IK, MORTENSEN,A, KRISTIANSEN,E, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; SHORT-TERM CARCINOGENICITY TESTING OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) AND 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE (IQ) IN EU-PIM-1 TRANSGENIC MICE; CARCINOGENESIS 17(10):2221-2227, 1996]"
5096,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,MOUSE,NON-TRANSGENIC WILD-TYPE/MALE,ORAL,0; 0.03% IN DIET FOR 31 WK (STUDY DURATION: 31 WK),,NEGATIVE,"[SOERENSEN,IK, MORTENSEN,A, KRISTIANSEN,E, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; SHORT-TERM CARCINOGENICITY TESTING OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) AND 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE (IQ) IN EU-PIM-1 TRANSGENIC MICE; CARCINOGENESIS 17(10):2221-2227, 1996]"
5097,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,MOUSE,NON-TRANSGENIC WILD-TYPE/FEMALE,ORAL,0; 0.03% IN DIET FOR 31 WK (STUDY DURATION: 31 WK),,NEGATIVE,"[SOERENSEN,IK, MORTENSEN,A, KRISTIANSEN,E, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; SHORT-TERM CARCINOGENICITY TESTING OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) AND 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE (IQ) IN EU-PIM-1 TRANSGENIC MICE; CARCINOGENESIS 17(10):2221-2227, 1996]"
5098,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,F344/MALE,ORAL,0; 400 PPM IN DIET FOR 52 WK (STUDY DURATION: 52 WK),PROSTATE (VENTRAL): CARCINOMA,POSITIVE,"[SHIRAI,T, SANO,M, TAMANO,S, TAKAHASHI,S, HIROSE,M, FUTAKUCHI,M, HASEGAWA,R, IMAIDA,K, MATSUMOTO,K, WAKABAYASHI,K, SUGIMURA,T AND ITO,N; THE PROSTATE: A TARGET FOR CARCINOGENICITY OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) FROM COOKED FOOD; CANCER RES. 57(2):195-198, 1997]"
5099,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,MOUSE,WILD-TYPE/MALE,ORAL,0; 0.03% IN DIET FOR 31 WK (STUDY DURATION: 31 WK),,NEGATIVE,"[SOERENSEN,IK, KRISTIANSEN,E, MORTENSEN,A, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; LYMPHOMA INDUCTION BY HETEROCYCLIC AMINES IN EU-PIM-1 TRANSGENIC MICE; ARCH. TOXICOL., SUPPL. 19(APPLIED TOXICOLOGY: APPROACHES THROUGH BASIC SCIENCE):377-386, 1997]"
5100,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,MOUSE,WILD-TYPE/FEMALE,ORAL,0; 0.03% IN DIET FOR 31 WK (STUDY DURATION: 31 WK),,NEGATIVE,"[SOERENSEN,IK, KRISTIANSEN,E, MORTENSEN,A, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; LYMPHOMA INDUCTION BY HETEROCYCLIC AMINES IN EU-PIM-1 TRANSGENIC MICE; ARCH. TOXICOL., SUPPL. 19(APPLIED TOXICOLOGY: APPROACHES THROUGH BASIC SCIENCE):377-386, 1997]"
5101,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,MOUSE,EU-PIM-1/MALE,ORAL,0; 0.03% IN DIET FOR 31 WK (STUDY DURATION: 31 WK),,NEGATIVE,"[SOERENSEN,IK, KRISTIANSEN,E, MORTENSEN,A, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; LYMPHOMA INDUCTION BY HETEROCYCLIC AMINES IN EU-PIM-1 TRANSGENIC MICE; ARCH. TOXICOL., SUPPL. 19(APPLIED TOXICOLOGY: APPROACHES THROUGH BASIC SCIENCE):377-386, 1997]"
5102,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,MOUSE,EU-PIM-1/FEMALE,ORAL,0; 0.03% IN DIET FOR 31 WK (STUDY DURATION: 31 WK),,NEGATIVE,"[SOERENSEN,IK, KRISTIANSEN,E, MORTENSEN,A, VAN KREIJL,C, ADAMSON,RH AND THORGEIRSSON,SS; LYMPHOMA INDUCTION BY HETEROCYCLIC AMINES IN EU-PIM-1 TRANSGENIC MICE; ARCH. TOXICOL., SUPPL. 19(APPLIED TOXICOLOGY: APPROACHES THROUGH BASIC SCIENCE):377-386, 1997]"
5103,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 25; 100; 200 PPM IN DIET FOR DURATION OF STUDY (STUDY DURATION: 48 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[IMAIDA,K, HAGIWARA,A, YADA,H, MASUI,T, HASEGAWA,R, HIROSE,M, SUGIMURA,T, ITO,N AND SHIRAI,T; DOSE-DEPENDENT INDUCTION OF MAMMARY CARCINOMAS IN FEMALE SPRAGUE-DAWLEY RATS WITH 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE; JPN. J. CANCER RES. 87(11):1116-1120, 1996]"
5104,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 12.5; 50 PPM IN DIET FOR DURATION OF STUDY (STUDY DURATION: 48 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[IMAIDA,K, HAGIWARA,A, YADA,H, MASUI,T, HASEGAWA,R, HIROSE,M, SUGIMURA,T, ITO,N AND SHIRAI,T; DOSE-DEPENDENT INDUCTION OF MAMMARY CARCINOMAS IN FEMALE SPRAGUE-DAWLEY RATS WITH 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE; JPN. J. CANCER RES. 87(11):1116-1120, 1996]"
5105,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,HAMSTER,RAPID ACETYLATOR CONGENIC/MALE,ORAL,"75 MG/KG BW/DOSE BY GAVAGE, 2 DOSES/WK FOR 4 WK FOLLOWED BY 1 DOSE/WK FOR 1 WK AND 1 DOSE/2 WK FOR 4 WK, FOLLOWED BY A HIGH-FAT DIET FOR DURATION OF STUDY (STUDY DURATION: 65 WK)",,NEGATIVE,"[FRETLAND,AJ DEVANABOYINA,US FENG,Y LEFF,MA XIAO,GH WEBB,SJ AND HEIN,DW; ORAL ADMINISTRATION OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) YIELDS PHIP-DNA ADDUCTS BUT NOT TUMORS IN MALE SYRIAN HAMSTERS CONGENIC AT THE N-ACETYLTRANSFERASE 2 (NAT2) LOCUS; TOXICOL. SCI. 59(2):226-230, 2001]"
5106,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,HAMSTER,SLOW ACETYLATOR CONGENIC/MALE,ORAL,"75 MG/KG BW/DOSE BY GAVAGE, 2 DOSES/WK FOR 4 WK FOLLOWED BY 1 DOSE/WK FOR 1 WK AND 1 DOSE/2 WK FOR 4 WK, FOLLOWED BY A HIGH-FAT DIET FOR DURATION OF STUDY (STUDY DURATION: 65 WK)",,NEGATIVE,"[FRETLAND,AJ DEVANABOYINA,US FENG,Y LEFF,MA XIAO,GH WEBB,SJ AND HEIN,DW; ORAL ADMINISTRATION OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) YIELDS PHIP-DNA ADDUCTS BUT NOT TUMORS IN MALE SYRIAN HAMSTERS CONGENIC AT THE N-ACETYLTRANSFERASE 2 (NAT2) LOCUS; TOXICOL. SCI. 59(2):226-230, 2001]"
5107,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,F344/MALE,ORAL,0; 100; 300 PPM IN DIET FOR 40 WK (STUDY DURATION: 40 WK),PROSTATE (VENTRAL): PROSTATIC INTRAEPITHELIAL NEOPLASIA,POSITIVE,"[IMAIDA,K SANO,M TAMANO,S ASAMOTO,M OGAWA,K FUTAKUCHI,M AND SHIRAI,T; ORGAN DEPENDENT ENHANCEMENT OF RAT 3,2'-DIMETHYL-4-AMINOBIPHENYL (DMAB) CARCINOGENESIS BY 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP): POSITIVE EFFECTS ON THE INTESTINE BUT NOT THE PROSTATE; CARCINOGENESIS 22(8):1295-1299, 2001]"
5108,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,MOUSE,C57/MALE,ORAL,"0; 300 PPM IN HIGH FAT DIET FOR 40 WK, FOLLOWED BY CONTINUOUS FEEDING OF HIGH FAT DIET UNTIL STUDY TERMINATION (STUDY DURATION: 95 WK)",SMALL INTESTINE: ADENOCARCINOMAS OR ADENOMAS; LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[OCHIAI,M IMAI,H SUGIMURA,T NAGAO,M AND NAKAGAMA,H; INDUCTION OF INTESTINAL TUMORS AND LYMPHOMAS IN C57BL/6N MICE BY A FOOD-BORNE CARCINOGEN, 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE; JPN. J. CANCER RES. 93(5):478-483, 2002]"
5109,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,MOUSE,C57/FEMALE,ORAL,"0; 300 PPM IN HIGH FAT DIET FOR 40 WK, FOLLOWED BY CONTINUOUS FEEDING OF HIGH FAT DIET UNTIL STUDY TERMINATION (STUDY DURATION: 95 WK)",SMALL INTESTINE: ADENOCARCINOMAS OR ADENOMAS,POSITIVE,"[OCHIAI,M IMAI,H SUGIMURA,T NAGAO,M AND NAKAGAMA,H; INDUCTION OF INTESTINAL TUMORS AND LYMPHOMAS IN C57BL/6N MICE BY A FOOD-BORNE CARCINOGEN, 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE; JPN. J. CANCER RES. 93(5):478-483, 2002]"
5110,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Active,,,,RAT,"SPRAGUE DAWLEY/FEMALE, 43 D OLD",ORAL,"75 MG/DOSE, 10 DOSES GIVEN ONCE/D OVER 12 D (STUDY DURATION: 6 MO)",MAMMARY GLAND,POSITIVE (5% INCIDENCE),"[SHAN,L YU,M SCHUT,HAJ AND SNYDERWINE,EG; SUSCEPTIBILITY OF RATS TO MAMMRY GLAND CARCINOGENESIS BY THE FOOD-DERIVED CARCINOGEN 2-AMINO-1-METHLY-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) VARIES WITH AGE AND IS ASSOCIATED WITH THE INDUCTION OF DIFFENTIAL GENE EXPRESSION; AM. J. PATHOL. 165(1):191-202, 2004]"
5111,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,RAT,"SPRAGUE DAWLEY/FEMALE, 150 D OLD",ORAL,"75 MG/DOSE, 10 DOSES GIVEN ONCE/D OVER 12 D (STUDY DURATION: 6 MO)",MAMMARY GLAND,NEGATIVE (0%  INCIDENCE),"[SHAN,L YU,M SCHUT,HAJ AND SNYDERWINE,EG; SUSCEPTIBILITY OF RATS TO MAMMRY GLAND CARCINOGENESIS BY THE FOOD-DERIVED CARCINOGEN 2-AMINO-1-METHLY-6-PHENYLIMIDAZO[4,5-B]PYRIDINE (PHIP) VARIES WITH AGE AND IS ASSOCIATED WITH THE INDUCTION OF DIFFENTIAL GENE EXPRESSION; AM. J. PATHOL. 165(1):191-202, 2004]"
5112,363900904,1530,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N,Inactive,,,,RAT,"F344/MALE, FEMALE",MATERNAL MILK,200 PPM IN DIET TO MOTHERS FROM D OF MATING TO WEANING; THEN OFFSPRING ON CONTROL DIET FOR 60 WKS (STUDY DURATION: 63 WKS),,NEGATIVE; PROSTATE AND COLON TUMORS NOT ENHANCED; MULTIPLICITY OF ABERRANT CRYPT FOCI IN FEMALE OFFSPRING INCREASED,"[IKEDA,Y CHO,YM TAKAHASHI,S TANG,M ASAMOTO,M OGAWA,K AND SHIRAI,T; EQUIVOCAL IMPACT OF TRANSPLACENTAL AND LACTATIONAL EXPOSURE TO A FOOD-DERIVED CARCINOGEN, 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE, ON PROSTATE ADN COLON LESION DEVELOPMENT IN F344; CANCER LETT. 224(1):23-30, 2005]"
5113,363900909,163926,C1=CC2=C(C=CC3=C2C=C[C@@H]([C@H]3O)O)N=C1,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5114,363900909,163926,C1=CC2=C(C=CC3=C2C=C[C@@H]([C@H]3O)O)N=C1,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5115,363900910,,,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5116,363900910,,,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5117,363900911,150583,C1=CC2=C(C3=C(C=C2)[C@@H]([C@H](C=C3)O)O)N=C1,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5118,363900911,150583,C1=CC2=C(C3=C(C=C2)[C@@H]([C@H](C=C3)O)O)N=C1,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5119,363900924,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 8000; 20000; 50000 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),PITUITARY GLAND: ADENOMA,NEGATIVE,"[CLEVENGER,MA, TURNBULL,D, INOUE,H, ENOMOTO,M, ALLEN,JA, HENDERSON,LM AND JONES,E; TOXICOLOGICAL EVALUATION OF NEOSUGAR: GENOTOXICITY, CARCINOGENICITY, AND CHRONIC TOXICITY; J. AM. COLL. TOXICOL. 7(5):643-662, 1988]"
5120,363900924,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 8000; 20000; 50000 PPM IN DIET FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[CLEVENGER,MA, TURNBULL,D, INOUE,H, ENOMOTO,M, ALLEN,JA, HENDERSON,LM AND JONES,E; TOXICOLOGICAL EVALUATION OF NEOSUGAR: GENOTOXICITY, CARCINOGENICITY, AND CHRONIC TOXICITY; J. AM. COLL. TOXICOL. 7(5):643-662, 1988]"
5121,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 100; 700 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5122,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 100; 700 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5123,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,0; 100 NMOL ON DAY 1 OF LIFE (STUDY DURATION: 32 WK),LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5124,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,0; 100 NMOL ON DAY 1 OF LIFE (STUDY DURATION: 32 WK),LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5125,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 7.7 UG TOTAL DOSE (1.1 UG/5 UL, 2.2 UG/10 UL, 4.4 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)","LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
5126,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 7.7 UG TOTAL DOSE (1.1 UG/5 UL, 2.2 UG/10 UL, 4.4 UG/20 UL DMSO ON DAYS 1, 8 AND 15) ADMINISTERED TO NEWBORN ANIMALS (STUDY DURATION: 6 MO)","LUNG: ADENOMA, ADENOCARCINOMA",POSITIVE,"[BUSBY,WF JR, STEVENS,EK, MARTIN,CN, CHOW,FL AND GARNER,RC; COMPARATIVE LUNG TUMORIGENICITY OF PARENT AND MONONITRO-POLYNUCLEAR AROMATIC HYDROCARBONS IN THE BLU:HA NEWBORN MOUSE ASSAY; TOXICOL. APPL. PHARMACOL. 99(3):555-563, 1989]"
5127,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED 1/7, 2/7 AND 4/7 ON DAY 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 32 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH, AMIN,S AND HECHT,SS; THE EFFECTS OF BAY-REGION METHYL SUBSTITUTION ON 6-NITROCHRYSENE MUTAGENICITY IN SALMONELLA TYPHIMURIUM AND TUMORIGENICITY IN NEWBORN MICE; CARCINOGENESIS (LONDON) 10(9):1685-9, 1989]"
5128,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED 1/7, 2/7 AND 4/7 ON DAY 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH, AMIN,S AND HECHT,SS; THE EFFECTS OF BAY-REGION METHYL SUBSTITUTION ON 6-NITROCHRYSENE MUTAGENICITY IN SALMONELLA TYPHIMURIUM AND TUMORIGENICITY IN NEWBORN MICE; CARCINOGENESIS (LONDON) 10(9):1685-9, 1989]"
5129,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 7.5; 15; 30 UL OF A 26.7 NMOL/UL DMSO SOLUTION ON 1,8, AND 15 D OF AGE RESPECTIVELY (TOTAL DOSE: 0; 1.4 UMOL) (STUDY DURATION; 24 WK)",LUNG: ADENOMA,POSITIVE,"[IMAIDA,K, UNEYAMA,C, OGASAWARA,H, HAYASHI,S, FUKUHARA,K, MIYATA,N AND TAKAHASHI,M; INDUCTION OF COLON ADENOCARCINOMAS IN CD RATS AND LUNG ADENOMAS IN ICR MICE BY 6-NITROCHRYSENE: COMPARISON OF CARCINOGENICITY AND ARYL HYDROCARBON HYDROXYLASE INDUCTION IN THE TARGET ORGANS ON EACH SPECIES; CANCER RES. 52(6):1542-1545, 1992]"
5130,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 7.5; 15; 30 UL OF A 26.7 NMOL/UL DMSO SOLUTION ON 1,8, AND 15 D OF AGE RESPECTIVELY (TOTAL DOSE: 0; 1.4 UMOL) (STUDY DURATION: 24 WK)",LUNG: ADENOMA,POSITIVE,"[IMAIDA,K, UNEYAMA,C, OGASAWARA,H, HAYASHI,S, FUKUHARA,K, MIYATA,N AND TAKAHASHI,M; INDUCTION OF COLON ADENOCARCINOMAS IN CD RATS AND LUNG ADENOMAS IN ICR MICE BY 6-NITROCHRYSENE: COMPARISON OF CARCINOGENICITY AND ARYL HYDROCARBON HYDROXYLASE INDUCTION IN THE TARGET ORGANS ON EACH SPECIES; CANCER RES. 52(6):1542-1545, 1992]"
5131,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,RAT,CD-1/MALE,INTRAPERITONEAL,"0; 15; 30; 60; 150; 300 UL OF A 26.7 NMOL/UL DMSO SOLUTION ON 1, 8, 15, 22 AND 29 D OF AGE RESPECTIVELY (TOTAL DOSE: 0; 14.8 UMOL/RAT) (STUDY DURATION: 32 WK)","COLON: ADENOCARCINOMA, ADENOMA",POSITIVE,"[IMAIDA,K, UNEYAMA,C, OGASAWARA,H, HAYASHI,S, FUKUHARA,K, MIYATA,N AND TAKAHASHI,M; INDUCTION OF COLON ADENOCARCINOMAS IN CD RATS AND LUNG ADENOMAS IN ICR MICE BY 6-NITROCHRYSENE: COMPARISON OF CARCINOGENICITY AND ARYL HYDROCARBON HYDROXYLASE INDUCTION IN THE TARGET ORGANS ON EACH SPECIES; CANCER RES. 52(6):1542-1545, 1992]"
5132,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,"0; 15; 30; 60; 150; 300 UL OF A 26.7 NMOL/UL SOLUTION ON 1, 8, 15, 22, AND 29 D OF AGE RESPECTIVELY (TOTAL DOSE: 0; 14.8 UMOL/RAT) (STUDY DURATION: 32 WK)","COLON: ADENOCARCINOMA, ADENOMA/DYSPLASIA",POSITIVE,"[IMAIDA,K, UNEYAMA,C, OGASAWARA,H, HAYASHI,S, FUKUHARA,K, MIYATA,N AND TAKAHASHI,M; INDUCTION OF COLON ADENOCARCINOMAS IN CD RATS AND LUNG ADENOMAS IN ICR MICE BY 6-NITROCHRYSENE: COMPARISON OF CARCINOGENICITY AND ARYL HYDROCARBON HYDROXYLASE INDUCTION IN THE TARGET ORGANS ON EACH SPECIES; CANCER RES. 52(6):1542-1545, 1992]"
5133,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED IN 3 SUBDOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 8 AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[EL-BAYOUMY,K, DESAI,D, UPADHYAYA,P, AMIN,S AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF NITROCHRYSENE ISOMERS IN NEWBORN MICE; CARCINOGENESIS 13(12):2271-2275, 1992]"
5134,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED IN 3 SUBDOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 8 AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMORS,POSITIVE,"[EL-BAYOUMY,K, DESAI,D, UPADHYAYA,P, AMIN,S AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF NITROCHRYSENE ISOMERS IN NEWBORN MICE; CARCINOGENESIS 13(12):2271-2275, 1992]"
5135,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 2.04 UMOL IN 100 UL DMSO INJECTED INTO 3 THORACIC MAMMARY GLANDS ON DAY 1 AND INTO 3 INQUINAL MAMMARY GLANDS ON DAY 2 (STUDY DURATION: 43 WK),"MAMMARY GLAND: FIBROADENOMA, ADENOCARCINOMA, SPINDLE CELL SARCOMA",POSITIVE,"[EL-BAYOUMY,K, RIVENSON,A, UPADHYAYA,P, CHAE,YH AND HECHT,SS; INDUCTION OF MAMMARY CANCER BY 6-NITROCHRYSENE IN FEMALE CD RATS; CANCER RES. 53(16): 3719-3722, 1993]"
5136,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,BLU:HA/MALE,INTRAPERITONEAL,"0; 38.5; 189 UG (TOTAL DOSE) GIVEN TO NEWBORN MICE IN 3 DOSES OF 1/7, 2/7 AND 4/7 OF THE TOTAL ON DAYS 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 26 WK)",LUNG: TUMORS,POSITIVE,"[BUSBY,WF,JR, GARNER,RC, CHOW,FL, MARTIN,CN, STEVENS,EK, NEWBERNE,PM AND WOGAN, GN; 6-NITROCHRYSENE IS A POTENT TUMORIGEN IN NEWBORN MICE; CARCINOGENESIS 6(5):801-803, 1985]"
5137,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,BLU:HA/FEMALE,INTRAPERITONEAL,"0; 38.5; 189 UG (TOTAL DOSE) GIVEN TO NEWBORN MICE IN 3 DOSES OF 1/7, 2/7 AND 4/7 OF THE TOTAL ON DAYS 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 26 WK)",LUNG: TUMORS,POSITIVE,"[BUSBY,WF,JR, GARNER,RC, CHOW,FL, MARTIN,CN, STEVENS,EK, NEWBERNE,PM AND WOGAN, GN; 6-NITROCHRYSENE IS A POTENT TUMORIGEN IN NEWBORN MICE; CARCINOGENESIS 6(5):801-803, 1985]"
5138,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/ FEMALE,INJECTION,0; 2.04 UMOL IN 0.1 ML DMSO INJECTED BENEATH EACH OF THREE LEFT THORACIC NIPPLES THEN ON THE NEXT DAY BENEATH EACH THE THREE LEFT INGUINAL NIPPLES (STUDY DURATION: 38 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
5139,363900925,24121,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",LIVER: ADENOMA OR CARCINOMA; LUNG: TUMOR,POSITIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
5140,363900926,149858,C1=CC=C2C(=C1)C3=C(C=CC=N3)C4=C2O4,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5141,363900926,149858,C1=CC=C2C(=C1)C3=C(C=CC=N3)C4=C2O4,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5142,363900927,3028003,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)N=O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5143,363900927,3028003,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)N=O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5144,363900928,1853,C1=CC=C2C(=C1)C3=CC=CC=C3NC2=O,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5145,363900928,1853,C1=CC=C2C(=C1)C3=CC=CC=C3NC2=O,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 5; 10 AND 20 UL OF A 0.05 MOLAR SOLUTION ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (TOTAL DOSE: 1.75 UMOL) (STUDY DURATION: 52 WK)",,NEGATIVE,"[KUMAR,S, SIKKA,HC, DUBEY,SK, CZECH,A, GEDDIE,N, WANG,CX AND LAVOIE,EJ; MUTAGENICITY AND TUMORIGENICITY OF DIHYDRODIOLS, DIOL EPOXIDES, AND OTHER DERIVATIVES OF BENZO[F]QUINOLINE AND BENZO[H]QUINOLINE; CANCER RES. 49(1):20-24, 1989]"
5146,363900929,104944,C1=CC2C(O2)C=C1,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 7.4; 18.6 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5147,363900929,104944,C1=CC2C(O2)C=C1,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 7.4; 18.6 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5148,363900932,149186,C1=C[C@H]([C@@H](C=C1)O)O,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 10; 50 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5149,363900932,149186,C1=C[C@H]([C@@H](C=C1)O)O,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 10; 50 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5150,363900934,152006,C1=C[C@@H]2[C@@H](O2)[C@@H]([C@H]1O)O,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 2.7; 13.7 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5151,363900934,152006,C1=C[C@@H]2[C@@H](O2)[C@@H]([C@H]1O)O,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 2.7; 13.7 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5152,363900935,147504,C1=C[C@H]2[C@H](O2)[C@@H]([C@H]1O)O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 13.7 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5153,363900935,147504,C1=C[C@H]2[C@H](O2)[C@@H]([C@H]1O)O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 13.7 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5154,363900936,147652,C1=C[C@@H]2[C@@H](O2)[C@H]([C@@H]1O)O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 13.7 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5155,363900936,147652,C1=C[C@@H]2[C@@H](O2)[C@H]([C@@H]1O)O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 13.7 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
5156,363900952,135511839,COC(=O)N/N=C/C1=[N+](C2=CC=CC=C2[N+](=C1)[O-])[O-],Active,,,,RAT,WISTAR/MALE,ORAL,0; 50; 100; 250; 500 PPM IN DIET FOR 12 MO (STUDY DURATION: 12 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[SHIOZAWA,M, KOEDA,T AND FUJIWARA,H; LIVER CARCINOGENESIS BY CARBADOX IN WISTAR RATS; IGAKU TO SEIBUTSUGAKU 127(4):283-288, 1993]"
5157,363900952,135511839,COC(=O)N/N=C/C1=[N+](C2=CC=CC=C2[N+](=C1)[O-])[O-],Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 50; 100; 250; 500 PPM IN DIET FOR 12 MO (STUDY DURATION: 12 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[SHIOZAWA,M, KOEDA,T AND FUJIWARA,H; LIVER CARCINOGENESIS BY CARBADOX IN WISTAR RATS; IGAKU TO SEIBUTSUGAKU 127(4):283-288, 1993]"
5158,363900954,115211,C1=CC=C2C(=C1)C3=C(C=C2[N+](=O)[O-])C4=C(C=C3)[C@@H]([C@H](C=C4)O)O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5159,363900954,115211,C1=CC=C2C(=C1)C3=C(C=C2[N+](=O)[O-])C4=C(C=C3)[C@@H]([C@H](C=C4)O)O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5160,363900992,107900,C1=CC=C2C(=C1)C3=C(C=C2N)C4=C(C=C3)[C@@H]([C@H](C=C4)O)O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5161,363900992,107900,C1=CC=C2C(=C1)C3=C(C=C2N)C4=C(C=C3)[C@@H]([C@H](C=C4)O)O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) 1/7, 2/7 AND 4/7 ADMINISTERED ON DAYS 1, 8 AND 15 OF LIFE RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF 6-NITROCHRYSENE AND ITS METABOLITES IN NEWBORN MICE; CARCINOGENESIS 10(2): 369-372, 1989]"
5162,363900993,3763,C(C(F)(F)F)(OC(F)F)Cl,Inactive,,,,MOUSE,SWISS/MALE,INHALATION,0; 0.1; 0.4% IN AIR 4 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: 81 WK),,NEGATIVE,"[BADEN,JM, KUNDOMAL,YR, MAZZE,RI AND KOSEK,JC; CARCINOGEN BIOASSAY OF ISOFLURANE IN MICE ANESTHESIOLOGY 69(5):750-753, 1988]"
5163,363900993,3763,C(C(F)(F)F)(OC(F)F)Cl,Inactive,,,,MOUSE,SWISS/FEMALE,INHALATION,0; 0.1; 0.4% IN AIR 4 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: 81 WK),,NEGATIVE,"[BADEN,JM, KUNDOMAL,YR, MAZZE,RI AND KOSEK,JC; CARCINOGEN BIOASSAY OF ISOFLURANE IN MICE ANESTHESIOLOGY 69(5):750-753, 1988]"
5164,363900994,17317,CO[Si](CCCOCC1CO1)(OC)OC,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 5 MG IN ACETONE 3/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[DEPASS,LR, BALLANTYNE,B, FOWLER,EH AND WEIL,CS; DERMAL ONCOGENICITY STUDIES ON TWO METHOXYSILANES AND TWO ETHOXYSILANES IN MALE C3H MICE; FUNDAM. APPL. TOXICOL. 12(3):579-583, 1989]"
5165,363900995,154915,CCO[Si](CCC1CCC2C(C1)O2)(OCC)OCC,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 2 MG IN ACETONE 3/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[DEPASS,LR, BALLANTYNE,B, FOWLER,EH AND WEIL,CS; DERMAL ONCOGENICITY STUDIES ON TWO METHOXYSILANES AND TWO ETHOXYSILANES IN MALE C3H MICE; FUNDAM. APPL. TOXICOL. 12(3):579-583, 1989]"
5166,363900996,102856,CCO[Si](CCCOCC1CO1)(OCC)OCC,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 2 MG IN ACETONE 3/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),,NEGATIVE,"[DEPASS,LR, BALLANTYNE,B, FOWLER,EH AND WEIL,CS; DERMAL ONCOGENICITY STUDIES ON TWO METHOXYSILANES AND TWO ETHOXYSILANES IN MALE C3H MICE; FUNDAM. APPL. TOXICOL. 12(3):579-583, 1989]"
5167,363900997,18819,CO[Si](CCC1CCC2C(C1)O2)(OC)OC,Active,,,,MOUSE,C3H/MALE,DERMAL,0; 25 MG IN ACETONE 3/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),SKIN: CARCINOMA,POSITIVE,"[DEPASS,LR, BALLANTYNE,B, FOWLER,EH AND WEIL,CS; DERMAL ONCOGENICITY STUDIES ON TWO METHOXYSILANES AND TWO ETHOXYSILANES IN MALE C3H MICE; FUNDAM. APPL. TOXICOL. 12(3):579-583, 1989]"
5168,363900999,104856,CN(CCCC(C1=CN=CC=C1)O)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (TOTAL DOSE: 0; 0.69 MMOL/KG) (STUDY DURATION: 112 WK),"LUNG: ADENOCARCINOMA, ADENOSQUAMOUS CARCINOMA; EXOCRINE PANCREAS: ACINAR ADENOMA OR ACINAR ADENOCARCINOMA OR DUCTAL ADENOCARCINOMA",POSITIVE,"[RIVENSON,A, HOFFMANN,D, PROKOPCZYK,B, AMIN,S AND HECHT,SS; INDUCTION OF LUNG AND EXOCRINE PANCREAS TUMORS IN F344 RATS BY TOBACCO-SPECIFIC AND ARECA-DERIVED N-NITROSAMINES; CANCER RES. 48(23):6912-6917, 1988]"
5169,363900999,104856,CN(CCCC(C1=CN=CC=C1)O)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 10; 50 UMOL TOTAL DOSE ADMINISTERED IN SUBDOSES 3/WK FOR 7 WK (STUDY DURATION: 37 WK),LUNG: TUMOR,POSITIVE,"[HOFFMANN,D, DJORDJEVIC,MV, RIVENSON,A, ZANG,E, DESAI,D AND AMIN,S; A STUDY OF TOBACCO CARCINOGENESIS. LI. RELATIVE POTENCIES OF TOBACCO-SPECIFIC N-NITROSAMINES AS INDUCERS OF LUNG TUMORS IN A/J MICE; CANCER LETT. 71(1-3): 25-30, 1993]"
5170,363901000,62103,COC(=O)C1=CCCN(C1)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 20 PPM IN DRINKING WATER FOR DURATION OF STUDY (TOTAL DOSE: 0; 4.1 MMOL/KG) (STUDY DURATION: 128 WK),EXOCRINE PANCREAS: ACINAR ADENOMA,POSITIVE,"[RIVENSON,A, HOFFMANN,D, PROKOPCZYK,B, AMIN,S AND HECHT,SS; INDUCTION OF LUNG AND EXOCRINE PANCREAS TUMORS IN F344 RATS BY TOBACCO-SPECIFIC AND ARECA-DERIVED N-NITROSAMINES; CANCER RES. 48(23):6912-6917, 1988]"
5171,363901002,154203,COC1=C2C(=C3CCCC3=C1)C=CC4=CC=CC=C42,Active,,,,MOUSE,"TO/MALE, FEMALE",DERMAL,0; 50 UG (10 UL OF A 0.5% W/V TOLUENE SOLUTION) 2/WK FOR 70 WK (STUDY DURATION: 70 WK),SKIN: PAPILLOMA OR CARCINOMA,POSITIVE,"[BHATT,TS; SYNTHESIS AND BIOLOGICAL ACTIVITY OF SOME FURTHER CYCLOPENTA[A]PHENANTHRENES; CARCINOGENESIS 9(9):1669-1672, 1988]"
5172,363901003,154202,C1CC2=CC(=C3C(=C2C1)C=CC4=CC=CC=C43)O,Active,,,,MOUSE,"TO/MALE, FEMALE",DERMAL,0; 50 UG (10 UL OF A 0.5% W/V TOLUENE SOLUTION) 2/WK FOR 70 WK (STUDY DURATION: 70 WK),SKIN: PAPILLOMA OR CARCINOMA,POSITIVE,"[BHATT,TS; SYNTHESIS AND BIOLOGICAL ACTIVITY OF SOME FURTHER CYCLOPENTA[A]PHENANTHRENES; CARCINOGENESIS 9(9):1669-1672, 1988]"
5173,363901004,154201,CCCCCCOC1=C2C(=C3CCC(=O)C3=C1)C=CC4=CC=CC=C42,Inactive,,,,MOUSE,"TO/MALE, FEMALE",DERMAL,0; 50 UG (10 UL OF A 0.5% W/V TOLUENE SOLUTION) 2/WK FOR 70 WK (STUDY DURATION: 70 WK),,NEGATIVE,"[BHATT,TS; SYNTHESIS AND BIOLOGICAL ACTIVITY OF SOME FURTHER CYCLOPENTA[A]PHENANTHRENES; CARCINOGENESIS 9(9):1669-1672, 1988]"
5174,363901005,59909,C1=CC2=C3C(=C1)C=C(OC3=CC=C2)[N+](=O)[O-],Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 0.5 MG IN DMSO 1/WK FOR DURATION OF STUDY (TOTAL DOSE: 0; 19.5 MG) (STUDY DURATION: 271 D),INJECTION SITE: FIBROSARCOMA,POSITIVE,"[SALMON,RJ, BUISSON,JP, HENDRICKX,B, VIELH,PH, AUSSEPE,L, MOENS,W AND ROYER,R; IN-VIVO CARCINOGENICITY OF 2-NITRO-OXAPHENALENES; CARCINOGENESIS 10(5):803-805, 1989]"
5175,363901006,59910,COC1=C2C=CC=C3C2=C(C=C1)C=C(O3)[N+](=O)[O-],Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 0.5 MG IN DMSO 1/WK FOR DURATION OF STUDY (TOTAL DOSE: 0; 10.23 MG) (STUDY DURATION: 156 D),INJECTION SITE: FIBROSARCOMA,POSITIVE,"[SALMON,RJ, BUISSON,JP, HENDRICKX,B, VIELH,PH, AUSSEPE,L, MOENS,W AND ROYER,R; IN-VIVO CARCINOGENICITY OF 2-NITRO-OXAPHENALENES; CARCINOGENESIS 10(5):803-805, 1989]"
5176,363901008,25418,CCN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 1.8 MG/KG 1/WK FOR 23-30 WK (TOTAL DOSE: 0; 0.53 MMOL) (STUDY DURATION: LIFETIME),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA, CHOLANGIOCARCINOMA, CHOLANGIOMA, HEMANGIOSARCOMA; NASAL MUCOSA: CARCINOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
5177,363901008,25418,CCN(C)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 2.3 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 30 WK (TOTAL DOSE 1.6 MMOL) (STUDY DURATION: LIFESPAN),LIVER: HEMANGIOSARCOMA; LUNG: TUMOR; KIDNEY: TUMOR,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
5178,363901008,25418,CCN(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 4.6 MG/WK FOR A TOTAL DOSE OF 1.6 MMOL (STUDY DURATION: 60 WK),LIVER: TUMOR; LUNG: TUMOR; NASAL MUCOSA: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
5179,363901008,25418,CCN(C)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 4.6 MG/WK FOR A TOTAL DOSE OF 1.4 MMOL (STUDY DURATION: 40 WK),LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
5180,363901009,25805,CCCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 5.6 MG/KG 1/WK FOR 23-30 WK (TOTAL DOSE: 0; 1.1 MMOL) (STUDY DURATION: LIFETIME),"LIVER: HEPATOCELLULAR ADENOMA, HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIAL ADENOMA; NASAL MUCOSA: CARCINOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
5181,363901009,25805,CCCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 5.6 MG/KG 1/WK FOR 23-30 WK (TOTAL DOSE: 0; 1.1 MMOL) (STUDY DURATION: LIFETIME),"LUNG: ALVEOLAR/BRONCHIAL ADENOMA; NASAL MUCOSA: CARCINOMA, ADENOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
5182,363901009,25805,CCCCCN(C)N=O,Inactive,,,,RAT,"WISTAR/MALE,FEMALE",INTRAPERITONEAL,"0; 6; 12.5 MG/KG ONCE AT 1 AND 3 DAYS OF AGE, RESPECTIVELY (STUDY DURATION: >82 WK)",,NEGATIVE,"[MIRVISH,SS, NICKOLS,J, WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. 107(2):171-177, 1996]"
5183,363901009,25805,CCCCCN(C)N=O,Active,,,,RAT,"WISTAR/MALE,FEMALE",INTRAPERITONEAL,0; 50 MG/KG (7 FEMALE RATS); 60 MG/KG (2 FEMALE RATS); 70 MG/KG (10 MALE RATS) ONCE AT 42-50 DAYS OF AGE (STUDY DURATION: >63 WK),ESOPHAGUS: CARCINOMA,POSITIVE,"[MIRVISH,SS, NICKOLS,J, WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. 107(2):171-177, 1996]"
5184,363901009,25805,CCCCCN(C)N=O,Inactive,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAPERITONEAL,"0; 3; 6 MG/KG ONCE ON DAYS 1 AND 3 OF AGE, RESPECTIVELY (STUDY DURATION: >75 WK)",,NEGATIVE,"[MIRVISH,SS, NICKOLS,J, WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. 107(2):171-177, 1996]"
5185,363901009,25805,CCCCCN(C)N=O,Inactive,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAPERITONEAL,0; 70 MG/KG (3 MALE HAMSTERS); 100 MG/KG (11 FEMALE HAMSTERS) ONCE AT 46-49 DAYS OF AGE (STUDY DURATION: >43 WK),,NEGATIVE,"[MIRVISH,SS, NICKOLS,J, WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. 107(2):171-177, 1996]"
5186,363901009,25805,CCCCCN(C)N=O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAPERITONEAL,0; 75 MG/KG 1/WK FOR 6 WK BEGINNING AT 38 DAYS OF AGE (STUDY DURATION: >33 WK),FORESTOMACH: PAPILLOMA; LUNG: ADENOMA; NASAL CAVITY: TUMOR,POSITIVE,"[SHAMON,LA, PEZZUTO,JM, GRAVES,JM, MEHTA,RR, WANGCHAROENTRAKUL,S, SANGSUWAN,R, CHAICHANA,S, TUCHINDA,P, CLEASON,P AND REUTRAKUL,V; EVALUATION OF THE MUTAGENIC, CYTOTOXIC, AND ANTITUMOR POTENTIAL OF TRIPTOLIDE, A HIGHLY OXYGENATED DITERPENE ISOLATED FROM TRIPTERYGIUM WILFORDII; CANCER LETT. 112(1):113-117, 1997]"
5187,363901009,25805,CCCCCN(C)N=O,Active,,,,MOUSE,"SWISS/MALE,FEMALE",INTRAPERITONEAL,0; 15 MG/KG 1/WK FOR 3 WK BEGINNING AT 38 DAYS OF AGE (STUDY DURATION: >79 WK),ESOPHAGUS: PAPILLOMA; LUNG: ADENOMA,POSITIVE,"[MIRVISH,SS, NICKOLS,J, WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. 107(2):171-177, 1996]"
5188,363901009,25805,CCCCCN(C)N=O,Active,,,,MOUSE,"101/N/MALE, FEMALE",ORAL,0; 0.0015% IN DRINKING WATER FOR 8 WK (STUDY DURATION: 24 WK),ESOPHAGUS: TUMOR,POSITIVE,"[KUROOKA,M, HONGYO,T, NAKAJIMA,H, BASKAR,B, LI,LY, FUKUDA,K, SUTOH,K, MIYATA,M, MATSUDA,H AND NOMURA,T; HIGH INCIDENCE OF ESOPHAGEAL CANCER IN ESOPHAGEAL ACHALASIA BY THE ORAL ADMINISTRATION OF N-AMYL-N-METHYLNITROSAMINE AND ITS PREVENTION BY NICARDIPINE HYDROCHLORIDE IN MICE; CANCER LETT. 127(1-2):55-61, 1998]"
5189,363901009,25805,CCCCCN(C)N=O,Active,,,,MOUSE,"STX/LE/MALE,FEMALE",ORAL,0; 0.0015% IN DRINKING WATER FOR 8 WK (STUDY DURATION: 24 WK),ESOPHAGUS: TUMOR,POSITIVE,"[KUROOKA,M, HONGYO,T, NAKAJIMA,H, BASKAR,B, LI,LY, FUKUDA,K, SUTOH,K, MIYATA,M, MATSUDA,H AND NOMURA,T; HIGH INCIDENCE OF ESOPHAGEAL CANCER IN ESOPHAGEAL ACHALASIA BY THE ORAL ADMINISTRATION OF N-AMYL-N-METHYLNITROSAMINE AND ITS PREVENTION BY NICARDIPINE HYDROCHLORIDE IN MICE; CANCER LETT. 127(1-2):55-61, 1998]"
5190,363901009,25805,CCCCCN(C)N=O,Active,,,,MOUSE,"BXH-8/MALE, FEMALE",ORAL,0; 0.0015% IN DRINKING WATER FOR 8 WK (STUDY DURATION: 24 WK),ESOPHAGUS: TUMOR,POSITIVE,"[KUROOKA,M, HONGYO,T, NAKAJIMA,H, BASKAR,B, LI,LY, FUKUDA,K, SUTOH,K, MIYATA,M, MATSUDA,H AND NOMURA,T; HIGH INCIDENCE OF ESOPHAGEAL CANCER IN ESOPHAGEAL ACHALASIA BY THE ORAL ADMINISTRATION OF N-AMYL-N-METHYLNITROSAMINE AND ITS PREVENTION BY NICARDIPINE HYDROCHLORIDE IN MICE; CANCER LETT. 127(1-2):55-61, 1998]"
5191,363901009,25805,CCCCCN(C)N=O,Active,,,,MOUSE,"C57BL/MALE,FEMALE",ORAL,0; 0.0015% IN DRINKING WATER FOR 8 WK (STUDY DURATION: 24 WK),ESOPHAGUS:TUMOR,POSITIVE,"[KUROOKA,M, HONGYO,T, NAKAJIMA,H, BASKAR,B, LI,LY, FUKUDA,K, SUTOH,K, MIYATA,M, MATSUDA,H AND NOMURA,T; HIGH INCIDENCE OF ESOPHAGEAL CANCER IN ESOPHAGEAL ACHALASIA BY THE ORAL ADMINISTRATION OF N-AMYL-N-METHYLNITROSAMINE AND ITS PREVENTION BY NICARDIPINE HYDROCHLORIDE IN MICE; CANCER LETT. 127(1-2):55-61, 1998]"
5192,363901009,25805,CCCCCN(C)N=O,Inactive,,,,RAT,"WISTAR/MALE,FEMALE",INTRAPERITONEAL,0; 6 MG/KG ONCE TO NEWBORN ANIMALS (STUDY DURATION: LIFETIME),,NEGATIVE,"[MIRVISH,SS NICHOLS,J WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. (SHANNON, IREL.) 107(2):171-177, 1996]"
5193,363901009,25805,CCCCCN(C)N=O,Inactive,,,,RAT,"WISTAR/MALE,FEMALE",INTRAPERITONEAL,0; 12.5 MG/KG ONCE TO 3 D-OLD ANIMALS (STUDY DURATION: LIFETIME),,NEGATIVE,"[MIRVISH,SS NICHOLS,J WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. (SHANNON, IREL.) 107(2):171-177, 1996]"
5194,363901009,25805,CCCCCN(C)N=O,Active,,,,RAT,"WISTAR/MALE,FEMALE",INTRAPERITONEAL,0; 50-70 MG/KG ONCE TO ADULT ANIMALS (STUDY DURATION: LIFETIME),"ESOPHAGUS: PAPILLOMA, CARCINOMA",POSITIVE,"[MIRVISH,SS NICHOLS,J WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. (SHANNON, IREL.) 107(2):171-177, 1996]"
5195,363901009,25805,CCCCCN(C)N=O,Inactive,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAPERITONEAL,0; 3 MG/KG ONCE TO NEWBORN ANIMALS (STUDY DURATION: LIFETIME),,NEGATIVE,"[MIRVISH,SS NICHOLS,J WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. (SHANNON, IREL.) 107(2):171-177, 1996]"
5196,363901009,25805,CCCCCN(C)N=O,Inactive,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAPERITONEAL,0; 6 MG/KG ONCE TO 3 D-OLD ANIMALS (STUDY DURATION: LIFETIME),,NEGATIVE,"[MIRVISH,SS NICHOLS,J WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. (SHANNON, IREL.) 107(2):171-177, 1996]"
5197,363901009,25805,CCCCCN(C)N=O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAPERITONEAL,0; 70-100 MG/KG ONCE TO ADULT ANIMALS (STUDY DURATION: LIFETIME),ESOPHAGUS: PAPILLOMA OR CARCINOMA,POSITIVE,"[MIRVISH,SS NICHOLS,J WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. (SHANNON, IREL.) 107(2):171-177, 1996]"
5198,363901009,25805,CCCCCN(C)N=O,Active,,,,HAMSTER,"SYRIAN/MALE,FEMALE",INTRAPERITONEAL,0; 75 MG/KG 1/WK FOR 6 WK TO ADULT ANIMALS (STUDY DURATION: LIFETIME),"ESOPHAGUS: PAPILLOMA; FORESTOMACH: PAPILLOMA; LUNG: ADENOMA; NASAL CAVITY: ADENOMA, ADENOCARCINOMA OR SQUAMOUS CARCINOMA; LIVER: TUMOR, HEMANGIOMA; BILE DUCT: PAPILLOMA",POSITIVE,"[MIRVISH,SS NICHOLS,J WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. (SHANNON, IREL.) 107(2):171-177, 1996]"
5199,363901009,25805,CCCCCN(C)N=O,Active,,,,MOUSE,"SWISS/MALE,FEMALE",INTRAPERITONEAL,0; 15 MG/KG 1/WK FOR 3 WK TO ADULT ANIMALS (STUDY DURATION: LIFETIME),ESOPHAGUS: PAPILLOMA; LUNG: ADENOMA,POSITIVE,"[MIRVISH,SS NICHOLS,J WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. (SHANNON, IREL.) 107(2):171-177, 1996]"
5200,363901010,34273,CCCCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 6.2 MG/KG 1/WK FOR 50 WK (TOTAL DOSE: 0; 2.1 MMOL) (STUDY DURATION: LIFETIME),"LIVER: HEPATOCELLULAR ADENOMA, CHOLANGIOMA, HEMANGIOSARCOMA; LUNG: ALVEOLAR/ BRONCHIAL ADENOMA; NASAL MUCOSA: CARCINOMA, ADENOMA; URINARY BLADDER: TRANSITIONAL CELL PAPILLOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
5201,363901010,34273,CCCCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 6.2 MG/KG 1/WK FOR 50 WK (TOTAL DOSE: 0; 2.1 MMOL) (STUDY DURATION: LIFETIME),"LIVER: CHOLANGIOMA; LUNG: ALVEOLAR/BRONCHIAL CARCINOMA, ALVEOLAR/BRONCHIAL ADENOMA; URINARY BLADDER: TRANSITIONAL CELL CARCINOMA, TRANSITIONAL CELL PAPILLOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
5202,363901010,34273,CCCCCCN(C)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 3.75 MG IN 0.4 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 30 WK (TOTAL DOSE 1.6 MMOL) (STUDY DURATION: LIFESPAN),BLADDER: TUMOR; LUNG: SQUAMOUS CELL CARCINOMA; UTERUS: TUMOR,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
5203,363901011,27822,CCCCCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 6.8 MG/KG 1/WK FOR 40 WK (TOTAL DOSE: 0; 2.1 MMOL) (STUDY DURATION: LIFETIME),"LIVER: CHOLANGIOMA, HEMANGIOSARCOMA; LUNG: ALVEOLAR/BRONCHIAL CARCINOMA, ALVEOLAR/BRONCHIAL ADENOMA, ADENOSQUAMOUS CARCINOMA; NASAL MUCOSA: CARCINOMA, ADENOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
5204,363901011,27822,CCCCCCCN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 6.8 MG/KG 1/WK FOR 40 WK (TOTAL DOSE: 0; 2.1 MMOL) (STUDY DURATION: LIFETIME),"LIVER: CHOLANGIOMA; LUNG: ALVEOLAR/BRONCHIAL CARCINOMA, ALVEOLAR/BRONCHIAL ADENOMA, ADENOSQUAMOUS CARCINOMA; NASAL MUCOSA: CARCINOMA, ADENOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
5205,363901012,21567,CN(C1CCCCC1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 2.5 MG/KG 1/WK FOR 50 WK (TOTAL DOSE: 0; 0.9 MMOL) (STUDY DURATION: LIFETIME),"LUNG: ALVEOLAR/BRONCHIAL ADENOMA, ADENOSQUAMOUS CARCINOMA",POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
5206,363901012,21567,CN(C1CCCCC1)N=O,Inactive,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 2.5 MG/KG 1/WK FOR 50 WK (TOTAL DOSE: 0; 0.9 MMOL) (STUDY DURATION: LIFETIME),,NEGATIVE,"[LIJINSKY,W AND KOVATCH,RM; COMPARATIVE CARCINOGENESIS BY NITROSOMETHYLALKYLAMINES IN SYRIAN HAMSTERS; CANCER RES. 48(23):6648-6652, 1988]"
5207,363901016,6440822,CCC/C=C/C=C/C=C/C1C2C1C3C(C2/C=C\C=C)/C=C/CC(=O)O[C@@]45C[C@H]([C@]6([C@H]([C@@H]4[C@]5(COC3=O)C)C=C(C[C@]7(C6C=C(C7=O)C)O)CO)O)C,Inactive,,,,MOUSE,CD-1/FEMALE (15),DERMAL,0; 2 UG IN 0.1 ML OF METHANOL 2/WK FOR 16 WK BEGINNING 1 WK POST CARCINOGEN DOSE THEN 5 UG 2/WK FOR 13 WK (STUDY DURATION: 30 WK),,NEGATIVE,"[HIROTA,M, SUTTAJIT,M, SUGURI,H, ENDO,Y, SHUDO,K, WONGCHAI,V, HECKER,E AND FUJIKI,H;A NEW TUMOR PROMOTER FROM THE SEED OIL OF JATROPHA CURCAS L., AN INTRAMOLECULAR DIESTER OF 12-DEOXY-16-HYDROXYPHORBOL; CANCER RES. 48(20): 5800-5804, 1988]"
5208,363901027,1174,C1=CNC(=O)NC1=O,Active,,,,RAT,F344/MALE,ORAL,0; 3% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"URINARY BLADDER: TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA; RENAL PELVIS: PAPILLOMA, CARCINOMA",POSITIVE,"[FUKUSHIMA,S, TANAKA,H, ASAKAWA,E, KAGAWA,M, YAMAMOTO,A AND SHIRAI,T; CARCINOGENICITY OF URACIL, A NONGENOTOXIC CHEMICAL, IN RATS AND MICE AND ITS RATIONALE; CANCER RES. 52(7):1675-1680, 1992]"
5209,363901027,1174,C1=CNC(=O)NC1=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 3% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[FUKUSHIMA,S, TANAKA,H, ASAKAWA,E, KAGAWA,M, YAMAMOTO,A AND SHIRAI,T; CARCINOGENICITY OF URACIL, A NONGENOTOXIC CHEMICAL, IN RATS AND MICE AND ITS RATIONALE; CANCER RES. 52(7):1675-1680, 1992]"
5210,363901027,1174,C1=CNC(=O)NC1=O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3% IN DIET FOR WK 1-6 OF STUDY THEN 0; 2.5% IN DIET FOR WK 7-96 (STUDY DURATION: 96 WK),,NEGATIVE,"[FUKUSHIMA,S, TANAKA,H, ASAKAWA,E, KAGAWA,M, YAMAMOTO,A AND SHIRAI,T; CARCINOGENICITY OF URACIL, A NONGENOTOXIC CHEMICAL, IN RATS AND MICE AND ITS RATIONALE; CANCER RES. 52(7):1675-1680, 1992]"
5211,363901027,1174,C1=CNC(=O)NC1=O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3% IN DIET FOR WK 1-6 OF STUDY THEN 0; 2.5% IN DIET FOR WK 7-96 (STUDY DURATION: 96 WK),URINARY BLADDER: TRANSITIONAL CELL CARCINOMA,POSITIVE,"[FUKUSHIMA,S, TANAKA,H, ASAKAWA,E, KAGAWA,M, YAMAMOTO,A AND SHIRAI,T; CARCINOGENICITY OF URACIL, A NONGENOTOXIC CHEMICAL, IN RATS AND MICE AND ITS RATIONALE; CANCER RES. 52(7):1675-1680, 1992]"
5212,363901030,174174,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 25 UG/KG BW 2/D FOR 5 D TO VIRGIN FEMALE RATS (STUDY DURATION: 28 MO),,NEGATIVE,"[CABELLO,G VALENZUELA,M VILAXA,A DURAN,V RUDOLPH,I HREPIC,N AND CALAF,G; A RAT MAMMARY TUMOR MODEL INDUCED BY THE ORGANOPHOSPHOROUS PESTICIDES PARATHION AND MALATHION, POSSIBLY THROUGH ACETYLCHOLINESTERASE INHIBITION; ENVIRON. HEALTH PERSPECT. 109(5):471-479, 2001]"
5213,363901039,12302,CCCC[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,GAVAGE,0; 2 MMOL/KG BW 1/WK FOR 50 WK (STUDY DURATION: 83 WK),,NEGATIVE,"[FIALA,ES, SODUM,RS, HUSSAIN,NS, RIVENSON,A AND DOLAN,L; SECONDARY NITROALKANES: INDUCTION OF DNA REPAIR IN RAT HEPATOCYTES, ACTIVATION BY ARYL SULFOTRANSFERASE AND HEPATOCARCINOGENICITY OF 2-NITROBUTANE AND 3-NITROPENTANE IN MALE F344 RATS; TOXICOLOGY 99(1-2):89-97, 1995]"
5214,363901040,11749,CCC(C)[N+](=O)[O-],Active,,,,RAT,F344/MALE,GAVAGE,0; 2 MMOL/KG BW 1/WK FOR 50 WK (STUDY DURATION: 83 WK),LIVER: CARCINOMA,POSITIVE,"[FIALA,ES, SODUM,RS, HUSSAIN,NS, RIVENSON,A AND DOLAN,L; SECONDARY NITROALKANES: INDUCTION OF DNA REPAIR IN RAT HEPATOCYTES, ACTIVATION BY ARYL SULFOTRANSFERASE AND HEPATOCARCINOGENICITY OF 2-NITROBUTANE AND 3-NITROPENTANE IN MALE F344 RATS; TOXICOLOGY 99(1-2):89-97, 1995]"
5215,363901043,7434,C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],Inactive,,,,RAT,F344/MALE,ORAL,0; 5; 60; 300 PPM IN THE DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[REDDY,TV, OLSON,GR, WIECHMAN,B, REDDY,G, TORSELLA,JA, DANIEL,FB AND LEACH,GJ; CHRONIC TOXICITY OF 1,3,5-TRINITROBENZENE IN FISCHER 344 RATS; INT. J. TOXICOL. 20(2): 59-67, 20001]"
5216,363901043,7434,C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5; 60; 300 PPM IN THE DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[REDDY,TV, OLSON,GR, WIECHMAN,B, REDDY,G, TORSELLA,JA, DANIEL,FB AND LEACH,GJ; CHRONIC TOXICITY OF 1,3,5-TRINITROBENZENE IN FISCHER 344 RATS; INT. J. TOXICOL. 20(2): 59-67, 20001]"
5217,363901096,16741,C1=CC=C(C=C1)CCN=C=S,Active,,,,RAT,F344/MALE,ORAL,0.1% IN DIET FOR 48 WK (STUDY DURATION: 48 WK),URINARY BLADDER: CARCINOMA,POSITIVE,"[SUGIURA,S OGAWA,K HIROSE,M TAKESHITA,F ASAMOTO,M AND SHIRAI,T; REVERSIBILITY OF PROLIFERATIVE LESIONS AND INDUCTION OF NON-PAPILLARY TUMORS IN RAT URINARY BLADDER TREATED WITH PHENYLETHYL ISOTHIOCYANATE; CARCINOGENESIS 24(3):547-553, 2003]"
5218,363901096,16741,C1=CC=C(C=C1)CCN=C=S,Active,,,,RAT,F344/MALE,ORAL,"0.1% IN DIET FOR 32 WK, THEN SWITCHED TO BASAL DIET FOR 16 WK (STUDY DURATION: 48 WK)",URINARY BLADDER: CARCINOMA,POSITIVE,"[SUGIURA,S OGAWA,K HIROSE,M TAKESHITA,F ASAMOTO,M AND SHIRAI,T; REVERSIBILITY OF PROLIFERATIVE LESIONS AND INDUCTION OF NON-PAPILLARY TUMORS IN RAT URINARY BLADDER TREATED WITH PHENYLETHYL ISOTHIOCYANATE; CARCINOGENESIS 24(3):547-553, 2003]"
5219,363901096,16741,C1=CC=C(C=C1)CCN=C=S,Inactive,,,,RAT,F344/MALE,DIET (ORAL),0.1% FOR 12 WK (STUDY DURATION: 48 WK),,NEGATIVE (BLADDER HYPERPLASIAS OBSERVED),"[TAKAGI,H SHIBUTANI,M UNEYAMA,C LEE,KY KATO,N INOUE,K AND HIROSE,M; LIMITED TUMOR-INITIATING ACTIVITY OF PHENYLETHYL ISOTHIOCYANATE BY PROMOTION WITH SODIUM-ASCORBATE IN A RAT TWO-STAGE URINARY BLADDER CARCINOGENESIS; CANCER LETT. 219(2):147-153, 2005]"
5220,363901096,16741,C1=CC=C(C=C1)CCN=C=S,Inactive,,,,RAT,F344/MALE,DIET (ORAL),0.1% FOR 24 WK (STUDY DURATION: 48 WK),,NEGATIVE (BLADDER HYPERPLASIAS OBSERVED),"[TAKAGI,H SHIBUTANI,M UNEYAMA,C LEE,KY KATO,N INOUE,K AND HIROSE,M; LIMITED TUMOR-INITIATING ACTIVITY OF PHENYLETHYL ISOTHIOCYANATE BY PROMOTION WITH SODIUM-ASCORBATE IN A RAT TWO-STAGE URINARY BLADDER CARCINOGENESIS; CANCER LETT. 219(2):147-153, 2005]"
5221,363901096,16741,C1=CC=C(C=C1)CCN=C=S,Inactive,,,,RAT,F344/MALE,DIET (ORAL),0.1% FOR 48 WK (STUDY DURATION: 48 WK),,NEGATIVE (BLADDER HYPERPLASIAS AND DYSPLASIAS OBSERVED),"[TAKAGI,H SHIBUTANI,M UNEYAMA,C LEE,KY KATO,N INOUE,K AND HIROSE,M; LIMITED TUMOR-INITIATING ACTIVITY OF PHENYLETHYL ISOTHIOCYANATE BY PROMOTION WITH SODIUM-ASCORBATE IN A RAT TWO-STAGE URINARY BLADDER CARCINOGENESIS; CANCER LETT. 219(2):147-153, 2005]"
5222,363901109,8029,C1=COC=C1,Active,,,,RAT,F344/MALE,GAVAGE,0; 2; 4; 8 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LIVER:CHOLANGIOCARCINOMA, HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-402 Y93]"
5223,363901109,8029,C1=COC=C1,Active,,,,RAT,B6C3F1/FEMALE,GAVAGE,0; 2; 4; 8 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),"LIVER: CHOLANGIOCARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-402 Y93]"
5224,363901109,8029,C1=COC=C1,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 8; 15 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),"ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-402 Y93]"
5225,363901109,8029,C1=COC=C1,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 8; 15 MG/KG IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),"ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-402 Y93]"
5226,363901109,8029,C1=COC=C1,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 400 MG/KG BW ONCE ON POSTNATAL DAY 15 (STUDY DURATION: 95 WK),,NEGATIVE,"[JOHANSSON,E, REYNOLDS,S, ANDERSON,M AND MARONPOT,R; FREQUENCY OF HA-RAS-1 GENE MUTATIONS INVERSELY CORRELATED WITH FURAN DOSE IN MOUSE LIVER TUMORS; MOL. CARCINOG. 18(4):199-205, 1997]"
5227,363901109,8029,C1=COC=C1,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 200 MG/KG BW ONCE EACH ON POSTNATAL DAYS 3, 6, 9, 12, 15 AND 18 (STUDY DURATION: 95 WK)",LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[JOHANSSON,E, REYNOLDS,S, ANDERSON,M AND MARONPOT,R; FREQUENCY OF HA-RAS-1 GENE MUTATIONS INVERSELY CORRELATED WITH FURAN DOSE IN MOUSE LIVER TUMORS; MOL. CARCINOG. 18(4):199-205, 1997]"
5228,363901110,237332,C1=C(OC(=C1)C=O)CO,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 50 UMOL/0.1 ML DMSO 2/WK FOR 5 WK FOLLOWED 1 WK LATER BY 0.1 ML ACETONE 2/WK FOR 47 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MIYAKAWA,Y, NISHI,Y, KATO,K, SATO,K, TAKAHASHI,M AND HAYASHI,Y; INITIATING ACTIVITY OF EIGHT PYROLYSATES OF CARBOHYDRATES IN A TWO-STAGE MOUSE SKIN TUMORIGENESIS MODEL; CARCINOGENESIS 12(7):1169-1173, 1991]"
5229,363901110,237332,C1=C(OC(=C1)C=O)CO,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.25; 1 UMOL/G BW IN 5 UL DMSO/G BW ONCE,,NEGATIVE,"[SURH,YJ, LIEM,A, MILLER,JA AND TANNENBAUM,SR; 5-SULFOOXYMETHYLFURFURAL AS A POSSIBLE ULTIMATE MUTAGENIC AND CARCINOGENIC METABOLITE OF THE MAILLARD REACTION PRODUCT 5-HYDROXYMETHYLFURFURAL; CARCINOGENESIS 15(10):2375-2377, 1994]"
5230,363901110,237332,C1=C(OC(=C1)C=O)CO,Inactive,,,,Rat,F344/N / Female (50/Group),Oral,0; 188; 375; 750 mg/kg by gavage in deionized water for 2 yr,,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-554 Y10]"
5231,363901110,237332,C1=C(OC(=C1)C=O)CO,Inactive,,,,Rat,F344/N / Male (50/Group),Oral,0; 188; 375; 750 mg/kg by gavage in deionized water for 2 yr,,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-554 Y10]"
5232,363901110,237332,C1=C(OC(=C1)C=O)CO,Inactive,,,,Mouse,B6C3F1/ Female (50/Group),Oral,0; 188; 375; 750 mg/kg by gavage in deionized water for 2 yr,"Liver: hepatocellular adenoma (14/50, 26/49, 26/50, 6/50)",Negative (NTP reports as some evidence based on increased incidences of hepatocellular adenoma in the 188 and 375 mg/kg groups),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-554 Y10]"
5233,363901110,237332,C1=C(OC(=C1)C=O)CO,Inactive,,,,Mouse,B6C3F1/ Male (50/Group),Oral,0; 188; 375; 750 mg/kg by gavage in deionized water for 2 yr,,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-554 Y10]"
5234,363901138,62542,CC1=CC(=C(C=C1N=NC2=C(C3=CC=CC=C3C(=C2)S(=O)(=O)[O-])O)S(=O)(=O)[O-])C.[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 19.5 MO (STUDY DURATION: 19.5 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
5235,363901138,62542,CC1=CC(=C(C=C1N=NC2=C(C3=CC=CC=C3C(=C2)S(=O)(=O)[O-])O)S(=O)(=O)[O-])C.[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 19.5 MO (STUDY DURATION: 19.5 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
5236,363901139,637511,C1=CC=C(C=C1)/C=C/C=O,Inactive,,,,MOUSE,"B6C3F1/MALE, FEMALE (50/GROUP)",ORAL,0; 1000; 2100; 4100 PPM MICROENCAPSULATED IN DIET FOR 2 YR (STUDY DURATION: 2 YR),NONE,NEGATIVE,"[HOOTH,MJ SILLS,RC BURKA,LT HASEMAN,JK WITT,KL ORZECH,DP FUCIARELLI,AF GRAVES,SW JOHNSON,JD AND BUCHER,JR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF MICROENCAPSULATED TRANS-CINNAMALDEHYDE IN RATS AND MICE; FOOD CHEM. TOXICOL. 42(11);1757-1768, 2004]"
5237,363901139,637511,C1=CC=C(C=C1)/C=C/C=O,Inactive,,,,RAT,"F344/N/MALE, FEMALE (50/GROUP)",ORAL,0; 1000; 2100; 4100 PPM MICROENCAPSULATED IN DIET FOR 2 YR (STUDY DURATION: 2 YR),NONE,NEGATIVE,"[HOOTH,MJ SILLS,RC BURKA,LT HASEMAN,JK WITT,KL ORZECH,DP FUCIARELLI,AF GRAVES,SW JOHNSON,JD AND BUCHER,JR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF MICROENCAPSULATED TRANS-CINNAMALDEHYDE IN RATS AND MICE; FOOD CHEM. TOXICOL. 42(11);1757-1768, 2004]"
5238,363901156,14814,O=[V](=O)O[V](=O)=O,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 1; 2; 4 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA",POSITIVE,"[RESS,NB ROYCROFT,JH BRISTOL,DW BUCHER,JR HAILEY,JR  HASEMAN,JK HERBERT,RA MARONPOT,RR ORZECH,DP PEDDADA,SD  RAO,GN SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL REPORT  ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF VANADIUM  PENTOXIDE (CAS NO 1314-62-1) IN F344/N RATS AND B6C3F1 MICE  (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER.  507: 1-344, 2002]"
5239,363901156,14814,O=[V](=O)O[V](=O)=O,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 1; 2; 4 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA",POSITIVE,"[RESS,NB ROYCROFT,JH BRISTOL,DW BUCHER,JR HAILEY,JR  HASEMAN,JK HERBERT,RA MARONPOT,RR ORZECH,DP PEDDADA,SD  RAO,GN SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL REPORT  ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF VANADIUM  PENTOXIDE (CAS NO 1314-62-1) IN F344/N RATS AND B6C3F1 MICE  (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER.  507: 1-344, 2002]"
5240,363901156,14814,O=[V](=O)O[V](=O)=O,Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.5; 1; 2 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA",NEGATIVE,"[RESS,NB ROYCROFT,JH BRISTOL,DW BUCHER,JR HAILEY,JR  HASEMAN,JK HERBERT,RA MARONPOT,RR ORZECH,DP PEDDADA,SD  RAO,GN SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL REPORT  ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF VANADIUM  PENTOXIDE (CAS NO 1314-62-1) IN F344/N RATS AND B6C3F1 MICE  (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER.  507: 1-344, 2002]"
5241,363901156,14814,O=[V](=O)O[V](=O)=O,Unspecified,,,,RAT,F344/MALE,INHALATION,0; 0.5; 1; 2 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA",EQUIVOCAL,"[RESS,NB ROYCROFT,JH BRISTOL,DW BUCHER,JR HAILEY,JR  HASEMAN,JK HERBERT,RA MARONPOT,RR ORZECH,DP PEDDADA,SD  RAO,GN SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL REPORT  ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF VANADIUM  PENTOXIDE (CAS NO 1314-62-1) IN F344/N RATS AND B6C3F1 MICE  (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER.  507: 1-344, 2002]"
5242,363901156,14814,O=[V](=O)O[V](=O)=O,Unspecified,,,,RAT,F344/MALE,INHALATION,0; 0.5; 1; 2 MG/M3 FOR 6 HR PLUS 12 MIN/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LUNG (ALVEOLAR/BRONCHIOLAR): CARCINOMA, ADENOMA OR CARCINOMA",EQUIVOCAL,"[RESS,NB ROYCROFT,JH BRISTOL,DW BUCHER,JR HAILEY,JR  HASEMAN,JK HERBERT,RA MARONPOT,RR ORZECH,DP PEDDADA,SD  RAO,GN SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL REPORT  ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF VANADIUM  PENTOXIDE (CAS NO 1314-62-1) IN F344/N RATS AND B6C3F1 MICE  (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER.  507: 1-344, 2002]"
5243,363901156,14814,O=[V](=O)O[V](=O)=O,Unspecified,,,,RAT,F344/FEMALE,INHALATION,0; 0.5; 1; 2 MG/M3 FOR 6 HR PLUS 12 MIN/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA, ADENOMA OR CARCINOMA",EQUIVOCAL,"[RESS,NB ROYCROFT,JH BRISTOL,DW BUCHER,JR HAILEY,JR  HASEMAN,JK HERBERT,RA MARONPOT,RR ORZECH,DP PEDDADA,SD  RAO,GN SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL REPORT  ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF VANADIUM  PENTOXIDE (CAS NO 1314-62-1) IN F344/N RATS AND B6C3F1 MICE  (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER.  507: 1-344, 2002]"
5244,363901156,14814,O=[V](=O)O[V](=O)=O,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 1; 2; 4 MG/M3 FOR 6 HR PLUS 12 MIN/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA",POSITIVE,"[RESS,NB ROYCROFT,JH BRISTOL,DW BUCHER,JR HAILEY,JR  HASEMAN,JK HERBERT,RA MARONPOT,RR ORZECH,DP PEDDADA,SD  RAO,GN SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL REPORT  ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF VANADIUM  PENTOXIDE (CAS NO 1314-62-1) IN F344/N RATS AND B6C3F1 MICE  (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER.  507: 1-344, 2002]"
5245,363901156,14814,O=[V](=O)O[V](=O)=O,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 1; 2; 4 MG/M3 FOR 6 HR PLUS 12 MIN/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA",POSITIVE,"[RESS,NB ROYCROFT,JH BRISTOL,DW BUCHER,JR HAILEY,JR  HASEMAN,JK HERBERT,RA MARONPOT,RR ORZECH,DP PEDDADA,SD  RAO,GN SMITH,CS TRAVLOS,GS AND WITT,KL; NTP TECHNICAL REPORT  ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF VANADIUM  PENTOXIDE (CAS NO 1314-62-1) IN F344/N RATS AND B6C3F1 MICE  (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER.  507: 1-344, 2002]"
5246,363901197,2756,CC1=C(N=CN1)CSCCNC(=NC)NC#N,Inactive,,,,MOUSE,C57BL/FEMALE,ORAL,0; 18.8; 190 MG/D IN DRINKING WATER BEGINNING AT 7-8 WK OF AGE AND CONTINUING FOR STUDY DURATION (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[ANDERSON,LM, GINER-SOROLLA,A, HALLER,IM AND BUDINGER,JM; EFFECTS OF CIMETIDINE, NITRITE, CIMETIDINE PLUS NITRITE, AND NITROSOCIMETIDINE ON TUMORS IN MICE FOLLOWING TRANSPLACENTAL PLUS CHRONIC LIFETIME EXPOSURE; CANCER RES. 45(8): 3561-3566, 1985]"
5247,363901197,2756,CC1=C(N=CN1)CSCCNC(=NC)NC#N,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 18.8; 190 MG/D IN DRINKING WATER FOR LIFE ADMINISTERED TO MICE OF MOTHERS EXPOSED TO SAME DOSES THROUGH PREGNANCY AND LACTATION (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[ANDERSON,LM, GINER-SOROLLA,A, HALLER,IM AND BUDINGER,JM; EFFECTS OF CIMETIDINE, NITRITE, CIMETIDINE PLUS NITRITE, AND NITROSOCIMETIDINE ON TUMORS IN MICE FOLLOWING TRANSPLACENTAL PLUS CHRONIC LIFETIME EXPOSURE; CANCER RES. 45(8): 3561-3566, 1985]"
5248,363901197,2756,CC1=C(N=CN1)CSCCNC(=NC)NC#N,Inactive,,,,DOG,BEAGLE/MALE,ORAL,0; 144 MG/KG/D FOR 385 WK (STUDY DURATION: 385 WK),,NEGATIVE,"[WALKER,TF, WHITEHEAD,SM, LESLIE,GB, CREAN,GP AND ROE,FJC; SAFETY EVALUATION OF CIMETIDINE: REPORT AT THE TERMINATION OF A SEVEN-YEAR STUDY IN DOGS; HUM. TOXICOL. 6:159-164, 1987]"
5249,363901197,2756,CC1=C(N=CN1)CSCCNC(=NC)NC#N,Inactive,,,,DOG,BEAGLE/FEMALE,ORAL,0; 144 MG/KG/D FOR 385 WK (STUDY DURATION: 385 WK),,NEGATIVE,"[WALKER,TF, WHITEHEAD,SM, LESLIE,GB, CREAN,GP AND ROE,FJC; SAFETY EVALUATION OF CIMETIDINE: REPORT AT THE TERMINATION OF A SEVEN-YEAR STUDY IN DOGS; HUM. TOXICOL. 6:159-164, 1987]"
5250,363901197,2756,CC1=C(N=CN1)CSCCNC(=NC)NC#N,Inactive,,,,RAT,WISTAR/FEMALE,GAVAGE,0; 150; 378; 950 MG/KG/D FOR 2 YR (STUDY DURATION: 106 WK),,NEGATIVE,"[LESLIE,GB, NOAKES,DN, POLLITT,FD, ROE,FJC AND WALKER,TF; A TWO-YEAR STUDY WITH CIMETIDINE IN THE RAT: ASSESSMENT FOR CHRONIC TOXICITY AND CARCINOGENICITY; TOXICOL. APPL. PHARMACOL. 61:119-137, 1981]"
5251,363901225,2733526,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,"0; 2.8; 11.3; 45.2 MG/KG/D IN CARBOXYMETHYL-CELLULOSE FOR UP TO 1 YR WITH 2 RECOVERY PERIODS, 4 WK OF RECOVERY AFTER 6 MO EXPOSURE AND 3 MO OF RECOVERY AFTER 12 MO EXPOSURE (STUDY DURATION: 15 MO)","LIVER: ADENOMA, CARCINOMA",POSITIVE,"[WILLIAMS,GM, IATROPOULOS,MJ, DJORDJEVIC,MV AND KALTENBERG,OP; THE TRIPHENYLETHYLENE DRUG TAMOXIFEN IS A STRONG LIVER CARCINOGEN IN THE RAT; CARCINOGENESIS 14(2):315-317, 1993]"
5252,363901225,2733526,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,Active,,,,RAT,ALDERLEY PARK/MALE,GAVAGE,0; 5; 20; 35 MG/KG/D IN 0.5% HYDROXYPROPYL METHYLCELLULOSE FOR 2 YR (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATO/CHOLANGIOCELLULAR CARCINOMA",POSITIVE,"[GREAVES,P, GOONETILLEKE,R, NUNN,G, TOPHAM,J AND ORTON,T; TWO-YEAR CARCINOGENICITY STUDY OF TAMOXIFEN IN ALDERLEY PARK WISTAR-DERIVED RATS; CANCER RES. 53(17):3919-3924, 1993]"
5253,363901225,2733526,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,Active,,,,RAT,ALDERLEY PARK/FEMALE,GAVAGE,0; 5; 20; 35 MG/KG/D IN 0.5% HYDROXYPROPYL METHYLCELLULOSE FOR 2 YR (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATO/CHOLANGIOCELLULAR CARCINOMA",POSITIVE,"[GREAVES,P, GOONETILLEKE,R, NUNN,G, TOPHAM,J AND ORTON,T; TWO-YEAR CARCINOGENICITY STUDY OF TAMOXIFEN IN ALDERLEY PARK WISTAR-DERIVED RATS; CANCER RES. 53(17):3919-3924, 1993]"
5254,363901225,2733526,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 420 PPM IN DIET FOR 3 MO (STUDY DURATION: LIFETIME),LIVER: TUMOR,POSITIVE,"[CARTHEW,P, MARTIN,EA, WHITE,INH, DE MATTEIS,F, EDWARDS,RE, DORMAN,BM, HEYDON, RT AND SMITH,LL; TAMOXIFEN INDUCES SHORT-TERM CUMULATIVE DNA DAMAGE AND LIVER TUMORS IN RATS: PROMOTION BY PHENOBARBITAL;CANCER RES. 55(3):544-547, 1995]"
5255,363901225,2733526,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 1 MG/KG BW/D IN PEANUT OIL/LECITHIN/CONDENSED MILK MIXTURE ON DAYS 2-5 OF AGE (STUDY DURATION: 35 MONTHS),UTERUS: ADENOCARCINOMA; VAGINA/CERVIX: SQUAMOUS CELL CARCINOMA,POSITIVE,"[CARTHEW,P EDWARDS,RE NOLAN,BM MARTIN,EA HEYDON,RT WHITE,INH AND TUCKER,MJ; TAMOXIFEN INDUCES ENDOMETRIAL AND VAGINAL CANCER IN RATS IN THE ABSENCE OF ENDOMETRIAL HYPERPLASIA; CARCINOGENESIS 21(4):793-797, 2000]"
5256,363901225,2733526,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,Inactive,,,,MONKEY,CYNOMOLGUS/FEMALE,ORAL,0; 20 MG/WOMAN/D HUMAN DOSE EQUIVALENT IN DIET FOR 36 MONTHS BEGINNING 3 MONTHS POST BILATERAL OVARIECTOMY (STUDY DURATION: 39 MONTHS),,NEGATIVE,"[CLINE,JM, SODERQVIST,G, VON SCHOULTZ,E, SKOOG,L AND VON SCHOULTZ,B; EFFECTS OF CONJUGATED ESTROGENS, MEDROXYPROGESTERONE ACETATE, AND TAMOXIFEN ON THE MAMMARY GLANDS OF MACAQUES; BREAST CANCER RES. TREAT. 48:221-229, 1998]"
5257,363901225,2733526,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,Active,,,,MOUSE,CD-1/FEMALE,SUBCUTANEOUS,0; 1; 2; 5; 10; 25; 50 UG/D ON DAYS 1-5 OF LIFE (STUDY DURATION: 17 MO),UTERUS: ADENOCARCINOMA,POSITIVE,"[NEWBOLD,RR, JEFFERSON,WN, PADILLA-BURGOS,E AND BULLOCK,BC; UTERINE CARCINOMA IN MICE TREATED NEONATALLY WITH TAMOXIFEN; CARCINOGENESIS 18(12):2293-2298, 1997]"
5258,363901227,5881,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)O)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.45% (WEIGHT/WEIGHT) IN SEMIPURIFIED DIET OIL STRIPPED OF VITAMIN E FOR STUDY DURATION; (STUDY DURATION: 84 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[RAO,MS, SUBBARAO,V, YELDANDI,AV AND REDDY,JK; HEPATOCARCINOGENICITY OF DEHYDROEPIANDROSTERONE IN THE RAT; CANCER RES. 52(10):2977-2979, 1992]"
5259,363901227,5881,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)O)C,Active,,,,RAT,F344/MALE,ORAL,0; 0.5; 1% IN DIET FOR 78 WK (STUDY DURATION: 78 WK),LIVER: NEOPLASM,POSITIVE,"[HAYASHI,F, TAMURA,H, YAMADA,J, KASAI,H AND SUGA,T; CHARACTERISTICS OF THE HEPATOCARCINOGENESIS CAUSED BY DEHYDROEPIANDROSTERONE, A PEROXISOME PROLIFERATOR, IN MALE F-344 RATS; CARCINOGENESIS 15(10):2215-2219, 1994]"
5260,363901227,5881,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)O)C,Active,,,,FISH,"RAINBOW TROUT/MALE, FEMALE",ORAL,0; 55; 111; 222; 444; 888 PPM IN DIET 1/D 5 D/WK FOR 42 WK (STUDY DURATION: 42 WK),LIVER: TUMOR,POSITIVE,"[ORNER,GA, MATHEWS,C, HENDRICKS,JD, CARPENTER,HM, BAILEY,GS AND WILLIAMS,DE; DEHYDROEPIANDROSTERONE IS A COMPLETE HEPATOCARCINOGEN AND POTENT TUMOR PROMOTER IN THE ABSENCE OF PEROXISOME PROLIFERATION IN RAINBOW TROUT; CARCINOGENESIS 16(12):2893-2898, 1995]"
5261,363901227,5881,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)O)C,Active,,,,FISH,"RAINBOW TROUT/MALE,FEMALE",ORAL,0; 55; 111; 222; 444; 888 PPM IN DIET FOR 7 MO (STUDY DURATION: 10 MO),LIVER: TUMOR,POSITIVE,"[ORNER,GA, HENDRICKS,JD, ARBOGAST,D AND WILLIAMS,DE; MODULATION OF N-METHYL-N'-NITRO-NITROSOGUANIDINE MULTIORGAN CARCINOGENESIS BY DEHYDROEPIANDROSTERONE IN RAINBOW TROUT; TOXICOL. APPL. PHARMACOL. 141(2):548-554, 1996]"
5262,363901228,7847,C=CC=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 100; 250; 625 MG/L IN DRINKING WATER 5 D/WK FOR UP TO 120 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5263,363901228,7847,C=CC=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 625 MG/L IN DRINKING WATER 5 D/WK FOR 100 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5264,363901228,7847,C=CC=O,Inactive,,,,MOUSE,CD-1/FEMALE,GAVAGE,0; 0.5; 2; 4.5 MG/KG (STABILIZED WITH 0.25%-0.3% HYDROQUINONE) 1/D FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[PARENT,RA, CARAVELLO,HE AND LONG,JE; ONCOGENICITY STUDY OF ACROLEIN IN MICE; J. AM. COLL. TOXICOL. 10(6):647-659, 1991]"
5265,363901228,7847,C=CC=O,Inactive,,,,MOUSE,CD-1/MALE,GAVAGE,"0; 0.5; 2, 4.5 MG/KG (STABILIZED WITH 0.25%-0.31 HYDROQUINONE) 1/D FOR 18 MO (STUDY DURATION: 18 MO)",,NEGATIVE,"[PARENT,RA, CARAVELLO,HE AND LONG,JE; ONCOGENICITY STUDY OF ACROLEIN IN MICE; J. AM. COLL. TOXICOL. 10(6):647-659, 1991]"
5266,363901228,7847,C=CC=O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 0.05; 0.5; 2.5 MG/KG/D IN WATER FOR 102 WK (STUDY DURATION: 24 MO),,NEGATIVE,"[PARENT,RA, CARAVELLO,HE AND LONG,JE; TWO-YEAR TOXICITY AND CARCINOGENICITY STUDY OF ACROLEIN IN RATS; J. APPL. TOXICOL. 12(2):131-139, 1992]"
5267,363901228,7847,C=CC=O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 0.05; 0.5; 2.5 MG/KG/D IN WATER FOR 102 WK (STUDY DURATION: 24 MO),,NEGATIVE,"[PARENT,RA, CARAVELLO,HE AND LONG,JE; TWO-YEAR TOXICITY AND CARCINOGENICITY STUDY OF ACROLEIN IN RATS; J. APPL. TOXICOL. 12(2):131-139, 1992]"
5268,363901228,7847,C=CC=O,Inactive,,,,RAT,F344/MALE,INTRAPERITONEAL,"0; 2 MG/KG 2/WK FOR 9 WK THEN 1.5 MG/KG ONCE IN WK 4 THEN 2/WK FOR 7 WK FOLLOWED BY 1 MG/KG ONCE IN WK 12, TWICE IN WK 13 AND ONCE IN WK 14 AND 15 (STUDY DURATION: 53 WK)",,NEGATIVE,"[COHEN,SM, GARLAND,EM, ST.JOHN,M, OKAMURA,T AND SMITH,RA; ACROLEIN INITIATES RAT URINARY BLADDER CARCINOGENESIS; CANCER RES. 52(13):3577-3581, 1992]"
5269,363901228,7847,C=CC=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 75 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 15 MO OF AGE (STUDY DURATION: 15 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5270,363901228,7847,C=CC=O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 75 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 15 MO OF AGE (STUDY DURATION: 15 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5271,363901228,7847,C=CC=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 150 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 12 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5272,363901228,7847,C=CC=O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 150 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 12 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5273,363901241,23667548,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)[O-])O)O.[Na+],Inactive,,,,RAT,F344/MALE,ORAL,"0; 1; 5; 7% IN DIET OF MALE RATS, PARENTAL GENERATION ALSO FED SODIUM ASCORBATE FOR 4 WK BEFORE MATING THEN CONTINUING IN MOTHERS DURING GESTATION AND LACTATION (STUDY DURATION: LIFETIME)",,NEGATIVE,"[COHEN,SM, ANDERSON,TA DE OLIVEIRA,LM AND ARNOLD,LL; TUMORIGENICITY OF SODIUM ASCORBATE IN MALE RATS; CANCER RES. 58(12):2557-2561, 1998]"
5274,363901241,23667548,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)[O-])O)O.[Na+],Inactive,,,,Rat,Non-tg/Male,Oral,"5% sodium ascorbate in diet, continuous, for 57 wk until sacrifice",Total tumor-bearing animals (20.0% in experimental animals vs 25.0% in controls); no bladder tumors,Negative. Parallel experiment in Hras128 rat line was conducted to determine bladder tumor incidence (10/27 in experimental animals vs 4/13 in controls; not statistically significant),"[MORIMURA,K KANG,JS WEI,M WANIBUCHI,H TSUDA,H AND FUKUSHIMA,S; LACK OF URINARY BLADDER CARCINOGENICITY OF SODIUM L-ASCORBATE IN HUMAN C-HA-RAS PROTO-ONCOGENE TRANSGENIC RATS; TOXICOLOGIC PATHOLOGY 33(7):764-7, 2005]"
5275,363901270,14184,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 15; 60 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 108 WK),,NEGATIVE,"[ROSENKRANTZ,H AND FLEISCHMAN,RW; IN VIVO CARCINOGENESIS ASSAY OF DL-METHADONE HCL IN RODENTS; FUNDAM. APPL. TOXICOL. 11(4):640-651, 1988]"
5276,363901270,14184,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 15; 60 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 108 WK),,NEGATIVE,"[ROSENKRANTZ,H AND FLEISCHMAN,RW; IN VIVO CARCINOGENESIS ASSAY OF DL-METHADONE HCL IN RODENTS; FUNDAM. APPL. TOXICOL. 11(4):640-651, 1988]"
5277,363901270,14184,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 16; 46 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 108 WK),,NEGATIVE,"[ROSENKRANTZ,H AND FLEISCHMAN,RW; IN VIVO CARCINOGENESIS ASSAY OF DL-METHADONE HCL IN RODENTS; FUNDAM. APPL. TOXICOL. 11(4):640-651, 1988]"
5278,363901270,14184,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 28; 88 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 108 WK),,NEGATIVE,"[ROSENKRANTZ,H AND FLEISCHMAN,RW; IN VIVO CARCINOGENESIS ASSAY OF DL-METHADONE HCL IN RODENTS; FUNDAM. APPL. TOXICOL. 11(4):640-651, 1988]"
5279,363901271,39371,CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 7.6; 30.1 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[ROSENKRANTZ,H AND FLEISCHMAN,RW; IN VIVO CARCINOGENESIS ASSAY OF L-ALPHA- ACETYLMETHADOL HCL IN RODENTS; FUNDAM. APPL. TOXICOL. 11(4):626-639, 1988]"
5280,363901271,39371,CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 7.6; 30.1 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[ROSENKRANTZ,H AND FLEISCHMAN,RW; IN VIVO CARCINOGENESIS ASSAY OF L-ALPHA- ACETYLMETHADOL HCL IN RODENTS; FUNDAM. APPL. TOXICOL. 11(4):626-639, 1988]"
5281,363901271,39371,CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.Cl,Active,,,,RAT,F344/MALE,ORAL,0; 3.1; 9.7 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 24 MO),LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[ROSENKRANTZ,H AND FLEISCHMAN,RW; IN VIVO CARCINOGENESIS ASSAY OF L-ALPHA- ACETYLMETHADOL HCL IN RODENTS; FUNDAM. APPL. TOXICOL. 11(4):626-639, 1988]"
5282,363901271,39371,CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.Cl,Active,,,,RAT,F344/FEMALE,ORAL,0; 5.7; 16.6 MG/KG IN DIET FOR DURATION OF STUDY (STUDY DURATION: 24 MO),LIVER: ADENOMA OR CARCINOMA; UTERUS: ENDOMETRIAL STROMAL POLYP,POSITIVE,"[ROSENKRANTZ,H AND FLEISCHMAN,RW; IN VIVO CARCINOGENESIS ASSAY OF L-ALPHA- ACETYLMETHADOL HCL IN RODENTS; FUNDAM. APPL. TOXICOL. 11(4):626-639, 1988]"
5283,363901283,9958,CC1=CC(=C(C=C1)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA; GLANDULAR STOMACH: ADENOMA, ADENOCARCINOMA",POSITIVE,"[ASAKAWA,E, HIROSE,M, HAGIWARA,A, TAKAHASHI,S AND ITO,N; CARCINOGENICITY OF 4-METHOXYPHENOL AND 4-METHYLCATECHOL IN F344 RATS; INT. J. CANCER 56(2):146-152, 1994]"
5284,363901283,9958,CC1=CC(=C(C=C1)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA; GLANDULAR STOMACH: ADENOMA, ADENOCARCINOMA",POSITIVE,"[ASAKAWA,E, HIROSE,M, HAGIWARA,A, TAKAHASHI,S AND ITO,N; CARCINOGENICITY OF 4-METHOXYPHENOL AND 4-METHYLCATECHOL IN F344 RATS; INT. J. CANCER 56(2):146-152, 1994]"
5285,363901285,5984,C([C@H]([C@H]([C@@H](C(=O)CO)O)O)O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 120 G/L IN DRINKING WATER AD LIBITUM FOR 30 WK (STUDY DURATION: 501 D),,NEGATIVE,"[ENZMANN,H, OHLHAUSER,D, DETTLER,T AND BANNASCH,P; ENHANCEMENT OF HEPATOCARCINOGENESIS IN RATS BY DIETARY FRUCTOSE; CARCINOGENESIS 10(7): 1247-1252, 1989]"
5286,363901299,6337,CCCl,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 15000 PPM IN AIR 6 HR/D 5 D/WK FOR 100 WK (STUDY DURATION: 100 WK),LIVER: HEPATOCELLULAR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; UTERUS: CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-346 Y89]"
5287,363901299,6337,CCCl,Unspecified,,,,RAT,F344/MALE,INHALATION,0; 15000 PPM IN AIR 6 HR/D 5 D/WK FOR 102 WK (STUDY DURATION: 102 WK),"SKIN: TRICHOEPITHELIOMA, SEBACEOUS GLAND ADENOMA OR BASAL CELL CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-346 Y89]"
5288,363901299,6337,CCCl,Unspecified,,,,RAT,F344/FEMALE,INHALATION,0; 15000 PPM IN AIR 6 HR/D 5 D/WK FOR 102 WK (STUDY DURATION: 102 WK),BRAIN: ASTROCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-346 Y89]"
5289,363901299,6337,CCCl,Inactive,,,,Rat,F344/Male (50/Group),Inhalation,"0; 15,000 ppm 6 hr/d, 5 d/wk for 102 wk",,Negative,"[HOLDER,JW; ANALYSIS OF CHLOROETHANE TOXICITY AND CARCINOGENICITY INCLUDING A COMPARISON WITH BROMOETHANE. TOXICOLOGY AND INDUSTRIAL HEALTH. 24(10): 655-675, 2008]"
5290,363901299,6337,CCCl,Inactive,,,,Rat,F344/Female (50/Group),Inhalation,"0; 15,000 ppm 6 hr/d, 5 d/wk for 102 wk",,Negative,"[HOLDER,JW; ANALYSIS OF CHLOROETHANE TOXICITY AND CARCINOGENICITY INCLUDING A COMPARISON WITH BROMOETHANE. TOXICOLOGY AND INDUSTRIAL HEALTH. 24(10): 655-675, 2008]"
5291,363901299,6337,CCCl,Inactive,,,,Mouse,B6C3F1/Male (50/Group),Inhalation,"0; 15,000 ppm 6 hr/d, 5 d/wk for 100 wk",,Negative,"[HOLDER,JW; ANALYSIS OF CHLOROETHANE TOXICITY AND CARCINOGENICITY INCLUDING A COMPARISON WITH BROMOETHANE. TOXICOLOGY AND INDUSTRIAL HEALTH. 24(10): 655-675, 2008]"
5292,363901299,6337,CCCl,Active,,,,Mouse,B6C3F1/Female (50/Group),Inhalation,"0; 15,000 ppm 6 hr/d, 5 d/wk for 100 wk","Uterus: carcinoma (2% vs 90%, p<10-8); Uterus: lymphoma (2% vs 14%, p=0.03); Liver: adenoma and carcinoma (6% vs 17%, p=0.025)",Positive,"[HOLDER,JW; ANALYSIS OF CHLOROETHANE TOXICITY AND CARCINOGENICITY INCLUDING A COMPARISON WITH BROMOETHANE. TOXICOLOGY AND INDUSTRIAL HEALTH. 24(10): 655-675, 2008]"
5293,363901306,6439953,C1=CC=C(C=C1)/C=C/C2=CC=C(C=C2)N(C=O)O,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 10 UMOL/KG BW 2/WK FOR 6 WK (STUDY DURATION: 62 WK),LIVER: NEOPLASTIC NODULE; MAMMARY GLAND: TUMOR,POSITIVE,"[HIROSE,M, SHIRAI,T, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF THE N-ACYL DERIVATIVES OF N-HYDROXY-TRANS-4-AMINOSTILBENE IN CD RATS; CHEM.-BIOL. INTERACT. 106(2):123-132, 1997]"
5294,363901306,6439953,C1=CC=C(C=C1)/C=C/C2=CC=C(C=C2)N(C=O)O,Active,,,,RAT,STRAIN-CD/MALE,INTRAPERITONEAL,0; 10 UMOL/KG BW 2/WK FOR 6 WK (STUDY DURATION: 62 WK),TESTICLE: MESOTHELIOMA; PANCREAS(ACINUS): ADENOMA,POSITIVE,"[HIROSE,M, SHIRAI,T, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF THE N-ACYL DERIVATIVES OF N-HYDROXY-TRANS-4-AMINOSTILBENE IN CD RATS; CHEM.-BIOL. INTERACT. 106(2):123-132, 1997]"
5295,363901307,54159,C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)O,Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 100 UMOL/KG BW 2/WK FOR 6 WK (STUDY DURATION: 62 WK),,NEGATIVE,"[HIROSE,M, SHIRAI,T, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF THE N-ACYL DERIVATIVES OF N-HYDROXY-TRANS-4-AMINOSTILBENE IN CD RATS; CHEM.-BIOL. INTERACT. 106(2):123-132, 1997]"
5296,363901310,6366991,CCC(=O)N(C1=CC=C(C=C1)/C=C/C2=CC=CC=C2)O,Active,,,,RAT,STRAIN-CD/MALE,INTRAPERITONEAL,0; 10 UMOL/KG BW 2/WK FOR 6 WK (STUDY DURATION: 62 WK),"TESTICLE: MESOTHELIOMA; PANCREAS(ACINUS): ADENOMA; PANCREAS(ISLET CELL): CARCINOMA; EAR DUCT: ADENOMA, CARCINOMA; LIVER: NEOPLASTIC NODULE; LUNG: TUMOR",POSITIVE,"[HIROSE,M, SHIRAI,T, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF THE N-ACYL DERIVATIVES OF N-HYDROXY-TRANS-4-AMINOSTILBENE IN CD RATS; CHEM.-BIOL. INTERACT. 106(2):123-132, 1997]"
5297,363901310,6366991,CCC(=O)N(C1=CC=C(C=C1)/C=C/C2=CC=CC=C2)O,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 10 UMOL/KG BW 2/WK FOR 6 WK (STUDY DURATION: 62 WK),LIVER: NEOPLASTIC NODULE; MAMMARY GLAND: TUMOR; EAR DUCT: TUMOR; PITUITARY GLAND: CARCINOMA,POSITIVE,"[HIROSE,M, SHIRAI,T, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF THE N-ACYL DERIVATIVES OF N-HYDROXY-TRANS-4-AMINOSTILBENE IN CD RATS; CHEM.-BIOL. INTERACT. 106(2):123-132, 1997]"
5298,363901311,149799,CCC(=O)N(C1=CC=C(C=C1)C2=CC=CC=C2)O,Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 100 UMOL/KG BW 2/WK FOR 6 WK (STUDY DURATION: 62 WK),,NEGATIVE,"[HIROSE,M, SHIRAI,T, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF THE N-ACYL DERIVATIVES OF N-HYDROXY-TRANS-4-AMINOSTILBENE IN CD RATS; CHEM.-BIOL. INTERACT. 106(2):123-132, 1997]"
5299,363901313,115104,CC1=CN=C2C=CC3=C(C2=N1)N=C(N3C)NO,Active,,,,RAT,ACI/SEG/MALE,INTRAPERITONEAL,0; 50 UMOL/KG BW 2X/WK FOR 10 WK BEGINNING AT 3 D OF AGE (STUDY DURATION: 68 WK),SOFT TISSUE: TUMOR,POSITIVE,"[ARCHER,CL MORSE,P JONES,RF SHIRAI,T HAAS,GP AND WANG,CY; CARCINOGENICITY OF THE N-HYDROXY DERIVATIVE OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE,2-AMINO-3,8-DIMETHYL-IMIDAZO[4,5 -F]QUINOXALINE AND 3,2'-DIMETHYL-4-AMINOBIPHENYL IN THE RAT; CANCER LETT. (SHANNON, IREL.) 155(1):55-60, 2000]"
5300,363901324,13090,C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)[N+](=O)[O-])C=C2,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG/BW IN 25 UMOL/ML DMSO 3/WK FOR 4 WK (TOTAL DOSE: 0; 119 UMOL) ADMINISTERED TO WEANLING RATS (STUDY DURATION: 61 WK),HEMATOPOIETIC SYSTEM: LEUKEMIA OR LYMPHOMA,POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
5301,363901324,13090,C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)[N+](=O)[O-])C=C2,Inactive,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 0.1 ML IN 20.3 UMOL/ML DMSO INJECTED INTO MAMMARY TISSUE OF THE 3 LEFT THORACIC NIPPLES FOLLOWED THE NEXT D BY SIMILAR TREATMENT OF THE INGUINAL NIPPLE AREA (TOTAL DOSE: 0; 12.3 UMOL) (STUDY DURATION: 77 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
5302,363901324,13090,C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)[N+](=O)[O-])C=C2,Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG BW IN DMSO 3/WK FOR 4 WK (STUDY DURATION: 61 WK),"HEMATOPOIETIC SYSTEM: LEUKEMIA, LYMPHOMA",POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
5303,363901324,13090,C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)[N+](=O)[O-])C=C2,Inactive,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 0.1 ML OF A 20.3 UMOL/ML SOLUTION IN DMSO INJECTED INTO MAMMARY TISSUE UNDERLYING 3 LEFT THORACIC NIPPLES THE FOLLOWING DAY INGUINAL NIPPLE AREA TREATED SIMILARLY (STUDY DURATION: 77 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
5304,363901331,53230,C1=CC2=C3C(=C1)C=CC4=C(C=C(C(=C43)C=C2)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),"MAMMARY GLAND: ADENOCARCINOMA, FIBROADENOMA, ADENOMA",POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
5305,363901331,53230,C1=CC2=C3C(=C1)C=CC4=C(C=C(C(=C43)C=C2)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,STRAIN CD/FEMALE,INTRAGASTRIC,10 UMOL IN DMSO 3/WK FOR 4 WK (TOTAL DOSE: 16 UMOL/RAT) (STUDY DURATION: 78 WK),ADRENAL GLAND: CORTICAL ADENOMA; PITUITARY GLAND: CARCINOMA,POSITIVE,"[IMAIDA,K, LEE,MS, WANG,CY AND KING,CM; CARCINOGENICITY OF DINITROPYRENES IN THE WEANLING FEMALE CD RAT; CARCINOGENESIS 12(7):1187-1191, 1991]"
5306,363901331,53230,C1=CC2=C3C(=C1)C=CC4=C(C=C(C(=C43)C=C2)[N+](=O)[O-])[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,0; 6.3 UMOL (TOTAL DOSE) ADMINISTERED OVER 8 WK BEGINNING ON DAY OF BIRTH (STUDY DURATION: 67 WK),INTEGUMENTARY SYSTEM: MALIGNANT FIBROUS HISTIOCYTOMA,POSITIVE,"[IMAIDA,K, LEE,MS, LAND,SJ, WANG,CY AND KING,CM; CARCINOGENICITY OF NITROPYRENES IN THE NEWBORN FEMALE RAT; CARCINOGENESIS 16(12):3027-3030, 1995]"
5307,363901351,8846,CCCCOC(=O)C=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 15; 45; 135 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 130 WK),,NEGATIVE,"[REININGHAUS,W, KOESTNER,A AND KLIMISCH,HJ; CHRONIC TOXICITY AND ONCOGENICITY OF INHALED METHYL ACRYLATE AND N-BUTYL ACRYLATE IN SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 29(5):329-339, 1991]"
5308,363901351,8846,CCCCOC(=O)C=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 15; 45; 135 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 130 WK),,NEGATIVE,"[REININGHAUS,W, KOESTNER,A AND KLIMISCH,HJ; CHRONIC TOXICITY AND ONCOGENICITY OF INHALED METHYL ACRYLATE AND N-BUTYL ACRYLATE IN SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 29(5):329-339, 1991]"
5309,363901351,8846,CCCCOC(=O)C=C,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 0.2 MG IN 25 UL ACETONE 3/WK FOR LIFESPAN (STUDY DURATION: LIFESPAN),,NEGATIVE,"[DEPASS,LR, FOWLER,EH, MECKLEY,DR AND WEIL,CS; DERMAL ONCOGENICITY BIOASSAYS OF ACRYLIC ACID, ETHYL ACRYLATE, AND BUTYL ACRYLATE; J. TOXICOL. ENVIRON. HEALTH 14(2-3):115-120, 1984]"
5310,363901360,7044,C1CCC2CCCCC2C1,Active,,,,RAT,F344/MALE,INHALATION,"0; 25; 50; 100; 400 PPM IN AIR , 6 H PLUS 12 MIN/D, 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR)","KIDNEY: RENAL TUBULE ADENOMA, RENAL TUBULE ADENOMA OR CARCINOMA",POSITIVE,"[DILL,JA LEE,KM RENNE,RA MILLER,RA FUCIARELLI,AF GIDEON,,KM CHAN,PC BURKA,LT AND ROYCROFT,JH; ALPHA 2U - GLOBULIN NEPHROPATHY AND CARCINOGENICITY FOLLOWING EXPOSURE TO DECALIN (DECAHYDRONAPHTHALENE) IN F344/N RATS; TOXICOL. SCI. 72(2):223-234, 2003]"
5311,363901360,7044,C1CCC2CCCCC2C1,Inactive,,,,RAT,F344/FEMALE,INHALATION,"0; 25; 100; 400 PPM IN AIR, 6 H PLUS 12 MIN/D, 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR)",,NEGATIVE,"[DILL,JA LEE,KM RENNE,RA MILLER,RA FUCIARELLI,AF GIDEON,,KM CHAN,PC BURKA,LT AND ROYCROFT,JH; ALPHA 2U - GLOBULIN NEPHROPATHY AND CARCINOGENICITY FOLLOWING EXPOSURE TO DECALIN (DECAHYDRONAPHTHALENE) IN F344/N RATS; TOXICOL. SCI. 72(2):223-234, 2003]"
5312,363901360,7044,C1CCC2CCCCC2C1,Inactive,,,,RAT,F344/N/FEMALE (50/GROUP),INHALATION,"0; 25; 100; 400 PPM 6 HR/D, 5 D/WK FOR 105 WKS (STUDY DURATION: 105 WKS)",,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DECALIN  (CAS NO. 91-17-8) IN F344/N RATS AND B6C3F1 MICE AND A TOXICOLOGY STUDY OF DECALIN IN MALE NBR RATS (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 513:1-316, 2005]"
5313,363901360,7044,C1CCC2CCCCC2C1,Active,,,,RAT,F344/N/MALE (50/GROUP),INHALATION,"0; 25; 50; 100 PPM 6 HR/D, 5 D/WK FOR 105 WKS (STUDY DURATION: 105 WKS)",KIDNEY: RENAL TUBULE ADENOMA OR CARCINOMA (2%; 6%; 14%; 24%); ADRENAL: BENIGN OR MALIGNANT PHEOCHROMOCYTOMA (16%; 18%; 27%; 33%),"POSITIVE; ALPHA-2U-GLOBULIN, INCIDENCES OF RENAL TUBULE REGENERATION AND GRANULAR CASTS IN MEDULLA AND DOSE-RELATED INCREASE IN SEVERITY OF HYALINE DROPLETS IN MALE RATS","[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DECALIN  (CAS NO. 91-17-8) IN F344/N RATS AND B6C3F1 MICE AND A TOXICOLOGY STUDY OF DECALIN IN MALE NBR RATS (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 513:1-316, 2005]"
5314,363901360,7044,C1CCC2CCCCC2C1,Inactive,,,,MOUSE,B6C3F1/MALE (50/GROUP),INHALATION,"0; 25; 100; 400 PPM 6 HR/D, 5 D/WK FOR 105 WKS (STUDY DURATION: 105 WKS)",,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DECALIN  (CAS NO. 91-17-8) IN F344/N RATS AND B6C3F1 MICE AND A TOXICOLOGY STUDY OF DECALIN IN MALE NBR RATS (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 513:1-316, 2005]"
5315,363901360,7044,C1CCC2CCCCC2C1,Unspecified,,,,MOUSE,B6C3F1/FEMALE (50/GROUP),INHALATION,"0; 25; 100; 400 PPM 6 HR/D, 5 D/WK FOR 105 WKS (STUDY DURATION: 105 WKS)",LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA (22%; 54%; 28%; 42%),EQUIVOCAL; NTP SAYS MARGINAL INCREASE IN UTERINE TUMORS BUT P VALUES DID NOT REACH SIGNIFICANCE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DECALIN  (CAS NO. 91-17-8) IN F344/N RATS AND B6C3F1 MICE AND A TOXICOLOGY STUDY OF DECALIN IN MALE NBR RATS (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 513:1-316, 2005]"
5316,363901360,7044,C1CCC2CCCCC2C1,Active,,,,RAT,F344/N/MALE (20/GROUP),INHALATION,"400 PPM 6 HR/D, 5 D/WK FOR 105 WKS (STUDY DURATION: 105 WKS)",KIDNEY: RENAL TUBULE ADENOMA OR CARCINOMA (30%); ADRENAL: PHEOCHROMOCYTOMA (40%),POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DECALIN  (CAS NO. 91-17-8) IN F344/N RATS AND B6C3F1 MICE AND A TOXICOLOGY STUDY OF DECALIN IN MALE NBR RATS (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 513:1-316, 2005]"
5317,363901363,12734,CC(C)N=C=NC(C)C,Inactive,,,,Mouse,B6C3F1/Female (50/Group),Dermal,0; 10; 20; 40 mg/kg in anhydrous ethanol 5 d/wk for 2 yr,,Negative,[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
5318,363901363,12734,CC(C)N=C=NC(C)C,Inactive,,,,Rat,F344/N/Female (50/Group),Dermal,0; 10; 20; 40 mg/kg in anhydrous ethanol 5 d/wk for 2 yr,,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-523 Y07]"
5319,363901363,12734,CC(C)N=C=NC(C)C,Inactive,,,,Mouse,B6C3F1/Male (50/Group),Dermal,0; 10; 20; 40 mg/kg in anhydrous ethanol 5 d/wk for 2 yr,,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-523 Y07]"
5320,363901363,12734,CC(C)N=C=NC(C)C,Inactive,,,,Rat,F344/N/Male (50/Group),Dermal,0; 10; 20; 40 mg/kg in anhydrous ethanol 5 d/wk for 2 yr,,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-523 Y07]"
5321,363901369,27880,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Fe+3],Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 5 MG IRON/KG BW FOR 3 D THEN 10 MG IRON/KG FOR THE NEXT 2 D AND THEN 10 MG IRON/KG 5 D/WK FOR 11 WK (STUDY DURATION: LIFESPAN),KIDNEY: RENAL CELL CARCINOMA,POSITIVE,"[TOYOKUNI,S, TANAKA,T, NISHIYAMA,Y, OKAMOTO,K, NAKASHIMA,Y, HAMAZAKI,S, OKADA,S AND HIAI,H; INDUCTION OF RENAL CELL CARCINOMA IN MALE WISTAR RATS TREATED WITH CUPRIC NITRILOTRIACETATE; LAB. INVEST. 75(2):239-248, 1996]"
5322,363901372,5983,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE (70/GROUP),SUBCUTANEOUS (INGUINAL REGION),0; 3.3 UG/KG BW; 2/D FOR 5 D (STUDY DURATION: 28 MO),MAMMARY GLAND: TUMOR,POSITIVE,"[CABELLO,G VALENZUELA,M VILAXA,A DURAN,V RUDOLPH,I HREPIC,N AND CALAF,G; A RAT MAMMARY TUMOR MODEL INDUCED BY THE ORGANOPHOSPHOROUS PESTICIDES PARATHION AND MALATHION, POSSIBLY THROUGH ACETYLCHOLINESTERASE INHIBITION; ENVIRON. HEALTH PERSPECT. 109(5):471-479, 2001]"
5323,363901380,7636,CCCCC(CC)COC(=O)C=C,Inactive,,,,MOUSE,NMRI/MALE,DERMAL,0; 21.5; 43; 85% (W/W) IN ACETONE 3/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MELLERT,W, KUEHBORTH,B, GEMBARDT,C AND MUNK,R; 2-YEAR CARCINOGENICITY STUDY IN THE MALE NMRI MOUSE WITH 2-ETHYLHEXYL ACRYLATE BY EPICUTANEOUS ADMINISTRATION; FOOD CHEM. TOXICOL. 32(3):233-237, 1994]"
5324,363901402,104936,C1=CC2=C3C(=C1)C=CC4=C(C=C(C(=C43)C=C2)[N+](=O)[O-])O,Inactive,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,0; 63 UMOL (TOTAL DOSE) ADMINISTERED OVER 8 WK BEGINNING WITHIN 24 HR OF BIRTH (STUDY DURATION: 86 WK),,NEGATIVE,"[IMAIDA,K, LEE,MS, LAND,SJ, WANG,CY AND KING,CM; CARCINOGENICITY OF NITROPYRENES IN THE NEWBORN FEMALE RAT; CARCINOGENESIS 16(12):3027-3030, 1995]"
5325,363901403,104988,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)O)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 7 NMOL (TOTAL DOSE), 1/7, 2/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED WITHIN 24 HR OF BIRTH AND AT 8 AND 15 D OF AGE, RESPECTIVELY (STUDY DURATION: 72 WK)",,NEGATIVE,"[MORI,H, MORISHITA,Y, SUGIE,S, TANAKA,T, KOJIMA,T, SUZUI,M, KATAOKA,K, KINOUCHI,T AND OHNISHI,Y; CARCINOGENICITY EXAMINATION OF 1-NITROPYRENE OXIDES AND RELATED CHEMICALS: LACK OF THEIR TUMORIGENIC EFFECTS IN A NEWBORN MICE ASSAY; J. TOXICOL. SCI. 17(4):235-241, 1992]"
5326,363901403,104988,C1=CC2=C(C=CC3=C2C4=C1C=CC(=C4C=C3)O)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 7 NMOL (TOTAL DOSE), 1/7, 2/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED WITHIN 24 HR OF BIRTH AND AT 8 AND 15 D OF AGE, RESPECTIVELY (STUDY DURATION: 72 WK)",,NEGATIVE,"[MORI,H, MORISHITA,Y, SUGIE,S, TANAKA,T, KOJIMA,T, SUZUI,M, KATAOKA,K, KINOUCHI,T AND OHNISHI,Y; CARCINOGENICITY EXAMINATION OF 1-NITROPYRENE OXIDES AND RELATED CHEMICALS: LACK OF THEIR TUMORIGENIC EFFECTS IN A NEWBORN MICE ASSAY; J. TOXICOL. SCI. 17(4):235-241, 1992]"
5327,363901405,61870,CNNC.CN(C)N,Active,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 10 MG/KG/WK FOR 4 WK (STUDY DURATION: 1 YEAR),PANCREAS: ADENOCARCINOMA; COLON: ADENOCARCINOMA,POSITIVE,"[SHIN,HS, LEE,KS, KIM,HM, SUH,YL, KHANG,SK AND PARK,E; THE CHARACTERISTIC OF PANCREATIC TUMOR INDUCED BY DIMETHYLHYDRAZINE IN RAT; INKAN KWAHAK 12(6):375-80, 1988]"
5328,363901428,10005,C(#N)N=C(N)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN DIET FOR 104 WK (STUDY DURATION: 113 WK),,NEGATIVE,"[YASUHARA,K, SHIMO,T, MITSUMORI,K, ONODERA,H, KITAURA,K AND TAKAHASHI,M; LACK OF CARCINOGENICITY OF CYANOGUANIDINE IN F344 RATS; FOOD CHEM. TOXICOL. 35(5):475-480, 1997]"
5329,363901428,10005,C(#N)N=C(N)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN DIET FOR 104 WK (STUDY DURATION: 113 WK),,NEGATIVE,"[YASUHARA,K, SHIMO,T, MITSUMORI,K, ONODERA,H, KITAURA,K AND TAKAHASHI,M; LACK OF CARCINOGENICITY OF CYANOGUANIDINE IN F344 RATS; FOOD CHEM. TOXICOL. 35(5):475-480, 1997]"
5330,363901434,,,Inactive,,,,RAT,CD-1/MALE,ORAL,0; 0.6; 2.0; 6.0 MG/KG/D IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[OSHEROFF,MR, ANDO,T AND MIYAJIMA,H; ONCOGENICITY STUDY IN RATS WITH MANIDIPINE HYDROCHLORIDE [CV-4093(2HCL)]; YAKURI TO CHIRYO 17(SUPPL.4):1217-31,1989]"
5331,363901434,,,Inactive,,,,RAT,CD-1/FEMALE,ORAL,0; 0.6; 2.0; 6.0 MG/KG/D IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[OSHEROFF,MR, ANDO,T AND MIYAJIMA,H; ONCOGENICITY STUDY IN RATS WITH MANIDIPINE HYDROCHLORIDE [CV-4093(2HCL)]; YAKURI TO CHIRYO 17(SUPPL.4):1217-31,1989]"
5332,363901434,,,Inactive,,,,MOUSE,ICR/MALE,ORAL,0; 1.2; 4.0; 12; 40 MG/KG/D IN THE DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[OSHEROFF,MR, ANDO,T AND MIYAJIMA,H; ONCOGENICITY STUDY IN MICE WITH MANIDIPINE HYDROCHLORIDE [CV-4093(2HCL)]; YAKURI TO CHIRYO 17(SUPPL.4):1205-16, 1989]"
5333,363901434,,,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 1.2; 4.0; 12; 40 MG/KG/D IN THE DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[OSHEROFF,MR, ANDO,T AND MIYAJIMA,H; ONCOGENICITY STUDY IN MICE WITH MANIDIPINE HYDROCHLORIDE [CV-4093(2HCL)]; YAKURI TO CHIRYO 17(SUPPL.4):1205-16, 1989]"
5334,363901438,12161,CC1=CC=C(C=C1)C=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAGASTRIC,"0; 10; 50; 250; 500 MG/KG IN OLIVE OIL 1/D, 5 D/WK FOR 104 WK (STUDY DURATION: 123 WK)",,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
5335,363901438,12161,CC1=CC=C(C=C1)C=C,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAGASTRIC,"0; 10; 50; 250; 500 MG/KG IN OLIVE OIL 1/D, 5 D/WK FOR 104 WK (STUDY DURATION: 123 WK)",,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
5336,363901438,12161,CC1=CC=C(C=C1)C=C,Inactive,,,,MOUSE,SWISS/MALE,INTRAGASTRIC,"0; 10; 50; 250 MG/KG IN OLIVE OIL 1/D, 5 D/WK FOR 78 WK (STUDY DURATION: 83 WK)",,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
5337,363901438,12161,CC1=CC=C(C=C1)C=C,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAGASTRIC,"0; 10; 50; 250 MG/KG IN OLIVE OIL 1/D, 5 D/WK FOR 78 WK (STUDY DURATION: 83 WK)",,NEGATIVE,"[CONTI,B, MALTONI,C, PERINO,G AND CILIBERTI,A; LONG-TERM CARCINOGENICITY BIOASSAYS ON STYRENE ADMINISTERED BY INHALATION, INGESTION AND INJECTION AND STYRENE OXIDE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS, AND PARA-METHYLSTYRENE ADMINISTERED BY INGESTION IN SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):203-234, 1988]"
5338,363901439,96277,COC(=O)COC1=CC=C(C=C1)Cl,Inactive,,,,NEWT,,IMMERSION,0; 100; 200; 400 PPM 4 D/WK FOR 12 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[ZAVANELLA,T, PACCES ZAFFARONI,N AND ARIAS,E; EVALUATION OF THE CARCINOGENIC RISK OF THE PHENOXYHERBICIDE MCPA TO AN URODELE AMPHIBIAN; ECOTOXICOL. ENVIRON. SAF. 16(2):114-22, 1988]"
5339,363901440,44155,CC(C)(C)[NH2+]CC(COC1=CN(C(=O)C2=CC=CC=C21)C)O.[Cl-],Inactive,,,,MOUSE,CD-1/FEMALE,GAVAGE,0; 3; 10; 30 MG/KG/D FOR 80 WK IN WATER (STUDY DURATION: 80 WK),,NEGATIVE,"[JAMES,RW, HOOKS,WN, GOPINATH,C, LEWIS,DJ AND KAWASE,S; TUMORIGENICITY STUDY OF ORALLY ADMINISTERED (+/-)-4-(3-TERT-BUTYLAMINO-2-HYDROXYPROPOXY)-2-METHYL-1(2H)- ISOQUINOLINONE HYDROCHLORIDE (N-696), A BETA-ADRENERGIC BLOCKING AGENT, IN CD-1 MICE; OYO YAKURI 36(4):261-70, 1988]"
5340,363901440,44155,CC(C)(C)[NH2+]CC(COC1=CN(C(=O)C2=CC=CC=C21)C)O.[Cl-],Inactive,,,,MOUSE,CD-1/MALE,GAVAGE,0; 3; 10; 30 MG/KG/D FOR 80 WK IN WATER (STUDY DURATION: 80 WK),,NEGATIVE,"[JAMES,RW, HOOKS,WN, GOPINATH,C, LEWIS,DJ AND KAWASE,S; TUMORIGENICITY STUDY OF ORALLY ADMINISTERED (+/-)-4-(3-TERT-BUTYLAMINO-2-HYDROXYPROPOXY)-2-METHYL-1(2H)- ISOQUINOLINONE HYDROCHLORIDE (N-696), A BETA-ADRENERGIC BLOCKING AGENT, IN CD-1 MICE; OYO YAKURI 36(4):261-70, 1988]"
5341,363901441,44073,C1=CC(=C(C=C1C(F)(F)F)Cl)OC2=CC(=C(C=C2)[N+](=O)[O-])C(=O)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 625; 1250; 2500 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),"LIVER: ADENOMA, CARCINOMA; STOMACH: PAPILLOMA",POSITIVE,"[QUEST,JA, PHANG,W, HAMERNIK,KL, VAN GEMERT,M, FISHER,B, LEVY,R, FARBER,TM, BURNAM,WL AND ENGLER,R; EVALUATION OF THE CARCINOGENIC POTENTIAL OF PESTICIDES. 1. ACIFLUORFEN; REGUL. TOXICOL. PHARMACOL. 10(2):149-59, 1989]"
5342,363901441,44073,C1=CC(=C(C=C1C(F)(F)F)Cl)OC2=CC(=C(C=C2)[N+](=O)[O-])C(=O)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 625; 1250; 2500 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),"LIVER: ADENOMA, CARCINOMA; STOMACH: PAPILLOMA",POSITIVE,"[QUEST,JA, PHANG,W, HAMERNIK,KL, VAN GEMERT,M, FISHER,B, LEVY,R, FARBER,TM, BURNAM,WL AND ENGLER,R; EVALUATION OF THE CARCINOGENIC POTENTIAL OF PESTICIDES. 1. ACIFLUORFEN; REGUL. TOXICOL. PHARMACOL. 10(2):149-59, 1989]"
5343,363901441,44073,C1=CC(=C(C=C1C(F)(F)F)Cl)OC2=CC(=C(C=C2)[N+](=O)[O-])C(=O)O,Inactive,,,,RAT,"F344/MALE, FEMALE",ORAL,0; 25; 150; 500; 2500; 5000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[QUEST,JA, PHANG,W, HAMERNIK,KL, VAN GEMERT,M, FISHER,B, LEVY,R, FARBER,TM, BURNAM,WL AND ENGLER,R; EVALUATION OF THE CARCINOGENIC POTENTIAL OF PESTICIDES. 1. ACIFLUORFEN; REGUL. TOXICOL. PHARMACOL. 10(2):149-59, 1989]"
5344,363901441,44073,C1=CC(=C(C=C1C(F)(F)F)Cl)OC2=CC(=C(C=C2)[N+](=O)[O-])C(=O)O,Active,,,,MOUSE,CR-CD-1/MALE,ORAL,0; 7.5; 4.5; 270 PPM IN DIET FOR 24 MO (STUDY DURATION: 24 MO),LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[QUEST,JA, PHANG,W, HAMERNIK,KL, VAN GEMERT,M, FISHER,B, LEVY,R, FARBER,TM, BURNAM,WL AND ENGLER,R; EVALUATION OF THE CARCINOGENIC POTENTIAL OF PESTICIDES. 1. ACIFLUORFEN; REGUL. TOXICOL. PHARMACOL. 10(2):149-59, 1989]"
5345,363901441,44073,C1=CC(=C(C=C1C(F)(F)F)Cl)OC2=CC(=C(C=C2)[N+](=O)[O-])C(=O)O,Active,,,,MOUSE,CR-CD-1/FEMALE,ORAL,0; 7.5; 4.5; 270 PPM IN DIET FOR 24 MO (STUDY DURATION: 24 MO),LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[QUEST,JA, PHANG,W, HAMERNIK,KL, VAN GEMERT,M, FISHER,B, LEVY,R, FARBER,TM, BURNAM,WL AND ENGLER,R; EVALUATION OF THE CARCINOGENIC POTENTIAL OF PESTICIDES. 1. ACIFLUORFEN; REGUL. TOXICOL. PHARMACOL. 10(2):149-59, 1989]"
5346,363901442,42128,C1=C2C3=CC(=C(C(=C3OC2=CC(=C1Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 4; 40 UG ONCE IN OLIVE OIL (STUDY DURATION: 104 WK),LIVER: NODULE; INJECTION SITE: TUMOR,POSITIVE,"[NISHIZUMI,M; CARCINOGENICITY OF 2,3,4,7,8-PENTACHLORODIBENZOFURAN AND 1,2,3,4,7,8-HEXACHLORODIBENZOFURAN IN RATS; FUKUOKA IGAKU ZASSHI 80(5):240-5, 1989]"
5347,363901442,42128,C1=C2C3=CC(=C(C(=C3OC2=CC(=C1Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 20 UG IN OLIVE OIL INTO BACK 1/WK FOR 4 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR CARCINOMA, NODULE",POSITIVE,"[NISHIZUMI,M; CARCINOGENICITY OF 2,3,4,7,8-PENTACHLORODIBENZOFURAN AND 1,2,3,4,7,8-HEXACHLORODIBENZOFURAN IN RATS; FUKUOKA IGAKU ZASSHI 80(5):240-5, 1989]"
5348,363901442,42128,C1=C2C3=CC(=C(C(=C3OC2=CC(=C1Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 20 UG IN OLIVE OIL 1/WK INTO BACK FOR 4 WK (STUDY DURATION: 104 WK),LIVER: NODULE; INJECTION SITE: TUMOR,POSITIVE,"[NISHIZUMI,M; CARCINOGENICITY OF 2,3,4,7,8-PENTACHLORODIBENZOFURAN AND 1,2,3,4,7,8-HEXACHLORODIBENZOFURAN IN RATS; FUKUOKA IGAKU ZASSHI 80(5):240-5, 1989]"
5349,363901442,42128,C1=C2C3=CC(=C(C(=C3OC2=CC(=C1Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 4; 40 UG ONCE IN OLIVE OIL (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR CARCINOMA, NODULE; INJECTION SITE: TUMOR",POSITIVE,"[NISHIZUMI,M; CARCINOGENICITY OF 2,3,4,7,8-PENTACHLORODIBENZOFURAN AND 1,2,3,4,7,8-HEXACHLORODIBENZOFURAN IN RATS; FUKUOKA IGAKU ZASSHI 80(5):240-5, 1989]"
5350,363901442,42128,C1=C2C3=CC(=C(C(=C3OC2=CC(=C1Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 6; 20; 44; 92; 200 NG/KG/D (STUDY DURATION: 2 YRS),,NEGATIVE,"[YOSHIZAWA,K, WALKER,NJ, JOKINEN,MP, BRIX,AE, SELLS,DM,  MARSH,T, WYDE,ME, ORZECH,D, HASEMAN,JK, AND NYSKA,A;  GINGIVAL CARCINOGENICITY IN FEMALE HARLAN SPRAGUE-DAWLEY  RATS FOLLOWING TWO YEAR ORAL TREATMENT WITH  2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN AND DIOXIN-LIKE  COMPOUNDS. [ERRATUM TO DOCUMENT CITED IN CA142:234804];  TOXICOL. SCI. 83(2):405-406, 2005]"
5351,363901442,42128,C1=C2C3=CC(=C(C(=C3OC2=CC(=C1Cl)Cl)Cl)Cl)Cl,Active,,,,Rat,Harlan Sprague-Dawley/Female,Gavage,0; 200 ng 5 d/wk in corn oil:acetone (99:1) for 30 wk and then vehicle for remainder of 2 yr study,"Oral Mucosa: Gingival squamous cell carcinoma (1/53, 3/50) Pancreas: Acinar adenoma or carcinoma (0/53, 2/49)","Positive Trend (not statistically significant); For stop study vs. controls, incidence in liver, lung and uterus same as controls. NTP reports results as some evidence.","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-525 Y06]"
5352,363901442,42128,C1=C2C3=CC(=C(C(=C3OC2=CC(=C1Cl)Cl)Cl)Cl)Cl,Active,,,,Rat,Harlan Sprague-Dawley/Female,Gavage,0; 6; 20; 44; 92; 200 ng in corn oil:acetone (99:1) 5 d/wk for 2 yrs,"Liver: Hepatocellular adenoma (1/53, 0/53, 1/53, 0/52, 2/53, 4/53); Cholangiocarcinoma (0/53, 0/53, 0/53, 1/52, 1/53, 2/53) Oral Mucosa: Gingival squamous cell carcinoma (1/53, 2/53, 1/53, 0/53, 3/53) Lung: Cystic keratinizing epithelioma (multiple) (0/53, 0/53, 0/53, 0/53, 0/53, 1/52) Pancreas: Acinar adenoma or carcinoma (0/53, 0/53, 0/53, 0/52, 2/52, 0/52) Uterus: Carcinoma (1/53, 1/53, 0/53, 1/53, 5/53, 2/53)","Positive (NTP reports as Some Evidence; Findings in lung, pancreas, and uterus described as equivocal.)","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-525 Y06]"
5353,363901443,33258,CC1=CC(=C(C=C1S(=O)(=O)[O-])OC)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.37; 1.39; 5.19% OF DIET BEGINNING WITH PARENTAL GENERATION AND CONTINUING WITH THE PUPS FOLLOWING WEANING (STUDY DURATION: LIFETIME),,NEGATIVE,"[BORZELLECA,JF, OLSON,JW AND RENO,FE; LIFETIME TOXICITY/CARCINOGENICITY STUDY OF FD & C RED NO. 40 (ALLURA RED) IN SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 27(11):701-5, 1989]"
5354,363901443,33258,CC1=CC(=C(C=C1S(=O)(=O)[O-])OC)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.37; 1.39; 5.19% OF DIET BEGINNING WITH PARENTAL GENERATION AND CONTINUING WITH THE OFFSPRING FOLLOWING WEANING (STUDY DURATION: LIFETIME),,NEGATIVE,"[BORZELLECA,JF, OLSON,JW AND RENO,FE; LIFETIME TOXICITY/CARCINOGENICITY STUDY OF FD & C RED NO. 40 (ALLURA RED) IN SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 27(11):701-5, 1989]"
5355,363901443,33258,CC1=CC(=C(C=C1S(=O)(=O)[O-])OC)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,HAM/ICR/MALE,ORAL,"0; 0.37; 1.39; 5.19% IN DIET FOR LIFE TO OFFSPRING OF ANIMALS ADMINISTERED THE SAME DOSES DURING BREEDING, GESTATION AND LACTATION (STUDY DURATION: 104 WK)",,NEGATIVE,"[BORZELLECA,JF, OLSON,JW AND RENO,FE; LIFETIME TOXICITY/CARCINOGENICITY STUDIES OF FD AND C RED NO. 40 (ALLURA RED) IN MICE; FOOD CHEM. TOXICOL. 29(5):313-319, 1991]"
5356,363901443,33258,CC1=CC(=C(C=C1S(=O)(=O)[O-])OC)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,HAM/ICR/FEMALE,ORAL,"0; 0.37; 1.39; 5.19% IN DIET FOR LIFE TO OFFSPRING OF ANIMALS ADMINISTERED THE SAME DOSES DURING BREEDING, GESTATION AND LACTATION (STUDY DURATION: 104 WK)",,NEGATIVE,"[BORZELLECA,JF, OLSON,JW AND RENO,FE; LIFETIME TOXICITY/CARCINOGENICITY STUDIES OF FD AND C RED NO. 40 (ALLURA RED) IN MICE; FOOD CHEM. TOXICOL. 29(5):313-319, 1991]"
5357,363901443,33258,CC1=CC(=C(C=C1S(=O)(=O)[O-])OC)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,CD-1/MALE,ORAL,"0; 0.37; 1.39; 5.19% IN DIET FOR LIFE TO OFFSPRING OF ANIMALS ADMINISTERED THE SAME DOSES DURING BREEDING, GESTATION AND LACTATION (STUDY DURATION: 109 WK)",,NEGATIVE,"[BORZELLECA,JF, OLSON,JW AND RENO,FE; LIFETIME TOXICITY/CARCINOGENICITY STUDIES OF FD AND C RED NO. 40 (ALLURA RED) IN MICE; FOOD CHEM. TOXICOL. 29(5):313-319, 1991]"
5358,363901443,33258,CC1=CC(=C(C=C1S(=O)(=O)[O-])OC)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,"0; 0.37; 1.39; 5.19% IN DIET FOR LIFE TO OFFSPRING OF ANIMALS ADMINISTERED THE SAME DOSES DURING BREEDING, GESTATION AND LACTATION (STUDY DURATION:; 109 WK)",,NEGATIVE,"[BORZELLECA,JF, OLSON,JW AND RENO,FE; LIFETIME TOXICITY/CARCINOGENICITY STUDIES OF FD AND C RED NO. 40 (ALLURA RED) IN MICE; FOOD CHEM. TOXICOL. 29(5):313-319, 1991]"
5359,363901444,24644,O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 2% IN DIET FOR 96 WK FOLLOWED BY CONTROL DIET FOR 8 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KURATA,Y, TAMANO,S, SHIBATA,MA, HAGIWARA,A, FUKUSHIMA,S AND ITO,N; LACK OF CARCINOGENICITY OF MAGNESIUM CHLORIDE IN A LONG-TERM FEEDING STUDY IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 27(9):559-63, 1989]"
5360,363901444,24644,O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.5; 2% IN DIET FOR 96 WK FOLLOWED BY CONTROL DIET FOR 8 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KURATA,Y, TAMANO,S, SHIBATA,MA, HAGIWARA,A, FUKUSHIMA,S AND ITO,N; LACK OF CARCINOGENICITY OF MAGNESIUM CHLORIDE IN A LONG-TERM FEEDING STUDY IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 27(9):559-63, 1989]"
5361,363901445,11932,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)[NH3+])C)[NH3+].[Cl-].[Cl-],Active,,,,MOUSE,BALB/MALE,ORAL,0; 5; 9; 18; 35; 70; 140 PPM IN DRINKING WATER 7 D/WK FOR DURATION OF STUDY (STUDY DURATION: 112 WK),LUNG: ALVEOLAR CELL ADENOMA AND ADENOCARCINOMA,POSITIVE,"[SCHIEFERSTEIN,GJ, SHINOHARA,Y, ALLEN,RR, SHELDON,W, GREENMAN,DL AND ALLABEN,WT; CARCINOGENICITY STUDY OF 3,3'-DIMETHYLBENZIDINE DIHYDROCHLORIDE IN BALB/C MICE; FOOD CHEM. TOXICOL. 27(12):801-6, 1989]"
5362,363901445,11932,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)[NH3+])C)[NH3+].[Cl-].[Cl-],Inactive,,,,MOUSE,BALB/FEMALE,ORAL,0; 5; 9; 18; 35; 70; 140 PPM IN DRINKING WATER 7 D/WK FOR DURATION OF STUDY (STUDY DURATION: 112 WK),,NEGATIVE,"[SCHIEFERSTEIN,GJ, SHINOHARA,Y, ALLEN,RR, SHELDON,W, GREENMAN,DL AND ALLABEN,WT; CARCINOGENICITY STUDY OF 3,3'-DIMETHYLBENZIDINE DIHYDROCHLORIDE IN BALB/C MICE; FOOD CHEM. TOXICOL. 27(12):801-6, 1989]"
5363,363901445,11932,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)[NH3+])C)[NH3+].[Cl-].[Cl-],Active,,,,RAT,F344/MALE,ORAL,0; 30; 70; 150 PPM IN DRINKING WATER 7 D/WK FOR 60-61 WK (STUDY DURATION: 60-61 WK),"PREPUTIAL GLAND: ADENOMA, ADENOMA OR CARCINOMA; LARGE INTESTINE: ADENOMATOUS POLYP, ADENOCARCINOMA; SMALL INTESTINE: ADENOCARCINOMA, ADENOMATOUS POLYP OR ADENOCARCINOMA; LIVER: NEOPLASTIC NODULE, HEPATOCELLULAR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; ORAL CAVITY (TONGUE AND PHARYNX): SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA; SKIN: BASAL CELL ADENOMA, KERATOACANTHOMA, BASAL CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, (SEBACEOUS GLAND) ADENOMA; ZYMBAL'S GLAND: ADENOMA, CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-390 Y91]"
5364,363901445,11932,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)[NH3+])C)[NH3+].[Cl-].[Cl-],Active,,,,RAT,F344/FEMALE,ORAL,0; 30; 70; 150 PPM IN DRINKING WATER 7 D/WK FOR 60-61 WK (STUDY DURATION: 60-61 WK),"CLITORAL GLAND: ADENOMA, CARCINOMA; LARGE INTESTINE: ADENOMATOUS POLYP, ADENOMATOUS POLYP OR ADENOCARCINOMA; SMALL INTESTINE: ADENOCARCINOMA, ADENOMATOUS POLYP OR ADENOCARCINOMA; LIVER: NEOPLASTIC NODULE, NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; MAMMARY GLAND: ADENOCARCINOMA, FIBROADENOMA OR ADENOCARCINOMA; ORAL CAVITY (TONGUE AND PHARYNX): SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; SKIN: BASAL CELL ADENOMA, BASAL CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; ZYMBAL'S GLAND: ADENOMA, CARCINOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA, (LYMPHOCYTIC, MONOCYTIC OR UNDIFFERENTIATED)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-390 Y91]"
5365,363901446,62477,CCOC(C=C)OCC,Inactive,,,,RAT,F344/MALE,ORAL,0; 470; 1200 MG/L IN DRINKING WATER 5 D/WK FOR 100 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5366,363901446,62477,CCOC(C=C)OCC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 470; 1200 MG/L IN DRINKING WATER 5 D/WK FOR 100 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5367,363901446,62477,CCOC(C=C)OCC,Inactive,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 2 MG/WK FOR 54 OR 64 WK (STUDY DURATION: 92 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5368,363901447,9577004,C=C/C=N/O,Inactive,,,,RAT,F344/MALE,ORAL,0; 320 MG/L IN DRINKING WATER 5 D/WK FOR 100 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5369,363901447,9577004,C=C/C=N/O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 320 MG/L IN DRINKING WATER 5 D/WK FOR 100 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5370,363901447,9577004,C=C/C=N/O,Inactive,,,,RAT,F344/MALE,ORAL,0; 800 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5371,363901447,9577004,C=C/C=N/O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 800 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5372,363901447,9577004,C=C/C=N/O,Inactive,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 2 MG/WK FOR 53 WK (STUDY DURATION: 92 WK),,NEGATIVE,"[LIJINSKY,W; CHRONIC STUDIES IN RODENTS OF VINYL ACETATE AND COMPOUNDS RELATED TO ACROLEIN; ANN. N.Y. ACAD. SCI. 534(LIVING CHEM. WORLD):246-254, 1988]"
5373,363901448,61148,C(N)[N+](=O)[O-],Active,,,,RAT,BDVI/MALE,GAVAGE,0; 38; 76 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),SPINAL CORD: NEURINOMA; SPINAL NERVES: NEURINOMA,POSITIVE,"[SCHERF,HR, FREI,E AND WIESSLER,M; CARCINGENIC PROPERTIES OF N-NITRODIMETHYLAMINE AND N-NITROMETHYLAMINE IN THE RAT; CARCINOGENESIS (LONDON) 10(11):1977-81, 1989]"
5374,363901448,61148,C(N)[N+](=O)[O-],Active,,,,RAT,BDVI/FEMALE,GAVAGE,0; 38; 76 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),SPINAL CORD: NEURINOMA; SPINAL NERVES: NEURINOMA,POSITIVE,"[SCHERF,HR, FREI,E AND WIESSLER,M; CARCINGENIC PROPERTIES OF N-NITRODIMETHYLAMINE AND N-NITROMETHYLAMINE IN THE RAT; CARCINOGENESIS (LONDON) 10(11):1977-81, 1989]"
5375,363901449,20120,CN(C)[N+](=O)[O-],Active,,,,RAT,BDVI/MALE,GAVAGE,0; 45; 90 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),NASAL CAVITY: ESTHESIONEUROEPITHELIOMA; SPINAL CORD: NEURINOMA; SPINAL NERVES: NEURINOMA,POSITIVE,"[SCHERF,HR, FREI,E AND WIESSLER,M; CARCINGENIC PROPERTIES OF N-NITRODIMETHYLAMINE AND N-NITROMETHYLAMINE IN THE RAT; CARCINOGENESIS (LONDON) 10(11):1977-81, 1989]"
5376,363901449,20120,CN(C)[N+](=O)[O-],Active,,,,RAT,BDVI/FEMALE,GAVAGE,0; 45; 90 MG/KG 1/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),NASAL CAVITY: ESTHESIONEUROEPITHELIOMA,POSITIVE,"[SCHERF,HR, FREI,E AND WIESSLER,M; CARCINGENIC PROPERTIES OF N-NITRODIMETHYLAMINE AND N-NITROMETHYLAMINE IN THE RAT; CARCINOGENESIS (LONDON) 10(11):1977-81, 1989]"
5377,363901450,6319,C1=CC=C(C=C1)NC2=CC=C(C=C2)NC3=CC=CC=C3,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.5; 2% IN DIET FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[HASEGAWA,R, FUKUSHIMA,S, HAGIWARA,A, MASUI,T, MASUDA,A AND ITO,N; LONG-TERM FEEDING STUDY OF N,N'-DIPHENYL-P-PHENYLENEDIAMINE IN F344 RATS; TOXICOLOGY 54(1):69-78, 1989]"
5378,363901450,6319,C1=CC=C(C=C1)NC2=CC=C(C=C2)NC3=CC=CC=C3,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.5; 2% IN DIET FOR 104 WK (STUDY DURATION: 112 WK),,NEGATIVE,"[HASEGAWA,R, FUKUSHIMA,S, HAGIWARA,A, MASUI,T, MASUDA,A AND ITO,N; LONG-TERM FEEDING STUDY OF N,N'-DIPHENYL-P-PHENYLENEDIAMINE IN F344 RATS; TOXICOLOGY 54(1):69-78, 1989]"
5379,363901451,6391,C(F)(F)(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
5380,363901451,6391,C(F)(F)(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
5381,363901451,6391,C(F)(F)(Cl)Cl,Inactive,,,,MOUSE,SWISS/MALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
5382,363901451,6391,C(F)(F)(Cl)Cl,Inactive,,,,MOUSE,SWISS/FEMALE,INHALATION,0; 1000; 5000 PPM 4 HR/D 5 D/WK FOR 78 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C, LEFEMINE,G, TOVOLI,D AND PERINO,G; LONG-TERM CARCINOGENICITY BIOASSAYS ON THREE CHLOROFLUOROCARBONS (TRICHLOROFLUOROMETHANE, FC11; DICHLORODIFLUOROMETHANE, FC12; CHLORODIFLUOROMETHANE, FC22) ADMINISTERED BY INHALATION TO SPRAGUE-DAWLEY RATS AND SWISS MICE; ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):261-282, 1988]"
5383,363901451,6391,C(F)(F)(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 1000; 5000 PPM IN AIR 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
5384,363901451,6391,C(F)(F)(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 1000; 5000 PPM IN AIR 4 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
5385,363901466,39562,C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 20; 60; 180 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[PATTON,DSG, HEYWOOD,R AND SCORZA BARCELLONA,P; CARCINOGENICITY ASSESSMENT OF LONIDAMINE BY DIETARY ADMINISTRATION TO SPRAGUE-DAWLEY RATS; TOXICOL. LETT. 62(2-3):209-214, 1992]"
5386,363901466,39562,C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 20; 60; 180 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[PATTON,DSG, HEYWOOD,R AND SCORZA BARCELLONA,P; CARCINOGENICITY ASSESSMENT OF LONIDAMINE BY DIETARY ADMINISTRATION TO SPRAGUE-DAWLEY RATS; TOXICOL. LETT. 62(2-3):209-214, 1992]"
5387,363901471,5382,C1=CC(=CC=C1OC2=C(C=C(C=N2)Cl)Cl)OC3=C(C=C(C=N3)Cl)Cl,Active,,,,MOUSE,C57BL/MALE,INTRAPERITONEAL,0; 3 MG/KG BW IN CORN OIL 1/2 WK FOR 24 WK (STUDY DURATION: 55 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[DIWAN,BA, LUBET,RA, WARD,JM, HRABIE,JA AND RICE,JM; TUMOR-PROMOTING AND HEPATOCARCINOGENIC EFFECTS OF 1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE (TCPOBOP) IN DBA/2NCR AND C57BL/6NCR MICE AND AN APPARENT PROMOTING EFFECT ON NASAL CAVITY TUMORS IN F344/NCR RATS INITIATED WITH N-NITROSODIETHYLAMINE; CARCINOGENESIS 13(10):1893-1901, 1992]"
5388,363901471,5382,C1=CC(=CC=C1OC2=C(C=C(C=N2)Cl)Cl)OC3=C(C=C(C=N3)Cl)Cl,Active,,,,MOUSE,C57BL/MALE,INTRAGASTRIC,0; 3 MG/KG BW IN CORN OIL 1/2 WK FOR 24 WK (STUDY DURATION: 55 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[DIWAN,BA, LUBET,RA, WARD,JM, HRABIE,JA AND RICE,JM; TUMOR-PROMOTING AND HEPATOCARCINOGENIC EFFECTS OF 1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE (TCPOBOP) IN DBA/2NCR AND C57BL/6NCR MICE AND AN APPARENT PROMOTING EFFECT ON NASAL CAVITY TUMORS IN F344/NCR RATS INITIATED WITH N-NITROSODIETHYLAMINE; CARCINOGENESIS 13(10):1893-1901, 1992]"
5389,363901471,5382,C1=CC(=CC=C1OC2=C(C=C(C=N2)Cl)Cl)OC3=C(C=C(C=N3)Cl)Cl,Active,,,,MOUSE,DBA/MALE,INTRAPERITONEAL,0; 3 MG/KG BW IN CORN OIL 1/2 WK FOR 24 WK (STUDY DURATION: 55 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[DIWAN,BA, LUBET,RA, WARD,JM, HRABIE,JA AND RICE,JM; TUMOR-PROMOTING AND HEPATOCARCINOGENIC EFFECTS OF 1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE (TCPOBOP) IN DBA/2NCR AND C57BL/6NCR MICE AND AN APPARENT PROMOTING EFFECT ON NASAL CAVITY TUMORS IN F344/NCR RATS INITIATED WITH N-NITROSODIETHYLAMINE; CARCINOGENESIS 13(10):1893-1901, 1992]"
5390,363901471,5382,C1=CC(=CC=C1OC2=C(C=C(C=N2)Cl)Cl)OC3=C(C=C(C=N3)Cl)Cl,Active,,,,MOUSE,DBA/MALE,INTRAGASTRIC,0; 3 MG/KG BW IN CORN OIL 1/2 WK FOR 24 WK (STUDY DURATION: 55 WK),,POSITIVE,"[DIWAN,BA, LUBET,RA, WARD,JM, HRABIE,JA AND RICE,JM; TUMOR-PROMOTING AND HEPATOCARCINOGENIC EFFECTS OF 1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE (TCPOBOP) IN DBA/2NCR AND C57BL/6NCR MICE AND AN APPARENT PROMOTING EFFECT ON NASAL CAVITY TUMORS IN F344/NCR RATS INITIATED WITH N-NITROSODIETHYLAMINE; CARCINOGENESIS 13(10):1893-1901, 1992]"
5391,363901471,5382,C1=CC(=CC=C1OC2=C(C=C(C=N2)Cl)Cl)OC3=C(C=C(C=N3)Cl)Cl,Inactive,,,,RAT,F344/MALE,INTRAPERITONEAL,0; 30 MG/KG IN CORN OIL 1/2 WK FOR 71 WK (STUDY DURATION: 73 WK),,NEGATIVE,"[DIWAN,BA, LUBET,RA, WARD,JM, HRABIE,JA AND RICE,JM; TUMOR-PROMOTING AND HEPATOCARCINOGENIC EFFECTS OF 1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE (TCPOBOP) IN DBA/2NCR AND C57BL/6NCR MICE AND AN APPARENT PROMOTING EFFECT ON NASAL CAVITY TUMORS IN F344/NCR RATS INITIATED WITH N-NITROSODIETHYLAMINE; CARCINOGENESIS 13(10):1893-1901, 1992]"
5392,363901471,5382,C1=CC(=CC=C1OC2=C(C=C(C=N2)Cl)Cl)OC3=C(C=C(C=N3)Cl)Cl,Inactive,,,,RAT,F344/MALE,INTRAGASTRIC,0; 30 MG/KG IN CORN OIL 1/2 WK FOR 71 WK (STUDY DURATION: 73 WK),,NEGATIVE,"[DIWAN,BA, LUBET,RA, WARD,JM, HRABIE,JA AND RICE,JM; TUMOR-PROMOTING AND HEPATOCARCINOGENIC EFFECTS OF 1,4-BIS[2-(3,5-DICHLOROPYRIDYLOXY)]BENZENE (TCPOBOP) IN DBA/2NCR AND C57BL/6NCR MICE AND AN APPARENT PROMOTING EFFECT ON NASAL CAVITY TUMORS IN F344/NCR RATS INITIATED WITH N-NITROSODIETHYLAMINE; CARCINOGENESIS 13(10):1893-1901, 1992]"
5393,363901477,6683,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3O)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 1% IN DIET FOR 520 D (STUDY DURATION: 520 D),URINARY BLADDER: CARCINOMA,POSITIVE,"[MORI,H, OHNISHI,M, KAWAMORI,T, SUGIE,S, TANAKA,T, INO,N AND KAWAI,K; TOXICITY AND TUMORIGENICITY OF PURPURIN, A NATURAL HYDROXYANTHRAQUINONE IN RATS: INDUCTION OF BLADDER NEOPLASMS; CANCER LETT. 102(1,2):193-198, 1996]"
5394,363901478,3220,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 280; 830; 2500 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-493 Y01][NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF EMODIN: (CAS NO. 518-82-1) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 493:1-281, 2001, ]"
5395,363901478,3220,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 312; 625; 1250 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-493 Y01][NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF EMODIN: (CAS NO. 518-82-1) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 493:1-281, 2001, ]"
5396,363901478,3220,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 280; 830; 2500 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),ZYMBAL GLAND: CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-493 Y01]"
5397,363901478,3220,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 160; 312; 625 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),"KIDNEY: RENAL TUBULE ADENOMA, RENAL TUBULE CARCINOMA, RENAL TUBULE ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-493 Y01]"
5398,363901479,2950,C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O,Active,,,,RAT,ACI/MALE,ORAL,0; 1% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 16 MO),INTESTINE: ADENOMA OR CARCINOMA,POSITIVE,"[MORI,H, SUGIE,S, NIWA,K, TAKAHASHI,M AND KAWAI,K; INDUCTION OF INTESTINAL TUMOURS IN RATS BY CHRYSAZIN; BR. J. CANCER 52:781-783, 1985]"
5399,363901479,2950,C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O,Active,,,,MOUSE,C3H/HEN/MALE,ORAL,0; 0.2% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 540 D),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[MORI,H, SUGIE,S, NIWA,K, YOSHIMI,N, TANAKA,T AND HIRONO,I; CARCINOGENICITY OF CHRYSAZIN IN LARGE INTESTINE AND LIVER OF MICE; JPN. J. CANCER RES. (GANN) 77:871-876, 1986]"
5400,363901510,147799,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C(=C3)[N+](=O)[O-],Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED 1/7, 2/7 AND 4/7 ON DAY 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 32 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH, AMIN,S AND HECHT,SS; THE EFFECTS OF BAY-REGION METHYL SUBSTITUTION ON 6-NITROCHRYSENE MUTAGENICITY IN SALMONELLA TYPHIMURIUM AND TUMORIGENICITY IN NEWBORN MICE; CARCINOGENESIS (LONDON) 10(9):1685-9, 1989]"
5401,363901510,147799,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C(=C3)[N+](=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED 1/7, 2/7 AND 4/7 ON DAY 1, 8 AND 15 RESPECTIVELY (STUDY DURATION: 32 WK)",LUNG: TUMOR,POSITIVE,"[EL-BAYOUMY,K, SHIUE,GH, AMIN,S AND HECHT,SS; THE EFFECTS OF BAY-REGION METHYL SUBSTITUTION ON 6-NITROCHRYSENE MUTAGENICITY IN SALMONELLA TYPHIMURIUM AND TUMORIGENICITY IN NEWBORN MICE; CARCINOGENESIS (LONDON) 10(9):1685-9, 1989]"
5402,363901515,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPLEURAL,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5403,363901515,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPLEURAL,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5404,363901515,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5405,363901515,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5406,363901515,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5407,363901515,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5408,363901563,60960,C([C@@H](C(=O)O)N)S.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.25; 0.5% IN DRINKING WATER FOR 108 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[KITAHORI,Y KONISHI,N NAKAGAWA,Y CHO,M NAITOH,H YAMAMOTO,K  MATSUI,E ADN HIASA,Y; LACK OF CARCINOGENICITY OF L-CYSTEINE  MONOHYDROCHLORIDE IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 10: 83-89, 1997]"
5409,363901563,60960,C([C@@H](C(=O)O)N)S.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.25; 0.5% IN DRINKING WATER FOR 108 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[KITAHORI,Y KONISHI,N NAKAGAWA,Y CHO,M NAITOH,H YAMAMOTO,K  MATSUI,E ADN HIASA,Y; LACK OF CARCINOGENICITY OF L-CYSTEINE  MONOHYDROCHLORIDE IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 10: 83-89, 1997]"
5410,363901575,23672308,C(CC(=O)O)[C@@H](C(=O)[O-])N.[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 0.6; 1.25; 2.5; 5% IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[SHIBATA,MA, TANAKA,H, KAWABE,M, SANO,M, HAGIWARA,A AND SHIRAI,T; LACK OF CARCINOGENICITY OF MONOSODIUM L-GLUTAMATE IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 33(5):383-391, 1995]"
5411,363901575,23672308,C(CC(=O)O)[C@@H](C(=O)[O-])N.[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.6; 1.25; 2.5; 5% IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[SHIBATA,MA, TANAKA,H, KAWABE,M, SANO,M, HAGIWARA,A AND SHIRAI,T; LACK OF CARCINOGENICITY OF MONOSODIUM L-GLUTAMATE IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 33(5):383-391, 1995]"
5412,363901593,4911,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 100; 400 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-395 Y91]"
5413,363901593,4911,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 100; 400 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-395 Y91]"
5414,363901593,4911,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 100; 400 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-395 Y91]"
5415,363901593,4911,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100; 400 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-395 Y91]"
5416,363901594,6055,CC(CC1=CC=CC=C1)N.CC(CC1=CC=CC=C1)N.OS(=O)(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 20; 100 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-387 Y91]"
5417,363901594,6055,CC(CC1=CC=CC=C1)N.CC(CC1=CC=CC=C1)N.OS(=O)(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 20; 100 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-387 Y91]"
5418,363901594,6055,CC(CC1=CC=CC=C1)N.CC(CC1=CC=CC=C1)N.OS(=O)(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 20; 100 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-387 Y91]"
5419,363901594,6055,CC(CC1=CC=CC=C1)N.CC(CC1=CC=CC=C1)N.OS(=O)(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 20; 100 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-387 Y91]"
5420,363901606,26924,O[Si](=O)[O-].O[Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,F344/MALE,INHALATION,0; 6; 18 MG/M3 6 HR/D 5 D/WK FOR 113 WK (STUDY DURATION: 114 WK),"ADRENAL MEDULLA: BENIGN, MALIGNANT OR COMPLEX PHEOCHROMOCYTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-421 Y93]"
5421,363901606,26924,O[Si](=O)[O-].O[Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[Mg+2].[Mg+2].[Mg+2],Active,,,,RAT,F344/FEMALE,INHALATION,0; 6; 18 MG/M3 6 HR/D 5 D/WK FOR 122 WK (STUDY DURATION: 123 WK),"ADRENAL MEDULLA: BENIGN OR MALIGNANT PHEOCHROMOCYTOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-421 Y93]"
5422,363901606,26924,O[Si](=O)[O-].O[Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[Mg+2].[Mg+2].[Mg+2],Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 6; 18 MG/M3 6 HR/D 5 D/WK FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-421 Y93]"
5423,363901606,26924,O[Si](=O)[O-].O[Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[Mg+2].[Mg+2].[Mg+2],Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 6; 18 MG/M3 6 HR/D 5 D/WK FOR 103-104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-421 Y93]"
5424,363901619,13144,CC(C(=O)[O-])O.CC(C(=O)[O-])O.[Ca+2],Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN DRINKING WATER FOR 104 WK (MEAN TOTAL INTAKE 0; 329.4; 625.4 G/RAT) (STUDY DURATION: 113 WK),,NEGATIVE,"[MAEKAWA,A, MATSUSHIMA,Y, ONODERA,H, SHIBUTANI,M, YOSHIDA,J, KODAMA,Y, KUROKAWA,Y AND HAYASHI,Y; LONG-TERM TOXICITY/CARCINOGENICITY STUDY OF CALCIUM LACTATE IN F344 RATS; FOOD CHEM. TOXICOL. 29(9):589-594, 1991]"
5425,363901619,13144,CC(C(=O)[O-])O.CC(C(=O)[O-])O.[Ca+2],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN DRINKING WATER FOR 104 WK (MEAN TOTAL INTAKE 0; 237.7; 412.1 G/RAT) (STUDY DURATION: 113 WK),,NEGATIVE,"[MAEKAWA,A, MATSUSHIMA,Y, ONODERA,H, SHIBUTANI,M, YOSHIDA,J, KODAMA,Y, KUROKAWA,Y AND HAYASHI,Y; LONG-TERM TOXICITY/CARCINOGENICITY STUDY OF CALCIUM LACTATE IN F344 RATS; FOOD CHEM. TOXICOL. 29(9):589-594, 1991]"
5426,363901631,62790,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O.C1C(O1)CCl,Inactive,,,,MOUSE,CF-1/FEMALE,DERMAL,0; 1; 10% EPON 828 IN ACETONE (TOTAL DOSE 0.2 ML) 2/WK APPLIED TO DORSAL SKIN FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[PERISTIANIS,GC, DOAK,SMA, COLE,PN AND HEND,RW; TWO-YEAR CARCINOGENICITY STUDY ON THREE AROMATIC EPOXY RESINS APPLIED CUTANEOUSLY TO CF1 MICE; FOOD CHEM. TOXICOL. 26(7):611-624, 1988]"
5427,363901631,62790,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O.C1C(O1)CCl,Inactive,,,,MOUSE,CF-1/MALE,DERMAL,0; 1; 10% EPON 828 IN ACETONE (TOTAL DOSE 0.2 ML) 2/WK APPLIED TO DORSAL SKIN FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[PERISTIANIS,GC, DOAK,SMA, COLE,PN AND HEND,RW; TWO-YEAR CARCINOGENICITY STUDY ON THREE AROMATIC EPOXY RESINS APPLIED CUTANEOUSLY TO CF1 MICE; FOOD CHEM. TOXICOL. 26(7):611-624, 1988]"
5428,363901631,62790,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O.C1C(O1)CCl,Inactive,,,,MOUSE,CF-1/MALE,DERMAL,0; 1; 10% EPIKOTE 828 IN ACETONE (TOTAL DOSE 0.2 ML) 2/WK APPLIED TO DORSAL SKIN FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[PERISTIANIS,GC, DOAK,SMA, COLE,PN AND HEND,RW; TWO-YEAR CARCINOGENICITY STUDY ON THREE AROMATIC EPOXY RESINS APPLIED CUTANEOUSLY TO CF1 MICE; FOOD CHEM. TOXICOL. 26(7):611-624, 1988]"
5429,363901631,62790,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O.C1C(O1)CCl,Active,,,,MOUSE,CF-1/FEMALE,DERMAL,0; 1; 10% EPIKOTE 828 IN ACETONE (TOTAL DOSE 0.2 ML) 2/WK APPLIED TO DORSAL SKIN FOR DURATION OF STUDY (STUDY DURATION: 2 YR),HEMATOPOIETIC SYSTEM: RETICULUM-CELL SARCOMA; LYMPHOBLASTIC LYMPHOSARCOMA,POSITIVE,"[PERISTIANIS,GC, DOAK,SMA, COLE,PN AND HEND,RW; TWO-YEAR CARCINOGENICITY STUDY ON THREE AROMATIC EPOXY RESINS APPLIED CUTANEOUSLY TO CF1 MICE; FOOD CHEM. TOXICOL. 26(7):611-624, 1988]"
5430,363901633,115108,CN(C(CCC(=O)O)C1=CN=CC=C1)N=O,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 2.23 MG 3/WK FOR 20 WK (STUDY DURATION: 50 WK),,NEGATIVE,"[DJORDJEVIC,MV, BRUNNEMANN,KD AND HOFFMANN,D; IDENTIFICATION AND ANALYSIS OF A NICOTINE-DERIVED N-NITROSOAMINO ACID AND OTHER NITROSOAMINO ACIDS IN TOBACCO; CARCINOGENESIS (LONDON) 10(9):1725-31, 1989]"
5431,363901633,115108,CN(C(CCC(=O)O)C1=CN=CC=C1)N=O,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 200 UMOL MOUSE (TOTAL DOSE) ADMINISTERED IN 0.1 ML SALINE 3/WK (TOTAL 20 INJECTIONS) (STUDY DURATION: 37 WK),,NEGATIVE,"[RIVENSON,A, DJORDJEVIC,MV, AMIN,S AND HOFFMANN,R; A STUDY OF TOBACCO CARCINOGENESIS. XLIV. BIOASSAY IN A/J MICE OF SOME N-NITROSAMINES; CANCER LETT. 47(1-2):111-114, 1989]"
5432,363901633,115108,CN(C(CCC(=O)O)C1=CN=CC=C1)N=O,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 200 UMOL TOTAL DOSE ADMINISTERED IN SUBDOSES 3/WK FOR 7 WK (STUDY DURATION: 37 WK),,NEGATIVE,"[HOFFMANN,D, DJORDJEVIC,MV, RIVENSON,A, ZANG,E, DESAI,D AND AMIN,S; A STUDY OF TOBACCO CARCINOGENESIS. LI. RELATIVE POTENCIES OF TOBACCO-SPECIFIC N-NITROSAMINES AS INDUCERS OF LUNG TUMORS IN A/J MICE; CANCER LETT. 71(1-3): 25-30, 1993]"
5433,363901643,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPLEURAL,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5434,363901643,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPLEURAL,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5435,363901643,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5436,363901643,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5437,363901643,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5438,363901643,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 25 MG IN 1 ML OF WATER ONCE AT 8 WK OF AGE (STUDY DURATION: LIFETIME),,NEGATIVE,"[MALTONI,C AND MINARDI,F; FIRST AVAILABLE RESULTS OF LONG-TERM CARCINOGENICITY BIOASSAY ON DETERGENCY ZEOLITES (MS 4A AND MS 5A); ANN. N.Y. ACAD. SCI. 534 (LIVING CHEM. WORLD):978-985, 1988]"
5439,363901644,8512,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)O,Active,,,,RAT,ACI/N/MALE,ORAL,0; 1% IN BASAL DIET FOR DURATION OF STUDY (STUDY DURATION: 480 D),"CECUM: ADENOMA, ADENOCARCINOMA; COLON: ADENOMA, ADENOCARCINOMA; LIVER: TUMOR; STOMACH: TUMOR",POSITIVE,"[MORI,H, YOSHIMI,N, IWATA,H, MORI,Y, HARA,A, TANAKA,T AND KAWAI,K; CARCINOGENI- CITY OF NATURALLY OCCURRING 1-HYDROXYANTHRAQUINONE IN RATS: INDUCTION OF LARGE BOWEL, LIVER AND STOMACH NEOPLASMS; CARCINOGENESIS (LONDON) 11(5):799-802, 1990]"
5440,363901645,24849109,[C@H]([C@@H]([C@H](C(=O)[O-])O)O)([C@@H](C(=O)O)O)O.[C@H]([C@@H]([C@H](C(=O)[O-])O)O)([C@@H](C(=O)O)O)O.[C@H]([C@@H]([C@H](C(=O)[O-])O)O)([C@@H](C(=O)O)O)O.[Fe+3],Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,"0; 5 MG/KG IN GLUCOSE SOLUTION 1/D 6 D/WK FOR 3 MO (STUDY DURATION: 1 YR, 3 MO)",PERITONEAL CAVITY: MESOTHELIOMA,POSITIVE,"[OKADA,S, HAMAZAKI,S, TOYOKUNI,S AND MIDORIKAWA,O; INDUCTION OF MESOTHELIOMA BY INTRAPERITONEAL INJECTIONS OF FERRIC SACCHARATE IN MALE WISTAR RATS; BR. J. CANCER 60(5):708-711, 1989]"
5441,363901647,16682746,CCCC[Sn](CCCC)(CCCC)O[Sn](CCCC)(CCCC)CCCC,Active,,,,RAT,WISTAR/MALE,ORAL,0; 0.5; 5; 50 MG/KG DIET FOR 30 MO (STUDY DURATION: 30 MO),ADRENAL GLAND: PHEOCHROMOCYTOMA; PITUITARY: TUMOR; PARATHYROID: ADENOMA,POSITIVE,"[WESTER,PW, KRAJNC,EI, VAN LEEUWEN,FXR, LOEBER,JG, VAN DER HEIJDEN,CA, VAESSEN, HAMG AND HELLEMAN,PW; CHRONIC TOXICITY AND CARCINOGENICITY OF BIS(TRI-N-BUTYLTIN)OXIDE (TBTO) IN THE RAT; FOOD CHEM. TOXICOL. 28(3):179-96, 1990]"
5442,363901647,16682746,CCCC[Sn](CCCC)(CCCC)O[Sn](CCCC)(CCCC)CCCC,Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 0.5; 5; 50 MG/KG DIET FOR 30 MO (STUDY DURATION: 30 MO),ADRENAL GLAND: PHEOCHROMOCYTOMA; PITUITARY: TUMOR,POSITIVE,"[WESTER,PW, KRAJNC,EI, VAN LEEUWEN,FXR, LOEBER,JG, VAN DER HEIJDEN,CA, VAESSEN, HAMG AND HELLEMAN,PW; CHRONIC TOXICITY AND CARCINOGENICITY OF BIS(TRI-N-BUTYLTIN)OXIDE (TBTO) IN THE RAT; FOOD CHEM. TOXICOL. 28(3):179-96, 1990]"
5443,363901648,88735,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O)O)O)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 2.5; 5; 10% IN DIET FOR LIFE (PARENTS FED DIETS BEFORE AND AFTER PREGNANCY AND DURING LACTATION) (STUDY DURATION: 128 WK),,NEGATIVE,"[SMITS-VAN PROOIJE,AE, DE GROOT,AP, DREEF-VAN DER MEULEN,HC AND SINKELDAM,EJ; CHRONIC TOXICITY AND CARCINOGENICITY STUDY OF ISOMALT IN RATS AND MICE; FOOD CHEM. TOXICOL. 28(4):243-51, 1990]"
5444,363901648,88735,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O)O)O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 2.5; 5; 10% IN DIET FOR LIFE (PARENTS FED DIETS BEFORE AND AFTER PREGNANCY AND DURING LACTATION) (STUDY DURATION: 130 WK),,NEGATIVE,"[SMITS-VAN PROOIJE,AE, DE GROOT,AP, DREEF-VAN DER MEULEN,HC AND SINKELDAM,EJ; CHRONIC TOXICITY AND CARCINOGENICITY STUDY OF ISOMALT IN RATS AND MICE; FOOD CHEM. TOXICOL. 28(4):243-51, 1990]"
5445,363901648,88735,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O)O)O)O,Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 2.5; 5; 10% IN DIET FOR LIFE (PARENTS FED DIETS BEFORE AND AFTER PREGNANCY AND DURING LACTATION) (STUDY DURATION: 94 WK),,NEGATIVE,"[SMITS-VAN PROOIJE,AE, DE GROOT,AP, DREEF-VAN DER MEULEN,HC AND SINKELDAM,EJ; CHRONIC TOXICITY AND CARCINOGENICITY STUDY OF ISOMALT IN RATS AND MICE; FOOD CHEM. TOXICOL. 28(4):243-51, 1990]"
5446,363901648,88735,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O)O)O)O,Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 2.5; 5; 10% IN DIET FOR LIFE (PARENTS FED DIETS BEFORE AND AFTER PREGNANCY AND DURING LACTATION) (STUDY DURATION: 104 WK),,NEGATIVE,"[SMITS-VAN PROOIJE,AE, DE GROOT,AP, DREEF-VAN DER MEULEN,HC AND SINKELDAM,EJ; CHRONIC TOXICITY AND CARCINOGENICITY STUDY OF ISOMALT IN RATS AND MICE; FOOD CHEM. TOXICOL. 28(4):243-51, 1990]"
5447,363901649,24261,O=[Si]=O,Inactive,,,,MOUSE,STRAIN-A/MALE,INTRATRACHEAL,0; 9.75 MG/KG IN SALINE 1/WK FOR 15 WK (STUDY DURATION: 20 WK),,NEGATIVE,"[MCNEILL,DA, CHRISP,CE AND FISHER,GL; PULMONARY ADENOMAS IN A/J MICE TREATED WITH SILICA; DRUG CHEM. TOXICOL. 13(1):87-92, 1990]"
5448,363901649,24261,O=[Si]=O,Active,,,,RAT,F344/FEMALE,INHALATION,0; 50 MG/M3 6 HR/D 5 D/WK FOR UP TO 24 MO (STUDY DURATION: 24 MO),LUNG: CARCINOMA OR ADENOMA,POSITIVE,"[SANDERS,CL AND DAGLE,GE; A THRESHOLD MODEL OF PULMONARY CARCINOGENESIS: CARCINOMA IN THE RAT AFTER DEPOSITION OF PLUTONIUM OR QUARTZ; APPL. OCCUP. ENVIRON. HYG. 11(4):391-397, 1996]"
5449,363901649,24261,O=[Si]=O,Inactive,,,,RAT,F344/MALE,INHALATION,0; 50 MG/M3 6 HR/D 5 D/WK FOR UP TO 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[SANDERS,CL AND DAGLE,GE; A THRESHOLD MODEL OF PULMONARY CARCINOGENESIS: CARCINOMA IN THE RAT AFTER DEPOSITION OF PLUTONIUM OR QUARTZ; APPL. OCCUP. ENVIRON. HYG. 11(4):391-397, 1996]"
5450,363901649,24261,O=[Si]=O,Active,,,,RAT,"F344/MALE,FEMALE",INHALATION,0; 1 MG/M3 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 25.5 MO),LUNG: TUMOR,POSITIVE,"[MUHLE,H, KITTEL,B, ERNST,H, MOHR,U AND MERMELSTEIN,R; NEOPLASTIC LUNG LESIONS IN RAT AFTER CHRONIC EXPOSURE TO CRYSTALLINE SILICA; SCAND. J. WORK, ENVIRON. HEALTH 21(SUPPL. 2):27-29, 1995]"
5451,363901649,24261,O=[Si]=O,Active,,,,Rat,Wistar/Female (48/group),Intratracheal,"3 mg of 0.09-0.2 um particles given as 10 instillations before wk 26, study duration 112 wk or no treatment",Lung: Bronchiolo-alveolar adenoma (2/37 experimental animals vs 0/46 control animals),"Positive, low incidence of benign tumors.","[MOHR,U, ERNST,H, ROLLER,M, AND POTT,F; PULMONARY TUMOR TYPES INDUCED IN WISTAR RATS OF THE SO-CALLED 19-DUST STUDY; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 58:13-20, 2006]"
5452,363901650,9020,C(CC(=O)[O-])C(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 1; 2% IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MAEKAWA,A, TODATE,A, ONODERA,H, MATSUSHIMA,Y, NAGAOKA,T, SHIBUTANI,M, OGASAWARA, H, KODAMA,Y AND HAYASHI,Y; LACK OF TOXICITY/CARCINOGENICITY OF MONOSODIUM SUCCINATE IN F344 RATS; FOOD CHEM. TOXICOL. 28(4):235-41, 1990]"
5453,363901650,9020,C(CC(=O)[O-])C(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1; 2% IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MAEKAWA,A, TODATE,A, ONODERA,H, MATSUSHIMA,Y, NAGAOKA,T, SHIBUTANI,M, OGASAWARA, H, KODAMA,Y AND HAYASHI,Y; LACK OF TOXICITY/CARCINOGENICITY OF MONOSODIUM SUCCINATE IN F344 RATS; FOOD CHEM. TOXICOL. 28(4):235-41, 1990]"
5454,363901651,5327,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C,Active,,,,RAT,F344/FEMALE,ORAL; TRANS-PLACENTAL,0; 10; 40; 600 1200; 2400 PPM IN DIET FOR 24 MO (PARENTS FED 0; 10; 600; 1200; 2400 PPM RESPECTIVELY IN DIET) (STUDY DURATION: 24 MO),THYROID GLAND: FOLLICULAR CELL ADENOCARCINOMA,POSITIVE,"[LITTLEFIELD,NA, SHELDON,WG, ALLEN,R AND GAYLOR,DW; CHRONIC TOXICITY/CARCINOGENI- CITY STUDIES OF SULFAMETHAZINE IN FISCHER 344/N RATS: TWO-GENERATION EXPOSURE; FOOD CHEM. TOXICOL. 28(3):157-67, 1990]"
5455,363901651,5327,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C,Active,,,,RAT,F344/MALE,ORAL; TRANS-PLACENTAL,0; 10; 40; 600 1200; 2400 PPM IN DIET FOR 24 MO (PARENTS FED 0; 10; 600; 1200; 2400 PPM RESPECTIVELY IN DIET) (STUDY DURATION: 24 MO),THYROID GLAND: FOLLICULAR CELL ADENOCARCINOMA,POSITIVE,"[LITTLEFIELD,NA, SHELDON,WG, ALLEN,R AND GAYLOR,DW; CHRONIC TOXICITY/CARCINOGENI- CITY STUDIES OF SULFAMETHAZINE IN FISCHER 344/N RATS: TWO-GENERATION EXPOSURE; FOOD CHEM. TOXICOL. 28(3):157-67, 1990]"
5456,363901652,43172,C1COCCN1C(C(Cl)(Cl)Cl)NC=O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 67; 330; 665 MG/KG IN DIET LESS THAN 2 YR (STUDY DURATION: LESS THAN 2 YR),,NEGATIVE,"[VARGOVA,M, KOBZOVA,D, JAKUBOVSKY,J, GAJDOVA,M AND GRUNT,J; COMBINED CHRONIC TOXICITY/CARCINOGENESIS STUDY OF THE FUNGICIDE TRIMORPHAMIDE IN RATS; CANCER LETT. 49(1):31-9, 1990]"
5457,363901652,43172,C1COCCN1C(C(Cl)(Cl)Cl)NC=O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 67; 330; 665 MG/KG IN DIET LESS THAN 2 YR (STUDY DURATION: LESS THAN 2 YR),,NEGATIVE,"[VARGOVA,M, KOBZOVA,D, JAKUBOVSKY,J, GAJDOVA,M AND GRUNT,J; COMBINED CHRONIC TOXICITY/CARCINOGENESIS STUDY OF THE FUNGICIDE TRIMORPHAMIDE IN RATS; CANCER LETT. 49(1):31-9, 1990]"
5458,363901653,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 12500; 25000; 50000 PPM IN DIET FOR 103 WK (TOTAL DOSE: 143.46; 179.55; 581.18 G) (STUDY DURATION: 24 MO),,NEGATIVE,"[TAKIZAWA,Y, HIRASAWA,F, NORITOMI,E, AIDA,M, TSUNODA,H AND UESUGI,S; ORAL INGESTION OF SYLOID BY MICE AND RATS ITS CHRONIC TOXICITY AND CARCINOGENICITY; ACTA. MED. BIOL. 36(1):27-56, 1988]"
5459,363901653,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 12500; 25000; 50000 PPM IN DIET FOR 103 WK (STUDY DURATION: 24 MO),,NEGATIVE,"[TAKIZAWA,Y, HIRASAWA,F, NORITOMI,E, AIDA,M, TSUNODA,H AND UESUGI,S; ORAL INGESTION OF SYLOID BY MICE AND RATS ITS CHRONIC TOXICITY AND CARCINOGENICITY; ACTA. MED. BIOL. 36(1):27-56, 1988]"
5460,363901653,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 12500; 25000; 50000 PPM IN DIET FOR 93 WK (TOTAL DOSE: 38.45; 79.78; 160.23 G) (STUDY DURATION: 21 MO),,NEGATIVE,"[TAKIZAWA,Y, HIRASAWA,F, NORITOMI,E, AIDA,M, TSUNODA,H AND UESUGI,S; ORAL INGESTION OF SYLOID BY MICE AND RATS ITS CHRONIC TOXICITY AND CARCINOGENICITY; ACTA. MED. BIOL. 36(1):27-56, 1988]"
5461,363901653,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 12500; 25000; 50000 PPM IN DIET FOR 93 WK (TOTAL DOSE: 37.02; 72.46; 157.59 G) (STUDY DURATION: 21 MO),,NEGATIVE,"[TAKIZAWA,Y, HIRASAWA,F, NORITOMI,E, AIDA,M, TSUNODA,H AND UESUGI,S; ORAL INGESTION OF SYLOID BY MICE AND RATS ITS CHRONIC TOXICITY AND CARCINOGENICITY; ACTA. MED. BIOL. 36(1):27-56, 1988]"
5462,363901654,40585,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,Inactive,,,,MOUSE,C57BL/MALE,INTRAGASTRIC,0; 1; 4; 8 MG/KG IN ARACHIS OIL 5 D/WK FOR 104 WK (STUDY DURATION: 120 WK),,NEGATIVE,"[CABRAL,JRP, GALENDO,D, LAVAL,M AND LYANDRAT,N; CARCINOGENICITY STUDIES WITH DELTAMETHRIN IN MICE AND RATS; CANCER LETT. 49(2):147-52, 1990]"
5463,363901654,40585,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,Inactive,,,,MOUSE,C57BL/FEMALE,INTRAGASTRIC,0; 1; 4; 8 MG/KG IN ARACHIS OIL 5 D/WK FOR 104 WK (STUDY DURATION: 120 WK),,NEGATIVE,"[CABRAL,JRP, GALENDO,D, LAVAL,M AND LYANDRAT,N; CARCINOGENICITY STUDIES WITH DELTAMETHRIN IN MICE AND RATS; CANCER LETT. 49(2):147-52, 1990]"
5464,363901654,40585,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,Active,,,,RAT,BDVI/MALE,INTRAGASTRIC,0; 3; 6 MG/KG IN ARACHIS OIL 5 D/WK FOR 104 WK (STUDY DURATION: 120 WK),THYROID: ADENOMA,POSITIVE,"[CABRAL,JRP, GALENDO,D, LAVAL,M AND LYANDRAT,N; CARCINOGENICITY STUDIES WITH DELTAMETHRIN IN MICE AND RATS; CANCER LETT. 49(2):147-52, 1990]"
5465,363901654,40585,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,Active,,,,RAT,BDVI/FEMALE,INTRAGASTRIC,0; 3; 6 MG/KG IN ARACHIS OIL 5 D/WK FOR 104 WK (STUDY DURATION: 120 WK),THYROID: ADENOMA,POSITIVE,"[CABRAL,JRP, GALENDO,D, LAVAL,M AND LYANDRAT,N; CARCINOGENICITY STUDIES WITH DELTAMETHRIN IN MICE AND RATS; CANCER LETT. 49(2):147-52, 1990]"
5466,363901654,40585,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,Inactive,,,,MOUSE,"SWISS/MALE, FEMALE",DERMAL,0; 1; 2; 4 MG/KG BW IN 200 UL ACETONE 3/WK FOR 32 WK (STUDY DURATION: 32 WK),,NEGATIVE,"[SHUKLA,Y ARORA,A AND SINGH,A; TUMORIGENIC STUDIES ON DELTAMETHRIN IN SWISS ALBINO MICE; TOXICOLOGY 163(1):1-9, 2001]"
5467,363901654,40585,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,Inactive,,,,Rat,Crl:CD(SD)BR/Male (50/Group),Oral,0; 25; 125; 500; 800 ppm in feed for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DELTAMETHRIN (MAY 24, 2000)]"
5468,363901654,40585,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,Inactive,,,,Rat,Crl:CD(SD)BR/Female (50/Group),Oral,0; 25; 125; 500; 800 ppm in feed for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DELTAMETHRIN (MAY 24, 2000)]"
5469,363901654,40585,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Male (50/Group),Oral,0; 10; 100; 1000; 2000 ppm in feed for 97 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DELTAMETHRIN (MAY 24, 2000)]"
5470,363901654,40585,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Br)Br)C,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Female (50/Group),Oral,0; 10; 100; 1000; 2000 ppm in feed for 97 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DELTAMETHRIN (MAY 24, 2000)]"
5471,363901655,38668,C1=CC=C(C(=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCO)O)F,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 3; 10; 30 MG/KG IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BORELLI,G, BERTOLI,D AND CHIECO,P; CARCINOGENICITY STUDY OF DOXEFAZEPAM ADMINISTERED IN THE DIET TO SPRAGUE-DAWLEY RATS; FUNDAM. APPL. TOXICOL. 15(1): 82-92, 1990]"
5472,363901655,38668,C1=CC=C(C(=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCO)O)F,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 3; 10; 30 MG/KG IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BORELLI,G, BERTOLI,D AND CHIECO,P; CARCINOGENICITY STUDY OF DOXEFAZEPAM ADMINISTERED IN THE DIET TO SPRAGUE-DAWLEY RATS; FUNDAM. APPL. TOXICOL. 15(1): 82-92, 1990]"
5473,363901675,31253,CC(=CCCC(=C)C=C)C,Active,,,,Rat,F344/N / Male (50/Group),Oral,"0; 0.25; 0.5; 1 g/kg in corn oil, by gavage, 5 d/wk for 105 wk","Kidney: renal tubule adenoma (standard evaluation - 0/50, 4/50, 8/50; standard and extended evaluations combined - 0/50, 12/50, 13/50); renal tubule adenoma or carcinoma (standard evaluation - 0/50, 7/50, 9/50; standard and extended evaluations combined - 0/50, 14/50, 13/50)",Positive (Authors describe as clear evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-556 Y10]"
5474,363901675,31253,CC(=CCCC(=C)C=C)C,Inactive,,,,Rat,F344/N / Female (50/Group),Oral,"0; 0.25; 0.5; 1 g/kg in corn oil, by gavage, 5 d/wk for 105 wk",,"Negative. (Authors describe findings as equivocal based on renal tubule adenoma (standard evaluation - 0/50, 1/50, 0/50, 2/50; standard and extended evaluations combined - 0/50, 2/50, 1/50, 3/50))","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-556 Y10]"
5475,363901675,31253,CC(=CCCC(=C)C=C)C,Active,,,,Mouse,B6C3F1 / Male (50/Group),Oral,"0; 0.25; 0.5; 1 g/kg in corn oil, by gavage, 5 d/wk for 104-105 wk","Liver: hepatocellular adenoma (26/50, 41/50, 43/50); hepatocellular carcinoma (14/50, 20/50, 28/50); hepatocellular adenoma or carcinoma (33/50, 44/50, 48/50); hepatoblastoma (4/50, 6/50, 11/50); hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma (34/50, 45/50, 48/50)",Positive (Authors describe as clear evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-556 Y10]"
5476,363901675,31253,CC(=CCCC(=C)C=C)C,Inactive,,,,Mouse,B6C3F1 / Female (50/Group),Oral,"0; 0.25; 0.5; 1 g/kg in corn oil, by gavage, 5 d/wk for 104-105 wk",,"Negative. (Authors describe results as equivocal based on incidences of hepatocellular adenoma (6/50, 13/50, 6/50); hepatocellular carcinoma (1/50, 7/50, 2/50); and hepatocellular adenoma or carcinoma (7/50, 18/50, 8/50)","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-556 Y10]"
5477,363901682,24586,[O-]S(=O)(=O)[O-].[Ni+2],Inactive,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 63; 83; UMOL/KG GIVEN IN 14 INJECTIONS OVER 26 D (STUDY DURATION; 2 YR),,NEGATIVE,"[KNIGHT,JA, PLOWMAN,MR, HOPFER,SM AND SUNDERMAN,FW JR.; PATHOLOGICAL REACTIONS IN LUNG, LIVER, THYMUS, AND SPLEEN OF RATS AFTER SUBACUTE PARENTERAL ADMINISTRATION OF NICKEL SULFATE; ANN. CLIN. LAB. SCI. 21(4):275-283, 1991]"
5478,363901682,24586,[O-]S(=O)(=O)[O-].[Ni+2],Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.12; 0.25; 0.5 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-454 Y96]"
5479,363901682,24586,[O-]S(=O)(=O)[O-].[Ni+2],Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.12; 0.25; 0.5 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-454 Y96]"
5480,363901682,24586,[O-]S(=O)(=O)[O-].[Ni+2],Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.25; 0.5; 1 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-454 Y96]"
5481,363901682,24586,[O-]S(=O)(=O)[O-].[Ni+2],Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.25; 0.5; 1 MG/M3 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-454 Y96]"
5482,363901682,24586,[O-]S(=O)(=O)[O-].[Ni+2],Inactive,,,,Rat,Fischer 344/Male (50/group),Oral,0; 10; 30; 50 mg/kg/day by gavage once daily for 104 wk,,Negative,"[HEIM,KE BATES,HK RUSH,RE AND OLLER,AR; ORAL CARCINOGENICITY STUDY WITH NICKEL SULFATE HEXAHYDRATE IN FISCHER 344 RATS; TOXICOLOGY AND APPLIED PHARMACOLOGY 224(2):126-37, 2007]"
5483,363901682,24586,[O-]S(=O)(=O)[O-].[Ni+2],Inactive,,,,Rat,Fischer 344/Female (50/group),Oral,0; 10; 30; 50 mg/kg/day by gavage once daily for 104 wk,,Negative,"[HEIM,KE BATES,HK RUSH,RE AND OLLER,AR; ORAL CARCINOGENICITY STUDY WITH NICKEL SULFATE HEXAHYDRATE IN FISCHER 344 RATS; TOXICOLOGY AND APPLIED PHARMACOLOGY 224(2):126-37, 2007]"
5484,363901683,28094,S=[Ni],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
5485,363901694,174,C(CO)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 6250; 12500; 25000 PPM IN DIET FOR 721 D (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-413 Y93]"
5486,363901694,174,C(CO)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 12500; 25000; 50000 PPM IN DIET FOR 721 D (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-413 Y93]"
5487,363901696,8456,CC(C)(C)C1=C(C=CC(=C1)OC)O,Active,,,,HAMSTER,SYRIAN/MALE,ORAL,1% IN DIET FOR 24 WK (STUDY DURATION: 24 WK),FORESTOMACH: PAPILLOMA,POSITIVE,"[LAM,LKT AND GARG,P; TUMORIGENICITY OF DI-TERT-BUTYL-SUBSTITUTED HYDROQUINONE AND HYDROXYANISOLES IN THE FORESTOMACH OF SYRIAN GOLDEN HAMSTERS; CARCINOGENESIS 12(7):1341-1344, 1991]"
5488,363901727,2018,CC(=O)NC1=CC=C(C=C1)CC(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 300; 1000; 3000 MG/KG IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[TRUTTER,J, MACHOTKA,SV, ALSAKER,RD, SUMI,N AND TOSHIDA,K; CARCINOGENICITY STUDY OF A NEW ORALLY ACTIVE ANTIRHEUMATIC DRUG 4-ACETYLAMINOPHENYLACETIC ACID (MS-932) IN MICE; OYO YAKURI 40(3):325-335, 1990]"
5489,363901727,2018,CC(=O)NC1=CC=C(C=C1)CC(=O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0;300; 1000; 3000 MG/KG IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[TRUTTER,J, MACHOTKA,SV, ALSAKER,RD, SUMI,N AND TOSHIDA,K; CARCINOGENICITY STUDY OF A NEW ORALLY ACTIVE ANTIRHEUMATIC DRUG 4-ACETYLAMINOPHENYLACETIC ACID (MS-932) IN MICE; OYO YAKURI 40(3):325-335, 1990]"
5490,363901727,2018,CC(=O)NC1=CC=C(C=C1)CC(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 300; 1000; 3000 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[TRUTTER,JA, MACHOTKA,SV, ALSAKER,RD, SUMI,N AND TOSHIDA,K; CARCINOGENICITY STUDY OF A NEW ORALLY ACTIVE ANTIRHEUMATIC DRUG 4-ACETYLAMINOPHENYLACETIC ACID (MS-932) IN RATS; OYO YAKURI 40(3):337-349, 1990]"
5491,363901727,2018,CC(=O)NC1=CC=C(C=C1)CC(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 300; 1000; 3000 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[TRUTTER,JA, MACHOTKA,SV, ALSAKER,RD, SUMI,N AND TOSHIDA,K; CARCINOGENICITY STUDY OF A NEW ORALLY ACTIVE ANTIRHEUMATIC DRUG 4-ACETYLAMINOPHENYLACETIC ACID (MS-932) IN RATS; OYO YAKURI 40(3):337-349, 1990]"
5492,363901750,3485,C(CC=O)CC=O,Inactive,,,,Rat,Fischer 344/Male (80/Group),Oral,0; 50; 250; 1000 ppm (0; 3.6; 17.1; 63.9 mg/kg/d) in drinking water for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR GLUTARALDEHYDE (January 19, 2001)]"
5493,363901750,3485,C(CC=O)CC=O,Active,,,,Rat,Fischer 344/Female (80/Group),Oral,0; 50; 250; 1000 ppm (0; 5.5; 25.1; 85.9 mg/kg/d) in drinking water for 104 wk; study duration 104 wk,"Large granular lymphocyte leukemia (24, 41, 41, 53/100 animals)",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR GLUTARALDEHYDE (January 19, 2001)]"
5494,363901750,3485,C(CC=O)CC=O,Inactive,,,,RAT,F344/N/MALE,INHALATION,0; 250; 500; 750 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-490 Y99][VAN BIRGELEN,APJM CHOU,BJ RENNE,RA GRUMBEIN,SL ROYCROFT,JH HAILEY,JR AND BUCHER,JR; EFFECTS OF GLUTARALDEHYDE IN A 2-YEAR INHALATION STUDY IN RATS AND MICE; TOXICOL. SCI. 55(1):195-205, 2000, ]"
5495,363901750,3485,C(CC=O)CC=O,Inactive,,,,RAT,F344/N/FEMALE,INHALATION,0; 250; 500; 750 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-490 Y99][VAN BIRGELEN,APJM CHOU,BJ RENNE,RA GRUMBEIN,SL ROYCROFT,JH HAILEY,JR AND BUCHER,JR; EFFECTS OF GLUTARALDEHYDE IN A 2-YEAR INHALATION STUDY IN RATS AND MICE; TOXICOL. SCI. 55(1):195-205, 2000, ]"
5496,363901750,3485,C(CC=O)CC=O,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 62.5; 125; 250 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-490 Y99][VAN BIRGELEN,APJM CHOU,BJ RENNE,RA GRUMBEIN,SL ROYCROFT,JH HAILEY,JR AND BUCHER,JR; EFFECTS OF GLUTARALDEHYDE IN A 2-YEAR INHALATION STUDY IN RATS AND MICE; TOXICOL. SCI. 55(1):195-205, 2000, ]"
5497,363901750,3485,C(CC=O)CC=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 62.5; 125; 250 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-490 Y99][VAN BIRGELEN,APJM CHOU,BJ RENNE,RA GRUMBEIN,SL ROYCROFT,JH HAILEY,JR AND BUCHER,JR; EFFECTS OF GLUTARALDEHYDE IN A 2-YEAR INHALATION STUDY IN RATS AND MICE; TOXICOL. SCI. 55(1):195-205, 2000, ]"
5498,363901750,3485,C(CC=O)CC=O,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 100 PPB 6 HR/D 5 D/WK FOR 52 OR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[ZISSU,D, BONNET,P AND BINET,S; HISTOPATHOLOGICAL STUDY IN B6C3F1 MICE CHRONICALLY EXPOSED BY INHALATION TO GLUTARALDEHYDE; TOXICOL. LETT. 95:131-139, 1998]"
5499,363901750,3485,C(CC=O)CC=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 100 PPB 6 HR/D 5 D/WK FOR 52 OR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[ZISSU,D, BONNET,P AND BINET,S; HISTOPATHOLOGICAL STUDY IN B6C3F1 MICE CHRONICALLY EXPOSED BY INHALATION TO GLUTARALDEHYDE; TOXICOL. LETT. 95:131-139, 1998]"
5500,363901750,3485,C(CC=O)CC=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 50; 250; 1000 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[VAN MILLER,JP HERMANSKY,SJ LOSCO,PE AND BALLANTYNE,B; CHRONOIC TOXICITY AND ONCOGENICITY STUDY WITH GLUTARALDEHYDE DOSED IN THE DRINKING WATER OF FISCHER 344 RATS; TOXICOLOGY 175(1-3):177-189, 2002]"
5501,363901750,3485,C(CC=O)CC=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 50; 250; 1000 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[VAN MILLER,JP HERMANSKY,SJ LOSCO,PE AND BALLANTYNE,B; CHRONOIC TOXICITY AND ONCOGENICITY STUDY WITH GLUTARALDEHYDE DOSED IN THE DRINKING WATER OF FISCHER 344 RATS; TOXICOLOGY 175(1-3):177-189, 2002]"
5502,363901828,88446,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)Cl,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1600 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7 WITHIN 24 HR OF BIRTH, 2/7 AT 8 DAYS OF AGE AND 4/7 AT 15 DAYS OF AGE (STUDY DURATION: 12 MO)","LIVER: ADENOMA, CARCINOMA",POSITIVE,"[FU,PP, VON TUNGELN,LS, ZHAN,DJ AND BUCCI,T;POTENT TUMORIGENICITY OF 7-CHLOROBENZ[A]ANTHRACENE AND 7-BROMOBENZ[A]ANTHRACENE IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 101(1):37-42, 1996]"
5503,363901832,72849,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)Br,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1600 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7 WITHIN 24 HR OF BIRTH, 2/7 AT 8 DAYS OF AGE AND 4/7 AT 15 DAYS OF AGE (STUDY DURATION: 12 MO)","LIVER: ADENOMA, CARCINOMA",POSITIVE,"[FU,PP, VON TUNGELN,LS, ZHAN,DJ AND BUCCI,T;POTENT TUMORIGENICITY OF 7-CHLOROBENZ[A]ANTHRACENE AND 7-BROMOBENZ[A]ANTHRACENE IN THE NEONATAL B6C3F1 MALE MOUSE; CANCER LETT. 101(1):37-42, 1996]"
5504,363901866,146461,CCCCCCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 17.5 MG/ML (TOTAL DOSE 0; 2 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 50 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: TUMOR; BODY CAVITY: MESOTHELIOMA,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
5505,363901866,146461,CCCCCCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 17.5 MG/ML (TOTAL DOSE 0; 2 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 50 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: TUMOR; MAMMARY GLAND: TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
5506,363901866,146461,CCCCCCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 17.5 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 50 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LUNG: TUMOR; PERITONEUM: MESOTHELIOMA; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
5507,363901866,146461,CCCCCCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 17.5 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 50 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LUNG: TUMOR; MAMMARY GLAND: TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
5508,363901867,96019,C=CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 13 MG/ML (TOTAL DOSE 0; 1.2 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; LUNG: TUMOR; COLON: TUMOR; ZYMBAL GLAND: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
5509,363901867,96019,C=CCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 13 MG/ML (TOTAL DOSE 0; 1.2 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),FORESTOMACH: SQUAMOUS CELL CARCINOMA; MAMMARY GLAND: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
5510,363901867,96019,C=CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 13 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 30 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LUNG: COLON: TUMOR; ZYMBAL GLAND: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
5511,363901867,96019,C=CCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 13 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 30 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; MAMMARY GLAND: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
5512,363901868,96395,C1=CC=C(C=C1)CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 20 MG/ML (TOTAL DOSE 0; 0.9 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 22 WK (STUDY DURATION: LIFETIME),LIVER: TUMOR; FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
5513,363901868,96395,C1=CC=C(C=C1)CCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 20 MG/ML (TOTAL DOSE 0; 0.9 MMOL) IN 2 ML ETHYL ACETATE AND CORN OIL (1:2) 2/WK FOR 22 WK (STUDY DURATION: LIFETIME),LIVER: TUMOR; FORESTOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; TOXICOL. IND. HEALTH 5(6):925-935, 1989]"
5514,363901868,96395,C1=CC=C(C=C1)CCN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 20 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 22 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LIVER: TUMOR; DUODENUM: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
5515,363901868,96395,C1=CC=C(C=C1)CCN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 20 MG/ML IN 0.2 ML ETHYL ACETATE AND CORN OIL 2/WK FOR 22 WK (STUDY DURATION: LIFESPAN),FORESTOMACH: TUMOR; LIVER: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; SIMILAR CARCINOGENIC ACTIONS OF NITROSOALKYLUREAS OF VARYING STRUCTURE GIVEN TO RATS BY GAVAGE; J. CLEAN TECHNOL.,ENVIRON. TOXICOL., OCCUP. MED. 5(2):155-165, 1996]"
5516,363901870,151519,CN(CCC(=O)O)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 200 UMOL MOUSE (TOTAL DOSE) ADMINISTERED IN 0.1 ML SALINE 3/WK (TOTAL 20 INJECTIONS) (STUDY DURATION: 37 WK),"LUNG: ADENOCARCINOMA, ADENOMA",POSITIVE,"[RIVENSON,A, DJORDJEVIC,MV, AMIN,S AND HOFFMANN,R; A STUDY OF TOBACCO CARCINOGENESIS. XLIV. BIOASSAY IN A/J MICE OF SOME N-NITROSAMINES; CANCER LETT. 47(1-2):111-114, 1989]"
5517,363901873,3308,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 3; 9; 15 MG/KG/D IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[WRENN,JM, INHELDER,JL, HEMM,RD, POLLOCK,JJ AND SUMI,N; EIGHTEEN MONTH CARCINOGENICITY STUDY OF ETODOLAC, A NONSTEROIDAL ANTI-INFLAMMATORY AGENT, IN CHARLES RIVER CD-1 MICE; OYO YAKURI 41(2):113-128, 1991]"
5518,363901873,3308,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0;3; 9; 15 MG/KG/D IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[WRENN,JM, INHELDER,JL, HEMM,RD, POLLOCK,JJ AND SUMI,N; EIGHTEEN MONTH CARCINOGENICITY STUDY OF ETODOLAC, A NONSTEROIDAL ANTI-INFLAMMATORY AGENT, IN CHARLES RIVER CD-1 MICE; OYO YAKURI 41(2):113-128, 1991]"
5519,363901873,3308,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,Inactive,,,,RAT,STRAIN-CD/MALE,ORAL,0; 3; 9; 15 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[WRENN,JM, INHELDER,JL, HEMM,RD, POLLOCK,JJ AND SUMI,N; TWO YEAR CARCINOGENICITY STUDY OF ETODOLAC, A NONSTEROIDAL ANTI-INFLAMMATORY AGENT, IN CHARLES RIVER CR- CD RATS; OYO YAKURI 41(2):129-146, 1991]"
5520,363901873,3308,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,Inactive,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 3; 9; 15 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[WRENN,JM, INHELDER,JL, HEMM,RD, POLLOCK,JJ AND SUMI,N; TWO YEAR CARCINOGENICITY STUDY OF ETODOLAC, A NONSTEROIDAL ANTI-INFLAMMATORY AGENT, IN CHARLES RIVER CR- CD RATS; OYO YAKURI 41(2):129-146, 1991]"
5521,363901874,5369403,C1=CC=C(C=C1)/C=C(/C=O)\Br,Inactive,,,,MOUSE,SLC:DDY/FEMALE,DERMAL,0; 0.25; 1; 4% IN OLIVE OIL 2/WK FOR 79 WK (STUDY DURATION: 79 WK),,NEGATIVE,"[MOMMA,J, UCHIDA,O, TAKADA,K, AIDA,Y, YOSHIMOTO,H, SUZUKI,Y, KOBAYASHI,K, NAKAJI,Y, KOROKAWA,Y AND TOBE,M; COMBINED LONG-TERM TOXICITY/CARCINOGENICITY TEST OF A-BROMOCINNAMIC ALDEHYDE APPLIED TO FEMALE MOUSE SKIN; EISEI SHIKENSHO HOKOKU (107):29-36, 1989]"
5522,363901901,656671,[O-]S(=O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 0.125; 0.25; 0.5; 1; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[TIL,HP, FERON,VJ AND DE GROOT,AP; THE TOXICITY OF SULFITE. I. LONG-TERM FEEDING AND MULTIGENERATION STUDIES IN RATS; FOOD COSMET. TOXICOL. 10:291-310, 1972]"
5523,363901901,656671,[O-]S(=O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 0.125; 0.25; 0.5; 1; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[TIL,HP, FERON,VJ AND DE GROOT,AP; THE TOXICITY OF SULFITE. I. LONG-TERM FEEDING AND MULTIGENERATION STUDIES IN RATS; FOOD COSMET. TOXICOL. 10:291-310, 1972]"
5524,363901901,656671,[O-]S(=O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 0.125; 0.25; 0.5; 1; 2% IN DIET FOR 104 WK TO OFFSPRING OF RATS ADMINISTERED THE SAME DOSES IN THEIR DIETS (STUDY DURATION: 104 WK),,NEGATIVE,"[TIL,HP, FERON,VJ AND DE GROOT,AP; THE TOXICITY OF SULFITE. I. LONG-TERM FEEDING AND MULTIGENERATION STUDIES IN RATS; FOOD COSMET. TOXICOL. 10:291-310, 1972]"
5525,363901901,656671,[O-]S(=O)S(=O)(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 0.125; 0.25; 0.5; 1; 2% IN DIET FOR 104 WK TO OFFSPRING OF RATS ADMINISTERED THE SAME DOSES IN THEIR DIETS (STUDY DURATION: 104 WK),,NEGATIVE,"[TIL,HP, FERON,VJ AND DE GROOT,AP; THE TOXICITY OF SULFITE. I. LONG-TERM FEEDING AND MULTIGENERATION STUDIES IN RATS; FOOD COSMET. TOXICOL. 10:291-310, 1972]"
5526,363901914,9162,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC5=CC=CC=C54,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,0; 36; 40; 108; 308; 399 NMOL IN TRICAPRYLIN ONCE (STUDY DURATION: 112 WK),INJECTION SITE: FIBROSARCOMA,POSITIVE,"[PLATT,KL, PFEIFFER,E, PETROVIC,P, FRIESEL,H, BEERMANN,D, HECKER,E AND OESCH,F; COMPARATIVE TUMORIGENICITY OF PICENE AND DIBENZ[A,H]ANTHRACENE IN THE MOUSE; CARCINOGENESIS (LONDON) 11(10):1721-6, 1990]"
5527,363901914,9162,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC5=CC=CC=C54,Active,,,,MOUSE,NMRI/FEMALE,DERMAL,0; 136; 448; 1358 NMOL (TOTAL DOSE) APPLIED AS 1 DROP OF ACETONE SOLUTION 3/WK FOR DURATION OF STUDY (STUDY DURATION: 112 WK),SKIN: PAPILLOMA,POSITIVE,"[PLATT,KL, PFEIFFER,E, PETROVIC,P, FRIESEL,H, BEERMANN,D, HECKER,E AND OESCH,F; COMPARATIVE TUMORIGENICITY OF PICENE AND DIBENZ[A,H]ANTHRACENE IN THE MOUSE; CARCINOGENESIS (LONDON) 11(10):1721-6, 1990]"
5528,363901914,9162,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC5=CC=CC=C54,Active,,,,MOUSE,NMRI/FEMALE,SUBCUTANEOUS,0; 40; 400 NMOL IN 0.05 ML OF AN AQUEOUS SOLUTION CONTAINING 1% (W/W) GELATIN 0.9% (W/W) SODIUM CHLORIDE AND 0.4% (W/W) TWEEN 20 ONCE ON DAY 2 OF LIFE (STUDY DURATION: 40 WK),LUNG: ADENOMA,POSITIVE,"[PLATT,KL, PFEIFFER,E, PETROVIC,P, FRIESEL,H, BEERMANN,D, HECKER,E AND OESCH,F; COMPARATIVE TUMORIGENICITY OF PICENE AND DIBENZ[A,H]ANTHRACENE IN THE MOUSE; CARCINOGENESIS (LONDON) 11(10):1721-6, 1990]"
5529,363901915,161732,CC1=CC=C(C=C1)[N+]#N.[O-]S(=O)(=O)[O-],Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 50 UG/G 1/WK FOR 16 OR 19 WK (STUDY DURATION: 140 WK),SUBCUTANEOUS TISSUE: TUMOR,POSITIVE,"[TOTH,B, TAYLOR,J, MATTSON,B AND GANNETT,P; TUMOR INDUCTION BY 4-(METHYL)BENZENEDIAZONIUM SULFATE IN MICE; IN VIVO 3(1):17-21, 1989]"
5530,363901915,161732,CC1=CC=C(C=C1)[N+]#N.[O-]S(=O)(=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 50 UG/G 1/WK FOR 16 OR 19 WK (STUDY DURATION: 140 WK),SUBCUTANEOUS TISSUE: TUMOR; SKIN: TUMOR,POSITIVE,"[TOTH,B, TAYLOR,J, MATTSON,B AND GANNETT,P; TUMOR INDUCTION BY 4-(METHYL)BENZENEDIAZONIUM SULFATE IN MICE; IN VIVO 3(1):17-21, 1989]"
5531,363901916,24849108,C1=CC(=CC=C1[N+]#N)O.OS(=O)(=O)[O-],Inactive,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 10 UG 1/WK FOR 2 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[TOTH,B, PATIL,K, TAYLOR,J, STESSMAN,C AND GANNETT,P; CANCER INDUCTION IN MICE BY 4-HYDROXYBENZENEDIAZONIUM SULFATE OF THE AGARICUS XANTHODERMUS MUSHROOM; IN VIVO 3(5):301-305, 1989]"
5532,363901916,24849108,C1=CC(=CC=C1[N+]#N)O.OS(=O)(=O)[O-],Inactive,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 10 UG 1/WK FOR 2 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[TOTH,B, PATIL,K, TAYLOR,J, STESSMAN,C AND GANNETT,P; CANCER INDUCTION IN MICE BY 4-HYDROXYBENZENEDIAZONIUM SULFATE OF THE AGARICUS XANTHODERMUS MUSHROOM; IN VIVO 3(5):301-305, 1989]"
5533,363901916,24849108,C1=CC(=CC=C1[N+]#N)O.OS(=O)(=O)[O-],Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 2 UG 1/WK FOR 36 WK (STUDY DURATION: 110 WK),SUBCUTANEOUS TISSUE: TUMOR,POSITIVE,"[TOTH,B, PATIL,K, TAYLOR,J, STESSMAN,C AND GANNETT,P; CANCER INDUCTION IN MICE BY 4-HYDROXYBENZENEDIAZONIUM SULFATE OF THE AGARICUS XANTHODERMUS MUSHROOM; IN VIVO 3(5):301-305, 1989]"
5534,363901916,24849108,C1=CC(=CC=C1[N+]#N)O.OS(=O)(=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 2 UG 1/WK FOR 36 WK (STUDY DURATION: 120 WK),SUBCUTANEOUS TISSUE: TUMOR,POSITIVE,"[TOTH,B, PATIL,K, TAYLOR,J, STESSMAN,C AND GANNETT,P; CANCER INDUCTION IN MICE BY 4-HYDROXYBENZENEDIAZONIUM SULFATE OF THE AGARICUS XANTHODERMUS MUSHROOM; IN VIVO 3(5):301-305, 1989]"
5535,363901917,516871,C(#N)[S-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 0.32% IN DRINKING WATER 5 D/WK FOR 112 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W AND KOVATCH,RM; CHRONIC TOXICITY TESTS OF SODIUM THIOCYANATE WITH SODIUM NITRATE IN F344 RATS; TOXICOL. IND. HEALTH 5(1):25-29, 1989]"
5536,363901917,516871,C(#N)[S-].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.32% IN DRINKING WATER 5 D/WK FOR 112 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[LIJINSKY,W AND KOVATCH,RM; CHRONIC TOXICITY TESTS OF SODIUM THIOCYANATE WITH SODIUM NITRATE IN F344 RATS; TOXICOL. IND. HEALTH 5(1):25-29, 1989]"
5537,363901918,409301,C[Hg]Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.4; 2; 10 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"KIDNEY: CARCINOMA, ADENOMA",POSITIVE,"[MITSUMORI,K, HIRANO,M, UEDA,H, MAITA,K AND SHIRASU,Y; CHRONIC TOXICITY AND CARCINOGENICITY OF METHYLMERCURY CHLORIDE IN B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 14(1):179-190, 1990]"
5538,363901918,409301,C[Hg]Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.4; 2; 10 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MITSUMORI,K, HIRANO,M, UEDA,H, MAITA,K AND SHIRASU,Y; CHRONIC TOXICITY AND CARCINOGENICITY OF METHYLMERCURY CHLORIDE IN B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 14(1):179-190, 1990]"
5539,363901918,409301,C[Hg]Cl,Active,,,,MOUSE,ICR/MALE,ORAL,0; 10 PPM IN BASAL DIET FOR 80 WK (STUDY DURATION: 80 WK),KIDNEY: ADENOCARCINOMA,POSITIVE,"[HIRANO,M, UEDA,H, MITSUMORI,K, MAITA,K AND SHIRASU,Y; HORMONAL INFLUENCE ON CARCINOGENICITY OF METHYLMERCURY IN MICE; JPN. J. VET. SCI. 50(4):886-893, 1988]"
5540,363901918,409301,C[Hg]Cl,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 10 PPM IN BASAL DIET FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[HIRANO,M, UEDA,H, MITSUMORI,K, MAITA,K AND SHIRASU,Y; HORMONAL INFLUENCE ON CARCINOGENICITY OF METHYLMERCURY IN MICE; JPN. J. VET. SCI. 50(4):886-893, 1988]"
5541,363901918,409301,C[Hg]Cl,Inactive,,,,MOUSE,ICR/MALE,ORAL,0; 10 PPM IN BASAL DIET ADMINISTERED TO CASTRATED MICE FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[HIRANO,M, UEDA,H, MITSUMORI,K, MAITA,K AND SHIRASU,Y; HORMONAL INFLUENCE ON CARCINOGENICITY OF METHYLMERCURY IN MICE; JPN. J. VET. SCI. 50(4):886-893, 1988]"
5542,363901918,409301,C[Hg]Cl,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 10 PPM IN BASAL DIET ADMINISTERED TO SPAYED MICE FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[HIRANO,M, UEDA,H, MITSUMORI,K, MAITA,K AND SHIRASU,Y; HORMONAL INFLUENCE ON CARCINOGENICITY OF METHYLMERCURY IN MICE; JPN. J. VET. SCI. 50(4):886-893, 1988]"
5543,363901918,409301,C[Hg]Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.4; 2; 10 PPM IN DIET FOR 130 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[MITSUMORI,K, MAITA,K AND SHIRASU,Y; CHRONIC TOXICITY OF METHYLMERCURY CHLORIDE IN RATS: PATHOLOGICAL STUDY; JPN. J. VET. SCI. 46:549-557, 1984]"
5544,363901918,409301,C[Hg]Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.4; 2; 10 PPM IN DIET FOR 130 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[MITSUMORI,K, MAITA,K AND SHIRASU,Y; CHRONIC TOXICITY OF METHYLMERCURY CHLORIDE IN RATS: PATHOLOGICAL STUDY; JPN. J. VET. SCI. 46:549-557, 1984]"
5545,363901918,409301,C[Hg]Cl,Active,,,,MOUSE,ICR/MALE,ORAL,0; 0.4; 2; 10 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),KIDNEY: ADENOCARCINOMA,POSITIVE,"[HIRANO,M, MITSUMORI,K, MAITA,K AND SHIRASU,Y; FURTHER CARCINOGENICITY STUDY ON METHYLMERCURY CHLORIDE IN ICR MICE; JPN. J. VET. SCI. 48:127-135, 1986]"
5546,363901918,409301,C[Hg]Cl,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 0.4; 2; 10 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HIRANO,M, MITSUMORI,K, MAITA,K AND SHIRASU,Y; FURTHER CARCINOGENICITY STUDY ON METHYLMERCURY CHLORIDE IN ICR MICE; JPN. J. VET. SCI. 48:127-135, 1986]"
5547,363901918,409301,C[Hg]Cl,Active,,,,MOUSE,ICR/MALE,ORAL,0; 15 PPM IN DIET FOR 78 WK (STUDY DURATION: 78 WK),"KIDNEY: ADENOCARCINOMA, ADENOMA",POSITIVE,"[MITSUMORI,K, MAITA,K, SAITO,T, TSUDA,S AND SHIRASU,Y; CARCINOGENICITY OF METHYLMERCURY CHLORIDE IN ICR MICE: PRELIMINARY NOTE ON RENAL CARCINOGENESIS CANCER LETT. 12:305-310, 1981]"
5548,363901918,409301,C[Hg]Cl,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 15 PPM IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[MITSUMORI,K, MAITA,K, SAITO,T, TSUDA,S AND SHIRASU,Y; CARCINOGENICITY OF METHYLMERCURY CHLORIDE IN ICR MICE: PRELIMINARY NOTE ON RENAL CARCINOGENESIS CANCER LETT. 12:305-310, 1981]"
5549,363901935,6694,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=CC=CC=C4C(=O)O.[Cl-],Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 121.4 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5550,363901935,6694,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=CC=CC=C4C(=O)O.[Cl-],Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 121.4 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5551,363901960,25760,C1=CC=C2C(=C1)C3=CC=CC4=CC(=CC2=C43)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",,NEGATIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
5552,363901961,108032,C1C(O1)OC(=O)N,Active,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 11.5 UMOL IN WEEKS 1 AND 2 THEN 5.7 UMOL IN WEEKS 3 AND 4 FOLLOWED BY 3.8 UMOL/WK FOR 28 WK (STUDY DURATION: 42 WK),"SKIN: PAPILLOMA, CARCINOMA",POSITIVE,"[PARK,KK, LIEM,A, STEWART,BC AND MILLER,JA; VINYL CARBAMATE EPOXIDE, A MAJOR STRONG ELECTROPHILIC, MUTAGENIC AND CARCINOGENIC METABOLITE OF VINYL CARBAMATE AND ETHYL CARBAMATE (URETHANE); CARCINOGENESIS 14(3):441-450, 1993]"
5553,363901961,108032,C1C(O1)OC(=O)N,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 34; 68 NMOL/G BW IN 5 UL TRIOCTANOIN ONCE (STUDY DURATION: 6 MO),LUNG: ADENOMA,POSITIVE,"[PARK,KK, LIEM,A, STEWART,BC AND MILLER,JA; VINYL CARBAMATE EPOXIDE, A MAJOR STRONG ELECTROPHILIC, MUTAGENIC AND CARCINOGENIC METABOLITE OF VINYL CARBAMATE AND ETHYL CARBAMATE (URETHANE); CARCINOGENESIS 14(3):441-450, 1993]"
5554,363901961,108032,C1C(O1)OC(=O)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.5; 1.25; 2.5 UG/G BW IN 10 UL TRIOCTANOIN ONCE (STUDY DURATION: 9 MO),LIVER: HEPATOMA,POSITIVE,"[PARK,KK, LIEM,A, STEWART,BC AND MILLER,JA; VINYL CARBAMATE EPOXIDE, A MAJOR STRONG ELECTROPHILIC, MUTAGENIC AND CARCINOGENIC METABOLITE OF VINYL CARBAMATE AND ETHYL CARBAMATE (URETHANE); CARCINOGENESIS 14(3):441-450, 1993]"
5555,363901961,108032,C1C(O1)OC(=O)N,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAMUSCULAR,0; 1.15; 2.30 UMOL IN 0.25 ML TRIOCTANOIN 1/WK FOR 10 WK (STUDY DURATION: 18 MO),INJECTION SITE: SARCOMA; MAMMARY GLAND: TUMOR,POSITIVE,"[PARK,KK, LIEM,A, STEWART,BC AND MILLER,JA; VINYL CARBAMATE EPOXIDE, A MAJOR STRONG ELECTROPHILIC, MUTAGENIC AND CARCINOGENIC METABOLITE OF VINYL CARBAMATE AND ETHYL CARBAMATE (URETHANE); CARCINOGENESIS 14(3):441-450, 1993]"
5556,363901962,9198,C1=CC=C2C(=C1)C=CC3=C2SC4=CC=CC=C34,Active,,,,RAT,OSBORNE-MENDEL/FEMALE,INTRAPULMONARY IMPLANT,0; 1; 3; 6 MG IN BEESWAX AND TRIOCTANOIN IMPLANTED IN LUNG (STUDY DURATION: 141 WK),LUNG: CARCINOMA,POSITIVE,"[WENZEL-HARTUNG,R, BRUNE,H, GRIMMER,G, GERMANN,P, TIMM,J AND WOSNIOK,W; EVALUATION OF THE CARCINOGENIC POTENCY OF 4 ENVIRONMENTAL POLYCYCLIC AROMATIC COMPOUNDS FOLLOWING INTRAPULMONARY APPLICATION IN RATS; EXP. PATHOL. 40(4):221-227, 1990]"
5557,363901963,17047,CC1=CC(=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O)[N+](=O)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 6000; 12500; 25000 PPM IN FEED FOR 2 YR (STUDY DURATION: 2 YR),ADRENAL MEDULLA: PHEOCHROMOCYTOMA (BENIGN OR MALIGNANT),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-407 Y92]"
5558,363901963,17047,CC1=CC(=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O)[N+](=O)[O-],Active,,,,RAT,F344/FEMALE,ORAL,0; 6000; 12500; 25000 PPM IN FEED FOR 2 YR (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-407 Y92]"
5559,363901963,17047,CC1=CC(=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 12500; 25000; 50000 PPM IN FEED FOR 2 YR (STUDY DURATION: 2 YR),KIDNEY (CORTEX): ADENOMA; THYROID GLAND (FOLLICULAR CELL): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-407 Y92]"
5560,363901963,17047,CC1=CC(=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O)[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 12500; 25000; 50000 PPM IN FEED FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-407 Y92]"
5561,363901964,44144565,C(C(CBr)Br)OP(=O)(O)OCC(CBr)Br.[Mg],Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 80; 400; 2000 IN DIET FOR 24 MO (STUDY DURATION: 24 MO),LIVER: HEPATOCELLULAR CARCINOMA; SMALL INTESTINE: ADENOCARCINOMA; FORESTOMACH: PAPILLOMA; ESOPHAGUS: PAPILLOMA,POSITIVE,"[TAKADA,K, NAITO,K, KOBAYASHI,K, TOBE,M, KUROKAWA,Y AND FUKUOKA,M; CARCINOGENIC EFFECTS OF BIS(2,3-DIBROMOPROPYL)-PHOSPHATE IN WISTAR RATS; J. APPL. TOXICOL. 11(5):323-331, 1991]"
5562,363901964,44144565,C(C(CBr)Br)OP(=O)(O)OCC(CBr)Br.[Mg],Active,,,,RAT,WISTAR/MALE,ORAL,0; 80; 400; 2000 IN DIET FOR 24 MO (STUDY DURATION: 24 MO),SMALL INTESTINE: ADENOCARCINOMA; FORESTOMACH: PAPILLOMA; ESOPHAGUS: PAPILLOMA,POSITIVE,"[TAKADA,K, NAITO,K, KOBAYASHI,K, TOBE,M, KUROKAWA,Y AND FUKUOKA,M; CARCINOGENIC EFFECTS OF BIS(2,3-DIBROMOPROPYL)-PHOSPHATE IN WISTAR RATS; J. APPL. TOXICOL. 11(5):323-331, 1991]"
5563,363901965,6421,C(=O)(C(Cl)(Cl)Cl)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5 G/L (0; 31 MILLIMOLAR) IN DRINKING WATER FOR 61 WK (STUDY DURATION: 61 WK),LIVER: CARCINOMA,POSITIVE,"[DEANGELO,AB AND MCMILLIAN,LP; CARCINOGENICITY OF CHLORINATED ACETIC ACIDS; WATER CHLORINATION 6:193-199, 1990]"
5564,363901965,6421,C(=O)(C(Cl)(Cl)Cl)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1; 2 G/L IN DRINKING WATER FOR 52 WK (STUDY DURATION: 52 WK),LIVER: ADENOMA OR HEPATOCELLULAR CARCINOMA,POSITIVE,"[BULL,RJ, SANCHEZ,IM, NELSON,MA, LARSON,JL, AND LANSING,AJ; LIVER TUMOR INDUCTION IN B6C3F1/MICE BY DICHLOROACETATE AND TRICHLOROACETATE; TOXICOLOGY 63(3):341-359, 1990]"
5565,363901965,6421,C(=O)(C(Cl)(Cl)Cl)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2; 6.67; 20 MMOL/L IN DRINKING WATER FOR 360 D (STUDY DURATION: 360 D),LIVER: CARCINOMA,POSITIVE,"[PEREIRA,MA; CARCINOGENIC ACTIVITY OF DICHLOROACETIC ACID AND TRICHLOROACETIC ACID IN THE LIVER OF FEMALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(2):192-199, 1996]"
5566,363901965,6421,C(=O)(C(Cl)(Cl)Cl)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2; 6.67; 20 MMOL/L IN DRINKING WATER FOR 576 D (STUDY DURATION: 576 D),"LIVER: ADENOMA, CARCINOMA",POSITIVE,"[PEREIRA,MA; CARCINOGENIC ACTIVITY OF DICHLOROACETIC ACID AND TRICHLOROACETIC ACID IN THE LIVER OF FEMALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(2):192-199, 1996]"
5567,363901965,6421,C(=O)(C(Cl)(Cl)Cl)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.05; 0.5; 5 G/L IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[DEANGELO,AB, DANIEL,FB, MOST,BM AND OLSON,GR; FAILURE OF MONOCHLOROACETIC ACID AND TRICHLOROACETIC ACID ADMINISTERED IN THE DRINKING WATER TO PRODUCE LIVER CANCER IN MALE F344/N RATS; J. TOXICOL. ENVIRON. HEALTH 52(5):425-445, 1997]"
5568,363901965,6421,C(=O)(C(Cl)(Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 1000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 20 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5569,363901965,6421,C(=O)(C(Cl)(Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 20 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5570,363901965,6421,C(=O)(C(Cl)(Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 2000 NMOL TOTAL DOSE, 3/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5571,363901965,6421,C(=O)(C(Cl)(Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 2000 NMOL TOTAL DOSE, 3/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5572,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1 G; 2 G/L (TOTAL DOSE) IN DRINKING WATER FOR 52 WK (STUDY DURATION: 52 WK),"LIVER: HEPATOCELLULAR CARCINOMA, ADENOMA, HYPERPLASTIC NODULES",POSITIVE,"[BULL,RJ; IMPORTANCE OF DICHLOROACETATE AND TRICHLOROACETATE TO THE HEPATOCARCINOGENIC RESPONSE TO TRICHLOROETHYLENE IN B6C3F1 MICE; U.S. AIR FORCE OFFICE OF SCIENTIFIC RESEARCH, NTIS AD-A214501, 1989]"
5573,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2 G/L (TOTAL DOSE) IN DRINKING WATER FOR 37 WK (STUDY DURATION: 52 WK),"LIVER: ADENOMA, HYPERPLASTIC NODULES",POSITIVE,"[BULL,RJ; IMPORTANCE OF DICHLOROACETATE AND TRICHLOROACETATE TO THE HEPATOCARCINOGENIC RESPONSE TO TRICHLOROETHYLENE IN B6C3F1 MICE; U.S. AIR FORCE OFFICE OF SCIENTIFIC RESEARCH, NTIS AD-A214501, 1989]"
5574,363901966,6597,C(C(=O)O)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2 G/L (TOTAL DOSE) IN DRINKING WATER FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[BULL,RJ; IMPORTANCE OF DICHLOROACETATE AND TRICHLOROACETATE TO THE HEPATOCARCINOGENIC RESPONSE TO TRICHLOROETHYLENE IN B6C3F1 MICE; U.S. AIR FORCE OFFICE OF SCIENTIFIC RESEARCH, NTIS AD-A214501, 1989]"
5575,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5 G/L (0; 39 MILLIMOLAR) IN DRINKING WATER FOR 61 WK (STUDY DURATION: 61 WK),LIVER: CARCINOMA,POSITIVE,"[DEANGELO,AB AND MCMILLIAN,LP; CARCINOGENICITY OF CHLORINATED ACETIC ACIDS; WATER CHLORINATION 6:193-199, 1990]"
5576,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1; 2 G/L IN DRINKING WATER FOR 52 WK (STUDY DURATION: 52 WK),LIVER: ADENOMA OR HEPATOCELLULAR CARCINOMA,POSITIVE,"[BULL,RJ, SANCHEZ,IM, NELSON,MA, LARSON,JL, AND LANSING,AJ; LIVER TUMOR INDUCTION IN B6C3F1/MICE BY DICHLOROACETATE AND TRICHLOROACETATE; TOXICOLOGY 63(3):341-359, 1990]"
5577,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5 G/L DISTILLED DRINKING WATER FOR STUDY DURATION (93 MG/KG/D) (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA",POSITIVE,"[DANIEL,FB, DEANGELO,AB, STOBER,JA, OLSON,GR AND PAGE,NP; HEPATOCARCINOGENICITY OF CHLORAL HYDRATE, 2-CHLOROACETALDEHYDE, AND DICHLOROACETIC ACID IN THE MALE B6C3F1 MOUSE; FUNDAM. APPL. TOXICOL. 19(2):159-168, 1992]"
5578,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2; 6.67; 20 MMOL/L IN DRINKING WATER FOR 360 D (STUDY DURATION: 360 D),LIVER: ADENOMA,POSITIVE,"[PEREIRA,MA; CARCINOGENIC ACTIVITY OF DICHLOROACETIC ACID AND TRICHLOROACETIC ACID IN THE LIVER OF FEMALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(2):192-199, 1996]"
5579,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2; 6.67; 20 MMOL/L IN DRINKING WATER FOR 576 D (STUDY DURATION: 576 D),"LIVER: ADENOMA, CARCINOMA",POSITIVE,"[PEREIRA,MA; CARCINOGENIC ACTIVITY OF DICHLOROACETIC ACID AND TRICHLOROACETIC ACID IN THE LIVER OF FEMALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(2):192-199, 1996]"
5580,363901966,6597,C(C(=O)O)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 20 MMOL/L IN DRINKING WATER FOR 24 D FOLLOWED BY 48 D WITHOUT EXPOSURE THIS 72-DAY CYCLE REPEATED FOR THE DURATION OF STUDY (STUDY DURATION: 360 D),,NEGATIVE,"[PEREIRA,MA; CARCINOGENIC ACTIVITY OF DICHLOROACETIC ACID AND TRICHLOROACETIC ACID IN THE LIVER OF FEMALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(2):192-199, 1996]"
5581,363901966,6597,C(C(=O)O)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 20 MMOL/L IN DRINKING WATER FOR 24 D FOLLOWED BY 48 D WITHOUT EXPOSURE THIS 72-DAY CYCLE REPEATED FOR THE DURATION OF STUDY (STUDY DURATION: 576 D),,NEGATIVE,"[PEREIRA,MA; CARCINOGENIC ACTIVITY OF DICHLOROACETIC ACID AND TRICHLOROACETIC ACID IN THE LIVER OF FEMALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 31(2):192-199, 1996]"
5582,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 0.05; 0.5 G/L IN DRINKING WATER FOR 100 WK (STUDY DURATION: 100 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[DEANGELO,AB, DANIEL,FB, MOST,BM AND OLSON,GR; THE CARCINOGENICITY OF DICHLOROACETIC ACID IN THE MALE FISCHER 344 RAT; TOXICOLOGY 114(3):207-221, 1996]"
5583,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,RAT,F344/MALE,ORAL,0; 2.5 G/L IN DRINKING WATER DOSE LOWERED TO 1 G/L AFTER 18 WK (STUDY DURATION: 103 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[DEANGELO,AB, DANIEL,FB, MOST,BM AND OLSON,GR; THE CARCINOGENICITY OF DICHLOROACETIC ACID IN THE MALE FISCHER 344 RAT; TOXICOLOGY 114(3):207-221, 1996]"
5584,363901966,6597,C(C(=O)O)(Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1.0; 2; 3.5 G/L IN DRINKING WATER FOR 26 WK (STUDY DURATION: 26 WK),,NEGATIVE,"[DEANGELO,AB GEORGE,MH AND HOUSE,DE; HEPATOCARCINOGENICITY IN THE MALE B6C3F1 MOUSE FOLLOWING A LIFETIME EXPOSURE TO DICHLOROACETIC ACID IN THE DRINKING WATER: DOSE-RESPONSE DETERMINATION AND MODES OF ACTION; J. TOXICOL. ENVIRON. HEALTH, PART A 58(8):485-507, 1999]"
5585,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1.0; 2; 3.5 G/L IN DRINKING WATER FOR 52 WK (STUDY DURATION: 52 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[DEANGELO,AB GEORGE,MH AND HOUSE,DE; HEPATOCARCINOGENICITY IN THE MALE B6C3F1 MOUSE FOLLOWING A LIFETIME EXPOSURE TO DICHLOROACETIC ACID IN THE DRINKING WATER: DOSE-RESPONSE DETERMINATION AND MODES OF ACTION; J. TOXICOL. ENVIRON. HEALTH, PART A 58(8):485-507, 1999]"
5586,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1.0; 2; 3.5 G/L IN DRINKING WATER FOR 78 WK (STUDY DURATION: 78 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[DEANGELO,AB GEORGE,MH AND HOUSE,DE; HEPATOCARCINOGENICITY IN THE MALE B6C3F1 MOUSE FOLLOWING A LIFETIME EXPOSURE TO DICHLOROACETIC ACID IN THE DRINKING WATER: DOSE-RESPONSE DETERMINATION AND MODES OF ACTION; J. TOXICOL. ENVIRON. HEALTH, PART A 58(8):485-507, 1999]"
5587,363901966,6597,C(C(=O)O)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.5; 1.0; 2; 3.5 G/L IN DRINKING WATER FOR 100 WK (STUDY DURATION: 100 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[DEANGELO,AB GEORGE,MH AND HOUSE,DE; HEPATOCARCINOGENICITY IN THE MALE B6C3F1 MOUSE FOLLOWING A LIFETIME EXPOSURE TO DICHLOROACETIC ACID IN THE DRINKING WATER: DOSE-RESPONSE DETERMINATION AND MODES OF ACTION; J. TOXICOL. ENVIRON. HEALTH, PART A 58(8):485-507, 1999]"
5588,363901967,2566,CC1(CC2=C(O1)C(=CC=C2)OC(=O)NC)C,Inactive,,,,MOUSE,ICR/MALE,ORAL,0; 3; 8 PPM IN DRINKING WATER FOR 12 MO (STUDY DURATION: 12 MO),,NEGATIVE,"[WANG,D; STUDIES ON CARCINOGENICITY OF FURADAN IN ICR MICE BY CHRONIC INGESTION; HUANJING KEXUE XUEBAO 9(4):505-508, 1989]"
5589,363901967,2566,CC1(CC2=C(O1)C(=CC=C2)OC(=O)NC)C,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 3; 8 PPM IN DRINKING WATER FOR 12 MO (STUDY DURATION: 12 MO),,NEGATIVE,"[WANG,D; STUDIES ON CARCINOGENICITY OF FURADAN IN ICR MICE BY CHRONIC INGESTION; HUANJING KEXUE XUEBAO 9(4):505-508, 1989]"
5590,363901967,2566,CC1(CC2=C(O1)C(=CC=C2)OC(=O)NC)C,Inactive,,,,Rat,Charles River CD/Male (60/group),Oral,0; 10; 20; 100 ppm in diet for 2 yrs,,Negative (Study details not given in source; Purity 95.6%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  CARBOFURAN (APRIL 10, 2003)]"
5591,363901967,2566,CC1(CC2=C(O1)C(=CC=C2)OC(=O)NC)C,Inactive,,,,Rat,Charles River CD/Female (60/group),Oral,0; 10; 20; 100 ppm in diet for 2 yrs,,Negative (Study details not given in source; Purity 95.6%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  CARBOFURAN (APRIL 10, 2003)]"
5592,363901967,2566,CC1(CC2=C(O1)C(=CC=C2)OC(=O)NC)C,Inactive,,,,Mouse,Charles River CD-1/Male (60/group),Oral,0; 20; 125; 500 ppm in diet for 2 yrs,,Negative (Study details not given in source; purity 95.6%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  CARBOFURAN (APRIL 10, 2003)]"
5593,363901967,2566,CC1(CC2=C(O1)C(=CC=C2)OC(=O)NC)C,Inactive,,,,Mouse,Charles River CD-1/Female (60/group),Oral,0; 20; 125; 500 ppm in diet for 2 yrs,,Negative (Study details not given in source; purity 95.6%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  CARBOFURAN (APRIL 10, 2003)]"
5594,363901968,158605,[O-2].[O-2].[O-2].[Ga+3].[Ga+3],Inactive,,,,MOUSE,ICR/MALE,SUBCUTANEOUS,0; 480 MG/KG AS GALLIUM SUSPENDED IN OLIVE OIL ONCE (STUDY DURATION: 18 MO),,NEGATIVE,"[TANAKA,A, HISANAGA,A, HIRATA,M AND ISHINISHI,N; COMPARATIVE STUDY ON THE TUMORIGENICITY IN MICE OF GALLIUM ARSENIDE, GALLIUM PHOSPHIDE AND GALLIUM OXIDE FOLLOWING SUBCUTANEOUS AND INTRAPERITONEAL INJECTIONS; APPL. ORGANOMET. CHEM. 4(3):231-237, 1990]"
5595,363901968,158605,[O-2].[O-2].[O-2].[Ga+3].[Ga+3],Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,0; 480 MG/KG AS GALLIUM SUSPENDED IN OLIVE OIL ONCE (STUDY DURATION: 18 MO),,NEGATIVE,"[TANAKA,A, HISANAGA,A, HIRATA,M AND ISHINISHI,N; COMPARATIVE STUDY ON THE TUMORIGENICITY IN MICE OF GALLIUM ARSENIDE, GALLIUM PHOSPHIDE AND GALLIUM OXIDE FOLLOWING SUBCUTANEOUS AND INTRAPERITONEAL INJECTIONS; APPL. ORGANOMET. CHEM. 4(3):231-237, 1990]"
5596,363901968,158605,[O-2].[O-2].[O-2].[Ga+3].[Ga+3],Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,0; 48 MG/KG AS GALLIUM SUSPENDED IN OLIVE OIL ONCE (STUDY DURATION: 18 MO),,NEGATIVE,"[TANAKA,A, HISANAGA,A, HIRATA,M AND ISHINISHI,N; COMPARATIVE STUDY ON THE TUMORIGENICITY IN MICE OF GALLIUM ARSENIDE, GALLIUM PHOSPHIDE AND GALLIUM OXIDE FOLLOWING SUBCUTANEOUS AND INTRAPERITONEAL INJECTIONS; APPL. ORGANOMET. CHEM. 4(3):231-237, 1990]"
5597,363901968,158605,[O-2].[O-2].[O-2].[Ga+3].[Ga+3],Inactive,,,,MOUSE,ICR/MALE,SUBCUTANEOUS,0; 48 MG/KG AS GALLIUM SUSPENDED IN OLIVE OIL ONCE (STUDY DURATION: 18 MO),,NEGATIVE,"[TANAKA,A, HISANAGA,A, HIRATA,M AND ISHINISHI,N; COMPARATIVE STUDY ON THE TUMORIGENICITY IN MICE OF GALLIUM ARSENIDE, GALLIUM PHOSPHIDE AND GALLIUM OXIDE FOLLOWING SUBCUTANEOUS AND INTRAPERITONEAL INJECTIONS; APPL. ORGANOMET. CHEM. 4(3):231-237, 1990]"
5598,363901969,82901,P#[Ga],Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,0; 48; 480 MG/KG AS GALLIUM SUSPENDED IN OLIVE OIL ONCE (STUDY DURATION: 18 MO),,NEGATIVE,"[TANAKA,A, HISANAGA,A, HIRATA,M AND ISHINISHI,N; COMPARATIVE STUDY ON THE TUMORIGENICITY IN MICE OF GALLIUM ARSENIDE, GALLIUM PHOSPHIDE AND GALLIUM OXIDE FOLLOWING SUBCUTANEOUS AND INTRAPERITONEAL INJECTIONS; APPL. ORGANOMET. CHEM. 4(3):231-237, 1990]"
5599,363901969,82901,P#[Ga],Inactive,,,,MOUSE,ICR/MALE,SUBCUTANEOUS,0; 48; 480 MG/KG AS GALLIUM SUSPENDED IN OLIVE OIL ONCE (STUDY DURATION: 18 MO),,NEGATIVE,"[TANAKA,A, HISANAGA,A, HIRATA,M AND ISHINISHI,N; COMPARATIVE STUDY ON THE TUMORIGENICITY IN MICE OF GALLIUM ARSENIDE, GALLIUM PHOSPHIDE AND GALLIUM OXIDE FOLLOWING SUBCUTANEOUS AND INTRAPERITONEAL INJECTIONS; APPL. ORGANOMET. CHEM. 4(3):231-237, 1990]"
5600,363901970,14770,[Ga]#[As],Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,0; 48; 480 MG/KG AS GALLIUM SUSPENDED IN OLIVE OIL ONCE (STUDY DURATION: 18 MO),,NEGATIVE,"[TANAKA,A, HISANAGA,A, HIRATA,M AND ISHINISHI,N; COMPARATIVE STUDY ON THE TUMORIGENICITY IN MICE OF GALLIUM ARSENIDE, GALLIUM PHOSPHIDE AND GALLIUM OXIDE FOLLOWING SUBCUTANEOUS AND INTRAPERITONEAL INJECTIONS; APPL. ORGANOMET. CHEM. 4(3):231-237, 1990]"
5601,363901970,14770,[Ga]#[As],Inactive,,,,MOUSE,ICR/MALE,SUBCUTANEOUS,0; 48; 480 MG/KG AS GALLIUM SUSPENDED IN OLIVE OIL ONCE (STUDY DURATION: 18 MO),,NEGATIVE,"[TANAKA,A, HISANAGA,A, HIRATA,M AND ISHINISHI,N; COMPARATIVE STUDY ON THE TUMORIGENICITY IN MICE OF GALLIUM ARSENIDE, GALLIUM PHOSPHIDE AND GALLIUM OXIDE FOLLOWING SUBCUTANEOUS AND INTRAPERITONEAL INJECTIONS; APPL. ORGANOMET. CHEM. 4(3):231-237, 1990]"
5602,363901970,14770,[Ga]#[As],Inactive,,,,RAT,F344/N/MALE,INHALATION,0; 0.01; 0.1; 1 MG/M3 6 HR/D 5D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-492 Y00]"
5603,363901970,14770,[Ga]#[As],Active,,,,RAT,F344/N/FEMALE,INHALATION,0; 0.01; 0.1; 1 MG/M3 6 HR/D 5D/WK FOR 105 WK (STUDY DURATION: 105 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-492 Y00]"
5604,363901970,14770,[Ga]#[As],Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.1; 0.5; 1 MG/M3 6 HR/D 5D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-492 Y00]"
5605,363901970,14770,[Ga]#[As],Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.1; 0.5; 1 MG/M3 6 HR/D 5D/WK FOR 106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-492 Y00]"
5606,363901971,134734,C(CCCCC(=O)[O-])CCCC(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 500; 1000 MG/KG/BW IN DIET FOR 6 MO (STUDY DURATION: 181 D),,NEGATIVE,"[GRECO,AV, MINGRONE,G, ARCIERI,ME, FINOTTI,E AND CASTAGNETO,M; TOXICITY OF DISODIUM SEBACATE; DRUGS EXP. CLIN. RES. 16(10):531-536, 1990]"
5607,363901971,134734,C(CCCCC(=O)[O-])CCCC(=O)[O-].[Na+].[Na+],Inactive,,,,RABBIT,NEW ZEALAND/FEMALE,ORAL,0; 750; 1000 MG/KG/BW IN DIET FOR 6 MO (STUDY DURATION: 181 D),,NEGATIVE,"[GRECO,AV, MINGRONE,G, ARCIERI,ME, FINOTTI,E AND CASTAGNETO,M; TOXICITY OF DISODIUM SEBACATE; DRUGS EXP. CLIN. RES. 16(10):531-536, 1990]"
5608,363901971,134734,C(CCCCC(=O)[O-])CCCC(=O)[O-].[Na+].[Na+],Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 500; 1000 MG/KG/BW IN DIET FOR 6 MO (STUDY DURATION: 181 D),,NEGATIVE,"[GRECO,AV, MINGRONE,G, ARCIERI,ME, FINOTTI,E AND CASTAGNETO,M; TOXICITY OF DISODIUM SEBACATE; DRUGS EXP. CLIN. RES. 16(10):531-536, 1990]"
5609,363901971,134734,C(CCCCC(=O)[O-])CCCC(=O)[O-].[Na+].[Na+],Inactive,,,,RABBIT,NEW ZEALAND/MALE,ORAL,0; 750; 1000 MG/KG/BW IN DIET FOR 6 MO (STUDY DURATION: 181 D),,NEGATIVE,"[GRECO,AV, MINGRONE,G, ARCIERI,ME, FINOTTI,E AND CASTAGNETO,M; TOXICITY OF DISODIUM SEBACATE; DRUGS EXP. CLIN. RES. 16(10):531-536, 1990]"
5610,363901972,25423,NCl,Inactive,,,,RAT,F344/MALE,ORAL,"0; 50; 100; 200 PPM IN BUFFERED, CHARCOAL-FILTERED, DEIONIZED WATER FOR 103 WK (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-392 Y92]"
5611,363901972,25423,NCl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,"0; 50; 100; 200 PPM IN BUFFERED, CHARCOAL-FILTERED, DEIONIZED WATER FOR 104 WK (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-392 Y92]"
5612,363901972,25423,NCl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,"0; 50; 100; 200 PPM IN BUFFERED, CHARCOAL-FILTERED, DEIONIZED WATER FOR 104 WK (STUDY DURATION: 2 YR)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-392 Y92]"
5613,363901974,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 0.5 (STABILIZED AND UNSTABILIZED CHROMIUM DIOXIDE DUST); 25 MG/M3 (STABILIZED) FOR 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[LEE,KP, ULRICH,CE, GEIL,RG AND TROCHIMOWICZ,HJ; INHALATION TOXICITY OF CHROMIUM DIOXIDE DUST TO RATS AFTER TWO YEARS EXPOSURE; SCI. TOTAL ENVIRON. 86(1-2):83-108, 1989]"
5614,363901974,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 0.5 (STABILIZED AND UNSTABILIZED CHROMIUM DIOXIDE DUST); 25 MG/M3 (STABILIZED) FOR 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[LEE,KP, ULRICH,CE, GEIL,RG AND TROCHIMOWICZ,HJ; INHALATION TOXICITY OF CHROMIUM DIOXIDE DUST TO RATS AFTER TWO YEARS EXPOSURE; SCI. TOTAL ENVIRON. 86(1-2):83-108, 1989]"
5615,363902002,5054,C1=CC(=CC(=C1)O)O,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 112; 225 MG/KG IN DEIONIZED WATER 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-403 Y92]"
5616,363902002,5054,C1=CC(=CC(=C1)O)O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 50; 100; 150 MG/KG IN DEIONIZED WATER 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-403 Y92]"
5617,363902002,5054,C1=CC(=CC(=C1)O)O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 112; 225 MG/KG IN DEIONIZED WATER 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-403 Y92]"
5618,363902002,5054,C1=CC(=CC(=C1)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 112; 225 MG/KG IN DEIONIZED WATER 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-403 Y92]"
5619,363902015,119170,CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 400; 1200; 3600 PPM IN FEED FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[INOUE,H, SHOJI,A, YAMAMOTO,T, WATARI,N, HIROUCHI,Y, ENOMOTO,M, SAKASHITA,M AND NISHI,N; TEST OF NZ-105 CARCINOGENICITY IN RATS; YAKURI TO CHIRYO 20(5): 1775-1803, 1992]"
5620,363902015,119170,CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 400; 1200; 3600 PPM IN FEED FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[INOUE,H, SHOJI,A, YAMAMOTO,T, WATARI,N, HIROUCHI,Y, ENOMOTO,M, SAKASHITA,M AND NISHI,N; TEST OF NZ-105 CARCINOGENICITY IN RATS; YAKURI TO CHIRYO 20(5): 1775-1803, 1992]"
5621,363902015,119170,CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 1600; 5000 PPM IN FEED FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[INOUE,H, SHOJI,A, YAMAMOTO,T, WATARI,N, SHIGA,A, ENOMOTO,M, SAKASHITA,M AND NISHI,N; CARCINOGENICITY TEST OF NZ-105 IN MICE; YAKURI TO CHIRYO 20(5): 1747-1773, 1992]"
5622,363902015,119170,CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1600; 5000 PPM IN FEED FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[INOUE,H, SHOJI,A, YAMAMOTO,T, WATARI,N, SHIGA,A, ENOMOTO,M, SAKASHITA,M AND NISHI,N; CARCINOGENICITY TEST OF NZ-105 IN MICE; YAKURI TO CHIRYO 20(5): 1747-1773, 1992]"
5623,363902051,86386,C1=CC=C2C(=C1)C3=C4C(=C2[N+](=O)[O-])C=CC5=C4C(=C(C=C5)[N+](=O)[O-])C=C3,Inactive,,,,RAT,F344/MALE,SUBCUTANEOUS IMPLANT,0; 8; 40; 200; 1000 UG IN 50 UL BEESWAX/TRICAPRYLIN IMPLANTED FOR UP TO 45 WK (STUDY DURATION: 45 WK),,NEGATIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, OTOFUJI,T, TOKIWA,H, IZUMI,K AND OTSUKA,H; CARCINOGENICITY OF DINITROBENZO[A]PYRENES AND DINITROFLUORANTHENES IN F344 RATS; IN: DAI,Q, ARMOUR,MA AND ZHENG,Q (EDS.), RECENT ADV. CHEM. MOL. BIOL. CANCER RES., INT. SYMP., SCIENCE PRESS, BEIJING, CHINA, 1991, PP. 319-325]"
5624,363902051,86386,C1=CC=C2C(=C1)C3=C4C(=C2[N+](=O)[O-])C=CC5=C4C(=C(C=C5)[N+](=O)[O-])C=C3,Inactive,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 8; 40; 200; 1000 UG SUSPENDED IN BEESWAX/TRICAPRYLIN (1:1) ONCE,,NEGATIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, SANO,N, IZUMI,K AND TOKIWA,H; COMPARATIVE TUMORIGENICITY OF 1- AND 3-NITROBENZO[A]PYRENES, AND 3,6- AND 1,6-DINITROBENZO[A]PYRENES IN F344/DUCRJ RATS; TOXICOL. LETT. 98(1-2):51-58, 1998]"
5625,363902052,86387,C1=CC=C2C(=C1)C3=C4C(=C2[N+](=O)[O-])C=CC5=C(C=CC(=C54)C=C3)[N+](=O)[O-],Active,,,,RAT,F344/MALE,SUBCUTANEOUS IMPLANT,0; 8; 40; 200; 1000 UG IN 50 UL BEESWAX/TRICAPRYLIN IMPLANTED FOR UP TO 45 WK (STUDY DURATION: 45 WK),IMPLANT SITE: TUMOR,POSITIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, OTOFUJI,T, TOKIWA,H, IZUMI,K AND OTSUKA,H; CARCINOGENICITY OF DINITROBENZO[A]PYRENES AND DINITROFLUORANTHENES IN F344 RATS; IN: DAI,Q, ARMOUR,MA AND ZHENG,Q (EDS.), RECENT ADV. CHEM. MOL. BIOL. CANCER RES., INT. SYMP., SCIENCE PRESS, BEIJING, CHINA, 1991, PP. 319-325]"
5626,363902052,86387,C1=CC=C2C(=C1)C3=C4C(=C2[N+](=O)[O-])C=CC5=C(C=CC(=C54)C=C3)[N+](=O)[O-],Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 8; 40; 200; 1000 UG SUSPENDED IN BEESWAX/TRICAPRYLIN (1:1) ONCE (STUDY DURATION: LIFETIME),SUBCUTANEOUS TISSUE: TUMOR,POSITIVE,"[HORIKAWA,K, SERA,N, MURAKAMI,K, SANO,N, IZUMI,K AND TOKIWA,H; COMPARATIVE TUMORIGENICITY OF 1- AND 3-NITROBENZO[A]PYRENES, AND 3,6- AND 1,6-DINITROBENZO[A]PYRENES IN F344/DUCRJ RATS; TOXICOL. LETT. 98(1-2):51-58, 1998]"
5627,363902054,91827184,CC1=C(C2=C(C=CC3=C2[C@@H]4[C@@H](O4)[C@H]([C@@H]3O)O)C5=CC=CC=C15)C,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,0; 8 NMOL IN 5 UL DMSO TO PUPS ON D 1/OF LIFE THEN 16 NMOL IN 10 UL ON D 8 AND 3 NMOL IN 20 UL D 15 (STUDY DURATION: 35 WK),LUNG: TUMOR,POSITIVE,"[MISRA,B, AMIN,S AND HECHT,SS; DIMETHYLCHRYSENEDIOL EPOXIDES: MUTAGENICITY IN SALMONELLA TYPHIMURIUM, TUMORIGENICITY IN NEWBORN MICE, AND REACTIVITY WITH DEOXYADENOSINE IN DNA; CHEM. RES. TOXICOL. 5(2):248-254, 1992]"
5628,363902054,91827184,CC1=C(C2=C(C=CC3=C2[C@@H]4[C@@H](O4)[C@H]([C@@H]3O)O)C5=CC=CC=C15)C,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,0; 8 NMOL IN 5 UL DMSO TO PUPS ON D 1/OF LIFE THEN 16 NMOL IN 10 UL ON D 8 AND 3 NMOL IN 20 UL ON D 15 (STUDY DURATION: 35 WK),LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[MISRA,B, AMIN,S AND HECHT,SS; DIMETHYLCHRYSENEDIOL EPOXIDES: MUTAGENICITY IN SALMONELLA TYPHIMURIUM, TUMORIGENICITY IN NEWBORN MICE, AND REACTIVITY WITH DEOXYADENOSINE IN DNA; CHEM. RES. TOXICOL. 5(2):248-254, 1992]"
5629,363902055,132251,CC1=C2C=C(C3=C(C2=CC=C1)C=CC4=C3C5C(O5)C(C4O)O)C,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,0; 8 NMOL IN 5 UL DMSO TO PUPS ON D 1/OF LIFE THEN 16 NMOL IN 10 UL ON D 8 AND 3 NMOL IN 20 UL ON D 15 (STUDY DURATION: 35 WK),LUNG: TUMOR,POSITIVE,"[MISRA,B, AMIN,S AND HECHT,SS; DIMETHYLCHRYSENEDIOL EPOXIDES: MUTAGENICITY IN SALMONELLA TYPHIMURIUM, TUMORIGENICITY IN NEWBORN MICE, AND REACTIVITY WITH DEOXYADENOSINE IN DNA; CHEM. RES. TOXICOL. 5(2):248-254, 1992]"
5630,363902055,132251,CC1=C2C=C(C3=C(C2=CC=C1)C=CC4=C3C5C(O5)C(C4O)O)C,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,0; 8 NMOL IN 5 UL DMSO TO PUPS ON D 1/OF LIFE THEN 16 NMOL IN 10 UL ON D 8 AND 3 NMOL IN 20 UL ON D 15 (STUDY DURATION: 35 WK),LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[MISRA,B, AMIN,S AND HECHT,SS; DIMETHYLCHRYSENEDIOL EPOXIDES: MUTAGENICITY IN SALMONELLA TYPHIMURIUM, TUMORIGENICITY IN NEWBORN MICE, AND REACTIVITY WITH DEOXYADENOSINE IN DNA; CHEM. RES. TOXICOL. 5(2):248-254, 1992]"
5631,363902057,104954,CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1NO,Inactive,,,,RAT,ACI/SEG/MALE,INTRAPERITONEAL,0; 50 UMOL/KG BW 2X/WK FOR 10 WK BEGINNING AT 3 D OF AGE (STUDY DURATION: 68 WK),,NEGATIVE,"[ARCHER,CL MORSE,P JONES,RF SHIRAI,T HAAS,GP AND WANG,CY; CARCINOGENICITY OF THE N-HYDROXY DERIVATIVE OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE,2-AMINO-3,8-DIMETHYL-IMIDAZO[4,5 -F]QUINOXALINE AND 3,2'-DIMETHYL-4-AMINOBIPHENYL IN THE RAT; CANCER LETT. (SHANNON, IREL.) 155(1):55-60, 2000]"
5632,363902064,4891,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2,Inactive,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 300 MG/KG IN CORN OIL 1/5 WK FOR A TOTAL OF 5 DOSES (STUDY DURATION: 40 WK),,NEGATIVE,"[THAMAVIT,W, MOORE, MA, RUCHIRAWAT,S AND ITO,N; REPEATED EXPOSURE TO OPISTHORCHIS VIVERRINI AND TREATMENT WITH THE ANTIHELMINTIC PRAZIQUANTEL LACKS CARCINOGENIC POTENTIAL; CARCINOGENESIS 13(2):309-311, 1992]"
5633,363902081,3840,C1=C(OC=C(C1=O)O)CO,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1.5; 3% IN DIET FOR 20 MONTHS (STUDY DURATION: 20 MONTHS),THYROID: ADENOMA,POSITIVE,"[FUJIMOTO,N, WATANABE,H, NAKATANI,T, ROY,G AND ITO,A; INDUCTION OF THYROID TUMOURS IN (C57BL/6N X C3H/N)F1 MICE BY ORAL ADMINISTRATION OF KOJIC ACID; FOOD CHEM. TOXICOL. 36(8):697-703, 1998]"
5634,363902081,3840,C1=C(OC=C(C1=O)O)CO,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1.5; 3% IN DIET FOR 20 MONTHS (STUDY DURATION: 20 MONTHS),THYROID: ADENOMA. LIVER: HEPATOMA,POSITIVE,"[FUJIMOTO,N, WATANABE,H, NAKATANI,T, ROY,G AND ITO,A; INDUCTION OF THYROID TUMOURS IN (C57BL/6N X C3H/N)F1 MICE BY ORAL ADMINISTRATION OF KOJIC ACID; FOOD CHEM. TOXICOL. 36(8):697-703, 1998]"
5635,363902081,3840,C1=C(OC=C(C1=O)O)CO,Inactive,,,,Rat,F344/Male (20/experimental group (10 killed at 31 wk & 10 killed at 44 wk); 15/controls),Oral,Kojic acid at 2.0% in drinking water for 31 wk; recovery for 13 wk; study duration 44 wk,Thyroid: 1 adenoma at 44 wk,"Negative (However, significantly greater increase in thyroid follicular cell hyperplasia at end of exposure period vs end of study; also significantly greater than untreated control group)","[TAMURA,T MITSUMORI,K TOTSUKA,Y WAKABAYASHI,K KIDO,R KASAI,H NASU,M AND HIROSE,M; ABSENCE OF IN VIVO GENOTOXIC POTENTIAL AND TUMOR INITIATION ACTIVITY OF KOJIC ACID IN THE RAT THYROID; TOXICOLOGY 222(3):213-224, 2006]"
5636,363902091,5284433,CC1=C[C@@H]2[C@]([C@@H](C1=O)O)([C@]3([C@@H]([C@H]([C@H]([C@@]34CO4)O2)O)O)C)CO,Inactive,,,,MOUSE,C57BL/6CRSLC/FEMALE,ORAL,0; 6; 12; 30 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[OHTSUBO,K, RYU,JC, NAKAMURA,K, IZUMIYAMA,N, TANAKA,T, YAMAMURA,H, KOBAYASHI,T AND UENO,Y; CHRONIC TOXICITY OF NIVALENOL IN FEMALE MICE: A 2-YEAR FEEDING STUDY WITH FUSARIUM NIVALE FN 2B-MOULDED RICE; FOOD CHEM. TOXICOL. 27(9):591-598, 1989]"
5637,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1 G/L DISTILLED DRINKING WATER FOR STUDY DURATION (166 MG/KG/D) (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA",POSITIVE,"[DANIEL,FB, DEANGELO,AB, STOBER,JA, OLSON,GR AND PAGE,NP; HEPATOCARCINOGENICITY OF CHLORAL HYDRATE, 2-CHLOROACETALDEHYDE, AND DICHLOROACETIC ACID IN THE MALE B6C3F1 MOUSE; FUNDAM. APPL. TOXICOL. 19(2):159-168, 1992]"
5638,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 15; 45; 135 MG/KG BW/D IN DRINKING WATER FOR 128 WK (STUDY DURATION: 128 WK),,NEGATIVE,"[LEUSCHNER,J AND BEUSCHER,N; STUDIES ON THE MUTAGENIC AND CARCINOGENIC POTENTIAL OF CHLORAL HYDRATE; ARZNEIM.-FORSCH. 48(10):961-968, 1998]"
5639,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 15; 45; 135 MG/KG BW/D IN DRINKING WATER FOR 124 WK (STUDY DURATION: 124 WK),,NEGATIVE,"[LEUSCHNER,J AND BEUSCHER,N; STUDIES ON THE MUTAGENIC AND CARCINOGENIC POTENTIAL OF CHLORAL HYDRATE; ARZNEIM.-FORSCH. 48(10):961-968, 1998]"
5640,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,RAT,F344/N/MALE,ORAL,0; 0.05; 0.5; 2 G/L IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[GEORGE,MH MOORE,T KILBURN,S OLSON,GR AND DEANGELO,AB; CARCINOGENICITY OF CHLORAL HYDRATE ADMINISTERED IN DRINKING WATER TO THE MALE F344/N RAT AND MALE B6C3F1 MOUSE; TOXICOL. PATHOL. 28(4):610-618, 2000]"
5641,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.05; 0.5; 1 G/L IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[GEORGE,MH MOORE,T KILBURN,S OLSON,GR AND DEANGELO,AB; CARCINOGENICITY OF CHLORAL HYDRATE ADMINISTERED IN DRINKING WATER TO THE MALE F344/N RAT AND MALE B6C3F1 MOUSE; TOXICOL. PATHOL. 28(4):610-618, 2000]"
5642,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 25; 50; 100 MG/KG BW ONCE AT 28 DAYS OF AGE (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-502 Y02]"
5643,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 10; 25; 50 MG/KG BW ONCE AT 15 DAYS OF AGE (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-502 Y02]"
5644,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 10; 25; 50 MG/KG BW ONCE AT 15 DAYS OF AGE (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-502 Y02]"
5645,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100 MG/KG BW 5 D/WK FOR 3 MO (STUDY DURATION: 104 WK),PITUITARY GLAND (PARS DISTALIS): ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-502 Y02]"
5646,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100 MG/KG BW 5 D/WK FOR 6 MO (STUDY DURATION: 104 WK),PITUITARY GLAND (PARS DISTALIS): ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-502 Y02]"
5647,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 100 MG/KG BW 5 D/WK FOR 12 MO (STUDY DURATION: 104 WK),PITUITARY GLAND (PARS DISTALIS): ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-502 Y02]"
5648,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 25; 50; 100 MG/KG 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),PITUITARY GLAND (PARS DISTALIS): ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-502 Y02]"
5649,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 1000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 20 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5650,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 20 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5651,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 2000 NMOL TOTAL DOSE, 3/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5652,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 2000 NMOL TOTAL DOSE, 3/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5653,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 25; 50; 100 MG/KG IN WATER 5X/WK FOR STUDY DURATION WITH AD LIBITUM FEEDING (STUDY DURATION: 104-105 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[SCHWETZ,BA ALLABEN,WT BELAND,FA BUCHER,JR CONTRERA,JF GAYLOR,DW GREENLEES,KJ LORENTZEN,RJ AND SISTARE,FD; TOXICOLOGY AND CARCINOGENESIS STUDY OF CHLORAL HYDRATE (AD LIBITUM AND DIETARY CONTROLLED) (CAS NO. 302-17-0) IN MALE B6C3F1 MICE (GAVAGE STUDY); NATL. TOXICOL. PROGRAM TECH. REP. SER. 503: 1-5, 7-29, 31-39, 41-55, 57-59, 61-75, 77-107, 109-189, 191-218, 2002]"
5654,363902092,2707,C(C(Cl)(Cl)Cl)(O)O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 25; 50; 100 MG/KG IN WATER 5X/WK FOR STUDY DURATION WITH DIETARY-CONTROLLED FEEDING TO MAINTAIN IDEAL BODY WEIGHT (STUDY DURATION: 104-105 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[SCHWETZ,BA ALLABEN,WT BELAND,FA BUCHER,JR CONTRERA,JF GAYLOR,DW GREENLEES,KJ LORENTZEN,RJ AND SISTARE,FD; TOXICOLOGY AND CARCINOGENESIS STUDY OF CHLORAL HYDRATE (AD LIBITUM AND DIETARY CONTROLLED) (CAS NO. 302-17-0) IN MALE B6C3F1 MICE (GAVAGE STUDY); NATL. TOXICOL. PROGRAM TECH. REP. SER. 503: 1-5, 7-29, 31-39, 41-55, 57-59, 61-75, 77-107, 109-189, 191-218, 2002]"
5655,363902139,154430,C1=CC=C2C(=C1)C=CC3=C4C=CC5=C(C4=C6C(=C32)O6)C(=C(C=C5)O)O,Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 0.2 UMOL IN 0.1 ML DMSO INJECTED UNDER EACH OF THE 3 LEFT THORACIC NIPPLES FOLLOWED THE NEXT DAY BY SIMILAR TREATMENT OF THE 3 LEFT INGUINAL NIPPLES (STUDY DURATION: 41 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[SHANTU,A, KRZEMINSKI,J, RIVENSON,A, KURTZKE,C, HECHT,SS AND EL-BAYOUMY, K; MAMMARY CARCINOGENICITY IN FEMALE CD RATS OF FJORD REGION DIOL EPOXIDES OF BENZO[C]PHENANTHRENE, BENZO[G]CHRYSENE AND DIBENZO[A,L]PYRENE; CARCINOGENESIS 16(8):1971-1974, 1995]"
5656,363902139,154430,C1=CC=C2C(=C1)C=CC3=C4C=CC5=C(C4=C6C(=C32)O6)C(=C(C=C5)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 25 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
5657,363902139,154430,C1=CC=C2C(=C1)C=CC3=C4C=CC5=C(C4=C6C(=C32)O6)C(=C(C=C5)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 25 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
5658,363902139,154430,C1=CC=C2C(=C1)C=CC3=C4C=CC5=C(C4=C6C(=C32)O6)C(=C(C=C5)O)O,Active,,,,RAT,CD-1/FEMALE,INJECTION,0; 0.2 UMOL IN 0.1 ML DMSO INJECTED BENEATH EACH OF THE 6 NIPPLES ON THE LEFT SIDE (STUDY DURATION: 41 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
5659,363902139,154430,C1=CC=C2C(=C1)C=CC3=C4C=CC5=C(C4=C6C(=C32)O6)C(=C(C=C5)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 25 NMOL TOTAL DOSE INJECTED IN DOSES OF 1/7 ON DAY 1, 2.7 ON DAY 8, AND 4/7 ON DAY 15 OF LIFE (STUDY DURATION: 35 WK)",LUNG:TUMOR; LIVER: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
5660,363902139,154430,C1=CC=C2C(=C1)C=CC3=C4C=CC5=C(C4=C6C(=C32)O6)C(=C(C=C5)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 25 NMOL TOTAL DOSE INJECTED IN DOSES OF 1/7 ON DAY 1, 2/7 ON DAY 8, AND 4/7 ON DAY 15 OF LIFE (STUDY DURATION: 35 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
5661,363902141,,,Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 0.2 UMOL IN 0.1 ML DMSO INJECTED UNDER EACH OF THE 3 LEFT THORACIC NIPPLES FOLLOWED THE NEXT DAY BY SIMILAR TREATMENT OF THE 3 LEFT INGUINAL NIPPLES (STUDY DURATION: 41 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[SHANTU,A, KRZEMINSKI,J, RIVENSON,A, KURTZKE,C, HECHT,SS AND EL-BAYOUMY, K; MAMMARY CARCINOGENICITY IN FEMALE CD RATS OF FJORD REGION DIOL EPOXIDES OF BENZO[C]PHENANTHRENE, BENZO[G]CHRYSENE AND DIBENZO[A,L]PYRENE; CARCINOGENESIS 16(8):1971-1974, 1995]"
5662,363902141,,,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 25 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
5663,363902141,,,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 25 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
5664,363902141,,,Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 2.04 UMOL IN 0.1 ML DMSO 3 INJECTIONS INTO MAMMARY TISSUE BENEATH THE 3 LEFT THORACIC NIPPLES ON THE NEXT DAY PROCEDURE REPEATED ON THE 3 LEFT INGUINAL NIPPLES (STUDY DURATION: 38 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[HECHT,SS, EL-BAYOUMY,K, RIVENSON,A AND AMIN,S; POTENT MAMMARY CARCINOGENICITY IN FEMALE CD RATS OF A FJORD REGION DIOL-EPOXIDE OF BENZO[C]PHENANTHRENE COMPARED TO A BAY REGION DIOL-EPOXIDE OF BENZO[A]PYRENE; CANCER RES. 54(1): 21-24, 1994]"
5665,363902145,,,Active,,,,RAT,CD-1/FEMALE,INJECTION,0; 0.2 UMOL IN 0.1 ML DMSO INJECTED UNDER EACH OF THE 3 LEFT THORACIC NIPPLES THEN 1 DAY LATER SAME DOSES INJECTED UNDER THE 3 LEFT INGUINAL NIPPLES (STUDY DURATION: 44 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[HECHT,SS, RIVENSON,A, AMIN,S, KRZEMINSKI,J, EL-BAYOUMY,K, REDDY,BS, KURTZKE,C AND LA VOIE,EJ; MAMMARY CARCINOGENICITY OF DIOL EPOXIDE METABOLITES OF BENZO[J]FLUORANTHENE IN FEMALE CD RATS; CANCER LETT. 106(2):251-255, 1996]"
5666,363902145,,,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.11; 0.275 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
5667,363902145,,,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.11; 0.275 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
5668,363902179,14786,O=[Co],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRATRACHEAL,0; 2; 10 MG/KG EVERY 14 D FOR TOTAL DOSES OF 0; 78; 390 MG/KG (STUDY DURATION: 2 YR),LUNG: TUMOR,POSITIVE,"[STEINHOFF,D AND MOHR,U; ON THE QUESTION OF CARCINOGENIC ACTION OF COBALT- CONTAINING COMPOUNDS; EXP. PATHOL. 41(4):169-174, 1991]"
5669,363902179,14786,O=[Co],Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRATRACHEAL,0; 2; 10 MG/KG EVERY 14 D FOR TOTAL DOSES OF 0; 78; 390 MG/KG (STUDY DURATION: 2 YR),,NEGATIVE,"[STEINHOFF,D AND MOHR,U; ON THE QUESTION OF CARCINOGENIC ACTION OF COBALT- CONTAINING COMPOUNDS; EXP. PATHOL. 41(4):169-174, 1991]"
5670,363902179,14786,O=[Co],Active,,,,RAT,"SPRAGUE-DAWLEY/MALE,FEMALE",INTRAPERITONEAL,0; 200 MG/KG EVERY 2 MO FOR TOTAL DOSES OF 0; 600 MG/KG,PERITONEUM: TUMORS,POSITIVE,"[STEINHOFF,D AND MOHR,U; ON THE QUESTION OF CARCINOGENIC ACTION OF COBALT- CONTAINING COMPOUNDS; EXP. PATHOL. 41(4):169-174, 1991]"
5671,363902179,14786,O=[Co],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 2 MG/KG 5/WK FOR TOTAL DOSES OF 0; 1000 MG/KG (STUDY DURATION: 2 YR),SUBCUTANEOUS TISSUE: TUMORS,POSITIVE,"[STEINHOFF,D AND MOHR,U; ON THE QUESTION OF CARCINOGENIC ACTION OF COBALT- CONTAINING COMPOUNDS; EXP. PATHOL. 41(4):169-174, 1991]"
5672,363902179,14786,O=[Co],Active,,,,RAT,SPRAGUE-DAWLEY/MALE,SUBCUTANEOUS,0; 10 MG/KG 1/WK FOR TOTAL DOSES OF 0; 1000 MG/KG (STUDY DURATION: 2 YR),SUBCUTANEOUS TISSUE: TUMORS,POSITIVE,"[STEINHOFF,D AND MOHR,U; ON THE QUESTION OF CARCINOGENIC ACTION OF COBALT- CONTAINING COMPOUNDS; EXP. PATHOL. 41(4):169-174, 1991]"
5673,363902180,6595,CC(=C)C(=O)N,Active,,,,MOUSE,DDY,INTRAPERITONEAL,0; 2.35 MMOL/KG 1/D FOR 5 D (STUDY DURATION: 6 MO),LUNG: ADENOMA,POSITIVE,"[MATSUDA,H; STUDIES ON LUNG TUMOR FORMATION IN MICE BY METHACRYLAMIDE; KANAZAWA DAIGAKU JUZEN IGAKKAI ZASSHI 98(2):428-438, 1989]"
5674,363902180,6595,CC(=C)C(=O)N,Active,,,,MOUSE,DDY,INTRAPERITONEAL,0; 2.35 MMOL/KG 1/2 D FOR 5 DOSES (STUDY DURATION: 6 MO),LUNG: ADENOMA,POSITIVE,"[MATSUDA,H; STUDIES ON LUNG TUMOR FORMATION IN MICE BY METHACRYLAMIDE; KANAZAWA DAIGAKU JUZEN IGAKKAI ZASSHI 98(2):428-438, 1989]"
5675,363902181,62134,C1=CC2=C3C(=C1)C=C(C4=CC=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG/BW IN 25 UMOL/ML DMSO 3/WK FOR 4 WK (TOTAL DOSE: 0; 119 UMOL) ADMINISTERED TO WEANLING RATS (STUDY DURATION: 61 WK),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
5676,363902181,62134,C1=CC2=C3C(=C1)C=C(C4=CC=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 0.1 ML IN 20.3 UMOL/ML DMSO INJECTED INTO MAMMARY TISSUE OF THE 3 LEFT THORACIC NIPPLES FOLLOWED THE NEXT D BY SIMILAR TREATMENT OF THE INGUINAL NIPPLE AREA (TOTAL DOSE: 0; 12.3 UMOL) (STUDY DURATION: 77 WK),"MAMMARY GLAND: FIBROADENOMA, ADENOCARCINOMA",POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
5677,363902181,62134,C1=CC2=C3C(=C1)C=C(C4=CC=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG BW IN DMSO 3/WK FOR 4 WK (STUDY DURATION: 61 WK),MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
5678,363902181,62134,C1=CC2=C3C(=C1)C=C(C4=CC=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 0.1 ML OF A 20.3 UMOL/ML SOLUTION IN DMSO INJECTED INTO MAMMARY TISSUE UNDERLYING 3 LEFT THORACIC NIPPLES THE FOLLOWING DAY INGUINAL NIPPLE AREA TREATED SIMILARLY (STUDY DURATION: 77 WK),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
5679,363902181,62134,C1=CC2=C3C(=C1)C=C(C4=CC=CC(=C43)C=C2)[N+](=O)[O-],Active,,,,RAT,STRAIN-CD/FEMALE,SUBCUTANEOUS,0; 75 UMOL (TOTAL DOSE) ADMINISTERED OVER 8 WK BEGINNING WITHIN 24 HR OF BIRTH (STUDY DURATION: 86 WK),MAMMARY GLAND: TUMOR; INTEGUMENTARY SYSTEM: MALIGNANT FIBROUS HISTIOCYTOMA; HEMATOPOIETIC SYSTEM: LEUKEMIA; ZYMBAL GLAND: CARCINOMA,POSITIVE,"[IMAIDA,K, LEE,MS, LAND,SJ, WANG,CY AND KING,CM; CARCINOGENICITY OF NITROPYRENES IN THE NEWBORN FEMALE RAT; CARCINOGENESIS 16(12):3027-3030, 1995]"
5680,363902182,56886,CC(=O)N(C1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1)O,Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG/BW IN 25 UMOL/ML DMSO 3/WK FOR 4 WK (TOTAL DOSE: 0; 119 UMOL) ADMINISTERED TO WEANLING RATS (STUDY DURATION: 61 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
5681,363902182,56886,CC(=O)N(C1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1)O,Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG BW IN DMSO 3/WK FOR 4 WK (STUDY DURATION: 61 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
5682,363902183,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.99; 4.76; 9.09% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[WOOD,FE, TIERNEY,WJ, KNEZEVICH,AL, BOLTE,HF, MAURER,JK AND BRUCE,RD; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF OLESTRA IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 29(4):223-230, 1991]"
5683,363902183,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.99; 4.76; 9.09% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[WOOD,FE, TIERNEY,WJ, KNEZEVICH,AL, BOLTE,HF, MAURER,JK AND BRUCE,RD; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF OLESTRA IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 29(4):223-230, 1991]"
5684,363902183,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 9.09% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[WOOD,FE, TIERNEY,WJ, KNEZEVICH,AL, BOLTE,HF, MAURER,JK AND BRUCE,RD; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF OLESTRA IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 29(4):223-230, 1991]"
5685,363902183,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 9.09% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[WOOD,FE, TIERNEY,WJ, KNEZEVICH,AL, BOLTE,HF, MAURER,JK AND BRUCE,RD; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF OLESTRA IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 29(4):223-230, 1991]"
5686,363902183,,,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 2.5; 5; 10% IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[LAFRANCONI,WM, LONG,PH, ATKINSON,JE, KNEZEVICH,AL AND WOODING,WL; CHRONIC TOXICITY AND CARCINOGENICITY OF OLESTRA IN SWISS CD-1 MICE; FOOD CHEM. TOXICOL. 32(9):789-798, 1994]"
5687,363902183,,,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 2.5; 5; 10% IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[LAFRANCONI,WM, LONG,PH, ATKINSON,JE, KNEZEVICH,AL AND WOODING,WL; CHRONIC TOXICITY AND CARCINOGENICITY OF OLESTRA IN SWISS CD-1 MICE; FOOD CHEM. TOXICOL. 32(9):789-798, 1994]"
5688,363902184,,,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.11; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
5689,363902184,,,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.11; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
5690,363902184,,,Active,,,,RAT,CD-1/FEMALE,INJECTION,0; 0.2 UMOL IN 0.1 ML DMSO INJECTED UNDER EACH OF THE 3 LEFT THORACIC NIPPLES THEN 1 DAY LATER SAME DOSES INJECTED UNDER THE 3 LEFT INGUINAL NIPPLES (STUDY DURATION: 44 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[HECHT,SS, RIVENSON,A, AMIN,S, KRZEMINSKI,J, EL-BAYOUMY,K, REDDY,BS, KURTZKE,C AND LA VOIE,EJ; MAMMARY CARCINOGENICITY OF DIOL EPOXIDE METABOLITES OF BENZO[J]FLUORANTHENE IN FEMALE CD RATS; CANCER LETT. 106(2):251-255, 1996]"
5691,363902187,126308,C1C2=CC=CC=C2C3=C1C=C(C=C3)N[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O,Inactive,,,,RAT,F344/MALE,INJECTION,0;1 UMOL IN 0.5 ML OF SOLUTION CONTAINING 0.4 ML PHOSPHATE BUFFERED SALINE/ GENTAMYCIN (PH 7) AND 0.1 ML DMSO INJECTED INTO HETEROTOPICALLY TRANSPLANTED BLADDERS 1/WK FOR 20 WK (STUDY DURATION: 50 WK),,NEGATIVE,"[WANG,CY, IMAIDA,K, ZUKOWSKI,K AND LEE,MS; LACK OF CARCINOGENICITY OF 2-AMINOFLUORENE, ITS GLUCURONIDE AND THE GLUCURONIDE OF N-HYDROXY-2- ACETYLAMINOFLUORENE IN HETEROTOPIC BLADDER OF THE RAT; CANCER LETT. 56(2):153-157, 1991]"
5692,363902188,92183,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O,Inactive,,,,RAT,F344/MALE,INJECTION,0; 1 UMOL IN 0.5 ML OF SOLUTION CONTAINING 0.4 ML PHOSPHATE BUFFERED SALINE/ GENTAMYCIN (PH 7) AND 0.1 ML DMSO INJECTED INTO HETEROTOPICALLY TRANSPLANTED BLADDERS 1/WK FOR 20 WK (STUDY DURATION: 50 WK),,NEGATIVE,"[WANG,CY, IMAIDA,K, ZUKOWSKI,K AND LEE,MS; LACK OF CARCINOGENICITY OF 2-AMINOFLUORENE, ITS GLUCURONIDE AND THE GLUCURONIDE OF N-HYDROXY-2- ACETYLAMINOFLUORENE IN HETEROTOPIC BLADDER OF THE RAT; CANCER LETT. 56(2):153-157, 1991]"
5693,363902188,92183,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O,Inactive,,,,RAT,F344/MALE,INJECTION,0; 1 UMOL IN 0.5 ML OF SOLUTION CONTAINING 0.4 ML PHOSPHATE BUFFERED SALINE/ GENTAMYCIN (PH 8) AND 0.1 ML DMSO INJECTED INTO HETEROTOPICALLY TRANSPLANTED BLADDERS 1/WK FOR 20 WK (STUDY DURATION: 50 WK),,NEGATIVE,"[WANG,CY, IMAIDA,K, ZUKOWSKI,K AND LEE,MS; LACK OF CARCINOGENICITY OF 2-AMINOFLUORENE, ITS GLUCURONIDE AND THE GLUCURONIDE OF N-HYDROXY-2- ACETYLAMINOFLUORENE IN HETEROTOPIC BLADDER OF THE RAT; CANCER LETT. 56(2):153-157, 1991]"
5694,363902189,,,Active,,,,FISH,RAINBOW TROUT,ORAL,0; 0.3; 1.5; 7.5 UG/KG DIET FOR 5.5 MO (STUDY DURATION: 5.5 MO),LIVER: HEPATOMA,POSITIVE,"[LAFONT,P, SIRIWARDANA,MG AND LAFONT,J; GENOTOXICITY OF HYDROXY-AFLATOXINS M1 AND M4; MICROBIOL., ALIMENTS, NUTR. 7(1):1-8,1989]"
5695,363902190,23688094,CC1=C2C(=C(C3=CC=CC=C13)COS(=O)(=O)[O-])C=CC4=CC=CC=C42.[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 2 UMOL IN 0.25 ML TRIOCTANOIN ONCE INTO LEFT HIND LEG AT ABOUT 40 D OF AGE (STUDY DURATION: 16 MO),,NEGATIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
5696,363902190,23688094,CC1=C2C(=C(C3=CC=CC=C13)COS(=O)(=O)[O-])C=CC4=CC=CC=C42.[Na+],Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 2 UMOL IN 0.25 ML TRIOCTANOIN INTO LEFT HIND LEG AT ABOUT 40 D OF AGE FOLLOWED BY A SECOND DOSE 6 D LATER (STUDY DURATION: 16 MO),,NEGATIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
5697,363902190,23688094,CC1=C2C(=C(C3=CC=CC=C13)COS(=O)(=O)[O-])C=CC4=CC=CC=C42.[Na+],Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 0.1 001;0.003; 0.01 UMOL/G IN 5 UL DMSO/G ONCE AT 4-6 WK OF AGE (STUDY DURATION: 6 MO),,NEGATIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
5698,363902190,23688094,CC1=C2C(=C(C3=CC=CC=C13)COS(=O)(=O)[O-])C=CC4=CC=CC=C42.[Na+],Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 0.0025 UMO1/G IN 10 ML/G TRIOCTANOIN ON 12, 16, 20, AND 24 D OF AGE (STUDY DURATION: 10 MO)",LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
5699,363902190,23688094,CC1=C2C(=C(C3=CC=CC=C13)COS(=O)(=O)[O-])C=CC4=CC=CC=C42.[Na+],Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.0025 UMOL/G IN 10 UL/G TRIOCTANOIN ONCE ON D 12 OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
5700,363902190,23688094,CC1=C2C(=C(C3=CC=CC=C13)COS(=O)(=O)[O-])C=CC4=CC=CC=C42.[Na+],Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.001; 0.003; 0.01 UMOL/G IN 5 UL/G DMSO ONCE ON D 12 OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; 7-SULFOOXYMETHYL-12-METHYLBENZ[A] ANTHRACENE IS AN ELECTROPHILIC MUTAGEN, BUT DOES NOT APPEAR TO PLAY A ROLE IN CARCINOGENESIS BY 7,12-DIMETHYLBENZ[A]ANTHRACENE OR 7-HYDROXYMETHYL-12- METHYLBENZ[A]ANTHRACENE; CARCINOGENESIS 12(2):339-347, 1991]"
5701,363902190,23688094,CC1=C2C(=C(C3=CC=CC=C13)COS(=O)(=O)[O-])C=CC4=CC=CC=C42.[Na+],Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL 3/WK FOR 20 DOSES (STUDY DURATION: 52 WK),INJECTION SITE: SARCOMA,POSITIVE,"[FLESHER,JW, HORN,J AND LEHNER,AF; 7-SULFOOXYMETHYL-12-METHYLBENZ[A]ANTHRACENE IS AN EXCEPTIONALLY REACTIVE ELECTROPHILIC MUTAGEN AND ULTIMATE CARCINOGEN; BIOCHEM. BIOPHYS. RES. COMMUN. 231(1):144-148, 1997]"
5702,363902191,124535,CCN(C(=O)NCCO)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 37; 74 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; BLADDER: TUMOR; MESOTHELIUM: TUMOR; NERVOUS SYSTEM: TUMOR; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5703,363902191,124535,CCN(C(=O)NCCO)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 37; 74 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR; MAMMARY GLAND: TUMOR; UTERUS: TUMOR; NERVOUS SYSTEM: TUMOR; SKIN: TUMOR; MOUTH: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5704,363902191,124535,CCN(C(=O)NCCO)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 3.6 MG 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR; BRAIN: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
5705,363902191,124535,CCN(C(=O)NCCO)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 3.6 MG IN 0.2 ML ETHYL ACETATE/CORN OIL (1:1) 2/WK FOR 31 WK (TOTAL DOSE: 223 MG) (STUDY DURATION: 80 WK),"LUNG: CARCINOMA, ADENOMA; BRAIN: TUMORS; THYROID: CARCINOMA OR ADENOMA; PERITONEUM: MESOTHELIOMA; ZYMBAL GLAND: CARCINOMA",POSITIVE,"[LIJINSKY,W, SINGER,GM AND KOVATCH,RM; SIMILAR CARCINOGENIC EFFECTS IN RATS OF 1-ETHYL-1-NITROSO-3-HYDROXYETHYLUREA AND 1-HYDROXYETHYL-1-NITROSO-3- ETHYLUREA; CARCINOGENESIS 6(4):641-643, 1985]"
5706,363902192,124536,CCNC(=O)N(CCO)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 37; 74 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),LIVER: TUMOR; LUNG: TUMOR; THYROID: FOLLICULAR TUMOR; MESOTHELIUM: TUMOR; NERVOUS SYSTEM: TUMOR; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5707,363902192,124536,CCNC(=O)N(CCO)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 37; 74 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),MAMMARY GLAND: CARCINOMA,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5708,363902192,124536,CCNC(=O)N(CCO)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 3.6 MG 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
5709,363902192,124536,CCNC(=O)N(CCO)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 3.6 MG IN 0.2 ML ETHYL ACETATE/CORN OIL (1:1) 2/WK FOR 31 WK (TOTAL DOSE: 223 MG) (STUDY DURATION: 80 WK),LIVER: CARCINOMA; LUNG: CARCINOMA OR ADENOMA; BRAIN: TUMORS; THYROID: CARCINOMA OR ADENOMA; PERITONEUM: MESOTHELIOMA,POSITIVE,"[LIJINSKY,W, SINGER,GM AND KOVATCH,RM; SIMILAR CARCINOGENIC EFFECTS IN RATS OF 1-ETHYL-1-NITROSO-3-HYDROXYETHYLUREA AND 1-HYDROXYETHYL-1-NITROSO-3- ETHYLUREA; CARCINOGENESIS 6(4):641-643, 1985]"
5710,363902193,124537,C(CCl)NC(=O)N(CCO)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 42 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),LIVER: TUMOR; LUNG: TUMOR; MESOTHELIUM: TUMOR; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5711,363902193,124537,C(CCl)NC(=O)N(CCO)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 42 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),LIVER: TUMOR; UTERUS: TUMOR; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5712,363902194,124538,CC(CN(C(=O)NCCCl)N=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 46 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5713,363902194,124538,CC(CN(C(=O)NCCCl)N=O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 46 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR; THYROID: FOLLICULAR TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5714,363902194,124538,CC(CN(C(=O)NCCCl)N=O)O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 4.6 MG 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
5715,363902195,129381,CC(CNC(=O)N(CCCl)N=O)O,Active,,,,RAT,F344/MALE,ORAL,0; 18 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5716,363902195,129381,CC(CNC(=O)N(CCCl)N=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 18 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5717,363902196,135720,CC(=O)CN(C(=O)NCCCl)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 46 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5718,363902196,135720,CC(=O)CN(C(=O)NCCCl)N=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 46 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5719,363902196,135720,CC(=O)CN(C(=O)NCCCl)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 11.5 MG/ML IN CORN OIL/ETHYL ACETATE (2:1) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),NERVOUS SYSTEM: TUMOR; SMALL INTESTINE: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5720,363902196,135720,CC(=O)CN(C(=O)NCCCl)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 11.5 MG/ML IN CORN OIL/ETHYL ACETATE (2:1) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),LIVER: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5721,363902197,154041,CCN(C(=O)NCC(=O)C)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 40; 80 MG/L IN DRINKING WATER FOR 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; THYROID: FOLLICULAR TUMOR; COLON: TUMOR; MESOTHELIUM: TUMOR; NERVOUS SYSTEM: TUMOR; SKIN: TUMOR; ZYMBAL GLAND: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5722,363902197,154041,CCN(C(=O)NCC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 40; 80 MG/L IN DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: LIFETIME),LIVER: TUMOR; LUNG: TUMOR; MAMMARY GLAND: CARCINOMA; UTERUS: TUMOR; THYROID: FOLLICULAR TUMOR; COLON: TUMOR; NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5723,363902197,154041,CCN(C(=O)NCC(=O)C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 9.5; 19 MG/ML IN CORN OIL/ETHYL ACETATE (2:1) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),LIVER: TUMOR; LUNG: TUMOR; MESOTHELIUM: TUMOR; NERVOUS SYSTEM: TUMOR; THYROID: FOLLICULAR TUMOR; FORESTOMACH: TUMOR; SPLEEN: TUMOR; ZYMBAL GLAND: TUMOR; COLON: TUMOR; SMALL INTESTINE: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5724,363902197,154041,CCN(C(=O)NCC(=O)C)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 9.5; 19 MG/ML IN CORN OIL/ETHYL ACETATE (2:1) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; MAMMARY GLAND: CARCINOMA; UTERUS: TUMOR; FORESTOMACH: TUMOR; SPLEEN: TUMOR; ZYMBAL GLAND: TUMOR; SMALL INTESTINE: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5725,363902201,5282164,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 200; 600; 2000 MG/KG/BW A DAY IN DIET FOR 78 WK (STUDY DURATION: 79 WK),,NEGATIVE,"[TAMAGAWA,M, OTAKI,Y, TAKAHASHI,T, OTAKA,T, KIMURA,S AND MIWA,T; CARCINOGENICITY STUDY OF GAMMA-ORYZANOL IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 30(1):49-56, 1992]"
5726,363902201,5282164,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 200; 600; 2000 MG/KG/BW A DAY IN DIET FOR 78 WK (STUDY DURATION: 79 WK),,NEGATIVE,"[TAMAGAWA,M, OTAKI,Y, TAKAHASHI,T, OTAKA,T, KIMURA,S AND MIWA,T; CARCINOGENICITY STUDY OF GAMMA-ORYZANOL IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 30(1):49-56, 1992]"
5727,363902201,5282164,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 200; 600; 2000 MG/KG/BW/D IN DIET FOR 2 YR (STUDY DURATION: 105 WK),,NEGATIVE,"[TAMAGAWA,M, SHIMIZU,Y, TAKAHASHI,T, OTAKA,T, KIMURA,S, KADOWAKI,H, UDA,F AND MIWA,T; CARCINOGENICITY STUDY OF GAMMA-ORYZANOL IN F344 RATS; FOOD CHEM. TOXICOL. 30(1):41-48, 1992]"
5728,363902201,5282164,C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CC[C@]34[C@H]2CC[C@@H]5[C@]3(C4)CC[C@@H](C5(C)C)OC(=O)/C=C/C6=CC(=C(C=C6)O)OC)C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 200; 600; 2000 MG/KG/BW/D IN DIET FOR 2 YR (STUDY DURATION: 105 WK),,NEGATIVE,"[TAMAGAWA,M, SHIMIZU,Y, TAKAHASHI,T, OTAKA,T, KIMURA,S, KADOWAKI,H, UDA,F AND MIWA,T; CARCINOGENICITY STUDY OF GAMMA-ORYZANOL IN F344 RATS; FOOD CHEM. TOXICOL. 30(1):41-48, 1992]"
5729,363902208,62158,C1=CC(=C(C=C1[N+](=O)[O-])OCCO)NCCO,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5000; 10000 PPM IN FEED 7 D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-419 Y92]"
5730,363902208,62158,C1=CC(=C(C=C1[N+](=O)[O-])OCCO)NCCO,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5000; 10000 PPM IN FEED 7 D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-419 Y92]"
5731,363902208,62158,C1=CC(=C(C=C1[N+](=O)[O-])OCCO)NCCO,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5000; 10000 PPM IN FEED 7 D/WK FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-419 Y92]"
5732,363902208,62158,C1=CC(=C(C=C1[N+](=O)[O-])OCCO)NCCO,Unspecified,,,,RAT,F344/MALE,ORAL,0; 5000; 10000 PPM IN FEED 7 D/WK FOR 104 WK (STUDY DURATION: 105 WK),PITUITARY GLAND (PARS DISTALIS): ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-419 Y92]"
5733,363902220,119557,CC(=O)CN(C(=O)N)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 8 MG/ML IN CORN OIL/ETHYL ACETATE (2:1) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; MESOTHELIUM: TUMOR; KIDNEY MESENCHYME: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5734,363902220,119557,CC(=O)CN(C(=O)N)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 8 MG/ML IN CORN OIL/ETHYL ACETATE (2:1) 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),KIDNEY MESENCHYME: TUMOR; THYROID: FOLLICULAR TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING OXYGENATED ALKYL GROUPS; IN VIVO 4(1):1-6, 1990]"
5735,363902221,9556443,CCCCC/C=N/N(C)C=O,Active,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 50; 100 UG/G/BW IN 0.01 ML OF PROPYLENE GLYCOL 1/WK FOR 52 WK (STUDY DURATION: 130 WK),LUNG: ADENOMA OR ADENOCARCINOMA; LIVER: HEPATOMA OR CARCINOMA,POSITIVE,"[TOTH,B, TAYLOR,J AND GANNET,P; TUMOR INDUCTION WITH HEXANAL METHYLFORMYLHYDRAZONE OF GYROMITRA ESCULENTA; MYCOPATHOLOGIA 115(2):65-71, 1991]"
5736,363902221,9556443,CCCCC/C=N/N(C)C=O,Active,,,,MOUSE,SWISS/MALE,GAVAGE,0; 50; 100 UG/G/BW IN 0.01 ML OF PROPYLENE GLYCOL 1/WK FOR 52 WK (STUDY DURATION: 130 WK),LUNG: ADENOMA AND ADENOCARCINOMA; PREPUTIAL GLAND: SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA OR ADENOMA,POSITIVE,"[TOTH,B, TAYLOR,J AND GANNET,P; TUMOR INDUCTION WITH HEXANAL METHYLFORMYLHYDRAZONE OF GYROMITRA ESCULENTA; MYCOPATHOLOGIA 115(2):65-71, 1991]"
5737,363902222,114839,C([C@@H]([C@@H](CO)O)O)C(=O)C=O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 20 UMOL/0.1 ML DMSO 2/WK FOR 5 WK FOLLOWED 1 WK LATER BY 0.1 ML ACETONE 2/WK FOR 47 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MIYAKAWA,Y, NISHI,Y, KATO,K, SATO,K, TAKAHASHI,M AND HAYASHI,Y; INITIATING ACTIVITY OF EIGHT PYROLYSATES OF CARBOHYDRATES IN A TWO-STAGE MOUSE SKIN TUMORIGENESIS MODEL; CARCINOGENESIS 12(7):1169-1173, 1991]"
5738,363902223,2724705,C1[C@@H]2[C@H]([C@@H]([C@H]([C@H](O1)O2)O)O)O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 20 UMOL/0.1 ML DMSO 2/WK FOR 5 WK FOLLOWED 1 WK LATER BY 0.1 ML ACETONE 2/WK FOR 47 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MIYAKAWA,Y, NISHI,Y, KATO,K, SATO,K, TAKAHASHI,M AND HAYASHI,Y; INITIATING ACTIVITY OF EIGHT PYROLYSATES OF CARBOHYDRATES IN A TWO-STAGE MOUSE SKIN TUMORIGENESIS MODEL; CARCINOGENESIS 12(7):1169-1173, 1991]"
5739,363902224,699486,C1[C@@H]2C=CC(=O)[C@H](O1)O2,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 2.5 UMOL/0.1 DMSO 2/WK FOR 5 WK FOLLOWED 1 WK LATER BY 0.1 ML ACETONE 2/WK FOR 47 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MIYAKAWA,Y, NISHI,Y, KATO,K, SATO,K, TAKAHASHI,M AND HAYASHI,Y; INITIATING ACTIVITY OF EIGHT PYROLYSATES OF CARBOHYDRATES IN A TWO-STAGE MOUSE SKIN TUMORIGENESIS MODEL; CARCINOGENESIS 12(7):1169-1173, 1991]"
5740,363902225,10444,C1CSCN1,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 50 UMOL/0.1 ML DMSO 2/WK FOR 5 WK FOLLOWED 1 WK LATER BY 0.1 ML ACETONE 2/WK FOR 47 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MIYAKAWA,Y, NISHI,Y, KATO,K, SATO,K, TAKAHASHI,M AND HAYASHI,Y; INITIATING ACTIVITY OF EIGHT PYROLYSATES OF CARBOHYDRATES IN A TWO-STAGE MOUSE SKIN TUMORIGENESIS MODEL; CARCINOGENESIS 12(7):1169-1173, 1991]"
5741,363902226,10658,C1=CC2=C(C=CO2)C3=C1C=CC(=O)O3,Inactive,,,,MOUSE,C3H/HEN/FEMALE,DERMAL,215 UG IN 70% ETHANOL 3/WK FOR 48 WK (STUDY DURATION: 68 WK),,NEGATIVE,"[ALCALAY,J, DALL'ACQUA,F AND KRIPKE,ML; PHOTOCARCINOGENESIS IN MICE BY 4,4',6 TRIMETHYLANGELICIN PLUS UVA RADIATION; PHOTODERMATOL. PHOTOIMMUNOL. PHOTOMED. 7(3):116-118, 1990]"
5742,363902227,107731,CC1=CC2=C(C3=C1OC=C3C)OC(=O)C=C2C,Inactive,,,,MOUSE,C3H/HEN/FEMALE,DERMAL,0; 250 UG IN 70% ETHANOL 3/WK FOR 48 WK (STUDY DURATION: 68 WK),,NEGATIVE,"[ALCALAY,J, DALL'ACQUA,F AND KRIPKE,ML; PHOTOCARCINOGENESIS IN MICE BY 4,4',6 TRIMETHYLANGELICIN PLUS UVA RADIATION; PHOTODERMATOL. PHOTOIMMUNOL. PHOTOMED. 7(3):116-118, 1990]"
5743,363902228,5284419,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)OC)O)O)O)O)O)O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1.25; 5% IN DIET FOR 96 WK FOLLOWED BY BASAL DIET FOR AN ADDITIONAL 8 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KURATA,Y, FUKUSHIMA,S, HAGIWARA,A, ITO,H, OGAWA,K AND ITO,N; CARCINOGENICITY STUDY OF METHYL HESPERIDIN IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 28(9):613-618, 1990]"
5744,363902228,5284419,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)OC)O)O)O)O)O)O)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1.25; 5% IN DIET FOR 96 WK FOLLOWED BY BASAL DIET FOR AN ADDITIONAL 8 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KURATA,Y, FUKUSHIMA,S, HAGIWARA,A, ITO,H, OGAWA,K AND ITO,N; CARCINOGENICITY STUDY OF METHYL HESPERIDIN IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 28(9):613-618, 1990]"
5745,363902229,14116,C1=CC=C(C=C1)C2=C(C=CC(=C2)O)O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 10 MG IN DMSO 5 D/WK FOR 40 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SATO,H, TOYODA,K, TAKAMURA,N, FURUKAWA,F, HASEGAWA,R, FUKUOKA,M, IMAIDA,K, TAKAHASHI,M AND HAYASHI,Y; EFFECTS OF 2-PHENYL-1,4-BENZOQUINONE AND 2,5-DIHYDROXYBIPHENYL ON TWO-STAGE MOUSE SKIN CARCINOGENESIS; CANCER LETT. 55(3):233-238, 1990]"
5746,363902229,14116,C1=CC=C(C=C1)C2=C(C=CC(=C2)O)O,Inactive,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 1% IN 0.2 ML SALINE 2/WK FOR 5 WK (STUDY DURATION: 36 WK),,NEGATIVE,"[HASEGAWA,R, FURUKAWA,F, TOYODA,K, SATO,H, TAKAHASHI,M AND HAYASHI,Y; UROTHELIAL DAMAGE AND TUMOR INITIATION BY URINARY METABOLITES OF SODIUM O-PHENYLPHENATE IN THE URINARY BLADDER OF FEMALE RATS; JPN. J. CANCER RES. 81(5):483-8, 1990]"
5747,363902230,9688,C1=CC=C(C=C1)C2=CC(=O)C=CC2=O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 1 MG IN DMSO 5/D WK FOR 40 WK (STUDY DURATION: 40 WK),,NEGATIVE,"[SATO,H, TOYODA,K, TAKAMURA,N, FURUKAWA,F, HASEGAWA,R, FUKUOKA,M, IMAIDA,K, TAKAHASHI,M AND HAYASHI,Y; EFFECTS OF 2-PHENYL-1,4-BENZOQUINONE AND 2,5-DIHYDROXYBIPHENYL ON TWO-STAGE MOUSE SKIN CARCINOGENESIS; CANCER LETT. 55(3):233-238, 1990]"
5748,363902230,9688,C1=CC=C(C=C1)C2=CC(=O)C=CC2=O,Inactive,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 1% IN 0.2 ML SALINE 2/WK FOR 5 WK (STUDY DURATION: 36 WK),,NEGATIVE,"[HASEGAWA,R, FURUKAWA,F, TOYODA,K, SATO,H, TAKAHASHI,M AND HAYASHI,Y; UROTHELIAL DAMAGE AND TUMOR INITIATION BY URINARY METABOLITES OF SODIUM O-PHENYLPHENATE IN THE URINARY BLADDER OF FEMALE RATS; JPN. J. CANCER RES. 81(5):483-8, 1990]"
5749,363902257,255653,CC(=O)NC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG/BW IN 25 UMOL/ML DMSO 3/WK FOR 4 WK (TOTAL DOSE: 0; 119 UMOL) ADMINISTERED TO WEANLING RATS (STUDY DURATION: 61 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51(11):2902-2907, 1991]"
5750,363902257,255653,CC(=O)NC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,Inactive,,,,RAT,STRAIN-CD/FEMALE,INTRAPERITONEAL,0; 67 UMOL/KG BW IN DMSO 3/WK FOR 4 WK (STUDY DURATION: 61 WK),,NEGATIVE,"[IMAIDA,K, HIROSE,M, TAY,L, LEE,MS, WANG,CY AND KING,CM; COMPARATIVE CARCINOGENICITIES OF 1-, 2-, AND 4-NITROPYRENE AND STRUCTURALLY RELATED COMPOUNDS IN THE FEMALE CD RAT; CANCER RES. 51:2902-2907, 1991]"
5751,363902258,128980,C1C2=CC=CC=C2C3=C1C=C(C=C3)N([C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O,Active,,,,RAT,F344/MALE,INJECTION,0; 1 UMOL IN 0.5 ML OF SOLUTION CONTAINING 0.4 ML PHOSPHATE BUFFERED SALINE/ GENTAMYCIN (PH 7) AND 0.1 ML DMSO INJECTED INTO HETEROTOPICALLY TRANSPLANTED BLADDERS 1/WK FOR 20 WK (STUDY DURATION: 50 WK),BLADDER: CARCINOMA,POSITIVE,"[WANG,CY, IMAIDA,K, ZUKOWSKI,K AND LEE,MS; LACK OF CARCINOGENICITY OF 2-AMINOFLUORENE, ITS GLUCURONIDE AND THE GLUCURONIDE OF N-HYDROXY-2- ACETYLAMINOFLUORENE IN HETEROTOPIC BLADDER OF THE RAT; CANCER LETT. 56(2):153-157, 1991]"
5752,363902302,165746,CC(C)CCCCCOC(=O)C=C,Inactive,,,,MOUSE,C3H/MALE,DERMAL,25 UL (5% V/V) IN ACETONE APPLIED TO BACK 3 D/WK FOR LIFE (STUDY DURATION: LIFE),,NEGATIVE,"[GORDON,SC, ZIMMERMAN,DD, AND GRIFFITH,FD; ACUTE TOXICITY, GENOTOXICITY, AND DERMAL CARCINOGENICITY ASSESSMENT OF ISOOCTYL ACRYLATE; J. TOXICOL. ENVIRON. HEALTH 34(3):297-308, 1991]"
5753,363902303,111811,CCC(=O)OCCCCCC(C)C,Inactive,,,,MOUSE,C3H/MALE,DERMAL,25 UL (19% W/V IN 70:30 ACETONE/HEPTANE APPLIED TO BACK 3 D/WK FOR LIFE (STUDY DURATION: LIFE),,NEGATIVE,"[GORDON,SC, ZIMMERMAN,DD, AND GRIFFITH,FD; ACUTE TOXICITY, GENOTOXICITY, AND DERMAL CARCINOGENICITY ASSESSMENT OF ISOOCTYL ACRYLATE; J. TOXICOL. ENVIRON. HEALTH 34(3):297-308, 1991]"
5754,363902324,,,Active,,,,RAT,"WISTAR/MALE, FEMALE",INTRATRACHEAL,0; 0.648; 13.656; 20 MG 1/WK FOR 10 WK (STUDY DURATION: 20.5 MO),"LUNG: SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA",POSITIVE,"[CHANG,F, WANG,L, ZHAO,Q, ZHU,Q, WU,Y, CHEN,C, SYRJANEN,S AND SYRJANEN,K; INVESTIGATION ON THE CARCINOGENIC EFFECTS OF COAL TAR PITCH IN RAT RESPIRATORY TRACT BY INTRATRACHEAL INSTILLATIONS; CARCINOGENESIS 13(2):233-239, 1992]"
5755,363902325,39468,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 12; 50; 200 MG/KG/D IN DIET FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[ROTHWELL,CE, MCGUIRE,EJ, MARTIN,RA AND DE LA IGLESIA,FA; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE BETA-ADRENOCEPTOR ANTAGONIST LEVOBUNOLOL; FUNDAM. APPL. TOXICOL. 18(3):353-359, 1992]"
5756,363902325,39468,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,Unspecified,,,,MOUSE,SWISS/FEMALE,ORAL,0; 12; 50; 200 MG/KG/D IN DIET FOR 80 WK (STUDY DURATION: 80 WK),UTERUS: LEIOMYOMA,,"[ROTHWELL,CE, MCGUIRE,EJ, MARTIN,RA AND DE LA IGLESIA,FA; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE BETA-ADRENOCEPTOR ANTAGONIST LEVOBUNOLOL; FUNDAM. APPL. TOXICOL. 18(3):353-359, 1992]"
5757,363902325,39468,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 0.5; 2; 5 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[ROTHWELL,CE, MCGUIRE,EJ, MARTIN,RA AND DE LA IGLESIA,FA; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE BETA-ADRENOCEPTOR ANTAGONIST LEVOBUNOLOL; FUNDAM. APPL. TOXICOL. 18(3):353-359, 1992]"
5758,363902325,39468,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 0.5; 2; 5 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[ROTHWELL,CE, MCGUIRE,EJ, MARTIN,RA AND DE LA IGLESIA,FA; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE BETA-ADRENOCEPTOR ANTAGONIST LEVOBUNOLOL; FUNDAM. APPL. TOXICOL. 18(3):353-359, 1992]"
5759,363902325,39468,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 5; 30; 180 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[ROTHWELL,CE, MCGUIRE,EJ, MARTIN,RA AND DE LA IGLESIA,FA; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE BETA-ADRENOCEPTOR ANTAGONIST LEVOBUNOLOL; FUNDAM. APPL. TOXICOL. 18(3):353-359, 1992]"
5760,363902325,39468,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,Active,,,,RAT,WISTAR/MALE,ORAL,0; 5; 30; 180 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),LIVER: HEPATOMA,POSITIVE,"[ROTHWELL,CE, MCGUIRE,EJ, MARTIN,RA AND DE LA IGLESIA,FA; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES WITH THE BETA-ADRENOCEPTOR ANTAGONIST LEVOBUNOLOL; FUNDAM. APPL. TOXICOL. 18(3):353-359, 1992]"
5761,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 200 MG/KG RBW 07105/SV2 SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5762,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 200 MG/KG RBW 07105/SV2 SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5763,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/FEMALE,INTRATRACHEAL,10 MG/KG RBW 07105/SV2 SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 38 WK THEN 10 MG/KG 1/4 WK FOR 44 WK (TOTAL DOSE: 390 MG/KG) STUDY DURATION: 920 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5764,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/MALE,INTRATRACHEAL,10 MG/KG RBW 07105/SV2 SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 38 WK THEN 10 MG/KG 1/4 WK FOR 44 WK (TOTAL DOSE: 390 MG/KG) (STUDY DURATION: 920 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5765,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 200 MG/KG BAYFERROX AC1500 M SUSPENDED IN PHYSIOLOGICAL SALINE 1/ WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5766,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 200 MG/KG BAYFERROX AC1500 M SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5767,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/FEMALE,INTRATRACHEAL,10 MG/KG BAYFERROX AC1500 M SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 38 WK THEN 10 MG/KG 1/4 WK FOR 44 WK (TOTAL DOSE: 390 MG/KG) (STUDY DURATION: 920 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5768,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/MALE,INTRATRACHEAL,10 MG/KG BAYFERROX AC1500 M SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 38 WK THEN 10 MG/KG 1/4 WK FOR 44 WK (TOTAL DOSE: 390 MG/KG) (STUDY DURATION: 920 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5769,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 200 MG/KG BAYFERROX 306 SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5770,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 200 MG/KG BAYFERROX 306 SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5771,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/MALE,INTRATRACHEAL,10 MG/KG BAYFERROX 306 SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG) (STUDY DURATION: 798 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5772,363902326,14789,O[Fe]=O.O[Fe]=O.[Fe],Inactive,,,,RAT,CD-1/FEMALE,INTRATRACHEAL,10 MG/KG BAYFERROX 306 SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG) (STUDY DURATION: 798 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5773,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 200 MG/KG BAYFERROX 1352 SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5774,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 200 MG/KG BAYFERROX 1352 SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5775,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/MALE,INTRATRACHEAL,10 MG/KG BAYFERROX 1352 SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG (STUDY DURATION: 798 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5776,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/FEMALE,INTRATRACHEAL,10 MG/KG BAYFERROX 1352 SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG (STUDY DURATION: 798 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5777,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 200 MG/KG BAYFERROX 130 SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5778,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 200 MG/KG BAYFERROX 130 SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5779,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/MALE,INTRATRACHEAL,10 MG/KG BAYFERROX 130 SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG) (STUDY DURATION: 798 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5780,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/FEMALE,INTRATRACHEAL,10 MG/KG BAYFERROX 130 SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG) (STUDY DURATION: 798 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5781,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 200 MG/KG BRAZILLIAN IRON ORE AC5031N SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5782,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 200 MG/KG BRAZILLIAN IRON ORE AC5031N SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5783,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/MALE,INTRATRACHEAL,10 MG/KG BRAZILLIAN IRON ORE AC5031N SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG) (STUDY DURATION: 798 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5784,363902327,14833,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],Inactive,,,,RAT,CD-1/FEMALE,INTRATRACHEAL,10 MG/KG BRAZILLIAN IRON ORE AC5031N SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG) (STUDY DURATION: 798 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5785,363902328,,,Inactive,,,,RAT,CD-1/MALE,INTRAPERITONEAL,0; 200 MG/KG SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5786,363902328,,,Inactive,,,,RAT,CD-1/FEMALE,INTRAPERITONEAL,0; 200 MG/KG SUSPENDED IN PHYSIOLOGICAL SALINE 1/8 WK (TOTAL DOSE: 600 MG/KG) (STUDY DURATION: 914 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5787,363902328,,,Inactive,,,,RAT,CD-1/FEMALE,INTRATRACHEAL,10 MG/KG SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG) (STUDY DURATION: 798 D),NEGATIVE,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5788,363902328,,,Inactive,,,,RAT,CD-1/MALE,INTRATRACHEAL,10 MG/KG SUSPENDED IN PHYSIOLOGICAL SALINE 1/2 WK FOR 26 WK THEN 20 MG/KG FOR 12 WK THEN 40 MG/KG FOR STUDY DURATION (TOTAL DOSE: 1530 MG/KG) (STUDY DURATION: 798 D),,NEGATIVE,"[STEINHOFF,D, MOHR,U AND HAHNEMANN,S; CARCINOGENESIS STUDIES WITH IRON OXIDES; EXP. PATHOL. 43(3-4):189-194, 1991]"
5789,363902332,146842,CN(C)CCN(C)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 7 MG IN 0.2 ML ETHANOL: DEIONIZED WATER (1:3) 2/WK FOR 23 WK (TOTAL DOSE 2.5 NMOL) (STUDY DURATION: LIFESPAN),ESOPHAGUS: TUMOR; NASAL MUCOSA: TUMOR,POSITIVE,"[MURAI,T, MORI,S, HOSONO,M, TAKEUCHI,Y, OHARA,T, MAKINO,S, TAKEDA,R, HAYASHI,Y AND FUKUSHIMA,S; RENAL PELVIC CARCINOMA WHICH SHOWS METASTATIC POTENTIAL TO DISTANT ORGANS, INDUCED BY N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE IN NON/SHI MICE; JPN. J. CANCER RES. 82(12):1371-1377, 1991]"
5790,363902332,146842,CN(C)CCN(C)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 14; MG/WK FOR A TOTAL DOSE OF 2.2 MMOL (STUDY DURATION: 40 WK),ESOPHAGUS: TUMOR; NASAL MUCOSA: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
5791,363902332,146842,CN(C)CCN(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 14 MG/WK FOR A TOTAL DOSE OF 2.2 MMOL (STUDY DURATION: 40 WK),ESOPHAGUS: TUMOR; NASAL MUCOSA: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY SUBSTITUTED DIALKYLNITROSAMINES GIVEN BY GAVAGE; IN VIVO 5(2):85-89, 1991]"
5792,363902332,146842,CN(C)CCN(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAGASTRIC,0; 36 MG/ML CORN OIL/ETHYL ACETATE (2:1) SOLUTION ADMINISTERED AS 0.2 ML 1/WK FOR 61 WK (STUDY DURATION: 106 WK),"NASAL CAVITY: ADENOMA, CARCINOMA; LIVER: HEPATOCELLULAR TUMOR",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND SAAVEDRA,JE; CARCINOGENESIS AND MUTAGENESIS BY N- NITROSO COMPOUNDS HAVING A BASIC CENTER; CANCER LETT. 63(2):101-107, 1992]"
5793,363902332,146842,CN(C)CCN(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,INTRAGASTRIC,0; 36 MG/ML CORN OIL/ETHYL ACETATE (2:1) SOLUTION ADMINISTERED AS 0.2 ML 1/WK FOR 61 WK (STUDY DURATION: 106 WK),"NASAL CAVITY: ADENOMA; ESOPHAGUS: CARCINOMA, PAPILLOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND SAAVEDRA,JE; CARCINOGENESIS AND MUTAGENESIS BY N- NITROSO COMPOUNDS HAVING A BASIC CENTER; CANCER LETT. 63(2):101-107, 1992]"
5794,363902332,146842,CN(C)CCN(C)N=O,Active,,,,RAT,F344/FEMALE,INTRAGASTRIC,0; 36 MG/ML CORN OIL/ETHYL ACETATE (2:1) SOLUTION ADMINISTERED AS 0.2 ML 2/WK FOR 20 WK (STUDY DURATION: 38 WK),"NASAL CAVITY: ADENOMA; ESOPHAGUS: CARCINOMA, PAPILLOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND SAAVEDRA,JE; CARCINOGENESIS AND MUTAGENESIS BY N- NITROSO COMPOUNDS HAVING A BASIC CENTER; CANCER LETT. 63(2):101-107, 1992]"
5795,363902332,146842,CN(C)CCN(C)N=O,Active,,,,RAT,F344/MALE,INTRAGASTRIC,0; 36 MG/ML CORN OIL/ETHYL ACETATE (2:1) SOLUTION ADMINISTERED AS 0.2 ML 2/WK FOR 20 WK (STUDY DURATION: 38 WK),"NASAL CAVITY: ADENOMA, CARCINOMA; ESOPHAGUS: CARCINOMA, PAPILLOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND SAAVEDRA,JE; CARCINOGENESIS AND MUTAGENESIS BY N- NITROSO COMPOUNDS HAVING A BASIC CENTER; CANCER LETT. 63(2):101-107, 1992]"
5796,363902332,146842,CN(C)CCN(C)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 144 MG/L DEIONIZED DRINKING WATER ADMINISTERED AS 80 ML/WK FOR 20 WK (STUDY DURATION: 38 WK),"NASAL CAVITY: ADENOMA; ESOPHAGUS: CARCINOMA, PAPILLOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND SAAVEDRA,JE; CARCINOGENESIS AND MUTAGENESIS BY N- NITROSO COMPOUNDS HAVING A BASIC CENTER; CANCER LETT. 63(2):101-107, 1992]"
5797,363902333,42725,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)N,Active,,,,RAT,CD-1/MALE,GAVAGE,0; 1; 3; 9 (WK 1-25); 6 (WK 26-46); 5 (WK 47-106) MG/KG IN 0.8% METHOCEL(TOTAL VOLUME 0.2-0.5 ML/RAT 2/WK FOR 105 WK (MEDIAN TOTAL DOSE 0; 1.97; 5.86; 12.53 G/KG) (STUDY DURATION: LIFESPAN),ADRENAL GLAND: TUMOR; TESTES: TUMOR,POSITIVE,"[BERGER,MR AND SCHMAEHL,D; ON THE LONG-TERM RISK OF DINALINE; CANCER LETT. 60(3):237-243, 1991]"
5798,363902333,42725,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)N,Active,,,,RAT,CD-1/FEMALE,GAVAGE,0; 1; 3; 9 (WK 1-25); 6 (WK 26-46); 5 (WK 47-106) MG/KG IN 0.8% METHOCEL (TOTAL VOLUME 0.2-0.5 ML/RAT 2/WK FOR 105 WK (MEDIAN TOTAL DOSE 0; 1.97; 5.86; 12.53; G/KG) (STUDY DURATION: LIFESPAN),ADRENAL GLAND: TUMOR; OVARIES: TUMOR; VAGINA: TUMOR,POSITIVE,"[BERGER,MR AND SCHMAEHL,D; ON THE LONG-TERM RISK OF DINALINE; CANCER LETT. 60(3):237-243, 1991]"
5799,363902334,98533,CN(CCC=O)N=O,Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 6.57 MG (0.057 MMOL) IN 0.3 ML TRIOCTANOIN 3 D/WK FOR 15 WK (STUDY DURATION: 100 WK),NASAL CAVITY: PAPILLOMA; LIVER: ADENOMA; LUNG: ADENOMA,POSITIVE,"[NISHIKAWA,A, PROKOPCZYK,B, RIVENSON,A, ZANG,E AND HOFFMANN,D; A STUDY OF BETEL QUID CARCINOGENESIS. VIII. CARCINOGENICITY OF 3-(METHYLNITROSAMINO)PROPIONALDEHYDE IN F344 RATS; CARCINOGENESIS 13(3):369-372, 1992]"
5800,363902335,9880,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,Inactive,,,,RAT,WISTAR/MALE,GAVAGE,0; 50 MG/KG IN TAP WATER 1/D FOR 21 D (STUDY DURATION: 79 WK),,NEGATIVE,"[BOSLAND,MC, PRINSEN,MK, RIVENSON,A AND WEISBURGER,JH; INDUCTION OF SKIN AND THYROID TUMORS IN MALE RATS BY N-METHYL-N-NITROSOUREA AFTER SEQUENTIAL TREATMENT WITH CYPROTERONE ACETATE AND TESTOSTERONE PROPIONATE: EFFECTS OF CASTRATION, RAT STRAIN AND TIME OF CARCINOGEN INJECTION; CARCINOGENESIS 13(4):669-674, 1992]"
5801,363902335,9880,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,Active,,,,MOUSE,C57BL/MALE,ORAL,0; 800 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[TUCKER,MJ, KALINOWSKI,AE AND ORTON,TC; CARCINOGENICITY OF CYPROTERONE ACETATE IN THE MOUSE; CARCINOGENESIS 17(7):1473-1476, 1996]"
5802,363902335,9880,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,Active,,,,MOUSE,C57BL/FEMALE,ORAL,0; 800 PPM IN DIET FOR 97 WK (STUDY DURATION: 97 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[TUCKER,MJ, KALINOWSKI,AE AND ORTON,TC; CARCINOGENICITY OF CYPROTERONE ACETATE IN THE MOUSE; CARCINOGENESIS 17(7):1473-1476, 1996]"
5803,363902380,6433499,C1=CC(=C(C=C1/C=C/C2=C(C=C(C=C2)N)S(=O)(=O)[O-])S(=O)(=O)[O-])N.[Na+].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 12500; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-412 Y92]"
5804,363902380,6433499,C1=CC(=C(C=C1/C=C/C2=C(C=C(C=C2)N)S(=O)(=O)[O-])S(=O)(=O)[O-])N.[Na+].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 12500; 25000 PPM IN DIET FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-412 Y92]"
5805,363902380,6433499,C1=CC(=C(C=C1/C=C/C2=C(C=C(C=C2)N)S(=O)(=O)[O-])S(=O)(=O)[O-])N.[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 6250; 12500 PPM IN DIET FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-412 Y92]"
5806,363902380,6433499,C1=CC(=C(C=C1/C=C/C2=C(C=C(C=C2)N)S(=O)(=O)[O-])S(=O)(=O)[O-])N.[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 6250; 12500 PPM IN DIET FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-412 Y92]"
5807,363902383,2733487,CCCC[C@@H](C)[C@H]([C@H](C[C@@H](C)C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O,Active,,,,RAT,BDIX/MALE,ORAL,0; 50 MG/KG DIET FOR 26 MO (STUDY DURATION: 26 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[GELDERBLOM,WCA, KRIEK,NPJ, MARASAS,WFO AND THIEL,PG; TOXICITY AND CARCINOGENICITY OF THE FUSARIUM MONILIFORME METABOLITE, FUMONISIN B1 IN RATS; CARCINOGENESIS 12(7):1247-1251, 1991]"
5808,363902383,2733487,CCCC[C@@H](C)[C@H]([C@H](C[C@@H](C)C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O,Inactive,,,,RAT,"BDIX/MALE,FEMALE",ORAL,0; 1; 10; 25 MG/KG DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[GELDERBLOM,WCA LEBEPE-MAZUR,S SNIJMAN,PW ABEL,S SWANEVELDER,S KRIEK,NPJ AND MARASAS,WFO; TOXICOLOGICAL EFFECTS IN RATS CHRONICALLY FED LOW DIETARY LEVELS OF FUMONISIN B1; TOXICOLOGY 161(1-2):39-51, 2001]"
5809,363902383,2733487,CCCC[C@@H](C)[C@H]([C@H](C[C@@H](C)C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O,Inactive,,,,FISH,"SHASTA RAINBOW TROUT/MALE,FEMALE",ORAL,"0; 3.2; 23; 104 PPM IN DIET FOR 4 WK, RESUMED AFTER 2 WK FOR 30 WK (STUDY DURATION: 60 WK)",,NEGATIVE,"[CARLSON,DB WILLIAMS,DE SPITSBERGEN,JM ROSS,PF BACON,CW MEREDITH,FI AND RILEY,RT; FUMONISIN B1 PROMOTES AFLATOXIN B1 AND N-METHYL-N'-NITRO-NITROSOGUANIDINE-INITIATED LIVER TUMORS IN RAINBOW TROUT; TOXICOL. APPL. PHARMACOL. 172(1):29-36, 2001]"
5810,363902383,2733487,CCCC[C@@H](C)[C@H]([C@H](C[C@@H](C)C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5; 15; 80; 150 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HOWARD,PC EPPLEY,RM STACK,ME WARBRITTON,A VOSS,KA LORENTZEN,RJ KOVACH,RM AND BUCCI,TJ; FUMONISIN B1 CARCINOGENICITY IN A TWO-YEAR FEEDING STUDY USING F344 RATS AND B6C3F1 MICE; ENVIRON. HEALTH PERSPECT. SUPPL. 109(2):277-282, 2001]"
5811,363902383,2733487,CCCC[C@@H](C)[C@H]([C@H](C[C@@H](C)C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5; 15; 50; 80 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[HOWARD,PC EPPLEY,RM STACK,ME WARBRITTON,A VOSS,KA LORENTZEN,RJ KOVACH,RM AND BUCCI,TJ; FUMONISIN B1 CARCINOGENICITY IN A TWO-YEAR FEEDING STUDY USING F344 RATS AND B6C3F1 MICE; ENVIRON. HEALTH PERSPECT. SUPPL. 109(2):277-282, 2001]"
5812,363902383,2733487,CCCC[C@@H](C)[C@H]([C@H](C[C@@H](C)C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O,Active,,,,RAT,F344/MALE,ORAL,0; 5; 15; 50; 150 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"KIDNEY: RENAL TUBULE ADENOMA, RENAL TUBULE CARCINOMA",POSITIVE,"[HOWARD,PC EPPLEY,RM STACK,ME WARBRITTON,A VOSS,KA LORENTZEN,RJ KOVACH,RM AND BUCCI,TJ; FUMONISIN B1 CARCINOGENICITY IN A TWO-YEAR FEEDING STUDY USING F344 RATS AND B6C3F1 MICE; ENVIRON. HEALTH PERSPECT. SUPPL. 109(2):277-282, 2001]"
5813,363902383,2733487,CCCC[C@@H](C)[C@H]([C@H](C[C@@H](C)C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O)OC(=O)C[C@@H](CC(=O)O)C(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 5; 15; 50; 100 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HOWARD,PC EPPLEY,RM STACK,ME WARBRITTON,A VOSS,KA LORENTZEN,RJ KOVACH,RM AND BUCCI,TJ; FUMONISIN B1 CARCINOGENICITY IN A TWO-YEAR FEEDING STUDY USING F344 RATS AND B6C3F1 MICE; ENVIRON. HEALTH PERSPECT. SUPPL. 109(2):277-282, 2001]"
5814,363902393,522325,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0.4% IN DRINKING WATER FOR 72 WK (STUDY DURATION: 83 WK),,NEGATIVE,"[IZUMI,K, SANO,N, OTSUKA,H, KINOUCHI,T AND OHNISHI,Y; TUMOR PROMOTING POTENTIAL IN MALE F344 RATS AND MUTAGENICITY IN SALMONELLA TYPHIMURIUM OF DIPYRONE; CARCINOGENESIS 12(7):1221-1225, 1991]"
5815,363902393,522325,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+],Unspecified,,,,RAT,F344/MALE,ORAL,,,,"[IZUMI,K, SANO,N, OTSUKA,H, KINOUCHI,T AND OHNISHI,Y; TUMOR PROMOTING POTENTIAL IN MALE F344 RATS AND MUTAGENICITY IN SALMONELLA TYPHIMURIUM OF DIPYRONE; CARCINOGENESIS 12(7):1221-1225, 1991]"
5816,363902434,131320,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)COS(=O)(=O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL IN 0.1 ML SESAME OIL:DMSO (9:1) 1/2 D FOR 20 DOSES (STUDY DURATION: 52 WK),INJECTION SITE: SARCOMA,POSITIVE,"[HORN,J, FLESHER,JW AND LEHNER,AF; 1-SULFOOXYMETHYLPYRENE IS AN ELECTROPHILIC MUTAGEN AND ULTIMATE CARCINOGEN OF 1-METHYL- AND 1-HYDROXYMETHYLPYRENE; BIOCHEM. BIOPHYS. RES. COMMUN. 228(1):105-109, 1996]"
5817,363902445,14794,[O-2].[O-2].[O-2].[Sb+3].[Sb+3],Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.06; 0.51; 4.50 MG/M3 6 HR/D 5 D/WK FOR 12 MO FOLLOWED BY A 12 MO OBSERVATION PERIOD (STUDY DURATION: 24 MO),,NEGATIVE,"[NEWTON,PE, BOLTE,HF, DALY,IW, PILLSBURY,BD, TERRILL,JB, DREW,RT, BEN-DYKE,R, SHELDON,AW AND RUBIN,LF; SUBCHRONIC AND CHRONIC INHALATION TOXICITY OF ANTIMONY TRIOXIDE IN THE RAT; FUNDAM. APPL. TOXICOL. 22(4):561-576, 1994]"
5818,363902445,14794,[O-2].[O-2].[O-2].[Sb+3].[Sb+3],Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.06; 0.51; 4.50 MG/M3 6 HR/D 5 D/WK FOR 12 MO FOLLOWED BY A 12 MO OBSERVATION PERIOD (STUDY DURATION: 24 MO),,NEGATIVE,"[NEWTON,PE, BOLTE,HF, DALY,IW, PILLSBURY,BD, TERRILL,JB, DREW,RT, BEN-DYKE,R, SHELDON,AW AND RUBIN,LF; SUBCHRONIC AND CHRONIC INHALATION TOXICITY OF ANTIMONY TRIOXIDE IN THE RAT; FUNDAM. APPL. TOXICOL. 22(4):561-576, 1994]"
5819,363902445,14794,[O-2].[O-2].[O-2].[Sb+3].[Sb+3],Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 45 MG/M3; 7 HR/D; 5 D/WK UP TO 52 WK (STUDY DURATION: 72 WKS),LUNG: TUMORS,POSITIVE; 27% INCIDENCE,"[GROTH,DH, STETTLER,LE, BURG,JR, BUSEY,WM, GRANT,GC AND WONG,L; CARCINOGENIC EFFECTS OF ANTIMONY TRIOXIDE AND ANTIMONY ORE CONCENTRATE IN RATS; J. TOXICOL. ENVIRON. HEALTH 18(4):607-626, 1986]"
5820,363902445,14794,[O-2].[O-2].[O-2].[Sb+3].[Sb+3],Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 45 MG/M3; 7 HR/D; 5 D/WK UP TO 52 WK (STUDY DURATION: 72 WKS),,NEGATIVE,"[GROTH,DH, STETTLER,LE, BURG,JR, BUSEY,WM, GRANT,GC AND WONG,L; CARCINOGENIC EFFECTS OF ANTIMONY TRIOXIDE AND ANTIMONY ORE CONCENTRATE IN RATS; J. TOXICOL. ENVIRON. HEALTH 18(4):607-626, 1986]"
5821,363902453,24823,[O-][O+]=O,Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.12; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-440 Y94]"
5822,363902453,24823,[O-][O+]=O,Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 125 WK (STUDY DURATION: 125 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-440 Y94]"
5823,363902453,24823,[O-][O+]=O,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.12; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-440 Y94]"
5824,363902453,24823,[O-][O+]=O,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 125 WK (STUDY DURATION: 125 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-440 Y94]"
5825,363902453,24823,[O-][O+]=O,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.12; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-440 Y94]"
5826,363902453,24823,[O-][O+]=O,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 130 WK (STUDY DURATION: 130 WK),LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-440 Y94]"
5827,363902453,24823,[O-][O+]=O,Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.12; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 20 MO (STUDY DURATION: 20 MO),,NEGATIVE,"[STOCKSTILL,BL, CHANG,LY, MENACHE,MG, MELLICK,PW, MERCER,RR AND CRAPO,JD; BRONCHIOLARIZED METAPLASIA AND INTERSTITIAL FIBROSIS IN RAT LUNGS CHRONICALLY EXPOSED TO HIGH AMBIENT LEVELS OF OZONE; TOXICOL. APPL. PHARMACOL. 134(2): 251-263, 1995]"
5828,363902453,24823,[O-][O+]=O,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.12; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 20 MO (STUDY DURATION: 20 MO),,NEGATIVE,"[STOCKSTILL,BL, CHANG,LY, MENACHE,MG, MELLICK,PW, MERCER,RR AND CRAPO,JD; BRONCHIOLARIZED METAPLASIA AND INTERSTITIAL FIBROSIS IN RAT LUNGS CHRONICALLY EXPOSED TO HIGH AMBIENT LEVELS OF OZONE; TOXICOL. APPL. PHARMACOL. 134(2): 251-263, 1995]"
5829,363902453,24823,[O-][O+]=O,Unspecified,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.12; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-440 Y94]"
5830,363902453,24823,[O-][O+]=O,Unspecified,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.5; 1 PPM 6 HR/D 5 D/WK FOR 130 WK (STUDY DURATION: 130 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-440 Y94]"
5831,363902456,14986,CC1=C(C=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)O,Active,,,,MOUSE,6HF1/MALE,ORAL,0; 5% IN BASAL DIET FOR 104 WK (STUDY DURATION: 104 WK),LIVER: TUMOR,POSITIVE,"[NITTA,Y, KAMIYA,K, TANIMOTO,M, KAGIMOTO,O, NIWA,O AND YOKORO,K; EFFECTS OF ADMINISTRATION OF NATURAL VITAMIN E ON SPONTANEOUS HEPATOCARCINOGENESIS AND N- NITROSODIETHYLAMINE INITIATED TUMORS IN MICE; J. TOXICOL. PATHOL. 4(1):55-61, 1991]"
5832,363902460,5430,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.05; 0.1; 0.2; 0.4% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[FUJII,T, MIKURIYA,H AND SASAKI,M; CHRONIC ORAL TOXICITY AND CARCINOGENICITY STUDY OF THIABENDAZOLE IN RATS; FOOD CHEM. TOXICOL. 29(11):771-775, 1991]"
5833,363902460,5430,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.05; 0.1; 0.2; 0.4% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[FUJII,T, MIKURIYA,H AND SASAKI,M; CHRONIC ORAL TOXICITY AND CARCINOGENICITY STUDY OF THIABENDAZOLE IN RATS; FOOD CHEM. TOXICOL. 29(11):771-775, 1991]"
5834,363902460,5430,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,Inactive,,,,MOUSE,ICR/MALE,ORAL,0; 0.8; 1.2; 1.6% IN DIET FOR 44 WK (STUDY DURATION: 44 WK),,NEGATIVE,"[TADA,Y FUJITANI,T YANO,N YUZAWA,K NAGASAWA,A AND YONEYAMA,M; THIABENDAZOLE INDUCES URINARY TRACT TOXICITY IN MALE ICR MICE; TOXICOLOGY 162(1):1-10, 2001]"
5835,363902460,5430,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 0.031; 0.125; 0.5% IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[TADA,Y FUJITANI,T YANO,N YUZAWA,K NAGASAWA,A AOKI,N OGATA,A  AND YONEYAMA,M; CHRONIC TOXICITY OF THIABENDAZOLE (TBZ) IN CD-1 MICE;  TOXICOLOGY 169(3): 163-176, 2001]"
5836,363902460,5430,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.031; 0.125; 0.5% IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[TADA,Y FUJITANI,T YANO,N YUZAWA,K NAGASAWA,A AOKI,N OGATA,A  AND YONEYAMA,M; CHRONIC TOXICITY OF THIABENDAZOLE (TBZ) IN CD-1 MICE;  TOXICOLOGY 169(3): 163-176, 2001]"
5837,363902461,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3; 6% IN DIET FOR 104 WK (MEAN INTAKE 0; 56.9; 102.2 G/MOUSE) (STUDY DURATION: 104 WK),,NEGATIVE,"[MORI,H, IWATA,H, TANAKA,T, MORISHITA,Y, MORI,Y, KOJIMA,T AND OKUMURA,A; CARCINOGENICITY STUDY OF COCHINEAL IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 29(9): 585-588, 1991]"
5838,363902461,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3; 6% IN DIET FOR 104 WK (MEAN INTAKE 0; 57; 104.4 G/MOUSE) (STUDY DURATION: 104 WK),,NEGATIVE,"[MORI,H, IWATA,H, TANAKA,T, MORISHITA,Y, MORI,Y, KOJIMA,T AND OKUMURA,A; CARCINOGENICITY STUDY OF COCHINEAL IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 29(9): 585-588, 1991]"
5839,363902461,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3; 6% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MORI,H AND TANAKA,T; CARCINOGENICITY TEST OF COCHINEAL IN B6C3F1 MICE; FOODS FOOD INGREDIENTS J. 157:42-45, 1993]"
5840,363902461,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3; 6% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MORI,H AND TANAKA,T; CARCINOGENICITY TEST OF COCHINEAL IN B6C3F1 MICE; FOODS FOOD INGREDIENTS J. 157:42-45, 1993]"
5841,363902462,55784,CCOCCC1=C(N=C(N2C1=NC=N2)N)C3=CC=CC=C3,Active,,,,RAT,STRAIN-CD/MALE,ORAL,0; 50; 150; 450 MG/KG/D IN DIET FOR 97 WK (STUDY DURATION: 105 WK),LIVER: ADENOMA OR CARCINOMA; THYROID GLAND: ADENOMA OR CARCINOMA,POSITIVE,"[GAD,SC, BURTON,E, CHENGELIS,CP, LEVIN,S, PIPER,CE, OSHIRO,Y AND SEMLER,D; PROMOTIONAL ACTIVITIES OF THE NONGENOTOXIC CARCINOGEN BEMITRADINE(SC-33643); J. APPL. TOXICOL. 12(3):157-164, 1992]"
5842,363902462,55784,CCOCCC1=C(N=C(N2C1=NC=N2)N)C3=CC=CC=C3,Active,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 50; 150; 450 MG/KG/D IN DIET FOR 97 WK (STUDY DURATION: 105 WK),LIVER: ADENOMA OR CARCINOMA; MAMMARY GLAND: ADENOMA OR CARCINOMA; THYROID GLAND: ADENOMA,POSITIVE,"[GAD,SC, BURTON,E, CHENGELIS,CP, LEVIN,S, PIPER,CE, OSHIRO,Y AND SEMLER,D; PROMOTIONAL ACTIVITIES OF THE NONGENOTOXIC CARCINOGEN BEMITRADINE(SC-33643); J. APPL. TOXICOL. 12(3):157-164, 1992]"
5843,363902490,5677,C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 3; 10; 30 MG/KG/D IN DISTILLED WATER FOR 24 MO (STUDY DURATION: 110 WK),,NEGATIVE,"[NONOYAMA,T, IMAI,R, TENSHA,S, NAGAI,H, SAKURA,Y AND WADA,T; ONCOGENICITY STUDY OF AO-128 IN RATS; YAKURI TO CHIRYO 19(11):4415-4425, 1991]"
5844,363902490,5677,C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 3; 10; 30 MG/KG/D IN DISTILLED WATER FOR 24 MO (STUDY DURATION: 110 WK),,NEGATIVE,"[NONOYAMA,T, IMAI,R, TENSHA,S, NAGAI,H, SAKURA,Y AND WADA,T; ONCOGENICITY STUDY OF AO-128 IN RATS; YAKURI TO CHIRYO 19(11):4415-4425, 1991]"
5845,363902490,5677,C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO,Inactive,,,,MOUSE,CD-1/MALE,GAVAGE,0; 15; 50; 150 MG/KG/D IN DISTILLED WATER (STUDY DURATION: 105 WK),,NEGATIVE,"[ATKINSON,JE, DALY,IW, SAULOG,TM, FUKUDA,R, TANAKAMARU,Z AND NONOYAMA,T; ONCOGENICITY OF AO-128 IN MICE; YAKURI TO CHIRYO 19(11):4427-4438, 1991]"
5846,363902490,5677,C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO,Inactive,,,,MOUSE,CD-1/FEMALE,GAVAGE,0; 15; 50; 150 MG/KG/D IN DISTILLED WATER (STUDY DURATION: 105 WK),,NEGATIVE,"[ATKINSON,JE, DALY,IW, SAULOG,TM, FUKUDA,R, TANAKAMARU,Z AND NONOYAMA,T; ONCOGENICITY OF AO-128 IN MICE; YAKURI TO CHIRYO 19(11):4427-4438, 1991]"
5847,363902494,84482,C1=CC=C(C=C1)C[N+]2=NOC(=C2CC(=O)N)[O-],Inactive,,,,MOUSE,DDD/MALE,ORAL,0; 0.02% IN DRINKING WATER FOR 12 MO (STUDY DURATION: 12 MO),,NEGATIVE,"[OHTSUBO,K; HEPATOTOXIC AND HEPATOCARCINOGENIC EFFECTS OF A SYDNONE DERIVATIVE, 3-BENZYLSYDNONE-4-ACETAMIDE, ON MICE: DIFFERENCES IN SUSCEPTIBILITY BY STRAIN AND SEX; J. TOXICOL. PATHOL. 4(1):45-54, 1991]"
5848,363902494,84482,C1=CC=C(C=C1)C[N+]2=NOC(=C2CC(=O)N)[O-],Active,,,,MOUSE,DDD/FEMALE,ORAL,0; 0.002; 0.01; 0.02% IN DRINKING WATER FOR 12 MO (STUDY DURATION: 12 MO),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[OHTSUBO,K; HEPATOTOXIC AND HEPATOCARCINOGENIC EFFECTS OF A SYDNONE DERIVATIVE, 3-BENZYLSYDNONE-4-ACETAMIDE, ON MICE: DIFFERENCES IN SUSCEPTIBILITY BY STRAIN AND SEX; J. TOXICOL. PATHOL. 4(1):45-54, 1991]"
5849,363902494,84482,C1=CC=C(C=C1)C[N+]2=NOC(=C2CC(=O)N)[O-],Active,,,,RAT,DONRYU/MALE,ORAL,0; 60 PPM IN DRINKING WATER FOR 41 WK (STUDY DURATION: 104 WK),LIVER: TUMOR,POSITIVE,"[OHTSUBO,K, HATANAKA,Y, UENO,I, ENOMOTO,M AND SAITO,M; EFFECTS OF DOSAGE AND SEX ON THE LIVER INJURY AND INCIDENCE OF HEPATOCELLULAR TUMORS INDUCED BY 3-BENZYLSYDNONE-4-ACETAMIDE IN RATS; J. TOXICOL. PATHOL. 7(1):35-41, 1994]"
5850,363902494,84482,C1=CC=C(C=C1)C[N+]2=NOC(=C2CC(=O)N)[O-],Active,,,,RAT,DONRYU/MALE,ORAL,0; 60; 200 PPM IN DIET FOR 15 WK (STUDY DURATION: 104 WK),LIVER: TUMOR,POSITIVE,"[OHTSUBO,K, HATANAKA,Y, UENO,I, ENOMOTO,M AND SAITO,M; EFFECTS OF DOSAGE AND SEX ON THE LIVER INJURY AND INCIDENCE OF HEPATOCELLULAR TUMORS INDUCED BY 3-BENZYLSYDNONE-4-ACETAMIDE IN RATS; J. TOXICOL. PATHOL. 7(1):35-41, 1994]"
5851,363902494,84482,C1=CC=C(C=C1)C[N+]2=NOC(=C2CC(=O)N)[O-],Inactive,,,,RAT,DONRYU/MALE,ORAL,0; 20 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[OHTSUBO,K, HATANAKA,Y, UENO,I, ENOMOTO,M AND SAITO,M; EFFECTS OF DOSAGE AND SEX ON THE LIVER INJURY AND INCIDENCE OF HEPATOCELLULAR TUMORS INDUCED BY 3-BENZYLSYDNONE-4-ACETAMIDE IN RATS; J. TOXICOL. PATHOL. 7(1):35-41, 1994]"
5852,363902494,84482,C1=CC=C(C=C1)C[N+]2=NOC(=C2CC(=O)N)[O-],Active,,,,RAT,DONRYU/FEMALE,ORAL,0; 60; 200; 400 PPM IN DRINKING WATER FOR 41 WK (STUDY DURATION: 104 WK),LIVER: TUMOR,POSITIVE,"[OHTSUBO,K, HATANAKA,Y, UENO,I, ENOMOTO,M AND SAITO,M; EFFECTS OF DOSAGE AND SEX ON THE LIVER INJURY AND INCIDENCE OF HEPATOCELLULAR TUMORS INDUCED BY 3-BENZYLSYDNONE-4-ACETAMIDE IN RATS; J. TOXICOL. PATHOL. 7(1):35-41, 1994]"
5853,363902529,7265,C1=CC(=C(C=C1Cl)N)O,Active,,,,Rat,F344/DuCrlCrlj / Female,Oral,0; 1280; 3200; 8000 ppm in diet for 2 yr study duration,Forestomach: squamous cell papilloma/carcinoma,Positive,"[YAMAZAKI,K, SUZUKI,M, KANO,H, UMEDA,Y, MATSUMOTO,M,   ASAKURA,M, NAGANO,K, ARITO,H, FUKUSHIMA,S; ORAL   CARCINOGENICITY AND TOXICITY OF 2-AMINO-4-CHLOROPHENOL IN   RATS. J. OCCUP. HEALTH 51(3): 249-260, 2009]"
5854,363902529,7265,C1=CC(=C(C=C1Cl)N)O,Active,,,,Rat,F344/DuCrlCrlj / Male,Oral,0; 1280; 3200; 8000 ppm in diet for 2 yr study duration,Forestomach: squamous cell papilloma/carcinoma. Urinary bladder: papilloma/carcinoma,Positive,"[YAMAZAKI,K, SUZUKI,M, KANO,H, UMEDA,Y, MATSUMOTO,M,   ASAKURA,M, NAGANO,K, ARITO,H, FUKUSHIMA,S; ORAL   CARCINOGENICITY AND TOXICITY OF 2-AMINO-4-CHLOROPHENOL IN   RATS. J. OCCUP. HEALTH 51(3): 249-260, 2009]"
5855,363902551,75492608,CNC.C1=CC(=C(C=C1Cl)Cl)OCC(=O)O.C(=O)(C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,DERMAL,0; 100; 200 MG/KG BW IN ETHANOL 5/WK FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA OR HEPATOBLASTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-479 Y01][NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF COCONUT OIL ACID DIETHANOLAMINE CONDENSATE (CAS NO. 68603-42-9) IN F344/N RATS AND BSC3F1 MICE (DERMAL STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 479, 1-3, 5-13, 15-55, 57-61, 63-89, 91-145, 147-177, 179, 203, 205-207, 209-226, 2001, ]"
5856,363902551,75492608,CNC.C1=CC(=C(C=C1Cl)Cl)OCC(=O)O.C(=O)(C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 100; 200 MG/KG BW IN ETHANOL 5/WK FOR 104 WK (STUDY DURATION: 104 WK),"KIDNEY: RENAL TUBULE ADENOMA, RENAL TUBULE ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA OR HEPATOBLASTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-479 Y01][NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF COCONUT OIL ACID DIETHANOLAMINE CONDENSATE (CAS NO. 68603-42-9) IN F344/N RATS AND BSC3F1 MICE (DERMAL STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 479, 1-3, 5-13, 15-55, 57-61, 63-89, 91-145, 147-177, 179, 203, 205-207, 209-226, 2001, ]"
5857,363902551,75492608,CNC.C1=CC(=C(C=C1Cl)Cl)OCC(=O)O.C(=O)(C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,Inactive,,,,RAT,F344/MALE,DERMAL,0; 50; 100 MG/KG BW IN ETHANOL 5/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-479 Y01][NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF COCONUT OIL ACID DIETHANOLAMINE CONDENSATE (CAS NO. 68603-42-9) IN F344/N RATS AND BSC3F1 MICE (DERMAL STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 479, 1-3, 5-13, 15-55, 57-61, 63-89, 91-145, 147-177, 179, 203, 205-207, 209-226, 2001, ]"
5858,363902551,75492608,CNC.C1=CC(=C(C=C1Cl)Cl)OCC(=O)O.C(=O)(C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,Unspecified,,,,RAT,F344/FEMALE,DERMAL,0; 50; 100 MG/KG BW IN ETHANOL 5/WK FOR 104 WK (STUDY DURATION: 104 WK),KIDNEY: RENAL TUBULE ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-479 Y01][NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF COCONUT OIL ACID DIETHANOLAMINE CONDENSATE (CAS NO. 68603-42-9) IN F344/N RATS AND BSC3F1 MICE (DERMAL STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 479, 1-3, 5-13, 15-55, 57-61, 63-89, 91-145, 147-177, 179, 203, 205-207, 209-226, 2001, ]"
5859,363902557,7290,C(C(CCl)O)O,Active,,,,Rat,Sprague-Dawley/Female,Oral,0; 25; 100; 400 ppm in drinking water for 2 yr (Study duration: 104 wk),Kidney: Renal tubule adenoma or carcinoma,Positive,"[CHO,W, HAN,BS, NAM,KT, PARK,K, CHOI,M, KIM,SH, JEONG,J,  JANG,DD; CARCINOGENICITY STUDY OF  3-MONOCHLOROPROPANE-1,2-DIOL IN SPRAGUE-DAWLEY RATS. FOOD  CHEM. TOXICOL. 46(9): 3172-3177, 2008]"
5860,363902557,7290,C(C(CCl)O)O,Active,,,,Rat,Sprague-Dawley/Male,Oral,0; 25; 100; 400 ppm in drinking water for 2 yr (Study duration: 100 wk),Kidney: Renal tubule adenoma or carcinoma; Testes: Leydig cell tumor,Positive,"[CHO,W, HAN,BS, NAM,KT, PARK,K, CHOI,M, KIM,SH, JEONG,J,  JANG,DD; CARCINOGENICITY STUDY OF  3-MONOCHLOROPROPANE-1,2-DIOL IN SPRAGUE-DAWLEY RATS. FOOD  CHEM. TOXICOL. 46(9): 3172-3177, 2008]"
5861,363902573,31374,CC(=O)N(C)C,Inactive,,,,RAT,CRL:CD BR/MALE,INHALATION,0; 25; 100; 350 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MALLEY,LA, SLONE,TW, MAKOVEC,GT, ELLIOTT,GS AND KENNEDY,GL; CHRONIC TOXICITY/ONCOGENICITY OF DIMETHYLACETAMIDE IN RATS AND MICE FOLLOWING INHALATION EXPOSURE; FUNDAM. APPL. TOXICOL. 28(1):80-93, 1995]"
5862,363902573,31374,CC(=O)N(C)C,Inactive,,,,RAT,CRL:CD BR/FEMALE,INHALATION,0; 25; 100; 350 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MALLEY,LA, SLONE,TW, MAKOVEC,GT, ELLIOTT,GS AND KENNEDY,GL; CHRONIC TOXICITY/ONCOGENICITY OF DIMETHYLACETAMIDE IN RATS AND MICE FOLLOWING INHALATION EXPOSURE; FUNDAM. APPL. TOXICOL. 28(1):80-93, 1995]"
5863,363902573,31374,CC(=O)N(C)C,Inactive,,,,MOUSE,CRL:CD-1 (ICR)BR/MALE,INHALATION,0; 25; 100; 350 PPM 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[MALLEY,LA, SLONE,TW, MAKOVEC,GT, ELLIOTT,GS AND KENNEDY,GL; CHRONIC TOXICITY/ONCOGENICITY OF DIMETHYLACETAMIDE IN RATS AND MICE FOLLOWING INHALATION EXPOSURE; FUNDAM. APPL. TOXICOL. 28(1):80-93, 1995]"
5864,363902573,31374,CC(=O)N(C)C,Inactive,,,,MOUSE,CRL:CD-1 (ICR)BR/FEMALE,INHALATION,0; 25; 100; 350 PPM 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[MALLEY,LA, SLONE,TW, MAKOVEC,GT, ELLIOTT,GS AND KENNEDY,GL; CHRONIC TOXICITY/ONCOGENICITY OF DIMETHYLACETAMIDE IN RATS AND MICE FOLLOWING INHALATION EXPOSURE; FUNDAM. APPL. TOXICOL. 28(1):80-93, 1995]"
5865,363902612,8430,CCCCCCCCCCCC(=O)N(CCO)CCO,Inactive,,,,RAT,F344/N/MALE,DERMAL,0; 50; 100 MG/KG BW IN ETHANOL FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-480  Y99]"
5866,363902612,8430,CCCCCCCCCCCC(=O)N(CCO)CCO,Inactive,,,,RAT,F344/N/FEMALE,DERMAL,0; 50; 100 MG/KG BW IN ETHANOL FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-480  Y99]"
5867,363902612,8430,CCCCCCCCCCCC(=O)N(CCO)CCO,Inactive,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 100; 200 MG/KG BW IN ETHANOL FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-480  Y99]"
5868,363902612,8430,CCCCCCCCCCCC(=O)N(CCO)CCO,Unspecified,,,,MOUSE,B6C3F1/FEMALE,DERMAL,0; 100; 200 MG/KG BW IN ETHANOL FOR 105 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA, HEPATOCELLULAR CARCINOMA OR HEPATOBLASTOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA OR HEPATOBLASTOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-480 Y99]"
5869,363902644,31070,CCOP(=O)(NC(C)C)OC1=CC(=C(C=C1)SC)C,Inactive,,,,Rat,Strain not specified/Male (50/Group),Oral,"0; 2; 10; 50 ppm Nemacure (89% fenamiphos) in diet for 2 yr, study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENAMIPHOS February 8, 2000)]"
5870,363902644,31070,CCOP(=O)(NC(C)C)OC1=CC(=C(C=C1)SC)C,Inactive,,,,Rat,Strain not specified/Female (50/Group),Oral,"0; 2; 10; 50 ppm Nemacure (89% fenamiphos) in diet for 2 yr, study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENAMIPHOS February 8, 2000)]"
5871,363902644,31070,CCOP(=O)(NC(C)C)OC1=CC(=C(C=C1)SC)C,Inactive,,,,Mouse,CD-1/Male (50/Group),Oral,"0; 2; 10; 50 ppm of 89.2-90.5% fenamiphos in diet for 20 mo, study duration 20 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENAMIPHOS February 8, 2000)]"
5872,363902644,31070,CCOP(=O)(NC(C)C)OC1=CC(=C(C=C1)SC)C,Inactive,,,,Mouse,CD-1/Female (50/Group),Oral,"0; 2; 10; 50 ppm of 89.2-90.5% fenamiphos in diet for 20 mo, study duration 20 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENAMIPHOS February 8, 2000)]"
5873,363902662,5281744,C/C=C\1/CC(=C)[C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(CO)O,Active,,,,RAT,F344/MALE,GAVAGE,0; 1 MG/KG IN 0.1 M PHOSPHATE BUFFER 5 D/WK FOR 72 WK (STUDY DURATION: 72 WK),"LIVER: HEMANGIOSARCOMA, HEPATOCELLULAR ADENOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA",POSITIVE,"[CHAN,PC HASEMAN,JK PREJEAN,JD AND NYSKA,A; TOXICITY AND CARCINOGENICITY OF RIDDELLIINE IN RATS AND MICE; TOXICOL. LETT. 144(3): 295-311, 2003]"
5874,363902662,5281744,C/C=C\1/CC(=C)[C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(CO)O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 0.01; 0.033; 0.1; 0.33 MG/KG IN 0.1 M PHOSPHATE BUFFER 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[CHAN,PC HASEMAN,JK PREJEAN,JD AND NYSKA,A; TOXICITY AND CARCINOGENICITY OF RIDDELLIINE IN RATS AND MICE; TOXICOL. LETT. 144(3): 295-311, 2003]"
5875,363902662,5281744,C/C=C\1/CC(=C)[C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(CO)O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 1 MG/KG IN 0.1 M PHOSPHATE BUFFER 5 D/WK FOR 97 WK (STUDY DURATION: 97 WK),"LIVER: HEMANGIOSARCOMA, HEPATOCELLULAR ADENOMA, ADENOMA OR CARCINOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA",POSITIVE,"[CHAN,PC HASEMAN,JK PREJEAN,JD AND NYSKA,A; TOXICITY AND CARCINOGENICITY OF RIDDELLIINE IN RATS AND MICE; TOXICOL. LETT. 144(3): 295-311, 2003]"
5876,363902662,5281744,C/C=C\1/CC(=C)[C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(CO)O,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 3 MG/KG IN 0.1 M PHOSPHATE BUFFER 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"LUNG (ALVEOLAR/BRONCHIOLAR): ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[CHAN,PC HASEMAN,JK PREJEAN,JD AND NYSKA,A; TOXICITY AND CARCINOGENICITY OF RIDDELLIINE IN RATS AND MICE; TOXICOL. LETT. 144(3): 295-311, 2003]"
5877,363902662,5281744,C/C=C\1/CC(=C)[C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(CO)O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 0.1; 0.3; 1;  3 MG/KG IN 0.1 M PHOSPHATE BUFFER 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),LIVER: HEMANGIOSARCOMA,POSITIVE,"[CHAN,PC HASEMAN,JK PREJEAN,JD AND NYSKA,A; TOXICITY AND CARCINOGENICITY OF RIDDELLIINE IN RATS AND MICE; TOXICOL. LETT. 144(3): 295-311, 2003]"
5878,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Active,,,,RAT,F344/MALE,GAVAGE,0; 84; 168; 337.5 MG/KG BW IN CORN OIL 5 D/WK FOR 105 WK OR 337.5 MG/KG 5/D WK FOR 6 MO (STOP EXPOSURE GROUP)(STUDY DURATION: 105 WK),URINARY BLADDER: TRANSITIONAL EPITHELIAL PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-457 Y97]"
5879,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 675; 1350; 2700 MG/KG BW IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-457 Y97]"
5880,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Active,,,,RAT,F344/MALE,GAVAGE,"0; 337.5 MG/KG IN CORN OIL 5 D/WK FOR 103 WK, CONTROL AND DOSED GROUPS FED AD LIBITUM (STUDY DURATION: 103 WK)",URINARY BLADDER: PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
5881,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 2700 MG/KG IN CORN OIL 5 D/WK FOR 156 WK, CONTROL GROUP DIET WAS RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUPS (STUDY DURATION: 156 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
5882,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 2700 MG/KG IN CORN OIL 5 D/WK FOR 104 WK, CONTROL GROUP DIET WAS RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUPS (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
5883,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 2700 MG/KG IN CORN OIL 5 D/WK FOR 103 WK, CONTROL GROUP WAS WEIGHT-MATCHED TO DOSED GROUP (STUDY DURATION: 103 WK)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
5884,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 2700 MG/KG IN CORN OIL 5 D/WK FOR 103 WK, CONTROL AND DOSED GROUPS WERE FED AD LIBITUM (STUDY DURATION: 103 WK)",LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
5885,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Inactive,,,,RAT,F344/MALE,GAVAGE,"0; 337.5 MG/KG IN CORN OIL 5 D/WK FOR 130 WK, CONTROL GROUP DIET WAS RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUPS (STUDY DURATION: 130 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
5886,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Inactive,,,,RAT,F344/MALE,GAVAGE,"0; 337.5 MG/KG IN CORN OIL 5 D/WK FOR 104 WK, CONTROL GROUP DIET WAS RESTRICTED TO LIMIT WEIGHT TO 85% OF AD LIBITUM-FED GROUPS (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
5887,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Active,,,,RAT,F344/MALE,GAVAGE,"0; 337.5 MG/KG IN CORN OIL 5 D/WK FOR 103 WK, CONTROL GROUP WAS WEIGHT-MATCHED TO DOSED GROUP (STUDY DURATION: 103 WK)",URINARY BLADDER: PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
5888,363902663,5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 675; 1350; 2700 MG/KG BW IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-457 Y97]"
5889,363902676,16078,CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 12.5; 25; 50 MG/KG BW IN CORN OIL FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-446 Y96]"
5890,363902676,16078,CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 12.5; 25; 50 MG/KG BW IN CORN OIL FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-446 Y96]"
5891,363902676,16078,CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 125; 250; 500 MG/KG BW IN CORN OIL FOR 104-105 WK (STUDY DURATION: 104-105 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-446 Y96]"
5892,363902676,16078,CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 125; 250; 500 MG/KG BW IN CORN OIL FOR 105-106 WK (STUDY DURATION: 105-106 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-446 Y96]"
5893,363902679,2153,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 7.5; 25; 75 MG/KG BW IN CORN OIL 5 D/WK FOR 729 D (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-473 Y98]"
5894,363902679,2153,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 7.5; 25; 75 MG/KG BW IN CORN OIL 5 D/WK FOR 729 D (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-473 Y98]"
5895,363902679,2153,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 15; 50; 150 MG/KG BW IN CORN OIL 5 D/WK FOR 726 D (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-473 Y98]"
5896,363902679,2153,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 7.5; 25; 75 MG/KG BW IN CORN OIL 5 D/WK FOR 726 D (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-473 Y98]"
5897,363902698,8478,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],Inactive,,,,RAT,F344/MALE,DERMAL,0; 0.15; 0.5; 1.5 MG/KG BW IN ACETONE 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-438 Y95]"
5898,363902698,8478,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],Inactive,,,,RAT,F344/FEMALE,DERMAL,0; 0.15; 0.5; 1.5 MG/KG BW IN ACETONE 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-438 Y95]"
5899,363902698,8478,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],Inactive,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 0.15; 0.5; 1.5 MG/KG BW IN ACETONE 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-438 Y95]"
5900,363902698,8478,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],Inactive,,,,MOUSE,B6C3F1/FEMALE,DERMAL,0; 0.15; 0.5; 1.5 MG/KG BW IN ACETONE 5 D/WK FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-438 Y95]"
5901,363902705,6386,CC(C)(C)O,Active,,,,RAT,F344/MALE,ORAL,0; 1.25; 2.5; 5 MG/ML IN DRINKING WATER FOR 103 WK (STUDY DURATION: 103 WK),KIDNEY (RENAL TUBULE): ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-436 Y95]"
5902,363902705,6386,CC(C)(C)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5; 10 MG/ML IN DRINKING WATER FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-436 Y95]"
5903,363902705,6386,CC(C)(C)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 5; 10; 20 MG/ML IN DRINKING WATER FOR 103 WK (STUDY DURATION: 103 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-436 Y95]"
5904,363902705,6386,CC(C)(C)O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 5; 10; 20 MG/ML IN DRINKING WATER FOR 103 WK (STUDY DURATION: 103 WK),THYROID GLAND: FOLLICULAR CELL ADENOMA OR CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-436 Y95]"
5905,363902716,31370,CC(CCl)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 150; 325; 650 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-477 Y98]"
5906,363902716,31370,CC(CCl)O,Inactive,,,,RAT,F344/FEMALE,ORAL,10; 150; 325; 650 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-477 Y98]"
5907,363902716,31370,CC(CCl)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 250; 500; 1000 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-477 Y98]"
5908,363902716,31370,CC(CCl)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 250; 500; 1000 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-477 Y98]"
5909,363902745,8981,CC1=CC(NC2=CC=CC=C12)(C)C,Active,,,,RAT,F344/MALE,DERMAL,0; 36; 60; 100 MG/KG BW IN ACETONE 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),KIDNEY(RENAL TUBULE): ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-456 Y97]"
5910,363902745,8981,CC1=CC(NC2=CC=CC=C12)(C)C,Inactive,,,,RAT,F344/FEMALE,DERMAL,0; 36; 60; 100 MG/KG BW IN ACETONE 5 D/WK FOR 104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-456 Y97]"
5911,363902745,8981,CC1=CC(NC2=CC=CC=C12)(C)C,Inactive,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 3.6; 6; 10 MG/KG BW IN ACETONE 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-456 Y97]"
5912,363902745,8981,CC1=CC(NC2=CC=CC=C12)(C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,DERMAL,0; 3.6; 6; 10 MG/KG BW IN ACETONE 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-456 Y97]"
5913,363902759,,,Unspecified,,,,Rat,F344/N/Male,Inhalation,0; 100; 200; 400 ppm 6 hr and 12 min/d 5 d/wk for up to 105 wk,"Kidney: Renal tubule carcinoma (0/50, 0/49, 0/50, 2/49); Renal tubule adenoma or carcinoma (combined) (0/50, 0/49, 2/50, 3/49) Brain: Oligodendroglioma or astrocytoma (0/49, 1/50, 3/50, 0/50)",Equivocal; Test material was 80% pure,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-534 Y06]"
5914,363902759,,,Inactive,,,,Rat,F344/N/Female,Inhalation,0; 100; 200; 400 ppm 6 hr and 12 min/d 5 d/wk for up to 105 wk,,Negative; Test material was 80% pure,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-534 Y06]"
5915,363902759,,,Inactive,,,,Mouse,B6C3F1/Male,Inhalation,0; 10; 30; 100 ppm 6 hr and 12 min/d 5 d/wk for up to 105 wk,,Negative; Test material was 80% pure,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-534 Y06]"
5916,363902759,,,Unspecified,,,,Mouse,B6C3F1/Female,Inhalation,0; 10; 30; 100 ppm 6 hr and 12 min/d 5 d/wk for up to 105 wk,"Lung: Alveolar/bronchiolar adenoma or carcinoma (6/50, 12/50, 8/50, 13/49)",Equivocal; Test material was 80% pure,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-534 Y06]"
5917,363902761,11224,CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C.C(CC(=O)O)C(=O)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 190; 375; 750 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA; THYROID: FOLLICULAR CELL ADENOMA,POSITIVE,"[JACKSON,CD AND SHELDON,W; TWO-YEAR TOXICITY STUDY OF DOXYLAMINE SUCCINATE IN B6C3F1 MICE; J. AM. COLL. TOXICOL. 12(4):311-321, 1993]"
5918,363902761,11224,CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C.C(CC(=O)O)C(=O)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 190; 375; 750 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA; THYROID: FOLLICULAR CELL ADENOMA,POSITIVE,"[JACKSON,CD AND SHELDON,W; TWO-YEAR TOXICITY STUDY OF DOXYLAMINE SUCCINATE IN B6C3F1 MICE; J. AM. COLL. TOXICOL. 12(4):311-321, 1993]"
5919,363902761,11224,CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C.C(CC(=O)O)C(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 500; 1000; 2000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[JACKSON,CD AND BLACKWELL,BN; 2-YEAR TOXICITY STUDY OF DOXYLAMINE SUCCINATE IN THE FISCHER 344 RAT; J. AM. COLL. TOXICOL. 12(1):1-11, 1993]"
5920,363902770,6466,C[C@@]12[C@H](C=C[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@](C4)(C(=C)C5)O)C(=O)O)OC2=O)O,Active,,,,MOUSE,SWISS/MALE,GAVAGE,0; 3 PPM IN 0.3 ML PHYSIOLOGICAL SALINE 2/WK FOR 22 MO (STUDY DURATION: 22 MO),SKIN: SEBACEOUS ADENOMA; LUNG: TUMOR,POSITIVE,"[EL-MOFTY,MM, SAKR,SA, RIZK,AM AND MOUSSA,EA; CARCINOGENIC EFFECT OF GIBBERELLIN A3 IN SWISS ALBINO MICE; NUTR. CANCER 21(2):183-190, 1994]"
5921,363902770,6466,C[C@@]12[C@H](C=C[C@@]3([C@@H]1[C@@H]([C@]45[C@H]3CC[C@](C4)(C(=C)C5)O)C(=O)O)OC2=O)O,Active,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 3 PPM IN 0.3 ML PHYSIOLOGICAL SALINE 2/WK FOR 22 MO (STUDY DURATION: 22 MO),BREAST: ADENOCARCINOMA; SKIN: SEBACEOUS ADENOMA,POSITIVE,"[EL-MOFTY,MM, SAKR,SA, RIZK,AM AND MOUSSA,EA; CARCINOGENIC EFFECT OF GIBBERELLIN A3 IN SWISS ALBINO MICE; NUTR. CANCER 21(2):183-190, 1994]"
5922,363902788,24085,Cl[Hg]Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 2.5; 5 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103-104 WK (STUDY DURATION: 104 WK),"THYROID GLAND: FOLLICULAR CELL CARCINOMA, FOLLICULAR CELL CARCINOMA OR ADENOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-408 Y93]"
5923,363902788,24085,Cl[Hg]Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 5; 10 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103-104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-408 Y93]"
5924,363902788,24085,Cl[Hg]Cl,Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 5 PPM (HG) IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
5925,363902788,24085,Cl[Hg]Cl,Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 5 PPM (HG) IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
5926,363902788,24085,Cl[Hg]Cl,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 2.5; 5 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103-104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-408 Y93]"
5927,363902788,24085,Cl[Hg]Cl,Unspecified,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 5; 10 MG/KG IN DEIONIZED WATER 5 D/WK FOR 103-104 WK (STUDY DURATION: 104 WK),"KIDNEY (RENAL TUBLE): ADENOMA, ADENOCARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-408 Y93]"
5928,363902791,31368,CC(=C)C#N,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 3; 10; 30 MG/KG 5 D/WK FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF METHACRYLONITRILE (CAS NO. 126-98-7) IN F344/N  RATS AND B6C3F1 MICE (GAVAGE STUDIES) ; NATL. TOXICOL. PROGRAM TECH. REP. SER. 497:1-231, 2001]"
5929,363902791,31368,CC(=C)C#N,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 3; 10; 30 MG/KG 5 D/WK FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF METHACRYLONITRILE (CAS NO. 126-98-7) IN F344/N  RATS AND B6C3F1 MICE (GAVAGE STUDIES) ; NATL. TOXICOL. PROGRAM TECH. REP. SER. 497:1-231, 2001]"
5930,363902791,31368,CC(=C)C#N,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 1.5; 3; 6 MG/KG 5 D/WK FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF METHACRYLONITRILE (CAS NO. 126-98-7) IN F344/N  RATS AND B6C3F1 MICE (GAVAGE STUDIES) ; NATL. TOXICOL. PROGRAM TECH. REP. SER. 497:1-231, 2001]"
5931,363902791,31368,CC(=C)C#N,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 1.5; 3; 6 MG/KG 5 D/WK FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF METHACRYLONITRILE (CAS NO. 126-98-7) IN F344/N  RATS AND B6C3F1 MICE (GAVAGE STUDIES) ; NATL. TOXICOL. PROGRAM TECH. REP. SER. 497:1-231, 2001]"
5932,363902843,23668192,CC1=C(C=C(C=C1)S(=O)(=O)[O-])C.[Na+],Inactive,,,,RAT,F344/MALE,DERMAL,0; 60; 120; 240 MG/KG IN 50% ETHANOL 5D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-464 Y98]"
5933,363902843,23668192,CC1=C(C=C(C=C1)S(=O)(=O)[O-])C.[Na+],Inactive,,,,RAT,F344/FEMALE,DERMAL,0; 60; 120; 240 MG/KG IN 50% ETHANOL 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-464 Y98]"
5934,363902843,23668192,CC1=C(C=C(C=C1)S(=O)(=O)[O-])C.[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 182; 364; 727 MG/KG IN 50% ETHANOL 5D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-464 Y98]"
5935,363902843,23668192,CC1=C(C=C(C=C1)S(=O)(=O)[O-])C.[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,DERMAL,0; 182; 364; 727 MG/KG IN 50% ETHANOL 5D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-464 Y98]"
5936,363902846,22979,COC1=C(C=C(C=C1)[N+](=O)[O-])N=NC2=C(C(=CC3=CC=CC=C32)C(=O)NC4=CC(=CC=C4)[N+](=O)[O-])O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 10000; 25000; 50000 PPM IN DIET FOR 720 D (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-411 Y92]"
5937,363902846,22979,COC1=C(C=C(C=C1)[N+](=O)[O-])N=NC2=C(C(=CC3=CC=CC=C32)C(=O)NC4=CC(=CC=C4)[N+](=O)[O-])O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 10000; 25000; 50000 PPM IN DIET FOR 720 D (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-411 Y92]"
5938,363902846,22979,COC1=C(C=C(C=C1)[N+](=O)[O-])N=NC2=C(C(=CC3=CC=CC=C32)C(=O)NC4=CC(=CC=C4)[N+](=O)[O-])O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10000; 25000; 50000 PPM IN DIET FOR 720 D (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-411 Y92]"
5939,363902846,22979,COC1=C(C=C(C=C1)[N+](=O)[O-])N=NC2=C(C(=CC3=CC=CC=C32)C(=O)NC4=CC(=CC=C4)[N+](=O)[O-])O,Unspecified,,,,RAT,F344/MALE,ORAL,0; 10000; 25000; 50000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),KIDNEY: RENAL TUBULE ADENOMA OR CARCINOMA; MULTIPLE ORGANS: MONONUCLEAR CELL LEUKEMIA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-411 Y92]"
5940,363902848,,,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 50; 100 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 24 MO),THYROID GLAND: ADENOMA OR CARCINOMA,POSITIVE,"[MAYES,BA, MCCONNELL,EE, NEAL,BH, BRUNNER,MJ, HAMILTON,SB, SULLIVAN,TM, PETERS,AC, RYAN,MJ, TOFT,JD, SINGER,AW, BROWN,JF,JR, MENTON,RG AND MOORE,JA; COMPARATIVE CARCINOGENICITY IN SPRAGUE-DAWLEY RATS OF THE POLYCHLORINATED BIPHENYL MIXTURES AROCLORS 1016, 1242, 1254, AND 1260; TOXICOL. SCI. 41(1):62-76, 1998]"
5941,363902848,,,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 50; 100 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 24 MO),LIVER: TUMOR,POSITIVE,"[MAYES,BA, MCCONNELL,EE, NEAL,BH, BRUNNER,MJ, HAMILTON,SB, SULLIVAN,TM, PETERS,AC, RYAN,MJ, TOFT,JD, SINGER,AW, BROWN,JF,JR, MENTON,RG AND MOORE,JA; COMPARATIVE CARCINOGENICITY IN SPRAGUE-DAWLEY RATS OF THE POLYCHLORINATED BIPHENYL MIXTURES AROCLORS 1016, 1242, 1254, AND 1260; TOXICOL. SCI. 41(1):62-76, 1998]"
5942,363902849,670,C(C(=O)CO)O,Inactive,,,,MOUSE,SWISS/MALE,DERMAL,0; 5%; 40% AQUEOUS SOLUTION APPLIED 1/WK FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[AKIN,FJ AND MARLOWE,E; NONCARCINOGENICITY OF DIHYDROXYACETONE BY SKIN PAINTING; J. ENVIRON. PATHOL., TOXICOL. ONCOL. 5(4-5):349-351, 1984]"
5943,363902849,670,C(C(=O)CO)O,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 5; 40% AQUEOUS SOLUTION APPLIED 1/WK FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[AKIN,FJ AND MARLOWE,E; NONCARCINOGENICITY OF DIHYDROXYACETONE BY SKIN PAINTING; J. ENVIRON. PATHOL., TOXICOL. ONCOL. 5(4-5):349-351, 1984]"
5944,363902850,11689,C1=CC=C2C(=C1)C(=O)OC23C4=C(C(=C(C=C4)O)Br)OC5=C3C=CC(=C5Br)O,Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 136.5 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5945,363902850,11689,C1=CC=C2C(=C1)C(=O)OC23C4=C(C(=C(C=C4)O)Br)OC5=C3C=CC(=C5Br)O,Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 136.5 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5946,363902851,92311,C1=CC=C2C(=C1)C(=O)OC23C4=C(C(=C(C=C4)O)I)OC5=C3C=CC(=C5I)O,Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 132.6 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5947,363902851,92311,C1=CC=C2C(=C1)C(=O)OC23C4=C(C(=C(C=C4)O)I)OC5=C3C=CC(=C5I)O,Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 132.6 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5948,363902852,18981,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-])O,Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 143.7 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5949,363902852,18981,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-])O,Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 143.7 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5950,363902853,135423095,CC1=CC(=C(C=C1)N=NC2=C(C(=CC3=CC=CC=C32)C(=O)O)[O-])S(=O)(=O)[O-].[Ca+2],Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 130.6 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5951,363902853,135423095,CC1=CC(=C(C=C1)N=NC2=C(C(=CC3=CC=CC=C32)C(=O)O)[O-])S(=O)(=O)[O-].[Ca+2],Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 130.6 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5952,363902854,27020,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)Br)O)Br)Br)O)Br,Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 140.1 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5953,363902854,27020,C1=CC=C2C(=C1)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)Br)O)Br)Br)O)Br,Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 140.1 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5954,363902855,83511,C1=C2C(=C(C(=C1Br)O)Br)OC3=C(C(=C(C=C3C24C5=C(C(=C(C(=C5Cl)Cl)Cl)Cl)C(=O)O4)Br)O)Br,Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 128.5 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5955,363902855,83511,C1=C2C(=C(C(=C1Br)O)Br)OC3=C(C(=C(C=C3C24C5=C(C(=C(C(=C5Cl)Cl)Cl)Cl)C(=O)O4)Br)O)Br,Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 128.5 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5956,363902856,135565537,C1=CC=C(C=C1)N=NC2=C(C(=CC3=CC=CC=C32)C(=O)O)[O-].C1=CC=C(C=C1)N=NC2=C(C(=CC3=CC=CC=C32)C(=O)O)[O-].[Ca+2],Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 122.2 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5957,363902856,135565537,C1=CC=C(C=C1)N=NC2=C(C(=CC3=CC=CC=C32)C(=O)O)[O-].C1=CC=C(C=C1)N=NC2=C(C(=CC3=CC=CC=C32)C(=O)O)[O-].[Ca+2],Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 122.2 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5958,363902857,17778,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C=C3)[N+](=O)[O-])Cl)O,Inactive,,,,MOUSE,ICR/MALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 117.1 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5959,363902857,17778,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C=C3)[N+](=O)[O-])Cl)O,Inactive,,,,MOUSE,ICR/FEMALE,DERMAL,0; 1 MG IN 0.1 ML DISTILLED WATER 2/WK FOR A MEAN TOTAL DOSE OF 117.1 MG (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE WITH 14 FD & C AND D & C COLORS: FD & C BLUE NO. 1, RED NO. 3, AND YELLOW NO. 5, D & C RED NO. 7, RED NO. 9, RED NO. 10, RED NO. 19, RED NO. 21, RED NO. 27, RED NO.31, RED NO. 36, ORANGE NO. 5, ORANGE NO. 10, AND ORANGE NO. 17; J. TOXICOL. CUTANEOUS. OCUL. TOXICOL. 3(4):357-370, 1984]"
5960,363902867,7308,CC1=CC(=C(C=C1SC2=CC(=C(C=C2C)O)C(C)(C)C)C(C)(C)C)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 500; 1000; 2500 PPM IN DIET FOR 2 YR (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-435 Y94]"
5961,363902867,7308,CC1=CC(=C(C=C1SC2=CC(=C(C=C2C)O)C(C)(C)C)C(C)(C)C)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 500; 1000; 2500 PPM IN DIET FOR 2 YR (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-435 Y94]"
5962,363902867,7308,CC1=CC(=C(C=C1SC2=CC(=C(C=C2C)O)C(C)(C)C)C(C)(C)C)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 250; 500; 1000 PPM IN DIET FOR 2 YR (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-435 Y94]"
5963,363902867,7308,CC1=CC(=C(C=C1SC2=CC(=C(C=C2C)O)C(C)(C)C)C(C)(C)C)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 250; 500; 1000 PPM IN DIET FOR 2 YR (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-435 Y94]"
5964,363902872,304599,CC1=C[C@@H]2[C@]([C@@H](C1=O)O)([C@]3([C@@H]([C@H]([C@H]([C@@]34CO4)O2)O)OC(=O)C)C)CO,Inactive,,,,MOUSE,BDF1/FEMALE,GAVAGE,0; 3.5 MG/KG 1/4 WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NAKAMURA,K, IZUMIYAMA,N AND OHTSUBO,K; HISTOPATHOLOGICAL STUDY ON THE CHRONIC EFFECT OF FUSARENONE X IN MICE; MAIKOTOKISHIN 21:38-40, 1985]"
5965,363902872,304599,CC1=C[C@@H]2[C@]([C@@H](C1=O)O)([C@]3([C@@H]([C@H]([C@H]([C@@]34CO4)O2)O)OC(=O)C)C)CO,Inactive,,,,MOUSE,BDF1/FEMALE,GAVAGE,0; 3.5 MG/KG 1/8 WK FOR 1 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NAKAMURA,K, IZUMIYAMA,N AND OHTSUBO,K; HISTOPATHOLOGICAL STUDY ON THE CHRONIC EFFECT OF FUSARENONE X IN MICE; MAIKOTOKISHIN 21:38-40, 1985]"
5966,363902873,11050,C1=CC2=C3C(=C1)C=CC(=O)C3=CC=C2,Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 0.84; 2.1; 4.2 MG (TOTAL DOSES) ADMINISTERED TO NEWBORN MICE AS 1/7 ON DAY 1, 2/7 ON DAY 8 AND 4/7 ON DAY 15 (STUDY DURATION: 6 MO)",,NEGATIVE,"[WANG,JS AND BUSBY,WF,JR; BACTERIAL AND HUMAN CELL MUTAGENICITY AND MOUSE LUNG TUMORIGENICITY OF THE OXYGENATED POLYNUCLEAR AROMATIC HYDROCARBON PHENALENONE; FUNDAM. APPL. TOXICOL. 33(2):212-219, 1996]"
5967,363902873,11050,C1=CC2=C3C(=C1)C=CC(=O)C3=CC=C2,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 0.84; 2.1; 4.2 MG (TOTAL DOSES) ADMINISTERED TO NEWBORN MICE AS 1/7 ON DAY 1, 2/7 ON DAY 8 AND 4/7 ON DAY 15 (STUDY DURATION: 6 MO)",LUNG: TUMOR,POSITIVE,"[WANG,JS AND BUSBY,WF,JR; BACTERIAL AND HUMAN CELL MUTAGENICITY AND MOUSE LUNG TUMORIGENICITY OF THE OXYGENATED POLYNUCLEAR AROMATIC HYDROCARBON PHENALENONE; FUNDAM. APPL. TOXICOL. 33(2):212-219, 1996]"
5968,363902899,62535,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC(=C4)[N+](=O)[O-],Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED IN 3 SUBDOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 8 AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 32 WK)",,NEGATIVE,"[EL-BAYOUMY,K, DESAI,D, UPADHYAYA,P, AMIN,S AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF NITROCHRYSENE ISOMERS IN NEWBORN MICE; CARCINOGENESIS 13(12):2271-2275, 1992]"
5969,363902899,62535,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC(=C4)[N+](=O)[O-],Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED IN 3 SUBDOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 8 AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 32 WK)",,NEGATIVE,"[EL-BAYOUMY,K, DESAI,D, UPADHYAYA,P, AMIN,S AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF NITROCHRYSENE ISOMERS IN NEWBORN MICE; CARCINOGENESIS 13(12):2271-2275, 1992]"
5970,363902903,154510,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=CC(=CC(=C54)C=C3)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
5971,363903005,12333,CCC(CC)[N+](=O)[O-],Active,,,,RAT,F344/MALE,GAVAGE,0; 2 MMOL/KG BW 1/WK FOR 12 WK THEN 1 MMOL/KG FOR 38 WK (STUDY DURATION: 83 WK),LIVER: CARCINOMA,POSITIVE,"[FIALA,ES, SODUM,RS, HUSSAIN,NS, RIVENSON,A AND DOLAN,L; SECONDARY NITROALKANES: INDUCTION OF DNA REPAIR IN RAT HEPATOCYTES, ACTIVATION BY ARYL SULFOTRANSFERASE AND HEPATOCARCINOGENICITY OF 2-NITROBUTANE AND 3-NITROPENTANE IN MALE F344 RATS; TOXICOLOGY 99(1-2):89-97, 1995]"
5972,363903074,637564,C/C=C/C=C/C=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 22.5; 45; 90 MG/KG IN CORN OIL 5 D/WK FOR DURATION OF STUDY (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-509 Y02]"
5973,363903074,637564,C/C=C/C=C/C=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 22.5; 45; 90 MG/KG IN CORN OIL 5 D/WK FOR DURATION OF STUDY (STUDY DURATION: 105 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-509 Y02]"
5974,363903074,637564,C/C=C/C=C/C=O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 30; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR DURATION OF STUDY (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-509 Y02]"
5975,363903074,637564,C/C=C/C=C/C=O,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 30; 60; 120 MG/KG IN CORN OIL 5 D/WK FOR DURATION OF STUDY (STUDY DURATION: 105 WK),"FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-509 Y02]"
5976,363903118,10964,C(C=O)C=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 1500 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 15 MO OF AGE (STUDY DURATION: 15 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5977,363903118,10964,C(C=O)C=O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1500 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 15 MO OF AGE (STUDY DURATION: 15 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5978,363903118,10964,C(C=O)C=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 3000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 12 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5979,363903118,10964,C(C=O)C=O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 3000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 12 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
5980,363903167,21307,CC1=C(SCCO1)C(=O)NC2=CC=CC=C2,Inactive,,,,Rat,Crl:CD SD/Male (50 per group),Oral,0; 20; 200; 400 ppm in diet for 102 wk,,Negative (Purity 97.7%; Study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CARBOXIN (MAY 2, 1994)]"
5981,363903167,21307,CC1=C(SCCO1)C(=O)NC2=CC=CC=C2,Inactive,,,,Rat,Crl:CD SD/Female (50 per group),Oral,0; 20; 300; 600 ppm in diet for 102 wk,,Negative (Purity 97.7%; study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CARBOXIN (MAY 2, 1994)]"
5982,363903167,21307,CC1=C(SCCO1)C(=O)NC2=CC=CC=C2,Inactive,,,,Mouse,Charles River/Female (50 per group in experimental animals; 75 controls),Oral,"0; 50; 2,500; 5,000 ppm in diet for 19 mo",,Negative (Purity >99%; study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CARBOXIN (MAY 2, 1994)]"
5983,363903167,21307,CC1=C(SCCO1)C(=O)NC2=CC=CC=C2,Active,,,,Mouse,Charles River/Male (50 per group in experimental animals; 75 controls),Oral,"0; 50; 2,500; 5,000 ppm in diet for 19 mo",LUNG; Pulmonary adenomas and alveolar-bronchiolar adenomas (34% in high dose group vs 17% in controls; significant),Positive (Purity >99%; study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CARBOXIN (MAY 2, 1994)]"
5984,363903168,2374,CC(C)(C)C1=CC(=C(C=C1O)C(C)(C)C)O,Active,,,,HAMSTER,SYRIAN/MALE,ORAL,1% IN DIET FOR 24 WK (STUDY DURATION: 24 WK),FORESTOMACH: PAPILLOMA,POSITIVE,"[LAM,LKT AND GARG,P; TUMORIGENICITY OF DI-TERT-BUTYL-SUBSTITUTED HYDROQUINONE AND HYDROXYANISOLES IN THE FORESTOMACH OF SYRIAN GOLDEN HAMSTERS; CARCINOGENESIS 12(7):1341-1344, 1991]"
5985,363903169,10269,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)OC,Inactive,,,,HAMSTER,SYRIAN/MALE,ORAL,1% IN DIET FOR 24 WK (STUDY DURATION: 24 WK),,NEGATIVE,"[LAM,LKT AND GARG,P; TUMORIGENICITY OF DI-TERT-BUTYL-SUBSTITUTED HYDROQUINONE AND HYDROXYANISOLES IN THE FORESTOMACH OF SYRIAN GOLDEN HAMSTERS; CARCINOGENESIS 12(7):1341-1344, 1991]"
5986,363903170,74812,CC(C)(C)C1=CC(=C(C=C1OC)C(C)(C)C)O,Inactive,,,,HAMSTER,SYRIAN/MALE,ORAL,1% IN DIET FOR 24 WK (STUDY DURATION: 24 WK),,NEGATIVE,"[LAM,LKT AND GARG,P; TUMORIGENICITY OF DI-TERT-BUTYL-SUBSTITUTED HYDROQUINONE AND HYDROXYANISOLES IN THE FORESTOMACH OF SYRIAN GOLDEN HAMSTERS; CARCINOGENESIS 12(7):1341-1344, 1991]"
5987,363903171,93376,CCC(C)OC(C(=O)C1=CC=CC=C1)OC(C)CC,Inactive,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 22.4 MG UNDILUTED 3/WK FOR LIFESPAN (STUDY DURATION: LIFESPAN),,NEGATIVE,"[DEPASS,LR, FOWLER,EH AND WEIL,CS; DERMAL ONCOGENICITY BIOASSAYS OF DI-SEC- BUTOXY ACETOPHENONE AND DIETHOXYACETOPHENONE; J. TOXICOL. ENVIRON. HEALTH. 13(4-6):757-761, 1984]"
5988,363903172,22555,CCOC(C(=O)C1=CC=CC=C1)OCC,Inactive,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 25 MG UNDILUTED 3/WK FOR LIFESPAN (STUDY DURATION: LIFESPAN),,NEGATIVE,"[DEPASS,LR, FOWLER,EH AND WEIL,CS; DERMAL ONCOGENICITY BIOASSAYS OF DI-SEC- BUTOXY ACETOPHENONE AND DIETHOXYACETOPHENONE; J. TOXICOL. ENVIRON. HEALTH. 13(4-6):757-761, 1984]"
5989,363903172,22555,CCOC(C(=O)C1=CC=CC=C1)OCC,Inactive,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 11.3 MG AS A 50% DILUTION IN ACETONE 3/WK FOR LIFESPAN (STUDY DURATION: LIFESPAN),,NEGATIVE,"[DEPASS,LR, FOWLER,EH AND WEIL,CS; DERMAL ONCOGENICITY BIOASSAYS OF DI-SEC- BUTOXY ACETOPHENONE AND DIETHOXYACETOPHENONE; J. TOXICOL. ENVIRON. HEALTH. 13(4-6):757-761, 1984]"
5990,363903173,6107,CN1CCC=C(C1)C(=O)OC.Cl,Active,,,,MOUSE,SWISS/MALE,GAVAGE,0; 1 MG/D 5 D/WK FOR LIFE (STUDY DURATION: LIFE),LIVER: HEMANGIOMA; LUNG: ADENOCARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA,POSITIVE,"[BHIDE,SV, GOTHOSKAR,SV AND SHIVAPURKAR,NM; ARECOLINE TUMORIGENICITY IN SWISS STRAIN MICE ON NORMAL AND VITAMIN B DEFICIENT DIET; J. CANCER RES. CLIN. ONCOL. 107(3):169-171, 1984]"
5991,363903173,6107,CN1CCC=C(C1)C(=O)OC.Cl,Inactive,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 1 MG/D 5 D/WK FOR LIFE (STUDY DURATION: LIFE),,NEGATIVE,"[BHIDE,SV, GOTHOSKAR,SV AND SHIVAPURKAR,NM; ARECOLINE TUMORIGENICITY IN SWISS STRAIN MICE ON NORMAL AND VITAMIN B DEFICIENT DIET; J. CANCER RES. CLIN. ONCOL. 107(3):169-171, 1984]"
5992,363903174,3301,C(CN)N,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 25 UL OF A 1% DEIONIZED WATER SOLUTION 3/WK FOR LIFESPAN (STUDY DURATION: LIFESPAN),,NEGATIVE,"[DEPASS,LR, FOWLER,EH AND YANG,RSH; DERMAL ONCOGENICITY STUDIES ON ETHYLENEDIAMINE IN MALE C3H MICE; FUNDAM. APPL. TOXICOL. 4(4):641-645, 1984]"
5993,363903180,5281004,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 5 UG/ML IN DRINKING WATER FOR AN AVERAGE DAILY DOSE OF 46.6 UG/KG FOR 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[RYRFELDT,A, SQUIRE,RA AND EKMAN,L; LIVER TUMORS IN MALE RATS FOLLOWING TREATMENT WITH GLUCOCORTICOSTEROIDS; TOXICOL. PATHOL. 20(1):115-117, 1992]"
5994,363903181,6436,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 1.5 UG/ML IN DRINKING WATER FOR AN AVERAGE DAILY DOSE OF 12.7 UG/KG DURING WK10-20 THEN 4.8 UG/KG DURING WK 21-104 (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[RYRFELDT,A, SQUIRE,RA AND EKMAN,L; LIVER TUMORS IN MALE RATS FOLLOWING TREATMENT WITH GLUCOCORTICOSTEROIDS; TOXICOL. PATHOL. 20(1):115-117, 1992]"
5995,363903184,76962233,C[C@@H]1CCC[C@@H](N1CCC[C@@](C2=CC=CC=C2)(C3=CC=CC=N3)O)C.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 10; 25; 50 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MACALLUM,GE, ROTHWELL,CE AND SMITH,GS; CARCINOGENICITY STUDIES OF PIRMENOL IN MICE AND RATS; DRUG INVEST. 3(4):278-289, 1991]"
5996,363903184,76962233,C[C@@H]1CCC[C@@H](N1CCC[C@@](C2=CC=CC=C2)(C3=CC=CC=N3)O)C.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10; 25; 50 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MACALLUM,GE, ROTHWELL,CE AND SMITH,GS; CARCINOGENICITY STUDIES OF PIRMENOL IN MICE AND RATS; DRUG INVEST. 3(4):278-289, 1991]"
5997,363903184,76962233,C[C@@H]1CCC[C@@H](N1CCC[C@@](C2=CC=CC=C2)(C3=CC=CC=N3)O)C.Cl,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 10; 25; 50 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MACALLUM,GE, ROTHWELL,CE AND SMITH,GS; CARCINOGENICITY STUDIES OF PIRMENOL IN MICE AND RATS; DRUG INVEST. 3(4):278-289, 1991]"
5998,363903184,76962233,C[C@@H]1CCC[C@@H](N1CCC[C@@](C2=CC=CC=C2)(C3=CC=CC=N3)O)C.Cl,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 10; 25; 50 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MACALLUM,GE, ROTHWELL,CE AND SMITH,GS; CARCINOGENICITY STUDIES OF PIRMENOL IN MICE AND RATS; DRUG INVEST. 3(4):278-289, 1991]"
5999,363903188,7521,C=CC1=CC=CC=N1,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN 0.1 ML OLIVE OIL 3/WK FOR 20 DOSES (TOTAL DOSE: 200 UMOL) (STUDY DURATION: 27 WK),,NEGATIVE,"[BRUNNEMANN,KD, RIVENSON,A, CHENG,SC, SAA,V AND HOFFMANN,D; A STUDY OF TOBACCO CARCINOGENESIS XLVII. BIOASSAYS OF VINYLPYRIDINES FOR GENOTOXICITY AND FOR TUMORIGENICITY IN A/J MICE; CANCER LETT. 65(2):107-113, 1992]"
6000,363903189,14272,C=CC1=CN=CC=C1,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN 0.1 ML OLIVE OIL 3/WK FOR 20 DOSES (TOTAL DOSE: 200 UMOL) (STUDY DURATION: 27 WK),,NEGATIVE,"[BRUNNEMANN,KD, RIVENSON,A, CHENG,SC, SAA,V AND HOFFMANN,D; A STUDY OF TOBACCO CARCINOGENESIS XLVII. BIOASSAYS OF VINYLPYRIDINES FOR GENOTOXICITY AND FOR TUMORIGENICITY IN A/J MICE; CANCER LETT. 65(2):107-113, 1992]"
6001,363903190,7502,C=CC1=CC=NC=C1,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 10 UMOL IN 0.1 ML OLIVE OIL 3/WK FOR 20 DOSES (TOTAL DOSE: 200 UMOL) (STUDY DURATION: 27 WK),,NEGATIVE,"[BRUNNEMANN,KD, RIVENSON,A, CHENG,SC, SAA,V AND HOFFMANN,D; A STUDY OF TOBACCO CARCINOGENESIS XLVII. BIOASSAYS OF VINYLPYRIDINES FOR GENOTOXICITY AND FOR TUMORIGENICITY IN A/J MICE; CANCER LETT. 65(2):107-113, 1992]"
6002,363903221,16166309,[O-]P(=O)=O.[O-]P(=O)=O.[O-]P(=O)=O.[Na+].[Ca+2],Inactive,,,,RAT,F344/MALE,INHALATION,0; 1; 5; 25 MG/M3 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[NAIR,RS, JOHANNSEN,FR, BOLTE,HF, NEWTON,PE AND RINEHART,WE; TOXICITY OF CALCIUM SODIUM METAPHOSPHATE FIBER. II. CHRONIC INHALATION AND ONCOGENICITY STUDY; FUNDAM. APPL. TOXICOL. 19(1):79-90, 1992]"
6003,363903221,16166309,[O-]P(=O)=O.[O-]P(=O)=O.[O-]P(=O)=O.[Na+].[Ca+2],Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 1; 5; 25 MG/M3 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[NAIR,RS, JOHANNSEN,FR, BOLTE,HF, NEWTON,PE AND RINEHART,WE; TOXICITY OF CALCIUM SODIUM METAPHOSPHATE FIBER. II. CHRONIC INHALATION AND ONCOGENICITY STUDY; FUNDAM. APPL. TOXICOL. 19(1):79-90, 1992]"
6004,363903222,50026,C1=CC=C2C(=C1)C3=C4C(=C2COS(=O)(=O)O)C=CC5=CC=CC(=C54)C=C3,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.0025 UMOL/G ONCE AT 12 DAYS OF AGE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,EC AND MILLER,JA; THE STRONG HEPATOCARCINOGENICITY OF THE ELECTROPHILIC AND MUTAGENIC METABOLITE 6-SULFOOXYMETHYLBENZO[A]PYRENE AND ITS FORMATION OF BENZYLIC DNA ADDUCTS IN THE LIVERS OF INFANT MALE B6C3F1 MICE; BIOCHEM. BIOPHYS. RES. COMMUN. 172(1):85-91, 1990]"
6005,363903222,50026,C1=CC=C2C(=C1)C3=C4C(=C2COS(=O)(=O)O)C=CC5=CC=CC(=C54)C=C3,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL 3/WK FOR 20 DOSES (STUDY DURATION: 52 WK),INJECTION SITE: SARCOMA,POSITIVE,"[FLESHER,JW, HORN,J AND LEHNER,AF; 6-SULFOOXYMETHYLBENZO[A]PYRENE IS AN ULTIMATE ELECTROPHILIC AND CARCINOGENIC FORM OF THE INTERMEDIARY METABOLITE 6-HYDROXYMETHYLBENZO[A]PYRENE; BIOCHEM. BIOPHYS. RES. COMMUN. 234(3):554-558, 1997]"
6006,363903223,39965,CN1C(=NC(=O)N(C1=O)C2CCCCC2)N(C)C,Inactive,,,,RAT,CRL-CD/MALE,ORAL,0; 200; 1000; 2500 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KENNEDY,GL,JR AND KAPLAN,AM; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES OF HEXAZINONE; FUNDAM. APPL. TOXICOL. 4(6):960-971,1984]"
6007,363903223,39965,CN1C(=NC(=O)N(C1=O)C2CCCCC2)N(C)C,Inactive,,,,RAT,CRL-CD/FEMALE,ORAL,0; 200; 1000; 2500 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KENNEDY,GL,JR AND KAPLAN,AM; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES OF HEXAZINONE; FUNDAM. APPL. TOXICOL. 4(6):960-971,1984]"
6008,363903223,39965,CN1C(=NC(=O)N(C1=O)C2CCCCC2)N(C)C,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 200; 2500; 10000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KENNEDY,GL,JR AND KAPLAN,AM; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES OF HEXAZINONE; FUNDAM. APPL. TOXICOL. 4(6):960-971,1984]"
6009,363903223,39965,CN1C(=NC(=O)N(C1=O)C2CCCCC2)N(C)C,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 200; 2500; 10000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[KENNEDY,GL,JR AND KAPLAN,AM; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES OF HEXAZINONE; FUNDAM. APPL. TOXICOL. 4(6):960-971,1984]"
6010,363903223,39965,CN1C(=NC(=O)N(C1=O)C2CCCCC2)N(C)C,Inactive,,,,DOG,BEAGLE/MALE,ORAL,"0; 200; 1000 PPM IN DIET FOR 90 D OR 5000 PPM FOR 1 WK, THEN 2500 PPM FOR 4 D IN WK 2 THEN 3750 PPM FOR 3 D FOLLOWED BY 5000 PPM FOR DURATION OF STUDY (STUDY DURATION: 97 D)",,NEGATIVE,"[KENNEDY,GL,JR AND KAPLAN,AM; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES OF HEXAZINONE; FUNDAM. APPL. TOXICOL. 4(6):960-971,1984]"
6011,363903223,39965,CN1C(=NC(=O)N(C1=O)C2CCCCC2)N(C)C,Inactive,,,,DOG,BEAGLE/FEMALE,ORAL,"0; 200; 1000 PPM IN DIET FOR 90 D OR 5000 PPM FOR 1 WK, THEN 2500 PPM FOR 4 D IN WK 2 THEN 3750 PPM FOR 3 D FOLLOWED BY 5000 PPM FOR DURATION OF STUDY (STUDY DURATION: 97 D)",,NEGATIVE,"[KENNEDY,GL,JR AND KAPLAN,AM; CHRONIC TOXICITY, REPRODUCTIVE, AND TERATOGENIC STUDIES OF HEXAZINONE; FUNDAM. APPL. TOXICOL. 4(6):960-971,1984]"
6012,363903224,83273,CNC(=O)N(C)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 2.4 MG 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),"BRAIN: TUMOR, KIDNEY: TUMOR",POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
6013,363903224,83273,CNC(=O)N(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 20; 40 UMOL/WK IN CORN OIL/ETHYL ACETATE (2: 1) FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),NERVOUS SYSTEM: TUMOR; TESTIS: MESOTHELIOMA,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6014,363903224,83273,CNC(=O)N(C)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 20; 40 UMOL/WK IN CORN OIL/ETHYL ACETATE (2: 1) FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6015,363903224,83273,CNC(=O)N(C)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 20; 40 UMOL/WK IN DRINKING WATER FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),TESTIS: MESOTHELIOMA; NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6016,363903224,83273,CNC(=O)N(C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 20; 40 UMOL/WK IN DRINKING WATER FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),UTERUS: TUMOR; THYROID: FOLLICULAR CELL TUMOR; NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6017,363903225,96620,CCNC(=O)N(CC)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 3 MG 2/WK FOR 30 WK (STUDY DURATION: LIFETIME),MAMMARY GLAND: TUMOR; LUNG: TUMOR; ZYMBAL GLAND: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
6018,363903225,96620,CCNC(=O)N(CC)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 20; 40 UMOL/WK IN CORN OIL/ETHYL ACETATE (2: 1) FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),LUNG: TUMOR; TESTIS: MESOTHELIOMA; NERVOUS SYSTEM: TUMOR; ZYMBAL GLAND: TUMOR; COLON: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6019,363903225,96620,CCNC(=O)N(CC)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 20; 40 UMOL/WK IN CORN OIL/ETHYL ACETATE (2: 1) FOR 30 WK (LOW DOSE) OR 22.5 WK (HIGH DOSE) FOR TOTAL DOSES OF 0; 0.6; 0.9 MMOL (STUDY DURATION: LIFETIME),MAMMARY GLAND: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6020,363903225,96620,CCNC(=O)N(CC)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 20; 40 UMOL/WK IN DRINKING WATER FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),LUNG: TUMOR; TESTIS: MESOTHELIOMA; COLON: TUMOR; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6021,363903225,96620,CCNC(=O)N(CC)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 20; 40 UMOL/WK IN DRINKING WATER FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),LUNG: TUMOR; MAMMARY GLAND: TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6022,363903226,148247,C1COC(=O)N1N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICULAR,0; 2.4 MG 2/WK FOR 8 WK (STUDY DURATION: LIFETIME),BLADDER: TUMOR,POSITIVE,"[LIJINSKY,W, THOMAS,BJ AND KOVATCH,RM; SYSTEMIC AND LOCAL CARCINOGENESIS BY DIRECTLY ACTING N-NITROSO COMPOUNDS GIVEN TO RATS BY INTRAVESICULAR ADMINISTRATION; CARCINOGENESIS 13(7):1101-1105, 1992]"
6023,363903226,148247,C1COC(=O)N1N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 12 MG/ML ((0.2 ML OF A SOLUTION IN ETHYL ACETATE/CORN OIL (1:2)) 1/WK FOR 30 WK (STUDY DURATION: LIFE SPAN),FORESTOMACH: SQUAMOUS CELL CARCINOMA OR ADENOMA,POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
6024,363903279,9556442,CC(C)C/C=N/N(C)C=O,Active,,,,MOUSE,SWISS/MALE,GAVAGE,0; 50 UG/G BW DISSOLVED IN PROPYLENE GLYCOL 1/WK FOR 2 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; THYROID: TUMOR,POSITIVE,"[TOTH,B AND GANNETT,P; CARCINOGENESIS STUDY IN MICE BY 3-METHYLBUTANOL METHYLFORMYLHYDRAZONE OF GYROMITRA ESCULENTA; IN VIVO 4(5):283-288, 1990]"
6025,363903279,9556442,CC(C)C/C=N/N(C)C=O,Active,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 50 UG/G BW DISSOLVED IN PROPYLENE GLYCOL 1/WK FOR 2 WK (STUDY DURATION: LIFETIME),THYROID: TUMOR; LUNG: TUMOR,POSITIVE,"[TOTH,B AND GANNETT,P; CARCINOGENESIS STUDY IN MICE BY 3-METHYLBUTANOL METHYLFORMYLHYDRAZONE OF GYROMITRA ESCULENTA; IN VIVO 4(5):283-288, 1990]"
6026,363903279,9556442,CC(C)C/C=N/N(C)C=O,Active,,,,MOUSE,SWISS/MALE,GAVAGE,0; 50 UG/G BW DISSOLVED IN PROPYLENE GLYCOL 1/WK FOR 53 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; LIVER: TUMOR; GALLBLADDER: TUMOR; PREPUTIAL GLAND: TUMOR,POSITIVE,"[TOTH,B AND GANNETT,P; CARCINOGENESIS STUDY IN MICE BY 3-METHYLBUTANOL METHYLFORMYLHYDRAZONE OF GYROMITRA ESCULENTA; IN VIVO 4(5):283-288, 1990]"
6027,363903279,9556442,CC(C)C/C=N/N(C)C=O,Active,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 50 UG/G BW DISSOLVED IN PROPYLENE GLYCOL 1/WK FOR 53 WK (STUDY DURATION: LIFETIME),LUNG: TUMOR; LIVER: TUMOR; GALLBLADDER: TUMOR,POSITIVE,"[TOTH,B AND GANNETT,P; CARCINOGENESIS STUDY IN MICE BY 3-METHYLBUTANOL METHYLFORMYLHYDRAZONE OF GYROMITRA ESCULENTA; IN VIVO 4(5):283-288, 1990]"
6028,363903359,152287,C1=C[C@@H]([C@H](C=C1)O)O,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 50 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
6029,363903359,152287,C1=C[C@@H]([C@H](C=C1)O)O,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 50 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",,NEGATIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
6030,363903360,147652,C1=C[C@@H]2[C@@H](O2)[C@H]([C@@H]1O)O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 2.7; 13.7 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
6031,363903360,147652,C1=C[C@@H]2[C@@H](O2)[C@H]([C@@H]1O)O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 2.7; 13.7 UMOL ADMINISTERED AS 3 UNEQUAL DOSES (1/7, 2/7, AND 4/7 OF THE TOTAL DOSE) OVER A 2-WK PERIOD (STUDY DURATION: 28 WK)",LUNG: ADENOMA,POSITIVE,"[BUSBY,WF, JR, WANG,JS, STEVENS,EK, PADYKULA,RE, ALEKSEJCZYK,RA AND BERCHTOLD, GA; LUNG TUMORIGENICITY IN BENZENE OXIDE, BENZENE DIHYDRODIOLS AND BENZENEDIOL EPOXIDES IN THE BLU:HA NEWBORN MOUSE ASSAY;CARCINOGENESIS 11(9):1473-1478, 1990]"
6032,363903361,24227,C(#CCl)Cl,Active,,,,MOUSE,NMRI/FEMALE,INHALATION,0; 2 PPM 6 HR/D 2 D/WK FOR 18 MO (STUDY DURATION: LIFE),HARDERIAN GLAND: CYSTADENOMA,POSITIVE,"[REICHERT,D, SPENGLER,U, ROMEN,W AND HENSCHLER,D; CARCINOGENICITY OF DICHLOROACETYLENE: AN INHALATION STUDY; CARCINOGENESIS 5(11):1411-1420, 1984]"
6033,363903361,24227,C(#CCl)Cl,Active,,,,MOUSE,NMRI/MALE,INHALATION,0; 2 PPM 6 HR/D 2 D/WK FOR 18 MO (STUDY DURATION: LIFE),KIDNEY: CYSTADENOMA; HARDERIAN GLAND: CYSTADENOMA,POSITIVE,"[REICHERT,D, SPENGLER,U, ROMEN,W AND HENSCHLER,D; CARCINOGENICITY OF DICHLOROACETYLENE: AN INHALATION STUDY; CARCINOGENESIS 5(11):1411-1420, 1984]"
6034,363903361,24227,C(#CCl)Cl,Active,,,,MOUSE,NMRI/FEMALE,INHALATION,0; 2 PPM 6 HR/D 1 D/WK FOR 18 MO (STUDY DURATION: LIFE),KIDNEY: CYSTADENOMA; LUNG: ADENOMA; HARDERIAN GLAND: CYSTADENOMA,POSITIVE,"[REICHERT,D, SPENGLER,U, ROMEN,W AND HENSCHLER,D; CARCINOGENICITY OF DICHLOROACETYLENE: AN INHALATION STUDY; CARCINOGENESIS 5(11):1411-1420, 1984]"
6035,363903361,24227,C(#CCl)Cl,Active,,,,MOUSE,NMRI/MALE,INHALATION,0; 2 PPM 6 HR/D 1 D/WK FOR 18 MO (STUDY DURATION: LIFE),"KIDNEY: CYSTADENOMA, CYSTADENOCARCINOMA; HARDERIAN GLAND: CYSTADENOMA",POSITIVE,"[REICHERT,D, SPENGLER,U, ROMEN,W AND HENSCHLER,D; CARCINOGENICITY OF DICHLOROACETYLENE: AN INHALATION STUDY; CARCINOGENESIS 5(11):1411-1420, 1984]"
6036,363903361,24227,C(#CCl)Cl,Active,,,,MOUSE,NMRI/FEMALE,INHALATION,0; 9 PPM 6 HR/D 1 D/WK FOR 12 MO (STUDY DURATION: LIFE),KIDNEY: CYSTADENOMA; HARDERIAN GLAND: CYSTADENOMA,POSITIVE,"[REICHERT,D, SPENGLER,U, ROMEN,W AND HENSCHLER,D; CARCINOGENICITY OF DICHLOROACETYLENE: AN INHALATION STUDY; CARCINOGENESIS 5(11):1411-1420, 1984]"
6037,363903361,24227,C(#CCl)Cl,Active,,,,MOUSE,NMRI/MALE,INHALATION,0; 9 PPM 6 HR/D 1 D/WK FOR 12 MO (STUDY DURATION: LIFE),"KIDNEY: CYSTADENOMA, CYSTADENOCARCINOMA",POSITIVE,"[REICHERT,D, SPENGLER,U, ROMEN,W AND HENSCHLER,D; CARCINOGENICITY OF DICHLOROACETYLENE: AN INHALATION STUDY; CARCINOGENESIS 5(11):1411-1420, 1984]"
6038,363903361,24227,C(#CCl)Cl,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 14 PPM 6 HR/D 2 D/WK FOR 18 MO (STUDY DURATION: LIFE),KIDNEY: CYSTADENOMA; LIVER: CHOLANGIOMA; HEMOPOIETIC SYSTEM: MALIGNANT LYMPHOMA,POSITIVE,"[REICHERT,D, SPENGLER,U, ROMEN,W AND HENSCHLER,D; CARCINOGENICITY OF DICHLOROACETYLENE: AN INHALATION STUDY; CARCINOGENESIS 5(11):1411-1420, 1984]"
6039,363903361,24227,C(#CCl)Cl,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 14 PPM 6 HR/D 2 D/WK FOR 18 MO (STUDY DURATION: LIFE),KIDNEY: CYSTADENOMA; LIVER: CHOLANGIOMA,POSITIVE,"[REICHERT,D, SPENGLER,U, ROMEN,W AND HENSCHLER,D; CARCINOGENICITY OF DICHLOROACETYLENE: AN INHALATION STUDY; CARCINOGENESIS 5(11):1411-1420, 1984]"
6040,363903362,56841464,C1=CC=C2C(=C1)C=C3C=CC4=C(C3=N2)[C@@H]([C@H](C=C4)O)O,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",,NEGATIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6041,363903362,56841464,C1=CC=C2C(=C1)C=C3C=CC4=C(C3=N2)[C@@H]([C@H](C=C4)O)O,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",,NEGATIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6042,363903363,53653,C1=CC=C2C(=C1)C=C3C=CC4=C(C3=N2)C=C[C@H]([C@@H]4O)O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6043,363903363,53653,C1=CC=C2C(=C1)C=C3C=CC4=C(C3=N2)C=C[C@H]([C@@H]4O)O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA; LIVER: NEOPLASTIC NODULE,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6044,363903364,150735,C1=CC=C2C(=C1)C=C3[C@H]([C@@H](C4=CC=CC=C4C3=N2)O)O,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",,NEGATIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6045,363903364,150735,C1=CC=C2C(=C1)C=C3[C@H]([C@@H](C4=CC=CC=C4C3=N2)O)O,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",,NEGATIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6046,363903365,56842958,C1=CC=C2C(=C1)C=CC3=CC4=C(C=C[C@@H]([C@H]4O)O)N=C32,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6047,363903365,56842958,C1=CC=C2C(=C1)C=CC3=CC4=C(C=C[C@@H]([C@H]4O)O)N=C32,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6048,363903366,56842959,C1=CC=C2C(=C1)C=CC3=CC4=C([C@@H]([C@H](C=C4)O)O)N=C32,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6049,363903366,56842959,C1=CC=C2C(=C1)C=CC3=CC4=C([C@@H]([C@H](C=C4)O)O)N=C32,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA; LIVER: NEOPLASTIC NODULE,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6050,363903367,163488,C1=CC=C2C(=C1)C=C3C=CC4=C(C3=N2)C5C(O5)C(C4O)O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6051,363903367,163488,C1=CC=C2C(=C1)C=C3C=CC4=C(C3=N2)C5C(O5)C(C4O)O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA; LIVER: NEOPLASTIC NODULE,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6052,363903368,150767,C1=CC=C2C(=C1)C=C3C4=C(O4)C5=CC=CC=C5C3=N2,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6053,363903368,150767,C1=CC=C2C(=C1)C=C3C4=C(O4)C5=CC=CC=C5C3=N2,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",,NEGATIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6054,363903369,163488,C1=CC=C2C(=C1)C=C3C=CC4=C(C3=N2)C5C(O5)C(C4O)O,Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 0.5 UMOL GIVEN AS 70 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 140 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 280 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6055,363903369,163488,C1=CC=C2C(=C1)C=C3C=CC4=C(C3=N2)C5C(O5)C(C4O)O,Active,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 0.5 UMOL GIVEN AS 70 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 140 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 280 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",LUNG: ADENOMA; LIVER: NEOPLASTIC NODULE,POSITIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6056,363903370,163485,C1=CC=C2C(=C1)C=CC3=CC4=C(C5C(O5)C(C4O)O)N=C32,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",,NEGATIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6057,363903370,163485,C1=CC=C2C(=C1)C=CC3=CC4=C(C5C(O5)C(C4O)O)N=C32,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",,NEGATIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6058,363903371,163486,C1=CC=C2C(=C1)C=CC3=CC4=C(C(C(C5C4O5)O)O)N=C32,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",,NEGATIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6059,363903371,163486,C1=CC=C2C(=C1)C=CC3=CC4=C(C(C(C5C4O5)O)O)N=C32,Inactive,,,,MOUSE,SWISS/MALE,INTRAPERITONEAL,"0; 1.05 UMOL GIVEN AS 150 NMOL IN 5 UL DMSO WITHIN 24 HR OF BIRTH, 300 NMOL IN 10 UL DMSO ON D 8 OF LIFE, AND 600 NMOL IN 20 UL DMSO ON D 15 OF LIFE (STUDY DURATION: 37 WK)",,NEGATIVE,"[CHANG,RL, LEVIN,W, WOOD,AW, KUMAR,S, YAGI,H, JERINA,DM, LEHR,RE AND CONNEY,AH; TUMORIGENICITY OF DIHYDRODIOLS AND DIOL EPOXIDES OF BENZ[C]ACRIDINE IN NEWBORN MICE; CANCER RES. 44(11):5161-5164, 1984]"
6060,363903386,152014,CCN=[N+](C)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 12; 48 MG/ML IN A NEUTRAL DEIONIZED DRINKING WATER SOLUTION 5 D/WK FOR 30 WK (TOTAL DOSE 36; 144 MG) (STUDY DURATION: LIFESPAN),"LIVER: CARCINOMA, HEMANGIOSARCOMA; KIDNEY: TUMOR",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; ORGAN-SPECIFIC CARCINOGENESIS IN RATS BY METHYL AND ETHYLAZOXYALKANES; CANCER RES. 45(1):76-79, 1985]"
6061,363903387,152160,CC[N+](=NC)[O-],Active,,,,RAT,F344/MALE,ORAL,0; 12; 48 MG/ML IN A NEUTRAL DEIONIZED DRINKING WATER SOLUTION 5 D/WK FOR 30 WK (TOTAL DOSE 36; 115 MG) (STUDY DURATION: LIFESPAN),"LIVER: CARCINOMA, HEMANGIOSARCOMA; COLON: ADENOCARCINOMA, ADENOMA; ILEUM: TUMOR",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; ORGAN-SPECIFIC CARCINOGENESIS IN RATS BY METHYL AND ETHYLAZOXYALKANES; CANCER RES. 45(1):76-79, 1985]"
6062,363903388,44146708,CC[NH2+]C(=O)N(CCN(C)C)C=O.N(=O)[O-],Active,,,,RAT,F344/FEMALE,INTRAGASTRIC,0; 25 MG/ML CORN OIL/ETHYL ACETATE (2:1) SOLUTION ADMINISTERED AS 0.2 ML 2/WK FOR 37 WK (STUDY DURATION: 102 WK),NASAL CAVITY: ADENOMA,POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND SAAVEDRA,JE; CARCINOGENESIS AND MUTAGENESIS BY N- NITROSO COMPOUNDS HAVING A BASIC CENTER; CANCER LETT. 63(2):101-107, 1992]"
6063,363903388,44146708,CC[NH2+]C(=O)N(CCN(C)C)C=O.N(=O)[O-],Inactive,,,,RAT,F344/MALE,INTRAGASTRIC,0; 25 MG/ML CORN OIL/ETHYL ACETATE (2:1) SOLUTION ADMINISTERED AS 0.2 ML 2/WK FOR 37 WK (STUDY DURATION: 102 WK),,NEGATIVE,"[LIJINSKY,W, KOVATCH,RM AND SAAVEDRA,JE; CARCINOGENESIS AND MUTAGENESIS BY N- NITROSO COMPOUNDS HAVING A BASIC CENTER; CANCER LETT. 63(2):101-107, 1992]"
6064,363903390,5284340,C1=C(OC(=C1)[N+](=O)[O-])/C=C/C2=NOC(=N2)N,Active,,,,MOUSE,CD-1/FEMALE,GAVAGE,0; 41; 82; 173 MG/KG/D SUSPENDED IN 25% GLYCEROL 4 D/WK FOR 371 D (TOTAL DOSE 0; 15.4; 30.9; 64.2 G) (STUDY DURATION: LIFE),"THYMUS: LYMPHOMA; BLADDER: TRANSITIONAL CELL CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS PAPILLOMA; LUNG: ADENOMA; ENDOMETRIUM: ADENOCARCINOMA; RETICULOENDOTHELIAL SYSTEM: TUMOR; MAMMARY GLAND: ADENOCARCINOMA",POSITIVE,"[DUNSFORD,HA, KEYSSER,CH, DOLAN,PM, SEED,JL AND BUEDING,E; CARCINOGENICITY OF THE ANTISCHISTOSOMAL NITROFURAN TRANS-5-AMINO-3-[2-(5-NITRO-2-FURYL)VINYL]-1,2,4- OXADIAZOLE; JNCI, J. NATL. CANCER INST. 73(1):151-160, 1984]"
6065,363903390,5284340,C1=C(OC(=C1)[N+](=O)[O-])/C=C/C2=NOC(=N2)N,Active,,,,MOUSE,CD-1/MALE,GAVAGE,0; 45; 87; 185 MG/KG/D SUSPENDED IN 25% GLYCEROL 4 D/WK FOR 371 D (TOTAL DOSE 0; 16.8; 32.3; 68.8 G) (STUDY DURATION: LIFE),"THYMUS: LYMPHOMA; BLADDER: TRANSITIONAL CELL CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS PAPILLOMA; LUNG: ADENOMA; LIVER: HEPATOCARCINOMA, HEMANGIOMA; RETICULOENDOTHELIAL SYSTEM: TUMOR",POSITIVE,"[DUNSFORD,HA, KEYSSER,CH, DOLAN,PM, SEED,JL AND BUEDING,E; CARCINOGENICITY OF THE ANTISCHISTOSOMAL NITROFURAN TRANS-5-AMINO-3-[2-(5-NITRO-2-FURYL)VINYL]-1,2,4- OXADIAZOLE; JNCI, J. NATL. CANCER INST. 73(1):151-160, 1984]"
6066,363903390,5284340,C1=C(OC(=C1)[N+](=O)[O-])/C=C/C2=NOC(=N2)N,Active,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.17% IN DIET FOR 58 WK (STUDY DURATION: 91 WK),"HEMATOPOIETIC SYSTEM: LYMPHOMA; THYMUS: LYMPHOMA; STOMACH: SQUAMOUS CELL CARCINOMA, SPINDLE CELL TUMOR",POSITIVE,"[DUNSFORD,HA, KEYSSER,CH, DOLAN,PM, SEED,JL AND BUEDING,E; CARCINOGENICITY OF THE ANTISCHISTOSOMAL NITROFURAN TRANS-5-AMINO-3-[2-(5-NITRO-2-FURYL)VINYL]-1,2,4- OXADIAZOLE; JNCI, J. NATL. CANCER INST. 73(1):151-160, 1984]"
6067,363903390,5284340,C1=C(OC(=C1)[N+](=O)[O-])/C=C/C2=NOC(=N2)N,Active,,,,MOUSE,CD-1/MALE,ORAL,0; 0.18% IN DIET FOR 58 WK (STUDY DURATION: 92 WK),"THYMUS: LYMPHOMA; BLADDER: TRANSITIONAL CELL CARCINOMA; STOMACH: SQUAMOUS CELL CARCINOMA, SPINDLE CELL TUMOR",POSITIVE,"[DUNSFORD,HA, KEYSSER,CH, DOLAN,PM, SEED,JL AND BUEDING,E; CARCINOGENICITY OF THE ANTISCHISTOSOMAL NITROFURAN TRANS-5-AMINO-3-[2-(5-NITRO-2-FURYL)VINYL]-1,2,4- OXADIAZOLE; JNCI, J. NATL. CANCER INST. 73(1):151-160, 1984]"
6068,363903390,5284340,C1=C(OC(=C1)[N+](=O)[O-])/C=C/C2=NOC(=N2)N,Active,,,,MOUSE,CD-1/MALE,ORAL,0; 0.25% IN DIET FOR 38 WK (STUDY DURATION: LIFE),"THYMUS: LYMPHOMA; BLADDER: TRANSITIONAL CELL CARCINOMA, SPINDLE CELL TUMOR; STOMACH: SQUAMOUS CELL CARCINOMA, SQUAMOUS PAPILLOMA",POSITIVE,"[DUNSFORD,HA, KEYSSER,CH, DOLAN,PM, SEED,JL AND BUEDING,E; CARCINOGENICITY OF THE ANTISCHISTOSOMAL NITROFURAN TRANS-5-AMINO-3-[2-(5-NITRO-2-FURYL)VINYL]-1,2,4- OXADIAZOLE; JNCI, J. NATL. CANCER INST. 73(1):151-160, 1984]"
6069,363903390,5284340,C1=C(OC(=C1)[N+](=O)[O-])/C=C/C2=NOC(=N2)N,Active,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.25% IN DIET FOR 31 WK (STUDY DURATION: LIFE),THYMUS: LYMPHOMA; STOMACH: SQUAMOUS CELL CARCINOMA; LUNG: ADENOMA; MAMMARY GLAND: ADENOCARCINOMA,POSITIVE,"[DUNSFORD,HA, KEYSSER,CH, DOLAN,PM, SEED,JL AND BUEDING,E; CARCINOGENICITY OF THE ANTISCHISTOSOMAL NITROFURAN TRANS-5-AMINO-3-[2-(5-NITRO-2-FURYL)VINYL]-1,2,4- OXADIAZOLE; JNCI, J. NATL. CANCER INST. 73(1):151-160, 1984]"
6070,363903405,14888,[O-2].[O-2].[O-2].[As+3].[As+3],Active,,,,HAMSTER,SYRIAN/MALE,INTRATRACHEAL,0; 0.25 MG IN 3 MG CARRIER DUST CONTAINING 3 MG CARBON PARTICLES AND 0.03 MG OF SULFURIC ACID 1/WK FOR 15 WK (STUDY DURATION: 140 WK),"LARYNX, TRACHEA, BRONCHUS OR LUNG: CARCINOMA, ADENOMA, ADENOMATOID LESIONS OR PAPILLOMA",POSITIVE,"[PERSHAGEN,G, NORDBERG,G AND BJOERKLUND,NE; CARCINOMAS OF THE RESPIRATORY TRACT IN HAMSTERS GIVEN ARSENIC TRIOXIDE AND/OR BENZO[A]PYRENE BY THE PULMONARY ROUTE; ENVIRON. RES. 34(2):227-241, 1984]"
6071,363903406,134601,COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)N,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAVESICULAR,0; 4-4.4 MG IN CHOLESTEROL PELLET (STUDY DURATION: 26 WK),,NEGATIVE,"[BRYAN,GT; ARTIFICIAL SWEETENERS AND BLADDER CANCER: ASSESSMENT OF POTENTIAL URINARY BLADDER CARCINOGENICITY OF ASPARTAME AND IS DIKETOPIPERAZINE DERIVATIVE IN MICE; FOOD SCI. TECHNOL. 12(ASPARTAME):321-348, 1984]"
6072,363903406,134601,COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)N,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAVESICULAR,0; 4-4.4 MG IN CHOLESTEROL PELLET (STUDY DURATION: 56 WK),,NEGATIVE,"[BRYAN,GT; ARTIFICIAL SWEETENERS AND BLADDER CANCER: ASSESSMENT OF POTENTIAL URINARY BLADDER CARCINOGENICITY OF ASPARTAME AND IS DIKETOPIPERAZINE DERIVATIVE IN MICE; FOOD SCI. TECHNOL. 12(ASPARTAME):321-348, 1984]"
6073,363903407,111054,C1=CC=C(C=C1)C[C@H]2C(=O)N[C@H](C(=O)N2)CC(=O)O,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAVESICULAR,0; 4-4.4 MG IN CHOLESTEROL PELLET (STUDY DURATION: 26 WK),,NEGATIVE,"[BRYAN,GT; ARTIFICIAL SWEETENERS AND BLADDER CANCER: ASSESSMENT OF POTENTIAL URINARY BLADDER CARCINOGENICITY OF ASPARTAME AND IS DIKETOPIPERAZINE DERIVATIVE IN MICE; FOOD SCI. TECHNOL. 12(ASPARTAME):321-348, 1984]"
6074,363903407,111054,C1=CC=C(C=C1)C[C@H]2C(=O)N[C@H](C(=O)N2)CC(=O)O,Inactive,,,,MOUSE,SWISS/FEMALE,INTRAVESICULAR,0; 4-4.4 MG IN CHOLESTEROL PELLET (STUDY DURATION: 56 WK),,NEGATIVE,"[BRYAN,GT; ARTIFICIAL SWEETENERS AND BLADDER CANCER: ASSESSMENT OF POTENTIAL URINARY BLADDER CARCINOGENICITY OF ASPARTAME AND IS DIKETOPIPERAZINE DERIVATIVE IN MICE; FOOD SCI. TECHNOL. 12(ASPARTAME):321-348, 1984]"
6075,363903408,30717,C1C2=CC=CC=C2C(=O)N3N1C(=O)C4=CC=CC=C4C3,Active,,,,MOUSE,BALB/MALE,ORAL,0; 300; 600; 1200 PPM IN DIET FOR 80 WK (STUDY DURATION: 120 WK),"LIVER: ANGIOMA, ANGIOSARCOMA",POSITIVE,"[DELLA PORTA,G, DRAGANI,TA, BARALE,R AND ZUCCONI,D; CARCINOGENIC ACTIVITY IN MICE OF DIFTALONE, AN ANTI-INFLAMMATORY AGENT; J. CANCER RES. CLIN. ONCOL. 108(3): 308-311, 1984]"
6076,363903408,30717,C1C2=CC=CC=C2C(=O)N3N1C(=O)C4=CC=CC=C4C3,Active,,,,MOUSE,BALB/FEMALE,ORAL,0; 300; 600; 1200 PPM IN DIET FOR 80 WK (STUDY DURATION: 120 WK),"LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA, ANGIOSARCOMA",POSITIVE,"[DELLA PORTA,G, DRAGANI,TA, BARALE,R AND ZUCCONI,D; CARCINOGENIC ACTIVITY IN MICE OF DIFTALONE, AN ANTI-INFLAMMATORY AGENT; J. CANCER RES. CLIN. ONCOL. 108(3): 308-311, 1984]"
6077,363903409,439517,C1=CC(=CC=C1CO)NNC(=O)CC[C@@H](C(=O)O)N,Inactive,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 100 UG IN 0.01 ML PHYSIOLOGICAL SALINE 1/WK FOR 5 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[TOTH,B AND SORNSON,H; LACK OF CARCINOGENICITY OF AGARITINE BY SUBCUTANEOUS ADMINISTRATION IN MICE; MYCOPATHOLOGIA 85(1-2):75-79, 1984]"
6078,363903409,439517,C1=CC(=CC=C1CO)NNC(=O)CC[C@@H](C(=O)O)N,Inactive,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 100 UG IN 0.01 ML PHYSIOLOGICAL SALINE 1/WK FOR 5 WK (STUDY DURATION: LIFETIME),,NEGATIVE,"[TOTH,B AND SORNSON,H; LACK OF CARCINOGENICITY OF AGARITINE BY SUBCUTANEOUS ADMINISTRATION IN MICE; MYCOPATHOLOGIA 85(1-2):75-79, 1984]"
6079,363903409,439517,C1=CC(=CC=C1CO)NNC(=O)CC[C@@H](C(=O)O)N,Inactive,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 50 UG IN 0.01 ML PHYSIOLOGICAL SALINE ONCE (STUDY DURATION: LIFETIME),,NEGATIVE,"[TOTH,B AND SORNSON,H; LACK OF CARCINOGENICITY OF AGARITINE BY SUBCUTANEOUS ADMINISTRATION IN MICE; MYCOPATHOLOGIA 85(1-2):75-79, 1984]"
6080,363903409,439517,C1=CC(=CC=C1CO)NNC(=O)CC[C@@H](C(=O)O)N,Inactive,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 100 UG IN 0.01 ML PHYSIOLOGICAL SALINE ONCE (STUDY DURATION: LIFETIME),,NEGATIVE,"[TOTH,B AND SORNSON,H; LACK OF CARCINOGENICITY OF AGARITINE BY SUBCUTANEOUS ADMINISTRATION IN MICE; MYCOPATHOLOGIA 85(1-2):75-79, 1984]"
6081,363903410,133796,CC(=O)OCN(C1=CC=CC=C1)N=O,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 6.25; 12.5 MG/KG/WK IN OLIVE OIL FOR 4 WK (STUDY DURATION: 60 WK),,NEGATIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6082,363903410,133796,CC(=O)OCN(C1=CC=CC=C1)N=O,Inactive,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 6.25; 12.5 MG/KG/WK IN OLIVE OIL FOR 4 WK (STUDY DURATION: 60 WK),,NEGATIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6083,363903410,133796,CC(=O)OCN(C1=CC=CC=C1)N=O,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 1.56; 3.13 MG/KG/WK IN OLIVE OIL FOR LIFE (STUDY DURATION: 60 WK),,NEGATIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6084,363903410,133796,CC(=O)OCN(C1=CC=CC=C1)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 1.56; 3.13 MG/KG/WK IN OLIVE OIL FOR LIFE (STUDY DURATION: 60 WK),INJECTION SITE: TUMOR,POSITIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6085,363903411,,,Inactive,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 1.19; 2.38 MG/KG/WK IN 0.9% SALINE FOR LIFE (STUDY DURATION: 60 WK),,NEGATIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6086,363903411,,,Inactive,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 4.75; 9.5; 19 MG/KG/WK IN 0.9% SALINE FOR 10 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6087,363903411,,,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 4.75; 9.5; 19 MG/KG/WK IN 0.9% SALINE FOR 10 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6088,363903411,,,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 1.19; 2.38 MG/KG/WK IN 0.9% SALINE FOR LIFE (STUDY DURATION: 80 WK),,NEGATIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6089,363903411,,,Inactive,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 8.75; 17.5; 35 MG/KG/WK IN DISTILLED WATER (STUDY DURATION: 80 WK),,NEGATIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6090,363903411,,,Inactive,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 8.75; 17.5; 35 MG/KG/WK IN DISTILLED WATER (STUDY DURATION: 80 WK),,NEGATIVE,"[GOLD,B AND SALMASI,S; CARCINOGENICITY TESTS OF ACETOXYMETHYLPHENYLNITROSAMINE AND BENZENEDIAZONIUM TETRAFLUOROBORATE IN SYRIAN HAMSTERS; CANCER LETT. 15:289-300, 1982]"
6091,363903481,9015,COC1=CC=C(C=C1)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[ASAKAWA,E, HIROSE,M, HAGIWARA,A, TAKAHASHI,S AND ITO,N; CARCINOGENICITY OF 4-METHOXYPHENOL AND 4-METHYLCATECHOL IN F344 RATS; INT. J. CANCER 56(2):146-152, 1994]"
6092,363903481,9015,COC1=CC=C(C=C1)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"FORESTOMACH: PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[ASAKAWA,E, HIROSE,M, HAGIWARA,A, TAKAHASHI,S AND ITO,N; CARCINOGENICITY OF 4-METHOXYPHENOL AND 4-METHYLCATECHOL IN F344 RATS; INT. J. CANCER 56(2):146-152, 1994]"
6093,363903481,9015,COC1=CC=C(C=C1)O,Inactive,,,,RAT,F344/MALE,ORAL,"0, 0.4% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK)",,NEGATIVE,"[HIROSE,M, TAKESADA,Y, TANAKA,H, TAMANO,S, KATO,T AND SHIRAI,T; CARCINOGENICITY OF ANTIOXIDANTS BHA, CAFFEIC ACID, SESAMOL, 4-METHOXYPHENOL AND CATECHOL AT LOW DOSES, EITHER ALONE OR IN COMBINATION, AND MODULATION OF THEIR EFFECTS IN A RAT MEDIUM-TERM MULTI-ORGAN CARCINOGENESIS MODEL; CARCINOGENESIS 19(1):207-212, 1998]"
6094,363903504,443495,[O-][As]=O.[Na+],Inactive,,,,Mouse,C3H/Female offspring,Oral,0; 85 ppm (in drinking water of dam) in utero,,Negative,"[AHLBORN,GJ, NELSON,GM, GRINDSTAFF,RD, WAALKES,MP, DIWAN,BA,   ALLEN,JW, KITCHIN,KT, PRESTON,RJ, HERNANDEZ-ZAVALA,A,   ADAIR,B, THOMAS,DJ, DELKER,DA; IMPACT OF LIFE STAGE AND   DURATION OF EXPOSURE ON ARSENIC-INDUCED PROLIFERATIVE   LESIONS AND NEOPLASIA IN C3H MICE. TOXICOLOGY 262(2):   106-113, 2009]"
6095,363903504,443495,[O-][As]=O.[Na+],Inactive,,,,Mouse,C3H/Female offspring,Oral,0; 85 ppm in utero and in drinking water to 365 days,,Negative,"[AHLBORN,GJ, NELSON,GM, GRINDSTAFF,RD, WAALKES,MP, DIWAN,BA,   ALLEN,JW, KITCHIN,KT, PRESTON,RJ, HERNANDEZ-ZAVALA,A,   ADAIR,B, THOMAS,DJ, DELKER,DA; IMPACT OF LIFE STAGE AND   DURATION OF EXPOSURE ON ARSENIC-INDUCED PROLIFERATIVE   LESIONS AND NEOPLASIA IN C3H MICE. TOXICOLOGY 262(2):   106-113, 2009]"
6096,363903504,443495,[O-][As]=O.[Na+],Inactive,,,,Mouse,C3H/Female offspring,Oral,0; 85 ppm in drinking water prior to pubescence (PND 21) to 365 days,,"Negative (hyperplasia only, no increase in tumors)","[AHLBORN,GJ, NELSON,GM, GRINDSTAFF,RD, WAALKES,MP, DIWAN,BA,   ALLEN,JW, KITCHIN,KT, PRESTON,RJ, HERNANDEZ-ZAVALA,A,   ADAIR,B, THOMAS,DJ, DELKER,DA; IMPACT OF LIFE STAGE AND   DURATION OF EXPOSURE ON ARSENIC-INDUCED PROLIFERATIVE   LESIONS AND NEOPLASIA IN C3H MICE. TOXICOLOGY 262(2):   106-113, 2009]"
6097,363903504,443495,[O-][As]=O.[Na+],Inactive,,,,Mouse,C3H/Female offspring,Oral,0; 85 ppm in drinking water post pubescence (PND 56) to 365 days,,"Negative (Hyperplasia only, no tumors)","[AHLBORN,GJ, NELSON,GM, GRINDSTAFF,RD, WAALKES,MP, DIWAN,BA,   ALLEN,JW, KITCHIN,KT, PRESTON,RJ, HERNANDEZ-ZAVALA,A,   ADAIR,B, THOMAS,DJ, DELKER,DA; IMPACT OF LIFE STAGE AND   DURATION OF EXPOSURE ON ARSENIC-INDUCED PROLIFERATIVE   LESIONS AND NEOPLASIA IN C3H MICE. TOXICOLOGY 262(2):   106-113, 2009]"
6098,363903504,443495,[O-][As]=O.[Na+],Inactive,,,,Mouse,C3H/Male offspring,Oral,0; 85 ppm (in drinking water of dam) in utero,,Negative,"[AHLBORN,GJ, NELSON,GM, GRINDSTAFF,RD, WAALKES,MP, DIWAN,BA,   ALLEN,JW, KITCHIN,KT, PRESTON,RJ, HERNANDEZ-ZAVALA,A,   ADAIR,B, THOMAS,DJ, DELKER,DA; IMPACT OF LIFE STAGE AND   DURATION OF EXPOSURE ON ARSENIC-INDUCED PROLIFERATIVE   LESIONS AND NEOPLASIA IN C3H MICE. TOXICOLOGY 262(2):   106-113, 2009]"
6099,363903504,443495,[O-][As]=O.[Na+],Active,,,,Mouse,C3H/Male offspring,Oral,0; 85 ppm in utero and in drinking water to 365 days,"Liver: adenoma and carcinoma (30%, 0%)",Positive,"[AHLBORN,GJ, NELSON,GM, GRINDSTAFF,RD, WAALKES,MP, DIWAN,BA,   ALLEN,JW, KITCHIN,KT, PRESTON,RJ, HERNANDEZ-ZAVALA,A,   ADAIR,B, THOMAS,DJ, DELKER,DA; IMPACT OF LIFE STAGE AND   DURATION OF EXPOSURE ON ARSENIC-INDUCED PROLIFERATIVE   LESIONS AND NEOPLASIA IN C3H MICE. TOXICOLOGY 262(2):   106-113, 2009]"
6100,363903504,443495,[O-][As]=O.[Na+],Inactive,,,,Mouse,C3H/Male offspring,Oral,0; 85 ppm in drinking water prior to pubescence (PND 21) to 365 days,,Negative (Decreased incidence of spontaneous tumors),"[AHLBORN,GJ, NELSON,GM, GRINDSTAFF,RD, WAALKES,MP, DIWAN,BA,   ALLEN,JW, KITCHIN,KT, PRESTON,RJ, HERNANDEZ-ZAVALA,A,   ADAIR,B, THOMAS,DJ, DELKER,DA; IMPACT OF LIFE STAGE AND   DURATION OF EXPOSURE ON ARSENIC-INDUCED PROLIFERATIVE   LESIONS AND NEOPLASIA IN C3H MICE. TOXICOLOGY 262(2):   106-113, 2009]"
6101,363903504,443495,[O-][As]=O.[Na+],Inactive,,,,Mouse,C3H/Male offspring,Oral,0; 85 ppm in drinking water post pubescence (PND 56) to 365 days,,Negative (Decreased incidence of spontaneous tumors),"[AHLBORN,GJ, NELSON,GM, GRINDSTAFF,RD, WAALKES,MP, DIWAN,BA,   ALLEN,JW, KITCHIN,KT, PRESTON,RJ, HERNANDEZ-ZAVALA,A,   ADAIR,B, THOMAS,DJ, DELKER,DA; IMPACT OF LIFE STAGE AND   DURATION OF EXPOSURE ON ARSENIC-INDUCED PROLIFERATIVE   LESIONS AND NEOPLASIA IN C3H MICE. TOXICOLOGY 262(2):   106-113, 2009]"
6102,363903504,443495,[O-][As]=O.[Na+],Active,,,,Mouse,"C3H/10 pregnant dams/group, 25 male and 25 female offspring per group assigned at 4 wks of age",Oral,"0, 42.5, 85 ppm in drinking water of dams, offspring followed for 90 wks",Hepatocellular carcinoma in offspring,Positive,"[WAALKES,MP LIU,J WARD,JM  AND DIWAN,BA; ANIMAL MODELS FOR ARSENIC CARCINOGENESIS: INORGANIC ARSENIC IS A TRANSPLACENTAL CARCINOGEN IN MICE; TOXICOL. APPL. PHARMACOL. 198(3):377-384, 2004]"
6103,363903504,443495,[O-][As]=O.[Na+],Active,,,,Mouse,C3H/HeNCr F344/ Male and female (25-35/Group as offspring of 10 dams per exposure level),Drinking water,"0, 42.5, 85 ppm ad lib on gestation days 8-18, study duration for offspring 90 wks","Male offspring: Liver: hepatocellular carcinoma (statistically significant increase in incidence and multiplicity); Adrenal gland: adrenal cortical adenoma (dose related increases in incidence and multiplicity). Female offspring: Ovary: ovarian tumors, Lung: adenocarcinomas (both dose related)",Positive,"[WAALKES,M, MICHAEL,P, LIU,J AND DIWAN,BA; TRANSPLACENTAL ARSENIC CARCINOGENESIS IN MICE; TOXICOL. APPL. PHARMACOL. 222(3):271-280, 2007]"
6104,363903510,177577,O.[O-]S(=O)(=O)[O-].[Mn+2],Inactive,,,,RAT,F344/MALE,ORAL,0; 1500; 5000; 15000 PPM IN DIET (0; 60; 200; 615 MG/KG/D) FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-428 Y93]"
6105,363903510,177577,O.[O-]S(=O)(=O)[O-].[Mn+2],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1500; 5000; 15000 PPM IN DIET (0; 70; 230; 715 MG/KG/D) FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-428 Y93]"
6106,363903510,177577,O.[O-]S(=O)(=O)[O-].[Mn+2],Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1500; 5000; 15000 PPM IN DIET (0; 60; 200; 615 MG/KG/D) FOR 105 WK (STUDY DURATION: 105 WK),THYROID GLAND (FOLLICULAR CELL): ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-428 Y93]"
6107,363903510,177577,O.[O-]S(=O)(=O)[O-].[Mn+2],Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1500; 5000; 15000 PPM IN DIET (0; 60; 200; 615 MG/KG/D) FOR 105 WK (STUDY DURATION: 105 WK),THYROID GLAND (FOLLICULAR CELL): ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-428 Y93]"
6108,363903521,13791,CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,Active,,,,RAT,STRAIN-CD/MALE,SUBCUTANEOUS,0; 1 MG IN CASTOR OIL 1/4 WK FOR LIFE (STUDY DURATION: LIFE),MAMMARY GLAND: TUMOR,POSITIVE,"[NORONHA,RFX AND GOODALL,CM; THE EFFECTS OF ESTROGEN ON SINGLE DOSE DIMETHYLNITROSAMINE CARCINOGENESIS IN MALE INBRED CRL/CDF RATS; CARCINOGENESIS 5(8):1003-1007, 1984]"
6109,363903532,91827143,C1=CC(=CC=C1CO)[N+]#N.OS(=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 50 UG/G BW IN 0.01 ML 0.9% SALINE 1/WK FOR 26 WK (STUDY DURATION: 140 WK),SUBCUTIS: TUMOR; SKIN: TUMOR,POSITIVE,"[TOTH,B; CANCER INDUCTION BY THE SULFATE FORM OF 4-(HYDROXYMETHYL) BENZENEDIAZONIUM ION OF AGARICUS BISPORUS; IN VIVO 1:39-42, 1987]"
6110,363903532,91827143,C1=CC(=CC=C1CO)[N+]#N.OS(=O)[O-],Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 50 UG/G BW IN 0.01 ML 0.9% SALINE 1/WK FOR 26 WK (STUDY DURATION: 140 WK),SUBCUTIS: TUMOR; SKIN: TUMOR,POSITIVE,"[TOTH,B; CANCER INDUCTION BY THE SULFATE FORM OF 4-(HYDROXYMETHYL) BENZENEDIAZONIUM ION OF AGARICUS BISPORUS; IN VIVO 1:39-42, 1987]"
6111,363903534,1135,CC1=CNC(=O)NC1=O,Active,,,,RAT,F344/MALE,ORAL,0; 1; 3% IN DIET FOR 36 WK (STUDY DURATION: 40 WK),"BLADDER: PAPILLOMA, CARCINOMA",POSITIVE,"[OKUMURA,M, HASEGAWA,R, SHIRAI,T, ITO,M, YAMADA,S AND FUKUSHIMA,S; RELATIONSHIP BETWEEN CALCULUS FORMATION AND CARCINOGENESIS IN THE URINARY BLADDER OF RATS ADMINISTERED THE NON-GENOTOXIC AGENTS, THYMINE OR MELAMINE; CARCINOGENESIS 13(6):1043-1045, 1992]"
6112,363903535,39589,CCN(CC)C(=O)N(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 7.75; 14.15; 28.3; 56.6 MG/KG IN 0.1 ML OLIVE OIL 1/WK FOR 52 WK (STUDY DURATION: LIFESPAN),"NASAL CAVITY: SQUAMOUS CELL CARCINOMA; SPLEEN: HEMANGIOENDOTHELIOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA, PAPILLOMA",POSITIVE,"[KETKAR,MB, MOHR,U AND LIJINSKY,W; THE CARCINOGENIC EFFECT OF 1,1-DIETHYL-3- METHYL-3-NITROSOUREA IN SYRIAN GOLDEN HAMSTERS; CANCER LETT. 23(2):177-182, 1984]"
6113,363903535,39589,CCN(CC)C(=O)N(C)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 7.75; 14.15; 28.3; 56.6 MG/KG IN 0.1 ML OLIVE OIL 1/WK FOR 52 WK (STUDY DURATION: LIFESPAN),"NASAL CAVITY: SQUAMOUS CELL CARCINOMA; SPLEEN: HEMANGIOENDOTHELIOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA, PAPILLOMA",POSITIVE,"[KETKAR,MB, MOHR,U AND LIJINSKY,W; THE CARCINOGENIC EFFECT OF 1,1-DIETHYL-3- METHYL-3-NITROSOUREA IN SYRIAN GOLDEN HAMSTERS; CANCER LETT. 23(2):177-182, 1984]"
6114,363903535,39589,CCN(CC)C(=O)N(C)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 40 MG/ML ((0.2 ML OF A SOLUTION IN ETHYL ACETATE/CORN OIL (1:2)) 1/WK FOR 25 WK (STUDY DURATION: LIFE SPAN),"LIVER: HEMANGIOSARCOMA, CHOLANGIOMA OR CARCINOMA; SPLEEN: HEMANGIOSARCOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA OR PAPILLOMA",POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
6115,363903536,27135,C1CN(C1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAGASTRIC,0; 50 MG/ML IN 0.2 ML STERILIZED WATER 1/WK FOR 50 WK (TOTAL DOSE 500 MG) (STUDY DURATION: LIFESPAN),"LIVER: ADENOMA, HEPATOCELLULAR CARCINOMA, HEMANGIOSARCOMA; NOSE: CARCINOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOAZETIDINE GIVEN BY GAVAGE TO SYRIAN GOLDEN HAMSTERS; CARCINOGENESIS 5(7):875-878, 1984]"
6116,363903537,21116826,CC1CN(CCO1)N=O,Active,,,,HAMSTER,SYRIAN/MALE,INTRAGASTRIC,0; 27 MG/ML IN 0.2 ML STERILIZED WATER 1/WK FOR 30 WK (TOTAL DOSE 162 MG) (STUDY DURATION: LIFESPAN),"LIVER: HEMANGIOSARCOMA; NASAL CAVITY: CARCINOMA; LUNG: CARCINOMA, ADENOMA; FORESTOMACH: PAPILLOMA; TRACHEA: ADENOMA",POSITIVE,"[LIJINSKY,W, KOVATCH,RM AND KNUTSEN,GL; CARCINOGENESIS BY NITROSOMORPHOLINES, NITROSOOXAZOLIDINES AND NITROSOAZETIDINE GIVEN BY GAVAGE TO SYRIAN GOLDEN HAMSTERS; CARCINOGENESIS 5(7):875-878, 1984]"
6117,363903538,123017,CC1CN(CCC1=O)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 80 ML OF SOLUTION OF 126 MG/L IN NEUTRAL DEIONIZED DRINKING WATER 5 D/WK FOR 26 WK (STUDY DURATION: 40 WK),NASAL CAVITY: SQUAMOUS CELL CARCINOMA; TONGUE: TUMOR; FORESTOMACH: TUMOR; ESOPHAGUS: TUMOR; TRACHEA: TUMOR,POSITIVE,"[SINGER,GM, REUBER,MD, MANGINO,MM AND LIJINSKY,W; THE EFFECT OF 3-METHYL SUBSTITUTION ON THE CARCINOGENICITY OF NITROSO-4-PIPERIDONE; CARCINOGENESIS 5(10):1351-1353, 1984]"
6118,363903539,41469,C1CN(CCC1=O)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 80 ML OF SOLUTION OF 115 MG/L IN NEUTRAL DEIONIZED DRINKING WATER 5 D/WK FOR 30 WK (STUDY DURATION: 60 WK),NASAL CAVITY: ESTHESIONEUROEPITHELIOMA; FORESTOMACH: TUMOR; ESOPHAGUS: TUMOR; TONGUE: TUMOR; LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[SINGER,GM, REUBER,MD, MANGINO,MM AND LIJINSKY,W; THE EFFECT OF 3-METHYL SUBSTITUTION ON THE CARCINOGENICITY OF NITROSO-4-PIPERIDONE; CARCINOGENESIS 5(10):1351-1353, 1984]"
6119,363903540,151883,C(CNCCO)C(=O)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 50 MG/L DRINKING WATER 5 D/WK FOR 50 WK (TOTAL DOSE 250 MG) (STUDY DURATION: LIFESPAN),"ESOPHAGUS: CARCINOMA, PAPILLOMA; TONGUE: CARCINOMA, PAPILLOMA",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; CARCINOGENESIS IN F-344 RATS BY NITROSOBIS(2-OXOPROPYL)AMINE AND RELATED COMPOUNDS ADMINISTERED IN DRINKING WATER; J. CANCER RES. CLIN. ONCOL. 107(3):178-182, 1984]"
6120,363903541,151884,CC(=O)CNCC(C(N=O)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 15; 60 MG/L DRINKING WATER 5 D/WK FOR 31; 24 WK (TOTAL DOSE 47; 144 MG) (STUDY DURATION: LIFESPAN),"ESOPHAGUS: CARCINOMA, PAPILLOMA; FORESTOMACH: CARCINOMA, PAPILLOMA; LUNG: TUMOR; TONGUE: CARCINOMA, PAPILLOMA",POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND REUBER,MD; CARCINOGENESIS IN F-344 RATS BY NITROSOBIS(2-OXOPROPYL)AMINE AND RELATED COMPOUNDS ADMINISTERED IN DRINKING WATER; J. CANCER RES. CLIN. ONCOL. 107(3):178-182, 1984]"
6121,363903714,,,Active,,,,RAT,WISTAR/MALE,ORAL,0; 100 PPM IN DIET FOR DURATION OF STUDY (STUDY DURATION: 832 D),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[SHAEFFER,E, GREIM,H AND GOESSNER,W; PATHOLOGY OF CHRONIC POLYCHLORINATED BIPHENYL (PCB) FEEDING IN RATS; TOXICOL. APPL. PHARMACOL. 75(2):278-288, 1984]"
6122,363903753,660,C1CC(=O)OC2=CC=CC=C21,Active,,,,RAT,F344/MALE,GAVAGE,0; 150; 300; 600 MG/KG IN CORN OIL 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),KIDNEY (RENAL TUBULE): ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-423 Y93]"
6123,363903753,660,C1CC(=O)OC2=CC=CC=C21,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 150; 300; 600 MG/KG IN CORN OIL 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-423 Y93]"
6124,363903753,660,C1CC(=O)OC2=CC=CC=C21,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 200; 400; 800 MG/KG IN CORN OIL 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-423 Y93]"
6125,363903753,660,C1CC(=O)OC2=CC=CC=C21,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 200; 400; 800 MG/KG IN CORN OIL 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-423 Y93]"
6126,363903754,969516,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 2000; 10000; 50000 PPM IN FEED FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-427 Y93]"
6127,363903754,969516,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,Unspecified,,,,RAT,F344/FEMALE,ORAL,0; 2000; 10000; 50000 PPM IN FEED FOR 104 WK (STUDY DURATION: 104 WK),"CLITORAL GLAND: ADENOMA, ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-427 Y93]"
6128,363903754,969516,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,Unspecified,,,,MOUSE,B6C3F1/MALE,ORAL,0; 2000; 10000; 50000 PPM IN FEED FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; SMALL INTESTINE: CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-427 Y93]"
6129,363903754,969516,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,Unspecified,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 2000; 10000; 50000 PPM IN FEED FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-427 Y93]"
6130,363903821,16307,C1=CC(=CC(=C1)Cl)C2=CC(=CC=C2)Cl,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 100 PPM IN DIET FOR DURATION OF STUDY (STUDY DURATION: 832 D),,NEGATIVE,"[SHAEFFER,E, GREIM,H AND GOESSNER,W; PATHOLOGY OF CHRONIC POLYCHLORINATED BIPHENYL (PCB) FEEDING IN RATS; TOXICOL. APPL. PHARMACOL. 75(2):278-288, 1984]"
6131,363903822,5546,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 150; 300; 600 PPM IN FEED FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-420 Y93]"
6132,363903822,5546,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 100; 200; 400 PPM IN FEED FOR 104 WK (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-420 Y93]"
6133,363903822,5546,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 400 PPM IN FEED FOR 104 WK (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-420 Y93]"
6134,363903822,5546,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 100; 200; 400 PPM IN FEED FOR 104 WK (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-420 Y93]"
6135,363903822,5546,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 400 PPM IN FEED FOR 104 WK (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-420 Y93]"
6136,363903822,5546,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Unspecified,,,,RAT,F344/MALE,ORAL,0; 150; 300; 600 PPM IN FEED FOR 104 WK (STUDY DURATION: 105 WK),LIVER: ADENOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-420 Y93]"
6137,363903823,6014,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C.Cl,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 8.3; 16.6; 33.3 MG/KG IN WATER 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-425 Y93]"
6138,363903823,6014,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C.Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 8.3; 16.6; 33.3 MG/KG IN WATER 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-425 Y93]"
6139,363903823,6014,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 11.25; 22.5; 45 MG/KG IN WATER 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-425 Y93]"
6140,363903823,6014,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 3.75; 7.5; 15 MG/KG IN WATER 1/D 5 D/WK FOR 103 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-425 Y93]"
6141,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,RAT,F344/MALE,GAVAGE,0; 3; 10; 30 MG/KG BW IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 2 YR),"KIDNEY (RENAL TUBULE): ADENOMA; PANCREAS: ADENOMA; PHARYNX: SQUAMOUS CELL CARCINOMA; PREPUTIAL GLAND: ADENOMA, CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; TONGUE: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; ZYMBAL'S GLAND: CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-384 Y93]"
6142,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 3; 10; 30 MG/KG BW IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 2 YR),"CLITORAL GLAND: ADENOMA, CARCINOMA; MAMMARY GLAND: CARCINOMA; PHARYNX: SQUAMOUS CELL CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; TONGUE: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; ZYMBAL'S GLAND: CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-384 Y93]"
6143,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 6; 20; 60 MG/KG BW IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 2 YR),"HARDERIAN GLAND: ADENOMA; LIVER: HEPATOCELLULAR ADENOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-384 Y93]"
6144,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 6; 20; 60 MG/KG BW IN CORN OIL 5 D/WK FOR 104 WK (STUDY DURATION: 2 YR),"HARDERIAN GLAND: ADENOMA; LIVER: HEPATOCELLULAR ADENOMA; PHARYNX: SQUAMOUS CELL CARCINOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; UTERUS: ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-384 Y93]"
6145,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,GUPPIE,MALE,AQUARIUM WATER,0; 4.5; 9; 18 MG/L FOR 16 MO (STUDY DURATION: 16 MO),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6146,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,GUPPIE,MALE,AQUARIUM WATER,0; 4.5; 9; 18 MG/L FOR  9 MO THEN IN CLEAN WATER FOR 7 MO (STUDY DURATION: 16 MO),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6147,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,GUPPIE,FEMALE,AQUARIUM WATER,0; 4.5; 9; 18 MG/L FOR 16 MO (STUDY DURATION: 16 MO),"LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA, CHOLANGIOCARCINOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6148,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,GUPPIE,FEMALE,AQUARIUM WATER,0; 4.5; 9; 18 MG/L FOR  9 MO THEN IN CLEAN WATER FOR 7 MO (STUDY DURATION: 16 MO),"LIVER: CHOLANGIOCARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6149,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,MEDAKA,MALE,AQUARIUM WATER,0; 4.5; 9; 18 MG/L FOR 13 MO (STUDY DURATION: 13 MO),"LIVER: CHOLANGIOCARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; GALL BLADDER: ADENOMA, HEPATOCHOLANGIOCARCINOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6150,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,MEDAKA,MALE,AQUARIUM WATER,0; 4.5; 9; 18 MG/L FOR 9 MO THEN IN CLEAN WATER FOR 4 MO (STUDY DURATION: 13 MO),"LIVER: CHOLANGIOCARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; GALL BLADDER: ADENOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6151,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,MEDAKA,FEMALE,AQUARIUM WATER,0; 4.5; 9; 18 MG/L FOR 13 MO (STUDY DURATION: 13 MO),"LIVER: CHOLANGIOCARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA, HEPATOCHOLANGIOCARCINOMA; GALL BLADDER: ADENOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6152,363903824,7285,C(C(CCl)Cl)Cl,Active,,,,MEDAKA,FEMALE,AQUARIUM WATER,0; 4.5; 9; 18 MG/L FOR 9 MO THEN IN CLEAN WATER FOR 4 MO (STUDY DURATION: 13 MO),"LIVER: CHOLANGIOCARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; GALL BLADDER: ADENOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6153,363903834,6681,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3Br)Br)N,Active,,,,RAT,F344/MALE,ORAL,0; 2000; 5000; 10000 PPM IN DIET FOR UP TO 104 WK (STUDY DURATION: 106 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATOCHOLANGIOCARCINOMA; LARGE INTESTINE: ADENOMA, CARCINOMA; KIDNEY(RENAL TUBULE): ADENOMA, CARCINOMA; URINARY BLADDER: TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-383 Y96]"
6154,363903834,6681,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3Br)Br)N,Active,,,,RAT,F344/FEMALE,ORAL,0; 2000; 5000; 10000 PPM IN DIET FOR UP TO 104 WK (STUDY DURATION: 106 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATOCHOLANGIOCARCINOMA; LARGE INTESTINE: ADENOMA, CARCINOMA; KIDNEY(RENAL TUBULE): ADENOMA, CARCINOMA; URINARY BLADDER: TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-383 Y96]"
6155,363903834,6681,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3Br)Br)N,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 104 WK (STUDY DURATION: 106 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATOBLASTOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-383 Y96]"
6156,363903834,6681,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3Br)Br)N,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 10000; 20000 PPM IN DIET FOR 104 WK (STUDY DURATION: 106 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; FORESTOMACH: SQUAMOUS CELL ADENOMA, SQUAMOUS CELL CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-383 Y96]"
6157,363903835,22487,CCN1C2=C(C=C(C=C2)[NH3+])C3=CC=CC=C31.[Cl-],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 800; 1200 PPM IN DIET FOR 78 WK (STUDY DURATION: 95-97 WK),LIVER: HEPATOCELLULAR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-93 Y78]"
6158,363903835,22487,CCN1C2=C(C=C(C=C2)[NH3+])C3=CC=CC=C31.[Cl-],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 800; 1200 PPM IN DIET FOR 78 WK (STUDY DURATION: 94-96 WK),"LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-93  Y78]"
6159,363903835,22487,CCN1C2=C(C=C(C=C2)[NH3+])C3=CC=CC=C31.[Cl-],Active,,,,RAT,F344/FEMALE,ORAL,0; 800; 2000 PPM IN DIET FOR 78 WK (STUDY DURATION: 105-110 WK),"LIVER: NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; UTERUS OR ENDOMETRIUM: ADENOCARCINOMA (NOS); EAR (ZYMBAL GLAND): SQUAMOUS CELL CARCINOMA, CARCINOMA (NOS) OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-93  Y78]"
6160,363903835,22487,CCN1C2=C(C=C(C=C2)[NH3+])C3=CC=CC=C31.[Cl-],Active,,,,RAT,F344/MALE,ORAL,0; 800; 2000 PPM IN DIET FOR 78 WK (STUDY DURATION: 104-109 WK),"INTEGUMENTARY SYSTEM: BASAL CELL OR SQUAMOUS CELL CARCINOMA OR SQUAMOUS CELL PAPILLOMA; LIVER: HEPATOCELLULAR CARCINOMA, NEOPLASTIC NODULE OR HEPATOCELLULAR CARCINOMA; EAR (ZYMBAL GLAND): CARCINOMA (NOS) OR SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-93  Y78]"
6161,363903843,2513,C[As](=O)(C)O,Inactive,,,,MOUSE,C57BL/6J/MALE,ORAL,0; 50; 200 PPM IN DRINKING WATER FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[SALIM,EI WANIBUCHI,H MORIMURA,K WEI,M MITSUHASHI,M YOSHIDA,K ENDO,G AND FUKUSHIMA,S; CARCINOGENICITY OF DIMETHYLARSINIC ACID IN P53 HETEROZYGOUS KNOCKOUT AND WILD-TYPE C57BL/6J MICE; CARCINOGENESIS 24(2):335-342, 2003]"
6162,363903843,2513,C[As](=O)(C)O,Active,,,,MOUSE,STRAIN-A/MALE,ORAL,0; 50; 200; 400 PPM IN DRINKING WATER FOR 50 WK (STUDY DURATION: 50 WK),LUNG: TUMOR,POSITIVE,"[HAYASHI,H, KANISAWA,M, YAMANAKA,K, ITO,T, UDAKA,N, OHJI,H, OKUDELA,K, OKADA,S AND KITAMURA,H; DIMETHYLARSINIC ACID, A MAIN METABOLITE OF INORGANIC ARSENICS, HAS TUMORIGENICITY AND PROGRESSION EFFECTS IN THE PULMONARY TUMORS OF A/J MICE; CANCER LETT. 125(1-2):83-88, 1998]"
6163,363903843,2513,C[As](=O)(C)O,Active,,,,RAT,F344/MALE,ORAL,0; 12.5; 50; 200 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),"URINARY BLADDER: PAPILLOMA, CARCINOMA",POSITIVE,"[WEI,M, WANIBUCHI,H, YAMAMOTO,S, LI,W AND FUKUSHIMA,S; URINARY BLADDER CARCINOGENICITY OF DIMETHYLARSINIC ACID IN MALE F344 RATS; CARCINOGENESIS 20(9):1873-1876, 1999]"
6164,363903843,2513,C[As](=O)(C)O,Active,,,,Rat,F344/Male (60/group),Oral,0; 2; 10; 40; 100 ppm  in diet  for 2 yr,URINARY BLADDER: Transitional cell papillomas and carcinomas,Positive (Study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CACODYLIC ACID (FEBRUARY 20, 1996)]"
6165,363903843,2513,C[As](=O)(C)O,Active,,,,Rat,F344/Female (60/group),Oral,0; 2; 10; 40; 100 ppm  in diet  for 2 yr,URINARY BLADDER: Transitional cell papillomas and carcinomas,Positive (High dose only; study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CACODYLIC ACID (FEBRUARY 20, 1996)]"
6166,363903843,2513,C[As](=O)(C)O,Active,,,,Mouse,B6C3F1/Female (55/group),Oral,0; 8; 40; 200; 500 ppm in diet for 2 yr,MULTIPLE ORGANS: Fibrosarcomas,Positive (High dose only; study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CACODYLIC ACID (FEBRUARY 20, 1996)]"
6167,363903843,2513,C[As](=O)(C)O,Active,,,,Mouse,B6C3F1/Male (55/group),Oral,0; 8; 40; 200; 500 ppm in diet for 2 yr,MULTIPLE ORGANS: Fibrosarcomas,Positive (Study details not given in source),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CACODYLIC ACID (FEBRUARY 20, 1996)]"
6168,363903843,2513,C[As](=O)(C)O,Active,,,,Mouse,Mmh/OGG1 knockout mice (40 males and females) and wild-type mice derived from C57BL/6J background (44 males and females),Oral,200 ppm ad libitum in drinking water; dose and study duration 72 wk,Lung; Malignant lymphoma/leukemia,Positive (Significant increase in tumor incidence and multiplicity in knockout mice administered carcinogen compared to knockout controls and carcinogen-treated wild type mice),"[KINOSHITA,A WANIBUCHI,H MORIMURA,K WEI,M NAKAE,D ARAI,T MINOWA,O NODA,T NISHIMURA,S AND FUKUSHIMA,S; CARCINOGENICITY OF DIMETHYLARSINIC ACID IN OGGL-DEFICIENT MICE; CANCER SCIENCE 98(6):803-814, 2007]"
6169,363903843,2513,C[As](=O)(C)O,Active,,,,Rat,F344.Male (36/group),Oral,"0; 12.5; 50; 200 ppm in drinking water for 104 wk, study duration 104 wk","Urinary bladder: Papilloma (0/28, 0/28, 2/31, 2/31); transitional cell carcinoma (0/28, 0/28, 6/31, 12/31)",Positive,"[WEI,M WANIBUCHI,H MORIMURA,K AND FUKUSHIMA,S; CARCINOGENICITY OF DIMETHYLARSINIC ACID RELEVEANT MECHANISMS; ARSENIC EXPOSURE HEALTH EFF. V, PROC. IN 211-223, 2003]"
6170,363903856,8113,C(CO)NCCO,Inactive,,,,RAT,F344/N/MALE,DERMAL,0; 16; 32; 64 MG/KG BW IN ETHANOL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-478  Y99]"
6171,363903856,8113,C(CO)NCCO,Inactive,,,,RAT,F344/N/FEMALE,DERMAL,0; 8; 16; 32 MG/KG BW IN ETHANOL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-478  Y99]"
6172,363903856,8113,C(CO)NCCO,Active,,,,MOUSE,B6C3F1/MALE,DERMAL,0; 40; 80; 160 MG/KG BW IN ETHANOL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, OR HEPATOBLASTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-478  Y99]"
6173,363903856,8113,C(CO)NCCO,Active,,,,MOUSE,B6C3F1/FEMALE,DERMAL,0; 40; 80; 160 MG/KG BW IN ETHANOL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, OR HEPATOBLASTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-478  Y99]"
6174,363903865,750,C(C(=O)O)N,Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN DRINKING WATER FOR 108 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[KITAHORI,Y, KONISHI,N, HAYASHI,I, NAKAHASHI,K, KITAMURA,M, NAKAMURA,Y, MATSUDA,H, FUKUSHIMA,Y, YOSHIOKA,N AND HIASA,Y; CARCINOGENICITY STUDY OF GLYCINE IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 7(4):471-480, 1994]"
6175,363903865,750,C(C(=O)O)N,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN DRINKING WATER FOR 108 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[KITAHORI,Y, KONISHI,N, HAYASHI,I, NAKAHASHI,K, KITAMURA,M, NAKAMURA,Y, MATSUDA,H, FUKUSHIMA,Y, YOSHIOKA,N AND HIASA,Y; CARCINOGENICITY STUDY OF GLYCINE IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 7(4):471-480, 1994]"
6176,363903869,6478,C1(=C(C(C(=C1Cl)Cl)(Cl)Cl)Cl)Cl,Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.01; 0.05; 0.2 PPM IN AIR 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-437 Y94]"
6177,363903869,6478,C1(=C(C(C(=C1Cl)Cl)(Cl)Cl)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.01; 0.05; 0.2 PPM IN AIR 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-437 Y94]"
6178,363903869,6478,C1(=C(C(C(=C1Cl)Cl)(Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.01; 0.05; 0.2 PPM IN AIR 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-437 Y94]"
6179,363903869,6478,C1(=C(C(C(=C1Cl)Cl)(Cl)Cl)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.01; 0.05; 0.2 PPM IN AIR 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-437 Y94]"
6180,363903897,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 75; 150; 300 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-433 Y94]"
6181,363903897,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 75; 150; 300 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-433 Y94]"
6182,363903897,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 60; 125; 250 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-433 Y94]"
6183,363903897,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 60; 125; 250 PPM IN DIET FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-433 Y94]"
6184,363903916,25157,O.O.[Cl-].[Cl-].[Ba+2],Inactive,,,,RAT,F344/MALE,ORAL,0; 500; 1250; 2500 PPM IN DRINKING WATER (APPROXIMATELY 0; 15; 30; 60 MG/KG BW) FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-432 Y94]"
6185,363903916,25157,O.O.[Cl-].[Cl-].[Ba+2],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 500; 1250; 2500 PPM IN DRINKING WATER (APPROXIMATELY 0; 15; 45; 75 MG/KG BW) FOR 105 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-432 Y94]"
6186,363903916,25157,O.O.[Cl-].[Cl-].[Ba+2],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 1250; 2500 PPM IN DRINKING WATER (APPROXIMATELY 0; 30; 75; 160 MG/KG BW) FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-432 Y94]"
6187,363903916,25157,O.O.[Cl-].[Cl-].[Ba+2],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1250; 2500 PPM IN DRINKING WATER (APPROXIMATELY 0; 40; 90; 200 MG/KG BW) FOR 104 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-432 Y94]"
6188,363903922,18692,C(C(CO)(CBr)CBr)O,Active,,,,RAT,F344/MALE,ORAL,0; 2500; 5000; 10000 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 105 WK),"ESOPHAGUS: SQUAMOUS CELL PAPILLOMA; LARGE INTESTINE: ADENOMATOUS POLYP; MAMMARY GLAND: FIBROADENOMA, FIBROADENOMA OR ADENOMA; ORAL CAVITY: SQUAMOUS CELL PAPILLOMA; SKIN: SQUAMOUS CELL PAPILLOMA, KERATOACANTHOMA, TRICHOEPITHELIOMA, BASAL CELL ADENOMA, BASAL CELL CARCINOMA; SKIN(SUBCUTANEOUS TISSUE): FIBROMA, FIBROSARCOMA OR SARCOMA; THYROID(FOLLICULAR CELL): ADENOMA OR CARCINOMA; TONGUE: SQUAMOUS CELL PAPILLOMA; ALL ORGANS: MONONUCLEAR CELL LEUKEMIA, MALIGNANT MESOTHELIOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-452 Y96]"
6189,363903922,18692,C(C(CO)(CBr)CBr)O,Active,,,,RAT,F344/MALE,ORAL,0; 20000 PPM IN DIET FOR 3 MO FOLLOWED BY NORMAL DIET FOR 21 MO (STUDY DURATION: 2 YR),"LARGE INTESTINE: ADENOMATOUS POLYP; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; MAMMARY GLAND: FIBROADENOMA; ORAL CAVITY: SQUAMOUS CELL PAPILLOMA; PHARYNX: SQUAMOUS CELL PAPILLOMA; SKIN: SQUAMOUS CELL PAPILLOMA, KERATOACANTHOMA, TRICHOEPITHELIOMA, BASAL CELL ADENOMA OR SQUAMOUS CELL CARCINOMA; SKIN(SUBCUTANEOUS TISSUE): FIBROMA, FIBROSARCOMA OR SARCOMA; FORESTOMACH: SQUAMOUS CELL PAPILLOMA; THYROID (FOLLICULAR CELL): ADENOMA, ADENOMA OR CARCINOMA; TONGUE: SQUAMOUS CELL PAPILLOMA; ZYMBAL'S GLAND: CARCINOMA; ALL ORGANS: MALIGNANT MESOTHELIOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-452 Y96]"
6190,363903922,18692,C(C(CO)(CBr)CBr)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2500; 5000; 10000 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 105 WK),ESOPHAGUS: SQUAMOUS CELL PAPILLOMA; MAMMARY GLAND: FIBROADENOMA; ORAL CAVITY: SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA; THYROID(FOLLICULAR CELL): ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-452 Y96]"
6191,363903922,18692,C(C(CO)(CBr)CBr)O,Active,,,,MOUSE,B63CF1/MALE,ORAL,0; 312; 625; 1250 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 106 WK),"HARDERIAN GLAND: ADENOMA, ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-452 Y96]"
6192,363903922,18692,C(C(CO)(CBr)CBr)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 312; 625; 1250 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 106 WK),"HARDERIAN GLAND: ADENOMA, CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; SKIN(SUBCUTANEOUS TISSUE): SARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-452 Y96]"
6193,363903922,18692,C(C(CO)(CBr)CBr)O,Active,,,,GUPPIE,MALE,AQUARIUM WATER,0; 24; 60; 150 MG/L FOR 16 MO (STUDY DURATION: 16 MO),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,"POSITIVE; DUE TO MORTALITY, EXPOSURE IN 150 MG/L GROUP TERMINATED ON DAY 443","[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6194,363903922,18692,C(C(CO)(CBr)CBr)O,Active,,,,GUPPIE,MALE,AQUARIUM WATER,0; 24; 60; 150 MG/L FOR 9 MO THEN IN CLEAN WATER FOR 7 MO (STUDY DURATION: 16 MO),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6195,363903922,18692,C(C(CO)(CBr)CBr)O,Active,,,,MEDAKA,MALE,AQUARIUM WATER,0; 24; 60; 150 MG/L FOR 14 MO (STUDY DURATION: 14 MO),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6196,363903922,18692,C(C(CO)(CBr)CBr)O,Active,,,,MEDAKA,MALE,AQUARIUM WATER,0; 24; 60; 150 MG/L FOR 9 MO THEN IN CLEAN WATER FOR 5 MO (STUDY DURATION: 14 MO),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6197,363903922,18692,C(C(CO)(CBr)CBr)O,Inactive,,,,MEDAKA,FEMALE,AQUARIUM WATER,0; 24; 60; 150 MG/L FOR 14 MO (STUDY DURATION: 14 MO),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, NITROMETHANE, AND 1,2,3-TRICHLOROPROPANE (CAS  NO. 3296-90-0, 75-52-5, AND 96-18-4) IN GUPPIES (POECILIA RETICULATA) AND MEDAKA (ORYZIAS LATIPES) (WATERBORNE  STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER.  528:1-190, 2005]"
6198,363903935,8133,CCCCOCCO,Inactive,,,,RAT,F344/MALE,INHALATION,0; 31.2; 62.5; 125 PPM 6 HR/D 5D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-484 Y00]"
6199,363903935,8133,CCCCOCCO,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 62.5; 125; 250 PPM 6 HR/D 5D/WK FOR 104 WK (STUDY DURATION: 104 WK),"LIVER: HEMANGIOSARCOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-484 Y00]"
6200,363903935,8133,CCCCOCCO,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 62.5; 125; 250 PPM 6 HR/D 5D/WK FOR 104 WK (STUDY DURATION: 104 WK),FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-484 Y00]"
6201,363903935,8133,CCCCOCCO,Unspecified,,,,RAT,F344/FEMALE,INHALATION,0; 31.2; 62.5; 125 PPM 6 HR/D 5D/WK FOR 104 WK (STUDY DURATION: 104 WK),ADRENAL MEDULLA: BENIGN OR MALIGNANT PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-484 Y00]"
6202,363903952,76960584,O.O.O.O.O.O.O.OS(=O)(=O)O.[Co+2],Active,,,,RAT,F344/N/MALE,INHALATION,0; 0.3; 1; 3 MG/M3 6HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-471 Y98]"
6203,363903952,76960584,O.O.O.O.O.O.O.OS(=O)(=O)O.[Co+2],Active,,,,RAT,F344/FEMALE,INHALATION,0; 0.3; 1; 3 MG/M3 6HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA; ADRENAL MEDULLA: BENIGN, COMPLEX, OR MALIGNANT PHEOCHROMOCYTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-471 Y98]"
6204,363903952,76960584,O.O.O.O.O.O.O.OS(=O)(=O)O.[Co+2],Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.3; 1; 3 MG/M3 6HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-471 Y98]"
6205,363903952,76960584,O.O.O.O.O.O.O.OS(=O)(=O)O.[Co+2],Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.3; 1; 3 MG/M3 6HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-471 Y98]"
6206,363903954,460,COC1=CC=CC=C1O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 20; 50; 200 MG/KG/D IN 0.5% CARBOXYMETHYLCELLULOSE SUSPENSION FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[KUGE,T SHIBATA,T WILLETT,MS TURCK,P AND TRAUL,KA; LACK OF ONCOGENICITY OF WOOD CREOSOTE, THE PRINCIPAL ACTIVE INGREDIENT OF SEIROGAN, AN HERBAL ANTIDIARRHEAL MEDICATION, IN SPRAGUE-DAWLEY RATS; INTL. J. TOXICOL. 20(5):297-305, 2001]"
6207,363903954,460,COC1=CC=CC=C1O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 20; 50; 200 MG/KG/D IN 0.5% CARBOXYMETHYLCELLULOSE SUSPENSION FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[KUGE,T SHIBATA,T WILLETT,MS TURCK,P AND TRAUL,KA; LACK OF ONCOGENICITY OF WOOD CREOSOTE, THE PRINCIPAL ACTIVE INGREDIENT OF SEIROGAN, AN HERBAL ANTIDIARRHEAL MEDICATION, IN SPRAGUE-DAWLEY RATS; INTL. J. TOXICOL. 20(5):297-305, 2001]"
6208,363903956,,,Inactive,,,,Rat,F344/N /Male (50/group),Oral,"0; 1500; 5000; 15,000 ppm in food for 2 yr","Equivocal findings: Kidney: renal tubule adenoma (0/50, 0/50, 0/50, 3/50)",Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-550 Y08]"
6209,363903956,,,Active,,,,Mouse,B6C3F1/Female (50/group),Oral,"0; 1000; 3000; 10,000 ppm in food for 2 yr","Forestomach: squamous cell papilloma (0/50, 1/50, 1/49, 10/50)",Positive; statistically significant only at top dose. (NTP describes as Some Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-550 Y08]"
6210,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,RAT,CD/MALE,ORAL,0; 10; 30; 100 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[SCHOENIG,GP OSIMITZ,TG GABRIEL,KL HARTNAGEL,R GILL,MW AND GOLDENTHAL,EI; EVALUATION OF THE CHRONIC TOXICITY AND ONCOGENICITY OF N,N-DIETHYL-M-TOLUAMIDE (DEET); TOXICOL. SCI. 47(1):99-109, 1999]"
6211,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,RAT,CD/FEMALE,ORAL,0; 30; 100; 400 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[SCHOENIG,GP OSIMITZ,TG GABRIEL,KL HARTNAGEL,R GILL,MW AND GOLDENTHAL,EI; EVALUATION OF THE CHRONIC TOXICITY AND ONCOGENICITY OF N,N-DIETHYL-M-TOLUAMIDE (DEET); TOXICOL. SCI. 47(1):99-109, 1999]"
6212,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 250; 500; 1000 MG/KG/D IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[SCHOENIG,GP OSIMITZ,TG GABRIEL,KL HARTNAGEL,R GILL,MW AND GOLDENTHAL,EI; EVALUATION OF THE CHRONIC TOXICITY AND ONCOGENICITY OF N,N-DIETHYL-M-TOLUAMIDE (DEET); TOXICOL. SCI. 47(1):99-109, 1999]"
6213,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,RAT,CD-1/FEMALE,ORAL,0; 250; 500; 1000 MG/KG/D IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[SCHOENIG,GP OSIMITZ,TG GABRIEL,KL HARTNAGEL,R GILL,MW AND GOLDENTHAL,EI; EVALUATION OF THE CHRONIC TOXICITY AND ONCOGENICITY OF N,N-DIETHYL-M-TOLUAMIDE (DEET); TOXICOL. SCI. 47(1):99-109, 1999]"
6214,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,DOG,BEAGLE/MALE,ORAL,0; 30; 100; 400 MG/KG/D IN DIET FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[SCHOENIG,GP OSIMITZ,TG GABRIEL,KL HARTNAGEL,R GILL,MW AND GOLDENTHAL,EI; EVALUATION OF THE CHRONIC TOXICITY AND ONCOGENICITY OF N,N-DIETHYL-M-TOLUAMIDE (DEET); TOXICOL. SCI. 47(1):99-109, 1999]"
6215,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,DOG,BEAGLE/FEMALE,ORAL,0; 30; 100; 400 MG/KG/D IN DIET FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[SCHOENIG,GP OSIMITZ,TG GABRIEL,KL HARTNAGEL,R GILL,MW AND GOLDENTHAL,EI; EVALUATION OF THE CHRONIC TOXICITY AND ONCOGENICITY OF N,N-DIETHYL-M-TOLUAMIDE (DEET); TOXICOL. SCI. 47(1):99-109, 1999]"
6216,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,Rat,Charles River CD/Male (60/Group),Oral,0; 10; 30; 100 mg/kg in diet for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DEET (JUNE 21, 1999)]"
6217,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,Rat,Charles River CD/Female (60/Group),Oral,0; 10; 30; 100 mg/kg in diet for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DEET (JUNE 21, 1999)]"
6218,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,Mouse,CD-1/Male (60/Group),Oral,0; 250; 500; 1000 mg/kg in diet for 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DEET (JUNE 21, 1999)]"
6219,363903968,4284,CCN(CC)C(=O)C1=CC=CC(=C1)C,Inactive,,,,Mouse,CD-1/Female (60/Group),Oral,0; 250; 500; 1000 mg/kg in diet for 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DEET (JUNE 21, 1999)]"
6220,363903985,12968,CCCN(CCC)C(=O)SCC,Inactive,,,,Mouse,Crl:CD-1/Male (60/Group),Oral,"0; 200; 600; 1800 ppm in diet for 73 wks, study duration 73 wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR EPTC  (October 22, 1999)]"
6221,363903985,12968,CCCN(CCC)C(=O)SCC,Inactive,,,,Mouse,Crl:CD-1/Female (60/Group),Oral,"0; 200; 600; 1800 ppm in diet for 73 wks, study duration 73 wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR EPTC  (October 22, 1999)]"
6222,363903985,12968,CCCN(CCC)C(=O)SCC,Inactive,,,,Rat,Crl:CD (SD) BR/Female (90/Group),Oral,"0; 9; 18; 36; 72 mg/kg/day  in diet for 2 yr, study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR EPTC  (October 22, 1999)]"
6223,363903985,12968,CCCN(CCC)C(=O)SCC,Inactive,,,,Rat,Crl:CD (SD) BR/Male (90/Group),Oral,"0; 9; 18; 36; 72 mg/kg/day  in diet for 2 yr, study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR EPTC  (October 22, 1999)]"
6224,363904017,7407,CC(=C)C1=CC=CC=C1,Inactive,,,,Mouse,B6C3F1/Male (50/group),Inhalation,"0; 100; 300; 600 ppm for 6 hr/d, 5 d/wk, except holidays, for 105 wk","Liver: hepatocellular adenoma and carcinoma combined (28/50, 36/50, 33/50, 37/50 (considered equivocal))",Negative; p value not significant (NTP reports as Equivocal Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-543 T07]"
6225,363904017,7407,CC(=C)C1=CC=CC=C1,Inactive,,,,Rat,F344/N / Female (50/group),Inhalation,"0; 100; 300; 1000 ppm for 6 hr/d, 5 d/wk, except holidays, for 105 wk",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-543 Y07]"
6226,363904017,7407,CC(=C)C1=CC=CC=C1,Active,,,,Rat,F344/N / Male (50/group),Inhalation,"0; 100; 300; 1000 ppm for 6 hr/d, 5 d/wk, except holidays, for 105 wk","Kidney: renal tubule adenoma and carcinoma combined (0/50, 0/50, 3/50, 7/50 (single and step sections)) Mononuclear cell leukemia (26/50, 32/50, 29/50, 38/50 (considered equivocal))",Positive (NTP reports as Some Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-543 Y07]"
6227,363904017,7407,CC(=C)C1=CC=CC=C1,Active,,,,Mouse,B6C3F1/Female (50/group),Inhalation,"0; 100; 300; 600 ppm for 6 hr/d, 5 d/wk, except holidays, for 105 wk","Liver: hepatocelllular carcinoma (3/50, 9/50, 6/50, 18/50); hepatocellular adenoma and carcinoma combined (13/50, 26/50, 24/50, 33/50)",Positive (NTP reports as Clear Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-543 Y07]"
6228,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 1; 5; 25 MG/KG IN DISTILLED WATER FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-445 Y97]"
6229,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,RAT,F344/FEMALE,GAVAGE,1; 1; 5; 25 MG/KG IN DISTILLED WATER FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-445 Y97]"
6230,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 1; 5; 25 MG/KG IN DISTILLED WATER FOR 104-105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-445 Y97]"
6231,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 1; 5; 25 MG/KG IN DISTILLED WATER FOR 104-105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-445 Y97]"
6232,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 25 MG/KG IN WATER 5 D/WK FOR 104 WK, CONTROL AND DOSED GROUPS FED AD LIBITUM (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
6233,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 25 MG/KG IN WATER 5 D/WK FOR 104 WK, CONTROL GROUP WAS WEIGHT-MATCHED TO DOSED GROUP (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
6234,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 25 MG/KG IN WATER 5 D/WK FOR 104 WK, CONTROL GROUP DIET RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM FED GROUP (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
6235,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,"0; 25 MG/KG IN WATER 5 D/WK FOR 157 WK, CONTROL GROUP DIET RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUPS (STUDY DURATION: 157 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
6236,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 25 MG/KG IN WATER 5 D/WK FOR 104 WK, CONTROL AND DOSED GROUPS FED AD LIBITUM (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
6237,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 25 MG/KG IN WATER 5 D/WK FOR 104 WK, CONTROL GROUP WAS WEIGHT-MATCHED TO DOSED GROUP (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
6238,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 25 MG/KG IN WATER 5 D/WK FOR 104 WK, CONTROL GROUP DIET RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUP (STUDY DURATION: 104 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
6239,363904049,20055509,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4.O.O.O.Br,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,"0; 25 MG/KG IN WATER 5 D/WK FOR 157 WK, CONTROL GROUP DIET RESTRICTED TO LIMIT WEIGHTS TO 85% OF AD LIBITUM-FED GROUPS (STUDY DURATION: 157 WK)",,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-460 Y97]"
6240,363904056,31357,CCCCOP(=O)(OCCCC)OCCCC,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 200; 700; 3000 PPM IN DIET FOR 24 MO (STUDY DURATION: 24 MO),"URINARY BLADDER: PAPILLOMA, TRANSITIONAL CELL CARCINOMA",POSITIVE,"[AULETTA,CS, WEINER,ML AND RICHTER,WR; A DIETARY TOXICITY/ONCOGENICITY STUDY OF TRIBUTYL PHOSPHATE IN THE RAT; TOXICOLOGY 128(2):125-134, 1998]"
6241,363904056,31357,CCCCOP(=O)(OCCCC)OCCCC,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 200; 700; 3000 PPM IN DIET FOR 24 MO (STUDY DURATION: 24 MO),URINARY BLADDER: PAPILLOMA,POSITIVE,"[AULETTA,CS, WEINER,ML AND RICHTER,WR; A DIETARY TOXICITY/ONCOGENICITY STUDY OF TRIBUTYL PHOSPHATE IN THE RAT; TOXICOLOGY 128(2):125-134, 1998]"
6242,363904056,31357,CCCCOP(=O)(OCCCC)OCCCC,Active,,,,MOUSE,CD-1/ MALE,ORAL,0; 150; 1000; 3500 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[AULETTA,CS, WEINER,ML AND RICHTER,WR; A DIETARY TOXICITY/ONCOGENICTY STUDY OF TRIBUTYL PHOSPHATE IN THE RAT; TOXICOLOGY 128(2):135-141, 1998]"
6243,363904056,31357,CCCCOP(=O)(OCCCC)OCCCC,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 150; 1000; 3500 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[AULETTA,CS, WEINER,ML AND RICHTER,WR; A DIETARY TOXICITY/ONCOGENICTY STUDY OF TRIBUTYL PHOSPHATE IN THE RAT; TOXICOLOGY 128(2):135-141, 1998]"
6244,363904066,442089,C[C@@]12CCC[C@@]([C@H]1CC[C@]34[C@H]2CC[C@](C3)(C(=C)C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)(C)C(=O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 0.2; 0.6; 1.2% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[XILI,L, CHENGJIANY,B, ERYI,X, REIMING,S, YUENGMING,W, HAODONG,S AND ZHIYIAN,H; CHRONIC ORAL TOXICITY AND CARCINOGENICITY STUDY OF STEVIOSIDE IN RATS; FOOD CHEM. TOXICOL. 30(11):957-965, 1992]"
6245,363904066,442089,C[C@@]12CCC[C@@]([C@H]1CC[C@]34[C@H]2CC[C@](C3)(C(=C)C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)(C)C(=O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 0.2; 0.6%; 1.2% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[XILI,L, CHENGJIANY,B, ERYI,X, REIMING,S, YUENGMING,W, HAODONG,S AND ZHIYIAN,H; CHRONIC ORAL TOXICITY AND CARCINOGENICITY STUDY OF STEVIOSIDE IN RATS; FOOD CHEM. TOXICOL. 30(11):957-965, 1992]"
6246,363904066,442089,C[C@@]12CCC[C@@]([C@H]1CC[C@]34[C@H]2CC[C@](C3)(C(=C)C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)(C)C(=O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN DIET FOR 104 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[TOYODA,K, MATSUI,H, SHODA,T, UNEYAMA,C, TAKADA,K AND TAKAHASHI,M; ASSESSMENT OF THE CARCINOGENICITY OF STEVIOSIDE IN F344 RATS; FOOD CHEM. TOXICOL. 35(6):597-603, 1997]"
6247,363904066,442089,C[C@@]12CCC[C@@]([C@H]1CC[C@]34[C@H]2CC[C@](C3)(C(=C)C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)(C)C(=O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN DIET FOR 104 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[TOYODA,K, MATSUI,H, SHODA,T, UNEYAMA,C, TAKADA,K AND TAKAHASHI,M; ASSESSMENT OF THE CARCINOGENICITY OF STEVIOSIDE IN F344 RATS; FOOD CHEM. TOXICOL. 35(6):597-603, 1997]"
6248,363904092,9570455,C1=CC(=C(C=C1C2=CC(=C(C=C2)N/N=C/3\C(=O)C4=C(C=C3S(=O)(=O)[O-])C=C(C=C4N)S(=O)(=O)[O-])O)O)N/N=C/5\C(=O)C6=C(C=C5S(=O)(=O)[O-])C=C(C=C6N)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Cu].[Cu],Active,,,,RAT,F344/MALE,ORAL,0; 1000; 3000; 10000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),PHARYNX: SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-430 Y94]"
6249,363904092,9570455,C1=CC(=C(C=C1C2=CC(=C(C=C2)N/N=C/3\C(=O)C4=C(C=C3S(=O)(=O)[O-])C=C(C=C4N)S(=O)(=O)[O-])O)O)N/N=C/5\C(=O)C6=C(C=C5S(=O)(=O)[O-])C=C(C=C6N)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Cu].[Cu],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1000; 3000; 10000 PPM IN DIET FOR 103 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-430 Y94]"
6250,363904092,9570455,C1=CC(=C(C=C1C2=CC(=C(C=C2)N/N=C/3\C(=O)C4=C(C=C3S(=O)(=O)[O-])C=C(C=C4N)S(=O)(=O)[O-])O)O)N/N=C/5\C(=O)C6=C(C=C5S(=O)(=O)[O-])C=C(C=C6N)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Cu].[Cu],Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1000; 3000; 10000 PPM IN DIET FOR 103 WK (STUDY DURATION: 106 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-430 Y94]"
6251,363904092,9570455,C1=CC(=C(C=C1C2=CC(=C(C=C2)N/N=C/3\C(=O)C4=C(C=C3S(=O)(=O)[O-])C=C(C=C4N)S(=O)(=O)[O-])O)O)N/N=C/5\C(=O)C6=C(C=C5S(=O)(=O)[O-])C=C(C=C6N)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Cu].[Cu],Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1000; 3000; 10000 PPM IN DIET FOR 103 WK (STUDY DURATION: 106 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-430 Y94]"
6252,363904096,149482,CCNC(=O)N(C)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 20; 40 UMOL/WK IN CORN OIL/ETHYL ACETATE (2: 1) FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),NERVOUS SYSTEM: TUMOR; TESTIS: MESOTHELIOMA,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6253,363904096,149482,CCNC(=O)N(C)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 20; 40 UMOL/WK IN CORN OIL/ETHYL ACETATE (2: 1) FOR 30 WK (LOW DOSE) OR 15 WK (HIGH DOSE) FOR TOTAL DOSES OF 0; 0.6; 0.6 MMOL (STUDY DURATION: LIFETIME),NERVOUS SYSTEM: TUMOR; THYMUS: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6254,363904096,149482,CCNC(=O)N(C)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 20; 40 UMOL/WK IN DRINKING WATER FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),LUNG: TUMOR; NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6255,363904096,149482,CCNC(=O)N(C)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 20; 40 UMOL/WK IN DRINKING WATER FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),NERVOUS SYSTEM: TUMOR; KIDNEY: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6256,363904097,126434,CCN(C(=O)NC)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 20; 40 UMOL/WK IN CORN OIL/ETHYL ACETATE (2: 1) FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),LUNG: TUMOR; TESTIS: MESOTHELIOMA; ZYMBAL GLAND: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6257,363904097,126434,CCN(C(=O)NC)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 20; 40 UMOL/WK IN CORN OIL/ETHYL ACETATE (2: 1) FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),MAMMARY GLAND: TUMOR; UTERUS: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6258,363904097,126434,CCN(C(=O)NC)N=O,Active,,,,RAT,F344/MALE,ORAL,0; 20; 40 UMOL/WK IN DRINKING WATER FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),LUNG: TUMOR; THYROID: FOLLICULAR CELL TUMOR; TESTIS: MESOTHELIOMA; NERVOUS SYSTEM: TUMOR; ZYMBAL GLAND: TUMOR; COLON: TUMOR; SKIN: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6259,363904097,126434,CCN(C(=O)NC)N=O,Active,,,,RAT,F344/FEMALE,ORAL,0; 20; 40 UMOL/WK IN DRINKING WATER FOR 30 WK FOR TOTAL DOSES OF 0; 0.6; 1.2 MMOL (STUDY DURATION: LIFETIME),LUNG: TUMOR; MAMMARY GLAND: TUMOR; UTERUS: TUMOR; THYROID: FOLLICULAR CELL TUMOR; NERVOUS SYSTEM: TUMOR,POSITIVE,"[LIJINSKY,W, SAAVEDRA,JE AND KOVATCH,RM; CARCINOGENESIS IN RATS BY NITROSODIALKYLUREAS CONTAINING METHYL AND ETHYL GROUPS GIVEN BY GAVAGE AND IN DRINKING WATER; J. TOXICOL. ENVIRON. HEALTH 28(1):27-38, 1989]"
6260,363904098,44334,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC=C4[N+](=O)[O-],Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED IN 3 SUBDOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 8 AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 32 WK)",,NEGATIVE,"[EL-BAYOUMY,K, DESAI,D, UPADHYAYA,P, AMIN,S AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF NITROCHRYSENE ISOMERS IN NEWBORN MICE; CARCINOGENESIS 13(12):2271-2275, 1992]"
6261,363904098,44334,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC=C4[N+](=O)[O-],Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED IN 3 SUBDOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 8 AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 32 WK)",,NEGATIVE,"[EL-BAYOUMY,K, DESAI,D, UPADHYAYA,P, AMIN,S AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF NITROCHRYSENE ISOMERS IN NEWBORN MICE; CARCINOGENESIS 13(12):2271-2275, 1992]"
6262,363904099,151998,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=C(C=C4)[N+](=O)[O-],Inactive,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED IN 3 SUBDOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 8 AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 32 WK)",,NEGATIVE,"[EL-BAYOUMY,K, DESAI,D, UPADHYAYA,P, AMIN,S AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF NITROCHRYSENE ISOMERS IN NEWBORN MICE; CARCINOGENESIS 13(12):2271-2275, 1992]"
6263,363904099,151998,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=C(C=C4)[N+](=O)[O-],Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 100 NMOL (TOTAL DOSE) ADMINISTERED IN 3 SUBDOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 8 AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 32 WK)",,NEGATIVE,"[EL-BAYOUMY,K, DESAI,D, UPADHYAYA,P, AMIN,S AND HECHT,SS; COMPARATIVE TUMORIGENICITY OF NITROCHRYSENE ISOMERS IN NEWBORN MICE; CARCINOGENESIS 13(12):2271-2275, 1992]"
6264,363904100,62857,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.001; 0.0045; 0.02% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BENDELE,RA, ADAMS,ER, HOFFMAN,WP, GRIES,CL AND MORTON,DM; CARCINOGENICITY STUDIES OF FLUOXETINE HYDROCHLORIDE IN RATS AND MICE; CANCER RES. 52(24): 6931-6935, 1992]"
6265,363904100,62857,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.001; 0.0045; 0.02% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BENDELE,RA, ADAMS,ER, HOFFMAN,WP, GRIES,CL AND MORTON,DM; CARCINOGENICITY STUDIES OF FLUOXETINE HYDROCHLORIDE IN RATS AND MICE; CANCER RES. 52(24): 6931-6935, 1992]"
6266,363904100,62857,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.001; 0.004; 0.01% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BENDELE,RA, ADAMS,ER, HOFFMAN,WP, GRIES,CL AND MORTON,DM; CARCINOGENICITY STUDIES OF FLUOXETINE HYDROCHLORIDE IN RATS AND MICE; CANCER RES. 52(24): 6931-6935, 1992]"
6267,363904100,62857,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.001; 0.004; 0.01% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BENDELE,RA, ADAMS,ER, HOFFMAN,WP, GRIES,CL AND MORTON,DM; CARCINOGENICITY STUDIES OF FLUOXETINE HYDROCHLORIDE IN RATS AND MICE; CANCER RES. 52(24): 6931-6935, 1992]"
6268,363904101,7002,CC1=CC=CC2=CC=CC=C12,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.075; 0.15% IN DIET FOR 81 WK (STUDY DURATION: 81 WK),,NEGATIVE,"[MURATA,Y, DENDA,A, MARUYAMA,H AND KONISHI,Y; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF 1-METHYLNAPHTHALENE IN B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 21(1):44-51, 1993]"
6269,363904101,7002,CC1=CC=CC2=CC=CC=C12,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.075; 0.15% IN DIET FOR 81 WK (STUDY DURATION: 81 WK),LUNG: ADENOMA,POSITIVE,"[MURATA,Y, DENDA,A, MARUYAMA,H AND KONISHI,Y; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF 1-METHYLNAPHTHALENE IN B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 21(1):44-51, 1993]"
6270,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Active,,,,RAT,WISTAR/MALE,ORAL,0; 25; 50; 100; 200 PPM IN DIET FOR 77 WK TO RATS MAINTAINED ON ZINC ADEQUATE (60 PPM) DIET (STUDY DURATION: 79 WK),HEMATOPOIETIC SYSTEM: LEUKEMIA; TESTIS: TUMOR,POSITIVE,"[WAALKES,MP AND REHM,S; CARCINOGENICITY OF ORAL CADMIUM IN THE MALE WISTAR (WF/NCR) RAT: EFFECT OF CHRONIC DIETARY ZINC DEFICIENCY; FUNDAM. APPL. TOXICOL. 19(4):512-520, 1992]"
6271,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Active,,,,RAT,WISTAR/MALE,ORAL,0; 25; 50; 100; 200 PPM IN DIET FOR 77 WK TO RATS MAINTAINED ON ZINC DEFICIENT (7 PPM) DIET (STUDY DURATION: 79 WK),HEMATOPOIETIC SYSTEM: LEUKEMIA,POSITIVE,"[WAALKES,MP AND REHM,S; CARCINOGENICITY OF ORAL CADMIUM IN THE MALE WISTAR (WF/NCR) RAT: EFFECT OF CHRONIC DIETARY ZINC DEFICIENCY; FUNDAM. APPL. TOXICOL. 19(4):512-520, 1992]"
6272,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 1; 3; 10; 50 PPM IN DIET FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[LOSER,E; A 2-YR ORAL CARCINOGENICITY STUDY WITH CADMIUM ON RATS; CANCER LETT. 9:191-198, 1980]"
6273,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 1; 3; 10; 50 PPM IN DIET FOR 104 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[LOSER,E; A 2-YR ORAL CARCINOGENICITY STUDY WITH CADMIUM ON RATS; CANCER LETT. 9:191-198, 1980]"
6274,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Inactive,,,,MOUSE,C57/MALE,SUBCUTANEOUS,0; 20 UMOL/KG ONCE (STUDY DURATION: 104 WK),,NEGATIVE,"[WAALKES,MP, REHM,S, SASS,B, KOVATCH,R AND WARD,JM; CHRONIC CARCINOGENIC AND TOXIC EFFECTS OF A SINGLE SUBCUTANEOUS DOSE OF CADMIUM IN MALE NFS AND C57 MICE AND MALE SYRIAN HAMSTERS; TOXIC SUBST. J. 13(1):15-28, 1994]"
6275,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Active,,,,MOUSE,NFS/MALE,SUBCUTANEOUS,0; 20 UMOL/KG ONCE (STUDY DURATION: 104 WK),LYMPHOID TISSUE: LYMPHOMA,POSITIVE,"[WAALKES,MP, REHM,S, SASS,B, KOVATCH,R AND WARD,JM; CHRONIC CARCINOGENIC AND TOXIC EFFECTS OF A SINGLE SUBCUTANEOUS DOSE OF CADMIUM IN MALE NFS AND C57 MICE AND MALE SYRIAN HAMSTERS; TOXIC SUBST. J. 13(1):15-28, 1994]"
6276,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS,0; 20 UMOL/KG ONCE (STUDY DURATION: 104 WK),ADRENAL GLAND: TUMOR,POSITIVE,"[WAALKES,MP, REHM,S, SASS,B, KOVATCH,R AND WARD,JM; CHRONIC CARCINOGENIC AND TOXIC EFFECTS OF A SINGLE SUBCUTANEOUS DOSE OF CADMIUM IN MALE NFS AND C57 MICE AND MALE SYRIAN HAMSTERS; TOXIC SUBST. J. 13(1):15-28, 1994]"
6277,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 5; 10; 30 UMOL ONCE ADMINISTERED TO RATS FED DIETS DEFICIENT (7 PPM) IN ZINC (STUDY DURATION: 92 WK),TESTES: ADENOMA; INJECTION SITE: SARCOMA,POSITIVE,"[WAALKES,MP, KOVATCH,R AND REHM,S; EFFECT OF CHRONIC DIETARY ZINC DEFICIENCY ON CADMIUM TOXICITY AND CARCINOGENESIS IN THE MALE WISTAR [HSD: (WI)BR] RAT; TOXICOL. APPL. PHARMACOL. 108:448-456, 1991]"
6278,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Active,,,,RAT,WISTAR/MALE,SUBCUTANEOUS,0; 5; 10; 30 UMOL ONCE ADMINISTERED TO RATS FED DIETS ADEQUATE (60 PPM) IN ZINC (STUDY DURATION: 92 WK),TESTES: ADENOMA,POSITIVE,"[WAALKES,MP, KOVATCH,R AND REHM,S; EFFECT OF CHRONIC DIETARY ZINC DEFICIENCY ON CADMIUM TOXICITY AND CARCINOGENESIS IN THE MALE WISTAR [HSD: (WI)BR] RAT; TOXICOL. APPL. PHARMACOL. 108:448-456, 1991]"
6279,363904102,24978551,O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cl-].[Cd+2].[Cd+2],Inactive,,,,HAMSTER,SYRIAN/FEMALE,SUBCUTANEOUS,0; 30; 40; 50 UMOL/KG ONCE ON THE FOURTH DAY OF THE ESTROUS CYCLE (STUDY DURATION: 78 WK),,NEGATIVE,"[WAALKES,MP AND REHM,S; LACK OF CARCINOGENICITY OF CADMIUM CHLORIDE IN FEMALE SYRIAN HAMSTERS; TOXICOLOGY 126(3):173-178, 1998]"
6280,363904103,27821,C=CCN(CC=C)N=O,Active,,,,RAT,BDIX/MALE,ORAL,0; 20; 40; 80 MG/KG IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),NASAL/PARANASAL CAVITY: TUMORS,POSITIVE,"[POUR,PM, GRANDJEAN,CJ AND KNEPPER,S; SELECTIVE INDUCTION OF NASAL CAVITY TUMORS IN RATS BY DIALLYLNITROSAMINE; J. CANCER RES. CLIN. ONCOL. 109(1): 5-8, 1985]"
6281,363904103,27821,C=CCN(CC=C)N=O,Active,,,,RAT,BDIX/FEMALE,ORAL,0; 20; 40; 80 MG/KG IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE TIME),NASAL/PARANASAL CAVITY: TUMORS,POSITIVE,"[POUR,PM, GRANDJEAN,CJ AND KNEPPER,S; SELECTIVE INDUCTION OF NASAL CAVITY TUMORS IN RATS BY DIALLYLNITROSAMINE; J. CANCER RES. CLIN. ONCOL. 109(1): 5-8, 1985]"
6282,363904104,51291,C1C=CCN([C@@H]1C2=CN=CC=C2)N=O,Inactive,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 1; 3; 9 MMOL/KG BW (TOTAL DOSE) WITH SUBDOSES GIVEN 3/WK FOR 20 WK WITH A 2 WK INTERRUPTION AFTER 7 WK (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[HOFFMANN,D, RIVENSON,A, AMIN,S AND HECHT,SS; DOSE-RESPONSE STUDY OF THE CARCINOGENICITY OF TOBACCO-SPECIFIC N-NITROSAMINES IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 108(1):81-86, 1984]"
6283,363904104,51291,C1C=CCN([C@@H]1C2=CN=CC=C2)N=O,Inactive,,,,RAT,F344/FEMALE,SUBCUTANEOUS,0; 1; 3; 9 MMOL/KG BW (TOTAL DOSE) WITH SUBDOSES GIVEN 3/WK FOR 20 WK WITH A 2 WK INTERRUPTION AFTER 7 WK (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[HOFFMANN,D, RIVENSON,A, AMIN,S AND HECHT,SS; DOSE-RESPONSE STUDY OF THE CARCINOGENICITY OF TOBACCO-SPECIFIC N-NITROSAMINES IN F344 RATS; J. CANCER RES. CLIN. ONCOL. 108(1):81-86, 1984]"
6284,363904105,37248,C1=CC(=C(C=C1Cl)C2=C(C=CC(=C2)Cl)Cl)Cl,Inactive,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,"0; 0.1; 0.2 UMOL/UL OF DMSO 5, 10 AND 20 UL GIVEN ON DAYS 4, 8 AND 15 AFTER BIRTH, RESPECTIVELY (STUDY DURATION: 28 WK)",,NEGATIVE,"[PRESTON,BD, MILLER,EC AND MILLER,JA; THE ACTIVITIES OF 2,2',5,5'- TETRACHLOROBIPHENYL, ITS 3,4-OXIDE METABOLITE, AND 2,2',4,4'- TETRACHLOROBIPHENYL IN TUMOR INDUCTION AND PROMOTION ASSAYS; CARCINOGENESIS 6(3):451-453, 1985]"
6285,363904105,37248,C1=CC(=C(C=C1Cl)C2=C(C=CC(=C2)Cl)Cl)Cl,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,"0; 0.1; 0.2 UMOL/UL OF DMSO 5, 10 AND 20 UL GIVEN ON DAYS 4, 8 AND 15 AFTER BIRTH, RESPECTIVELY (STUDY DURATION: 28 WK)",,NEGATIVE,"[PRESTON,BD, MILLER,EC AND MILLER,JA; THE ACTIVITIES OF 2,2',5,5'- TETRACHLOROBIPHENYL, ITS 3,4-OXIDE METABOLITE, AND 2,2',4,4'- TETRACHLOROBIPHENYL IN TUMOR INDUCTION AND PROMOTION ASSAYS; CARCINOGENESIS 6(3):451-453, 1985]"
6286,363904106,121489661,C1=CC(=C(C=C1Cl)C2=C([C@@H]3[C@@H](O3)C(=C2)Cl)Cl)Cl,Inactive,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,"0; 0.1; 0.2 UMOL/UL OF DMSO 5, 10 AND 20 UL GIVEN ON DAYS 4, 8 AND 15 AFTER BIRTH, RESPECTIVELY (STUDY DURATION: 28 WK)",,NEGATIVE,"[PRESTON,BD, MILLER,EC AND MILLER,JA; THE ACTIVITIES OF 2,2',5,5'- TETRACHLOROBIPHENYL, ITS 3,4-OXIDE METABOLITE, AND 2,2',4,4'- TETRACHLOROBIPHENYL IN TUMOR INDUCTION AND PROMOTION ASSAYS; CARCINOGENESIS 6(3):451-453, 1985]"
6287,363904106,121489661,C1=CC(=C(C=C1Cl)C2=C([C@@H]3[C@@H](O3)C(=C2)Cl)Cl)Cl,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,"0; 0.1; 0.2 UMOL/UL OF DMSO 5, 10 AND 20 UL GIVEN ON DAYS 4, 8 AND 15 AFTER BIRTH, RESPECTIVELY (STUDY DURATION: 28 WK)",,NEGATIVE,"[PRESTON,BD, MILLER,EC AND MILLER,JA; THE ACTIVITIES OF 2,2',5,5'- TETRACHLOROBIPHENYL, ITS 3,4-OXIDE METABOLITE, AND 2,2',4,4'- TETRACHLOROBIPHENYL IN TUMOR INDUCTION AND PROMOTION ASSAYS; CARCINOGENESIS 6(3):451-453, 1985]"
6288,363904107,25199586,CC(CCC(=O)N(CC(=O)O)N=O)C1CCC2C1([C@H](CC3C2C(CC4C3(CC[C@H](C4)O)C)O)O)C,Active,,,,RAT,F344/MALE,GAVAGE,0; 10 MG IN 50 UL DMSO 5 D/WK FOR 6 WK (STUDY DURATION: 108 WK),LIVER: CARCINOMA,POSITIVE,"[BUSBY,WF,JR, SHUKER,DEG, CHARNLEY,G, NEWBERNE,PM, TANNENBAUM,SR AND WOGAN, GN; CARCINOGENICITY IN RATS OF THE NITROSATED BILE ACID CONJUGATES N-NITROSOGLYCOCHOLIC ACID AND N-NITROSOTAUROCHOLIC ACID; CANCER RES. 45(3): 1367-1371, 1985]"
6289,363904108,23694677,C[C@H](CCC(=O)N(CCS(=O)(=O)[O-])N=O)[C@H]1CCC2[C@@]1([C@H](CC3C2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C.[Na+],Active,,,,RAT,F344/MALE,GAVAGE,0; 10 MG IN 50 UL DMSO 5 D/WK FOR 6 WK (STUDY DURATION: 108 WK),LIVER: CARCINOMA,POSITIVE,"[BUSBY,WF,JR, SHUKER,DEG, CHARNLEY,G, NEWBERNE,PM, TANNENBAUM,SR AND WOGAN, GN; CARCINOGENICITY IN RATS OF THE NITROSATED BILE ACID CONJUGATES N-NITROSOGLYCOCHOLIC ACID AND N-NITROSOTAUROCHOLIC ACID; CANCER RES. 45(3): 1367-1371, 1985]"
6290,363904109,14791,[OH-].[OH-].[Mg+2],Active,,,,RAT,WISTAR/MALE,INHALATION,0; 10 MG/M3 OF RESPIRABLE DUST 7 HR/D 5 D/WK FOR 224 DAYS DURING A PERIOD OF 12 MO (STUDY DURATION: 29 MO),LUNG: ADENOMA OR CARCINOMA,POSITIVE,"[DAVIS,JMG, ADDISON,J, BOLTON,RE, DONALDSON,K, JONES,AD AND MILLER,BG; INHALATION STUDIES ON THE EFFECTS OF TREMOLITE AND BRUCITE DUST IN RATS; CARCINOGENESIS 6(5):667-674, 1985]"
6291,363904109,14791,[OH-].[OH-].[Mg+2],Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 25 MG OF DUST SUSPENDED IN 2 ML PHOSPHATE BUFFERED SALINE (STUDY DURATION: >418 D),LUNG: MESOTHELIOMA,POSITIVE,"[DAVIS,JMG, ADDISON,J, BOLTON,RE, DONALDSON,K, JONES,AD AND MILLER,BG; INHALATION STUDIES ON THE EFFECTS OF TREMOLITE AND BRUCITE DUST IN RATS; CARCINOGENESIS 6(5):667-674, 1985]"
6292,363904110,133239,CC1CN(C(=O)O1)N=O,Active,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 14 MG/ML ((0.2 ML OF A SOLUTION IN ETHYL ACETATE/CORN OIL (1:2)) 1/WK FOR 28 WK (STUDY DURATION: LIFE SPAN),FORESTOMACH: SQUAMOUS CELL CARCINOMA OR PAPILLOMA,POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
6293,363904111,39587,CCN(CC)C(=O)N(CC)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 45 MG/ML (0.2 ML OF A SOLUTION IN 50% ETHANOL) 1/WK FOR 25 WK (STUDY DURATION: LIFE SPAN),SPLEEN: HEMANGIOSARCOMA; FORESTOMACH: SQUAMOUS CELL CARCINOMA OR PAPILLOMA,POSITIVE,"[LIJINSKY,W, KNUTSEN,GL AND KOVATCH,RM; CARCINOGENIC EFFECT OF NITROSOALKYLUREAS AND NITROSOALKYLCARBAMATES IN SYRIAN HAMSTER; CANCER RES. 45(2):542-545, 1985]"
6294,363904112,57136,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@H]([C@@H](C=C4)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
6295,363904112,57136,CC1=CC2=CC=CC=C2C3=C1C4=C(C=C3)[C@H]([C@@H](C=C4)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
6296,363904113,57137,CC1=CC2=C(C=C[C@H]([C@@H]2O)O)C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
6297,363904113,57137,CC1=CC2=C(C=C[C@H]([C@@H]2O)O)C3=C1C4=CC=CC=C4C=C3,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
6298,363904115,119140,CC1=CC2=C([C@H]3[C@H](O3)[C@@H]([C@H]2O)O)C4=C1C5=CC=CC=C5C=C4,Inactive,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",,NEGATIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
6299,363904115,119140,CC1=CC2=C([C@H]3[C@H](O3)[C@@H]([C@H]2O)O)C4=C1C5=CC=CC=C5C=C4,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"8 NMOL/5 UL DMSO ON DAY 1, 16 NMOL/10 UL ON DAY 8, AND 32 NMOL/20 UL ON DAY 15 OF AGE (STUDY DURATION: 35 WK)",LUNG: TUMORS,POSITIVE,"[HECHT,SS, RADOK,L, AMIN,S, HUIE,K, MELIKIAN,AA, HOFFMANN,D, PATAKI,J AND HARVEY,RG; TUMORIGENICITY OF 5-METHYLCHRYSENE DIHYDRODIOLS AND DIHYDRODIOL EPOXIDES IN NEWBORN MICE AND ON MOUSE SKIN; CANCER RES. 45(4):1449-1452, 1985]"
6300,363904155,8425,C1=CC=C(C=C1)CC2=C(C=CC(=C2)Cl)O,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 30; 60; 120 MG/KG BW IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-424 Y94]"
6301,363904155,8425,C1=CC=C(C=C1)CC2=C(C=CC(=C2)Cl)O,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 120; 240; 480 MG/KG BW IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),"KIDNEY (RENAL TUBULE): ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-424 Y94]"
6302,363904155,8425,C1=CC=C(C=C1)CC2=C(C=CC(=C2)Cl)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 120; 240; 480 MG/KG BW IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-424 Y94]"
6303,363904155,8425,C1=CC=C(C=C1)CC2=C(C=CC(=C2)Cl)O,Inactive,,,,MOUSE,CD-1/MALE,DERMAL,10 MG IN ACETONE ONCE FOLLOWED BY 0.1; 1; 3 MG 3/WK FOR 51 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-444 Y95]"
6304,363904155,8425,C1=CC=C(C=C1)CC2=C(C=CC(=C2)Cl)O,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,10 MG IN ACETONE ONCE FOLLOWED BY 0.1; 1; 3 MG 3/WK FOR 51 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-444 Y95]"
6305,363904155,8425,C1=CC=C(C=C1)CC2=C(C=CC(=C2)Cl)O,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 30; 60; 120 MG/KG BW IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 105 WK),KIDNEY (TRANSITIONAL CELL): CARCINOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-424 Y94]"
6306,363904156,9756,CC(=O)[O-].CC(=O)[O-].[Ni+2],Active,,,,RAT,F344/MALE,TRANSPLACENTAL,0; 90 UMOL/KG BW GIVEN INTRAPERITONEALLY TO MOTHERS ON DAY 17 OF GESTATION (STUDY DURATION: 85 WK),PITUITARY GLAND: ADENOMA OR CARCINOMA,POSITIVE,"[DIWAN,BA, KASPRZAK,KS AND RICE,JM; TRANSPLACENTAL CARCINOGENIC EFFECTS OF NICKEL(II) ACETATE IN THE RENAL CORTEX, RENAL PELVIS AND ADENOHYPOPHYSIS IN F344/NCR RATS; CARCINOGENESIS 13(8):1351-1357, 1992]"
6307,363904156,9756,CC(=O)[O-].CC(=O)[O-].[Ni+2],Active,,,,RAT,F344/FEMALE,TRANSPLACENTAL,0; 90 UMOL/KG BW GIVEN INTRAPERITONEALLY TO MOTHERS ON DAY 17 OF GESTATION (STUDY DURATION: 85 WK),PITUITARY GLAND: CARCINOMA,POSITIVE,"[DIWAN,BA, KASPRZAK,KS AND RICE,JM; TRANSPLACENTAL CARCINOGENIC EFFECTS OF NICKEL(II) ACETATE IN THE RENAL CORTEX, RENAL PELVIS AND ADENOHYPOPHYSIS IN F344/NCR RATS; CARCINOGENESIS 13(8):1351-1357, 1992]"
6308,363904156,9756,CC(=O)[O-].CC(=O)[O-].[Ni+2],Active,,,,RAT,F344/MALE,TRANSPLACENTAL,0; 45 UMOL/KG BW GIVEN INTRAPERITONEALLY TO MOTHERS ON DAYS 16 AND 18 OF GESTATION (STUDY DURATION: 85 WK),PITUITARY GLAND: ADENOMA OR CARCINOMA,POSITIVE,"[DIWAN,BA, KASPRZAK,KS AND RICE,JM; TRANSPLACENTAL CARCINOGENIC EFFECTS OF NICKEL(II) ACETATE IN THE RENAL CORTEX, RENAL PELVIS AND ADENOHYPOPHYSIS IN F344/NCR RATS; CARCINOGENESIS 13(8):1351-1357, 1992]"
6309,363904156,9756,CC(=O)[O-].CC(=O)[O-].[Ni+2],Active,,,,RAT,F344/FEMALE,TRANSPLACENTAL,0; 45 UMOL/KG BW GIVEN INTRAPERITONEALLY TO MOTHERS ON DAYS 16 AND 18 OF GESTATION (STUDY DURATION: 85 WK),PITUITARY GLAND: ADENOMA OR CARCINOMA,POSITIVE,"[DIWAN,BA, KASPRZAK,KS AND RICE,JM; TRANSPLACENTAL CARCINOGENIC EFFECTS OF NICKEL(II) ACETATE IN THE RENAL CORTEX, RENAL PELVIS AND ADENOHYPOPHYSIS IN F344/NCR RATS; CARCINOGENESIS 13(8):1351-1357, 1992]"
6310,363904156,9756,CC(=O)[O-].CC(=O)[O-].[Ni+2],Active,,,,RAT,F344/MALE,SUBCUTANEOUS,0; 30 MG/KG ONCE OR TWICE A WK FOR 5-8 WK (STUDY DURATION: 80 WK),SUBCUTANEOUS TISSUE: TUMORS,POSITIVE,"[TERAKI,Y AND UCHIUMI,A; EXPERIMENTAL STUDIES ON METAL CARCINOGENESIS: A COMPARATIVE ASSESSMENT OF NICKEL AND LEAD; ADV. ENVIRON. SCI. TECHNOL. 25(NICKEL AND HUMAN HEALTH):527-535, 1992]"
6311,363904156,9756,CC(=O)[O-].CC(=O)[O-].[Ni+2],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6312,363904156,9756,CC(=O)[O-].CC(=O)[O-].[Ni+2],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6313,363904190,713,C(=O)N,Inactive,,,,Rat,F344/N/Male,Oral,"0, 20, 40, 80 mg/kg in deioninzed water, by gavage, 5 d/wk for 104-105 wk",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-541-2008]"
6314,363904190,713,C(=O)N,Inactive,,,,Rat,F344/N/Female,Oral,"0, 20, 40, 80 mg/kg in deioninzed water, by gavage, 5 d/wk for 104-105 wk",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-541-2008]"
6315,363904190,713,C(=O)N,Active,,,,Mouse,B6C3F1/Male,Oral,"0, 20, 40, 80 mg/kg in deioninzed water, by gavage, 5 d/wk for 104-105 wk",Liver: hemangiosarcoma,"Positive, Authors described results as clear evidence of carcinogenic activity","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-541-2008]"
6316,363904190,713,C(=O)N,Active,,,,Mouse,B5C3F1/Female,Oral,"0, 20, 40, 80 mg/kg in deioninzed water, by gavage, 5 d/wk for 104-105 wk",Liver: hepatocellular adenoma and carcinoma (combined),"Positive, Authors described results as equivocal evidence of carcinogenic activity","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-541-2008]"
6317,363904203,6557,CC(=C)C=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 70; 220; 700; 2200; 7000 PPM 6 HR/D 5 D/WK FOR 26 WK FOLLOWED BY A 26-WK RECOVERY PERIOD (STUDY DURATION: 52 WK),LIVER: ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; FORESTOMACH: PAPILLOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA,POSITIVE,"[MELNICK,RL, SILLS,RC, ROYCROFT,JH, CHOU,BJ, RAGAN,HA AND MILLER,RA; ISOPRENE, AN ENDOGENOUS HYDROCARBON AND INDUSTRIAL CHEMICAL, INDUCES MULTIPLE ORGAN NEOPLASIA IN RODENTS AFTER 26 WEEKS OF INHALATION EXPOSURE; CANCER RES. 54(20): 5333-5339, 1994]"
6318,363904203,6557,CC(=C)C=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 10; 70; 280; 700; 2200 PPM 8 HR/D 5 D/WK FOR 80 WK (STUDY DURATION: 104 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA,POSITIVE,"[PLACKE,ME, GRIFFIS,L, BIRD,M, BUS,J, PERSING,RL AND COX,LA,JR; CHRONIC INHALATION ONCOGENICITY STUDY OF ISOPRENE IN B6C3F1 MICE; TOXICOLOGY 113(1-3):253-262, 1996]"
6319,363904203,6557,CC(=C)C=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 70; 140; 2200 PPM 8 HR/D 5 D/WK FOR 40 WK (STUDY DURATION: 104 WK),LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA,POSITIVE,"[PLACKE,ME, GRIFFIS,L, BIRD,M, BUS,J, PERSING,RL AND COX,LA,JR; CHRONIC INHALATION ONCOGENICITY STUDY OF ISOPRENE IN B6C3F1 MICE; TOXICOLOGY 113(1-3):253-262, 1996]"
6320,363904203,6557,CC(=C)C=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 280 PPM 8 HR/D 5 D/WK FOR 20 WK (STUDY DURATION: 104 WK),HARDERIAN GLAND: ADENOMA; LIVER: ADENOMA,POSITIVE,"[PLACKE,ME, GRIFFIS,L, BIRD,M, BUS,J, PERSING,RL AND COX,LA,JR; CHRONIC INHALATION ONCOGENICITY STUDY OF ISOPRENE IN B6C3F1 MICE; TOXICOLOGY 113(1-3):253-262, 1996]"
6321,363904203,6557,CC(=C)C=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 2200 PPM 4 HR/D 5 D/WK FOR 20 WK (STUDY DURATION: 104 WK),HARDERIAN GLAND: ADENOMA; LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[PLACKE,ME, GRIFFIS,L, BIRD,M, BUS,J, PERSING,RL AND COX,LA,JR; CHRONIC INHALATION ONCOGENICITY STUDY OF ISOPRENE IN B6C3F1 MICE; TOXICOLOGY 113(1-3):253-262, 1996]"
6322,363904203,6557,CC(=C)C=C,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 2200 PPM 4 HR/D 5 D/WK FOR 80 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; HARDERIAN GLAND: ADENOMA,POSITIVE,"[PLACKE,ME, GRIFFIS,L, BIRD,M, BUS,J, PERSING,RL AND COX,LA,JR; CHRONIC INHALATION ONCOGENICITY STUDY OF ISOPRENE IN B6C3F1 MICE; TOXICOLOGY 113(1-3):253-262, 1996]"
6323,363904203,6557,CC(=C)C=C,Active,,,,RAT,F344/N/MALE,INHALATION,0; 220; 700; 7000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),KIDNEY: ADENOMA OR CARCINOMA; MAMMARY GLAND: FIBROADENOMA OR CARCINOMA; TESTES: ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-486  Y99]"
6324,363904203,6557,CC(=C)C=C,Active,,,,RAT,F344/N/FEMALE,INHALATION,0; 220; 700; 7000 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),MAMMARY GLAND: FIBROADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-486  Y99]"
6325,363904208,9280,COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 100; 500; 1000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-439 Y95]"
6326,363904208,9280,COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 100; 500; 1000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-439 Y95]"
6327,363904208,9280,COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 50; 250; 500 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOBLASTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-439 Y95]"
6328,363904208,9280,COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 50; 250; 500 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-439 Y95]"
6329,363904216,4764,C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O,Active,,,,RAT,F344/MALE,ORAL,0; 12000; 25000; 50000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),"ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA; KIDNEY(RENAL TUBULE): ADENOMA, ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-465 Y96]"
6330,363904216,4764,C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 12000; 25000; 50000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),"ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA, BENIGN OR MALIGNANT PHEOCHROMOCYTOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-465 Y96]"
6331,363904216,4764,C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O,Active,,,,MOUSE,B6C3F1/MALE,ORAL,0; 3000; 6000; 12000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),LIVER: HISTIOCYTIC SARCOMA; LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA (THYMIC ORIGIN),POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-465 Y96]"
6332,363904216,4764,C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 3000; 6000; 12000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),"OVARY: BENIGN SEX-CORD STROMAL TUMOR; LIVER: HISTIOCYTIC SARCOMA; LYMPHATIC SYSTEM: MALIGNANT LYMPHOMA, MALIGNANT LYMPHOMA (THYMIC ORIGIN)",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-465 Y96]"
6333,363904226,8028,C1CCOC1,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 200; 600; 1800 PPM 6HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[CHHABRA,RS, HERBERT,RA, ROYCROFT,JH, CHOU,B, MILLER,RA AND RENNE,RA; CARCINOGENESIS STUDIES OF TETRAHYDROFURAN VAPORS IN RATS AND MICE; TOXICOL. SCI. 41:183-188, 1998]"
6334,363904226,8028,C1CCOC1,Active,,,,RAT,F344/MALE,INHALATION,0; 200; 600; 1800 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),KIDNEY: RENAL TUBULE ADENOMA OR CARCINOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-475 Y98]"
6335,363904226,8028,C1CCOC1,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 200; 600; 1800 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-475 Y98]"
6336,363904226,8028,C1CCOC1,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 200; 600; 1800 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-475 Y98]"
6337,363904226,8028,C1CCOC1,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 200; 600; 1800 PPM 6 HR/D 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-475 Y98]"
6338,363904234,26177,C(C(CCl)OP(=O)(OC(CCl)CCl)OC(CCl)CCl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY CD/MALE,ORAL,0; 5; 20; 80 MG/KG/D IN FEED FOR 2 YR (STUDY DURATION: 2 YR),KIDNEY: RENAL CORTICAL ADENOMA; LIVER: HEPATOCELLULAR ADENOMA; TESTES: INTERSTITIAL CELL TUMOR,POSITIVE,"[FREUDENTHAL,RI AND HENRICH,RT; CHRONIC TOXICITY AND CARCINOGENIC POTENTIAL OF TRIS-(1,3-DICHLORO-2-PROPYL)PHOSPHATE IN SPRAGUE-DAWLEY RAT; INT. J. TOXICOL. 19(2):119-125, 2000]"
6339,363904234,26177,C(C(CCl)OP(=O)(OC(CCl)CCl)OC(CCl)CCl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY CD/FEMALE,ORAL,0; 5; 20; 80 MG/KG/D IN FEED FOR 2 YR (STUDY DURATION: 2 YR),ADRENAL GLAND: CORTICAL ADENOMA; KIDNEY: CORTICAL ADENOMA; LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[FREUDENTHAL,RI AND HENRICH,RT; CHRONIC TOXICITY AND CARCINOGENIC POTENTIAL OF TRIS-(1,3-DICHLORO-2-PROPYL)PHOSPHATE IN SPRAGUE-DAWLEY RAT; INT. J. TOXICOL. 19(2):119-125, 2000]"
6340,363904251,4628,CCN1C=C(C(=O)C2=CC3=C(C=C21)OCO3)C(=O)O,Active,,,,RAT,WISTAR/MALE,ORAL,0; 30; 100; 300; 1000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),TESTIS: BENIGN LEYDIG CELL TUMOR,POSITIVE,"[YAMADA,T, MAITA,K, NAKAMURA,J, MURAKAMI,M, OKUNO,Y, HOSOKAWA,S, MATSUO,M AND YAMADA,H;CARCINOGENICITY STUDIES OF OXOLINIC ACID IN RATS AND MICE; FOOD CHEM. TOXICOL. 32(5):397-408, 1994]"
6341,363904251,4628,CCN1C=C(C(=O)C2=CC3=C(C=C21)OCO3)C(=O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 30; 100; 300; 1000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[YAMADA,T, MAITA,K, NAKAMURA,J, MURAKAMI,M, OKUNO,Y, HOSOKAWA,S, MATSUO,M AND YAMADA,H;CARCINOGENICITY STUDIES OF OXOLINIC ACID IN RATS AND MICE; FOOD CHEM. TOXICOL. 32(5):397-408, 1994]"
6342,363904251,4628,CCN1C=C(C(=O)C2=CC3=C(C=C21)OCO3)C(=O)O,Inactive,,,,MOUSE,ICR/MALE,ORAL,0; 50; 150; 500 PPM IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[YAMADA,T, MAITA,K, NAKAMURA,J, MURAKAMI,M, OKUNO,Y, HOSOKAWA,S, MATSUO,M AND YAMADA,H;CARCINOGENICITY STUDIES OF OXOLINIC ACID IN RATS AND MICE; FOOD CHEM. TOXICOL. 32(5):397-408, 1994]"
6343,363904251,4628,CCN1C=C(C(=O)C2=CC3=C(C=C21)OCO3)C(=O)O,Inactive,,,,MOUSE,ICR/FEMALE,ORAL,0; 50; 150; 500 PPM IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[YAMADA,T, MAITA,K, NAKAMURA,J, MURAKAMI,M, OKUNO,Y, HOSOKAWA,S, MATSUO,M AND YAMADA,H;CARCINOGENICITY STUDIES OF OXOLINIC ACID IN RATS AND MICE; FOOD CHEM. TOXICOL. 32(5):397-408, 1994]"
6344,363904252,4539,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,Inactive,,,,Rat,F344/Male (15/Group),Oral,"0, 750, 1500 mg/kg daily for 3 wks after 2/3rd partial hepatectomy; from 2 wks after carcinogen dosing, 500 ppm phenobarbital [50-06-6] as promoter administered in drinking water to 17, 34, or 51 wks",Liver,Negative,"[ITOH,T MOTO,M KUROIWA,Y SAKAI,H AND  MITSUMORI,K; THE INITIATION ACTIVITY OF NORFLOXACIN DOES NOT RESULT IN THE INDUCTION OF HEPATOCELLULAR TUMORS IN RATS; TOXICOLOGY 231(2-3):234-242, 2007]"
6345,363904263,108211,CC1=CC=CC=C1C2=CC(=C(C=C2)NO)C,Active,,,,RAT,F344/MALE,INTRAPERITONEAL,0; 5; 10; 20 MG/KG 1/2 WK FOR 20 WK (STUDY DURATION: 60 WK),PROSTATE: CARCINOMA; PERITONEUM: TUMOR; COLON: TUMOR,POSITIVE,"[SHIRAI,T, IWASAKI,S, NAITO,H, MASUI,T, KATO,T AND IMAIDA,K; DOSE DEPENDENCE OF N-HYDROXY-3,2'-DIMETHYL-4-AMINOBIPHENYL-INDUCED RAT PROSTATE CARCINOGENESIS; JPN. J. CANCER RES. 83(7):695-698, 1992]"
6346,363904263,108211,CC1=CC=CC=C1C2=CC(=C(C=C2)NO)C,Active,,,,RAT,ACI/SEG/MALE,INTRAPERITONEAL,0; 50 UMOL/KG BW 2X/WK FOR 10 WK BEGINNING AT 3 D OF AGE (STUDY DURATION: 68 WK),COLON: CARCINOMA,POSITIVE,"[ARCHER,CL MORSE,P JONES,RF SHIRAI,T HAAS,GP AND WANG,CY; CARCINOGENICITY OF THE N-HYDROXY DERIVATIVE OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE,2-AMINO-3,8-DIMETHYL-IMIDAZO[4,5 -F]QUINOXALINE AND 3,2'-DIMETHYL-4-AMINOBIPHENYL IN THE RAT; CANCER LETT. (SHANNON, IREL.) 155(1):55-60, 2000]"
6347,363904264,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1.25; 5% IN DIET FOR 96 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[HAGIWARA,A, BOONYAPHIPHAT,P, KAWABE,M, NAITO,H, SHIRAI,T AND ITO,N; LACK OF CARCINOGENICITY OF TRAGACANTH GUM IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 30(8): 673-679, 1992]"
6348,363904264,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1.25; 5% IN DIET FOR 96 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[HAGIWARA,A, BOONYAPHIPHAT,P, KAWABE,M, NAITO,H, SHIRAI,T AND ITO,N; LACK OF CARCINOGENICITY OF TRAGACANTH GUM IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 30(8): 673-679, 1992]"
6349,363904265,157354,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O.O.O,Inactive,,,,MOUSE,CPB:SWISS/MALE,ORAL,0; 2; 5; 10% IN DIET FOR 104 WK (STUDY DURATION: 730 D),,NEGATIVE,"[TIL,HP, HOLLANDERS,VMH, WOUTERSEN,RA AND BAER,A; CHRONIC TOXICITY AND CARCINOGENICITY STUDY OF LACTITOL IN MICE; J. AM. COLL. TOXICOL. 11(2):209-217, 1992]"
6350,363904265,157354,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O.O.O,Inactive,,,,MOUSE,CPB:SWISS/FEMALE,ORAL,0; 2; 5; 10% IN DIET FOR 104 WK (STUDY DURATION: 734 D),,NEGATIVE,"[TIL,HP, HOLLANDERS,VMH, WOUTERSEN,RA AND BAER,A; CHRONIC TOXICITY AND CARCINOGENICITY STUDY OF LACTITOL IN MICE; J. AM. COLL. TOXICOL. 11(2):209-217, 1992]"
6351,363904281,114983,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C2C6=C(C=C5C=C4)C(C(C=C6)O)O,Active,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 1; 4 NMOL IN 100 UL ACETONE 2/WK FOR 40 WK (STUDY DURATION: 48 WK),SKIN: TUMORS,POSITIVE,"[HIGGINBOTHAM,S, RAMAKRISHNA,NVS, JOHANSSON,SL, ROGAN,EG AND CAVALIERI,EL; TUMOR-INITIATING ACTIVITY AND CARCINOGENICITY OF DIBENZO[A,L]PYRENE VERSUS 7,12-DIMETHYLBENZ[A]ANTHRACENE AND BENZO[A]PYRENE AT LOW DOSE IN MOUSE SKIN; CARCINOGENESIS 14(5):875-878, 1993]"
6352,363904282,125404,C1=CC=C2C(=C1)C=C3C(C(C4=CC=CC5=C4C3=C2C6=CC=CC=C56)O)O,Inactive,,,,MOUSE,SWISS/FEMALE,DERMAL,0; 1; 4 NMOL IN 100 UL ACETONE 2/WK FOR 40 WK (STUDY DURATION: 48 WK),,NEGATIVE,"[HIGGINBOTHAM,S, RAMAKRISHNA,NVS, JOHANSSON,SL, ROGAN,EG AND CAVALIERI,EL; TUMOR-INITIATING ACTIVITY AND CARCINOGENICITY OF DIBENZO[A,L]PYRENE VERSUS 7,12-DIMETHYLBENZ[A]ANTHRACENE AND BENZO[A]PYRENE AT LOW DOSE IN MOUSE SKIN; CARCINOGENESIS 14(5):875-878, 1993]"
6353,363904285,96148,CN(C=O)N=O,Active,,,,RAT,F344/MALE,GAVAGE,0; 0.6 MG IN CORN OIL 2/WK FOR 20 WK (STUDY DURATION: 40 WK),FORESTOMACH: TUMOR,POSITIVE,"[ELESPURU,RK, SAAVEDRA,JE, KOVATCH,RM AND LIJINSKY,W; EXAMINATION OF ALPHA- CARBONYL DERIVATIVES OF NITROSODIMETHYLAMINE AND ETHYLNITROSOMETHYLAMINE AS PUTATIVE PROXIMATE CARCINOGENS; CARCINOGENESIS 14(6):1189-1193, 1993]"
6354,363904285,96148,CN(C=O)N=O,Active,,,,RAT,F344/FEMALE,GAVAGE,0; 0.6 MG IN CORN OIL 2/WK FOR 20 WK (STUDY DURATION: 40 WK),FORESTOMACH: TUMOR; ESOPHAGUS: TUMOR,POSITIVE,"[ELESPURU,RK, SAAVEDRA,JE, KOVATCH,RM AND LIJINSKY,W; EXAMINATION OF ALPHA- CARBONYL DERIVATIVES OF NITROSODIMETHYLAMINE AND ETHYLNITROSOMETHYLAMINE AS PUTATIVE PROXIMATE CARCINOGENS; CARCINOGENESIS 14(6):1189-1193, 1993]"
6355,363904285,96148,CN(C=O)N=O,Active,,,,HAMSTER,SYRIAN/MALE,GAVAGE,0; 0.6 MG IN CORN OIL 1/WK FOR 15 WK (STUDY DURATION: 35 WK),FORESTOMACH: TUMOR,POSITIVE,"[ELESPURU,RK, SAAVEDRA,JE, KOVATCH,RM AND LIJINSKY,W; EXAMINATION OF ALPHA- CARBONYL DERIVATIVES OF NITROSODIMETHYLAMINE AND ETHYLNITROSOMETHYLAMINE AS PUTATIVE PROXIMATE CARCINOGENS; CARCINOGENESIS 14(6):1189-1193, 1993]"
6356,363904285,96148,CN(C=O)N=O,Inactive,,,,HAMSTER,SYRIAN/FEMALE,GAVAGE,0; 0.6 MG IN CORN OIL 1/WK FOR 15 WK (STUDY DURATION: 30 WK),,NEGATIVE,"[ELESPURU,RK, SAAVEDRA,JE, KOVATCH,RM AND LIJINSKY,W; EXAMINATION OF ALPHA- CARBONYL DERIVATIVES OF NITROSODIMETHYLAMINE AND ETHYLNITROSOMETHYLAMINE AS PUTATIVE PROXIMATE CARCINOGENS; CARCINOGENESIS 14(6):1189-1193, 1993]"
6357,363904294,108005,O.O.[O-][Cr](=O)(=O)O[Cr](=O)(=O)[O-].[Na+].[Na+],Active,,,,Rat,F344/N/Male,Oral,"0, 14.3, 57.3, 172, 516 mg/l of water, in drinking water for 2 yr (average daily dose of 0, 0.6, 2.2, 6, and 17 mg/kg)",Mouth and tongue: Squamous cell  papilloma and carcinoma,"Positive, Authors describe as clear evidence of carcinogenic activity","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-546-Y08][STOUT,MD, HERBERT,RA, KISSLING,GE, COLLINS,BJ, TRAVLOS,GS,  WITT,KL, MELNICK,RL, ABDO,KM, MALARKEY,DE, HOOTH,MJ;   HEXAVALENT CHROMIUM IS CARCINOGENIC TO F344/N RATS AND   B6C3F1 MICE AFTER CHRONIC ORAL EXPOSURE; ENVIRON. HEALTH   PERSP. 117(5):716-722, 2009 , ]"
6358,363904294,108005,O.O.[O-][Cr](=O)(=O)O[Cr](=O)(=O)[O-].[Na+].[Na+],Active,,,,Rat,F344/N/Female,Oral,"0, 14.3, 57.3, 172, 516 mg/l of water, in drinking water for 2 yr (average daily dose of 0, 0.7, 2.7, 7, and 20 mg/kg)",Mouth and tongue: Squamous cell  papilloma and carcinoma,"Positive, Authors describe as clear evidence of carcinogenic activity","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-546-Y08][STOUT,MD, HERBERT,RA, KISSLING,GE, COLLINS,BJ, TRAVLOS,GS,  WITT,KL, MELNICK,RL, ABDO,KM, MALARKEY,DE, HOOTH,MJ;   HEXAVALENT CHROMIUM IS CARCINOGENIC TO F344/N RATS AND   B6C3F1 MICE AFTER CHRONIC ORAL EXPOSURE; ENVIRON. HEALTH   PERSP. 117(5):716-722, 2009 , ]"
6359,363904294,108005,O.O.[O-][Cr](=O)(=O)O[Cr](=O)(=O)[O-].[Na+].[Na+],Active,,,,Mouse,B6C3F1/Male,Oral,"0, 14.3, 28.6, 85.7, 257.4 mg/l of water, in drinking water for 2 yr (average daily dose of 0, 1.1, 2.6, 7, and 17 mg/kg)","Small intestine (duodenum, jejunum, ileum): Adenomas and carcinomas","Positive, Authors describe as clear evidence of carcinogenic activity","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-546-Y08][STOUT,MD, HERBERT,RA, KISSLING,GE, COLLINS,BJ, TRAVLOS,GS,  WITT,KL, MELNICK,RL, ABDO,KM, MALARKEY,DE, HOOTH,MJ;   HEXAVALENT CHROMIUM IS CARCINOGENIC TO F344/N RATS AND   B6C3F1 MICE AFTER CHRONIC ORAL EXPOSURE; ENVIRON. HEALTH   PERSP. 117(5):716-722, 2009 , ]"
6360,363904294,108005,O.O.[O-][Cr](=O)(=O)O[Cr](=O)(=O)[O-].[Na+].[Na+],Active,,,,Mouse,B6C3F1/Female,Oral,"0, 14.3, 57.3, 172, 516 mg/l of water, in drinking water for 2 yr (average daily dose of 0, 1.1, 3.9, 9, and 25 mg/kg)","Small intestine (duodenum, jejunum, ileum):  Adenomas and carcinomas","Positive, Authors describe as clear evidence of carcinogenic activity","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-546-Y08][STOUT,MD, HERBERT,RA, KISSLING,GE, COLLINS,BJ, TRAVLOS,GS,  WITT,KL, MELNICK,RL, ABDO,KM, MALARKEY,DE, HOOTH,MJ;   HEXAVALENT CHROMIUM IS CARCINOGENIC TO F344/N RATS AND   B6C3F1 MICE AFTER CHRONIC ORAL EXPOSURE; ENVIRON. HEALTH   PERSP. 117(5):716-722, 2009 , ]"
6361,363904378,28094,S=[Ni],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6362,363904381,38078,CC(C)N.C(C(=O)O)NCP(=O)(O)O,Inactive,,,,Rat,Sprague-Dawley/Male (50/Group),Oral,"0; 2000; 8000; 20,000 ppm of 96.5% glyphosate, isopropylamine salt in diet for 24 mo; study duration 24 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR GLYPHOSATE, ISOPROPYLAMINE SALT (November 3, 1992)]"
6363,363904381,38078,CC(C)N.C(C(=O)O)NCP(=O)(O)O,Active,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,"0; 2000; 8000; 20,000 ppm of 96.5% glyphosate, isopropylamine salt in diet for 24 mo; study duration 24 mo",Adrenal cortex: carcinoma (3/50 in high dose group vs 0 in all other groups),Positive. (Department of Pesticides Regulation reviewer describes as a possible adverse effect.),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR GLYPHOSATE, ISOPROPYLAMINE SALT (November 3, 1992)]"
6364,363904460,104977,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)CO,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL IN 0.1 ML SESAME OIL:DMSO (9:1) 1/2 D FOR 20 DOSES (STUDY DURATION: 52 WK),,NEGATIVE,"[HORN,J, FLESHER,JW AND LEHNER,AF; 1-SULFOOXYMETHYLPYRENE IS AN ELECTROPHILIC MUTAGEN AND ULTIMATE CARCINOGEN OF 1-METHYL- AND 1-HYDROXYMETHYLPYRENE; BIOCHEM. BIOPHYS. RES. COMMUN. 228(1):105-109, 1996]"
6365,363904492,27492,C=COC(=O)N,Active,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 11.5 UMOL IN WEEKS 1 AND 2 THEN 5.7 UMOL IN WEEKS 3 AND 4 FOLLOWED BY 3.8 UMOL/WK FOR 28 WK (STUDY DURATION: 42 WK),"SKIN: PAPILLOMA, CARCINOMA",POSITIVE,"[PARK,KK, LIEM,A, STEWART,BC AND MILLER,JA; VINYL CARBAMATE EPOXIDE, A MAJOR STRONG ELECTROPHILIC, MUTAGENIC AND CARCINOGENIC METABOLITE OF VINYL CARBAMATE AND ETHYL CARBAMATE (URETHANE); CARCINOGENESIS 14(3):441-450, 1993]"
6366,363904492,27492,C=COC(=O)N,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 34; 68 NMOL/G BW IN 5 UL TRIOCTANOIN ONCE (STUDY DURATION: 6 MO),LUNG: ADENOMA,POSITIVE,"[PARK,KK, LIEM,A, STEWART,BC AND MILLER,JA; VINYL CARBAMATE EPOXIDE, A MAJOR STRONG ELECTROPHILIC, MUTAGENIC AND CARCINOGENIC METABOLITE OF VINYL CARBAMATE AND ETHYL CARBAMATE (URETHANE); CARCINOGENESIS 14(3):441-450, 1993]"
6367,363904492,27492,C=COC(=O)N,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 2.5 UG/G BW IN 10 UL TRIOCTANOIN ONCE (STUDY DURATION: 9 MO),LIVER: HEPATOMA,POSITIVE,"[PARK,KK, LIEM,A, STEWART,BC AND MILLER,JA; VINYL CARBAMATE EPOXIDE, A MAJOR STRONG ELECTROPHILIC, MUTAGENIC AND CARCINOGENIC METABOLITE OF VINYL CARBAMATE AND ETHYL CARBAMATE (URETHANE); CARCINOGENESIS 14(3):441-450, 1993]"
6368,363904492,27492,C=COC(=O)N,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAMUSCULAR,0; 1.15; 2.3 UMOL IN 0.25 ML TRIOCTANOIN 1/WK FOR 10 WK (STUDY DURATION: 18 MO),,NEGATIVE,"[PARK,KK, LIEM,A, STEWART,BC AND MILLER,JA; VINYL CARBAMATE EPOXIDE, A MAJOR STRONG ELECTROPHILIC, MUTAGENIC AND CARCINOGENIC METABOLITE OF VINYL CARBAMATE AND ETHYL CARBAMATE (URETHANE); CARCINOGENESIS 14(3):441-450, 1993]"
6369,363904549,5461123,[Si],Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS IMPLANT,10 X 20 X 0.3 MM SHEETS IMPLANTED INTO 2 SITES IN LATERAL ABDOMINAL REGION AND 1 SITE ON THE BACK (STUDY DURATION: 741 D),IMPLANT SITE: MALIGNANT HISTIOCYTOMA,POSITIVE,"[HATANAKA,S, ONEDA,S, OKAZAKI,K, SHONG,L, YOSHIDA,A, ISAKA,H AND YOSHIDA,H; INDUCTION OF MALIGNANT FIBROUS HISTIOCYTOMA IN FEMALE FISHER RATS BY IMPLANTATION OF CYANOACRYLATE, ZIRCONIA, POLYVINYL CHLORIDE OR SILICONE; IN VIVO 7(2):111-115, 1993]"
6370,363904550,,,Inactive,,,,RAT,F344/FEMALE,SUBCUTANEOUS IMPLANT,10 X 20 X 0.3 MM SHEETS IMPLANTED INTO 2 SITES IN LATERAL ABDOMINAL REGION AND 1 SITE ON THE BACK (STUDY DURATION: 741 D),,NEGATIVE,"[HATANAKA,S, ONEDA,S, OKAZAKI,K, SHONG,L, YOSHIDA,A, ISAKA,H AND YOSHIDA,H; INDUCTION OF MALIGNANT FIBROUS HISTIOCYTOMA IN FEMALE FISHER RATS BY IMPLANTATION OF CYANOACRYLATE, ZIRCONIA, POLYVINYL CHLORIDE OR SILICONE; IN VIVO 7(2):111-115, 1993]"
6371,363904551,62395,O=[Zr]=O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS IMPLANT,4 CM SHEET IMPLANTED INTO 1 SITE ON THE ABDOMEN (STUDY DURATION: 741 D),IMPLANT SITE: MALIGNANT HISTIOCYTOMA,POSITIVE,"[HATANAKA,S, ONEDA,S, OKAZAKI,K, SHONG,L, YOSHIDA,A, ISAKA,H AND YOSHIDA,H; INDUCTION OF MALIGNANT FIBROUS HISTIOCYTOMA IN FEMALE FISHER RATS BY IMPLANTATION OF CYANOACRYLATE, ZIRCONIA, POLYVINYL CHLORIDE OR SILICONE; IN VIVO 7(2):111-115, 1993]"
6372,363904551,62395,O=[Zr]=O,Active,,,,Rat,Wistar/Female (48/group),Intratracheal,"6 mg of 1.8-4 um particles given as 10 instillations before wk 26, study duration 115 wk or no treatment","Lung: Bronchiolo-alveolar adenoma (2/47 experimental animals vs 0/46 control animals), cystic keratinizing epithelioma (2/47 vs 0/46)","Positive, low incidence of benign tumors.","[MOHR,U, ERNST,H, ROLLER,M, AND POTT,F; PULMONARY TUMOR TYPES INDUCED IN WISTAR RATS OF THE SO-CALLED 19-DUST STUDY; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 58:13-20, 2006]"
6373,363904552,27488,C=C(C#N)C(=O)O,Active,,,,RAT,F344/FEMALE,SUBCUTANEOUS IMPLANT,"0.12 G INJECTED INTO 2 SITES ON THE LATERAL ABDOMEN, 2 SITES ON THE LATERAL CHEST REGION AND 1 SITE ON THE BACK (STUDY DURATION: 741 D)",IMPLANT SITE: MALIGNANT HISTIOCYTOMA,POSITIVE,"[HATANAKA,S, ONEDA,S, OKAZAKI,K, SHONG,L, YOSHIDA,A, ISAKA,H AND YOSHIDA,H; INDUCTION OF MALIGNANT FIBROUS HISTIOCYTOMA IN FEMALE FISHER RATS BY IMPLANTATION OF CYANOACRYLATE, ZIRCONIA, POLYVINYL CHLORIDE OR SILICONE; IN VIVO 7(2):111-115, 1993]"
6374,363904553,6335834,O.O[Si](O)(O)O.O[Si](O)(O)O.[Mg].[Mg].[Mg],Inactive,,,,MOUSE,"ALBINO/MALE, FEMALE",INTRAPERITONEAL,0; 25 MG IN 0.5 ML SALINE ONCE AT 2 MO OF AGE AND ONCE AT 3 MO OF AGE (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[FRASH,VN, VANCHUGOVA,NN, RUKOLEEVA,SN, ZUKOVA,VA, GREBENNIKOV,SA AND SCHERBAKOV,SV; CARCINOGENIC EFFECTS OF SOME NONFIBROUS MINERAL DUSTS; BYULL. EKSP. BIOL. MED. 114(12):648-651, 1992]"
6375,363904554,9942228,O=[Al]O[Al]=O.O=[Si]=O,Active,,,,MOUSE,"ALBINO/MALE, FEMALE",INTRAPERITONEAL,0; 25 MG IN 0.5 ML SALINE ONCE AT 2 MO OF AGE AND ONCE AT 3 MO OF AGE (STUDY DURATION: LIFE SPAN),PERITONEUM: MESOTHELIOMA,POSITIVE,"[FRASH,VN, VANCHUGOVA,NN, RUKOLEEVA,SN, ZUKOVA,VA, GREBENNIKOV,SA AND SCHERBAKOV,SV; CARCINOGENIC EFFECTS OF SOME NONFIBROUS MINERAL DUSTS; BYULL. EKSP. BIOL. MED. 114(12):648-651, 1992]"
6376,363904555,9989226,[O-2].[O-2].[O-2].[Al+3].[Al+3],Active,,,,MOUSE,"ALBINO/MALE, FEMALE",INTRAPERITONEAL,0; 10 MG IN 0.5 ML SALINE ONCE AT 2 MO OF AGE AND ONCE AT 3 MO OF AGE (STUDY DURATION: LIFE SPAN),PERITONEUM: MESOTHELIOMA,POSITIVE,"[FRASH,VN, VANCHUGOVA,NN, RUKOLEEVA,SN, ZUKOVA,VA, GREBENNIKOV,SA AND SCHERBAKOV,SV; CARCINOGENIC EFFECTS OF SOME NONFIBROUS MINERAL DUSTS; BYULL. EKSP. BIOL. MED. 114(12):648-651, 1992]"
6377,363904555,9989226,[O-2].[O-2].[O-2].[Al+3].[Al+3],Active,,,,Rat,Wistar/Female (48/group),Intratracheal,"5 and 10 instillations of 6 mg of 0.01-0.03 um particles given before wk 26, study duration 97 and 111 wk or no treatment","Lung: Bronchiolo-alveolar adenoma (10/44 and 10/47 experimental animals vs 1/46 control animals), bronchiolo-alveolar carcinoma (24/44 and 9/47 vs 0/46), adenosquamous cell carcinoma (1/44 and 0/47 vs 0/46), squamous cell carcinoma (12/44 and 20/47 vs 0/46, cystic keratinizing epithelioma (21/44 and 28/47 vs 0/46), non-keratinizing epithelioma (1/44 and 0/47 vs 0/46), >1 tumor type (23/44 and 20/47 vs 0/46)",Positive,"[MOHR,U, ERNST,H, ROLLER,M, AND POTT,F; PULMONARY TUMOR TYPES INDUCED IN WISTAR RATS OF THE SO-CALLED 19-DUST STUDY; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 58:13-20, 2006]"
6378,363904560,126865,CNC(=O)C1=C(N=CN1C)N(C)N=O,Active,,,,RAT,"BD-IX/MALE, FEMALE",ORAL,0; 3; 5; 15 MG/KG/D IN DRINKING WATER 5D/WK FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),NASAL CAVITY: TUMOR,POSITIVE,"[IVANKOVIC,S, SEIBEL,J, KOMITOWSKI,D, SPIEGELHALDER,B, PREUSSMANN,R AND SIDDIQI,M; CAFFEINE-DERIVED N-NITROSO COMPOUNDS. V. CARCINOGENICITY OF MONONITROSOCAFFEIDINE AND DINITROSOCAFFEIDINE IN BD-IX RATS; CARCINOGENSIS 19(5):933-937, 1998]"
6379,363904561,126866,CN1C=NC(=C1C(=O)N(C)N=O)N(C)N=O,Active,,,,RAT,"BD-IX/MALE, FEMALE",GAVAGE,0; 6; 60 MG/KG 2/WK AFTER 2 WK HIGH DOSE REDUCED TO 30 MG/KG FOR DURATION OF STUDY (STUDY DURATION: LIFETIME),FORESTOMACH: TUMOR,POSITIVE,"[IVANKOVIC,S, SEIBEL,J, KOMITOWSKI,D, SPIEGELHALDER,B, PREUSSMANN,R AND SIDDIQI,M; CAFFEINE-DERIVED N-NITROSO COMPOUNDS. V. CARCINOGENICITY OF MONONITROSOCAFFEIDINE AND DINITROSOCAFFEIDINE IN BD-IX RATS; CARCINOGENSIS 19(5):933-937, 1998]"
6380,363904601,7069270,C1CCN([C@@H](C1)C2=CN=CC=C2)N=O,Active,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 100 UMOL TOTAL DOSE ADMINISTERED IN SUBDOSES 3/WK FOR 7 WK (STUDY DURATION: 37 WK),LUNG: TUMOR,POSITIVE,"[HOFFMANN,D, DJORDJEVIC,MV, RIVENSON,A, ZANG,E, DESAI,D AND AMIN,S; A STUDY OF TOBACCO CARCINOGENESIS. LI. RELATIVE POTENCIES OF TOBACCO-SPECIFIC N-NITROSAMINES AS INDUCERS OF LUNG TUMORS IN A/J MICE; CANCER LETT. 71(1-3): 25-30, 1993]"
6381,363904602,105067,CN(C(CCCO)C1=CN=CC=C1)N=O,Inactive,,,,MOUSE,STRAIN-A/FEMALE,INTRAPERITONEAL,0; 200 UMOL TOTAL DOSE ADMINISTERED IN SUBDOSES 3/WK FOR 7 WK (STUDY DURATION: 37 WK),,NEGATIVE,"[HOFFMANN,D, DJORDJEVIC,MV, RIVENSON,A, ZANG,E, DESAI,D AND AMIN,S; A STUDY OF TOBACCO CARCINOGENESIS. LI. RELATIVE POTENCIES OF TOBACCO-SPECIFIC N-NITROSAMINES AS INDUCERS OF LUNG TUMORS IN A/J MICE; CANCER LETT. 71(1-3): 25-30, 1993]"
6382,363904664,338,C1=CC=C(C(=C1)C(=O)O)O,Inactive,,,,Mouse,SKH-1/Male (18/Group),Dermal,"0, 2, 4% administered as topical cream (pH 4) , 5 d/wk, 40 wk, animals held an additional 12 wk for study duration of 1 yr","Skin: Carcinoma in situ, squamous cell carcinoma, basal cell carcinoma","Negative. When synthetic solar light (SSL) at 0.3 and 0.6 the minimal erythema dose (MED) was also administered 5 d/wk, 4 hr/d for 40 wk, salicylic acid was photoprotective, reducing the carcinogenicity of 0.3 MED SSL.",[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
6383,363904664,338,C1=CC=C(C(=C1)C(=O)O)O,Inactive,,,,Mouse,SKH-1/Female (18/Group),Dermal,"0, 2, 4% administered as topical cream (pH 4) , 5 d/wk, 40 wk, animals held an additional 12 wk for study duration of 1 yr","Skin: Carcinoma in situ, squamous cell carcinoma, basal cell carcinoma","Negative. When synthetic solar light (SSL) at 0.3 and 0.6 the minimal erythema dose (MED) was also administered 5 d/wk, 4 hr/d for 40 wk, salicylic acid was photoprotective, reducing the carcinogenicity of 0.3 MED SSL.","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-524 Y07]"
6384,363904668,2733525,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 11.3; 22.6 MG/KG IN 0.5% CARBOXYMETHYLCELLULOSE 1/D 7 D/WK FOR UP TO 12 MO (STUDY DURATION: 15 MO),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",POSITIVE,"[HARD,GC, IATROPOULOS,MJ, JORDAN,K, RADI,L, KALTENBERG,OP, IMONDI,AR AND WILLIAMS,GM; MAJOR DIFFERENCE IN THE HEPATOCARCINOGENICITY AND DNA ADDUCT FORMING ABILITY BETWEEN TOREMIFENE AND TAMOXIFEN IN FEMALE CRL:CD(BR) RATS; CANCER RES. 53(19):4534-4541, 1993]"
6385,363904668,2733525,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,Inactive,,,,Mouse,CD-1/Female (30/group),Subcutaneous,"0; 10 ug as tamoxifen in peanut oil; dosed on days 1-5 of life and retained for 1.5 (4 animals), 3 (4 animals), 6 (4 animals), 12 (4 animals) or 18 (14 animals) months",Uterus and ovaries examined,Negative,"[RAZVI,N GREAVES,P STYLES,J EDWARDS,R AND WHITE,INH; ABSENCE OF UTERINE TUMOURS IN CD-1 MICE TREATED NEONATALLY WITH SUBCUTANEOUS TAMOXIFEN OR 4-HYDROXYOESTRADIOL; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 59(3-4):177-85, 2007]"
6386,363904668,2733525,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,Inactive,,,,Mouse,CD-1/Female (35/group),Subcutaneous,"0; 5; 10; 25; 50 ug as tamoxifen in peanut oil; dosed on days 1-5 of life and retained for 3 (4 animals), 6 (4 animals), 12 (4 animals) or 18 (14 animals) months",Uterus and ovaries examined,Negative (Nonneoplastic changes were observed),"[RAZVI,N GREAVES,P STYLES,J EDWARDS,R AND WHITE,INH; ABSENCE OF UTERINE TUMOURS IN CD-1 MICE TREATED NEONATALLY WITH SUBCUTANEOUS TAMOXIFEN OR 4-HYDROXYOESTRADIOL; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 59(3-4):177-85, 2007]"
6387,363904669,3005572,CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 12; 24 MG/KG IN 0.5% CARBOXYMETHYLCELLULOSE 1/D 7 D/WK FOR UP TO 12 MO (STUDY DURATION: 15 MO),,NEGATIVE,"[HARD,GC, IATROPOULOS,MJ, JORDAN,K, RADI,L, KALTENBERG,OP, IMONDI,AR AND WILLIAMS,GM; MAJOR DIFFERENCE IN THE HEPATOCARCINOGENICITY AND DNA ADDUCT FORMING ABILITY BETWEEN TOREMIFENE AND TAMOXIFEN IN FEMALE CRL:CD(BR) RATS; CANCER RES. 53(19):4534-4541, 1993]"
6388,363904669,3005572,CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.12; 1.2; 5; 12 MG/KG/D IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[KARLSSON,S, HIRSIMAKI,Y, MANTYLA,E, NIEMINEN,L, KANGAS,L, HIRSIMAKI,P, PERRY,CJ, MULHERN,M, MILLAR,P, HANDA,J AND WILLIAMS,GM; A TWO-YEAR DIETARY CARCINOGENICITY STUDY OF THE ANTIESTROGEN TOREMIFENE IN SPRAGUE-DAWLEY RATS; DRUG CHEM. TOXICOL. 19(4):245-266, 1996]"
6389,363904669,3005572,CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.12; 1.2; 5; 12 MG/KG/D IN DIET FOR DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[KARLSSON,S, HIRSIMAKI,Y, MANTYLA,E, NIEMINEN,L, KANGAS,L, HIRSIMAKI,P, PERRY,CJ, MULHERN,M, MILLAR,P, HANDA,J AND WILLIAMS,GM; A TWO-YEAR DIETARY CARCINOGENICITY STUDY OF THE ANTIESTROGEN TOREMIFENE IN SPRAGUE-DAWLEY RATS; DRUG CHEM. TOXICOL. 19(4):245-266, 1996]"
6390,363904679,71157,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 30; 90; 270 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KAJIMURA,T, SATOH,H, RAJASEKARAN,D, SPICER,EJF, NAKASHIMA,N AND TAKAYAMA,S; ONCOGENICITY STUDIES OF THE COGNITION-ENHANCING AGENT NEFIRACETAM IN MICE AND RATS; ARZNEIM.-FORSCH. 44-1(2A):254-259, 1994]"
6391,363904679,71157,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 30; 90; 270 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KAJIMURA,T, SATOH,H, RAJASEKARAN,D, SPICER,EJF, NAKASHIMA,N AND TAKAYAMA,S; ONCOGENICITY STUDIES OF THE COGNITION-ENHANCING AGENT NEFIRACETAM IN MICE AND RATS; ARZNEIM.-FORSCH. 44-1(2A):254-259, 1994]"
6392,363904679,71157,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O,Inactive,,,,RAT,F344/MALE,ORAL,0; 200; 600; 1800 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KAJIMURA,T, SATOH,H, RAJASEKARAN,D, SPICER,EJF, NAKASHIMA,N AND TAKAYAMA,S; ONCOGENICITY STUDIES OF THE COGNITION-ENHANCING AGENT NEFIRACETAM IN MICE AND RATS; ARZNEIM.-FORSCH. 44-1(2A):254-259, 1994]"
6393,363904679,71157,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 200; 600; 1800 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[KAJIMURA,T, SATOH,H, RAJASEKARAN,D, SPICER,EJF, NAKASHIMA,N AND TAKAYAMA,S; ONCOGENICITY STUDIES OF THE COGNITION-ENHANCING AGENT NEFIRACETAM IN MICE AND RATS; ARZNEIM.-FORSCH. 44-1(2A):254-259, 1994]"
6394,363904691,34457,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CCCC4=CC=C(C=C4)N(CCCl)CCCl)O)CCC5=CC(=O)C=C[C@]35C)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,"0; 12 MG/KG ADMINISTERED 1, 2, 4.5 OR 9 TIMES PER MO FOR 18 MO TO GIVE MEDIAN TOTAL DOSES OF 216; 432; 938; 1872 MG/KG (STUDY DURATION: LIFETIME)",EAR CANAL: SQUAMOUS-CELL CARCINOMA,POSITIVE,"[BERGER,MR, HABS,M AND SCHMAHL,D; COMPARATIVE CARCINOGENIC ACTIVITY OF PREDNIMUSTINE, CHLORAMBUCIL, PREDNISOLONE AND CHLORAMBUCIL PLUS PREDNISOLONE IN SPRAGUE-DAWLEY RATS; ARCH. GESCHWULSTFORSCH. 55:429-442, 1985][BERGER,MR, HABS,M AND SCHMAHL,D; LONG-TERM TOXICOLOGY EFFECTS OF PREDNIMUSTINE IN COMPARISON WITH CHLORAMBUCIL, PREDNISOLONE, AND CHLORAMBUCIL PLUS PREDNISOLONE IN SPRAGUE-DAWLEY RATS; SEMIN. ONCOL. 13(SUPPL. 1):8-13, 1986]"
6395,363904692,65114,C1=NN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,Inactive,,,,RAT,F344/MALE,INTRAPERITONEAL,0; 2.5 MG/KG IN 0.9% SALINE 3/WK FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[CARR,BI, RAHBAR,S, ASMERON,Y, RIGGS,A AND WINBERG,CD; CARCINOGENICITY AND HAEMOGLOBIN SYNTHESIS INDUCTION BY CYTIDINE ANALOGUES; BR. J. CANCER 57:395-402, 1988]"
6396,363904693,99681,C1N=C(NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Inactive,,,,RAT,F344/MALE,INTRAPERITONEAL,0; 50 MG/KG IN 0.9% SALINE 3/WK FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[CARR,BI, RAHBAR,S, ASMERON,Y, RIGGS,A AND WINBERG,CD; CARCINOGENICITY AND HAEMOGLOBIN SYNTHESIS INDUCTION BY CYTIDINE ANALOGUES; BR. J. CANCER 57:395-402, 1988]"
6397,363904694,6369,C=C(F)F,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 4.12; 8.25 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
6398,363904694,6369,C=C(F)F,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 4.12; 8.25 MG/KG BW IN OLIVE OIL 1/D 4-5 D/WK FOR 52 WK (STUDY DURATION: LIFETIME),[BRAIN WAS ONLY SITE EVALUATED],NEGATIVE,"[MALTONI,C, CILIBERTI,A AND CARRETTI,P; EXPERIMENTAL CONTRIBUTIONS IN IDENTIFYING BRAIN POTENTIAL CARCINOGENS IN THE PETROCHEMICAL INDUSTRY; ANN. N.Y. ACAD. SCI. 381:216-249, 1982]"
6399,363904713,8259,C(C(Cl)(Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 1000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 20 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
6400,363904713,8259,C(C(Cl)(Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 1000 NMOL TOTAL DOSE, 1/3 AND 2/3 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 20 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
6401,363904713,8259,C(C(Cl)(Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,"0; 2000 NMOL TOTAL DOSE, 3/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
6402,363904713,8259,C(C(Cl)(Cl)Cl)O,Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 2000 NMOL TOTAL DOSE, 3/7 AND 4/7 OF THE TOTAL DOSE ADMINISTERED AT 8 AND 15 DAYS OF AGE RESPECTIVELY, ANIMALS TERMINATED AT 20 MO OF AGE (STUDY DURATION: 12 MO)",,NEGATIVE,"[VON TUNGELN,LS YI,P BUCCI,TJ SAMOKYSZYN,VM CHOU,MW KADLUBAR,FF AND FU,PP; TUMORIGENICITY OF CHLORAL HYDRATE, TRICHLOROACETIC ACID, TRICHLOROETHANOL, MALONDIALDEHYDE, 4-HYDROXY-2-NONENAL, CROTONALDEHYDE, AND ACROLEIN IN THE B6C3F1 NEONATAL MOUSE; CANCER LETT. (SHANNON, IRELAND) 185(1):13-19, 2002]"
6403,363904731,7859,C#CCO,Inactive,,,,Rat,F344/N  / Female (50/Group),Inhalation,"0; 16; 32; 64 ppm for 6 hr plus 14 min per d, 5 d per wk for 105 wk (Study duration: 105 wk)",None,Negative. Conclusions of authors: No evidence of carcinogenic activity.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-552 Y08]"
6404,363904731,7859,C#CCO,Inactive,,,,Rat,F344/N  / Male (50/Group),Inhalation,"0; 16; 32; 64 ppm for 6 hr plus 14 min per d, 5 d per wk for 105 wk (Study duration: 105 wk)",Respiratory epithelium: Adenoma (0/49; 0/49; 0/50; 3/49),Negative  (although incidence at highest dose exceeded historical controls). Conclusions of authors: Some evidence of carcinogenic activity.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-552 Y08]"
6405,363904731,7859,C#CCO,Active,,,,Mouse,B6C3F1/Male (50/Group),Inhalation,"0; 8; 16; 32 ppm for 6 hr plus 14 min per d, 5 d per wk for 105 wk (Study duration: 105 wk)",Respiratory epithelium: Adenoma (0/49; 1/50; 4/50; 7/50); Harderian gland (3/50; 10/50; 6/50; 11/50),Positive. Conclusions of authors: Some evidence of carcinogenic activity based on increased incidences of nasal respiratory epithelial adenoma; increased incidences of Harderian gland adenoma may have been related to exposure).,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-552 Y08]"
6406,363904731,7859,C#CCO,Active,,,,Mouse,B6C3F1/Female (50/Group),Inhalation,"0; 8; 16; 32 ppm for 6 hr plus 14 min per d, 5 d per wk for 105 wk (Study duration: 105 wk)",Respiratory epithelium: Adenoma (0/50; 2/50; 4/50; 6/50),Positive. Conclusions of authors: Some evidence of carcinogenic activity.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-552 Y08]"
6407,363904757,6433718,C1=C2C(=C(C(=C1Br)[O-])Br)OC3=C(C(=C(C=C3C24C5=C(C(=C(C(=C5Cl)Cl)Cl)Cl)C(=O)O4)Br)[O-])Br.[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.1; 0.4% IN DIET FOR 90 WK (STUDY DURATION: 90 WK),,NEGATIVE,"[ITO,A, FUJIMOTO,N, OKAMOTO,T, ANDO,Y AND WATANABE,H; TUMORIGENICITY STUDY OF PHLOXINE (FR 104) IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 32(6):517-520, 1994]"
6408,363904757,6433718,C1=C2C(=C(C(=C1Br)[O-])Br)OC3=C(C(=C(C=C3C24C5=C(C(=C(C(=C5Cl)Cl)Cl)Cl)C(=O)O4)Br)[O-])Br.[Na+].[Na+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.1; 0.4% IN DIET FOR 90 WK (STUDY DURATION: 90 WK),,NEGATIVE,"[ITO,A, FUJIMOTO,N, OKAMOTO,T, ANDO,Y AND WATANABE,H; TUMORIGENICITY STUDY OF PHLOXINE (FR 104) IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 32(6):517-520, 1994]"
6409,363904773,30773,CCNC1=NC(=NC(=N1)Cl)NC(C)(C)C#N,Inactive,,,,RAT,CRL:CD BR/FEMALE,ORAL,0; 1; 5; 25; 50 PPM FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[BOGDANFFY,MS O'CONNOR,JC HANSEN,JF GADDAMIDI,V VAN PELT,CS GREEN,JW AND COOK,JC; CHRONIC TOXICITY AND ONCOGENICITY BIOASSAY IN RATS WITH THE CHLORO-S-TRIAZINE HERBICIDE CYANAZINE; J. TOXICOL. ENVIRON. HEALTH, PART A 60(8):567-586, 2000]"
6410,363904773,30773,CCNC1=NC(=NC(=N1)Cl)NC(C)(C)C#N,Inactive,,,,Mouse,CD/Female (50 per group; 100 per group for controls),Oral,"0; 10; 25; 1,000 ppm of 98% pure cyanazine in feed for two yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYANAZINE (MAY 18, 1995)]"
6411,363904773,30773,CCNC1=NC(=NC(=N1)Cl)NC(C)(C)C#N,Inactive,,,,Mouse,CD/Male (50 per group; 100 per group for controls),Oral,"0; 10; 25; 1,000 ppm of 98% pure cyanazine in feed for two yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYANAZINE (MAY 18, 1995)]"
6412,363904774,6327054,C1CCC(CC1)[Sn](C2CCCCC2)C3CCCCC3.O,Inactive,,,,Mouse,B6C3F1/Male (50/group),Oral,0; 1; 3; 6 mg/kg of 98% pure cyhexatin in diet for 2 years,,"Negative, (DPR evaluator indicated inadequate justification of dose and too narrow a range with exposures at two lower doses not discrete.)","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYHEXATIN (MAY 27, 1987)]"
6413,363904774,6327054,C1CCC(CC1)[Sn](C2CCCCC2)C3CCCCC3.O,Inactive,,,,Mouse,B6C3F1/Female (50/group),Oral,0; 1; 3; 6 mg/kg of 98% pure cyhexatin in diet for 2 years,,"Negative, (DPR evaluator indicated inadequate justification of dose and too narrow a range with exposures at two lower doses not discrete.)","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYHEXATIN (MAY 27, 1987)]"
6414,363904791,119263,CN1C(=CN=C1C2=NOC3C2CCCC3)[N+](=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,INTRAPERITONEAL,0; 80 UG/G BW 1/D FOR 30 DAYS (STUDY DURATION: LIFETIME),LYMPHATIC SYSTEM: LYMPHOMA,POSITIVE,"[TEIXEIRA,ARL, CALIXTO,MA AND TEIXEIRA,ML; CHAGAS' DISEASE: CARCINOGENIC ACTIVITY OF THE ANTITRYPANOSOMAL NITROARENES IN MICE; MUTAT. RES. 305(2): 189-196, 1994]"
6415,363904792,24856,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Al+3].[K+],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1; 2.5; 5; 10% (W/W) IN DIET FOR 20 MO (STUDY DURATION: 20 MO),,NEGATIVE,"[ONEDA,S, TAKASAKI,T, KURIWAKI,K, OHI,Y, UMEKITA,Y, HATANAKA,S, FUJIYOSHI,T, YOSHIDA,A AND YOSHIDA,H; CHRONIC TOXICITY AND TUMORIGENICITY STUDY OF ALUMINUM POTASSIUM SULFATE IN B6C3F1 MICE; IN VIVO 8(3):271-277, 1994]"
6416,363904792,24856,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Al+3].[K+],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1; 2.5; 5; 10% (W/W) IN DIET FOR 20 MO (STUDY DURATION: 20 MO),,NEGATIVE,"[ONEDA,S, TAKASAKI,T, KURIWAKI,K, OHI,Y, UMEKITA,Y, HATANAKA,S, FUJIYOSHI,T, YOSHIDA,A AND YOSHIDA,H; CHRONIC TOXICITY AND TUMORIGENICITY STUDY OF ALUMINUM POTASSIUM SULFATE IN B6C3F1 MICE; IN VIVO 8(3):271-277, 1994]"
6417,363904792,24856,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Al+3].[K+],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6418,363904792,24856,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Al+3].[K+],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6419,363904793,61300,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Fe+3],Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.06; 0.12% IN DRINKING WATER FOR 96 WK (STUDY DURATION: 100 WK),,NEGATIVE,"[INAI,K, FUJIHARA,M, YONEHARA,S AND KOBUKE,T; TUMORIGENICITY STUDY OF FERRIC CITRATE ADMINISTERED ORALLY TO MICE; FOOD CHEM. TOXICOL. 32(6):493-498, 1994]"
6420,363904793,61300,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Fe+3],Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.06%; 0.12% IN DRINKING WATER FOR 96 WK (STUDY DURATION: 100 WK),,NEGATIVE,"[INAI,K, FUJIHARA,M, YONEHARA,S AND KOBUKE,T; TUMORIGENICITY STUDY OF FERRIC CITRATE ADMINISTERED ORALLY TO MICE; FOOD CHEM. TOXICOL. 32(6):493-498, 1994]"
6421,363904794,93038,CC1CC(CC(C1)(OOC(C)(C)C)OOC(C)(C)C)(C)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 0.25; 0.5% IN DIET FOR 78 WK (STUDY DURATION: 83 WK),,NEGATIVE,"[MITSUI,M, FURUKAWA,F, SATO,M, ENAMI,T, IMAZAWA,T, NISHIKAWA,A AND TAKAHASHI,M; CARCINOGENICITY STUDY OF 1,1-BIS(TERT-BUTYLPEROXY)-3,3,5-TRIMETHYLCYCLOHEXANE IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 31(12):929-933, 1993]"
6422,363904794,93038,CC1CC(CC(C1)(OOC(C)(C)C)OOC(C)(C)C)(C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.25; 0.5% IN DIET FOR 78 WK (STUDY DURATION: 83 WK),,NEGATIVE,"[MITSUI,M, FURUKAWA,F, SATO,M, ENAMI,T, IMAZAWA,T, NISHIKAWA,A AND TAKAHASHI,M; CARCINOGENICITY STUDY OF 1,1-BIS(TERT-BUTYLPEROXY)-3,3,5-TRIMETHYLCYCLOHEXANE IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 31(12):929-933, 1993]"
6423,363904795,21492,C(COC(=O)N)O,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 1.12; 4.6; 11.2 MMOL/KG IN ISOTONIC SALINE ONCE AT 6 WK OF AGE (STUDY DURATION: 16 WK),LUNG: ADENOMA,POSITIVE,"[MIRVISH,SS, SMYRK,T, PAYNE,S, TUATOO,H AND CHEN,SC; WEAK CARCINOGENICITY OF 2-HYDROXYETHYL CARBAMATE IN STRAIN A MICE: INDICATION THAT THIS IS NOT A PROXIMAL METABOLITE OF ETHYL CARBAMATE; CANCER LETT. 77(1):1-5, 1994]"
6424,363904796,15142,CN1C2=CC=CC=C2C3=CC=CC=C31,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",,NEGATIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
6425,363904796,15142,CN1C2=CC=CC=C2C3=CC=CC=C31,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",,NEGATIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
6426,363904797,6836,CCN1C2=CC=CC=C2C3=CC=CC=C31,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",,NEGATIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
6427,363904797,6836,CCN1C2=CC=CC=C2C3=CC=CC=C31,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 1.75 UMOL/MOUSE (TOTAL DOSE) ADMINISTERED DURING DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",,NEGATIVE,"[WEYAND,EH, DEFAUW,J, MCQUEEN,CA, MESCHTER,CL, MEEGALLA,SK AND LAVOIE,EJ; BIOASSAY OF QUINOLINE, 5-FLUOROQUINOLINE, CARBAZOLE, 9-METHYLCARBAZOLE, AND 9-ETHYLCARBAZOLE IN NEWBORN MICE; FOOD CHEM. TOXICOL. 31(10):707-715, 1993]"
6428,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Active,,,,MOUSE,CD-1/FEMALE,GAVAGE,0; 0.3; 15; 30 MG/KG/D FOR 52 OR 85 WK (STUDY DURATION: 86 WK),FORESTOMACH: PAPILLOMA,POSITIVE,"[ROBISON,RL, SUTER,W AND COX,RH; CARCINOGENICITY AND MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUNDAM. APPL. TOXICOL. 23(1):9-20, 1994]"
6429,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,MOUSE,CD-1/MALE,GAVAGE,0; 0.3; 15; 30 MG/KG/D FOR 52 OR 85 WK (STUDY DURATION: 86 WK),,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH; CARCINOGENICITY AND MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUNDAM. APPL. TOXICOL. 23(1):9-20, 1994]"
6430,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,MOUSE,CD-1/MALE,GAVAGE,0; 50; 150; 350 MG/KG/D FOR 52 OR 84 WK (HIGH DOSE GROUP TERMINATED IN WK 23) (STUDY DURATION: 84 WK),,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH; CARCINOGENICITY AND MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUNDAM. APPL. TOXICOL. 23(1):9-20, 1994]"
6431,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,MOUSE,CD-1/FEMALE,GAVAGE,0; 50; 150; 350 MG/KG/D FOR 52 OR 84 WK (HIGH DOSE GROUP TERMINATED IN WK 23) (STUDY DURATION: 93 WK),,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH; CARCINOGENICITY AND MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUNDAM. APPL. TOXICOL. 23(1):9-20, 1994]"
6432,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,RAT,STRAIN-CD/MALE,GAVAGE,0; 0.03; 0.3; 3 MG/KG/D FOR 95 WK (STUDY DURATION: 114 WK),,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH; CARCINOGENICITY AND MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUNDAM. APPL. TOXICOL. 23(1):9-20, 1994]"
6433,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,RAT,STRAIN-CD/FEMALE,GAVAGE,0; 0.03; 0.3; 3 MG/KG/D FOR 95 WK (STUDY DURATION: 114 WK),,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH; CARCINOGENICITY AND MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUNDAM. APPL. TOXICOL. 23(1):9-20, 1994]"
6434,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,RAT,STRAIN-CD/MALE,GAVAGE,0; 6; 9; 18-24 MG/KG/D FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH; CARCINOGENICITY AND MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUNDAM. APPL. TOXICOL. 23(1):9-20, 1994]"
6435,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,RAT,STRAIN-CD/FEMALE,GAVAGE,0; 6; 9; 18-24 MG/KG/D FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH; CARCINOGENICITY AND MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUNDAM. APPL. TOXICOL. 23(1):9-20, 1994]"
6436,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Active,,,,MOUSE,CD-1/FEMALE (70/GROUP),ORAL (GAVAGE),0; 0.3; 15; 30 MG/KG/D IN 1% CARBOXYMETHYLCELLULOSE FOR 85 WK,FORESTOMACH: SQUAMOUS PAPILLOMAS,POSITIVE,"[ROBISON,RL, SUTER,W AND COX,RH;CARCINOGENICITY AND  MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY  SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUND. APPL. TOXICOL.  23(1):9-20, 1994]"
6437,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,MOUSE,CD-1/MALE (70/GROUP),ORAL (GAVAGE),0; 0.3; 15; 30 MG/KG/D IN 1% CARBOXYMETHYLCELLULOSE FOR 85 WK,,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH;CARCINOGENICITY AND  MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY  SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUND. APPL. TOXICOL.  23(1):9-20, 1994]"
6438,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,MOUSE,CD-1/MALE (80/GROUP),ORAL (GAVAGE),0; 50; 150; 350 MG/KG/D IN 1% CARBOXYMETHYLCELLULOSE FOR 84 WK,,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH;CARCINOGENICITY AND  MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY  SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUND. APPL. TOXICOL.  23(1):9-20, 1994]"
6439,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,MOUSE,CD-1/FEMALE (80/GROUP),ORAL (GAVAGE),0; 50; 150; 350 MG/KG/D IN 1% CARBOXYMETHYLCELLULOSE FOR 93 WK,,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH;CARCINOGENICITY AND  MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY  SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUND. APPL. TOXICOL.  23(1):9-20, 1994]"
6440,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,RAT,CD (SPRAGUE-DAWLEY)/MALE (75/GROUP),ORAL (GAVAGE),0; 0.03; 0.3; 3 MG/KG/D IN 1% CARBOXYMETHYLCELLULOSE FOR 95 WKS,,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH;CARCINOGENICITY AND  MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY  SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUND. APPL. TOXICOL.  23(1):9-20, 1994]"
6441,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,RAT,CD (SPRAGUE-DAWLEY)/FEMALE (75/GROUP),ORAL (GAVAGE),0; 0.03; 0.3; 3 MG/KG/D IN 1% CARBOXYMETHYLCELLULOSE FOR 101 WKS,,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH;CARCINOGENICITY AND  MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY  SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUND. APPL. TOXICOL.  23(1):9-20, 1994]"
6442,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Active,,,,RAT,CD (SPRAGUE-DAWLEY)/MALE (75/GROUP),ORAL (GAVAGE),0; 6; 9; 18-24 MG/KG/D IN 1% CARBOXYMETHYLCELLULOSE FOR 104 WKS,THYROID: FOLLICULAR ADENOMA (11/75),POSITIVE,"[ROBISON,RL, SUTER,W AND COX,RH;CARCINOGENICITY AND  MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY  SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUND. APPL. TOXICOL.  23(1):9-20, 1994]"
6443,363904798,23679527,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+],Inactive,,,,RAT,CD (SPRAGUE-DAWLEY)/FEMALE  (75/GROUP),ORAL (GAVAGE),0; 6; 9; 18-24 MG/KG/D IN 1% CARBOXYMETHYLCELLULOSE FOR 104 WKS,,NEGATIVE,"[ROBISON,RL, SUTER,W AND COX,RH;CARCINOGENICITY AND  MUTAGENICITY STUDIES WITH FLUVASTATIN, A NEW, ENTIRELY  SYNTHETIC HMG-COA REDUCTASE INHIBITOR; FUND. APPL. TOXICOL.  23(1):9-20, 1994]"
6444,363904805,9064,C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,Active,,,,RAT,F344/MALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOCARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369:43-52, 1991]"
6445,363904805,9064,C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,Active,,,,RAT,F344/FEMALE,ORAL,0; 2% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),GLANDULAR STOMACH: ADENOCARCINOMA,POSITIVE,"[ITO,N, HIROSE,M AND TAKAHASHI,S; CELLULAR PROLIFERATION AND STOMACH CARCINOGENESIS INDUCED BY ANTIOXIDANTS; PROG. CLIN. BIOL. RES. 369:43-52, 1991]"
6446,363904834,24500,O[As](=O)([O-])[O-].[Na+].[Na+],Inactive,,,,MOUSE,SWISS/MALE,INTRAVENOUS,0; 0.5 MG/KG/WK FOR 20 WK (STUDY DURATION: 96 WK),,NEGATIVE,"[WAALKES,MP KEEFER,LK AND DIWAN,BA; INDUCTION OF PROLIFERATIVE LESIONS OF THE UTERUS, TESTES, AND LIVER IN SWISS MICE GIVEN REPEATED INJECTIONS OF SODIUM ARSENATE: POSSIBLE ESTROGENIC MODE OF ACTION; TOXICOL. APPL. PHARMACOL. 166(1):24-35, 2000]"
6447,363904834,24500,O[As](=O)([O-])[O-].[Na+].[Na+],Inactive,,,,MOUSE,SWISS/FEMALE,INTRAVENOUS,0; 0.5 MG/KG/WK FOR 20 WK (STUDY DURATION: 96 WK),,NEGATIVE,"[WAALKES,MP KEEFER,LK AND DIWAN,BA; INDUCTION OF PROLIFERATIVE LESIONS OF THE UTERUS, TESTES, AND LIVER IN SWISS MICE GIVEN REPEATED INJECTIONS OF SODIUM ARSENATE: POSSIBLE ESTROGENIC MODE OF ACTION; TOXICOL. APPL. PHARMACOL. 166(1):24-35, 2000]"
6448,363904877,5283344,CCCCCC(/C=C/C=O)O,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 50; 100; 200 NMOL/MOUSE (TOTAL DOSE) ADMINISTERED IN 3 DOSES ON DAY 1, 8 AND 15 OF STUDY (STUDY DURATION: 6 WK)",,NEGATIVE,"[CHUNG,FL, CHEN,HJC, GUTTENPLAN,JB, NISHIKAWA,A AND HARD,GC; 2,3-EPOXY-4- HYDROXYNONANAL AS A POTENTIAL TUMOR-INITIATING AGENT OF LIPID PEROXIDATION; CARCINOGENESIS 14(10):2073-2077, 1993]"
6449,363904877,5283344,CCCCCC(/C=C/C=O)O,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 50; 100; 200 NMOL/MOUSE (TOTAL DOSE) ADMINISTERED IN 3 DOSES ON DAY 1, 8 AND 15 OF STUDY (STUDY DURATION: 6 WK)",,NEGATIVE,"[CHUNG,FL, CHEN,HJC, GUTTENPLAN,JB, NISHIKAWA,A AND HARD,GC; 2,3-EPOXY-4- HYDROXYNONANAL AS A POTENTIAL TUMOR-INITIATING AGENT OF LIPID PEROXIDATION; CARCINOGENESIS 14(10):2073-2077, 1993]"
6450,363904878,21845,C1CN(CCN1)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICAL,0; 3.8 G (TOTAL DOSE) INJECTED INTO BLADDER 2/WK OVER 48 WK (STUDY DURATION: 102 WK),NASAL CAVITY: TUMOR; BLADDER: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; CARCINOGENIC EFFECTS IN RATS OF NITROSOPIPERAZINES ADMINISTERED INTRAVESICALLY: POSSIBLE IMPLICATIONS FOR THE USE OF PIPERAZINE; CANCER LETT. 74(1-2):101-103, 1993]"
6451,363904879,8819,C1CN(CCN1N=O)N=O,Active,,,,RAT,F344/FEMALE,INTRAVESICAL,0; 374 MG (TOTAL DOSE) INJECTED INTO BLADDER 2/WK OVER 36 WK (STUDY DURATION: 102 WK),NASAL CAVITY: TUMOR,POSITIVE,"[LIJINSKY,W AND KOVATCH,RM; CARCINOGENIC EFFECTS IN RATS OF NITROSOPIPERAZINES ADMINISTERED INTRAVESICALLY: POSSIBLE IMPLICATIONS FOR THE USE OF PIPERAZINE; CANCER LETT. 74(1-2):101-103, 1993]"
6452,363904880,33743,C1=CC2=C3C(=C1)C=C4C=CC5=C4C3=C(C=C2)C=C5,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 10; 50; 100; 200 MG/KG ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[NESNOW,S, ROSS,JA, NELSON,G, WILSON,K, ROOP,BC, JEFFERS,AJ, GALATI,AJ, STONER,GD, SANGAIAH,R, GOLD,A AND MASS,MJ; CYCLOPENTA[CD]PYRENE-INDUCED TUMORIGENICITY, KI-RAS CODON 12 MUTATIONS AND DNA ADDUCTS IN STRAIN A/J MOUSE LUNG; CARCINOGENESIS 15(4):601-606, 1994]"
6453,363904880,33743,C1=CC2=C3C(=C1)C=C4C=CC5=C4C3=C(C=C2)C=C5,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0; 10; 50; 100; 200 MG/KG BW ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[ROSS,JA, NELSON,GB, WILSON,KH, RABINOWITZ,JR, GALATI,A, STONER,GD, NESNOW,S AND MASS,MJ; ADENOMAS INDUCED BY POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MOUSE LUNG CORRELATE WITH TIME-INTEGRATED DNA ADDUCT LEVELS; CANCER RES. 55(5): 1039-1044, 1995]"
6454,363904880,33743,C1=CC2=C3C(=C1)C=C4C=CC5=C4C3=C(C=C2)C=C5,Active,,,,MOUSE,STRAIN-A/MALE,INTRAPERITONEAL,0-200 MG/KG IN TRICAPRYLIN ONCE (STUDY DURATION: 8 MO),LUNG: ADENOMA,POSITIVE,"[NESNOW,S, ROSS,JA, STONER,GD AND MASS,MJ; TUMORIGENESIS OF CARCINOGENIC ENVIRONMENTAL POLYCYCLIC AROMATIC HYDROCARBONS IN STRAIN A/J MICE: LINKAGE TO DNA ADDUCTS AND MUTATIONS IN ONCOGENES; POLYCYCLIC AROMAT. COMPD. 10(1-4):259-266, 1996]"
6455,363904881,19212,C[C@@H]([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O)[C@@H](CCC(C)(C)O)O,Active,,,,MOUSE,SWISS/FEMALE,ORAL,0; 3 PPM/25 G BW IN DIET FOR 22 MO (STUDY DURATION: 22 MO),MAMMARY GLAND: TUMOR; LUNG: TUMOR,POSITIVE,"[EL-MOFTY,MM, SAKR,SA, RIZK,AM AND MOUSSA,EA; INDUCTION OF BREAST AND LUNG NEOPLASTIC LESIONS IN MICE BY ALPHA ECDYSONE; ONCOL. REP. 1(2):435-438, 1994]"
6456,363904881,19212,C[C@@H]([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O)[C@@H](CCC(C)(C)O)O,Active,,,,MOUSE,SWISS/MALE,ORAL,0; 3 PPM/25 G BW IN DIET FOR 22 MO (STUDY DURATION: 22 MO),LUNG: TUMOR,POSITIVE,"[EL-MOFTY,MM, SAKR,SA, RIZK,AM AND MOUSSA,EA; INDUCTION OF BREAST AND LUNG NEOPLASTIC LESIONS IN MICE BY ALPHA ECDYSONE; ONCOL. REP. 1(2):435-438, 1994]"
6457,363904882,35702,CC1=CC2=C3C(=CC=C2)C4=CC=CC=C4C3=C1,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 3.46; 17.3 UMOL (TOTAL DOSE) IN DMSO ADMINISTERED ON DAYS 1,8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[LAVOIE,EJ, CAI,ZW, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF FLUORANTHENE, 2-METHYLFLUORANTHENE AND 3-METHYLFLUORANTHENE IN NEWBORN CD-1 MICE. CARCINOGENESIS 15(10):2131-2135, 1994]"
6458,363904882,35702,CC1=CC2=C3C(=CC=C2)C4=CC=CC=C4C3=C1,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 3.46; 17.3 UMOL (TOTAL DOSE) IN DMSO ADMINISTERED ON DAYS 1,8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",LUNG: TUMORS; LIVER: TUMORS,POSITIVE,"[LAVOIE,EJ, CAI,ZW, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF FLUORANTHENE, 2-METHYLFLUORANTHENE AND 3-METHYLFLUORANTHENE IN NEWBORN CD-1 MICE. CARCINOGENESIS 15(10):2131-2135, 1994]"
6459,363904883,15565,CC1=C2C=CC=C3C2=C(C=C1)C4=CC=CC=C43,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 3.46; 17.3 UMOL (TOTAL DOSE) IN DMSO ADMINISTERED ON DAYS 1,8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",,NEGATIVE,"[LAVOIE,EJ, CAI,ZW, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF FLUORANTHENE, 2-METHYLFLUORANTHENE AND 3-METHYLFLUORANTHENE IN NEWBORN CD-1 MICE. CARCINOGENESIS 15(10):2131-2135, 1994]"
6460,363904883,15565,CC1=C2C=CC=C3C2=C(C=C1)C4=CC=CC=C43,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 3.46; 17.3 UMOL (TOTAL DOSE) IN DMSO ADMINISTERED ON DAYS 1,8, AND 15 OF LIFE (STUDY DURATION: 52 WK)",LIVER: TUMORS,POSITIVE,"[LAVOIE,EJ, CAI,ZW, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF FLUORANTHENE, 2-METHYLFLUORANTHENE AND 3-METHYLFLUORANTHENE IN NEWBORN CD-1 MICE. CARCINOGENESIS 15(10):2131-2135, 1994]"
6461,363904927,2328,CC(C)N1C(=O)C2=CC=CC=C2NS1(=O)=O,Inactive,,,,Rat,Fischer 344/DU CRJ/Male (70/sex/group),Oral,0; 200; 800; 4000 ppm in diet for 2 yr,,Negative; Purity 93.3%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENTAZON/BENTAZON SODIUM (SEPTEMBER 30, 1999)]"
6462,363904927,2328,CC(C)N1C(=O)C2=CC=CC=C2NS1(=O)=O,Inactive,,,,Rat,Fischer 344/DU CRJ/Female (70/sex/group),Oral,0; 200; 800; 4000 ppm in diet for 2 yr,,Negative; Purity 93.3%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENTAZON/BENTAZON SODIUM (SEPTEMBER 30, 1999)]"
6463,363904927,2328,CC(C)N1C(=O)C2=CC=CC=C2NS1(=O)=O,Active,,,,Mouse,B6C3F1/Male (70/sex/group),Oral,0; 100; 400; 2000 ppm in diet for 2 yr,Liver: Combined hepatocellular adenoma and carcinoma (13/49 in controls and 22/49 at highest dose),Positive; Purity 93.3%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENTAZON/BENTAZON SODIUM (SEPTEMBER 30, 1999)]"
6464,363904927,2328,CC(C)N1C(=O)C2=CC=CC=C2NS1(=O)=O,Inactive,,,,Mouse,B6C3F1/Female (70/sex/group),Oral,0; 100; 400; 2000 ppm in diet for 2 yr,,Negative; Purity 93.3%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENTAZON/BENTAZON SODIUM (SEPTEMBER 30, 1999)]"
6465,363905002,22932,CCCCC(CC)COC(=O)C1=CC=C(C=C1)C(=O)OCC(CC)CCCC,Inactive,,,,Rat,Fischer 344/Male,Oral,"0; 1500; 6000; 12,000 ppm in diet for 104 wk (average daily dose 0, 79, 324, 666 mg/kg/day)",,Negative,"[DEYO,JA; CARCINOGENICITY AND CHRONIC TOXICITY OF DI-2-ETHYLHEXYL TEREPHTHALATE (DEHT) FOLLOWING A 2-YEAR DIETARY EXPOSURE IN FISCHER 344 RATS; FOOD AND CHEMICAL TOXICOLOGY 46(3):990-1005, 2008]"
6466,363905002,22932,CCCCC(CC)COC(=O)C1=CC=C(C=C1)C(=O)OCC(CC)CCCC,Inactive,,,,Rat,Fischer 344/Female,Oral,"0; 1500; 6000; 12,000 ppm in diet for 104 wk (average daily dose 0, 102, 418, 901 mg/kg/day)",,Negative,"[DEYO,JA; CARCINOGENICITY AND CHRONIC TOXICITY OF DI-2-ETHYLHEXYL TEREPHTHALATE (DEHT) FOLLOWING A 2-YEAR DIETARY EXPOSURE IN FISCHER 344 RATS; FOOD AND CHEMICAL TOXICOLOGY 46(3):990-1005, 2008]"
6467,363905022,2724063,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(C=C2[N+](=O)[O-])[N+](=O)[O-])[O-].[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6468,363905022,2724063,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(C=C2[N+](=O)[O-])[N+](=O)[O-])[O-].[Na+].[Na+],Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML DISTILLED WATER 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6469,363905023,6680,CC1=CC=C(C=C1)NC2=C3C(=C(C=C2)O)C(=O)C4=CC=CC=C4C3=O,Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML 0.1% SODIUM LAURYL SULFATE 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6470,363905023,6680,CC1=CC=C(C=C1)NC2=C3C(=C(C=C2)O)C(=O)C4=CC=CC=C4C3=O,Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML 0.1% SODIUM LAURYL SULFATE 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6471,363905024,62331,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=NC3=C(C=CC4=CC=CC=C43)O,Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML 0.1% SODIUM LAURYL SULFATE 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6472,363905024,62331,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=NC3=C(C=CC4=CC=CC=C43)O,Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML 0.1% SODIUM LAURYL SULFATE 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6473,363905025,135487685,C1=CC=C2C(=C1)C=CC(=C2S(=O)(=O)[O-])N=NC3=C(C(=CC4=CC=CC=C43)C(=O)O)[O-].[Ca+2],Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML 0.1% SODIUM LAURYL SULFATE 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6474,363905025,135487685,C1=CC=C2C(=C1)C=CC(=C2S(=O)(=O)[O-])N=NC3=C(C(=CC4=CC=CC=C43)C(=O)O)[O-].[Ca+2],Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML 0.1% SODIUM LAURYL SULFATE 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6475,363905026,16850,C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O,Inactive,,,,MOUSE,SWISS-WEBSTER/MALE,DERMAL,0; 1% IN 0.1 ML 0.1% SODIUM LAURYL SULFATE 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6476,363905026,16850,C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O,Inactive,,,,MOUSE,SWISS-WEBSTER/FEMALE,DERMAL,0; 1% IN 0.1 ML 0.1% SODIUM LAURYL SULFATE 1/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[CARSON,S; SKIN PAINTING STUDIES IN MICE ON 11 FD&C AND D&C COLORS: FD&C GREEN NO. 3, RED NO. 2, RED NO. 4, YELLOW NO. 6, AND EXTERNAL D&C NO. 7, D&C ORANGE NO. 4, VIOLET NO. 2, RED NO. 17, RED NO. 34, AND YELLOW NO. 7; J. TOXICOL., CUTANEOUS OCUL. TOXICOL. 3(3):309-331, 1984]"
6477,363905027,157355,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O,Active,,,,RAT,SPF/MALE,ORAL,0; 2; 5; 10% IN DIET FOR DURATION OF STUDY ADMINISTERED TO OFFSPRING OF RATS FED THE SAME DIETS (STUDY DURATION: 130 WK),TESTES: LEYDIG CELL TUMOR,POSITIVE,"[SINKELDAM,EJ, WOUTERSEN,RA, HOLLANDERS,VMH, TIL,HP, VAN GARDEREN-HOETMER,A AND BAR,A; SUBCHRONIC AND CHRONIC TOXICITY/CARCINOGENICITY FEEDING STUDIES WITH LACTITOL IN RATS; J. AM. COLL. TOXICOL. 11(2):165-188, 1992]"
6478,363905027,157355,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O,Inactive,,,,RAT,SPF/FEMALE,ORAL,0; 2; 5; 10% IN DIET FOR DURATION OF STUDY ADMINISTERED TO OFFSPRING OF RATS FED THE SAME DIETS (STUDY DURATION: 130 WK),,NEGATIVE,"[SINKELDAM,EJ, WOUTERSEN,RA, HOLLANDERS,VMH, TIL,HP, VAN GARDEREN-HOETMER,A AND BAR,A; SUBCHRONIC AND CHRONIC TOXICITY/CARCINOGENICITY FEEDING STUDIES WITH LACTITOL IN RATS; J. AM. COLL. TOXICOL. 11(2):165-188, 1992]"
6479,363905028,3037558,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)O)O)O)O,Active,,,,RAT,SPF/MALE,ORAL,0; 20% IN DIET FOR DURATION OF STUDY ADMINISTERED TO OFFSPRING OF RATS FED THE SAME DIETS (STUDY DURATION: 130 WK),ADRENAL GLAND: MEDULLARY TUMORS; TESTES: LEYDIG CELL TUMOR,POSITIVE,"[SINKELDAM,EJ, WOUTERSEN,RA, HOLLANDERS,VMH, TIL,HP, VAN GARDEREN-HOETMER,A AND BAR,A; SUBCHRONIC AND CHRONIC TOXICITY/CARCINOGENICITY FEEDING STUDIES WITH LACTITOL IN RATS; J. AM. COLL. TOXICOL. 11(2):165-188, 1992]"
6480,363905028,3037558,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)O)O)O)O,Inactive,,,,RAT,SPF/FEMALE,ORAL,0; 20% IN DIET FOR DURATION OF STUDY ADMINISTERED TO OFFSPRING OF RATS FED THE SAME DIETS (STUDY DURATION: 130 WK),,NEGATIVE,"[SINKELDAM,EJ, WOUTERSEN,RA, HOLLANDERS,VMH, TIL,HP, VAN GARDEREN-HOETMER,A AND BAR,A; SUBCHRONIC AND CHRONIC TOXICITY/CARCINOGENICITY FEEDING STUDIES WITH LACTITOL IN RATS; J. AM. COLL. TOXICOL. 11(2):165-188, 1992]"
6481,363905029,147300,CC(C)(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OS(=O)(=O)C,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 25; 100; 400 PPM IN DIET FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[IMAI,S, YAMAMOTO,H AND TSUBURA,Y; THE ANTISPERMATOGENIC EFFECT AND TOXICITY OF 2,4-DINITRO-6-TERT-BUTYLPHENYL METHANESULFONATE ON SPRAGUE-DAWLEY RATS; J. TOXICOL. SCI. 9(2):161-174, 1984]"
6482,363905029,147300,CC(C)(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OS(=O)(=O)C,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 25; 100; 400 PPM IN DIET FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[IMAI,S, YAMAMOTO,H AND TSUBURA,Y; THE ANTISPERMATOGENIC EFFECT AND TOXICITY OF 2,4-DINITRO-6-TERT-BUTYLPHENYL METHANESULFONATE ON SPRAGUE-DAWLEY RATS; J. TOXICOL. SCI. 9(2):161-174, 1984]"
6483,363905030,5284403,CCN(CC)CCCNC(=O)CN1C(=C(C=N1)C2=CC=CC=C2)C3=CC=CC=C3.C(=C/C(=O)O)\C(=O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 20; 80; 160 MG/KG 1/D FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[GREENER,Y, BARBOLT,TA, ZELINGER,DJ AND GOSSETT,KA; CHRONIC (1-YEAR) SAFETY EVALUATION OF IPAZILIDE FUMARATE, AN ANTIARRHYTHMIC AGENT, ADMINISTERED ORALLY TO RATS; FUNDAM. APPL. TOXICOL. 20(2):147-154, 1993]"
6484,363905030,5284403,CCN(CC)CCCNC(=O)CN1C(=C(C=N1)C2=CC=CC=C2)C3=CC=CC=C3.C(=C/C(=O)O)\C(=O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 20; 80; 160 MG/KG 1/D FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[GREENER,Y, BARBOLT,TA, ZELINGER,DJ AND GOSSETT,KA; CHRONIC (1-YEAR) SAFETY EVALUATION OF IPAZILIDE FUMARATE, AN ANTIARRHYTHMIC AGENT, ADMINISTERED ORALLY TO RATS; FUNDAM. APPL. TOXICOL. 20(2):147-154, 1993]"
6485,363905031,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 50; 100; 200 MG/KG 1/D FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[FELETTI,F, DE BERNARDI DI VALSERRA,M, CONTOS,S, MATTABONI,P AND GERMOGLI,R; CHRONIC TOXICITY STUDY ON A NEW GLUCAN EXTRACTED FROM CANDIDA ALBICANS IN RATS; ARZNEIM. FORSCH. 42(11):1363-1367, 1992]"
6486,363905031,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 50; 100; 200 MG/KG 1/D FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[FELETTI,F, DE BERNARDI DI VALSERRA,M, CONTOS,S, MATTABONI,P AND GERMOGLI,R; CHRONIC TOXICITY STUDY ON A NEW GLUCAN EXTRACTED FROM CANDIDA ALBICANS IN RATS; ARZNEIM. FORSCH. 42(11):1363-1367, 1992]"
6487,363905032,9416,CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,Active,,,,RAT,WISTAR/FEMALE,INTRAMUSCULAR,0; 12.5 MG 1/WK FOR 24 WK (STUDY DURATION: 24 WK),BLADDER: PAPILLOMA OR CARCINOMA,POSITIVE,"[TERADA,S, SUZUKI,N, UCHIDE,K, AKASOFU,K AND NISHIDA,E; EFFECT OF TESTOSTERONE ON THE DEVELOPMENT OF BLADDER TUMORS AND CALCULI IN FEMALE RATS; GYNECOL. OBSTET. INVEST. 34(2):105-110, 1992]"
6488,363905032,9416,CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,Inactive,,,,RAT,WISTAR/FEMALE,INTRAMUSCULAR,0; 12.5 MG 1/WK FOR 24 WK ADMINISTERED TO OOPHORECTOMIZED RATS (STUDY DURATION: 24 WK),,NEGATIVE,"[TERADA,S, SUZUKI,N, UCHIDE,K, AKASOFU,K AND NISHIDA,E; EFFECT OF TESTOSTERONE ON THE DEVELOPMENT OF BLADDER TUMORS AND CALCULI IN FEMALE RATS; GYNECOL. OBSTET. INVEST. 34(2):105-110, 1992]"
6489,363905033,3476,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 20; 1000; 50000 PPM IN DIET FOR 12 MO (STUDY DURATION: 13 MO),,NEGATIVE,"[DONAUBAUER,HH AND MAYER,D; ACUTE, SUBCHRONIC AND CHRONIC TOXICITY OF THE NEW SULFONYLUREA GLIMEPIRIDE IN RATS; ARZNEIM. FORSCH. 43-1(5):547-549, 1993]"
6490,363905033,3476,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 20; 1000; 50000 PPM IN DIET FOR 12 MO (STUDY DURATION: 13 MO),,NEGATIVE,"[DONAUBAUER,HH AND MAYER,D; ACUTE, SUBCHRONIC AND CHRONIC TOXICITY OF THE NEW SULFONYLUREA GLIMEPIRIDE IN RATS; ARZNEIM. FORSCH. 43-1(5):547-549, 1993]"
6491,363905033,3476,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,Inactive,,,,DOG,BEAGLE/MALE,ORAL,0; 0.8; 16; 320 MG/KG BW IN GELATIN CAPSULE 1/D 7 D/WK FOR 12 MO (STUDY DURATION: 13 MO),,NEGATIVE,"[SCHOLLMEIER,U, BRUNK,R AND MAYER,D; SUBCHRONIC AND CHRONIC TOXICITY OF THE NEW SULFONYLUREA GLIMEPIRIDE IN DOGS; ARZNEIM. FORSCH. 43-2(10):1068-1071, 1993]"
6492,363905033,3476,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,Inactive,,,,DOG,BEAGLE/FEMALE,ORAL,0; 0.8; 16; 320 MG/KG BW IN GELATIN CAPSULE 1/D 7 D/WK FOR 12 MO (STUDY DURATION: 15 MO),,NEGATIVE,"[SCHOLLMEIER,U, BRUNK,R AND MAYER,D; SUBCHRONIC AND CHRONIC TOXICITY OF THE NEW SULFONYLUREA GLIMEPIRIDE IN DOGS; ARZNEIM. FORSCH. 43-2(10):1068-1071, 1993]"
6493,363905034,20056604,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O)I)N(C)C(=O)C)I,Active,,,,MOUSE,ICR/FEMALE,INTRABRONCHIAL,0; 75 UL ONCE ADMINISTERED TO WEANLING MICE (STUDY DURATION: LIFETIME),LUNG: TUMOR,POSITIVE,"[BAKER,DG, ALFORD,BA AND FELDMAN,PS; LUNG TUMOR INCIDENCE AFTER INTRABRONCHIAL ADMINISTRATION OF THE NONIONIC CONTRAST AGENT METRIZAMIDE; INVEST. RADIOL. 27(7):525-528, 1992]"
6494,363905035,13709,COC1=NN(C(=O)S1)CSP(=S)(OC)OC,Inactive,,,,DOG,BEAGLE/MALE,ORAL,0; 0.5; 2; 4; 40; 140 PPM IN DIET FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[CHANG,JCF, WALBERG,JA AND CAMPBELL,WR; ONE-YEAR DIETARY TOXICITY STUDY WITH METHIDATHION IN BEAGLE DOGS; FUNDAM. APPL. TOXICOL. 19(2):307-314, 1992]"
6495,363905035,13709,COC1=NN(C(=O)S1)CSP(=S)(OC)OC,Inactive,,,,DOG,BEAGLE/FEMALE,ORAL,0; 0.5; 2; 4; 40; 140 PPM IN DIET FOR 1 YR (STUDY DURATION: 1 YR),,NEGATIVE,"[CHANG,JCF, WALBERG,JA AND CAMPBELL,WR; ONE-YEAR DIETARY TOXICITY STUDY WITH METHIDATHION IN BEAGLE DOGS; FUNDAM. APPL. TOXICOL. 19(2):307-314, 1992]"
6496,363905043,5484006,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@H](O4)[C@@H](CO)O)O)O)O)O,Inactive,,,,RAT,F344 DUCRJ/FEMALE (50/GROUP),ORAL;  DIET,119.2; 352.8 MG/KG DAILY FOR 104 WK (STUDY DURATION: 104 WK); TEST MATERIAL WAS ENZYMATICALLY MODIFIED,NONE,NEGATIVE,"[SALIM,EI KANEKO,M WANIBUCHI,H MORIMURA,K AND FUKUSHIMA,S; LACK OF CARCINOGENICITY OF ENZYMATICLLAY MODIFIED ISOQUERCITRIN IN F344/DUCRJ RATS; FOOD CHEM. TOXICOL. 42(12):1949-1969, 2004]"
6497,363905043,5484006,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@H](O4)[C@@H](CO)O)O)O)O)O,Inactive,,,,RAT,F344 DUCRJ/MALE (50/GROUP),ORAL; DIET,142.5; 431.1 MG/KG DAILY FOR 104 WK (STUDY DURATION: 104 WK); TEST MATERIAL WAS ENZYMATICALLY MODIFIED,NONE,NEGATIVE,"[SALIM,EI KANEKO,M WANIBUCHI,H MORIMURA,K AND FUKUSHIMA,S; LACK OF CARCINOGENICITY OF ENZYMATICLLAY MODIFIED ISOQUERCITRIN IN F344/DUCRJ RATS; FOOD CHEM. TOXICOL. 42(12):1949-1969, 2004]"
6498,363905094,2730,CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.05; 0.1; 1; 10 MG/KG BW/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[YANO,BL YOUNG,JT AND MATTSSON,JL; LACK OF CARCINOGENICITY OF CHLORPYRIFOS INSECTICIDE IN A HIGH-DOSE,2-YEAR DIETARY TOXICITY STUDY IN FISCHER 344 RATS; TOXICOL. SCI. 53(1):135-144, 2000]"
6499,363905094,2730,CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.05; 0.1; 1; 10 MG/KG BW/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[YANO,BL YOUNG,JT AND MATTSSON,JL; LACK OF CARCINOGENICITY OF CHLORPYRIFOS INSECTICIDE IN A HIGH-DOSE,2-YEAR DIETARY TOXICITY STUDY IN FISCHER 344 RATS; TOXICOL. SCI. 53(1):135-144, 2000]"
6500,363905094,2730,CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl,Inactive,,,,Mouse,CD-1/Male (59/group),Oral,0; 5; 50; 250 ppm in diet for 79 wk,,Negative (Study details not given in source; purity 99.6%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORPYRIFOS  (SEPTEMBER 27, 2001)]"
6501,363905094,2730,CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl,Inactive,,,,Mouse,CD-1/Female (59/group),Oral,0; 5; 50; 250 ppm in diet for 79 wk,,Negative (Study details not given in source; purity 99.6%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORPYRIFOS  (SEPTEMBER 27, 2001)]"
6502,363905108,39230,COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-],Inactive,,,,Rat,Sprague-Dawley/Male (50/sex/group),Oral,0; 500; 1580; 5000 ppm in feed for 104 wk,,Negative; Purity 98%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENOX (AUGUST 4, 1988)]"
6503,363905108,39230,COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-],Inactive,,,,Rat,Sprague-Dawley/Female (50/sex/group),Oral,0; 500; 1580; 5000 ppm in feed for 104 wk,,Negative; Purity 98%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENOX (AUGUST 4, 1988)]"
6504,363905108,39230,COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-],Inactive,,,,Mouse,B6C3F1/Female (60/sex/group),Oral,0; 50; 200; 1000 ppm in feed for 24 mo,,Negative; Purity 98.3%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENOX (AUGUST 4, 1988)]"
6505,363905108,39230,COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-],Active,,,,Mouse,B6C3F1/Male (60/sex/group),Oral,0; 50; 200; 1000 ppm in feed for 24 mo,Liver: Significant increase in hepatic adenomas and carcinomas at highest dose,Positive; Purity 98.3%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENOX (AUGUST 4, 1988)]"
6506,363905113,14500,C1CCC(=NO)C1,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 2 MMOL/KG BW 1/WK FOR 50 WK (STUDY DURATION: 83 WK),,NEGATIVE,"[FIALA,ES, SODUM,RS, HUSSAIN,NS, RIVENSON,A AND DOLAN,L; SECONDARY NITROALKANES: INDUCTION OF DNA REPAIR IN RAT HEPATOCYTES, ACTIVATION BY ARYL SULFOTRANSFERASE AND HEPATOCARCINOGENICITY OF 2-NITROBUTANE AND 3-NITROPENTANE IN MALE F344 RATS; TOXICOLOGY 99(1-2):89-97, 1995]"
6507,363905129,,,Active,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 24 MO),SKIN: TUMOR,POSITIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6508,363905149,11954041,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O)OC,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),KIDNEY: TUMOR,POSITIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
6509,363905150,115116,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H](C2=O)O)CCC4=C3C=CC(=C4)O,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),KIDNEY: TUMOR,POSITIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
6510,363905151,68568,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O)OC,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),KIDNEY: TUMOR,POSITIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
6511,363905152,23619914,C[C@H]1C[C@]2([C@@H](CC[C@@H]2O)[C@H]3[C@H]1C4=C(CC3)C=C(C=C4)O)C,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),,NEGATIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
6512,363905153,68570,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@H]2O)CCC4=C3C=CC(=C4)O,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),,NEGATIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
6513,363905154,5888,C[C@@]12CCC[C@H]1[C@@H]3CCC4=C([C@H]3CC2)C=CC(=C4)O,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),,NEGATIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
6514,363905155,114716,CCC1C2=C(C=C(C=C2)O)C(=C1C3=CC=C(C=C3)O)C,Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),KIDNEY: TUMOR,POSITIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
6515,363905156,156224,CCC1C(C(C2=C1C=CC(=C2)O)C)C3=CC=C(C=C3)O,Inactive,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),,NEGATIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
6516,363905157,23676225,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+],Active,,,,HAMSTER,SYRIAN/MALE,SUBCUTANEOUS IMPLANT,0; 20 MG IN PELLETS IMPLANTED EVERY 2.5 MO FOR 9 MO (STUDY DURATION: 9 MO),KIDNEY: TUMOR,POSITIVE,"[LI,JJ, LI,SA, OBERLEY,TD AND PARSONS,JA; CARCINOGENIC ACTIVITIES OF VARIOUS STEROIDAL AND NONSTEROIDAL ESTROGENS IN THE HAMSTER KIDNEY: RELATION TO HORMONAL ACTIVITY AND CELL PROLIFERATION; CANCER RES. 55(19):4347-4351, 1995]"
6517,363905158,15586,CC(F)(Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 1500; 5000; 20000 PPM 6 HR/D 5 D/WK FOR 104 WK (THE HIGH EXPOSURE LEVEL WAS INCREASED FROM 15000 PPM TO 20000 PPM AFTER 17 WK) (STUDY DURATION: 104 WK),TESTES: INTERSTITIAL CELL ADENOMA,POSITIVE,"[MILLISCHER,RJ, DE ROOIJ,CG, RUSH,GM, FARR,CH, BEN-DYKE,R, HARDY,CJ, LEWIS,DJ AND HODSON-WALKER,G; EVALUATION OF THE GENOTOXICITY POTENTIAL AND CHRONIC INHALATION TOXICITY OF 1,1-DICHLORO-1-FLUOROETHANE (HCFC-141B); FOOD CHEM. TOXICOL. 33(6):491-500, 1995]"
6518,363905158,15586,CC(F)(Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 1500; 5000; 20000 PPM 6 HR/D 5 D/WK FOR 104 WK (THE HIGH EXPOSURE LEVEL WAS INCREASED FROM 15000 PPM TO 20000 PPM AFTER 17 WK) (STUDY DURATION: 104 WK),,NEGATIVE,"[MILLISCHER,RJ, DE ROOIJ,CG, RUSH,GM, FARR,CH, BEN-DYKE,R, HARDY,CJ, LEWIS,DJ AND HODSON-WALKER,G; EVALUATION OF THE GENOTOXICITY POTENTIAL AND CHRONIC INHALATION TOXICITY OF 1,1-DICHLORO-1-FLUOROETHANE (HCFC-141B); FOOD CHEM. TOXICOL. 33(6):491-500, 1995]"
6519,363905159,1031,CCCO,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 50; 500 MG/KG 1/D FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[ALEMAN,CL, FERREIRO,RM, PUIG,MN, GUERRA,IR, ORTEGA,CH AND CAPOTE,A; CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY; TERATOG., CARCINOG., MUTAGEN. 14(5):239-249, 1994]"
6520,363905159,1031,CCCO,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 50; 500 MG/KG 1/D FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[ALEMAN,CL, FERREIRO,RM, PUIG,MN, GUERRA,IR, ORTEGA,CH AND CAPOTE,A; CARCINOGENICITY OF POLICOSANOL IN SPRAGUE DAWLEY RATS: A 24 MONTH STUDY; TERATOG., CARCINOG., MUTAGEN. 14(5):239-249, 1994]"
6521,363905159,1031,CCCO,Inactive,,,,MOUSE,SWISS/MALE,GAVAGE,0; 50; 500 MG/KG/D FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ALEMAN,CL, PUIG,MN, ELIAS,EC, ORTEGA,CH, GUERRA,IR, FERREIRO,RM AND BRINIS,F; CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18 MONTH STUDY; FOOD CHEM. TOXICOL. 33(7):573-578, 1995]"
6522,363905159,1031,CCCO,Inactive,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 50; 500 MG/KG/D FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ALEMAN,CL, PUIG,MN, ELIAS,EC, ORTEGA,CH, GUERRA,IR, FERREIRO,RM AND BRINIS,F; CARCINOGENICITY OF POLICOSANOL IN MICE: AN 18 MONTH STUDY; FOOD CHEM. TOXICOL. 33(7):573-578, 1995]"
6523,363905159,1031,CCCO,Inactive,,,,DOG,BEAGLE/MALE,GAVAGE,0; 30; 180 MG/KG/D 7 D/WK FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MESA,AR, MAS,R, NOA,M, HERNANDEZ,C, RODEIRO,I, GAMEZ,R, GARCIA,M, CAPOTE,A AND ALEMAN,CL; TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY; TOXICOL. LETT. 73(2):81-90, 1994]"
6524,363905159,1031,CCCO,Inactive,,,,DOG,BEAGLE/FEMALE,GAVAGE,0; 30; 180 MG/KG/D 7 D/WK FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[MESA,AR, MAS,R, NOA,M, HERNANDEZ,C, RODEIRO,I, GAMEZ,R, GARCIA,M, CAPOTE,A AND ALEMAN,CL; TOXICITY OF POLICOSANOL IN BEAGLE DOGS: ONE-YEAR STUDY; TOXICOL. LETT. 73(2):81-90, 1994]"
6525,363905159,1031,CCCO,Inactive,,,,MONKEY,MACACA ARCTODIES/MALE,ORAL,0; 0.25; 2.5; 25 MG/KG 1/D FOR 54 WK (STUDY DURATION: 54 WK),,NEGATIVE,"[RODRIGUEZ-ECHENIQUE,C, MESA,R, MAS,R, NOA,M, MENENDEZ,R, GONZALEZ,RM, AMOR, AM, FRAGA,V, SOTOLONGO,V AND LAGUNA,A; EFFECTS OF POLICOSANOL CHRONICALLY ADMINISTERED IN MALE MONKEYS (MACACA ARCTOIDES); FOOD CHEM. TOXICOL. 32(6): 565-575, 1994]"
6526,363905160,3446,C1CCC(CC1)(CC(=O)O)CN,Active,,,,RAT,WISTAR/MALE,ORAL,0; 250; 1000; 2000 MG/KG IN DIET FOR 104 WK (STUDY DURATION: 104 WK),"PANCREAS: ACINAR CELL ADENOMA, ACINAR CELL CARCINOMA",POSITIVE,"[SIGLER,RE, GOUGH,AW AND DE LA IGLESIA,FA; PANCREATIC ACINAR CELL NEOPLASIA IN MALE WISTAR RATS FOLLOWING 2 YEARS OF GABAPENTIN EXPOSURE; TOXICOLOGY 98(1-3): 73-82, 1995]"
6527,363905160,3446,C1CCC(CC1)(CC(=O)O)CN,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 250; 1000; 2000 MG/KG IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[SIGLER,RE, GOUGH,AW AND DE LA IGLESIA,FA; PANCREATIC ACINAR CELL NEOPLASIA IN MALE WISTAR RATS FOLLOWING 2 YEARS OF GABAPENTIN EXPOSURE; TOXICOLOGY 98(1-3): 73-82, 1995]"
6528,363905161,3365,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 2.5; 5; 10 MG/KG IN DIET FOR 24 MO (STUDY DURATION: 24 MO),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[PAULUS,G, LONGEART,L AND MONRO,AM; HUMAN CARCINOGENIC RISK ASSESSMENT BASED ON HORMONAL EFFECTS IN A CARCINOGENICITY STUDY IN RATS WITH THE ANTIFUNGAL AGENT, FLUCONAZOLE; TERATOG., CARCINOG., MUTAGEN. 14(6):251-257, 1994]"
6529,363905161,3365,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 2.5; 5; 10 MG/KG IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[PAULUS,G, LONGEART,L AND MONRO,AM; HUMAN CARCINOGENIC RISK ASSESSMENT BASED ON HORMONAL EFFECTS IN A CARCINOGENICITY STUDY IN RATS WITH THE ANTIFUNGAL AGENT, FLUCONAZOLE; TERATOG., CARCINOG., MUTAGEN. 14(6):251-257, 1994]"
6530,363905162,5282443,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,Inactive,,,,RAT,F344/MALE,ORAL,0; 250; 1000; 2000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[GREENMAN,DL, SHELDON,W, SCHIEFERSTEIN,G, ALLEN,R AND ALLABEN,WT; TRIPROLIDINE: 104-WEEK FEEDING STUDY IN RATS; FUNDAM. APPL. TOXICOL. 27(2):223-231, 1995]"
6531,363905162,5282443,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 250; 1000; 2000 PPM IN DIET FOR 103 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[GREENMAN,DL, SHELDON,W, SCHIEFERSTEIN,G, ALLEN,R AND ALLABEN,WT; TRIPROLIDINE: 104-WEEK FEEDING STUDY IN RATS; FUNDAM. APPL. TOXICOL. 27(2):223-231, 1995]"
6532,363905163,6339,C=CF,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 25; 250; 2500 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),LIVER: HEMANGIOSARCOMA; ZYMBAL'S GLAND: TUMOR,POSITIVE,"[BOGDANFFY,MS, MAKOVEC,GT AND FRAME,SR; INHALATION ONCOGENICITY BIOASSAY IN RATS AND MICE WITH VINYL FLUORIDE; FUNDAM. APPL. TOXICOL. 26(2):223-238, 1995]"
6533,363905163,6339,C=CF,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 25; 250; 2500 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),"LIVER: HEMANGIOSARCOMA, ADENOMA OR CARCINOMA; ZYMBAL'S GLAND: TUMOR",POSITIVE,"[BOGDANFFY,MS, MAKOVEC,GT AND FRAME,SR; INHALATION ONCOGENICITY BIOASSAY IN RATS AND MICE WITH VINYL FLUORIDE; FUNDAM. APPL. TOXICOL. 26(2):223-238, 1995]"
6534,363905163,6339,C=CF,Active,,,,MOUSE,SWISS/MALE,INHALATION,0; 25; 250; 2500 PPM 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),LUNG: ADENOMA; LIVER: HEMANGIOSARCOMA,POSITIVE,"[BOGDANFFY,MS, MAKOVEC,GT AND FRAME,SR; INHALATION ONCOGENICITY BIOASSAY IN RATS AND MICE WITH VINYL FLUORIDE; FUNDAM. APPL. TOXICOL. 26(2):223-238, 1995]"
6535,363905163,6339,C=CF,Active,,,,MOUSE,SWISS/FEMALE,INHALATION,0; 25; 250; 2500 PPM 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),LUNG: ADENOMA; LIVER: HEMANGIOSARCOMA; MAMMARY GLAND: TUMOR,POSITIVE,"[BOGDANFFY,MS, MAKOVEC,GT AND FRAME,SR; INHALATION ONCOGENICITY BIOASSAY IN RATS AND MICE WITH VINYL FLUORIDE; FUNDAM. APPL. TOXICOL. 26(2):223-238, 1995]"
6536,363905164,13129,C(C(F)(F)F)F,Active,,,,RAT,ALPK:APFSD/MALE,INHALATION,0; 2500; 10000; 50000 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),TESTES: LEYDIG CELL ADENOMA,POSITIVE,"[COLLINS,MA, RUSCH,GM, SATO,F, HEXT,PM AND MILLISCHER,RJ; 1,1,1,2-TETRAFLUOROETHANE: REPEAT EXPOSURE INHALATION TOXICITY IN THE RAT, DEVELOPMENTAL TOXICITY IN THE RABBIT, AND GENOTOXICITY IN VITRO AND IN VIVO; FUNDAM. APPL. TOXICOL. 25(2):271-280, 1995]"
6537,363905164,13129,C(C(F)(F)F)F,Inactive,,,,RAT,ALPK:APFSD/FEMALE,INHALATION,0; 2500; 10000; 50000 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[COLLINS,MA, RUSCH,GM, SATO,F, HEXT,PM AND MILLISCHER,RJ; 1,1,1,2-TETRAFLUOROETHANE: REPEAT EXPOSURE INHALATION TOXICITY IN THE RAT, DEVELOPMENTAL TOXICITY IN THE RABBIT, AND GENOTOXICITY IN VITRO AND IN VIVO; FUNDAM. APPL. TOXICOL. 25(2):271-280, 1995]"
6538,363905164,13129,C(C(F)(F)F)F,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 2500; 15000; 75000 PPM SNOUT-ONLY INHALATION 1 HR/D FOR AT LEAST 104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[ALEXANDER,DJ, LIBRETTO,SE, CHEVALIER,HJ, IMAMURA,T, PAPPRITZ,G AND WILSON,J; HFA-134A (1,1,1,2-TETRAFLUOROETHANE):LACK OF ONCOGENICITY IN RODENTS AFTER INHALATION; HUM. EXP. TOXICOL. 14(9):706-714, 1995]"
6539,363905164,13129,C(C(F)(F)F)F,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2500; 15000; 75000 PPM SNOUT-ONLY INHALATION 1 HR/D FOR AT LEAST 104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[ALEXANDER,DJ, LIBRETTO,SE, CHEVALIER,HJ, IMAMURA,T, PAPPRITZ,G AND WILSON,J; HFA-134A (1,1,1,2-TETRAFLUOROETHANE):LACK OF ONCOGENICITY IN RODENTS AFTER INHALATION; HUM. EXP. TOXICOL. 14(9):706-714, 1995]"
6540,363905164,13129,C(C(F)(F)F)F,Inactive,,,,RAT,WISTAR/MALE,INHALATION,0; 2500; 10000; 50000 PPM SNOUT-ONLY INHALATION 1 HR/D FOR AT LEAST 108 WK (STUDY DURATION: 110 WK),,NEGATIVE,"[ALEXANDER,DJ, LIBRETTO,SE, CHEVALIER,HJ, IMAMURA,T, PAPPRITZ,G AND WILSON,J; HFA-134A (1,1,1,2-TETRAFLUOROETHANE):LACK OF ONCOGENICITY IN RODENTS AFTER INHALATION; HUM. EXP. TOXICOL. 14(9):706-714, 1995]"
6541,363905164,13129,C(C(F)(F)F)F,Inactive,,,,RAT,WISTAR/FEMALE,INHALATION,0; 2500; 10000; 50000 PPM SNOUT-ONLY INHALATION 1 HR/D FOR AT LEAST 108 WK (STUDY DURATION: 110 WK),,NEGATIVE,"[ALEXANDER,DJ, LIBRETTO,SE, CHEVALIER,HJ, IMAMURA,T, PAPPRITZ,G AND WILSON,J; HFA-134A (1,1,1,2-TETRAFLUOROETHANE):LACK OF ONCOGENICITY IN RODENTS AFTER INHALATION; HUM. EXP. TOXICOL. 14(9):706-714, 1995]"
6542,363905165,5284472,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3.O.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 500; 2000; 4000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[GREENMAN,DL, SHELDON,W, SCHIEFERSTEIN,G, ALLEN,R AND ALLABEN,WT; CHRONIC STUDY OF TRIPROLIDINE FOR ONCOGENICITY IN MICE; FUNDAM. APPL. TOXICOL. 25(1):138-145, 1995]"
6543,363905165,5284472,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3.O.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 2000; 4000 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[GREENMAN,DL, SHELDON,W, SCHIEFERSTEIN,G, ALLEN,R AND ALLABEN,WT; CHRONIC STUDY OF TRIPROLIDINE FOR ONCOGENICITY IN MICE; FUNDAM. APPL. TOXICOL. 25(1):138-145, 1995]"
6544,363905166,9385,C(C(F)(F)F)(Cl)Cl,Active,,,,RAT,CRL:CDBR/MALE,INHALATION,0; 300; 1000; 5000 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),LIVER: ADENOMA; PANCREAS: ADENOMA; TESTES: ADENOMA,POSITIVE,"[MALLEY,LA, CARAKOSTAS,M, HANSEN,JF, RUSCH,GM, KELLY,DP AND TROCHIMOWICZ,HJ; TWO-YEAR INHALATION TOXICITY STUDY IN RATS WITH HYDROCHLOROFLUOROCARBON 123; FUNDAM. APPL. TOXICOL. 25(1):101-114, 1995]"
6545,363905166,9385,C(C(F)(F)F)(Cl)Cl,Active,,,,RAT,CRL:CDBR/FEMALE,INHALATION,0; 300; 1000; 5000 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),"LIVER: ADENOMA, CHOLANGIOFIBROMA",POSITIVE,"[MALLEY,LA, CARAKOSTAS,M, HANSEN,JF, RUSCH,GM, KELLY,DP AND TROCHIMOWICZ,HJ; TWO-YEAR INHALATION TOXICITY STUDY IN RATS WITH HYDROCHLOROFLUOROCARBON 123; FUNDAM. APPL. TOXICOL. 25(1):101-114, 1995]"
6546,363905177,,,Inactive,,,,RAT,F344/MALE,INTRAVESICAL,0; 0.5 ML OF 500 NG/ML IN PHOSPHATE-BUFFERED SALINE INSTILLED INTO HETEROTOPICALLY TRANSPLANTED URINARY BLADDER 1/WK FOR 30 WK (STUDY DURATION: 31 WK),,NEGATIVE,"[KAWAI,K, KAWAMATA,H, KAMEYAMA,S, RADEMAKER,A AND OYASU,R; INTRALUMINAL EPIDERMAL GROWTH FACTOR AFFECTS GROWTH OF N-METHYL-N-NITROSOUREA-INITIATED RAT BLADDER CARCINOMA; JPN. J. CANCER RES. 86(5):429-434, 1995]"
6547,363905178,5484182,C1=CC(=C(C=C1[N+](=O)[O-])N)NC(CO)(CO)CO,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.2; 0.6; 2% IN DIET OF MATED AND NONMATED RATS FOR UP TO 6 MO (STUDY DURATION: 6 MO),MAMMARY GLAND: TUMOR,POSITIVE,"[DRESSLER,WE, RE,TE, ACKERMAN,LJ AND CORBETT,JF; CARCINOGENICITY OF N1-[TRIS(HYDROXYMETHYL)]-METHYL-4-NITRO-O-PHENYLENEDIAMINE FED TO MATED AND NONMATED SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 33(8):681-693, 1995]"
6548,363905178,5484182,C1=CC(=C(C=C1[N+](=O)[O-])N)NC(CO)(CO)CO,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.2; 0.6; 2% IN DIET FOR UP TO 6 MO (STUDY DURATION: 6 MO),,NEGATIVE,"[DRESSLER,WE, RE,TE, ACKERMAN,LJ AND CORBETT,JF; CARCINOGENICITY OF N1-[TRIS(HYDROXYMETHYL)]-METHYL-4-NITRO-O-PHENYLENEDIAMINE FED TO MATED AND NONMATED SPRAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 33(8):681-693, 1995]"
6549,363905185,297,C,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 7.4 MG/M3 18 HR/D 5 D/WK FOR 4 MO INCREASED TO 12.2 MG/M3 FOR 20 MO FOLLOWED BY CLEAN AIR FOR 6 MO (STUDY DURATION: 30 MO),LUNG: TUMOR,POSITIVE,"[HEINRICH,U, FUHST,R, RITTINGHAUSEN,S, CREUTZENBERG,O, BELLMANN,B, KOCH,W AND LEVSEN,K; CHRONIC INHALATION EXPOSURE OF WISTAR RATS AND TWO DIFFERENT STRAINS OF MICE TO DIESEL ENGINE EXHAUST, CARBON BLACK, AND TITANIUM DIOXIDE; INHALATION TOXICOL. 7(4):533-556, 1995]"
6550,363905185,297,C,Inactive,,,,MOUSE,NMRI/FEMALE,INHALATION,0; 7.4 MG/M3 18 HR/D 5 D/WK FOR 4 MO INCREASED TO 12.2 MG/M3 FOR 9.5 MO FOLLOWED BY CLEAN AIR FOR 9.5 MO (STUDY DURATION: 23 MO),,NEGATIVE,"[HEINRICH,U, FUHST,R, RITTINGHAUSEN,S, CREUTZENBERG,O, BELLMANN,B, KOCH,W AND LEVSEN,K; CHRONIC INHALATION EXPOSURE OF WISTAR RATS AND TWO DIFFERENT STRAINS OF MICE TO DIESEL ENGINE EXHAUST, CARBON BLACK, AND TITANIUM DIOXIDE; INHALATION TOXICOL. 7(4):533-556, 1995]"
6551,363905185,297,C,Active,,,,RAT,F344/MALE,INHALATION,0; 2.5; 6.5 MG/M3 OF AIR 16 HR/D 5 D/WK FOR UP TO 24 MO (STUDY DURATION: LIFE SPAN),LUNG: MALIGNANT TUMOR,POSITIVE,"[MAUDERLY,JL, SNIPES,MB, BARR,EB, BELINSKY,SA, BOND,JA, BROOKS,AL, CHANG,IY, CHENG,YS, GILLETT,NA, GRIFFITH,WC, HENDERSON,RF, MITCHELL,CE, NIKULA,KJ AND THOMASSEN,DG; PULMONARY TOXICITY OF INHALED DIESEL EXHAUST AND CARBON BLACK IN CHRONICALLY EXPOSED RATS; RES. REP. - HEALTH EFF. INST. 68:1-97, 1994]"
6552,363905185,297,C,Active,,,,RAT,F344/FEMALE,INHALATION,0; 2.5; 6.5 MG/M3 OF AIR 16 HR/D 5 D/WK FOR UP TO 24 MO (STUDY DURATION: LIFE SPAN),LUNG: MALIGNANT TUMOR,POSITIVE,"[MAUDERLY,JL, SNIPES,MB, BARR,EB, BELINSKY,SA, BOND,JA, BROOKS,AL, CHANG,IY, CHENG,YS, GILLETT,NA, GRIFFITH,WC, HENDERSON,RF, MITCHELL,CE, NIKULA,KJ AND THOMASSEN,DG; PULMONARY TOXICITY OF INHALED DIESEL EXHAUST AND CARBON BLACK IN CHRONICALLY EXPOSED RATS; RES. REP. - HEALTH EFF. INST. 68:1-97, 1994]"
6553,363905185,297,C,Active,,,,RAT,F344/FEMALE,INHALATION,0; 2.5; 6.5 MG/M3 IN AIR 16 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 25.5 MO),LUNG: BENIGN OR MALIGNANT NEOPLASM,POSITIVE,"[NIKULA,KJ, SNIPES,MB, BARR,EB, GRIFFITH,WC, HENDERSON,RF AND MAUDERLY,JL; COMPARATIVE PULMONARY TOXICITIES AND CARCINOGENICITIES OF CHRONICALLY INHALED DIESEL EXHAUST AND CARBON BLACK IN F344 RATS; FUNDAM. APPL. TOXICOL. 25:80-94, 1995]"
6554,363905185,297,C,Inactive,,,,RAT,F344/MALE,INHALATION,0; 2.5; 6.5 MG/M3 IN AIR 16 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 25.5 MO),,NEGATIVE,"[NIKULA,KJ, SNIPES,MB, BARR,EB, GRIFFITH,WC, HENDERSON,RF AND MAUDERLY,JL; COMPARATIVE PULMONARY TOXICITIES AND CARCINOGENICITIES OF CHRONICALLY INHALED DIESEL EXHAUST AND CARBON BLACK IN F344 RATS; FUNDAM. APPL. TOXICOL. 25:80-94, 1995]"
6555,363905186,5284442,C1=CC=C(C=C1)/C(=C\CCCCC(=O)O)/C2=CN=CC=C2,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 10; 30; 100; 300 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHATANI,F, NISHIDA,N, SHIKATA,M, SPICER,EJF, DRAFTA,RE, BLAIR,M, THORSTENSON, JH, GORDON,DE AND GEIL,RG; TWO-YEAR DIETARY CARCINOGENICITY STUDY OF CV-4151 IN MICE; YAKURI TO CHIRYO 23(5):1205-1223, 1995]"
6556,363905186,5284442,C1=CC=C(C=C1)/C(=C\CCCCC(=O)O)/C2=CN=CC=C2,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 10; 30; 100; 300 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHATANI,F, NISHIDA,N, SHIKATA,M, SPICER,EJF, DRAFTA,RE, BLAIR,M, THORSTENSON, JH, GORDON,DE AND GEIL,RG; TWO-YEAR DIETARY CARCINOGENICITY STUDY OF CV-4151 IN MICE; YAKURI TO CHIRYO 23(5):1205-1223, 1995]"
6557,363905186,5284442,C1=CC=C(C=C1)/C(=C\CCCCC(=O)O)/C2=CN=CC=C2,Inactive,,,,RAT,STRAIN-CD/MALE,ORAL,0; 10; 30; 100 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHATANI,F, NISHIDA,N, SHIKATA,M, SPICER,EJF, DRAFTA,RE, BLAIR,M, THORSTENSON, JH, CHANDRA,M AND GEIL,RG; TWO-YEAR DIETARY CARCINOGENICITY STUDY OF CV-4151 IN RATS; YAKURI TO CHIRYO 23(5):1225-1238, 1995]"
6558,363905186,5284442,C1=CC=C(C=C1)/C(=C\CCCCC(=O)O)/C2=CN=CC=C2,Inactive,,,,RAT,STRAIN-CD/FEMALE,ORAL,0; 10; 30; 100 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[CHATANI,F, NISHIDA,N, SHIKATA,M, SPICER,EJF, DRAFTA,RE, BLAIR,M, THORSTENSON, JH, CHANDRA,M AND GEIL,RG; TWO-YEAR DIETARY CARCINOGENICITY STUDY OF CV-4151 IN RATS; YAKURI TO CHIRYO 23(5):1225-1238, 1995]"
6559,363905188,34007,[O-]S(=O)(=O)[O-].O=[V+2],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6560,363905188,34007,[O-]S(=O)(=O)[O-].O=[V+2],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6561,363905189,56841016,C(=O)(C(=O)[O-])[O-].C(=O)(C(=O)[O-])[O-].O=[Ti+2].[K+].[K+],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6562,363905189,56841016,C(=O)(C(=O)[O-])[O-].C(=O)(C(=O)[O-])[O-].O=[Ti+2].[K+].[K+],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6563,363905190,10980,CC(=O)[O-].CC(=O)[O-].[Ba+2],Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6564,363905190,10980,CC(=O)[O-].CC(=O)[O-].[Ba+2],Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 5 PPM IN DRINKING WATER FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6565,363905191,16682934,CC(=O)O[Hg]C,Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 5 PPM (HG) IN DRINKING WATER FOR 70 D THEN 1 PPM (HG) FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6566,363905191,16682934,CC(=O)O[Hg]C,Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 5 PPM (HG) IN DRINKING WATER FOR 70 D THEN 1 PPM (HG) FOR DURATION OF STUDY (STUDY DURATION: LIFE SPAN),,NEGATIVE,"[SCHROEDER,HA AND MITCHENER,M; LIFE-TERM EFFECTS OF MERCURY, METHYL MERCURY AND NINE OTHER TRACE METALS ON MICE; J. NUTR. 105:452-458, 1975]"
6567,363905220,127824,C1=CC(=CC=C1C(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,Inactive,,,,MOUSE,NMRI/MALE,ORAL,0; 100; 300; 900 MG/KG BW/D IN DIET FOR 120 WK (HIGH DOSE INCREASED TO 1800 MG/KG BW FROM WK 21) (STUDY DURATION: 120 WK),,NEGATIVE,"[HERZOG,R AND LEUSCHNER,J; ONCOGENICITY STUDIES OF BENZALAZINE IN MICE AND RATS; ARZNEIM.-FORSCH. 44(12):1371-1381, 1994]"
6568,363905220,127824,C1=CC(=CC=C1C(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,Inactive,,,,RAT,SPRAGUE/DAWLEY/FEMALE,ORAL,0; 300; 900; 2700 MG/KG BW/D IN DIET FOR 119 WK (HIGH DOSE REDUCED TO 1800 MG/KG BW FROM WK 68) (STUDY DURATION: 119 WK),,NEGATIVE,"[HERZOG,R AND LEUSCHNER,J; ONCOGENICITY STUDIES OF BENZALAZINE IN MICE AND RATS; ARZNEIM.-FORSCH. 44(12):1371-1381, 1994]"
6569,363905220,127824,C1=CC(=CC=C1C(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 300; 900; 2700 MG/KG BW/D IN DIET FOR 118 WK (HIGH DOSE REDUCED TO 1800 MG/KG BW FROM WK 68) (STUDY DURATION: 118 WK),,NEGATIVE,"[HERZOG,R AND LEUSCHNER,J; ONCOGENICITY STUDIES OF BENZALAZINE IN MICE AND RATS; ARZNEIM.-FORSCH. 44(12):1371-1381, 1994]"
6570,363905220,127824,C1=CC(=CC=C1C(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,Inactive,,,,MOUSE,NMRI/FEMALE,ORAL,0; 100; 300; 900 MG/KG BW/D IN DIET FOR 107 WK (HIGH DOSE INCREASED TO 1800 MG/KG BW FROM WK 21) (STUDY DURATION: 107 WK),,NEGATIVE,"[HERZOG,R AND LEUSCHNER,J; ONCOGENICITY STUDIES OF BENZALAZINE IN MICE AND RATS; ARZNEIM.-FORSCH. 44(12):1371-1381, 1994]"
6571,363905334,164497,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C2C6=C(C=C5C=C4)[C@H]([C@@H]([C@H]7[C@@H]6O7)O)O,Active,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 0.2 UMOL IN 0.1 ML DMSO INJECTED UNDER EACH OF THE 3 LEFT THORACIC NIPPLES FOLLOWED THE NEXT DAY BY SIMILAR TREATMENT OF THE 3 LEFT INGUINAL NIPPLES (STUDY DURATION: 41 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[SHANTU,A, KRZEMINSKI,J, RIVENSON,A, KURTZKE,C, HECHT,SS AND EL-BAYOUMY, K; MAMMARY CARCINOGENICITY IN FEMALE CD RATS OF FJORD REGION DIOL EPOXIDES OF BENZO[C]PHENANTHRENE, BENZO[G]CHRYSENE AND DIBENZO[A,L]PYRENE; CARCINOGENESIS 16(8):1971-1974, 1995]"
6572,363905334,164497,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C2C6=C(C=C5C=C4)[C@H]([C@@H]([C@H]7[C@@H]6O7)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 1 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
6573,363905334,164497,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C2C6=C(C=C5C=C4)[C@H]([C@@H]([C@H]7[C@@H]6O7)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 1 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
6574,363905334,164497,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C2C6=C(C=C5C=C4)[C@H]([C@@H]([C@H]7[C@@H]6O7)O)O,Active,,,,RAT,CD-1/FEMALE,INJECTION,0; 0.2 UMOL IN 0.1 ML DMSO INJECTED BENEATH EACH OF THE 6 NIPPLES ON THE LEFT SIDE (STUDY DURATION: 41 WK),MAMMARY GLAND: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
6575,363905334,164497,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C2C6=C(C=C5C=C4)[C@H]([C@@H]([C@H]7[C@@H]6O7)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,0; 0.7 NMOL TOTAL DOSE INJECTED ON DAY 1 OF LIFE (STUDY DURATION: 35 WK),LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
6576,363905334,164497,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C2C6=C(C=C5C=C4)[C@H]([C@@H]([C@H]7[C@@H]6O7)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,0; 0.7 NMOL TOTAL DOSE INJECTED ON DAY 1 OF LIFE (STUDY DURATION: 35 WK),LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
6577,363905334,164497,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C2C6=C(C=C5C=C4)[C@H]([C@@H]([C@H]7[C@@H]6O7)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 1 NMOL TOTAL DOSE INJECTED IN DOSES OF 1/7 ON DAY 1, 2/7 ON DAY 8, AND 4/7 ON DAY 15 OF LIFE (STUDY DURATION: 35 WK)",LIVER: TUMOR; LUNG:TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
6578,363905334,164497,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C2C6=C(C=C5C=C4)[C@H]([C@@H]([C@H]7[C@@H]6O7)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 1 NMOL TOTAL DOSE INJECTED IN DOSES OF 1/7 ON DAY 1, 2/7 ON DAY 8, AND 4/7 ON DAY 15 OF LIFE (STUDY DURATION: 35 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, EL-BAYOUMY,K, RIVENSON,A AND HECHT,SS; TUMORIGENICITY OF FJORD REGION DIOL EPOXIDES OF POLYCYCLIC AROMATIC HYDROCARBONS; POLYCYCLIC AROMAT. COMPD. 11(1-4):365-371, 1996]"
6579,363905388,57363,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,Active,,,,MOUSE,CD-1/MALE,GAVAGE,0; 2.5; 25; 250 MG/KG/D FOR 83 WK (STUDY DURATION: 83 WK),TESTES: LEYDIG CELL ADENOMA,POSITIVE,"[PRAHALADA,S, MAJKA,JA, SOPER,KA, NETT,TM, BAGDON,WJ, PETER,CP, BUREK,JD, MACDONALD,JS AND VAN ZWIETEN,MJ; LEYDIG CELL HYPERPLASIA AND ADENOMAS IN MICE TREATED WITH FINASTERIDE, A 5ALPHA-REDUCTASE INHIBITOR: A POSSIBLE MECHANISM; FUNDAM. APPL. TOXICOL. 22(2):211-219, 1994]"
6580,363905389,3036234,CC1=NC=C(C(=N1)N)CN(C=O)/C(=C(/CCOC(=O)C2=CC=CC=C2)\SC(=O)C3=CC=CC=C3)/C.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 1000; 10000 PPM IN DIET FOR DURATION OF STUDY (STUDY DURATION: 105 WK),,NEGATIVE,"[HEYWOOD,R, WOOD,JD AND MAJEED,SK; TUMORIGENIC AND TOXIC EFFECT OF O,S-DIBENZOYL THIAMINE HYDROCHLORIDE IN PROLONGED DIETARY ADMINISTRATION TO RATS; TOXICOL. LETT. 26(1):53-58, 1985]"
6581,363905389,3036234,CC1=NC=C(C(=N1)N)CN(C=O)/C(=C(/CCOC(=O)C2=CC=CC=C2)\SC(=O)C3=CC=CC=C3)/C.Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 1000; 10000 PPM IN DIET FOR DURATION OF STUDY (STUDY DURATION: 105 WK),,NEGATIVE,"[HEYWOOD,R, WOOD,JD AND MAJEED,SK; TUMORIGENIC AND TOXIC EFFECT OF O,S-DIBENZOYL THIAMINE HYDROCHLORIDE IN PROLONGED DIETARY ADMINISTRATION TO RATS; TOXICOL. LETT. 26(1):53-58, 1985]"
6582,363905390,77577,CC(C)(C(C)(C)[N+](=O)[O-])[N+](=O)[O-],Inactive,,,,MOUSE,SENCAR/FEMALE,GAVAGE,0; 20 MG/KG DIVIDED INTO 6 DOSES OVER 2 WK (STUDY DURATION: 30 WK),,NEGATIVE,"[REDDY,TV, OLSON,GR, DANIEL,FB AND ROBINSON,M; CARCINOGENIC EVALUATION OF 2,3-DIMETHYL-2,3-DINITROBUTANE VIA THE MOUSE SKIN BIOASSAY; J. APPL. TOXICOL. 14(3):231-232, 1994]"
6583,363905406,,,Inactive,,,,MOUSE,"STRAIN-A/MALE,FEMALE",INTRAVENOUS,0; 2; 4; 8 UG/KG ONCE (STUDY DURATION: 24 WK),,NEGATIVE,"[LINSEMAN,DA, BRANSTETTER,DG, YU,RL AND AARON,CS; LUNG TUMOR INDUCTION IN A/J MICE AND CLASTOGENIC EFFECTS IN CD-1 MICE OF THE SEQUENCE-SELECTIVE DNA ALKYLATING AGENTS (+)-CC-1065 AND (-)-CC-1065; NAT. TOXINS 3(1):32-40, 1995]"
6584,363905407,151996,C(CNCC(=O)[O-])NCC(=O)[O-].C(CNCC(=O)[O-])NCC(=O)[O-].C(CNCC(=O)[O-])NCC(=O)[O-].[Fe+3].[Fe+3],Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 10 MG/KG BW 2/WK FOR 3 MO (STUDY DURATION: 1 YR),KIDNEY: TUMOR,POSITIVE,"[LIU,M AND OKADA,S; INDUCTION OF FREE RADICALS AND TUMORS IN THE KIDNEYS OF WISTAR RATS BY FERRIC ETHYLENEDIAMINE-N,N'-DIACETATE; CARCINOGENESIS 15 (12):2817-2821, 1994]"
6585,363905458,74191,C1=C(OC(=C1)C=O)CCl,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.1; 0.25 UMOL/G IN 5 UL DMSO/G BW ONCE (STUDY DURATION: 10 MO),LIVER: TUMOR,POSITIVE,"[SURH,YJ, LIEM,A, MILLER,JA AND TANNENBAUM,SR; 5-SULFOOXYMETHYLFURFURAL AS A POSSIBLE ULTIMATE MUTAGENIC AND CARCINOGENIC METABOLITE OF THE MAILLARD REACTION PRODUCT 5-HYDROXYMETHYLFURFURAL; CARCINOGENESIS 15(10):2375-2377, 1994]"
6586,363905463,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 1; 5; 10% IN DIET FOR 62 WK (STUDY DURATION: 62 WK),,NEGATIVE,"[KIMOTO,T, SHIBUYA,T AND SHIOBARA,S; SAFETY STUDIES OF A NOVEL STARCH, PULLULAN: CHRONIC TOXICITY IN RATS AND BACTERIAL MUTAGENICITY; FOOD CHEM. TOXICOL. 35(3-4):323-329, 1997]"
6587,363905463,,,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 1; 5; 10% IN DIET FOR 62 WK (STUDY DURATION: 62 WK),,NEGATIVE,"[KIMOTO,T, SHIBUYA,T AND SHIOBARA,S; SAFETY STUDIES OF A NOVEL STARCH, PULLULAN: CHRONIC TOXICITY IN RATS AND BACTERIAL MUTAGENICITY; FOOD CHEM. TOXICOL. 35(3-4):323-329, 1997]"
6588,363905503,,,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 500 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7 AND 15 OF LIFE , RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
6589,363905503,,,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 500 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
6590,363905504,44148075,C1C2=CC=CC3=C2C4=C(C=C3)C5=C(C=C41)C(C(C6C5O6)O)O,Active,,,,MOUSE,ICR/MALE,INTRAPERITONEAL,"0; 500 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7 AND 15 OF LIFE , RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR; LIVER: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
6591,363905504,44148075,C1C2=CC=CC3=C2C4=C(C=C3)C5=C(C=C41)C(C(C6C5O6)O)O,Active,,,,MOUSE,ICR/FEMALE,INTRAPERITONEAL,"0; 500 NMOL (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 ON DAYS 1, 7, AND 15 OF LIFE, RESPECTIVELY (STUDY DURATION: 35 WK)",LUNG: TUMOR,POSITIVE,"[AMIN,S, DESAI,D, DAI,W, HARVEY,RG AND HECHCT,SS; TUMORIGENICITY IN NEWBORN MICE OF FJORD REGION AND OTHER STERICALLY HINDERED DIOL EPOXIDES OF BENZO[G]CHRYSENE, DIBENZO[A,L]PYRENE (DIBENZO[DEF,P]CHRYSENE), 4H-CYCLOPENTA[DEF]CHRYSENE AND FLUORANTHENE; CARCINOGENESIS 16(11):2813-2817, 1995]"
6592,363905505,5284371,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 750; 1500; 3000 PPM IN DIET FOR UP TO 106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-455 Y96]"
6593,363905505,5284371,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 750; 1500; 3000 PPM IN DIET FOR UP TO 106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-455 Y96]"
6594,363905505,5284371,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 400; 800; 1600 PPM IN DIET FOR UP TO 106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-455 Y96]"
6595,363905505,5284371,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 400; 800; 1600 PPM IN DIET FOR UP TO 106 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-455 Y96]"
6596,363905529,,,Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6597,363905530,25199732,S=[Ni].S=[Ni].[Ni],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6598,363905531,62394,[Ni]=[Se],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6599,363905532,,,Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6600,363905533,62780,[Ni]=[Te],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6601,363905534,,,Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6602,363905535,62391,[Ni]#[As],Inactive,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),,NEGATIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6603,363905536,,,Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6604,363905537,62391,[Ni]#[As],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6605,363905538,61553,[Ni]#[Sb],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6606,363905539,197200,[S-2].[S-2].[S-2].[S-2].[Fe+3].[Ni+2].[Ni+2].[Ni+2].[Ni+2],Active,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),INJECTION SITE: SARCOMA,POSITIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6607,363905540,10080372,[Fe].[Ni],Inactive,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),,NEGATIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6608,363905541,,,Inactive,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),,NEGATIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6609,363905542,61767,[O-][Cr](=O)(=O)[O-].[Ni+2],Inactive,,,,RAT,F344/MALE,INTRAMUSCULAR,0; 14 MG NICKEL/RAT IN 0.3-0.5 ML OF GLYCEROL:WATER (1:1) ONCE (STUDY DURATION: 1 YR),,NEGATIVE,"[SUNDERMAN,FW,JR; CARCINOGENICITY OF NICKEL COMPOUNDS IN ANIMALS; IARC SCI. PUBL. 53(NICKEL HUM. ENVIRON.):127-142, 1984]"
6610,363905543,9570246,CN(/C(=N/[N+](=O)[O-])/N)[N+](=O)[O-],Inactive,,,,RAT,WHITE OUTBRED/MALE,DERMAL,0; 0.2 ML OF A 1% ACETONE SOLUTION 3/WK FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[ZABEZHINSKII,MA, PLISS,GB, OKULOV,VB AND PETROV,AS; SKIN TUMORS INDUCED BY LOCAL AND SYSTEMIC ACTION OF N-NITROSO-COMPOUNDS IN RATS; ARCH. GESCHWULSTFORSCH. 55(2):117-122, 1985]"
6611,363905545,2247,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Inactive,,,,MOUSE,SWISS/MALE,ORAL,0; 2.5; 10; 40 MG/100 G OF DIET FOR DURATION OF STUDY (STUDY DURATION: 18 MO),,NEGATIVE,"[BENZE,J, GYPEN,L, VANDENBERGHE,J, LAMPO,A, DE COSTER,R, BOWDEN,C AND VAN CAUTEREN,H; CARCINOGENICITY STUDIES OF ASTEMIZOLE IN MICE AND RATS; CANCER RES. 55(23):5589-5594, 1995]"
6612,363905545,2247,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Inactive,,,,MOUSE,SWISS/FEMALE,ORAL,0; 2.5; 10; 40 MG/100 G OF DIET FOR DURATION OF STUDY (STUDY DURATION: 18 Mo),,NEGATIVE,"[BENZE,J, GYPEN,L, VANDENBERGHE,J, LAMPO,A, DE COSTER,R, BOWDEN,C AND VAN CAUTEREN,H; CARCINOGENICITY STUDIES OF ASTEMIZOLE IN MICE AND RATS; CANCER RES. 55(23):5589-5594, 1995]"
6613,363905545,2247,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 5; 20; 80 MG/100 G OF DIET FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[BENZE,J, GYPEN,L, VANDENBERGHE,J, LAMPO,A, DE COSTER,R, BOWDEN,C AND VAN CAUTEREN,H; CARCINOGENICITY STUDIES OF ASTEMIZOLE IN MICE AND RATS; CANCER RES. 55(23):5589-5594, 1995]"
6614,363905545,2247,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 5; 20; 80 MG/100 G OF DIET FOR DURATION OF STUDY (STUDY DURATION: 2 YR),,NEGATIVE,"[BENZE,J, GYPEN,L, VANDENBERGHE,J, LAMPO,A, DE COSTER,R, BOWDEN,C AND VAN CAUTEREN,H; CARCINOGENICITY STUDIES OF ASTEMIZOLE IN MICE AND RATS; CANCER RES. 55(23):5589-5594, 1995]"
6615,363905546,15413,CC(C)(C)OC,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 250; 1000 MG/KG BW IN 1 ML OLIVE OIL 1/D 4 D/WK FOR 104 WK (STUDY DURATION: 166 WK),TESTES: LEYDIG CELL TUMOR,POSITIVE,"[BELPOGGI,F, SOFFRITTI,M AND MALTONI,C; METHYL-TERTIARY-BUTYL ETHER (MTBE)- A GASOLINE ADDITIVE- CAUSES TESTICULAR AND LYMPHOHAEMATOPOIETIC CANCERS IN RATS; TOXICOL. IND. HEALTH 11(2):119-149, 1995]"
6616,363905546,15413,CC(C)(C)OC,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 250; 1000 MG/KG BW IN 1 ML OLIVE OIL 1/D 4 D/WK FOR 104 WK (STUDY DURATION: 166 WK),HEMOLYMPHORETICULAR SYSTEM: LYMPHOMA OR LEUKEMIA,POSITIVE,"[BELPOGGI,F, SOFFRITTI,M AND MALTONI,C; METHYL-TERTIARY-BUTYL ETHER (MTBE)- A GASOLINE ADDITIVE- CAUSES TESTICULAR AND LYMPHOHAEMATOPOIETIC CANCERS IN RATS; TOXICOL. IND. HEALTH 11(2):119-149, 1995]"
6617,363905546,15413,CC(C)(C)OC,Inactive,,,,MOUSE,CD-1/MALE,INHALATION,0; 400; 3000; 8000 PPM IN AIR 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[BIRD,MG, BURLEIGH-FLAYER,HD, CHUN,JS, DOUGLAS,JF, KNEISS,JJ AND ANDREWS,LS; ONCOGENICITY STUDIES OF INHALED METHYL TERTIARY-BUTYL ETHER (MTBE) IN CD-1 MICE AND F-344 RATS; J. APPL. TOXICOL. 17(SUPPL. 1):45-55, 1997]"
6618,363905546,15413,CC(C)(C)OC,Active,,,,MOUSE,CD-1/FEMALE,INHALATION,0; 400; 3000; 8000 PPM IN AIR 6 HR/D 5 D/WK FOR 18 MO (STUDY DURATION: 18 MO),LIVER: ADENOMA,POSITIVE,"[BIRD,MG, BURLEIGH-FLAYER,HD, CHUN,JS, DOUGLAS,JF, KNEISS,JJ AND ANDREWS,LS; ONCOGENICITY STUDIES OF INHALED METHYL TERTIARY-BUTYL ETHER (MTBE) IN CD-1 MICE AND F-344 RATS; J. APPL. TOXICOL. 17(SUPPL. 1):45-55, 1997]"
6619,363905546,15413,CC(C)(C)OC,Active,,,,RAT,F344/MALE,INHALATION,0; 400; 3000; 8000 PPM IN AIR 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),KIDNEY(RENAL TUBULE): ADENOMA OR CARCINOMA,POSITIVE,"[BIRD,MG, BURLEIGH-FLAYER,HD, CHUN,JS, DOUGLAS,JF, KNEISS,JJ AND ANDREWS,LS; ONCOGENICITY STUDIES OF INHALED METHYL TERTIARY-BUTYL ETHER (MTBE) IN CD-1 MICE AND F-344 RATS; J. APPL. TOXICOL. 17(SUPPL. 1):45-55, 1997]"
6620,363905546,15413,CC(C)(C)OC,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 400; 3000; 8000 PPM IN AIR 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[BIRD,MG, BURLEIGH-FLAYER,HD, CHUN,JS, DOUGLAS,JF, KNEISS,JJ AND ANDREWS,LS; ONCOGENICITY STUDIES OF INHALED METHYL TERTIARY-BUTYL ETHER (MTBE) IN CD-1 MICE AND F-344 RATS; J. APPL. TOXICOL. 17(SUPPL. 1):45-55, 1997]"
6621,363905546,15413,CC(C)(C)OC,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 250; 1000 MG/KG BW IN OLIVE OIL 1/D 4D/WK FOR 104 WK (STUDY DURATION: LIFE SPAN),TESTES: LEYDIG CELL TUMOR,POSITIVE,"[BELPOGGI,F, SOFFRITTI,M, FILIPPINI,F AND MALTONI,C; RESULTS OF LONG-TERM EXPERIMENTAL STUDIES ON THE CARCINOGENICITY OF METHYL TERT-BUTYL ETHER;ANN. N.Y. ACAD. SCI. 837(PREVENTIVE STRATEGIES FOR LIVING IN A CHEMICAL WORLD):77-95, 1997]"
6622,363905546,15413,CC(C)(C)OC,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 250; 1000 MG/KG BW IN OLIVE OIL 1/D 4D/WK FOR 104 WK (STUDY DURATION: LIFE SPAN),MULTIPLE SITES: LYMPHOMA OR LEUKEMIA,POSITIVE,"[BELPOGGI,F, SOFFRITTI,M, FILIPPINI,F AND MALTONI,C; RESULTS OF LONG-TERM EXPERIMENTAL STUDIES ON THE CARCINOGENICITY OF METHYL TERT-BUTYL ETHER;ANN. N.Y. ACAD. SCI. 837(PREVENTIVE STRATEGIES FOR LIVING IN A CHEMICAL WORLD):77-95, 1997]"
6623,363905548,114862,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=O)C4=O,Inactive,,,,RAT,STRAIN-CD/FEMALE,INJECTION,0; 30 UMOL (TOTAL DOSE) 1/6 INJECTED UNDER EACH OF 3 THORACIC AND 3 INGUINAL NIPPLES ONCE (STUDY DURATION: 44 WK),,NEGATIVE,"[EL-BAYOUMY,K, JI,BY, UPADHYAYA,P, CHAE,YH, KURTZKE,C, RIVENSON,A, REDDY,BS, AMIN,S AND HECHCT,SS; LACK OF TUMORIGENICITY OF CHOLESTEROL EPOXIDES AND ESTRONE-3,4-QUINONE IN THE RAT MAMMARY GLAND; CANCER RES. 56(9):1970-197 3, 1996]"
6624,363905586,12433,C(C(=O)O)(Br)Br,Active,,,,Rat,F344/N/Male,Oral,0; 50; 500; 1000 mg/l in drinking water continuous for 2 yr,"All organs: Malignant mesothelioma (3/50, 1/50, 0/50, 10/50); Mononuclear cell leukemia (17/50, 31/50, 24/50, 13/50)",Positive (Malignant mesothelioma) (NTP reports as Some Evidence); Mononuclear cell leukemia results described by NTP as equivocal.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-537 Y07]"
6625,363905586,12433,C(C(=O)O)(Br)Br,Active,,,,Rat,F344/N/Female,Oral,0; 50; 500; 1000 mg/l in drinking water for 2 yr,"All organs: Mononuclear cell leukemia (11/50, 13/50, 16/50, 22/50)",Positive trend (not statistically significant) (NTP reports as Some Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-537 Y07]"
6626,363905586,12433,C(C(=O)O)(Br)Br,Active,,,,Mouse,B6C3F1/Male,Oral,"0; 50; 500; 1,000 mg/l in drinking water for 2 yr","Liver: Hepatocellular adenoma (18/49; 37/50; 37/50; 42/50); Hepatocellular carcinoma (14/49, 9/50, 19/50, 26/50); Hepatocellular adenoma or carcinoma (28/49, 41/50, 42/50, 47/50); Hepatoblastoma (0/49, 4/50, 6/50, 18/50) Lung: Alveolar/bronchiolar adenoma (7/49, 5/50, 17/50, 12/50); Alveolar/bronchiolar adenoma or carcinoma (12/49, 12/50, 22/50, 17/50)",Positive (NTP reports as Clear Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-537 Y07]"
6627,363905586,12433,C(C(=O)O)(Br)Br,Active,,,,Mouse,B6C3F1/Female,Oral,"0; 50; 500; 1,000 mg/l in drinking water for 2 yr","Liver: Hepatocellular adenoma (19/49; 26/50; 32/50; 35/49); Hepatocellular carcinoma (3/49, 3/50, 12/50, 8/49); Hepatocellular adenoma or carcinoma (22/49, 28/50, 37/50, 37/49)",Positive (NTP reports as Clear Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-537 Y07]"
6628,363905625,5280961,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,"During pregnancy, ingested doses for dams were ~0, 0.5, 9, and 45 mg/kg bw/day. During lactation, ingested doses for dams were 0, 0.7,15, and 75 mg/kg/day (with minimal transfer to pups via dam's milk. Exposure from conception through weaning followed by control diet to 2 years (F3T21)","Mammary gland: adenoma and adenocarcinoma combined (13.2%, 16.3%, 22.0%, 26.0%)",Negative. Positive trend but results do not reach statistical significance (NTP describes results as Equivocal),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-545 Y08]"
6629,363905625,5280961,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,"During pregnancy, ingested doses for dams were ~0, 0.5, 9, and 45 mg/kg bw/day. During lactation, ingested doses for dams were 0, 0.7,15, and 75 mg/kg/day (with minimal transfer to pups via dam's milk); doses from weaning to 20 wk were 0, 0.4, 8, and 44 mg/kg/day (0, 5, 100, and 500 ppm). Exposure was from conception through 20 wk followed by control diet to 2 years (F1T140).","Pituitary gland: adenoma and carcinoma combined (Overall rate 70.4%, 65.3%, 80.0%, 88.0%)",Negative (NTP describes as Equivocal),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-545 Y08]"
6630,363905625,5280961,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,"During pregnancy, ingested doses for dams were ~0, 0.5, 9, and 45 mg/kg bw/day. During lactation, ingested doses for dams were 0, 0.7,15, and 75 mg/kg/day (with minimal transfer to pups via dam's milk); doses from weaning to 20 wk were 0, 0.4, 8, and 44 mg/kg/day. The remaining ingested doses were approximately 0.3, 5, and 29 mg/kg (0, 5, 100, and 500 ppm). Continuous exposure from gestation through 2 yrs (F1C)","Mammary gland: adenoma and adenocarcinoma combined (16.7%, 8.0%, 16.0%, 32.7%) Pituitary gland: neoplasms (70.4%, 80.0%, 68.0%, 93.9%):","Positive but at 2 lower doses, there was a negative trend for the mammary tumors (NTP describes the results as Some Evidence)","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-545 Y08]"
6631,363905625,5280961,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,Inactive,,,,Rat,Sprague-Dawley/Male (50/Group),Oral,"During pregnancy, ingested doses for dams were ~0, 0.5, 9, and 45 mg/kg bw/day. During lactation, ingested doses for dams were 0, 0.7,15, and 75 mg/kg/day (with minimal transfer to pups via dam's milk); doses from weaning to 20 wk were 0, 0.4, 7, and 37 mg/kg/day. The remaining ingested doses were approximately 0.2, 4, and 20 mg/kg (0, 5, 100, and 500 ppm). Continuous exposure from gestation through 2 yrs (F1C)",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-545 Y08]"
6632,363905625,5280961,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,Inactive,,,,Rat,Sprague-Dawley/Male (50/Group),Oral,"During pregnancy, ingested doses for dams were ~0, 0.5, 9, and 45 mg/kg bw/day. During lactation, ingested doses for dams were 0, 0.7,15, and 75 mg/kg/day (with minimal transfer to pups via dam's milk. Exposure from conception through weaning followed by control diet to 2 years (F3T21)",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-545 Y08]"
6633,363905625,5280961,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,"During pregnancy, ingested doses for dams were ~0, 0.5, 9, and 45 mg/kg bw/day. During lactation, ingested doses for dams were 0, 0.7,15, and 75 mg/kg/day (with minimal transfer to pups via dam's milk); doses from weaning to 20 wk were 0, 0, 0.4, 7, and 37 mg/kg/day (0, 5, 100, and 500 ppm). Exposure was from conception through 20 wk followed by control diet to 2 years (F1T140).",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-545 Y08]"
6634,363905637,154823,CC1=C2CC(C3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1)OS(=O)(=O)O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,SUBCUTANEOUS,0; 0.2 UMOL IN 0.1 ML SESAME OIL: DMSO (9:1) 3/WK FOR 20 DOSES (STUDY DURATION: 52 WK),INJECTION SITE: SARCOMA,POSITIVE,"[FLESHER,JW, HORN,J AND LEHNER,AF; CARCINOGENICITY OF 1-HYDROXY-3-METHYLCHOLANTHRENE AND ITS ELECTROPHILIC SULFATE ESTER 1-SULFOOXY-3-METHYLCHOLANTHRENE IN SPRAGUE-DAWLEY RATS; BIOCHEM. BIOPHYS. RES. COMMUN. 243(1):30-35, 1998]"
6635,363905652,93296,C1=CC(=CC=C1N)N(CCO)CCO.OS(=O)(=O)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 300; 1000; 3000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HAGIWARA,A, MIYATA,E, TAMANO,S, SHIBATA,MA, SUGIURA,S, INOUE,M AND HIROSE,M; NON-CARCINOGENICITY OF 2,2'-[(4-AMINOPHENYL)IMINO]BISETHANOL SULFATE IN A LONG-TERM FEEDING STUDY IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 34(6):537-546, 1996]"
6636,363905652,93296,C1=CC(=CC=C1N)N(CCO)CCO.OS(=O)(=O)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 300; 1000; 3000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HAGIWARA,A, MIYATA,E, TAMANO,S, SHIBATA,MA, SUGIURA,S, INOUE,M AND HIROSE,M; NON-CARCINOGENICITY OF 2,2'-[(4-AMINOPHENYL)IMINO]BISETHANOL SULFATE IN A LONG-TERM FEEDING STUDY IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 34(6):537-546, 1996]"
6637,363905653,,,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1.25; 5% IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[SANO,M, MIYATA,E, TAMANO,S, HAGIWARA,A, ITO,N AND SHIRAI,T; LACK OF CARCINOGENICITY OF TAMARIND SEED POLYSACCHARIDE IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 34(5):463-467, 1996]"
6638,363905653,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1.25; 5% IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[SANO,M, MIYATA,E, TAMANO,S, HAGIWARA,A, ITO,N AND SHIRAI,T; LACK OF CARCINOGENICITY OF TAMARIND SEED POLYSACCHARIDE IN B6C3F1 MICE; FOOD CHEM. TOXICOL. 34(5):463-467, 1996]"
6639,363905654,107999,CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 1; 10; 30; 100 MG/KG/D FOR DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[TABATA,H, SAKAI,T, MIKI,H, SUZUKI,H, RUCKMAN,SA, READ,RM, GOPINATH,C, HEALEY,GF, BARKER,MH, CHASSEAUD, LF, GAZLEY,MJS, INCE,G AND HEDGE,A; ONCOGENICITY STUDIES OF THE NEW SEROTONIN (5-HT)3-RECEPTOR ANTAGONIST RAMOSETRON IN MICE AND RATS; ARZNEIM.-FORSCH. 46(6):560-566, 1996]"
6640,363905654,107999,CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 1; 10; 30; 100 MG/KG/D FOR DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[TABATA,H, SAKAI,T, MIKI,H, SUZUKI,H, RUCKMAN,SA, READ,RM, GOPINATH,C, HEALEY,GF, BARKER,MH, CHASSEAUD, LF, GAZLEY,MJS, INCE,G AND HEDGE,A; ONCOGENICITY STUDIES OF THE NEW SEROTONIN (5-HT)3-RECEPTOR ANTAGONIST RAMOSETRON IN MICE AND RATS; ARZNEIM.-FORSCH. 46(6):560-566, 1996]"
6641,363905654,107999,CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4.Cl,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 1; 10; 30; 100 MG/KG/D FOR DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[TABATA,H, SAKAI,T, MIKI,H, SUZUKI,H, RUCKMAN,SA, READ,RM, GOPINATH,C, HEALEY,GF, BARKER,MH, CHASSEAUD, LF, GAZLEY,MJS, INCE,G AND HEDGE,A; ONCOGENICITY STUDIES OF THE NEW SEROTONIN (5-HT)3-RECEPTOR ANTAGONIST RAMOSETRON IN MICE AND RATS; ARZNEIM.-FORSCH. 46(6):560-566, 1996]"
6642,363905654,107999,CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4.Cl,Inactive,,,,RAT,F344/FEMALE,GAVAGE,0; 1; 10; 30; 100 MG/KG/D FOR DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[TABATA,H, SAKAI,T, MIKI,H, SUZUKI,H, RUCKMAN,SA, READ,RM, GOPINATH,C, HEALEY,GF, BARKER,MH, CHASSEAUD, LF, GAZLEY,MJS, INCE,G AND HEDGE,A; ONCOGENICITY STUDIES OF THE NEW SEROTONIN (5-HT)3-RECEPTOR ANTAGONIST RAMOSETRON IN MICE AND RATS; ARZNEIM.-FORSCH. 46(6):560-566, 1996]"
6643,363905655,5281233,C/C(=C\C=C\C=C(\C=C\C=C(\C(=O)O[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO[C@@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)CO)/C)/C)/C=C/C=C(/C(=O)O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)\C,Inactive,,,,MOUSE,C57BL/FEMALE,ORAL,0; 0.2; 0.8% IN DRINKING WATER FOR 95 WK (STUDY DURATION: 95 WK),,NEGATIVE,"[FUJIMOTO,N, SAKAI,Y, KURISU,K, ROY,G, WATANABE,H AND ITO,A; CHRONIC TOXICITY STUDY OF GARDENIA YELLOW COLOR IN C57BL MICE; TOXICOL. J. TOXICOL. PATHOL. 7(4):455-460, 1994]"
6644,363905655,5281233,C/C(=C\C=C\C=C(\C=C\C=C(\C(=O)O[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO[C@@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)CO)/C)/C)/C=C/C=C(/C(=O)O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)\C,Inactive,,,,MOUSE,C57BL/MALE,ORAL,0; 0.2; 0.8% IN DRINKING WATER FOR 95 WK (STUDY DURATION: 95 WK),,NEGATIVE,"[FUJIMOTO,N, SAKAI,Y, KURISU,K, ROY,G, WATANABE,H AND ITO,A; CHRONIC TOXICITY STUDY OF GARDENIA YELLOW COLOR IN C57BL MICE; TOXICOL. J. TOXICOL. PATHOL. 7(4):455-460, 1994]"
6645,363905677,47326,CC1(C(C1(C)C)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,Inactive,,,,Rat,CD/Male (50/Group),Oral,"0; 50; 150; 450 ppm of 91.4-92.5% fenpropathrin in diet for >52 wk, study duration up to 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENPROPATHRIN (March 12, 1991)]"
6646,363905677,47326,CC1(C(C1(C)C)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,Inactive,,,,Rat,CD/Female (50/Group),Oral,"0; 50; 150; 450 ppm of 91.4-92.5% fenpropathrin in diet for >52 wk, study duration up to 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENPROPATHRIN (March 12, 1991)]"
6647,363905677,47326,CC1(C(C1(C)C)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,Inactive,,,,Mouse,CD-1/Male (52/Group),,"0; 40; 150; 600 ppm of 91.4 - 92.5 % fenpropathrin in diet for 2 yr, study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENPROPATHRIN (March 12, 1991)]"
6648,363905677,47326,CC1(C(C1(C)C)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,Inactive,,,,Mouse,CD-1/Female (52/Group),,"0; 40; 150; 600 ppm of 91.4 - 92.5 % fenpropathrin in diet for 2 yr, study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENPROPATHRIN (March 12, 1991)]"
6649,363905688,8301,C(=C(F)F)(F)F,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 312; 625; 1250 PPM 6 HR/D 5 D/WK FOR 95-96 WK (STUDY DURATION: 96 WK),"LIVER: HEMANGIOMA, HEMANGIOSARCOMA, HEPATOCELLULAR CARCINOMA; HEMATOPOIETIC SYSTEM: HISTIOCYTIC SARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-450 Y97]"
6650,363905688,8301,C(=C(F)F)(F)F,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 312; 625; 1250 PPM 6 HR/D 5 D/WK FOR 95-96 WK (STUDY DURATION: 96 WK),"LIVER: HEMANGIOMA, HEMANGIOSARCOMA, HEPATOCELLULAR CARCINOMA; HEMATOPOIETIC SYSTEM: HISTIOCYTIC SARCOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-450 Y97]"
6651,363905688,8301,C(=C(F)F)(F)F,Active,,,,RAT,F344/FEMALE,INHALATION,0; 312; 625; 1250 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 106 WK),"KIDNEY(RENAL TUBULE): ADENOMA, ADENOMA OR CARCINOMA; LIVER: HEMANGIOSARCOMA, HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA; HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-450 Y97]"
6652,363905688,8301,C(=C(F)F)(F)F,Active,,,,RAT,F344/MALE,INHALATION,0; 156; 312; 625 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 106 WK),"KIDNEY(RENAL TUBULE): ADENOMA; LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-450 Y97]"
6653,363905738,6928,CCC1=CC(=C(C(=C1)C(C)(C)C)O)CC2=C(C(=CC(=C2)CC)C(C)(C)C)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 0.03; 0.1; 0.3% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 18 MO),,NEGATIVE,"[TAKAGI,A, TAKADA,K, SAI,K, MOMMA,J, AIDA,Y, SUZUKI,S, NAITOH,K, TOBE,M, HASEGAWA,R AND KUROKAWA,Y; CHRONIC ORAL TOXICITY OF A SYNTHETIC ANTIOXIDANT, 2,2'-METHYLENEBIS(4-ETHYL-6-TERT-BUTYLPHENOL), IN RATS; J. APPL. TOXICOL. 16(1):15-23, 1996]"
6654,363905738,6928,CCC1=CC(=C(C(=C1)C(C)(C)C)O)CC2=C(C(=CC(=C2)CC)C(C)(C)C)O,Unspecified,,,,RAT,WISTAR/FEMALE,ORAL,0; 0.03; 0.1; 0.3% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 18 MO),NEGATIVE,,"[TAKAGI,A, TAKADA,K, SAI,K, MOMMA,J, AIDA,Y, SUZUKI,S, NAITOH,K, TOBE,M, HASEGAWA,R AND KUROKAWA,Y; CHRONIC ORAL TOXICITY OF A SYNTHETIC ANTIOXIDANT, 2,2'-METHYLENEBIS(4-ETHYL-6-TERT-BUTYLPHENOL), IN RATS; J. APPL. TOXICOL. 16(1):15-23, 1996]"
6655,363905739,,,Active,,,,RAT,WISTAR/FEMALE,INHALATION,0; 0.056; 0.19; 0.62; 2.32; 24.3 GY NOSE-ONLY EXPOSURE FOR 30-60 MIN ONCE (STUDY DURATION: LIFESPAN),LUNG: CARCINOMA,POSITIVE,"[SANDERS,CL AND DAGLE,GE; A THRESHOLD MODEL OF PULMONARY CARCINOGENESIS: CARCINOMA IN THE RAT AFTER DEPOSITION OF PLUTONIUM OR QUARTZ; APPL. OCCUP. ENVIRON. HYG. 11(4):391-397, 1996]"
6656,363905751,40024,CC1=C[C@@H]2[C@]([C@@H](C1=O)O)([C@]3(C[C@H]([C@H]([C@@]34CO4)O2)O)C)CO,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1; 5; 10 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[IVERSON,F, ARMSTRONG,C, NERA,E, TRUELOVE,J, FERNIE,S, SCOTT,P, STAPLEY,R, HAYWARD,S AND GUNNER,S; CHRONIC FEEDING STUDY OF DEOXYNIVALENOL IN B6C3F1 MALE AND FEMALE MICE; TERATOG. CARCINOG. MUTAGEN. 15:283-306, 1995]"
6657,363905751,40024,CC1=C[C@@H]2[C@]([C@@H](C1=O)O)([C@]3(C[C@H]([C@H]([C@@]34CO4)O2)O)C)CO,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1; 5; 10 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[IVERSON,F, ARMSTRONG,C, NERA,E, TRUELOVE,J, FERNIE,S, SCOTT,P, STAPLEY,R, HAYWARD,S AND GUNNER,S; CHRONIC FEEDING STUDY OF DEOXYNIVALENOL IN B6C3F1 MALE AND FEMALE MICE; TERATOG. CARCINOG. MUTAGEN. 15:283-306, 1995]"
6658,363905752,61819,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Cu+2],Active,,,,RAT,WISTAR/MALE,INTRAPERITONEAL,0; 3 MG COPPER/KG BW FOR 3 D THEN 5 MG COPPER/KG FOR THE NEXT 2 D AND THEN 5 MG COPPER/KG 5 D/WK FOR 11 WK (STUDY DURATION: LIFESPAN),KIDNEY: RENAL CELL CARCINOMA,POSITIVE,"[TOYOKUNI,S, TANAKA,T, NISHIYAMA,Y, OKAMOTO,K, NAKASHIMA,Y, HAMAZAKI,S, OKADA,S AND HIAI,H; INDUCTION OF RENAL CELL CARCINOMA IN MALE WISTAR RATS TREATED WITH CUPRIC NITRILOTRIACETATE; LAB. INVEST. 75(2):239-248, 1996]"
6659,363905753,,,Inactive,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6660,363905754,,,Active,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 31-32 MO),SKIN: TUMOR,POSITIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6661,363905755,,,Inactive,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6662,363905756,,,Active,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 24 MO),SKIN: TUMOR,POSITIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6663,363905757,,,Active,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 24 MO),SKIN: TUMOR,POSITIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6664,363905758,,,Active,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 24 MO),SKIN: TUMOR,POSITIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6665,363905759,,,Active,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 24 MO),SKIN: TUMOR,POSITIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6666,363905759,,,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 100% IN 50 UL MINERAL OIL 2/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NESSEL,CS, PRISTON,RAJ, MCKEE,RH, CRUZAN,G, RILEY,AJ, HAGEMANN,R, PLUTNICK,RT AND SIMPSON,BJ; A COMPREHENSIVE EVALUATION OF THE MECHANISM OF SKIN TUMORIGENESIS BY STRAIGHT-RUN AND CRACKED PETROLEUM MIDDLE DISTILLATES; TOXICOL. SCI. 44(1):22-31, 1998]"
6667,363905759,,,Active,,,,MOUSE,C3H/MALE,DERMAL,0; 50% IN 50 UL MINERAL OIL 4/WK FOR 2 YR (STUDY DURATION: 2 YR),SKIN: PAPILLOMA OR CARCINOMA,POSITIVE,"[NESSEL,CS, PRISTON,RAJ, MCKEE,RH, CRUZAN,G, RILEY,AJ, HAGEMANN,R, PLUTNICK,RT AND SIMPSON,BJ; A COMPREHENSIVE EVALUATION OF THE MECHANISM OF SKIN TUMORIGENESIS BY STRAIGHT-RUN AND CRACKED PETROLEUM MIDDLE DISTILLATES; TOXICOL. SCI. 44(1):22-31, 1998]"
6668,363905759,,,Active,,,,MOUSE,C3H/MALE,DERMAL,"0; 50 UL/ DOSE, 28.5% IN 50 UL MINERAL OIL 7/WK FOR 2 YR (STUDY DURATION: 2 YR)",SKIN: PAPILLOMA OR CARCINOMA,POSITIVE,"[NESSEL,CS, PRISTON,RAJ, MCKEE,RH, CRUZAN,G, RILEY,AJ, HAGEMANN,R, PLUTNICK,RT AND SIMPSON,BJ; A COMPREHENSIVE EVALUATION OF THE MECHANISM OF SKIN TUMORIGENESIS BY STRAIGHT-RUN AND CRACKED PETROLEUM MIDDLE DISTILLATES; TOXICOL. SCI. 44(1):22-31, 1998]"
6669,363905760,,,Active,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50 UL 2/WK FOR DURATION OF STUDY (STUDY DURATION: 31-32 MO),SKIN: TUMOR,POSITIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6670,363905761,,,Active,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 0.1; 10% (W/V) IN TOLUENE 2/WK FOR DURATION OF STUDY (STUDY DURATION: 31-32 MO),SKIN: TUMOR,POSITIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6671,363905762,,,Inactive,,,,MOUSE,C3H/HEJ/MALE,DERMAL,0; 50% (W/V) IN TOLUENE 2/WK FOR DURATION OF STUDY (STUDY DURATION: 31-32 WK),,NEGATIVE,"[BRODDLE,WD, DENNIS,MW, KITCHEN,DN AND VERNOT,EH; CHRONIC DERMAL STUDIES OF PETROLEUM STREAMS IN MICE; FUNDAM. APPL. TOXICOL. 30:47-54, 1996]"
6672,363905763,9863,[C-]#[Si+],Active,,,,RAT,F344/FEMALE,INTRAPERITONEAL,0; 20 MG SILICON CARBIDE WHISKERS ONCE (STUDY DURATION: LIFESPAN),PLEURAL CAVITY: MESOTHELIOMA,POSITIVE,"[JOHNSON,NF AND HAHN,FF; INDUCTION OF MESOTHELIOMA AFTER INTRAPLEURAL INOCULATION OF F344 RATS WITH SILICON CARBIDE WHISKERS OR CONTINUOUS CERAMIC FILAMENTS; OCCUP. ENVIRON. MED. 53(12):813-816, 1996]"
6673,363905763,9863,[C-]#[Si+],Active,,,,RAT,AF/HAN,INHALATION,0; 1000 FIBERS/ML IN AIR 7 HR/D 5 D/WK FOR 1 YR (STUDY DURATION: LIFESPAN),"LUNG: ADENOMA, CARCINOMA",POSITIVE,"[DAVIS,JMG, BROWN,DM, CULLEN,RT, DONALDSON,K, JONES,AD, MILLER,BG, MCINTOSH,C AND SEARL,A; A COMPARISON OF METHODS OF DETERMINING AND PREDICTING THE PATHOGENICITY OF MINERAL FIBERS; INHALATION TOXICOL. 8(8):747-77, 1996]"
6674,363905764,517335,C1=C(NC=N1)CC(C(=O)O)N.O.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 1.25; 2.5% IN DIET FOR 104 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[IKEZAKI,S, NISHIKAWA,A, FURUKAWA,F, ENAMI,T, MITSUI,M, TANAKAMARU,Z, KIM,HC, LEE,IS, IMAZAWA,T AND TAKAHASHI,M; LONG-TERM TOXICITY/CARCINOGENICITY STUDY OF L-HISTIDINE MONOHYDROCHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 34(8):687-691, 1996]"
6675,363905764,517335,C1=C(NC=N1)CC(C(=O)O)N.O.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1.25; 2.5% IN DIET FOR 104 WK (STUDY DURATION: 107 WK),,NEGATIVE,"[IKEZAKI,S, NISHIKAWA,A, FURUKAWA,F, ENAMI,T, MITSUI,M, TANAKAMARU,Z, KIM,HC, LEE,IS, IMAZAWA,T AND TAKAHASHI,M; LONG-TERM TOXICITY/CARCINOGENICITY STUDY OF L-HISTIDINE MONOHYDROCHLORIDE IN F344 RATS; FOOD CHEM. TOXICOL. 34(8):687-691, 1996]"
6676,363905814,154830,CCCC(=O)CN(C)N=O,Active,,,,RAT,"WISTAR/MALE,FEMALE",INTRAPERITONEAL,0; 75 MG/KG 1/WK FOR 6 WK BEGINNING AT 52-61 DAYS OF AGE (STUDY DURATION: >35 WK),ESOPHAGUS: PAPILLOMA; NASAL CAVITY: TUMOR; INJECTION SITE: SARCOMA,POSITIVE,"[MIRVISH,SS, NICKOLS,J, WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. 107(2):171-177, 1996]"
6677,363905814,154830,CCCC(=O)CN(C)N=O,Active,,,,RAT,"WISTAR/MALE, FEMALE",SUBCUTANEOUS,0; 75 MG/KG 1/WK FOR 6 WK TO ADULT ANIMALS (STUDY DURATION: LIFETIME),"ESOPHAGUS: PAPILLOMA; NASAL CAVITY: PAPILLOMA, SQUAMOUS CARCINOMA OR ADENOMA; SOFT TISSUE (INJECTION SITE): SARCOMA; THYROID GLAND: ADENOMA",POSITIVE,"[MIRVISH,SS NICHOLS,J WEISENBURGER,DD AND SMYRK,T; CARCINOGENICITY TESTS OF METHYL-N-AMYLNITROSAMINE (MNAN) ADMINISTERED TO NEWBORN AND ADULT RATS AND HAMSTERS AND ADULT MICE AND OF 2-OXO-MNAN ADMINISTERED TO ADULT RATS; CANCER LETT. (SHANNON, IREL.) 107(2):171-177, 1996]"
6678,363905851,222285,C([C@H]([C@H](CO)O)O)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 2; 5; 10% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[LINA,BAR, BOS-KUIJPERS,MHM, TIL,HP AND BAR,A; CHRONIC TOXICITY AND CARCINOGENICITY STUDY OF ERYTHRITOL IN RATS; REGUL. TOXICOL. PHARMACOL. 24(2, PT. 2):S264-S279, 1996]"
6679,363905851,222285,C([C@H]([C@H](CO)O)O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 2; 5; 10% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[LINA,BAR, BOS-KUIJPERS,MHM, TIL,HP AND BAR,A; CHRONIC TOXICITY AND CARCINOGENICITY STUDY OF ERYTHRITOL IN RATS; REGUL. TOXICOL. PHARMACOL. 24(2, PT. 2):S264-S279, 1996]"
6680,363905851,222285,C([C@H]([C@H](CO)O)O)O,Inactive,,,,DOG,BEAGLE/MALE,ORAL,0; 2; 5; 10% IN DIET FOR 53 WK (STUDY DURATION: 53 WK),,NEGATIVE,"[DEAN,I, JACKSON,F AND GREENOUGH,RJ; CHRONIC (1-YEAR) ORAL TOXICITY STUDY OF ERYTHRITOL IN DOGS; REGUL. TOXICOL. PHARMACOL. 24:S254-S260, 1996]"
6681,363905851,222285,C([C@H]([C@H](CO)O)O)O,Inactive,,,,DOG,BEAGLE/FEMALE,ORAL,0; 2; 5; 10% IN DIET FOR 53 WK (STUDY DURATION: 53 WK),,NEGATIVE,"[DEAN,I, JACKSON,F AND GREENOUGH,RJ; CHRONIC (1-YEAR) ORAL TOXICITY STUDY OF ERYTHRITOL IN DOGS; REGUL. TOXICOL. PHARMACOL. 24:S254-S260, 1996]"
6682,363905866,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.075; 0.15% IN DIET FOR 81 WK (STUDY DURATION: 81 WK),,NEGATIVE,"[MURATA,Y, DENDA,A, MARUYAMA,H, NAKAE,D, TSUTSUMI,M, TSUJIUCHI,T AND KONISHI,Y; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF 2-METHYLNAPHTHALENE IN B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 36(1):90-93, 1997]"
6683,363905867,23672344,C([C@@H](C(=O)[O-])N)C(=O)O.[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN DRINKING WATER FOR 100 WK (STUDY DURATION: 100 WK),,NEGATIVE,"[KITAHORI,Y KONISHI,N NAKAGAWA,Y CHO,M NAITOH,H YAMAMOTO,K  MATSUI,E ADN HIASA,Y; LACK OF CARCINOGENICITY OF L-CYSTEINE  MONOHYDROCHLORIDE IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 10: 83-89, 1997]"
6684,363905867,23672344,C([C@@H](C(=O)[O-])N)C(=O)O.[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN DRINKING WATER FOR 100 WK (STUDY DURATION: 100 WK),,NEGATIVE,"[KITAHORI,Y KONISHI,N NAKAGAWA,Y CHO,M NAITOH,H YAMAMOTO,K  MATSUI,E ADN HIASA,Y; LACK OF CARCINOGENICITY OF L-CYSTEINE  MONOHYDROCHLORIDE IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 10: 83-89, 1997]"
6685,363905871,148165,CCN(CC)CC#CC(C)(C)OC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 30; 100; 300 MG/KG/D IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[HATCH,RC, REGAN,KS, ISHIBASHI,S, NAKAZAWA,M, IWAKURA,K AND SUMI,N; SEVENTY-EIGHT-WEEK DIETARY CARCINOGENICITY STUDY OF (+/-)-4-DIETHYLAMINO-1,1-DIMETHYLBUT-2-YN-1-YL 2-CYCLOHEXYL-2-HYDROXY-2-PHENYLACETATE MONOHYDROCHLORIDE MONOHYDRATE (NS-21), A NOVEL DRUG FOR URINARY FREQUENCY AND INCONTINENCE, IN MICE; J. TOXICOL. SCI. 22(SUPPL. 1):275-287, 1997]"
6686,363905871,148165,CCN(CC)CC#CC(C)(C)OC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 30; 100; 300 MG/KG/D IN DIET FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[HATCH,RC, REGAN,KS, ISHIBASHI,S, NAKAZAWA,M, IWAKURA,K AND SUMI,N; SEVENTY-EIGHT-WEEK DIETARY CARCINOGENICITY STUDY OF (+/-)-4-DIETHYLAMINO-1,1-DIMETHYLBUT-2-YN-1-YL 2-CYCLOHEXYL-2-HYDROXY-2-PHENYLACETATE MONOHYDROCHLORIDE MONOHYDRATE (NS-21), A NOVEL DRUG FOR URINARY FREQUENCY AND INCONTINENCE, IN MICE; J. TOXICOL. SCI. 22(SUPPL. 1):275-287, 1997]"
6687,363905871,148165,CCN(CC)CC#CC(C)(C)OC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 10; 30; 100 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HATCH,RC, REGAN,KS, ISHIBASHI,S, NAKAZAWA,M, IWAKURA,K AND  SUMI,N; TWO-YEAR DIETARY CARCINGENICITY STUDY OF  (+/-)-4-DIETHYLAMINO-1,1-DIMETHYLBUT-2-YN-1-YL  2-CYCLOHEXYL-2-HYDROXY-2-PHENYLACETATE MONOHYDROCHLORIDE  MONOHYDRATE (NS-21), A NOVEL DRUG FOR URINARY FREQUENCY AND  INCONTINENCE, IN RATS; J TOXICOL SCI 22(SUPPL. 1):289-306, 1997]"
6688,363905871,148165,CCN(CC)CC#CC(C)(C)OC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 30; 100 MG/KG/D IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[HATCH,RC, REGAN,KS, ISHIBASHI,S, NAKAZAWA,M, IWAKURA,K AND  SUMI,N; TWO-YEAR DIETARY CARCINGENICITY STUDY OF  (+/-)-4-DIETHYLAMINO-1,1-DIMETHYLBUT-2-YN-1-YL  2-CYCLOHEXYL-2-HYDROXY-2-PHENYLACETATE MONOHYDROCHLORIDE  MONOHYDRATE (NS-21), A NOVEL DRUG FOR URINARY FREQUENCY AND  INCONTINENCE, IN RATS; J TOXICOL SCI 22(SUPPL. 1):289-306, 1997]"
6689,363905872,,,Active,,,,RAT,WISTAR/MALE,INHALATION,0; 0.2; 1; 6 MG/M3 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 106 WK),LUNG: ADENOMA,POSITIVE,"[REUZEL,PGJ, ARTS,JHE, LOMAX,LG, KUIJPERS,MHM, KUPER,CF, GEMBARDT,C, FERON,VJ AND LOSER,E; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDY OF RESPIRABLE POLYMERIC METHYLENE DIPHENYL DIISOCYANATE (POLYMERIC MDI) AEROSOL IN RATS; FUNDAM. APPL. TOXICOL. 22(2):195-210, 1994]"
6690,363905872,,,Inactive,,,,RAT,WISTAR/FEMALE,INHALATION,0; 0.2; 1; 6 MG/M3 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 106 WK),,NEGATIVE,"[REUZEL,PGJ, ARTS,JHE, LOMAX,LG, KUIJPERS,MHM, KUPER,CF, GEMBARDT,C, FERON,VJ AND LOSER,E; CHRONIC INHALATION TOXICITY AND CARCINOGENICITY STUDY OF RESPIRABLE POLYMERIC METHYLENE DIPHENYL DIISOCYANATE (POLYMERIC MDI) AEROSOL IN RATS; FUNDAM. APPL. TOXICOL. 22(2):195-210, 1994]"
6691,363905875,446925,CC(=CCC/C(=C/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)/C)/C)C,Inactive,,,,MOUSE,C57BL/6J/MALE,ORAL,0; 50; 200 PPM IN DRINKING WATER FOR 80 WK (STUDY DURATION: 80 WK),,NEGATIVE,"[SALIM,EI WANIBUCHI,H MORIMURA,K WEI,M MITSUHASHI,M YOSHIDA,K ENDO,G AND FUKUSHIMA,S; CARCINOGENICITY OF DIMETHYLARSINIC ACID IN P53 HETEROZYGOUS KNOCKOUT AND WILD-TYPE C57BL/6J MICE; CARCINOGENESIS 24(2):335-342, 2003]"
6692,363905877,590836,CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.03; 0.3; 0.6% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[LINGTON,AW, BIRD,MG, PLUTNICK,RT, STUBBLEFIELD,WA AND SCALA,RA; CHRONIC TOXICITY AND CARCINOGENICITY OF DIISONONYL PHTHALATE IN RATS; FUNDAM. APPL. TOXICOL. 36(1):79-89, 1997]"
6693,363905877,590836,CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.03; 0.3; 0.6% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[LINGTON,AW, BIRD,MG, PLUTNICK,RT, STUBBLEFIELD,WA AND SCALA,RA; CHRONIC TOXICITY AND CARCINOGENICITY OF DIISONONYL PHTHALATE IN RATS; FUNDAM. APPL. TOXICOL. 36(1):79-89, 1997]"
6694,363905949,90547,C1=CC(=CC=C1C(=O)O)NN.Cl,Inactive,,,,MOUSE,STRAIN-A/FEMALE,ORAL,0; 1000 PPM IN DRINKING WATER FOR 26 WK (STUDY DURATION: 26 WK),,NEGATIVE,"[PILEGAARD,K, KRISTIANSEN,E, MEYER,OA AND GRY,J; FAILURE OF THE CULTIVATED MUSHROOM (AGARICUS BISPORUS) TO INDUCE TUMORS IN THE A/J MOUSE LUNG TUMOR MODEL; CANCER LETT. 120(1):79-85, 1997]"
6695,363906038,124682,C1C(O1)OC2=CC=C(C=C2)[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 60 NMOL/G BW IN 10 UL TRIOCTANOIN ONCE (STUDY DURATION: 10 MO),LIVER: HEPATOMA,POSITIVE,"[PARK,KK, SOHN,Y, LIEM,A, KIM,HJ, STEWART,BC AND MILLER,JA; THE ELECTROPHILIC, MUTAGENIC AND TUMORIGENIC ACTIVITIES OF PHENYL AND 4-NITROPHENYL VINYL ETHERS AND THEIR EPOXIDE METABOLITES;CARCINOGENESIS 18(2):431-437, 1997]"
6696,363906056,65869,C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 50; 200; 500 MG/KG FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ROMERO,A, RIVES,A, GRAU,MT, VILLAMAYOR,F, SACRISTAN,A AND ORTIZ,JA; CARCINOGENICITY STUDIES ON EBROTIDINE; ARZNEIM.-FORSCH. 47(4A):515-519, 1997]"
6697,363906056,65869,C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 50; 200; 500 MG/KG FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ROMERO,A, RIVES,A, GRAU,MT, VILLAMAYOR,F, SACRISTAN,A AND ORTIZ,JA; CARCINOGENICITY STUDIES ON EBROTIDINE; ARZNEIM.-FORSCH. 47(4A):515-519, 1997]"
6698,363906056,65869,C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 50; 200; 500 MG/KG FOR 13 MO THEN 0; 50; 150; 300; 500 MG/KG FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[ROMERO,A, RIVES,A, GRAU,MT, VILLAMAYOR,F, SACRISTAN,A AND ORTIZ,JA; CARCINOGENICITY STUDIES ON EBROTIDINE; ARZNEIM.-FORSCH. 47(4A):515-519, 1997]"
6699,363906056,65869,C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 50; 200; 500 MG/KG FOR 13 MO THEN 0; 50; 150; 300; 500 MG/KG FOR DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[ROMERO,A, RIVES,A, GRAU,MT, VILLAMAYOR,F, SACRISTAN,A AND ORTIZ,JA; CARCINOGENICITY STUDIES ON EBROTIDINE; ARZNEIM.-FORSCH. 47(4A):515-519, 1997]"
6700,363906056,65869,C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,INITIALLY: 0; 50; 200; 500 MG/KG BW; THEN 0; 50; 150; 300; 500 (200 MG/KG DOSE LOWERED TO 150 MG/KG AFTER 13 MONTHS AND A NEW GROUP ADMINISTERED 300 MG/KG) FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[ROMERO,A VILLAMAYOR,F RIVES,A GRAU,MT SACRISTAN,A AND ORTIZ,JA; TWENTY-FOUR-MONTH ORAL CARCINOGENICTIY STUDY OF EBROTIDINE IN RATS; TERATOG., CARCINOG., MUTAGEN. 18(6):263-277, 1998]"
6701,363906056,65869,C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,INITIALLY: 0; 50; 200; 500 MG/KG BW; THEN 0; 50; 150; 300; 500 (200 MG/KG DOSE LOWERED TO 150 MG/KG AFTER 13 MONTHS AND A NEW GROUP ADMINISTERED 300 MG/KG) FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[ROMERO,A VILLAMAYOR,F RIVES,A GRAU,MT SACRISTAN,A AND ORTIZ,JA; TWENTY-FOUR-MONTH ORAL CARCINOGENICTIY STUDY OF EBROTIDINE IN RATS; TERATOG., CARCINOG., MUTAGEN. 18(6):263-277, 1998]"
6702,363906118,4875,[K+].[I-],Active,,,,RAT,F344/MALE,ORAL,0; 10; 100; 1000 PPM IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),SALIVARY GLAND: SQUAMOUS CELL CARCINOMA,POSITIVE,"[TAKEGAWA,K, MITSUMORI,K, ONODERA,H, YASUHARA,K, KITAURA,K, SHIMO,T AND TAKAHASHI,M; INDUCTION OF SQUAMOUS CELL CARCINOMA IN THE SALIVARY GLANDS OF RATS BY POTASSIUM IODIDE; JPN. J. CANCER RES. 89(2):105-109, 1998]"
6703,363906118,4875,[K+].[I-],Active,,,,RAT,F344/FEMALE,ORAL,0; 10; 100; 1000 PPM IN DRINKING WATER FOR 2 YR (STUDY DURATION: 2 YR),SALIVARY GLAND: SQUAMOUS CELL CARCINOMA,POSITIVE,"[TAKEGAWA,K, MITSUMORI,K, ONODERA,H, YASUHARA,K, KITAURA,K, SHIMO,T AND TAKAHASHI,M; INDUCTION OF SQUAMOUS CELL CARCINOMA IN THE SALIVARY GLANDS OF RATS BY POTASSIUM IODIDE; JPN. J. CANCER RES. 89(2):105-109, 1998]"
6704,363906170,6441835,CCCCCC[C@H](C/C=C\CCCCCCCC(=O)O)O.C(C(CO)O)O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 5% IN DIET FOR 2 YR (STUDY DURATION: 2 YEARS),,NEGATIVE,"[SMITH,MR, WILSON,R AND HEPBURN,PA; ASSESSMENT OF THE CARCINOGENIC POTENTIAL OF POLYGLYCEROL POLYRICINOLEATE (PGPR) IN RATS AND MICE; FOOD CHEM. TOXICOL. 36(9-10):747-754, 1998]"
6705,363906170,6441835,CCCCCC[C@H](C/C=C\CCCCCCCC(=O)O)O.C(C(CO)O)O,Inactive,,,,MOUSE,C57BL/FEMALE,ORAL,0; 5% IN DIET FOR 80 WKS (STUDY DURATION: 80 WKS),,NEGATIVE,"[SMITH,MR, WILSON,R AND HEPBURN,PA; ASSESSMENT OF THE CARCINOGENIC POTENTIAL OF POLYGLYCEROL POLYRICINOLEATE (PGPR) IN RATS AND MICE; FOOD CHEM. TOXICOL. 36(9-10):747-754, 1998]"
6706,363906170,6441835,CCCCCC[C@H](C/C=C\CCCCCCCC(=O)O)O.C(C(CO)O)O,Inactive,,,,MOUSE,C57BL/MALE,ORAL,0; 5% IN DIET FOR 80 WKS (study duration: 80 WKS),,NEGATIVE,"[SMITH,MR, WILSON,R AND HEPBURN,PA; ASSESSMENT OF THE CARCINOGENIC POTENTIAL OF POLYGLYCEROL POLYRICINOLEATE (PGPR) IN RATS AND MICE; FOOD CHEM. TOXICOL. 36(9-10):747-754, 1998]"
6707,363906170,6441835,CCCCCC[C@H](C/C=C\CCCCCCCC(=O)O)O.C(C(CO)O)O,Inactive,,,,RAT,WISTAR/FEMALE,ORAL,0; 5% IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[SMITH,MR, WILSON,R AND HEPBURN,PA; ASSESSMENT OF THE CARCINOGENIC POTENTIAL OF POLYGLYCEROL POLYRICINOLEATE (PGPR) IN RATS AND MICE; FOOD CHEM. TOXICOL. 36(9-10):747-754, 1998]"
6708,363906171,39223,CCOP(=S)(OCC)OC1=NN(C(=N1)Cl)C(C)C,Inactive,,,,Rat,Crl:CD(SD)BR/Male (60/Group),Oral,0; 0.1; 1.0; 300 ppm of 94.9% of isazophos in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ISAZOPHOS (July 21, 1992)]"
6709,363906171,39223,CCOP(=S)(OCC)OC1=NN(C(=N1)Cl)C(C)C,Inactive,,,,Rat,Crl:CD(SD)BR/Female (60/Group),Oral,0; 0.1; 1.0; 300 reduced to 250 at wk 22 and then to 200 ppm at wk 66 of 94.9% of isazophos in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ISAZOPHOS (July 21, 1992)]"
6710,363906171,39223,CCOP(=S)(OCC)OC1=NN(C(=N1)Cl)C(C)C,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Male (60/Group),Oral,0; 0.3; 1.0; 30; 300 ppm (reduced to 250 at wk 23) ppm of 94.9% of isazophos in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ISAZOPHOS (July 21, 1992)]"
6711,363906171,39223,CCOP(=S)(OCC)OC1=NN(C(=N1)Cl)C(C)C,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Female (60/Group),Oral,0; 0.3; 1.0; 30; 300 ppm of 94.9% of isazophos in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ISAZOPHOS (July 21, 1992)]"
6712,363906178,542762,C(C(=O)O)(Cl)Br,Active,,,,Rat,F344/N / Male (50/Group),Oral,"0; 250; 500; 1,000 mg/l in drinking water for 105 wk",Mesothelium: malignant mesothelioma; Large Intestine: adenoma;  Pancreatic Islet: adenoma (may have been related),Positive. Authors describe as clear evidence.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-549 Y09]"
6713,363906178,542762,C(C(=O)O)(Cl)Br,Active,,,,Rat,F344/N / Female (50/Group),Oral,"0; 250; 500; 1,000 mg/l in drinking water for 105 wk",Large Intestine: adenoma; Mammary Gland: multiple fibroadenomas; Pancreatic Islet: adenoma (may have been related),Positive (some of the p values do not reach significance.) Authors describe as clear evidence.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-549 Y09]"
6714,363906178,542762,C(C(=O)O)(Cl)Br,Active,,,,Mouse,B6C3F1 / Male (50/Group),Oral,"0; 250; 500; 1,000 mg/l in drinking water for 105 wk",Liver: hepatocellular neoplasms and hepatoblastoma,Positive. Authors describe as clear evidence,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-549 Y09]"
6715,363906178,542762,C(C(=O)O)(Cl)Br,Active,,,,Mouse,B6C3F1 / Female (50/Group),Oral,"0; 250; 500; 1,000 mg/l in drinking water for 105 wk",Liver: hepatocellular neoplasms,Positive. Authors describe as clear evidence,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-549 Y09]"
6716,363906185,163759,C1=CC=C2C(=C1)C=CC3=C2C4=C[C@@H]([C@H](C5=CC=CC3=C54)O)O,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
6717,363906185,163759,C1=CC=C2C(=C1)C=CC3=C2C4=C[C@@H]([C@H](C5=CC=CC3=C54)O)O,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
6718,363906205,115326,C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C5=C(C=C4)[C@@H]([C@H](C=C5)O)O,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
6719,363906205,115326,C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C5=C(C=C4)[C@@H]([C@H](C=C5)O)O,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.275; 1.1 UMOL(TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
6720,363906206,,,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.11; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
6721,363906206,,,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.11; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
6722,363906207,,,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 0.11; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WEEKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
6723,363906207,,,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 0.11; 0.275; 1.1 UMOL (TOTAL DOSE) ADMINISTERED OVER DAYS 1, 8, AND 15 OF LIFE (STUDY DURATION: 52 WKS)",LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA; LIVER: ADENOMA OR CARCINOMA,POSITIVE,"[LAVOIE,EJ, HE,ZM, WU,Y, MESCHTER,CL AND WEYAND,EH; TUMORIGENIC ACTIVITY OF THE 4,5-AND 9,10-DIHYDRODIOLS OF BENZO[J]FLUORANTHENE AND THEIR SYN- AND ANTI-DIOL EPOXIDES IN NEWBORN MICE; CANCER RES. 54(4):962-968, 1994]"
6724,363906254,154575,COC1=C(C=C(C=C1)C(=O)NC2=C(C=NC=C2Cl)Cl)OC3CCCC3,Active,,,,RAT,SPRAGUE-DAWLEY/MALE,INHALATION,0; 0.125; 0.5; 1.0 MG/KG BW/D 1 HR/D IN A DRY-POWDER FORMULATION WITH LACTOSE VEHICLE USING A NOSE-ONLY AEROSOL EXPOSURE FOR 104 WK (STUDY DURATION: 104 WK),NASAL OLFACTORY REGION: TUMORS,POSITIVE,"[PINO,MV VALERIO,MG MILLER,GK LARSON,JL ROSOLIA,DL JAYYOSI,Z CROUCH,CN TROJANOWSKI,JQ AND GEIGER,LE; TOXICOLOGIC AND CARCINOGENIC EFFECTS OF THE TYPE IV PHOSPHODIESTERASE INHIBITOR RP 73401 ON THE NASAL OLFACTORY TISSUE IN RATS; TOXICOL. PATHOL. 27(4):383-394, 1999]"
6725,363906254,154575,COC1=C(C=C(C=C1)C(=O)NC2=C(C=NC=C2Cl)Cl)OC3CCCC3,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 0.125; 0.5; 1.0 MG/KG BW/D 1 HR/D IN A DRY-POWDER FORMULATION WITH LACTOSE VEHICLE USING A NOSE-ONLY AEROSOL EXPOSURE FOR 102 WK (STUDY DURATION: 102 WK),NASAL OLFACTORY REGION: TUMORS,POSITIVE,"[PINO,MV VALERIO,MG MILLER,GK LARSON,JL ROSOLIA,DL JAYYOSI,Z CROUCH,CN TROJANOWSKI,JQ AND GEIGER,LE; TOXICOLOGIC AND CARCINOGENIC EFFECTS OF THE TYPE IV PHOSPHODIESTERASE INHIBITOR RP 73401 ON THE NASAL OLFACTORY TISSUE IN RATS; TOXICOL. PATHOL. 27(4):383-394, 1999]"
6726,363906255,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5.0% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[IMAZAWA,T NISHIKAWA,A FURUKAWA,F KASAHARA,K IKEDA,T TAKAHASHI,M AND HIROSE,M; LACK OF CARCINOGENICITY OF GARDENIA BLUE COLOR GIVEN CHRONICALLY IN THE DIET TO F344 RATS; FOOD CHEM. TOXICOL. 38(4):313-318, 2000]"
6727,363906255,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5.0% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[IMAZAWA,T NISHIKAWA,A FURUKAWA,F KASAHARA,K IKEDA,T TAKAHASHI,M AND HIROSE,M; LACK OF CARCINOGENICITY OF GARDENIA BLUE COLOR GIVEN CHRONICALLY IN THE DIET TO F344 RATS; FOOD CHEM. TOXICOL. 38(4):313-318, 2000]"
6728,363906260,56840998,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].[Cr+3],Unspecified,,,,,,,,,,[]
6729,363906359,93414,CC(COCC(C)OC(=O)C=C)OCC(C)OC(=O)C=C,Active,,,,MOUSE,TG.AC/FEMALE,DERMAL,0; 1; 5; 10 UMOL IN 200 UL ACETONE 3/WK FOR 20 WK (STUDY DURATION: 20 WK),SKIN: PAPILLOMA,POSITIVE,"[NYLANDER-FRENCH,LA AND FRENCH,JE; TRIPROPYLENE GLYCOL DIACRYLATE BUT NOT ETHYL ACRYLATE INDUCES SKIN TUMORS IN A TWENTY-WEEK SHORT-TERM TUMORIGENESIS STUDY IN TG.AC (V-HA-RAS) MICE; TOXICOL. PATHOL. 26(4):476-483, 1998]"
6730,363906374,148989,C1=CC=C2C(=C1)C=CC3=C2C=C4C=CC5=CC=CC=C5C4=C3[N+](=O)[O-],Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO (TOTAL DOSE) ADMINISTERED IN DOSES OF 1/7, 2/7, AND 4/7 OF THE TOTAL DOSE ON DAYS 1,8, AND 15 OF AGE, RESPECTIVELY (STUDY DURATION: 12 MO)",LIVER :ADENOMA,POSITIVE,"[FU,PP, VON TUNGELN,LS, CHIU,LH, ZHAN,DJ, DECK,J, BUCCI,T AND WANG,JC; STRUCTURE, TUMORIGENICITY, MICROSOMAL METABOLISM, AND DNA BINDING OF 7-NITRODIBENZ[A,H]ANTHRACENE; CHEM. RES. TOXICOL. 11(8):937-945, 1998]"
6731,363906398,7700,CCCCCCCCCC1=CC=C(C=C1)OCCO,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1000; 3000; 9000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[INOUE,H YAMAMOTO,T SHOJI,A WATARI,N HIROUCHI,Y ENOMOTO,M AND MORITA,K; ORAL CHRONIC TOXICITY AND CARCINOGENICITY TEST OF POLYOXYETHYLEN(10)NONYLPHENYL ETHER(NP-10)IN FEMALE F344; J. TOXICOL. SCI. 24(SUPPL. 2):167-193, 1999]"
6732,363906398,7700,CCCCCCCCCC1=CC=C(C=C1)OCCO,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 500; 1500; 4500 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[INOUE,H YAMAMOTO,T SHOJI,A WATARI,N HIROUCHI,Y ENOMOTO,M AND MORITA,K; CARCINOGENICITY TEST OF POLYOXYETHYLENE(10)NONYLPHENYL ETHER(NP-10) IN FEMALE B6C3F1 MICE; J. TOXICOL. SCI. 24(SUPPL. 2):149-166, 2000]"
6733,363906399,71485,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CCl)O)O)CCl)O)O)Cl)O,Inactive,,,,MOUSE,CD-1/MALE,ORAL,"0; 3000; 10,000; 30,000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK)",,NEGATIVE,"[MANN,SW YUSCHAK,MM AMYES,SJG AUGHTON,P AND FINN,JP; A CARCINOGENICITY STUDY OF SUCRALOSE IN THE CD-1 MOUSE; FOOD CHEM. TOXICOL. 38(SUPPL. 2):S91-S98, 2000]"
6734,363906399,71485,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CCl)O)O)CCl)O)O)Cl)O,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,"0; 3000; 10,000; 30,000 PPM IN DIET FOR 104 WK (STUDY DURATION: 104 WK)",,NEGATIVE,"[MANN,SW YUSCHAK,MM AMYES,SJG AUGHTON,P AND FINN,JP; A CARCINOGENICITY STUDY OF SUCRALOSE IN THE CD-1 MOUSE; FOOD CHEM. TOXICOL. 38(SUPPL. 2):S91-S98, 2000]"
6735,363906399,71485,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CCl)O)O)CCl)O)O)Cl)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 0.3; 1.0; 3.0% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MANN,SW YUSCHAK,MM AMYES,SJG AUGHTON,P AND FINN,JP; A COMBINED CHRONIC TOXICITY/CARINOGENICITY STUDY OF SUCRALOSE IN SPAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 38(SUPPL. 2):S71-S89, 2000]"
6736,363906399,71485,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CCl)O)O)CCl)O)O)Cl)O,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 0.3; 1.0; 3.0% IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[MANN,SW YUSCHAK,MM AMYES,SJG AUGHTON,P AND FINN,JP; A COMBINED CHRONIC TOXICITY/CARINOGENICITY STUDY OF SUCRALOSE IN SPAGUE-DAWLEY RATS; FOOD CHEM. TOXICOL. 38(SUPPL. 2):S71-S89, 2000]"
6737,363906420,12496962,C1=CC=C(C=C1)[N+]#N.OS(=O)(=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 10 UG/G BW IN 0.01 ML OF 0.9% SALINE 1/WK FOR 26 WK (STUDY DURATION: 140WK),SUBCUTANEOUS TISSUE: TUMOR,POSITIVE,"[TOTH,B, PATIL,K, ERICKSON,J AND GANNETT,P; CARCINOGENESIS BY BENZENEDIAZONIUM SULFATE IN MICE; IN VIVO 12(4):379-382, 1998]"
6738,363906420,12496962,C1=CC=C(C=C1)[N+]#N.OS(=O)(=O)[O-],Active,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 10 UG/G BW IN 0.01 ML OF 0.9% SALINE 1/WK FOR 26 WK (STUDY DURATION: 140 WK),SUBCUTANEOUS TISSUE: TUMOR,POSITIVE,"[TOTH,B, PATIL,K, ERICKSON,J AND GANNETT,P; CARCINOGENESIS BY BENZENEDIAZONIUM SULFATE IN MICE; IN VIVO 12(4):379-382, 1998]"
6739,363906420,12496962,C1=CC=C(C=C1)[N+]#N.OS(=O)(=O)[O-],Inactive,,,,MOUSE,SWISS/MALE,SUBCUTANEOUS,0; 25 MG/KG BW 1X/WK FOR 10 WK (STUDY DURATION: 120 WK),,NEGATIVE,"[TOTH,B PATIL,K ERICKSON,J AND GANNETT,P; CANCER INDUCTION STUDIES USING DIFFERENT ADMINISTRATIONS OF BENZENEDIAZONIUM SULFATE IN MICE; IN VIVO 13(2):125-128, 1999]"
6740,363906420,12496962,C1=CC=C(C=C1)[N+]#N.OS(=O)(=O)[O-],Active,,,,MOUSE,SWISS/MALE,GAVAGE,0; 100 MG/KG BW 1X/WK FOR 52 WK (STUDY DURATION: 130 WK),LUNG: TUMOR,POSITIVE,"[TOTH,B PATIL,K ERICKSON,J AND GANNETT,P; CANCER INDUCTION STUDIES USING DIFFERENT ADMINISTRATIONS OF BENZENEDIAZONIUM SULFATE IN MICE; IN VIVO 13(2):125-128, 1999]"
6741,363906420,12496962,C1=CC=C(C=C1)[N+]#N.OS(=O)(=O)[O-],Inactive,,,,MOUSE,SWISS/FEMALE,SUBCUTANEOUS,0; 25 MG/KG BW 1X/WK FOR 10 WK (STUDY DURATION: 130 WK),,NEGATIVE,"[TOTH,B PATIL,K ERICKSON,J AND GANNETT,P; CANCER INDUCTION STUDIES USING DIFFERENT ADMINISTRATIONS OF BENZENEDIAZONIUM SULFATE IN MICE; IN VIVO 13(2):125-128, 1999]"
6742,363906420,12496962,C1=CC=C(C=C1)[N+]#N.OS(=O)(=O)[O-],Active,,,,MOUSE,SWISS/FEMALE,GAVAGE,0; 100 MG/KG BW 1X/WK FOR 52 WK (STUDY DURATION: 140 WK),LUNG: TUMOR,POSITIVE,"[TOTH,B PATIL,K ERICKSON,J AND GANNETT,P; CANCER INDUCTION STUDIES USING DIFFERENT ADMINISTRATIONS OF BENZENEDIAZONIUM SULFATE IN MICE; IN VIVO 13(2):125-128, 1999]"
6743,363906431,38037,C1=CC(=CC(=C1)Cl)C2=CC(=CC(=C2)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,ORAL,0; 50; 100; 200 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 24 MO),,NEGATIVE,"[MAYES,BA, MCCONNELL,EE, NEAL,BH, BRUNNER,MJ, HAMILTON,SB, SULLIVAN,TM, PETERS,AC, RYAN,MJ, TOFT,JD, SINGER,AW, BROWN,JF,JR, MENTON,RG AND MOORE,JA; COMPARATIVE CARCINOGENICITY IN SPRAGUE-DAWLEY RATS OF THE POLYCHLORINATED BIPHENYL MIXTURES AROCLORS 1016, 1242, 1254, AND 1260; TOXICOL. SCI. 41(1):62-76, 1998]"
6744,363906431,38037,C1=CC(=CC(=C1)Cl)C2=CC(=CC(=C2)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 50; 100; 200 PPM IN DIET FOR THE DURATION OF STUDY (STUDY DURATION: 24 MO),LIVER: TUMOR,POSITIVE,"[MAYES,BA, MCCONNELL,EE, NEAL,BH, BRUNNER,MJ, HAMILTON,SB, SULLIVAN,TM, PETERS,AC, RYAN,MJ, TOFT,JD, SINGER,AW, BROWN,JF,JR, MENTON,RG AND MOORE,JA; COMPARATIVE CARCINOGENICITY IN SPRAGUE-DAWLEY RATS OF THE POLYCHLORINATED BIPHENYL MIXTURES AROCLORS 1016, 1242, 1254, AND 1260; TOXICOL. SCI. 41(1):62-76, 1998]"
6745,363906460,6328269,CCOP(=O)=O.CCOP(=O)=O.CCOP(=O)=O.[Al+3],Active,,,,Rat,CD Sprague-Dawley/Male (80/Group),Oral,0; 88; 348; 1372 mg/kg/day in diet for 24 mo; study duration 24 mo,"Adrenal medulla: pheochromocytoma (5/80, 7/79. 15/81, 16/81). Urinary bladder: Carcinoma and papilloma combined (1/78 in controls vs 14/79 at highest dose)",Positive. (Department of Pesticides Regulation reviewer described as a possible adverse effect.),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FOSETYL-AL (ALUMINUM TRIS (o-ETHYLPHOSPHONATE) (December 23,  1998)]"
6746,363906460,6328269,CCOP(=O)=O.CCOP(=O)=O.CCOP(=O)=O.[Al+3],Inactive,,,,Rat,CD Sprague-Dawley/Male (80/Group),Oral,0; 117; 450; 1786 mg/kg/day in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FOSETYL-AL (ALUMINUM TRIS (o-ETHYLPHOSPHONATE) (December 23,  1998)]"
6747,363906460,6328269,CCOP(=O)=O.CCOP(=O)=O.CCOP(=O)=O.[Al+3],Inactive,,,,Mouse,CD-1/Male (60/Group),Oral,"0; 2500; 10,000; 20,000 increased to 30,000 ppm at wk 19 of 96.9% fosetyl-Al in diet for 24 mo; study duration 24 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FOSETYL-AL (ALUMINUM TRIS (o-ETHYLPHOSPHONATE) (December 23,  1998)]"
6748,363906460,6328269,CCOP(=O)=O.CCOP(=O)=O.CCOP(=O)=O.[Al+3],Inactive,,,,Mouse,CD-1/Female (60/Group),Oral,"0; 2500; 10,000; 20,000 increased to 30,000 ppm at wk 19 of 96.9% fosetyl-Al in diet for 24 mo; study duration 24 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FOSETYL-AL (ALUMINUM TRIS (o-ETHYLPHOSPHONATE) (December 23,  1998)]"
6749,363906461,5282165,C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O,Inactive,,,,RAT,F344/MALE,ORAL,"0; 1.25, 2.5% IN DIET FOR 104 WK (STUDY DURATION: 106 WK)",,NEGATIVE,"[KASAHARA,K, NISHIKAWA,A, FURUKAWA,F, IKEZAKI,S, TANAKAMARU,Z, TAKAGI,H, IKEDA,T, IMAZAWA,T AND TAKAHASHI,M; SUPPRESSIVE EFFECTS OF JOSAMYCIN ON THE DEVELOPMENT OF ALTERED LIVER CELL FOCI AND CHRONIC NEPHROPATHY IN A CARCINGENICITY STUDY; FOOD CHEM. TOXICOL. 37(1):61-67, 1999]"
6750,363906461,5282165,C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1.25; 2.5% IN DIET FOR 104 WK (STUDY DURATION: 106 WK),,NEGATIVE,"[KASAHARA,K, NISHIKAWA,A, FURUKAWA,F, IKEZAKI,S, TANAKAMARU,Z, TAKAGI,H, IKEDA,T, IMAZAWA,T AND TAKAHASHI,M; SUPPRESSIVE EFFECTS OF JOSAMYCIN ON THE DEVELOPMENT OF ALTERED LIVER CELL FOCI AND CHRONIC NEPHROPATHY IN A CARCINGENICITY STUDY; FOOD CHEM. TOXICOL. 37(1):61-67, 1999]"
6751,363906463,114750,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N,Inactive,,,,MOUSE,CD-1/MALE,GAVAGE,0; 5; 15; 50 MG/KG 1/D 7 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[YAMAMURA,T, NISHIMURA,T, KUWAMURA,Y, INUI,T, AUGHTON,P AND KAWAI,Y; ONCOGENICITY STUDIES OF TALTIRELIN TETRAHYDRATE (TA-0910) BY ORAL (GAVAGE) ADMINISTRATION IN CD-1 MICE AND CD RATS; J. TOXICOL. SCI. 22(SUPPL.2):419-430, 1997]"
6752,363906463,114750,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N,Inactive,,,,MOUSE,CD-1/FEMALE,GAVAGE,0; 5; 15; 50 MG/KG 1/D 7 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[YAMAMURA,T, NISHIMURA,T, KUWAMURA,Y, INUI,T, AUGHTON,P AND KAWAI,Y; ONCOGENICITY STUDIES OF TALTIRELIN TETRAHYDRATE (TA-0910) BY ORAL (GAVAGE) ADMINISTRATION IN CD-1 MICE AND CD RATS; J. TOXICOL. SCI. 22(SUPPL.2):419-430, 1997]"
6753,363906463,114750,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N,Inactive,,,,RAT,STRAIN-CD/MALE,GAVAGE,0; 20; 60; 200 MG/KG 1/D 7 D/WK FOR 90 WK (STUDY DURATION: 90 WK),,NEGATIVE,"[YAMAMURA,T, NISHIMURA,T, KUWAMURA,Y, INUI,T, AUGHTON,P AND KAWAI,Y; ONCOGENICITY STUDIES OF TALTIRELIN TETRAHYDRATE (TA-0910) BY ORAL (GAVAGE) ADMINISTRATION IN CD-1 MICE AND CD RATS; J. TOXICOL. SCI. 22(SUPPL.2):419-430, 1997]"
6754,363906463,114750,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N,Inactive,,,,RAT,STRAIN-CD/FEMALE,GAVAGE,0; 20; 60; 200 MG/KG 1/D 7 D/WK FOR 94 WK (STUDY DURATION: 94 WK),,NEGATIVE,"[YAMAMURA,T, NISHIMURA,T, KUWAMURA,Y, INUI,T, AUGHTON,P AND KAWAI,Y; ONCOGENICITY STUDIES OF TALTIRELIN TETRAHYDRATE (TA-0910) BY ORAL (GAVAGE) ADMINISTRATION IN CD-1 MICE AND CD RATS; J. TOXICOL. SCI. 22(SUPPL.2):419-430, 1997]"
6755,363906466,17822,C(C(F)(F)F)(F)Cl,Inactive,,,,RAT,CRL:CD/MALE,INHALATION,"0; 2000; 10,000; 50,000 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR)",,NEGATIVE,"[MALLEY,LA, FRAME,SR, ELLIOTT,GS, BENTLY,KS, BROCK,WJ, TROCHIMOWICZ,HJ AND RUSCH,GM; CHRONIC TOXICITY, ONCOGENICITY, AND MUTAGENICITY STUDIES WITH CHLOROTETRAFLUOROETHANE (HCFC-124); DRUG CHEM. TOXICOL. 21(4):417-477, 1998]"
6756,363906466,17822,C(C(F)(F)F)(F)Cl,Inactive,,,,RAT,CRL:CD/FEMALE,INHALATION,"0; 2000; 10,000; 50,000 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR)",,NEGATIVE,"[MALLEY,LA, FRAME,SR, ELLIOTT,GS, BENTLY,KS, BROCK,WJ, TROCHIMOWICZ,HJ AND RUSCH,GM; CHRONIC TOXICITY, ONCOGENICITY, AND MUTAGENICITY STUDIES WITH CHLOROTETRAFLUOROETHANE (HCFC-124); DRUG CHEM. TOXICOL. 21(4):417-477, 1998]"
6757,363906474,24579,[O-]P1(=O)OP(=O)(OP(=O)(O1)[O-])[O-].[Na+].[Na+].[Na+],Inactive,,,,RAT,F344/MALE,ORAL,0; 1.5; 3% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 108 WK),,NEGATIVE,"[KITAHORI,Y, KONISHI,N, CHO,M, YAMAMOTO,K, NAKAGAWA,Y, MATSUI,E AND HIASA,Y; LACK OF CARCINOGENICITY OF SODIUM METAPHOSPHATE IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 11(1):41-47, 1998]"
6758,363906474,24579,[O-]P1(=O)OP(=O)(OP(=O)(O1)[O-])[O-].[Na+].[Na+].[Na+],Inactive,,,,RAT,F344/FEMALE,ORAL,0; 1.5; 3% IN DIET FOR DURATION OF STUDY (STUDY DURATION: 108 WK),,NEGATIVE,"[KITAHORI,Y, KONISHI,N, CHO,M, YAMAMOTO,K, NAKAGAWA,Y, MATSUI,E AND HIASA,Y; LACK OF CARCINOGENICITY OF SODIUM METAPHOSPHATE IN FISCHER 344 RATS; J. TOXICOL. PATHOL. 11(1):41-47, 1998]"
6759,363906476,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAVAGINAL,0; 20 UL OF 25% POLYVINYL ALCOHOL IN DEIONIZED WATER 5 D/WK FOR 105 WK (STUDY DURATION: 105 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-474  Y98]"
6760,363906482,,,Active,,,,MOUSE,C3H/MALE,DERMAL,0; 100% IN 50 UL MINERAL OIL 2/WK FOR 2 YR (STUDY DURATION: 2 YR),SKIN: PAPILLOMA OR CARCINOMA,POSITIVE,"[NESSEL,CS, PRISTON,RAJ, MCKEE,RH, CRUZAN,G, RILEY,AJ, HAGEMANN,R, PLUTNICK,RT AND SIMPSON,BJ; A COMPREHENSIVE EVALUATION OF THE MECHANISM OF SKIN TUMORIGENESIS BY STRAIGHT-RUN AND CRACKED PETROLEUM MIDDLE DISTILLATES; TOXICOL. SCI. 44(1):22-31, 1998]"
6761,363906482,,,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 50% IN 50 UL MINERAL OIL 4/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NESSEL,CS, PRISTON,RAJ, MCKEE,RH, CRUZAN,G, RILEY,AJ, HAGEMANN,R, PLUTNICK,RT AND SIMPSON,BJ; A COMPREHENSIVE EVALUATION OF THE MECHANISM OF SKIN TUMORIGENESIS BY STRAIGHT-RUN AND CRACKED PETROLEUM MIDDLE DISTILLATES; TOXICOL. SCI. 44(1):22-31, 1998]"
6762,363906482,,,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 28.5% IN 50 UL MINERAL OIL 7/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NESSEL,CS, PRISTON,RAJ, MCKEE,RH, CRUZAN,G, RILEY,AJ, HAGEMANN,R, PLUTNICK,RT AND SIMPSON,BJ; A COMPREHENSIVE EVALUATION OF THE MECHANISM OF SKIN TUMORIGENESIS BY STRAIGHT-RUN AND CRACKED PETROLEUM MIDDLE DISTILLATES; TOXICOL. SCI. 44(1):22-31, 1998]"
6763,363906483,,,Active,,,,MOUSE,C3H/MALE,DERMAL,0; 100% IN 50 UL MINERAL OIL 2/WK FOR 2 YR (STUDY DURATION: 2 YR),SKIN: PAPILLOMA OR CARCINOMA,POSITIVE,"[NESSEL,CS, PRISTON,RAJ, MCKEE,RH, CRUZAN,G, RILEY,AJ, HAGEMANN,R, PLUTNICK,RT AND SIMPSON,BJ; A COMPREHENSIVE EVALUATION OF THE MECHANISM OF SKIN TUMORIGENESIS BY STRAIGHT-RUN AND CRACKED PETROLEUM MIDDLE DISTILLATES; TOXICOL. SCI. 44(1):22-31, 1998]"
6764,363906483,,,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 50% IN 50 UL MINERAL OIL 4/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NESSEL,CS, PRISTON,RAJ, MCKEE,RH, CRUZAN,G, RILEY,AJ, HAGEMANN,R, PLUTNICK,RT AND SIMPSON,BJ; A COMPREHENSIVE EVALUATION OF THE MECHANISM OF SKIN TUMORIGENESIS BY STRAIGHT-RUN AND CRACKED PETROLEUM MIDDLE DISTILLATES; TOXICOL. SCI. 44(1):22-31, 1998]"
6765,363906483,,,Inactive,,,,MOUSE,C3H/MALE,DERMAL,0; 28.5% IN 50 UL MINERAL OIL 7/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[NESSEL,CS, PRISTON,RAJ, MCKEE,RH, CRUZAN,G, RILEY,AJ, HAGEMANN,R, PLUTNICK,RT AND SIMPSON,BJ; A COMPREHENSIVE EVALUATION OF THE MECHANISM OF SKIN TUMORIGENESIS BY STRAIGHT-RUN AND CRACKED PETROLEUM MIDDLE DISTILLATES; TOXICOL. SCI. 44(1):22-31, 1998]"
6766,363906486,123868,C[N+](C)(C)NCCC(=O)[O-],Inactive,,,,MOUSE,B6D2F1/FEMALE,GAVAGE,0; 400; 4000 MG/KG BW IN 0.2 ML WATER 3X/WK FOR 22 MONTHS (STUDY DURATION: 22 MONTHS),,NEGATIVE,"[BELITSKY,GA, KALVINSH,IY, ANISIMOV,VN, KHOVANOVA,EM, UGVINENKO,YG AND TOLCHEEV,YD;CONCERNING THE ABSENCE OF MUTAGENICITY AND CARCINOGENICITY OF MIDRONATE; VOPR. ONKOL. 45(3):279-282, 1999]"
6767,363906486,123868,C[N+](C)(C)NCCC(=O)[O-],Inactive,,,,MOUSE,C3H/FEMALE,ORAL,0; 0.1% IN DRINKING WATER FOR LIFETIME (STUDY DURATION: LIFETIME),,NEGATIVE,"[BELITSKY,GA, KALVINSH,IY, ANISIMOV,VN, KHOVANOVA,EM, UGVINENKO,YG AND TOLCHEEV,YD;CONCERNING THE ABSENCE OF MUTAGENICITY AND CARCINOGENICITY OF MIDRONATE; VOPR. ONKOL. 45(3):279-282, 1999]"
6768,363906486,123868,C[N+](C)(C)NCCC(=O)[O-],Inactive,,,,MOUSE,SHR/FEMALE,SUBCUTANEOUS,0; 0.1 MG IN ISOTONIC SALINE 1X/D FOR 5 D WITH 4-WK INTERVALS FOR LIFETIME (STUDY DURATION: LIFETIME),,NEGATIVE,"[BELITSKY,GA, KALVINSH,IY, ANISIMOV,VN, KHOVANOVA,EM, UGVINENKO,YG AND TOLCHEEV,YD;CONCERNING THE ABSENCE OF MUTAGENICITY AND CARCINOGENICITY OF MIDRONATE; VOPR. ONKOL. 45(3):279-282, 1999]"
6769,363906500,31339,CC(C)C(=O)OC[C@@H]1[C@H]([C@@H]([C@](O1)(COC(=O)C)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.5; 1; 2 G/KG BW IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MACKENZIE,KM, TISDEL,PJ, HALL,RL, BOYSEN,BG, FIELD,WE AND CHAPPEL,CI; ORAL TOXICITY AND CARCINOGENICITY STUDIES OF SUCROSE ACETATE ISOBUTYRATE (SAIB) IN THE FISCHER 344 RAT AND B6C3F1 MOUSE; FOOD CHEM. TOXICOL. 36(2):111-120, 1998]"
6770,363906500,31339,CC(C)C(=O)OC[C@@H]1[C@H]([C@@H]([C@](O1)(COC(=O)C)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0 0.5; 1; 2 G/KG BE IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MACKENZIE,KM, TISDEL,PJ, HALL,RL, BOYSEN,BG, FIELD,WE AND CHAPPEL,CI; ORAL TOXICITY AND CARCINOGENICITY STUDIES OF SUCROSE ACETATE ISOBUTYRATE (SAIB) IN THE FISCHER 344 RAT AND B6C3F1 MOUSE; FOOD CHEM. TOXICOL. 36(2):111-120, 1998]"
6771,363906500,31339,CC(C)C(=O)OC[C@@H]1[C@H]([C@@H]([C@](O1)(COC(=O)C)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 1.25; 2.5; 5 G/KG BW IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MACKENZIE,KM, TISDEL,PJ, HALL,RL, BOYSEN,BG, FIELD,WE AND CHAPPEL,CI; ORAL TOXICITY AND CARCINOGENICITY STUDIES OF SUCROSE ACETATE ISOBUTYRATE (SAIB) IN THE FISCHER 344 RAT AND B6C3F1 MOUSE; FOOD CHEM. TOXICOL. 36(2):111-120, 1998]"
6772,363906500,31339,CC(C)C(=O)OC[C@@H]1[C@H]([C@@H]([C@](O1)(COC(=O)C)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 1.25; 2.5; 5 G/KG BW IN DIET FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[MACKENZIE,KM, TISDEL,PJ, HALL,RL, BOYSEN,BG, FIELD,WE AND CHAPPEL,CI; ORAL TOXICITY AND CARCINOGENICITY STUDIES OF SUCROSE ACETATE ISOBUTYRATE (SAIB) IN THE FISCHER 344 RAT AND B6C3F1 MOUSE; FOOD CHEM. TOXICOL. 36(2):111-120, 1998]"
6773,363906500,31339,CC(C)C(=O)OC[C@@H]1[C@H]([C@@H]([C@](O1)(COC(=O)C)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C,Inactive,,,,MONKEY,CYNOMOLGUS/MALE,GAVAGE,0; 500; 1450; 2400 MG/KG BW 1X/D FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[BLAIR,M AND CHAPPEL,CI; 4-WEEK RANGE-FINDING AND 1-YEAR ORAL TOXICITY STUDIES OF SUCROSE ACETATE ISOBUTYRATE (SAIB) IN THE CYNOMOLGUS MONKEY; FOOD CHEM. TOXICOL. 36:121-126, 1998]"
6774,363906500,31339,CC(C)C(=O)OC[C@@H]1[C@H]([C@@H]([C@](O1)(COC(=O)C)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C)OC(=O)C(C)C,Inactive,,,,MONKEY,CYNOMOLGUS/FEMALE,GAVAGE,0; 500; 1450; 2400 MG/KG BW 1X/D FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[BLAIR,M AND CHAPPEL,CI; 4-WEEK RANGE-FINDING AND 1-YEAR ORAL TOXICITY STUDIES OF SUCROSE ACETATE ISOBUTYRATE (SAIB) IN THE CYNOMOLGUS MONKEY; FOOD CHEM. TOXICOL. 36:121-126, 1998]"
6775,363906503,11819368,C[C@H]1[C@H](O1)C2=CC=C(C=C2)OC,Active,,,,MOUSE,CD-1/FEMALE,DERMAL,"0; 5 UMOL 1X/WK FOR 3 WK BEGINNING 24 HR POST FIRST TPA DOSE (2.5 UG IN 0.1 ML ACETONE), FOLLOWED BY 2.5 UG TPA IN 0.1 ML ACETONE 2X/WK FOR 20 WK (STUDY DURATION: 20 WK)",SKIN: PAPILLOMA,POSITIVE,"[KIM,SG, LIEM,A, STEWART,BC AND MILLER,JA; NEW STUDIES ON TRANS-ANETHOLE OXIDE AND TRANS-ASARONE OXIDE; CARCINOGENESIS 20(7):1303-1307, 1999]"
6776,363906503,11819368,C[C@H]1[C@H](O1)C2=CC=C(C=C2)OC,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.25; 0.5 UMOL/G BW ONCE (STUDY DURATION: 10-11 MONTHS),LIVER: HEPATOMA,POSITIVE,"[KIM,SG, LIEM,A, STEWART,BC AND MILLER,JA; NEW STUDIES ON TRANS-ANETHOLE OXIDE AND TRANS-ASARONE OXIDE; CARCINOGENESIS 20(7):1303-1307, 1999]"
6777,363906504,,,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,"0; 5 UMOL 1X/WK FOR 3 WK BEGINNING 24 HR POST FIRST TPA DOSE (2.5 UG IN 0.1 ML ACETONE), FOLLOWED BY 2.5 UG TPA IN 0.1 ML ACETONE 2X/WK FOR 20 WK (STUDY DURATION: 20 WK)",,NEGATIVE,"[KIM,SG, LIEM,A, STEWART,BC AND MILLER,JA; NEW STUDIES ON TRANS-ANETHOLE OXIDE AND TRANS-ASARONE OXIDE; CARCINOGENESIS 20(7):1303-1307, 1999]"
6778,363906504,,,Active,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 0.125; 0.25; 0.5 UMOL/G BW ONCE (STUDY DURATION: 10-11 MONTHS),LIVER: HEPATOMA,POSITIVE,"[KIM,SG, LIEM,A, STEWART,BC AND MILLER,JA; NEW STUDIES ON TRANS-ANETHOLE OXIDE AND TRANS-ASARONE OXIDE; CARCINOGENESIS 20(7):1303-1307, 1999]"
6779,363906508,24849110,CCN(C(=O)C)N=O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 1000; 2000 PPM IN DRINKING WATER FOR 2 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[HIASA,Y PAUL,M HAYASHI,I MOCHIZUKI,M TSUTSUMI,H KUWASHIMA,S KITAHORI,Y AND KONISHI,N; CARCINOGENIC EFFECTS OF N-ETHYL-N-HYDROXYETHYLNITROSAMINE AND ITS METABOLITES IN RATS AND MICE; CANCER LETT. (SHANNON, IREL.) 145(1-2):143-149, 1999]"
6780,363906508,24849110,CCN(C(=O)C)N=O,Active,,,,MOUSE,BALB/C/MALE,ORAL,0; 1000; 2000 PPM IN DRINKING WATER FOR 2 WK (STUDY DURATION: 52 WK),LUNG: TUMOR,POSITIVE,"[HIASA,Y PAUL,M HAYASHI,I MOCHIZUKI,M TSUTSUMI,H KUWASHIMA,S KITAHORI,Y AND KONISHI,N; CARCINOGENIC EFFECTS OF N-ETHYL-N-HYDROXYETHYLNITROSAMINE AND ITS METABOLITES IN RATS AND MICE; CANCER LETT. (SHANNON, IREL.) 145(1-2):143-149, 1999]"
6781,363906509,170434,CCN(CC(=O)O)N=O,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 1000; 2000 PPM IN DRINKING WATER FOR 2 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[HIASA,Y PAUL,M HAYASHI,I MOCHIZUKI,M TSUTSUMI,H KUWASHIMA,S KITAHORI,Y AND KONISHI,N; CARCINOGENIC EFFECTS OF N-ETHYL-N-HYDROXYETHYLNITROSAMINE AND ITS METABOLITES IN RATS AND MICE; CANCER LETT. (SHANNON, IREL.) 145(1-2):143-149, 1999]"
6782,363906509,170434,CCN(CC(=O)O)N=O,Inactive,,,,MOUSE,BALB/C/MALE,ORAL,0; 1000; 2000 PPM IN DRINKING WATER FOR 2 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[HIASA,Y PAUL,M HAYASHI,I MOCHIZUKI,M TSUTSUMI,H KUWASHIMA,S KITAHORI,Y AND KONISHI,N; CARCINOGENIC EFFECTS OF N-ETHYL-N-HYDROXYETHYLNITROSAMINE AND ITS METABOLITES IN RATS AND MICE; CANCER LETT. (SHANNON, IREL.) 145(1-2):143-149, 1999]"
6783,363906519,86480,CCCC(CCC)C(=O)[O-].CCCC(CCC)C(=O)[O-].[Ca+2],Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 125; 250; 500 MG/KG BW IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[WATKINS,JR, GOUGH,AW, MCGUIRE,EJ, GOLDENTHAL,E AND DE LA IGLESIA,FA; CALCIUM VALPROATE-INDUCED UTERINE ADENOCARCINOMAS IN WISTAR RATS; TOXICOLOGY 71:35-47, 1992]"
6784,363906519,86480,CCCC(CCC)C(=O)[O-].CCCC(CCC)C(=O)[O-].[Ca+2],Active,,,,RAT,WISTAR/FEMALE,ORAL,0; 125; 250; 500 MG/KG BW IN DIET FOR 104 WK (STUDY DURATION: 104 WK),UTERUS: ADENOCARCINOMA,POSITIVE,"[WATKINS,JR, GOUGH,AW, MCGUIRE,EJ, GOLDENTHAL,E AND DE LA IGLESIA,FA; CALCIUM VALPROATE-INDUCED UTERINE ADENOCARCINOMAS IN WISTAR RATS; TOXICOLOGY 71:35-47, 1992]"
6785,363906521,160539,C1CC2=C3C1=CC=CC3=CC4=CC=CC=C24,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175; 437.5; 875 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",LUNG: ADENOMA OR ADENOCARCINOMA,POSITIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
6786,363906521,160539,C1CC2=C3C1=CC=CC3=CC4=CC=CC=C24,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175; 437.5; 875 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",,NEGATIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
6787,363906521,160539,C1CC2=C3C1=CC=CC3=CC4=CC=CC=C24,Inactive,,,,MOUSE,BLU:HA/MALE,INTRAPERITONEAL,"0; 175 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",,NEGATIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
6788,363906521,160539,C1CC2=C3C1=CC=CC3=CC4=CC=CC=C24,Inactive,,,,MOUSE,BLU:HA/FEMALE,INTRAPERITONEAL,"0; 175 UG/KG/D ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 9 MONTHS)",,NEGATIVE,"[WANG,JS, HE,X, MULDER,PPJ, BOERE,BB, CORNELISSE,J, LUGTENBURG,J AND BUSBY,WF,JR;COMPARATIVE TUMORIGENICITY OF THE CYCLOPENTA-FUSED POLYCYCLIC AROMATIC HYDROCARBONS ACEANTHRYLENE, DIHYDROACEANTHRYLENE AND ACEPHENANTHRYLENE IN PREWEANLING CD-1 AND BLU:HA MOUSE BIOASSAYS; CARCINOGENESIS 20(6):1137-1141, 1999]"
6789,363906523,150723,C1=CC=C2C(=C1)C=C3C4=CC=CC=C4C5=CC=CC=C5C3=C2[N+](=O)[O-],Inactive,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,"0; 400 NMOL IN 35 UL DMSO ON DAYS 1 (1/7 TOTAL DOSE), 8 (2/7 TOTAL DOSE), AND 15 (4/7 TOTAL DOSE) AFTER BIRTH (STUDY DURATION: 12 MONTHS)",,NEGATIVE,"[VON TUNGELN,LS XIA,Q HERRENO-SAENZ,D BUCCI,TJ HELFLICH,RH AND FU,PP; TUMORIGENICITY OF NITROPOLYCYCLIC AROMATIC HYDROCARBONS IN THE NEONATAL B6C3F1 MOUSE BIOASSAY AND CHARACTERIZATION OF RAS MUTATIONS IN LIVER TUMORS FROM TREATED MICE; CANCER LETT. (SHANNON, IREL.) 146(1):1-7, 1999]"
6790,363906525,125098,CCC(C)OC(=O)N1CCCCC1CCO,Inactive,,,,MOUSE,CD-1/MALE,DERMAL,0; 50; 100; 200 MG/KG BW FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[WAHLE,BS SANGHA,GK ELCOCK,LE SHEETS,LP AND CHRISTENSON,WR; CARCINOGENICITY TESTING IN THE CD-1 MOUSE OF A PROSPECTIVE INSECT REPELLANT (KBR 3023) USING THE DERMAL ROUTE OF EXPOSURE; TOXICOLOGY 142(1):29-39, 1999]"
6791,363906525,125098,CCC(C)OC(=O)N1CCCCC1CCO,Inactive,,,,MOUSE,CD-1/FEMALE,DERMAL,0; 50; 100; 200 MG/KG BW FOR 78 WK (STUDY DURATION: 78 WK),,NEGATIVE,"[WAHLE,BS SANGHA,GK ELCOCK,LE SHEETS,LP AND CHRISTENSON,WR; CARCINOGENICITY TESTING IN THE CD-1 MOUSE OF A PROSPECTIVE INSECT REPELLANT (KBR 3023) USING THE DERMAL ROUTE OF EXPOSURE; TOXICOLOGY 142(1):29-39, 1999]"
6792,363906525,125098,CCC(C)OC(=O)N1CCCCC1CCO,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,DERMAL,0; 50; 100; 200 MG/KG BW FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[WAHLE,BS SANGHA,GK LAKE,SG SHEETS,LP CROUTCH,C AND CHRISTENSON,WR; CHRONIC TOXICITY AND CARCINOGENICITY TESTING IN THE SPRAGUE-DAWLEY RAT OF A PROSPECTIVE INSECT REPELLANT (KRB 3023) USING THE DERMAL ROUTE OF EXPOSURE; TOXICOLOGY 142(1):41-56, 1999]"
6793,363906525,125098,CCC(C)OC(=O)N1CCCCC1CCO,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,DERMAL,0; 50; 100; 200 MG/KG BW FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[WAHLE,BS SANGHA,GK LAKE,SG SHEETS,LP CROUTCH,C AND CHRISTENSON,WR; CHRONIC TOXICITY AND CARCINOGENICITY TESTING IN THE SPRAGUE-DAWLEY RAT OF A PROSPECTIVE INSECT REPELLANT (KRB 3023) USING THE DERMAL ROUTE OF EXPOSURE; TOXICOLOGY 142(1):41-56, 1999]"
6794,363906526,233706,C1[C@@H](O1)[C@@H]2CO2,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 2.5; 5.0 PPM 6 HR/D 5 D/WK FOR 6 WK (STUDY DURATION: 84 WK),NASAL MUCOSA: TUMOR,POSITIVE,"[HENDERSON,RF HAHN,FF BARR,EB BELINSKY,SA MENACHE,MG AND BENSON,JM; CARCINOGENICITY OF INHALED BUTADIENE DIEPOXIDE IN FEMALE B6C3F1 MICE AND SPRAGUE-DAWLEY RATS; TOXICOL. SCI. 52(1):33-44, 1999]"
6795,363906526,233706,C1[C@@H](O1)[C@@H]2CO2,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 2.5; 5.0 PPM 6 HR/D 5 D/WK FOR 6 WK (STUDY DURATION: 84 WK),HARDERIAN GLAND: TUMOR,POSITIVE,"[HENDERSON,RF HAHN,FF BARR,EB BELINSKY,SA MENACHE,MG AND BENSON,JM; CARCINOGENICITY OF INHALED BUTADIENE DIEPOXIDE IN FEMALE B6C3F1 MICE AND SPRAGUE-DAWLEY RATS; TOXICOL. SCI. 52(1):33-44, 1999]"
6796,363906527,24404,P,Inactive,,,,RAT,F344/MALE,INHALATION,0; 0.3; 1.0; 3.0 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NEWTON,PE HILASKI,RJ BANAS,DA WILSON,NH BUSEY,WM AND SHAHEEN,DG; A 2-YEAR INHALATION STUDY OF PHOSPHINE IN RATS; INHALATION TOXICOL. 11(8):693-708, 1999]"
6797,363906527,24404,P,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 0.3; 1.0; 3.0 PPM 6 HR/D 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[NEWTON,PE HILASKI,RJ BANAS,DA WILSON,NH BUSEY,WM AND SHAHEEN,DG; A 2-YEAR INHALATION STUDY OF PHOSPHINE IN RATS; INHALATION TOXICOL. 11(8):693-708, 1999]"
6798,363906528,9521,C(CN)N.Cl.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 20; 100; 350 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HERMANSKY,SJ YANG,RSH GARMAN,RH AND LEUNG,HW; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF ETHYLENEDIAMINE DIHYDROCHLORIDE BY DIETARY INCORPORATION IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 37(7):765-776, 1999]"
6799,363906528,9521,C(CN)N.Cl.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 20; 100; 350 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HERMANSKY,SJ YANG,RSH GARMAN,RH AND LEUNG,HW; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF ETHYLENEDIAMINE DIHYDROCHLORIDE BY DIETARY INCORPORATION IN FISCHER 344 RATS; FOOD CHEM. TOXICOL. 37(7):765-776, 1999]"
6800,363906529,449459,CC/C(=C(\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,DERMAL,0; 20; 140; 1000 UG/KG/D FOR 101 WK (STUDY DURATION: 101 WK),,NEGATIVE,"[SAUVEZ,F, DROUIN,DS, ATTIA,M, BERTHEUX,H AND FORSTER,R; CUTANEOUSLY APPLIED 4-HYDROXYTAMOXIFEN IS NOT CARCINOGENIC IN FEMALE RATS; CARCINOGENESIS 20(5):843-850, 1999]"
6801,363906530,6917,C=CN1CCCC1=O,Active,,,,RAT,SPRAGUE-DAWLEY/ MALE,INHALATION,0; 5; 10; 20 PPM 6 HR/D 5D/WK FOR 24 MO (STUDY DURATION: 24 MO),"LARYNX: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA; NASAL CAVITY: ADENOCARCINOMA, ADENOMA",POSITIVE,"[KLIMISCH,HJ, DECKARDT,K, GEMBARDT,CHR, HILDEBRAND,B, KUTTLER,K AND ROE,FJC; LONG-TERM INHALATION TOXICITY OF N-VINYLPYRROLIDONE-2 VAPOURS. STUDIES IN RATS; FOOD CHEM. TOXICOL. 35(10/11):1041-1060, 1997]"
6802,363906530,6917,C=CN1CCCC1=O,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INHALATION,0; 5; 10; 20 PPM 6 HR/D 5 D/WK FOR 24 MO (STUDY DURATION: 24 MO),"LARYNX: SQUAMOUS CELL CARCINOMA; LIVER: HEPATOCELLULAR CARCINOMA; NASAL CAVITY: ADENOCARCINOMA, ADENOMA",POSITIVE,"[KLIMISCH,HJ, DECKARDT,K, GEMBARDT,CHR, HILDEBRAND,B, KUTTLER,K AND ROE,FJC; LONG-TERM INHALATION TOXICITY OF N-VINYLPYRROLIDONE-2 VAPOURS. STUDIES IN RATS; FOOD CHEM. TOXICOL. 35(10/11):1041-1060, 1997]"
6803,363906536,,,Inactive,,,,RAT,F344/MALE,ORAL,0; 2.5; 5% IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[SHODA,T, TOYODA,K, UNEYAMA,C, TAKADA,K AND TAKAHASHI,M; LACK OF CARCINOGENICITY OF MEDIUM-VISCOSITY LIQUID PARAFFIN GIVEN IN THE DIET TO F344 RATS; FOOD CHEM. TOXICOL. 35(12):1181-1190, 1997]"
6804,363906536,,,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 2.5; 5% IN THE DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[SHODA,T, TOYODA,K, UNEYAMA,C, TAKADA,K AND TAKAHASHI,M; LACK OF CARCINOGENICITY OF MEDIUM-VISCOSITY LIQUID PARAFFIN GIVEN IN THE DIET TO F344 RATS; FOOD CHEM. TOXICOL. 35(12):1181-1190, 1997]"
6805,363906537,27200,CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O,Inactive,,,,RAT,F344/MALE,ORAL,0; 125; 250 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[KITAMURA,T, ANDO,J, ISHIHARA,R, TAKANO,S, IIJIMA,T, NISHIMURA,S, YOSHIDA,M, TAKAHASHI,M AND MAEKAWA,A; LACK OF CARCINOGENICITY OF THIAMPHENICOL IN F344 RATS; FOOD CHEM. TOXICOL. 35(10/11):1075-1080, 1997]"
6806,363906537,27200,CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 125; 250 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 108 WK),,NEGATIVE,"[KITAMURA,T, ANDO,J, ISHIHARA,R, TAKANO,S, IIJIMA,T, NISHIMURA,S, YOSHIDA,M, TAKAHASHI,M AND MAEKAWA,A; LACK OF CARCINOGENICITY OF THIAMPHENICOL IN F344 RATS; FOOD CHEM. TOXICOL. 35(10/11):1075-1080, 1997]"
6807,363906538,54690031,CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3,Inactive,,,,RAT,SPRAGUE-DAWLEY/MALE,GAVAGE,0; 0.0625; 0.125; 0.250 MG/KG BW/D FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[POHLMEYER-ESCH,G, MEHDI,N, CLARKE,D AND RADHOFER-WELTE,S; EVALUATION OF CHRONIC ORAL TOXICITY AND CARCINOGENIC POTENTIAL OF LORNOXICAM IN RATS; FOOD CHEM. TOXICOL. 35(9):909-922, 1997]"
6808,363906538,54690031,CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 0.0625; 0.125; 0.250 MG/KG BW/D FOR 104 WK; HIGH DOSE REDUCED TO 0.0200 MG/KG FROM STUDY WK 42 TO 50 THEN TO 0.160 MG/KG FOR THE DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[POHLMEYER-ESCH,G, MEHDI,N, CLARKE,D AND RADHOFER-WELTE,S; EVALUATION OF CHRONIC ORAL TOXICITY AND CARCINOGENIC POTENTIAL OF LORNOXICAM IN RATS; FOOD CHEM. TOXICOL. 35(9):909-922, 1997]"
6809,363906555,1982,CC(=O)NP(=O)(OC)SC,Inactive,,,,Mouse,CD-1/Male,Oral,0; 50; 250; 1000 ppm (0; 7; 36; 146 mg/kg/d) in feed for 104 wk,,"Negative; Purity = 92.7, 92.1%","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACEPHATE (FEBRUARY 9, 2004)]"
6810,363906555,1982,CC(=O)NP(=O)(OC)SC,Inactive,,,,Mouse,CD-1/Female,Oral,0; 50; 250; 1000 ppm (0; 8; 42; 167 mg/kg/d) in feed for 104 wk,Liver: Hepatocellular carcinoma and adenoma (highest dose only),"Negative; Purity = 92.7, 92.1%","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACEPHATE (FEBRUARY 9, 2004)]"
6811,363906580,,,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.01; 0.03; 0.1; 0.6; 1% (COAL TAR COMPOSITE FROM 7 WASTE SITES) IN DIET FOR 2 YR (STUDY DURATION:2 YR),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; FORESTOMACH: PAPILLOMA OR CARCINOMA; SMALL INTESTINE: ADENOCARCINOMA,POSITIVE,"[CULP,SJ, GAYLOR,DW, SHELDON,WG, GOLDSTEIN,LS AND BELAND,FA; A COMPARISON OF THE TUMORS INDUCED BY COAL TAR AND BENZO[A]PYRENE IN A 2-YEAR BIOASSAY; CARCINOGENESIS 19(1):117-124, 1998]"
6812,363906580,,,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 0.03; 0.1; 0.3% (COAL TAR COMPOSITE FROM 3 WASTE SITES) IN DIET FOR 2 YR (STUDY DURATION: 2 YR),LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA; FORESTOMACH: PAPILLOMA OR CARCINOMA,POSITIVE,"[CULP,SJ, GAYLOR,DW, SHELDON,WG, GOLDSTEIN,LS AND BELAND,FA; A COMPARISON OF THE TUMORS INDUCED BY COAL TAR AND BENZO[A]PYRENE IN A 2-YEAR BIOASSAY; CARCINOGENESIS 19(1):117-124, 1998]"
6813,363906583,122073,CC1=C(C(C(=C(N1)C)C(=O)OCCC2=CC=C(C=C2)N3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5)C6=CC(=CC=C6)[N+](=O)[O-])C(=O)OC,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 30; 90; 300 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ISHIDA,S, IKEYA,M, FUKUZUMI,H, TAMURA,K, HATAYAMA,K, ISHII,S, KAWABATA,Y, KOSHIBA,H AND ABE,S; CARCINOGENICITY STUDY OF WATANIDIPINE HYDROCHLORIDE IN MICE BY DIETARY ADMINISTRATION; YAKURI TO CHIRYO 25(SUPPL. 3):685-704, 1997]"
6814,363906583,122073,CC1=C(C(C(=C(N1)C)C(=O)OCCC2=CC=C(C=C2)N3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5)C6=CC(=CC=C6)[N+](=O)[O-])C(=O)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 30; 90; 300 PPM IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[ISHIDA,S, IKEYA,M, FUKUZUMI,H, TAMURA,K, HATAYAMA,K, ISHII,S, KAWABATA,Y, KOSHIBA,H AND ABE,S; CARCINOGENICITY STUDY OF WATANIDIPINE HYDROCHLORIDE IN MICE BY DIETARY ADMINISTRATION; YAKURI TO CHIRYO 25(SUPPL. 3):685-704, 1997]"
6815,363906583,122073,CC1=C(C(C(=C(N1)C)C(=O)OCCC2=CC=C(C=C2)N3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5)C6=CC(=CC=C6)[N+](=O)[O-])C(=O)OC,Inactive,,,,RAT,F344/MALE,ORAL,0; 30; 90; 300 PPM IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[ISHIDA,S, IKEYA,M, FUKUZUMI,H, TAMURA,K, HATAYAMA,K, ISHII,S, KAWABATA,Y, KOSHIBA,H AND ABE,S; CARCINOGENICITY STUDY OF WATANIDIPINE HYDROCHLORIDE IN RATS BY DIETARY ADMINISTRATION; YAKURI TO CHIRYO 25(SUPPL. 3):705-728, 1997]"
6816,363906583,122073,CC1=C(C(C(=C(N1)C)C(=O)OCCC2=CC=C(C=C2)N3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5)C6=CC(=CC=C6)[N+](=O)[O-])C(=O)OC,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 30; 90; 300 PPM IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[ISHIDA,S, IKEYA,M, FUKUZUMI,H, TAMURA,K, HATAYAMA,K, ISHII,S, KAWABATA,Y, KOSHIBA,H AND ABE,S; CARCINOGENICITY STUDY OF WATANIDIPINE HYDROCHLORIDE IN RATS BY DIETARY ADMINISTRATION; YAKURI TO CHIRYO 25(SUPPL. 3):705-728, 1997]"
6817,363906614,67215,CN(C)C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC=C(C=C3)N(C)C,Unspecified,,,,RAT,F344/N/MALE,ORAL (DIET),0; 91; 272; 543 PPM IN DIET FOR 2 YRS,TESTIS: INTERSTITIAL CELL ADENOMA; THYROID: FOLLICULAR CELL ADENOMA OR CARCINOMA,EQUIVOCAL; THYROID TUMORS DID NOT REACH STATISTICAL SIGNIFICANCE,"[CULP,SJ; NTP TECHNICAL REPORT ON THE TOXICITY STUDIES OF MALACHITE GREEN CHLORIDE AND LEUCOMALACHITE GREEN (CAS NOS. 569-64-2 AND 129-73-7) ADMINISTERED IN FEED TO F344/N RATS AND B6C3F1 MICE; NATL. TOXICOL. PROG. TOXI. REP. SER. 71:1-5, 7-9, 11-49, A1-A7, B1-B7, C1-C9, D1-D5, E1-E6, F1-F10, 2004]"
6818,363906614,67215,CN(C)C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC=C(C=C3)N(C)C,Active,,,,MOUSE,B6C3F1/FEMALE,ORAL (DIET),0; 91; 204; 408 PPM IN DIET FOR 2 YRS,LIVER: HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE; INCIDENCE OF TUMORS WAS STATISTICALLY SIGNIFICANT,"[CULP,SJ; NTP TECHNICAL REPORT ON THE TOXICITY STUDIES OF MALACHITE GREEN CHLORIDE AND LEUCOMALACHITE GREEN (CAS NOS. 569-64-2 AND 129-73-7) ADMINISTERED IN FEED TO F344/N RATS AND B6C3F1 MICE; NATL. TOXICOL. PROG. TOXI. REP. SER. 71:1-5, 7-9, 11-49, A1-A7, B1-B7, C1-C9, D1-D5, E1-E6, F1-F10, 2004]"
6819,363906614,67215,CN(C)C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC=C(C=C3)N(C)C,Unspecified,,,,RAT,F344/N/FEMALE,DIET,0; 91; 272; 543 PPM IN DIET FOR 2 YRS,LIVER: HEPATOCELLULAR ADENOMA; THYROID: FOLLICULAR CELL ADENOMA OR CARCINOMA,"EQUIVOCAL; NONE OF THE TUMOR INCIDENCES REACHED STATISTICAL SIGNIFICANCE; FOR THE THYROID, THE INCREASE IN TUMORS WAS MINIMAL","[CULP,SJ; NTP TECHNICAL REPORT ON THE TOXICITY STUDIES OF MALACHITE GREEN CHLORIDE AND LEUCOMALACHITE GREEN (CAS NOS. 569-64-2 AND 129-73-7) ADMINISTERED IN FEED TO F344/N RATS AND B6C3F1 MICE; NATL. TOXICOL. PROG. TOXI. REP. SER. 71:1-5, 7-9, 11-49, A1-A7, B1-B7, C1-C9, D1-D5, E1-E6, F1-F10, 2004]"
6820,363906633,2725002,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC.O.O.Cl.Cl,Inactive,,,,Mouse,CD-1/Female (23/24)/(24/24)(23/24)(22/23),Intraperitoneal,0; 10; 50; 150 mg/kg on days 8 and 15 after birth (Study duration: 52 weeks) (Test material solvent: 1% w/v carboxymethyl cellulose in 0.9% saline),,Negative,"[CANCEL,A, SMITH,T, REHKEMPER,U, DILLBERGER,J, SOKAL,D, AND MCCLAIN,R; INTERNATIONAL JOURNAL OF TOXICOLOGY 25(2):109-118, 2006]"
6821,363906633,2725002,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC.O.O.Cl.Cl,Inactive,,,,Mouse,CD-1/Male (32/32)/(23/24)(23/24)(25/25),Intraperitoneal,0; 10; 50; 150 mg/kg on days 8 and 15 after birth (Study duration: 52 weeks) (Test material solvent: 1% w/v carboxymethyl cellulose in 0.9% saline),,Negative,"[CANCEL,A, SMITH,T, REHKEMPER,U, DILLBERGER,J, SOKAL,D, AND MCCLAIN,R; INTERNATIONAL JOURNAL OF TOXICOLOGY 25(2):109-118, 2006]"
6822,363906634,68554,CC1=C(C(=CC=C1)C)NC2=NCCCS2.Cl,Active,,,,RAT,F344/MALE,ORAL,"0; 1,000 PPM IN FEED FOR 52 WK (STUDY DURATION: 52 WK)",THYROID: ADENOMA,POSITIVE,"[YASUHARA,K KOUJITANI,T TAKEGAWA,K NASU,M ONODERA,H TAKAGI,H HIROSE,M AND MITSUMORI,K; PROMOTING EFFECT OF XYLAZINE ON DEVELOPMENT OF THYROID TUMORS IN RATS INITIATED WITH N-BIS(2-HYDROXYPROPYL)NITROSAMINE AND THE MECHANISM OF ACTION; CARCINOGENESIS 22(4):613-618, 2001]"
6823,363906639,152946,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,Inactive,,,,RAT,"WISTAR/MALE, FEMALE",GAVAGE,0; 500 MG/KG BW/D FOR 38 WK (STUDY DURATION: 38 WK),,NEGATIVE,"[IATROPOULOS,MJ JEFFREY,AM ENZMANN,HG VON KEUTZ,E SCHLUETER,G AND WILLIAMS,GM; ASSESSMENT OF CHRONIC TOXICITY AND CARCINOGENICITY IN AN ACCELERATED CANCER BIOASSAY IN RATS OF MOXIFLOXACIN, A QUINOLONE ANTIBIOTIC; EXP. TOXICOL. PATHOL. 53(5):345-357, 2001]"
6824,363906658,247304,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)O)O,Active,,,,MOUSE,CD-1/FEMALE,SUBCUTANEOUS,0; 2 UG/D IN CORN OIL ON DAYS 1-5 OF LIFE (STUDY DURATION: 12-18 WK),UTERUS: ADENOCARCINOMA,POSITIVE,"[NEWBOLD,RR AND LIEHR,JG; INDUCTION OF UTERINE ADENOCARCINOMA IN CD-1 MICE BY CATECHOL ESTROGENS; CANCER RES. 60(2):235-237, 2000]"
6825,363906659,5282360,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4O)O,Active,,,,MOUSE,CD-1/FEMALE,SUBCUTANEOUS,0; 2 UG/D IN CORN OIL ON DAYS 1-5 OF LIFE (STUDY DURATION: 12-18 WK),UTERUS: ADENOCARCINOMA,POSITIVE,"[NEWBOLD,RR AND LIEHR,JG; INDUCTION OF UTERINE ADENOCARCINOMA IN CD-1 MICE BY CATECHOL ESTROGENS; CANCER RES. 60(2):235-237, 2000]"
6826,363906659,5282360,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4O)O,Inactive,,,,Mouse,CD-1/Female (45/experimental group; 40/control group),Subcutaneous,"0; 2 ug in peanut oil; dosed on days 1-5 of life and retained for 1.5 (4 animals), 3 (4 animals), 6 (4 animals), 9 (4 animals), 12 (4 animals) or 18 (25 experimental animals and 20 control animals) months",Uterus and ovaries examined,Negative; nonneoplastic changes observed,"[RAZVI,N GREAVES,P STYLES,J EDWARDS,R AND WHITE,INH; ABSENCE OF UTERINE TUMOURS IN CD-1 MICE TREATED NEONATALLY WITH SUBCUTANEOUS TAMOXIFEN OR 4-HYDROXYOESTRADIOL; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 59(3-4):177-85, 2007]"
6827,363906748,31170,P#[In],Active,,,,RAT,F344/FEMALE,INHALATION,0; 0.03; 0.1; 0.3 MG/M3 AEROSOL FOR 6 HR/D 5 D/WK FOR 105 WK (CONTROL AND LOW DOSE GROUPS) OR 22 WK (MID AND HIGH DOSE GROUPS)(STUDY DURATION: 105 WK),"ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-499 Y01][ANON; NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF INDIUM PHOSPHIDE (CAS NO. 22398-80-7) IN F344/N RATS AND B6C3F1 MNICE (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 499:1-5, 7-23, 25-89, 91-101, 103, 105-185, 187-229, 231-311, 313-340, 6 PLATES, 2001, ]"
6828,363906748,31170,P#[In],Active,,,,RAT,F344/MALE,INHALATION,0; 0.03; 0.1; 0.3 MG/M3 AEROSOL FOR 6 HR/D 5 D/WK FOR 105 WK (CONTROL AND LOW DOSE GROUPS) OR 22 WK (MID AND HIGH DOSE GROUPS)(STUDY DURATION: 105 WK),"ADRENAL MEDULLA: BENIGN PHEOCHROMOCYTOMA, BENIGN OR MALIGNANT PHEOCHROMOCYTOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA, SQUAMOUS CELL CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-499 Y01][ANON; NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF INDIUM PHOSPHIDE (CAS NO. 22398-80-7) IN F344/N RATS AND B6C3F1 MNICE (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 499:1-5, 7-23, 25-89, 91-101, 103, 105-185, 187-229, 231-311, 313-340, 6 PLATES, 2001, ]"
6829,363906748,31170,P#[In],Active,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 0.03; 0.1; 0.3 MG/M3 AEROSOL FOR 6 HR/D 5 D/WK FOR 105 WK (CONTROL AND LOW DOSE GROUPS) OR 21 WK (MID AND HIGH DOSE GROUPS)(STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-499 Y01][ANON; NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF INDIUM PHOSPHIDE (CAS NO. 22398-80-7) IN F344/N RATS AND B6C3F1 MNICE (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 499:1-5, 7-23, 25-89, 91-101, 103, 105-185, 187-229, 231-311, 313-340, 6 PLATES, 2001, ]"
6830,363906748,31170,P#[In],Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 0.03; 0.1; 0.3 MG/M3 AEROSOL FOR 6 HR/D 5 D/WK FOR 105 WK (CONTROL AND LOW DOSE GROUPS) OR 21 WK (MID AND HIGH DOSE GROUPS)(STUDY DURATION: 105 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-499 Y01][ANON; NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF INDIUM PHOSPHIDE (CAS NO. 22398-80-7) IN F344/N RATS AND B6C3F1 MNICE (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER., 499:1-5, 7-23, 25-89, 91-101, 103, 105-185, 187-229, 231-311, 313-340, 6 PLATES, 2001, ]"
6831,363906750,101644674,C1=C(C(=C(C(=C1SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O,Active,,,,RAT,EKER(TSC2 MUTANT)/MALE,INTRAPERITIONEAL,0; 2.5 UMOL/KG BW 5 BW 5 D/WK FOR 4 MO FOLLOWED BY 3.5 UMOL/KG BW 5 D/WK FOR 6 MO (STUDY DURATION: 10 MO),KIDNEY: ADENOMA OR CARCINOMA,POSITIVE,"[LAU,SS MONKS,TJ EVERITT,JI KLEYMENOVA,E AND WALKER,CL; CARCINOGENICITY OF A NEPHROTOXIC METABOLITE OF THE NONGENOTOXIC CARCINOGEN HYDROQUINONE; CHEM. RES. TOXICOL. 14(1):25-33, 2001]"
6832,363906752,2776282,C(=O)(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)[O-].[NH4+],Active,,,,RAT,CD-1/MALE,ORAL,0; 300 PPM IN DIET FOR 2 YR (STUDY DURATION: 2 YR),"LIVER: ADENOMA, ADENOMA OR CARCINOMA; TESTES: LEYDIG CELL ADENOMA; PANCREAS: ACINAR CELL ADENOMA, ACINAR CELL ADENOMA OR CARCINOMA",POSITIVE,"[BIEGEL,LB HURTT,ME FRAME,SR O'CONNOR,JC AND COOK,JC; MECHANISMS OF EXTRAHEPATIC TUMOR INDUCTION BY PEROXISOME PROLIFERATORS IN MALE CD RATS; TOXICOL. SCI. 60(1):44-55, 2001]"
6833,363906762,6625,C1=CC(=CC=C1S(=O)(=O)C2=CC=C(C=C2)Cl)Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 10; 30; 100; 300 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[CHHABRA,RS HERBERT,RA BUCHER,JR TRAVLOS,GS JOHNSON,JD AND HEJTMANCIK,MR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF P,P'-DICHLORODIPHENYL SULFONE IN RATS AND MICE; TOXICOL. SCI. 60(1):28-37, 2001]"
6834,363906762,6625,C1=CC(=CC=C1S(=O)(=O)C2=CC=C(C=C2)Cl)Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 30; 100; 300 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[CHHABRA,RS HERBERT,RA BUCHER,JR TRAVLOS,GS JOHNSON,JD AND HEJTMANCIK,MR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF P,P'-DICHLORODIPHENYL SULFONE IN RATS AND MICE; TOXICOL. SCI. 60(1):28-37, 2001]"
6835,363906762,6625,C1=CC(=CC=C1S(=O)(=O)C2=CC=C(C=C2)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/MALE,ORAL,0; 30; 100; 300 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[CHHABRA,RS HERBERT,RA BUCHER,JR TRAVLOS,GS JOHNSON,JD AND HEJTMANCIK,MR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF P,P'-DICHLORODIPHENYL SULFONE IN RATS AND MICE; TOXICOL. SCI. 60(1):28-37, 2001]"
6836,363906762,6625,C1=CC(=CC=C1S(=O)(=O)C2=CC=C(C=C2)Cl)Cl,Inactive,,,,MOUSE,B6C3F1/FEMALE,ORAL,0; 30; 100; 300 PPM IN DIET FOR 104-105 WK (STUDY DURATION: 104-105 WK),,NEGATIVE,"[CHHABRA,RS HERBERT,RA BUCHER,JR TRAVLOS,GS JOHNSON,JD AND HEJTMANCIK,MR; TOXICOLOGY AND CARCINOGENESIS STUDIES OF P,P'-DICHLORODIPHENYL SULFONE IN RATS AND MICE; TOXICOL. SCI. 60(1):28-37, 2001]"
6837,363906773,,,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6838,363906773,,,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6839,363906774,151986,C1CC2=C([C@@H]3[C@H]1O3)C4=C(C=C2)C=C5C=CC6=CC=CC=C6C5=N4,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 28 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 35-36 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6840,363906774,151986,C1CC2=C([C@@H]3[C@H]1O3)C4=C(C=C2)C=C5C=CC6=CC=CC=C6C5=N4,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 28 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 35-36 WK)",LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6841,363906775,151985,C1CC2=C([C@H]3[C@@H]1O3)C4=C(C=C2)C=C5C=CC6=CC=CC=C6C5=N4,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 28 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 35-36 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6842,363906775,151985,C1CC2=C([C@H]3[C@@H]1O3)C4=C(C=C2)C=C5C=CC6=CC=CC=C6C5=N4,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 28 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 35-36 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6843,363906776,,,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6844,363906776,,,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6845,363906777,,,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6846,363906777,,,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6847,363906778,,,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6848,363906778,,,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6849,363906779,12628781,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@H]([C@@H](C=C5)O)O)N=C32,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6850,363906779,12628781,C1=CC=C2C(=C1)C=CC3=CC4=C(C5=C(C=C4)[C@H]([C@@H](C=C5)O)O)N=C32,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6851,363906780,180266,C1CC2=C(C=CC3=C2N=C4C(=C3)C=CC5=CC=CC=C54)[C@@H]([C@H]1O)O,Inactive,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6852,363906780,180266,C1CC2=C(C=CC3=C2N=C4C(=C3)C=CC5=CC=CC=C54)[C@@H]([C@H]1O)O,Inactive,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",,NEGATIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6853,363906781,,,Active,,,,MOUSE,CD-1/MALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LIVER: TUMOR; LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6854,363906781,,,Active,,,,MOUSE,CD-1/FEMALE,INTRAPERITONEAL,"0; 175 NMOL (TOTAL DOSE) ADMINISTERED AS 1/7 OF DOSE WITHIN 24 HR AFTER BIRTH, 2/7 OF DOSE AT 8 D OLD, 4/7 OF DOSE AT 15 D OLD (STUDY DURATION: 36-39 WK)",LUNG: TUMOR,POSITIVE,"[CHANG,RL WOOD,AW KUMAR,S LEHR,RE SHIRAI,N JERINA,DM AND CONNEY,AH; TUMORIGENICITY OF FOUR OPTICALLY ACTIVE BAY-REGION 3,4-DIOL 1,2-EPOXIDES AND OTHER DERIVATIVES OF THE NITROGEN HETEROCYCLE DIBENZ[C,H]ACRIDINE ON MOUSE SKIN AND IN NEWBORN MICE; CARCINOGENESIS 21(11):1997-2003, 2000]"
6855,363906788,6435110,CCC(C)[C@@H]1[C@H](CC[C@@]2(O1)CC3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)OC7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(CC3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)OC7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C,Inactive,,,,RAT,WISTAR/MALE,ORAL,0; 2 PPM IN DIET FOR DURATION OF STUDY (STUDY DURATION: 1 YR),,NEGATIVE,"[O'CONNOR,PJ MACNAUGHT,F BUTLER,WH COOPER,DP MARGISON,GP AND POVEY,AC; INCREASED PATHOLOGY INCIDENCE IN THE FORESTOMACH OF RATS MAINTAINED ON A DIET CONTAINING IVERMECTIN AND GIVEN A SINGLE DOES OF N-METHLY-N'-NITRO-N-NITROSOGUANIDINE; J. ENVIRON. PATHOL. TOXICOL. ONCOL. 20(3):223-227, 2001]"
6856,363906811,63090,C1=CC(=C(C=C1C2=CC(=C(C(=C2)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 30; 100; 175; 300; 550; 1000 NG/KG BW 5 D/WK FOR 2 YRS,LIVER: CHOLANGIOCARCINOMA; HEPATOCELLULAR ADENOMA OR CARCINOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS   STUDIES OF 3,3',4,4',5-PENTACHLOROBIPHENYL (PCB 126) (CAS  NO. 57465-28-8) IN FEMALE HARLAN SPRAGUE-DAWLEY RATS (GAVAGE STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER. 520:1-246, 2006]"
6857,363906811,63090,C1=CC(=C(C=C1C2=CC(=C(C(=C2)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 30; 100; 175; 300; 550; 1000 NG/KG BW 5 D/WK FOR 2 YRS,LUNG: CYSTIC KERATINIZING EPITHELIOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS   STUDIES OF 3,3',4,4',5-PENTACHLOROBIPHENYL (PCB 126) (CAS  NO. 57465-28-8) IN FEMALE HARLAN SPRAGUE-DAWLEY RATS (GAVAGE STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER. 520:1-246, 2006]"
6858,363906811,63090,C1=CC(=C(C=C1C2=CC(=C(C(=C2)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,0; 30; 100; 175; 300; 550; 1000 NG/KG BW 5 D/WK FOR 2 YRS,ORAL CAVITY: SQUAMOUS CELL CARCINOMA,POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS   STUDIES OF 3,3',4,4',5-PENTACHLOROBIPHENYL (PCB 126) (CAS  NO. 57465-28-8) IN FEMALE HARLAN SPRAGUE-DAWLEY RATS (GAVAGE STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER. 520:1-246, 2006]"
6859,363906811,63090,C1=CC(=C(C=C1C2=CC(=C(C(=C2)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,GAVAGE,1000 NG/KG BW 5 D/WK FOR 30 WKS (STUDY DURATION: 2 YRS),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS   STUDIES OF 3,3',4,4',5-PENTACHLOROBIPHENYL (PCB 126) (CAS  NO. 57465-28-8) IN FEMALE HARLAN SPRAGUE-DAWLEY RATS (GAVAGE STUDIES); NATL.  TOXICOL.  PROGRAM TECH. REP. SER. 520:1-246, 2006]"
6860,363906811,63090,C1=CC(=C(C=C1C2=CC(=C(C(=C2)Cl)Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 30; 100; 175; 300; 550; 1000 NG/KG/D (STUDY DURATION: 2 YRS),ORAL MUCOSA: SQUAMOUS CELL CARCINOMA,POSITIVE; HIGHEST DOSE ONLY,"[YOSHIZAWA,K, WALKER,NJ, JOKINEN,MP, BRIX,AE, SELLS,DM,  MARSH,T, WYDE,ME, ORZECH,D, HASEMAN,JK, AND NYSKA,A;  GINGIVAL CARCINOGENICITY IN FEMALE HARLAN SPRAGUE-DAWLEY  RATS FOLLOWING TWO YEAR ORAL TREATMENT WITH  2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN AND DIOXIN-LIKE  COMPOUNDS. [ERRATUM TO DOCUMENT CITED IN CA142:234804];  TOXICOL. SCI. 83(2):405-406, 2005]"
6861,363906818,,,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 14; 42; 126 MG/KG IN DEIONIZED WATER 5 D/WK FOR DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-512 Y02]"
6862,363906818,,,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 28; 84; 252 MG/KG IN DEIONIZED WATER 5 D/WK FOR DURATION OF STUDY (STUDY DURATION: 104 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-512 Y02]"
6863,363906818,,,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 56; 168; 504 MG/KG IN DEIONIZED WATER 5 D/WK FOR DURATION OF STUDY (STUDY DURATION: 104 WK),LIVER: HEMANGIOSARCOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-512 Y02]"
6864,363906818,,,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 56; 168; 504 MG/KG IN DEIONIZED WATER 5 D/WK FOR DURATION OF STUDY (STUDY DURATION: 104 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA; ALL ORGANS: MALIGNANT LYMPHOMA",POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-512 Y02]"
6865,363906819,18948,CS(=O)(=O)OCCC[NH2+]CCCOS(=O)(=O)C.[Cl-],Unspecified,,,,RAT,SPRAGUE-DAWLEY/MALE,INTRAPERITONEAL,0; 12 MG/KG 3/WK FOR 52 WK; 24 MG/KG 3/WK FOR 34 WK; 48 MG/KG 3/WK FOR 23 WK (STUDY DURATION: 23-52 WK),"PERITONEUM: SARCOMA, FIBROMA OR FIBROSARCOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-18 Y78]"
6866,363906819,18948,CS(=O)(=O)OCCC[NH2+]CCCOS(=O)(=O)C.[Cl-],Unspecified,,,,RAT,SPRAGUE-DAWLEY/FEMALE,INTRAPERITONEAL,0; 12 MG/KG 3/WK FOR 52 WK; 24 MG/KG 3/WK FOR 34 WK; 48 MG/KG 3/WK FOR 27 WK (STUDY DURATION: 27-52 WK),"PERITONEUM: SARCOMA, FIBROMA OR FIBROSARCOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-18 Y78]"
6867,363906819,18948,CS(=O)(=O)OCCC[NH2+]CCCOS(=O)(=O)C.[Cl-],Unspecified,,,,MOUSE,B6C3F1/MALE,INTRAPERITONEAL,0; 20; 40 MG/KG 3/WK FOR 52 WK (STUDY DURATION: 52 WK),SUBCUTANEOUS TISSUE: SQUAMOUS CELL CARCINOMA; HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-18 Y78]"
6868,363906819,18948,CS(=O)(=O)OCCC[NH2+]CCCOS(=O)(=O)C.[Cl-],Unspecified,,,,MOUSE,B6C3F1/FEMALE,INTRAPERITONEAL,0; 20; 40 MG/KG 3/WK FOR 52 WK (STUDY DURATION: 52 WK),SUBCUTANEOUS TISSUE: SQUAMOUS CELL CARCINOMA; HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-18 Y78]"
6869,363906820,22833490,CC(CCCC(CCCC(CCCC(CCCC(CCCC(CCCl)Cl)Cl)Cl)Cl)Cl)Cl,Active,,,,MOUSE,B6C3F1/MALE,GAVAGE,0; 2500; 5000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),HEMATOPOIETIC SYSTEM: MALIGNANT LYMPHOMA,POSITIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-305 Y86]"
6870,363906820,22833490,CC(CCCC(CCCC(CCCC(CCCC(CCCC(CCCl)Cl)Cl)Cl)Cl)Cl)Cl,Unspecified,,,,RAT,F344/FEMALE,GAVAGE,0; 100; 300; 900 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),ADRENAL GLAND: MEDULLARY PHEOCHROMOCYTOMA,EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-305 Y86]"
6871,363906820,22833490,CC(CCCC(CCCC(CCCC(CCCC(CCCC(CCCl)Cl)Cl)Cl)Cl)Cl)Cl,Inactive,,,,RAT,F344/MALE,GAVAGE,0; 1875; 3750 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),,NEGATIVE,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-305 Y86]"
6872,363906820,22833490,CC(CCCC(CCCC(CCCC(CCCC(CCCC(CCCl)Cl)Cl)Cl)Cl)Cl)Cl,Unspecified,,,,MOUSE,B6C3F1/FEMALE,GAVAGE,0; 2500; 5000 MG/KG IN CORN OIL 5 D/WK FOR 103 WK (STUDY DURATION: 103 WK),"LIVER: HEPATOCELLULAR ADENOMA, HEPATOCELLULAR CARCINOMA",EQUIVOCAL,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-305 Y86]"
6873,363906821,3032390,CCC(O)OC,Inactive,,,,RAT,F344/MALE,INHALATION,0; 300; 1000; 3000 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[SPENCER,PJ CRISSMAN,JW STOTT,WT CORLEY,RA CIESZLAK,FS SCHUMANN,AM AND HARDISTY,JF; PROPYLENE GLYCOL MONOMETHYL ETHER (PGME): INHALATION TOXICITY AND CARCINOGENICTY IN FISCHER 344 RATS AND B6C3F1 MICE; TOXICOL. PATHOL. 30(5):570-579, 2002]"
6874,363906821,3032390,CCC(O)OC,Inactive,,,,RAT,F344/FEMALE,INHALATION,0; 300; 1000; 3000 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[SPENCER,PJ CRISSMAN,JW STOTT,WT CORLEY,RA CIESZLAK,FS SCHUMANN,AM AND HARDISTY,JF; PROPYLENE GLYCOL MONOMETHYL ETHER (PGME): INHALATION TOXICITY AND CARCINOGENICTY IN FISCHER 344 RATS AND B6C3F1 MICE; TOXICOL. PATHOL. 30(5):570-579, 2002]"
6875,363906821,3032390,CCC(O)OC,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,0; 300; 1000; 3000 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[SPENCER,PJ CRISSMAN,JW STOTT,WT CORLEY,RA CIESZLAK,FS SCHUMANN,AM AND HARDISTY,JF; PROPYLENE GLYCOL MONOMETHYL ETHER (PGME): INHALATION TOXICITY AND CARCINOGENICTY IN FISCHER 344 RATS AND B6C3F1 MICE; TOXICOL. PATHOL. 30(5):570-579, 2002]"
6876,363906821,3032390,CCC(O)OC,Inactive,,,,MOUSE,B6C3F1/FEMALE,INHALATION,0; 300; 1000; 3000 PPM 6 HR/D 5 D/WK FOR 2 YR (STUDY DURATION: 2 YR),,NEGATIVE,"[SPENCER,PJ CRISSMAN,JW STOTT,WT CORLEY,RA CIESZLAK,FS SCHUMANN,AM AND HARDISTY,JF; PROPYLENE GLYCOL MONOMETHYL ETHER (PGME): INHALATION TOXICITY AND CARCINOGENICTY IN FISCHER 344 RATS AND B6C3F1 MICE; TOXICOL. PATHOL. 30(5):570-579, 2002]"
6877,363906860,13195,CC1=CN=CN1,Active,,,,Mouse,B6C3F1/Female,Oral,0; 312; 625; 1250 ppm in feed for 106 wk (study duration: 106 wk),"Lung: Alveolar/Bronchiolar adenoma (0/50, 8/50, 16/50, 8/50); Alveolar/Bronchiolar carcinoma (3/50, 0/50, 2/50, 7/50); Alveolar/Bronchiolar adenoma or carcinoma (combined) (3/50, 8/50, 17/50, 14/50)",Positive,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-535 Y07][CHAN,PC HILLS,GD KISSLING,GE AND NYSKA,A; TOXICITY AND CARCINOGENICITY STUDIES OF 4-METHYLIMIDAZOLE IN F344/N RATS AND B6C3F1 MICE; ARCHIVES OF TOXICOLOGY 82(1):45-53, 2008 , ]"
6878,363906860,13195,CC1=CN=CN1,Active,,,,Mouse,B6C3F1/Male,Oral,0; 312; 625; 1250 ppm in feed for 106 wk (study duration: 106 wk),"Lung: Alveolar/Bronchiolar carcinoma (2/50, 4/50, 4/50, 4/50, 8/50); Alveolar/Bronchiolar adenoma or carcinoma (combined) (9/50, 13/50, 16/50, 22/50)",Positive,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-534 Y07][CHAN,PC HILLS,GD KISSLING,GE AND NYSKA,A; TOXICITY AND CARCINOGENICITY STUDIES OF 4-METHYLIMIDAZOLE IN F344/N RATS AND B6C3F1 MICE; ARCHIVES OF TOXICOLOGY 82(1):45-53, 2008 , ]"
6879,363906860,13195,CC1=CN=CN1,Unspecified,,,,Rat,F344/N/Female,Oral,0; 1250; 2500; 5000  ppm in feed for 106 wk (study duration: 106 wk),"Mononuclear cell leukemia: (9/50, 7/50, 16/50, 20/50)",Equivocal,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-534 Y07][CHAN,PC HILLS,GD KISSLING,GE AND NYSKA,A; TOXICITY AND CARCINOGENICITY STUDIES OF 4-METHYLIMIDAZOLE IN F344/N RATS AND B6C3F1 MICE; ARCHIVES OF TOXICOLOGY 82(1):45-53, 2008 , ]"
6880,363906860,13195,CC1=CN=CN1,Inactive,,,,Rat,F344/N/Male,Oral,0; 625; 1250; 2500 ppm in feed for 106 wk (study duration: 106 wk),,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-534 Y07][CHAN,PC HILLS,GD KISSLING,GE AND NYSKA,A; TOXICITY AND CARCINOGENICITY STUDIES OF 4-METHYLIMIDAZOLE IN F344/N RATS AND B6C3F1 MICE; ARCHIVES OF TOXICOLOGY 82(1):45-53, 2008 , ]"
6881,363906885,443059,CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3[C@@H]2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0.0025; 0.008; 0.036 % IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[STEBBINS,KE BOND,DM NOVILLA,MN AND REASOR MJ; SPINOSAD INSECTICIDE: SUBCHRONIC AND CHRONIC TOXICITY AND LACK OF CARCINOGENICITY IN CD-1 MICE; TOXICOL. SCI. 65(2): 276-287, 2002]"
6882,363906885,443059,CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3[C@@H]2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0.0025; 0.008; 0.036 % IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[STEBBINS,KE BOND,DM NOVILLA,MN AND REASOR MJ; SPINOSAD INSECTICIDE: SUBCHRONIC AND CHRONIC TOXICITY AND LACK OF CARCINOGENICITY IN CD-1 MICE; TOXICOL. SCI. 65(2): 276-287, 2002]"
6883,363906885,443059,CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3[C@@H]2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C,Inactive,,,,RAT,F344/MALE,ORAL,0.005; 0.02; 0.05; 0.1 % IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[YANE,BL BOND,DM NOVILLA,MN MCFADDEN,LG AND REASOR,MJ; SPINOSAD INSECTICIDE: DUBCHRONIC AND CHRONIC TOXICITY AND LACK OF CARCINOGENICTY IN FISCHER 344 RATS; TOXICOL. SCI. 65(2):288-298, 2002]"
6884,363906885,443059,CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3[C@@H]2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0.005; 0.02; 0.05; 0.1% IN DIET FOR 24 MO (STUDY DURATION: 24 MO),,NEGATIVE,"[YANE,BL BOND,DM NOVILLA,MN MCFADDEN,LG AND REASOR,MJ; SPINOSAD INSECTICIDE: DUBCHRONIC AND CHRONIC TOXICITY AND LACK OF CARCINOGENICTY IN FISCHER 344 RATS; TOXICOL. SCI. 65(2):288-298, 2002]"
6885,363906885,443059,CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3[C@@H]2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C,Inactive,,,,MOUSE,CD-1/MALE,ORAL,0; 0.0008; 0.0025; 0.008; 0.024; 0.036% IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[STEBBINS,KE BOND,DM NOVILLA,MN AND REASOR,MJ; SPINOSAD INSECTICIDE: SUBCHRONIC AND CHRONIC TOXICITY AND LACK OF CARCINOGENICITY IN CD-1 MICE; TOXICOL. SCI. 65(2):276-287, 2002]"
6886,363906885,443059,CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3[C@@H]2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C,Inactive,,,,MOUSE,CD-1/FEMALE,ORAL,0; 0.0025; 0.008; 0.024; 0.0008% IN DIET FOR 18 MO (STUDY DURATION: 18 MO),,NEGATIVE,"[STEBBINS,KE BOND,DM NOVILLA,MN AND REASOR,MJ; SPINOSAD INSECTICIDE: SUBCHRONIC AND CHRONIC TOXICITY AND LACK OF CARCINOGENICITY IN CD-1 MICE; TOXICOL. SCI. 65(2):276-287, 2002]"
6887,363906886,119153,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)(C)CN(C)CC2=CC=CC=C2)C3=C(C=CC(=C3)[N+](=O)[O-])F)C(=O)OC.Cl,Inactive,,,,RAT,F344/MALE,ORAL,0; 0.67; 2; 6 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HAMADA,NN KOKA,M AND QUANDER,R; TOXICITY STUDIES OF PALONIDIPINE HYDROCHLORIDE (TC-81); CLIN. REP. 26(7): 3075-3096, 1992]"
6888,363906886,119153,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)(C)CN(C)CC2=CC=CC=C2)C3=C(C=CC(=C3)[N+](=O)[O-])F)C(=O)OC.Cl,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 0.67; 2; 6 MG/KG/D IN DIET FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[HAMADA,NN KOKA,M AND QUANDER,R; TOXICITY STUDIES OF PALONIDIPINE HYDROCHLORIDE (TC-81); CLIN. REP. 26(7): 3075-3096, 1992]"
6889,363906887,2449,CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C,Inactive,,,,RAT,F344/MALE,ORAL,0; 3; 10; 30; 100 MG/KG/D IN THE DIET FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[NONOYAMA,T; FIFTY-TWO-WEEK DIETARY TOXICITY STUDY OF AA-2414 IN RATS; JPN. PHARMACOL. THER. 21(SUPPL): S1723-1737, 1993]"
6890,363906887,2449,CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C,Inactive,,,,RAT,F344/FEMALE,ORAL,0; 3; 10; 30; 100 MG/KG/D IN THE DIET FOR 52 WK (STUDY DURATION: 52 WK),,NEGATIVE,"[NONOYAMA,T; FIFTY-TWO-WEEK DIETARY TOXICITY STUDY OF AA-2414 IN RATS; JPN. PHARMACOL. THER. 21(SUPPL): S1723-1737, 1993]"
6891,363906896,642197,C(/C=C/CCl)Cl,Active,,,,RAT,CD/MALE,INHALATION,0; 0.1; 0.3; 1.0 PPM 6 HR/D 5 D/WK FOR 86 WK (STUDY DURATION: 86 WK),"NASAL CAVITY: ADENOMA, ADENOCARCINOMA, CARCINOSARCOMA, MIXED CARCINOMA",POSITIVE,"[MULLIN,LS KENNEDY,GL AND WOOD,CK; NASAL TUMORS IN RATS FOLLOWING LONG-TERM INHALATION EXPOSURE TO 1,4-DICHLOROBUTENE-2 (DCB); DRUG CHEM. TOXICOL. 23(3):403-417, 2000]"
6892,363906896,642197,C(/C=C/CCl)Cl,Active,,,,Rat,CD BR/Male (140/group),Inhalation,"0; 0.5 6 hr/d for 2 yr; 5 ppm 6 hr/d lowered to 2.5 ppm after 7 mo and continued an additional 5 mo with a 1-yr maintenance period, study duration 2 yr","Nasal Passages: Benign (0 (0%), 33 (25.4%), 2 (1.6%)) and malignant tumors (0 (0%), 11 (8.5%), 114 (88.4%))",Positive,"[MULLIN,LS CHIU,T AND KENNEDY,GL; INITIAL STUDY IN RATS EVALUATING THE EFFECTS OF 1,4-DICHLOROBUTENT-2 (DCB) ON THE RESPIRATORY TRACT; DRUG CHEM. TOXICOL. 25(2):227-230, 2002]"
6893,363906896,642197,C(/C=C/CCl)Cl,Active,,,,Rat,CD BR/Female (140/group),Inhalation,"0; 0.5 6 hr/d for 2 yr; 5 ppm 6 hr/d lowered to 2.5 ppm after 7 mo and continued an additional 5 mo with a 1-yr maintenance period, study duration 2 yr","Nasal Passages: Benign (0 (0%), 23 (18%), 5 (3.9%)) and malignant tumors (0 (0%), 2 (1.6%), 113 (88.3%))",Positive,"[MULLIN,LS CHIU,T AND KENNEDY,GL; INITIAL STUDY IN RATS EVALUATING THE EFFECTS OF 1,4-DICHLOROBUTENT-2 (DCB) ON THE RESPIRATORY TRACT; DRUG CHEM. TOXICOL. 25(2):227-230, 2002]"
6894,363906902,,,Inactive,,,,MOUSE,B6C3F1/FEMALE,INTRAVAGINAL,0; 2% IN GEL MICROEMULSION 5 D/WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[WATANABE,T HASEI,T TAKAHASHI,T ASANOMA,M MURAHASHI,T HIRAYAMA,T AND WAKABAYASHI,K; DETECTION OF A NOVEL MUTAGEN, 3,6-DINITROBENZO[E]PYRENE, AS A MAJOR CONTAMINANT IN SURFACE SOIL IN OSAKA AND AICHI PREFECTURES, JAPAN; CHEM. RES. TOXICOL. 181(2):283-289, 2005]"
6895,363906904,104930,C[As](=O)(C)C,Active,,,,RAT,F344/MALE,ORAL,0; 50; 200 PPM IN DRINKING WATER FOR 104 WK (STUDY DURATION: 104 WK),LIVER: HEPATOCELLULAR ADENOMA,POSITIVE,"[SHEN,J WANIBUCHI,H SALIM,EI WEI,M KINOSHITA,A YOSHIDA,K ENDO,G AND FUKUSHIMA,S; LIVER TUMORIGENICITY OF TRIMETHYLARSINE OXIDE IN MALE FISCHER 344 RATS-ASSOCIATION WITH OXIDATIVE DNA DAMAGE AND ENHANCED CELL PROFLIFERATION; CARCINOGENESIS 24(11):1827-1835, 2003]"
6896,363906950,2825690,C1=CC=C2C(=C1)C3=C4C(=C(C=C3)[N+](=O)[O-])C=CC=C4C2=O,Active,,,,RAT,F344/FEMALE,INTRATRACHEAL,0; 1.5 MG TOTAL; 2.5 MG TOTAL OVER 18 MO (STUDY DURATION: 18 MO),LUNG: CARCINOMA,POSITIVE (AT HIGHER DOSAGE AND LONGER DURATION),"[NAGY,E, ZEISIG,M, KAWAMURA,K, HISAMATSU,Y, SUGETA,A, ADACHI,S AND MOELLER,L; DNA ADDUCT AND TUMOR FORMATIONS IN RATS AFTER INTRATRACHEAL ADMINISTRATION OF THE URBAN AIR POLLUTANT 3-NITROBENZANTHRONE; CARCINOGENESIS 26(10):1821-1828, 2005]"
6897,363906956,154224,C1=CC=C2C(=C1)C3=C(N2C4=CC=C(C=C4)N)C=NC=C3,Active,,,,RAT,"F344/MALE (30-33/GROUP), FEMALE (28-32/GROUP)",ORAL,0; 20; 40 PPM IN DIET FOR 85 WK (STUDY DURATION: 85 WK),"LIVER: ADENOMA, HEPATOCELLULAR CARCINOMA; COLON: ADENOCARCINOMA; THYROID: FOLLICULAR CELL ADENOMA AND CARCINOMA, MONONUCLEAR CELL LEUKEMIA",POSITIVE,"[KAWAMORI,T TOTSUKA,Y UCHIYA,N KITAMURA,T SHIBATA,H SUGIMURA,T AND WAKABAYASHI,K; CARCINOGENICITY OF AMINOPHENYLNORHARMAN, A POSSIBLE NOVEL ENDOGENOUS MUTAGEN, FORMED FROM NORHARMAN AND ANILINE, IN F344 RATS; CARCINOGENESIS 25(10): 1967-1972, 2004]"
6898,363906957,7275810,C1=CC=C2C(=C1)C(=CN2)C[C@H](C(=O)O)NC(=O)CC[C@H](C(=O)O)N,Inactive,,,,MOUSE,C57BL.CBA,SC,0.0145 AND 0.145 MG/KG 2X WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[PYLEV,LN VASIL'EVA,LA KHRUSTALEV,SA AND DEIGIN,VI; CARCINOGENIC ACTIVITY OF A NEW DRUG THYMODEPRESSIN STUDIED IN CHRONIC TESTS ON RATS AND MICE; EKSP. KLIN. FARMAKOTER. 67(4): 61-63, 2004]"
6899,363906957,7275810,C1=CC=C2C(=C1)C(=CN2)C[C@H](C(=O)O)NC(=O)CC[C@H](C(=O)O)N,Inactive,,,,RAT,WISTAR,SC,0.0145 AND 0.145 MG/KG 2X WK FOR 104 WK (STUDY DURATION: 104 WK),,NEGATIVE,"[PYLEV,LN VASIL'EVA,LA KHRUSTALEV,SA AND DEIGIN,VI; CARCINOGENIC ACTIVITY OF A NEW DRUG THYMODEPRESSIN STUDIED IN CHRONIC TESTS ON RATS AND MICE; EKSP. KLIN. FARMAKOTER. 67(4): 61-63, 2004]"
6900,363906960,25894,CC1=C2C(=C(C3=CC=CC=C13)C=O)C=CC4=CC=CC=C42,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE (13/GROUP),SUBCUTANEOUS,0.2 UMOL 3X A WK FOR 20 DOSES (STUDY DURATION: 52 WK),MAMMARY: ADENOCARCINOMA,POSITIVE (15%),"[HORN,J LEHNER,AF AND FLESHER,JW; RAPID INDUCTION OF MAMMARY CANCER BY REPEATED SUBCUTANEOUS INJECTION OF THE TRANS-A3,4-DIHYDRODIOL OF 7,12-DIMETHYLBENZ[A]ANTHRACENE IN THE FEMALE SPRAGUE-DAWLEY RAT; CANCER LETT. 220(2):155-160, 2005]"
6901,363906960,25894,CC1=C2C(=C(C3=CC=CC=C13)C=O)C=CC4=CC=CC=C42,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE (13/GROUP),SUBCUTANEOUS,0.2 UMOL 3X A WK FOR 20 DOSES (STUDY DURATION: 52 WK),SUBCUTANEOUS; SARCOMA,POSITIVE (85%),"[HORN,J LEHNER,AF AND FLESHER,JW; RAPID INDUCTION OF MAMMARY CANCER BY REPEATED SUBCUTANEOUS INJECTION OF THE TRANS-A3,4-DIHYDRODIOL OF 7,12-DIMETHYLBENZ[A]ANTHRACENE IN THE FEMALE SPRAGUE-DAWLEY RAT; CANCER LETT. 220(2):155-160, 2005]"
6902,363906969,91430,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O.CS(=O)(=O)O,Active,,,,RAT,"CRL:CD BR/MALE, FEMALE (65/GROUP)",ORAL (GAVAGE),10; 50; 150 MG/KG DAILY IN DISTILLED WATER  (STUDY DURATION: 101 WK),PITUITARY: ADENOMA,POSITIVE,"[POULET,FM BERADI,MR HALLIWLL,W HARTMAN,B AULETTA,C AND BOLTE,H; DEVELOPMENT OF HIBERNOMAS IN RATS DOSED WITH PHENTOLAMINE MESYLATE DURING THE 24-MONTH CARCINOGENICITY STUDY; TOXICOL. PATHOL. 32(5):558-566, 2004]"
6903,363906969,91430,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O.CS(=O)(=O)O,Active,,,,RAT,"CRL:CD BR/MALE, FEMALE (65/GROUP)",ORAL (GAVAGE),10; 50; 150 MG/KG DAILY IN DISTILLED WATER  (STUDY DURATION: 101 WK),BROWN ADIPOSE TISSUE: HIBERNOMA,POSITIVE,"[POULET,FM BERADI,MR HALLIWLL,W HARTMAN,B AULETTA,C AND BOLTE,H; DEVELOPMENT OF HIBERNOMAS IN RATS DOSED WITH PHENTOLAMINE MESYLATE DURING THE 24-MONTH CARCINOGENICITY STUDY; TOXICOL. PATHOL. 32(5):558-566, 2004]"
6904,363906970,37270,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,"ORAL, GAVAGE IN CORN OIL",0; 1.0; 2.8; 3.1; 3.4; 3.8; 4.1 MG/KG BW ONCE (STUDY DURATION: LIFESPAN),LUNG: CARCINOMA,POSITIVE,"[ROZMAN,KK LEBOFSKY,M AND PINSON,DM; CHRONIC TOXICITY AND CARCINOGENICITY OF 1,2,3,4,6,7,8-HEPTACHLORODIBENZO-P-DIOXIN DISPLAYS A DISTINCT DOSE/TME TOXICITY THRESHOLD (C X T - K) AND A LIFE-PROLONGING SUBTHRESHOLD EFFECT; FOOD CHEM. TOXICOL. 43(5):729-740, 2005]"
6905,363906970,37270,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE,"ORAL, GAVAGE IN CORN OIL",0; 1.0; 2.8; 3.1; 3.4; 3.8; 4.1 MG/KG BW ONCE (STUDY DURATION: LIFESPAN),LIVER: CARCINOMA,POSITIVE AT HIGHER DOSES,"[ROZMAN,KK LEBOFSKY,M AND PINSON,DM; CHRONIC TOXICITY AND CARCINOGENICITY OF 1,2,3,4,6,7,8-HEPTACHLORODIBENZO-P-DIOXIN DISPLAYS A DISTINCT DOSE/TME TOXICITY THRESHOLD (C X T - K) AND A LIFE-PROLONGING SUBTHRESHOLD EFFECT; FOOD CHEM. TOXICOL. 43(5):729-740, 2005]"
6906,363906970,37270,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE (30),"ORAL, GAVAGE IN CORN OIL",2.5 MG/KG BW PLUS 0.63 MG/KG 0N D 150; TOTAL DOSE 3.1 MG/KG (STUDY DURATION: LIFESPAN),LIVER: CARCINOMA,POSITIVE,"[ROZMAN,KK LEBOFSKY,M AND PINSON,DM; CHRONIC TOXICITY AND CARCINOGENICITY OF 1,2,3,4,6,7,8-HEPTACHLORODIBENZO-P-DIOXIN DISPLAYS A DISTINCT DOSE/TME TOXICITY THRESHOLD (C X T - K) AND A LIFE-PROLONGING SUBTHRESHOLD EFFECT; FOOD CHEM. TOXICOL. 43(5):729-740, 2005]"
6907,363906970,37270,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE (30),"ORAL, GAVAGE IN CORN OIL",2.5 MG/KG BW PLUS 0.63 MG/KG ON D 150; TOTAL DOSE 3.1 MG/KG (STUDY DURATION: LIFESPAN),LUNG: CARCINOMA,POSITIVE,"[ROZMAN,KK LEBOFSKY,M AND PINSON,DM; CHRONIC TOXICITY AND CARCINOGENICITY OF 1,2,3,4,6,7,8-HEPTACHLORODIBENZO-P-DIOXIN DISPLAYS A DISTINCT DOSE/TME TOXICITY THRESHOLD (C X T - K) AND A LIFE-PROLONGING SUBTHRESHOLD EFFECT; FOOD CHEM. TOXICOL. 43(5):729-740, 2005]"
6908,363906970,37270,C1=C2C(=C(C(=C1Cl)Cl)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,Active,,,,RAT,SPRAGUE-DAWLEY/FEMALE (30),"ORAL, GAVAGE IN CORN OIL",2.8 MG/KG BW PLUS 0.086 MG/KG EVERY OTHER WK FOR LIFESPAN; TOTAL DOSE 4.6 MG/KG (STUDY DURATION: LIFESPAN),LUNG: CARCINOMA,POSITIVE,"[ROZMAN,KK LEBOFSKY,M AND PINSON,DM; CHRONIC TOXICITY AND CARCINOGENICITY OF 1,2,3,4,6,7,8-HEPTACHLORODIBENZO-P-DIOXIN DISPLAYS A DISTINCT DOSE/TME TOXICITY THRESHOLD (C X T - K) AND A LIFE-PROLONGING SUBTHRESHOLD EFFECT; FOOD CHEM. TOXICOL. 43(5):729-740, 2005]"
6909,363906973,5821911,CN\1COCN(/C1=N/[N+](=O)[O-])CC2=CN=C(S2)Cl,Inactive,,,,MOUSE,TIF:MAGF/MALE,DIET,0; 50; 200; 500; 1250; 2500; 5000 PPM IN DIET FOR UP TO 50 WKS (STUDY DURATION: 50 WKS),,NEGATIVE FOR TUMORS BUT APOPTOSIS AND NECROSIS OBSERVED IN LIVER AT DOSES OF 500 PPM AND HIGHER,"[GREEN,T TOGHILL,A LEE,R WAECHTER,F WEBER,E AND NOAKES,J; THIAMETHOXAM INDUCED MOUSE LIVER TUMORS AND THEIR RELEVANCE TO HUMANS; TOXICOL. SCI. 86(1):36-47, 2005]"
6910,363906973,5821911,CN\1COCN(/C1=N/[N+](=O)[O-])CC2=CN=C(S2)Cl,Inactive,,,,RAT,TIF:RAIF/FEMALE,ORAL (DIET),"0; 1000; 3000 PPM FOR 1, 10, 20, 30, 40, OR 50 WKS",,NEGATIVE,"[GREEN,T TOGHILL,A LEE,R WAECHTER,F WEBER,E PEFFER,R NOAKES,J AND ROBINSON,M; THIAMETHOXAM INDUCED MOUSE LIVER TUMORS AND THEIR RELEVANCE TO HUMANS; TOXICOL. SCI. 86(1):48-55, 2005]"
6911,363906974,6027,C1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)O,Inactive,,,,RAT,F344/MALE,ORAL (DIET),0; 2.5%; 5% FOR 104 WKS (STUDY DURATION: 104 WKS),,NEGATIVE,"[KUROIWA,Y NISHIKAWA,A IMAZAWA,T KITAMURA,Y KANKI,K UMEMURA,T AND HIROSE,M; LACK OF CARCINOGENICITY OF -XYLOSE GIVEN IN THE DIET TO F344 RATS FOR TWO YEARS; FOOD CHEM. TOXICOL. 43(9):1399-1404, 2005]"
6912,363906974,6027,C1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)O,Inactive,,,,RAT,F344/FEMALE,ORAL (DIET),0; 2.5%; 5% FOR 104 WKS (STUDY DURATION: 104 WKS),,NEGATIVE,"[KUROIWA,Y NISHIKAWA,A IMAZAWA,T KITAMURA,Y KANKI,K UMEMURA,T AND HIROSE,M; LACK OF CARCINOGENICITY OF -XYLOSE GIVEN IN THE DIET TO F344 RATS FOR TWO YEARS; FOOD CHEM. TOXICOL. 43(9):1399-1404, 2005]"
6913,363906985,,,Active,,,,RAT,F344/N/MALE,INHALATION,"0; 138; 550; 1100 MG/M3 FOR 6 HR/D, 5 D/WK FOR 104-105 WKS (STUDY DURATION: 105 WKS)",ADRENAL: PHEOCHROMOCYTOMA; 6/50; 9/50; 13/90; 19/50,"POSITIVE; P VALUES AT 2 HIGHER LEVELS SIGNIFICANT, KIDNEY TUMORS INCREASED BUT NOT SIGNIFICANT","[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF STODDARD SOLVENT IIC (CAS NO. 64742-88-7) IN F344/N RATS AND B6C3F1 MICE (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 519:1-274, 2004]"
6914,363906985,,,Inactive,,,,RAT,F344/N/FEMALE,INHALATION,"0;  550; 1100; 2200 MG/M3 FOR 6 HR/D, 5 D/WK FOR 104-105 WKS (STUDY DURATION: 105 WKS)",,NEGATIVE; ADENOMAS OF CLITORAL GLAND INCREASED SIGNIFICANTLY AT 2 HIGHEST DOSES,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF STODDARD SOLVENT IIC (CAS NO. 64742-88-7) IN F344/N RATS AND B6C3F1 MICE (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 519:1-274, 2004]"
6915,363906985,,,Inactive,,,,MOUSE,B6C3F1/MALE,INHALATION,"0;  550; 1100; 2200 MG/M3 FOR 6 HR/D, 5 D/WK FOR 104-105 WKS (STUDY DURATION: 105 WKS)",,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF STODDARD SOLVENT IIC (CAS NO. 64742-88-7) IN F344/N RATS AND B6C3F1 MICE (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 519:1-274, 2004]"
6916,363906985,,,Unspecified,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0;  550; 1100; 2200 MG/M3 FOR 6 HR/D, 5 D/WK FOR 104-105 WKS (STUDY DURATION: 105 WKS)",LIVER: HEPATOCELLULAR ADENOMA; P = 0.032 AT HIGHEST DOSE,EQUIVOCAL,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF STODDARD SOLVENT IIC (CAS NO. 64742-88-7) IN F344/N RATS AND B6C3F1 MICE (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 519:1-274, 2004]"
6917,363906986,92629,CC(COC(C)(C)C)O,Unspecified,,,,RAT,F344/N/MALE,INHALATION,"0; 75; 300; 1200 PPM 6 HR/D, 5 D/WK FOR 104 WKS",NO STATISTICALLY SIGNIFICANT INCREASE IN TUMORS BUT KIDNEY TUBULE TUMORS INCREASED SLIGHTLY,EQUIVOCAL,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF PROPYLENE GLYCOL MONO-T-BUTYL ETHER (CAS NO. 57018-52-7) IN F344/N RATS AND B6C3F1 MICE AND A TOXICOLOGY STUDY OF PROPYLENE GLYCOL MONO-T-BUTYL ETHER IN MALE NBR RATS (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 515:1-306, 2005]"
6918,363906986,92629,CC(COC(C)(C)C)O,Inactive,,,,RAT,F344/N/FEMALE,INHALATION,"0; 75; 300; 1200 PPM 6 HR/D, 5 D/WK FOR 104 WKS",,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF PROPYLENE GLYCOL MONO-T-BUTYL ETHER (CAS NO. 57018-52-7) IN F344/N RATS AND B6C3F1 MICE AND A TOXICOLOGY STUDY OF PROPYLENE GLYCOL MONO-T-BUTYL ETHER IN MALE NBR RATS (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 515:1-306, 2005]"
6919,363906986,92629,CC(COC(C)(C)C)O,Active,,,,MOUSE,B6C3F1/MALE,INHALATION,"0; 75; 300; 1200 PPM 6 HR/D, 5 D/WK FOR 104 WKS","LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA OR HEPATOBLASTOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF PROPYLENE GLYCOL MONO-T-BUTYL ETHER (CAS NO. 57018-52-7) IN F344/N RATS AND B6C3F1 MICE AND A TOXICOLOGY STUDY OF PROPYLENE GLYCOL MONO-T-BUTYL ETHER IN MALE NBR RATS (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 515:1-306, 2005]"
6920,363906986,92629,CC(COC(C)(C)C)O,Active,,,,MOUSE,B6C3F1/FEMALE,INHALATION,"0; 75; 300; 1200 PPM 6 HR/D, 5 D/WK FOR 104 WKS","LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA OR HEPATOBLASTOMA",POSITIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF PROPYLENE GLYCOL MONO-T-BUTYL ETHER (CAS NO. 57018-52-7) IN F344/N RATS AND B6C3F1 MICE AND A TOXICOLOGY STUDY OF PROPYLENE GLYCOL MONO-T-BUTYL ETHER IN MALE NBR RATS (INHALATION STUDIES); NATL. TOXICOL. PROGRAM TECH. REP. SER. 515:1-306, 2005]"
6921,363907009,2314,CC1(OC2=C(O1)C(=CC=C2)OC(=O)NC)C,Inactive,,,,Mouse,CD-1/Male,Oral,0; 50; 250; 1250 ppm in diet for 89 wks,,Negative; Purity 92.7%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENDIOCARBAMATE (APRIL 3, 1997)]"
6922,363907009,2314,CC1(OC2=C(O1)C(=CC=C2)OC(=O)NC)C,Inactive,,,,Mouse,CD-1/Female,Oral,0; 50; 250; 1250 ppm in diet for 94 wks,,Negative; Purity 92.7%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENDIOCARBAMATE (APRIL 3, 1997)]"
6923,363907130,105036,C1=CC(=CC=C1C2=C(C=C(C=C2Cl)Cl)Cl)O,Active,,,,MOUSE,BALB/CCRGL/FEMALE,SUBCUTANEOUS,20 UG DAILY FOR 5 D BEGINNING 16 HR AFTER BIRTH (STUDY DURATION: 20 MO),MAMMARY GLAND: CARCINOMA (5/33); CERVICOVAGINAL TRACT: CARCINOMA (2/33); LUNG TUMORS (3/33),POSITIVE; (STATISTICALLY SIGNIFICANT FOR TOTAL NUMBER OF TUMORS),"[MARTINEZ,J, STEPHENS,LC AND JONES,LA; LONG-TERM EFFECTS OF NEONATAL EXPOSURE TO HYDROXYLATED POLYCHLORINATED BIPHENYLS IN THE BALB/CCRGL MOUSE; ENVIRON. HEALTH PERSPECT. 113(8):1022-1025, 2005]"
6924,363907130,105036,C1=CC(=CC=C1C2=C(C=C(C=C2Cl)Cl)Cl)O,Active,,,,MOUSE,BALB/CCRGL/FEMALE,SUBCUTANEOUS,200 UG DAILY FOR 5 D BEGINNING 16 HR AFTER BIRTH (STUDY DURATION: 20 MO),CERVICOVAGINAL TRACT: CARCINOMA (10/22),POSITIVE,"[MARTINEZ,J, STEPHENS,LC AND JONES,LA; LONG-TERM EFFECTS OF NEONATAL EXPOSURE TO HYDROXYLATED POLYCHLORINATED BIPHENYLS IN THE BALB/CCRGL MOUSE; ENVIRON. HEALTH PERSPECT. 113(8):1022-1025, 2005]"
6925,363907131,105101,C1=CC(=CC=C1C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)O,Active,,,,MOUSE,BALB/CCRGL/FEMALE,SUBCUTANEOUS,40 UG DAILY FOR 5 D BEGINNING 16 HR AFTER BIRTH (STUDY DURATION: 20 MO),MAMMARY GLAND: CARCINOMA (4/30); CERVICOVAGINAL TRACT: CARCINOMA (4/30),POSITIVE,"[MARTINEZ,J, STEPHENS,LC AND JONES,LA; LONG-TERM EFFECTS OF NEONATAL EXPOSURE TO HYDROXYLATED POLYCHLORINATED BIPHENYLS IN THE BALB/CCRGL MOUSE; ENVIRON. HEALTH PERSPECT. 113(8):1022-1025, 2005]"
6926,363907131,105101,C1=CC(=CC=C1C2=CC(=C(C(=C2Cl)Cl)Cl)Cl)O,Active,,,,MOUSE,BALB/CCRGL/FEMALE,SUBCUTANEOUS,400 UG DAILY FOR 5 D BEGINNING 16 HR AFTER BIRTH (STUDY DURATION: 20 MO),CERVICOVAGINAL TRACT: CARCINOMA (5/24),POSITIVE,"[MARTINEZ,J, STEPHENS,LC AND JONES,LA; LONG-TERM EFFECTS OF NEONATAL EXPOSURE TO HYDROXYLATED POLYCHLORINATED BIPHENYLS IN THE BALB/CCRGL MOUSE; ENVIRON. HEALTH PERSPECT. 113(8):1022-1025, 2005]"
6927,363907132,516902,[O-]Cl(=O)=O.[Na+],Active,,,,RAT,"F344/N/MALE (50, 50, 50, 50)",DRINKING WATER,0; 125; 1000; 2000 MG/L FOR 105 WK (STUDY DURATION: 105 WKS),THYROID: FOLLICULAR CELL ADENOMA OR CARCINOMA,POSITIVE (P = 0.052); NTP REPORTS AS SOME EVIDENCE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF SODIUM CHLORATE (CAS NO. 7775-09-9) IN F344/N  RATS AND B6C3F1 MICE (DRINKING WATER STUDIES); NATL. TOXICOL. PROGRAM  TECH. REP. SER. 517:1-256, 2005]"
6928,363907132,516902,[O-]Cl(=O)=O.[Na+],Inactive,,,,RAT,"F344/N/FEMALE (50, 50, 50, 50)",DRINKING WATER,0; 125; 1000; 2000 MG/L FOR 105 WK (STUDY DURATION: 105 WKS),,NEGATIVE; NTP REPORTS AS SOME EVIDENCE FOR THYROID BUT P VALUES ARE NOT STATISTICALLY SIGNIFICANT,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF SODIUM CHLORATE (CAS NO. 7775-09-9) IN F344/N  RATS AND B6C3F1 MICE (DRINKING WATER STUDIES); NATL. TOXICOL. PROGRAM  TECH. REP. SER. 517:1-256, 2005]"
6929,363907132,516902,[O-]Cl(=O)=O.[Na+],Unspecified,,,,MOUSE,"B6C3F1/FEMALE (50, 50, 50, 50)",DRINKING WATER,0; 500; 1000; 2000 MG/L FOR 105 WKS (STUDY DURATION: 105 WKS),PANCREAS: ADENOMA OR CARCINOMA,EQUIVOCAL,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF SODIUM CHLORATE (CAS NO. 7775-09-9) IN F344/N  RATS AND B6C3F1 MICE (DRINKING WATER STUDIES); NATL. TOXICOL. PROGRAM  TECH. REP. SER. 517:1-256, 2005]"
6930,363907132,516902,[O-]Cl(=O)=O.[Na+],Inactive,,,,MOUSE,"B6C3F1/MALE (50, 50, 50, 50)",DRINKING WATER,0; 500; 1000; 2000 MG/L FOR 105 WKS (STUDY DURATION: 105 WKS),,NEGATIVE,"[NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS  STUDIES OF SODIUM CHLORATE (CAS NO. 7775-09-9) IN F344/N  RATS AND B6C3F1 MICE (DRINKING WATER STUDIES); NATL. TOXICOL. PROGRAM  TECH. REP. SER. 517:1-256, 2005]"
6931,363907151,37034,C1=C(C(=CC(=C1Cl)Cl)Cl)C2=CC(=C(C=C2Cl)Cl)Cl,Inactive,,,,RAT,SPRAGUE-DAWLEY/FEMALE,ORAL,0; 10; 100; 300; 1000; 3000 NG/KG/D (STUDY DURATION: 2 YRS),,NEGATIVE,"[YOSHIZAWA,K, WALKER,NJ, JOKINEN,MP, BRIX,AE, SELLS,DM,  MARSH,T, WYDE,ME, ORZECH,D, HASEMAN,JK, AND NYSKA,A;  GINGIVAL CARCINOGENICITY IN FEMALE HARLAN SPRAGUE-DAWLEY  RATS FOLLOWING TWO YEAR ORAL TREATMENT WITH  2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN AND DIOXIN-LIKE  COMPOUNDS. [ERRATUM TO DOCUMENT CITED IN CA142:234804];  TOXICOL. SCI. 83(2):405-406, 2005]"
6932,363907151,37034,C1=C(C(=CC(=C1Cl)Cl)Cl)C2=CC(=C(C=C2Cl)Cl)Cl,Unspecified,,,,Rat,Harlan Sprague-Dawley/Female,Gavage,0; 10; 100; 300; 1000; 3000 ug/kg in corn oil:acetone (99:1) 5 d/wk for 2 yr,"Liver: Cholangioma   0/53, 0/54, 0/53, 0/53, 2/53, 0/51)",Equivocal,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-529 Y06]"
6933,363907151,37034,C1=C(C(=CC(=C1Cl)Cl)Cl)C2=CC(=C(C=C2Cl)Cl)Cl,Unspecified,,,,Rat,Harlan Sprague-Dawley/Female,Gavage,0; 3000 ug/kg in corn oil:acetone (99:1) 5 d/wk for 30 wk then vehicle for remainder of 2 yr study,"Liver: Cholangioma  (0/53, 2/50)",Equivocal,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-529 Y06]"
6934,363907180,108004,C(C(=O)O)C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)O)C(CC(=O)[O-])(C(=O)[O-])O.[Pu],Active,,,,MOUSE,C3H/FEMALE,IP INJECTION ONCE,100; 500; 1000; 5000 BQ (STUDY DURATION: LIFESPAN),BONE: OSTEOSARCOMAS,POSITIVE,"[OGHISO,Y AND YAMADA,Y; STRAIN DIFFERENCES IN CARCINOGENIC AND HEMATOPOIETIC RESPONSES OF MICE AFTER INJECTION OF PLUTONIUM CITRATE; RADIAT. RES. 154(4):447-454, 2000]"
6935,363907180,108004,C(C(=O)O)C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)O)C(CC(=O)[O-])(C(=O)[O-])O.[Pu],Active,,,,MOUSE,C57BL/6/FEMALE,IP INJECTION ONCE,100; 500; 1000; 5000 BQ (STUDY DURATION: LIFESPAN),BONE: OSTEOSARCOMAS,POSITIVE,"[OGHISO,Y AND YAMADA,Y; STRAIN DIFFERENCES IN CARCINOGENIC AND HEMATOPOIETIC RESPONSES OF MICE AFTER INJECTION OF PLUTONIUM CITRATE; RADIAT. RES. 154(4):447-454, 2000]"
6936,363907180,108004,C(C(=O)O)C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)O)C(CC(=O)[O-])(C(=O)[O-])O.[Pu],Active,,,,MOUSE,BC3F1/FEMALE,IP INJECTION ONCE,100; 500; 1000; 5000 BQ (STUDY DURATION: LIFESPAN),BONE: OSTEOSARCOMAS,POSITIVE,"[OGHISO,Y AND YAMADA,Y; STRAIN DIFFERENCES IN CARCINOGENIC AND HEMATOPOIETIC RESPONSES OF MICE AFTER INJECTION OF PLUTONIUM CITRATE; RADIAT. RES. 154(4):447-454, 2000]"
6937,363907185,213021,CC(=NC#N)N(C)CC1=CN=C(C=C1)Cl,Inactive,,,,Rat,Crl:CD BR/Female,Oral,0; 160; 400; 1000 ppm (0; 8.8; 22.6; 60.0 mg/kg/day) in feed for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACETAMIPRID (OCTOBER 11, 2000)]"
6938,363907185,213021,CC(=NC#N)N(C)CC1=CN=C(C=C1)Cl,Inactive,,,,Rat,Crl:CD BR/Male,Oral,0; 160; 400; 1000 ppm (0; 7.1; 17.5; 46.4 mg/kg/day) in feed for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACETAMIPRID (OCTOBER 11, 2000)]"
6939,363907185,213021,CC(=NC#N)N(C)CC1=CN=C(C=C1)Cl,Inactive,,,,Mouse,Crl:CD-1 (ICR)BR/Male,Oral,0; 130; 400; 1200 ppm (0; 20; 66; 186 mg/kg/day) in feed for 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACETAMIPRID (OCTOBER 11, 2000)]"
6940,363907185,213021,CC(=NC#N)N(C)CC1=CN=C(C=C1)Cl,Inactive,,,,Mouse,Crl:CD-1 (ICR)BR/Female,Oral,0; 130; 400; 1200 ppm (0; 25; 76; 215 mg/kg/day) in feed for 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACETAMIPRID (OCTOBER 11, 2000)]"
6941,363907186,86412,CSC(=O)C1=C2C(=CC=C1)N=NS2,Active,,,,Rat,Tif:Ralf (SPF) (Rll/1 x Rll/2 hybrid)/Male,Oral,0; 20; 200; 2500; 7500 ppm (0; 0.77; 7.77; 96.9; 312 mg/kg/day) in feed for 2 years,Small intestine: Mucinous carcinoma (1/60; 1/59; 2/59 at three highest doses),Positive; DPR reviewer notes that only 1 case of mucinous carcinoma has been seen in historical controls from 12 studies evaluated,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACIBENZOLAR-S-METHYL  (JANUARY 10, 2006)]"
6942,363907186,86412,CSC(=O)C1=C2C(=CC=C1)N=NS2,Inactive,,,,Rat,Tif:Ralf (SPF) (Rll/1 x Rll/2 hybrid)/Female,Oral,0; 20; 200; 2500; 7500 ppm (0; 0.90; 9.08; 111; 388 mg/kg/day) in feed for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACIBENZOLAR-S-METHYL  (JANUARY 10, 2006)]"
6943,363907186,86412,CSC(=O)C1=C2C(=CC=C1)N=NS2,Inactive,,,,Mouse,Tif:MAGf (SPF) (NIH x MAG hybrid)/Male,Oral,0; 10; 100; 2000; 6000 ppm (0; 1.14; 11.1; 237; 698 mg/kg/day) in feed for 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACIBENZOLAR-S-METHYL  (JANUARY 10, 2006)]"
6944,363907186,86412,CSC(=O)C1=C2C(=CC=C1)N=NS2,Inactive,,,,Mouse,Tif:MAGf (SPF) (NIH x MAG hybrid)/Female,Oral (diet),0; 10; 100; 2000; 6000 ppm (0; 1.14; 10.8; 234; 696 mg/kg/day) for 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ACIBENZOLAR-S-METHYL  (JANUARY 10, 2006)]"
6945,363907187,213012,C1=C(C(=C(N=C1Cl)C(=O)O)Cl)N,Inactive,,,,Rat,F344/Male,Oral,0; 5; 50; 500; 1000 mg/kg/d in feed for 24 mo,,Negative; Purity was 94.5%,"[U.S. ENVIRONMENTAL PROTECTION AGENCY; AMINOPYRALID: AGGREGATE HUMAN HEALTH RISK ASSESSMENT FOR THE PROPOSED USES ON WHEAT, GRASSES, NON-CROPLAND AREAS, AND NATURAL AREAS. (JULY 12, 2005)]"
6946,363907187,213012,C1=C(C(=C(N=C1Cl)C(=O)O)Cl)N,Inactive,,,,Rat,F344/Female,Oral,0; 5; 50; 500; 1000 mg/kg/d in feed for 24 mo,,Negative; Purity was 94.5%,"[U.S. ENVIRONMENTAL PROTECTION AGENCY; AMINOPYRALID: AGGREGATE HUMAN HEALTH RISK ASSESSMENT FOR THE PROPOSED USES ON WHEAT, GRASSES, NON-CROPLAND AREAS, AND NATURAL AREAS. (JULY 12, 2005)]"
6947,363907187,213012,C1=C(C(=C(N=C1Cl)C(=O)O)Cl)N,Inactive,,,,Mouse,CD-1/Female,Oral,0; 5; 250; 1000 mg/kg/d in feed for 18 mo,,Negative; Purity was 94.5%,"[U.S. ENVIRONMENTAL PROTECTION AGENCY; AMINOPYRALID: AGGREGATE HUMAN HEALTH RISK ASSESSMENT FOR THE PROPOSED USES ON WHEAT, GRASSES, NON-CROPLAND AREAS, AND NATURAL AREAS. (JULY 12, 2005)]"
6948,363907187,213012,C1=C(C(=C(N=C1Cl)C(=O)O)Cl)N,Inactive,,,,Mouse,CD-1/Male,Oral,0; 5; 250; 1000 mg/kg/d in feed for 18 mo,,Negative; Purity was 94.5%,"[U.S. ENVIRONMENTAL PROTECTION AGENCY; AMINOPYRALID: AGGREGATE HUMAN HEALTH RISK ASSESSMENT FOR THE PROPOSED USES ON WHEAT, GRASSES, NON-CROPLAND AREAS, AND NATURAL AREAS. (JULY 12, 2005)]"
6949,363907188,14621415,CC(C)NC1=NC(=NC(=N1)NCC(=O)O)Cl,Active,,,,Rat,Crl:CD BR/Male,Oral,0; 5; 15; 30; 300; 900 ppm in diet for 24 mo,Thyroid: Thyroid follicular cell adenoma,Positive (At highest dose only); CA DPR describes as a possible adverse effect,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR PROGLINAZINE (SEPTEMBER 7, 2000)]"
6950,363907188,14621415,CC(C)NC1=NC(=NC(=N1)NCC(=O)O)Cl,Inactive,,,,Rat,Crl:CD BR/Female,Oral,0; 5; 15; 30; 300; 900 ppm in diet for 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR PROGLINAZINE (SEPTEMBER 7, 2000)]"
6951,363907188,14621415,CC(C)NC1=NC(=NC(=N1)NCC(=O)O)Cl,Active,,,,Mouse,Crl:CD-1(ICR)BR/Male,Oral,0; 10; 30; 300; 900 ppm in diet for 18 mo,Liver: Multiple hepatocellular adenomas (3/60 at 900 ppm vs. 0/60 in controls) Blood Vessels: Hemangiosarcomas (2/60 at 900 ppm vs. 0/60 in controls),Positive (Only at highest dose),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR PROGLINAZINE (SEPTEMBER 7, 2000)]"
6952,363907188,14621415,CC(C)NC1=NC(=NC(=N1)NCC(=O)O)Cl,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Female,Oral,0; 10; 30; 300; 900 ppm in diet for 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR PROGLINAZINE (SEPTEMBER 7, 2000)]"
6953,363907189,2319,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Active,,,,Rat,CDF (F344)CrlBR/Male (50/sex/group),Oral,0; 10; 100; 2500; 5000 ppm (about 0; 0.5; 5.4; 136; 275 mg/kg/day ) in diet for 104 wks,Thyroid: thyroid follicular adenomas and carcinomas (1/50; 1/50; 1/50; 7/50; 8/50) Liver: Hepatocellular tumors (primarily adenomas) (2/50; 2/50; 1/50; 5/50; 11/50),Positive; CA DPR judged the study as showing possible adverse effects,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENFLURALIN (APRIL 21, 2000)]"
6954,363907189,2319,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Active,,,,Rat,CDF (F344)CrlBR/Female (50/sex/group),Oral,0; 10; 100; 2500; 5000 ppm (about 0; 0.7; 6.8; 168; 331 mg/kg/day ) in diet for 104 wks,Thyroid: thyroid follicular adenomas and carcinomas (0/50; 0/50; 1/50; 5/50; 4/50),Positive; CA DPR judged the study as showing possible adverse effects,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENFLURALIN (APRIL 21, 2000)]"
6955,363907189,2319,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,Mouse,B6C3F1/Male,Oral,0; 0.005; 0.03; 0.15% in diet for 2 yrs in 2 replicates of 30 mice/sex/group,,Negative; Slight but not statistically elevated incidence of  total neoplastic tumors (adenomas and carcinomas) in high dose females,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENFLURALIN (APRIL 21, 2000)]"
6956,363907189,2319,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,Mouse,B6C3F1/Female,Oral,0; 0.005; 0.03; 0.15% in diet for 2 yrs in 2 replicates of 30 mice/sex/group,,Negative; Slight but not statistically elevated incidence of total neoplastic tumors (adenomas and carcinomas) in high dose females,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENFLURALIN (APRIL 21, 2000)]"
6957,363907191,16181,CCSC(=O)N(CC(C)C)CC(C)C,Inactive,,,,Mouse,CD-1/Male (50/sex/group),Oral,0; 20; 80; 320 mg/kg/d in diet for 2 yrs,,Negative; Probable purity of 97-98%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BUTYLATE (FEBRUARY 27, 1998)]"
6958,363907191,16181,CCSC(=O)N(CC(C)C)CC(C)C,Inactive,,,,Mouse,CD-1/Female (50/sex/group),Oral,0; 20; 80; 320 mg/kg/d in diet for 2 yrs,,Negative; Probable purity of 97-98%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BUTYLATE (FEBRUARY 27, 1998)]"
6959,363907191,16181,CCSC(=O)N(CC(C)C)CC(C)C,Inactive,,,,Rat,Sprague-Dawley/Male (70/sex/group),Oral,"0; 50; 100; 200; 400 mg/kg/d in diet for 12, 18, or 24 mo",,"Negative; Probable purity of 97-98% (There were probably 10 animals in each interim sacrifice, but the information is not given by CA DPR)","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BUTYLATE (FEBRUARY 27, 1998)]"
6960,363907191,16181,CCSC(=O)N(CC(C)C)CC(C)C,Inactive,,,,Rat,Sprague-Dawley/Female (70/sex/group),Oral,"0; 50; 100; 200; 400 mg/kg/d in diet for 12, 18, or 24 mo",,"Negative; Probable purity of 97-98% (There were probably 10 animals in each interim sacrifice, but the information is not given by CA DPR)","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BUTYLATE (FEBRUARY 27, 1998)]"
6961,363907192,23682789,COC1=CC(=NC(=N1)OC2=C(C(=CC=C2)OC3=NC(=CC(=N3)OC)OC)C(=O)[O-])OC.[Na+],Inactive,,,,Rat,F344/Male (48/sex/dose),Oral,0; 20; 200; 3500; 7000 ppm in diet for 104 wk,,"Negative; Purity 97.2%; Interim sacrifices of 10 additional animals/sex/dose at wks 13, 26, 52, 78","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KIH-2023 (BISPYRIBAC-SODIUM) (MAY 23, 2001)]"
6962,363907192,23682789,COC1=CC(=NC(=N1)OC2=C(C(=CC=C2)OC3=NC(=CC(=N3)OC)OC)C(=O)[O-])OC.[Na+],Inactive,,,,Rat,F344/Female (48/sex/dose),Oral,0; 20; 200; 3000; 10000 ppm in diet for 104 wk,,"Negative; Purity 97.2%; Interim sacrifices of 10 additional animals/sex/dose at wks 13, 26, 52, 78","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KIH-2023 (BISPYRIBAC-SODIUM) (MAY 23, 2001)]"
6963,363907192,23682789,COC1=CC(=NC(=N1)OC2=C(C(=CC=C2)OC3=NC(=CC(=N3)OC)OC)C(=O)[O-])OC.[Na+],Inactive,,,,Mouse,B6C3F1/Male (50/sex/dose),Oral,0; 10; 100; 2500; 5000 ppm in diet for 104 wk,,"Negative; Purity 98.4%; Interim sacrifices of 10 additional animals/sex/dose at wks 26, 52, 78","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KIH-2023 (BISPYRIBAC-SODIUM) (MAY 23, 2001)]"
6964,363907192,23682789,COC1=CC(=NC(=N1)OC2=C(C(=CC=C2)OC3=NC(=CC(=N3)OC)OC)C(=O)[O-])OC.[Na+],Inactive,,,,Mouse,B6C3F1/Female (50/sex/dose),Oral,0; 10; 100; 2500; 5000 ppm in diet for 104 wk,,"Negative; Purity 98.4%; Interim sacrifices of 10 additional animals/sex/dose at wks 26, 52, 78","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KIH-2023 (BISPYRIBAC-SODIUM) (MAY 23, 2001)]"
6965,363907193,12932,CC(C)OP(=S)(OC(C)C)SCCNS(=O)(=O)C1=CC=CC=C1,Inactive,,,,Mouse,CD-1/Male (50/group),Oral,0; 10; 30; 100 mg/kg/d in feed,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENSULIDE (MARCH 26, 2001)]"
6966,363907193,12932,CC(C)OP(=S)(OC(C)C)SCCNS(=O)(=O)C1=CC=CC=C1,Inactive,,,,Mouse,CD-1/Female (50/group),Oral,0; 10; 30; 100 mg/kg/d in feed,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BENSULIDE (MARCH 26, 2001)]"
6967,363907194,176879,CC(C)OC(=O)NNC1=C(C=CC(=C1)C2=CC=CC=C2)OC,Inactive,,,,Rat,Sprague-Dawley/Male (60/group),Oral,0; 20; 80; 200 ppm in diet for 104 wks,,Negative; Purity 92.5%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENAZATE (AUGUST 25, 2000)]"
6968,363907194,176879,CC(C)OC(=O)NNC1=C(C=CC(=C1)C2=CC=CC=C2)OC,Inactive,,,,Rat,Sprague-Dawley/Female (60/group),Oral,0; 20; 80; 160 ppm in diet for 104 wks,,Negative; Purity 92.5%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENAZATE (AUGUST 25, 2000)]"
6969,363907194,176879,CC(C)OC(=O)NNC1=C(C=CC(=C1)C2=CC=CC=C2)OC,Inactive,,,,Mouse,B6C3F1/Female (50/group),Oral,0; 10; 100; 175 ppm in diet for 78 wks,,Negative; Purity 92.5%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENAZATE (AUGUST 25, 2000)]"
6970,363907195,9411,CCC(C)N1C(=O)C(=C(NC1=O)C)Br,Inactive,,,,Rat,Crl:CD (BR)/Male (62/sex/group),Oral,0; 50; 250; 2500 ppm in diet for 2 yr,,Negative (MTD may have been exceeded); Purity: 95-99%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMACIL (NOVEMBER 14, 1997)]"
6971,363907195,9411,CCC(C)N1C(=O)C(=C(NC1=O)C)Br,Inactive,,,,Rat,Crl:CD (BR)/Female (62/sex/group),Oral,0; 50; 250; 2500 ppm in diet for 2 yr,,Negative (MTD may have been exceeded); Purity: 95-99%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMACIL (NOVEMBER 14, 1997)]"
6972,363907195,9411,CCC(C)N1C(=O)C(=C(NC1=O)C)Br,Active,,,,Mouse,CD-1/Male (80/sex/dose),Oral,0; 250; 1250; 5000 ppm in diet for 18 mo,Liver: significant increase in combined hepatocellular adenomas and carcinomas at highest dose; liver lesions (neoplastic or nonneoplastic) were observed at all doses,Positive: Purity 95%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMACIL (NOVEMBER 14, 1997)]"
6973,363907195,9411,CCC(C)N1C(=O)C(=C(NC1=O)C)Br,Inactive,,,,Mouse,CD-1/Female (80/sex/dose),Oral,0; 250; 1250; 5000 ppm in diet for 18 mo,,Negative; Purity 95%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMACIL (NOVEMBER 14, 1997)]"
6974,363907196,6442842,CC1=C(C=CC=C1C2=CC=CC=C2)COC(=O)[C@@H]3[C@@H](C3(C)C)/C=C(/C(F)(F)F)\Cl,Inactive,,,,Rat,Sprague-Dawley/Male (60/group),Oral,0; 12; 50; 100; 200 ppm in feed for 2 yr,,Negative; Purity 88.35% (98% cis- and 2% trans-isomer),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENTHRIN (APRIL 4, 2000)]"
6975,363907196,6442842,CC1=C(C=CC=C1C2=CC=CC=C2)COC(=O)[C@@H]3[C@@H](C3(C)C)/C=C(/C(F)(F)F)\Cl,Inactive,,,,Rat,Sprague-Dawley/Female (50/sex/group),Oral,0; 12; 50; 100; 200 ppm in feed for 2 yr,,Negative; Purity 88.35% (98% cis- and 2% trans-isomer),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENTHRIN (APRIL 4, 2000)]"
6976,363907196,6442842,CC1=C(C=CC=C1C2=CC=CC=C2)COC(=O)[C@@H]3[C@@H](C3(C)C)/C=C(/C(F)(F)F)\Cl,Inactive,,,,Mouse,Swiss-Webster Derived Tac(SW)fBR/Female (50/sex/group),Oral,0; 50; 200; 500; 600 ppm in feed for 20-21 months,,Negative; Purity 88.35% (98% cis- and 2% trans-isomer),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENTHRIN (APRIL 4, 2000)]"
6977,363907196,6442842,CC1=C(C=CC=C1C2=CC=CC=C2)COC(=O)[C@@H]3[C@@H](C3(C)C)/C=C(/C(F)(F)F)\Cl,Active,,,,Mouse,Swiss-Webster Derived Tac(SW)fBR/Male (50/sex/group),Oral,0; 50; 200; 500; 600 ppm in feed for 20-21 months,"Urinary bladder: Leiomyosarcoma (Dose related increase, 29% at 600 ppm)",Positive; Purity 88.35% (98% cis- and 2% trans-isomer),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BIFENTHRIN (APRIL 4, 2000)]"
6978,363907197,23667633,CCOC(=O)C(=C(C1=CC=CC=C1)N[O-])C(=O)OCC.[Na+],Inactive,,,,Mouse,Swiss Albino/Female (60/sex/group),Oral,0; 10; 30; 100 ppm in feed for 18 mo,,Negative; Purity 97%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMOXYNIL OCTANOATE, BROMOXYNIL (AUGUST 11, 2005)]"
6979,363907197,23667633,CCOC(=O)C(=C(C1=CC=CC=C1)N[O-])C(=O)OCC.[Na+],Active,,,,Mouse,Swiss Albino/Male (60/sex/group),Oral,0; 10; 30; 100 ppm in feed for 18 mo,"Liver: Hepatocellular adenoma (2/47, 4/48, 3/49, 5/53); Hepatocellular carcinoma (0/47, 0/48, 2/49, 4/53); Combined (2/47, 4/48, 5/49, 9/53)",Positive (statistically significant trend but not incidence); Purity 97%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMOXYNIL OCTANOATE, BROMOXYNIL (AUGUST 11, 2005)]"
6980,363907197,23667633,CCOC(=O)C(=C(C1=CC=CC=C1)N[O-])C(=O)OCC.[Na+],Inactive,,,,Rat,Sprague-Dawley /Male (70/sex/group in dosed animals; 105 controls/sex),Oral,0; 60; 190; 600 ppm in feed for 104 wks,,Negative: Purity 98.5%; Liver: Nonneoplastic liver lesions (eosinophilic cellular alteration and spongiosis hepatitis),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMOXYNIL OCTANOATE, BROMOXYNIL (AUGUST 11, 2005)]"
6981,363907197,23667633,CCOC(=O)C(=C(C1=CC=CC=C1)N[O-])C(=O)OCC.[Na+],Inactive,,,,Rat,Sprague-Dawley /Female (70/sex/group in dosed animals; 105 controls/sex),Oral,0; 60; 190; 600 ppm in feed for 104 wks,,Negative: Purity 98.5%; Liver: Nonneoplastic liver lesions (eosinophilic cellular alteration and spongiosis hepatitis),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR BROMOXYNIL OCTANOATE, BROMOXYNIL (AUGUST 11, 2005)]"
6982,363907198,91778,CCOCN1C(=C(C(=C1C(F)(F)F)Br)C#N)C2=CC=C(C=C2)Cl,Inactive,,,,Rat,Sprague-Dawley/Female (65/group),Oral,0; 60; 300; 600 ppm in diet for up to 104 wk,,Negative (Study details not given in source; purity 94.5%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORFENAPYR (AUGUST 24, 2001)]"
6983,363907198,91778,CCOCN1C(=C(C(=C1C(F)(F)F)Br)C#N)C2=CC=C(C=C2)Cl,Inactive,,,,Rat,Sprague-Dawley/Male (65/group),Oral,0; 60; 300; 600 ppm in diet for up to 104 wk,,Negative (Study details not given in source; purity 94.5%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORFENAPYR (AUGUST 24, 2001)]"
6984,363907198,91778,CCOCN1C(=C(C(=C1C(F)(F)F)Br)C#N)C2=CC=C(C=C2)Cl,Inactive,,,,Mouse,CD-1/Female (65/group),Oral,0; 20; 120; 240 ppm in diet for 80 wk,,Negative (Study details not given in source; purity 94.5%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORFENAPYR (AUGUST 24, 2001)]"
6985,363907198,91778,CCOCN1C(=C(C(=C1C(F)(F)F)Br)C#N)C2=CC=C(C=C2)Cl,Inactive,,,,Mouse,CD-1/Male (65/group),Oral,0; 20; 120; 240 ppm in diet for 80 wk,,Negative (Study details not given in source; purity 94.5%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORFENAPYR (AUGUST 24, 2001)]"
6986,363907199,5564,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,Inactive,,,,Rat,Sprague-Dawley/Female (60/group),Oral,"0; 300; 1,200; 3,000 ppm in diet for 78 wk",,Negative (Study details not given in source; purity 99%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR TRICLOSAN (JULY 24, 2007)]"
6987,363907199,5564,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,Inactive,,,,Rat,Sprague-Dawley/Male (60/group),Oral,"0; 300; 1,200; 3,000 ppm in diet for 78 wk",,Negative (Study details not given in source; purity 99%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR TRICLOSAN (JULY 24, 2007)]"
6988,363907199,5564,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,Inactive,,,,Hamster,Bio FID Alexander Syrian/Female (60/group),Oral,0; 12.5; 75; 250 mg/kg in diet for 90-95 wk,,Negative (Study details not given in source; purity 99.5%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR TRICLOSAN (JULY 24, 2007)]"
6989,363907199,5564,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,Inactive,,,,Hamster,Bio FID Alexander Syrian/Male (60/group),Oral,0; 12.5; 75; 250 mg/kg in diet for 90-95 wk,,Negative (Study details not given in source; purity 99.5%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR TRICLOSAN (JULY 24, 2007)]"
6990,363907204,206044,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC,Inactive,,,,Mouse,Crl:CD-1 (ICR)BR/Male (60/group),Oral,0; 0; 1; 5; 20 mg/kg (initial group) or 0; 40 mg/kg (supplemental group) by gavage daily for up to 105 wks; vehicle controls administered alkaline PEG-400,"GALLBLADDER: adenoma (1/60 at  20 mg/kg, 2/60 at 40 mg/kg); not significant","Negative (Although statistical significance was not obtained, the authors considered the gallbladder adenomas to be related to the chemical, which is a peroxisome proliferator-activated receptor alpha/gamma agonist. Slight increases in hepatocellular carcinoma and malignant lymphoma were within historical limits and considered not treatment-related.)","[TANNEHILL-GREGG,SH, SANDERSON,TP, MINNEMA,D, VOELKER,R, ULLAND,B, COHEN,SM, ARNOLD,LL, SCHILLING,BE, WAITES,CR AND DOMINICK,MA; RODENT CARCINOGENICITY PROFILE OF THE ANTIDIABETIC DUAL PPAR ALPHA AND GAMMA AGONIST MURAGLITAZAR; TOXICOL. SCI. 98(1):258-270, 2007]"
6991,363907204,206044,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC,Inactive,,,,Mouse,Crl:CD-1 (ICR)BR/Female (60/group),Oral,0; 0; 1; 5; 20 mg/kg (initial group) or 0; 40 mg/kg (supplemental group) by gavage daily for up to 105 wks; vehicle controls administered alkaline PEG-400,,Negative (Slight increases in hemangiosarcoma (multiple organs) and mammary gland carcinoma were not considered treatment related.),"[TANNEHILL-GREGG,SH, SANDERSON,TP, MINNEMA,D, VOELKER,R, ULLAND,B, COHEN,SM, ARNOLD,LL, SCHILLING,BE, WAITES,CR AND DOMINICK,MA; RODENT CARCINOGENICITY PROFILE OF THE ANTIDIABETIC DUAL PPAR ALPHA AND GAMMA AGONIST MURAGLITAZAR; TOXICOL. SCI. 98(1):258-270, 2007]"
6992,363907204,206044,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC,Active,,,,Rat,Hsd:Sprague Dawley SD/Male (65/group),Oral,0; 0; 1; 5; 30; 50 mg/kg by gavage daily for up to 105 wks; vehicle controls administered alkaline PEG-400,"URINARY BLADDER: transitional cell carcinoma and papilloma at 5, 30, and 50 mg/kg associated with increased urinary solids. SUBCUTANEOUS TISSUE: combined lipoma, liposarcoma, and fibrolipoma (50 mg/kg only).","Positive, Muraglitazar reported to be a peroxisome proliferator-activated receptor alpha/gamma agonist.","[TANNEHILL-GREGG,SH, SANDERSON,TP, MINNEMA,D, VOELKER,R, ULLAND,B, COHEN,SM, ARNOLD,LL, SCHILLING,BE, WAITES,CR AND DOMINICK,MA; RODENT CARCINOGENICITY PROFILE OF THE ANTIDIABETIC DUAL PPAR ALPHA AND GAMMA AGONIST MURAGLITAZAR; TOXICOL. SCI. 98(1):258-270, 2007]"
6993,363907204,206044,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC,Active,,,,Rat,Hsd:Sprague Dawley SD/Female (65/group),Oral,0; 0; 1; 5; 30; 50 mg/kg by gavage daily for up to 105 wks; vehicle controls administered alkaline PEG-400,SUBCUTANEOUS TISSUE: lipoma (50 mg/kg only). UTERUS: Squamous cell carcinoma; adenoma and carcinoma; and squamous cell papilloma and carcinoma (increased incidences but trends not statistically significant).,Positive (Weak response),"[TANNEHILL-GREGG,SH, SANDERSON,TP, MINNEMA,D, VOELKER,R, ULLAND,B, COHEN,SM, ARNOLD,LL, SCHILLING,BE, WAITES,CR AND DOMINICK,MA; RODENT CARCINOGENICITY PROFILE OF THE ANTIDIABETIC DUAL PPAR ALPHA AND GAMMA AGONIST MURAGLITAZAR; TOXICOL. SCI. 98(1):258-270, 2007]"
6994,363907205,2728,CC(C)OC(=O)NC1=CC(=CC=C1)Cl,Inactive,,,,Mouse,CD-1/Male (50/group),Oral,"0; 100; 500; 1,000 mg/kg/day in diet for 18 mo",,Negative (Study details not given in source; purity 96.2%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORPROPHAM (JUNE 17, 2003)]"
6995,363907205,2728,CC(C)OC(=O)NC1=CC(=CC=C1)Cl,Inactive,,,,Mouse,CD-1/Female (50/group),Oral,"0; 100; 500; 1,000 mg/kg/day in diet for 18 mo",,Negative (Study details not given in source; purity 96.2%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORPROPHAM (JUNE 17, 2003)]"
6996,363907205,2728,CC(C)OC(=O)NC1=CC(=CC=C1)Cl,Active,,,,Rat,Sprague-Dawley/Male (50/group),Oral,"0; 30; 100; 500; 1,000 mg/kg/day in diet for 24 mo","Testis: Interstitial cell tumors (1, 4, 2, 4, 9; Significant at highest dose)",Positive (Study details not given in source; purity 96.2%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORPROPHAM (JUNE 17, 2003)]"
6997,363907205,2728,CC(C)OC(=O)NC1=CC(=CC=C1)Cl,Inactive,,,,Rat,Sprague-Dawley/Female (50/group),Oral,"0; 30; 100; 500; 1,000 mg/kg/day in diet for 24 mo",,Negative (Study details not given in source; purity 96.2%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORPROPHAM (JUNE 17, 2003)]"
6998,363907206,47491,CC1=NC(=NC(=N1)OC)NC(=O)NS(=O)(=O)C2=CC=CC=C2Cl,Inactive,,,,Rat,CD/Male (50/group),Oral,"0; 100; 500; 2,500 ppm in diet for 2 yr",,Negative (Study details not given in source; purity 92-95%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORSULFURON (SEPTEMBER 20, 1991)]"
6999,363907206,47491,CC1=NC(=NC(=N1)OC)NC(=O)NS(=O)(=O)C2=CC=CC=C2Cl,Inactive,,,,Rat,CD/Female (50/group),Oral,"0; 100; 500; 2,500 ppm in diet for 2 yr",,Negative (Study details not given in source; purity 92-95%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORSULFURON (SEPTEMBER 20, 1991)]"
7000,363907207,2943,COC(=O)C1=C(C(=C(C(=C1Cl)Cl)C(=O)OC)Cl)Cl,Active,,,,Rat,Sprague-Dawley/Male (60/group),Oral,"0; 1; 10; 50; 500; 1,000 mg/kg/day in diet for 2 yr",Thyroid: Follicular cell adenomas,Positive (Evaluated as adverse effect by CA DPR; study details not given in source; purity 97.7%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORTHAL-DIMETHYL (DCPA) (APRIL 26, 1994)]"
7001,363907207,2943,COC(=O)C1=C(C(=C(C(=C1Cl)Cl)C(=O)OC)Cl)Cl,Active,,,,Rat,Sprague-Dawley/Female (60/group),Oral,"0; 1; 10; 50; 500; 1,000 mg/kg/day in diet for 2 yr",Thyroid: Follicular cell adenomas. Liver: Hepatocellular tumors,Positive (as evaluated by CA DPR; study details not given in source; purity 97.7%,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORTHAL-DIMETHYL (DCPA) (APRIL 26, 1994)]"
7002,363907207,2943,COC(=O)C1=C(C(=C(C(=C1Cl)Cl)C(=O)OC)Cl)Cl,Inactive,,,,Mouse,CD-1/Male (60/group),Oral,"0; 100; 1,000; 3,500; 7,500 ppm in diet for 2 yr",,Negative (Study details not given in source; purity 96.7%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORTHAL-DIMETHYL (DCPA) (APRIL 26, 1994)]"
7003,363907207,2943,COC(=O)C1=C(C(=C(C(=C1Cl)Cl)C(=O)OC)Cl)Cl,Active,,,,Mouse,CD-1/Female (60/group),Oral,"0; 100; 1,000; 3,500; 7,500 ppm in diet for 2 yr",Liver: Hepatocellular tumors (Significant only at highest dose),Positive  (Study details not given in source; purity 96.7%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CHLORTHAL-DIMETHYL (DCPA) (APRIL 26, 1994)]"
7004,363907208,135491728,CC/C(=N\OC/C=C/Cl)/C1=C(CC(CC1=O)CC(C)SCC)O,Inactive,,,,Mouse,???/Male (50/group),Oral,"0; 20; 200; 1,000; 2,000 ppm increased to 3,000 ppm after 15th wk in diet for 78 wk",,Negative (Study details not given in source; purity 83.3%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CLETHODIM  (NOVEMBER 9, 1993)]"
7005,363907208,135491728,CC/C(=N\OC/C=C/Cl)/C1=C(CC(CC1=O)CC(C)SCC)O,Inactive,,,,Mouse,???/Female (50/group),Oral,"0; 20; 200; 1,000; 2,000 ppm increased to 3,000 ppm after 15th wk in diet for 78 wk",,Negative (Study details not given in source; purity 83.3%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CLETHODIM  (NOVEMBER 9, 1993)]"
7006,363907210,213027,CN=C(NCC1=CN=C(S1)Cl)N[N+](=O)[O-],Inactive,,,,Rat,???/Male (60/group),Oral,"0; 150; 500; 1,500; 3,000 ppm in diet for 2 yr",,Negative (Study details not given in source; purity 95.2%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CLOTHIANIDIN (APRIL 28, 2003)]"
7007,363907210,213027,CN=C(NCC1=CN=C(S1)Cl)N[N+](=O)[O-],Inactive,,,,Rat,???/Female (60/group),Oral,"0; 150; 500; 1,500; 3,000 ppm in diet for 2 yr",,Negative (Study details not given in source; purity 95.2%),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CLOTHIANIDIN (APRIL 28, 2003)]"
7008,363907213,180089,CCCCOC(=O)[C@@H](C)OC1=CC=C(C=C1)OC2=C(C=C(C=C2)C#N)F,Inactive,,,,Mouse,ICR (Crj:CD-1)/(Male (52/group),Oral,0; 3; 10; 100 ppm (0; 0.31; 0.99; 10.1 mg/kg/day) of 97.1% pure cyhalofop-butyl in diet for 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYHALOFOP-BUTYL (FEBRUARY 12, 2001)]"
7009,363907213,180089,CCCCOC(=O)[C@@H](C)OC1=CC=C(C=C1)OC2=C(C=C(C=C2)C#N)F,Inactive,,,,Mouse,ICR (Crj:CD-1)/Female (52/group),Oral,0; 3; 10; 100 ppm (0; 0.29; 0.99; 10.3 mg/kg/day) of 97.1% pure cyhalofop-butyl in diet for 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYHALOFOP-BUTYL (FEBRUARY 12, 2001)]"
7010,363907214,38283,CC(=CC1C(C1(C)C)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,Inactive,,,,Mouse,B6C3F1/Male (80/group),Oral,"0; 100; 300; 1,000 ppm of 94.6-94.9% pure cyphenothrin for 104 wk",,Negative (Study details not presented by DPR evaluator),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYPHENOTHRIN (MAY 1, 1995)]"
7011,363907214,38283,CC(=CC1C(C1(C)C)C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C,Inactive,,,,Mouse,B6C3F1/Female (80/group),Oral,"0; 100; 300; 1,000 ppm of 94.6-94.9% pure cyphenothrin for 104 wk",,Negative (Study details not presented by DPR evaluator),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYPHENOTHRIN (MAY 1, 1995)]"
7012,363907215,104926,CC1(C(C1C(=O)OC(C#N)C2=CC(=C(C=C2)F)OC3=CC=CC=C3)C=C(Cl)Cl)C,Inactive,,,,Rat,Fisher 344/Male (55/dose),Oral,0; 50; 225; 450 ppm (2.6; 11.6; 22.8 mg/kg/day) of 93.9-95.1% pure cyfluthrin in feed for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYFLUTHRIN (MARCH 30, 2004)]"
7013,363907215,104926,CC1(C(C1C(=O)OC(C#N)C2=CC(=C(C=C2)F)OC3=CC=CC=C3)C=C(Cl)Cl)C,Inactive,,,,Rat,Fisher 344/Female (55/dose),Oral,0; 50; 225; 450 ppm (3.3; 14.4; 28.3 mg/kg/day) of 93.9-95.1% pure cyfluthrin in feed for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYFLUTHRIN (MARCH 30, 2004)]"
7014,363907215,104926,CC1(C(C1C(=O)OC(C#N)C2=CC(=C(C=C2)F)OC3=CC=CC=C3)C=C(Cl)Cl)C,Inactive,,,,Mouse,CD-1/Male (56/dose),Oral,"0; 200; 750; 1,400 ppm (0; 31.9; 114.8; 232.7 mg/kg/day) of 94-95% pure cyfluthrin in feed for 18 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYFLUTHRIN (MARCH 30, 2004)]"
7015,363907215,104926,CC1(C(C1C(=O)OC(C#N)C2=CC(=C(C=C2)F)OC3=CC=CC=C3)C=C(Cl)Cl)C,Inactive,,,,Mouse,CD-1/Female (56/dose),Oral,"0; 200; 750; 1,600 ppm (0; 38.4; 140/6; 309.7 mg/kg/day) of 94-95% pure cyfluthrin in feed for 18 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYFLUTHRIN (MARCH 30, 2004)]"
7016,363907216,14337,CCN(C1CCCCC1)C(=O)SCC,Inactive,,,,Mouse,C57 BL/10JfCD-1/Alpk/Male (50/group),Oral,"0; 300; 1,000; 3,000 ppm of 98.1% pure cycloate in feed for 18 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYCLOATE (OCTOBER 9, 1998)]"
7017,363907216,14337,CCN(C1CCCCC1)C(=O)SCC,Inactive,,,,Mouse,C57 BL/10JfCD-1/Alpk/Female (50/group),Oral,"0; 300; 1,000; 3,000 ppm of 98.1% pure cycloate in feed for 18 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR CYCLOATE (OCTOBER 9, 1998)]"
7018,363907228,44144451,[O-][Si]([O-])([O-])[O-].[Al+3],Active,,,,Rat,Wistar/Female (48/group),Intratracheal,"5 and 10 instillations of 6 mg of  0.01-0.03 um particles given before wk 26, study duration 107-108 wk or no treatment","Lung: Bronchiolo-alveolar adenoma (8/47 and 17/45 experimental animals vs 1/46 control animals), bronchiolo-alveolar carcinoma (11/47 and 12/45 vs 0/46), squamous cell carcinoma (12/47  and 10/45 vs 0/46), cystic keratinizing epithelioma (18/47 vs 25/45), non-keratinizing epithelioma (0/48 and 1/45 vs 0/46), >1 tumor type (14/47 and 20/45vs 0/46)",Positive,"[MOHR,U, ERNST,H, ROLLER,M, AND POTT,F; PULMONARY TUMOR TYPES INDUCED IN WISTAR RATS OF THE SO-CALLED 19-DUST STUDY; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 58:13-20, 2006]"
7019,363907233,8490,C1N(CN(CN1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],Unspecified,,,,Mouse,B6C3F1/Female (85/Group),Oral,"0; 1.5; 7; 35; 175 (reduced to 100 at wk 11) mg/kg/day in diet for  6 mo (10 animals per group), 1 yr  (10 animals per group) or 2 yr (65 animals per group)",Liver: Hepatocellular adenoma/carcinoma,Equivocal (based on reanalysis of histologic sections archived from a 1984 study). Authors note unusually low incidence in controls,"[PARKER,GA, REDDY,G, AND MAJOR,MA; REEVALUATION OF A  TWENTY-FOUR-MONTH CHRONIC TOXICITY/CARCINOGENICITY STUDY OF HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE (RDX) IN THE B6C3F1 HYBRID MOUSE; INTERNATIONAL JOURNAL OF TOXICOLOGY 25(5):373-378, 2006]"
7020,363907234,56841936,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,Active,,,,Rat,Wistar/Female (48/group),Intratracheal,"6 mg instillations of 0.01-0.03 um particles given as 10 or 20 doses wk 26, study duration 115 or 121 wk or no treatment","Lung: Bronchiolo-alveolar adenoma (12/48 and 11/47 in experimental animals vs 1/46 control animals), bronchiolo-alveolar carcinoma (10/48 and 22/47 vs 0/46), adenosquamous cell carcinoma (0/48 and 1/47 vs 0/46), squamous cell carcinoma (3/48 and 11/47 vs 0/46), cystic keratinizing epithelioma (6/48 and 5/47 vs 0/46), non-keratinizing epithelioma (1/48 and 0/47 vs 0/46), >1 tumor type (7/48 and 11/47 vs 0/46)",Positive,"[MOHR,U, ERNST,H, ROLLER,M, AND POTT,F; PULMONARY TUMOR TYPES INDUCED IN WISTAR RATS OF THE SO-CALLED 19-DUST STUDY; EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY 58:13-20, 2006]"
7021,363907252,24743,CCOC(=O)NC1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2,Inactive,,,,Rat,Wistar KFM-Han/Male (50/Group),Oral,0; 60; 300; 1500 ppm in diet for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DESMEDIPHAM (JUNE 20, 2000)]"
7022,363907252,24743,CCOC(=O)NC1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2,Inactive,,,,Rat,Wistar KFM-Han/Female (50/Group),Oral,0; 60; 300; 1500 ppm in diet for 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DESMEDIPHAM (JUNE 20, 2000)]"
7023,363907252,24743,CCOC(=O)NC1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2,Inactive,,,,Mouse,NMRI/Male (50/Group),Oral,0; 30; 150; 750 ppm in diet for 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DESMEDIPHAM (JUNE 20, 2000)]"
7024,363907252,24743,CCOC(=O)NC1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2,Inactive,,,,Mouse,NMRI/Female (50/Group),Oral,0; 30; 150; 750 ppm in diet for 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DESMEDIPHAM (JUNE 20, 2000)]"
7025,363907253,48132,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C(C(Br)(Br)Br)Br)C,Inactive,,,,Rat,Not reported by DPR/Male (60-80/Group),Gavage,0; 0.75; 3.0; 12.0 mg/kg/day in corn oil for 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DELTAMETHRIN (MAY 24, 2000)]"
7026,363907253,48132,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C(C(Br)(Br)Br)Br)C,Inactive,,,,Rat,Not reported by DPR/Female (60-80/Group),Gavage,0; 0.75; 3.0; 12.0 mg/kg/day in corn oil for 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DELTAMETHRIN (MAY 24, 2000)]"
7027,363907253,48132,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C(C(Br)(Br)Br)Br)C,Inactive,,,,Mouse,Not reported by DPR/Male (60-80/Group),Gavage,0; 0.75; 3.0; 10.0 mg/kg/day in corn oil for 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DELTAMETHRIN (MAY 24, 2000)]"
7028,363907253,48132,CC1([C@H]([C@H]1C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C(C(Br)(Br)Br)Br)C,Inactive,,,,Mouse,Not reported by DPR/Female (60-80/Group),Gavage,0; 0.75; 3.0; 10.0 mg/kg/day in corn oil for 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DELTAMETHRIN (MAY 24, 2000)]"
7029,363907255,135413519,C1[C@@H]([C@H]([C@@H]1N2C=NC3=C2N=C(NC3=O)N)CO)CO,Active,,,,Mouse,CD-1/Female (60/Group),Oral,0; 30; 150; 750 mg/kg in diet for 104 wk,"Upper digestive tract: squamous cell papilloma and carcinoma (0/60 and 0/60 in controls vs 0/60, 3/60, and 4/60, respectively, in dosed animals); Vagina: squamous cell carcinoma (0/57 and 0/56 in controls vs 0/58, 2/58, and 10/58, respectively, in dosed animals); Integumentary system: cutaneous squamous cell papilloma in inguinal area of 2 high dose females",Positive,"[WOICKE,J DURHAM,SK AND MENSE,MG; LOBUCAVIR-INDUCED PROLIFERATIVE CHANGES IN MICE; EXPERIMENTAL TOXICOLOGY PATHOLOGY 59(3-4):197-204, 2007]"
7030,363907255,135413519,C1[C@@H]([C@H]([C@@H]1N2C=NC3=C2N=C(NC3=O)N)CO)CO,Active,,,,Mouse,CD-1/Male (60/Group),Oral,0; 10; 50; 250 mg/kg in diet for 104 wk,"Upper digestive tract: squamous cell papilloma or carcinoma (0/60 and 0/60 in controls vs 0/60, 3/60, and 4/60, respectively, in dosed animals; Harderian glands: adenoma and adenocarcinoma (3/60 or 1/60 in controls vs 3/60, 7/60, and 8/60, respectively, in dosed animals)",Positive,"[WOICKE,J DURHAM,SK AND MENSE,MG; LOBUCAVIR-INDUCED PROLIFERATIVE CHANGES IN MICE; EXPERIMENTAL TOXICOLOGY PATHOLOGY 59(3-4):197-204, 2007]"
7031,363907258,104827,CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.O.O.O.[Cl-],Unspecified,,,,Mouse,B6C3F1/Female,Oral,0; 2.5; 12.5; 25 mg/kg 5 d per wk for 2 yr,Lymphatic system: Malignant lymphomas (6/50; 4/50; 9/50; 12/50) (Marginal increase),Equivocal,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-540 Y08]"
7032,363907258,104827,CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.O.O.O.[Cl-],Active,,,,Mouse,B6C3F1/Male,Oral,0; 2.5; 12.5; 25 mg/kg 5 d per wk for 2 yr,Small intestine: Carcinomas (0/50; 1/50; 2/50; 4/50); Adenomas or carcinomas (1/50; 2/50; 4/50; 6/50) (incidences not statistically significant); Malignant lymphomas (2/50; 2/50; 2/50; 5/50) (Possibly related to title compound),Positive (for lymphoma only at high does) (NTP describes results as Some Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-540 Y08]"
7033,363907258,104827,CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.O.O.O.[Cl-],Active,,,,Rat,F344/Male,Oral,0; 5; 25; 50 mg/kg 5 d per wk for 2 yr,Pancreas: Pancreatic islet adenomas (4/50; 9/50; 12/50; 8/50); Pancreatic islet adenomas or carcinomas (4/50; 9/50; 14/50; 8/50),Positive (statistically significant only at 25 mg/kg dose) (NTP describes as Some Evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-540 Y08]"
7034,363907258,104827,CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.O.O.O.[Cl-],Inactive,,,,Rat,F344/Female,Oral,0; 5; 25; 50 mg/kg 5 d per wk for 2 yr,,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-540 Y08]"
7035,363907264,86418,C1CN(C(=N1)N[N+](=O)[O-])CC2=CN=C(C=C2)Cl,Active,,,,Rat,Wistar/Male (60/Group),Oral,0; 100; 300; 900 ppm and 0; 1800 ppm (2 related studies) of 94.3% imidacloprid in diet for 24 mo; study duration 24 mo,Liver: Cholangiocellular carcinoma (2/60 at 1800 ppm vs 0/60 all other groups),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMIDACLOPRID (March 30, 2004)]"
7036,363907264,86418,C1CN(C(=N1)N[N+](=O)[O-])CC2=CN=C(C=C2)Cl,Inactive,,,,Rat,Wistar/Female (60/Group),Oral,0; 100; 300; 900 ppm and 0;1800 ppm (2 related studies) of 94.3% imidacloprid in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMIDACLOPRID (March 30, 2004)]"
7037,363907264,86418,C1CN(C(=N1)N[N+](=O)[O-])CC2=CN=C(C=C2)Cl,Inactive,,,,Mouse,B6C3F1/Male (60/Group),Oral,0; 100; 330; 1000 ppm and 0; 2000 ppm (2 related studies) of 95.3% imidacloprid in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMIDACLOPRID (March 30, 2004)]"
7038,363907264,86418,C1CN(C(=N1)N[N+](=O)[O-])CC2=CN=C(C=C2)Cl,Inactive,,,,Mouse,B6C3F1/Female (60/Group),Oral,0; 100; 330; 1000 ppm and 0; 2000 ppm (2 related studies) of 95.3% imidacloprid in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMIDACLOPRID (March 30, 2004)]"
7039,363907266,42586,CC1=C(C(=CC=C1)C)N(C(C)C(=O)OC)C(=O)COC,Inactive,,,,Rat,CD (Sprague-Dawley derived)/Male (70/Group),Oral,0; 50; 250; 1250 ppm of 93% metalaxyl in diet for 105 wk; study duration 105 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METALAXYL (February 15, 1996)]"
7040,363907266,42586,CC1=C(C(=CC=C1)C)N(C(C)C(=O)OC)C(=O)COC,Active,,,,Rat,CD (Sprague-Dawley derived)/Female (70/Group),Oral,0; 50; 250; 1250 ppm of 93% metalaxyl in diet for 105 wk; study duration 105 wk,Thyroid: follicular cell adenoma,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METALAXYL (February 15, 1996)]"
7041,363907266,42586,CC1=C(C(=CC=C1)C)N(C(C)C(=O)OC)C(=O)COC,Inactive,,,,Mouse,ICI Alderly Park (Swiss strain origin)/Male (60/Group),Oral,0; 50; 250; 1250 ppm of 93.8-95.2% metalaxyl in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METALAXYL (February 15, 1996)]"
7042,363907266,42586,CC1=C(C(=CC=C1)C)N(C(C)C(=O)OC)C(=O)COC,Inactive,,,,Mouse,ICI Alderly Park (Swiss strain origin)/Female (60/Group),Oral,0; 50; 250; 1250 ppm of 93.8-95.2% metalaxyl in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METALAXYL (February 15, 1996)]"
7043,363907303,1738118,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,Inactive,,,,Rat,F344/Male,Oral,"0, 2.5, 5% in diet for 104 wk",,Negative,"[TAKAHASHI,M INOUE,K YOSHIDA,M MORIKAWA,T SHIBUTANI,M AND NISHIKAWA,A; LACK OF CHRONIC TOXICITY OR CARCINOGENICITY OF DIETARY N-ACETYLGLUCOSAMINE IN F344 RATS; FOOD AND CHEMICAL TOXICOLOGY 47(2):462-471, 2009]"
7044,363907303,1738118,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,Inactive,,,,Rat,F344/Female,Oral,"0, 2.5, 5% in diet for 104 wk",,Negative,"[TAKAHASHI,M INOUE,K YOSHIDA,M MORIKAWA,T SHIBUTANI,M AND NISHIKAWA,A; LACK OF CHRONIC TOXICITY OR CARCINOGENICITY OF DIETARY N-ACETYLGLUCOSAMINE IN F344 RATS; FOOD AND CHEMICAL TOXICOLOGY 47(2):462-471, 2009]"
7045,363907304,,,Active,,,,Rat,F344/DcCrj/Female,Oral,"0, 2.5, 5% in diet for 104 wk",Kidney: Adenoma and carcinoma. Liver: Adenoma and carcinoma,Positive,"[INOUE,K YOSHIDA,M TAKAHASHI,M SHIBUTANI,M TAKAGI,H HIROSE,M AND NISHIKAWA,A; INDUCTION OF KIDNEY AND LIVER CANCERS BY THE NATURAL FOOD ADDITIVE MADDER COLOR IN A TWO-YEAR RAT CARCINOGENICITY STUDY; FOOD AND CHEMICAL TOXICOLOGY 47(1):184-191, 2008]"
7046,363907304,,,Active,,,,Rat,F344/DuCrj/Male,Oral,"0, 2.5, 5% in diet for 104 wk",Kidney: Adenoma and carcinoma. Liver: Adenoma,Positive,"[INOUE,K YOSHIDA,M TAKAHASHI,M SHIBUTANI,M TAKAGI,H HIROSE,M AND NISHIKAWA,A; INDUCTION OF KIDNEY AND LIVER CANCERS BY THE NATURAL FOOD ADDITIVE MADDER COLOR IN A TWO-YEAR RAT CARCINOGENICITY STUDY; FOOD AND CHEMICAL TOXICOLOGY 47(1):184-191, 2008]"
7047,363907323,,,Inactive,,,,Rat,Wistar/Female,Inhalation,"0, 4, 20, 100 mg/cu m 6 hr/d for 24 mo",,Negative,"[FUHST,R CREUTZANBERG,O ERNST,H HANSEN,T POHLMANN,G PREISS,A AND RITTINGHAUSEN,S; 24 MONTHS INHALATION CARCINOGENICITY STUDY OF BITUMEN FUMES IN WISTAR (WU) RATS; JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE 4(SUPPL 1):20-43, 2007]"
7048,363907323,,,Inactive,,,,Rat,Wistar/Male,Inhalation,"0, 4, 20, 100 mg/cu m 6 hr/d for 24 mo",,Negative,"[FUHST,R CREUTZANBERG,O ERNST,H HANSEN,T POHLMANN,G PREISS,A AND RITTINGHAUSEN,S; 24 MONTHS INHALATION CARCINOGENICITY STUDY OF BITUMEN FUMES IN WISTAR (WU) RATS; JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE 4(SUPPL 1):20-43, 2007]"
7049,363907394,9888484,CO[C@@H](CC1=CC=C(C=C1)OCCCOC2=CC=C(C=C2)OC3=CC=CC=C3)C(=O)O,Active,,,,Rat,F344/N / Female (60/Group),Oral (gavage),"0; 0.1; 0.3; 1.0 mg/kg bw daily for 104 wk, study duration 104 wk","Bladder: carcinoma (0, 0, 2, 8), papilloma (0, 0, 0, 6)",Positive. Study primarily directed to urine characteristics.,"[LONG,GG, REYNOLDS,VL, LOPEZ-MARTINEZ,A, RYAN,TE, WHITE,SL, ELDRIDGE,SR; UROTHELIAL CARCINOGENESIS IN THE URINARY BLADDER OF RATS TREATED WITH NAVEGLITAZAR, A GAMMA-DOMINANT PPAR ALPHA/GAMMA AGONIST: LACK OF EVIDENCE FOR UROLITHIASIS AS AN INCITING EVENT. TOXICOLOGIC PATHOLOGY. 36(2): 218-231, 2008]"
7050,363907394,9888484,CO[C@@H](CC1=CC=C(C=C1)OCCCOC2=CC=C(C=C2)OC3=CC=CC=C3)C(=O)O,Inactive,,,,Rat,F344/N / Male (60/Group),Oral (gavage),"0; 0.3; 1.0; 3.0 mg/kg bw daily for 104 wk, study duration 104 wk",,Negative,"[LONG,GG, REYNOLDS,VL, LOPEZ-MARTINEZ,A, RYAN,TE, WHITE,SL, ELDRIDGE,SR; UROTHELIAL CARCINOGENESIS IN THE URINARY BLADDER OF RATS TREATED WITH NAVEGLITAZAR, A GAMMA-DOMINANT PPAR ALPHA/GAMMA AGONIST: LACK OF EVIDENCE FOR UROLITHIASIS AS AN INCITING EVENT. TOXICOLOGIC PATHOLOGY. 36(2): 218-231, 2008]"
7051,363907401,7406,CC(C)C1=CC=CC=C1,Inactive,,,,Rat,F344/N / Female (50/Group),Inhalation,"0; 250; 500; 1,000 ppm for 6 hr plus 12 min per d, 5 d/wk, 105 wk (Study duration: 105 wk)",Nose (respiratory epithelium): Adenoma (0/50; 5/48; 4/50; 3/50),Negative. Authors describe as some evidence of carcinogenicity.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-542 Y09]"
7052,363907401,7406,CC(C)C1=CC=CC=C1,Active,,,,Rat,F344/N / Male (50/Group),Inhalation,"0; 250; 500; 1,000 ppm for 6 hr plus 12 min per d, 5 d/wk, 105 wk (Study duration: 105 wk)",Nose (respiratory epithelium): Adenoma (0/50; 7/50; 18/49; 10/50; Renal tubule: Adenoma (1/50; 4/50; 5/50; 4/50); Renal tubule: Carcinoma (1/50; 1/50; 3/50; 3/50); Testis: Adenoma (36/50; 38/50; 40/50; 46/50),Positive. Authors describe as clear evidence of carcinogenicity except that testicular tumors were considered equivocal.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-542 Y09]"
7053,363907401,7406,CC(C)C1=CC=CC=C1,Active,,,,Mouse,B5C3F1/ Female (50/Group),Inhalation,"0; 125; 250; 500 ppm for 6 hr plus 12 min per d, 5 d/wk, 105 wk (Study duration: 105 wk)","Lung: Alveolar/bronchiolar adenoma (1/50; 26/50; 36/50; 38/50);  Alveolar/bronchiolar carcinoma (3/50; 16/50; 20/50; 34/50); Liver: Hepatocellular adenoma or carcinoma (25/50; 26/50; 29/50; 36/50); Hemangiosarcoma, spleen (0/49; 0/50; 3/50; 1/50), all organs (1/50; 3/50; 6/50; 1/50)",Positive. Authors describe as clear evidence of carcinogenicity based on increased incidences of alveolar/bronchiolar neoplasms. Increased incidences of hepatocellular adenoma or carcinoma (combined) were also considered to be compound-related.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-542 Y09]"
7054,363907401,7406,CC(C)C1=CC=CC=C1,Active,,,,Mouse,B5C3F1/ Male (50/Group),Inhalation,"0; 250; 500; 1,000 ppm for 6 hr plus 12 min per d, 5 d/wk, 105 wk (Study duration: 105 wk)","Lung: Alveolar/bronchiolar adenoma (13/50; 31/50; 31/50; 29/50); Alveolar/bronchiolar carcinoma (9/50; 19/50; 32/50; 33/50). Liver: Hepatocellular adenoma or carcinoma (40/50; 42/50; 43/50; 41/50); Blood: Hemangiosarcoma, spleen (0/50; 0/50; 0/50; 4/50), all organs (0/50; 1/50; 2/50; 4/50); Thyroid: Follicular cell adenoma (0/50; 0/50; 0/49; 3/50)",Positive. Authors describe as clear evidence of carcinogenicity based on increased incidences of alveolar/bronchiolar neoplasms. The increased incidences of hemangiosarcoma in the spleen and follicular cell adenoma in the thyroid gland may have been related to cumene exposure.,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-542 Y09]"
7055,363907420,757,C(C(=O)O)O,Inactive,,,,Mouse,SKH-1/Male (18/Group),Dermal,"0, 4, 10% administered as topical cream (pH 3.5) , 5 d/wk, 40 wk, animals held an additional 12 wk for study duration of 1 yr","Skin: Carcinoma in situ, squamous cell carcinoma, basal cell carcinoma","Negative. When synthetic solar light (SSL) at 0.3 and 0.6 the minimal erythema dose (MED) was also administered 5 d/wk, 4 hr/d for 40 wk, salicylic acid was photoprotective, reducing the carcinogenicity of 0.3 MED SSL.",[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES]
7056,363907420,757,C(C(=O)O)O,Inactive,,,,Mouse,SKH-1/Female (18/Group),Dermal,"0, 4, 10% administered as topical cream (pH 3.5) , 5 d/wk, 40 wk, animals held an additional 12 wk for study duration of 1 yr","Skin: Carcinoma in situ, squamous cell carcinoma, basal cell carcinoma","Negative. When synthetic solar light (SSL) at 0.3 and 0.6 the minimal erythema dose (MED) was also administered 5 d/wk, 4 hr/d for 40 wk, salicylic acid was photoprotective, reducing the carcinogenicity of 0.3 MED SSL.","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-524 Y07]"
7057,363907421,61948,C(CC(CBr)(C#N)Br)C#N,Inactive,,,,Rat,F344/N / Male (50/Group),Dermal,0; 2; 6; 18 mg/kg in 95% ethanol on clipped area of skin 5 d/wk for 2 yr,,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-555 Y10]"
7058,363907421,61948,C(CC(CBr)(C#N)Br)C#N,Inactive,,,,Mouse,B6C3F1/Male (50/Group),Dermal,"0; 0.6, 2; 6 mg/kg in 95% ethanol on clipped area of skin 5 d/wk for 2 yr",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-555 Y10]"
7059,363907421,61948,C(CC(CBr)(C#N)Br)C#N,Inactive,,,,Mouse,B6C3F1/Female (50/Group),Dermal,"0; 0.6, 2; 6 mg/kg in 95% ethanol on clipped area of skin 5 d/wk for 2 yr",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-555 Y10]"
7060,363907421,61948,C(CC(CBr)(C#N)Br)C#N,Inactive,,,,Rat,F344/N / Female (50/Group),Dermal,0; 2; 6; 18 mg/kg in 95% ethanol on clipped area of skin 5 d/wk for 2 yr,,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-555 Y10]"
7061,363907422,22833491,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].O.[Cr+3],Inactive,,,,Mouse,B6C3F1/Male (50/Group),Oral,"0; 2,000; 10,000; 50,000 ppm in diet for 105 wk (Study duration: 105 wk)",,Negative,"[STOUT,MD, NYSKA,A, COLLINS,BJ, WITT,KL, KISSLING,GE, MALARKEY,DE, HOOTH,MJ; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF CHROMIUM PICOLINATE MONOHYDRATE ADMINISTERED IN FEED TO F344/N RATS AND B6C3F1 MICE FOR 2 YEARS. FOOD CHEM. TOXICOL. 47(4): 729-733, 2009]"
7062,363907422,22833491,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].O.[Cr+3],Inactive,,,,Mouse,B6C3F1/Female (50/Group),Oral,"0; 2,000; 10,000; 50,000 ppm in diet for 105 wk (Study duration: 105 wk)",,Negative,"[STOUT,MD, NYSKA,A, COLLINS,BJ, WITT,KL, KISSLING,GE, MALARKEY,DE, HOOTH,MJ; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF CHROMIUM PICOLINATE MONOHYDRATE ADMINISTERED IN FEED TO F344/N RATS AND B6C3F1 MICE FOR 2 YEARS. FOOD CHEM. TOXICOL. 47(4): 729-733, 2009]"
7063,363907422,22833491,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].O.[Cr+3],Inactive,,,,Rat,F344/N / Male (50/Group),Oral,"0; 2,000; 10,000; 50,000 ppm in diet for 105 wk (Study duration: 105 wk)","Preputial gland: adenoma (1, 1, 7, 4; P</=0.05 at 10,000 ppm only)",Negative. Authors describe as equivocal evidence of carcinogenicity.,"[STOUT,MD, NYSKA,A, COLLINS,BJ, WITT,KL, KISSLING,GE, MALARKEY,DE, HOOTH,MJ; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF CHROMIUM PICOLINATE MONOHYDRATE ADMINISTERED IN FEED TO F344/N RATS AND B6C3F1 MICE FOR 2 YEARS. FOOD CHEM. TOXICOL. 47(4): 729-733, 2009]"
7064,363907422,22833491,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].O.[Cr+3],Inactive,,,,Rat,F344/N / Female (50/Group),Oral,"0; 2,000; 10,000; 50,000 ppm in diet for 105 wk (Study duration: 105 wk)",,Negative,"[STOUT,MD, NYSKA,A, COLLINS,BJ, WITT,KL, KISSLING,GE, MALARKEY,DE, HOOTH,MJ; CHRONIC TOXICITY AND CARCINOGENICITY STUDIES OF CHROMIUM PICOLINATE MONOHYDRATE ADMINISTERED IN FEED TO F344/N RATS AND B6C3F1 MICE FOR 2 YEARS. FOOD CHEM. TOXICOL. 47(4): 729-733, 2009]"
7065,363907422,22833491,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].O.[Cr+3],Unspecified,,,,Rat,F344/N / Male (50/Group),Oral,"0; 2000; 10,000; 50,000 ppm (average daily doses of 0; 90; 460; 2400 mg/kg) in diet for 105 wk","Preputial gland: adenoma (1/50, 1/50, 7/50, 4/50)",Equivocal,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-556 Y10]"
7066,363907422,22833491,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].O.[Cr+3],Inactive,,,,Rat,F344/N / Female (50/Group),Oral,"0; 2000; 10,000; 50,000 ppm (average daily doses of 0; 100; 510; 2630 mg/kg) in diet for 105 wk",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-556 Y10]"
7067,363907422,22833491,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].O.[Cr+3],Inactive,,,,Mouse,B6C3F1/Male (50/Group),Oral,"0; 2000; 10,000; 50,000 ppm (average daily doses of 0; 250; 1200; 6565 mg/kg) in diet for 105 wk",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-556 Y10]"
7068,363907422,22833491,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].O.[Cr+3],Inactive,,,,Mouse,B6C3F1 /Female (50/Group),Oral,"0; 2000; 10,000; 50,000 ppm (average daily doses of 0; 240; 1200; 6100 mg/kg) in diet  for 105 wk",,Negative,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-556 Y10]"
7069,363907428,23956,[Ta],Inactive,,,,Rat,F344/Male (46/Group),Intramuscular,10 metal pellets per hind leg; each pellet 1x2 mm (wt 27 mg); study duration 52 wk,,Negative,"[KALINICH,JF, EMOND,CA, DALTON,TK, MOG,SR, COLEMAN,GD, KORDELL,JE, MILLER,AC, AND MCCLAIN,DE; EMBEDDED WEAPONS-GRADE TUNGSTEN ALLOY SHARPNEL RAPIDLY INDUCES METASTATIC HIGH-GRADE RHABDOMYOSARCOMAS IN F344 RATS; ENVIRONMENTAL HEALTH PRESPECTIVES 113(6):729-734, 2005]"
7070,363907430,23964,[W],Active,,,,Rat,F344/Male (46/Group),Intramuscular,10 metal pellets per hind leg; each pellet 1x2 mm (wt 27.5 mg); study duration 27 wk,Muscle: rhabdomyosarcoma,Positive,"[KALINICH,JF, EMOND,CA, DALTON,TK, MOG,SR, COLEMAN,GD, KORDELL,JE, MILLER,AC, AND MCCLAIN,DE; EMBEDDED WEAPONS-GRADE TUNGSTEN ALLOY SHARPNEL RAPIDLY INDUCES METASTATIC HIGH-GRADE RHABDOMYOSARCOMAS IN F344 RATS; ENVIRONMENTAL HEALTH PRESPECTIVES 113(6):729-734, 2005]"
7071,363907430,23964,[W],Active,,,,Rat,F344/Male (46/Group),Intramuscular,2 tungsten and 8 tantalum pellets per hind leg; each pellet 1x2 mm; study duration 38 wk,Muscle: rhabdomyosarcoma,Positive,"[KALINICH,JF, EMOND,CA, DALTON,TK, MOG,SR, COLEMAN,GD, KORDELL,JE, MILLER,AC, AND MCCLAIN,DE; EMBEDDED WEAPONS-GRADE TUNGSTEN ALLOY SHARPNEL RAPIDLY INDUCES METASTATIC HIGH-GRADE RHABDOMYOSARCOMAS IN F344 RATS; ENVIRONMENTAL HEALTH PRESPECTIVES 113(6):729-734, 2005]"
7072,363907455,5781,C1(=O)C(=O)NC(=O)NC1=O,Active,,,,Rat,WBN/Kob (Diabetic)/Male (31/ group),Intravenous,"0, 50 mg/kg once, study duration 75 wks",Forestomach: squamous cell carcinoma,Positive,"[KODAMA,Y, OZAKI,K, SANO,T, MATSUURA,T, AKAGI,H AND NARAMA,I; INDUCTION OF SQUAMOUS CELL CARCINOMA OF FORESTOMACH IN DIABETIC RATS BY SINGLE ALLOXAN TREATMENT; CANCER SCI. 97(10):1023-1030, 2006]"
7073,363907455,5781,C1(=O)C(=O)NC(=O)NC1=O,Active,,,,Rat,WBN/Kob (Diabetic)/Female (17/group),Intravenous,"0, 40 mg/kg once, study duration 75 wks",Forestomach: squamous cell carcinoma,Positive,"[KODAMA,Y, OZAKI,K, SANO,T, MATSUURA,T, AKAGI,H AND NARAMA,I; INDUCTION OF SQUAMOUS CELL CARCINOMA OF FORESTOMACH IN DIABETIC RATS BY SINGLE ALLOXAN TREATMENT; CANCER SCI. 97(10):1023-1030, 2006]"
7074,363907457,6128,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C,Inactive,,,,Rat,F344/N / Male (50/Group),Oral,"0; 10; 20; 50 mg/kg in 0.5% methylcellulose solution, by gavage, 5 d/wk for 2 yr",,"Negative. (Authors describe as equivocal evidence based on alveolar/bronchiolar adenoma (0/50, 0/50, 5/50, 2/50); alveolar/bronchiolar adenoma or carcinoma (combined) (0/50, 0/50, 5/50, 3/50))","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-560 Y10]"
7075,363907457,6128,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C,Inactive,,,,Rat,F344/N / Female (50/Group),Oral,"0; 10; 20; 50 mg/kg in 0.5% methylcellulose solution, by gavage, 5 d/wk for 2 yr",,"Negative. (Authors describe as equivocal evidence based on incidence of mononuclear cell leukemia: (5/50, 11/50, 18/50, 15/50))","[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-560 Y10]"
7076,363907457,6128,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C,Active,,,,Mouse,B6C3F1/Female (50/Group),Oral,"0; 2; 10; 50 mg/kg in 0.5% methylcellulose solution, by gavage, 5 d/wk for 2 yr","Liver: hepatocellular adenoma (14/50, 16/50, 18/50, 28/50); hepatocellular carcinoma (5/50, 13/50, 15/50, 15/50); hepatocellular adenoma or carcinoma (17/50, 23/50, 27/50, 32/50). Pancreatic islets: adenoma (0/49, 2/50, 4/49, 4/48).",Positive. (Authors describe as clear evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-560 Y10]"
7077,363907457,6128,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C,Active,,,,Mouse,B6C3F1/Male (50/Group),Oral,"0; 10; 20; 50 mg/kg in 0.5% methylcellulose solution, by gavage, 5 d/wk for 2 yr","Liver: hepatocellular adenoma, multiple (16/50, 27/50, 23/50, 34/50); hepatocellular adenoma (includes multiples) (32/50, 38/50, 29/50, 43/50); hepatocellular carcinoma, multiple (7/50, 12/50, 10/50, 17/50); hepatocellular adenoma or hepatocellular carcinoma (combined; includes multiples) (41/50, 47/50, 42/50, 48/50); hepatoblastoma (3/50, 8/50, 7/50, 8/50); hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma (combined) (41/50, 47/50, 43/50, 48/50). Pancreatic islets: adenoma (includes multiples) (2/50, 2/50, 2/50, 5/49).",Positive. (Authors describe as clear evidence),"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-560 Y10]"
7078,363907458,10788,CN1CN(C(=S)SC1)C,Inactive,,,,Rat,Wistar/Male (50/Group),Oral,"0; 0.27, 1.08, 4.43 mg/kg in diet for 2 yr, study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAZOMET  (July 21, 1988)]"
7079,363907458,10788,CN1CN(C(=S)SC1)C,Inactive,,,,Rat,Wistar/Female (50/Group),Oral,"0; 0.35, 1.37, 5.66 mg/kg in diet for 2 yr, study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAZOMET  (July 21, 1988)]"
7080,363907458,10788,CN1CN(C(=S)SC1)C,Inactive,,,,Mouse,B6C3F1/Male (50/Group),Oral,"0; 4; 16; 68 mg/kg in diet for 78 wk, study duration 78 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAZOMET  (July 21, 1988)]"
7081,363907458,10788,CN1CN(C(=S)SC1)C,Inactive,,,,Mouse,B6C3F1/Female (50/Group),Oral,"0; 6; 22; 93 mg/kg in diet for 78 wk, study duration 78 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DAZOMET  (July 21, 1988)]"
7082,363907460,17110,CCCCCCCCCCCCN=C(N)N.CC(=O)O,Inactive,,,,Rat,Sprague-Dawley/Male (60/Group),Oral,"0; 10.2; 20.3; 41.9 mg/kg/day in diet on wks 1-101, study duration 2 yrs. Test sample purity, 98.6%",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DODINE  (N-DODECYLGUANIDINE ACETATE) (May 27, 1999)]"
7083,363907460,17110,CCCCCCCCCCCCN=C(N)N.CC(=O)O,Inactive,,,,Rat,Sprague-Dawley/Female (60/Group),Oral,"0; 13.2; 26.5; 53.5 mg/kg/day in diet on wks 1-101, study duration 2 yrs. Test sample purity, 98.6%.",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DODINE  (N-DODECYLGUANIDINE ACETATE) (May 27, 1999)]"
7084,363907460,17110,CCCCCCCCCCCCN=C(N)N.CC(=O)O,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Male (70/Group),Oral,"0; 200; 750; 1500 ppm in diet for 78 wk, study duration 78 wk. Test sample purity, 98%.",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DODINE  (N-DODECYLGUANIDINE ACETATE) (May 27, 1999)]"
7085,363907460,17110,CCCCCCCCCCCCN=C(N)N.CC(=O)O,Active,,,,Mouse,Crl:CD-1(ICR)BR/Female (70/Group),Oral,"0; 200; 750; 1500 ppm in diet for 78 wk, study duration 78 wk. Test sample purity, 98%.",Liver: Hepatocellular adenoma and carcinoma combined (high dose only),"Positive, (Neither tumor type, alone, was statistically significant.)","[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR DODINE  (N-DODECYLGUANIDINE ACETATE) (May 27, 1999)]"
7086,363907461,22833503,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)[NH2+]C)OC)OC)\C)C.C1=CC=C(C=C1)C(=O)[O-],Inactive,,,,Rat,Strain not specified/Male (65/Group),Oral,"0; 0.25; 1; 5 (lowered to 2.5 at wk 6) mg/kg/day in the diet for 105 wk, study duration 105 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  EMAMECTIN BENZOATE (December 2, 1999)]"
7087,363907461,22833503,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)[NH2+]C)OC)OC)\C)C.C1=CC=C(C=C1)C(=O)[O-],Inactive,,,,Rat,Strain not specified/Female (65/Group),Oral,"0; 0.25; 1; 5 (lowered to 2.5 at wk 10) mg/kg/day in the diet for 105 wk, study duration 105 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  EMAMECTIN BENZOATE (December 2, 1999)]"
7088,363907461,22833503,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)[NH2+]C)OC)OC)\C)C.C1=CC=C(C=C1)C(=O)[O-],Inactive,,,,Mouse,Strain not specified/Male (50/Group),Oral,"0; 0.5; 2.5; 12.5 (lowered to 7.5 at wk 9 and to 5 at wk 31) mg/kg/day in the diet for 79 wk, study duration 79 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  EMAMECTIN BENZOATE (December 2, 1999)]"
7089,363907461,22833503,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)[NH2+]C)OC)OC)\C)C.C1=CC=C(C=C1)C(=O)[O-],Inactive,,,,Mouse,Strain not specified/Female (50/Group),Oral,"0; 0.5; 2.5; 12.5 (lowered to 7.5 at wk 48) mg/kg/day in the diet for 79 wk, study duration 79 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  EMAMECTIN BENZOATE (December 2, 1999)]"
7090,363907462,10342051,CC(C)[C@@H](C1=CC=C(C=C1)Cl)C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,Inactive,,,,Mouse,Crl:CD-17BR/Male (80/Group),Oral,0; 35; 150 ppm in diet for 18 mo; study duration 18 mo,,Negative. A 350 ppm group was terminated at study day 58 due to self-trauma and infection which also caused decreased survival rates in the 150 ppm group.,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENVALERATE AND ESFENVALERATE (February 21, 2001)]"
7091,363907462,10342051,CC(C)[C@@H](C1=CC=C(C=C1)Cl)C(=O)O[C@H](C#N)C2=CC(=CC=C2)OC3=CC=CC=C3,Inactive,,,,Mouse,Crl:CD-17BR/Female (80/Group),Oral,0; 35; 150 ppm in diet for 18 mo; study duration 18 mo,,Negative. A 350 ppm group was terminated at study day 58 due to self-trauma and infection which also caused decreased survival rates in the 150 ppm group.,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENVALERATE AND ESFENVALERATE (February 21, 2001)]"
7092,363907463,62097,CCCCNC(=O)OCC#CI,Inactive,,,,Mouse,CD-1/Male (50/Group),Oral,0; 20; 50; 150 mg/kg/day of 97% 3-iodo-2-propynyl butyl carbamate in diet for 78 wk; study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR 3-IODO-2-PROPYNYL BUTYL CARBAMATE (December 1, 2004)]"
7093,363907463,62097,CCCCNC(=O)OCC#CI,Inactive,,,,Mouse,CD-1/Female (50/Group),Oral,0; 20; 50; 150 mg/kg/day of 97% 3-iodo-2-propynyl butyl carbamate in diet for 78 wk; study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR 3-IODO-2-PROPYNYL BUTYL CARBAMATE (December 1, 2004)]"
7094,363907463,62097,CCCCNC(=O)OCC#CI,Inactive,,,,Rat,Sprague-Dawley/Male (50/group),Oral,0; 20; 40; 80 mg/kg/day of 97% 3-iodo-2-propynyl butyl carbamate in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR 3-IODO-2-PROPYNYL BUTYL CARBAMATE (December 1, 2004)]"
7095,363907463,62097,CCCCNC(=O)OCC#CI,Inactive,,,,Rat,Sprague-Dawley/Female (50/group),Oral,0; 20; 40; 80 mg/kg/day of 97% 3-iodo-2-propynyl butyl carbamate in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR 3-IODO-2-PROPYNYL BUTYL CARBAMATE (December 1, 2004)]"
7096,363907464,41381,CCN(CC(=C)C)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,Rat,Fischer 344/Male (30/Group; replicate studies using 94.5% ethalfluralin),Oral,0; 0.01; 0.025; 0.075% (0; 4.2; 10.7; 32.3 mg/kg/d) in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF   PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR   ETHALFLURALIN (September 21, 1993)]"
7097,363907464,41381,CCN(CC(=C)C)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Active,,,,Rat,Fischer 344/Female (30/Group; replicate studies using 94.5% ethalfluralin),Oral,0; 0.01; 0.025; 0.075% (0; 4.2; 10.7; 32.3 mg/kg/d) in diet for 2 yr; study duration 2 yr,Mammary gland: Benign fibroadenomas,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF   PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR   ETHALFLURALIN (September 21, 1993)]"
7098,363907464,41381,CCN(CC(=C)C)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,Mouse,B6C3F1/Male (40/Experimental group; 60/Control group),Oral,0; 100; 400; 1500 ppm of 94.5% ethalfluralin in diet for 2 yr; study duration 2 yr (2 replicate studies).,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF   PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR   ETHALFLURALIN (September 21, 1993)]"
7099,363907464,41381,CCN(CC(=C)C)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],Inactive,,,,Mouse,B6C3F1/Female (40/Experimental group; 60/Control group),Oral,0; 100; 400; 1500 ppm of 94.5% ethalfluralin in diet for 2 yr; study duration 2 yr (2 replicate studies).,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF   PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR   ETHALFLURALIN (September 21, 1993)]"
7100,363907465,27982,C(CCl)P(=O)(O)O,Inactive,,,,Rat,Sprague-Dawley CD/Male (30 or 50/Group),Oral,"0; 300; 3000; 10,000; 30,000 ppm of 70.6-72.1% ethephon for 97 wks, study duration 97 wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF     PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR     ETHEPHON (November 24, 1997)]"
7101,363907465,27982,C(CCl)P(=O)(O)O,Inactive,,,,Rat,Sprague-Dawley CD/Female (30 or 50/Group),Oral,"0; 300; 3000; 10,000; 30,000 ppm of 70.6-72.1% ethephon for 104 wks, study duration 104 wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF     PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR     ETHEPHON (November 24, 1997)]"
7102,363907465,27982,C(CCl)P(=O)(O)O,Inactive,,,,Mouse,CD-1 albino/Male (20 or 50/Group),Oral,"0; 100; 1000; 10,000 ppm of 70.6-72.1% ethephon for 52 (20/Group) wks and 78 (50/Group) wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF     PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR     ETHEPHON (November 24, 1997)]"
7103,363907465,27982,C(CCl)P(=O)(O)O,Inactive,,,,Mouse,CD-1 albino/Female (20 or 50/Group),Oral,"0; 100; 1000; 10,000 ppm of 70.6-72.1% ethephon for 52 (20/Group) wks and 78 (50/Group) wks",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF     PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR     ETHEPHON (November 24, 1997)]"
7104,363907466,3289,CCCSP(=O)(OCC)SCCC,Inactive,,,,Rat,Crl:CD(SD)BR VAF/Plus/Male (80-90/Group),Oral,"0; 60; 400 (reduced from 600 during wk 3) ppm of 95.6% ethoprop in diet for 104 wk, study duration 104 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF       PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR       ETHOPROP (December 22, 2005)]"
7105,363907466,3289,CCCSP(=O)(OCC)SCCC,Inactive,,,,Rat,Crl:CD(SD)BR VAF/Plus/Female (80-90/Group),Oral,"0; 60; 400 (reduced from 600 during wk 3) ppm of 95.6% ethoprop in diet for 104 wk, study duration 104 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF       PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR       ETHOPROP (December 22, 2005)]"
7106,363907466,3289,CCCSP(=O)(OCC)SCCC,Inactive,,,,Mouse,B6C3F1/Male (50/Group),Oral,"0; 0.2; 2; 30 ppm of 94.6% ethoprop in diet for 104 wk, study duration 104 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF       PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR       ETHOPROP (December 22, 2005)]"
7107,363907466,3289,CCCSP(=O)(OCC)SCCC,Inactive,,,,Mouse,B6C3F1/Female (50/Group),Oral,"0; 0.2; 2; 30 ppm of 94.6% ethoprop in diet for 104 wk, study duration 104 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF       PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR       ETHOPROP (December 22, 2005)]"
7108,363907467,213032,CC1(C(=O)N(C(=O)O1)NC2=CC=CC=C2)C3=CC=C(C=C3)OC4=CC=CC=C4,Inactive,,,,Rat,CRL: CD BR/Male (62/Group),Oral,"0; 0.42; 1.62; 8.4; 16.8 mg/kg/day of 97.4% famoxadone in diet for 23 mo, study duration 23 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF      PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR       FAMOXADONE (March 9, 2004)]"
7109,363907467,213032,CC1(C(=O)N(C(=O)O1)NC2=CC=CC=C2)C3=CC=C(C=C3)OC4=CC=CC=C4,Inactive,,,,Rat,CRL: CD BR/Female (62/Group),Oral,"0; 0.53; 2.15; 10.7; 23.0 mg/kg/day of 97.4% famoxadone in diet for 24 mo, study duration 24 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF      PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR       FAMOXADONE (March 9, 2004)]"
7110,363907467,213032,CC1(C(=O)N(C(=O)O1)NC2=CC=CC=C2)C3=CC=C(C=C3)OC4=CC=CC=C4,Inactive,,,,Mouse,CRL: CD1 (ICR)BR/Female (60/Group),Oral,"0; 1.0; 9.8; 130; 392 mg/kg/day of 97.4% famoxadone in diet for 18 mo, study duration 18 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF      PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR       FAMOXADONE (March 9, 2004)]"
7111,363907467,213032,CC1(C(=O)N(C(=O)O1)NC2=CC=CC=C2)C3=CC=C(C=C3)OC4=CC=CC=C4,Inactive,,,,Mouse,CRL: CD1 (ICR)BR/Male (60/Group),Oral,"0; 0.7; 6.8; 96; 274 mg/kg/day of 97.4% famoxadone in diet for 18 mo, study duration 18 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF      PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR       FAMOXADONE (March 9, 2004)]"
7112,363907468,44318676,C1C[C@H]2[C@@H]([C@@H]([C@@H]1O2)C(=O)[O-])C(=O)[O-].[Na+].[Na+],Inactive,,,,Rat,Cr; CD(SD)BR/Male (62/group),Oral,"Nominal concentrations of 0; 300; 900; 1800 ppm in diet for 104 wk, study duration 104 wk (actual concentration about 18% lower)",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ENDOTHALL (October 25, 1995)]"
7113,363907468,44318676,C1C[C@H]2[C@@H]([C@@H]([C@@H]1O2)C(=O)[O-])C(=O)[O-].[Na+].[Na+],Active,,,,Rat,Cr; CD(SD)BR/Female (62/group),Oral,"Nominal concentrations of 0; 300; 900; 1800 ppm in diet for 104 wk, study duration 104 wk (actual concentration about 18% lower)","Uterus: endometrial stromal tumors (0, 0, 4/60, 5/59)",Positive (CA Department of Pesticide Regulation evaluator described as a possible adverse effect),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ENDOTHALL (October 25, 1995)]"
7114,363907468,44318676,C1C[C@H]2[C@@H]([C@@H]([C@@H]1O2)C(=O)[O-])C(=O)[O-].[Na+].[Na+],Active,,,,Mouse,Crl; CD-1(ICR)BR/Male and female (60/Group),Oral,"0; 750; 1500 ppm of endothal disodium, purity 19-23.1%, in diet for at least 78 wk, study duration 18 mo",Duodenum and jejunum: increased incidence of tumors in high dose group,Positive (Results not described separately for each sex),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ENDOTHALL (October 25, 1995)]"
7115,363907469,10403199,C[C@@]1(C(=O)N(C(=N1)SC)NC2=CC=CC=C2)C3=CC=CC=C3,Inactive,,,,Rat,Sprague-Dawley/Male (70/Group),Oral,0; 60; 150; 1000 ppm (0; 2.83; 7.07; 47.68 mg/kg/day) in diet for 104 wks; study duration 104 wks,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENAMIDONE (March 21, 2002)]"
7116,363907469,10403199,C[C@@]1(C(=O)N(C(=N1)SC)NC2=CC=CC=C2)C3=CC=CC=C3,Inactive,,,,Rat,Sprague-Dawley/Female (70/Group),Oral,0; 60; 150; 1000 ppm (0; 3.63; 9.24; 60.93 mg/kg/day) in diet for 104 wks; study duration 104 wks,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENAMIDONE (March 21, 2002)]"
7117,363907469,10403199,C[C@@]1(C(=O)N(C(=N1)SC)NC2=CC=CC=C2)C3=CC=CC=C3,Inactive,,,,Rat,Sprague-Dawley/Male (70/Group),Oral,0; 5000 ppm in diet for 104 wks; study duration 104 wks,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENAMIDONE (March 21, 2002)]"
7118,363907469,10403199,C[C@@]1(C(=O)N(C(=N1)SC)NC2=CC=CC=C2)C3=CC=CC=C3,Inactive,,,,Rat,Sprague-Dawley/Female (70/Group),Oral,0; 5000 ppm in diet for 104 wks; study duration 104 wks,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENAMIDONE (March 21, 2002)]"
7119,363907469,10403199,C[C@@]1(C(=O)N(C(=N1)SC)NC2=CC=CC=C2)C3=CC=CC=C3,Inactive,,,,Mouse,C57BL/10JfCD-1 Alpk/Male (55/Group),Oral,0; 70; 350; 3500; 7000 ppm (0; 9.5; 47.5; 525.5; 1100.2 mg/kg/d) for 80 wks; study duration 80 wks,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENAMIDONE (March 21, 2002)]"
7120,363907469,10403199,C[C@@]1(C(=O)N(C(=N1)SC)NC2=CC=CC=C2)C3=CC=CC=C3,Inactive,,,,Mouse,C57BL/10JfCD-1 Alpk/Female (55/Group),Oral,0; 70; 350; 3500; 7000 ppm (0; 12.6;  63.8; 690.5; 1393.2 mg/kg/d) for 80 wks; study duration 80 wks,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENAMIDONE (March 21, 2002)]"
7121,363907470,16683004,CC(C)(C[Sn](CC(C)(C)C1=CC=CC=C1)(CC(C)(C)C2=CC=CC=C2)O[Sn](CC(C)(C)C3=CC=CC=C3)(CC(C)(C)C4=CC=CC=C4)CC(C)(C)C5=CC=CC=C5)C6=CC=CC=C6,Inactive,,,,Rat,Carworth Farm E/Male (96/Control group; 48/Experimental group),Oral,0; 50; 100; 300; 600 ppm of 97% fenbutatin oxide in the diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENBUTATIN OXIDE (July 2, 2004)]"
7122,363907470,16683004,CC(C)(C[Sn](CC(C)(C)C1=CC=CC=C1)(CC(C)(C)C2=CC=CC=C2)O[Sn](CC(C)(C)C3=CC=CC=C3)(CC(C)(C)C4=CC=CC=C4)CC(C)(C)C5=CC=CC=C5)C6=CC=CC=C6,Inactive,,,,Rat,Carworth Farm E/Female (96/Control group; 48/Experimental group),Oral,0; 50; 100; 300; 600 ppm of 97% fenbutatin oxide in the diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENBUTATIN OXIDE (July 2, 2004)]"
7123,363907470,16683004,CC(C)(C[Sn](CC(C)(C)C1=CC=CC=C1)(CC(C)(C)C2=CC=CC=C2)O[Sn](CC(C)(C)C3=CC=CC=C3)(CC(C)(C)C4=CC=CC=C4)CC(C)(C)C5=CC=CC=C5)C6=CC=CC=C6,Inactive,,,,Mouse,Unspecified strain/Male (96/Control group; 48/Experimental group),Oral,0; 50; 100; 300; 600 ppm of 97% fenbutatin oxide in the diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENBUTATIN OXIDE (July 2, 2004)]"
7124,363907470,16683004,CC(C)(C[Sn](CC(C)(C)C1=CC=CC=C1)(CC(C)(C)C2=CC=CC=C2)O[Sn](CC(C)(C)C3=CC=CC=C3)(CC(C)(C)C4=CC=CC=C4)CC(C)(C)C5=CC=CC=C5)C6=CC=CC=C6,Inactive,,,,Mouse,Unspecified strain/Female (96/Control group; 48/Experimental group),Oral,0; 50; 100; 300; 600 ppm of 97% fenbutatin oxide in the diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENBUTATIN OXIDE (July 2, 2004)]"
7125,363907471,43226,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)(C3=CN=CN=C3)O)Cl,Inactive,,,,Rat,Wistar/Male (120/Control group; 80/Experimental group),Oral,0; 50; 130; 350 ppm in diet for 24 mo; study duration 24 mo,,Negative (nonstatistical increase in hepatocellular adenomas),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENARIMOL (September 9, 1993)]"
7126,363907471,43226,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)(C3=CN=CN=C3)O)Cl,Inactive,,,,Rat,Wistar/Female (120/Control group; 80/Experimental group),Oral,0; 50; 130; 350 ppm in diet for 24 mo; study duration 24 mo,,Negative (nonstatistical increase in hepatocellular adenomas),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENARIMOL (September 9, 1993)]"
7127,363907472,47938,CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl,Inactive,,,,Rat,Strain not given in source/Male (60/Group),Oral,0; 5; 30; 180 ppm (0; 0.26; 1.58; 9.43 mg/kg) in diet for up to 28 mo; study duration 28 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT  OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENOXAPROP-ETHYL (February 18, 1994)]"
7128,363907472,47938,CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl,Inactive,,,,Rat,Strain not given in source/Female (60/Group),Oral,0; 5; 30; 180 ppm (0; 0.33; 2.00; 11.87 mg/kg) in diet for up to 28 mo; study duration 28 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT  OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENOXAPROP-ETHYL (February 18, 1994)]"
7129,363907472,47938,CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl,Inactive,,,,Mouse,Strain not given in source/Male (50/Group),Oral,0; 2.5; 10; 40 ppm in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT  OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENOXAPROP-ETHYL (February 18, 1994)]"
7130,363907472,47938,CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl,Inactive,,,,Mouse,Strain not given in source/Female (50/Group),Oral,0; 2.5; 10; 40 ppm in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT  OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENOXAPROP-ETHYL (February 18, 1994)]"
7131,363907473,51605,CCOC(=O)NCCOC1=CC=C(C=C1)OC2=CC=CC=C2,Inactive,,,,Rat,Crl:CD(SD)BR/Male (50/Group),Oral,0; 200; 600; 1800 ppm of 96.6% fenoxycarb in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT  OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENOXYCARB (November 21, 1997)]"
7132,363907473,51605,CCOC(=O)NCCOC1=CC=C(C=C1)OC2=CC=CC=C2,Inactive,,,,Rat,Crl:CD(SD)BR/Female (50/Group),Oral,0; 200; 600; 1800 ppm of 96.6% fenoxycarb in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT  OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENOXYCARB (November 21, 1997)]"
7133,363907473,51605,CCOC(=O)NCCOC1=CC=C(C=C1)OC2=CC=CC=C2,Active,,,,Mouse,CD-1/Male (50/Group),Oral,0; 30; 110; 420 ppm of 96.6% fenoxycarb in diet for 80 wk; study duration 80 wk,"Lung: alveolar/bronchial adenomas and carcinomas, significant at 420 ppm only",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT  OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENOXYCARB (November 21, 1997)]"
7134,363907473,51605,CCOC(=O)NCCOC1=CC=C(C=C1)OC2=CC=CC=C2,Inactive,,,,Mouse,CD-1/Female (50/Group),Oral,0; 30; 110; 420 ppm of 96.6% fenoxycarb in diet for 80 wk; study duration 80 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT  OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FENOXYCARB (November 21, 1997)]"
7135,363907474,9576412,CC1=NN(C(=C1/C=N/OCC2=CC=C(C=C2)C(=O)OC(C)(C)C)OC3=CC=CC=C3)C,Inactive,,,,Rat,CD/Male (50/Group),Oral,0; 10; 25; 75; 150 ppm of 97.2% fenpyroximate (0; 0.40; 0.97; 3.00; 6.20 mg/kg/day) for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENPYROXIMATE (August 29, 2001)]"
7136,363907474,9576412,CC1=NN(C(=C1/C=N/OCC2=CC=C(C=C2)C(=O)OC(C)(C)C)OC3=CC=CC=C3)C,Inactive,,,,Rat,CD/Female (50/Group),Oral,0; 10; 25; 75; 150 ppm of 97.2% fenpyroximate (0; 0.49; 1.21; 3.81; 8.01 mg/kg/day) for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENPYROXIMATE (August 29, 2001)]"
7137,363907474,9576412,CC1=NN(C(=C1/C=N/OCC2=CC=C(C=C2)C(=O)OC(C)(C)C)OC3=CC=CC=C3)C,Inactive,,,,Mouse,ICR (Crj:CD-1)/Male (50/Group),Oral,0; 25; 100; 400; 800 ppm (0; 2.4; 9.5; 38.0; 69.6 mg/kg/day) for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENPYROXIMATE (August 29, 2001)]"
7138,363907474,9576412,CC1=NN(C(=C1/C=N/OCC2=CC=C(C=C2)C(=O)OC(C)(C)C)OC3=CC=CC=C3)C,Inactive,,,,Mouse,ICR (Crj:CD-1)/Female (50/Group),Oral,0; 25; 100; 400; 800  ppm (0; 2.4; 10.2; 41.4; 73.1 mg/kg/day) for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FENPYROXIMATE (August 29, 2001)]"
7139,363907476,3352,C1=C(C=C(C(=C1Cl)N2C(=C(C(=N2)C#N)S(=O)C(F)(F)F)N)Cl)C(F)(F)F,Active,,,,Rat,CD/Male (50/Group),Oral,0; 0.5; 1.5; 30; 300 ppm of 95.4% fipronil in diet for 89-91 wks; study duration 104 wks,Thyroid: follicular cell adenoma and carcinoma at highest dose,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FIPRONIL (March 25, 2011)]"
7140,363907476,3352,C1=C(C=C(C(=C1Cl)N2C(=C(C(=N2)C#N)S(=O)C(F)(F)F)N)Cl)C(F)(F)F,Active,,,,Rat,CD/Female (50/Group),Oral,0; 0.5; 1.5; 30; 300 ppm of 95.4% fipronil in diet for 89-91 wks; study duration 104 wks,Thyroid: follicular cell adenoma and carcinoma at highest dose,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FIPRONIL (March 25, 2011)]"
7141,363907476,3352,C1=C(C=C(C(=C1Cl)N2C(=C(C(=N2)C#N)S(=O)C(F)(F)F)N)Cl)C(F)(F)F,Active,,,,Mouse,CD-1/Male (32/Group),Oral,0; 0.1; 0.5; 10; 30 ppm of 95.4% fipronil in diet for 78 wks; study duration 78 wks,Liver: malignant hepatocellular tumors at highest dose,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FIPRONIL (March 25, 2011)]"
7142,363907476,3352,C1=C(C=C(C(=C1Cl)N2C(=C(C(=N2)C#N)S(=O)C(F)(F)F)N)Cl)C(F)(F)F,Inactive,,,,Mouse,CD-1/Female (32/Group),Oral,0; 0.1; 0.5; 10; 30 ppm of 95.4% fipronil in diet for 78 wks; study duration 78 wks,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FIPRONIL (March 25, 2011)]"
7143,363907477,92425,C#CCN1C(=O)COC2=CC(=C(C=C21)N3C(=O)C4=C(C3=O)CCCC4)F,Inactive,,,,Rat,Crj:CD(SD)/Male (50/Group),Oral,0; 1.8; 18.0; 36.5 mg/kg/day of 94.8% flumioxazin in diet for up to 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUMIOXAZIN (January 31, 2003)]"
7144,363907477,92425,C#CCN1C(=O)COC2=CC(=C(C=C21)N3C(=O)C4=C(C3=O)CCCC4)F,Inactive,,,,Rat,Crj:CD(SD)/Female (50/Group),Oral,0; 2.2; 21.8; 43.6 mg/kg/day of 94.8% flumioxazin in diet for up to 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUMIOXAZIN (January 31, 2003)]"
7145,363907477,92425,C#CCN1C(=O)COC2=CC(=C(C=C21)N3C(=O)C4=C(C3=O)CCCC4)F,Inactive,,,,Mouse,Crj:CD-1 (ICR)/Male (51/Group),Oral,0; 31.1; 314.9; 754.1 mg/kg/day of 94.8% flumioxazin in diet for 78 wk; study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUMIOXAZIN (January 31, 2003)]"
7146,363907477,92425,C#CCN1C(=O)COC2=CC(=C(C=C21)N3C(=O)C4=C(C3=O)CCCC4)F,Inactive,,,,Mouse,Crj:CD-1 (ICR)/Female (51/Group),Oral,0; 36.6; 346.4; 859.1 mg/kg/day of 94.8% flumioxazin in diet for 78 wk; study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUMIOXAZIN (January 31, 2003)]"
7147,363907478,11048796,CO/N=C(\C1=CC=CC=C1OC2=C(C(=NC=N2)OC3=CC=CC=C3Cl)F)/C4=NOCCO4,Inactive,,,,Rat,Wistar/Male (50/Group),Oral,0; 2.1; 5.2; 53.0; 271.9 mg/kg/day of 94.3-94.6% fluoxastrobin in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUOXASTROBIN (September 11, 2007)]"
7148,363907478,11048796,CO/N=C(\C1=CC=CC=C1OC2=C(C(=NC=N2)OC3=CC=CC=C3Cl)F)/C4=NOCCO4,Active,,,,Rat,Wistar/Female (50/Group),Oral,0; 6.9; 35.2; 181.3; 1083.2 mg/kg/day of 94.3-94.6% fluoxastrobin in diet for 2 yr; study duration 2 yr,Uterus: adenocarcinoma (highest dose only),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUOXASTROBIN (September 11, 2007)]"
7149,363907478,11048796,CO/N=C(\C1=CC=CC=C1OC2=C(C(=NC=N2)OC3=CC=CC=C3Cl)F)/C4=NOCCO4,Inactive,,,,Mouse,CD-1/Male (50/Group),Oral,0; 18.6; 135.4; 775.6 mg/kg/day of 94.3% - 94.5% fluoxastrobin in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUOXASTROBIN (September 11, 2007)]"
7150,363907478,11048796,CO/N=C(\C1=CC=CC=C1OC2=C(C(=NC=N2)OC3=CC=CC=C3Cl)F)/C4=NOCCO4,Inactive,,,,Mouse,CD-1/Female (50/Group),Oral,0; 29.5; 204.0; 1265.1 mg/kg/day of 94.3% - 94.5% fluoxastrobin in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUOXASTROBIN (September 11, 2007)]"
7151,363907479,443048,CCCCCOC(=O)COC1=C(C=C(C(=C1)N2C(=O)C3=C(C2=O)CCCC3)F)Cl,Inactive,,,,Rat,Crj:CD(SD)/Male (50/Group),Oral,0; 3.5; 35.4; 360.4; 744.9 mg/kg/day of 94.4% flumiclorac pentyl in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUMICLORAC PENTYL (February 1, 2006)]"
7152,363907479,443048,CCCCCOC(=O)COC1=C(C=C(C(=C1)N2C(=O)C3=C(C2=O)CCCC3)F)Cl,Inactive,,,,Rat,Crj:CD(SD)/Female (50/Group),Oral,0; 4.3; 43.6; 443.8; 919.4 mg/kg/day of 94.4% flumiclorac pentyl in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUMICLORAC PENTYL (February 1, 2006)]"
7153,363907479,443048,CCCCCOC(=O)COC1=C(C=C(C(=C1)N2C(=O)C3=C(C2=O)CCCC3)F)Cl,Inactive,,,,Mouse,CD-1 (ICR)/Male (51/Group),Oral,0; 31.5; 307.9; 731.4 mg/kg/day of 94.7% flumiclorac pentyl in diet for 78 wk; study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUMICLORAC PENTYL (February 1, 2006)]"
7154,363907479,443048,CCCCCOC(=O)COC1=C(C=C(C(=C1)N2C(=O)C3=C(C2=O)CCCC3)F)Cl,Inactive,,,,Mouse,CD-1 (ICR)/Female (51/Group),Oral,0; 37.8; 368.1; 850.1 mg/kg/day of 94.7% flumiclorac pentyl in diet for 78 wk; study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUMICLORAC PENTYL (February 1, 2006)]"
7155,363907480,3033674,CCCCOC(=O)[C@@H](C)OC1=CC=C(C=C1)OC2=NC=C(C=C2)C(F)(F)F,Inactive,,,,Rat,Wistar/Male (60/Group),Oral,0; 2; 10; 80; 250 ppm of 94.8% fluazifop-o-butyl (0; 0.08; 0.41; 3.3; 10.2 mg/kg/day) in diet for 2 yrs; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUAZIFOP-P-BUTYL (May 5, 2003)]"
7156,363907480,3033674,CCCCOC(=O)[C@@H](C)OC1=CC=C(C=C1)OC2=NC=C(C=C2)C(F)(F)F,Inactive,,,,Rat,Wistar/Female (60/Group),Oral,0; 2; 10; 80; 250 ppm of 94.8% fluazifop-o-butyl (0; 0.11; 0.53; 4.3; 13.4 mg/kg/day) in diet for 2 yrs; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUAZIFOP-P-BUTYL (May 5, 2003)]"
7157,363907480,3033674,CCCCOC(=O)[C@@H](C)OC1=CC=C(C=C1)OC2=NC=C(C=C2)C(F)(F)F,Inactive,,,,Hamster,Syrian golden/Male (51/Group),Oral,0; 200; 750; 3000 ppm of 91.6% fluazifop-o-butyl (0; 11.1; 42; 174 mg/kg/day) in diet for 81-83 wks; study duration 83 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUAZIFOP-P-BUTYL (May 5, 2003)]"
7158,363907480,3033674,CCCCOC(=O)[C@@H](C)OC1=CC=C(C=C1)OC2=NC=C(C=C2)C(F)(F)F,Inactive,,,,Hamster,Syrian golden/Female (51/Group),Oral,0; 200; 750; 3000 ppm of 91.6% fluazifop-o-butyl (0; 10.6; 40; 158 mg/kg/day) in diet for 81-83 wks; study duration 83 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUAZIFOP-P-BUTYL (May 5, 2003)]"
7159,363907481,9834513,C1=CN=CC(=C1C(F)(F)F)C(=O)NCC#N,Inactive,,,,Rat,Wistar (Jcl:Wistar)/Male (52/Group),Oral,0; 50; 100; 200; 1000 ppm (0; 1.84; 3.68; 7.32; 36.5 mg/kg/day) in diet  for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FLONICAMID (April 28, 2005)]"
7160,363907481,9834513,C1=CN=CC(=C1C(F)(F)F)C(=O)NCC#N,Inactive,,,,Rat,Wistar (Jcl:Wistar)/Female (52/Group),Oral,0; 200; 1000; 5000 ppm (0; 8.92; 44.1; 219 mg/kg/day) in diet  for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FLONICAMID (April 28, 2005)]"
7161,363907481,9834513,C1=CN=CC(=C1C(F)(F)F)C(=O)NCC#N,Active,,,,Mouse,Crl:CD-1(ICR)BR VAF/Plus / Male (60/Group),Oral,0; 250; 750; 2250 ppm (0; 29; 88; 261 mg/kg/day) in diet for 18 mo; study duration 18 mo,Lung: alveolar/bronchiolar adenomas and carcinomas,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FLONICAMID (April 28, 2005)]"
7162,363907481,9834513,C1=CN=CC(=C1C(F)(F)F)C(=O)NCC#N,Active,,,,Mouse,Crl:CD-1(ICR)BR VAF/Plus / Female (60/Group),Oral,0; 250; 750; 2250 ppm (0; 38; 112; 334 mg/kg/day) in diet for 18 mo; study duration 18 mo,Lung: alveolar/bronchiolar adenomas and carcinomas,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF  PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR  FLONICAMID (April 28, 2005)]"
7163,363907482,43079,CN1C=C(C(=O)C(=C1)C2=CC(=CC=C2)C(F)(F)F)C3=CC=CC=C3,Inactive,,,,Rat,Fischer 344/Male (60/Group),Oral,0; 200; 650; 2000 ppm of 97.2-97.8% fluridone in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLURIDONE (February 9, 2000)]"
7164,363907482,43079,CN1C=C(C(=O)C(=C1)C2=CC(=CC=C2)C(F)(F)F)C3=CC=CC=C3,Inactive,,,,Rat,Fischer 344/Female (60/Group),Oral,0; 200; 650; 2000 ppm of 97.2-97.8% fluridone in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLURIDONE (February 9, 2000)]"
7165,363907482,43079,CN1C=C(C(=O)C(=C1)C2=CC(=CC=C2)C(F)(F)F)C3=CC=CC=C3,Inactive,,,,Mouse,ICR/Male (60?/Group),Oral,"0; 33, 100, 330 ppm (0; 3.5; 10.9; 30.7 mg/kg/day) of 97.2-97.8% fluridone in diet for 2 yr; study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLURIDONE (February 9, 2000)]"
7166,363907482,43079,CN1C=C(C(=O)C(=C1)C2=CC(=CC=C2)C(F)(F)F)C3=CC=CC=C3,Inactive,,,,Mouse,ICR/Female (60?/Group),Oral,"0; 33, 100, 330 ppm (0; 4.0; 12.3; 34.5 mg/kg/day) of 97.2-97.8% fluridone in diet for 2 yr; study duration 2 yr",,Negative. (Possible increased incidence of skin fibrosarcomas in high dose females),"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLURIDONE (February 9, 2000)]"
7167,363907483,50465,C(C(=O)O)OC1=NC(=C(C(=C1Cl)N)Cl)F,Inactive,,,,Rat,Fischer 344/Male (50/Group),Oral,0; 100; 500; 1000 mg/kg/day of 99.0% fluroxypyr in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUROXYPYR (December 18, 2003)]"
7168,363907483,50465,C(C(=O)O)OC1=NC(=C(C(=C1Cl)N)Cl)F,Inactive,,,,Rat,Fischer 344/Female (50/Group),Oral,0; 100; 500; 1000 mg/kg/day of 99.0% fluroxypyr in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUROXYPYR (December 18, 2003)]"
7169,363907483,50465,C(C(=O)O)OC1=NC(=C(C(=C1Cl)N)Cl)F,Inactive,,,,Mouse,CD-1/Female (60/Group),Oral,0; 100; 500; 1000 mg/kg/day of 98.9% fluroxypyr in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUROXYPYR (December 18, 2003)]"
7170,363907483,50465,C(C(=O)O)OC1=NC(=C(C(=C1Cl)N)Cl)F,Inactive,,,,Mouse,CD-1/Male (60/Group),Oral,0; 100; 500; 1000 mg/kg/day of 98.9% fluroxypyr in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUROXYPYR (December 18, 2003)]"
7171,363907484,91727,C1=CC=C(C(=C1)C(CN2C=NC=N2)(C3=CC=C(C=C3)F)O)F,Inactive,,,,Rat,Alpk:AP/Male (52/Group),Oral,0; 20; 200; 2000 ppm (0; 1; 10; 100 mg/kg/day) of 93% flutriafol in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUTRIAFOL (December 16, 2009)]"
7172,363907484,91727,C1=CC=C(C(=C1)C(CN2C=NC=N2)(C3=CC=C(C=C3)F)O)F,Inactive,,,,Rat,Alpk:AP/Female (52/Group),Oral,0; 20; 200; 2000 ppm (0; 1; 10; 100 mg/kg/day) of 93% flutriafol in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUTRIAFOL (December 16, 2009)]"
7173,363907484,91727,C1=CC=C(C(=C1)C(CN2C=NC=N2)(C3=CC=C(C=C3)F)O)F,Inactive,,,,Mouse,C57BL/10JfCD-1/Alpk (C57BL/10J)/Male (50/Group),Oral,0; 10; 50; 200 ppm (0; 1.5; 7.5; 30 mg/kg/day) of 93% flutriafol in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUTRIAFOL (December 16, 2009)]"
7174,363907484,91727,C1=CC=C(C(=C1)C(CN2C=NC=N2)(C3=CC=C(C=C3)F)O)F,Inactive,,,,Mouse,C57BL/10JfCD-1/Alpk (C57BL/10J)/Female (50/Group),Oral,0; 10; 50; 200 ppm (0; 1.5; 7.5; 30 mg/kg/day) of 93% flutriafol in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FLUTRIAFOL (December 16, 2009)]"
7175,363907485,13676,CCOP(=S)(CC)SC1=CC=CC=C1,Inactive,,,,Rat,Sprague-Dawley/Male (20 or 60/Group),Oral,0; 3.7; 14.2; 57.7; 116 ppm (sacrifice at 1 yr) of Dyfonate Technical (94% pure) in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FONOFOS (March 31, 1998)]"
7176,363907485,13676,CCOP(=S)(CC)SC1=CC=CC=C1,Inactive,,,,Rat,Sprague-Dawley/Female (20 or 60/Group),Oral,0; 3.7; 14.2; 57.7; 116 ppm (sacrifice at 1 yr) of Dyfonate Technical (94% pure) in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FONOFOS (March 31, 1998)]"
7177,363907485,13676,CCOP(=S)(CC)SC1=CC=CC=C1,Inactive,,,,Mouse,CD-1 (Crl:CD-1[ICR]-BR[Swiss]/Male (60/Group),Oral,0; 4.6; 23.5; 94.7 ppm of Dyfonate Technical (94% pure) in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FONOFOS (March 31, 1998)]"
7178,363907485,13676,CCOP(=S)(CC)SC1=CC=CC=C1,Inactive,,,,Mouse,CD-1 (Crl:CD-1[ICR]-BR[Swiss]/Female (60/Group),Oral,0; 4.6; 23.5; 94.7 ppm of Dyfonate Technical (94% pure) in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FONOFOS (March 31, 1998)]"
7179,363907486,11419598,CN(C)C(=O)C1=C(C=C(C=C1)NC=O)S(=O)(=O)NC(=O)NC2=NC(=CC(=N2)OC)OC,Inactive,,,,Rat,Sprague Dawley CRL:CD (IGS) BR/Male (50/Group),Oral,"0; 100; 600; 6000; 20,000 ppm of 94.6% foramsulfuron in diet for 104 wk; study duration 104 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORAMSULFURON (October 10, 2003)]"
7180,363907486,11419598,CN(C)C(=O)C1=C(C=C(C=C1)NC=O)S(=O)(=O)NC(=O)NC2=NC(=CC(=N2)OC)OC,Inactive,,,,Rat,Sprague Dawley CRL:CD (IGS) BR/Female (50/Group),Oral,"0; 100; 600; 6000; 20,000 ppm of 94.6% foramsulfuron in diet for 104 wk; study duration 104 wk",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORAMSULFURON (October 10, 2003)]"
7181,363907486,11419598,CN(C)C(=O)C1=C(C=C(C=C1)NC=O)S(=O)(=O)NC(=O)NC2=NC(=CC(=N2)OC)OC,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Male (51/Group),Oral,0; 40; 800; 8000 ppm of 94.6% foramsulfuron in diet for 80 wk; study duration 80 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORAMSULFURON (October 10, 2003)]"
7182,363907486,11419598,CN(C)C(=O)C1=C(C=C(C=C1)NC=O)S(=O)(=O)NC(=O)NC2=NC(=CC(=N2)OC)OC,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Female (51/Group),Oral,0; 40; 800; 8000 ppm of 94.6% foramsulfuron in diet for 80 wk; study duration 80 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORAMSULFURON (October 10, 2003)]"
7183,363907487,93379,C1=CC=C(C=C1)NC(=O)NC2=CC(=NC=C2)Cl,Inactive,,,,Rat,Strain not specified by Department of Pesticides Regulation/Male (70/Group),Oral,0; 7; 93; 352 mg/kg/day of 98.5% forchlorfenuron in diet for up to 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORCHLORFENURON (July 9, 2004)]"
7184,363907487,93379,C1=CC=C(C=C1)NC(=O)NC2=CC(=NC=C2)Cl,Inactive,,,,Rat,Strain not specified by Department of Pesticides Regulation/Female (70/Group),Oral,0; 9; 122; 518 mg/kg/day of 98.5% forchlorfenuron in diet for up to 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORCHLORFENURON (July 9, 2004)]"
7185,363907487,93379,C1=CC=C(C=C1)NC(=O)NC2=CC(=NC=C2)Cl,Inactive,,,,Mouse,CD-1/Male (60/Group),Oral,0; 10; 1000 mg/kg/day of 96.9% forchlorfenuron in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORCHLORFENURON (July 9, 2004)]"
7186,363907487,93379,C1=CC=C(C=C1)NC(=O)NC2=CC(=NC=C2)Cl,Inactive,,,,Mouse,CD-1/Female (60/Group),Oral,0; 10; 1000 mg/kg/day of 96.9% forchlorfenuron in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORCHLORFENURON (July 9, 2004)]"
7187,363907488,31899,CNC(=O)OC1=CC=CC(=C1)N=CN(C)C.Cl,Inactive,,,,Rat,Crl:COBS CD(SD)BR/Male (50/Group),Oral,0; 10; 50; 250 ppm of 95.1-96% formetanate HCl in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORMETANATE HCl (August 29, 2002)]"
7188,363907488,31899,CNC(=O)OC1=CC=CC(=C1)N=CN(C)C.Cl,Inactive,,,,Rat,Crl:COBS CD(SD)BR/Female (50/Group),Oral,0; 10; 50; 250 ppm of 95.1-96% formetanate HCl in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORMETANATE HCl (August 29, 2002)]"
7189,363907488,31899,CNC(=O)OC1=CC=CC(=C1)N=CN(C)C.Cl,Inactive,,,,Mouse,Crl:CD-1(ICR) BR/Male (50/Group),Oral,0; 10; 50; 500 ppm of 95.7% formetanate HCl in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORMETANATE HCl (August 29, 2002)]"
7190,363907488,31899,CNC(=O)OC1=CC=CC(=C1)N=CN(C)C.Cl,Inactive,,,,Mouse,Crl:CD-1(ICR) BR/Female (50/Group),Oral,0; 10; 50; 500 ppm of 95.7% formetanate HCl in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FORMETANATE HCl (August 29, 2002)]"
7191,363907489,91758,CCC(C)SP(=O)(N1CCSC1=O)OCC,Inactive,,,,Rat,CD/Male (50/Group),Oral,0; 0.039; 0.38; 1.94; 8.34 mg/kg/day of 93.3% fosthiazate in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FOSTHIAZATE (June 9, 2008)]"
7192,363907489,91758,CCC(C)SP(=O)(N1CCSC1=O)OCC,Inactive,,,,Rat,CD/Female (50/Group),Oral,0; 0.051; 0.50; 2.45; 11.69 mg/kg/day of 93.3% fosthiazate in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FOSTHIAZATE (June 9, 2008)]"
7193,363907489,91758,CCC(C)SP(=O)(N1CCSC1=O)OCC,Inactive,,,,Mouse,CD-1/Male (60/Group),Oral,0; 1.02; 3.10; 10.3; 30.5 mg/kg/day of 93.3% fosthiazate in diet for 104 wk; study duration 102 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FOSTHIAZATE (June 9, 2008)]"
7194,363907489,91758,CCC(C)SP(=O)(N1CCSC1=O)OCC,Inactive,,,,Mouse,CD-1/Female (60/Group),Oral,0; 1.11; 3.20; 10.4; 39.2 mg/kg/day of 93.3% fosthiazate in diet for 104 wk; study duration 102 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR FOSTHIAZATE (June 9, 2008)]"
7195,363907490,13218777,C[C@H]1[C@@H](SC(=O)N1C(=O)NC2CCCCC2)C3=CC=C(C=C3)Cl,Active,,,,Rat,Fischer 344/Male (70/Group),Oral,0; 60; 430; 3000 ppm in diet for 24 mo; study duration 24 mo,"Mammary gland: fibroadenoma (0, 1, 2, 6)",Positive. (Department of Pesticides Regulation reviewer describes as possible adverse effect),[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR HEXYTHIZOX (Undated)]
7196,363907490,13218777,C[C@H]1[C@@H](SC(=O)N1C(=O)NC2CCCCC2)C3=CC=C(C=C3)Cl,Inactive,,,,Rat,Fischer 344/Female (70/Group),Oral,0; 60; 430; 3000 ppm in diet for 24 mo; study duration 24 mo,,Negative,[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR HEXYTHIZOX (Undated)]
7197,363907491,5281875,CC1(CN=C(NC1)NN=C(/C=C/C2=CC=C(C=C2)C(F)(F)F)/C=C/C3=CC=C(C=C3)C(F)(F)F)C,Inactive,,,,Rat,CD/Male (50/Group),Oral,0; 25; 50; 100; 200 ppm in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR HYDRAMETHYLNON (June 14, 2002)]"
7198,363907491,5281875,CC1(CN=C(NC1)NN=C(/C=C/C2=CC=C(C=C2)C(F)(F)F)/C=C/C3=CC=C(C=C3)C(F)(F)F)C,Inactive,,,,Rat,CD/Female (50/Group),Oral,0; 25; 50; 100; 200 ppm in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR HYDRAMETHYLNON (June 14, 2002)]"
7199,363907491,5281875,CC1(CN=C(NC1)NN=C(/C=C/C2=CC=C(C=C2)C(F)(F)F)/C=C/C3=CC=C(C=C3)C(F)(F)F)C,Inactive,,,,Mouse,CD-1/Male (?/Group),Oral,0; 25; 50; 100; 200 ppm of 92% hydramethylnon in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR HYDRAMETHYLNON (June 14, 2002)]"
7200,363907491,5281875,CC1(CN=C(NC1)NN=C(/C=C/C2=CC=C(C=C2)C(F)(F)F)/C=C/C3=CC=C(C=C3)C(F)(F)F)C,Inactive,,,,Mouse,CD-1/Female (?/Group),Oral,0; 25; 50; 100; 200 ppm of 92% hydramethylnon in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR HYDRAMETHYLNON (June 14, 2002)]"
7201,363907492,37175,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl,Inactive,,,,Rat,Cpb:WU/Male (20/Group),Oral,0; 25; 100; 400 ppm 98.1% imazalil in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZALIL (November 10, 1995)]"
7202,363907492,37175,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl,Inactive,,,,Rat,Cpb:WU/Female (20/Group),Oral,0; 25; 100; 400 ppm 98.1% imazalil in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZALIL (November 10, 1995)]"
7203,363907492,37175,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl,Active,,,,Mouse,Swiss/Male (50/Group),Oral,0; 50; 200; 600 ppm 93% imazalil in diet in 50:50 Aerosil:corn starch for 2 yr; study duration 2 yr,Liver: hepatocytic neoplasms,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZALIL (November 10, 1995)]"
7204,363907492,37175,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl,Active,,,,Mouse,Swiss/Female (50/Group),Oral,0; 50; 200; 600 ppm 93% imazalil in diet in 50:50 Aerosil:corn starch for 2 yr; study duration 2 yr,Liver: hepatocytic neoplasms,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZALIL (November 10, 1995)]"
7205,363907493,21873022,CC1=CC(=C(C=C1)C(=O)OC)C2=NC(C(=O)N2)(C)C(C)C.CC1=CC(=C(C=C1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)OC,Inactive,,,,Rat,Crl:CD(SD)BR/Male (65/Group),Oral,0; 240; 1000; 4000 ppm 94.2% imazamethabenz-methyl in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAMETHABENZ-METHYL (April 6, 1999)]"
7206,363907493,21873022,CC1=CC(=C(C=C1)C(=O)OC)C2=NC(C(=O)N2)(C)C(C)C.CC1=CC(=C(C=C1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)OC,Inactive,,,,Rat,Crl:CD(SD)BR/Female (65/Group),Oral,0; 240; 1000; 4000 ppm 94.2% imazamethabenz-methyl in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAMETHABENZ-METHYL (April 6, 1999)]"
7207,363907493,21873022,CC1=CC(=C(C=C1)C(=O)OC)C2=NC(C(=O)N2)(C)C(C)C.CC1=CC(=C(C=C1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)OC,Inactive,,,,Mouse,CD-1/Male (65/Group),Oral,0; 130; 525; 2100 ppm 94.2% imazamethabenz-methyl in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAMETHABENZ-METHYL (April 6, 1999)]"
7208,363907493,21873022,CC1=CC(=C(C=C1)C(=O)OC)C2=NC(C(=O)N2)(C)C(C)C.CC1=CC(=C(C=C1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)OC,Inactive,,,,Mouse,CD-1/Female (65/Group),Oral,0; 130; 525; 2100 ppm 94.2% imazamethabenz-methyl in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAMETHABENZ-METHYL (April 6, 1999)]"
7209,363907494,86137,CC(C)C1(C(=O)NC(=N1)C2=C(C=C(C=N2)COC)C(=O)O)C,Inactive,,,,Rat,Sprague-Dawley/Male (65/Group),Oral,0; 52; 528; 1068 mg/kg/day of 97.1% imazamox in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAMOX (October 24, 2000)]"
7210,363907494,86137,CC(C)C1(C(=O)NC(=N1)C2=C(C=C(C=N2)COC)C(=O)O)C,Inactive,,,,Rat,Sprague-Dawley/Female (65/Group),Oral,0; 63; 626; 1284 mg/kg/day of 97.1% imazamox in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAMOX (October 24, 2000)]"
7211,363907494,86137,CC(C)C1(C(=O)NC(=N1)C2=C(C=C(C=N2)COC)C(=O)O)C,Inactive,,,,Mouse,CD-1/Male (55/Group),Oral,0; 73; 535; 1053 mg/kg/day of 97.1% imazamox in diet for at least 18 mo; study duration at least 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAMOX (October 24, 2000)]"
7212,363907494,86137,CC(C)C1(C(=O)NC(=N1)C2=C(C=C(C=N2)COC)C(=O)O)C,Inactive,,,,Mouse,CD-1/Female (55/Group),Oral,0; 96; 664; 1348 mg/kg/day of 97.1% imazamox in diet for at least 18 mo; study duration at least 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAMOX (October 24, 2000)]"
7213,363907495,91770,CC1=CC(=C(N=C1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)O,Inactive,,,,Rat,Crl:CD(SD)BR/Male (55/Group),Oral,"0; 5000; 10,000; 20,000 ppm of 96.4% imazapic in diet for 24 mo; study duration 24 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAPIC (June 15, 2005)]"
7214,363907495,91770,CC1=CC(=C(N=C1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)O,Inactive,,,,Rat,Crl:CD(SD)BR/Female (55/Group),Oral,"0; 5000; 10,000; 20,000 ppm of 96.4% imazapic in diet for 24 mo; study duration 24 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAPIC (June 15, 2005)]"
7215,363907495,91770,CC1=CC(=C(N=C1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)O,Inactive,,,,Mouse,CD-1[Crl(ICR)BR]/Male (55/Group),Oral,0; 1750; 3500; 7000 ppm of 96.9% imazapic in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAPIC (June 15, 2005)]"
7216,363907495,91770,CC1=CC(=C(N=C1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)O,Inactive,,,,Mouse,CD-1[Crl(ICR)BR]/Female (55/Group),Oral,0; 1750; 3500; 7000 ppm of 96.9% imazapic in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZAPIC (June 15, 2005)]"
7217,363907496,92433,COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=C(N=C3N2C=CC=C3)Cl)OC,Inactive,,,,Rat,CD (Sprague-Dawley derived)/Male (50/Group),Oral,0; 10.39; 106.10; 1123.99 mg/kg/day of 99.6-99.8% imazosulfuron in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZOSULFURON (January 14, 2010)]"
7218,363907496,92433,COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=C(N=C3N2C=CC=C3)Cl)OC,Inactive,,,,Rat,CD (Sprague-Dawley derived)/Female (50/Group),Oral,0; 12.94; 132.46; 1554.35 mg/kg/day of 99.6-99.8% imazosulfuron in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZOSULFURON (January 14, 2010)]"
7219,363907496,92433,COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=C(N=C3N2C=CC=C3)Cl)OC,Inactive,,,,Mouse,CD-1/Male (50/Group),Oral,0; 72.7; 741.3; 7848.1 mg/kg/day of 99.6-99.8% imazosulfuron in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZOSULFURON (January 14, 2010)]"
7220,363907496,92433,COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=C(N=C3N2C=CC=C3)Cl)OC,Inactive,,,,Mouse,CD-1/Female (50/Group),Oral,"0; 86.8; 870.0; 10,303.5 mg/kg/day of 99.6-99.8% imazosulfuron in diet for 18 mo; study duration 18 mo",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMAZOSULFURON (January 14, 2010)]"
7221,363907497,123622,CC(=CC1C(C1(C)C)C(=O)OCN2C(=O)CN(C2=O)CC#C)C,Inactive,,,,Rat,Sprague-Dawley/Male (50/Group),Oral,0; 50; 250; 2500; 5000 ppm of 92.9% imiprothrin in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMIPROTHRIN (March 3, 1999)]"
7222,363907497,123622,CC(=CC1C(C1(C)C)C(=O)OCN2C(=O)CN(C2=O)CC#C)C,Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,0; 50; 250; 2500; 5000 ppm of 92.9% imiprothrin in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMIPROTHRIN (March 3, 1999)]"
7223,363907497,123622,CC(=CC1C(C1(C)C)C(=O)OCN2C(=O)CN(C2=O)CC#C)C,Inactive,,,,Mouse,Crj:CD-1 (ICR)/Male (51/Group),Oral,0; 100; 3500; 7000 ppm of 92.9% imiprothrin in diet for 78 wk; study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMIPROTHRIN (March 3, 1999)]"
7224,363907497,123622,CC(=CC1C(C1(C)C)C(=O)OCN2C(=O)CN(C2=O)CC#C)C,Inactive,,,,Mouse,Crj:CD-1 (ICR)/Female (51/Group),Oral,0; 100; 3500; 7000 ppm of 92.9% imiprothrin in diet for 78 wk; study duration 78 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IMIPROTHRIN (March 3, 1999)]"
7225,363907498,44146693,C[C@H]1CC2=C([C@@H]1NC3=NC(=NC(=N3)N)C(C)F)C=C(C=C2)C,Inactive,,,,Rat,Wistar/Female (60/Group),Oral,"0; 17; 167; 661 (wks 0-40), 452 (overall) mg/kg/day of 93.14% indaziflam in diet for 2 yr; study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR INDAZIFLAM (OCTOBER 28, 2009)]"
7226,363907498,44146693,C[C@H]1CC2=C([C@@H]1NC3=NC(=NC(=N3)N)C(C)F)C=C(C=C2)C,Inactive,,,,Rat,Wistar/Male (60/Group),Oral,0; 12; 118; 414 mg/kg/day of 93.14% indaziflam in diet for 2 yr; study duration 2 yr,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR INDAZIFLAM (OCTOBER 28, 2009)]"
7227,363907498,44146693,C[C@H]1CC2=C([C@@H]1NC3=NC(=NC(=N3)N)C(C)F)C=C(C=C2)C,Inactive,,,,Mouse,C57BL/6J/Male (50/Group),Oral,0; 6.8; 34; 142 mg/kg/day of 93.14% indaziflam in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR INDAZIFLAM (OCTOBER 28, 2009)]"
7228,363907498,44146693,C[C@H]1CC2=C([C@@H]1NC3=NC(=NC(=N3)N)C(C)F)C=C(C=C2)C,Inactive,,,,Mouse,C57BL/6J/Female (50/Group),Oral,0; 8.4; 42; 168 mg/kg/day of 93.14% indaziflam in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR INDAZIFLAM (OCTOBER 28, 2009)]"
7229,363907499,107720,COC(=O)[C@]12CC3=C(C1=NN(CO2)C(=O)N(C4=CC=C(C=C4)OC(F)(F)F)C(=O)OC)C=CC(=C3)Cl,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Male (70/Group),Oral,0; 20; 100; 125/150/200 ppm for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR INDOXACARB (April 21, 2008)]"
7230,363907499,107720,COC(=O)[C@]12CC3=C(C1=NN(CO2)C(=O)N(C4=CC=C(C=C4)OC(F)(F)F)C(=O)OC)C=CC(=C3)Cl,Inactive,,,,Mouse,Crl:CD-1(ICR)BR/Female (70/Group),Oral,0; 20; 100; 125/150/200 ppm for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR INDOXACARB (April 21, 2008)]"
7231,363907500,37517,CC(C)NC(=O)N1CC(=O)N(C1=O)C2=CC(=CC(=C2)Cl)Cl,Active,,,,Rat,Sprague-Dawley/Male (60/Group),Oral,0; 6.1; 12.4; 69 mg/kg/day of 94.5-95.7% iprodione in diet for 104 wk; study duration 104 wk,Testes: Interstitial cell adenoma (high dose only),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IPRODIONE (October 24, 1997)]"
7232,363907500,37517,CC(C)NC(=O)N1CC(=O)N(C1=O)C2=CC(=CC(=C2)Cl)Cl,Inactive,,,,Rat,Sprague-Dawley/Female (60/Group),Oral,0; 8.4; 16.5; 95 mg/kg/day of 94.5-95.7% iprodione in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IPRODIONE (October 24, 1997)]"
7233,363907500,37517,CC(C)NC(=O)N1CC(=O)N(C1=O)C2=CC(=CC(=C2)Cl)Cl,Active,,,,Mouse,CD-1/Male (50/Group),Oral,0; 160; 800; 4000 ppm of 95.7% iprodione in diet for 99 wk; study duration 99 wk,Liver: hepatocellular adenoma and carcinoma in high dose mice,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IPRODIONE (October 24, 1997)]"
7234,363907500,37517,CC(C)NC(=O)N1CC(=O)N(C1=O)C2=CC(=CC(=C2)Cl)Cl,Active,,,,Mouse,CD-1/Female (50/Group),Oral,0; 160; 800; 4000 ppm of 95.7% iprodione in diet for 99 wk; study duration 99 wk,Liver: hepatocellular adenoma and carcinoma in high dose mice,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR IPRODIONE (October 24, 1997)]"
7235,363907501,73672,CCC(C)(CC)C1=NOC(=C1)NC(=O)C2=C(C=CC=C2OC)OC,Active,,,,Rat,Fischer 344/Male (60/Group),Oral,"0; 125; 1250; 12,500 ppm of 85% isoxaben (plus 10.5% closely related isomers) in diet for  2 yr; study duration 2 yr",Adrenal gland: pheochromocytoma (highest dose),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ISOXABEN (September 25, 1991)]"
7236,363907501,73672,CCC(C)(CC)C1=NOC(=C1)NC(=O)C2=C(C=CC=C2OC)OC,Inactive,,,,Rat,Fischer 344/Female (60/Group),Oral,"0; 125; 1250; 12,500 ppm of 85% isoxaben (plus 10.5% closely related isomers) in diet for  2 yr; study duration 2 yr",,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ISOXABEN (September 25, 1991)]"
7237,363907501,73672,CCC(C)(CC)C1=NOC(=C1)NC(=O)C2=C(C=CC=C2OC)OC,Active,,,,Mouse,B6C3F1/Male (60/Group),Oral,"0; 100; 1000; 12,500 ppm of 85% isoxaben (plus 10.5% closely related isomers) in diet for  2 yr; study duration 2 yr","Liver: Hepatocellular adenomas (increased incidence and multiplicity at 12,500 ppm)",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ISOXABEN (September 25, 1991)]"
7238,363907501,73672,CCC(C)(CC)C1=NOC(=C1)NC(=O)C2=C(C=CC=C2OC)OC,Active,,,,Mouse,B6C3F1/Male (60/Group),Oral,"0; 100; 1000; 12,500 ppm of 85% isoxaben (plus 10.5% closely related isomers) in diet for  2 yr; study duration 2 yr","Liver: Hepatocellular adenomas (increased incidence and multiplicity at 12,500 ppm)",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR ISOXABEN (September 25, 1991)]"
7239,363907502,6112114,CC1=CC=CC=C1OCC2=CC=CC=C2/C(=N\OC)/C(=O)OC,Active,,,,Rat,Wistar/Male (20/Group),Oral,0; 9; 36; 370; 746 mg/kg/day of 93.7-96.6% kresoxim-methyl in diet for 24 mo; study duration 24 mo,"Liver: hepatocellular carcinoma (0/20, 1/20, 1/20, 3/20, 8/20)",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KRESOXIM-METHYL (December 23, 1999)]"
7240,363907502,6112114,CC1=CC=CC=C1OCC2=CC=CC=C2/C(=N\OC)/C(=O)OC,Active,,,,Rat,Wistar/Female (20/Group),Oral,0; 12; 48; 503; 985 mg/kg/day of 93.7-96.6% kresoxim-methyl in diet for 24 mo; study duration 24 mo,"Liver: hepatocellular carcinoma (1/20, 0/20, 2/20, 6/20, 6/20)",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KRESOXIM-METHYL (December 23, 1999)]"
7241,363907502,6112114,CC1=CC=CC=C1OCC2=CC=CC=C2/C(=N\OC)/C(=O)OC,Active,,,,Rat,Wistar/Male (50/Group),Oral,0; 9; 36; 375; 770 mg/kg/day of 93.7-96.6% kresoxim-methyl in diet for 24 mo; study duration 24 mo,"Liver: hepatocellular carcinoma (7/50, 5/50, 2/50, 18/50, 11/50). Spleen: hemangiosarcoma (0/50, 0/50, 2/50, 2/50, 3/50)",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KRESOXIM-METHYL (December 23, 1999)]"
7242,363907502,6112114,CC1=CC=CC=C1OCC2=CC=CC=C2/C(=N\OC)/C(=O)OC,Active,,,,Rat,Wistar/Female (50/Group),Oral,0; 12; 47; 497; 1046 mg/kg/day of 93.7-96.6% kresoxim-methyl in diet for 24 mo; study duration 24 mo,"Liver: hepatocellular carcinoma (1/50, 1/50, 2/50, 13/50, 16/50)",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KRESOXIM-METHYL (December 23, 1999)]"
7243,363907502,6112114,CC1=CC=CC=C1OCC2=CC=CC=C2/C(=N\OC)/C(=O)OC,Inactive,,,,Mouse,Strain not specified by Department of Pesticide Regulation /Male (50/Group),Oral,0; 60; 304; 1305 mg/kg/day of 93.7-96.6% kresoxim-methyl in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KRESOXIM-METHYL (December 23, 1999)]"
7244,363907502,6112114,CC1=CC=CC=C1OCC2=CC=CC=C2/C(=N\OC)/C(=O)OC,Inactive,,,,Mouse,Strain not specified by Department of Pesticide Regulation /Female (50/Group),Oral,0; 81; 400; 1662 mg/kg/day of 93.7-96.6% kresoxim-methyl in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR KRESOXIM-METHYL (December 23, 1999)]"
7245,363907503,9502,CN(C(=O)NC1=CC(=C(C=C1)Cl)Cl)OC,Active,,,,Rat,Charles River CD/Male (70/Group),Oral,0; 50; 125; 625 ppm 97% linuron in diet for 24 mo; study duration 24 mo,Testes: Interstitial cell adenoma,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR LINURON (September 30, 1993)]"
7246,363907503,9502,CN(C(=O)NC1=CC(=C(C=C1)Cl)Cl)OC,Inactive,,,,Rat,Charles River CD/Female (70/Group),Oral,0; 50; 125; 625 ppm 97% linuron in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR LINURON (September 30, 1993)]"
7247,363907503,9502,CN(C(=O)NC1=CC(=C(C=C1)Cl)Cl)OC,Active,,,,Rat,Crl:CD (SD)BR /Male (25/Group),Oral,0 (control diet); control diet for 18 mo followed by 625 ppm linuron for 6 mo; control diet for 1 yr followed by 625 ppm linuron for 1 yr; study duration up to 24 mo,"Testes: interstitial cell tumors (0/25, 2/25 (6-mo. feed), 6/25 (12 mo feed))",Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR LINURON (September 30, 1993)]"
7248,363907503,9502,CN(C(=O)NC1=CC(=C(C=C1)Cl)Cl)OC,Inactive,,,,Mouse,CD-1/Male (80/Group),Oral,0; 50; 150; 1500 ppm of 97% linuron in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR LINURON (September 30, 1993)]"
7249,363907503,9502,CN(C(=O)NC1=CC(=C(C=C1)Cl)Cl)OC,Active,,,,Mouse,CD-1/Female (80/Group),Oral,0; 50; 150; 1500 ppm of 97% linuron in diet for 24 mo; study duration 24 mo,Liver: hepatocellular adenomas (high dose only),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR LINURON (September 30, 1993)]"
7250,363907504,23695319,C1=CC(=NNC1=O)[O-].[K+],Inactive,,,,Rat,Sprague-Dawley/Male (50/Group),Oral,0; 25; 500; 1000 mg/kg/day of 72.5-73.8% as maleic hydrazide in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MALEIC HYDRAZIDE (November 29, 1995)]"
7251,363907504,23695319,C1=CC(=NNC1=O)[O-].[K+],Inactive,,,,Rat,Sprague-Dawley/Female (50/Group),Oral,0; 25; 500; 1000 mg/kg/day of 72.5-73.8% as maleic hydrazide in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MALEIC HYDRAZIDE (November 29, 1995)]"
7252,363907504,23695319,C1=CC(=NNC1=O)[O-].[K+],Inactive,,,,Mouse,Charles River CD-1/Male (50/Group),Oral,0; 157; 509; 1545 mg/kg/day of 90% maleic hydrazide potassium salt in diet for 98 wk; study duration 98 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MALEIC HYDRAZIDE (November 29, 1995)]"
7253,363907504,23695319,C1=CC(=NNC1=O)[O-].[K+],Inactive,,,,Mouse,Charles River CD-1/Female (50/Group),Oral,0; 189; 598; 1811 mg/kg/day of 90% maleic hydrazide potassium salt in diet for 98 wk; study duration 98 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MALEIC HYDRAZIDE (November 29, 1995)]"
7254,363907505,11292824,COC1=C(C=CC(=C1)CCNC(=O)C(C2=CC=C(C=C2)Cl)OCC#C)OCC#C,Inactive,,,,Rat,Alpk:AP SD (Wistar-derived)/Male (52/Group),Oral,0; 3.0; 15.2; 61.3 mg/kg/day of 96.5% mandipropamid in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANDIPROPAMID (April 17, 2008)]"
7255,363907505,11292824,COC1=C(C=CC(=C1)CCNC(=O)C(C2=CC=C(C=C2)Cl)OCC#C)OCC#C,Inactive,,,,Rat,Alpk:AP SD (Wistar-derived)/Female (52/Group),Oral,0; 3.5; 17.6; 69.7 mg/kg/day of 96.5% mandipropamid in diet for 104 wk; study duration 104 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANDIPROPAMID (April 17, 2008)]"
7256,363907505,11292824,COC1=C(C=CC(=C1)CCNC(=O)C(C2=CC=C(C=C2)Cl)OCC#C)OCC#C,Inactive,,,,Mouse,C57BL/10J CD-1 / Male (50/Group),Oral,0; 10.6; 55.2; 222.7 mg/kg/day of 96.5% mandipropamid in diet for  80 wk; study duration 80 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANDIPROPAMID (April 17, 2008)]"
7257,363907505,11292824,COC1=C(C=CC(=C1)CCNC(=O)C(C2=CC=C(C=C2)Cl)OCC#C)OCC#C,Inactive,,,,Mouse,C57BL/10J CD-1 / Female (50/Group),Oral,0; 13.2; 67.8; 284.6 mg/kg/day of 96.5% mandipropamid in diet for  80 wk; study duration 80 wk,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MANDIPROPAMID (April 17, 2008)]"
7258,363907506,7153,CC1=C(C=CC(=C1)Cl)OC(C)C(=O)O,Inactive,,,,Rat,Wistar/Male (65/Group),Oral,0; 20; 100; 400 ppm of 92.7% mecoprop in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MCPP (September 15, 1999)]"
7259,363907506,7153,CC1=C(C=CC(=C1)Cl)OC(C)C(=O)O,Inactive,,,,Rat,Wistar/Female (65/Group),Oral,0; 20; 100; 400 ppm of 92.7% mecoprop in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MCPP (September 15, 1999)]"
7260,363907506,7153,CC1=C(C=CC(=C1)Cl)OC(C)C(=O)O,Active,,,,Mouse,B6C3F1/CrlBR/Male (50/Group),Oral,0; 25; 250 ppm of 92.7% mecoprop in diet for 18 mo; study duration 18 mo,Lung: carcinoma,Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MCPP (September 15, 1999)]"
7261,363907506,7153,CC1=C(C=CC(=C1)Cl)OC(C)C(=O)O,Inactive,,,,Mouse,B6C3F1/CrlBR/Female (50/Group),Oral,0; 25; 250 ppm of 92.7% mecoprop in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MCPP (September 15, 1999)]"
7262,363907507,62067,CC1=CC(=C(C=C1NC(=O)C)NS(=O)(=O)C(F)(F)F)C.C(CO)NCCO,Inactive,,,,Mouse,Strain not specified by Department of Pesticide Regulation/Male (60/Group),Oral,0; 600; 1800; 6000 ppm of 93% mefluidide in diet for 18-19 mo; study duration 19 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MEFLUIDIDE, DIETHANOLAMINE SALT (November 21, 1994)]"
7263,363907507,62067,CC1=CC(=C(C=C1NC(=O)C)NS(=O)(=O)C(F)(F)F)C.C(CO)NCCO,Inactive,,,,Mouse,Strain not specified by Department of Pesticide Regulation/Female (60/Group),Oral,0; 600; 1800; 6000 ppm of 93% mefluidide in diet for 18-19 mo; study duration 19 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MEFLUIDIDE, DIETHANOLAMINE SALT (November 21, 1994)]"
7264,363907508,62781,C[N+]1(CCCCC1)C.[Cl-],Inactive,,,,Rat,Wistar/Male (50/Group),Oral,0; 13; 105; 269 mg/kg/day of 57.9% mepiquat chloride in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MEPIQUAT CHLORIDE (January 17, 2003)]"
7265,363907508,62781,C[N+]1(CCCCC1)C.[Cl-],Inactive,,,,Rat,Wistar/Female (50/Group),Oral,0; 17; 141; 370 mg/kg/day of 57.9% mepiquat chloride in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MEPIQUAT CHLORIDE (January 17, 2003)]"
7266,363907509,11409499,COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=C(C=CC(=C2)CNS(=O)(=O)C)C(=O)OC)OC,Inactive,,,,Rat,Hoe:WISK(SPF71)/Male (50/Group),Oral,0; 7.46; 73.8; 764.0 mg/kg/day of 94.6% mesosulfuron-methyl in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MESOSULFURON-METHYL (October 29, 2004)]"
7267,363907509,11409499,COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=C(C=CC(=C2)CNS(=O)(=O)C)C(=O)OC)OC,Inactive,,,,Rat,Hoe:WISK(SPF71)/Female (50/Group),Oral,0; 9.39; 94.7; 952.3 mg/kg/day of 94.6% mesosulfuron-methyl in diet for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MESOSULFURON-METHYL (October 29, 2004)]"
7268,363907509,11409499,COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=C(C=CC(=C2)CNS(=O)(=O)C)C(=O)OC)OC,Inactive,,,,Mouse,CD-1/Male (60/Group),Oral,0; 10.6; 102.8; 1069 mg/kg/day of 94.6-95.3% mesosulfuron-methyl in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MESOSULFURON-METHYL (October 29, 2004)]"
7269,363907509,11409499,COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=C(C=CC(=C2)CNS(=O)(=O)C)C(=O)OC)OC,Inactive,,,,Mouse,CD-1/Female (60/Group),Oral,0; 13.9; 129.8; 1356 mg/kg/day of 94.6-95.3% mesosulfuron-methyl in diet for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR MESOSULFURON-METHYL (October 29, 2004)]"
7270,363907510,35823,C1=CC(=C(C=C1C2=CC(=C(C=C2Cl)Cl)Cl)Cl)Cl,Active,,,,Rat,Harlan Sprague-Dawley/Female (80/Group),Oral,"0; 100; 220; 460; 1000; 4600 ug/kg in corn oil, by gavage, 5 d/wk for 2 yr","Liver: cholangiocarcinoma (0/52, 0/51, 0/52, 0/52, 3/52, 36/49, 29/49); hepatocellular adenoma (0/52, 1/51, 1/52, 4/52, 12/52, 24/49, 1/49); hepatocholangioma (0/52, 0/51, 0/52, 0/52, 0/52, 4/49, 0/49). Lung: cystic keratinizing epithelioma (0/51, 0/52, 0/52, 0/52, 0/52, 20/50, 0/50). Uterus: carcinoma (2/52, 2/52, 1/52, 3/52, 4/52, 3/52, 11/50).",Positive,"[NCI/NTP CARCINOGENESIS TECHNICAL REPORT SERIES; NATIONAL CANCER INSTITUTE/NATIONAL TOXICOLOGY PROGRAM; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TR-559 Y 2010]"
7271,363907511,,,Inactive,,,,Rat,Sprague-Dawley/Male (60/Group),Oral,0; 50; 1000; 5000 ppm of 99% metaldehyde in diet for 104 mo; study duration 104 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METALDEHYDE (January 2, 2001)]"
7272,363907511,,,Active,,,,Rat,Sprague-Dawley/Female (60/Group),Oral,0; 50; 1000; 5000 ppm of 99% metaldehyde in diet for 104 mo; study duration 104 mo,Liver: adenoma (high dose only),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METALDEHYDE (January 2, 2001)]"
7273,363907511,,,Active,,,,Mouse,Swiss Crl:CD-1(ICR)BR/Male (60/Group),Oral,0;135 mg/kg/d of 100% metaldehyde in diet for 78 wk; study duration 78 wk,Liver: hepatocellular adenoma (14/60 vs 4/60) and carcinoma (4/60 vs 2/60),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METALDEHYDE (January 2, 2001)]"
7274,363907511,,,Active,,,,Mouse,Swiss Crl:CD-1(ICR)BR/Female (60/Group),Oral,0; 163 mg/kg/d of 100% metaldehyde in diet for 78 wk; study duration 78 wk,Liver: hepatocellular adenoma (5/60 vs 0/60),Positive,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METALDEHYDE (January 2, 2001)]"
7275,363907512,11614934,C1=CC(=CC(=C1)C(F)(F)F)/C(=N/NC(=O)NC2=CC=C(C=C2)OC(F)(F)F)/CC3=CC=C(C=C3)C#N,Inactive,,,,Rat,Sprague-Dawley/Male (80/Group),Oral,0 (aqueous carboxymethylcellulose); 30; 60; 300 mg/kg/day of 96.3% metaflumizone by gavage for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METAFLUMIZONE (August 1, 2006)]"
7276,363907512,11614934,C1=CC(=CC(=C1)C(F)(F)F)/C(=N/NC(=O)NC2=CC=C(C=C2)OC(F)(F)F)/CC3=CC=C(C=C3)C#N,Inactive,,,,Rat,Sprague-Dawley/Female (80/Group),Oral,0 (aqueous carboxymethylcellulose); 30; 60; 300 mg/kg/day (adjusted to 200 mg after 2 weeks of treatment) of 96.3% metaflumizone by gavage for 24 mo; study duration 24 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METAFLUMIZONE (August 1, 2006)]"
7277,363907512,11614934,C1=CC(=CC(=C1)C(F)(F)F)/C(=N/NC(=O)NC2=CC=C(C=C2)OC(F)(F)F)/CC3=CC=C(C=C3)C#N,Inactive,,,,Mouse,CD-1/Male (65/Group),Oral,0 (aqueous carboxymethylcellulose); 100; 250; 1000 mg/kg/day of 96.3% metaflumizone by gavage for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METAFLUMIZONE (August 1, 2006)]"
7278,363907512,11614934,C1=CC(=CC(=C1)C(F)(F)F)/C(=N/NC(=O)NC2=CC=C(C=C2)OC(F)(F)F)/CC3=CC=C(C=C3)C#N,Inactive,,,,Mouse,CD-1/Female (65/Group),Oral,0 (aqueous carboxymethylcellulose); 100; 250; 1000 mg/kg/day of 96.3% metaflumizone by gavage for 18 mo; study duration 18 mo,,Negative,"[CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION; SUMMARY OF TOXICOLOGY DATA FOR METAFLUMIZONE (August 1, 2006)]"
